

19.10.2018

**11:50 - 13:30**    **Type: Opening Session**    **Hall A2 - Room 18**  
**Title: Opening session and award lectures**  
 Chair(s): Josep Tabernero, ES; Emile Voest, NL

11:50 - 12:00    **ESMO Presidential Address**  
J. Tabernero, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES

12:00 - 12:06    **ESMO 2018 Scientific Address**  
S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

12:06 - 12:12    **EONS Address**  
L. Sharp, Regional Cancer Center Stockholm Gotland, Stockholm, SE

12:12 - 12:20    **Thanks to ESMO 2018 Officers and presentation of the ESMO Award**  
E. Voest, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

12:20 - 12:35    **ESMO Award lecture**  
J.-C. Soria, Medimmune, Gaithersburg, US

12:35 - 12:53    **ESMO Translational Research Award: Presentation and lecture**  
P. Janne, Dana Farber Cancer Institute, Boston, US

12:53 - 13:11    **ESMO Women for Oncology Award: Presentation and lecture - Professional advancement of women in oncology: A matter of great urgency for patients**  
M. Foti, Philpadelphia, US

13:11 - 13:29    **ESMO Lifetime Achievement Award: Presentation and lecture**  
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

13:29 - 13:30    **Closing and Welcome reception in the exhibition**

**13:30 - 15:30**    **Type: Special session**    **Hall B4 - Room 24**  
**Title: Sharing the power - ESMO Women for Oncology Forum**  
 Chair(s): Solange Peters, CH

- 13:30 - 13:35    **Welcome**  
S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH
- 13:35 - 13:50    **Oceans apart or bridging the gap?**  
M. Dosanjh, Cern, Geneva, CH
- 13:50 - 14:05    **Feminisation and recomposition of professional hierarchies: Challenges and opportunities for medicine**  
F. Panese, Institute of Social Sciences, UNIL, Lausanne, CH
- 14:05 - 14:20    **DGHO Women's working group**  
A. Letsch, Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE
- 14:20 - 14:35    **Women for Oncology Italy**  
M. Garassino, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 14:35 - 14:50    **Women for Oncology Greece**  
H. Linardou, Metropolitan Hospital, Athens, GR
- 14:50 - 15:20    **Discussion in small groups about specific relevant themes**
- 15:20 - 15:30    **Conclusions and take-home messages**  
S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

**14:00 - 15:30**    **Type: Educational session**    **Hall A1 - Room 17**  
**Title: Standards and advances in rectal cancer**  
 Chair(s): Miriam Koopman, NL; Karen-Lise Spindler, DK

14:00 - 14:22    **Imaging of rectal tumours: What is standard (and to be known by the clinician)?**  
G. Brown, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

14:22 - 14:44    **Organ preservation and local treatment in localised rectal cancers**  
D. Sebag-Montefiore, University of Leeds, Leeds, GB

14:44 - 15:06    **Optimal multimodal treatment in advanced rectal cancers**  
M.A. Gambacorta, Università Cattolica del Sacro Cuore, Rome, IT

15:06 - 15:28    **Controlling systemic disease: What is needed, and in which sequence?**  
M. Koopman, University Hospital Utrecht, Utrecht, NL

**14:00 - 15:30**    **Type: Proffered Paper session**    **Hall A1 - Room 15**  
**Title: Proffered paper session - Gynaecological cancers**  
 Chair(s): Susana Banerjee, GB; Sandro Pignata, IT

14:00 - 14:15    **9320 - Phase III trial of Lurbinectedin versus PLD or Topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial**  
S. Gaillard<sup>1</sup>, A. Oaknin<sup>2</sup>, I. Ray-Coquard<sup>3</sup>, I. Vergote<sup>4</sup>, G. Scambia<sup>5</sup>, N. Colombo<sup>6</sup>, S. Ghamande<sup>7</sup>, A. Soto-Matos<sup>8</sup>, C. Fernandez<sup>9</sup>, C. Kahatt<sup>9</sup>, J. Gomez<sup>9</sup>, A. Nieto<sup>9</sup>, N. Torres<sup>8</sup>, B. Pardo-Burdalo<sup>10</sup>, Z. Papai<sup>11</sup>, R. Kristeleit<sup>12</sup>, D. O'Malley<sup>13</sup>, I. Benjamin<sup>14</sup>, P. Pautier<sup>15</sup>, D. Lorusso<sup>16</sup>, <sup>1</sup>Duke University Medical Center, Baltimore, US, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>Centre Léon Bérard, Lyon, FR, <sup>4</sup>University Hospitals Leuven, Leuven, BE, <sup>5</sup>Policlinico Universitario A. Gemelli, Roma, IT, <sup>6</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>7</sup>Georgia Cancer Center at Augusta University, Augusta, US, <sup>8</sup>Pharma Mar, Madrid, ES, <sup>9</sup>PharmaMar - Spain, Colmenar Viejo, ES, <sup>10</sup>Institut Catala Oncologia-Hospital Duran i Reynals, Barcelona, ES, <sup>11</sup>Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, HU, <sup>12</sup>University College London UCL Cancer Institute, London, GB, <sup>13</sup>The Ohio State University, James Cancer Center, Columbus, US, <sup>14</sup>Arizona Center for Cancer Care, Peoria, US, <sup>15</sup>Gustave Roussy, Villejuif, FR, <sup>16</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

14:15 - 14:30    **9330 - Carboplatin/pegylated liposomal Doxorubicin/Bevacizumab (CD-BEV) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in patients with recurrent ovarian cancer. A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO Study Group, AGO-Austria, ANZGOG, GINECO, SGCTG).**  
J. Pfisterer<sup>1</sup>, A. Dean<sup>2</sup>, K. Baumann<sup>3</sup>, J. Rau<sup>4</sup>, P. Harter<sup>5</sup>, F. Joly<sup>6</sup>, J. Sehouli<sup>7</sup>, U. Canzler<sup>8</sup>, B. Schmalfeldt<sup>9</sup>, C. Shannon<sup>10</sup>, A. Hein<sup>11</sup>, D. Reimer<sup>12</sup>, L. Hanka<sup>13</sup>, T. Petit<sup>14</sup>, F. Marmé<sup>15</sup>, A. El-Balat<sup>16</sup>, R. Glasspool<sup>17</sup>, N. De Gregorio<sup>18</sup>, S. Mahner<sup>19</sup>, J.-E. Kurtz<sup>20</sup>, <sup>1</sup>Gynecologic Oncology, Kiel, DE, <sup>2</sup>AGO Study Group & St. John of God Hospital, Subiaco, AU, <sup>3</sup>AGO Study Group & Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, DE, <sup>4</sup>AGO Study Group & Coordinating Center for Clinical Trials

Philipps-University of Marburg, Marburg, DE, <sup>5</sup>Kliniken Essen Mitte Evang. HuysSENS-Stiftung, Essen, DE, <sup>6</sup>GINECO & Centre Francois Baclesse Caen, Caen, FR, <sup>7</sup>Department of Gynecology, Charité, Campus-Virchow-Klinikum, Berlin, DE, <sup>8</sup>AGO Study Group & Medical Faculty and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, DE, <sup>9</sup>AGO Study Group & Technical University of Munich - Klinikum rechts der Isar; current address: University of Medical Center Hamburg-Eppendorf, Hamburg, DE, <sup>10</sup>Mater Adult Hospital, Brisbane, AU, <sup>11</sup>AGO Study Group & Erlangen University Hospital, Erlangen, DE, <sup>12</sup>AGO Austria & Innsbruck Medical University, Innsbruck, AT, <sup>13</sup>AGO Study Group & University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, DE, <sup>14</sup>GINECO & Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, FR, <sup>15</sup>AGO Study Group & National Center for Tumor disease, University of Heidelberg, Heidelberg, DE, <sup>16</sup>AGO Study Group & University Hospital Frankfurt, Frankfurt, DE, <sup>17</sup>AGO Study Group & Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>18</sup>AGO Study Group & University of Ulm, Ulm, DE, <sup>19</sup>AGO Study Group & University Medical Center Hamburg-Eppendorf and University of Munich; current address University of Munich, München, DE, <sup>20</sup>GINECO & CHRU de Strasbourg Hôpital Civil, Strasbourg, FR

14:30 - 14:45 **Invited Discussant 9320 and 9330**

S. Pignata, Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

14:45 - 15:00 **9340 - Alienor/ENGOT-ov7 randomized trial exploring weekly Paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian Sex Cord tumors (SCT) in relapse**

I. Ray-Coquard<sup>1</sup>, P. Harter<sup>2</sup>, D. Lorusso<sup>3</sup>, C. Dalban<sup>1</sup>, I. Vergote<sup>4</sup>, K. Fujiwara<sup>5</sup>, L. Gladieff<sup>6</sup>, H.-J. Lueck<sup>7</sup>, A. Floquet<sup>8</sup>, A.F. Lesoin<sup>9</sup>, A. Schnelzer<sup>10</sup>, S. Pignata<sup>11</sup>, F. Selle<sup>12</sup>, J. Sehouli<sup>13</sup>, F. Brocard<sup>14</sup>, G. Mangili<sup>15</sup>, P. Pautier<sup>16</sup>, U. De Giorgi<sup>17</sup>, M. Provansal<sup>18</sup>, P.-E. Heudel<sup>1</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, FR, <sup>2</sup>Kliniken Essen Mitte Evang. HuysSENS-Stiftung, Essen, DE, <sup>3</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>4</sup>University Hospitals Leuven, Leuven, BE, <sup>5</sup>Saitama Medical University Internatl Medical Centre, Saitama, JP, <sup>6</sup>Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, <sup>7</sup>Gynökologisch-onkologische Praxis, Hamburg, DE, <sup>8</sup>Institute Bergonié, Bordeaux, FR, <sup>9</sup>Centre Oscar Lambret, Lille, FR, <sup>10</sup>Klinikum rechts der Isar, Munchen, DE, <sup>11</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>12</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>13</sup>Department of Gynecology, Charité, Campus-Virchow-Klinikum, Berlin, DE, <sup>14</sup>Centre d'Oncologie de Gentilly, Nancy, FR, <sup>15</sup>Ospedale San Raffaele, Milano, IT, <sup>16</sup>Gustave Roussy, Villejuif, FR, <sup>17</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>18</sup>Institut Paoli Calmettes, Marseille, FR

15:00 - 15:15 **9400 - OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer**

S. Blagden<sup>1</sup>, G. Bertelli<sup>2</sup>, E. Frangou<sup>3</sup>, C. Butcher<sup>3</sup>, S. Love<sup>4</sup>, M. Mackean<sup>5</sup>, R. Glasspool<sup>6</sup>, A. Cook<sup>7</sup>, S. Nicum<sup>1</sup>, R. Lord<sup>8</sup>, M. Ferguson<sup>9</sup>, R. Roux<sup>10</sup>, M. Martinez<sup>11</sup>, S. Black<sup>12</sup>, A. James<sup>12</sup>, H. Palmer<sup>13</sup>, S. Hughes<sup>12</sup>, C. Marriott<sup>14</sup>, L. Howells<sup>15</sup>, <sup>1</sup>Churchill Hospital University of Oxford, Oxford, GB, <sup>2</sup>Royal Sussex County Hospital Sussex Cancer Centre, Brighton, GB, <sup>3</sup>University of Oxford, Oxford, GB, <sup>4</sup>Centre for Statistics in Medicine, Oxford, GB, <sup>5</sup>Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB, <sup>6</sup>Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>7</sup>Gloucester Oncology Centre, Cheltenham, GB, <sup>8</sup>Clatterbridge Cancer Center, Wirral, GB, <sup>9</sup>Ninewells Hospital,

Dundee, GB, <sup>10</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>11</sup>Imperial College London, London, GB, <sup>12</sup>Maggie's Swansea, Swansea, GB, <sup>13</sup>Maggie's Oxford, Oxford, GB, <sup>14</sup>Maggie's Centres, Oxford, GB, <sup>15</sup>Maggie's Centres, London, GB

15:15 - 15:30 **Invited Discussant 9340 and 9400**

S. Banerjee, Royal Marsden Hospital NHS Foundation Trust, London, GB

**14:00 - 15:30** **Type: Special session** **Hall A1 - Room 16**  
**Title: Big data in cancer management: Genomics and disease stratification**  
 Chair(s): Carlos Caldas, GB; Stefan Pfister, DE

14:00 - 14:20 **Lung cancer**

C. Swanton, The Francis Crick Institute, London, GB

14:20 - 14:40 **Breast cancer**

C. Caldas, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

14:40 - 15:00 **CNS tumours**

S. Pfister, HI-STEM gGmbH im Deutschen Krebsforschungszentrum DKFZ, Heidelberg, DE

15:00 - 15:30 **Discussion**

**14:00 - 15:30** **Type: Educational session** **Hall A2 - Room 18**  
**Title: Emerging opportunities in cancer immunotherapy**  
 Chair(s): Ignacio Melero, ES

14:00 - 14:25 **Mutanomes and neoantigens**

M. Bassani-Sternberg, Ludwig Cancer Center(Division d'Onco-Immunologie Clinique) of the University of Lausanne - CHUV, Lausanne, CH

14:25 - 14:50 **Host biomarkers that affect response to immunotherapy (microbiomes)**

N. Chaput-Gras, Institut Gustave Roussy, Villejuif, FR

14:50 - 15:15 **Emerging targets for immunotherapy**

I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

15:15 - 15:30 **Discussion**



**14:00 - 15:30**    **Type: Educational session**    **ICM - Room 1**  
**Title: Clinical implementation of PARP inhibitors**  
 Chair(s): Andrew Tutt, GB; Serena Di Cosimo, IT

14:00 - 14:25    **Who, when and how to test for BRCA mutations**  
D. Stoppa-Lyonnet, Institut Curie, Paris, FR

14:25 - 14:55    **What is the true impact of PARP inhibitors in clinical practice?**  
A. Tutt, The Institute of Cancer Research (ICR), London, GB

14:55 - 15:15    **Managing side effects of PARP inhibitors**  
S. Paluch-Shimon, Shaare Zedek M.C, Jerusalem, IL

15:15 - 15:30    **Discussion**

**14:00 - 15:00**    **Type: Poster Discussion session**    **ICM - Room 14b**  
**Title: Poster Discussion session - NSCLC, metastatic 1**  
 Chair(s): Raffaele Califano, GB; Pasi Janne, US; Fedor Moiseyenko, RU

14:00 - 14:00    **LBA57 - Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)**  
E. Felip<sup>1</sup>, M. Nishio<sup>2</sup>, S. Orlov<sup>3</sup>, K. Park<sup>4</sup>, C.-J. Yu<sup>5</sup>, C.-M. Tsai<sup>6</sup>, M. Cobo<sup>7</sup>, M. Mckeage<sup>8</sup>, W.-C. Su<sup>9</sup>, T. Mok<sup>10</sup>, G.V. Scagliotti<sup>11</sup>, D. Spigel<sup>12</sup>, V.Q. Passos<sup>13</sup>, Z. Chen<sup>13</sup>, A.T. Shaw<sup>14</sup>,  
<sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>Japanese Foundation for Cancer Research, Tokyo, JP, <sup>3</sup>Department of Thoracic Oncology, St. Petersburg State Medical University, St. Petersburg, RU, <sup>4</sup>Division of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, <sup>5</sup>National Taiwan University, Taipei, TW, <sup>6</sup>Department of Oncology, Taipei Veterans General Hospital, Taipei, TW, <sup>7</sup>Medical Oncology Section, Hospital Regional Universitario Carlos Haya, IBIMA, Málaga, ES, <sup>8</sup>Auckland City Hospital and University of Auckland, Auckland, NZ, <sup>9</sup>Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, TW, <sup>10</sup>Chinese University of Hong Kong, Shatin, CN, <sup>11</sup>University of Torino, Department of Oncology, Orbassano, Torino, IT, <sup>12</sup>Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, US, <sup>13</sup>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, US, <sup>14</sup>Massachusetts General Hospital, Boston, Massachusetts, US

14:00 - 14:00    **LBA58 - Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L trial**  
S. Popat<sup>1</sup>, H.R. Kim<sup>2</sup>, M.-J. Ahn<sup>3</sup>, J.C.-H. Yang<sup>4</sup>, J.-Y. Han<sup>5</sup>, M. Hochmair<sup>6</sup>, K.H. Lee<sup>7</sup>, A. Delmonte<sup>8</sup>, M.R. Garcia Campelo<sup>9</sup>, D.-W. Kim<sup>10</sup>, F. Griesinger<sup>11</sup>, E. Felip<sup>12</sup>, R. Califano<sup>13</sup>, A. Spira<sup>14</sup>, S. Gettinger<sup>15</sup>, M. Tiseo<sup>16</sup>, J. Haney<sup>17</sup>, D. Kerstein<sup>17</sup>, D. Camidge<sup>18</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>Yonsei Cancer Center Yonsei University, Seoul, KR, <sup>3</sup>Samsung Medical Center, Seoul, KR, <sup>4</sup>National Taiwan University Hospital, Taipei, TW, <sup>5</sup>National Cancer Center, Goyang, KR, <sup>6</sup>Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Respiratory

Epidemiology, Vienna, AT, <sup>7</sup>Chungbuk National University Hospital, Cheongju, KR, <sup>8</sup>Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola, IT, <sup>9</sup>Hospital Universitario a Coruna - a Corunac, A Coruna, ES, <sup>10</sup>Seoul National University Hospital, Seoul, KR, <sup>11</sup>Pius Hospital, Oldenburg, DE, <sup>12</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>13</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>14</sup>Virginia Cancer Specialists, Fairfax, US, <sup>15</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>16</sup>AOU di Parma, Parma, IT, <sup>17</sup>Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, US, <sup>18</sup>University of Colorado Cancer Center, Aurora, US

14:00 - 14:00

**1379PD - Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study**

R. Dziadziuszko<sup>1</sup>, T. Mok<sup>2</sup>, D.R. Camidge<sup>3</sup>, A. Shaw<sup>4</sup>, J. Noe<sup>5</sup>, M. Nowicka<sup>6</sup>, T. Liu<sup>7</sup>, E. Mitry<sup>8</sup>, S. Peters<sup>9</sup>, <sup>1</sup>Medical University of Gdansk, Gdansk, PL, <sup>2</sup>The Chinese University of Hong Kong, Hong Kong, HK, <sup>3</sup>University of Colorado, Aurora, CO, US, <sup>4</sup>Massachusetts General Hospital, Boston, US, <sup>5</sup>Hoffmann La Roche, Basel, CH, <sup>6</sup>F. Hoffman-La Roche, Basel, CH, <sup>7</sup>F. Hoffmann-La Roche Ltd., Basel, CH, <sup>8</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>9</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

14:00 - 14:00

**1380PD - Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations**

B. Solomon<sup>1</sup>, J.-F. Martini<sup>2</sup>, S.-H. Ou<sup>3</sup>, R. Chiari<sup>4</sup>, R. Soo<sup>5</sup>, A. Bearz<sup>6</sup>, S. Li<sup>2</sup>, H. Thurm<sup>7</sup>, C.-C. Lin<sup>8</sup>, G. Riely<sup>9</sup>, T. Bauer<sup>10</sup>, A. Shaw<sup>9</sup>, <sup>1</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>2</sup>Pfizer Inc, La Jolla, US, <sup>3</sup>Chao Family Comprehensive Cancer Center, Irvine, US, <sup>4</sup>Azienda Ospedaliera di Perugia S. Maria della Misericordia, Perugia, IT, <sup>5</sup>National University Hospital, Singapore, SG, <sup>6</sup>National Institute for Cancer Research, Aviano, IT, <sup>7</sup>Pfizer Oncology, La Jolla, US, <sup>8</sup>National Taiwan University Hospital, Taipei city, TW, <sup>9</sup>Massachusetts General Hospital, Boston, US, <sup>10</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US

14:00 - 14:00

**LBA59 - Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC ASCEND-8)**

B.C. Cho<sup>1</sup>, R. Obermannova<sup>2</sup>, S. Orlov<sup>3</sup>, U. Batra<sup>4</sup>, S. Geater<sup>5</sup>, M. Mckeage<sup>6</sup>, C.-T. Yang<sup>7</sup>, P. Postmus<sup>8</sup>, G. De Castro<sup>9</sup>, S.-W. Kim<sup>10</sup>, P. De Marchi<sup>11</sup>, G.B. Kanakasetty<sup>12</sup>, V. Sriuranpong<sup>13</sup>, P.J. Voon<sup>14</sup>, Y.Y. Lau<sup>15</sup>, F. Kiertsman<sup>16</sup>, V. Passos<sup>17</sup>, Z. Chen<sup>16</sup>, R. Dziadziuszko<sup>18</sup>, <sup>1</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>Masaryk Memorial Cancer Institute and School of Medicine, Masaryk University, Brno, CZ, <sup>3</sup>Pavlov Medical University, St.Petersburg, RU, <sup>4</sup>Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, <sup>5</sup>Prince of Songkla University, Songkhla, TH, <sup>6</sup>University of Auckland, Auckland, NZ, <sup>7</sup>Chang Gung Memorial Hospital, Taoyuan, TW, <sup>8</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>9</sup>Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, <sup>10</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>11</sup>Barretos Cancer Hospital, Barretos, SP, BR, <sup>12</sup>HCG Curie Centre of Oncology & Kidwai Memorial Institute of Oncology, Bengaluru, IN, <sup>13</sup>Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok, TH, <sup>14</sup>Hospital Umum Sarawak, Kuching, MY, <sup>15</sup>Novartis Institutes for BioMedical Research, East Hanover, US, <sup>16</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>17</sup>Novartis Pharmaceuticals, East Hanover, US, <sup>18</sup>Medical University of Gdansk, Gdansk,

PL

- 14:00 - 14:20 **Invited Discussant LBA57, LBA58, 1379PD, 1380PD and LBA59**  
P. Janne, Dana Farber Cancer Institute, Boston, US
- 14:20 - 14:30 **Q&A led by Discussant**
- 14:30 - 14:30 **LBA60 - Uncommon EGFR mutations in lung adenocarcinomas: clinical features and response to tyrosine kinase inhibitors**  
A. Brindel<sup>1</sup>, W. Althakfi<sup>1</sup>, M. Barritault<sup>2</sup>, P.-P. Bringuier<sup>1</sup>, E. Watkin<sup>3</sup>, J.-M. Maury<sup>4</sup>, N. Girard<sup>5</sup>, M. Brevet<sup>1</sup>, <sup>1</sup>Groupement Hospitalier Est, Bron, FR, <sup>2</sup>Hospices Civiles de Lyon, Lyon, FR, <sup>3</sup>selas cypath, villeurbanne, FR, <sup>4</sup>Hopital Cardiologique, Bron, FR, <sup>5</sup>Institut Curie, Paris, FR
- 14:30 - 14:30 **1381PD - Gefitinib With or Without Pemetrexed in Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutation (mut): Final Overall Survival (OS) Results From a Randomized Phase II Study**  
J.C.-H. Yang<sup>1</sup>, Y. Cheng<sup>2</sup>, H. Murakami<sup>3</sup>, P.-C. Yang<sup>1</sup>, J. He<sup>4</sup>, K. Nakagawa<sup>5</sup>, J.H. Kang<sup>6</sup>, J.-H. Kim<sup>7</sup>, X. Wnag<sup>8</sup>, S. Enatsu<sup>9</sup>, T. Puri<sup>10</sup>, M. Orlando<sup>11</sup>, <sup>1</sup>National Taiwan University Hospital, Taipei, TW, <sup>2</sup>Jilin Provincial Cancer Hospital, Changchun, CN, <sup>3</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>4</sup>The First Affiliated Hospital of Guangzhou Medical College, Guangdong, CN, <sup>5</sup>Kinki University School of Medicine, Osaka, JP, <sup>6</sup>The Catholic University of Korea, Seoul, KP, <sup>7</sup>CHA Bundang Medical Center, CHA University, Gyeonggi-do, KP, <sup>8</sup>Eli Lilly and Company, Sanghai, CN, <sup>9</sup>Eli Lilly and Company, Kobe, JP, <sup>10</sup>Eli Lilly and Company, Gurgaon, IN, <sup>11</sup>Instituto Alexander Fleming, Buenos Aires, AR
- 14:30 - 14:30 **1382PD - Phase III Study of Gefitinib (G) versus Gefitinib+Carboplatin+Pemetrexed (GCP) as 1st-line Treatment for Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations (NEJ009)**  
M. Seike<sup>1</sup>, A. Inoue<sup>2</sup>, S. Sugawara<sup>3</sup>, S. Morita<sup>4</sup>, Y. Hosomi<sup>5</sup>, S. Ikeda<sup>6</sup>, K. Watanabe<sup>7</sup>, K. Takahashi<sup>8</sup>, Y. Fujita<sup>9</sup>, T. Harada<sup>10</sup>, K. Minato<sup>11</sup>, K. Takamura<sup>12</sup>, K. Kobayashi<sup>13</sup>, T. Nukiwa<sup>14</sup>, <sup>1</sup>Nippon Medical School Main Hospital, Tokyo, JP, <sup>2</sup>ohoku University School of Medicine, Miyagi, JP, <sup>3</sup>Sendai Kousei Hospital, Sendai, JP, <sup>4</sup>Kyoto University Graduate School of Medicine 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JP, <sup>5</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, <sup>6</sup>Cardiovascular & Respiratory Center, Yokohama, JP, <sup>7</sup>Miyagi Cancer Center, Natori, JP, <sup>8</sup>Juntendo University, Tokyo, JP, <sup>9</sup>Asahikawa Medical Center, Asahikawa, JP, <sup>10</sup>JCHO Hokkaido Hospital, Sapporo, JP, <sup>11</sup>Gunma Prefectural Cancer Center, Ota, JP, <sup>12</sup>Obihiro Kosei General Hospital, Obihiro, JP, <sup>13</sup>Saitama Medical University Internatl Medical Centre, Saitama, JP, <sup>14</sup>Tohoku University, Sendai, JP
- 14:30 - 14:30 **1383PD - An open-label, multicenter, phase 1 study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)**  
R. Camidge<sup>1</sup>, R. Heist<sup>2</sup>, J. Goldman<sup>3</sup>, E. Angevin<sup>4</sup>, J. Strickler<sup>5</sup>, D. Morgensztern<sup>6</sup>, M.



Barve<sup>7</sup>, T. Bauer<sup>8</sup>, E. Vokes<sup>9</sup>, T. Yi<sup>10</sup>, M. Motwani<sup>11</sup>, A. Parikh<sup>10</sup>, J. Wu<sup>11</sup>, K. Kelly<sup>12</sup>,  
<sup>1</sup>University Of Colorado Hospital, Aurora, US, <sup>2</sup>Massachusetts General Hospital, Boston, US, <sup>3</sup>UCLA, Santa Monica, US, <sup>4</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>5</sup>Duke University Medical Center, Durham, US, <sup>6</sup>Washington University School of Medicine, St. Louis, US, <sup>7</sup>Mary Crowley Cancer Research, Dallas, US, <sup>8</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>9</sup>The University of Chicago Medical Centre, Chicago, US, <sup>10</sup>AbbVie Inc., Redwood City, US, <sup>11</sup>AbbVie Inc., North Chicago, US, <sup>12</sup>University of California Davis Cancer Center, Sacramento, US

14:30 - 14:30 **LBA61 - Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC)**

D.S.W. Tan<sup>1</sup>, S.-W. Kim<sup>2</sup>, L. Sequist<sup>3</sup>, S. Ponce Aix<sup>4</sup>, E. Smit<sup>5</sup>, T. Hida<sup>6</sup>, J. Yang<sup>7</sup>, E. Felip<sup>8</sup>, T. Seto<sup>9</sup>, C. Grohe<sup>10</sup>, J. Wolf<sup>11</sup>, J. Ko<sup>12</sup>, E. Marriere<sup>13</sup>, R. Belli<sup>13</sup>, M. Giovannini<sup>14</sup>, D.-W. Kim<sup>15</sup>, <sup>1</sup>National Cancer Center Singapore, Singapore, SG, <sup>2</sup>Asan Medical Center, Seoul, KR, <sup>3</sup>Massachusetts General Hospital, Boston, US, <sup>4</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>5</sup>Hospital Universitario, Madrid, ES, <sup>6</sup>Department of Thoracic Oncology, Aichi, JP, <sup>7</sup>National Taiwan University Hospital, Taipei, TW, <sup>8</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>9</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>10</sup>Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, <sup>11</sup>University Hospital Cologne, Cologne, DE, <sup>12</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>13</sup>Novartis Pharma AG, Basel, CH, <sup>14</sup>Novartis, East Hanover, US, <sup>15</sup>Seoul National University Hospital, Seoul, KR

14:30 - 14:50 **Invited Discussant LBA60, 1381PD, 1382PD, 1383PD and LBA61**

R. Califano, The Christie NHS Foundation Trust, Manchester, GB

14:50 - 15:00 **Q&A led by Discussant**

**14:00 - 15:30 Type: Proffered Paper session ICM - Room 13**  
**Title: Proffered paper session - Genitourinary tumours, prostate**  
 Chair(s): Eleni Efstathiou, US; Silke Gillissen, GB

14:00 - 14:15 **7910 - Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.**

K. Fizazi<sup>1</sup>, A. Carmel<sup>1</sup>, F. Joly<sup>2</sup>, R. Delva<sup>3</sup>, G. Gravis<sup>4</sup>, F. Rolland<sup>5</sup>, F. Priou<sup>6</sup>, J.-M. Ferrero<sup>7</sup>, N. Houede<sup>8</sup>, L. Mourey<sup>9</sup>, C. Theodore<sup>10</sup>, I. Krakowski<sup>11</sup>, J.-F. Berdah<sup>12</sup>, M. Baciuchka Palmaro<sup>13</sup>, B. Laguerre<sup>14</sup>, A. Flechon<sup>15</sup>, A. Ravaud<sup>16</sup>, M. Brihoum<sup>17</sup>, S. Culine<sup>18</sup>, G. Le Teuff<sup>1</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>GINECO & Centre Francois Baclesse Caen, Caen, FR, <sup>3</sup>Centre Paul Papin, Angers, FR, <sup>4</sup>Institute Paoli Calmettes, Marseille, FR, <sup>5</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>6</sup>CHD Vendee - Hopital Les Oudairies, La Roche sur Yon, FR, <sup>7</sup>Centre Antoine Lacassagne, Nice, FR, <sup>8</sup>Institut de cancérologie du Gard, Nimes, FR, <sup>9</sup>Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, <sup>10</sup>Hopital Foch, Suresnes, FR, <sup>11</sup>Institute Bergonié, Bordeaux, FR, <sup>12</sup>Oncovar, Hyeres, FR, <sup>13</sup>Hopital Nord, Marseille, FR, <sup>14</sup>Centre Eugene - Marquis, Rennes, FR, <sup>15</sup>Centre Léon Bérard, Lyon, FR, <sup>16</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>17</sup>Unicancer, Kremlin-Bicêtre, FR, <sup>18</sup>Hôpital St. Louis, Paris, FR

14:15 - 14:30 **Invited Discussant 7910**

E. Efstathiou, The M. D. Anderson Cancer Center, Houston, US

14:30 - 14:45 **LBA30 - ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)**

M. Smith<sup>1</sup>, C. Parker<sup>2</sup>, F. Saad<sup>3</sup>, K. Miller<sup>4</sup>, B. Tombal<sup>5</sup>, Q.S. Ng<sup>6</sup>, M. Bögemann<sup>7</sup>, V. Matveev<sup>8</sup>, J.M. Piulats<sup>9</sup>, L. Zucca<sup>10</sup>, A. Heidenreich<sup>11</sup>, Y. Kakehi<sup>12</sup>, A. Zhang<sup>13</sup>, H. Krissel<sup>14</sup>, J. Shen<sup>13</sup>, V. Wagner<sup>15</sup>, C. Higano<sup>16</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, US, <sup>2</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>3</sup>Hospital St. Luc du CHUM, Montreal, CA, <sup>4</sup>Charité Berlin, Berlin, DE, <sup>5</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>6</sup>National Cancer Centre Singapore, Singapore, SG, <sup>7</sup>University of Muenster Medical Center, Muenchen, DE, <sup>8</sup>N.N. Blokhin Cancer Research Center, Moscow, RU, <sup>9</sup>Catalan Institute of Oncology, Barcelona, ES, <sup>10</sup>Barretos Cancer Hospital, Barretos, BR, <sup>11</sup>University Hospital Cologne, Cologne, DE, <sup>12</sup>Kagawa University, Takamatsu, JP, <sup>13</sup>Bayer HealthCare Pharmaceuticals, Whippany, US, <sup>14</sup>Bayer AG, Berlin, DE, <sup>15</sup>Bayer Pharma AG, Berlin, DE, <sup>16</sup>University of Washington, Seattle, US

14:45 - 15:00 **Invited Discussant LBA30**

D. Heinrich, Akershus University Hospital, Lørenskog, NO

15:00 - 15:15 **7920 - A Randomized Phase 2 Study of Cabazitaxel (CAB) vs (ABI) Abiraterone or (ENZ) Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

K. Chi<sup>1</sup>, S. Taavitsainen<sup>2</sup>, N. Iqbal<sup>3</sup>, C. Ferrario<sup>4</sup>, M. Ong<sup>5</sup>, D. Wadhwa<sup>6</sup>, S. Hotte<sup>7</sup>, G. Lo<sup>8</sup>, B. Tran<sup>9</sup>, A. Azad<sup>10</sup>, L. Wood<sup>11</sup>, J. Gingerich<sup>12</sup>, S. North<sup>13</sup>, C. Pezaro<sup>14</sup>, D. Ruether<sup>15</sup>, S. Sridhar<sup>16</sup>, M. Annala<sup>17</sup>, J. Bacon<sup>18</sup>, A. Wyatt<sup>2</sup>, <sup>1</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>2</sup>University of British Columbia, Vancouver, CA, <sup>3</sup>Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, CA, <sup>4</sup>Jewish General Hospital McGill University, Montreal, CA, <sup>5</sup>Ottawa Hospital Cancer Centre, Ottawa, CA, <sup>6</sup>BC Cancer - Kelowna Centre, Kelowna, CA, <sup>7</sup>Juravinski Cancer Centre, Hamilton, CA, <sup>8</sup>Durham Regional Cancer Centre, Oshawa, CA, <sup>9</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>10</sup>Monash Health, Melbourne, AU, <sup>11</sup>QEII Health Sciences Centre, Halifax, CA, <sup>12</sup>CancerCare Manitoba, Winnipeg, CA, <sup>13</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>14</sup>Eastern Health, Box Hill, AU, <sup>15</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>16</sup>Princess Margaret Hospital, Toronto, CA, <sup>17</sup>Vancouver Prostate Centre-Vancouver General Hospital, Vancouver, CA, <sup>18</sup>Vancouver Prostate Centre, Vancouver, CA

15:15 - 15:30 **Invited Discussant 7920**

S. Oudard, Hôpital Européen George Pompidou, Paris, FR

**14:00 - 15:30 Type: Proffered Paper session**  
**Title: Proffered paper session - Sarcoma**  
Chair(s): Rick L. Haas, NL

**Hall B3 - Room 21**

- 14:00 - 14:12 **16010 - Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017.**  
J.-Y. Blay<sup>1</sup>, M. Toulmonde<sup>2</sup>, N. Penel<sup>3</sup>, O. Mir<sup>4</sup>, C. Chevreau<sup>5</sup>, P. Anract<sup>6</sup>, E. Bompas<sup>7</sup>, M. Rios<sup>8</sup>, N. Firmin<sup>9</sup>, A. Italiano<sup>2</sup>, S. Piperno-Neumann<sup>10</sup>, J.-E. Kurtz<sup>11</sup>, F. Duffaud<sup>12</sup>, P. Rosset<sup>13</sup>, F. Bertucci<sup>14</sup>, C. Perrin<sup>15</sup>, C. Chemin<sup>1</sup>, F. Ducimetiere<sup>1</sup>, F. Gouin<sup>16</sup>, A. Le Cesne<sup>17</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, FR, <sup>2</sup>Institute Bergonié, Bordeaux, FR, <sup>3</sup>Centre Oscar Lambret, Lille, FR, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR, <sup>5</sup>Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, <sup>6</sup>Hopital Cochin, Paris, FR, <sup>7</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>8</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>9</sup>Institut de Cancerologie de Montpellier, Montpellier, FR, <sup>10</sup>Institut Curie, Paris, FR, <sup>11</sup>GINECO & CHRU de Strasbourg Hôpital Civil, Strasbourg, FR, <sup>12</sup>CHU La Timone Adultes, Marseille, FR, <sup>13</sup>CHU Tours, Tours, FR, <sup>14</sup>Institute Paoli Calmettes, Marseille, FR, <sup>15</sup>Centre Eugene - Marquis, Rennes, FR, <sup>16</sup>CHU Nantes, Nantes, FR, <sup>17</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 14:12 - 14:24 **16020 - Outcome following unplanned excision in soft tissue sarcoma. Results of a multicentre study including 728 patients.**  
M. Smolle<sup>1</sup>, P.-U. Tunn<sup>2</sup>, E. Goldenitsch<sup>3</sup>, F. Posch<sup>1</sup>, J. Szkandera<sup>1</sup>, M. Bergovec<sup>1</sup>, B. Liegl-Atzwanger<sup>1</sup>, A. Leithner<sup>1</sup>, <sup>1</sup>Medical University of Graz, Graz, AT, <sup>2</sup>HELIOS Klinikum Berlin-Buch, Berlin, DE, <sup>3</sup>Orthopaedic Hospital Gersthof, Vienna, AT
- 14:24 - 14:36 **LBA66 - A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advance soft tissue sarcoma of the extremity and trunk wall**  
S. Bonvalot<sup>1</sup>, P. Rutkowski<sup>2</sup>, J. Thariat<sup>3</sup>, S. Carrere<sup>4</sup>, M.-P. Sunyach<sup>5</sup>, E. Saada<sup>6</sup>, P. Agoston<sup>7</sup>, A. Hong<sup>8</sup>, A. Mervoyer<sup>9</sup>, M. Rastrelli<sup>10</sup>, C. Le Pechoux<sup>11</sup>, V. Moreno<sup>12</sup>, R. Li<sup>13</sup>, B. Tiangco<sup>14</sup>, A. Casado Herraes<sup>15</sup>, A. Gronchi<sup>16</sup>, L. Mangel<sup>17</sup>, P. Hohenberger<sup>18</sup>, M. Delannes<sup>19</sup>, Z. Papai<sup>20</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>3</sup>Centre François Baclesse, Caen, FR, <sup>4</sup>Centre Regional De Lutte Contre Le Cancer Paul Lamarque, Montpellier, FR, <sup>5</sup>Centre Léon Bérard, Lyon, FR, <sup>6</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>7</sup>Országos Onkologiai Intézet, HU, <sup>8</sup>The University of Sydney, Sydney, AU, <sup>9</sup>Institut de Cancerologie de l'Ouest- Rene Gauducheau, Saint-Herblain, FR, <sup>10</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>11</sup>Institut Gustave Roussy, Villejuif, FR, <sup>12</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>13</sup>St. Luke's Medical Center, Quezon city, PH, <sup>14</sup>The Medical City Cancer Center, Pasay City, PH, <sup>15</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>16</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>17</sup>University of Pecs, Faculty of Medicine, PTE AOK, Pecs, HU, <sup>18</sup>Universitätsklinikum Mannheim, Mannheim, DE, <sup>19</sup>Institut Claudius Regaud, Toulouse, FR, <sup>20</sup>MH Honvedkorhaz, Budapest, HU
- 14:36 - 14:51 **Invited Discussant 16010, 16020 and LBA66**  
R.L. Haas, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 14:51 - 15:03 **16030 - Initial Results of Phase 1 Study of DCC-2618, a Broad-spectrum KIT and PDGFRa Inhibitor, in Patients (pts) with Gastrointestinal Stromal Tumor (GIST)**



**by Number of Prior Regimens.**

S. George<sup>1</sup>, M. Heinrich<sup>2</sup>, P. Chi<sup>3</sup>, A. Razak<sup>4</sup>, M. Von Mehren<sup>5</sup>, M. Gordon<sup>6</sup>, K. Ganjoo<sup>7</sup>, N. Somaiah<sup>8</sup>, J.C. Trent<sup>9</sup>, J. Rodon Ahnert<sup>10</sup>, J. Wolf<sup>11</sup>, R. Ruiz-Soto<sup>12</sup>, O. Rosen<sup>13</sup>, F. Janku<sup>14</sup>, <sup>1</sup>Dana Faber Cancer Institute, Boston, US, <sup>2</sup>Oregon Health and Science University, Portland, US, <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>4</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, CA, <sup>5</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>6</sup>HonorHealth Virginia G Piper Cancer Care Network, Scottsdale, US, <sup>7</sup>Stanford Cancer Institute, Stanford, US, <sup>8</sup>Medical University of South Carolina, Charleston, US, <sup>9</sup>University of Miami Sylvester Comprehensive Cancer Center, Miami, US, <sup>10</sup>MD Anderson Cancer Center, Houston, US, <sup>11</sup>Wolf Consulting Biostatistician, Denver, US, <sup>12</sup>Deciphera Pharmaceuticals, Waltham, US, <sup>13</sup>Deciphera Pharmaceuticals, New York, US, <sup>14</sup>The University of Texas MD Anderson Cancer Center, Houston, US

15:03 - 15:15 **LBA67 - Cabozantinib in Patients With Advanced Osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study.**

A. Italiano<sup>1</sup>, N. Penel<sup>2</sup>, M. Toulmonde<sup>1</sup>, E. Bompas<sup>3</sup>, S. Piperno-Neumann<sup>4</sup>, M. Pulido<sup>1</sup>, N. Entz-Werle<sup>5</sup>, A. Le Cesne<sup>6</sup>, C. Chevreau<sup>7</sup>, F. Duffaud<sup>8</sup>, I. Ray-Coquard<sup>9</sup>, C. Bellera<sup>10</sup>, S. Mathoulin-Pelissier<sup>11</sup>, J.-Y. Blay<sup>9</sup>, <sup>1</sup>Institut Bergonié, Bordeaux, FR, <sup>2</sup>Centre Oscar Lambret, Lille, FR, <sup>3</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>4</sup>Institut Curie, Paris, FR, <sup>5</sup>CHU STRASBOURG, STRASBOURG, FR, <sup>6</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>7</sup>Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, <sup>8</sup>CHU La Timone Adultes, Marseille, FR, <sup>9</sup>Centre Léon Bérard, Lyon, FR, <sup>10</sup>Institut Bergonié, Comprehensive Cancer Center, BORDEAUX, FR, <sup>11</sup>Institut Bergonié, Bordeaux, FR

15:15 - 15:30 **Invited Discussant 16030 and LBA67**

D. Katz, Assaf Harofeh Medical Center, Be'er Ya'akov, IL

<b>14:00 - 15:30</b>	<b>Type: Educational session</b> <b>Title: Brain and leptomeningeal metastasis: Standard of diagnosis and treatment</b> Chair(s): Frank Winkler, DE; Carmen Balana, ES	<b>Hall B3 - Room 23</b>
----------------------	--	--------------------------

14:00 - 14:25 **Challenges in the diagnostic work-up of brain and leptomeningeal metastasis**

P. Wesseling, Vrije University Medical Centre (VUMC), Amsterdam, NL

14:25 - 14:50 **Multimodality treatment of brain metastasis**

F. Winkler, University Hospital of Heidelberg, Heidelberg, DE

14:50 - 15:15 **Multimodality treatment of leptomeningeal metastasis**

E. Le Rhun, Roger Salengro Hospital, Lille, FR

15:15 - 15:30 **Discussion**



**14:00 - 15:30**    **Type: Joint Symposium**    **Hall B3 -**  
**Title: ESMO-SIOPE: Multidisciplinary management of life-after-cancer**    **Room 22**  
**issues in adolescent and young adult survivors: Medicine and beyond**  
 Chair(s): Giannis Mountzios, GR; Daniel Stark, GB

- 14:00 - 14:05    **Introduction**  
D. Stark, St. James's University Hospital Leeds, Leeds, GB
- 14:05 - 14:25    **Fertility preservation, parenthood and sexual health in AYA cancer survivors**  
F. Peccatori, Istituto Europeo di Oncologia, Milan, IT
- 14:25 - 14:45    **Late cardiovascular toxicity of anti-cancer treatment in adolescents and young adults**  
K. Rugbjerg, Danish Cancer Society Research Center, Copenhagen, DK
- 14:45 - 15:05    **Going back to school or work after cancer diagnosis: Professional and social re-integration of AYA cancer survivors**  
P. Riis Olsen, Aarhus University Hospital, Aarhus, DK
- 15:05 - 15:25    **Psychosocial, nutritional and physical activity aspects of AYA cancer survivors**  
A. Stein, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
- 15:25 - 15:30    **Conclusions**  
G. Mountzios, University of Athens School of Medicine Clinical Therapeutics, Athens, GR

<b>14:00 - 15:00</b>	<b>Type: Special session</b> <b>Title: Treatment decisions and side effect management of new drugs (including immunotherapy) in lung cancer</b> Chair(s): Stefan Rauh, LU; Pilar Garrido Lopez, ES	<b>ICM - Room 14a</b>
14:00 - 14:05	<b>Topic 1 case presentation: Pseudo progression versus true progression: When is it time to switch treatment?</b> <u>S. Rauh</u> , Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU	
14:05 - 14:20	<b>General Discussion</b> <u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	
14:20 - 14:25	<b>Topic 2 case presentation: Side effects of immunotherapy in lung cancer: Focus on pulmonary toxicity</b> <u>S. Rauh</u> , Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU	
14:25 - 14:40	<b>General Discussion</b> <u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	
14:40 - 14:45	<b>Topic 3 case presentation: Side effects of TKI's</b> <u>S. Rauh</u> , Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU	
14:45 - 15:00	<b>General Discussion</b> <u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	

**14:00 - 15:30**    **Type: Special session**    **ICM - Room 14c**  
**Title: ESMO-MCBS in perspective**  
 Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL

14:00 - 14:05    **Introduction**  
E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

14:05 - 14:30    **Comparative assessment of clinical benefit using the ESMO-MCBS v1.1 and the ASCO Value Frameworks Net Health Benefit Score**  
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

14:30 - 14:55    **ESMO-MCBS v1.1 applied in haematological diseases**  
B. Kiesewetter-Wiederkehr, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

14:55 - 15:20    **How to help countries priorities their cancer systemic therapies -report from the WHO**  
A. Ilbawi, WHO - World Health Organization, Geneva, CH

15:20 - 15:30    **Conclusions**  
E.G.E. De Vries<sup>1</sup>, N. Cherny<sup>2</sup>, <sup>1</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>2</sup>Shaare Zedek Medical Center, Jerusalem, IL

**14:30 - 15:45**    **Type: Patient Advocacy Track**    **ICM - Room 5**  
**Title: Knowledge is power: Educating patients and advocates**  
 Chair(s): Jan Geissler, CH; Bettina Ryll, SE

14:30 - 14:45    **Welcome to ESMO2018**  
B. Ryll<sup>1</sup>, J. Taberero<sup>2</sup>, <sup>1</sup>Melanoma Patient network Europe, Uppsala, SE, <sup>2</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES

14:45 - 15:05    **Reaching patients: The podcast experience**  
F. Johansson, Lungcancerförbundet Stödet Sweden, Stockholm, SE

15:05 - 15:25    **The Myeloma Access Atlas: Training programme**  
A. Plate, Myeloma Patients Europe, Charleroi, BE

15:25 - 15:45    **The CML ECABs: Educating for excellence**  
J. Geissler, Leukemia Patient Advocates Foundation, Bern, CH

**15:45 - 17:30** **Type: Educational session** **ICM - Room 1**  
**Title: State of the art for systemic treatments in kidney and bladder cancers**  
 Chair(s): Maria De Santis, DE; Marco Gizzi, BE

15:45 - 16:10 **State of the art of immunotherapy in renal and bladder cancers**  
C. Sternberg, Azienda Ospedaliera S. Camillo Forlanini, Rome, IT

16:10 - 16:35 **The current use of TKI in renal cancer**  
M. Gizzi, Grand Hopital de Charleroi Site Notre Dame, Charleroi, BE

16:35 - 17:00 **Is there still a role for chemotherapy in bladder cancer?**  
M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE

17:00 - 17:25 **Abundance of riches in view of health care constraints:**  
A. Bex, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

**15:45 - 17:25** **Type: Poster Discussion session** **Hall B3 - Room 21**  
**Title: Poster Discussion session -Gastrointestinal, non-colorectal**  
 Chair(s): Florian Lordick, DE; Marcel Verheij, NL; Ann-Lii Cheng, TW; Ian Chau, GB; Eileen O'Reilly, US

15:45 - 15:45 **616PD - Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer**  
I. Chau<sup>1</sup>, S.-E. Al-Batran<sup>2</sup>, A. Luft<sup>3</sup>, R. Kowalyszyn<sup>4</sup>, C. Hernandez<sup>5</sup>, P. Pfeiffer<sup>6</sup>, E. Wojcik<sup>7</sup>, G. Bodoky<sup>8</sup>, A. Madi<sup>9</sup>, B. Brenner<sup>10</sup>, F. De Vita<sup>11</sup>, G. Folprecht<sup>12</sup>, K. Peltola<sup>13</sup>, S. Lorenzen<sup>14</sup>, C. Denlinger<sup>15</sup>, A. Liepa<sup>16</sup>, M. Das<sup>16</sup>, R. Wei<sup>16</sup>, C. Fuchs<sup>17</sup>, <sup>1</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>2</sup>Nordwest-Krankenhaus, Frankfurt am Main, DE, <sup>3</sup>St. Petersburg Regional Clinic and Hospital, Saint Petersburg, RU, <sup>4</sup>IMO Instituto Multidisciplinario Oncologico, Viedma, AR, <sup>5</sup>Oaxaca Site Management Organization SC, Oaxaca, MX, <sup>6</sup>Odense University Hospital, Odense C, DK, <sup>7</sup>NZOZ Centrum Medyczne HCP, Poznan, PL, <sup>8</sup>St. László Hospital, Budapest, HU, <sup>9</sup>Clatterbridge Cancer Center, Wirral, GB, <sup>10</sup>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tiqva, IL, <sup>11</sup>AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT, <sup>12</sup>Universitätsklinikum Dresden, Dresden, DE, <sup>13</sup>Helsinki University Central Hospital, Helsinki, FI, <sup>14</sup>Rechts der Isar Hospital, TUM, Munich, DE, <sup>15</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>16</sup>Eli Lilly, Indianapolis, US, <sup>17</sup>Yale University, New Haven, US

15:45 - 15:45 **617PD - A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.**  
T. Satoh<sup>1</sup>, L.-T. Chen<sup>2</sup>, Y.-K. Kang<sup>3</sup>, Y. Chao<sup>4</sup>, K. Kato<sup>5</sup>, H.C. Chung<sup>6</sup>, J.-S. Chen<sup>7</sup>, K. Muro<sup>8</sup>, W.K. Kang<sup>9</sup>, T. Yoshikawa<sup>10</sup>, S.C. Oh<sup>11</sup>, T. Tamura<sup>12</sup>, K.-W. Lee<sup>13</sup>, N. Boku<sup>14</sup>,



<sup>1</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>2</sup>National Health Research Institutes, Tainan, TW, <sup>3</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Taipei Veterans General Hospital, Taipei, TW, <sup>5</sup>National Cancer Center Hospital, Tokyo, JP, <sup>6</sup>Yonsei University College of Medicine, Seoul, KR, <sup>7</sup>Chung Gung University, Tao Yuan, TW, <sup>8</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>9</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>10</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>11</sup>Korea University Guro Hospital, College of Medicine, Korea University, Seoul, KR, <sup>12</sup>Kindai University Faculty of Medicine, Osakasayama, JP, <sup>13</sup>Seoul National University Bundang Hospital, Seoul, KR, <sup>14</sup>St. Marianna University School of Medicine, Kawasaki, JP

- 15:45 - 15:45 **619PD\_PR - Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: a pooled analysis of 4 randomised trials**  
M. Davidson<sup>1</sup>, A. Wagner<sup>2</sup>, K. Kouvelakis<sup>1</sup>, N. Starling<sup>1</sup>, I. Chau<sup>3</sup>, D. Watkins<sup>4</sup>, S. Rao<sup>1</sup>, C. Peckitt<sup>1</sup>, D. Cunningham<sup>3</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>3</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>4</sup>Royal Marsden Hospital, Sutton, GB
- 15:45 - 15:55 **Invited Discussant 616PD, 617PD and 619PD\_PR**  
F. Lordick, University of Leipzig, Leipzig, DE
- 15:55 - 16:05 **Q&A led by Discussant**
- 16:05 - 16:05 **618PD - Progression-free survival and recurrence results for AGITG DOCTOR. Pre-op cisplatin, 5FU &&**  
A. Barbour<sup>1</sup>, E. Walpole<sup>1</sup>, G. Mai<sup>1</sup>, L. Barnes<sup>2</sup>, D. Watson<sup>3</sup>, S. Ackland<sup>4</sup>, V. Wills<sup>5</sup>, J. Martin<sup>4</sup>, M. Burge<sup>6</sup>, C. Karapetis<sup>7</sup>, J. Shannon<sup>8</sup>, L. Nott<sup>9</sup>, V. GebSKI<sup>2</sup>, M. Oostendorp<sup>2</sup>, K. Wilson<sup>2</sup>, J. Thomas<sup>1</sup>, G. Lampe<sup>1</sup>, J. Zalcberg<sup>10</sup>, J. Simes<sup>11</sup>, M. Smithers<sup>1</sup>, <sup>1</sup>Princess Alexandra Hospital, Woolloongabba, AU, <sup>2</sup>NHMRC Clinical Trials Centre, Sydney, AU, <sup>3</sup>Flinders Medical Centre, Adelaide, AU, <sup>4</sup>Calvary Mater Hospital Newcastle, Newcastle, AU, <sup>5</sup>John Hunter Hospital, New Lambton Heights, AU, <sup>6</sup>Royal Brisbane and Women's Hospital, Brisbane, AU, <sup>7</sup>Flinders Centre for Innovation in Cancer, Bedford Park, AU, <sup>8</sup>Nepean Cancer Care Centre, Kingswood, AU, <sup>9</sup>private address, Tasmania, AU, <sup>10</sup>Alfred Hospital, Melbourne, AU, <sup>11</sup>The NHMRC Clinical Trials Centre, Camperdown, AU
- 16:05 - 16:05 **620PD - Influence of enteral nutrition on nutritional status, treatment toxicities, and short-term outcomes in esophageal carcinoma patients treated with concurrent chemoradiotherapy: a prospective, multicenter, randomized controlled study**  
T. Li<sup>1</sup>, J. Lyu<sup>1</sup>, G. Zhu<sup>2</sup>, J. Li<sup>3</sup>, R. Zhao<sup>4</sup>, S. Zhu<sup>5</sup>, J. Wang<sup>6</sup>, L. Xing<sup>7</sup>, D. Yang<sup>8</sup>, C. Xie<sup>9</sup>, L.-F. Shen<sup>10</sup>, H.-P. Shi<sup>11</sup>, J. Lang<sup>1</sup>, <sup>1</sup>Sichuan Cancer Hospital&institute, Chengdu, CN, <sup>2</sup>China-Japan Friendship Hospital, Beijing, CN, <sup>3</sup>Shanxi Cancer Hospital, Taiyuan, CN, <sup>4</sup>General Hospital of NingXia Medical University, Yinchuan, CN, <sup>5</sup>Fourth Hospital Of Hebei Medical University, Shijiazhuang, CN, <sup>6</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>7</sup>Shandong Cancer Hospital, Beijing, CN, <sup>8</sup>First Affiliated Hospital Of Zhengzhou University,

Zhengzhou, CN, <sup>9</sup>Zhongnan Hospital Of Wuhan University, Wuhan, CN, <sup>10</sup>Xiangya Hospital Central South University, Changsha, CN, <sup>11</sup>Beijing Century Altar Hospital Affiliated to the Capital Medical University, Beijing, CN

16:05 - 16:15 **Invited Discussant 618PD and 620PD**

M. Verheij, Radboud University Medical Centre Nijmegen, Nijmegen, NL

16:15 - 16:25 **Q&A led by Discussant**

16:25 - 16:25 **621PD - Phase 2 trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)**

B.-Y. Ryou<sup>1</sup>, Z. Ren<sup>2</sup>, T.-Y. Kim<sup>3</sup>, H. Pan<sup>4</sup>, K.-M. Rau<sup>5</sup>, H.J. Choi<sup>6</sup>, J.-W. Park<sup>7</sup>, J.H. Kim<sup>8</sup>, C.-J. Yen<sup>9</sup>, B.-H. Kim<sup>10</sup>, D. Zhou<sup>11</sup>, J. Straub<sup>12</sup>, C. Zhao<sup>13</sup>, S. Qin<sup>14</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Zhongshan Hospital, Fudan University, Shanghai, CN, <sup>3</sup>Department of Internal Medicine, Seoul, KR, <sup>4</sup>Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN, <sup>5</sup>Kaohsiung Chang Gung Memorial Hospital, Taiwan, CN, <sup>6</sup>Yonsei University College of Medicine Department of Internal Medicine, Seoul, KR, <sup>7</sup>National Cancer Center, Goyang-si, KR, <sup>8</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>9</sup>National Cheng Kung University Hospital, Taiwan, CN, <sup>10</sup>Kyung Hee University Hospital, Seoul, KR, <sup>11</sup>Merck Serono Pharmaceutical R&D Co, Beijing, CN, <sup>12</sup>Merck KGaA, Darmstadt, DE, <sup>13</sup>EMD Serono Inc, Billerica, US, <sup>14</sup>81 Hospital, Nanjing, CN

16:25 - 16:25 **622PD - Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase 3 studies (REACH-2 and REACH)**

A. Zhu<sup>1</sup>, R. Finn<sup>2</sup>, P. Galle<sup>3</sup>, J.M. Llovet<sup>4</sup>, J.F. Blanc<sup>5</sup>, T. Okusaka<sup>6</sup>, I. Chau<sup>7</sup>, D. Cella<sup>8</sup>, A. Girvan<sup>9</sup>, J. Gable<sup>9</sup>, L. Bowman<sup>9</sup>, Y. Hsu<sup>10</sup>, P. Abada<sup>11</sup>, M. Kudo<sup>12</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, US, <sup>2</sup>UCLA - School of Medicine, Los Angeles, US, <sup>3</sup>Universitätsmedizin Mainz, Mainz, DE, <sup>4</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>5</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>6</sup>National Cancer Center Hospital, Tokyo, JP, <sup>7</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>8</sup>Northwestern University, Chicago, US, <sup>9</sup>Eli Lilly and Company, Indianapolis, US, <sup>10</sup>Eli Lilly and Company, Basking Ridge, US, <sup>11</sup>Eli Lilly, Indianapolis, US, <sup>12</sup>Kindai University Faculty of Medicine, Osaka, JP

16:25 - 16:35 **Invited Discussant 621PD, 622PD and One LBA TBC**

A.-L. Cheng, National Taiwan University Hospital, Taipei, TW

16:35 - 16:45 **Q&A led by Discussant**

16:45 - 16:45 **LBA28 - Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions**

M. Javle<sup>1</sup>, R.K. Kelley<sup>2</sup>, S. Roychowdhury<sup>3</sup>, K.H. Weiss<sup>4</sup>, G. Abou-Alfa<sup>5</sup>, T. Macarulla<sup>6</sup>, S. Sadeghi<sup>7</sup>, D. Waldschmidt<sup>8</sup>, A. Zhu<sup>9</sup>, L. Goyal<sup>9</sup>, M. Borad<sup>10</sup>, W.P. Yong<sup>11</sup>, I. Borbath<sup>12</sup>, A. El-Khoueiry<sup>13</sup>, P. Philip<sup>14</sup>, S. Moran<sup>15</sup>, Y. Ye<sup>15</sup>, M. Ising<sup>16</sup>, N. Lewis<sup>17</sup>, T. Bekaii-Saab<sup>18</sup>,  
<sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>University of California San Francisco, San Francisco, US, <sup>3</sup>Ohio State Comprehensive Cancer Center/James Cancer Hospital, Columbus, US, <sup>4</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York City, US, <sup>6</sup>Hospital Vall D Hebron, Barcelona, ES, <sup>7</sup>University of California at Los Angeles, Santa Monica, US, <sup>8</sup>Klinikum der Universitaet zu Köln, Köln, DE, <sup>9</sup>Massachusetts General Hospital, Boston, US, <sup>10</sup>Mayo Clinic Arizona, Scottsdale, US, <sup>11</sup>National University Cancer Institute Singapore, Singapore, SG, <sup>12</sup>Cliniques universitaires St Luc Bruxelles, Bruxelles, BE, <sup>13</sup>USC/Kenneth Norris Comprehensive Cancer Center, Los Angeles, US, <sup>14</sup>Karmanos Cancer Institute, Detroit, US, <sup>15</sup>QED Therapeutics, San Francisco, US, <sup>16</sup>Novartis, Florham Park, US, <sup>17</sup>Novartis Pharmaceutical Corporation, East Hanover, US, <sup>18</sup>Mayo Clinic, Scottsdale, US

16:45 - 16:45 **623PD - The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced Biliary Tract Cancer.**

C. Morizane<sup>1</sup>, Y. Komatsu<sup>2</sup>, H. Takahashi<sup>3</sup>, M. Ueno<sup>4</sup>, J. Furuse<sup>5</sup>, T. Kudo<sup>6</sup>, S. Itoh<sup>7</sup>, S. Shimizu<sup>8</sup>, K. Nakamura<sup>9</sup>, K. Kamata<sup>10</sup>, K. Ohtsubo<sup>11</sup>, T. Mizukami<sup>12</sup>, Y. Kagawa<sup>13</sup>, S. Nomura<sup>3</sup>, T. Kuwata<sup>3</sup>, S. Fujii<sup>14</sup>, W. Okamoto<sup>3</sup>, K. Shitara<sup>3</sup>, A. Ohtsu<sup>3</sup>, T. Yoshino<sup>3</sup>,  
<sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Hokaido University Cancer Center, Sapporo, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>5</sup>Kyorin University, Tokyo, JP, <sup>6</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>7</sup>Kyushu University Hospital, Fukuoka, JP, <sup>8</sup>Saitama Cancer Center, Kitaadachigun, JP, <sup>9</sup>Chiba Cancer Center, Chiba, JP, <sup>10</sup>Kindai University Faculty of Medicine, ina, JP, <sup>11</sup>Kanazawa University, Kanazawa, JP, <sup>12</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>13</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>14</sup>National Cancer Center, Kashiwa, JP

16:45 - 16:45 **624PD - Preliminary Results of a Ph2a Study to Evaluate the Clinical Efficacy and Safety of Erdafitinib in Asian Patients with Biomarker-Selected Advanced Cholangiocarcinoma (CCA)**

Y.-Y. Chen<sup>1</sup>, J.O. Park<sup>2</sup>, W.-C. Su<sup>3</sup>, D.-Y. Oh<sup>4</sup>, K.-P. Kim<sup>5</sup>, Y.-H. Feng<sup>6</sup>, L. Shen<sup>7</sup>, H. Liao<sup>8</sup>, J. Nie<sup>9</sup>, M. Qing<sup>8</sup>, J. Li<sup>10</sup>, P. De Porre<sup>11</sup>,  
<sup>1</sup>Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, TW, <sup>2</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>3</sup>Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, TW, <sup>4</sup>Seoul National University Hospital, Seoul, KR, <sup>5</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>6</sup>Chi-Mei Medical Center, Tainan, TW, <sup>7</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>8</sup>Janssen China R & D Center, Shanghai, CN, <sup>9</sup>Janssen China R & D Cente, Beijing, CN, <sup>10</sup>Janssen China R & D Cente, Shanghai, CN, <sup>11</sup>Janssen R&D BE, Beerse, BE

16:45 - 16:55 **Invited Discussant LBA28, 623PD and 624PD**

I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

16:55 - 17:05 **Q&A led by Discussant**



- 17:05 - 17:05 **LBA29 - CARRIE: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Istimab (MM-141) plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer**
- A. Ko<sup>1</sup>, A. Cubillo<sup>2</sup>, M. Kundranda<sup>3</sup>, S. Zafar<sup>4</sup>, E. Meiri<sup>5</sup>, J. Bendell<sup>6</sup>, H. Alguel<sup>7</sup>, F. Rivera Herrero<sup>8</sup>, E. Ahn<sup>9</sup>, D. Watkins<sup>10</sup>, U. Pelzer<sup>11</sup>, V. Charu<sup>12</sup>, W. Downing<sup>13</sup>, B. Wang<sup>13</sup>, G. Kuesters<sup>13</sup>, J. Pipas<sup>13</sup>, S. Santillana<sup>14</sup>, V. Askoxylakis<sup>13</sup>, <sup>11</sup>University of California San Francisco Cancer Center, San Francisco, US, <sup>2</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>3</sup>Banner MD Anderson Cancer Center, Gilbert, US, <sup>4</sup>Florida Cancer Specialists, Fort Myers, US, <sup>5</sup>Southeastern Regional Medical Center, Newnan, US, <sup>6</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>7</sup>Rechts der Isar Hospital, Munich, DE, <sup>8</sup>Hospital Universitario Marques de Valdecilla, Santander, ES, <sup>9</sup>Midwestern Regional Medical Center, Zion, US, <sup>10</sup>Royal Marsden Hospital, Sutton, GB, <sup>11</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>12</sup>Pacific Cancer Medical Center, Anaheim, US, <sup>13</sup>Merrimack Pharmaceuticals, Inc., Cambridge, US, <sup>14</sup>Merrimack Pharmaceuticals, Cambridge, US
- 17:05 - 17:05 **625PD - Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase 2 KEYNOTE-158 study**
- M. Ueno<sup>1</sup>, H.C. Chung<sup>2</sup>, A. Nagrial<sup>3</sup>, A. Marabelle<sup>4</sup>, R. Kelley<sup>5</sup>, L. Xu<sup>6</sup>, J. Mahoney<sup>6</sup>, S. Pruitt<sup>6</sup>, D.-Y. Oh<sup>7</sup>, <sup>1</sup>Hepatobiliary and Pancreatic Oncology Division, Kanagawa Cancer Center, Yokohama, JP, <sup>2</sup>Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>Blacktown University of Sydney, Blacktown, AU, <sup>4</sup>Gustave Roussy, Villejuif, FR, <sup>5</sup>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, US, <sup>6</sup>Merck & Co., Inc., Kenilworth, US, <sup>7</sup>Seoul National University Hospital, Seoul, KR
- 17:05 - 17:05 **626PD - Randomized, Phase III Trial Comparing Adjuvant Gemcitabine (Gem) versus Gem plus Chemoradiation (CCRT) in Curatively Resected Pancreatic Ductal Adenocarcinoma (PDAC) - A Taiwan Cooperative Oncology Group Study**
- H.-J. Chang<sup>1</sup>, Y.-F. Chiu<sup>2</sup>, J.-S. Chen<sup>3</sup>, C.-P. Li<sup>4</sup>, C.-L. Ho<sup>5</sup>, Y.-M. Shyr<sup>4</sup>, W.-C. Chiou<sup>6</sup>, C.-N. Yeh<sup>6</sup>, R.-K. Hsieh<sup>7</sup>, Y.-L. Lin<sup>8</sup>, Y.-W. Tien<sup>8</sup>, T.-L. Hwang<sup>6</sup>, Y.-S. Shan<sup>9</sup>, L.-T. Chen<sup>1</sup>, <sup>1</sup>National Health Research Institutes, Tainan, TW, <sup>2</sup>National Health Research Institutes, Miaoli, TW, <sup>3</sup>Chang Gung Memorial Hospital, Taoyuan, TW, <sup>4</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>5</sup>Tri-service general hospital, Taipei, TW, <sup>6</sup>Chung Gung University, Tao Yuan, TW, <sup>7</sup>Mackay Memorial Hospital, Taipei, TW, <sup>8</sup>National Taiwan University Hospital, Taipei, TW, <sup>9</sup>National Cheng Kung University, Tainan, TW
- 17:05 - 17:15 **Invited Discussant LBA29, 625PD and 626PD**
- E. O'Reilly, Memorial Sloan-Kettering Cancer Center, New York, US
- 17:15 - 17:25 **Q&A led by Discussant**



**16:00 - 17:30**    **Type: Special Symposium**    **Hall A1 - Room 17**  
**Title: Targeting brain metastases**  
 Chair(s): Sheila Singh, CA; Dario Marchetti, US

16:00 - 16:05    **Introduction**

D. Marchetti, Houston Methodist Cancer Center, Houston, US

16:05 - 16:25    **Genetic heterogeneity in brain metastases: Therapeutic implications**

P. Brastianos, Massachusetts General Hospital, Boston, US

16:25 - 16:45    **Therapeutic targeting of the pre-metastatic stage in human lung-to-brain metastasis**

S. Singh, McMaster Stem Cell and Cancer Research Institute, Hamilton, CA

16:45 - 17:05    **CTCs: Advancing tools to combat brain metastasis**

D. Marchetti, Houston Methodist Cancer Center, Houston, US

17:05 - 17:25    **Lessons from Glioblastoma: DNA repair as a therapeutic target in GBM**

P. Hamerlik, The Danish Cancer Society, Copenhagen, DK

17:25 - 17:30    **Conclusions and perspectives**

S. Singh, McMaster Stem Cell and Cancer Research Institute, Hamilton, CA

**16:00 - 17:40**    **Type: Proffered Paper session**    **Hall A2 - Room 18**  
**Title: Proffered paper session - NSCLC, metastatic**  
 Chair(s): Tony S.K. Mok, HK; Noemi Reguart, ES

16:00 - 16:15    **LBA50 - Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study**

S. Ramalingam<sup>1</sup>, Y. Cheng<sup>2</sup>, C. Zhou<sup>3</sup>, Y. Ohe<sup>4</sup>, F. Imamura<sup>5</sup>, B.C. Cho<sup>6</sup>, M.-C. Lin<sup>7</sup>, M. Majem<sup>8</sup>, R. Shah<sup>9</sup>, Y. Rukazenkova<sup>10</sup>, A. Todd<sup>11</sup>, A. Markovets<sup>12</sup>, J.C. Barrett<sup>12</sup>, J. Chmielecki<sup>12</sup>, J. Gray<sup>13</sup>, <sup>1</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>2</sup>Jilin Province Tumor Hospital, Changchun, CN, <sup>3</sup>Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, <sup>4</sup>National Cancer Center Hospital, Tokyo, JP, <sup>5</sup>Osaka International Cancer Institution, Osaka, JP, <sup>6</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>7</sup>Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung city, TW, <sup>8</sup>Hospital De La Santa Creu I Sant Pau, Barcelona, ES, <sup>9</sup>Maidstone and Tunbridge Wells NHS Trust, Maidstone, GB, <sup>10</sup>Astrazeneca, Macclesfield, GB, <sup>11</sup>AstraZeneca, Cambridge, GB, <sup>12</sup>AstraZeneca, Waltham, US, <sup>13</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US

16:15 - 16:30    **LBA51 - Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study**

V. Papadimitrakopoulou<sup>1</sup>, Y.-L. Wu<sup>2</sup>, J.-Y. Han<sup>3</sup>, M.-J. Ahn<sup>4</sup>, S. Ramalingam<sup>5</sup>, T. John<sup>6</sup>, I. Okamoto<sup>7</sup>, J.C.-H. Yang<sup>8</sup>, K. Bulusu<sup>9</sup>, G. Laus<sup>10</sup>, B. Collins<sup>9</sup>, J.C. Barrett<sup>11</sup>, J.

Chmielecki<sup>11</sup>, T. Mok<sup>12</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>Guangdong General Hospital, Guangzhou, CN, <sup>3</sup>National Cancer Center, Goyang, KR, <sup>4</sup>Samsung Medical Center, Seoul, KR, <sup>5</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>6</sup>Olivia Newton John Cancer and Wellness Centre, Heidelberg, AU, <sup>7</sup>Kinki University School of Medicine, Osaka, JP, <sup>8</sup>National Taiwan University Hospital, Taipei, TW, <sup>9</sup>AstraZeneca, Cambridge, GB, <sup>10</sup>AstraZeneca, Melbourne, GB, <sup>11</sup>AstraZeneca, Waltham, US, <sup>12</sup>The Chinese University of Hong Kong, Hong Kong, HK

16:30 - 16:45 **Invited Discussant LBA50 and LBA51**

C. Rudin, Memorial Sloan-Kettering Cancer Center, New York, US

16:45 - 17:00 **LBA52 - Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)**

J. Wolf<sup>1</sup>, T. Seto<sup>2</sup>, J.-Y. Han<sup>3</sup>, N. Reguart<sup>4</sup>, E. Garon<sup>5</sup>, H. Groen<sup>6</sup>, D.S.W. Tan<sup>7</sup>, T. Hida<sup>8</sup>, M. De Jonge<sup>9</sup>, S. Orlov<sup>10</sup>, E. Smit<sup>11</sup>, P.-J. Souquet<sup>12</sup>, J. Vansteenkiste<sup>13</sup>, M. Giovannini<sup>14</sup>, S. Le Mouhaer<sup>15</sup>, A. Robeva<sup>16</sup>, M. Waldron-Lynch<sup>17</sup>, R. Heist<sup>18</sup>, <sup>1</sup>University Hospital Cologne, Cologne, DE, <sup>2</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>3</sup>National Cancer Center, Goyang, KR, <sup>4</sup>University Hospital Clinic of Barcelona, Barcelona, ES, <sup>5</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>6</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>7</sup>National Cancer Center Singapore, Singapore, SG, <sup>8</sup>Department of Thoracic Oncology, Aichi, JP, <sup>9</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>10</sup>Pavlov Medical University, St.Petersburg, RU, <sup>11</sup>VU University Medical Centre, Amsterdam, NL, <sup>12</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>13</sup>University Hospitals Leuven, Leuven, BE, <sup>14</sup>Novartis, East Hanover, US, <sup>15</sup>Novartis Pharma S.A.S, Rueil-Malmaison, FR, <sup>16</sup>Novartis Pharmaceuticals Corporation, East Hanover, GB, <sup>17</sup>Roche Products Limited - United Kingdom, Welwyn Garden City, GB, <sup>18</sup>Massachusetts General Hospital, Boston, US

17:00 - 17:12 **Invited Discussant LBA 52**

J.C.-H. Yang, National Taiwan University Hospital, Taipei, TW

17:12 - 17:27 **13770 - Phase 2 study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)**

Y.-L. Wu<sup>1</sup>, J. Zhou<sup>2</sup>, S. Lu<sup>3</sup>, Y. Zhang<sup>4</sup>, J. Zhao<sup>5</sup>, H. Pan<sup>6</sup>, Y.-M. Chen<sup>7</sup>, C.-F. Chian<sup>8</sup>, R. Bruns<sup>9</sup>, A. Johne<sup>9</sup>, J. Scheele<sup>9</sup>, Y. Cheng<sup>10</sup>, <sup>1</sup>Guangdong General Hospital, Guangzhou, CN, <sup>2</sup>The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, <sup>3</sup>Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>4</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>5</sup>Beijing Cancer Hospital, Beijing, CN, <sup>6</sup>Sir Run Run Shaw Hospital, Zhejiang Medical University, Zhejiang Sheng, CN, <sup>7</sup>Taipei Veterans General Hospital, Taipei, TW, <sup>8</sup>Tri-Service General Hospital, Taipei, TW, <sup>9</sup>Merck KGaA, Darmstadt, DE, <sup>10</sup>Jilin Province Cancer Hospital, Changchun, CN

17:27 - 17:39 **Invited Discussant 13770**

E. Smit, VU University Medical Centre, Amsterdam, NL

**16:00 - 17:30** **Type: Special Symposium** **ICM - Room 14b**  
**Title: Toxicities from specific agents**  
 Chair(s): Inge-Marie Svane, DK; Fiona Thistlethwaite, GB

16:00 - 16:05 **Introduction**  
I.-M. Svane, Herlev Hospital, Herlev, DK

16:05 - 16:25 **Acute and chronic toxicities**  
P. Ascierto, Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

16:25 - 16:45 **TILS therapy**  
I.-M. Svane, Herlev Hospital, Herlev, DK

16:45 - 17:05 **TCR and CAR in haematological malignancies**  
J. Svoboda, University of Pennsylvania, Philadelphia, US

17:05 - 17:25 **TCR and CAR in solid tumours**  
F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

17:25 - 17:30 **Conclusions and perspectives**  
F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB

**16:00 - 17:30** **Type: Proffered Paper session** **ICM - Room 13**  
**Title: Proffered paper session - Breast cancer, early stage**  
 Chair(s): Carlos Caldas, GB; Suzette Delaloge, FR

16:00 - 16:12 **1840 - Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-Year analysis in phase III NEOS trial**  
H. Iwata<sup>1</sup>, N. Masuda<sup>2</sup>, Y. Yamamoto<sup>3</sup>, T. Fujisawa<sup>4</sup>, T. Toyama<sup>5</sup>, N. Taira<sup>6</sup>, M. Kashiwaba<sup>7</sup>, S. Ohtani<sup>8</sup>, T. Sakai<sup>9</sup>, Y. Hasegawa<sup>10</sup>, R. Nakamura<sup>11</sup>, H. Akabane<sup>12</sup>, Y. Shibahara<sup>13</sup>, H. Sasano<sup>13</sup>, T. Yamaguchi<sup>13</sup>, Y. Ohashi<sup>14</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>NHO Osaka National Hospital, Osaka, JP, <sup>3</sup>Kumamoto University, Kumamoto, JP, <sup>4</sup>Gunma Prefectural Cancer Center, Gunma, JP, <sup>5</sup>Nagoya City University, Nagoya, JP, <sup>6</sup>Okayama university hospital, Okayama, JP, <sup>7</sup>Iwate Medical University School of Medicine, Morioka, JP, <sup>8</sup>Hiroshima City Hospital, Hiroshima, JP, <sup>9</sup>Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, <sup>10</sup>Hirosaki Municipal Hospital, Hirosaki, JP, <sup>11</sup>Chiba Cancer Center Hospital, Chiba, JP, <sup>12</sup>Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital, Hokkaido, JP, <sup>13</sup>Tohoku University Graduate School of Medicine, Sendai, JP, <sup>14</sup>Chuo University, Tokyo, JP

16:12 - 16:24 **1850\_PR - Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort**  
B. Pistilli<sup>1</sup>, A. Paci<sup>2</sup>, S. Michiels<sup>1</sup>, A. Ferreira<sup>3</sup>, V. Poinignon<sup>2</sup>, P. Cottu<sup>4</sup>, F. Lerebours<sup>5</sup>, C.

Coutant<sup>6</sup>, A. Lesur<sup>7</sup>, O. Tredan<sup>8</sup>, P. Soulie<sup>9</sup>, L. Vanlemmens<sup>10</sup>, C. Jouannaud<sup>11</sup>, C. Levy<sup>12</sup>, S. Everhard<sup>13</sup>, P. Arveux<sup>6</sup>, A. Partridge<sup>14</sup>, S. Delaloge<sup>1</sup>, F. André<sup>15</sup>, I. Vaz-Luis<sup>16</sup>,  
<sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>GUSTAVE ROUSSY, Villejuif, FR, <sup>3</sup>University of Lisbon, lisbon, PT, <sup>4</sup>Institut Curie, Paris, FR, <sup>5</sup>Institut Curie Saint Cloud, Saint Cloud, FR, <sup>6</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>7</sup>Institut de cancérologie de Lorraine, Nancy, FR, <sup>8</sup>Centre Léon Bérard, Lyon, FR, <sup>9</sup>Centre Paul Papin, Angers, FR, <sup>10</sup>Centre Oscar Lambret, Lille, FR, <sup>11</sup>Institut Jean Godinot, Reims, FR, <sup>12</sup>Centre Francois Baclesse, Caen, FR, <sup>13</sup>UNICANCER, Paris, FR, <sup>14</sup>Dana-Farber Cancer Institute, Boston, US, <sup>15</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>16</sup>Institut Gustave Roussy, Villejuif, FR

16:24 - 16:39 **Invited Discussant 1840 and 1850**

H. Earl, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

16:39 - 16:51 **LBA12\_PR - PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results**

C. Hulme<sup>1</sup>, P. Hall<sup>2</sup>, B. Shinkins<sup>1</sup>, F. Chehadah<sup>1</sup>, C. McCabe<sup>3</sup>, L. Hiller<sup>4</sup>, J. Dunn<sup>5</sup>, H. Earl<sup>6</sup>, <sup>1</sup>University of Leeds-Institute of Health Sciences, Leeds, GB, <sup>2</sup>University of Edinburgh, Edinburgh, GB, <sup>3</sup>University of Alberta, Edmonton, CA, <sup>4</sup>University of Warwick, Warwick, GB, <sup>5</sup>University of Warwick, Coventry, GB, <sup>6</sup>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

16:51 - 17:03 **1860 - Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized ShortHER trial.**

M.V. Dieci<sup>1</sup>, P.F. Conte<sup>1</sup>, G. Bisagni<sup>2</sup>, A. Brandes<sup>3</sup>, A. Frassoldati<sup>4</sup>, L. Cavanna<sup>5</sup>, A. Musolino<sup>6</sup>, F. Giotta<sup>7</sup>, A. Rimanti<sup>6</sup>, O. Garrone<sup>8</sup>, E. Bertone<sup>9</sup>, K. Cagossi<sup>10</sup>, S. Sarti<sup>11</sup>, A. Ferro<sup>12</sup>, C. Omarini<sup>13</sup>, A. Maiorana<sup>14</sup>, E. Orvieto<sup>15</sup>, M. Sanders<sup>16</sup>, R. D'Amico<sup>17</sup>, V. Guarneri<sup>1</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>3</sup>Ospedale Bellaria, Bologna, IT, <sup>4</sup>Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, <sup>5</sup>Azienda Ospedaliera Piacenza, Piacenza, IT, <sup>6</sup>Azienda Ospedaliera di Parma, Parma, IT, <sup>7</sup>Istituto Oncologico Bari, Bari, IT, <sup>8</sup>Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, <sup>9</sup>S. Anna Hospital, Torino, IT, <sup>10</sup>Ramazzini Hospital, Carpi, IT, <sup>11</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>12</sup>Ospedale Santa Chiara, Trento, IT, <sup>13</sup>Università degli studi di Modena e Reggio Emilia, Modena, IT, <sup>14</sup>University of Modena and Reggio Emilia, Modena, IT, <sup>15</sup>Ulss 5 Polesana, Rovigo, IT, <sup>16</sup>Vanderbilt University Medical Center, Nashville, US, <sup>17</sup>University Hospital of Modena and Reggio Emilia, Modena, IT

17:03 - 17:15 **1870 - High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with 4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study**

T. Steenbruggen<sup>1</sup>, L. Steggink<sup>2</sup>, C. Seynaeve<sup>3</sup>, J. Van Der Hoeven<sup>4</sup>, M. Hooning<sup>5</sup>, A. Jager<sup>3</sup>, I. Konings<sup>6</sup>, J. Kroep<sup>4</sup>, W. Smit<sup>7</sup>, V. Tjan-Heijnen<sup>8</sup>, E. Van Der Wall<sup>9</sup>, A. Bins<sup>10</sup>, S. Linn<sup>11</sup>, M. Schaapveld<sup>1</sup>, F. Van Leeuwen<sup>11</sup>, C.P. Schroder<sup>12</sup>, H. Van Tinteren<sup>1</sup>, E.G.E. De Vries<sup>2</sup>, G. Sonke<sup>13</sup>, J. Gietema<sup>2</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>3</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>4</sup>Leiden



University Medical Center (LUMC), Leiden, NL, <sup>5</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>6</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>7</sup>Medisch Spectrum Twente (MST), Enschede, NL, <sup>8</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>9</sup>UMC - University Medical Center Utrecht, Utrecht, NL, <sup>10</sup>Academic Medical Center (AMC), Amsterdam, NL, <sup>11</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>12</sup>University Medical Center Groningen, Groningen, NL, <sup>13</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

17:15 - 17:30 **Invited Discussant one LBA TBC, 1860 and 1870**  
J. Cortes Castan, Vall d'Hebron University Hospital, Barcelona, ES

**16:00 - 17:30** **Type: Educational session** **Hall A1 - Room 15**  
**Title: Exosomes and other EVs, why are they important?**  
Chair(s): Clotilde Théry, FR

16:00 - 16:25 **Therapeutic potential of exosomes and/or EVs in cancer**  
C. Théry, Institut Curie, Paris, FR

16:25 - 16:50 **Tumour educated platelets as cancer biomarkers**  
T. Würdinger, Vrije University Medical Centre (VUMC), Amsterdam, NL

16:50 - 17:15 **Extracellular Vesicles/Exosomes in Cancer**  
R. Kalluri, The University of Texas MD Anderson Cancer Center, Houston, US

17:15 - 17:30 **Discussion**

**16:00 - 17:30**    **Type: Joint Symposium**    **Hall A1 - Room 16**  
**Title: ESMO-ASCO Joint Symposium: Precision medicine and accessibility**  
 Chair(s): Josep Tabernero, ES; Monica Bertagnolli, US

16:00 - 16:05    **Introduction**  
J. Tabernero, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES

16:05 - 16:25    **Basket studies and rapid development in precision oncology**  
A. Drilon, Memorial Sloan-Kettering Cancer Center, New York, US

16:25 - 16:45    **The European regulator's point of view**  
F. Pignatti, European Medicines Agency (EMA), London, GB

16:45 - 17:05    **The potential role of conditional approvals**  
P.G. Casali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

17:05 - 17:25    **The US regulator's point of view**  
G. Blumenthal, US Food and Drug Administration, Silver Spring, US

17:25 - 17:30    **Conclusions**  
M. Bertagnolli, Brigham and Women's Hospital, Boston, US

**16:00 - 17:30**    **Type: Special session**    **Hall B3 - Room 23**  
**Title: Germline BRCA mutation: Ripe for precision oncology?**  
 Chair(s): Susana Banerjee, GB; Elena Castro Marcos, ES

16:00 - 16:20    **Breast cancer**  
S. Paluch-Shimon, Shaare Zedek M.C, Jerusalem, IL

16:20 - 16:40    **Ovarian cancer**  
A. George, Royal Marsden Hospital NHS Foundation Trust, London, GB

16:40 - 17:00    **Prostate cancer**  
E. Castro Marcos, CNIO- Spanish National Cancer Center, Madrid, ES

17:00 - 17:20    **Pancreatic cancer**  
T. Golan, Chaim Sheba Medical Center, Ramat Gan, IL

17:20 - 17:30    **Discussion**

**16:00 - 17:30**    **Type: Proffered Paper session**    **Hall B3 - Room 20**

**Title: Proffered Paper session - CNS tumours**

Chair(s): Matthias Preusser, AT; Carmen Balana, ES

- 16:00 - 16:12 **3710 - Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: a randomised, open-label trial**  
E. Le Rhun<sup>1</sup>, A. Mailliez<sup>2</sup>, J. Wallet<sup>2</sup>, I. Rodrigues<sup>2</sup>, T. Boulanger<sup>2</sup>, I. Desmoulins<sup>3</sup>, J. Barriere<sup>4</sup>, M. Fabbro<sup>5</sup>, S. Taillibert<sup>6</sup>, C. Andre<sup>2</sup>, M.C. Le Deley<sup>2</sup>, M. Weller<sup>7</sup>, J. Bonnetterre<sup>8</sup>, <sup>1</sup>Roger Salengro Hospital, Lille, FR, <sup>2</sup>Oscar Lambret Center, Lille, FR, <sup>3</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>4</sup>Centre Antoine Lacassagne, Nice, FR, <sup>5</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>6</sup>Pitié-Salpêtrière Hospital, Paris, FR, <sup>7</sup>University Hospital and University of Zurich, Zurich, CH, <sup>8</sup>Centre Oscar Lambret, Lille, FR
- 16:12 - 16:24 **3720 - Mutational and inflammatory microenvironment characteristics in primary and matched local recurrent non-small cell lung cancer brain metastases**  
A.S. Berghoff<sup>1</sup>, B. Erguener<sup>2</sup>, M.R. Schuster<sup>2</sup>, U. Rajky<sup>3</sup>, G. Ricken<sup>3</sup>, J. Frischer<sup>1</sup>, B. Gatterbauer<sup>1</sup>, C. Marosi<sup>1</sup>, K. Dieckmann<sup>1</sup>, G. Widhalm<sup>1</sup>, C. Bock<sup>2</sup>, M. Preusser<sup>4</sup>, <sup>1</sup>Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, <sup>2</sup>CeMM Research Center for Molecular Medicine, Vienna, AT, <sup>3</sup>Medical University of Vienna, Vienna, AT, <sup>4</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT
- 16:24 - 16:39 **Invited Discussant 3710 and 3720**  
J. Seoane, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 16:39 - 16:51 **3730 - Results of Phase 2 Trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)**  
D. Peereboom<sup>1</sup>, L.B. Nabors<sup>2</sup>, P. Kumthekar<sup>3</sup>, M. Badruddoja<sup>4</sup>, K. Fink<sup>5</sup>, F. Lieberman<sup>6</sup>, S. Phuphanich<sup>7</sup>, E. Dunbar<sup>8</sup>, T. Walbert<sup>9</sup>, D. Schiff<sup>10</sup>, D. Tran<sup>11</sup>, L. Ashby<sup>12</sup>, N. Butowski<sup>13</sup>, F. Iwamoto<sup>14</sup>, R. Lindsay<sup>15</sup>, J. Bullington<sup>15</sup>, M. Schulder<sup>16</sup>, J. Sherman<sup>17</sup>, C. Brooks<sup>18</sup>, D. Reardon<sup>19</sup>, <sup>1</sup>Cleveland Clinic Foundation, Cleveland, US, <sup>2</sup>University of Alabama Comprehensive Cancer Center, Birmingham, US, <sup>3</sup>The Ken & Roth Davee, Chicago, US, <sup>4</sup>Center for Neurosciences, Tucson, US, <sup>5</sup>Baylor Scott&White Neuro-Oncology Associates, Dallas, US, <sup>6</sup>University of Pittsburgh, Pittsburgh, US, <sup>7</sup>Barrow Neurological Institute, Phoenix, US, <sup>8</sup>Piedmont Helathcare, Atlanta, US, <sup>9</sup>Henry Ford Health System, Detroit, US, <sup>10</sup>University of Virginia School of Medicine, Charlottesville, US, <sup>11</sup>University of Florida, Gainesville, US, <sup>12</sup>St. Joseph's Hospital and Medical Center, Phoenix, US, <sup>13</sup>UCSF, San Francisco, US, <sup>14</sup>Columbia University Medical Center, New York, US, <sup>15</sup>Stemline Therapeutics, New York, US, <sup>16</sup>North Shore University Hospital, Manhasset, US, <sup>17</sup>George Washington University, Washignton DC, US, <sup>18</sup>Memorial Sloan Kettering Memorial Hospital, New York, US, <sup>19</sup>Dana-Farber Cancer Institute, Boston, US
- 16:51 - 17:03 **3740 - Mismatch repair deficiency (MMRd) in glioma patients (PTS): frequency and correlation with clinical, histological and molecular characteristics**  
G. Lombardi<sup>1</sup>, M. Caccese<sup>1</sup>, M. Simonelli<sup>2</sup>, M. Fassan<sup>3</sup>, P. Persico<sup>4</sup>, E. Lorenzi<sup>4</sup>, R. Bertorelle<sup>5</sup>, M.P. Gardiman<sup>6</sup>, L. Bellu<sup>1</sup>, A. Pambuku<sup>1</sup>, A. Santoro<sup>2</sup>, V. Zagone<sup>7</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>Istituto Clinico Humanitas, Rozzano, IT,

<sup>3</sup>University of Padova, Padova, IT, <sup>4</sup>Humanitas Clinical and Research Hospital, Rozzano, IT, <sup>5</sup>Veneto Institute of Oncology, IOV - IRCCS, Padova, IT, <sup>6</sup>University-Hospital of Padua, Padova, IT, <sup>7</sup>Istituto Oncologico Veneto-IRCCS, padova, IT

17:03 - 17:15 **3750 - radiological phenotyping of idh mutation status in gliomas using dynamic susceptibility contrast perfusion-weighted mri.**

D. Roettger<sup>1</sup>, E. Sanverdi<sup>2</sup>, C. Sudre<sup>2</sup>, S. Brandner<sup>2</sup>, V. Katsaros<sup>2</sup>, S. Bisdas<sup>2</sup>, <sup>1</sup>Image Analysis Ltd, London, GB, <sup>2</sup>University College London, London, GB

17:15 - 17:30 **Invited Discussant 3730, 3740 and 3750**

M. Van Den Bent, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

16:00 - 17:30	<b>Type: Special session</b> <b>Title: Best integration of supportive and palliative care in the continuum of care</b> Chair(s): Stein Kaasa, NO; Karin Jordan, DE	<b>Hall B3 - Room 22</b>
---------------	--	--------------------------

16:00 - 16:05 **Introduction**

K. Jordan, University of Heidelberg, Heidelberg, DE

16:05 - 16:25 **Highlights of the Lancet Oncology commission paper: Integration of oncology and palliative care**

S. Kaasa, Oslo University Hospital, Oslo, NO

16:25 - 16:45 **Insights of the ESMO position paper on supportive and palliative care**

K. Jordan, University of Heidelberg, Heidelberg, DE

16:45 - 17:05 **Palliative care in main stream oncology, how and how much: A Canadian perspective**

C. Zimmermann, Princess Margaret Cancer Center, Toronto, CA

17:05 - 17:25 **The place and content of Supportive and palliative care in a comprehensive cancer center in Europe**

A. Caraceni, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

17:25 - 17:30 **Conclusions**

S. Kaasa, Oslo University Hospital, Oslo, NO



**16:00 - 17:30**    **Type: Patient Advocacy Track**    **ICM - Room 5**  
**Title: Immune therapies going adjuvant: Benefits versus risks**  
 Chair(s): John Haanen, NL; Bettina Ryll, SE

16:00 - 16:20    **Introduction**  
B. Ryll, Melanoma Patient network Europe, Uppsala, SE

16:20 - 16:40    **How long should we treat patients?**  
J. Haanen, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:40 - 17:00    **Side effects**  
J. Larkin, Royal Marsden Hospital NHS Foundation Trust, London, GB

17:00 - 17:30    **Q&A**

**17:30 - 18:30**    **Type: Young Oncologist session**    **ICM - Foyer - Ground floor**  
**Title: YO Vesalius: Work / life balance at early stages of young oncologist's career**  
 Chair(s): Guillem Argiles, ES

17:30 - 17:35    **Introduction**  
G. Argiles Martinez, Vall d'Hebron University Hospital, Barcelona, ES

17:35 - 18:30    **Discussion**  
M. Piccart<sup>1</sup>, A. Cervantes<sup>2</sup>, S. Peters<sup>3</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>3</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

**17:45 - 19:15**    **Type: Patient Advocacy Track**    **ICM - Room 5**  
**Title: Life after cancer**  
 Chair(s): Isabelle Lebrocqy, NL; Tanja Spanic, SI

17:45 - 18:00    **When is a cancer patient cured?**  
L. Dal Maso, Centro di Riferimento Oncologico - CRO, Aviano, IT

18:00 - 18:15    **What is Europe doing in return to work?**  
M. Ludwig, Deloitte Consulting (Europe) B.V., Amsterdam, NL

18:15 - 18:30    **The right to be forgotten**  
A. Dumas, Institut Gustave Roussy, Villejuif, FR

18:30 - 18:45    **Advocating for survivors' rights**  
I. Lebrocqy, OPUCE, The Hague, NL

18:45 - 19:15    **Q&A**

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **Hall A1 - Room 17**  
**Title: Industry satellite symposium 1**

18:00 - 20:00    **Presentation**  
I. Melero<sup>1</sup>, A. Stein<sup>2</sup>, R. Finn<sup>3</sup>, <sup>1</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>2</sup>UKE  
 Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>3</sup>UCLA - School of  
 Medicine, Los Angeles, US

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 1**  
**Title: Industry satellite symposium 2**

18:00 - 20:00    **Presentation**  
A. Vogel<sup>1</sup>, A. Hollebecque<sup>2</sup>, J. Valle<sup>3</sup>, <sup>1</sup>Medizinische Hochschule Hannover, Hannover, DE,  
<sup>2</sup>Gustave Roussy, Villejuif, FR, <sup>3</sup>The Christie NHS Foundation Trust, Manchester, GB

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 14b**  
**Title: Industry satellite symposium 3**

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 13**  
**Title: Industry satellite symposium 4**

18:00 - 18:05    **Presentation 1**  
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

18:05 - 18:17    **Presentation 2**  
M. Colombo, Milan, IT

18:17 - 18:41    **Presentation 3**  
D. Planchard, Institut Gustave Roussy, Villejuif, FR

18:41 - 18:53    **Presentation 4**  
J.-P. Machiels, Cliniques Universitaires St. Luc, Brussels, BE

18:53 - 19:17    **Presentation 5**  
D. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US

19:17 - 19:38    **Presentation 6**  
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

19:38 - 19:58    **rolling slides**  
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **Hall A1 - Room 15**  
**Title: Industry satellite symposium 5**

18:00 - 20:00    **Presentation 1**

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **Hall A1 - Room 16**  
**Title: Industry satellite symposium 6**

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 21**  
**Title: Industry satellite symposium 8**

18:00 - 20:00    **presentation**  
B. Escudier<sup>1</sup>, A. Sella<sup>2</sup>, M. Schmidinger<sup>3</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Asaf Harofeh Medical Center, Zerifin, IL, <sup>3</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 20**  
**Title: Industry satellite symposium 7**

18:00 - 20:00    **Presentation**

M. De Santis<sup>1</sup>, H. Beltran<sup>2</sup>, A. Morgans<sup>3</sup>, <sup>1</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>2</sup>Weill Cornell Medical College, New York, US, <sup>3</sup>Northwestern University Feinberg School of Medicine, Chicago, US

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 22**  
**Title: Industry satellite symposium 9**

18:00 - 18:15    **Presentation 1**

A. Drilon, Memorial Sloan-Kettering Cancer Center, New York, US

18:15 - 19:15    **Presentation 2**

U. Lassen<sup>1</sup>, M.-J. Ahn<sup>2</sup>, A. Drilon<sup>3</sup>, <sup>1</sup>Rigshospitalet, Copenhagen, DK, <sup>2</sup>Samsung Medical Center, Seoul, KR, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York, US

19:15 - 19:30    **Presentation 3**

A. Drilon, Memorial Sloan-Kettering Cancer Center, New York, US

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 19**  
**Title: Industry satellite symposium 10**

18:00 - 20:00    **Presentation**

J. Luke<sup>1</sup>, G. Coukos<sup>2</sup>, M. Kok<sup>3</sup>, D. Jäger<sup>4</sup>, <sup>1</sup>The University of Chicago Medical Centre, Chicago, US, <sup>2</sup>Ludwig Center for Cancer Research of the UNIL, Epalinges, CH, <sup>3</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>4</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE



**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 14a**  
**Title: Industry satellite symposium 11**

18:00 - 18:20    **presentation 1**  
J. Cortes Castan, Vall d'Hebron University Hospital, Barcelona, ES

18:20 - 18:40    **presentation 2**  
M. Verrill, Newcastle, GB

18:40 - 19:00    **presentation 3**  
P. Declerck, Leuven, BE

19:00 - 19:20    **presentation 4**  
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

19:20 - 19:40    **presentation 5**  
J. Cortes Castan, Vall d'Hebron University Hospital, Barcelona, ES

**18:00 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 14c**  
**Title: Industry satellite symposium 12**

18:00 - 18:20    **Presentation 1**  
F. Esteva, NYU Langone Health, New York, US

18:20 - 18:40    **Presentation 2**  
J. Stebbing, London, GB

18:40 - 19:00    **Presentation 3**  
J. Lee, Seoul, KR

19:00 - 19:20    **Presentation 4**  
D.C. Suh, Seoul, KR

19:20 - 19:40    **Q & A**

20.10.2018

**08:00 - 09:00** **Type: Controversy Session** **Hall A1 - Room 15**  
**Title: HIPEC: Is there a role in ovarian cancer?**  
 Chair(s): Martin Gore, GB

08:00 - 08:10 **Introduction and 1st vote**  
M. Gore, Royal Marsden Hospital NHS Foundation Trust, London, GB

08:10 - 08:30 **Yes**  
G. Scambia, Policlinico Universitario A. Gemelli, Roma, IT

08:30 - 08:50 **No**  
A. Du Bois, Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE

08:50 - 09:00 **2nd vote and conclusions**  
M. Gore, Royal Marsden Hospital NHS Foundation Trust, London, GB

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 21**  
**Title: Treatment of metastatic castration sensitive prostate cancer**  
 Chair(s): Himisha Beltran, US

08:00 - 08:10 **Treatment of metastatic castration sensitive prostate cancer**  
N. James, Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB

08:10 - 09:00 **Discussion led by**  
H. Beltran, Weill Cornell Medical College, New York, US

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 23**  
**Title: Skin toxicity of anticancer treatments: How to diagnose, how to treat**  
 Chair(s): Petra Feyer, DE

08:00 - 08:10 **Skin toxicity of anticancer treatments: How to diagnose, how to treat**  
V. Sibaud, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR

08:10 - 09:00 **Discussion led by**  
P. Feyer, Vivantes Klinikum Neukölln, Berlin, DE

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 20**  
**Title: Thymic malignancies: Emerging systemic therapy options**  
 Chair(s): Heather Wakelee, US

08:00 - 08:10 **Thymic malignancies: Emerging systemic therapy options**  
N. Girard, Institut Curie, Paris, FR

08:10 - 09:00 **Discussion led by**  
H. Wakelee, Stanford Advanced Medicine Center, Stanford, US

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 22**  
**Title: Metabolic targets in cancer**  
 Chair(s): Christian Frezza, GB

08:00 - 08:10 **Metabolic targets in cancer**  
E. Gottlieb, Technion - Israel Institute of Technology, Haifa, IL

08:10 - 09:00 **Discussion led by**  
C. Frezza, University of Cambridge - MRC Cancer Unit, Cambridge, GB

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **ICM - Room 14a**  
**Title: Management of challenging patients with meningioma**  
 Chair(s): Priscilla Brastianos, US

08:00 - 08:10 **Management of challenging patients with meningioma**  
M. Preusser, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

08:10 - 09:00 **Discussion led by**  
P. Brastianos, Massachusetts General Hospital, Boston, US

**08:15 - 09:00** **Type: Keynote lecture** **Hall A1 - Room 17**  
**Title: Mutation signatures and targeting the DNA damage response**  
 Chair(s): Anton Berns, NL

08:15 - 09:00 **Mutation signatures and targeting the DNA damage response**  
T. Helleday, University of Sheffield Medical School, Sheffield, GB

**09:00 - 10:30** **Type: Educational session** **ICM - Room 1**  
**Title: Neo-adjuvant therapy management of early breast cancer**  
 Chair(s): Javier Cortes Castan, ES; Jean-Marc Classe, FR

09:00 - 09:18 **Neo-adjuvant therapy for ER+/Her2neg disease with endocrine therapy alone or in combination with targeted therapies**  
M. Ellis, Baylor College of Medicine, Houston, US

09:18 - 09:36 **Neo-adjuvant therapies for HER2 + for breast cancer**  
J. Cortes Castan, Vall d'Hebron University Hospital, Barcelona, ES

09:36 - 09:54 **Neo adjuvant therapies for triple negative in breast cancer**  
A. Tutt, The Institute of Cancer Research (ICR), London, GB

09:54 - 10:12 **Surgical management of breast cancer patients after completion of neo-adjuvant therapies**  
J.-M. Classe, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR

10:12 - 10:30 **Discussion**

**09:15 - 10:45** **Type: Proffered Paper session** **Hall A1 - Room 17**  
**Title: Proffered paper session - Genitourinary tumours, non prostate**  
 Chair(s): Karim Fizazi, FR; Andrea Necchi, IT

09:15 - 09:27 **LBA31 - Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)**  
B. Rini<sup>1</sup>, M. Huseni<sup>2</sup>, M. Atkins<sup>3</sup>, D. McDermott<sup>4</sup>, T. Powles<sup>5</sup>, B. Escudier<sup>6</sup>, R. Banchereau<sup>2</sup>, L.-F. Liu<sup>2</sup>, N. Leng<sup>2</sup>, J. Fan<sup>2</sup>, J. Doss<sup>2</sup>, S. Nalle<sup>2</sup>, S. Carroll<sup>2</sup>, S. Li<sup>2</sup>, C. Schiff<sup>2</sup>, M. Green<sup>2</sup>, R. Motzer<sup>7</sup>, <sup>1</sup>Cleveland Clinic, Cleveland, US, <sup>2</sup>Genentech, Inc., South San Francisco, US, <sup>3</sup>Lombardi Cancer Center Georgetown University, Washington DC, US, <sup>4</sup>Beth Israel Deaconess Med. Center, Boston, US, <sup>5</sup>St. Bartholomew's Hospital, London, GB, <sup>6</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>7</sup>Memorial Sloan-Kettering Cancer Center, New York, US

09:27 - 09:39 **8630 - Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results**  
M. Gross-Goupil<sup>1</sup>, T.G. Kwon<sup>2</sup>, M. Eto<sup>3</sup>, D. Ye<sup>4</sup>, H. Miyake<sup>5</sup>, S. Seo<sup>6</sup>, S. Byun<sup>7</sup>, J. Lee<sup>8</sup>, V. Master<sup>9</sup>, J. Jin<sup>10</sup>, R. Debenedetto<sup>11</sup>, R. Linke<sup>12</sup>, M. Casey<sup>13</sup>, B. Rosbrook<sup>14</sup>, M. Lechuga Frean<sup>15</sup>, O. Valota<sup>16</sup>, E. Grande<sup>17</sup>, D. Quinn<sup>18</sup>, <sup>1</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>2</sup>Kyungpook National University, Daegu, KR, <sup>3</sup>Kyushu University, Fukuoka, JP, <sup>4</sup>Fudan University, Shanghai, CN, <sup>5</sup>Hamamatsu University, Hamamatsu, JP, <sup>6</sup>Sungkyunkwan University, Seoul, KR, <sup>7</sup>Seoul National University, Seongnam, KR, <sup>8</sup>Asan



Medical Center, Seoul, KR, <sup>9</sup>Emory University School of Medicine, Atlanta, US, <sup>10</sup>Peking University First Hospital, Beijing, CN, <sup>11</sup>SFJ-Pharmaceuticals, Pleasanton, US, <sup>12</sup>SFJ-Pharmaceuticals, Inc., Pleasanton, US, <sup>13</sup>Pfizer Inc, Collegeville, US, <sup>14</sup>Pfizer Inc, La Jolla, US, <sup>15</sup>Pfizer Italia srl, Milano, IT, <sup>16</sup>Pfizer - Italy, Milan, IT, <sup>17</sup>MD Anderson Cancer Center Center Espana, Madrid, ES, <sup>18</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US

09:39 - 09:54 **Invited Discussant LBA31 and 8630**

M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

09:54 - 10:06 **8640 - Pembrolizumab for High-Risk (HR) Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial**

R. De Wit<sup>1</sup>, G. Kulkarni<sup>2</sup>, E. Uchio<sup>3</sup>, E. Singer<sup>4</sup>, L. Krieger<sup>5</sup>, P. Grivas<sup>6</sup>, D. Bajorin<sup>7</sup>, H.K. Seo<sup>8</sup>, L. Mourey<sup>9</sup>, A. Kamat<sup>10</sup>, H. Nishiyama<sup>11</sup>, E. Kapadia<sup>12</sup>, K. Nam<sup>13</sup>, T. Frenkl<sup>13</sup>, A. Balar<sup>14</sup>, <sup>1</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>2</sup>University Health Network, Toronto, CA, <sup>3</sup>UC Irvine Health, Toronto, CA, <sup>4</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, US, <sup>5</sup>Royal North Shore Hospital, Northern Cancer Institute, St. Leonards, AU, <sup>6</sup>Taussig Cancer Institute Cleveland Clinic, Cleveland, US, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>National Cancer Center, Goyang, KR, <sup>9</sup>Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, <sup>10</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>11</sup>University of Tsukuba, Tsukuba, JP, <sup>12</sup>MSD - Merck & Co USA, Kenilworth, US, <sup>13</sup>Merck & Co., Inc., Kenilworth, US, <sup>14</sup>NYU Langone Medical Center, New York, US

10:06 - 10:18 **Invited Discussant 8640**

S. Shariat, Medical University of Vienna, Vienna, AT

10:18 - 10:30 **LBA32 - Nivolumab (N) Alone or in Combination With Ipilimumab (I) in Patients (pts) With Platinum-Pretreated Metastatic Urothelial Carcinoma (mUC), Including the Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Expansion From CheckMate 032**

J. Rosenberg<sup>1</sup>, P. Sharma<sup>2</sup>, F.G. De Braud<sup>3</sup>, U. Basso<sup>4</sup>, E. Calvo<sup>5</sup>, P. Bono<sup>6</sup>, M. Morse<sup>7</sup>, P. Ascierto<sup>8</sup>, J. Lopez-Martin<sup>9</sup>, P. Brossart<sup>10</sup>, K. Rohrberg<sup>11</sup>, N. Reguart<sup>12</sup>, W.H. Lin<sup>13</sup>, S. Meadows-Shropshire<sup>14</sup>, A. Saci<sup>13</sup>, M. Callahan<sup>1</sup>, A. Siefker-Radtke<sup>15</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>MD Anderson Cancer Center, Houston, US, <sup>3</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>4</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>5</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>6</sup>Helsinki University Central Hospital (HUCH), Helsinki, FI, <sup>7</sup>Duke Cancer Institute, Durham, US, <sup>8</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>9</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>10</sup>Universitätsklinikum Bonn, Bonn, DE, <sup>11</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>12</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>13</sup>Bristol Myers Squibb, Plainsboro, US, <sup>14</sup>Bristol-Myers Squibb, Princeton, US, <sup>15</sup>The M. D. Anderson Cancer Center, Houston, US

10:30 - 10:45 **Invited Discussant LBA32**

C. Sternberg, Azienda Ospedaliera S. Camillo Forlanini, Rome, IT

**09:15 - 10:45** **Type: Special Symposium** **Hall A2 - Room 18**  
**Title: Immunotherapy and targeted therapy in the landscape of non-metastatic NSCLC**  
 Chair(s): Julie Brahmer, US; Johan Vansteenkiste, BE

09:15 - 09:20 **Introduction**  
J. Vansteenkiste, University Hospitals Leuven, Leuven, BE

09:20 - 09:40 **Translating advances in stage IV disease to non-metastatic lung cancer**  
J. Brahmer, Johns Hopkins Hospital, Baltimore, US

09:40 - 10:00 **Immunotherapy approaches in early stage disease**  
J. Vansteenkiste, University Hospitals Leuven, Leuven, BE

10:00 - 10:20 **TKI approaches in early stage disease**  
M. Tsuboi, National Cancer Center Hospital East, Kashiwa, JP

10:20 - 10:40 **Integrating immunotherapy and TKIs in stage III disease management**  
W. Eberhardt, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

10:40 - 10:45 **Conclusions and clinical perspectives**  
J. Brahmer, Johns Hopkins Hospital, Baltimore, US

**09:15 - 10:45** **Type: Proffered Paper session** **ICM - Room 14b**  
**Title: Proffered paper session - Translational research**  
 Chair(s): Nicola Normanno, IT; Caroline Dive, GB

09:15 - 09:27 **500 - Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the Circulating Cell-Free Genome Atlas (CCGA) study**  
M. Liu<sup>1</sup>, E. Klein<sup>2</sup>, E. Hubbell<sup>3</sup>, T. Maddala<sup>3</sup>, A. Aravanis<sup>3</sup>, J. Beausang<sup>3</sup>, D. Filippova<sup>3</sup>, S. Gross<sup>3</sup>, A. Jamshidi<sup>3</sup>, K. Kurtzman<sup>3</sup>, L. Shen<sup>3</sup>, N. Zhang<sup>3</sup>, O. Venn<sup>3</sup>, J. Yecies<sup>3</sup>, S. Patel<sup>3</sup>, D. Smith<sup>4</sup>, T. Yeatman<sup>5</sup>, M. Seiden<sup>6</sup>, A.-R. Hartman<sup>3</sup>, G. Oxnard<sup>7</sup>, <sup>1</sup>Mayo Clinic Cancer Center, Rochester, US, <sup>2</sup>Cleveland Clinic, Cleveland, US, <sup>3</sup>GRAIL, Inc., Menlo Park, US, <sup>4</sup>Compass Oncology, Vancouver, US, <sup>5</sup>Gibbs Cancer Center and Research Institute, Spartanburg, US, <sup>6</sup>US Oncology Research, The Woodlands, US, <sup>7</sup>Dana-Farber Cancer Institute, Boston, US

09:27 - 09:39 **13360 - Unbiased genomewide screening of circulating plasma DNA for cancer detection**  
L. Lenaerts<sup>1</sup>, N. Brison<sup>2</sup>, M. Neofytou<sup>2</sup>, H. Che<sup>2</sup>, L. Dehaspe<sup>1</sup>, M. Verheecke<sup>2</sup>, C. Maggen<sup>3</sup>, B. Dewaele<sup>2</sup>, S. Vanderschueren<sup>2</sup>, V. Vandecaveye<sup>2</sup>, P. Vandenberghe<sup>1</sup>, J. Vermeesch<sup>2</sup>, F. Amant<sup>4</sup>, <sup>1</sup>University Hospitals Leuven, Leuven, BE, <sup>2</sup>KU Leuven, Leuven, BE, <sup>3</sup>KU Leuven - University of Leuven, Leuven, BE, <sup>4</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

09:39 - 09:54 **Invited Discussant 500 and 13360**

C. Abbosh, St. James's University Hospital Leeds, Leeds, GB

09:54 - 10:06 **510 - Pan-cancer assessment of BRCA1/2 genomic alterations (GAs) by comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).**

N. Agarwal<sup>1</sup>, E. Sokol<sup>2</sup>, P. Lara Jr.<sup>3</sup>, J. Ross<sup>4</sup>, V. Miller<sup>2</sup>, A. Welsh<sup>5</sup>, J. Gregg<sup>3</sup>, G. Frampton<sup>2</sup>, S. Ali<sup>2</sup>, J. Chung<sup>2</sup>, <sup>1</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>2</sup>Foundation Medicine, Inc., Cambridge, US, <sup>3</sup>University of California, Davis, Sacramento, US, <sup>4</sup>SUNY Upstate Medical University, Syracuse, US, <sup>5</sup>Memorial Sloan Kettering Cancer Center, Lambertville, US

10:06 - 10:18 **520 - Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma**

L. Tan<sup>1</sup>, S. Sandhu<sup>1</sup>, R. Lee<sup>2</sup>, J. Li<sup>1</sup>, J. Callahan<sup>1</sup>, J. Raleigh<sup>1</sup>, A. Hatzimihalis<sup>1</sup>, P. Middlehurst<sup>3</sup>, M. Henderson<sup>1</sup>, M. Shackleton<sup>4</sup>, A. Haydon<sup>4</sup>, D. Gyorki<sup>1</sup>, D. Oudit<sup>2</sup>, R. Hicks<sup>1</sup>, P. Lorigan<sup>2</sup>, G. McArthur<sup>5</sup>, R. Marais<sup>3</sup>, S. Wong<sup>1</sup>, S.-J. Dawson<sup>1</sup>, <sup>1</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>3</sup>Cancer Research UK Manchester Institute, Manchester, GB, <sup>4</sup>Alfred Hospital, Melbourne, AU, <sup>5</sup>Peter MacCallum Cancer Centre, Melbourne, AU

10:18 - 10:30 **18300 - Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced Non-small cell lung cancer (aNSCLC): a prospective study.**

L. Bonanno<sup>1</sup>, E. Zulato<sup>1</sup>, I. Attili<sup>1</sup>, A. Pavan<sup>1</sup>, P. Del Bianco<sup>1</sup>, G. Nardo<sup>1</sup>, M. Verza<sup>1</sup>, L. Pasqualini<sup>1</sup>, G. Pasello<sup>1</sup>, G. Zago<sup>1</sup>, S. Frega<sup>1</sup>, M. Fassan<sup>2</sup>, F. Calabrese<sup>2</sup>, A. Amadori<sup>1</sup>, V. Guarneri<sup>1</sup>, P.F. Conte<sup>1</sup>, S. Indraccolo<sup>1</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>University of Padova, Padova, IT

10:30 - 10:45 **Invited Discussant 510, 520 and 18300**

C. Dive, Cancer Research UK Manchester Institute, Manchester, GB

**09:15 - 10:45 Type: Poster Discussion session ICM - Room 13**

**Title: Poster Discussion session - Gynaecological cancers**

Chair(s): Mansoor Raza Mirza, DK; Nicoletta Colombo, IT; Cristiana Sessa, CH; Antonio González-Martín, ES

09:15 - 09:15 **LBA35 - TROPHIMMUN, a 2 cohort phase II trial of the anti-PD-L1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia (GTN) patients: preliminary outcomes in cohort A.**

B. You<sup>1</sup>, P.A. Bolze<sup>2</sup>, J.-P. Lotz<sup>3</sup>, J. Massardier<sup>2</sup>, L. Gladieff<sup>4</sup>, T. Hajri<sup>5</sup>, D. Maucourt-Boulch<sup>6</sup>, S. Bin<sup>7</sup>, A. Roux<sup>7</sup>, P. Rousset<sup>2</sup>, G. Freyer<sup>6</sup>, F. Golfier<sup>5</sup>, <sup>1</sup>Hospices Civiles de Lyon, Lyon, FR, <sup>2</sup>Institut de Cancérologie des Hospices Civils de Lyon, Lyon, FR, <sup>3</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>4</sup>Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, <sup>5</sup>Centre de Reference des Maladies Trophoblastiques,

Gynecology, FR, <sup>6</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>7</sup>Pôle de Santé Publique, LYON, FR

09:15 - 09:15 **935PD - Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer**

A. Oaknin<sup>1</sup>, S. Ellard<sup>2</sup>, C. Leath Iii<sup>3</sup>, V. Moreno<sup>4</sup>, R. Kristeleit<sup>5</sup>, W. Guo<sup>6</sup>, S. Lu<sup>7</sup>, D. Jenkins<sup>7</sup>, K. Mceachern<sup>7</sup>, K. Yu Jen<sup>7</sup>, S. Dunlap<sup>7</sup>, E. Im<sup>8</sup>, L. Gilbert<sup>9</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>BC Cancer Agency, Kelowna, CA, <sup>3</sup>University of Alabama at Birmingham, Birmingham, US, <sup>4</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>5</sup>University College London UCL Cancer Institute, London, GB, <sup>6</sup>TESARO Inc., Waltham, US, <sup>7</sup>TESARO, Inc., Waltham, US, <sup>8</sup>Merck & Co. Inc., Kenilworth, US, <sup>9</sup>McGill University Health Center, Montreal, CA

09:15 - 09:27 **Invited Discussant LBA35 and 935PD**

M.R. Mirza, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK

09:27 - 09:37 **Q&A led by Discussant**

09:37 - 09:37 **LBA36 - Association of PD-L1 Expression and Gene Expression Profiling With Clinical Response to Pembrolizumab in Patients With Advanced Recurrent Ovarian Cancer: Results From the Phase 2 KEYNOTE-100 Study**

J. Ledermann<sup>1</sup>, R. Shapira-Frommer<sup>2</sup>, A. Santin<sup>3</sup>, A. Lisyanskaya<sup>4</sup>, S. Pignata<sup>5</sup>, I. Vergote<sup>6</sup>, F. Raspagliesi<sup>7</sup>, G. Sonke<sup>8</sup>, M. Birrer<sup>9</sup>, D. Provencher<sup>10</sup>, J. Sehouli<sup>11</sup>, N. Colombo<sup>12</sup>, A. González-Martín<sup>13</sup>, A. Oaknin<sup>14</sup>, P.B. Ottevanger<sup>15</sup>, V. Rudaitis<sup>16</sup>, R. Cristescu<sup>17</sup>, J. Kobie<sup>18</sup>, J. Ruman<sup>19</sup>, U. Matulonis<sup>20</sup>, <sup>1</sup>University College London Cancer Institute, London, GB, <sup>2</sup>Sheba Medical Center, Ramat-Gan, IL, <sup>3</sup>Yale School of Medicine, New Haven, US, <sup>4</sup>St. Petersburg City Oncology Hospital, St. Petersburg, RU, <sup>5</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>6</sup>BGOG & University Hospitals Leuven, Leuven, BE, <sup>7</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>8</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>9</sup>University of Alabama at Birmingham, Birmingham, US, <sup>10</sup>Centre Hospitalier de L'Université de Montréal, Montreal, CA, <sup>11</sup>Department of Gynecology, Charité, Campus-Virchow-Klinikum, Berlin, DE, <sup>12</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>13</sup>Clinica Universidad de Navarra, formerly of MD Anderson International España, Madrid, ES, <sup>14</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>15</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>16</sup>Vilnius University Faculty of Medicine, Vilnius, LT, <sup>17</sup>Merck, Kenilworth, US, <sup>18</sup>Merck & Co., Inc., Kenilworth, US, <sup>19</sup>MSD - Merck & Co USA, Kenilworth, US, <sup>20</sup>Dana Farber Cancer Institute, Boston, US

09:37 - 09:37 **936PD - A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)**

J.-M. Lee<sup>1</sup>, C. Annunziata<sup>1</sup>, N. Houston<sup>1</sup>, E. Kohn<sup>1</sup>, S. Lipkowitz<sup>1</sup>, L. Minasian<sup>1</sup>, E. Nichols<sup>1</sup>, J. Trepel<sup>1</sup>, K. Trewhitt<sup>1</sup>, F. Zia<sup>1</sup>, A. Zimmer<sup>2</sup>, <sup>1</sup>National Cancer Institute, Rockville, US, <sup>2</sup>National Cancer Institute, Bethesda, US



- 09:37 - 09:37 **937PD - A phase 2 trial of combination nivolumab and bevacizumab in recurrent ovarian cancer.**  
J. Liu<sup>1</sup>, C. Herold<sup>1</sup>, W. Luo<sup>1</sup>, R. Penson<sup>2</sup>, N. Horowitz<sup>1</sup>, P. Konstantinopoulos<sup>1</sup>, C. Castro<sup>2</sup>, J. Curtis<sup>1</sup>, U. Matulonis<sup>1</sup>, S. Cannistra<sup>3</sup>, D. Dizon<sup>4</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>Massachusetts General Hospital, Boston, US, <sup>3</sup>Beth Israel Deaconess Medical Center, Boston, US, <sup>4</sup>Lifespan Cancer Institute, Providence, US
- 09:37 - 09:49 **Invited Discussant LBA36, 936PD and 937PD**  
A. González Martín, Clínica Universidad de Navarra, Madrid, ES
- 09:49 - 09:59 **Q&A led by Discussant**
- 09:59 - 09:59 **939PD - Quality of life and symptoms in longterm survivors with ovarian cancer: It's still an issue. Expression VI - Carolin meets HANNA - Holistic Analysis of Long-term survival with Ovarian Cancer: the international NOGGO, ENGOT and GCIG survey**  
H. Woopen<sup>1</sup>, I. Braicu<sup>1</sup>, R. Richter<sup>1</sup>, K. Schnuppe<sup>1</sup>, P. Krabisch<sup>2</sup>, T. Boxler<sup>3</sup>, G. Emons<sup>4</sup>, J. Glajzer<sup>1</sup>, M. Rose<sup>1</sup>, L. Erdur<sup>1</sup>, R. Lindhorst<sup>1</sup>, M. Endres<sup>1</sup>, P. Hühnchen<sup>1</sup>, I. Vergote<sup>5</sup>, R. Berger<sup>6</sup>, C. Marth<sup>7</sup>, J. Sehouli<sup>1</sup>, <sup>1</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>2</sup>Klinikum Chemnitz, Chemnitz, DE, <sup>3</sup>Klinikum Fuerth, Fuerth, DE, <sup>4</sup>University of Göttingen, Göttingen, DE, <sup>5</sup>University Hospitals Leuven, Leuven, BE, <sup>6</sup>Medical University of Innsbruck, Innsbruck, AT, <sup>7</sup>University Hospital Innsbruck, Innsbruck, AT
- 09:59 - 09:59 **941PD - A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study**  
A. Gonzalez<sup>1</sup>, M.R. Mirza<sup>2</sup>, I. Vergote<sup>3</sup>, Y. Li<sup>4</sup>, S. Hazard<sup>4</sup>, R. Clark<sup>4</sup>, W. Graybill<sup>5</sup>, B. Pothuri<sup>6</sup>, B. Monk<sup>7</sup>, <sup>1</sup>Grupo Español de Investigación en Cáncer de Ovario (GEICO) & Clinica Universidad de Navarra, Madrid, ES, <sup>2</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>3</sup>BGOG & University Hospitals Leuven, Leuven, BE, <sup>4</sup>TESARO Inc., Waltham, US, <sup>5</sup>Medical University of South Carolina, Charleston, US, <sup>6</sup>NYU Langone Medical Center, New York, US, <sup>7</sup>University of Arizona and Creighton University, Phoenix, US
- 09:59 - 10:11 **Invited Discussant 939PD and 941PD**  
N. Colombo, Istituto Europeo di Oncologia, Milan, IT
- 10:11 - 10:21 **Q&A led by Discussant**
- 10:21 - 10:21 **938PD - Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group**  
T. De La Motte Rouge<sup>1</sup>, F. Derquin<sup>1</sup>, A. Floquet<sup>2</sup>, J. Edeline<sup>1</sup>, J.-P. Lotz<sup>3</sup>, J. Alexandre<sup>4</sup>, P. Pautier<sup>5</sup>, G. Ferron<sup>6</sup>, E. Boissier<sup>7</sup>, C. Lefeuvre-Plesse<sup>1</sup>, H. Vegas<sup>8</sup>, A. Patsouris<sup>9</sup>, E.

Kalbacher<sup>10</sup>, D. Berton-Rigaud<sup>11</sup>, A.-C. Hardy Bessard<sup>12</sup>, V. Lavoué<sup>13</sup>, I. Ray-Coquard<sup>14</sup>,  
<sup>1</sup>Centre Eugene - Marquis, Rennes, FR, <sup>2</sup>Institute Bergonié, Bordeaux, FR, <sup>3</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>4</sup>ONCO CARC CANCER, La Varenne Saint-Hilaire, FR, <sup>5</sup>Gustave Roussy, Villejuif, FR, <sup>6</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>7</sup>European George Pompidou Hospital, Paris, FR, <sup>8</sup>CHRU Bretonneau, Tours, FR, <sup>9</sup>Centre Paul Papin, Angers, FR, <sup>10</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>11</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>12</sup>Hôpital Privé des Côtes d'Armor, Plérin, FR, <sup>13</sup>CHU Anne-de-Bretagne, Rennes, FR, <sup>14</sup>Centre Léon Bérard, Lyon, FR

10:21 - 10:21

**943PD - Response to Neoadjuvant Chemotherapy in ICON8: A GCIG Phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment**

A. Clamp<sup>1</sup>, I. Mcneish<sup>2</sup>, A. Dean<sup>3</sup>, D. Gallardo-Rincon<sup>4</sup>, J.-W. Kim<sup>5</sup>, D. O'Donnell<sup>6</sup>, J. Hook<sup>7</sup>, S. Blagden<sup>8</sup>, J. Brenton<sup>9</sup>, R. Naik<sup>10</sup>, T. Perren<sup>11</sup>, S. Sundar<sup>12</sup>, A. Cook<sup>13</sup>, E. James<sup>13</sup>, H. Gabra<sup>2</sup>, R. Lord<sup>14</sup>, M. Hall<sup>15</sup>, G. Dark<sup>16</sup>, R. Kaplan<sup>17</sup>, J. Ledermann<sup>18</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Imperial College London - Hammersmith Hospital, London, GB, <sup>3</sup>Saint John of God Hospital Subiaco, Subiaco, AU, <sup>4</sup>Instituto Nacional de Cancerologia - Mexico, Ciudad de México, MX, <sup>5</sup>KGOG & Seoul National University, Seoul, KP, <sup>6</sup>St James's Hospital, Dublin, IE, <sup>7</sup>Leeds Teaching Hospitals NHS Trust, Leeds, GB, <sup>8</sup>Churchill Hospital University of Oxford, Oxford, GB, <sup>9</sup>Li Ka Shing Centre, Cancer Research UK, Cambridge Research Institute Addenbrooke's Hospital, Cambridge, GB, <sup>10</sup>Gateshead Health NHS Foundation Trust, Gateshead, GB, <sup>11</sup>St. James's University Hospital Leeds, Leeds, GB, <sup>12</sup>University of Birmingham, Birmingham, GB, <sup>13</sup>Institute of Clinical Trials and Methodology-UCL, London, GB, <sup>14</sup>Clatterbridge Cancer Center, Wirral, GB, <sup>15</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>16</sup>Newcastle University, Newcastle, GB, <sup>17</sup>MRC, London, GB, <sup>18</sup>University College London Cancer Institute, London, GB

10:21 - 10:33

**Invited Discussant 938PD and 943PD**

C. Sessa, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

10:33 - 10:43

**Q&A led by Discussant**

**09:15 - 10:45**    **Type: Joint Symposium**    **Hall B3 - Room 23**  
**Title: ESMO-DGHO Joint Symposium: Access to anti-cancer drugs**  
 Chair(s): Alexandru Eniu, RO; Volker Heinemann, DE

09:15 - 09:20    **Introduction**  
V. Heinemann, Ludwig Maximilians University - Grosshadern, Munich, DE

09:20 - 09:40    **The shortage of essential oncology drugs**  
A. Eniu, Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, RO

09:40 - 10:00    **Access to innovative/expensive drugs**  
R. Sullivan, Institute of cancer policy, London, GB

10:00 - 10:20    **What is a fair price?**  
C. Bokemeyer, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

10:20 - 10:40    **Strategies in Germany**  
B. Woermann, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Berlin, DE

10:40 - 10:45    **Conclusions**  
A. Eniu, Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, RO

**09:15 - 10:30**    **Type: Poster Discussion session**    **Hall B4 - Room 19**  
**Title: Poster Discussion session - Public health policy**  
 Chair(s): Fredericus Eskens, NL; Carin Uyl-de Groot, NL; Hans Westgeest, NL

09:15 - 09:15    **1560PD - Major determinants of delayed access to innovative medicines for metastatic melanoma: the results of Melanoma World Society and European Association of Dermato-oncology survey**  
L. Kandolf Sekulovic<sup>1</sup>, S. Agarwala<sup>2</sup>, A. Hauschild<sup>3</sup>, J. Guo<sup>4</sup>, G. Mcarthur<sup>5</sup>, P. Lorigan<sup>6</sup>, G. Cinat<sup>7</sup>, C. Caglevich<sup>8</sup>, C. Lebbé<sup>9</sup>, P. Rutkowski<sup>10</sup>, H. Gogas<sup>11</sup>, R. Dummer<sup>12</sup>, B. Neyns<sup>13</sup>, L. Bastholt<sup>14</sup>, A. Wainstein<sup>15</sup>, D. Herceg<sup>16</sup>, M. Banjin<sup>17</sup>, A. Zhukavets<sup>18</sup>, J. Ocvirk<sup>19</sup>, C. Garbe<sup>20</sup>, <sup>1</sup>Military Medical Academy, VMA, Belgrade, RS, <sup>2</sup>St. Luke's Hospital & Health Network, Bethlehem, US, <sup>3</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>4</sup>Beijing Cancer Hospital, Beijing, CN, <sup>5</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>6</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>7</sup>Janssen-Cilag Farmaceutica - Argentina, Buenos Aires, AR, <sup>8</sup>Instituto Oncologico Fundacion Arturo Lopez Perez, Santiago, CL, <sup>9</sup>Hôpital Saint Louis, Paris, FR, <sup>10</sup>The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>11</sup>Laiko General Hospital of Athens, Athens, GR, <sup>12</sup>Universitätsspital Zürich, Zurich, CH, <sup>13</sup>Vrije Universiteit Brussel-Campus Jette, Brussels, BE, <sup>14</sup>Odense University Hospital, Odense C, DK, <sup>15</sup>ONCAD, Belgrade, BR, <sup>16</sup>KBC - University Hospital Centre Zagreb, Zagreb, HR, <sup>17</sup>Clinical Centre of Sarajevo University, Sarajevo, BA, <sup>18</sup>N.N. Alexandrov Research Institute, Minsk, BY, <sup>19</sup>Institute of Oncology Ljubljana, Ljubljana, SI, <sup>20</sup>University of Tuebingen-Dermatology, Tübingen, DE

- 09:15 - 09:15 **1561PD - Variation in Oncology Drug Approvals in Canada, the United States and Europe**  
O. Khan<sup>1</sup>, N. Samuel<sup>2</sup>, S. Verma<sup>1</sup>, <sup>1</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>2</sup>University of Toronto, Toronto, CA
- 09:15 - 09:25 **Invited Discussant 1560PD and 1561PD**  
C. Uyl-De Groot, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, NL
- 09:25 - 09:35 **Q&A led by Discussant**
- 09:35 - 09:35 **1562PD - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)**  
C. Molto Valiente<sup>1</sup>, M. Borrell<sup>1</sup>, A. Ocana Fernandez<sup>2</sup>, A. Templeton<sup>3</sup>, L. Del Carpio<sup>1</sup>, J. Del Paggio<sup>4</sup>, A. Barnadas<sup>1</sup>, C. Booth<sup>5</sup>, A. Tibau<sup>1</sup>, E. Amir<sup>6</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>2</sup>Complejo Hospitalario Universitario de Albacete, Albacete, ES, <sup>3</sup>St. Claraspital AG, Basel, CH, <sup>4</sup>NCIC Clinical Trials Group, Cancer Research Institute, Kingston, CA, <sup>5</sup>Queen's University, Kingston, CA, <sup>6</sup>Princess Margaret Cancer Centre, Toronto, CA
- 09:35 - 09:35 **1563PD - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval**  
M. Borrell Puy<sup>1</sup>, C. Molto Valiente<sup>1</sup>, K. Vokinger<sup>2</sup>, T. Hwang<sup>3</sup>, A. Ocana Fernandez<sup>4</sup>, A. Templeton<sup>5</sup>, B. Seruga<sup>6</sup>, I. Gich Saladich<sup>1</sup>, A. Barnadas<sup>1</sup>, E. Amir<sup>7</sup>, A. Tibau<sup>1</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>2</sup>University of Zurich Hospital, Zurich, CH, <sup>3</sup>Harvard Medical School, Boston, US, <sup>4</sup>Complejo Hospitalario Universitario de Albacete, Albacete, ES, <sup>5</sup>St. Claraspital AG, Basel, CH, <sup>6</sup>Institute of Oncology Ljubljana, Ljubljana, SI, <sup>7</sup>Princess Margaret Cancer Centre, Toronto, CA
- 09:35 - 09:35 **1564PD - Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs**  
C. Molto Valiente<sup>1</sup>, M. Borrell<sup>1</sup>, T. Hwang<sup>2</sup>, I. Gich Saladich<sup>1</sup>, A. Barnadas<sup>1</sup>, E. Amir<sup>3</sup>, A. Kesselheim<sup>2</sup>, A. Tibau<sup>1</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>2</sup>Harvard Medical School, Boston, US, <sup>3</sup>Princess Margaret Cancer Centre, Toronto, CA
- 09:35 - 09:35 **1565PD - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores**  
U. Janzic<sup>1</sup>, L. Knez<sup>1</sup>, A. Janzic<sup>2</sup>, T. Cufer<sup>1</sup>, <sup>1</sup>University Clinic Golnik, Golnik, SI, <sup>2</sup>University of Ljubljana, Faculty of Pharmacy, Ljubljana, SI
- 09:35 - 09:50 **Invited Discussant 1563PD, 1564PD and 1565PD**  
F. Eskens, Erasmus University Medical Center, Rotterdam, NL



09:50 - 10:00 **Q&A led by Discussant**

10:00 - 10:00 **1566PD - Cascade BRCA Germline Mutation (BGM) Testing of women with Breast (BC) or Epithelial Ovarian Cancer( EOC) and their families with subsequent Risk Reducing Surgery(RRS): A Canadian Economics Model**

P. Hoskins<sup>1</sup>, A. Ecclestone<sup>1</sup>, M. Hurry<sup>2</sup>, M. Dyer<sup>3</sup>, <sup>1</sup>BC Cancer Agency, Vancouver, CA, <sup>2</sup>AstraZeneca Canada, Mississauga, CA, <sup>3</sup>AstraZeneca Academy House, Cambridge, GB

10:00 - 10:00 **1567PD - Genetic testing of BRCA mutations in breast cancer in six European countries: Barriers and opportunities**

M. Thrift-Perry<sup>1</sup>, S. Ahmed<sup>2</sup>, S. Wait<sup>2</sup>, J. Tate<sup>2</sup>, <sup>1</sup>Pfizer, New York, US, <sup>2</sup>The Health Policy Partnership, London, GB

10:00 - 10:00 **1568PD - Public awareness of cancer in the Gaza-Strip: a cross-sectional study**

M. Elshami<sup>1</sup>, M. Alkhatib<sup>2</sup>, A. Elshami<sup>2</sup>, K. Abu-Nemer<sup>2</sup>, A. Qandeel<sup>2</sup>, M. Hana<sup>2</sup>, N. Alshorbassi<sup>2</sup>, G. Matar<sup>2</sup>, O. Baraka<sup>2</sup>, M. Elblbessy<sup>2</sup>, L. Albarqouni<sup>3</sup>, B. Bottcher<sup>2</sup>, <sup>1</sup>Islamic university of gaza - medical collage, Gaza, PS, <sup>2</sup>Islamic University of Gaza, Gaza, PS, <sup>3</sup>Bond University, Queensland, AU

10:00 - 10:15 **Invited Discussant 1566PD, 1567PD and 1568PD**

H. Westgeest, Amphia Ziekenhuis-location Langendijk, Breda, NL

10:15 - 10:25 **Q&A led by Discussant**

**09:15 - 10:45**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: EONS-ONS Session: Innovation in cancer nursing and leadership**  
 Chair(s): Lena Sharp, SE

09:15 - 09:25    **Introduction and welcome**  
L. Sharp<sup>1</sup>, D. Kelly<sup>2</sup>, K. Paradies<sup>3</sup>, <sup>1</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE, <sup>2</sup>Royal College of Nursing, Cardiff, GB, <sup>3</sup>KOK - Konferenz Onkologischer Kranken- und Kinderkrankenpflege, Hamburg, DE

09:25 - 09:35    **Recognizing European Cancer Nursing, RECaN: Results from systematic review and meta-analyses (RECaN Phase 1)**  
D. Kelly, Royal College of Nursing, Cardiff, GB

09:35 - 09:45    **Results from case studies from four contrasting countries in Europe (RECaN Phase 2)**  
L. Sharp, Regional Cancer Center Stockholm Gotland, Stockholm, SE

09:45 - 09:55    **Promoting cancer nursing across Europe (RECaN Phase 2 qualitative insights and looking ahead to phase 3)**  
D. Kelly, Royal College of Nursing, Cardiff, GB

09:55 - 10:25    **Supporting cancer nursing leadership development: The USA experience**  
L. Fennimore, University of Pittsburgh Cancer Institute, Pittsburgh, US

10:25 - 10:45    **Discussion**

**09:30 - 10:30**    **Type: Controversy Session**    **Hall A1 - Room 15**  
**Title: Will CAR T cell therapy replace allogeneic transplantation in lymphoma?**  
 Chair(s): Martin Dreyling, DE

09:30 - 09:40    **Introduction and 1st vote**  
M. Dreyling, Ludwig Maximilians University - Grosshadern, Munich, DE

09:40 - 10:00    **Yes**  
M. Subklewe, LMU Klinikum der Universität München, Munich, DE

10:00 - 10:20    **No**  
D. Caballero, Instituto de Investigación Biomédica de Salamanca, Salamanca, ES

10:20 - 10:30    **2nd vote and conclusions**  
M. Dreyling, Ludwig Maximilians University - Grosshadern, Munich, DE

**09:30 - 10:35** **Type: Multidisciplinary interactive sessions** **Hall A1 - Room 16**  
**Title: Malignant pheochromocytoma / paraganglioma**  
 Chair(s): Alfredo Berruti, IT

09:30 - 09:35 **Case presentation**  
A. Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

09:35 - 09:45 **The surgical approach**  
M. Walz, Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE

09:45 - 09:55 **The nuclear medicine specialist perspective**  
V. Ambrosini, AOU Policlinico S. Orsola-Malpighi, Bologna, IT

09:55 - 10:05 **The endocrinologist and oncologist perspective**  
E. Baudin, Gustave Roussy Institut de Cancérologie, Villejuif, FR

10:05 - 10:35 **Discussion**

**09:30 - 10:30** **Type: Poster Discussion session** **Hall B3 - Room 21**  
**Title: Poster Discussion session - Supportive and palliative care 1**  
 Chair(s): Dorothy Keefe, AU; Florian Strasser, CH

09:30 - 09:30 **1683PD - Factors that influence oncology nutrition efficacy in breast cancer patients under antiestrogenic treatment**  
D. Artene<sup>1</sup>, A. Blidaru<sup>2</sup>, <sup>1</sup>"Carol Davila" University of Medicine and Pharmacy, Bucharest, RO, <sup>2</sup>Alexandru Trestioreanu Oncology Institute, Bucharest, RO

09:30 - 09:30 **1684PD\_PR - Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC)**  
A. Di Meglio<sup>1</sup>, M. El-Mouhebb<sup>2</sup>, S. Michiels<sup>3</sup>, D. Carene<sup>2</sup>, S. Everhard<sup>4</sup>, A.L. Martin<sup>5</sup>, P. Cottu<sup>6</sup>, F. Lerebours<sup>7</sup>, C. Coutant<sup>8</sup>, A. Lesur<sup>9</sup>, O. Tredan<sup>10</sup>, P. Soulie<sup>11</sup>, L. Vanlemmens<sup>12</sup>, P. Arveux<sup>8</sup>, S. Delaloge<sup>3</sup>, P. Ganz<sup>13</sup>, F. André<sup>1</sup>, A. Partridge<sup>14</sup>, L. Jones<sup>15</sup>, I. Vaz-Luis<sup>2</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>UNICANCER, Paris, FR, <sup>5</sup>Unicancer, Paris, FR, <sup>6</sup>Institut Curie, Paris, FR, <sup>7</sup>Institut Curie Saint Cloud, Saint Cloud, FR, <sup>8</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>9</sup>Institut de cancérologie de Lorraine, Nancy, FR, <sup>10</sup>Centre Léon Bérard, Lyon, FR, <sup>11</sup>Centre Paul Papin, Angers, FR, <sup>12</sup>Centre Oscar Lambret, Lille, FR, <sup>13</sup>UCLA, Los Angeles, US, <sup>14</sup>Dana-Farber Cancer Institute, Boston, US, <sup>15</sup>Memorial Sloan Kettering Cancer Center, New York, US

09:30 - 09:30 **1685PD - Effects of 6-month exercise training on quality of life in pancreatic cancer patients: results from a randomized controlled trial**  
K. Steindorf<sup>1</sup>, D. Clauss<sup>1</sup>, C. Tjaden<sup>2</sup>, F. Herbolsheimer<sup>1</sup>, L. Schneider<sup>2</sup>, C. Ulrich<sup>3</sup>, T. Hackert<sup>2</sup>, J. Wiskemann<sup>4</sup>, <sup>1</sup>German Cancer Research Center, Heidelberg, DE, <sup>2</sup>University

Hospital Heidelberg, Heidelberg, DE, <sup>3</sup>Huntsman Cancer Institute, Salt Lake City, US,  
<sup>4</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE

- 09:30 - 09:30 **1513PD - A prospective study examining cachexia predictors in patients with incurable cancer.**  
O.M. Vagnildhaug<sup>1</sup>, C. Brunelli<sup>2</sup>, M. Hjermstad<sup>3</sup>, F. Strasser<sup>4</sup>, V. Baracos<sup>5</sup>, A. Wilcock<sup>6</sup>, M. Nabal<sup>7</sup>, S. Kaasa<sup>3</sup>, B. Laird<sup>8</sup>, T. Solheim<sup>9</sup>, <sup>1</sup>Norwegian University of Science and Technology, Trondheim, NO, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, <sup>3</sup>Oslo University Hospital, Oslo, NO, <sup>4</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>5</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>6</sup>Nottingham University Hospital NHS Trust, Nottingham, GB, <sup>7</sup>Hospital Universitario Arnau de Vilanova de Lleida, Lleida, ES, <sup>8</sup>University of Edinburgh, Edinburgh, GB, <sup>9</sup>St. Olavs Hospital HF, Trondheim, NO
- 09:30 - 09:50 **Invited Discussant 1683PD, 1684PD, 1685PD and 1513PD**  
D. Keefe, Royal Adelaide Hospital RAH Cancer Centre, Adelaide, AU
- 09:50 - 10:00 **Q&A led by Discussant**
- 10:00 - 10:00 **1514PD - Timing of palliative care referral before and after a cluster randomized controlled trial (RCT) of early palliative care**  
D. Hausner<sup>1</sup>, C. Tricou<sup>2</sup>, D. Wadhwa<sup>3</sup>, A. Pope<sup>2</sup>, M. Giruparajah<sup>2</sup>, N. Swami<sup>2</sup>, M. Krzyzanowska<sup>2</sup>, K. Mah<sup>2</sup>, C. Zimmermann<sup>4</sup>, <sup>1</sup>University of Toronto, Toronto, CA, <sup>2</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>3</sup>BC Cancer - Kelowna Centre, Kelowna, CA, <sup>4</sup>Princess Margaret Cancer Center, Toronto, CA
- 10:00 - 10:00 **1515PD - Randomized clinical trial of an individualized intervention promotes cancer patients' prognostic awareness and reduces CPR received in the last month**  
C. Chen<sup>1</sup>, J.-S. Chen<sup>2</sup>, F.-H. Wen<sup>3</sup>, J.W.-C. Chang<sup>4</sup>, W.-C. Chou<sup>2</sup>, C.-H. Hsieh<sup>5</sup>, M.-M. Hou<sup>5</sup>, S.T. Tang<sup>6</sup>, <sup>1</sup>National Taipei University of Nursing and Health Sciences, Taipei city, TW, <sup>2</sup>Chung Gung University, Tao Yuan, TW, <sup>3</sup>Soochow University, taipei, TW, <sup>4</sup>Chang Gung Memorial Hospital-Taipei, Taipei, TW, <sup>5</sup>Chang Gung Memorial Hospital-Linkou, Taoyuan, TW, <sup>6</sup>Chung Gung University, Taoyuan, TW
- 10:00 - 10:15 **Invited Discussant 1514PD and 1515PD**  
F. Strasser, Kantonsspital St. Gallen, St. Gallen, CH
- 10:15 - 10:25 **Q&A led by Discussant**



**09:30 - 10:30** **Type: Challenge Your Expert (CYE) session** **Hall B3**  
**Title: Leiomyosarcomas: How to choose and sequence treatments, targeted vs non-targeted therapies, olaratumab yes or no, and other controversies** **- Room 22**  
 Chair(s): Silvia Stacchiotti, IT

09:30 - 09:40 **Leiomyosarcomas: How to choose and sequence treatments, targeted vs non-targeted therapies, olaratumab yes or no, and other controversies**  
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

09:40 - 10:30 **Discussion led by**  
S. Stacchiotti, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

**11:00 - 12:30** **Type: Special Symposium** **Hall A1 - Room 17**  
**Title: New aspects of targeted therapy of NSCLC**  
 Chair(s): Tony S.K. Mok, HK; Christian Rolfo, US; Lizza Hendriks, NL

11:00 - 11:05 **Introduction**  
C. Rolfo<sup>1</sup>, L. Hendriks<sup>2</sup>, <sup>1</sup>University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, US, <sup>2</sup>Maastricht University Medical Center (MUMC), Maastricht, NL

11:05 - 11:25 **Optimal sequencing in patients with EGFR mutations**  
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

11:25 - 11:45 **Optimal sequencing in patients with ALK/ROS1 alterations**  
F. Blackhall, The Christie NHS Foundation Trust, Manchester, GB

11:45 - 12:05 **New aspects in MET inhibition**  
S. Ekman, Karolinska University Hospital-Solna, Stockholm, SE

12:05 - 12:25 **Targets beyond EGFR and ALK inhibition**  
F. Cappuzzo, Ospedale Civile di Ravenna - S.ta Maria delle Croci, Ravenna, IT

12:25 - 12:30 **Conclusions and perspectives**  
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

**11:00 - 12:30**    **Type: Special Symposium**    **ICM -**  
**Title: The molecular classification of upper GI cancers: Are we ready to**    **Room 1**  
**translate them into clinical practice?**  
 Chair(s): Yoon-Koo Kang, KR; Ian Chau, GB

- 11:00 - 11:05    **Introduction**  
I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 11:05 - 11:25    **Oesophageal cancer**  
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES
- 11:25 - 11:45    **Gastric cancer**  
F. Lordick, University of Leipzig, Leipzig, DE
- 11:45 - 12:05    **Primary liver tumours**  
M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:05 - 12:25    **Pancreatic adenocarcinoma**  
I. Chau, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 12:25 - 12:30    **Conclusions and clinical perspectives**  
Y.-K. Kang, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

**11:00 - 12:30**    **Type: Special Symposium**    **ICM - Room 14b**  
**Title: Neo-adjuvant and adjuvant strategies in melanoma**  
 Chair(s): Piotr Rutkowski, PL; Paul Lorigan, GB

11:00 - 11:05    **Introduction**  
P. Lorigan, The Christie NHS Foundation Trust, Manchester, GB

11:05 - 11:25    **Pre-clinical data to prepare early treatment of melanoma**  
M. Soengas, CNIO- Spanish National Cancer Center, Madrid, ES

11:25 - 11:45    **Neo-adjuvant therapy**  
C. Blank, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

11:45 - 12:05    **Should we treat our patients with melanoma in the neoadjuvant, adjuvant or metastatic setting?**  
C. Lebbé, Hôpital Saint Louis, Paris, FR

12:05 - 12:25    **Adjuvant therapy (2018-2020)**  
A. Eggermont, Institut Gustave Roussy, Villejuif, FR

12:25 - 12:30    **Conclusions and clinical perspectives**  
P. Rutkowski, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL

**11:00 - 12:30**    **Type: Educational session**    **Hall A1 - Room 15**  
**Title: What is new in the management of recurrent ovarian cancer**  
 Chair(s): Domenica Lorusso, IT; Isabelle Ray-Coquard, FR

11:00 - 11:25    **When should biology drive treatment decisions?**  
I. Mcneish, Imperial College London - Hammersmith Hospital, London, GB

11:25 - 11:50    **The role of surgical management in 2018**  
S. Mahner, LMU Klinikum der Universität München, Munich, DE

11:50 - 12:15    **Advances in systemic therapy changing practice**  
D. Lorusso, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

12:15 - 12:30    **Discussion**

**11:00 - 12:45**    **Type: Proffered Paper session**    **Hall A2 - Room 18**  
**Title: Proffered paper session - Breast cancer, metastatic**  
 Chair(s): Frederique Penault-Llorca, FR; Nagi El Saghir, LB

11:00 - 11:03 **Introduction: Quality of Life and Clinical Trials**

N. El Saghir, American University of Beirut Medical Center, Beirut, LB

11:03 - 11:18 **1930 - An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23)- EORTC QLQ-BR45**

V. Bjelic-Radasic<sup>1</sup>, A. Bottomley<sup>2</sup>, F. Cardoso<sup>3</sup>, D. Cameron<sup>4</sup>, E. Brain<sup>5</sup>, K. Kuljanic<sup>6</sup>, R. De Costa<sup>7</sup>, T. Conroy<sup>8</sup>, E. Inwald<sup>9</sup>, S. Serpentine<sup>10</sup>, M. Pinto<sup>11</sup>, J. Weis<sup>12</sup>, O. Morag<sup>13</sup>, G. Guro Lindviksmoen Astrup<sup>14</sup>, K. Tomaszewski<sup>15</sup>, K. Pogoda<sup>16</sup>, P. Sinai<sup>17</sup>, M. Sprangers<sup>18</sup>, N. Aaronson<sup>19</sup>, E. Greimel<sup>1</sup>, <sup>1</sup>Medical University Graz, Graz, AT, <sup>2</sup>EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, <sup>3</sup>Champalimaud Foundation Cancer Center, Lisbon, PT, <sup>4</sup>Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB, <sup>5</sup>Institut Curie, Paris & Saint-Cloud, FR, <sup>6</sup>medical University Rijeka, Rijeka, HR, <sup>7</sup>HC Barretas, Barretas, BR, <sup>8</sup>ICL Alexis Vautin, Iorraine, FR, <sup>9</sup>Medical University Regensburg, Regensburg, DE, <sup>10</sup>IOV Oncologica Veneto Padova, Padova, IT, <sup>11</sup>Instituto Nazionale Tumori Fondazione Pascale Naples, Naples, IT, <sup>12</sup>Medical University Freiburg, Freiburg, DE, <sup>13</sup>SHEBA Israel, Tel Aviv, IL, <sup>14</sup>Oslo Univ. Hospital, Oslo, NO, <sup>15</sup>Jagillonian University Medical College Krakow, Krakow, PL, <sup>16</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>17</sup>University of Bristol, Bristol, GB, <sup>18</sup>Academic Medical Center (AMC), Amsterdam, NL, <sup>19</sup>NCI Amsterdam, Amsterdam, NL

11:18 - 11:33 **2900 - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3**

P.A. Fasching<sup>1</sup>, F. Esteva<sup>2</sup>, X. Pivot<sup>3</sup>, A. Nusch<sup>4</sup>, J. Beck<sup>5</sup>, A. Chan<sup>6</sup>, A. Pieris-Gunatilaka<sup>7</sup>, Y. Wang<sup>7</sup>, B. Lanoue<sup>7</sup>, D. Chandiwana<sup>7</sup>, P. Neven<sup>8</sup>, <sup>1</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>2</sup>NYU Langone Health, New York, US, <sup>3</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>4</sup>Onkologische Praxis Velbert, Velbert, DE, <sup>5</sup>Highlands Oncology Group, Fayetteville, US, <sup>6</sup>Curtin University, Nedlands, AU, <sup>7</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>8</sup>University Hospitals Leuven, Leuven, BE

11:33 - 11:48 **2910 - Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)**

N. Harbeck<sup>1</sup>, R. Villanueva<sup>2</sup>, F. Franke<sup>3</sup>, G. Babu<sup>4</sup>, P. Wheatley-Price<sup>5</sup>, Y.-H. Im<sup>6</sup>, K. Altundag<sup>7</sup>, B. Lanoue<sup>8</sup>, J. Alam<sup>8</sup>, D. Chandiwana<sup>8</sup>, M. Colleoni<sup>9</sup>, <sup>1</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>2</sup>Institut Català d'Oncologia, Barcelona, ES, <sup>3</sup>Hospital de Caridade de Ijuí, Ijuí, BR, <sup>4</sup>HCG Curie Centre of Oncology, Bangalore, IN, <sup>5</sup>University of Ottawa, Ottawa, CA, <sup>6</sup>Samsung Medical Center, Seoul, KR, <sup>7</sup>Hacettepe University Faculty of Medicine, Ankara, TR, <sup>8</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>9</sup>Istituto Europeo di Oncologia, Milan, IT

11:48 - 12:03 **2920 - Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation**



H. Rugo<sup>1</sup>, R. Quek<sup>2</sup>, J. Ettl<sup>3</sup>, S. Hurvitz<sup>4</sup>, H. Bhattacharyya<sup>5</sup>, A. Hannah<sup>6</sup>, J. Litton<sup>7</sup>,  
<sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>Pfizer, Inc., San Francisco, US, <sup>3</sup>Technische Universität München, Munich, DE, <sup>4</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>5</sup>Pfizer Inc., New York, US, <sup>6</sup>Consultant, New York, US, <sup>7</sup>MD Anderson Cancer Center, Houston, US

12:03 - 12:18 **Invited Discussant 1930, 2900, 2910 and 2920**

L. Fallowfield, Brighton and Sussex Medical School, University of Sussex, Brighton, GB

12:18 - 12:33 **2840 - Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)**

S. Pernas<sup>1</sup>, P. Villagrasa<sup>2</sup>, A. Vivancos<sup>3</sup>, M. Scaltriti<sup>4</sup>, J. Rodon<sup>3</sup>, O. Burgues<sup>5</sup>, P. Nuciforo<sup>3</sup>, J. Canes<sup>2</sup>, M. Dueñas<sup>6</sup>, M. Vidal<sup>7</sup>, A. Lluch<sup>8</sup>, A. Perelló<sup>9</sup>, A. Llombart<sup>10</sup>, J. Dorca<sup>11</sup>, Á. Montañó<sup>12</sup>, A.M. Antunes De Melo E Oliveira<sup>3</sup>, G. Ribas<sup>13</sup>, I. Rapado<sup>14</sup>, A. Prat<sup>15</sup>, E. Ciruelos<sup>16</sup>, <sup>1</sup>Institut Català d'Oncologia-Hospitalet, Hospitalet de Llobregat, ES, <sup>2</sup>SOLTI, Barcelona, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>5</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>6</sup>i+12, Madrid, ES, <sup>7</sup>Hospital Clinic i Provincial de Barcelona, Barcelona, ES, <sup>8</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>9</sup>Hospital Son Espases, Palma de Mallorca, ES, <sup>10</sup>Hospital Universitario Arnau Vilanova de Lleida, Lerida, ES, <sup>11</sup>Institut Català d'Oncologia-Girona, Girona, ES, <sup>12</sup>Hospital Virgen del Rocío, Sevilla, ES, <sup>13</sup>Hospital Clínico Universitario de Valencia / INCLIVA / CIBERONC, Valencia, ES, <sup>14</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>15</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>16</sup>Hospital Universitario 12 de Octubre, Madrid, ES

12:33 - 12:48 **Invited Discussant one LBA TBC and 2840**

C. Le Tourneau, Institut Curie, Paris, FR

**11:00 - 12:30 Type: Proffered Paper session Hall B3 - Room 21**  
**Title: Proffered paper session - Basic science**  
 Chair(s): Anton Berns, NL; Therese Sørlie, NO

11:00 - 11:12 **18910\_PR - Mutational landscape of metastatic cancers discovered from prospective clinical sequencing at community practice cancer program**

R. Alvarez<sup>1</sup>, A. Moran<sup>1</sup>, E. Meiri<sup>1</sup>, A. Loaiza-Bonilla<sup>1</sup>, A. Parikh<sup>1</sup>, P. Crilley<sup>1</sup>, J. Elvin<sup>2</sup>, P. Reddy<sup>2</sup>, V. Miller<sup>2</sup>, S. Zook<sup>1</sup>, S. Ali<sup>2</sup>, M. Markman<sup>1</sup>, <sup>1</sup>Cancer Treatment Centers of America, Newnan, US, <sup>2</sup>Foundation Medicine, Boston, US

11:12 - 11:24 **18920 - Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase 2 study of tazemetostat (NCT02601950)**

S. Daigle<sup>1</sup>, S. Stacchiotti<sup>2</sup>, P. Schöffski<sup>3</sup>, V. Villalobos<sup>4</sup>, G. Cote<sup>5</sup>, R. Chugh<sup>6</sup>, T.W.-W. Chen<sup>7</sup>, T. Jahan<sup>8</sup>, E. Loggers<sup>9</sup>, A. Italiano<sup>10</sup>, A. Gupta<sup>11</sup>, M. Agulnik<sup>12</sup>, S. Attia<sup>13</sup>, R. Jones<sup>14</sup>, B. Van Tine<sup>15</sup>, G.D. Demetri<sup>16</sup>, A. Clawson<sup>1</sup>, M. Roche<sup>1</sup>, S. Blakemore<sup>1</sup>, M. Gounder<sup>17</sup>, <sup>1</sup>Epizyme, Cambridge, US, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>University Hospitals Leuven, Leuven, BE, <sup>4</sup>University of Colorado, Denver, US, <sup>5</sup>Massachusetts General Hospital, Boston, US, <sup>6</sup>Michigan

Medicine Comprehensive Cancer Center, Ann Arbor, US, <sup>7</sup>National Taiwan University Hospital, Taipei City, TW, <sup>8</sup>University of California, San Francisco, US, <sup>9</sup>Seattle Cancer Care Alliance, Seattle, US, <sup>10</sup>Institute Bergonié, Bordeaux, FR, <sup>11</sup>Hospital for Sick Children, Toronto, CA, <sup>12</sup>Northwestern University, Chicago, US, <sup>13</sup>Mayo Clinic, Jacksonville, US, <sup>14</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>15</sup>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University, St. Louis, US, <sup>16</sup>Dana-Farber Cancer Institute, Boston, US, <sup>17</sup>Memorial Sloan-Kettering Cancer Center, New York, US

11:24 - 11:36

**LBA11 - Defining the lethal subclone in metastatic lung cancer**

M. Jamal-Hanjani<sup>1</sup>, A. Huebner<sup>2</sup>, N. Mcgranahan<sup>2</sup>, C. Swanton<sup>3</sup>, <sup>1</sup>UCL Cancer Institute/Paul O'Gorman Building, London, GB, <sup>2</sup>Cancer Research UK Lung Cancer Centre of Excellence, London, GB, <sup>3</sup>The Francis Crick Institute, London, GB

11:36 - 11:51

**Invited Discussant 18910, 18920 and LBA11**

S. Turajlic, Royal Marsden Hospital NHS Foundation Trust, London, GB

11:51 - 12:03

**10 - KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies**

A. Georgiou<sup>1</sup>, A. Stewart<sup>2</sup>, P. Thavasulu<sup>2</sup>, E. Coker<sup>2</sup>, S. Poelsterl<sup>2</sup>, B. Al-Lazikani<sup>2</sup>, D. Cunningham<sup>3</sup>, S. Whittaker<sup>2</sup>, U. Banerji<sup>3</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>Institute of Cancer Research, Sutton, GB, <sup>3</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

12:03 - 12:15

**20 - Receptor Tyrosine Kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines.**

P.P. Vitiello<sup>1</sup>, C. Cardone<sup>1</sup>, D. Ciardiello<sup>1</sup>, G. Barra<sup>2</sup>, N. Matrone<sup>1</sup>, V. Belli<sup>1</sup>, G. Martini<sup>3</sup>, L. Poliero<sup>1</sup>, C. Borrelli<sup>1</sup>, M. Terminiello<sup>1</sup>, T. Troiani<sup>1</sup>, F. Morgillo<sup>1</sup>, F. Ciardiello<sup>1</sup>, E. Martinelli<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT, <sup>3</sup>Vall D'Hebron institute o, Barcelona, ES

12:15 - 12:30

**Invited Discussant 10 and 20**

A. Bardelli, Istituto di Candiolo - FPO - IRCCS, Candiolo, IT

**11:00 - 12:30**    **Type: Special Symposium**    **Hall B4 - Room 19**  
**Title: How to balance efficacy and toxicity in Hodgkin's Lymphoma**  
 Chair(s): John Radford, GB; Simonetta Viviani, IT

11:00 - 11:05    **Introduction**  
J. Radford, The Christie NHS Foundation Trust, Manchester, GB

11:05 - 11:25    **Late toxicities**  
F. Van Leeuwen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

11:25 - 11:45    **Limited disease**  
J. Radford, The Christie NHS Foundation Trust, Manchester, GB

11:45 - 12:05    **Advanced disease**  
D. Eichenauer, University Hospital Cologne, Köln, DE

12:05 - 12:25    **Treatment of relapsed disease with novel agents**  
S. Viviani, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

12:25 - 12:30    **Conclusions and perspectives**  
S. Viviani, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

**11:00 - 12:00**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Cancer prevention and early detection from a nursing perspective**  
 Chair(s): Harald Titzer, AT

11:00 - 11:15    **Political and commercial barriers to cancer risk reduction**  
W. Yared, Association of European Cancer Leagues, Brussels, BE

11:15 - 11:30    **HPV vaccination for girls and boys**  
A. Castanon, King's College London - KCL, London, GB

11:30 - 11:45    **Prostate cancer risk in men of different ethnicities**  
D. Kelly, Royal College of Nursing, Cardiff, GB

11:45 - 12:00    **Cancer risk reduction in multicultural communities**  
A. Leppänen, Regional Cancer Center Stockholm Gotland, Stockholm, SE

**11:00 - 11:45** Type: **Young Oncologist session** ICM - Room 14c  
**Title: YO Brunch 1: Fertility and pregnancy in cancer**  
 Chair(s): Matteo Lambertini, BE; Claudia Cardone, IT

11:00 - 11:45 **Fertility and pregnancy in cancer**  
F. Peccatori, Istituto Europeo di Oncologia, Milan, IT

**11:15 - 12:15** Type: **Poster Discussion session** ICM - Room 13  
**Title: Poster Discussion session - Gastrointestinal tumours, colorectal 1**  
 Chair(s): Fortunato Ciardiello, IT; Sebastian Stintzing, DE

11:15 - 11:15 **Session DOI**

11:15 - 11:15 **453PD - 1st-line mFOLFOXIRI + Panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109).**

M. Geissler<sup>1</sup>, T. Klingler<sup>1</sup>, J. Riera Knorrenschild<sup>2</sup>, A. Tannapfel<sup>3</sup>, J. Greeve<sup>4</sup>, T. Seufferlein<sup>5</sup>, S. Kanzler<sup>6</sup>, S. Held<sup>7</sup>, V. Heinemann<sup>8</sup>, A. Reinacher-Schick<sup>9</sup>, U. Martens<sup>10</sup>,  
<sup>1</sup>Klinikum Esslingen, Esslingen, DE, <sup>2</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>3</sup>Ruhr-Universität Bochum, Bochum, DE, <sup>4</sup>St. Vincenz Krankenhaus, Paderborn, DE, <sup>5</sup>Ulm Medical University, Ulm, DE, <sup>6</sup>Leopoldina Krankenhaus Schweinfurt, Schweinfurt, DE, <sup>7</sup>Clinassess, Leverkusen, DE, <sup>8</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>9</sup>Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE, <sup>10</sup>SLK-Kliniken Heilbronn GmbH, Heilbronn, DE

11:15 - 11:15 **LBA22 - Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus Pan or single-agent Pan: translational analyses of the VALENTINO study**

F. Morano<sup>1</sup>, S. Corallo<sup>1</sup>, M. Di Bartolomeo<sup>2</sup>, S. Lonardi<sup>3</sup>, C. Cremolini<sup>4</sup>, L. Rimassa<sup>5</sup>, A. Sartore Bianchi<sup>6</sup>, R. Murialdo<sup>7</sup>, A. Zaniboni<sup>8</sup>, V. Adamo<sup>9</sup>, G. Tomasello<sup>10</sup>, M. Tampellini<sup>11</sup>, L. Fanchini<sup>12</sup>, M. Schirripa<sup>3</sup>, M. Clavarezza<sup>13</sup>, F. Petrelli<sup>14</sup>, R. Longarini<sup>15</sup>, S. Cinieri<sup>16</sup>, F.G. De Braud<sup>1</sup>, F. Pietrantonio<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>4</sup>Azienda Ospedaliera Universitaria S. Chiara, Pisa, IT, <sup>5</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>6</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, <sup>7</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>8</sup>Casa di Cura Poliambulanza, Brescia, IT, <sup>9</sup>AOU Policlinico G. Martino Università di Messina, Messina, IT, <sup>10</sup>Istituti Ospitalieri di Cremona, Cremona, IT, <sup>11</sup>A.O.U. San Luigi Gonzaga, Orbassano, IT, <sup>12</sup>P.O. Ospedale Molinette, Torino, IT, <sup>13</sup>Ospedali Galliera, Genova, IT, <sup>14</sup>Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, IT, <sup>15</sup>AO San Gerardo, Monza, IT, <sup>16</sup>Perrino Hospital, Brindisi, IT

11:15 - 11:15 **454PD - Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer.**



H. Taniguchi<sup>1</sup>, T. Yamanaka<sup>2</sup>, D. Sakai<sup>3</sup>, K. Yamazaki<sup>4</sup>, K. Muro<sup>1</sup>, M. Peeters<sup>5</sup>, T. Price<sup>6</sup>,  
<sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>Yokohama City University Hospital, Yokohama, JP, <sup>3</sup>Osaka University, Osaka, JP, <sup>4</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>5</sup>U.Z.A. University Hospital Antwerp, Edegem, BE, <sup>6</sup>Queen Elizabeth Hospital, Woodville, AU

11:15 - 11:30 **Invited Discussant 453PD, LBA22 and 454PD**

F. Ciardiello, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

11:30 - 11:45 **Q&A led by Discussant**

11:45 - 11:45 **455PD - NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC)**

S. Winther<sup>1</sup>, H. Skuladottir<sup>2</sup>, E. Hofslí<sup>3</sup>, C.-H. Shah<sup>4</sup>, M. Yilmaz<sup>5</sup>, P. Österlund<sup>6</sup>, Å. Berglund<sup>7</sup>, B. Glimelius<sup>7</sup>, C. Qvortrup<sup>8</sup>, H. Sorbye<sup>9</sup>, P. Pfeiffer<sup>1</sup>, <sup>1</sup>Odense University Hospital, Odense C, DK, <sup>2</sup>Regional Hospital West Jutland, Herning, DK, <sup>3</sup>Trondheim University Hospital, Trondheim, NO, <sup>4</sup>Karolinska University Hospital, Stockholm, SE, <sup>5</sup>Aalborg University Hospital, Aalborg, DK, <sup>6</sup>Tampere University Hospital (Tays), Tampere, FI, <sup>7</sup>Uppsala University Hospital, Uppsala, SE, <sup>8</sup>Odense University Hospital, Odense, DK, <sup>9</sup>Haukeland Universitetssykehus, Bergen, NO

11:45 - 11:45 **LBA23 - Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Metastatic Colorectal Cancer (mCRC)**

J. Hays<sup>1</sup>, J. Zhang<sup>2</sup>, J. Berlin<sup>3</sup>, M. O'Hara<sup>4</sup>, M. Shah<sup>5</sup>, W. Reichmann<sup>6</sup>, W. Senapedis<sup>7</sup>, H. Achour<sup>8</sup>, E. Baloglu<sup>6</sup>, S. Shacham<sup>9</sup>, M. Kauffman<sup>10</sup>, <sup>1</sup>Ohio State University, Columbus, US, <sup>2</sup>Moffitt Comprehensive Cancer Center, Tampa, US, <sup>3</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>4</sup>University of Pennsylvania, Philadelphia, US, <sup>5</sup>Weill Cornell Medicine/ New York Presbyterian Hospital, New York, US, <sup>6</sup>Karyopharm Therapeutics, Newton, US, <sup>7</sup>Karyopharm Therapeutics, Inc., Natick, US, <sup>8</sup>Tesaro Inc., Waltham, US, <sup>9</sup>Karyopharm, Newton, US, <sup>10</sup>Karyopharm Therapeutics, Natick, US

11:45 - 12:00 **Invited Discussant 455PD and LBA23**

S. Stintzing, Ludwig Maximilians University - Grosshadern, Munich, DE

12:00 - 12:15 **Q&A led by Discussant**

**11:15 - 12:15** **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 23**  
**Title: Brain metastases in GU malignancies**  
 Chair(s): Anna Patrikidou, GB

11:15 - 11:15 **Session DOI**

11:15 - 11:25 **Germ cell case presentation and discussion**  
A. Patrikidou, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

11:25 - 11:35 **Kidney case presentation and discussion**  
V. Khoo, The Francis Crick Institute, London, GB

11:35 - 11:45 **Bladder case presentation and discussion**  
J.-C. Tonn, Ludwig Maximilians University - Grosshadern, Munich, DE

11:45 - 12:15 **Discussion**  
A. Patrikidou, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

**11:15 - 12:15** **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 20**  
**Title: Expanding the neurooncologist's toolbox: Case-based discussions of challenges & opportunities**  
 Chair(s): Elizabeth Cohen-Jonathan Moyal, FR

11:15 - 11:25 **Methylation-based tumour profiling: A novel tool for improved diagnosis and treatment**  
S. Pfister, HI-STEM gGmbH im Deutschen Krebsforschungszentrum DKFZ, Heidelberg, DE

11:25 - 11:35 **A role for tumor-treating fields?**  
P. Roth, University of Zurich, Zurich, CH

11:35 - 11:45 **SRS and novel systemic therapies: A fruitful partnership?**  
E. Cohen-Jonathan Moyal, Centre Claudius-Regaud, Toulouse, FR

11:45 - 12:15 **Dicsussion**

**12:00 - 13:00** **Type: Poster Display session** **Hall B4 - Room 24**  
**Title: EONS Poster display**

12:00 - 12:00 **CN5 - Patients - power sources for cancer nurses**  
C. Beisel, University Hospital Heidelberg, Heidelberg, DE

- 12:00 - 12:00 **CN6 - BRAF/MEK-inhibition for patients with metastatic melanoma: towards patient-centered care**  
J. Koldenhof<sup>1</sup>, S. Vervoort<sup>2</sup>, C. Nierop<sup>3</sup>, K. Suijkerbuijk<sup>4</sup>, <sup>1</sup>UMC - University Medical Center Utrecht, Utrecht, NL, <sup>2</sup>University Medical Center Utrecht, Utrecht, NL, <sup>3</sup>HU University of Applied sciences, Utrecht, NL, <sup>4</sup>University Hospital Utrecht, Utrecht, NL
- 12:00 - 12:00 **CN7 - Perceptions of Rural Nurses Extending Their Role to Administer Chemotherapy**  
Q. Alnasser<sup>1</sup>, K. Cameron<sup>2</sup>, J. Prouse<sup>3</sup>, <sup>1</sup>King Faisal Specialist Hospital and Research Center, Riyadh, SA, <sup>2</sup>King Faisal Specialist Hospital & Research Center, Riyadh, SA, <sup>3</sup>Royal Adelaide Hospital, Adelaide, AU
- 12:00 - 12:00 **CN8 - AYA cancer nursing - An emerging sub-speciality - the first book about AYA cancer nursing, edited and authored by nurses.**  
S. Smith, Aarhus University Hospital, Aarhus C, DK
- 12:00 - 12:00 **CN9 - Nurse led follow-up for CML patients on oral cancer treatment**  
S. De Wilde<sup>1</sup>, J. De Munter<sup>2</sup>, M. Quaghebeur<sup>2</sup>, D. Mazure<sup>2</sup>, A. De Pauw<sup>2</sup>, B. Casteels<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University hospital Ghent, Gent, BE
- 12:00 - 12:00 **CN10 - Introducing a new role in cancer care, Coordinating Contact Nurses - patient-reported evaluation.**  
B. Westman<sup>1</sup>, H. Ullgren<sup>2</sup>, L. Sharp<sup>1</sup>, <sup>1</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE, <sup>2</sup>Karolinska University Hospital-Solna, Stockholm, SE
- 12:00 - 12:00 **CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: preliminary study.**  
E. Mahía<sup>1</sup>, G. Simó<sup>1</sup>, E. Heras<sup>2</sup>, M. Pascual<sup>2</sup>, F. Cobo<sup>1</sup>, J. Pujadas<sup>1</sup>, S. Albiol<sup>3</sup>, <sup>1</sup>Servei Andorra Atenció Sanitaria, Escaldes-Engordany, AD, <sup>2</sup>Servei Andorra Atenció Sanitaria, Escaldes-Engordany, AD, <sup>3</sup>Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, AD
- 12:00 - 12:00 **CN12 - Systemic Anticancer Therapy Administration Safety**  
S. Toland<sup>1</sup>, A. Simons<sup>2</sup>, <sup>1</sup>Birmingham City University, Birmingham, GB, <sup>2</sup>Birmingham City University, Birmingham city university, GB
- 12:00 - 12:00 **CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: the role of the nurse practitioner for early recognition and management**  
C. Roth, M. Labots, A. Eertwegh, Vrije University Medical Centre (VUMC), Amsterdam, NL
- 12:00 - 12:00 **CN14 - Experiences from a new advanced cancer nursing role in Sweden, an analysis based on EONS Cancer Nursing Education Framework using the Delphi method**  
H. Ullgren, Karolinska University Hospital-Solna, Stockholm, SE

- 12:00 - 12:00 **CN15 - Opinions and Experiences of Patients Receiving Oral Chemotherapy: A Qualitative Study**  
S. Kutlutürkan<sup>1</sup>, Ö. Yurtal<sup>1</sup>, K. Kirca<sup>2</sup>, <sup>1</sup>Gazi Üniversitesi, Ankara, TR, <sup>2</sup>Kırıkkale Üniversitesi, Kırıkkale, TR
- 12:00 - 12:00 **CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for Adolescents and Young Adults (AYAs) with an hematological disease**  
J. De Munter<sup>1</sup>, S. De Wilde<sup>1</sup>, M. Quaghebeur<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University hospital Ghent, Gent, BE
- 12:00 - 12:00 **CN17 - Standardising the psychosocial assessment of oncological patients at Donostia University Hospital**  
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria, Hospital Donostia, San Sebastian, ES
- 12:00 - 12:00 **CN18 - Are there differences between nurses' and patients' perceptions of cancer patients' quality of life in Greece?**  
M. Lavdaniti<sup>1</sup>, E. Gogou<sup>1</sup>, G.-C. Karagiannidou<sup>1</sup>, M. Delibaltidou<sup>1</sup>, E. Zioga<sup>1</sup>, K. Marmara<sup>2</sup>, E. Fradelos<sup>1</sup>, <sup>1</sup>Alexander Technological Educational Institute, Thessaloniki, GR, <sup>2</sup>Alexander Technological Educational Institute, thessaloniki, GR
- 12:00 - 12:00 **CN19 - How an empowerment program can touch cancer survivor's life by improving posttraumatic growth?**  
Y.S. Uzar Ozcetin, Hacettepe University Faculty of Nursing, Ankara, TR
- 12:00 - 12:00 **CN20 - Organising a general oncology nursing outpatient clinic**  
C. Lundgren<sup>1</sup>, A. Lagerquist<sup>1</sup>, M. Högman<sup>2</sup>, U. Östlund<sup>3</sup>, <sup>1</sup>Sjukhus Gävle, Gävle, SE, <sup>2</sup>Uppsala University, Uppsala, SE, <sup>3</sup>Region Gävleborg, Gävle, SE
- 12:00 - 12:00 **CN21 - Job content of advanced practice nurses in Flanders**  
E. Decoene<sup>1</sup>, A. Van Hecke<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University Ghent, Gent, BE
- 12:00 - 12:00 **CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professionals self-efficacy when supporting parents newly diagnosed with cancer who have dependent children**  
C. Semple<sup>1</sup>, E. Mccaughan<sup>2</sup>, <sup>1</sup>Ulster University / South Eastern Health and Social Care Trust, Belfast, GB, <sup>2</sup>Ulster University, Coleraine, GB
- 12:00 - 12:00 **CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals**  
J. Bird<sup>1</sup>, M. Nolan<sup>2</sup>, S. Danson<sup>3</sup>, <sup>1</sup>Weston Park Hospital Cancer Research Centre, Sheffield, GB, <sup>2</sup>University of Sheffield, Sheffield, GB, <sup>3</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB



- 12:00 - 12:00 **CN24 - Assessing the effect of telephone support on patients with myeloma Multiple (MM) in The Catalan Oncology Institut in Girona**  
C. Puigmarti, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona, ES
- 12:00 - 12:00 **CN28 - Transmural collaborative care in oncology: Experiences of general practitioners**  
M. Daem<sup>1</sup>, E. Van Rookeghem<sup>2</sup>, M. Grypdonck<sup>2</sup>, P. Pype<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>Ghent University, Ghent, BE
- 12:00 - 12:00 **CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: a systematic review**  
S. Colomer-Lahiguera<sup>1</sup>, D. Bryant-Lukosius<sup>2</sup>, S. Rietkoetter<sup>2</sup>, L. Martelli<sup>2</sup>, K. Ribic<sup>3</sup>, A. Orcurto<sup>1</sup>, R. Juergens<sup>4</sup>, M. Eicher<sup>5</sup>, <sup>1</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>2</sup>McMaster University, Hamilton, CA, <sup>3</sup>IBCSG International Breast Cancer Study Group, Bern, CH, <sup>4</sup>Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, CA, <sup>5</sup>University of Lausanne, Lausanne, CH
- 12:00 - 12:00 **CN30 - Laryngectomized patients caregivers' life experience: a phenomenological study**  
V. Bressan<sup>1</sup>, E. Dri<sup>1</sup>, S. Stevanin<sup>2</sup>, L. Cadorin<sup>3</sup>, A. Rizzuto<sup>4</sup>, G. Bulfone<sup>1</sup>, L. Ghirotto<sup>5</sup>, <sup>1</sup>University of Udine, Udine, IT, <sup>2</sup>Veneto Region, Venice, IT, <sup>3</sup>National Cancer Institute CRO Aviano, Aviano, IT, <sup>4</sup>Udine University Hospital, Udine, IT, <sup>5</sup>Azienda Santa Maria Nuova-IRCCS, Reggio Emilia, IT
- 12:00 - 12:00 **CN31 - Comparing nurses' and patients' research priorities in cancer care: A mixed methods systematic review**  
L. Cadorin<sup>1</sup>, I. Truccolo<sup>2</sup>, V. Bressan<sup>3</sup>, N. Suter<sup>4</sup>, <sup>1</sup>Cro, Pordenone, IT, <sup>2</sup>CRO Aviano National Cancer Institute, Aviano, IT, <sup>3</sup>University of Udine, Udine, IT, <sup>4</sup>CRO Aviano National Cancer Institute, Pordenone, IT
- 12:00 - 12:00 **CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy**  
A. Psychogyiou, S. Katsaragakis, C. Lemonidou, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:00 - 12:00 **CN33 - A new beginning of collaboration - the Danish Cancer Nursing Research Network**  
K. Dieperink<sup>1</sup>, M. Kjerholt<sup>2</sup>, P. Riis Olsen<sup>3</sup>, <sup>1</sup>Odense University Hospital, Odense C, DK, <sup>2</sup>Sjællands Universitets Hospital, Roskilde, DK, <sup>3</sup>Aarhus University Hospital, Aarhus, DK
- 12:00 - 12:00 **CN34 - Individual network meetings in cancer care - From young people with cancer to adults with brain tumours**  
P. Riis Olsen, Aarhus University Hospital, Aarhus, DK
- 12:00 - 12:00 **CN35 - Does being cancer patient or family caregiver of cancer patient effect**

**bone marrow donation awareness?**

G. Bagcivan<sup>1</sup>, N. Ozen<sup>2</sup>, D. Bayrak<sup>3</sup>, F.I. Cinar<sup>4</sup>, <sup>1</sup>Gulhane Training and Research Hospital, Ankara, TR, <sup>2</sup>Istinye University, Istanbul, TR, <sup>3</sup>Cankiri Karatekin University, Cankiri, TR, <sup>4</sup>University of Health Sciences, Ankara, TR

- 12:00 - 12:00 **CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment**  
C. Johnston<sup>1</sup>, M. Tanay<sup>2</sup>, <sup>1</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>2</sup>King's College London, London, GB
- 12:00 - 12:00 **CN37 - Evaluation of support and information needs for patients with cancer in a Phase I trials unit.**  
S. Stapleton<sup>1</sup>, L. O'Leary<sup>1</sup>, M. Van Zyl<sup>2</sup>, J. Hanwell<sup>1</sup>, T. Wiseman<sup>3</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>3</sup>The Royal Marsden NHS Foundation Trust, London, GB
- 12:00 - 12:00 **CN38 - Dignity of Greek patients with advanced cancer: a cross-sectional study**  
S. Katsaragakis, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:00 - 12:00 **CN39 - Development and implementation of national guidelines on lifestyle issues and cancer -Report from an on-going quality improvement project**  
K. Vuollet Karlsson<sup>1</sup>, C. Landegren<sup>2</sup>, B. Westman<sup>2</sup>, <sup>1</sup>Norrlands universitetssjukhus, Umea, SE, <sup>2</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:00 - 12:00 **CN40 - Developing a Patient Reported Experience Measure (PREM) in Secondary Breast Cancer (SBC)**  
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke, The Christie NHS Foundation Trust, Manchester, GB
- 12:00 - 12:00 **CN41 - Cancer situation in sub-Saharan Countries: development of educational, diagnosis and treatment plans.**  
J. De La Torre-Montero<sup>1</sup>, N. Gil-Gómez<sup>2</sup>, J. Ribes Bernal<sup>3</sup>, N. Domenech Climent<sup>4</sup>, A. Ojer Perea<sup>5</sup>, P. Beorlegui Murillo<sup>5</sup>, J.M. Gavala Arjona<sup>6</sup>, R. Cumplido Corbacho<sup>7</sup>, I. Magallon Pedrera<sup>8</sup>, M.A. Peñuelas Saiz<sup>8</sup>, <sup>1</sup>SPANISH SOCIETY OF ONCOLOGY NURSING, Madrid, ES, <sup>2</sup>HOSPITAL QUIRÓN MADRID, MADRID, ES, <sup>3</sup>HOSPITAL CLINIC, BARCELONA, ES, <sup>4</sup>HOSPITAL VIRGEN DE LOS LIRIOS, ALCOY, ES, <sup>5</sup>CLINICA UNIVERSITARIA DE NAVARRA, PAMPLONA, ES, <sup>6</sup>HOSPITAL SON ESPASES, PALMA DE MALLORCA, ES, <sup>7</sup>HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLE, ES, <sup>8</sup>Hospital Universitari Vall d'Hebron, BARCELONA, ES
- 12:00 - 12:00 **CN42 - The Gastrointestinal and Lymphoma unit Lead Nurse Research role in Royal Marsden Hospital.**  
J. Duncan<sup>1</sup>, V. Michalarea<sup>2</sup>, T. Coyne<sup>1</sup>, J. Thomas<sup>1</sup>, D. Cunningham<sup>2</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

- 12:00 - 12:00 **CN43 - Patients' learning and participation in their breast cancer care**  
L. Boman<sup>1</sup>, K. Sandelin<sup>2</sup>, Y. Wengström<sup>3</sup>, C. Silén<sup>1</sup>, <sup>1</sup>Karolinska Institute, Stockholm, SE, <sup>2</sup>Karolinska Institutet - Dept of Oncology-Pathology, Stockholm, SE, <sup>3</sup>Karolinska Institutet, Huddinge, SE
- 12:00 - 12:00 **CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration.**  
S.Y. Oh<sup>1</sup>, J.M. Lee<sup>1</sup>, J.W. Kim<sup>1</sup>, S.H. Kim<sup>1</sup>, J.M. Park<sup>1</sup>, G.Y. Yeo<sup>1</sup>, J.E. Hyun<sup>1</sup>, J.-H. Park<sup>2</sup>, <sup>1</sup>Asan Medical Center, Seoul, KR, <sup>2</sup>Ajou Univ. Hospital, Suwon, KR
- 12:00 - 12:00 **CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy**  
A. Frade, S. Miguel, Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P.E., LISBOA, PT
- 12:00 - 12:00 **CN46 - Safe navigation of CARs in a changing landscape**  
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB
- 12:00 - 12:00 **CN47 - Patients' interpretations and experiences of participation in cancer care**  
J. Jackson, J. Rundgren, Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:00 - 12:00 **CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab**  
M. Qiu<sup>1</sup>, Y. Chen<sup>2</sup>, B.-L. Zhang<sup>2</sup>, X.-Y. Wang<sup>2</sup>, <sup>1</sup>West China Hospital, Sichuan University, Chengdu, Sichuan Province, CN, <sup>2</sup>West China Hospital, Chengdu, CN
- 12:00 - 12:00 **CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care**  
J. De Munter<sup>1</sup>, P. Crombez<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>Jules Bordet, Brussel, BE
- 12:00 - 12:00 **CN50 - Overview of an Acute Oncology Service in A UK Cancer Centre**  
M. Foulkes, Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB
- 12:00 - 12:00 **CN51 - The development and evaluation of an online oncology portal**  
J. De Munter<sup>1</sup>, E. Decoene<sup>2</sup>, A. Van Hecke<sup>3</sup>, <sup>1</sup>Ghent University Hospital, Ghent, BE, <sup>2</sup>Gent University Hospital, Gent, BE, <sup>3</sup>University Ghent, Gent, BE
- 12:00 - 12:00 **CN52 - Pilot Study - Nurses' Role in Management of Cutaneous Toxicity in Patients with Targeted Therapies Anti EGFR-Is' Treatment.**  
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso, Istituto Oncologico Veneto IRCCS, Padova, IT

- 12:00 - 12:00 **CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?**  
D. Oliva<sup>1</sup>, F. Lewin<sup>1</sup>, N. Lewin<sup>2</sup>, M. Nilsson<sup>3</sup>, M. Strandéus<sup>1</sup>, B.-Å. Andersson<sup>2</sup>, L. Sharp<sup>4</sup>,  
<sup>1</sup>County Hospital Ryhov, Jönköping, SE, <sup>2</sup>Laboratory Medicine, Jönköping, SE, <sup>3</sup>Futurum -  
, Jönköping, SE, <sup>4</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:00 - 12:00 **CN58 - Effect of Aromatherapy Massage on Chemotherapy-Induced Peripheral Neuropathic Pain and Fatigue in Patients Receiving Oxaliplatin**  
N. Izgu<sup>1</sup>, L. Ozdemir<sup>2</sup>, F. Bugdayci Basal<sup>3</sup>, <sup>1</sup>Hacettepe University Faculty of Nursing, Ankara, TR, <sup>2</sup>Hacettepe University, Ankara, TR, <sup>3</sup>Ataturk Egitim ve Arastirma Hastanesi tibbi onkoloji klinik, Izmir, TR
- 12:00 - 12:00 **CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital**  
C. Palassari, S. Katsaragakis, J. Kaklamanos, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:00 - 12:00 **CN60 - The experience of dysgeusia in allogenic hematopoietic cell transplantation survivors: a qualitative study**  
D. Bomben<sup>1</sup>, A. Bin<sup>2</sup>, M. Venturini<sup>1</sup>, T. Bulfone<sup>1</sup>, L. Ghirotto<sup>3</sup>, V. Bressan<sup>1</sup>, <sup>1</sup>University of Udine, Udine, IT, <sup>2</sup>Udine University Hospital, Udine, IT, <sup>3</sup>Azienda Santa Maria Nuova-IRCCS, Reggio Emilia, IT
- 12:00 - 12:00 **CN61 - "It may not affect you" -- Lived experiences and support needs of women who developed peripheral neuropathy following chemotherapy treatment for cancer.**  
M. Tanay<sup>1</sup>, J. Armes<sup>2</sup>, <sup>1</sup>King's College London, London, GB, <sup>2</sup>University of Surrey, Surrey, GB
- 12:00 - 12:00 **CN62 - App about chemotherapy - helping the patient with cancer**  
B. Espersen, Aarhus University Hospital, Aarhus, DK
- 12:00 - 12:00 **CN63 - Usability Test For a CINV Diary Application For Smartphones at Oncology Nursing**  
P. Fernández- Ortega<sup>1</sup>, Y. Escobar<sup>2</sup>, E. Trigos<sup>3</sup>, R. Blat<sup>4</sup>, M. Cantero<sup>2</sup>, A. Alvarez<sup>5</sup>,  
<sup>1</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>2</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>3</sup>Hospital La Fé, Valencia, ES, <sup>4</sup>Hospital Mar Parc Salut, Barcelona, ES, <sup>5</sup>Hospital de Leon, Leon, ES
- 12:00 - 12:00 **CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the Memorial Symptom Assessment Scale**  
D. Palitzika<sup>1</sup>, E. Fradelos<sup>1</sup>, V. Alikari<sup>1</sup>, P. Charitopoulos<sup>1</sup>, E. Zioga<sup>1</sup>, S. Zyga<sup>2</sup>, M. Lavdaniti<sup>1</sup>, <sup>1</sup>Alexander Technological Educational Institute, Thessaloniki, GR, <sup>2</sup>University of Peloponnesus, Thessaloniki, GR
- 12:00 - 12:00 **CN65 - How to monitor outpatients undergoing active anticancer treatment? A**



**feasibility study of the web-based tool “Onco’nect®”**

M. Belhadj<sup>1</sup>, E. Kempf<sup>2</sup>, A. Lebel<sup>2</sup>, A. Guillemin<sup>2</sup>, H. Boussion<sup>3</sup>, C. Joly<sup>2</sup>, I. Baumgaertner<sup>4</sup>, E. Assaf<sup>5</sup>, C. Saldana<sup>4</sup>, B. Rousseau<sup>4</sup>, C. Tournigand<sup>4</sup>, <sup>1</sup>Université Paris-Est Créteil Val de Marne, Faculté de Médecine, Créteil, FR, <sup>2</sup>Hôpital Henri Mondor, AP-HP, Créteil, FR, <sup>3</sup>Assistance Publique - Hôpitaux De Paris, Paris, FR, <sup>4</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>5</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR

12:00 - 12:00 **CN66 - Medical makeup in cancer patients and its impact in their quality of life**  
R. Lechou, M. Lavdaniti, Alexander Technological Educational Institute, Thessaloniki, GR

**12:30 - 13:30** **Type: Poster Display session** **Hall A3 -**  
**Title: Poster display session: Biomarkers, Gynaecological cancers,** **Poster Area**  
**Haematological malignancies, Immunotherapy of cancer, New** **Networking**  
**diagnostic tools, NSCLC - early stage, locally advanced & metastatic,** **Hub**  
**SCLC, Thoracic malignancies, Translational research**

12:30 - 12:30 **Biomarkers**

12:30 - 12:30 **66P - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.**

T. Looney<sup>1</sup>, G. Lowman<sup>2</sup>, L. Miller<sup>2</sup>, E. Linch<sup>3</sup>, <sup>1</sup>Thermo Fisher Scientific, Singapore, SG, <sup>2</sup>Thermo Fisher Scientific, South San Francisco, US, <sup>3</sup>Thermo Fisher Scientific, Carlsbad, US

12:30 - 12:30 **67P - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors**

A. Awada<sup>1</sup>, F. Morschhauser<sup>2</sup>, J.-P. Machiels<sup>3</sup>, G. Salles<sup>4</sup>, S. Rottey<sup>5</sup>, S. Rule<sup>6</sup>, D. Cunningham<sup>7</sup>, F. Peyrade<sup>8</sup>, C. Fruchart<sup>9</sup>, H.-T. Arkenau<sup>10</sup>, I. Genvresse<sup>11</sup>, K. Koechert<sup>11</sup>, G. Cisternas<sup>11</sup>, C. Granvil<sup>12</sup>, C. Pena<sup>12</sup>, L. Liu<sup>12</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>CHRU - Hôpital Claude Huriez, Lille, FR, <sup>3</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>4</sup>Civil Hospices of Lyon, University Claude Bernard Lyon-1, Pierre Benite, FR, <sup>5</sup>Gent University Hospital, Gent, BE, <sup>6</sup>Plymouth University, Plymouth, GB, <sup>7</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>8</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>9</sup>Centre Francois Baclesse, Caen, FR, <sup>10</sup>Sarah Cannon Research Institute SCRI UK, London, GB, <sup>11</sup>Bayer AG, Berlin, DE, <sup>12</sup>Bayer HealthCare Pharmaceuticals Inc, Whippany, US

12:30 - 12:30 **68P - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association**

M. Montesin<sup>1</sup>, C. Chung<sup>2</sup>, E. Sokol<sup>3</sup>, S. Khan<sup>4</sup>, H. Kang<sup>5</sup>, L. Albacker<sup>1</sup>, J. Johnson<sup>6</sup>, G. Frampton<sup>3</sup>, V. Miller<sup>3</sup>, J. Ross<sup>7</sup>, S. Ali<sup>3</sup>, <sup>1</sup>Foundation Medicine, Inc., Cambridge, MA, US, <sup>2</sup>H. Lee Moffitt Cancer Center and Research Institute, Tampa, US, <sup>3</sup>Foundation Medicine, Inc., Cambridge, US, <sup>4</sup>University of Texas Southwestern Medical Center, Dallas, US, <sup>5</sup>Johns Hopkins University, Baltimore, US, <sup>6</sup>Thomas Jefferson University, Philadelphia, US, <sup>7</sup>Foundation Medicine Inc., Cambridge, US

- 12:30 - 12:30 **69P - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)**  
H. Chang<sup>1</sup>, S. Srinivasan<sup>2</sup>, A. Sasson<sup>3</sup>, R. Golhar<sup>3</sup>, D. Greenawalt<sup>1</sup>, S. Kirov<sup>3</sup>, J. Szustakowski<sup>1</sup>, <sup>1</sup>Bristol-Myers Squibb, Princeton, US, <sup>2</sup>Bristol-Myers Squibb, Hopewell, US, <sup>3</sup>Bristol-Myers Squibb, Pennington, US
- 12:30 - 12:30 **70P - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC**  
E. Smit<sup>1</sup>, J. Aerts<sup>2</sup>, M. Muller<sup>3</sup>, A.-L. Niemeijer<sup>4</sup>, H. Roder<sup>5</sup>, C. Oliveira<sup>5</sup>, J. Roder<sup>5</sup>, <sup>1</sup>VU University Medical Centre, Amsterdam, NL, <sup>2</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>3</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>4</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>5</sup>Biodesix, Inc., Boulder, US
- 12:30 - 12:30 **71P - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).**  
R. Ferguson<sup>1</sup>, A. Archambault<sup>1</sup>, D. Simpson<sup>1</sup>, E. Kazlow<sup>1</sup>, R. Lax<sup>1</sup>, U. Moran<sup>1</sup>, M. Wilson<sup>2</sup>, R. Shapiro<sup>2</sup>, A. Pavlick<sup>2</sup>, I. Osman<sup>1</sup>, D. Polsky<sup>1</sup>, T. Kirchhoff<sup>3</sup>, <sup>1</sup>New York University Medical Center, New York, US, <sup>2</sup>New York University - Perlmutter Cancer Center - Langone Medical Center, New York, US, <sup>3</sup>New York University, New York, US
- 12:30 - 12:30 **72P - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma**  
M. Yang<sup>1</sup>, J. Li<sup>2</sup>, N. Zhang<sup>2</sup>, H. Xing<sup>1</sup>, J. Liu<sup>1</sup>, <sup>1</sup>Shandong Cancer Hospital, Jinan, CN, <sup>2</sup>Shandong Cancer Hospital, Ji'nan, CN
- 12:30 - 12:30 **73P - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness**  
C.T. Choy<sup>1</sup>, C.H. Wong<sup>2</sup>, S. Chan<sup>2</sup>, <sup>1</sup>The Chinese University of Hong Kong, Shatin, HK, <sup>2</sup>The Chinese University of Hong Kong, Hong Kong, HK
- 12:30 - 12:30 **74P - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials**  
A. Madi<sup>1</sup>, D. Fisher<sup>2</sup>, T. Maughan<sup>3</sup>, J. Colley<sup>4</sup>, A. Meade<sup>2</sup>, J. Maynard<sup>4</sup>, V. Humphreys<sup>4</sup>, H. Wasan<sup>5</sup>, R. Adams<sup>4</sup>, S. Idziaszczyk<sup>4</sup>, R. Harris<sup>4</sup>, R. Kaplan<sup>2</sup>, J. Cheadle<sup>4</sup>, <sup>1</sup>Clatterbridge Cancer Center, Wirral, GB, <sup>2</sup>MRC, London, GB, <sup>3</sup>University of Oxford, Oxford, GB, <sup>4</sup>Cardiff University, Cardiff, GB, <sup>5</sup>Imperial College Healthcare NHS Trust, London, GB
- 12:30 - 12:30 **75P - The landscape of NTRK fusions in Chinese solid tumor patients**  
Q. Ling<sup>1</sup>, B. Li<sup>2</sup>, X. Wu<sup>3</sup>, H. Wang<sup>4</sup>, Y. Shen<sup>5</sup>, M. Xiao<sup>6</sup>, Z. Yang<sup>6</sup>, R. Ma<sup>7</sup>, D. Chen<sup>7</sup>, H. Chen<sup>7</sup>, X. Dong<sup>7</sup>, W. Wang<sup>7</sup>, M. Yao<sup>8</sup>, <sup>1</sup>the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, <sup>2</sup>Affiliated Tumor Hospital of Guangxi Medical University, Nanning, CN, <sup>3</sup>Nanfang Hospital, Guangzhou, CN, <sup>4</sup>Cancer Hospital of Shantou University Medical College, Shantou, CN, <sup>5</sup>Zhongda Hospital, Medical School, Southeast University, Nanjing, CN, <sup>6</sup>Shu Lan (Hangzhou) Hospital, Zhejiang University

International Hospital, Hangzhou, CN, <sup>7</sup>Origimed, Shanghai, CN, <sup>8</sup>Origimed, Shanghai, CN

- 12:30 - 12:30 **76P - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma**  
C.-H. Lee<sup>1</sup>, R. Motzer<sup>1</sup>, H. Glen<sup>2</sup>, M.D. Michaelson<sup>3</sup>, J. Larkin<sup>4</sup>, Y. Minoshima<sup>5</sup>, M. Kanekiyo<sup>6</sup>, R. Dairiki<sup>6</sup>, P. Sachdev<sup>7</sup>, C. Dutcus<sup>7</sup>, Y. Funahashi<sup>8</sup>, M. Voss<sup>1</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>3</sup>Massachusetts General Hospital, Boston, US, <sup>4</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>5</sup>Eisai Co., Ltd. Tsukuba Research Laboratories, Tsukuba-shi, JP, <sup>6</sup>Eisai Co., Ltd., Ibaraki, JP, <sup>7</sup>Eisai Inc, Woodcliff Lake, US, <sup>8</sup>Eisai Inc., Andover, US
- 12:30 - 12:30 **77P - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks**  
A. Meier<sup>1</sup>, K. Nekolla<sup>1</sup>, S. Earle<sup>2</sup>, L. Hewitt<sup>3</sup>, T. Aoyama<sup>4</sup>, T. Yoshikawa<sup>5</sup>, G. Schmidt<sup>1</sup>, R. Huss<sup>1</sup>, H. Grabsch<sup>3</sup>, <sup>1</sup>Definiens AG, Munich, DE, <sup>2</sup>University of Leeds, Leeds, GB, <sup>3</sup>Maastricht University, Maastricht, NL, <sup>4</sup>Yokohama City University Hospital, Yokohama, JP, <sup>5</sup>National Cancer Center Hospital, Tokyo, JP
- 12:30 - 12:30 **78P - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System**  
A. Parikh<sup>1</sup>, S. Ali<sup>2</sup>, A. Moran<sup>3</sup>, P. Crilley<sup>3</sup>, A. Schrock<sup>4</sup>, A. Tan<sup>5</sup>, P. Reddy<sup>2</sup>, V. Miller<sup>4</sup>, J. Ross<sup>6</sup>, S. Zook<sup>3</sup>, R. Alvarez<sup>3</sup>, M. Markman<sup>3</sup>, <sup>1</sup>Cancer Treatment Centers of America, Philadelphia, US, <sup>2</sup>Foundation Medicine, Boston, US, <sup>3</sup>Cancer Treatment Centers of America, Newnan, US, <sup>4</sup>Foundation Medicine, Inc., Cambridge, US, <sup>5</sup>Cancer Treatment Centers of America, Goodyear, US, <sup>6</sup>Foundation Medicine Inc., Cambridge, US
- 12:30 - 12:30 **79P - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies**  
Y. Li<sup>1</sup>, J. Sun<sup>2</sup>, J. Skoletsy<sup>2</sup>, C. Milbury<sup>3</sup>, C. Burns<sup>2</sup>, W.-K. Yip<sup>3</sup>, N. Dewal<sup>1</sup>, J. He<sup>2</sup>, J. Tuesdell<sup>2</sup>, E. Peters<sup>4</sup>, E. Schleifman<sup>5</sup>, J. Noe<sup>6</sup>, S. Jenkins<sup>7</sup>, J. Elvin<sup>1</sup>, G. Otto<sup>2</sup>, D. Lipson<sup>3</sup>, J. Ross<sup>8</sup>, V. Miller<sup>1</sup>, M. Doherty<sup>2</sup>, C. Vietz<sup>2</sup>, <sup>1</sup>Foundation Medicine, Inc., Cambridge, US, <sup>2</sup>Foundation Medicine, Inc., Cambridge, MA, US, <sup>3</sup>Foundation Medicine, Cambridge, US, <sup>4</sup>Genentech, Inc., San Francisco, US, <sup>5</sup>Genentech, Inc., South San Francisco, US, <sup>6</sup>Hoffmann La Roche, Basel, CH, <sup>7</sup>Astrazeneca, Macclesfield, GB, <sup>8</sup>SUNY Upstate Medical University, Syracuse, US
- 12:30 - 12:30 **80P - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.**  
B. Torrejón<sup>1</sup>, M. Pedregal Trujillo<sup>1</sup>, A. Santos<sup>1</sup>, J. Rubio<sup>1</sup>, M. Luque<sup>1</sup>, M. Sanz<sup>1</sup>, C. Carames<sup>2</sup>, S. Zazo<sup>1</sup>, J. Madoz-Gurpide<sup>1</sup>, F. Rojo<sup>1</sup>, J. Garcia Foncillas<sup>1</sup>, C. Ion<sup>1</sup>, <sup>1</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>2</sup>University Hospital "Fundacion Jimenez Diaz", madrid, ES
- 12:30 - 12:30 **81P - The functional MDM4 genetic variant in advanced lung adenocarcinoma**

**patients treated with EGFR-TKIs**

N. Zhang<sup>1</sup>, M. Yang<sup>2</sup>, H. Xing<sup>2</sup>, J. Liu<sup>2</sup>, <sup>1</sup>Shandong Cancer Hospital, Ji'nan, CN, <sup>2</sup>Shandong Cancer Hospital, Jinan, CN

- 12:30 - 12:30 **82P - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma**
- M. Khattak<sup>1</sup>, E. Gray<sup>2</sup>, A. Reid<sup>2</sup>, M. Periera<sup>2</sup>, A. Mcevoy<sup>2</sup>, C. Aya-Bonilla<sup>2</sup>, T. Meniawy<sup>3</sup>, A. Didan<sup>4</sup>, M. Millward<sup>3</sup>, M. Ziman<sup>2</sup>, <sup>1</sup>Royal Perth Hospital, Perth, AU, <sup>2</sup>Edith Cowan University, Perth, AU, <sup>3</sup>School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU, <sup>4</sup>Fiona Stanley Hospital, Perth, AU
- 12:30 - 12:30 **83P - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer**
- Y.-Z. Liu<sup>1</sup>, D. Hodgson<sup>1</sup>, G. Locker<sup>2</sup>, Z. Lai<sup>3</sup>, D. Balcerzak<sup>3</sup>, A. Sharpe<sup>3</sup>, J.C. Barrett<sup>4</sup>, M. Orr<sup>5</sup>, T. Gutjahr<sup>6</sup>, B. Dougherty<sup>7</sup>, M. Roudier<sup>3</sup>, X. Shi<sup>8</sup>, R. Miller<sup>9</sup>, W.H. Kim<sup>10</sup>, X. Zeng<sup>11</sup>, A. Ochiai<sup>12</sup>, S.-A. Im<sup>13</sup>, R.-H. Xu<sup>14</sup>, N. Boku<sup>15</sup>, Y.-J. Bang<sup>13</sup>, <sup>1</sup>Astrazeneca, Macclesfield, GB, <sup>2</sup>Astra Zeneca, Gaithersburg, US, <sup>3</sup>AstraZeneca, Cambridge, GB, <sup>4</sup>AstraZeneca, Waltham, US, <sup>5</sup>AstraZeneca UK, Melbourn, GB, <sup>6</sup>AstraZeneca UK, Royston, GB, <sup>7</sup>AstraZeneca, Boston, US, <sup>8</sup>AstraZeneca, Gaithersburg, US, <sup>9</sup>Ventana Medical Systems, Tucson, US, <sup>10</sup>Seoul National University College of Medicine, Seoul, KR, <sup>11</sup>Chinese Academy of Medical Sciences, Beijing, CN, <sup>12</sup>National Cancer Center Hospital East, Chiba, JP, <sup>13</sup>Seoul National University Hospital, Seoul, KR, <sup>14</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>15</sup>St. Marianna University School of Medicine, Kawasaki, JP
- 12:30 - 12:30 **84P - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study**
- T. Yang<sup>1</sup>, H. Xing<sup>1</sup>, G. Wang<sup>2</sup>, S. Cai<sup>3</sup>, F. Shen<sup>1</sup>, <sup>1</sup>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, CN, <sup>2</sup>Peking University Health Science Center, Beijing, CN, <sup>3</sup>3D Medicines Inc. Shanghai, P.R. China, Shanghai, CN
- 12:30 - 12:30 **85P - Dissecting Gastric Cancer biology and how and when to use immunotherapy**
- M. Das Thakur, K. Okrah, D. Shames, P. Hegde, C. Bais, Genentech Inc. - Roche - USA, South San Francisco, US
- 12:30 - 12:30 **86P - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence**
- K. Birkenkamp-Demtröder<sup>1</sup>, E. Christensen<sup>1</sup>, H. Sethi<sup>2</sup>, S. Sharma<sup>2</sup>, H.-T. Wu<sup>2</sup>, A. Taber<sup>3</sup>, M. Agerbæk<sup>1</sup>, R. Swenerton<sup>2</sup>, R. Salari<sup>2</sup>, D. Hafez<sup>2</sup>, I. Nordentoft<sup>3</sup>, P. Lamy<sup>3</sup>, R. Srinivasan<sup>2</sup>, M. Balcioglu<sup>2</sup>, S. Navarro<sup>2</sup>, Z. Assaf<sup>2</sup>, B. Zimmermann<sup>4</sup>, J. Lin<sup>4</sup>, J. Bjerggaard Jensen<sup>3</sup>, L. Dyrskjøt<sup>3</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Natera Inc., San Carlos, US, <sup>3</sup>Aarhus University Hospital, Aarhus N, DK, <sup>4</sup>Natera, San Carlos, US
- 12:30 - 12:30 **87P - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas**



E. Imyanitov<sup>1</sup>, T. Sokolova<sup>1</sup>, G. Raskin<sup>2</sup>, A. Ivantsov<sup>1</sup>, A. Iyevleva<sup>1</sup>, A. Sokolenko<sup>3</sup>, <sup>1</sup>N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, <sup>2</sup>A.M. Granov Russian Scientific Centre of Radiology and Surgical Technologies, Saint-Petersburg, RU, <sup>3</sup>St. Petersburg Clinical and Scientific Oncological Center, Saint-Petersburg, RU

12:30 - 12:30

**88P - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group**

M. Del Re<sup>1</sup>, S. Crucitta<sup>2</sup>, A. Sbrana<sup>2</sup>, E. Rofi<sup>2</sup>, F. Paolieri<sup>2</sup>, L. Galli<sup>3</sup>, A. Falcone<sup>2</sup>, R. Van Schaik<sup>4</sup>, G. Jenster<sup>4</sup>, R. Morganti<sup>2</sup>, S. Pignata<sup>5</sup>, R. Danesi<sup>6</sup>, <sup>1</sup>Univeristy Degli Studi di Pisa, Pisa, IT, <sup>2</sup>Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, <sup>3</sup>Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori, Pisa, IT, <sup>4</sup>Erasmus University, Rotterdam, NL, <sup>5</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>6</sup>Università di Pisa, Pisa, IT

12:30 - 12:30

**89P - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases**

Y. Zheng<sup>1</sup>, Y. Ding<sup>1</sup>, C. Xiao<sup>1</sup>, W. Zhong<sup>1</sup>, X. Teng<sup>1</sup>, Q. Gao<sup>1</sup>, Q. Wang<sup>2</sup>, Y. Sun<sup>3</sup>, C. Chen<sup>4</sup>, L. Chen<sup>4</sup>, J. Zhu<sup>4</sup>, Q. Xu<sup>4</sup>, N. Xu<sup>1</sup>, <sup>1</sup>The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>3</sup>Canhelp Genomics, Hangzhou, CN, <sup>4</sup>Canhelp Genomics Ltd., Hangzhou, CN

12:30 - 12:30

**90P - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types**

J. Bacher<sup>1</sup>, R. Halberg<sup>2</sup>, P. Ward<sup>3</sup>, E. Udho<sup>1</sup>, K. Murphy<sup>4</sup>, M. Uhr<sup>1</sup>, L. Dubeau<sup>3</sup>, J. Pettersson<sup>3</sup>, D. Storts<sup>1</sup>, S. Gallinger<sup>5</sup>, D. Buchanan<sup>6</sup>, M. Jenkins<sup>6</sup>, N. Lindor<sup>7</sup>, J. Eshleman<sup>8</sup>, <sup>1</sup>Promega Corporation, Madison, US, <sup>2</sup>University of Wisconsin-Madison, Madison, US, <sup>3</sup>University of Southern California, Los Angeles, US, <sup>4</sup>ProPath, Dallas, US, <sup>5</sup>University of Toronto, Toronto, CA, <sup>6</sup>The University of Melbourne, Melbourne, AU, <sup>7</sup>Mayo Clinic, Scottsdale, US, <sup>8</sup>Johns Hopkins University, Baltimore, US

12:30 - 12:30

**91P - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients**

Z. Wang<sup>1</sup>, H. Qin<sup>2</sup>, M. Wang<sup>3</sup>, J. Gong<sup>1</sup>, X. Wang<sup>1</sup>, J. Li<sup>1</sup>, J. Gao<sup>4</sup>, Z. Li<sup>1</sup>, D. Wang<sup>2</sup>, S. Cai<sup>2</sup>, Y. Bai<sup>2</sup>, L. Xiong<sup>5</sup>, F. Li<sup>5</sup>, L. Shen<sup>1</sup>, <sup>1</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>2</sup>3D medicines Inc., Shanghai, CN, <sup>3</sup>Changhai Hospital, Shanghai, CN, <sup>4</sup>Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, <sup>5</sup>3D Medicine Inc., Shanghai, China., Shanghai, CN

12:30 - 12:30

**92P - Vall d'Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).**

C. Hierro<sup>1</sup>, I. Matos<sup>1</sup>, J. Martin-Liberal<sup>2</sup>, M. Ochoa De Olza Amat<sup>1</sup>, E. Felip<sup>3</sup>, M. Costa Rivas<sup>4</sup>, M. Vieito Villar<sup>5</sup>, I. Brana<sup>6</sup>, A. Azaro<sup>1</sup>, M.C. Perez-Gago<sup>2</sup>, A. Gros<sup>2</sup>, J. Carles<sup>7</sup>, A. Oaknin<sup>1</sup>, T. Macarulla<sup>8</sup>, C. Saura<sup>9</sup>, N. Pardo<sup>8</sup>, E. Muñoz-Couselo<sup>10</sup>, J. Tabernero<sup>11</sup>, R. Dienstmann<sup>1</sup>, E. Garralda<sup>2</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>Vall

d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>3</sup>Germans Trias i Pujol Hospital, Catalan Institute of Oncology (ICO)-Badalona, Badalona, ES, <sup>4</sup>Hospital Universitario Alvaro Cunqueiro, Vigo, ES, <sup>5</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>6</sup>Vall D'Hebron Institute of Oncology, Barcelona, ES, <sup>7</sup>Vall Hebron Institute of Oncology, Barcelona, ES, <sup>8</sup>Vall d'Hebron University Hospital; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>9</sup>Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES, <sup>10</sup>Vall d'Hebron Hospital, Barcelona, ES, <sup>11</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES

12:30 - 12:30 **93P - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients**

N. Brieu<sup>1</sup>, C. Gavriel<sup>2</sup>, D. Harrison<sup>2</sup>, G. Schmidt<sup>1</sup>, P. Caie<sup>1</sup>, <sup>1</sup>Definiens AG, Munich, DE, <sup>2</sup>University of St Andrews, St Andrews, GB

12:30 - 12:30 **94P - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma**

A. Bernard-Tessier<sup>1</sup>, E. Jeannot<sup>2</sup>, D. Guenat<sup>3</sup>, M. Michel<sup>2</sup>, C. Proudhon<sup>2</sup>, A. Vincent-Salomon<sup>4</sup>, I. Bièche<sup>2</sup>, J.-Y. Pierga<sup>4</sup>, B. Buecher<sup>4</sup>, E. Francois<sup>5</sup>, S. Kim<sup>3</sup>, T. André<sup>6</sup>, M. Jary<sup>3</sup>, V. Vendrely<sup>7</sup>, E. Samalin<sup>8</sup>, F. El Hajbi<sup>9</sup>, N. Baba-Hamed<sup>10</sup>, A. Meurisse<sup>3</sup>, F.-C. Bidard<sup>4</sup>, C. Borg<sup>3</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Institut Curie, PARIS, FR, <sup>3</sup>CHU Besançon, Hôpital Jean Minjot, Besançon, FR, <sup>4</sup>Institut Curie, Paris, FR, <sup>5</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>6</sup>Hôpital Saint-Antoine, Paris, FR, <sup>7</sup>Centre Hospitalier Universitaire de Bordeaux, Bordeaux, FR, <sup>8</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>9</sup>Centre Oscar Lambret, Lille, FR, <sup>10</sup>Groupe Hospitalier Paris Saint-Joseph, PARIS, FR

12:30 - 12:30 **95P - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis**

M. Iafolla<sup>1</sup>, C. Yang<sup>2</sup>, V. Chandran<sup>3</sup>, M. Pintilie<sup>4</sup>, A. Hansen<sup>5</sup>, P. Bedard<sup>6</sup>, S. Lheureux<sup>6</sup>, A. Spreafico<sup>5</sup>, A. Razak<sup>2</sup>, P. Ohashi<sup>7</sup>, S. Hakgor<sup>2</sup>, A. Giesler<sup>2</sup>, T. Pugh<sup>4</sup>, L. Siu<sup>6</sup>, <sup>1</sup>Juravinski Cancer Centre, Hamilton, CA, <sup>2</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, CA, <sup>3</sup>University Health Network, Toronto, CA, <sup>4</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, CA, <sup>5</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>6</sup>Princess Margaret Hospital, Toronto, CA, <sup>7</sup>Campbell Family Institute for Cancer Research, University Health Network, Toronto, CA

12:30 - 12:30 **96P - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)**

C. Cardone<sup>1</sup>, B. Blauensteiner<sup>2</sup>, V. Moreno-Viedma<sup>2</sup>, M. Paul<sup>2</sup>, G. Martini<sup>3</sup>, P.P. Vitiello<sup>1</sup>, D. Ciardiello<sup>1</sup>, C. Borrelli<sup>1</sup>, L. Poliero<sup>1</sup>, P. Vitale<sup>1</sup>, N. Zanaletti<sup>1</sup>, V. Famiglietti<sup>1</sup>, A.M. Rachiglio<sup>4</sup>, D. Rizzi<sup>1</sup>, E. Maiello<sup>5</sup>, T. Latiano<sup>5</sup>, N. Normanno<sup>4</sup>, M. Sibilio<sup>6</sup>, F. Ciardiello<sup>1</sup>, E. Martinelli<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>Medical University of Vienna, Vienna, AT, <sup>3</sup>Vall D'Hebron institute o, Barcelona, ES, <sup>4</sup>National Cancer Institute 'Fondazione Giovanni Pascale', Napoli, IT, <sup>5</sup>Hospital Casa Sollievo della Sofferenza-IRCCS, san giovanni rotondo, IT, <sup>6</sup>Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

- 12:30 - 12:30 **97P - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)**  
T. Carr<sup>1</sup>, C. Adelman<sup>2</sup>, A. Barnicle<sup>2</sup>, I. Kozarewa<sup>2</sup>, S. Luke<sup>2</sup>, Z. Lai<sup>2</sup>, S. Menon<sup>2</sup>, S. Hollis<sup>3</sup>, B. Dougherty<sup>4</sup>, E. Harrington<sup>2</sup>, J.C. Barrett<sup>5</sup>, C. Goessl<sup>6</sup>, F. Saad<sup>7</sup>, N. Sala<sup>8</sup>, N. Clarke<sup>9</sup>, D. Hodgson<sup>10</sup>, <sup>1</sup>AstraZeneca UK, Cambridge, GB, <sup>2</sup>AstraZeneca, Cambridge, GB, <sup>3</sup>Phastar, London, GB, <sup>4</sup>AstraZeneca, Boston, US, <sup>5</sup>AstraZeneca, Waltham, US, <sup>6</sup>BN ImmunoTherapeutics, Inc., Mountain View, US, <sup>7</sup>Hospital St. Luc du CHUM, Montreal, CA, <sup>8</sup>ICO Girona, Hospital Josep Trueta, Girona, ES, <sup>9</sup>The Christie and Salford Royal Hospitals, Manchester, GB, <sup>10</sup>Astrazeneca, Macclesfield, GB
- 12:30 - 12:30 **98P - Identification of a highly suppressive Treg subset associated to immunotherapy response**  
E. Giunta<sup>1</sup>, S. Romano<sup>2</sup>, P. D'Arrigo<sup>2</sup>, A. Rea<sup>2</sup>, M. Tufano<sup>2</sup>, G. Matarese<sup>2</sup>, C. Procaccini<sup>2</sup>, N. Novizio<sup>2</sup>, V. Vigorito<sup>2</sup>, D. Faicchia<sup>2</sup>, G. Argenziano<sup>3</sup>, V. De Falco<sup>1</sup>, F. Ciardiello<sup>1</sup>, M.F. Romano<sup>2</sup>, T. Troiani<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>Università Federico II, naples, IT, <sup>3</sup>Università degli Studi della Campania Luigi Vanvitelli, naples, IT
- 12:30 - 12:30 **99P - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)**  
J. Evelhoch<sup>1</sup>, R. Mogg<sup>2</sup>, R. Cristescu<sup>2</sup>, D. Aurora-Garg<sup>2</sup>, L. Chow<sup>3</sup>, S. Loi<sup>4</sup>, D. Catenacci<sup>5</sup>, U. Matulonis<sup>6</sup>, P. Ott<sup>7</sup>, E. Antonarakis<sup>8</sup>, C. Poehlein<sup>9</sup>, A. Joe<sup>10</sup>, S. Keefe<sup>11</sup>, P. Kang<sup>12</sup>, V. Karantza<sup>9</sup>, J. Cheng<sup>11</sup>, E. Rubin<sup>11</sup>, <sup>1</sup>Merck, Sharpe & Dohme NA, New York, US, <sup>2</sup>Merck & Co., Inc., Kenilworth, US, <sup>3</sup>University of Washington Seattle Cancer Care Alliance, Seattle, US, <sup>4</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>5</sup>The University of Chicago Medical Centre, Chicago, US, <sup>6</sup>Dana Farber Cancer Institute, Boston, US, <sup>7</sup>Dana-Farber Cancer Institute, Boston, US, <sup>8</sup>Johns Hopkins University, Baltimore, US, <sup>9</sup>Merck & Co, Rahway, US, <sup>10</sup>MSD - Merck & Co USA, Kenilworth, US, <sup>11</sup>Merck & Co Inc, North Wales, US, <sup>12</sup>MSD, Kenilworth, US
- 12:30 - 12:30 **100P - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC**  
J. Garcia<sup>1</sup>, A. Delherme<sup>1</sup>, F. Geiguer<sup>1</sup>, P. Merle<sup>2</sup>, C. Tissot<sup>3</sup>, F. Jones<sup>4</sup>, D. Edelstein<sup>5</sup>, P.-J. Souquet<sup>6</sup>, C. Rodriguez-Lafrasse<sup>1</sup>, S. Couraud<sup>6</sup>, L. Payen<sup>1</sup>, Z. Xu<sup>7</sup>, <sup>1</sup>Hospices Civiles de Lyon, Lyon, FR, <sup>2</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>3</sup>CHU de Saint Etienne, Hôpital du Nord, St. Priest en Jarez, FR, <sup>4</sup>Sysmex-Inostics, Inc., New York, US, <sup>5</sup>Sysmex Inostics, New York, US, <sup>6</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>7</sup>Sophia-genetics, lausanne, CH
- 12:30 - 12:30 **101P - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer**  
O. Hamid<sup>1</sup>, A. Vanderwalde<sup>2</sup>, C. Szeto<sup>3</sup>, S. Reddy<sup>3</sup>, S. Pal<sup>4</sup>, <sup>1</sup>The Angeles Clinic and Research Institute, Los Angeles, US, <sup>2</sup>University of Tennessee, Memphis, US, <sup>3</sup>NantOmics, Culver City, US, <sup>4</sup>City of Hope, Duarte, US
- 12:30 - 12:30 **102P - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A**



**multicenter study**

Q. Zhang<sup>1</sup>, C. Xu<sup>1</sup>, W. Wang<sup>2</sup>, W. Zhuang<sup>1</sup>, Z. Song<sup>2</sup>, Y. Zhu<sup>3</sup>, Y. Chen<sup>1</sup>, G. Chen<sup>1</sup>, M. Fang<sup>2</sup>, T. Lv<sup>4</sup>, Y. Song<sup>4</sup>, <sup>1</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>2</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>3</sup>Zhejiang Rongjun Hospital, Jiaxing, CN, <sup>4</sup>Jinling Hospital, Nanjing, CN

12:30 - 12:30 **103P - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples**

D. Moran<sup>1</sup>, D. Maurus<sup>2</sup>, C. Rohde<sup>2</sup>, A. Arozullah<sup>1</sup>, <sup>1</sup>Astellas Pharma US, Inc., Chicago, US, <sup>2</sup>Formerly with Ganymed Pharmaceuticals GmbH, Mainz, DE

12:30 - 12:30 **104P - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer**

Y. Liu<sup>1</sup>, C.K. Tham<sup>2</sup>, S. Ong<sup>2</sup>, C.L. Tang<sup>1</sup>, Y. Zhao<sup>1</sup>, <sup>1</sup>Singapore General Hospital, Singapore, SG, <sup>2</sup>National Cancer Centre Singapore, Singapore, SG

12:30 - 12:30 **105P - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292**

B. Besse<sup>1</sup>, V. Subbiah<sup>2</sup>, A. Drilon<sup>3</sup>, M. Shah<sup>4</sup>, L. Wirth<sup>5</sup>, T. Bauer<sup>6</sup>, V. Velcheti<sup>7</sup>, N. Lakhani<sup>8</sup>, V. Boni<sup>9</sup>, B. Solomon<sup>10</sup>, M. Johnson<sup>6</sup>, K. Park<sup>11</sup>, J. Patel<sup>12</sup>, M. Cabanillas<sup>13</sup>, E. Sherman<sup>3</sup>, E. Zhu<sup>14</sup>, K. Gordon<sup>14</sup>, K. Ebata<sup>14</sup>, B. Tuch<sup>14</sup>, G. Oxnard<sup>15</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>The University of Texas, MD Anderson Cancer Center, Houston, US, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>4</sup>The Ohio State University, Columbus, US, <sup>5</sup>Massachusetts General Hospital, Boston, US, <sup>6</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>7</sup>Cleveland Clinic, Cleveland, US, <sup>8</sup>START - Midwest, Grand Rapids, US, <sup>9</sup>START Madrid-CIOCC HM Hospital Sanchinarro, Madrid, ES, <sup>10</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>11</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>12</sup>University of Chicago, Chicago, US, <sup>13</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>14</sup>Loxo Oncology, Inc, South San Francisco, US, <sup>15</sup>Dana-Farber Cancer Institute, Boston, US

12:30 - 12:30 **106P - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma**

N. Shen<sup>1</sup>, Y. Pan<sup>2</sup>, X. Mo<sup>3</sup>, <sup>1</sup>Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, <sup>2</sup>Deutsches Krebsforschungszentrum, Heidelberg, DE, <sup>3</sup>Shanghai Children's Medical Center, Shanghai, CN

12:30 - 12:30 **107P - Novel genomic classifier for early stage colorectal cancer patients**

E. Letellier<sup>1</sup>, M. Schmitz<sup>2</sup>, A. Ginolhac<sup>2</sup>, E. Koncina<sup>2</sup>, M. Marchese<sup>3</sup>, L. Antunes<sup>3</sup>, S. Rauh<sup>4</sup>, S. Haan<sup>2</sup>, <sup>1</sup>University of Luxembourg, Esch sur Alzette, LU, <sup>2</sup>University of Luxembourg, Belval, LU, <sup>3</sup>Integrated Biobank of Luxembourg, Dudelange, LU, <sup>4</sup>Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU

12:30 - 12:30 **108P - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer**

E. Romano<sup>1</sup>, T. Le Bourgeois<sup>1</sup>, S. Lopez-Lastra<sup>2</sup>, V. Servois<sup>1</sup>, S. Beaucaire-Danel<sup>1</sup>, C. Daniel<sup>1</sup>, J.-Y. Pierga<sup>1</sup>, F.-C. Bidard<sup>1</sup>, O. Lantz<sup>2</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>Institut Curie,



PSL Research University, Paris, FR

- 12:30 - 12:30 **109P - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.**  
J. Cohen<sup>1</sup>, B. Rousseau<sup>1</sup>, R. Bourgoïn<sup>1</sup>, C. Tournigand<sup>1</sup>, L. Larnaudie<sup>1</sup>, A. Dupuy<sup>2</sup>, M. Ollier<sup>3</sup>, A. Pujals<sup>1</sup>, <sup>1</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>2</sup>INSERM, Créteil, FR, <sup>3</sup>CHU Henry Mondor, Creteil, FR
- 12:30 - 12:30 **110P - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?**  
I. Matos Garcia<sup>1</sup>, A. Azaro<sup>2</sup>, C. Viaplana<sup>2</sup>, C. Hierro<sup>3</sup>, J. Martin-Liberal<sup>3</sup>, I. Brana<sup>4</sup>, I. Gardezabal<sup>5</sup>, P. Gomila<sup>6</sup>, M. Vieito Villar<sup>7</sup>, M. Ochoa De Olza Amat<sup>2</sup>, E. Elez Fernandez<sup>2</sup>, A.M. Antunes De Melo E Oliveira<sup>2</sup>, A. Oaknin<sup>2</sup>, H. Verdaguier<sup>2</sup>, A. Navarro Mendivil<sup>2</sup>, M. Alsina<sup>2</sup>, J. Tabernero<sup>8</sup>, T. Macarulla Mercade<sup>3</sup>, R. Dienstmann<sup>2</sup>, E. Garralda<sup>3</sup>, <sup>1</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>Vall d' Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>4</sup>Vall D'Hebron Institute of Oncology, Barcelona, ES, <sup>5</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>6</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>7</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>8</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES
- 12:30 - 12:30 **111P - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies**  
M.S. Cona<sup>1</sup>, M. Lecchi<sup>1</sup>, S. Damian<sup>2</sup>, M. Del Vecchio<sup>1</sup>, C. Cimminiello<sup>1</sup>, S. Cresta<sup>1</sup>, M. Duca<sup>2</sup>, A. Necchi<sup>2</sup>, D. Signorelli<sup>3</sup>, M. Poggi<sup>3</sup>, D. Raggi<sup>1</sup>, R. Ratta<sup>4</sup>, P. Verderio<sup>1</sup>, F.G. De Braud<sup>2</sup>, M. Di Nicola<sup>2</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>4</sup>Istituto Nazionale dei Tumori di Milano, Milan, IT
- 12:30 - 12:30 **112P - Effects of concomitant genetic alterations on cancer patient overall survival**  
Y. Wang<sup>1</sup>, P. Peng<sup>2</sup>, L. Shang<sup>1</sup>, Y.-A. Dong<sup>3</sup>, Z. Yang<sup>4</sup>, H. Zhong<sup>5</sup>, <sup>1</sup>Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, CN, <sup>2</sup>Guangdong Second Proxivcial General Hospital, Guangzhou, CN, <sup>3</sup>OrigiMed, Shanghai, CN, <sup>4</sup>Shu Lan (Hangzhou) Hospital, Zhejiang University International Hospital, Hangzhou, CN, <sup>5</sup>People's Hospital of Beihai, The 9th Affiliated Hospital of Guangxi Medical University, Beihai, CN
- 12:30 - 12:30 **113P - Circulating Exosomal Integrin  $\alpha_5$  Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer**  
D. Chu, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, CN
- 12:30 - 12:30 **114P - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?**

R. Sorrentino<sup>1</sup>, M. Terlizzi<sup>1</sup>, C. Colarusso<sup>1</sup>, A. Saccomanno<sup>1</sup>, R. Salvi<sup>2</sup>, R. Aquino<sup>1</sup>, A. Pinto<sup>1</sup>, <sup>1</sup>University of Salerno, Fisciano, IT, <sup>2</sup>AORN, Monaldi, Naples, IT

12:30 - 12:30 **115P - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?**

M. Terlizzi<sup>1</sup>, R. Sorrentino<sup>1</sup>, C. Colarusso<sup>1</sup>, A. Molino<sup>2</sup>, A. Saccomanno<sup>1</sup>, R. Aquino<sup>1</sup>, A. Pinto<sup>1</sup>, <sup>1</sup>University of Salerno, Fisciano, IT, <sup>2</sup>University of Salerno, Fisciano (SA), IT

12:30 - 12:30 **116P - Genomic characteristics of standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography in breast cancer**

S.-K. Kim<sup>1</sup>, S.G. Ahn<sup>2</sup>, S.-H. Leem<sup>3</sup>, J. Jeong<sup>2</sup>, I.-S. Chu<sup>4</sup>, <sup>1</sup>KRIBB-Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR, <sup>2</sup>Gananam Severance Hospital, Seoul, KR, <sup>3</sup>Dong-A University, Busan, KR, <sup>4</sup>Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR

12:30 - 12:30 **117P - Characterization of PD-L1, CD8, CD3, CD68 and PanCK in Tumor Microenvironment of GI Tract Tumors with respect to Patients' Mismatch Repair Status and Anti-PD-1 Treatment Outcome using 5Plex IHC and Whole Slide Image Analysis**

W. Zhang<sup>1</sup>, M. Khojasteh<sup>2</sup>, A. Hubbard<sup>1</sup>, J. Martin<sup>3</sup>, X. Wang<sup>3</sup>, S. Kamthamraju<sup>1</sup>, J. Munoz-Rodriguez<sup>1</sup>, D. Jiang<sup>1</sup>, Z. Cai<sup>1</sup>, J. Li<sup>1</sup>, R. Anders<sup>4</sup>, L. Diaz<sup>5</sup>, L. Pestic-Dragovich<sup>1</sup>, L. Tang<sup>1</sup>, <sup>1</sup>Roche Tissue Diagnostics - USA, Tucson, US, <sup>2</sup>Roche Tissue Diagnostics USA, Mountain View, US, <sup>3</sup>Roche Tissue Diagnostics - USA, Mountain View, US, <sup>4</sup>John Hopkins University Hospital, Baltimore, US, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York City, US

12:30 - 12:30 **118P - Exhaustion of Platelet Kinetics and its Implication in Post-resection HCC Recurrence**

B. Aryal<sup>1</sup>, T. Shimizu<sup>2</sup>, J. Kadono<sup>2</sup>, A. Furoi<sup>2</sup>, T. Komokata<sup>2</sup>, K. Gejima<sup>2</sup>, M. Yamakuchi<sup>2</sup>, T. Hashiguchi<sup>2</sup>, Y. Imoto<sup>2</sup>, <sup>1</sup>Kagoshima University, Kagoshima, JP, <sup>2</sup>Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, JP

12:30 - 12:30 **119P - Progastrin, a new blood biomarker for the diagnostic and therapeutic monitoring, in gastro-intestinal cancers: A BIG-RENAPE project.**

B. You<sup>1</sup>, V. Kepenekian<sup>1</sup>, A. Prieur<sup>2</sup>, M. Caceres<sup>1</sup>, L. Payen-Gay<sup>3</sup>, P. Liaud<sup>2</sup>, M. Flaceliere<sup>2</sup>, M. Tod<sup>4</sup>, L. Villeneuve<sup>1</sup>, F. Bibeau<sup>5</sup>, L. Bernard<sup>1</sup>, P. Jourdan-Enfer<sup>1</sup>, N. Medeghri<sup>6</sup>, D. Dayde<sup>6</sup>, S. Calattini<sup>6</sup>, G. Freyer<sup>1</sup>, D. Maucort-Boulch<sup>1</sup>, D. Joubert<sup>2</sup>, O. Glehen<sup>1</sup>, <sup>1</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>2</sup>ECS-Screening, Lausanne, CH, <sup>3</sup>Hospices Civiles de Lyon, Lyon, FR, <sup>4</sup>Univesité Claude Bernard Lyon 1, Oullins, FR, <sup>5</sup>CHU de Caen, Caen, FR, <sup>6</sup>Institut de Cancérologie des Hospices Civils de Lyon, PIERRE BENITE, FR

12:30 - 12:30 **120P - A new biomarker of breast cancer stage and patient response to neoadjuvant chemotherapy: HLA-DR expression in cytotoxic and regulatory T cells**

D. Saraiva<sup>1</sup>, A. Jacinto<sup>2</sup>, S. Braga<sup>2</sup>, M. Cabral<sup>2</sup>, <sup>1</sup>CEDOC, Lisbon, PT, <sup>2</sup>NOVA Medical School, Lisbon, PT

- 12:30 - 12:30 **121P - LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in Stage IV NSCLC patients**  
P. Garrido Lopez<sup>1</sup>, E. Felip<sup>2</sup>, L. Paz-Ares<sup>3</sup>, M. Majem<sup>4</sup>, T. Moran<sup>5</sup>, J. Gonzalez-Larriba<sup>6</sup>, J. Bosch Barrera<sup>7</sup>, J. Trigo Perez<sup>8</sup>, M.R. Garcia Campelo<sup>9</sup>, J.M. Sanchez Torres<sup>10</sup>, D. Isla<sup>11</sup>, N. Vinolas Segarra<sup>12</sup>, C. Camps<sup>13</sup>, A. Insa Molla<sup>14</sup>, O.J. Juan Vidal<sup>15</sup>, B. Massutí<sup>16</sup>, A. Paredes Lario<sup>17</sup>, A. Artal-Cortes<sup>18</sup>, M. Lopez-Brea Piqueras<sup>19</sup>, J. Palacios Calvo<sup>1</sup>,  
<sup>1</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>4</sup>Hospital De La Santa Creu I Sant Pau, Barcelona, ES, <sup>5</sup>ICO Badalona, Badalona, ES, <sup>6</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>7</sup>Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona, ES, <sup>8</sup>Hospital Universitario Virgen de la Victoria, Málaga, ES, <sup>9</sup>Hospital Universitario a Coruna - a Corunac, A Coruna, ES, <sup>10</sup>Hospital Universitario de La Princesa, Madrid, ES, <sup>11</sup>Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, <sup>12</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>13</sup>Consortio Hospital General Universitario de Valencia, Valencia, ES, <sup>14</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>15</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>16</sup>Hospital General Universitario Alicante, Alicante, ES, <sup>17</sup>Hospital Donostia, San Sebastian, ES, <sup>18</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>19</sup>Hospital Universitario Marques de Valdecilla, Santander, ES
- 12:30 - 12:30 **122P - Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with colorectal liver metastases**  
S. Stremitzer<sup>1</sup>, A. Graf<sup>2</sup>, B. Neudert<sup>2</sup>, M. Herac<sup>2</sup>, A. Beer<sup>2</sup>, C. Schwarz<sup>3</sup>, F. Wrba<sup>2</sup>, K. Kaczirek<sup>1</sup>, J. Stift<sup>2</sup>, <sup>1</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>2</sup>Medical University Vienna, Vienna, AT, <sup>3</sup>Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT
- 12:30 - 12:30 **123P - Gene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC)**  
N. Radošević-Robin<sup>1</sup>, S. Ong<sup>2</sup>, S. Warren<sup>3</sup>, M. Kossai<sup>1</sup>, C. Godfraind<sup>4</sup>, M. Masson<sup>1</sup>, H. Janicot<sup>4</sup>, P. Merle<sup>4</sup>, P. Dubray-Longueras<sup>1</sup>, X. Durando<sup>1</sup>, P. Morel<sup>2</sup>, A. Cesano<sup>3</sup>, F. Penault-Llorca<sup>1</sup>, <sup>1</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>2</sup>NanoString Technologies, Inc., Seattle, US, <sup>3</sup>NanoString Technologies, Seattle, US, <sup>4</sup>University Hospital Center of Clermont-Ferrand, Clermont-Ferrand, FR
- 12:30 - 12:30 **124P - Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)**  
L. Miller-Phillips<sup>1</sup>, L. Fischer Von Weikersthal<sup>2</sup>, F. Kaiser<sup>3</sup>, S.-E. Al-Batran<sup>4</sup>, T. Heintges<sup>5</sup>, D. Neureiter<sup>6</sup>, C. Kahl<sup>7</sup>, F. Kullmann<sup>8</sup>, M. Moehler<sup>9</sup>, W. Scheithauer<sup>10</sup>, C. Vazart<sup>11</sup>, K. Fontaine<sup>11</sup>, S. Held<sup>12</sup>, D. Modest<sup>1</sup>, J. Neumann<sup>13</sup>, A. Jung<sup>14</sup>, T. Kirchner<sup>1</sup>, V. Heinemann<sup>1</sup>, S. Stintzing<sup>1</sup>, <sup>1</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>2</sup>Health Center St. Marien GmbH, Amberg, DE, <sup>3</sup>VK&K, Landshut, DE, <sup>4</sup>Nordwest-Krankenhaus, Frankfurt am Main, DE, <sup>5</sup>Staedtisches Klinikum Neuss, Neuss, DE, <sup>6</sup>Paracelsus Medical University Salzburg, Salzburg, AT, <sup>7</sup>Klinikum Magdeburg, Magdeburg, DE, <sup>8</sup>Klinikum Weiden, Weiden in der Oberpfalz, DE, <sup>9</sup>Universitätsmedizin Mainz, Mainz, DE, <sup>10</sup>Medical University of Vienna, Vienna, AT, <sup>11</sup>IntegraGen, Evry, FR, <sup>12</sup>Clinassess, Leverkusen, DE, <sup>13</sup>Institute of Pathology University of Munich, Munich, DE, <sup>14</sup>Ludwig Maximilians



University, Munich, DE

12:30 - 12:30 **125P - Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study.**

H. Blons<sup>1</sup>, J.-B. Oudart<sup>2</sup>, J.-P. Merlio<sup>3</sup>, S. Hominal<sup>4</sup>, F. De Fraipont<sup>5</sup>, D. Debieuvre<sup>6</sup>, F. Escande<sup>7</sup>, C. Audigier Valette<sup>8</sup>, P.-P. Bringuier<sup>9</sup>, S. Moreau Fraboulet<sup>10</sup>, L. Ouafik<sup>11</sup>, D. Moro-Sibilot<sup>12</sup>, A. Lemoine<sup>13</sup>, A. Langlais<sup>14</sup>, P. Missy<sup>15</sup>, F. Morin<sup>15</sup>, P.-J. Souquet<sup>16</sup>, F. Barlesi<sup>17</sup>, J. Cadranel<sup>18</sup>, M. Beau-Faller<sup>19</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>CHU de Reims, Reims, FR, <sup>3</sup>Université de Bordeaux, Bordeaux, FR, <sup>4</sup>Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, <sup>5</sup>CHU Grenoble Alpes, Grenoble, FR, <sup>6</sup>Hopital Emile Muller, Mulhouse, FR, <sup>7</sup>Centre biologie et pathologie , Chru Lille, Lille, FR, <sup>8</sup>Hopital Sainte Musse, Toulon, FR, <sup>9</sup>CHU de Lyon, Lyon, FR, <sup>10</sup>Hopital Foch, Suresnes, FR, <sup>11</sup>Service de Transfert d'Oncologie Biologique, Marseille, FR, <sup>12</sup>CHU de Grenoble, La Tronche, FR, <sup>13</sup>Hopital Paul Brousse, Villejuif, FR, <sup>14</sup>IFCT, Paris, FR, <sup>15</sup>French Cooperative Thoracic Intergroup, Paris, FR, <sup>16</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>17</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>18</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>19</sup>Strasbourg, FR

12:30 - 12:30 **126P - Simultaneous identification and profiling of tumor-specific T cells by mass cytometry**

M. Fehlings, E. Newell, A\*STAR, Singapore, SG

12:30 - 12:30 **127P - Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value**

L. Chen<sup>1</sup>, Y. Zhao<sup>2</sup>, X. Hu<sup>2</sup>, H. Wu<sup>2</sup>, J. Liu<sup>2</sup>, X. Mu<sup>2</sup>, <sup>1</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>2</sup>Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN

12:30 - 12:30 **128P - Differential gene expression profiles in poor vs good responders to maintenance vinflunine in patients (p) with advanced urothelial carcinoma (aUC): Preliminary results of biomarker analyses from the MAJA trial (SOGUG 2011/02)**

J.L. Ramirez<sup>1</sup>, A. Font Pous<sup>2</sup>, J. Garcia-Donas<sup>3</sup>, B. Perez Valderrama<sup>4</sup>, I. Aguirre Egaña<sup>1</sup>, L. Nonell<sup>5</sup>, V. Ruiz De Porras Fontdevila<sup>1</sup>, M. Mallo<sup>1</sup>, D. Balaña<sup>1</sup>, J.A. Virizuela<sup>6</sup>, U. Anido<sup>7</sup>, M.M. Llorente Ostiategui<sup>8</sup>, M.A. Gonzalez Del Alba Baamonde<sup>9</sup>, N. Lainez<sup>10</sup>, B. Mellado<sup>11</sup>, M.A. Climent Duran<sup>12</sup>, J. Bellmunt<sup>13</sup>, <sup>1</sup>Catalan Institute of Oncology (ICO) - Germans Trias i Pujol Health Sciences Research Institute (IGTP), Badalona, ES, <sup>2</sup>Institut Català d' Oncologia, Badalona, ES, <sup>3</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>4</sup>Hospital Universitario Virgen del Rocio, Sevilla, ES, <sup>5</sup>Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, ES, <sup>6</sup>Hospital Virgen Macarena, Sevilla, ES, <sup>7</sup>CHU Santiago, Santiago, ES, <sup>8</sup>Hospital General de Elda, Elda, ES, <sup>9</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>10</sup>Complejo Hospitalario de Navarra, Pamplona, ES, <sup>11</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>12</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>13</sup>Hospital del Mar, Barcelona, ES

12:30 - 12:30 **129P - Pre-diagnostic measurements of high-sensitive C - reactive protein and risk of Prostate Cancer. The PROCA-life study**



E. Stikbakke<sup>1</sup>, H. Haugnes<sup>1</sup>, I. Thune<sup>2</sup>, T. Wilsgaard<sup>3</sup>, T. Knutsen<sup>1</sup>, E. Richardsen<sup>1</sup>,  
<sup>1</sup>University Hospital of North Norway, Tromsø, NO, <sup>2</sup>University of Tromsø The Arctic  
 University of Norway, Tromsø, NO, <sup>3</sup>Arctic University of Tromsø, Tromsø, NO

- 12:30 - 12:30 **130P - Training and validation of a gene expression signature for microsatellite instability**  
S. Warren<sup>1</sup>, P. Danaher<sup>1</sup>, S. Ong<sup>2</sup>, N. Elliott<sup>2</sup>, A. Cesano<sup>1</sup>, <sup>1</sup>NanoString Technologies, Seattle, US, <sup>2</sup>NanoString Technologies, Inc., Seattle, US
- 12:30 - 12:30 **131P - Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels**  
K. Quinn, E. Helman, T. Nance, C. Artieri, J. Yen, J. Zhao, S. Fairclough, M. Sikora, D. Chudova, R. Lanman, A. Talasaz, Guardant Health, Redwood City, US
- 12:30 - 12:30 **132P - Carbohydrate antigen 19-9 and apolipoprotein A2 isoform as early detection biomarkers for pancreatic cancer: a prospective evaluation by the EPIC study**  
K. Honda<sup>1</sup>, V. Katzke<sup>2</sup>, A. Hüsing<sup>2</sup>, S. Okaya<sup>3</sup>, H. Shoji<sup>1</sup>, K. Onidani<sup>1</sup>, F. Canzian<sup>2</sup>, R. Kaaks<sup>2</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>German Cancer Research Center, Heidelberg, DE, <sup>3</sup>National Cancer Center Research Institute, Tokyo, JP
- 12:30 - 12:30 **133P - Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)**  
M. Bilen<sup>1</sup>, D. Martini<sup>2</sup>, J. Shabto<sup>2</sup>, Y. Liu<sup>3</sup>, A. Khan<sup>2</sup>, M. Williams<sup>2</sup>, C. Lewis<sup>4</sup>, H. Collins<sup>4</sup>, H. Kissick<sup>3</sup>, B. Carthon<sup>4</sup>, M. Akce<sup>4</sup>, W. Shaib<sup>4</sup>, O. Alese<sup>4</sup>, D. Lawson<sup>4</sup>, R. Kudchadkar<sup>1</sup>, B. El-Rayes<sup>4</sup>, S. Ramalingam<sup>1</sup>, T. Owonikoko<sup>1</sup>, R. Harvey<sup>4</sup>, V. Master<sup>3</sup>, <sup>1</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>2</sup>Emory University School of Medicine, Atlanta, US, <sup>3</sup>Emory University, Atlanta, US, <sup>4</sup>Winship Cancer Institute of Emory University, Atlanta, US
- 12:30 - 12:30 **134P - Prediction of irAEs in Ipilimumab-treated melanoma patients based on serum autoantibodies**  
J. Hassel<sup>1</sup>, J. Mangana<sup>2</sup>, R. Dummer<sup>3</sup>, C. Pföhler<sup>4</sup>, K. Wistuba-Hamprecht<sup>5</sup>, B. Weide<sup>6</sup>, L. Hakim-Meibodi<sup>1</sup>, F. Meier<sup>7</sup>, J. Roth<sup>1</sup>, H.-D. Zucht<sup>8</sup>, P. Budde<sup>8</sup>, M. Tuschen<sup>8</sup>, P. Schulz-Knappe<sup>8</sup>, <sup>1</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>2</sup>University Hospital Zürich, Zürich, CH, <sup>3</sup>Universitätsspital Zürich, Zurich, CH, <sup>4</sup>University Hospital Homburg/Saar, Homburg/Saar, DE, <sup>5</sup>University Hospital Tübingen, Tübingen, DE, <sup>6</sup>Universitäts-Hautklinik, Tübingen, DE, <sup>7</sup>University Hospital Carl Gustav Carus Dresden, Dresden, DE, <sup>8</sup>Protagen AG, Dortmund, DE
- 12:30 - 12:30 **135P - Combined tumor-based BRCA/TP53 mutation testing in ovarian cancer**  
B. Edith<sup>1</sup>, A. Leary<sup>2</sup>, P. Pautier<sup>1</sup>, E. Santana<sup>1</sup>, L. Lacroix<sup>2</sup>, O. Cabaret<sup>1</sup>, M. Guillaud-Bataille<sup>1</sup>, J. Michels<sup>2</sup>, A. Auguste<sup>3</sup>, C. Genestie<sup>2</sup>, E. Rouleau<sup>4</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>4</sup>Institut Curie, Paris, FR

12:30 - 12:30

**136P - EML4-ALK fusion variants associate with gender and age in Chinese NSCLC patients**

W. Zhao<sup>1</sup>, G. Liang<sup>2</sup>, L. Wang<sup>3</sup>, L. Dai<sup>2</sup>, D. Wu<sup>4</sup>, K. Wang<sup>4</sup>, A. Wang<sup>5</sup>, H. Chen<sup>5</sup>, Y.-A. Dong<sup>5</sup>, M. Wang<sup>4</sup>, <sup>1</sup>the First Affiliated Hospital of Kunming Medical University, Kunming, CN, <sup>2</sup>First Affiliated Hospital of Guangxi Medical University, Nanning, CN, <sup>3</sup>Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, <sup>4</sup>Sun yat-sen memorial hospital, Sun yat-sen University, Guangzhou, CN, <sup>5</sup>OrigiMed, Shanghai, CN

**12:30 - 12:30 137P - Multi-Dimensional Immuno-Oncology Assays for Understanding the Immune System and Tumor Microenvironment**

F. Hyland<sup>1</sup>, T. Looney<sup>2</sup>, R. Chaudhury<sup>3</sup>, A. Kamat<sup>3</sup>, A. Pankov<sup>3</sup>, <sup>1</sup>Thermo Fisher Scientific, San Francisco, US, <sup>2</sup>Thermo Fisher Scientific, Singapore, SG, <sup>3</sup>Thermo Fisher Scientific, South San Francisco, US

**12:30 - 12:30 138P - Monitoring the effect of PI3K inhibition on HER2 therapy resistant breast cancer using serial analysis of PIK3CA mutant tumour DNA in plasma**

N. Keegan<sup>1</sup>, S. Toomey<sup>2</sup>, A. Farrelly<sup>2</sup>, A. Carr<sup>2</sup>, G. Calzaferri<sup>3</sup>, J. Walshe<sup>4</sup>, G. Gullo<sup>5</sup>, J. Crown<sup>5</sup>, K. Egan<sup>6</sup>, A. Hernando<sup>7</sup>, A. Teiserskiene<sup>7</sup>, L. Grogan<sup>1</sup>, O. Breathnach<sup>1</sup>, P. Morris<sup>1</sup>, B. Hennessy<sup>1</sup>, <sup>1</sup>Beaumont Hospital, Dublin, IE, <sup>2</sup>Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, IE, <sup>3</sup>Cancer Clinical Research Trust, Dublin, IE, <sup>4</sup>St Vincent's University Hospital, Dublin, IE, <sup>5</sup>St Vincents University Hospital, Dublin, IE, <sup>6</sup>Beaumont Hospital, Dublin 9, Ireland, Dublin, IE, <sup>7</sup>Cancer Trials Ireland, Dublin, IE

**12:30 - 12:30 139P - Analysis of circulating biomarkers in A randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study**

M. Boeri<sup>1</sup>, F. Nichetti<sup>2</sup>, L. Porcu<sup>3</sup>, V. Torri<sup>4</sup>, A. Del Conte<sup>5</sup>, A. Martinetti<sup>2</sup>, E. Sottotetti<sup>2</sup>, E. Vattei<sup>6</sup>, F. Verderame<sup>7</sup>, M. Garassino<sup>1</sup>, L. Cavanna<sup>8</sup>, A. Tuzi<sup>9</sup>, L. Irtelli<sup>10</sup>, F.G. De Braud<sup>1</sup>, M. Platania<sup>2</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>ASUIUD Azienda Ospedaliero-Universitaria di Udine, udine, IT, <sup>4</sup>No place of work provided, No City Provided, NA, <sup>5</sup>Azienda Ospedaliera Sta Maria degli Angeli, Pordenone, IT, <sup>6</sup>Ospedale Centrale di Bolzano ASDAA/SABES, Bolzano, IT, <sup>7</sup>Presidio Ospedaliero Cervello, Palermo, IT, <sup>8</sup>Azienda Ospedaliera Piacenza, Piacenza, IT, <sup>9</sup>Ospedale di Circolo Fondazione Macchi, Varese, IT, <sup>10</sup>P.O. Clinicizzato Ss. Annunziata Universita' Degli Studi, Chieti, IT

**12:30 - 12:30 140P - Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)**

J. Marquez, P. Lucero-Diaz, J.A. Matute-Briseno, M. Rosas-Delgado, A. Camacho-Hernandez, Y. Cortez-Vargas, I. Nava-Sanchez, G. Montano, L. Montijo-Fernandez, M. Perez-Astorga, Centro de Investigacion de Cancer en Sonora-CICS, Ciudad Obregon, MX

**12:30 - 12:30 141P - Tumor Mutational Burden (TMB) Standardization Initiative: Establishing a Consistent Methodology for TMB Measurement in Clinical Samples**

A. Stenzinger<sup>1</sup>, J. Allen<sup>2</sup>, J. Maas<sup>3</sup>, M. Stewart<sup>2</sup>, D. Merino<sup>2</sup>, M. Dietel<sup>4</sup>, <sup>1</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>2</sup>Friends of Cancer Research, Washington, US, <sup>3</sup>QuIP Quality in Pathology, Berlin, DE, <sup>4</sup>Charité Berlin, Berlin, DE

- 12:30 - 12:30 **142P - DNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?**  
C.M. Della Corte<sup>1</sup>, K. Ramkumar<sup>2</sup>, T. Sen<sup>2</sup>, P. Tong<sup>2</sup>, D. Gibbons<sup>2</sup>, J. Heymach<sup>2</sup>, J. Wang<sup>2</sup>, Y.-H. Fan<sup>2</sup>, R. Cardnell<sup>2</sup>, L. Byers<sup>2</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>MD ANDERSON CANCER CENTER, HOUSTON, US
- 12:30 - 12:30 **143P - Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)**  
J. Martin-Liberal<sup>1</sup>, F. Pagliuca<sup>2</sup>, C. Hierro<sup>1</sup>, C. Viaplana<sup>3</sup>, E. Muñoz Couselo<sup>3</sup>, J. Capdevila Castillon<sup>3</sup>, I. Matos<sup>3</sup>, L. Fariñas Madrid<sup>3</sup>, E. Zamora<sup>3</sup>, I. Braña Garcia<sup>3</sup>, E. Elez Fernandez<sup>3</sup>, M. Ochoa De Olza Amat<sup>3</sup>, A. Azaro<sup>3</sup>, M. Alsina<sup>3</sup>, M. Vieito Villar<sup>4</sup>, R. Fasani<sup>1</sup>, J. Taberero<sup>5</sup>, E. Garralda<sup>1</sup>, R. Dienstmann<sup>3</sup>, P. Nuciforo<sup>3</sup>, <sup>1</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>2</sup>University of Naples Federico II, Naples, IT, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>5</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES
- 12:30 - 12:30 **144P - Cyclin D1 differential activation and its prognostic impact among advanced breast cancer patients treated with trastuzumab.**  
G. Mountzios<sup>1</sup>, V. Kotoula<sup>2</sup>, G.-A. Koliou<sup>3</sup>, K. Papadopoulou<sup>3</sup>, G. Lazaridis<sup>4</sup>, C. Christodoulou<sup>5</sup>, G. Pentheroudakis<sup>6</sup>, M. Skondra<sup>7</sup>, A. Koutras<sup>8</sup>, H. Linardou<sup>5</sup>, E. Razi<sup>9</sup>, P. Papakostas<sup>7</sup>, S. Chrisafi<sup>10</sup>, G. Aravantinos<sup>11</sup>, I. Nicolaou<sup>10</sup>, A. Goussia<sup>3</sup>, K. Kalogeras<sup>10</sup>, D. Pectasides<sup>7</sup>, G. Fountzilas<sup>4</sup>, <sup>1</sup>University of Athens School of Medicine Clinical Therapeutics, Athens, GR, <sup>2</sup>Aristotle University of Thessaloniky, Thessaloniky, GR, <sup>3</sup>Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, <sup>4</sup>Papageorgiou Hospital Aristotle University of Thessaloniky, Thessaloniky, GR, <sup>5</sup>Metropolitan Hospital, Athens, GR, <sup>6</sup>University Hospital of Ioannina, Ioannina, GR, <sup>7</sup>Hippokration General Hospital, Athens, GR, <sup>8</sup>University Hospital Patras, Patras, GR, <sup>9</sup>Hygeia Hospital, Athens, GR, <sup>10</sup>Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, <sup>11</sup>General Oncological Hospital of Kifisia "Agioi Anargyroi", Kifisia, GR
- 12:30 - 12:30 **145P - Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer**  
S. Crucitta<sup>1</sup>, M. Del Re<sup>2</sup>, A. Fontana<sup>3</sup>, I. Bertolini<sup>3</sup>, E. Rofi<sup>1</sup>, C. De Angelis<sup>3</sup>, L. Diodati<sup>3</sup>, D. Cavallero<sup>3</sup>, B. Salvadori<sup>3</sup>, A. Falcone<sup>4</sup>, R. Morganti<sup>1</sup>, R. Danesi<sup>5</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, <sup>2</sup>Univeristy Degli Studi di Pisa, Pisa, IT, <sup>3</sup>University of Pisa, Pisa, IT, <sup>4</sup>University of Pisa, Pisa, Italy, Pisa, IT, <sup>5</sup>Università di Pisa, Pisa, IT
- 12:30 - 12:30 **146P - HER2 amplification is associated with higher tumor mutation burden in breast cancer**  
Y. Yin<sup>1</sup>, W. Li<sup>2</sup>, X. Huang<sup>2</sup>, H. Wu<sup>2</sup>, Y. Zhang<sup>3</sup>, S. Cai<sup>3</sup>, S. Zhou<sup>4</sup>, <sup>1</sup>jiangsu province hospital, nanjing, CN, <sup>2</sup>Jiangsu Province Hospital, Nanjing, CN, <sup>3</sup>3D medicines Inc., Shanghai, CN, <sup>4</sup>the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, CN
- 12:30 - 12:30 **147P - Application of CRISPR/Cas9 system for identification of genes involved in**



**the regulation of pancreatic cancer cells platinum sensitivity**

V. Skripova<sup>1</sup>, I. Serebriiskii<sup>1</sup>, R. Kiyamova<sup>1</sup>, I. Astsaturov<sup>2</sup>, <sup>1</sup>Kazan Federal University, Kazan, RU, <sup>2</sup>Fox Chase Cancer Center, Philadelphia, US

- 12:30 - 12:30 **148P - Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass**  
A. Athanasiou<sup>1</sup>, T. Orfanelli<sup>2</sup>, D. Lapolla<sup>3</sup>, E. Andreopoulou<sup>3</sup>, T.A. Moo<sup>3</sup>, J. Marti<sup>3</sup>, T. Cigler<sup>3</sup>, A.M. Bongiovanni<sup>1</sup>, S. Witkin<sup>1</sup>, <sup>1</sup>Weill Cornell Medical College, New York, US, <sup>2</sup>Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, US, <sup>3</sup>Weill Cornell Medicine/New York Presbyterian Hospital, New York, US
- 12:30 - 12:30 **149P - Only estrogen receptor “Positive” is not enough to predict the prognosis of breast cancer Running head: Revisiting estrogen positive tumors in 8th AJCC staging era**  
J.M. Ryu, S.K. Lee, J.E. Lee, S.J. Nam, J. Yu, H.J. Choi, I. Kim, S.W. Kim, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR
- 12:30 - 12:30 **150P - Adjuvant radiation therapy leads to an up-regulation of programmed death ligand 1 (PD-L1) on circulating epithelial tumor cells (CETCs) which might contribute to radioresistance in primary breast cancer patients**  
D. Schott<sup>1</sup>, M. Pizon<sup>2</sup>, U. Pachmann<sup>2</sup>, K. Pachmann<sup>2</sup>, M. Mäurer<sup>3</sup>, <sup>1</sup>SIMFO GmbH, Bayreuth, DE, <sup>2</sup>Transfusion Center Bayreuth, Bayreuth, DE, <sup>3</sup>University Hospital of Jena, Jena, DE
- 12:30 - 12:30 **151P - Recurrent and Metastatic Carcinomas of the Lacrimal Gland: High Frequency of ERBB2 Driven Disease**  
N. Girard<sup>1</sup>, R. Corona<sup>2</sup>, J. Chung<sup>3</sup>, S. Millis<sup>3</sup>, L. Gay<sup>4</sup>, J. Elvin<sup>3</sup>, J.-A. Vergilio<sup>3</sup>, S. Ramkissoon<sup>3</sup>, E. Severson<sup>3</sup>, S. Daniel<sup>3</sup>, J. Killian<sup>3</sup>, S. Ali<sup>3</sup>, A. Schrock<sup>3</sup>, V. Miller<sup>3</sup>, J. Ross<sup>5</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>Upstate Medical University, Syracuse, US, <sup>3</sup>Foundation Medicine, Inc., Cambridge, US, <sup>4</sup>Foundation Medicine, Cambridge, US, <sup>5</sup>SUNY Upstate Medical University, Syracuse, US
- 12:30 - 12:30 **152P - Circulating tumour DNA experience in patients with Cancer of Unknown Primary**  
H. Winter<sup>1</sup>, I. Faull<sup>2</sup>, P. Bains<sup>1</sup>, C. Murias<sup>1</sup>, M. Kushnir<sup>1</sup>, M. Forster<sup>3</sup>, A. Kulkarni<sup>4</sup>, D. Moore<sup>3</sup>, C. Swanton<sup>5</sup>, K. Shiu<sup>6</sup>, H.-T. Arkenau<sup>7</sup>, <sup>1</sup>Sarah Cannon Research Institute, London, GB, <sup>2</sup>Guardant Health, Barcelona, ES, <sup>3</sup>University College London Cancer Institute, London, GB, <sup>4</sup>Guy's and St Thomas' NHS Foundation Trust, London, GB, <sup>5</sup>The Francis Crick Institute, London, GB, <sup>6</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>7</sup>Sarah Cannon Research Institute SCRI UK, London, GB
- 12:30 - 12:30 **153P - Reproducibility of the mRECIST criteria for the assessment of HCC treated by anti- VEGFR therapy: Impact of readers' expertise**  
H. Beaumont<sup>1</sup>, S. Egels<sup>2</sup>, N. Faye<sup>1</sup>, C. Klifa<sup>3</sup>, A. Iannessi<sup>4</sup>, E. Bonnard<sup>4</sup>, O. Lucidarme<sup>5</sup>, <sup>1</sup>MEDIAN Technologies, Valbonne, FR, <sup>2</sup>Hôpital Pitié-Salpêtrière, Paris, FR, <sup>3</sup>Median Technologies, Vabonne, FR, <sup>4</sup>Hopital antoine Lacassagne, Nice, FR, <sup>5</sup>Groupe Hospitalier Pitié Salpetriere, Paris, FR



- 12:30 - 12:30 **154P - PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung.**  
D. Damotte<sup>1</sup>, M.C. Charpentier<sup>2</sup>, M. Bernardi<sup>3</sup>, E. Watkin<sup>4</sup>, I. Goubin Versini<sup>5</sup>, R. Lamy<sup>6</sup>, N. Piton<sup>7</sup>, L. Geriniere<sup>8</sup>, F. Forest<sup>9</sup>, R. Gervais<sup>10</sup>, I. Monnet<sup>11</sup>, A. Madrosyk<sup>12</sup>, F. Guisier<sup>13</sup>, C. Serrand<sup>14</sup>, C. Locher Genty<sup>15</sup>, C. Decroisette<sup>16</sup>, J.B. Auliac<sup>17</sup>, T. Jeanfaivre<sup>18</sup>, H. Doubre<sup>19</sup>, D. Arpin<sup>20</sup>, <sup>1</sup>Université Paris Descartes, Paris, FR, <sup>2</sup>APHP, paris, FR, <sup>3</sup>CH d'aix, aix en provence, FR, <sup>4</sup>selas cypath, villeurbane, FR, <sup>5</sup>CH rene Dubos, pontoise, FR, <sup>6</sup>CH Sud Bretagne, Lorient, FR, <sup>7</sup>CHU Charles Nicolle, rouen, FR, <sup>8</sup>CHLS, lyon, FR, <sup>9</sup>CHU st etienne, st etienne, FR, <sup>10</sup>Centre Francois Baclesse, Caen, FR, <sup>11</sup>CH Intercommunal de Créteil, Créteil, FR, <sup>12</sup>Institut paoli calmette, marseille, FR, <sup>13</sup>CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR, <sup>14</sup>hôpital nord ouest, villefranche sur saone, FR, <sup>15</sup>Centre hospitalier général Meaux, Meaux, FR, <sup>16</sup>Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, <sup>17</sup>CH François Quesnay, Mantes La Jolie, FR, <sup>18</sup>CHU zngers, angers, FR, <sup>19</sup>Hopital Foch, Suresnes, FR, <sup>20</sup>CH nord ouest, villefranche sur saone, FR
- 12:30 - 12:30 **155P - Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in Non-Small-Cell-Lung Cancer (NSCLC)**  
G. Williams<sup>1</sup>, A.G. Nicholson<sup>2</sup>, D. Snead<sup>3</sup>, E. Thunnissen<sup>4</sup>, S. Lantuejoul<sup>5</sup>, P. Cane<sup>6</sup>, K. Kerr<sup>7</sup>, M. Loddo<sup>1</sup>, M. Scott<sup>8</sup>, P. Scorer<sup>9</sup>, C. Barker<sup>10</sup>, <sup>1</sup>Oncologica UK Ltd., Cambridge, GB, <sup>2</sup>Imperial College - Royal Brompton Campus, London, GB, <sup>3</sup>University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB, <sup>4</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>5</sup>Centre Léon Bérard, Lyon, FR, <sup>6</sup>St Thomas' Hospital, London, GB, <sup>7</sup>Aberdeen Royal Infirmary, Aberdeen, GB, <sup>8</sup>Astrazeneca, Cambridge, GB, <sup>9</sup>Precision Medicine Laboratories, Precision Medicine and Genomics, Cambridge, GB, <sup>10</sup>AstraZeneca, Little Chesterford, GB
- 12:30 - 12:30 **156P - Relationship between ring-type dedicated breast PET and tumor-infiltrating lymphocytes in early breast cancer**  
S. Sasada<sup>1</sup>, N. Shiroma<sup>2</sup>, E. Suzuki<sup>2</sup>, S. Sueoka<sup>2</sup>, N. Goda<sup>2</sup>, K. Kajitani<sup>2</sup>, A. Emi<sup>2</sup>, N. Masumoto<sup>2</sup>, T. Kadoya<sup>2</sup>, R. Haruta<sup>2</sup>, T. Kataoka<sup>2</sup>, K. Arihiro<sup>2</sup>, M. Okada<sup>2</sup>, <sup>1</sup>Hiroshima University, Hiroshima, JP, <sup>2</sup>Hiroshima University Hospital, Hiroshima, JP
- 12:30 - 12:30 **157P - Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms**  
Y. Fan<sup>1</sup>, Y. Xu<sup>1</sup>, X. Tong<sup>2</sup>, J. Yan<sup>3</sup>, X. Wu<sup>2</sup>, Y.W. Shao<sup>2</sup>, <sup>1</sup>Zhejiang cancer hospital, Hangzhou, CN, <sup>2</sup>Translational Medicine Research Institute, Ontario, CA, <sup>3</sup>Nanjing Geneseeq Technology Inc, Nanjing, CN
- 12:30 - 12:30 **158P - Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy**  
L. Angus<sup>1</sup>, E. Van Helden<sup>2</sup>, S. Van Es<sup>3</sup>, E. Boon<sup>4</sup>, C. Van Herpen<sup>5</sup>, D.J. De Groot<sup>3</sup>, E.G.E. De Vries<sup>3</sup>, C.W. Menke-Van Der Houven Van Oordt<sup>6</sup>, S. Sleijfer<sup>7</sup>, H. Verheul<sup>8</sup>, M. Jansen<sup>1</sup>, <sup>1</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>2</sup>VU University Medical Center, Amsterdam, AN, <sup>3</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>4</sup>Radboudumc, Nijmegen, NL, <sup>5</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>6</sup>VUMC

Cancer Centre Amsterdam, Amsterdam, NL, <sup>7</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>8</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL

- 12:30 - 12:30 **159P - Quantifying circulating cell-free DNA as clinical biomarker**  
M. Romain, Z. Dache, A. Otandault, R. Tanos, B. Pastor, C. Sanchez, J. Azzi, G. Tusch, S. Azan, C. Mollevi, S. Thezenas, P. Blache, A. Thierry, ICM Regional Cancer Institute of Montpellier, Montpellier, FR
- 12:30 - 12:30 **160P - Gene Expression Profile (GEP) and Survival Among Patients With Advanced Ovarian Cancer**  
E. Høgdall<sup>1</sup>, C. Høgdall<sup>2</sup>, P.-T. Vo<sup>3</sup>, W. Zhou<sup>4</sup>, L. Huang<sup>5</sup>, M. Marton<sup>5</sup>, S. Keefe<sup>4</sup>, M. Busch-Sørensen<sup>5</sup>, S. Sørensen<sup>6</sup>, J. Georgsen<sup>7</sup>, E. Mejlgaard<sup>8</sup>, L. Nedergaard<sup>6</sup>, T. Steiniche<sup>7</sup>, <sup>1</sup>Herlev Hospital, Copenhagen, DK, <sup>2</sup>Rigshospitalet, Copenhagen, DK, <sup>3</sup>MSD - Merck & Co USA, Kenilworth, US, <sup>4</sup>Merck & Co Inc, North Wales, US, <sup>5</sup>Merck & Co., Inc., Kenilworth, US, <sup>6</sup>Rigshospitalet, University of Copenhagen, Copenhagen, DK, <sup>7</sup>Aarhus University Hospital, Aarhus C, DK, <sup>8</sup>Aarhus University Hospital, Aarhus, DK
- 12:30 - 12:30 **161P - Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics.**  
D. Yan<sup>1</sup>, M.-H. Ryu<sup>2</sup>, E. An<sup>1</sup>, Y.S. Park<sup>2</sup>, H. Na<sup>2</sup>, J. Ma<sup>2</sup>, Y. Tian<sup>1</sup>, F. Cecchi<sup>3</sup>, T. Hembrough<sup>1</sup>, Y.-K. Kang<sup>2</sup>, <sup>1</sup>NantOmics, LLC, Rockville, US, <sup>2</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>3</sup>NantOmics, LLC., New York, US
- 12:30 - 12:30 **162P - Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study**  
B. De Craene<sup>1</sup>, J. Van De Velde<sup>1</sup>, E. Bellon<sup>1</sup>, M. Gazin<sup>1</sup>, E. Rondelez<sup>1</sup>, L. Vandebroeck<sup>1</sup>, T. Vanhoey<sup>1</sup>, N. Elsen<sup>1</sup>, L. Melchior<sup>2</sup>, G.L. Willemoet<sup>2</sup>, E. Watkin<sup>3</sup>, N. Arens<sup>4</sup>, C. Altmann<sup>4</sup>, K. Decanniere<sup>1</sup>, E. Sablon<sup>5</sup>, G. Maertens<sup>5</sup>, <sup>1</sup>Biocartis nv, Mechelen, BE, <sup>2</sup>Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK, <sup>3</sup>selas cypath, villeurbane, FR, <sup>4</sup>Molekularpathologie Trier (MPT), Trier, DE, <sup>5</sup>Biocartis, Mechelen, BE
- 12:30 - 12:30 **163P - Accurate measurement of tumor mutation burden in liquid biopsy (bTMB) using a 500 gene panel**  
T. Jiang<sup>1</sup>, S. Zhang<sup>2</sup>, A. Jager<sup>2</sup>, S. Katz<sup>2</sup>, J. Lococo<sup>2</sup>, P. Le<sup>2</sup>, B. Andrian<sup>2</sup>, C. Zhao<sup>2</sup>, D. Baker<sup>2</sup>, T. Pawlowski<sup>2</sup>, S. Bilke<sup>2</sup>, <sup>1</sup>Illumina, San Diego, US, <sup>2</sup>Illumina, Inc, San diego, US
- 12:30 - 12:30 **164P - Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a Phase 1/II clinical trial in mCRPC patients**  
M. Tan<sup>1</sup>, S. Zhang<sup>1</sup>, Z. Zhao<sup>1</sup>, A. Wang<sup>1</sup>, D. Cheung<sup>1</sup>, P. Du<sup>1</sup>, J. Yu<sup>1</sup>, S. Jia<sup>2</sup>, C. Guo<sup>3</sup>, Y. Tong<sup>3</sup>, K. Zhou<sup>3</sup>, <sup>1</sup>Predicine, Inc, Hayward, US, <sup>2</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>3</sup>Suzhou Kintor Pharmaceuticals, Inc., Suzhou, CN
- 12:30 - 12:30 **165P - The frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type**  
J. Dvorak<sup>1</sup>, B. Rosova<sup>1</sup>, A. Filipova<sup>2</sup>, D. Hadzi Nikolov<sup>3</sup>, L. Dusek<sup>4</sup>, A. Rozsypalova<sup>1</sup>, J. Proks<sup>1</sup>, I. Richter<sup>5</sup>, B. Melichar<sup>6</sup>, T. Buchler<sup>1</sup>, R. Zacheval<sup>1</sup>, R. Matej<sup>1</sup>, <sup>1</sup>Thomayer

University Hospital, Prague, CZ, <sup>2</sup>Faculty of Military Health Sciences in Hradec Kralove, University of Defense in Brno, Hradec Kralove, CZ, <sup>3</sup>Regional Hospital, Kolin, CZ, <sup>4</sup>Masaryk University Brno, Brno, CZ, <sup>5</sup>Regional Hospital, Liberec, CZ, <sup>6</sup>University Hospital Olomouc, Olomouc, CZ

12:30 - 12:30

**166P - Association of MMR protein expression and MMR gene mutations in Chinese colorectal cancer patients**

S. Wang<sup>1</sup>, S. Zhang<sup>2</sup>, Z. Zeng<sup>2</sup>, Y. Ou<sup>3</sup>, M. Han<sup>4</sup>, J. Guo<sup>5</sup>, D. Chen<sup>6</sup>, X. Dong<sup>6</sup>, J. Hu<sup>6</sup>, G. Chirn<sup>6</sup>, W. Shi<sup>6</sup>, M. Yao<sup>7</sup>, <sup>1</sup>School of Basic Medical Sciences, Southern Medical University, Guangzhou, CN, <sup>2</sup>First Affiliated Hospital of Guangxi Medical University, Nanning, CN, <sup>3</sup>The First Affiliated Hospital of Clinical Medicine of Guangdong pharmaceutical University, Guangzhou, CN, <sup>4</sup>Jincheng General Hospital, Jincheng, CN, <sup>5</sup>Xingtai people's hospital, Xingtai, CN, <sup>6</sup>OrigiMed, Shanghai, CN, <sup>7</sup>Origimed, Shanghai, CN

12:30 - 12:30

**167P - Somatic and germline mutations of Chinese gastric cancer patients**

Y. Wang<sup>1</sup>, W. Gu<sup>2</sup>, Y. Zhang<sup>3</sup>, K. Li<sup>4</sup>, Z. Niu<sup>5</sup>, Y. Zheng<sup>6</sup>, Q. Cui<sup>7</sup>, A. Wang<sup>6</sup>, H. Chen<sup>6</sup>, W. Shi<sup>6</sup>, K. Wang<sup>6</sup>, M. Yao<sup>7</sup>, <sup>1</sup>shanxi provincial cancer hospital, Taiyuan, CN, <sup>2</sup>The people's Hospital of Nan Hai, Nanhai, CN, <sup>3</sup>Chaozhou People's Hospital, Chaozhou, CN, <sup>4</sup>Guangdong Second Proxivcial General Hospital, Guangzhou, CN, <sup>5</sup>The Affiliated Hospital of Qingdao University, Qingdao, CN, <sup>6</sup>OrigiMed, Shanghai, CN, <sup>7</sup>Origimed, Shanghai, CN

12:30 - 12:30

**168P - Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)**

P.A. Fasching<sup>1</sup>, M. Laible<sup>2</sup>, K. Weber<sup>3</sup>, R.M. Wirtz<sup>4</sup>, C. Denkert<sup>5</sup>, K. Schlombs<sup>2</sup>, S. Schmatloch<sup>6</sup>, O. Camara<sup>7</sup>, H.J. Lück<sup>8</sup>, J. Huober<sup>9</sup>, T. Karn<sup>10</sup>, M. Van Mackelenbergh<sup>11</sup>, F. Marme<sup>12</sup>, V. Müller<sup>13</sup>, C. Schem<sup>14</sup>, E. Stickeler<sup>15</sup>, U. Sahin<sup>16</sup>, S. Loibl<sup>3</sup>, M. Untch<sup>17</sup>, <sup>1</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>2</sup>BioNTech Diagnostics GmbH, Mainz, DE, <sup>3</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>4</sup>Paracelsus Medical University Nuremberg General Hospital, Nuremberg, DE, <sup>5</sup>Charite Berlin Mitte, Berlin, DE, <sup>6</sup>Elisabeth Krankenhaus, Kassel, DE, <sup>7</sup>Hufeland Klinikum, Bad Langensalza, DE, <sup>8</sup>Gynäkologisch-Onkologische Praxis, Hannover, DE, <sup>9</sup>Universitaetsfrauenklinik Ulm, Ulm, DE, <sup>10</sup>Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>11</sup>University Hospital Schleswig-Holstein, Kiel, DE, <sup>12</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, <sup>13</sup>Hamburg-Eppendorf University Medical Center, Hamburg, DE, <sup>14</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>15</sup>Uniklinik RWTH, Aachen, DE, <sup>16</sup>BioNTech AG, Mainz, DE, <sup>17</sup>Klinik für Gynäkologie und Geburtshilfe, Berlin, DE

12:30 - 12:30

**169P - Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer**

E. Rofi<sup>1</sup>, M. Del Re<sup>2</sup>, C. Vivaldi<sup>3</sup>, S. Crucitta<sup>1</sup>, E. Arrigoni<sup>1</sup>, G. Pasquini<sup>4</sup>, S. Catanese<sup>4</sup>, I. Pecora<sup>4</sup>, G. Musettini<sup>1</sup>, E. Vasile<sup>4</sup>, A. Falcone<sup>1</sup>, R. Danesi<sup>5</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, <sup>2</sup>Univeristy Degli Studi di Pisa, Pisa, IT, <sup>3</sup>Azienda Ospedaliera Universitaria Pisana, Pisa, IT, <sup>4</sup>University of Pisa, Pisa, Italy, Pisa, IT, <sup>5</sup>Università di Pisa, Pisa, IT



- 12:30 - 12:30 **170P - Ecological diversity indices as measurements of tumor heterogeneity correlates with clinical outcomes in late stage small cell lung cancer (SCLC)**  
S. Yaung<sup>1</sup>, L. Xi<sup>2</sup>, C. Woestmann<sup>3</sup>, S. Mcnamara<sup>3</sup>, B. Hinzmann<sup>3</sup>, S. Froehler<sup>3</sup>, N. Tikoo<sup>2</sup>, C. Ju<sup>2</sup>, A. Balasubramanyam<sup>2</sup>, H.-P. Adams<sup>3</sup>, M. Thomas<sup>4</sup>, F. Lasitschka<sup>5</sup>, M. Meister<sup>6</sup>, M. Schneider<sup>7</sup>, F. Herth<sup>8</sup>, T. Muley<sup>6</sup>, B. Wehnl<sup>9</sup>, J. Palma<sup>10</sup>, X.M. Ma<sup>2</sup>, <sup>1</sup>Roche, Pleasanton, US, <sup>2</sup>Roche Sequencing Solutions, Inc., Pleasanton, US, <sup>3</sup>Roche Sequencing Solutions, Inc., Potsdam, DE, <sup>4</sup>Thoraxklinik, Heidelberg, DE, <sup>5</sup>Heidelberg University Hospital, Heidelberg, DE, <sup>6</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>7</sup>Thoraxklinik at Heidelberg University Hospital; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE, <sup>8</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>9</sup>Roche Diagnostics GmbH, Penzberg, DE, <sup>10</sup>F. Hoffmann LaRoche, Ltd, Pleasanton, US
- 12:30 - 12:30 **171P - MET exon 14 splicing mutation and its correlation with clinocopathological features in subjects with non-small cell lung cancer**  
D. Katalinic<sup>1</sup>, I. Aleric<sup>2</sup>, A. Vcev<sup>3</sup>, <sup>1</sup>KBC - University Hospital Centre Zagreb, Zagreb, HR, <sup>2</sup>Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, HR, <sup>3</sup>Faculty of Medicine and Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek, HR
- 12:30 - 12:30 **172P - Cancer Stem Cell Markers in Pancreatic Ductal Adenocarcinoma**  
F. Aksoy<sup>1</sup>, E. Kaya<sup>1</sup>, U. Egeli<sup>2</sup>, H.Z. Dundar<sup>1</sup>, P. Tasar<sup>1</sup>, S. Aksoy<sup>1</sup>, Y. Ozen<sup>1</sup>, B. Tunca<sup>1</sup>, G. Cecener<sup>2</sup>, O. Yerci<sup>3</sup>, <sup>1</sup>Uludag University Medical Faculty, Bursa, TR, <sup>2</sup>uludag University Medical Faculty, bursa, TR, <sup>3</sup>uludag University Medical Faculty, Bursa, TR
- 12:30 - 12:30 **173P - Tumor mutation burden assessment on FFPE samples using a targeted next-generation sequencing assay**  
R. Chaudhary<sup>1</sup>, D. Cyanam<sup>2</sup>, V. Mittal<sup>1</sup>, W. Tom<sup>1</sup>, J. Au-Young<sup>1</sup>, C. Allen<sup>3</sup>, S. Sadis<sup>4</sup>, F. Hyland<sup>1</sup>, <sup>1</sup>Thermo Fisher Scientific, South San Francisco, US, <sup>2</sup>Thermo Fisher Scientific, Santa Clara, US, <sup>3</sup>Thermo Fisher Scientific, Liverpool, GB, <sup>4</sup>Thermo Fisher Scientific, Ann Arbor, US
- 12:30 - 12:30 **174P - Microsatellite instability-high (MSI-H) colorectal cancers with elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) signature represent a target population for immune checkpoint and DNA damaging therapies**  
K.T. Tan<sup>1</sup>, P.-N. Yu<sup>2</sup>, S.-J. Chen<sup>2</sup>, Y.-T. Liu<sup>2</sup>, S.-C. Chang<sup>3</sup>, M.-H. Chen<sup>4</sup>, <sup>1</sup>ACT Genomics, Co., LTD, Taipei, TW, <sup>2</sup>ACT Genomics Co., Ltd., Taipei, TW, <sup>3</sup>National Yang-Ming University, Taipei, TW, <sup>4</sup>Taipei Veterans General Hospital, Taipei, TW
- 12:30 - 12:30 **175P - Levels of circulating fibroblast growth factor (FGF) 23 and prognosis of cancer patients with bone metastasis**  
A. Mansinho<sup>1</sup>, A. Ferreira<sup>1</sup>, S. Casimiro<sup>2</sup>, I. Alho<sup>2</sup>, I. Vendrell<sup>1</sup>, A.L. Costa<sup>1</sup>, R. Sousa<sup>1</sup>, C. Abreu<sup>1</sup>, C. Pulido<sup>1</sup>, D. Macedo<sup>1</sup>, T. Pacheco<sup>1</sup>, L. Correia<sup>1</sup>, L. Costa<sup>3</sup>, <sup>1</sup>Centro Hospitalar Lisboa Norte - Hospital Sta Maria (HSM-CHLN), Lisbon, PT, <sup>2</sup>Instituto de Medicina Molecular, Lisbon, PT, <sup>3</sup>Institute of Molecular Medicine, Lissabon, PT



- 12:30 - 12:30 **176P - Clinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era**  
N. Tsoukalas<sup>1</sup>, E. Aravantinou<sup>2</sup>, K. Tsapakidis<sup>2</sup>, C. Giaginis<sup>3</sup>, M. Tolia<sup>4</sup>, I. Binas<sup>2</sup>, P. Baxevanos<sup>2</sup>, M. Galanopoulos<sup>2</sup>, M. Kiakou<sup>2</sup>, M. Tsiatas<sup>5</sup>, I. Kostakis<sup>3</sup>, C. Nikolaou<sup>2</sup>, I. Litos<sup>6</sup>, M. Lontos<sup>7</sup>, E. Tsiambas<sup>2</sup>, I. Gioulbasanis<sup>2</sup>, I. Sfiniadakis<sup>3</sup>, A. Karameris<sup>2</sup>, G. Kyrgias<sup>4</sup>, S. Theocharis<sup>3</sup>, 1417 NIMTS Army Veterans Hospital, Kolonaki, GR, 2Veterans Hospital (NIMTS), Athens, GR, 3Medical School, National and Kapodistrian University of Athens, Athens, GR, 4Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, GR, 5Athens Medical Center, Marousi, GR, 6University Hospital of Larissa, Larissa, GR, 7Alexandra Hospital, Athens, GR
- 12:30 - 12:30 **177P - Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung**  
S. Wang<sup>1</sup>, H. Chen<sup>2</sup>, J. Zhao<sup>3</sup>, J. Zhong<sup>4</sup>, J. Wang<sup>5</sup>, 1Bei jing Peking university cancer hospital, Beijing, CN, 2Peking University Cancer Hospital, Beijing, CN, 3Beijing Cancer Hospital, Beijing, CN, 4Peking University Cancer Hospital, Beijing, CN, 5National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN
- 12:30 - 12:30 **178P - XmaI-RRBS DNA methylation screening resolves breast cancer epigenetic heterogeneity**  
A. Tanas<sup>1</sup>, T. Kekeeva<sup>2</sup>, V. Sigin<sup>1</sup>, E. Kuznetsova<sup>1</sup>, E. Poddubskaya<sup>3</sup>, I. Trotsenko<sup>4</sup>, D. Zaletaev<sup>5</sup>, V. Strelnikov<sup>6</sup>, 1Research Centre for Medical Genetics, Moscow, RU, 2Medical and Rehabilitation Center, Moscow, RU, 3N. N. Blokhin Russian Cancer Research Center, Moscow, RU, 4Moscow Clinical Research Center, Moscow, RU, 5Sechenov First Moscow State Medical University, Moscow, RU, 6Institute of molecular medicine, Moscow, RU
- 12:30 - 12:30 **179P - Prognostic value of change in neutrophil-lymphocyte ratio during treatment with first-line anti-PD1 therapy in metastatic melanoma**  
J. Soon<sup>1</sup>, E. Blackley<sup>2</sup>, M. Moore<sup>2</sup>, L. Lim<sup>2</sup>, H.L. Yeoh<sup>2</sup>, M. Voskoboynik<sup>3</sup>, A. Haydon<sup>4</sup>, 1Eastern Health, Box Hill, AU, 2The Alfred Hospital, Melbourne, AU, 3Nucleus Network, Melbourne, AU, 4Alfred Hospital, Melbourne, AU
- 12:30 - 12:30 **180P - A serum microRNA expression signature for radiosensitivity of non-small cell lung cancer**  
L. Fan<sup>1</sup>, B. Li<sup>2</sup>, 1Shandong Provincial Western Hospital, Ji'nan, CN, 2Shandong cancer hospital affiliated to Shandong university, Jinan, CN
- 12:30 - 12:30 **181P - Anti-tNASP antibodies as a diagnostic marker for malignant tumors**  
O. Alekseev, K. Admire, J. Brogdon, B. Gorman, C. Davis, Z. Vaskalis, Campbell University, Lillington, US
- 12:30 - 12:30 **182TiP - EXPRESS study - A Multicenter, Prospective Trial In Progress Exploring The Association Between Low Level Of Genomic Alteration And Exceptional And Unexpected Response To Targeted Therapies In Patients With Solid Tumors**  
A. Italiano<sup>1</sup>, O. Le Saux<sup>2</sup>, F. André<sup>3</sup>, T. Filleron<sup>4</sup>, D. Spaeth<sup>5</sup>, P.-E. Heudel<sup>6</sup>, L. Albiges<sup>7</sup>, T. Bachelot<sup>6</sup>, A. Gonçalves<sup>8</sup>, J.-Y. Pierga<sup>9</sup>, F. Barlesi<sup>10</sup>, V. Boige<sup>7</sup>, C. Lebbé<sup>11</sup>, L. Mortier<sup>12</sup>, J.-

S. Frenel<sup>13</sup>, O. Tredan<sup>6</sup>, M. Jimenez<sup>14</sup>, F. Legrand<sup>15</sup>, C. Ferté<sup>7</sup>, <sup>1</sup>Institute Bergonié, Bordeaux, FR, <sup>2</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>3</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>4</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>5</sup>Centre d'Oncologie de Gentilly, Nancy, FR, <sup>6</sup>Centre Léon Bérard, Lyon, FR, <sup>7</sup>Institut Gustave Roussy, Villejuif, FR, <sup>8</sup>Institute Paoli Calmettes, Marseille, FR, <sup>9</sup>Institut Curie, Paris, FR, <sup>10</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>11</sup>Hôpital Saint Louis, Paris, FR, <sup>12</sup>Hôpital Huriez, Lille University Hospital, Lille, FR, <sup>13</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>14</sup>Unicancer, Paris, FR, <sup>15</sup>UNICANCER, Paris, FR

12:30 - 12:30 **183TiP - Neoadjuvant Biomarker Research Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast Cancer - the phase II NeORHEA trial**

M. Ignatiadis<sup>1</sup>, M. Brandao<sup>1</sup>, M. Maetens<sup>2</sup>, N. Ponde<sup>1</sup>, S. Martel<sup>3</sup>, S. Drisis<sup>1</sup>, I. Veys<sup>1</sup>, S. Mazy<sup>4</sup>, E. Bollue<sup>4</sup>, P. Neven<sup>5</sup>, F. Duhoux<sup>6</sup>, J. Chapiro<sup>7</sup>, A. Awada<sup>1</sup>, T. Besse-Hammer<sup>1</sup>, M. Paesmans<sup>1</sup>, M. Piccart<sup>1</sup>, P. Vuylsteke<sup>8</sup>, C. Sotiriou<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Breast International Group, Brussels, BE, <sup>3</sup>Hôpital Charles-Lemoyne, Greenfield Park, CA, <sup>4</sup>Clinique Sainte-Elisabeth, Namur, BE, <sup>5</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>6</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>7</sup>Centre Hospitalier Sud Francilien, Corbeil-Essonnes, FR, <sup>8</sup>CHU-UCL-Namur Clinique Ste Elisabeth, Namur, BE

12:30 - 12:30 **Gynaecological cancers**

12:30 - 12:30 **944P - QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: results from the tBRCAmut subset**

K. Moore<sup>1</sup>, A. Secord<sup>2</sup>, M. Geller<sup>3</sup>, D. Miller<sup>4</sup>, N. Cloven<sup>5</sup>, G. Fleming<sup>6</sup>, A. Wahner Hendrickson<sup>7</sup>, M. Azodi<sup>8</sup>, P. Disilvestro<sup>9</sup>, A. Oza<sup>10</sup>, M. Cristea<sup>11</sup>, J. Berek<sup>12</sup>, J. Chan<sup>13</sup>, B. Rimel<sup>14</sup>, Y. Li<sup>15</sup>, K. Luptakova<sup>15</sup>, R. Clark<sup>15</sup>, U. Matulonis<sup>16</sup>, B. Monk<sup>17</sup>, <sup>1</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>2</sup>Duke Cancer Institute, Duke University Medical Center, Durham, US, <sup>3</sup>University of Minnesota Medical School, Minneapolis, US, <sup>4</sup>University of Texas Southwestern Medical Center at Dallas, Dallas, US, <sup>5</sup>Texas Oncology, Fort Worth, US, <sup>6</sup>The University of Chicago Medical Centre, Chicago, US, <sup>7</sup>Mayo Clinic, Rochester, US, <sup>8</sup>Smilow Cancer Hospital at Yale and Yale University, New Haven, US, <sup>9</sup>Women and Infants Hospital, Providence, US, <sup>10</sup>University Health Network and Princess Margaret Cancer Centre, Toronto, CA, <sup>11</sup>City of Hope National Medical Center, Duarte, US, <sup>12</sup>Stanford Hospital & Clinics, Stanford, US, <sup>13</sup>Sutter Health, San Francisco, US, <sup>14</sup>Cedars-Sinai Medical Center, West Hollywood, US, <sup>15</sup>TESARO Inc., Waltham, US, <sup>16</sup>Dana Farber Cancer Institute, Boston, US, <sup>17</sup>University of Arizona and Creighton University, Phoenix, US

12:30 - 12:30 **945P - A phase 1/2 study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)**

R. O'Cearbhail<sup>1</sup>, A. Wolfer<sup>2</sup>, P. Disilvestro<sup>3</sup>, D. O'Malley<sup>4</sup>, P. Sabbatini<sup>5</sup>, L. Shohara<sup>6</sup>, P. Schwarzenberger<sup>7</sup>, T. Ricciardi<sup>6</sup>, M. Macri<sup>6</sup>, A. Ryan<sup>6</sup>, R. Venhaus<sup>6</sup>, J. Bryan<sup>8</sup>, P. Wong<sup>9</sup>, K. Homicsko<sup>10</sup>, L. Kandalaf<sup>11</sup>, S. Rusakiewicz<sup>11</sup>, A. Harari<sup>11</sup>, B. Monk<sup>12</sup>, G. Coukos<sup>13</sup>,

<sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>3</sup>Women and Infants Hospital, Providence, US, <sup>4</sup>The Ohio State University, James Cancer Center, Columbus, US, <sup>5</sup>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, <sup>6</sup>Ludwig Cancer Research, New York, US, <sup>7</sup>East Jefferson General Hospital, Metairie, US, <sup>8</sup>VentiRx Pharmaceuticals, New York, US, <sup>9</sup>Zuckerman Research Center and Memorial Sloan Kettering Cancer Center, New York, US, <sup>10</sup>Centre Multidisciplinaire d'Oncologie-CePo, Lausanne, CH, <sup>11</sup>University Hospital of Lausanne and Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne, CH, <sup>12</sup>University of Arizona and Creighton University, Phoenix, US, <sup>13</sup>Ludwig Center for Cancer Research of the UNIL, Epalinges, CH

12:30 - 12:30 **946P - Brain metastases in primary ovarian cancer: real-world data**

E. Ratner<sup>1</sup>, M. Bala<sup>2</sup>, M. Louie-Gao<sup>2</sup>, S. Hazard<sup>2</sup>, P. Brastianos<sup>3</sup>, <sup>1</sup>Yale University, New Haven, US, <sup>2</sup>TESARO Inc., Waltham, US, <sup>3</sup>Massachusetts General Hospital, Boston, US

12:30 - 12:30 **947P - Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: effect of prior chemotherapy regimens in ARIEL3**

D. Lorusso<sup>1</sup>, R. Coleman<sup>2</sup>, A. Oza<sup>3</sup>, C. Aghajanian<sup>4</sup>, A. Oaknin<sup>5</sup>, A. Dean<sup>6</sup>, N. Colombo<sup>7</sup>, J. Weberpals<sup>8</sup>, A. Clamp<sup>9</sup>, G. Scambia<sup>10</sup>, A. Leary<sup>11</sup>, R. Holloway<sup>12</sup>, M. Amedeo Gancedo<sup>13</sup>, P. Fong<sup>14</sup>, J. Goh<sup>15</sup>, D. O'Malley<sup>16</sup>, S. Banerjee<sup>17</sup>, S. Goble<sup>18</sup>, T. Cameron<sup>19</sup>, J. Ledermann<sup>20</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>2</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>3</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>4</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Saint John of God Hospital Subiaco, Subiaco, AU, <sup>7</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, <sup>9</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>10</sup>Policlinico Universitario A. Gemelli, Roma, IT, <sup>11</sup>Institut Gustave Roussy, Villejuif, FR, <sup>12</sup>Florida Hospital Cancer Institute, Orlando, US, <sup>13</sup>Fundacion Centro Oncologico de Galicia, A Coruña, ES, <sup>14</sup>Auckland City Hospital, Auckland, NZ, <sup>15</sup>Prince Charles Hospital, Brisbane, AU, <sup>16</sup>The Ohio State University, James Cancer Center, Columbus, US, <sup>17</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>18</sup>Clovis Oncology, Inc., Boulder, US, <sup>19</sup>Clovis Oncology Limited, Cambridge, GB, <sup>20</sup>University College London Cancer Institute, London, GB

12:30 - 12:30 **948P - Intraperitoneal Chemotherapy (IP CT) after cytoreductive surgery benefits survival in epithelial ovarian cancer (EOC): Results of a pooled meta-analysis including 9 randomized clinical trials (RCT)**

M. Jimenez-Heredia<sup>1</sup>, J.A. Perez Fidalgo<sup>2</sup>, M. Morales Suarez-Varela<sup>3</sup>, J. Sanchis<sup>4</sup>, M. Aranda<sup>4</sup>, A. Cervantes<sup>2</sup>, <sup>1</sup>Hospital Clínico Universitario de Valencia / INCLIVA, Valencia, ES, <sup>2</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>3</sup>University of Valencia. CIBERESP, Valencia, ES, <sup>4</sup>Hospital Clinico Universitario de Valencia. INCLIVA., Valencia, ES

12:30 - 12:30 **949P - Mirvetuximab soravtansine, a folate receptor alpha (FR<sub>α</sub>)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a Phase Ib study**



U. Matulonis<sup>1</sup>, K. Moore<sup>2</sup>, L. Martin<sup>3</sup>, I. Vergote<sup>4</sup>, C. Castro<sup>5</sup>, L. Gilbert<sup>6</sup>, K. Malek<sup>7</sup>, M. Birrer<sup>8</sup>, D. O'Malley<sup>9</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>3</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>4</sup>University Hospitals Leuven, Leuven, BE, <sup>5</sup>Massachusetts General Hospital, Boston, US, <sup>6</sup>McGill University Health Center, Montreal, CA, <sup>7</sup>Immuno Gen Inc., Waltham, US, <sup>8</sup>University of Alabama at Birmingham, Birmingham, US, <sup>9</sup>The Ohio State University, James Cancer Center, Columbus, US

12:30 - 12:30

**950P - Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy**

A. Oza<sup>1</sup>, D. Cibula<sup>2</sup>, A. Oaknin<sup>3</sup>, C. Poole<sup>4</sup>, R. Mathijssen<sup>5</sup>, G. Sonke<sup>6</sup>, N. Colombo<sup>7</sup>, J. Špaček<sup>8</sup>, P. Vuylsteke<sup>9</sup>, H. Hirte<sup>10</sup>, J. Pfisterer<sup>11</sup>, M. Plante<sup>12</sup>, L. Hanker<sup>13</sup>, A. Fielding<sup>14</sup>, V. Haddad<sup>15</sup>, J. Chmielecki<sup>16</sup>, M. Friedlander<sup>17</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>General University Hospital, Prague, CZ, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>University Hospitals Coventry & Warwickshire, Coventry, GB, <sup>5</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>6</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>7</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>University Hospital, Hradec Kralove, CZ, <sup>9</sup>CHU-UCL-Namur Clinique Ste Elisabeth, Namur, BE, <sup>10</sup>Juravinski Cancer Centre, Hamilton, CA, <sup>11</sup>Womens Cancer Center, Kiel, DE, <sup>12</sup>Laval University, Quebec City, CA, <sup>13</sup>AGO Study Group & University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, DE, <sup>14</sup>Astrazeneca, Macclesfield, GB, <sup>15</sup>AstraZeneca UK, Melbourn, GB, <sup>16</sup>AstraZeneca, Waltham, US, <sup>17</sup>Prince of Wales Hospital, Randwick, AU

12:30 - 12:30

**951P - A Phase 1b Study of Navicixizumab & Weekly Paclitaxel in Heavily Pre-Treated Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer.**

S. Fu<sup>1</sup>, B. Corr<sup>2</sup>, E. Hamilton<sup>3</sup>, R. Burger<sup>4</sup>, R. Wenham<sup>5</sup>, R. Naumann<sup>6</sup>, R. Stagg<sup>7</sup>, K. Moore<sup>8</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>University of Colorado Denver, Aurora, US, <sup>3</sup>Sarah Cannon at Tennessee Oncology, Nashville, US, <sup>4</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>5</sup>Moffitt Cancer Center, Tampa, US, <sup>6</sup>Levine Cancer Institute, Charlotte, US, <sup>7</sup>Oncomed Pharmaceuticals, Redwood City, US, <sup>8</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US

12:30 - 12:30

**952P - Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial**

J. Korach<sup>1</sup>, G. Freyer<sup>2</sup>, S. Banerjee<sup>3</sup>, R. Asher<sup>4</sup>, J. Cosin<sup>5</sup>, A. Oza<sup>6</sup>, A.M. Poveda Velasco<sup>7</sup>, M. Di Napoli<sup>8</sup>, C. Scott<sup>9</sup>, M. Lapresa<sup>10</sup>, F. Heitz<sup>11</sup>, K. Takehara<sup>12</sup>, G. Sonke<sup>13</sup>, S. Tjulandin<sup>14</sup>, J.-W. Kim<sup>15</sup>, R. Hegg<sup>16</sup>, I. Vergote<sup>17</sup>, S. Turner<sup>18</sup>, E. Pujade-Lauraine<sup>19</sup>, <sup>1</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>2</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>3</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>4</sup>University of Sydney, Camperdown, AU, <sup>5</sup>Hartford Healthcare Cancer Institute, New Britain, US, <sup>6</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>7</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>8</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>9</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>10</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>11</sup>Kliniken Essen-Mitte, Essen, DE, <sup>12</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>13</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>14</sup>N.N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>15</sup>KGOG



& Seoul National University, Seoul, KP, <sup>16</sup>Gynecological Clinical Service School of Medicine, Univ. Sao Paulo, Sao Paulo, BR, <sup>17</sup>University Hospitals Leuven, Leuven, BE, <sup>18</sup>AstraZeneca Academy House, Cambridge, GB, <sup>19</sup>Groupe hospitalier Hôtel Dieu (AP-HP), Paris, FR

- 12:30 - 12:30 **953P - the impact of lymph node dissection on high risk versus low risk endometrial cancer**  
C. Zhang, A. Soochit, J. Liu, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:30 - 12:30 **954P - HOXA9 methylation in circulating tumor DNA as a prognostic biomarker in BRCA-mutated ovarian cancer patients treated with PARP inhibitor**  
M. Rusan<sup>1</sup>, R. Fredslund Andersen<sup>2</sup>, A. Jakobsen<sup>1</sup>, K. Dahl Steffensen<sup>1</sup>, <sup>1</sup>Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, <sup>2</sup>Vejle Hospital, Vejle, DK
- 12:30 - 12:30 **955P - Prevalence and clinical implications of Mismatch Repair (MMR) deficiency in unselected endometrial cancer (EC) patients**  
C. Orbegoso Aguilar, K. Vroobel, S. Lalondrelle, A. Taylor, M. Nobbenhuis, A. Attygalle, S. Banerjee, A. George, Royal Marsden Hospital NHS Foundation Trust, London, GB
- 12:30 - 12:30 **956P - A Phase Ib and Randomised Phase II Trial of Pazopanib with or without Fosbretabulin in Advanced Recurrent Ovarian Cancer**  
R. Morgan<sup>1</sup>, G. Jayson<sup>1</sup>, S. Banerjee<sup>2</sup>, A. Clamp<sup>1</sup>, A. Lyon<sup>3</sup>, W.D. Ryder<sup>1</sup>, R. Hutson<sup>1</sup>, N. Mescallado<sup>1</sup>, C. Orbegoso Aguilar<sup>2</sup>, S. Taylor<sup>4</sup>, J. Tugwood<sup>4</sup>, M. Hall<sup>5</sup>, C. Dive<sup>6</sup>, G. Rustin<sup>5</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>3</sup>Royal Brompton Hospital and Imperial College, London, London, GB, <sup>4</sup>Cancer Research UK Manchester Institute, Macclesfield, GB, <sup>5</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>6</sup>Cancer Research UK Manchester Institute, Manchester, GB
- 12:30 - 12:30 **957P - Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy**  
J.-Y. Lee<sup>1</sup>, S. Paik<sup>2</sup>, <sup>1</sup>Yonsei Cancer Center Yonsei University, Seoul, KR, <sup>2</sup>Yonsei University, Seoul, KR
- 12:30 - 12:30 **958P - Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from Phase 1 cohorts**  
D. Rischin<sup>1</sup>, M. Gil-Martin<sup>2</sup>, A. González-Martín<sup>3</sup>, I. Brana<sup>4</sup>, J. Hou<sup>5</sup>, D. Cho<sup>6</sup>, G. Falchook<sup>7</sup>, S. Formenti<sup>8</sup>, S. Jabbour<sup>9</sup>, K. Moore<sup>10</sup>, A. Naing<sup>11</sup>, K. Papadopoulos<sup>12</sup>, J. Baranda<sup>13</sup>, A. Weise<sup>14</sup>, M. Fury<sup>15</sup>, M. Feng<sup>16</sup>, J. Li<sup>16</sup>, I. Lowy<sup>15</sup>, M. Mathias<sup>15</sup>, <sup>1</sup>Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, AU, <sup>2</sup>Institut Català d'Oncologia, Barcelona, ES, <sup>3</sup>Clinica Universidad de Navarra, formerly of MD Anderson International España, Madrid, ES, <sup>4</sup>Vall D'Hebron Institute of Oncology, Barcelona, ES, <sup>5</sup>Columbia University Medical Center, New York, US, <sup>6</sup>New York University, Langone Medical Center, New York, US, <sup>7</sup>Sarah Cannon Research Institute at HealthONE, Denver, US, <sup>8</sup>Weill Cornell Medicine, New York, US, <sup>9</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, US, <sup>10</sup>Stephenson Cancer Center at the University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Oklahoma City, US, <sup>11</sup>The University of Texas MD Anderson Cancer Center, Houston, US,

<sup>12</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>13</sup>Early Phase Program Clinical Research Center, Fairway, US, <sup>14</sup>Karmanos Cancer Institute, Detroit, US, <sup>15</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US, <sup>16</sup>Regeneron Pharmaceuticals, Inc., Basking Ridge, US

- 12:30 - 12:30 **959P - Molecular profiles as a function of treatment response/progression free survival in a prospective cervical cancer study (RAIDs)**  
S. Scholl<sup>1</sup>, L. De Koning<sup>2</sup>, M. Popovic<sup>3</sup>, D.L.R. Anne<sup>1</sup>, A. Floquet<sup>4</sup>, E. Berns<sup>5</sup>, G. Kenter<sup>6</sup>, A. Kereszt<sup>7</sup>, E. Girard<sup>1</sup>, H. Von Der Leyen<sup>8</sup>, S. Dureau<sup>1</sup>, V. Fourchette<sup>1</sup>, R. Rouzier<sup>1</sup>, M. Kamal<sup>1</sup>, R. Consortium<sup>1</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>Hôpital St. Louis, Paris, FR, <sup>3</sup>Institut of Oncology of Vojvodina, Novisad, RS, <sup>4</sup>Institute Bergonié, Bordeaux, FR, <sup>5</sup>ERASMUS, Rotterdam, NL, <sup>6</sup>NKI, Amsterdam, NL, <sup>7</sup>SeqOmics, moraholem, HU, <sup>8</sup>HCTC, hanover, DE
- 12:30 - 12:30 **960P - Phase I study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma: safety, clinical activity, and immunologic correlates**  
C.H. Choi<sup>1</sup>, H.J. Choi<sup>2</sup>, J.-W. Lee<sup>2</sup>, E.-S. Kang<sup>2</sup>, D. Cho<sup>2</sup>, Y.-M. Kim<sup>3</sup>, D. Kim<sup>3</sup>, H. Seo<sup>4</sup>, M. Park<sup>4</sup>, W. Kim<sup>5</sup>, T. Oh<sup>5</sup>, C.-Y. Kang<sup>4</sup>, B.-G. Kim<sup>2</sup>, <sup>1</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>2</sup>Samsung Medical Center, Seoul, KR, <sup>3</sup>Asan Medical Center, Seoul, KR, <sup>4</sup>Seoul National University, Seoul, KR, <sup>5</sup>Cellid Inc, seoul, KR
- 12:30 - 12:30 **961P - Risk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance**  
K. Thein<sup>1</sup>, A. Sultan<sup>2</sup>, M. Zaw<sup>3</sup>, M. Han<sup>4</sup>, R. Yendala<sup>2</sup>, M. Zin<sup>5</sup>, S. Awasthi<sup>2</sup>, N. D'Cunha<sup>2</sup>, F. Hardwicke<sup>2</sup>, C. Jones<sup>2</sup>, <sup>1</sup>TEXAS TECH UNIVERSITY, Lubbock, US, <sup>2</sup>Texas Tech University Health Sciences Center, Lubbock, US, <sup>3</sup>The Brooklyn Hospital Center, Brooklyn, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Kingsbrook Jewish Medical Center, Brooklyn, US
- 12:30 - 12:30 **962P\_PR - Indicators of non-participation in cervical cancer screening: Results from the EDIFICE 6 survey**  
T. De La Motte Rouge<sup>1</sup>, S. Couraud<sup>2</sup>, F. Eisinger<sup>3</sup>, M. Roupret<sup>4</sup>, L. Brignoli-Guibaudet<sup>5</sup>, C. Lhomel<sup>6</sup>, L. Greillier<sup>7</sup>, J. Viguier<sup>8</sup>, J.F. Morère<sup>9</sup>, <sup>1</sup>Centre Eugene - Marquis, Rennes, FR, <sup>2</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>3</sup>Institute Paoli Calmettes, Marseille, FR, <sup>4</sup>Hôpital Universitaire Pitié-Salpêtrière, Paris, FR, <sup>5</sup>Kantar Health, Paris, FR, <sup>6</sup>Products Roche - France, Neuilly-sur-Seine, FR, <sup>7</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>8</sup>Institut National du Cancer, Boulogne-Billancourt, FR, <sup>9</sup>Hôpital Paul Brousse, Villejuif, FR
- 12:30 - 12:30 **963P - A Phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: updated analysis of full cervical expansion cohort**  
N. Concin<sup>1</sup>, I. Vergote<sup>2</sup>, U. Lassen<sup>3</sup>, Y. Drew<sup>4</sup>, J.-P. Machiels<sup>5</sup>, H.-T. Arkenau<sup>6</sup>, M. Forster<sup>7</sup>, R. Jones<sup>8</sup>, M. Johnson<sup>9</sup>, B. Slomovitz<sup>10</sup>, J. Spicer<sup>11</sup>, N. Cornez<sup>12</sup>, C. Gennigens<sup>13</sup>, R. Coleman<sup>14</sup>, K. Windfeld<sup>15</sup>, S. Ghatta<sup>16</sup>, R. Rangwala<sup>16</sup>, D. Hong<sup>17</sup>, <sup>1</sup>Ogilvy CommonHealth, Parsippany, US, <sup>2</sup>University Hospitals Leuven, Leuven, BE, <sup>3</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>4</sup>Newcastle General Hospital

Northern Centre for Cancer Treatment, Newcastle upon Tyne, GB, <sup>5</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>6</sup>Sarah Cannon Research Institute SCRI UK, London, GB, <sup>7</sup>University College London Cancer Institute, London, GB, <sup>8</sup>Velindre Cancer Centre and Cardiff University, Cardiff, GB, <sup>9</sup>Sarah Cannon Research Institute, Nashville, US, <sup>10</sup>Brian M. Slomovitz, Miami, US, <sup>11</sup>King's College London Guy's Hospital, London, GB, <sup>12</sup>Oncology, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage, Mons, BE, <sup>13</sup>Chu Sart-Tilman, Liege, BE, <sup>14</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>15</sup>Genmab, Kobenhavn, DK, <sup>16</sup>Genmab US, Inc., Princeton, US, <sup>17</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US

12:30 - 12:30

**964P - Preoperative C-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer**

E.I. Braicu<sup>1</sup>, J. Sehouli<sup>2</sup>, R. Richter<sup>2</sup>, I. Vergote<sup>3</sup>, N. Concin<sup>3</sup>, E. Van Nieuwenhuysen<sup>3</sup>, P. Achimas<sup>4</sup>, A. Berger<sup>5</sup>, B. Fetica<sup>4</sup>, S. Mahner<sup>6</sup>, J. Glajzer<sup>2</sup>, A. Papadia<sup>7</sup>, L. Woelber<sup>8</sup>, M.L. Gasparri<sup>7</sup>, A. Vanderstichele<sup>3</sup>, P. Benedetti Panici<sup>9</sup>, M. Mueller<sup>10</sup>, I. Ruscito<sup>2</sup>, J. Zimmer<sup>2</sup>, H. Woopen<sup>2</sup>, <sup>1</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>2</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>3</sup>University Hospitals Leuven, Leuven, BE, <sup>4</sup>Oncological Institute Ion Chiricuta, Cluj-Napoca, RO, <sup>5</sup>Innsbruck Medical University, Innsbruck, AT, <sup>6</sup>AGO Study Group & University Medical Center Hamburg-Eppendorf and University of Munich; current address University of Munich, München, DE, <sup>7</sup>University of Bern and Inselspital University Hospital, Bern, CH, <sup>8</sup>University Medical Center Hamburg-Eppendorf, Hamburg, DE, <sup>9</sup>Universita La Sapienza, Roma, IT, <sup>10</sup>University of Bern and Inselspital University Hospital of Bern, Bern, CH

12:30 - 12:30

**965P - Prognostic factors in patients with uterine leiomyosarcoma: A multi-institutional retrospective study from the Japanese Gynecologic Oncology Group**

K. Takehara<sup>1</sup>, N. Yamashita<sup>2</sup>, T. Motohashi<sup>3</sup>, K. Harano<sup>4</sup>, T. Nakanishi<sup>5</sup>, H. Tokunaga<sup>6</sup>, N. Susumu<sup>7</sup>, Y. Ueda<sup>8</sup>, Y. Yokoyama<sup>9</sup>, Y. Watanabe<sup>5</sup>, R. Watanabe<sup>10</sup>, N. Teramoto<sup>1</sup>, H. Tsuda<sup>11</sup>, T. Saito<sup>12</sup>, <sup>1</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>2</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>3</sup>Kuwana City Hospital, Kuwana, JP, <sup>4</sup>Nippon Medical School Musashikosugi Hospital, Kawasaki, JP, <sup>5</sup>Tohoku Medical and Pharmaceutical University, Sendai, JP, <sup>6</sup>Tohoku University, Sendai, JP, <sup>7</sup>International University of Health and Welfare, Narita, JP, <sup>8</sup>Osaka University, Osaka, JP, <sup>9</sup>Hirosaki University Graduate School of Medicine, Hirosaki, JP, <sup>10</sup>National Cancer Center Hospital, Tokyo, JP, <sup>11</sup>National Defense Medical College Hospital, Tokorozawa, JP, <sup>12</sup>National Kyushu Cancer Center, Fukuoka, JP

12:30 - 12:30

**966P - Screening for inherited cancer syndromes in Chinese patients with endometrial cancer**

H. Wang<sup>1</sup>, W. Tian<sup>1</sup>, R. Bi<sup>1</sup>, Y. Ren<sup>2</sup>, H. He<sup>3</sup>, S. Shi<sup>3</sup>, B. Shan<sup>1</sup>, Q. Wang<sup>4</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Shanghai Cancer Center Fudan University, Shanghai, CN, <sup>3</sup>Shanghai Topgen Bio-Pharm Co, Ltd., Shanghai, CN, <sup>4</sup>Centre Léon Bérard, Lyon, FR

12:30 - 12:30

**967P - Clinical relevance of circulating MACC1 and S100A4 transcripts in serum of ovarian cancer patients**

P. Wimberger<sup>1</sup>, T. Link<sup>2</sup>, P. Herrmann<sup>3</sup>, D. Kobelt<sup>3</sup>, Y. Vassileva<sup>2</sup>, F. Kerstin<sup>4</sup>, J. Kuhlmann<sup>2</sup>, U. Stein<sup>3</sup>, <sup>1</sup>Universitätsklinikum Dresden, Dresden, DE, <sup>2</sup>Technische Universität Dresden, Dresden, DE, <sup>3</sup>Charité - Universitätsmedizin Berlin, Berlin, DE,



<sup>4</sup>ITM Plauen, Dresden, DE

- 12:30 - 12:30 **968P - Outcomes of Ovarian Clear Cell Carcinoma (OCCC) of the Vall d'Hebron Hospital/Vall d'Hebron Institute of Oncology (VHIO)**  
F. Amair Pinedo, L. Fariñas-Madrid, V. Rodriguez Freixinos, F.J. Ros Montaña, G. Villacampa, R. Dienstmann, A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES
- 12:30 - 12:30 **969P - A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of gastrointestinal and hepatic toxicities in patients with recurrent ovarian cancer treated with poly adenosine diphosphate ribose polymerase inhibitors maintenance**  
K. Thein<sup>1</sup>, A. Sultan<sup>2</sup>, M. Zaw<sup>3</sup>, M. Han<sup>4</sup>, A. Hein<sup>5</sup>, H. Aung<sup>6</sup>, S. Awasthi<sup>2</sup>, C. Jones<sup>2</sup>, F. Hardwicke<sup>2</sup>, N. D'Cunha<sup>2</sup>, <sup>1</sup>TEXAS TECH UNIVERSITY, Lubbock, US, <sup>2</sup>Texas Tech University Health Sciences Center, Lubbock, US, <sup>3</sup>The Brooklyn Hospital Center, Brooklyn, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Nassau University Medical Center, New York, US, <sup>6</sup>Kingsbrook Jewish Medical Center, New York, US
- 12:30 - 12:30 **970P - Evaluation of Chemotherapy Response Score and lymphocytic infiltration as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.**  
M. Lontos<sup>1</sup>, M. Sotiropoulou<sup>1</sup>, M. Kaparelou<sup>1</sup>, K. Tzannis<sup>1</sup>, G. Tsironis<sup>1</sup>, A. Kyriazoglou<sup>1</sup>, A. Tsiara<sup>1</sup>, R. Zakopoulou<sup>2</sup>, K. Koutsoukos<sup>1</sup>, F. Zagouri<sup>3</sup>, D. Vlachos<sup>1</sup>, N. Thomakos<sup>1</sup>, D. Haidopoulos<sup>1</sup>, A. Rodolakis<sup>1</sup>, M. Dimopoulos<sup>1</sup>, A. Bamias<sup>4</sup>, <sup>1</sup>Alexandra Hospital, Athens, GR, <sup>2</sup>University of Athens, Athens, GR, <sup>3</sup>General Hospital Konstantopoulou-Agia Olga, Athens, GR, <sup>4</sup>University of Athens, Sotiria General Chest Diseases Hospital, Athens, GR
- 12:30 - 12:30 **971P - Embryonic protein Nodal as a novel marker of progression and drug resistance in ovarian cancer**  
O. Bilyk<sup>1</sup>, L. Lee<sup>2</sup>, N. Le<sup>3</sup>, L. Cook<sup>4</sup>, M. Koebel<sup>5</sup>, L. Postovit<sup>2</sup>, <sup>1</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>2</sup>University of Alberta, Edmonton, CA, <sup>3</sup>British Columbia Cancer Research Center, Vancouver, CA, <sup>4</sup>University of New Mexico, New Mexico, US, <sup>5</sup>University of Calgary, Calgary, CA
- 12:30 - 12:30 **972P - Bcl-2 proteins expression and response to Navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)**  
P.E. Brachet<sup>1</sup>, F. Joly Lobbedez<sup>1</sup>, M. Fabbro<sup>2</sup>, A. Leary<sup>3</sup>, J. Medioni<sup>4</sup>, P. Follana<sup>5</sup>, A.F. Lesoin<sup>6</sup>, J.-S. Frenel<sup>7</sup>, S. Abadie Lacourtoisie<sup>8</sup>, A. Floquet<sup>9</sup>, L. Gladieff<sup>10</sup>, B. You<sup>11</sup>, C. Gavaille<sup>12</sup>, E. Kalbacher<sup>13</sup>, M. Briand<sup>1</sup>, P.A. Just<sup>14</sup>, C. Blanc-Fournier<sup>1</sup>, F. Giffard<sup>15</sup>, B. Clarisse<sup>1</sup>, L. Poulain<sup>1</sup>, <sup>1</sup>Centre Francois Baclesse, Caen, FR, <sup>2</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Gh Diaconesses Croix Saint-Simon, Paris, FR, <sup>5</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>6</sup>Centre Oscar Lambret, Lille, FR, <sup>7</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>8</sup>Centre Paul Papin, Angers, FR, <sup>9</sup>Institute Bergonié, Bordeaux, FR, <sup>10</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>11</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>12</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>13</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>14</sup>AP-HP Hôpital Cochin, Paris, FR, <sup>15</sup>Centre Francois Baclesse and INSERM U1086 "ANTICIPE" (Interdisciplinary Research Unit for Cancers Prevention and Treatment, Axis BioTICLA



“Biology and Innovative Therapeutics for Ovarian Cancers”), Caen, FR

- 12:30 - 12:30 **973P - Expression of CD4, CD8 and Foxp3 and its clinical significance in neoadjuvant chemotherapy for locally advanced cervical cancer**  
X. Yin, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN
- 12:30 - 12:30 **974P - Clinical study on the efficacy of apatinib treatment for advanced ovarian cancer after second-line chemotherapy failure**  
S. Sun<sup>1</sup>, D. Zhai<sup>2</sup>, C. Yu<sup>1</sup>, <sup>1</sup>Changhai Hospital of Shanghai, Shanghai, CN, <sup>2</sup>Changhai Hospital, Shanghai, CN
- 12:30 - 12:30 **975P - Clear Cell Ovarian Cancer (CCOC): Predicting Risk of Relapse (ROR)**  
M.-J. Devlin<sup>1</sup>, J. Ledermann<sup>2</sup>, M. Lockley<sup>3</sup>, N. Wilkinson<sup>4</sup>, J. Mcdermott<sup>4</sup>, R. Kristeleit<sup>5</sup>, R. Miller<sup>4</sup>, <sup>1</sup>NIHR UCLH Clinical Research Facility (CRF), London, GB, <sup>2</sup>University College London Cancer Institute, London, GB, <sup>3</sup>Queen Mary University of London, London, GB, <sup>4</sup>University College London Hospital UCLH NHS Foundation Trust, London, GB, <sup>5</sup>University College London UCL Cancer Institute, London, GB
- 12:30 - 12:30 **976P - Comparison of PARPi with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: a network meta-analysis**  
Y. Feng, J. Liu, H. Huang, C. Zhang, T. Wan, C. Tong, T. Deng, H. Tu, Y. Huang, G. Liu, Q. Huang, Z. Liu, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:30 - 12:30 **977P - The role of Bevacizumab plus Front-line Chemotherapy in patients with malignant ascites of Ovarian cancer**  
M. Nikolaou<sup>1</sup>, N. Ziras<sup>2</sup>, I. Athanasiadis<sup>3</sup>, A. Ardavanis<sup>4</sup>, M. Vaslamatzis<sup>5</sup>, N. Kentepozidis<sup>6</sup>, P. Makrantonakis<sup>7</sup>, A. Christopoulou<sup>8</sup>, V. Michalaki<sup>9</sup>, A. Polizos<sup>10</sup>, C. Emmanouilidis<sup>11</sup>, V. Georgoulis<sup>12</sup>, <sup>1</sup>University Hospital of Larissa, Larissa, GR, <sup>2</sup>metaxa, athens, GR, <sup>3</sup>Hygeia Hospital, Athens, GR, <sup>4</sup>Agios Savvas Regional Cancer Hospital, Athens, GR, <sup>5</sup>Evangelismos General Hospital of Athens, Athens, GR, <sup>6</sup>251 Hellenic Airforce General Hospital, Athens, GR, <sup>7</sup>Theagenio Cancer Hospital, Thessaloniki, GR, <sup>8</sup>Hospital AG. Andreas, Patras, GR, <sup>9</sup>Areteion Hospital, University of Athens, Athens, GR, <sup>10</sup>laiko, Athens, GR, <sup>11</sup>Balkan Medical Centre, Thessaloniki, GR, <sup>12</sup>University Hospital of Heraklion, Heraklion, GR
- 12:30 - 12:30 **978P - Quality of life in newly diagnosed patients with cervical cancer in Brazil: results of EVITA study (EVA/LACOG 0215).**  
A. Nogueira-Rodrigues<sup>1</sup>, A. De Melo<sup>2</sup>, A. Calabrich<sup>3</sup>, E. Cronenberger<sup>4</sup>, K. Torres<sup>5</sup>, F. Damian<sup>6</sup>, R. Cossetti<sup>7</sup>, C. De Azevedo<sup>8</sup>, A. Da Fonseca<sup>9</sup>, Y. Nerón<sup>10</sup>, J. Nunes<sup>11</sup>, A. Lopes<sup>12</sup>, F. Thomé<sup>13</sup>, R. Leal<sup>14</sup>, G. Borges<sup>15</sup>, P.R. Nunes Filho<sup>16</sup>, F. Zaffaroni Caorsi<sup>17</sup>, R. Freitas<sup>18</sup>, G. Werutsky<sup>19</sup>, F. Maluf<sup>20</sup>, <sup>1</sup>Federal University of Minas Gerais, Belo Horizonte, BR, <sup>2</sup>INCA - Instituto Nacional de Cancer, Rio de Janeiro, BR, <sup>3</sup>Assistencia Multidisciplinar em Oncologia Clinic, Salvador, BR, <sup>4</sup>Centro Regional Integrado de Oncologia, Fortaleza, BR, <sup>5</sup>Fundação Centro de Controle de Oncologia do Estado do Amazonas, Manaus, BR, <sup>6</sup>Hospital São Lucas, Porto Alegre, BR, <sup>7</sup>Hospital Aldenora Bello, São Luis, BR, <sup>8</sup>Instituto de Medicina Integral Professor Fernando Figueira, Recife, BR, <sup>9</sup>Hospital Geral de Roraima, Boa Vista, BR, <sup>10</sup>Centro de Pesquisas Oncológicas,

Florianópolis, BR, <sup>11</sup>Hospital Erasto Gaertner, Curitiba, BR, <sup>12</sup>Instituto Brasileiro de Controle do Câncer, São Paulo, BR, <sup>13</sup>Hospital São Vicente de Paulo, Passo Fundo, BR, <sup>14</sup>Hospital Universitário Walter Cantídio, Fortaleza, BR, <sup>15</sup>Clínica Neoplasias Litoral, Itajaí, BR, <sup>16</sup>Hospital Sao Lucas da PUCRS, Porto Alegre, BR, <sup>17</sup>Latin American Oncology Group, Porto Alegre, BR, <sup>18</sup>Latin American Cooperative Oncology Group, Porto Alegre, BR, <sup>19</sup>Hospital São Lucas da PUCRS, Porto Alegre, BR, <sup>20</sup>Hospital Beneficencia Portuguesa of Sao Paulo, Sao Paulo, BR

- 12:30 - 12:30 **979P - Oregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort**  
J. Chan<sup>1</sup>, S.H. Tan<sup>2</sup>, T.W. Lim<sup>2</sup>, T. Tan<sup>2</sup>, W.Y. Chay<sup>1</sup>, E. Lim<sup>2</sup>, L.T. Soh<sup>2</sup>, S.L. Lim<sup>3</sup>, J. Chia<sup>4</sup>, <sup>1</sup>National Cancer Center Singapore, Singapore, SG, <sup>2</sup>National Cancer Centre Singapore, Singapore, SG, <sup>3</sup>KK Women and Children's Hospital, Singapore, SG, <sup>4</sup>OncoCare Cancer Centre, Singapore, SG
- 12:30 - 12:30 **980P - Genomic characterization of vulvar squamous cell carcinoma**  
K. Prieske<sup>1</sup>, M. Alawi<sup>1</sup>, S.A. Joosse<sup>1</sup>, K. Eylmann<sup>1</sup>, E. Burandt<sup>1</sup>, B. Schmalfeldt<sup>2</sup>, L. Oliveira-Ferrer<sup>1</sup>, L. Woelber<sup>3</sup>, <sup>1</sup>Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, <sup>2</sup>AGO Study Group & Technical University of Munich - Klinikum rechts der Isar; current address: University of Medical Center Hamburg-Eppendorf, Hamburg, DE, <sup>3</sup>University Medical Center Hamburg-Eppendorf, Hamburg, DE
- 12:30 - 12:30 **981P - Economic and Humanistic Burden of Cervical Cancer in the United States**  
C. Nwankwo<sup>1</sup>, R. Shah<sup>2</sup>, Y. Kwon<sup>2</sup>, S. Corman<sup>3</sup>, <sup>1</sup>Merck & Co., Inc., Kenilworth, NJ, US, <sup>2</sup>Pharmerit International, Inc, Bethesda, US, <sup>3</sup>Pharmerit International, Bethesda, US
- 12:30 - 12:30 **982P - Risk of fatigue and neuropathy in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials**  
V. Ruiz-Schutz<sup>1</sup>, L. Gomes<sup>2</sup>, C. Oliveira<sup>2</sup>, R. Mariano<sup>3</sup>, D. Almeida<sup>4</sup>, J. Pimenta<sup>2</sup>, G. Dal Molin<sup>5</sup>, F. Kater<sup>6</sup>, R. Yamamura<sup>7</sup>, F. Maluf<sup>8</sup>, F. Schutz<sup>7</sup>, <sup>1</sup>Universidade de Sao Paulo, Sao Paulo, BR, <sup>2</sup>Hospital Beneficência Portuguesa de São Paulo, São Paulo, BR, <sup>3</sup>BP - A Beneficência Portuguesa de São Paulo, Sao Paulo, BR, <sup>4</sup>Hospital São Jose - Beneficencia Portuguesa de São Paulo, Sao Paulo, BR, <sup>5</sup>MD Anderson Cancer Center, Houston, US, <sup>6</sup>Centro Paulista de Oncologia, Sao Paulo, BR, <sup>7</sup>Hospital São José, Sao Paulo, BR, <sup>8</sup>Hospital Beneficencia Portuguesa of Sao Paulo, Sao Paulo, BR
- 12:30 - 12:30 **983P - Risk of cancer associated death in younger vs. older patients with FIGO stage I endometrial cancer**  
J. Ko<sup>1</sup>, B. Lester<sup>2</sup>, G. Bowering<sup>2</sup>, C. Rugayan<sup>2</sup>, I. Ghement<sup>3</sup>, K. Aalok<sup>4</sup>, <sup>1</sup>BC Cancer Agency, Abbotsford, CA, <sup>2</sup>BC Cancer - Abbotsford, Abbotsford, CA, <sup>3</sup>Ghement Statistics, Vancouver, CA, <sup>4</sup>BC Cancer - Surrey, Surrey, CA
- 12:30 - 12:30 **984P - Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC)**  
M. Hall<sup>1</sup>, G. Bertelli<sup>2</sup>, L. Li<sup>3</sup>, C. Green<sup>4</sup>, S. Chan<sup>5</sup>, C.C. Yeoh<sup>6</sup>, J. Hasan<sup>7</sup>, A. Ograbek<sup>8</sup>, T.

Perren<sup>9</sup>, <sup>1</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>2</sup>Royal Sussex County Hospital Sussex Cancer Centre, Brighton, GB, <sup>3</sup>James Cook University Hospital, Middlesbrough, GB, <sup>4</sup>Southampton University NHS Trust, Southampton, GB, <sup>5</sup>Nottingham University Hospital NHS Trust (City Hospital Campus), Nottingham, GB, <sup>6</sup>Queen Alexandra Hospital Portsmouth Oncology Centre, Portsmouth, GB, <sup>7</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>8</sup>Roche Products Ltd, Welwyn Garden City, GB, <sup>9</sup>St. James's University Hospital Leeds, Leeds, GB

12:30 - 12:30 **985P - Prolonged Survival (SV) Associated with Pulmonary Metastasectomy (PM) for Carcinomas of the Cervix (CC)**

J. Corona-Cruz<sup>1</sup>, A. Castillo-Castañon<sup>1</sup>, C. Deneken<sup>2</sup>, L. Ramirez-Tirado<sup>1</sup>, A. Gonzalez-Enciso<sup>1</sup>, D. Gallardo-Rincon<sup>1</sup>, E. Jimenez-Fuentes<sup>1</sup>, O. Arrieta<sup>3</sup>, <sup>1</sup>Instituto Nacional de Cancerologia - Mexico, Ciudad de México, MX, <sup>2</sup>Instituto Nacional de Cancerologia-Mexico, Ciudad de México, MX, <sup>3</sup>Instituto Nacional de Cancerologia, Ciudad de México, MX

12:30 - 12:30 **986P - Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort**

J. Gallagher, K. Heap, S. Carroll, Clarity Pharma Research, LLC, Spartanburg, US

12:30 - 12:30 **987P - Trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study**

S. Pignata<sup>1</sup>, G. Scambia<sup>2</sup>, T. Mazzei<sup>3</sup>, M. Arruti Barbia<sup>4</sup>, E. Naglieri<sup>5</sup>, L.M. De Sande<sup>6</sup>, <sup>1</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>2</sup>Policlinico Universitario A. Gemelli, Roma, IT, <sup>3</sup>Azienda Ospedaliero-Universitaria Careggi, Firenze, IT, <sup>4</sup>Hospital de Galdakao, Galdakao, ES, <sup>5</sup>Private Practice - Naglieri, Modugno - Bari, IT, <sup>6</sup>Hospital de León, Leon, ES

12:30 - 12:30 **988P - Benefit from subsequent conventional cytotoxic chemotherapy (CTx) to immunotherapy (IT) in patients (pts) with gynaecological malignancies (GM).**

F.J. Ros Montaña<sup>1</sup>, V. Rodriguez Freixinos<sup>1</sup>, L. Fariñas Madrid<sup>1</sup>, F. Amair Pinedo<sup>1</sup>, F. Ruiz-Pace<sup>2</sup>, E. Garralda<sup>2</sup>, R. Dienstmann<sup>1</sup>, A. Oaknin<sup>1</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

12:30 - 12:30 **989P - Identification research and application for protein phosphorylation modification sites in human ovarian carcinoma**

X. Zhan<sup>1</sup>, N. Li<sup>2</sup>, <sup>1</sup>Xiangya Hospital, Central South University, Changsha, CN, <sup>2</sup>Private Practice, Guangzhou, CN

12:30 - 12:30 **990P - Enhancing prognosis prediction using nodal SUVmax and HPV status in cervical squamous cell carcinoma**

S.Y. Jeong, G.O. Chong, C.M. Hong, Kyungpook National University School of Medicine, Daegu, KR

12:30 - 12:30 **991P - Clinical characteristics of ovarian cancer relapse in BRCA1/2 germ-line**



**mutation carriers and non-carriers**

A. Sokolenko<sup>1</sup>, T. Gorodnova<sup>2</sup>, A. Ivantsov<sup>3</sup>, I. Berlev<sup>2</sup>, E. Imyanitov<sup>2</sup>, <sup>1</sup>St. Petersburg Clinical and Scientific Oncological Center, Saint-Petersburg, RU, <sup>2</sup>N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, <sup>3</sup>Petrov institute of oncology, Saint-Petersburg, RU

12:30 - 12:30 **992P - Phase Ib study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.**

K. Broekman<sup>1</sup>, A. Reyners<sup>1</sup>, D. Touw<sup>2</sup>, M. Hof<sup>2</sup>, M. Jalving<sup>1</sup>, <sup>1</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>2</sup>University Medical Centre Groningen (UMCG), Groningen, NL

12:30 - 12:30 **993P - Individual and Familial Phenotype in Hereditary Ovarian Cancer**

M.B. Mira, I. Miguel, S. Fragoso, A. Opinião, A.C. Luís, A. Clara, S. Bento, P. Machado, S. Santos, P. Rodrigues, J. Parreira, F. Vaz, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon, PT

12:30 - 12:30 **994P - Role of FGFR2 amplification in prognosis of patients with ovarian cancer**

A. Tyulyandina<sup>1</sup>, I. Demidova<sup>2</sup>, M. Gikalo<sup>2</sup>, S. Tjulandin<sup>1</sup>, I. Tsimafeyeu<sup>3</sup>, <sup>1</sup>N. N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>2</sup>Moscow City Oncology Hospital No. 62, Moscow, RU, <sup>3</sup>Russian Society of Clinical Oncology, Moscow, RU

12:30 - 12:30 **995P - MONITOR VII - Treatment Strategies of Low grade Ovarian Carcinomas - A German survey of the Charité - Berlin and Kliniken Essen Mitte with support of the study groups NOGGO and AGO**

S. Alavi<sup>1</sup>, P. Harter<sup>2</sup>, R. Richter<sup>3</sup>, M. Keller<sup>4</sup>, G. Oskay-Özcelik<sup>1</sup>, A. Mustea<sup>5</sup>, B. Schmalfeldt<sup>6</sup>, P. Wimberger<sup>7</sup>, F. Trillsch<sup>8</sup>, S. Mahner<sup>9</sup>, M. Klar<sup>10</sup>, U. Wagner<sup>11</sup>, R. Chekerov<sup>1</sup>, A. Du Bois<sup>2</sup>, J. Sehouli<sup>3</sup>, <sup>1</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>2</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>3</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>4</sup>North-Eastern German Society of Gynecological Oncology, Berlin, DE, <sup>5</sup>Universitaetsklinik Greifswald, Greifswald, DE, <sup>6</sup>AGO Study Group & Technical University of Munich - Klinikum rechts der Isar; current address: University of Medical Center Hamburg-Eppendorf, Hamburg, DE, <sup>7</sup>Universitätsklinikum Dresden, Dresden, DE, <sup>8</sup>AGO Study Group & University of Munich, München, DE, <sup>9</sup>AGO Study Group & University Medical Center Hamburg-Eppendorf and University of Munich; current address University of Munich, München, DE, <sup>10</sup>University Clinics of Freiburg, Freiburg, DE, <sup>11</sup>"University of Gießen and Marburg GmbH Site Marburg", Marburg, DE

12:30 - 12:30 **996P - The ability of whole body SUVmax on F-FDG PET/CT in predicting suboptimal cytoreduction at primary debulking surgery in advanced ovarian cancer**

G.O. Chong, S.Y. Jeong, S.-W. Lee, Kyungpook National University School of Medicine, Daegu, KR

12:30 - 12:30 **997P - Brain metastasis in ovarian cancer patients**

A.A. Da Costa<sup>1</sup>, E. Dos Santos<sup>2</sup>, L. De Brot<sup>3</sup>, A. Ribeiro<sup>1</sup>, D. Cotrim<sup>1</sup>, N. Carvalho Pandolfi<sup>1</sup>, M. Cesca<sup>1</sup>, M. Chen<sup>1</sup>, G. Baiocchi<sup>1</sup>, <sup>1</sup>A. C. Camargo Cancer Center, Sao Paulo, BR, <sup>2</sup>Hospital Sirio Libanes, Sao Paulo, BR, <sup>3</sup>A.C. Camargo Cancer Center, Sao Paulo, BR



- 12:30 - 12:30 **998TiP - Pamiparib, a Novel PARP 1/2 Inhibitor, Monotherapy for gBRCAm Patients with Recurrent Ovarian, Fallopian, and Primary Peritoneal Cancer: an Open-label, Multicenter, Phase 2 trial in China**  
X. Wu<sup>1</sup>, J. Wang<sup>2</sup>, Q. Zhou<sup>3</sup>, T. Gu<sup>4</sup>, K. Zhang<sup>5</sup>, J. Liang<sup>6</sup>, S. Mu<sup>7</sup>, R. Ge<sup>6</sup>, H. Yang<sup>8</sup>, V. Huang<sup>9</sup>, R. Brachmann<sup>9</sup>, L. Wang<sup>6</sup>, M. Li<sup>6</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Huan Cancer Hospital, Hunan, CN, <sup>3</sup>Chongqing Cancer Hospital, Chongqing Shi, CN, <sup>4</sup>BeiGene (Beijing) Co. Ltd., Beijing, CN, <sup>5</sup>BeiGene USA, Inc., Emeryville, US, <sup>6</sup>BeiGene (Beijing) Co. Ltd., Beijing, CN, <sup>7</sup>BeiGene USA, Inc., Fort Lee, US, <sup>8</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>9</sup>BeiGene USA, Inc., San Mateo, US
- 12:30 - 12:30 **999TiP - OVARIO: A single-arm, open-label phase 2 study of maintenance therapy with niraparib + bevacizumab (bev) in patients (pts) with advanced ovarian cancer (OC) after response to frontline platinum-based chemotherapy (chemo)**  
M. Hardesty<sup>1</sup>, J. Hope<sup>1</sup>, T. Krivak<sup>2</sup>, J. Chen<sup>3</sup>, M. Wainszelbaum<sup>3</sup>, D. Gupta<sup>3</sup>, D. Richardson<sup>4</sup>, <sup>1</sup>Alaska Women's Cancer Care, Anchorage, US, <sup>2</sup>Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, US, <sup>3</sup>TESARO Inc., Waltham, US, <sup>4</sup>Oklahoma University, Health Sciences Center, Oklahoma City, US
- 12:30 - 12:30 **1000TiP - OPINION: A single-arm, open-label, phase 3b study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)**  
A.M. Poveda Velasco<sup>1</sup>, R. Davidson<sup>2</sup>, C. Blakeley<sup>3</sup>, A. Milner<sup>3</sup>, <sup>1</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>2</sup>AstraZeneca Academy House, Cambridge, GB, <sup>3</sup>AstraZeneca, Cambridge, GB
- 12:30 - 12:30 **1001TiP - A phase 2 clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer**  
A. Wahner Hendrickson<sup>1</sup>, B. Costello<sup>1</sup>, A. Jewell<sup>2</sup>, V. Kennedy<sup>3</sup>, G. Fleming<sup>4</sup>, B. Corr<sup>5</sup>, S. Taylor<sup>6</sup>, J. Lea<sup>7</sup>, J. Reid<sup>1</sup>, E. Swisher<sup>8</sup>, D. Satele<sup>1</sup>, J. Allred<sup>1</sup>, J. Lensing<sup>1</sup>, S.P. Ivy<sup>9</sup>, C. Erlichman<sup>1</sup>, A.A. Adjei<sup>1</sup>, S. Kaufmann<sup>1</sup>, <sup>1</sup>Mayo Clinic, Rochester, US, <sup>2</sup>University of Kansas, Kansas City, US, <sup>3</sup>University of California, Davis, Davis, US, <sup>4</sup>University of Chicago, Chicago, US, <sup>5</sup>University of Colorado Denver, Aurora, US, <sup>6</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>7</sup>University of Texas Southwestern Medical Center, Dallas, US, <sup>8</sup>University of Washington, Seattle, US, <sup>9</sup>National Cancer Institute, Bethesda, US
- 12:30 - 12:30 **1002TiP - BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib with continuous schedule vs. cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer**  
N. Colombo<sup>1</sup>, O. Nicoletto<sup>2</sup>, P. Benedetti Panici<sup>3</sup>, G. Tognon<sup>4</sup>, A.A. Lissoni<sup>5</sup>, A. Bologna<sup>6</sup>, F. Tomao<sup>7</sup>, R. Fossati<sup>8</sup>, F. Tettamanzi<sup>8</sup>, E. Rulli<sup>8</sup>, F. Galli<sup>8</sup>, M.F. Alvisi<sup>8</sup>, V. Torri<sup>9</sup>, E. Biagioli<sup>8</sup>, <sup>1</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>IRCCS Istituto Oncologico Veneto - IOV, Padova, IT, <sup>3</sup>Universita La Sapienza, Roma, IT, <sup>4</sup>Spedali civili di Brescia, Brescia, IT, <sup>5</sup>Ospedale S. Gerardo, Monza, IT, <sup>6</sup>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>7</sup>Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, IT, <sup>8</sup>Istituto Di Ricerche Farmacologiche Mario Negri, Milan, IT, <sup>9</sup>No place of work provided, No City Provided, NA

- 12:30 - 12:30 **1003TiP - Neoadjuvant chemotherapy and radical surgery versus chemorradiation for stage IB2, IIA2 e IIB cervical cancer: a randomized controlled trial**  
P. Reis Filho<sup>1</sup>, J. Andrade<sup>1</sup>, M. Batista<sup>2</sup>, C. Sousa<sup>1</sup>, T. Oliveira<sup>1</sup>, G. Arruda<sup>1</sup>, T. Oliveira<sup>1</sup>, F. Gabrielli<sup>2</sup>, M.L. Genta<sup>2</sup>, A.M. Poveda Velasco<sup>3</sup>, M. Estevez Diz<sup>2</sup>, F.J. Candido Dos Reis<sup>4</sup>,  
<sup>1</sup>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, BR, <sup>2</sup>Instituto do Cancer do Estado de Sao Paulo/Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, BR, <sup>3</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>4</sup>Ribeirão Preto Medical School, Ribeirão Preto, BR
- 12:30 - 12:30 **Haematological malignancies**
- 12:30 - 12:30 **1017P - Estimating the Incidence of Cryptogenic Organising Pneumonia in Chronic Lymphocytic Leukaemia Patients: A Real-World Cohort Study**  
I. Faghmous, H. Ramroth, C. Aguilar, A. Van Troostenburg, P. Badyal, Gilead Sciences, Uxbridge, GB
- 12:30 - 12:30 **1018P - Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death**  
C. Sortais<sup>1</sup>, A. Lok<sup>1</sup>, T. Gastinne<sup>1</sup>, B. Mahé<sup>1</sup>, V. Dubruille<sup>1</sup>, N. Blin<sup>1</sup>, S. Howlett<sup>2</sup>, A. Tabah<sup>2</sup>, P. Arnaud<sup>3</sup>, A. Moreau<sup>1</sup>, P. Moreau<sup>4</sup>, C. Leux<sup>1</sup>, S. Le Gouill<sup>1</sup>, <sup>1</sup>CHU de Nantes, Nantes, FR, <sup>2</sup>Celgene medical, Summit, US, <sup>3</sup>Hopital Bichat Claude Bernard, Paris, FR, <sup>4</sup>University Hospital Hôtel-Dieu, Nantes, FR
- 12:30 - 12:30 **1019P - Impact of genetic polymorphisms on prognosis and survival of diffuse large B-cell lymphoma**  
O. Novosad<sup>1</sup>, I. Pastushenko<sup>1</sup>, T. Skrypets<sup>1</sup>, I. Tytorenko<sup>1</sup>, T. Kadnikova<sup>1</sup>, O. Skachkova<sup>2</sup>, O. Gorbach<sup>2</sup>, N. Svergun<sup>2</sup>, N. Khranovska<sup>2</sup>, I. Kriachok<sup>3</sup>, <sup>1</sup>National Cancer Institute of the MPH Ukraine, Kiev, UA, <sup>2</sup>National Cancer Institute of the MPH Ukraine of the MPH Ukraine, Kiev, UA, <sup>3</sup>National Cancer Institute, Kyiv, UA
- 12:30 - 12:30 **Clinical-radiological features of Methotrexate induced sub-acute leukoencephalopathy in patients with Acute lymphoblastic leukemia: Incremental value of diffusion weighted magnetic resonance imaging.**  
T. Vaidya<sup>1</sup>, A. Mahajan<sup>2</sup>, H. Jain<sup>1</sup>, V. Simha<sup>3</sup>, M. Sengar<sup>1</sup>, S. Kumar<sup>1</sup>, <sup>1</sup>Tata Memorial Hospital, Mumbai, IN, <sup>2</sup>Tata Memorial Hospital Centre, Mumbai, IN, <sup>3</sup>PGIMER, Chandigarh, Chandigarh, IN
- 12:30 - 12:30 **1021P - Long term treatment outcome of patients with refractory or relapsed Hodgkin's lymphoma in the anthracycline era: a single-center intention-to-treat analysis**  
T. Bogatyreva<sup>1</sup>, A. Terekhova<sup>2</sup>, S. Shklyayev<sup>2</sup>, V. Pavlov<sup>2</sup>, N. Falaleeva<sup>2</sup>, <sup>1</sup>A. Tsyb - Medical Radiological Research Center, Obninsk, RU, <sup>2</sup>A.F. Tsyb Medical Radiological Research Center - branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, Obninsk, RU

- 12:30 - 12:30 **1022P - Population-based use of intravenous bisphosphonates in patients newly diagnosed with symptomatic multiple myeloma in Denmark in 2005-2015: impact of patient characteristics**  
V. Ehrenstein<sup>1</sup>, A. Ording<sup>1</sup>, S. Ulrichsen<sup>1</sup>, I. Andersen<sup>1</sup>, A. Seesaghur<sup>2</sup>, C. Helleberg<sup>3</sup>, T. Silkjær<sup>1</sup>, R. Hernandez<sup>4</sup>, D. Niepel<sup>5</sup>, N. Abildgaard<sup>6</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Amgen Limited, Cambridge, GB, <sup>3</sup>Herlev Hospital, Herlev, DK, <sup>4</sup>Amgen Inc., Thousand Oaks, US, <sup>5</sup>Amgen GmbH, Zug, CH, <sup>6</sup>Odense University Hospital, Odense, DK
- 12:30 - 12:30 **1023P - Role of Liposomal Doxorubicin as a first line agent with VTd regimen in newly diagnosed Multiple Myeloma**  
M. Khanderia<sup>1</sup>, G. Badarkhe<sup>2</sup>, S. Bj<sup>2</sup>, R. Naik<sup>2</sup>, <sup>1</sup>HCG Bangalore Institute of Oncology Speciality Centre, Bangalore, IN, <sup>2</sup>HCG Hospital, Bangalore, IN
- 12:30 - 12:30 **1024P - The  $\alpha_2$ -microgloulin Is Associated with the Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified**  
B.S. Sohn<sup>1</sup>, S.-N. Lim<sup>2</sup>, J. Kim<sup>3</sup>, D.H. Yoon<sup>3</sup>, S. Kim<sup>3</sup>, J. Huh<sup>3</sup>, S.-E. Park<sup>4</sup>, Y.J. Yuh<sup>4</sup>, C. Suh<sup>3</sup>, <sup>1</sup>Inje University - Sanggye Paik Hospital, Seoul, KR, <sup>2</sup>Inje University Haeundae Paik Hospital, Pusan, KR, <sup>3</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Inje University Sanggye Paik Hospital, Seoul, KR
- 12:30 - 12:30 **1026P - Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.**  
S. Dote<sup>1</sup>, K. Ito<sup>2</sup>, S. Itakura<sup>3</sup>, T. Yasu<sup>4</sup>, D. Hira<sup>5</sup>, S. Noda<sup>6</sup>, S. Yamada<sup>2</sup>, Y. Kobayashi<sup>1</sup>, T. Terada<sup>6</sup>, <sup>1</sup>Kyoto-Katsura Hospital, Kyoto, JP, <sup>2</sup>Fujita Health University Hospital, Aichi, JP, <sup>3</sup>Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, JP, <sup>4</sup>The Institute of Medical Science, The University of Tokyo, Tokyo, JP, <sup>5</sup>Ritsumeikan University, Shiga, JP, <sup>6</sup>Shiga University of Medical Science Hospital, Shiga, JP
- 12:30 - 12:30 **1027P - The significance of FMS-Like Tyrosine Kinase 3 surface receptor expression in acute myeloblastic leukemia and precursor B-acute lymphoblastic leukemia patients**  
S. Al Hassanin, I. Ahmedy, Faculty of Medicine - Menoufia University, Shebin El Kom, EG
- 12:30 - 12:30 **1028P - Prognostic factors of clinical use in acute myeloid leukemia**  
P. Chorão<sup>1</sup>, N. Tavares<sup>2</sup>, E. Aguiar<sup>3</sup>, M. Amorim<sup>3</sup>, P. Gomes<sup>3</sup>, F. Príncipe<sup>3</sup>, J. Guimarães<sup>3</sup>, <sup>1</sup>Universidade do Porto - Faculdade de Medicina, Porto, PT, <sup>2</sup>H SJ - Hospital de São João, EPE, Porto, PT, <sup>3</sup>Centro Hospitalar São João, EPE, Porto, PT
- 12:30 - 12:30 **1029P - Frequency and clinical impact of compound mutation in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitor**  
S. Bonecker, M. Carneiro, M. Bonamino, I. Zalberg, INCA - Instituto Nacional de Cancer, Rio de Janeiro, BR
- 12:30 - 12:30 **1030P - Poor outcome of double-protein expressor diffuse large B-cell lymphoma**  
E. Kharchenko<sup>1</sup>, T. Semiglazova<sup>1</sup>, A. Artemeva<sup>2</sup>, V. Kushnarev<sup>2</sup>, P. Shilo<sup>3</sup>, <sup>1</sup>N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation,

Saint Petersburg, RU, <sup>2</sup>N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, <sup>3</sup>N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, RU

12:30 - 12:30

**1031P - Combination of chemotherapy and radiation improve the prognosis of primary diffuse large B-cell lymphoma of the tonsil.**

S.-N. Lim<sup>1</sup>, B.S. Sohn<sup>2</sup>, H.-J. Shin<sup>3</sup>, C. Suh<sup>4</sup>, W.S. Kim<sup>5</sup>, W.S. Lee<sup>6</sup>, J.S. Kim<sup>7</sup>, <sup>1</sup>Inje University Haeundae Paik Hospital, Busan, KR, <sup>2</sup>Inje University - Sanggye Paik Hospital, Seoul, KR, <sup>3</sup>Pusan National University School of Medicine, Pusan National University Hospital, Busan, KR, <sup>4</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>5</sup>Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, KR, <sup>6</sup>Inje University College of Medicine, Busan Paik Hospital, Busan, KR, <sup>7</sup>Yonsei University College of Medicine, Severance Hospital, Seoul, KR

12:30 - 12:30

**1032P - The impact of serum microRNA-21 on outcome of diffuse large B-cell lymphoma patients**

S. Gohar<sup>1</sup>, S. Kamal Eldin<sup>1</sup>, F. El-Bassal<sup>1</sup>, A. Shehata<sup>2</sup>, A. Azzam<sup>3</sup>, E. Tawfik<sup>1</sup>, S. Al Hassanin<sup>1</sup>, <sup>1</sup>Faculty of Medicine - Menoufia University, Shebin El Kom, EG, <sup>2</sup>menoufia university, Menoufia, EG, <sup>3</sup>National liver institute, Menoufia, Egypt., Shebin El Kom, EG

12:30 - 12:30

**1033P - Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: subgroup analysis from the BELA trial**

H. Malhotra<sup>1</sup>, A. Maru<sup>2</sup>, N. Khattry<sup>3</sup>, M. Ramanan<sup>4</sup>, E. Leip<sup>5</sup>, R. Crescenzo<sup>6</sup>, C. Gambacorti-Passerini<sup>7</sup>, J. Cortes<sup>8</sup>, <sup>1</sup>Birla Cancer Center, Jaipur, IN, <sup>2</sup>Sarvodaya Multispecialty & Cancer Hospital, Hissar, IN, <sup>3</sup>Tata Memorial Hospital, Mumbai, IN, <sup>4</sup>Jehangir Hospital, Pune, IN, <sup>5</sup>Pfizer Inc, Cambridge, US, <sup>6</sup>Philadelphia College of Osteopathic Medicine, Philadelphia, US, <sup>7</sup>University of Milano-Bicocca, Monza, IT, <sup>8</sup>University of Texas MD Anderson Cancer Center, Houston, US

12:30 - 12:30

**1034P - A Prospective Multicenter Study of Primary Breast Lymphoma in the rituximab era: prognostic implication of beta 2 microglobulin and interleukin-6 & interleukin-10**

L. Ezz Elarab<sup>1</sup>, E. Hamada<sup>2</sup>, A. Mostafa<sup>1</sup>, A. Saber<sup>3</sup>, M. Abdel-Gawad<sup>4</sup>, R. Haggag<sup>5</sup>, H. Darwish<sup>6</sup>, S. Elhassanin<sup>7</sup>, M. Swellam<sup>8</sup>, <sup>1</sup>Ain Shams University Faculty of Medicine, Cairo, EG, <sup>2</sup>Minya University Medical School, Minya, EG, <sup>3</sup>Faculty of Medicine Minia university, Minya, EG, <sup>4</sup>faculty of medicine, Assuit University, Cairo, EG, <sup>5</sup>Zagazig University Faculty of Medicine, Zagazig, EG, <sup>6</sup>Damietta Cancer Institute (DCI), Damietta, EG, <sup>7</sup>faculty of medicine, Menoufia University, Cairo, EG, <sup>8</sup>National Research Center ,Egypt, Cairo, EG

12:30 - 12:30

**1035P - Experience in treatment of newly diagnosed multiple myeloma patients with renal failure required dialysis**

S. Semochkin<sup>1</sup>, E. Zhelnova<sup>2</sup>, E. Misyurina<sup>2</sup>, T. Tolstykh<sup>2</sup>, N. Arkhipova<sup>2</sup>, E. Baryakh<sup>2</sup>, E. Grishina<sup>2</sup>, E. Karimova<sup>2</sup>, O. Kochneva<sup>2</sup>, E. Mavrina<sup>2</sup>, Y. Polyakov<sup>2</sup>, E. Yaskova<sup>2</sup>, <sup>1</sup>N.I. Pirogov Russian National Research Medical University, Moscow, RU, <sup>2</sup>Moscow City Hospital #52, Moscow, RU



- 12:30 - 12:30 **1036P - Immunohistochemical (IHQ) classification of DLBCL into CGB and non-CGB subtypes to predict survival after chemoimmunotherapy, at the Virgen de la Victoria University Hospital**  
L. Galvez Carvajal<sup>1</sup>, C. Quero Blanco<sup>1</sup>, M. Robles Lasarte<sup>1</sup>, I. Moreno Perez<sup>1</sup>, L. Vicioso<sup>1</sup>, I. Ramos Garcia<sup>1</sup>, C. Bandera Lopez<sup>1</sup>, J. Baena Espinar<sup>1</sup>, C. Ithurbisquy<sup>1</sup>, E. Alba<sup>2</sup>,  
<sup>1</sup>Hospital Universitario Virgen de la Victoria, Málaga, ES, <sup>2</sup>Hospital Universitario Virgen de la Victoria, Malaga, ES
- 12:30 - 12:30 **1037P - Quality of life evaluation in acute leukemia patients receiving induction chemotherapy**  
T. Lymanets<sup>1</sup>, I. Skrypnyk<sup>2</sup>, G. Maslova<sup>1</sup>, I. Gusachenko<sup>3</sup>, <sup>1</sup>Poltava Regional Clinical Hospital n.a.M.V.Sklifosovsky, Poltava, UA, <sup>2</sup>Ukrainian Medical Stomatological Academy, Poltava, UA, <sup>3</sup>Poltava Regional Clinical Hospital n.a. M.V.Sklifosovsky, Poltava, UA
- 12:30 - 12:30 **1038P - PET-CT as a prognostic factor in patients with early stages in primary diagnosed Hodgkin Lymphoma.**  
T. Skrypets<sup>1</sup>, O. Novosad<sup>1</sup>, I. Pastushenko<sup>1</sup>, T. Kadnikova<sup>1</sup>, O. Gorbach<sup>2</sup>, Y. Kmetyuk<sup>3</sup>, O. Karpova<sup>3</sup>, L. Mykhalska<sup>3</sup>, E. Lukjanec<sup>4</sup>, V. Kozlov<sup>5</sup>, N. Novikov<sup>6</sup>, O. Oliinichenko<sup>7</sup>, N. Kostiukova<sup>8</sup>, O. Tkachenko<sup>8</sup>, O. Karnabeda<sup>9</sup>, V. Stratienco<sup>10</sup>, I. Kriachok<sup>11</sup>, <sup>1</sup>National Cancer Institute of the MPH Ukraine, Kiev, UA, <sup>2</sup>National Cancer Institute of the MPH Ukraine of the MPH Ukraine, Kiev, UA, <sup>3</sup>Clinical Hospital «Feofaniya», Kiev, UA, <sup>4</sup>Cherkassy Regional Oncology Center, Cherkassy, UA, <sup>5</sup>Odessa Regional Hospital, Odessa, UA, <sup>6</sup>Oncology Hospital “LISOD”, Kiev, UA, <sup>7</sup>Center of Nuclear Medicine KMCOC, Kiev, UA, <sup>8</sup>Kyiv centre of bone marrow transplatation, Kiev, UA, <sup>9</sup>Oncology Clinic "Innovation" National Medical Univesity, Liutizh, UA, <sup>10</sup>Regional Clinical Hospital, Kherson, UA, <sup>11</sup>National Cancer Institute, Kyiv, UA
- 12:30 - 12:30 **1039P - Assessment to predict survival and risk of progression in patients with newly multiple myeloma in different age groups.**  
I. Kriachok<sup>1</sup>, O. Novosad<sup>2</sup>, K. Ulianchenko<sup>2</sup>, T. Skrypets<sup>2</sup>, T. Kadnikova<sup>2</sup>, <sup>1</sup>National Cancer Institute, Kyiv, UA, <sup>2</sup>National Cancer Institute of the MPH Ukraine, Kiev, UA
- 12:30 - 12:30 **1040P - Impact of Bisphosphonate and Anti-myeloma therapy on Bone Turnover Markers in Multiple Myeloma**  
A. Jandial<sup>1</sup>, S. H J<sup>2</sup>, K. Mishra<sup>2</sup>, S. Bhadada<sup>2</sup>, A. Sood<sup>2</sup>, M. Prakash<sup>2</sup>, A. Meshram<sup>2</sup>, R. Sandal<sup>2</sup>, D. Lad<sup>2</sup>, R. Aggarwal<sup>2</sup>, G. Prakash<sup>2</sup>, S. Vikas<sup>2</sup>, A. Khadwal<sup>2</sup>, S. Kumari<sup>2</sup>, N. Varma<sup>2</sup>, S. Varma<sup>2</sup>, P. Malhotra<sup>2</sup>, <sup>1</sup>PGIMER, Chandigarh, Chandigarh, IN, <sup>2</sup>PGIMER, Chandigarh, IN
- 12:30 - 12:30 **1041P - Assessment of bleeding risk by sonoclot in acute lymphoblastic leukemia**  
K. Mishra<sup>1</sup>, A. Jandial<sup>2</sup>, A. Meshram<sup>1</sup>, R. Sandal<sup>1</sup>, D. Lad<sup>1</sup>, G. Prakash<sup>1</sup>, A. Khadwal<sup>1</sup>, R. Dhiman<sup>1</sup>, N. Varma<sup>1</sup>, S. Varma<sup>1</sup>, P. Malhotra<sup>1</sup>, <sup>1</sup>PGIMER, Chandigarh, IN, <sup>2</sup>PGIMER, Chandigarh, Chandigarh, IN
- 12:30 - 12:30 **1042P - Clinically Actionable Mutations Identified in Korean Patients with High-Risk Acute Lymphoblastic Leukemia**  
K.-J. Park, I.-S. Kim, Pusan National University Yangsan Hospital, Yangsan, KR

- 12:30 - 12:30 **1043TiP - A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML)**  
C.H. Ng<sup>1</sup>, S. Ting<sup>2</sup>, W. Hwang<sup>3</sup>, A. Bajel<sup>4</sup>, R. Eek<sup>5</sup>, M. Mchale<sup>6</sup>, H.-J. Shih<sup>7</sup>, N. McIntyre<sup>6</sup>, J. Kwek<sup>6</sup>, B. Lindmark<sup>6</sup>, <sup>1</sup>National University Hospital, Singapore, SG, <sup>2</sup>Box Hill Hospital, Box Hill, AT, <sup>3</sup>Singapore General Hospital, Singapore, SG, <sup>4</sup>Royal Melbourne Hospital, Parkville, AU, <sup>5</sup>Border Medical Oncology Research Unit, Albury, AU, <sup>6</sup>ASLAN Pharmaceuticals, Singapore, SG, <sup>7</sup>ASLAN Pharmaceuticals, Taipei, TW
- 12:30 - 12:30 **Immunotherapy of cancer**
- 12:30 - 12:30 **1143P - Responses and Durability of Clinical Benefit in Pancreatic Ductal Adenocarcinoma (PDAC) Patients Treated With Pegilodecakin (AM0010) in Combination With 5-FU/LV and Oxaliplatin (FOLFOX)**  
J.R. Hecht<sup>1</sup>, A. Naing<sup>2</sup>, G. Falchook<sup>3</sup>, M. Patel<sup>4</sup>, R. Aljumaily<sup>5</sup>, D. Wong<sup>6</sup>, K. Autio<sup>7</sup>, Z. Wainberg<sup>8</sup>, M. Javle<sup>9</sup>, J. Bendell<sup>10</sup>, S. Pant<sup>11</sup>, A. Hung<sup>12</sup>, M. Oft<sup>12</sup>, J. Leveque<sup>12</sup>, K. Papadopoulos<sup>13</sup>, <sup>1</sup>David Geffen School of Medicine at UCLA, Santa Monica, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>Sarah Cannon Research Institute at HealthONE, Denver, US, <sup>4</sup>U Minnesota Medical School, Minneapolis, US, <sup>5</sup>Oklahoma University Medical Center, Oklahoma City, US, <sup>6</sup>UCLA - School of Medicine, Los Angeles, US, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>David Geffen School of Medicine at UCLA, Los Angeles, US, <sup>9</sup>MD Anderson Cancer Center, Houston, US, <sup>10</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>11</sup>College of Pharmacy, OUHSC, Oklahoma City, US, <sup>12</sup>ARMO BioSciences, Redwood City, US, <sup>13</sup>START Center for Cancer Care, San Antonio, US
- 12:30 - 12:30 **1144P - Responses and Durability of Clinical Benefit in Non-Small Cell Lung Cancer Treated with Pegilodecakin in Combination With Anti-PD-1 Inhibitors**  
E. Garon<sup>1</sup>, D. Wong<sup>2</sup>, J. Schneider<sup>3</sup>, R. Aljumaily<sup>4</sup>, W.M. Korn<sup>5</sup>, M. Patel<sup>6</sup>, K. Autio<sup>7</sup>, K. Papadopoulos<sup>8</sup>, A. Naing<sup>9</sup>, N. Gabrail<sup>10</sup>, P. Munster<sup>11</sup>, J. Goldman<sup>12</sup>, A. Hung<sup>13</sup>, M. Oft<sup>13</sup>, J. Leveque<sup>13</sup>, D. Spigel<sup>14</sup>, <sup>1</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>2</sup>UCLA - School of Medicine, Los Angeles, US, <sup>3</sup>Winthrop University Hospital, Mineola, US, <sup>4</sup>Oklahoma University Medical Center, Oklahoma City, US, <sup>5</sup>Caris Life Sciences, Phoenix, US, <sup>6</sup>U Minnesota Medical School, Minneapolis, US, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>START Center for Cancer Care, San Antonio, US, <sup>9</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>10</sup>Gabrail Cancer Center, Canton, US, <sup>11</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>12</sup>UCLA, Santa Monica, US, <sup>13</sup>ARMO BioSciences, Redwood City, US, <sup>14</sup>Sarah Cannon Research Institute, Nashville, US
- 12:30 - 12:30 **1145P - Responses and Durability of Clinical Benefit in Triple Negative Breast Cancer Patients Treated with Pegilodecakin Monotherapy or in Combination With Platinum Plus Taxane-Based Chemotherapy**  
A. Naing<sup>1</sup>, K. Autio<sup>2</sup>, G. Falchook<sup>3</sup>, F. Meric-Bernstam<sup>4</sup>, J. Litton<sup>4</sup>, N. Ibrahim<sup>4</sup>, A. Hung<sup>5</sup>, M. Oft<sup>5</sup>, J. Leveque<sup>5</sup>, M. Patel<sup>6</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>Sarah Cannon Research Institute at HealthONE, Denver, US, <sup>4</sup>MD Anderson Cancer Center, Houston,

US, <sup>5</sup>ARMO BioSciences, Redwood City, US, <sup>6</sup>U Minnesota Medical School, Minneapolis, US

12:30 - 12:30

**1146P - Durability of Clinical Benefit in Metastatic Epithelial Ovarian Cancer Patients Treated With Pegilodocakin Monotherapy or in Combination With Platinum Plus Taxane-Based Chemotherapy**

K. Autio<sup>1</sup>, A. Naing<sup>2</sup>, A. Hung<sup>3</sup>, M. Oft<sup>3</sup>, J. Leveque<sup>3</sup>, G. Falchook<sup>4</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>ARMO BioSciences, Redwood City, US, <sup>4</sup>Sarah Cannon Research Institute at HealthONE, Denver, US

12:30 - 12:30

**1147P - Preliminary Results from a Phase 1 Study of GBR 1302, A Bispecific Antibody T-Cell Engager, in HER2 Positive Cancers**

M. Wermke<sup>1</sup>, J. Alt<sup>2</sup>, J. Kauh<sup>3</sup>, J. Back<sup>4</sup>, Y. Salhi<sup>3</sup>, V. Reddy<sup>3</sup>, M. Barve<sup>5</sup>, S. Ochsenreither<sup>6</sup>, <sup>1</sup>University Hospital Carl-Gustav-Carus, Dresden, DE, <sup>2</sup>Johannes Gutenberg University Mainz, Mainz, DE, <sup>3</sup>Glenmark Pharmaceuticals, Inc, Mahwah, US, <sup>4</sup>Glenmark Pharmaceuticals, SA, La Chaux-de-Fonds, CH, <sup>5</sup>Mary Crowley Cancer Research, Dallas, US, <sup>6</sup>Charité University of Medicine, Berlin, DE

12:30 - 12:30

**1148P - A phase Ia study of a personalized TSA-CTL (tumor specific antigen-induced cytotoxic T lymphocytes) therapy in metastatic melanoma**

B. Li, S. Qiu, BGI Tech Solutions (Hong Kong Co. Ltd), Shenzhen, CN

12:30 - 12:30

**1149P - Safety, Tolerability, and Pharmacokinetics of the OX40 Agonist ABBV-368 in Patients With Advanced Solid Tumors**

A. Spira<sup>1</sup>, K. Chung<sup>2</sup>, A. Patnaik<sup>3</sup>, A. Tolcher<sup>4</sup>, M. Blaney<sup>5</sup>, A. Parikh<sup>6</sup>, A. Reddy<sup>6</sup>, W. Henner<sup>6</sup>, M. Mcdevitt<sup>6</sup>, D. Afar<sup>6</sup>, J. Powderly<sup>7</sup>, <sup>1</sup>Virginia Cancer Specialist, Fairfax, US, <sup>2</sup>Greenville Health System, Greenville, US, <sup>3</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>4</sup>NEXT Oncology™, San Antonio, US, <sup>5</sup>AbbVie, Redwood City, US, <sup>6</sup>AbbVie Inc., Redwood City, US, <sup>7</sup>Carolina Biooncology Cancer Therapy, Huntersville, US

12:30 - 12:30

**1150P - Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study**

R. Xu<sup>1</sup>, F.H. Wang<sup>2</sup>, F.J. Feng<sup>3</sup>, Q. Li<sup>4</sup>, N. Xu<sup>5</sup>, X.C. Hu<sup>6</sup>, W.J. Liao<sup>7</sup>, Y. Jiang<sup>8</sup>, X. Lin<sup>9</sup>, Q.Y. Zhang<sup>10</sup>, X.L. Yuan<sup>11</sup>, H.X. Huang<sup>12</sup>, Y. Chen<sup>13</sup>, G.H. Dai<sup>14</sup>, J.H. Shi<sup>15</sup>, L. Shen<sup>16</sup>, C. Ren<sup>17</sup>, H. Wu<sup>18</sup>, H. Feng<sup>19</sup>, S. Yao<sup>18</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Sun Yat-sen University Cancer Center, Guang zhou, CN, <sup>3</sup>Jiangsu Cancer Hospital, Nan jing, CN, <sup>4</sup>Cancer Center of Shanghai First People's Hospital, Shanghai, CN, <sup>5</sup>The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, <sup>6</sup>Tumor Hospital Affiliated to Fudan University, Shang hai, CN, <sup>7</sup>Cancer Center of NanFang Hospital;Guangzhou, Guang zhou, CN, <sup>8</sup>The Affiliated Tumor Hospital of Shantou University Medical College, Shan tou, CN, <sup>9</sup>Fujian Medical University Union Hospital, Fuzhou, CN, <sup>10</sup>The Affiliated Tumor Hospital of Harbin Medical University, Ha er bin, CN, <sup>11</sup>Wuhan Tongji Hospital, Wu han, CN, <sup>12</sup>Liuzhou Worker's Hospital, Liu zhou, CN, <sup>13</sup>Cancer Center of West China Hospital of Sichuan University, chengdu, CN, <sup>14</sup>Beijing 301 Hospital,, Bei jing, CN, <sup>15</sup>shijianhualy@126.com, lin yi, CN, <sup>16</sup>Beijing



Cancer Hospital, Beijing, CN, <sup>17</sup>Sun Yat-sen University; Cancer Center, Guang zhou, CN, <sup>18</sup>Shanghai Junshi Biosciences Co, Shang hai, CN, <sup>19</sup>Shanghai Junshi Biosciences Co., Shang hai, CN

- 12:30 - 12:30 **1151P - Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a Phase 1 study**
- M. Pishvaian<sup>1</sup>, G. Weiss<sup>2</sup>, G. Falchook<sup>3</sup>, N. Yee<sup>4</sup>, M. Gil-Martin<sup>5</sup>, S. Shahda<sup>6</sup>, V. Moreno<sup>7</sup>, I. Brana<sup>8</sup>, M. Crittenden<sup>9</sup>, S. Formenti<sup>10</sup>, R. Al-Rajabi<sup>11</sup>, K. Papadopoulos<sup>12</sup>, E. Stankevich<sup>13</sup>, M. Feng<sup>13</sup>, J. Li<sup>13</sup>, M. Mathias<sup>14</sup>, G. Kroog<sup>14</sup>, I. Lowy<sup>14</sup>, M. Fury<sup>14</sup>, <sup>1</sup>Georgetown University, Washington, US, <sup>2</sup>University of Arizona College of Medicine - Phoenix, Phoenix, US, <sup>3</sup>Sarah Cannon Research Institute at HealthONE, Denver, US, <sup>4</sup>Hematology/Oncology Division and Penn State Hershey Cancer Institute, Hershey, US, <sup>5</sup>Institut Català d'Oncologia, Barcelona, ES, <sup>6</sup>Indiana University Melvin Bren Simon Cancer Center, Indianapolis, US, <sup>7</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>8</sup>Vall D'Hebron Institute of Oncology, Barcelona, ES, <sup>9</sup>Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center and The Oregon Clinic, Portland, US, <sup>10</sup>Weill Cornell Medicine, New York, US, <sup>11</sup>University of Kansas Cancer Center, Kansas City, US, <sup>12</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>13</sup>Regeneron Pharmaceuticals, Inc., Basking Ridge, US, <sup>14</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US
- 12:30 - 12:30 **1152P - Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors**
- B. Glisson<sup>1</sup>, R. Leidner<sup>2</sup>, R. Ferris<sup>3</sup>, J. Powderly<sup>4</sup>, N. Rizvi<sup>5</sup>, B. Keam<sup>6</sup>, R. Schneider<sup>7</sup>, S. Goel<sup>8</sup>, J. Ohr<sup>9</sup>, Y. Zheng<sup>10</sup>, S. Eck<sup>10</sup>, M. Gribbin<sup>10</sup>, D. Townsley<sup>10</sup>, V. Chiou<sup>10</sup>, S. Patel<sup>11</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>Providence Cancer Center Oncology and Hematology Care Clinic Eastside Portland, Portland, US, <sup>3</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>4</sup>Carolina BioOncology Institute, Huntersville, US, <sup>5</sup>Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, <sup>6</sup>Seoul National University Hospital, Seoul, KR, <sup>7</sup>Mary Crowley Cancer Research, Dallas, US, <sup>8</sup>Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, <sup>9</sup>UPMC Hillman Cancer Center, Pittsburgh, US, <sup>10</sup>MedImmune, Gaithersburg, US, <sup>11</sup>UC San Diego Moores Cancer Center, La Jolla, US
- 12:30 - 12:30 **1153P - Autologous dendritic-cell vaccine based on cancer-testis antigens "CaTeVac" in the treatment of soft tissue sarcoma**
- N. Pipia<sup>1</sup>, I. Baldueva<sup>2</sup>, T. Nekhaeva<sup>2</sup>, A. Novik<sup>1</sup>, A. Danilova<sup>2</sup>, N. Avdonkina<sup>2</sup>, S. Protsenko<sup>2</sup>, Y. Komarov<sup>3</sup>, D. Girdyuk<sup>4</sup>, A. Oganessian<sup>5</sup>, A. Belyaev<sup>6</sup>, <sup>1</sup>St. Petersburg Clinical and Scientific Oncological Center, Saint-Petersburg, RU, <sup>2</sup>N.N. Petrov Research Institute of Oncology, St. Petersburg, RU, <sup>3</sup>N.N. Petrov Research Inst. of Oncology, Saint Petersburg, RU, <sup>4</sup>N.N. Petrov Research Institute of Oncology, Saint-Petersburg, RU, <sup>5</sup>FSBI "Petrov Research Institute of Oncology" of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, RU, <sup>6</sup>N.N.Petrov Research Inst. of Oncology, St. Petersburg, RU
- 12:30 - 12:30 **1154P - A Phase 1 study of MEDI1873, a novel GITR agonist, in advanced solid tumors**



C. Denlinger<sup>1</sup>, J. Infante<sup>2</sup>, R. Aljumaily<sup>3</sup>, A. Naing<sup>4</sup>, A. Chintakuntlawar<sup>5</sup>, N. Rizvi<sup>6</sup>, H. Ross<sup>7</sup>, M. Gordon<sup>8</sup>, R. Kumar<sup>9</sup>, M. Ma<sup>9</sup>, L. Yan<sup>10</sup>, P. Vicini<sup>11</sup>, N. Standifer<sup>10</sup>, J. Cann<sup>9</sup>, A. Perera<sup>11</sup>, N. Durham<sup>9</sup>, S. Krishnan<sup>9</sup>, A. Balmanoukian<sup>12</sup>, <sup>1</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>2</sup>Sarah Cannon Research Institute-cancer centre, Nashville, US, <sup>3</sup>Oklahoma University Medical Center, Oklahoma City, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Mayo Clinic, Rochester, US, <sup>6</sup>Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, <sup>7</sup>Mayo Clinic, Scottsdale, US, <sup>8</sup>HonorHealth Virginia G Piper Cancer Care Network, Scottsdale, US, <sup>9</sup>MedImmune, Gaithersburg, US, <sup>10</sup>MedImmune, South San Francisco, US, <sup>11</sup>MedImmune, Cambridge, GB, <sup>12</sup>The Angeles Clinic and Research Institute, Los Angeles, US

12:30 - 12:30 **1155P - Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers**

A.-M. Tsimberidou<sup>1</sup>, H. Ma<sup>2</sup>, C. Stewart<sup>2</sup>, O. Schoor<sup>3</sup>, D. Maurer<sup>3</sup>, R. Mendrzyk<sup>3</sup>, A. Satelli<sup>2</sup>, J. Fritsche<sup>3</sup>, G. Stephens<sup>2</sup>, A. Mohamed<sup>2</sup>, P. Hwu<sup>1</sup>, C. Yee<sup>1</sup>, C. Reinhardt<sup>3</sup>, T. Weinschenk<sup>3</sup>, K. Gharpure<sup>1</sup>, A. Stungis<sup>1</sup>, D. Vining<sup>1</sup>, H. Singh<sup>2</sup>, S. Walter<sup>2</sup>, B. Andersson<sup>1</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>Immatics US., Inc., Houston, US, <sup>3</sup>immatics biotechnologies GmbH, Martinsried, DE

12:30 - 12:30 **1156P - Initial Safety Assessment of MAGE-A4 SPEAR T-cells**

D. Hong<sup>1</sup>, M. Butler<sup>2</sup>, M. Johnson<sup>3</sup>, A. Olszanski<sup>4</sup>, E. Norry<sup>5</sup>, E. Van Winkle<sup>5</sup>, K. Chagin<sup>6</sup>, R. Amado<sup>6</sup>, <sup>1</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>2</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>3</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>4</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>5</sup>Adaptimmune, Philadelphia, US, <sup>6</sup>Adaptimmune LLC, Philadelphia, US

12:30 - 12:30 **1157P - Phase 1 trial of a novel hTERT vaccination strategy addressing T effector cells and immune-suppressor mechanisms**

J. Spicer<sup>1</sup>, V. Kwatra<sup>1</sup>, C. Verma<sup>2</sup>, K. Ioannou<sup>1</sup>, R. Goldstein<sup>1</sup>, T. Brier<sup>1</sup>, J. Eremin<sup>1</sup>, N. Zareian<sup>1</sup>, L. Walker<sup>3</sup>, D. Lobo<sup>2</sup>, F. Farzaneh<sup>1</sup>, O. Eremin<sup>2</sup>, <sup>1</sup>King's College London Guy's Hospital, London, GB, <sup>2</sup>University of Nottingham, Nottingham, GB, <sup>3</sup>University of Hull, Hull, GB

12:30 - 12:30 **1158P - Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer**

C. Drescher<sup>1</sup>, K. Moore<sup>2</sup>, J. Liu<sup>3</sup>, D. O'Malley<sup>4</sup>, E. Wang<sup>5</sup>, J. Wang<sup>6</sup>, V. Subbiah<sup>7</sup>, B. Wilky<sup>8</sup>, G. Yuan<sup>9</sup>, C. Dupont<sup>9</sup>, A. Gonzalez<sup>9</sup>, D. Savitsky<sup>9</sup>, S. Coulter<sup>9</sup>, O. Shebanova<sup>9</sup>, E. Dow<sup>9</sup>, W. Ortuzar<sup>9</sup>, J. Buell<sup>9</sup>, R. Stein<sup>9</sup>, H. Youssoufian<sup>9</sup>, <sup>1</sup>Swedish Medical Center, Seattle, US, <sup>2</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>3</sup>Dana Farber Cancer Institute, Boston, US, <sup>4</sup>The Ohio State University, James Cancer Center, Columbus, US, <sup>5</sup>Penn State College of Medicine, Hershey, US, <sup>6</sup>Sarah Cannon, Nashville, US, <sup>7</sup>The University of Texas, MD Anderson Cancer Center, Houston, US, <sup>8</sup>Sylvester Comprehensive Cancer Center, Miami, US, <sup>9</sup>Agenus Bio, Inc., Lexington, US

12:30 - 12:30

**1159P - Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer**

C.-C. Lin<sup>1</sup>, M. Taylor<sup>2</sup>, V. Boni<sup>3</sup>, P. Brunsvig<sup>4</sup>, S. Geater<sup>5</sup>, S. Salvagni<sup>6</sup>, P. Garrido Lopez<sup>7</sup>, M. Özgüroğlu<sup>8</sup>, V. Sriuranpong<sup>9</sup>, S. Ponce Aix<sup>10</sup>, P. Ascierto<sup>11</sup>, A. Fasolo<sup>12</sup>, A. Sezer<sup>13</sup>, D. Kowalski<sup>14</sup>, J. Faris<sup>15</sup>, S. Cameron<sup>15</sup>, J. Mataraza<sup>15</sup>, H. Wu<sup>16</sup>, V. Antona<sup>17</sup>, M. Ochoa De Olza<sup>18</sup>, <sup>1</sup>National Taiwan University Hospital, Taipei city, TW, <sup>2</sup>Knight Cancer Institute-Portland, Portland, US, <sup>3</sup>START Madrid-CIOCC HM Hospital Sanchinarro, Madrid, ES, <sup>4</sup>Oslo University Hospital Rikshospitalet - Radiumhospitalet Trust, Oslo, NO, <sup>5</sup>Prince of Songkla University, Songkhla, TH, <sup>6</sup>Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>7</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>8</sup>Istanbul University Cerrahpasa School of Medicine, Istanbul, TR, <sup>9</sup>Chulalongkorn University Faculty of Medicine, Bangkok, TH, <sup>10</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>11</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>12</sup>IRCCS San Raffaele, Milan, IT, <sup>13</sup>Baskent University, Adana, TR, <sup>14</sup>The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, <sup>15</sup>Novartis Institutes for BioMedical Research, Cambridge, US, <sup>16</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>17</sup>Novartis Pharma AG, Basel, CH, <sup>18</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES

**12:30 - 12:30 1160P - Phase 1/2 evaluation of intratumoral INT230-6 for the treatment of solid tumors**

A. El-Khoeiry<sup>1</sup>, L. Siu<sup>2</sup>, N. Azad<sup>3</sup>, I. Walters<sup>4</sup>, L. Bender<sup>4</sup>, L. Kamen<sup>4</sup>, A. Olszanski<sup>5</sup>, <sup>1</sup>USC Norris Comprehensive Cancer Center, Los Angeles, US, <sup>2</sup>Princess Margaret Hospital, Toronto, CA, <sup>3</sup>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, <sup>4</sup>Intensity Therapeutics, Westport, US, <sup>5</sup>Fox Chase Cancer Center, Philadelphia, US

**12:30 - 12:30 1161P - OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments**

M. Fabre<sup>1</sup>, C. Ferrer<sup>1</sup>, S. Dominguez-Hormaetxe<sup>1</sup>, R. Kontermann<sup>2</sup>, K. Pfizenmaier<sup>2</sup>, O. Seifert<sup>2</sup>, P.P. López-Casas<sup>3</sup>, M. Abbas<sup>4</sup>, W. Richter<sup>5</sup>, L. Simon<sup>1</sup>, M. Hidalgo<sup>6</sup>, <sup>1</sup>Oncomatryx Biopharma S.L, Derio, ES, <sup>2</sup>Institute of Cell Biology and Immunology, Stuttgart, DE, <sup>3</sup>CNIO, Madrid, ES, <sup>4</sup>TUBE Pharmaceuticals, Wien, AT, <sup>5</sup>TUBE Pharmaceuticals, GmbH, Wien, AT, <sup>6</sup>Beth Israel Deaconess Medical Center, Boston, US

**12:30 - 12:30 1162P - Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small-cell lung cancer (NSCLC): Results from a Phase 1 expansion cohort (EC 2)**

V. Moreno<sup>1</sup>, M. Gil-Martin<sup>2</sup>, M. Johnson<sup>3</sup>, R. Aljumaily<sup>4</sup>, P. Lopez Criado<sup>5</sup>, D. Northfelt<sup>6</sup>, M. Crittenden<sup>7</sup>, S. Jabbour<sup>8</sup>, L. Rosen<sup>9</sup>, P. Garrido Lopez<sup>10</sup>, A. Hervás Morón<sup>11</sup>, P. Rietschel<sup>12</sup>, K.K. Mohan<sup>12</sup>, J. Li<sup>13</sup>, E. Stankevich<sup>13</sup>, T. Rowlands<sup>12</sup>, M. Feng<sup>13</sup>, I. Lowy<sup>12</sup>, M. Fury<sup>12</sup>, <sup>1</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>2</sup>Institut Català d'Oncologia, Barcelona, ES, <sup>3</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>4</sup>Oklahoma University Medical Center, Oklahoma City, US, <sup>5</sup>MD Anderson Cancer Center, Madrid, ES, <sup>6</sup>Mayo Clinic, Phoenix, US, <sup>7</sup>Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center and The Oregon Clinic, Portland, US, <sup>8</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, US, <sup>9</sup>UCLA, Los Angeles, US, <sup>10</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>11</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>12</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US, <sup>13</sup>Regeneron Pharmaceuticals, Inc., Basking Ridge, US

- 12:30 - 12:30 **1163P - Study on Treatment of Stage IV Solid Tumors with Mutant Neoantigen Specific T Cells**  
Q. Song<sup>1</sup>, J. Song<sup>2</sup>, H. Sun<sup>2</sup>, W. Du<sup>3</sup>, L. Wu<sup>3</sup>, L. Wang<sup>3</sup>, Z. Wei<sup>4</sup>, Y. Wang<sup>2</sup>, Y. Guan<sup>2</sup>, X. Xia<sup>2</sup>, X. Yi<sup>2</sup>, S. Jiao<sup>3</sup>, <sup>1</sup>Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, <sup>2</sup>Geneplus-Beijing Institute, Beijing, CN, <sup>3</sup>The General Hospital of People's Liberation Army, Beijing, CN, <sup>4</sup>Department of Health Care, Beijing, CN
- 12:30 - 12:30 **1164P - Efficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients**  
M. Hernandez<sup>1</sup>, E. Neningen<sup>2</sup>, E. Santiesteban<sup>3</sup>, K. Camacho<sup>3</sup>, N. Hernandez<sup>4</sup>, R. Amador<sup>5</sup>, S. Acosta<sup>6</sup>, Y. Gonzalez<sup>7</sup>, Y. Jimenez<sup>8</sup>, M. Corella<sup>9</sup>, R.A. Ortiz<sup>10</sup>, L. Bello<sup>11</sup>, A. Calana<sup>12</sup>, G. Pichs<sup>13</sup>, M. Cala<sup>14</sup>, Y. Flores<sup>15</sup>, C. Viada<sup>16</sup>, M. Robaina<sup>17</sup>, T. Crombet Ramos<sup>1</sup>, <sup>1</sup>Center of Molecular Immunology, Havana, CU, <sup>2</sup>Hospital Clinico Quirurgico Hermanos Ameijeiras, Havana, CU, <sup>3</sup>Jose R. Lopez Tabranes Hospital, Matanzas, CU, <sup>4</sup>Miguel Enriquez Hospital, La Habana, CU, <sup>5</sup>III Congreso Hospital, Pinar del Rio, CU, <sup>6</sup>Saturnino Lora Hospital, Santiago de Cuba, CU, <sup>7</sup>Comandante Pinares Hospital, Artemisa, CU, <sup>8</sup>Camilo Cienfuegos Hospital, Sancti Spiritus, CU, <sup>9</sup>Vladimir I. Lenin Hospital, Holguin, CU, <sup>10</sup>"Celestino Hernández" Hospital, Villa Clara, CU, <sup>11</sup>Antonio Luaces Iraola Hospital, Ciego de Avila, CU, <sup>12</sup>Gustavo Aldereguia Lima Hospital, Cienfuegos, CU, <sup>13</sup>Celia Sanchez Manduley Hospital, Granma, CU, <sup>14</sup>Juan Bruno Zayas Hospital, Santiago de Cuba, CU, <sup>15</sup>National Institute of oncology and Radiobiology, La Habana, CU, <sup>16</sup>Center of Molecular Immunology, La Habana, CU, <sup>17</sup>National Coordinating center for Clinical Trials, La Habana, CU
- 12:30 - 12:30 **1165P - Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors**  
L. Shen<sup>1</sup>, J. Cao<sup>2</sup>, J. Gong<sup>1</sup>, D. Ji<sup>2</sup>, Z. Qin<sup>3</sup>, H. Dai<sup>4</sup>, K. Wu<sup>5</sup>, J. Xu<sup>6</sup>, J. Yang<sup>5</sup>, <sup>1</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>3</sup>BeiGene, Beijing, CN, <sup>4</sup>CStone Pharmaceuticals, Shanghai, CN, <sup>5</sup>CStone Pharmaceuticals (Su Zhou) Co., Ltd., Shanghai, CN, <sup>6</sup>Merck Serono - China, Shanghai, CN
- 12:30 - 12:30 **1166P - An oral dual inhibitor of IDO and TDO enhances anti-cancer immunity and synergizes with immune checkpoint blockade**  
C. Kim<sup>1</sup>, N.K. Lee<sup>1</sup>, J.S. Kim<sup>2</sup>, W.R. Kim<sup>3</sup>, D.H. Kim<sup>3</sup>, D.J. Kim<sup>3</sup>, J.S. Oh<sup>3</sup>, S.K. Chang<sup>1</sup>, J.W. Kim<sup>3</sup>, H.J. Chon<sup>1</sup>, <sup>1</sup>Bundang Cha Medical Center, Seongnam, KR, <sup>2</sup>CMG pharmaceutical, Seongnam, KR, <sup>3</sup>CHA Bundang Medical Center, Seongnam, KR
- 12:30 - 12:30 **1167P - Phase 1, Open-Label Ascending Dose Trial of Anti-CTLA-4 Monoclonal Antibody AGEN1884 in Advanced Solid Malignancies, With Expansion to Patients Refractory to Recent Anti-PD-1/PD-L1 Therapy**  
B. Wilky<sup>1</sup>, P. Kumthekar<sup>2</sup>, R. Wesolowski<sup>3</sup>, J. Hwang<sup>4</sup>, S. Park<sup>5</sup>, G. Yuan<sup>6</sup>, C. Dupont<sup>6</sup>, M. Lim<sup>6</sup>, O. Shebanova<sup>6</sup>, J.-M. Cuillerot<sup>7</sup>, E. Dow<sup>6</sup>, W. Ortuzar<sup>6</sup>, J. Raizer<sup>8</sup>, E. Drouin<sup>9</sup>, N. Wilson<sup>10</sup>, A. Gonzalez<sup>6</sup>, J. Goldberg<sup>8</sup>, J. Buell<sup>6</sup>, R. Stein<sup>6</sup>, H. Youssoufian<sup>6</sup>, <sup>1</sup>Sylvester Comprehensive Cancer Center, Miami, US, <sup>2</sup>The Ken & Roth Davee, Chicago, US, <sup>3</sup>The Ohio State University Comprehensive Cancer Center, Columbus, US, <sup>4</sup>Levine Cancer



Institute, Carolinas HealthCare System, Charlotte, US, <sup>5</sup>Levine Cancer Institute, Cannon Research Center, Charlotte, US, <sup>6</sup>Agenus Bio, Inc., Lexington, US, <sup>7</sup>Agenus Bio, Inc., Cambridge, US, <sup>8</sup>Agenus Inc. or subsidiary there of (current or former employee), Lexington, US, <sup>9</sup>Jounce Therapeutics, Inc., Cambridge, US, <sup>10</sup>Gilead Sciences, Lexington, US

- 12:30 - 12:30 **1168P - Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into 2L Cervical Cancer and Solid Tumors**  
J. Coward<sup>1</sup>, C. Lemech<sup>2</sup>, T. Meniawy<sup>3</sup>, C. Dupont<sup>4</sup>, A. Gonzalez<sup>4</sup>, M. Lim<sup>4</sup>, D. Savitsky<sup>4</sup>, M. Carini<sup>4</sup>, S. Hu<sup>4</sup>, O. Shebanova<sup>4</sup>, E. Dow<sup>4</sup>, W. Ortuzar<sup>4</sup>, J. Buell<sup>4</sup>, R. Stein<sup>4</sup>, H. Youssoufian<sup>4</sup>, <sup>1</sup>Icon Cancer Care, South Brisbane, AU, <sup>2</sup>Scientia Clinical Research (Sydney), Randwick, AU, <sup>3</sup>School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU, <sup>4</sup>Agenus Bio, Inc., Lexington, US
- 12:30 - 12:30 **1169P - ROR\_ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: an open-label, multicenter Phase 1b trial**  
D. Camidge<sup>1</sup>, S. Gadgeel<sup>2</sup>, H. Wilkins<sup>3</sup>, G. Weems<sup>3</sup>, R. Santana-Davila<sup>4</sup>, M. Johnson<sup>5</sup>, <sup>1</sup>University of Colorado Cancer Center, Aurora, US, <sup>2</sup>University of Michigan, Ann Arbor, US, <sup>3</sup>Lycera, Philadelphia, US, <sup>4</sup>Seattle Cancer Care Alliance, Seattle, US, <sup>5</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US
- 12:30 - 12:30 **1170P - ABP-100: A Tetravalent Bispecific T-cell Engaging Antibody for HER2+ Solid Tumors**  
A. Boudot<sup>1</sup>, X. Huang<sup>1</sup>, S. Murphy<sup>1</sup>, V. Appleman<sup>1</sup>, H. Xu<sup>2</sup>, N.-K. Cheung<sup>2</sup>, G. Macbeath<sup>3</sup>, <sup>1</sup>Abpro, Woburn, US, <sup>2</sup>Memorial Sloan Kettering, New York, US, <sup>3</sup>Merrimack Pharmaceuticals, Inc., New York, US
- 12:30 - 12:30 **1171P - Phase 1 expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)**  
H. Babiker<sup>1</sup>, I. Brana<sup>2</sup>, D. Mahadevan<sup>3</sup>, T. Owonikoko<sup>4</sup>, E. Calvo<sup>5</sup>, D. Rischin<sup>6</sup>, V. Moreno<sup>7</sup>, K. Papadopoulos<sup>8</sup>, M. Crittenden<sup>9</sup>, S. Formenti<sup>10</sup>, J. Giralt<sup>11</sup>, P. Garrido Lopez<sup>12</sup>, A. Hervás Morón<sup>13</sup>, K.K. Mohan<sup>14</sup>, M. Fury<sup>14</sup>, I. Lowy<sup>14</sup>, E. Stankevich<sup>15</sup>, M. Feng<sup>15</sup>, J. Li<sup>15</sup>, M. Mathias<sup>14</sup>, <sup>1</sup>University of Arizona Cancer Center, Tucson, US, <sup>2</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>3</sup>The University of Arizona Cancer Center, Tucson, AZ, USA. Formerly of The University of Tennessee Health Science Center and West Cancer Center, Memphis, US, <sup>4</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>5</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>6</sup>Peter MacCallum Cancer Centre, and the University of Melbourne, Melbourne, AU, <sup>7</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>8</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>9</sup>Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center and The Oregon Clinic, Portland, US, <sup>10</sup>Weill Cornell Medicine, New York, US, <sup>11</sup>Vall d'Hebron University Hospital, Bar, ES, <sup>12</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>13</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>14</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US, <sup>15</sup>Regeneron Pharmaceuticals, Inc., Basking Ridge, US



- 12:30 - 12:30 **1172P - A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors**  
A. Awada<sup>1</sup>, F. Eskens<sup>2</sup>, D. Robbrecht<sup>2</sup>, U. Lassen<sup>3</sup>, M. Sorensen<sup>4</sup>, J. Schellens<sup>5</sup>, J. De Groot<sup>5</sup>, C. Jungels<sup>6</sup>, P. Aftimos<sup>6</sup>, S. Fretland<sup>7</sup>, L. Thorsson<sup>8</sup>, T.K. Guren<sup>7</sup>, <sup>1</sup>Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BE, <sup>2</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>3</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>4</sup>Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK, <sup>5</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>6</sup>Institute Jules Bordet, Brussels, BE, <sup>7</sup>Oslo University Hospital, Oslo, NO, <sup>8</sup>Cantargia AB, Lund, SE
- 12:30 - 12:30 **1173P - Immunostimulatory AdCD40L gene therapy in patients with advanced solid tumours**  
S. Irenaeus<sup>1</sup>, J. Wenthe<sup>2</sup>, E. Eriksson<sup>2</sup>, J. Krause<sup>3</sup>, A. Sundin<sup>3</sup>, H. Ahlström<sup>3</sup>, T. Tötterman<sup>4</sup>, A. Loskog<sup>4</sup>, G. Ullenhag<sup>5</sup>, <sup>1</sup>University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE, <sup>2</sup>Department of Immunology, Genetics and Pathology, Uppsala, SE, <sup>3</sup>Uppsala University and Uppsala University Hospital, Uppsala, SE, <sup>4</sup>Uppsala University, Uppsala, SE, <sup>5</sup>Akademiska sjukhuset, Uppsala, Uppsala, SE
- 12:30 - 12:30 **1174P - Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials**  
A. Bernard-Tessier<sup>1</sup>, C. Baldini<sup>2</sup>, E. Castanon Alvarez<sup>3</sup>, S. Ammari<sup>2</sup>, P. Martin Romano<sup>2</sup>, S. Champiat<sup>2</sup>, A. Hollebecque<sup>2</sup>, S. Postel-Vinay<sup>1</sup>, A. Varga<sup>2</sup>, R. Bahleda<sup>4</sup>, A. Gazzah<sup>1</sup>, J.-M. Michot<sup>1</sup>, V. Ribrag<sup>2</sup>, J.-P. Armand<sup>1</sup>, A. Marabelle<sup>2</sup>, J.-C. Soria<sup>5</sup>, C. Massard<sup>4</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Gustave Roussy, Villejuif, FR, <sup>3</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>4</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>5</sup>Medimmune, Gaithersburg, US
- 12:30 - 12:30 **1175P - Prognostic value of response according to tumour growth rate in a phase I trial on vaccine therapy**  
A. Bellucci<sup>1</sup>, C. Nevoret<sup>1</sup>, C. De Bazelaire<sup>2</sup>, S. Oudard<sup>1</sup>, L. Teixeira<sup>2</sup>, R. Defrance<sup>3</sup>, T. Huet<sup>4</sup>, L.D. Pierre<sup>4</sup>, V. Doppler<sup>4</sup>, J. Medioni<sup>5</sup>, S. Culine<sup>2</sup>, L. Fournier<sup>1</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>Hôpital St. Louis, Paris, FR, <sup>3</sup>Ipsen Pharma France, Boulogne-Billancourt, FR, <sup>4</sup>Invectys, Paris, FR, <sup>5</sup>Gh Diaconesses Croix Saint-Simon, Paris, FR
- 12:30 - 12:30 **1176P - Oncolytic Virotherapy For Multiple Myeloma Targeting CD40, 41BB and/or IL6R**  
J. Wenthe<sup>1</sup>, S. Naseri<sup>2</sup>, A.-C. Hellström<sup>2</sup>, E. Eriksson<sup>1</sup>, A. Loskog<sup>2</sup>, <sup>1</sup>Department of Immunology, Genetics and Pathology, Uppsala, SE, <sup>2</sup>Uppsala University, Uppsala, SE
- 12:30 - 12:30 **1177P - Humanized knock-in mouse models for evaluating in vivo efficacy of immune-oncology drugs targeting stimulatory immune checkpoint molecules**  
T. Gan<sup>1</sup>, J. Xiang<sup>2</sup>, C. Guo<sup>3</sup>, Y. Guo<sup>3</sup>, <sup>1</sup>Beijing Biocytogen Co., Ltd., Beijing北京, CN, <sup>2</sup>Biocytogen LLC, Worcester, US, <sup>3</sup>Beijing Biocytogen Co., Ltd., Beijing, CN
- 12:30 - 12:30 **1178P - Tackling fratricide to manufacture clinical grade NKG2D-CAR T cells for cancer therapy**

B. Demoulin, B. Eytan, D. Gilham, Celyad SA, Mont Saint Guibert, BE

- 12:30 - 12:30 **1179P - The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer .**  
S. Agaugue<sup>1</sup>, A. Hargreaves<sup>2</sup>, P. De Sousa<sup>3</sup>, P. De Waele<sup>3</sup>, D. Gilham<sup>4</sup>, <sup>1</sup>Theravectys, Villejuif, FR, <sup>2</sup>Pathcelerate, cheshire, GB, <sup>3</sup>unknown, Bruxells, BE, <sup>4</sup>Celyad SA, Mont Saint Guibert, BE
- 12:30 - 12:30 **1180P - Combination of Pegilodecakin and Docetaxel Shows Synergy in Tumor Rejection in Immune Resistant TNBC model**  
N. Ratti, N. Shifrin, S. Mccauley, R. Verma, P. Van Vlasselaer, M. Oft, J. Leveque, ARMO BioSciences, Redwood City, US
- 12:30 - 12:30 **1181P - Mutations in Interferon Gamma and Antigen Presentation Pathways are frequent in Hiper/Ultra-Mutated (HiMut) Tumors and could be result of Immune-editing processes in HiMut tumors.**  
J.M. Piulats Rodriguez<sup>1</sup>, S. Garcia-Mulero<sup>1</sup>, L. Valle<sup>1</sup>, V. Moreno<sup>1</sup>, X. Matias-Guiu<sup>2</sup>, R. Sanz-Pamplona<sup>1</sup>, <sup>1</sup>Institut Catala d'Oncologia (ICO), Barcelona, ES, <sup>2</sup>Hospital Universitario Arnau de Vilanova de Lleida, Lleida, ES
- 12:30 - 12:30 **1182P - Anti-CTLA4 toxicity associates with genetic variation correlating with serum antibody diversity.**  
D. Simpson<sup>1</sup>, R. Ferguson<sup>1</sup>, M. Gowen<sup>1</sup>, K. Giles<sup>1</sup>, J. Tchack<sup>1</sup>, H. Zhou<sup>1</sup>, U. Moran<sup>1</sup>, Z. Dawood<sup>1</sup>, A. Pavlick<sup>2</sup>, S. Hu<sup>3</sup>, M. Wilson<sup>2</sup>, H. Zhong<sup>4</sup>, M. Krogsgaard<sup>1</sup>, J. Weber<sup>5</sup>, I. Osman<sup>1</sup>, T. Kirchhoff<sup>6</sup>, <sup>1</sup>New York University Medical Center, New York, US, <sup>2</sup>New York University - Perlmutter Cancer Center - Langone Medical Center, New York, US, <sup>3</sup>CDI, Baltimore, US, <sup>4</sup>New York University Medical Center, new york, US, <sup>5</sup>NYU Langone Medical Center, New York, US, <sup>6</sup>New York University, New York, US
- 12:30 - 12:30 **1183P - PD-L1 expression is strongly associated with TIGIT, FOXP3 and LAG3 across advanced cancers, but not OX40, TIM3 and IDO**  
S. Pal<sup>1</sup>, A. Vanderwalde<sup>2</sup>, C. Szeto<sup>3</sup>, S. Reddy<sup>3</sup>, O. Hamid<sup>4</sup>, <sup>1</sup>City of Hope, Duarte, US, <sup>2</sup>University of Tennessee, Memphis, US, <sup>3</sup>NantOmics, Culver City, US, <sup>4</sup>The Angeles Clinic and Research Institute, Los Angeles, US
- 12:30 - 12:30 **1184P - Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)**  
O. Hamid<sup>1</sup>, S. Hu-Lieskovan<sup>2</sup>, W. Ros<sup>3</sup>, A. Diab<sup>4</sup>, A. El-Khoueiry<sup>5</sup>, J. Thompson<sup>6</sup>, F. Eskens<sup>7</sup>, J.-P. Spano<sup>8</sup>, E. Angevin<sup>9</sup>, N. Rizvi<sup>10</sup>, J. Wasser<sup>11</sup>, P. Ott<sup>12</sup>, A. Chiappori<sup>13</sup>, T. Joh<sup>14</sup>, H. Krupka<sup>14</sup>, S. Potluri<sup>14</sup>, X. Wang<sup>14</sup>, B. Ganguli<sup>14</sup>, J. Chou<sup>14</sup>, T. Doi<sup>15</sup>, <sup>1</sup>The Angeles Clinic and Research Institute, Los Angeles, US, <sup>2</sup>UCLA - School of Medicine, Los Angeles, US, <sup>3</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>4</sup>MD Anderson Cancer Center, Houston, US, <sup>5</sup>USC/Norris Comprehensive Cancer Center, Los Angeles, US, <sup>6</sup>University of Washington Seattle Cancer Care Alliance, Seattle, US, <sup>7</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>8</sup>Groupe Hospitalier Pitié Salpetriere, Paris, FR, <sup>9</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>10</sup>Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New

York, US, <sup>11</sup>University of Connecticut School of Medicine, Farmington, US, <sup>12</sup>Dana-Farber Cancer Institute, Boston, US, <sup>13</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, <sup>14</sup>Inc., New York, US, <sup>15</sup>National Cancer Center Hospital East, Kashiwa, JP

- 12:30 - 12:30 **1185P - Using MultiOmyx™ to analyze correlations between immunosuppressive cells and tumor-infiltrating lymphocytes in the pancreatic tumor microenvironment**  
A. Juncker-Jensen, J. Fang, J. Kuo, M. Nagy, R.K. Padmanabhan, E. Leones, F. Sahafi, S. Zhu, Q. Au, N. Hoe, J. William, NeoGenomics, Aliso Viejo, US
- 12:30 - 12:30 **1186P - Interim results from exploratory study to determine S-588410-induced tumor infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.**  
T. Kojima<sup>1</sup>, T. Marafioti<sup>2</sup>, T. Fujiwara<sup>3</sup>, Y. Shirakawa<sup>3</sup>, T. Nakatsura<sup>4</sup>, K. Kato<sup>5</sup>, I. Puccio<sup>2</sup>, M. Nagira<sup>6</sup>, N. Ide<sup>6</sup>, K. Stoeber<sup>7</sup>, A. Arimura<sup>6</sup>, H. Daiko<sup>8</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>University College London Hospital, London, GB, <sup>3</sup>Okayama University Hospital, Okayama, JP, <sup>4</sup>National Cancer Center, Kashiwa, JP, <sup>5</sup>National Cancer Center Hospital, Tokyo, JP, <sup>6</sup>morio.nagira@shionogi.co.jp, Tokyo, JP, <sup>7</sup>Shionogi Limited, London, GB, <sup>8</sup>National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP
- 12:30 - 12:30 **1187P - Clinical implication of PDL1 expression and TILs in male breast cancer: More Hype or New Hope? Results from the UMBREAC trial (NCT03240510)**  
S. Abdeljaoued<sup>1</sup>, I. Bettaieb<sup>1</sup>, A. Goucha<sup>1</sup>, O. Adouni<sup>1</sup>, H. El Mokh<sup>1</sup>, H. Bouzaiene<sup>1</sup>, J. Ben Hassouna<sup>1</sup>, H. Boussen<sup>2</sup>, K. Rahal<sup>1</sup>, A. Gamoudi<sup>1</sup>, <sup>1</sup>Institut Salah Azaïz, Tunis, TN, <sup>2</sup>Hopital Abderrahman Mami, Ariana, TN
- 12:30 - 12:30 **1188P - Identification of Prognostic and Predictive Factors for Durvalumab Efficacy by Modeling of Tumor Response and Overall Survival (OS) in Patients with Non-Small-Cell Lung Cancer (NSCLC)**  
Y. Zheng<sup>1</sup>, R. Narwal<sup>2</sup>, C. Jin<sup>2</sup>, P. Baverel<sup>3</sup>, A. Gupta<sup>4</sup>, P. Mukhopadhyay<sup>5</sup>, B. Higgs<sup>2</sup>, L. Roskos<sup>2</sup>, <sup>1</sup>Medimmune, Mountain View, US, <sup>2</sup>MedImmune, Gaithersburg, US, <sup>3</sup>MedImmune, Cambridge, GB, <sup>4</sup>AstraZeneca, Cambridge, GB, <sup>5</sup>AstraZeneca, Gaithersburg, US
- 12:30 - 12:30 **1189P - Intrinsic and Extrinsic regulation of PD-L2 Expression by transcription factor STAT3 or c-FOS in Oncogene-Driven Non-Small Cell Lung Cancer**  
D. Shibahara<sup>1</sup>, K. Tanaka<sup>2</sup>, E. Iwama<sup>2</sup>, N. Kubo<sup>2</sup>, K. Ota<sup>2</sup>, K. Azuma<sup>3</sup>, T. Harada<sup>2</sup>, J. Fujita<sup>1</sup>, Y. Nakanishi<sup>2</sup>, I. Okamoto<sup>4</sup>, <sup>1</sup>Ryukyu University Hospital, Okinawa, JP, <sup>2</sup>Kyushu University Hospital, FUKUOKA, JP, <sup>3</sup>kurume university school of medicine, Fukuoka, JP, <sup>4</sup>Kinki University School of Medicine, Osaka, JP
- 12:30 - 12:30 **1190P - Microsatellite instability detection by targeted sequencing of cell-free DNA**  
A. Artyomenko<sup>1</sup>, M. Sikora<sup>1</sup>, M. Lefterova<sup>1</sup>, V. Raymond<sup>1</sup>, D. Gavino<sup>1</sup>, C. Barbacioru<sup>1</sup>, C. Artieri<sup>1</sup>, E. Helman<sup>1</sup>, D. Chudova<sup>1</sup>, R. Lanman<sup>1</sup>, J. Odegaard<sup>1</sup>, J. Willis<sup>2</sup>, M. Fakih<sup>3</sup>, S. Kopetz<sup>4</sup>, A. Talasz<sup>1</sup>, <sup>1</sup>Guardant Health, Redwood City, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Huston, US, <sup>3</sup>City of Hope, Duarte, US, <sup>4</sup>MD Anderson Cancer



Center, Houston, US

- 12:30 - 12:30 **1191P - Immune Checkpoints and T-Lymphocytes as Immunotherapeutic Target in the Treatment of Sebaceous Gland Carcinoma**  
L. Singh<sup>1</sup>, M. Singh<sup>2</sup>, N. Pushker<sup>2</sup>, S. Bakhshi<sup>2</sup>, M. Rizvi<sup>3</sup>, S. Sen<sup>2</sup>, S. Kashyap<sup>2</sup>, <sup>1</sup>All India Institute of Medical Sciences, Delhi, IN, <sup>2</sup>All India Institute of Medical Sciences, New Delhi, IN, <sup>3</sup>Jamia Millia Islamia, New Delhi, IN
- 12:30 - 12:30 **1192P - Evaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade**  
H. Jackson<sup>1</sup>, S. Bhattacharya<sup>1</sup>, P. Bojczuk<sup>1</sup>, D. Kilian<sup>1</sup>, L. Seestaller Wehr<sup>1</sup>, A. Hahn<sup>1</sup>, H. Shi<sup>1</sup>, M. Bi<sup>1</sup>, M. Adam<sup>1</sup>, J. Jing<sup>1</sup>, P. Morley<sup>2</sup>, C. Hopson<sup>1</sup>, E. Paul<sup>1</sup>, A. Hoos<sup>1</sup>, J. Smothers<sup>1</sup>, R. Srinivasan<sup>1</sup>, N. Yanamandra<sup>1</sup>, <sup>1</sup>GlaxoSmithKline USA, Collegeville, US, <sup>2</sup>GlaxoSmithKline USA, SG NY, GB
- 12:30 - 12:30 **1193P - Impact of tissue processing and interferents on the reproducibility and robustness of a multi-plex gene expression assay measuring tumor inflammation.**  
B. Wallden, S. Church, I. Pekker, S. Zimmerman, S. Popa, A. Sullivan, C. Ngouenet, E. Harris, N. Dowidar, A. Bergdahl, C. Schaper, P. Danaher, S. Ferree, NanoString Technologies, Seattle, US
- 12:30 - 12:30 **1194P - Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with Durvalumab plus Monalizumab (anti-NKG2A)**  
J. Diamond<sup>1</sup>, N. Standifer<sup>2</sup>, M. Ascierto<sup>3</sup>, C. Morehouse<sup>3</sup>, H. Ghadially<sup>4</sup>, J. Rodriguez Canales<sup>3</sup>, M. Rebelatto<sup>3</sup>, J. Naidoo<sup>5</sup>, L. Mazzarella<sup>6</sup>, S. Patel<sup>7</sup>, M.J. Flor Oncala<sup>8</sup>, T. Alonso Gordo<sup>9</sup>, D. Wang<sup>10</sup>, X. Song<sup>3</sup>, D. Jones<sup>4</sup>, X. Li<sup>3</sup>, S. Marshall<sup>3</sup>, S. Abdullah<sup>3</sup>, M. Jure-Kunkel<sup>3</sup>, M. Hellmann<sup>11</sup>, <sup>1</sup>University of Colorado Denver, Denver, US, <sup>2</sup>MedImmune, Mountain View, US, <sup>3</sup>MedImmune, Gaithersburg, US, <sup>4</sup>MedImmune, Cambridge, GB, <sup>5</sup>Johns Hopkins University, Baltimore, US, <sup>6</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>7</sup>University of California San Diego, San Diego, US, <sup>8</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>9</sup>University Hospital Ramón y Cajal, Madrid, ES, <sup>10</sup>Henry Ford Hospital, Detroit, US, <sup>11</sup>Memorial Sloan Kettering Cancer Center, New York, US
- 12:30 - 12:30 **1195P - Alterations in peripheral T cell subsets, T cell Activation Markers and Immune Checkpoint Molecules in advanced Pancreatic Cancer Patients Receiving FOLFIRINOX or Gemcitabine + Nab-Paclitaxel**  
L. Sams<sup>1</sup>, S. Kruger<sup>1</sup>, V. Heinemann<sup>2</sup>, D. Bararia<sup>3</sup>, S. Haebe<sup>1</sup>, S. Alig<sup>1</sup>, B. Westphalen<sup>2</sup>, M. Haas<sup>2</sup>, T. Kirchner<sup>2</sup>, S. Ormanns<sup>2</sup>, S. Endres<sup>4</sup>, O. Weigert<sup>3</sup>, M. Von Bergwelt-Baildon<sup>1</sup>, S. Kobold<sup>4</sup>, F. Rataj<sup>4</sup>, S. Boeck<sup>2</sup>, <sup>1</sup>LMU Klinikum der Universität München, Munich, DE, <sup>2</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>3</sup>Experimentelle Leukämie- und Lymphom-Forschung, Munich, DE, <sup>4</sup>Ludwig Maximilians University - Campus Innenstadt, Munich, DE
- 12:30 - 12:30 **1196P - Resistance to anti-PD-1 therapy is associated with the retention of CXCR3+ CD4+ CD8- T cells in blood**



X. Han<sup>1</sup>, T. Tan<sup>2</sup>, J. Sun<sup>1</sup>, X. Chen<sup>3</sup>, X. Cai<sup>1</sup>, P. Lin<sup>1</sup>, Y. Tan<sup>2</sup>, B. Wang<sup>1</sup>, Y. Wang<sup>1</sup>, J. Wang<sup>1</sup>, Z. Yu<sup>1</sup>, X. Wu<sup>2</sup>, Q. Xu<sup>2</sup>, Y. Gu<sup>3</sup>, <sup>1</sup>Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing, CN, <sup>2</sup>Nanjing University, Nanjing, CN, <sup>3</sup>The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, CN

12:30 - 12:30 **1197P - Cerebrospinal fluid lymphocytosis: a hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment**

K. Suijkerbuijk<sup>1</sup>, F. De Vos<sup>1</sup>, J. Koldenhof<sup>2</sup>, T. Snijders<sup>3</sup>, <sup>1</sup>University Hospital Utrecht, Utrecht, NL, <sup>2</sup>UMC - University Medical Center Utrecht, Utrecht, NL, <sup>3</sup>University Medical Center Utrecht, Utrecht, NL

12:30 - 12:30 **1198P - Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real world scenario**

D. Iacono<sup>1</sup>, M.G. Vitale<sup>2</sup>, F. Cortiula<sup>2</sup>, M. Cinausero<sup>2</sup>, A. Tullio<sup>3</sup>, F. Valent<sup>3</sup>, M. Macerelli<sup>3</sup>, A. Follador<sup>3</sup>, A. Vogrig<sup>3</sup>, A. Minisini<sup>4</sup>, F. Puglisi<sup>5</sup>, G. Fasola<sup>1</sup>, <sup>1</sup>Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, <sup>2</sup>University of Udine, Udine, IT, <sup>3</sup>ASUIUD Santa Maria della Misericordia, Udine, IT, <sup>4</sup>ASUIUD Azienda Ospedaliero-Universitaria di Udine, Udine, IT, <sup>5</sup>CRO di Aviano, Aviano, IT

12:30 - 12:30 **1199P - Clinical and molecular characteristics associated with efficacy of PD-1/PD-L1 inhibitors for solid tumors: A Meta-analysis**

M. Peng<sup>1</sup>, Y. Weng<sup>2</sup>, Y. Yao<sup>1</sup>, Q. Song<sup>3</sup>, <sup>1</sup>Renmin Hospital of Wuhan University, Wuhan, CN, <sup>2</sup>Renmin Hospital of Wuhan University, wuhan, CN, <sup>3</sup>Renmin Hospital of Wuhan University, wuhan, CN

12:30 - 12:30 **1200P - Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer**

T. Ota<sup>1</sup>, T. Takeda<sup>2</sup>, T. Fukui<sup>3</sup>, Y. Nakahara<sup>3</sup>, K. Kudo<sup>4</sup>, T. Okabe<sup>5</sup>, H. Hayashi<sup>6</sup>, S. Otani<sup>3</sup>, Y. Hiyoshi<sup>3</sup>, K. Yonesaka<sup>6</sup>, T. Sugiura<sup>7</sup>, T. Suzumura<sup>8</sup>, M. Terashima<sup>7</sup>, Y. Nakano<sup>7</sup>, Y. Hasegawa<sup>7</sup>, H. Tsukuda<sup>7</sup>, K. Matsui<sup>7</sup>, N. Masuda<sup>9</sup>, M. Fukuoka<sup>7</sup>, <sup>1</sup>Izumi Municipal Hospital Cancer Center, Izumi, JP, <sup>2</sup>Uji-Tokushukai Medical Center, Uji, JP, <sup>3</sup>Kitasato University School of Medicine, Sagamihara, JP, <sup>4</sup>National Hospital Organization Osaka Minami Medical Center, Kawachinagano, JP, <sup>5</sup>Nara Hospital Kindai University Faculty of Medicine, Ikoma, JP, <sup>6</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>7</sup>Izumi City General Hospital, Izumi, JP, <sup>8</sup>Osaka City University, Osaka, JP, <sup>9</sup>Kitasato University School of Medicine, Kanagawa, JP

12:30 - 12:30 **1201P - Association of immune-related adverse (irAEs) with immune-checkpoint inhibitors (ICIs) efficacy in solid tumors**

M. Riudavets Melia<sup>1</sup>, L. Del Carpio<sup>1</sup>, I. Gabriela Sullivan<sup>1</sup>, A. Barba Joaquín<sup>1</sup>, P. Maroto Rey<sup>1</sup>, G. Anguera Palacios<sup>1</sup>, D. Páez López-Bravo<sup>1</sup>, A. Callejo Pérez<sup>1</sup>, C. González Blanco<sup>1</sup>, D. Castillo Villegas<sup>1</sup>, C. Facundo Molas<sup>2</sup>, E. Garcia Planella<sup>1</sup>, I. Genua Trullós<sup>1</sup>, A. López Pousa<sup>1</sup>, A. Sebio García<sup>1</sup>, C. Martín Lorente<sup>1</sup>, A.C. Virgili Manrique<sup>1</sup>, O. Gallego Rubio<sup>1</sup>, A. Barnadas Molins<sup>1</sup>, M. Majem Tarruella<sup>1</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>2</sup>Puigvert Foundation, Barcelona, ES

12:30 - 12:30 **1202P - Use of Immune Checkpoint Inhibitors (CPI) in Patients with Cancer and**

**Concomitant Myasthenia Gravis (MG)**

H. Safa, N. Abdel-Wahab, V.A. Trinh, D. Johnson, T.E. Rodgers, M. Suarez-Almazor, A. Diab, MD Anderson Cancer Center, Houston, US

12:30 - 12:30

**1203P - Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events.**

A. Simonaggio<sup>1</sup>, J.-M. Michot<sup>2</sup>, S. Champiat<sup>3</sup>, A. Vozy<sup>2</sup>, A. Lopera<sup>4</sup>, A. Marabelle<sup>3</sup>, J. Le Pavec<sup>5</sup>, A.-L. Voisin<sup>6</sup>, A. Lallart<sup>7</sup>, G. Cengizalp<sup>7</sup>, O. Lambotte<sup>8</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Gustave Roussy DITEP, villejuif, FR, <sup>5</sup>hôpital marie lannelongue, le plessi robinson, FR, <sup>6</sup>Gustave Roussy Institute, Villejuif, FR, <sup>7</sup>Gustave Roussy Pharmacovigilance, villejuif, FR, <sup>8</sup>Hôpital Bicêtre, Le Kremlin-Bicêtre, FR

12:30 - 12:30

**1204P - Long term disease control and abscopal effects by stereotactic radiotherapy for growing metastases during anti-PD1.**

K. Suijkerbuijk<sup>1</sup>, S. El Sharouni<sup>2</sup>, P. Damen<sup>3</sup>, A. Lindert<sup>1</sup>, G. Groenewegen<sup>3</sup>, J. Verhoeff<sup>2</sup>, <sup>1</sup>University Hospital Utrecht, Utrecht, NL, <sup>2</sup>UMC - University Medical Center Utrecht, Utrecht, NL, <sup>3</sup>University Medical Center Utrecht Cancer Center, Utrecht, NL

12:30 - 12:30

**1205P - Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab.**

T. Yamamoto, T. Nomizo, H. Ozasa, T. Tsuji, Y. Yasuda, H. Yoshida, Y. Sakamori, T. Hirai, Y. Kim, Kyoto University-Graduate school of medicine, Kyoto, JP

12:30 - 12:30

**1206P - Incidence of Immune Related Adverse Events in patients 70 years old treated with anti-PD-(L)1 therapy**

C. Baldini<sup>1</sup>, P. Martin-Romano<sup>2</sup>, A.-L. Voisin<sup>3</sup>, F.X. Danlos<sup>2</sup>, S. Champiat<sup>1</sup>, S. Laghouati<sup>2</sup>, M. Kfoury<sup>4</sup>, H. Vincent<sup>1</sup>, C. Nagera<sup>1</sup>, S. Postel-Vinay<sup>2</sup>, A. Varga<sup>1</sup>, V. Ribrag<sup>2</sup>, B. Besse<sup>5</sup>, A. Hollebecque<sup>1</sup>, O. Lambotte<sup>6</sup>, J.-M. Michot<sup>2</sup>, J.-C. Soria<sup>7</sup>, C. Massard<sup>8</sup>, A. Marabelle<sup>1</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Gustave Roussy Institute, Villejuif, FR, <sup>4</sup>Gustave Roussy, VILLEJUIF, FR, <sup>5</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>6</sup>hôpital kremlin bicetre, kremlin bicetre, FR, <sup>7</sup>Medimmune, Gaithersburg, US, <sup>8</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR

12:30 - 12:30

**1207P - PD-1 inhibitor-related pneumonitis in patients with minimal interstitial lung shadows before treatment**

K. Takahashi<sup>1</sup>, C. Kondo<sup>2</sup>, A. Inukai<sup>1</sup>, G. Asai<sup>1</sup>, M. Okuno<sup>2</sup>, H. Saito<sup>3</sup>, <sup>1</sup>Aichi Cancer Center - Aichi Hospital, Okazaki, JP, <sup>2</sup>Aichi Cancer Center, Aichi Hospital, Okazaki, JP, <sup>3</sup>Aichi Cancer Center Aichi Hospital, Okazaki, JP

12:30 - 12:30

**1208P - PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques - a safety study**

R. Carroll<sup>1</sup>, J. Zalcborg<sup>2</sup>, H. Tang<sup>3</sup>, <sup>1</sup>Royal Adelaide Hospital RAH Cancer Centre, Adelaide, AU, <sup>2</sup>Alfred Hospital, Melbourne, AU, <sup>3</sup>Royal Adelaide Hospital, Adelaide, AU

12:30 - 12:30

**1209P - Immunotherapy In The Immunodeficient- A Treatment Paradox?**

N. Campbell<sup>1</sup>, J. Longley<sup>1</sup>, A. Pascalis<sup>2</sup>, J. Bennett<sup>3</sup>, M. Remer<sup>1</sup>, R. Stone<sup>1</sup>, D. Muller<sup>1</sup>, I. Karydis<sup>1</sup>, O. Donnelly<sup>1</sup>, M. Wheeler<sup>1</sup>, C. Ottensmeier<sup>4</sup>, <sup>1</sup>Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB, <sup>2</sup>Institute of Cancer Research, London, GB, <sup>3</sup>University of Southampton, Southampton, GB, <sup>4</sup>University Hospital Southampton NHS Foundation Trust, Southampton, GB

12:30 - 12:30 **1211P - Hyperprogression during immuno-checkpoint inhibitors (ICIs): a clinically significant problem?**

E. Farè<sup>1</sup>, S. Sdao<sup>1</sup>, S. Damian<sup>2</sup>, S. Cresta<sup>1</sup>, M. Del Vecchio<sup>1</sup>, M. Di Bartolomeo<sup>3</sup>, L. Di Guardo<sup>1</sup>, M. Duca<sup>2</sup>, A. Indini<sup>1</sup>, A. Necchi<sup>2</sup>, M. Niger<sup>1</sup>, M. Prisciandaro<sup>4</sup>, G. Procopio<sup>2</sup>, D. Raggi<sup>1</sup>, E. Verzoni<sup>2</sup>, G. Pruneri<sup>1</sup>, M. Di Nicola<sup>2</sup>, F.G. De Braud<sup>2</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>Fondazione IRCCS, Milan, IT, <sup>4</sup>Istituto Nazionale dei Tumori di Milano, Milan, IT

12:30 - 12:30 **1212P - Pathogenesis, clinical evolution, and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: a multicentre study.**

L. Au<sup>1</sup>, R. Nathwani<sup>2</sup>, L. Possamai<sup>2</sup>, C. Barlow<sup>3</sup>, T. Tillett<sup>4</sup>, R. Bowen<sup>5</sup>, L. Spain<sup>1</sup>, J. Thomas<sup>1</sup>, M. Backhouse<sup>4</sup>, A. Gurung<sup>3</sup>, R. Morrison<sup>2</sup>, T. Cross<sup>6</sup>, C. Herbert<sup>7</sup>, R. Goldin<sup>2</sup>, M. Gore<sup>1</sup>, J. Larkin<sup>1</sup>, C. Antoniades<sup>2</sup>, S. Turajlic<sup>1</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>Imperial College London, London, GB, <sup>3</sup>Musgrove Park Hospital, Somerset, GB, <sup>4</sup>Royal United Hospitals Bath NHS, Avon, GB, <sup>5</sup>Royal United Hospitals Bath NHS Foundation trust, Bath, GB, <sup>6</sup>Royal Liverpool University Hospital, Liverpool, GB, <sup>7</sup>University Hospitals Bristol NHS Trust Bristol Haematology and Oncology Centre, Bristol, GB

12:30 - 12:30 **1213P\_PR - Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)**

A. Gobert<sup>1</sup>, M. Veyri<sup>2</sup>, A. Lavolé<sup>3</sup>, H. Montaudie<sup>4</sup>, N. Cloarec<sup>5</sup>, L. Doucet<sup>6</sup>, V. Gounant<sup>7</sup>, M.-A. Massiani<sup>8</sup>, C. Helissey<sup>9</sup>, S. Bregigeon<sup>10</sup>, C. Chouaid<sup>11</sup>, C.-H. Poulet<sup>12</sup>, M. Dewolf<sup>13</sup>, M. Kerjouan<sup>14</sup>, S. Beaucaire-Danel<sup>15</sup>, S. Brosseau<sup>7</sup>, G. Le Garff<sup>16</sup>, V. Garrait<sup>17</sup>, A.-G. Marcelin<sup>18</sup>, J.-P. Spano<sup>1</sup>, <sup>1</sup>Groupe Hospitalier Pitié Salpêtrière, Paris, FR, <sup>2</sup>Pitié-Salpêtrière Hospital, Paris, FR, <sup>3</sup>Hospital Tenon, APHP, Paris, FR, <sup>4</sup>Nice university hospital, INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, Team 12, Nice, FR, <sup>5</sup>CH Avignon, Avignon, FR, <sup>6</sup>Hôpital St. Louis, Paris, FR, <sup>7</sup>Hopital Bichat Claude Bernard, Paris, FR, <sup>8</sup>Institut Curie, Saint-Cloud, FR, <sup>9</sup>Bégin Military Teaching Hospital, Saint-Mandé, FR, <sup>10</sup>AP-HM, Marseille, FR, <sup>11</sup>Centre Hospitalier Intercommunal Créteil, Créteil, FR, <sup>12</sup>CHU Amiens-Picardie Site Sud, Amiens, FR, <sup>13</sup>CHU Reims, Reims, FR, <sup>14</sup>CHU Rennes, Rennes, FR, <sup>15</sup>Institut Curie, Paris, FR, <sup>16</sup>CH Saint Brieuc, Saint Brieuc, FR, <sup>17</sup>CHIC Créteil, Créteil, FR, <sup>18</sup>groupe Hospitalier Pitié Salpêtrière, Paris, FR

12:30 - 12:30 **1214P - Establishing the Need for Immuno-oncology (IO) Therapy (tx) in Second-Line (2L) Small Cell Lung Cancer (SCLC)**

L. Schwartzberg<sup>1</sup>, J. Penrod<sup>2</sup>, Y. Yuan<sup>2</sup>, T. Gu<sup>2</sup>, T.K. Le<sup>2</sup>, P. Abraham<sup>2</sup>, B. Korytowsky<sup>2</sup>, G. Selvaggi<sup>2</sup>, <sup>1</sup>West Cancer Center, Germantown, US, <sup>2</sup>Bristol-Myers Squibb, Princeton, US

12:30 - 12:30 **1215P - Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity**



**- from Case Report to Mice Model Validation**

Y.-J. Chen, W.-C. Huang, S.-Y. Liu, C.-C. Ko, Mackay Memorial Hospital, Taipei city, TW

- 12:30 - 12:30 **1216P - Impact of anti-infectious and corticosteroids on immunotherapy : Nivolumab and Pembrolizumab follow-up in a French study.**  
J.-P. Metges<sup>1</sup>, E. Michaud<sup>2</sup>, D. Deniel Lagadec<sup>3</sup>, F. Marhuenda<sup>4</sup>, A. Chaslerie<sup>2</sup>, F. Grude<sup>5</sup>,  
<sup>1</sup>C.H.U. Brest - Hôpital Morvan, Brest, FR, <sup>2</sup>Regional Health Insurance, NANTES, FR,  
<sup>3</sup>CHRU BREST, BREST, FR, <sup>4</sup>ICO Paul Papin, ANGERS, FR, <sup>5</sup>Centre Paul Papin, Angers, FR
- 12:30 - 12:30 **1217P - Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance**  
Y. Ohe<sup>1</sup>, A. Gemma<sup>2</sup>, K. Nakagawa<sup>3</sup>, N. Yamamoto<sup>4</sup>, T. Saito<sup>5</sup>, A. Akamatsu<sup>5</sup>, K. Kuwano<sup>6</sup>,  
Y. Nakanishi<sup>7</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Nippon Medical School Main Hospital, Tokyo, JP, <sup>3</sup>Kinki University School of Medicine, Osaka, JP, <sup>4</sup>Wakayama Medical University, Wakayama, JP, <sup>5</sup>Ono Pharmaceutical Co., Ltd., Osaka, JP, <sup>6</sup>The Jikei University School of Medicine, Tokyo, JP, <sup>7</sup>Kyushu University Hospital, FUKUOKA, JP
- 12:30 - 12:30 **1218P - Immune-related adverse events: comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy.**  
N. Duma<sup>1</sup>, A.-G. Azzouqa<sup>2</sup>, S. Yadav<sup>1</sup>, K. Hoversten<sup>1</sup>, C. Reed<sup>1</sup>, A. Sitek<sup>1</sup>, Y. Lou<sup>2</sup>, J. Molina<sup>1</sup>, T. Halfdanarson<sup>1</sup>, K. Leventakos<sup>1</sup>, R. Joseph<sup>2</sup>, R. Manochakian<sup>2</sup>, R. Dronca<sup>1</sup>,  
<sup>1</sup>Mayo Clinic, Rochester, US, <sup>2</sup>Mayo Clinic, Jacksonville, US
- 12:30 - 12:30 **1219P - Evaluation of a possible link between immunotherapy (IO) and acute vascular events.**  
J. Bar<sup>1</sup>, K. Shulman<sup>2</sup>, T. Kuznetsov<sup>1</sup>, G. Markel<sup>1</sup>, S. Daher<sup>1</sup>, R. Berger<sup>1</sup>, T. Golan<sup>1</sup>, D. Urban<sup>1</sup>, T. Sela<sup>1</sup>, E. Shacham Shmueli<sup>1</sup>, R. Klempfner<sup>1</sup>, A. Talianski<sup>1</sup>, A. Onn<sup>1</sup>, E. Dudnik<sup>3</sup>,  
<sup>1</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>2</sup>Hillel Yaffe Medical Center, Hadera, IL, <sup>3</sup>Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL
- 12:30 - 12:30 **1220P - Real-World Experience of Pembrolizumab in Patients with Advanced Melanoma: A Large Retrospective Observational Study**  
F.X. Liu<sup>1</sup>, W. Ou<sup>2</sup>, S. Diede<sup>2</sup>, E. Whitman<sup>3</sup>, <sup>1</sup>Merck & Co Inc, North Wales, US, <sup>2</sup>Merck & Co., Inc., Kenilworth, US, <sup>3</sup>Carol G. Simon Cancer Center, Morristown, US
- 12:30 - 12:30 **1221P - Sites of Metastasis and Association with Clinical Outcome (CO) in Advanced Stage Cancer Patients (Pts) Treated with Immunotherapy (IO)**  
M. Bilen<sup>1</sup>, J. Shabto<sup>2</sup>, D. Martini<sup>2</sup>, Y. Liu<sup>3</sup>, C. Lewis<sup>4</sup>, H. Collins<sup>4</sup>, M. Akce<sup>4</sup>, H. Kissick<sup>3</sup>, B. Carthon<sup>4</sup>, W. Shaib<sup>4</sup>, O. Alese<sup>4</sup>, C. Steuer<sup>4</sup>, C. Wu<sup>4</sup>, D. Lawson<sup>4</sup>, R. Kudchadkar<sup>1</sup>, V. Master<sup>2</sup>, B. El-Rayes<sup>4</sup>, S. Ramalingam<sup>1</sup>, T. Owonikoko<sup>1</sup>, R. Harvey<sup>4</sup>, <sup>1</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>2</sup>Emory University School of Medicine, Atlanta, US, <sup>3</sup>Emory University, Atlanta, US, <sup>4</sup>Winship Cancer Institute of Emory University, Atlanta, US



- 12:30 - 12:30 **1222P - Clinical outcome of immune related hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICIs).**  
N. Shah<sup>1</sup>, J. Puthiamadathil<sup>1</sup>, M. Serzan<sup>1</sup>, A. Belouali<sup>1</sup>, W. Kelly<sup>1</sup>, B. Ma<sup>1</sup>, M. Blackburn<sup>1</sup>, A. Knoedler<sup>1</sup>, S. Ochoagonzaelz<sup>1</sup>, M. Janni<sup>1</sup>, S. Madhavan<sup>1</sup>, G. Gibney<sup>2</sup>, M. Atkins<sup>1</sup>,  
<sup>1</sup>Lombardi Cancer Center Georgetown University, Washington DC, US, <sup>2</sup>Georgetown-Lombardi Comprehensive Cancer Center, Washington DC, US
- 12:30 - 12:30 **1223P - Potential Drug Cost Impact of Dual Agent Immunotherapy (DAIO) with Nivolumab (N) plus Ipilimumab (I) in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) in Canada.**  
K. Virik<sup>1</sup>, R. Wilson<sup>2</sup>, <sup>1</sup>Cancer Centre of Southeastern Ontario, Kingston, CA, <sup>2</sup>University of NSW, Liverpool, AU
- 12:30 - 12:30 **1224P - Q-TWiST Analysis to Assess Benefit-risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic NSCLC**  
M. Huang<sup>1</sup>, M.C. Pietanza<sup>2</sup>, A. Samkari<sup>1</sup>, J. Pellissier<sup>1</sup>, T. Burke<sup>2</sup>, S. Chandwani<sup>3</sup>, F. Kong<sup>1</sup>, A.S. Pickard<sup>4</sup>, <sup>1</sup>Merck & Co Inc, North Wales, US, <sup>2</sup>Merck & Co, Rahway, US, <sup>3</sup>Merck & Co., Lebanon, US, <sup>4</sup>Second City Outcomes Research, LLC, Oak Park, US
- 12:30 - 12:30 **1225P - Impact of immune-checkpoint inhibitors (ICPIs) as treatment of patients (pts) with metastatic primary uveal melanoma (UM): results of a single-institution database.**  
C.L. Lee<sup>1</sup>, G. Gullo<sup>1</sup>, N. Horgan<sup>2</sup>, D. Smith<sup>1</sup>, M. Moran<sup>1</sup>, J. Crown<sup>1</sup>, <sup>1</sup>St Vincents University Hospital, Dublin, IE, <sup>2</sup>Royal Victoria Eye & Ear Hospital,, Dublin, IE
- 12:30 - 12:30 **1226P - Anti-PD1 inhibitors: assessment of proper use, efficacy and economic impact in daily practice**  
M. Valery, Hôpital de la Salpêtrière, Paris, FR
- 12:30 - 12:30 **1227P - Immune-Related Adverse Events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients**  
J. Rogado<sup>1</sup>, N. Romero Laorden<sup>2</sup>, J.M. Sanchez Torres<sup>1</sup>, A.I. Ballesteros Garcia<sup>1</sup>, V. Pacheco-Barcia<sup>1</sup>, R. Arranz<sup>1</sup>, R. Mondéjar Solís<sup>1</sup>, P. Gullón<sup>3</sup>, A. Lorenzo<sup>4</sup>, R. Colomer Bosch<sup>1</sup>, <sup>1</sup>Hospital Universitario de La Princesa, Madrid, ES, <sup>2</sup>CNIO- Spanish National Cancer Center, Madrid, ES, <sup>3</sup>Universidad de Alcalá, Madrid, ES, <sup>4</sup>Hospital Universitario de Mostoles, Mostoles, ES
- 12:30 - 12:30 **1228P - Previous immunotherapy treatments may improve tumor responses with subsequent chemotherapy regimens**  
I. Baraibar Argota<sup>1</sup>, P. Martin-Romano<sup>2</sup>, M. Sanmamed<sup>3</sup>, M. Rodriguez-Ruiz<sup>4</sup>, J.L. Pérez-Gracia<sup>5</sup>, I. Gil-Bazo<sup>1</sup>, I. Melero<sup>1</sup>, L. Resano<sup>4</sup>, A. Chopitea Ortega<sup>1</sup>, J. Rodriguez<sup>4</sup>, J. Aramendia<sup>1</sup>, I. Gardezabal<sup>1</sup>, L. Cenicerros<sup>1</sup>, P. Sala Elarre<sup>1</sup>, M. Ponz-Sarvisé<sup>1</sup>, E. Castanon Alvarez<sup>1</sup>, <sup>1</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>4</sup>Clinica Universidad de Navarra, Pamplona, ES, <sup>5</sup>Clínica Universitaria de Navarra, Pamplona, ES

- 12:30 - 12:30 **1229P - Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)**  
M. Gutierrez<sup>1</sup>, A. Norden<sup>2</sup>, D. Lane<sup>3</sup>, B. Canavan<sup>4</sup>, E. Nwokeji<sup>3</sup>, Y. Xu<sup>3</sup>, S. Kaur<sup>5</sup>, S. Goldberg<sup>1</sup>, L. Noh<sup>5</sup>, L. Siegartel<sup>3</sup>, J. Whittington<sup>3</sup>, K. Tuell<sup>3</sup>, B. Korytowsky<sup>3</sup>, <sup>1</sup>The John Theurer Cancer Center, Hackensack, US, <sup>2</sup>Cota, New York, US, <sup>3</sup>Bristol-Myers Squibb, Lawrenceville, US, <sup>4</sup>Regional Cancer Care Associates, Edison, US, <sup>5</sup>Inc, New York, US
- 12:30 - 12:30 **1230P - Anti-PD-1 therapy combined with chemotherapy or target therapy in patients with advanced biliary tract cancer in real-world clinical setting**  
D. Sun<sup>1</sup>, J. Ma<sup>1</sup>, C. Han<sup>1</sup>, J. Wang<sup>1</sup>, Y. Qian<sup>1</sup>, G. Chen<sup>1</sup>, X. Li<sup>1</sup>, J. Zhang<sup>1</sup>, J. Song<sup>2</sup>, X. Zhao<sup>2</sup>, S. Cai<sup>2</sup>, Y. Hu<sup>1</sup>, <sup>1</sup>Chinese PLA General Hospital, Beijing, CN, <sup>2</sup>3D medicines Inc., Shanghai, CN
- 12:30 - 12:30 **1231P - The efficacy and safety of solid tumors combination therapy with immune checkpoint inhibitor: a systematic review and meta-analysis**  
M. Peng<sup>1</sup>, Y. Weng<sup>2</sup>, Y. Yao<sup>1</sup>, Q. Song<sup>3</sup>, <sup>1</sup>Renmin Hospital of Wuhan University, Wuhan, CN, <sup>2</sup>Renmin Hospital of Wuhan University, wuhan, CN, <sup>3</sup>enmin Hospital of Wuhan University, wuhan, CN
- 12:30 - 12:30 **1232P - Model-Based Assessment of Benefit-Risk Profile of Nivolumab (NIVO) Flat Dosing Schedules (Q2W and Q4W) Across Multiple Tumor Types**  
X. Zhao<sup>1</sup>, J. Shen<sup>1</sup>, M. Gopalakrishnan<sup>2</sup>, Y. Feng<sup>1</sup>, B. Schmidt<sup>1</sup>, P. Statkevich<sup>1</sup>, T. Kelleher<sup>3</sup>, M. Rashford<sup>1</sup>, V. Ivaturi<sup>2</sup>, J. Gobburu<sup>2</sup>, S. Agrawal<sup>1</sup>, A. Bello<sup>1</sup>, A. Roy<sup>1</sup>, <sup>1</sup>Bristol-Myers Squibb, Princeton, US, <sup>2</sup>University of Maryland, Baltimore, US, <sup>3</sup>Bristol-Myers Squibb, Wallingford, US
- 12:30 - 12:30 **1233P - Immunotherapy in Clinical Practice: Real World Multicentric Brazilian Experience.**  
J. Cé Coelho<sup>1</sup>, A.C. Zimmer Gelatti<sup>1</sup>, E. Mascarenhas<sup>2</sup>, C. Dutra<sup>3</sup>, T. Rebelato<sup>4</sup>, R. D'Avila<sup>5</sup>, F. Zaffaroni Caorsi<sup>6</sup>, B. Rocha Garcia<sup>3</sup>, A.C. De Miranda E Figueiredo<sup>3</sup>, M. Souto<sup>2</sup>, A. Baldasso Zanon<sup>4</sup>, N. Balzan<sup>4</sup>, G. Werutsky<sup>5</sup>, S. Jobim De Azevedo<sup>4</sup>, <sup>1</sup>Instituto do câncer Hospital Mãe de Deus, Porto Alegre, BR, <sup>2</sup>Nucleo de Oncologia da Bahia, Salvador, BR, <sup>3</sup>CEPON - Centro de Pesquisas Oncológicas, Florianópolis, BR, <sup>4</sup>Hospital de Clínicas de Porto Alegre, Porto Alegre, BR, <sup>5</sup>Hospital São Lucas da PUCRS, Porto Alegre, BR, <sup>6</sup>Latin American Oncology Group, Porto Alegre, BR
- 12:30 - 12:30 **1234P - Correlation, in a real-world setting, between clinical-disease characteristics and compliance with immunotherapy in solid metastatic tumors. First results of an Italian CORE-IMMUNO Study**  
C. Masini<sup>1</sup>, A. Berselli<sup>2</sup>, M. Banzi<sup>3</sup>, C. Bonelli<sup>1</sup>, A. Romagnani<sup>2</sup>, M. Pagano<sup>1</sup>, A. Damato<sup>1</sup>, G. Prati<sup>4</sup>, E. Gasparini<sup>2</sup>, G. Moretti<sup>1</sup>, I.T. Lorenzetti<sup>2</sup>, F. Zanelli<sup>1</sup>, F. Iachetta<sup>5</sup>, C. Pinto<sup>1</sup>, <sup>1</sup>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>2</sup>AUSL di Reggio Emilia-IRCCS, Reggio Emilia, IT, <sup>3</sup>arcispedale santa maria nuova-IRCCS, reggio emilia, IT, <sup>4</sup>IRCCS- AUSL Reggio Emilia, Guastalla, IT, <sup>5</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT
- 12:30 - 12:30 **1235P - Safety of immunotherapy in elderly patients: a retrospective analysis of**

**a phase I Unit**

E. Ferraro<sup>1</sup>, G. Viale<sup>2</sup>, B. Achutti Duso<sup>3</sup>, C. Belli<sup>3</sup>, C. Criscitiello<sup>4</sup>, L. Mazzaella<sup>4</sup>, A. Esposito<sup>2</sup>, S. Morganti<sup>3</sup>, D. Trapani<sup>3</sup>, P. Tarantino<sup>3</sup>, P. D'Amico<sup>4</sup>, C. Busacca<sup>3</sup>, M.A. Massaro<sup>2</sup>, G. Curigliano<sup>4</sup>, <sup>1</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>2</sup>European Institute of Oncology, Milano, IT, <sup>3</sup>European Institute of Oncology, Milan, IT, <sup>4</sup>Istituto Europeo di Oncologia, Milan, IT

12:30 - 12:30 **1236TiP - The Safety and Efficacy of Durvalumab in Combination with Paclitaxel for the treatment of Metastatic Triple Negative Breast Cancer**

H. Ghebeh, A. Alsayed, K. Suleman, T. Al-Tweigeri, King Faisal Specialist Hospital and Research Center, Riyadh, SA

12:30 - 12:30 **1237TiP - VSV-IFN<sub>γ</sub>-NIS intratumoral (IT) injection: a first-in-human (FIH), phase 1 study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors**

S. Powell<sup>1</sup>, M. Patel<sup>2</sup>, J. Merchan<sup>3</sup>, J. Strauss<sup>4</sup>, T. Cripe<sup>5</sup>, M. Old<sup>6</sup>, R. Diaz<sup>7</sup>, M. Reckner<sup>8</sup>, B. Brunton<sup>9</sup>, N. Packiriswamy<sup>9</sup>, D. Upreti<sup>9</sup>, L. Suksanpaisan<sup>10</sup>, R. Vandergaast<sup>10</sup>, R. Khan<sup>9</sup>, S. Russell<sup>7</sup>, K.W. Peng<sup>7</sup>, A. Bexon<sup>7</sup>, <sup>1</sup>Sanford Health, Sioux Falls, US, <sup>2</sup>U Minnesota Medical School, Minneapolis, US, <sup>3</sup>U Miami School of Medicine, Miami, US, <sup>4</sup>Mary Crowley Medical Research Center, Dallas, US, <sup>5</sup>Nationwide Children's Hospital, Columbus, US, <sup>6</sup>The Ohio State University, Columbus, US, <sup>7</sup>Vyriad, Rochester, US, <sup>8</sup>Bexon Clinical Consulting, Rochester, US, <sup>9</sup>Mayo Clinic, Rochester, US, <sup>10</sup>Imanis Life Sciences, Rochester, US

12:30 - 12:30 **1238TiP - A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma**

R. Jabulowsky<sup>1</sup>, C. Loquai<sup>2</sup>, E. Derhovanessian<sup>1</sup>, H. Mitzel-Rink<sup>2</sup>, J. Utikal<sup>3</sup>, J. Hassel<sup>4</sup>, R. Kaufmann<sup>5</sup>, A. Pinter<sup>5</sup>, M. Diken<sup>1</sup>, M. Gold<sup>1</sup>, L. Heesen<sup>1</sup>, K. Schreeb<sup>1</sup>, D. Schwarck-Kokarakis<sup>1</sup>, S. Kreiter<sup>1</sup>, M. Gaiser<sup>3</sup>, D. Jäger<sup>6</sup>, S. Grabbe<sup>2</sup>, Ö. Türeci<sup>7</sup>, U. Sahin<sup>1</sup>, <sup>1</sup>BioNTech AG, Mainz, DE, <sup>2</sup>Universitätsmedizin Mainz, Mainz, DE, <sup>3</sup>Universitätsklinikum Mannheim, Mannheim, DE, <sup>4</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>5</sup>University of Frankfurt, Frankfurt, DE, <sup>6</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, <sup>7</sup>Cluster for Individualized Immune Intervention, Mainz, DE

12:30 - 12:30 **1239TiP - MORPHEUS: a Phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types**

I. Chau<sup>1</sup>, G. Haag<sup>2</sup>, O. Rahma<sup>3</sup>, T. Macarulla<sup>4</sup>, S. Mccune<sup>5</sup>, D. Yardley<sup>6</sup>, B. Solomon<sup>7</sup>, M. Johnson<sup>8</sup>, G. Vidal<sup>9</sup>, P. Schmid<sup>10</sup>, G. Argiles<sup>11</sup>, K. Dimick<sup>12</sup>, S. Mahrus<sup>12</sup>, H. Abdullah<sup>12</sup>, X. He<sup>12</sup>, P. Sayyed<sup>12</sup>, H. Barak<sup>12</sup>, C. Bleul<sup>13</sup>, E. Cha<sup>12</sup>, A. Drakaki<sup>14</sup>, <sup>1</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>2</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>3</sup>Dana-Farber Cancer Institute, Boston, US, <sup>4</sup>Vall d'Hebron University Hospital (HUVH), Barcelona, ES, <sup>5</sup>Northwest Georgia Oncology Centers, Marietta, US, <sup>6</sup>Tennessee Oncology, Nashville, US, <sup>7</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>8</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>9</sup>University of Tennessee West Cancer Center, Germantown, US, <sup>10</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>11</sup>Vall d'Hebron Institute of



Oncology, VHIO, Barcelona, ES, <sup>12</sup>Genentech, Inc., South San Francisco, US, <sup>13</sup>F. Hoffmann-La Roche, Ltd, Basel, CH, <sup>14</sup>UCLA Medical Center, Los Angeles, US

- 12:30 - 12:30 **1240TiP - Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy**  
K. Lewis<sup>1</sup>, M. Fury<sup>2</sup>, E. Stankevich<sup>3</sup>, M. Mathias<sup>2</sup>, K.K. Mohan<sup>2</sup>, S. Li<sup>3</sup>, K. Nunnink<sup>2</sup>, C. Perry<sup>2</sup>, A. Narwal<sup>3</sup>, <sup>1</sup>University Of Colorado Hospital, Aurora, US, <sup>2</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US, <sup>3</sup>Regeneron Pharmaceuticals, Inc., Basking Ridge, US
- 12:30 - 12:30 **1241TiP - JAVELIN PARP Medley: a phase 1b/2 study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors**  
T. Yap<sup>1</sup>, J. Beck<sup>2</sup>, R. Stewart<sup>3</sup>, S. Dahm<sup>3</sup>, C. Chappey<sup>4</sup>, R. Cesari<sup>5</sup>, A. Scheuber<sup>6</sup>, M. Galsky<sup>7</sup>, D. Wise<sup>8</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>Highlands Oncology Group, Fayetteville, US, <sup>3</sup>Pfizer, San Diego, US, <sup>4</sup>Pfizer, San Francisco, US, <sup>5</sup>Pfizer Italy, Milano, IT, <sup>6</sup>Pfizer, Philadelphia, US, <sup>7</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, <sup>8</sup>NYU Laura and Isaac Perlmutter Cancer Center, New York, US
- 12:30 - 12:30 **1242TiP - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients with Solid Tumors**  
M. Butler<sup>1</sup>, H. Majeed<sup>2</sup>, M. Nelles<sup>2</sup>, S. Saibil<sup>2</sup>, L. Bonilla<sup>2</sup>, S. Boross-Harmer<sup>2</sup>, V. Sotov<sup>2</sup>, S. Elston<sup>2</sup>, K. Ross<sup>2</sup>, B. Van As<sup>2</sup>, M. Le<sup>2</sup>, M. Fyrsta<sup>2</sup>, C. Lo<sup>2</sup>, J. Yam<sup>2</sup>, J. Nie<sup>2</sup>, L. Scheid<sup>2</sup>, P. Ohashi<sup>3</sup>, L. Nguyen<sup>2</sup>, S. Tanaka<sup>4</sup>, N. Hirano<sup>2</sup>, <sup>1</sup>Princess Margaret Hospital, Toronto, CA, <sup>2</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>3</sup>Campbell Family Institute for Cancer Research, University Health Network, Toronto, CA, <sup>4</sup>Takara Bio Inc, Kusatsu, JP
- 12:30 - 12:30 **1243TiP - Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small-cell lung cancer (NSCLC) and other solid tumors**  
M. Johnson<sup>1</sup>, M. Patel<sup>2</sup>, S. Ulahannan<sup>3</sup>, A. Hansen<sup>4</sup>, B. George<sup>5</sup>, Q.S.-C. Chu<sup>6</sup>, M. Elgadi<sup>7</sup>, M. Ge<sup>8</sup>, C. Duffy<sup>8</sup>, R. Graeser<sup>9</sup>, S. Khedkar<sup>10</sup>, S. Jones<sup>11</sup>, H. Burris<sup>1</sup>, <sup>1</sup>Sarah Cannon Research Institute, Nashville, US, <sup>2</sup>U Minnesota Medical School, Minneapolis, US, <sup>3</sup>Sarah Cannon/Stephenson Cancer Center, Oklahoma City, US, <sup>4</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>5</sup>Medical College of Wisconsin, Milwaukee, US, <sup>6</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>7</sup>Boehringer Ingelheim (Canada) Ltd, Burlington, CA, <sup>8</sup>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, US, <sup>9</sup>Boehringer Ingelheim Pharma GmbH & Co. KG, Rhein, DE, <sup>10</sup>Sarah Cannon Development Innovations, Nashville, US, <sup>11</sup>Sarah Cannon, Nashville, US
- 12:30 - 12:30 **New diagnostic tools**
- 12:30 - 12:30 **1337P - Predictive models for CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?**



L. Jun<sup>1</sup>, Q. Chen<sup>1</sup>, L. Tang<sup>2</sup>, L. Yang<sup>3</sup>, E. Han<sup>4</sup>, Y. Chen<sup>5</sup>, L. Yuan<sup>6</sup>, <sup>1</sup>Sichuan Provincial People's Hospital, Chengdu, CN, <sup>2</sup>Fujian Provincial Cancer Hospital, Fuzhou, CN, <sup>3</sup>Yunnan Tumor Hospital Third Affiliated Hospital of Kunming Medical University, Kunming, CN, <sup>4</sup>Huangshi Central Hospital, Huangshi, CN, <sup>5</sup>Chengdu First People's Hospital, Chengdu, CN, <sup>6</sup>Tangdu Hospital, Xian, CN

12:30 - 12:30 **1338P - Tracking VSV-IFN<sub>γ</sub>-NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: the iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy**

J. Merchan<sup>1</sup>, M. Patel<sup>2</sup>, S. Powell<sup>3</sup>, J. Strauss<sup>4</sup>, T. Cripe<sup>5</sup>, M. Old<sup>6</sup>, R. Diaz<sup>7</sup>, S. Russell<sup>7</sup>, A. Bexon<sup>7</sup>, L. Suksanpaisan<sup>8</sup>, M. O'Connor<sup>9</sup>, K.W. Peng<sup>7</sup>, <sup>1</sup>U Miami School of Medicine, Miami, US, <sup>2</sup>U Minnesota Medical School, Minneapolis, US, <sup>3</sup>Sanford Health, Sioux Falls, US, <sup>4</sup>Mary Crowley Medical Research Center, Dallas, US, <sup>5</sup>Nationwide Children's Hospital, Columbus, US, <sup>6</sup>The Ohio State University, Columbus, US, <sup>7</sup>Vyriad, Rochester, US, <sup>8</sup>Imanis Life Sciences, Rochester, US, <sup>9</sup>Mayo Clinic, Rochester, US

12:30 - 12:30 **1339P - mRNA Expression of ER, PR, HER2 and Ki67 are Concordant to Central IHC and Predict Clinical Outcome: a Validation Study from the ABCSG-6 Biomarker Cohort**

M. Filipits<sup>1</sup>, M. Rudas<sup>1</sup>, C. Singer<sup>2</sup>, Z. Bago-Horvath<sup>3</sup>, R. Greil<sup>4</sup>, M. Balic<sup>5</sup>, S.F. Lax<sup>6</sup>, N. Wu<sup>7</sup>, S. Zhao<sup>7</sup>, J. Weidler<sup>7</sup>, M. Bates<sup>7</sup>, D. Hlauschek<sup>8</sup>, M. Gnant<sup>2</sup>, P. Dubsy<sup>9</sup>, <sup>1</sup>Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, <sup>2</sup>Medical University of Vienna, Vienna, AT, <sup>3</sup>Vienna General Hospital (AKH) - Medical University of Vienna, Vienna, AT, <sup>4</sup>Paracelsus Medical University Salzburg, Salzburg, AT, <sup>5</sup>Medical University Graz, Graz, AT, <sup>6</sup>Academic Teaching Hospital of the Medical University Graz, Graz, AT, <sup>7</sup>Cepheid, Sunnyvale, US, <sup>8</sup>Austrian Breast and Colorectal Cancer Study Group, Vienna, AT, <sup>9</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

12:30 - 12:30 **1340P - Clinical utility of complex multi-platform profiling in metastatic cancer patients**

J. Garcia Foncillas<sup>1</sup>, P. Aftimos<sup>2</sup>, P. Barthelemy<sup>3</sup>, J. Bellmunt<sup>4</sup>, G. Berchem<sup>5</sup>, C. Camps<sup>6</sup>, R. De Las Peñas<sup>7</sup>, A. Finzel<sup>8</sup>, J.P. Hervonen<sup>9</sup>, T. Joensuu<sup>10</sup>, A. Kong<sup>11</sup>, J. Mackay<sup>12</sup>, C. Mikropoulos<sup>13</sup>, K. Mokbel<sup>14</sup>, J.-L. Mouysset<sup>15</sup>, T. Perren<sup>16</sup>, G. Guitti<sup>8</sup>, J.-F. Laes<sup>8</sup>, <sup>1</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>2</sup>Institute Jules Bordet, Brussels, BE, <sup>3</sup>C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, <sup>4</sup>Hospital del Mar, Barcelona, ES, <sup>5</sup>Centre Hospitalier de Luxembourg, Luxembourg, LU, <sup>6</sup>Consorcio Hospital General Universitario de Valencia, Valencia, ES, <sup>7</sup>Consorcio Hospitalario Provincial de Castellón, Castellón, ES, <sup>8</sup>OncoDNA, Gosselies, BE, <sup>9</sup>Tampere University Hospital (Tays), Tampere, FI, <sup>10</sup>International Comprehensive Cancer Centre Docrates, Helsinki, FI, <sup>11</sup>The University of Birmingham Institute for Cancer Studies, Birmingham, GB, <sup>12</sup>University College London Cancer Institute, London, GB, <sup>13</sup>Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB, <sup>14</sup>The Princess Grace Hospital, London, GB, <sup>15</sup>Clinique Rambot-Provençale, Aix-en-Provence, FR, <sup>16</sup>St. James's University Hospital Leeds, Leeds, GB

12:30 - 12:30 **1341P - Comparison of Tissue-Based and Liquid Biopsy Genomic Tests to Guide Lung Cancer Therapy - Asian Experience**

M.-L. Nairismägi<sup>1</sup>, K.-C. Tung<sup>2</sup>, Y.-T. Yang<sup>2</sup>, Y.-J. Lu<sup>2</sup>, R.-S. Jhou<sup>2</sup>, P.-N. Yu<sup>2</sup>, Y.-T. Liu<sup>2</sup>, Y.-L.

Hsieh<sup>2</sup>, S.L. Poon<sup>1</sup>, S.-J. Chen<sup>2</sup>, K.T. Tan<sup>2</sup>, <sup>1</sup>ACT Genomics (Singapore) Pte Ltd, Singapore, SG, <sup>2</sup>ACT Genomics Co., Ltd., Taipei, TW

- 12:30 - 12:30 **1342P - 68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma and salivary duct carcinoma**  
W. Boxtel<sup>1</sup>, S. Lütje<sup>1</sup>, I. Van Engen-Van Grunsven<sup>1</sup>, G. Verhaegh<sup>1</sup>, J. Schalken<sup>2</sup>, M. Janssen<sup>1</sup>, J. Nagarajah<sup>1</sup>, M. Gotthardt<sup>1</sup>, C. Van Herpen<sup>2</sup>, <sup>1</sup>Radboudumc, Nijmegen, NL, <sup>2</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL
- 12:30 - 12:30 **1343P - Histology and detectability on ring-type dedicated breast PET in breast cancer**  
Y. Kimura<sup>1</sup>, S. Sasada<sup>2</sup>, N. Goda<sup>3</sup>, K. Kajitani<sup>3</sup>, A. Emi<sup>3</sup>, N. Masumoto<sup>3</sup>, T. Kadoya<sup>3</sup>, R. Haruta<sup>3</sup>, T. Kataoka<sup>3</sup>, M. Okada<sup>2</sup>, <sup>1</sup>Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JP, <sup>2</sup>Hiroshima University, Hiroshima, JP, <sup>3</sup>Hiroshima University Hospital, Hiroshima, JP
- 12:30 - 12:30 **1344P - Thermal Liquid Biopsy as a new tool for Lung Cancer patients diagnostic: pilot study**  
A. Rodrigo Cáceres<sup>1</sup>, O. Abian<sup>2</sup>, A. Velazquez-Campoy<sup>3</sup>, A. Callejo<sup>4</sup>, S. Vega<sup>5</sup>, A. Fernandez<sup>6</sup>, O. Sánchez-Gracia<sup>2</sup>, P. Iranzo Gomez<sup>7</sup>, M. Cruellas<sup>7</sup>, E. Quilez Bielsa<sup>7</sup>, D. Isla<sup>8</sup>, <sup>1</sup>Hospital Arnau de Vilanova, Lleida, ES, <sup>2</sup>IACS-ISS Aragón, Zaragoza, ES, <sup>3</sup>ARAID Foundation, Zaragoza, ES, <sup>4</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>5</sup>BIFI institute-University of Zaragoza, Zaragoza, ES, <sup>6</sup>Hospital Clínico Lozano Blesa, Zaragoza, ES, <sup>7</sup>Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, <sup>8</sup>Hospital Lozano Blesa, Zaragoza, ES
- 12:30 - 12:30 **1345P - Data-mining of 110 172 electronic patient records with the ConSoRe tool: An analysis of second primary cancer in a comprehensive cancer center**  
P. Heudel, T. Durand, B. Fervers, F. Gomez, M. Rivoire, T. Bachelot, L. Claude, C. Chassagne-Clement, F. Pilleul, T. Mognetti, Y. Devaux, J.-L. Soubirou, C. Lasset, D. Perol, G. Chvetzoff, C. Pezet, S. Beaupere, P. Zrounba, J. Blay, Centre Léon Bérard, Lyon, FR
- 12:30 - 12:30 **1346P - Real world cfDNA collection in EGFR-mutant NSCLC**  
N. Marcoux<sup>1</sup>, L. Sequist<sup>2</sup>, A. Hata<sup>2</sup>, M. Banwait<sup>2</sup>, I. Dagogo-Jack<sup>2</sup>, R. Nagy<sup>3</sup>, R. Lanman<sup>3</sup>, A. Muzikansky<sup>2</sup>, S.R. Digumarthy<sup>2</sup>, Z. Piotrowska<sup>2</sup>, <sup>1</sup>Centre Hospitalier Universitaire Pavillon l'Hôtel-Dieu de Quebec, Quebec, CA, <sup>2</sup>Massachusetts General Hospital, Boston, US, <sup>3</sup>Guardant Health, Redwood City, US
- 12:30 - 12:30 **1347TiP - Proof-of-concept study evaluating a new tool for standardising radiological assessment of tumour response to treatment in routine clinical practice**  
C. Mastier, C. De La Fouchardière, J. Fayette, M. Sarabi, P. Heudel, A. Coulon, N. Banaste, E. Mercier-Bischoff, M. Barma, M. Brahmi, P. Cassier, S. Couchon Thauat, L. Eberst, G. Fournier-Garin, P. Metral, F. Pilleul, J.-Y. Blay, Centre Léon Bérard, Lyon, FR
- 12:30 - 12:50 **NSCLC, early stage**

- 12:50 - 12:50 **1351P - Impact of the 8th edition AJCC classification in early stage lung cancer**  
A.S. Cortegoso Mosquera<sup>1</sup>, M. Vieito Villar<sup>1</sup>, C. Rodriguez Lopez<sup>1</sup>, V. Varela Pose<sup>1</sup>, V. Cebey Lopez<sup>1</sup>, J. Alvarez Fernandez<sup>1</sup>, M. Perez Martelo<sup>1</sup>, S. Aguin Losada<sup>1</sup>, U. Anido Herranz<sup>2</sup>, L. Leon Mateos<sup>1</sup>, F.J. Baron Duarte<sup>3</sup>, J.J. Garcia Gonzalez<sup>1</sup>, <sup>1</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>2</sup>Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, ES, <sup>3</sup>Complejo hospitalario universitario A Coruña, A Coruña, ES
- 12:50 - 12:50 **1352P - A Serum miRNA Biomarker Panel for the Detection of Early Stage Non-Small Cell Lung Cancer**  
L. Ying<sup>1</sup>, R. Zou<sup>2</sup>, L. Du<sup>3</sup>, L. Shi<sup>1</sup>, N. Zhang<sup>1</sup>, J. Jin<sup>1</sup>, J. Wu<sup>1</sup>, F. Zhang<sup>1</sup>, K. Chen<sup>1</sup>, M. Huang<sup>1</sup>, Y. Zhang<sup>4</sup>, A. Lin<sup>5</sup>, H. Yu<sup>6</sup>, L. Zhou<sup>2</sup>, W. Mao<sup>7</sup>, D. Su<sup>8</sup>, <sup>1</sup>Zhejiang cancer research institution, Hangzhou, CN, <sup>2</sup>MIRXES(hangzhou) biotechnology Co, hangzhou, CN, <sup>3</sup>Zhejiang Cancer Center, Hangzhou, CN, <sup>4</sup>Department of Clinical Laboratory, Hangzhou, CN, <sup>5</sup>Human Tissue Bank/Medical Research Center, taizhou, CN, <sup>6</sup>University of Hawaii Cancer Center, hawaii, US, <sup>7</sup>Department of Thoracic Surgery, hangzhou, CN, <sup>8</sup>Department of Pathology, hangzhou, CN
- 12:50 - 12:50 **1353P - Split-lobe resections versus lobectomy for stage IA-IB peripheral non-small cell lung cancer.**  
A. Levitckii<sup>1</sup>, D. Chichevatov<sup>2</sup>, M. Ter-Ovanesov<sup>1</sup>, E. Sinev<sup>2</sup>, <sup>1</sup>City clinical hospital No. 40, Moscow, RU, <sup>2</sup>Regional cancer center, Penza, RU
- 12:50 - 12:50 **1354P - Patient reported outcomes after the treatment of early stage non-small cell lung cancer by stereotactic body radiotherapy compared to surgery.**  
L. Alberts<sup>1</sup>, H. Wolff<sup>2</sup>, E.A. Kastelijn<sup>3</sup>, F.J. Lagerwaard<sup>2</sup>, S. Senan<sup>2</sup>, S.Y. El Sharouni<sup>4</sup>, F. Schramel<sup>3</sup>, V. Coupe<sup>2</sup>, <sup>1</sup>St. Antonius Ziekenhuis, Utrecht, NL, <sup>2</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>3</sup>St. Antonius Ziekenhuis, Nieuwegein, NL, <sup>4</sup>University Medical Center Utrecht, Utrecht, NL
- 12:50 - 12:50 **1355P - miR-200s in operated NSCLC: main drivers of epithelial to mesenchymal transition and independent prognostic factors**  
A. Legras, Assistance Publique - Hopitaux De Paris, Paris, FR
- 12:50 - 12:50 **1356P - The level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small-cell-lung-cancer**  
E. Picard<sup>1</sup>, Y. Godet<sup>1</sup>, C. Laheurte<sup>1</sup>, L. Boullerot<sup>1</sup>, E. Lauret Marie Joseph<sup>1</sup>, M. Jacquin<sup>2</sup>, V. Kaulek<sup>3</sup>, G. Eberst<sup>3</sup>, B. Gaugler<sup>1</sup>, P. Jacoulet<sup>4</sup>, M. Gainet-Brun<sup>4</sup>, J. Lahoucarde<sup>4</sup>, H. Almotlak<sup>5</sup>, F. Le Pimpec-Barthes<sup>6</sup>, E. Fabre-Guillevin<sup>7</sup>, C. Borg<sup>5</sup>, V. Westeel<sup>5</sup>, O. Adotevi<sup>1</sup>, <sup>1</sup>UMR1098, Besançon, FR, <sup>2</sup>CIC-1431, University Hospital of Besançon, F-25000 Besançon, France, Besançon, FR, <sup>3</sup>University Hospital of Besançon, Department of Pneumology, F-25000 Besançon, France, Besançon, FR, <sup>4</sup>University Hospital of Besançon, Department of Pneumology, Besançon, FR, <sup>5</sup>CHU Besançon, Hôpital Jean Minjot, Besançon, FR, <sup>6</sup>Service de Chirurgie Thoracique, AP-HP, Hôpital Européen Georges Pompidou, Paris, France, Paris, FR, <sup>7</sup>Dr. Elizabeth Fabre-Guillevin, La Défense, FR
- 12:50 - 12:50 **1357P - A positive correlation between the EZH2 and PD-L1 expression in**



**patients with resected lung adenocarcinoma**

G. Toyokawa<sup>1</sup>, K. Takada<sup>2</sup>, R. Hamamoto<sup>3</sup>, Y. Yamada<sup>2</sup>, T. Tagawa<sup>2</sup>, F. Shoji<sup>4</sup>, K. Yamazaki<sup>4</sup>, Y. Oda<sup>2</sup>, S. Takeo<sup>4</sup>, <sup>1</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>2</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, <sup>3</sup>Division of Molecular Modification and Cancer Biology, Tokyo, JP, <sup>4</sup>National Hospital Organization, Kyushu Medical Center, Fukuoka, JP

12:50 - 12:50 **1358P - Comprehensive analysis for immune profiles of tumor microenvironment in non-small cell lung cancers: Prognostic effect of immunomodulatory molecules**

K. Takamochi<sup>1</sup>, M. Hosoya<sup>2</sup>, K. Mogushi<sup>2</sup>, T. Hayashi<sup>3</sup>, M. Ito<sup>4</sup>, H. Kawaji<sup>5</sup>, Y. Hayashizaki<sup>5</sup>, K. Suzuki<sup>6</sup>, <sup>1</sup>Juntendo University International Center (JUIC), Tokyo, JP, <sup>2</sup>Juntendo University Graduate School of Medicine, Tokyo, JP, <sup>3</sup>Juntendo University School of Medicine, Tokyo, JP, <sup>4</sup>RIKEN Advanced Center for Computing and Communication, Tokyo, JP, <sup>5</sup>RIKEN Advanced Center for Computing and Communication, Yokohama, JP, <sup>6</sup>Juntendo University, Tokyo, JP

12:50 - 12:50 **1359P - Association between PD-L1 expression and survival in early-stage non-small cell carcinoma**

E. Gálvez<sup>1</sup>, C. Gálvez Muñoz<sup>2</sup>, A. Cotes Sanchís<sup>1</sup>, A. Gonzaga López<sup>1</sup>, M.M. Llorente Ostiategui<sup>1</sup>, M. Montero Gómez<sup>1</sup>, I. Aranda López<sup>2</sup>, C. Llorca Ferrandiz<sup>1</sup>, <sup>1</sup>Hospital General de Elda, Elda, ES, <sup>2</sup>Hospital General de Alicante, Alicante, ES

12:50 - 12:50 **1360P - Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC) - initial report of a phase I study, MK3475-223**

A. Ben Nun, N. Golan, E. Ofek, D. Urban, I. Kamer, D. Simansky, A. Onn, A. Ackerstein, S. Raskin, T. Shulimzon, N. Zeitlin, I. Redinsky, S. Halperin, M. Jurkowicz, J. Bar, Chaim Sheba Medical Center, Ramat Gan, IL

12:50 - 12:50 **1361P - Neoadjuvant chemotherapy with bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer: survival results from a phase II feasibility study (NAVAL)**

Y. Tsutani<sup>1</sup>, Y. Miyata<sup>1</sup>, K. Suzuki<sup>2</sup>, K. Takamochi<sup>2</sup>, F. Tanaka<sup>3</sup>, H. Nakayama<sup>4</sup>, Y. Yamashita<sup>5</sup>, M. Oda<sup>6</sup>, M. Tsuboi<sup>7</sup>, M. Okada<sup>1</sup>, <sup>1</sup>Hiroshima University, Hiroshima, JP, <sup>2</sup>Juntendo University, Tokyo, JP, <sup>3</sup>University of Occupational and Environmental Health, Kokura, JP, <sup>4</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>5</sup>Kure Medical Center, Kure, JP, <sup>6</sup>Kanazawa University, Kanazawa, JP, <sup>7</sup>National Cancer Center Hospital East, Kashiwa, JP

12:50 - 12:50 **1362P - Clinical outcomes and treatment strategies of sarcomatoid carcinoma of the lung**

Y. Wang, Hebei Provincial Tumor Hospital, Shijiazhuang, CN

12:50 - 12:50 **NSCLC, locally advanced**

12:50 - 12:50 **1366P - The impact of the new TNM classification on survival of patients in stage III non-small cell lung cancer**



M. Vrankar<sup>1</sup>, K. Stanic<sup>2</sup>, <sup>1</sup>Institute of Oncology Ljubljana, Ljubljana, SI, <sup>2</sup>Institute of Oncology, Ljubljana, SI

- 12:50 - 12:50 **1367P - Survival in never-smokers with non-small cell lung cancer: A population-based study from Sweden**  
L. Löfling<sup>1</sup>, S. Bahmanyar<sup>1</sup>, A. Karimi<sup>2</sup>, H. Kieler<sup>1</sup>, M. Lambe<sup>3</sup>, K. Lamberg Lundström<sup>4</sup>, F. Sandin<sup>5</sup>, G. Wagenius<sup>6</sup>, <sup>1</sup>Karolinska Institute, Stockholm, SE, <sup>2</sup>University Hospital Uppsala, Uppsala, SE, <sup>3</sup>Karolinska Institute, Solna, SE, <sup>4</sup>University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE, <sup>5</sup>Regional Oncologic Centre, Uppsala, SE, <sup>6</sup>Karolinska University Hospital, Solna, SE
- 12:50 - 12:50 **1368P - Clinical Features and Prognosis of Eighty-five Patients with Primary Pulmonary Lymphoepithelioma-like Carcinoma**  
Q. Yin, G. Gao, C. Zhou, Z. Zhu, Y. Liu, X. Xie, X. Lin, Z. Xie, J. Zhang, O. Ming, S. Li, R. Chen, The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 12:50 - 12:50 **1369P - Meta-analysis of prognostic factors of completely resected pathologic N2 stage IIIA non-small cell lung cancer: including 11,384 patients.**  
X. Zhan<sup>1</sup>, N. Li<sup>2</sup>, <sup>1</sup>Xiangya Hospital, Central South University, Changsha, CN, <sup>2</sup>Private Practice, Guangzhou, CN
- 12:50 - 12:50 **1370P - The results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy**  
E. Rodionov<sup>1</sup>, S. Miller<sup>1</sup>, S. Tuzikov<sup>2</sup>, M. Tsyganov<sup>2</sup>, N. Litviakov<sup>3</sup>, L. Efteev<sup>1</sup>, I. Deriusheva<sup>4</sup>, <sup>1</sup>Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RU, <sup>2</sup>Tomsk Cancer Research Institute, Tomsk, RU, <sup>3</sup>Tomsk Cancer Research Institute RAMS, Tomsk, RU, <sup>4</sup>Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RU
- 12:50 - 12:50 **1371P - Final results of RENO study: randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC. SLCG 10/02**  
M. Provencio Pulla<sup>1</sup>, R. De Las Peñas<sup>2</sup>, N. Martinez Banaclocha<sup>3</sup>, R. Marsé Fabregat<sup>4</sup>, A. Insa Molla<sup>5</sup>, T. Moran<sup>6</sup>, M.A. Sala Gonzalez<sup>7</sup>, B. Massuti Sureda<sup>8</sup>, P. Mut Sanchis<sup>9</sup>, A.L. Ortega Granados<sup>10</sup>, J.M. Jurado<sup>11</sup>, J. Gomez Codina<sup>12</sup>, A. Artal-Cortes<sup>13</sup>, F. Vazquez<sup>14</sup>, V. Gutierrez Calderon<sup>15</sup>, P. Diz Tain<sup>16</sup>, N. Vinolas Segarra<sup>17</sup>, I. Maestu Maiques<sup>18</sup>, C. Camps<sup>19</sup>, M.D. Isla Casado<sup>20</sup>, <sup>1</sup>Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, ES, <sup>2</sup>Consortio Hospitalario Provincial de Castellón, Castellón, ES, <sup>3</sup>Hospital General Universitario de Elche, Elche, ES, <sup>4</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>5</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>6</sup>ICO Badalona, Badalona, ES, <sup>7</sup>Hospital de Basurto, Bilbao, ES, <sup>8</sup>Hospital General Universitario de Alicante, Alicante, ES, <sup>9</sup>Private Practice, Palma de Mallorca, ES, <sup>10</sup>Complejo Hospitalario de Jaen Universidad de Jaen, Jaen, ES, <sup>11</sup>Hospital Clinico San Cecilio, Granada, ES, <sup>12</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>13</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>14</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>15</sup>JANSSEN SPAIN/AMEX BARCELO, Madrid, ES, <sup>16</sup>Hospital Universitario de León, Leon, ES, <sup>17</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>18</sup>Hospital Dr. Peset Aleixandre, Valencia, ES, <sup>19</sup>Consortio Hospital General Universitario de Valencia, Valencia, ES, <sup>20</sup>H. Clínico Zaragoza,

Zaragoza, ES

- 12:50 - 12:50 **1372P - Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018**  
Y. Takiguchi<sup>1</sup>, K. Yamada<sup>2</sup>, H. Tanaka<sup>3</sup>, K. Kubota<sup>4</sup>, K. Kishi<sup>5</sup>, T. Shimokawa<sup>6</sup>, H. Saito<sup>7</sup>, Y. Hosomi<sup>8</sup>, T. Kato<sup>7</sup>, N. Nogami<sup>9</sup>, S. Igawa<sup>10</sup>, T. Kasai<sup>11</sup>, Y. Nakamura<sup>11</sup>, T. Yamanaka<sup>12</sup>, H. Okamoto<sup>6</sup>, <sup>1</sup>Chiba University, School of Medicine, Chiba, JP, <sup>2</sup>Kurume University, Kurume, JP, <sup>3</sup>No place of work provided, No City Provided, NA, <sup>4</sup>Nippon Medical School, Tokyo, JP, <sup>5</sup>Toranomon Hospital, Tokyo, JP, <sup>6</sup>Yokohama Municipal Citizen's Hospital, Yokohama, JP, <sup>7</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>8</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, <sup>9</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>10</sup>Kitasato University School of Medicine, Kanagawa, JP, <sup>11</sup>Tochigi Cancer Center, Utsunomiya, JP, <sup>12</sup>Yokohama City University Hospital, Yokohama, JP
- 12:50 - 12:50 **1373P - Identification of subjects with locally advanced lung cancer who are likely to respond to standard-of-care chemoradiotherapy by a longitudinal monitoring of circulating tumor DNA (ctDNA) using a comprehensive ultra-sensitive NGS assay**  
P. Vitazka<sup>1</sup>, N. Tikoo<sup>1</sup>, A. Balasubramanyam<sup>2</sup>, L. Xi<sup>1</sup>, S. Yaung<sup>1</sup>, E. Kwok<sup>2</sup>, A. Lovejoy<sup>1</sup>, D. Klass<sup>1</sup>, M. Heibeck<sup>3</sup>, K. Probst<sup>3</sup>, A. Rehfeldt<sup>3</sup>, E. Meldgaard<sup>4</sup>, A. Madsen<sup>4</sup>, M. Clement<sup>4</sup>, J. Palma<sup>1</sup>, B. Sorensen<sup>4</sup>, P. Meldgaard<sup>4</sup>, <sup>1</sup>F. Hoffmann LaRoche, Ltd, Pleasanton, US, <sup>2</sup>Roche Sequencing Solutions, Inc., Pleasanton, US, <sup>3</sup>Roche Sequencing Solutions, Inc., Potsdam, DE, <sup>4</sup>Aarhus University Hospital, Aarhus, DK
- 12:50 - 12:50 **1374P - Correlations between Ape1/Ref-1, ICAM-1 and IL-17A Levels in Serum and Radiation Pneumonitis for Local Advanced Non-small Cell Lung Cancer Patients**  
L. Guo, Henan Cancer Hospital, Zhengzhou, CN
- 12:50 - 12:50 **1375P - Programmed cell death ligand 1 expression and CD8 positive lymphocytes in stage III non-small cell lung cancer after neo adjuvant concurrent chemoradiotherapy and their relation with prognosis**  
E. Choe<sup>1</sup>, C. Yoon-Jin<sup>2</sup>, H.-S. Shim<sup>3</sup>, C.-Y. Lee<sup>3</sup>, B.C. Cho<sup>4</sup>, H.-R. Kim<sup>5</sup>, <sup>1</sup>Yonsei University, Seoul, KR, <sup>2</sup>Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, KR, <sup>3</sup>Yonsei University College of Medicine, Seoul, KR, <sup>4</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>5</sup>Yonsei Cancer Center, Seoul, KR
- 12:50 - 12:50 **1376P - The standard of care for stage III NSCLC in the era of Immunotherapy: an Italian National Survey on the current pattern of care among Italian Thoracic Oncologists**  
A. Bruni<sup>1</sup>, F. Grossi<sup>2</sup>, F. Katia<sup>3</sup>, E. Capelletto<sup>4</sup>, L. Buffoni<sup>5</sup>, S. Badellino<sup>5</sup>, V. Poletti<sup>6</sup>, R. Chiari<sup>7</sup>, N. Giaj Levra<sup>8</sup>, G.L. Banna<sup>9</sup>, S. Vagge<sup>2</sup>, P. Borghetti<sup>10</sup>, E. Baldini<sup>11</sup>, E. Bria<sup>12</sup>, M. Tiseo<sup>13</sup>, M. Paci<sup>14</sup>, P. Ciammella<sup>15</sup>, M. Taraborrelli<sup>16</sup>, U. Ricardi<sup>17</sup>, V. Scotti<sup>18</sup>, <sup>1</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>2</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>3</sup>Unit, "Careggi" University Hospital, Florence, IT, <sup>4</sup>Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, <sup>5</sup>University of Turin, AOU Città della Salute e della Scienza, Turin, IT, <sup>6</sup>"Morgagni-Pierantoni" Hospital, Forlì, IT, <sup>7</sup>Azienda Ospedaliera di Perugia S. Maria

della Misericordia, Perugia, IT, <sup>8</sup>“Sacro Cuore Don Calabria” Hospital, Verona, IT, <sup>9</sup>Cannizzaro Hospital, Catania, IT, <sup>10</sup>“Spedali Civili” University Hospital, Brescia, IT, <sup>11</sup>S. Luca Hospital, Lucca, IT, <sup>12</sup>Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario Agostino Gemelli, Rome, IT, <sup>13</sup>AOU di Parma, Parma, IT, <sup>14</sup>Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, IT, <sup>15</sup>AUSL-IRCCS of Reggio Emilia, Reggio Emilia, IT, <sup>16</sup>SS. Annunziata Hospital, G. D'Annunzio, Chieti, IT, <sup>17</sup>Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, IT, <sup>18</sup>University of Florence, Firenze, IT

12:50 - 12:50 **NSCLC, metastatic**

12:50 - 12:50 **1387P - Randomized, double-blind, placebo (P)-controlled phase 3 noninferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: an ad hoc subgroup analysis of pts with baseline hemoglobin (Hb)  $\geq$  10.0 g/dL**

D. Henry<sup>1</sup>, V. Hirsh<sup>2</sup>, K. Kubota<sup>3</sup>, T. Steinmetz<sup>4</sup>, G. Thomas<sup>5</sup>, J.-H. Kang<sup>6</sup>, D. Gordon<sup>7</sup>, S. Orlov<sup>8</sup>, A. Fleishman<sup>9</sup>, C. De Oliveira Brandao<sup>9</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, US, <sup>2</sup>McGill University Health Centre Royal Victoria Hospital, Montreal, CA, <sup>3</sup>Nippon Medical School, Tokyo, JP, <sup>4</sup>Onkologie Köln, Outpatient Clinic for Hematology and Oncology, Cologne, DE, <sup>5</sup>St Joseph's/Candler and Hilton Head Hospital Oncology, Hilton Head Island, US, <sup>6</sup>The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, KR, <sup>7</sup>US Oncology Research, San Antonio, US, <sup>8</sup>Pavlov Medical University, St. Petersburg, RU, <sup>9</sup>Amgen Inc., Thousand Oaks, US

12:50 - 12:50 **1388P - Incidence of cardiac toxicities in patients with advanced non-small-cell lung cancer treated with osimertinib: a combined analysis of two phase III randomized controlled trials**

K. Thein<sup>1</sup>, S. Swarup<sup>2</sup>, S. Ball<sup>2</sup>, M. Quirch<sup>2</sup>, Y. Vorakunthada<sup>2</sup>, K. Htwe<sup>3</sup>, N. D'Cunha<sup>2</sup>, F. Hardwicke<sup>2</sup>, S. Awasthi<sup>2</sup>, L. Tijani<sup>2</sup>, <sup>1</sup>TEXAS TECH UNIVERSITY, Lubbock, US, <sup>2</sup>Texas Tech University Health Sciences Center, Lubbock, US, <sup>3</sup>Kingsbrook Jewish Medical Center, Brooklyn, US

12:50 - 12:50 **1389P - Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors**

G. Fucà<sup>1</sup>, M. Poggi<sup>2</sup>, G. Galli<sup>2</sup>, M. Imbimbo<sup>2</sup>, G. Lo Russo<sup>2</sup>, D. Signorelli<sup>2</sup>, M. Vitali<sup>1</sup>, M. Ganzinelli<sup>2</sup>, N. Zilembo<sup>1</sup>, F. De Braud<sup>2</sup>, M. Garassino<sup>3</sup>, C. Proto<sup>1</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

12:50 - 12:50 **1390P - Dose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: data from ALTER0303**

L. Zhang<sup>1</sup>, X. Si<sup>1</sup>, H. Wang<sup>1</sup>, X. Zhang<sup>1</sup>, M. Wang<sup>1</sup>, B. Han<sup>2</sup>, K. Li<sup>3</sup>, Q. Wang<sup>4</sup>, J. Shi<sup>5</sup>, Z. Wang<sup>6</sup>, Y. Cheng<sup>7</sup>, J. He<sup>8</sup>, Y. Shi<sup>9</sup>, W. Chen<sup>10</sup>, X. Wang<sup>11</sup>, Y. Luo<sup>12</sup>, K. Nan<sup>13</sup>, F. Jin<sup>14</sup>, B. Li<sup>15</sup>, Y. Chen<sup>16</sup>, <sup>1</sup>Peking Union Medical College Hospital, Beijing, CN, <sup>2</sup>Shanghai Chest Hospital, Shanghai, CN, <sup>3</sup>Tianjin Medical University Cancer Hospital, Tianjin, CN, <sup>4</sup>Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>5</sup>Linyi City Tumor Hospital, Linyi, CN, <sup>6</sup>Shandong Province Tumor Hospital, Jinan, CN, <sup>7</sup>Jilin Province Tumor Hospital, Changchun, CN, <sup>8</sup>First Affiliated



Hospital of Guangzhou Medical University, Guangzhou, CN, <sup>9</sup>Chinese Academy of Medical Sciences Cancer Hospital, Beijing, CN, <sup>10</sup>Lanzhou Military General Hospital, Lanzhou, CN, <sup>11</sup>Qilu Hospital, Shandong University, Jinan, CN, <sup>12</sup>Hunan Province Tumor Hospital, Changsha, CN, <sup>13</sup>First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), Xi'an, CN, <sup>14</sup>Tangdu Hospital, Xi'an, CN, <sup>15</sup>Beijing Chest Hospital, Capital Medical University, Beijing, CN, <sup>16</sup>Jiangxi Province Tumor Hospital, Nanchang, CN

12:50 - 12:50 **1391P - Immune-Related Adverse Events (irAEs) and Survival (OS) in Metastatic Non-small Cell Lung Cancer (mNSCLC) Patients (pts) Treated With Immunotherapy**

M. Melià Sosa<sup>1</sup>, C. Puchades<sup>1</sup>, J. Mendez<sup>1</sup>, A. Torres<sup>1</sup>, C. Rodrigo<sup>1</sup>, G. Gimeno<sup>1</sup>, E. Rama<sup>1</sup>, A. Martínez-Castillo<sup>1</sup>, J. Caballero Daroqui<sup>1</sup>, J. Gomez Codina<sup>1</sup>, O. Juan-Vidal<sup>2</sup>, D. Lorente<sup>3</sup>, <sup>1</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>2</sup>La Fe University Hospital, Valencia, ES, <sup>3</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

12:50 - 12:50 **1392P - Dose-determination results from a Phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)**

A. Santoro<sup>1</sup>, W.-C. Su<sup>2</sup>, A. Navarro<sup>3</sup>, M. Simonelli<sup>1</sup>, J.C.-H. Yang<sup>4</sup>, A. Ardizzoni<sup>5</sup>, F. Barlesi<sup>6</sup>, J.H. Kang<sup>7</sup>, S. Didominick<sup>8</sup>, A. Abdelhady<sup>9</sup>, B. Goswami<sup>8</sup>, A. Crystal<sup>8</sup>, E. Felip<sup>3</sup>, <sup>1</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>2</sup>National Cheng University Hospital, Tainan, TW, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>National Taiwan University Hospital, Taipei, TW, <sup>5</sup>S.Orsola-Malpighi Hospital, Bologna, IT, <sup>6</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>7</sup>The Catholic University of Korea, Seoul, KP, <sup>8</sup>Novartis Pharmaceutical Corporations, Cambridge, US, <sup>9</sup>Novartis Pharmaceutical Corporations, Hyderabad, IN

12:50 - 12:50 **1393P - Safety profile and effectiveness of alectinib in the real world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer**

Y. Ohe<sup>1</sup>, N. Yamamoto<sup>2</sup>, A. Gemma<sup>3</sup>, M. Kusumoto<sup>4</sup>, I. Yamada<sup>5</sup>, T. Ishii<sup>6</sup>, N. Masuda<sup>7</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Wakayama Medical University, Wakayama, JP, <sup>3</sup>Nippon Medical School, Tokyo, JP, <sup>4</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>5</sup>Chugai Pharmaceutical Co.,Ltd., Chuo-ku, Tokyo, JP, <sup>6</sup>Chugai Pharmaceutical Co., Ltd., Tokyo, JP, <sup>7</sup>Kitasato University School of Medicine, Kanagawa, JP

12:50 - 12:50 **1394P - A multicenter study of mutational profiling of Chinese ALK+ non-small cell lung cancer patients with required resistant to crizotinib using next generation sequencing**

C. Xu<sup>1</sup>, W. Wang<sup>2</sup>, W. Zhuang<sup>1</sup>, Z. Song<sup>2</sup>, Y. Zhu<sup>3</sup>, G. Chen<sup>1</sup>, M. Fang<sup>2</sup>, T. Lv<sup>4</sup>, Y. Song<sup>4</sup>, <sup>1</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>2</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>3</sup>Zhejiang Rongjun Hospital, Jiaxing, CN, <sup>4</sup>Jinling Hospital, Nanjing, CN

12:50 - 12:50 **1395P - Lung cancers carrying distinct ALK fusion variants demonstrate similar responsiveness to ALK tyrosine kinase inhibitors**

E. Imyanitov<sup>1</sup>, N. Mitiushkina<sup>1</sup>, V. Tiurin<sup>1</sup>, A. Iyevleva<sup>1</sup>, M. Holmatov<sup>1</sup>, E. Filippova<sup>2</sup>, F. Moiseyenko<sup>3</sup>, N. Levchenko<sup>1</sup>, S. Odintsova<sup>2</sup>, A. Lozhkina<sup>2</sup>, A. Togo<sup>1</sup>, N. Karaseva<sup>4</sup>, V. Moiseyenko<sup>5</sup>, S. Orlov<sup>6</sup>, <sup>1</sup>N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, <sup>2</sup>Pavlov



State Medical University, Saint Petersburg, RU, <sup>3</sup>St.-Petersburg City Cancer Center, St.-Petersburg, RU, <sup>4</sup>City Clinical Oncology Dispensary, Saint Petersburg, RU, <sup>5</sup>Petrov Research Institute of Oncology, Saint Petersburg, RU, <sup>6</sup>St. Petersburg State Medical University, Saint Petersburg, RU

12:50 - 12:50

**1396P - Efficacy and Safety of Crizotinib in Previously Treated Patients (Pts) with ALK+ Advanced Non-Small-Cell Lung Cancer (NSCLC) aged  $\geq$  65 years (y)**

D. Moro-Sibilot<sup>1</sup>, M.-J. Ahn<sup>2</sup>, B. Halmos<sup>3</sup>, D.-W. Kim<sup>4</sup>, G. Riely<sup>5</sup>, A. Shaw<sup>5</sup>, P.-C. Yang<sup>6</sup>, S. Lanzalone<sup>7</sup>, A. Polli<sup>7</sup>, K. Wilner<sup>8</sup>, J. De Castro Carpeño<sup>9</sup>, <sup>1</sup>Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, FR, <sup>2</sup>Samsung Medical Center, Seoul, KR, <sup>3</sup>Albert Einstein College of Medicine, New York, US, <sup>4</sup>Seoul National University Hospital, Seoul, KR, <sup>5</sup>Massachusetts General Hospital, Boston, US, <sup>6</sup>National Taiwan University Hospital, Taipei, TW, <sup>7</sup>Pfizer Oncology, Milan, IT, <sup>8</sup>Pfizer Oncology, La Jolla, US, <sup>9</sup>Hospital Universitario La Paz, Madrid, ES

12:50 - 12:50

**1397P - Long-Term Safety of Crizotinib in Previously Treated Patients (Pts) with ALK-positive Advanced/Metastatic Non-Small-Cell Lung Cancer (NSCLC)**

L. Crinò<sup>1</sup>, M.-J. Ahn<sup>2</sup>, J.-Y. Han<sup>3</sup>, X. Liu<sup>4</sup>, S.-H. Ou<sup>5</sup>, A. Shaw<sup>6</sup>, P.-C. Yang<sup>7</sup>, Y.-K. Shi<sup>8</sup>, S. Lanzalone<sup>9</sup>, A. Polli<sup>9</sup>, K. Wilner<sup>10</sup>, D.-W. Kim<sup>11</sup>, <sup>1</sup>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST)- IRCCS, Meldola, IT, <sup>2</sup>Samsung Medical Center, Seoul, KR, <sup>3</sup>National Cancer Center, Goyang, KR, <sup>4</sup>The 307 Hospital of Chinese People's Liberation Army, Beijing, CN, <sup>5</sup>Chao Family Comprehensive Cancer Center, Irvine, US, <sup>6</sup>Massachusetts General Hospital, Boston, US, <sup>7</sup>National Taiwan University Hospital, Taipei, TW, <sup>8</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>9</sup>Pfizer Oncology, Milan, IT, <sup>10</sup>Pfizer Oncology, La Jolla, US, <sup>11</sup>Seoul National University Hospital, Seoul, KR

12:50 - 12:50

**1398P - Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC)**

M. Jahanzeb<sup>1</sup>, H. Lin<sup>2</sup>, X. Pan<sup>2</sup>, Y. Yin<sup>2</sup>, P. Hou<sup>2</sup>, B. Nordstrom<sup>3</sup>, A. Desai<sup>2</sup>, M. Socinski<sup>4</sup>, <sup>1</sup>University of Miami, Deerfield Beach, US, <sup>2</sup>Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, US, <sup>3</sup>Evidera, Waltham, US, <sup>4</sup>Florida Hospital Cancer Institute, Orlando, US

12:50 - 12:50

**1399P - Impact of Lorlatinib on Patient-Reported Outcomes (PROs) in Patients (Pts) With Advanced ALK+ or ROS1+ Non-Small Cell Lung Cancer (NSCLC)**

S. Peters<sup>1</sup>, A. Shaw<sup>2</sup>, B. Besse<sup>3</sup>, E. Felip<sup>4</sup>, B. Solomon<sup>5</sup>, R. Soo<sup>6</sup>, A. Bearz<sup>7</sup>, S. Gadgeel<sup>8</sup>, C.-C. Lin<sup>9</sup>, S. Kao<sup>10</sup>, T. Seto<sup>11</sup>, E. Masters<sup>12</sup>, A. Abbattista<sup>13</sup>, J. Clancy<sup>14</sup>, H. Thurm<sup>15</sup>, A. Reisman<sup>16</sup>, D.R. Camidge<sup>17</sup>, <sup>1</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>2</sup>Massachusetts General Hospital, Boston, US, <sup>3</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>6</sup>National University Hospital, Singapore, SG, <sup>7</sup>National Institute for Cancer Research, Aviano, IT, <sup>8</sup>University of Michigan, Ann Arbor, US, <sup>9</sup>National Taiwan University Hospital, Taipei city, TW, <sup>10</sup>Chris O'Brien Lifehouse, Camperdown, AU, <sup>11</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>12</sup>Pfizer Oncology, New York, US, <sup>13</sup>Pfizer Oncology, Milan, IT, <sup>14</sup>Pfizer Oncology, Cambridge, US, <sup>15</sup>Pfizer Oncology, La Jolla, US, <sup>16</sup>Pfizer Global Product Development, New York, US, <sup>17</sup>University of Colorado, Aurora, US

- 12:50 - 12:50 **1401P - The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey**  
S. Kilickap<sup>1</sup>, Ö. Ölmez<sup>2</sup>, I. Cicin<sup>3</sup>, U. Demirci<sup>4</sup>, O. Alan<sup>5</sup>, D. Cabuk<sup>6</sup>, T. Şakalar<sup>7</sup>, A. Tatlı<sup>8</sup>, F. Başol Buğdaycı<sup>9</sup>, Y. Eralp<sup>10</sup>, M. Uysal<sup>11</sup>, A. Demirkazık<sup>12</sup>, B. Bilgin<sup>13</sup>, B. Yıldız<sup>14</sup>, M. Karaağaç<sup>15</sup>, K. Okutur<sup>16</sup>, A. Sakin<sup>17</sup>, <sup>1</sup>Hacettepe University Faculty of Medicine, Ankara, TR, <sup>2</sup>Medipol University, Istanbul, TR, <sup>3</sup>Trakya University Faculty of Medicine, Edirne, TR, <sup>4</sup>Dr. Abdurrahman Yurtaslan Ankara Onkoloji Training and Research Hospital, Ankara, TR, <sup>5</sup>Marmara University Hospital, Istanbul, TR, <sup>6</sup>Kocaeli University, Kocaeli, TR, <sup>7</sup>Erciyes University School of Medicine, Kayseri, TR, <sup>8</sup>Akdeniz University Faculty of Medicine, Antalya, TR, <sup>9</sup>Sanatoryum Chest Disease Hospital, Ankara, TR, <sup>10</sup>Istanbul University Faculty of Medicine, İstanbul, TR, <sup>11</sup>Afyon Kocatepe University Faculty of Medicine, Afyon, TR, <sup>12</sup>Ankara University faculty of Medicine, Ankara, TR, <sup>13</sup>Yildirim Beyazıt University Faculty of Medicine, Ankara, TR, <sup>14</sup>Gulhane Education and Research Hospital, Ankara, TR, <sup>15</sup>Meram University Faculty of Medicine, Konya, TR, <sup>16</sup>MedicalPark Hospitals, İstanbul, TR, <sup>17</sup>Okmeydanı Education and Research Hospital, Istanbul, TR
- 12:50 - 12:50 **1402P - Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer**  
D. Harada<sup>1</sup>, A. Hata<sup>2</sup>, C. Okuda<sup>3</sup>, R. Kaji<sup>3</sup>, Y. Masuda<sup>3</sup>, Y. Takechi<sup>4</sup>, T. Kozuki<sup>1</sup>, N. Nogami<sup>1</sup>, N. Katakami<sup>3</sup>, <sup>1</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>2</sup>Institute of Biomedical Research and Innovation, Kobe, JP, <sup>3</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>4</sup>National Hospital Organization Shikoku Cancer Center, Matsuyama, JP
- 12:50 - 12:50 **1403P - Open-label multicenter randomized phase II study of docetaxel plus bevacizumab or pemetrexed plus bevacizumab for elderly (>75 years old) patients (pts) with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC): TORG1323**  
T. Honda<sup>1</sup>, T. Kouzuki<sup>2</sup>, Y. Tsunozuka<sup>3</sup>, N. Seki<sup>1</sup>, T. Shibayama<sup>4</sup>, T. Okimoto<sup>5</sup>, H. Taniguchi<sup>6</sup>, Y. Takeda<sup>7</sup>, N. Hata<sup>8</sup>, K. Sugimoto<sup>9</sup>, N. Takahashi<sup>10</sup>, K. Sakai<sup>11</sup>, T. Nishimura<sup>12</sup>, S. Ikeda<sup>13</sup>, S. Watanabe<sup>14</sup>, K. Mori<sup>15</sup>, T. Shinkai<sup>16</sup>, <sup>1</sup>Teikyo University, Tokyo, JP, <sup>2</sup>Shikoku Cancer Center, Ehime, JP, <sup>3</sup>Ishikawa Prefectural Central Hospital, Ishikawa, JP, <sup>4</sup>Okayama Medical Center, Okayama, JP, <sup>5</sup>Shimane University Faculty of Medicine, Shimane, JP, <sup>6</sup>Toyama Prefectural Central Hospital, Toyama, JP, <sup>7</sup>Center Hospital of the National Center for Global Health and Medicine, Tokyo, JP, <sup>8</sup>Kawaguchi Municipal Medical Center, Saitama, JP, <sup>9</sup>Japanese Red Cross Kobe Hospital, Hyogo, JP, <sup>10</sup>University Itabashi Hospital, Tokyo, JP, <sup>11</sup>Saitama Medical Center, Saitama, JP, <sup>12</sup>Kyoto Katsura Hospital, Kyoto, JP, <sup>13</sup>Kanagawa Cardiovascular and Respiratory Center, Kanagawa, JP, <sup>14</sup>Niigata University Medical & Dental Hospital, Niigata, JP, <sup>15</sup>Jizankai Medical Foundation Tsuboi Cancer Center Hospital, Fukushima, JP, <sup>16</sup>Shonan East General Hospital, Kanagawa, JP
- 12:50 - 12:50 **1404P - Safety of Nintedanib plus Docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: the preliminary results of the SENECA (SEcond line NintEdanib in non-small cell lung Cancer) trial**  
A.M. Morelli<sup>1</sup>, M.R. Migliorino<sup>2</sup>, A. Morabito<sup>3</sup>, R. Chiari<sup>4</sup>, F. Grossi<sup>5</sup>, P. Bordi<sup>6</sup>, F. Di Costanzo<sup>7</sup>, A. Delmonte<sup>8</sup>, G. Romano<sup>9</sup>, A. Misino<sup>10</sup>, V. Scotti<sup>11</sup>, V. Gregorc<sup>12</sup>, S. Pisconti<sup>13</sup>, G.L. Ceresoli<sup>14</sup>, A. Del Conte<sup>15</sup>, I. Colantonio<sup>16</sup>, L. Ciuffreda<sup>17</sup>, E.

Capelletto<sup>18</sup>, I. Stura<sup>19</sup>, S. Novello<sup>20</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, <sup>2</sup>Azienda Ospedaliera S. Camillo Forlanini, Roma, IT, <sup>3</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>4</sup>Azienda Ospedaliera di Perugia S. Maria della Misericordia, Perugia, IT, <sup>5</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>6</sup>Azienda Ospedaliera di Parma, Parma, IT, <sup>7</sup>Careggi, Firenze, IT, <sup>8</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>9</sup>Ospedale Vito Fazzi, Lecce, IT, <sup>10</sup>Istituto Tumori Giovanni Paolo II, Bari, IT, <sup>11</sup>University of Florence, Firenze, IT, <sup>12</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>13</sup>Ospedale S. Giuseppe Moscati, Statte, IT, <sup>14</sup>Humanitas Gavazzeni, Bergamo, IT, <sup>15</sup>Azienda Ospedaliera Sta Maria degli Angeli, Pordenone, IT, <sup>16</sup>Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, <sup>17</sup>AOU S. Giovanni Battista - Molinette, Torino, IT, <sup>18</sup>AOU S LUIGI GONZAGA, Torino, IT, <sup>19</sup>University of Turin, Turin, IT, <sup>20</sup>Università Degli Studi Di Torino - Orbassano, Orbassano, IT

12:50 - 12:50

**1405P - Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): results from phase II trial (IFCT-1001 CHIVA)**

M. Wislez<sup>1</sup>, H. Blons<sup>2</sup>, C. Domblides<sup>3</sup>, F. Barlesi<sup>4</sup>, J. Mazieres<sup>5</sup>, I. Monnet<sup>6</sup>, L. Kiakouama Maleka<sup>7</sup>, X. Quantin<sup>8</sup>, L. Taillade<sup>9</sup>, H. Lena<sup>10</sup>, P. Fraisse<sup>11</sup>, H. Janicot<sup>12</sup>, C. Audigier Valette<sup>13</sup>, E. Amour<sup>14</sup>, A. Langlais<sup>15</sup>, N. Rabbe<sup>1</sup>, J. Cadranel<sup>1</sup>, P. Laurent Puig<sup>16</sup>, A. Lavolé<sup>17</sup>, <sup>1</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>2</sup>Hopital European George Pompidou, Paris, FR, <sup>3</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>4</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>5</sup>Hospital Larrey, Toulouse, FR, <sup>6</sup>CH Intercommunal de Créteil, Créteil, FR, <sup>7</sup>Hôpital de la Croix-Rousse, Lyon, FR, <sup>8</sup>Hopital Arnaud de Villeneuve, Montpellier, FR, <sup>9</sup>APHP, Pitie Salpetriere, Paris, FR, <sup>10</sup>CHU de Pontchaillou, Rennes, FR, <sup>11</sup>Hopital Civil, Str, FR, <sup>12</sup>University Hospital Center of Clermont-Ferrand, Clermont-Ferrand, FR, <sup>13</sup>Hospital Sainte Musse, Toulon, FR, <sup>14</sup>French Cooperative Thoracic Intergroup (IFCT), Paris, FR, <sup>15</sup>IFCT, Paris, FR, <sup>16</sup>Paris Descartes University, Paris, FR, <sup>17</sup>Hospital Tenon, APHP, Paris, FR

12:50 - 12:50

**1406P - Final results of the concordance analysis of PD-L1 immunohistochemistry (IHC) assays and polymerase chain reaction (PCR) in non-small lung cancer (NSCLC) patients**

I. Tsimafeyeu<sup>1</sup>, E. Imyanitov<sup>2</sup>, L. Zavalishina<sup>3</sup>, G. Raskin<sup>4</sup>, P. Povilaitite<sup>5</sup>, N. Savelov<sup>6</sup>, E. Kharitonova<sup>1</sup>, A. Rummyantsev<sup>7</sup>, I. Pugach<sup>1</sup>, Y. Andreeva<sup>3</sup>, A. Petrov<sup>5</sup>, G. Frank<sup>3</sup>, S. Tjulandin<sup>7</sup>, <sup>1</sup>Russian Society of Clinical Oncology, Moscow, RU, <sup>2</sup>N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, <sup>3</sup>Russian Medical Academy of Continuous Professional Education, Moscow, RU, <sup>4</sup>A.M. Granov Russian Scientific Centre of Radiology and Surgical Technologies, Saint-Petersburg, RU, <sup>5</sup>Rostov Regional Bureau of Pathology, Rostov-on-Don, RU, <sup>6</sup>Moscow City Oncology Hospital No. 62, Moscow, RU, <sup>7</sup>N.N. Blokhin Russian Cancer Research Center, Moscow, RU

12:50 - 12:50

**1407P - Derived Neutrophil-to Lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during Immune checkpoint inhibitors (ICI) in advanced Non-small Cell Lung Cancer (NSCLC) patients**

L. Mezquita Pérez<sup>1</sup>, K. Arbour<sup>2</sup>, E. Auclin<sup>3</sup>, D. Saravia<sup>4</sup>, H. Rizvi<sup>2</sup>, L. Hendriks<sup>5</sup>, D. Planchard<sup>6</sup>, W. Park<sup>4</sup>, E. Nadal<sup>7</sup>, J.C. Ruffinelli Rodriguez<sup>8</sup>, S. Ponce<sup>9</sup>, C. Audigier-Valette<sup>10</sup>, A.P. Marilniello<sup>11</sup>, G. Zalcman<sup>12</sup>, M. Majem<sup>13</sup>, G. Schiavone<sup>11</sup>, A.-M. Dingemans<sup>5</sup>, G. Lopes<sup>14</sup>, M.D. Hellmann<sup>2</sup>, B. Besse<sup>15</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR,



<sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>Hopital European George Pompidou, Paris, FR, <sup>4</sup>Sylvester Comprehensive Cancer Center, Miami, US, <sup>5</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>Institut Catala de Oncologia, Barcelona, ES, <sup>8</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>9</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>10</sup>Centre hospitalier Sainte Musse, Toulon, FR, <sup>11</sup>University of Turin, Turin, IT, <sup>12</sup>Hôpital Bichat, Paris, FR, <sup>13</sup>Hospital De La Santa Creu I Sant Pau, Barcelona, ES, <sup>14</sup>University of Miami Sylvester Comprehensive Cancer Center, Miami, US, <sup>15</sup>Gustave Roussy - Cancer Campus, Villejuif, FR

- 12:50 - 12:50 **1408P - Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI)**  
L. Hendriks<sup>1</sup>, C. Henon<sup>2</sup>, E. Auclin<sup>3</sup>, L. Mezquita Pérez<sup>2</sup>, R. Ferrara<sup>4</sup>, C. Audigier Valette<sup>5</sup>, J. Mazieres<sup>6</sup>, C. Lefebvre<sup>6</sup>, S. Le Moulec<sup>7</sup>, B. Duchemann<sup>8</sup>, C. Le Pechoux<sup>4</sup>, A. Botticella<sup>9</sup>, S. Ammari<sup>4</sup>, A. Gazzah<sup>4</sup>, C. Caramella<sup>2</sup>, J. Adam<sup>4</sup>, D. Planchard<sup>4</sup>, D. De Ruyscher<sup>10</sup>, A.-M. Dingemans<sup>1</sup>, B. Besse<sup>11</sup>, <sup>1</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>2</sup>Gustave Roussy, Villejuif, FR, <sup>3</sup>Hopital European George Pompidou, Paris, FR, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR, <sup>5</sup>Hospital Sainte Musse, Toulon, FR, <sup>6</sup>Hospital Larrey, Toulouse, FR, <sup>7</sup>HIA Val de Grace, Paris, FR, <sup>8</sup>Hôpital Avicenne, Bobigny, FR, <sup>9</sup>University Hospitals Leuven, Leuven, BE, <sup>10</sup>Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL, <sup>11</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:50 - 12:50 **1409P - Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)**  
M. Riudavets Melia<sup>1</sup>, I. Gabriela Sullivan<sup>1</sup>, A. Barba Joaquín<sup>1</sup>, G. Anguera Palacios<sup>1</sup>, L. Del Carpio<sup>1</sup>, C. Molto Valiente<sup>1</sup>, S.D. Camacho Arellano<sup>1</sup>, S. Moron Asensio<sup>1</sup>, P. Gomila Pons<sup>1</sup>, M. Andres Granyó<sup>1</sup>, D. Castillo Villegas<sup>1</sup>, C. Facundo Molas<sup>2</sup>, E. Garcia Planella<sup>1</sup>, C. González Blanco<sup>1</sup>, A. Barnadas Molins<sup>1</sup>, I. Gich Saladich<sup>1</sup>, M. Majem Tarruella<sup>1</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>2</sup>Puigvert Foundation, Barcelona, ES
- 12:50 - 12:50 **1410P - Tumor mutation burden (TMB) estimation using small-sized targeted next-generation sequencing (NGS) to predict efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC)**  
T. Ikeda<sup>1</sup>, K. Ohashi<sup>2</sup>, A. Sekine<sup>3</sup>, Y. Ohe<sup>4</sup>, T. Tsuda<sup>5</sup>, Y. Kataoka<sup>6</sup>, S. Hara<sup>7</sup>, N. Okamoto<sup>8</sup>, M. Kodani<sup>9</sup>, S. Matsumoto<sup>10</sup>, K. Goto<sup>10</sup>, <sup>1</sup>Nagasaki University Hospital, Nagasaki, JP, <sup>2</sup>Okayama, Okayama, JP, <sup>3</sup>Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, <sup>4</sup>National Cancer Center Hospital, Tokyo, JP, <sup>5</sup>Toyama Prefectural Central Hospital, Toyama, JP, <sup>6</sup>Hyogo Prefectural Amagasaki Hospital, Amagasaki, JP, <sup>7</sup>Itami City Hospital, Itami, JP, <sup>8</sup>Osaka Habikino Medical Center, Habikino, JP, <sup>9</sup>Tottori University Hospital, Yonago, JP, <sup>10</sup>National Cancer Center Hospital East, Kashiwa, JP
- 12:50 - 12:50 **1411P - Identification of genomic markers of sensitivity and resistance to checkpoint inhibitors in non-small cell lung cancer in a real world clinico-genomic database**  
K. Murugesan<sup>1</sup>, G. Li<sup>2</sup>, G. Kaushik<sup>2</sup>, G. Singal<sup>2</sup>, V. Miller<sup>2</sup>, G. Frampton<sup>2</sup>, L. Albacker<sup>1</sup>, <sup>1</sup>Foundation Medicine, Inc., Cambridge, MA, US, <sup>2</sup>Foundation Medicine, Inc., Cambridge, US



- 12:50 - 12:50 **1412P - HLA-DrbB1 heterozygosis and early auto-antibody rise predict prolonged survival in metastatic NSCLC patients undergone PD-1 blockade.**
- P. Correale<sup>1</sup>, R. Giannicola<sup>2</sup>, C. Botta<sup>3</sup>, P.S. Tagliaferri<sup>4</sup>, P. Pastina<sup>5</sup>, M. Monoriti<sup>1</sup>, R. Saladino<sup>1</sup>, A. Falzea<sup>1</sup>, V. Barbieri<sup>6</sup>, G. D'Arrigo<sup>7</sup>, G. Tripepi<sup>7</sup>, P. Tassone<sup>6</sup>, L. Pirtoli<sup>5</sup>,  
<sup>1</sup>Grande Ospedale Metropolitano, Reggio Calabria, IT, <sup>2</sup>Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, IT, <sup>3</sup>Medical Oncology Unit, AUO Mater Domini, Catanzaro, IT, <sup>4</sup>ZETATOURS INTERNATIONAL srl, Milan, IT, <sup>5</sup>University Hospital of Siena, Istituto Toscano Tumori, Siena, IT, <sup>6</sup>A.O. Policlinico Mater Domini Università Degli Studi, Catanzaro, IT, <sup>7</sup>CNR IFC, Reggio Calabria, Reggio Calabria, IT
- 12:50 - 12:50 **1413P - Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small-cell lung cancer (NSCLC) patients**
- X. Mielgo Rubio<sup>1</sup>, M. Sereno Moyano<sup>2</sup>, L. Chara<sup>3</sup>, R. López-Castro<sup>4</sup>, J. Rubio-Martínez<sup>5</sup>, A. Velastegui<sup>6</sup>, C. Olier-Garate<sup>7</sup>, S. Falagán<sup>8</sup>, I. Gómez-Barreda<sup>3</sup>, A. Riquelme<sup>9</sup>, J. Silva-Ruiz<sup>7</sup>, J. Moreno-Rubio<sup>10</sup>, C. López<sup>3</sup>, C. Bueno<sup>9</sup>, A. Cardaña<sup>1</sup>, E. Pérez-Fernández<sup>7</sup>, M.P. Martí-Castelló<sup>11</sup>, M. Sotelo-Lezama<sup>9</sup>,  
<sup>1</sup>Hospital Universitario Fundación Alcorcón, Madrid, ES, <sup>2</sup>Hospital Infanta Sofia, Madrid, ES, <sup>3</sup>Hospital Universitario Guadalajara, Guadalajara, ES, <sup>4</sup>Hospital Universitario Clínico de Valladolid, Valladolid, ES, <sup>5</sup>Hospital Universitario Móstoles, Móstoles (Madrid), ES, <sup>6</sup>Hospital Universitario Rey Juan Carlos, Móstoles (Madrid), ES, <sup>7</sup>Hospital Universitario Fundación Alcorcón, Alcorcón (Madrid), ES, <sup>8</sup>Hospital Infanta Sofia, SS de Los Reyes (Madrid), ES, <sup>9</sup>Hospital Infanta Cristina, Parla (Madrid), ES, <sup>10</sup>Hospital Infanta Sofia, San Sebastian De Los Reyes, ES, <sup>11</sup>Universidad Rey Juan Carlos, Alcorcón (Madrid), ES
- 12:50 - 12:50 **1414P - Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model**
- H. Wakelee<sup>1</sup>, J. Aredo<sup>2</sup>, S. Vali<sup>3</sup>, N. Singh<sup>4</sup>, S. Vasista<sup>4</sup>, U. Mitra<sup>4</sup>, T. Abbasi<sup>3</sup>, S. Padda<sup>2</sup>,  
<sup>1</sup>Stanford Advanced Medicine Center, Stanford, US, <sup>2</sup>Stanford University, Stanford, US, <sup>3</sup>Cellworks Group, San Jose, US, <sup>4</sup>Cellworks Research India Pvt. Ltd, Bangalore, IN
- 12:50 - 12:50 **1415P - Association between Early Immune-Related Adverse Events and Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab as First-line Therapy: A Retrospective Multicenter Cohort Study**
- K. Hosoya<sup>1</sup>, D. Fujimoto<sup>1</sup>, M. Tamiya<sup>2</sup>, A. Tamiya<sup>3</sup>, H. Suzuki<sup>4</sup>, K. Hirano<sup>5</sup>, T. Yokoyama<sup>6</sup>, M. Morita<sup>7</sup>, Y. Fukuda<sup>8</sup>, M. Kanazu<sup>9</sup>, T. Makio<sup>10</sup>,  
<sup>1</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>2</sup>Osaka International Cancer Institute, Osaka, JP, <sup>3</sup>Kinki-chuo Chest Medical Center, Sakai, JP, <sup>4</sup>Osaka Habikino Medical Center, Osaka, JP, <sup>5</sup>Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JP, <sup>6</sup>Kurashiki Central Hospital, Kurashiki, JP, <sup>7</sup>Kobe City Medical Center West Hospital, Kobe, JP, <sup>8</sup>Himeji Medical Center, Himeji, JP, <sup>9</sup>National Hospital Organization Toneyama National Hospital, Toyonaka, JP, <sup>10</sup>Itami City Hospital, Itami, JP
- 12:50 - 12:50 **1416P - Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO).**

R. Ferrara<sup>1</sup>, M. Naigeon<sup>1</sup>, E. Auclin<sup>2</sup>, B. Duchemann<sup>3</sup>, L. Cassard<sup>1</sup>, J. Medhi<sup>1</sup>, L. Boselli<sup>1</sup>, J. Grivel<sup>1</sup>, A. Desnoyer<sup>1</sup>, L. Mezquita Pérez<sup>4</sup>, F. Aboubakar<sup>5</sup>, L. Hendriks<sup>6</sup>, D. Planchard<sup>1</sup>, C. Caramella<sup>1</sup>, J. Remon<sup>7</sup>, M. Ngocamus<sup>1</sup>, C. Nicotra<sup>1</sup>, B. Besse<sup>8</sup>, N. Chaput<sup>9</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Hopital European George Pompidou, Paris, FR, <sup>3</sup>Hôpital Avicenne, Bobigny, FR, <sup>4</sup>Gustave Roussy, Villejuif, FR, <sup>5</sup>UCL Woluwé, Brussels, BE, <sup>6</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>9</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR

12:50 - 12:50

**1417P - Preliminary results of PRINCiPe (Predictors of Resistance to Immunotherapy with Nivolumab [NIV]) study in advanced pretreated non-small-cell lung cancer (APNSCLC), investigating the role of an Immune Genomic Signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations.**

S. Pilotto<sup>1</sup>, G. Grizzi<sup>2</sup>, I. Sperduti<sup>3</sup>, M. Simbolo<sup>4</sup>, C. Vicentini<sup>4</sup>, A. Calio<sup>4</sup>, M. Caccese<sup>2</sup>, A. Mafficini<sup>1</sup>, L. Carbognin<sup>1</sup>, V. Corbo<sup>4</sup>, A. Gkoutakos<sup>4</sup>, A. Santo<sup>2</sup>, M. Infante<sup>5</sup>, M. Brunelli<sup>4</sup>, A. Scarpa<sup>1</sup>, G. Tortora<sup>6</sup>, E. Bria<sup>7</sup>, <sup>1</sup>AOU Integrata Verona "Borgo Roma", Verona, IT, <sup>2</sup>University of Verona, AOUI Verona, Verona, IT, <sup>3</sup>Regina Elena National Cancer Institute, Rome, IT, <sup>4</sup>University and Hospital Trust of Verona, Verona, IT, <sup>5</sup>AOUI Verona, Verona, IT, <sup>6</sup>Fondazione Policlinico Universitario Gemelli -IRCCS Rome, Rome, IT, <sup>7</sup>Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario Agostino Gemelli, Rome, IT

12:50 - 12:50

**1418P - The need of re-biopsy: increase in PD-L1 expression from initial stage to recurrence of non-small cell lung cancer**

M. Lacour<sup>1</sup>, S.Y. Lee<sup>2</sup>, U. Rulle<sup>3</sup>, A. Soltermann<sup>4</sup>, E.J. Rushing<sup>2</sup>, D. Soldini<sup>2</sup>, S. Hiltbrunner<sup>2</sup>, W. Weder<sup>1</sup>, A. Curioni-Fontecedro<sup>2</sup>, <sup>1</sup>University Hospital Zürich, Zurich, CH, <sup>2</sup>University Hospital Zurich, Zurich, CH, <sup>3</sup>University Hospital Zürich, Zürich, CH, <sup>4</sup>Universitätsspital Zürich, Zürich, CH

12:50 - 12:50

**1419P - Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non small cell lung cancer**

G. Galli<sup>1</sup>, M. Poggi<sup>2</sup>, G. Fucà<sup>3</sup>, G. Lo Russo<sup>2</sup>, C. Proto<sup>3</sup>, D. Signorelli<sup>2</sup>, M. Vitali<sup>3</sup>, M. Ganzinelli<sup>2</sup>, N. Zilembo<sup>3</sup>, F. De Braud<sup>2</sup>, M. Garassino<sup>1</sup>, M. Imbimbo<sup>2</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

12:50 - 12:50

**1420P - Soluble immune biomarkers to anti-PD1 treatment in Non-Small-Cell Lung Cancer (NSCLC)**

J. Garde-Noguera<sup>1</sup>, E. Jantus-Lewintre<sup>2</sup>, B. Honrubia Peris<sup>1</sup>, S. Gallach Garcia<sup>3</sup>, F. Zhang<sup>4</sup>, J. García Sánchez<sup>1</sup>, S. Calabuig Fariñas<sup>3</sup>, A. Blasco Cordellat<sup>3</sup>, N. Piera Molons<sup>1</sup>, J. Vidal-Martinez<sup>1</sup>, J. Murado-Pardo<sup>1</sup>, L.D. Condori Farfan<sup>3</sup>, R. Gisbert-Criado<sup>1</sup>, E. Escorihuela<sup>2</sup>, C. Camps<sup>5</sup>, <sup>1</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>2</sup>Departament de Biotecnologia, Universitat Politècnica de València, Valencia, ES, <sup>3</sup>Hospital General Universitario Valencia, Valencia, ES, <sup>4</sup>Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, <sup>5</sup>Consortio Hospital General Universitario de Valencia, Valencia, ES

- 12:50 - 12:50 **1421P - Clinical characterization of rare EGFR mutations in non-small cell lung cancer and in silico prediction of drug sensitivity**  
S. Ikemura<sup>1</sup>, H. Yasuda<sup>1</sup>, S. Matsumoto<sup>2</sup>, M. Kamada<sup>3</sup>, T. Betsuyaku<sup>1</sup>, Y. Okuno<sup>3</sup>, K. Goto<sup>2</sup>, K. Tsuchihara<sup>4</sup>, K. Soejima<sup>1</sup>, <sup>1</sup>Keio University School of Medicine, Tokyo, JP, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>Kyoto University, Kyoto, JP, <sup>4</sup>National Cancer Center Hospital, Tokyo, JP
- 12:50 - 12:50 **1422P - Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial**  
A. Curioni<sup>1</sup>, E. Felip<sup>2</sup>, U. Dafni<sup>3</sup>, M.-A. Molina<sup>4</sup>, O. Gautschi<sup>5</sup>, S. Peters<sup>6</sup>, B. Massutí<sup>7</sup>, R. Palmero<sup>8</sup>, S. Ponce<sup>9</sup>, E. Carcereny<sup>10</sup>, M. Früh<sup>11</sup>, M. Pless<sup>12</sup>, S. Popat<sup>13</sup>, S. Cuffe<sup>14</sup>, N. Karachaliou<sup>15</sup>, R. Kammler<sup>16</sup>, M. Kassapian<sup>17</sup>, H. Roschitzki-Voser<sup>16</sup>, R. Stahel<sup>1</sup>, R. Rosell<sup>10</sup>, <sup>1</sup>University Hospital Zürich, Zurich, CH, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>University of Athens, Athens, GR, <sup>4</sup>Pangaea Biotech S.L., Barcelona, ES, <sup>5</sup>Cantonal Hospital Lucerne, Lucern, CH, <sup>6</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>7</sup>Hospital General Universitario Alicante, Alicante, ES, <sup>8</sup>Catalan Institute of Oncology, Bellvitge, ES, <sup>9</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>10</sup>Catalan Institute of Oncology, Badalona, ES, <sup>11</sup>Cantonal Hospital St. Gallen, St. Gallen, CH, <sup>12</sup>Kantonsspital Winterthur, Winterthur, CH, <sup>13</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>14</sup>St James's Hospital, Dublin, IE, <sup>15</sup>Institute of Oncology Rosell, Barcelona, ES, <sup>16</sup>ETOP - European Thoracic Oncology Platform, Bern, CH, <sup>17</sup>Frontier Science Foundation-Hellas, Athens, GR
- 12:50 - 12:50 **1423P - Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival?**  
I. Prediletto<sup>1</sup>, E. Vasile<sup>2</sup>, R. Bruno<sup>2</sup>, E. Macerola<sup>2</sup>, G. Pasquini<sup>2</sup>, G. Fontanini<sup>2</sup>, A. Falcone<sup>2</sup>, <sup>1</sup>University of Pisa, Pisa, IT, <sup>2</sup>University of Pisa, Pisa, Italy, Pisa, IT
- 12:50 - 12:50 **1424P - The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)**  
K. Usui<sup>1</sup>, T. Yokoyama<sup>2</sup>, A. Kisohara<sup>3</sup>, Y. Mori<sup>4</sup>, Y. Takeda<sup>5</sup>, H. Ishida<sup>6</sup>, N. Kusano<sup>7</sup>, K. Kishi<sup>8</sup>, U. Katsushima<sup>9</sup>, T. Kuwako<sup>10</sup>, H. Aono<sup>11</sup>, Y. Shikama<sup>12</sup>, K. Minato<sup>13</sup>, H. Matsushima<sup>14</sup>, K. Uemura<sup>15</sup>, Y. Ohashi<sup>16</sup>, H. Kunitoh<sup>17</sup>, <sup>1</sup>NTT Medical Center Tokyo, Tokyo, JP, <sup>2</sup>Kyorin University Hospital, -, JP, <sup>3</sup>Kasukabe City Hospital, Kasukabe, JP, <sup>4</sup>Iwate Prefectural Central Hospital, Iwate, JP, <sup>5</sup>National Center for Global Health and Medicine, Tokyo, JP, <sup>6</sup>Showa University School of Medicine, Tokyo, JP, <sup>7</sup>Fujisawa City Hospital, Kanagawa, JP, <sup>8</sup>Toranomon Hospital, Tokyo, JP, <sup>9</sup>Kansai Electric Power Hospital, Osaka, JP, <sup>10</sup>National Hospital Organization Shibukawa Medical Center, Gunma, JP, <sup>11</sup>Mitsui Memorial Hospital, Tokyo, JP, <sup>12</sup>Showa University Fujigaoka Hospital, Kanagawa, JP, <sup>13</sup>Gunma Prefectural Cancer Center, Ota, JP, <sup>14</sup>Japanese Red Cross Saitama Hospital, Saitama, JP, <sup>15</sup>The University of Tokyo, Tokyo, JP, <sup>16</sup>Chuo University, Tokyo, JP, <sup>17</sup>Japanese Red Cross Medical Center, Tokyo, JP
- 12:50 - 12:50 **1425P - ABCB1 Genetic Polymorphism and Pharmacokinetic Analysis of Low Dose Erlotinib in Frail Patients with EGFR Mutation (mt) -positive, Non-small Cell Lung Cancer: TORG1425**



S. Miyamoto<sup>1</sup>, T. Tokkito<sup>2</sup>, A. Bessho<sup>3</sup>, N. Fukamatsu<sup>3</sup>, H. Kunitoh<sup>1</sup>, M. Ishii<sup>4</sup>, H. Tanaka<sup>5</sup>, H. Aono<sup>6</sup>, T. Fukui<sup>7</sup>, K. Kusaka<sup>8</sup>, Y. Hosomi<sup>9</sup>, A. Hamada<sup>10</sup>, K. Yamada<sup>11</sup>, H. Okamoto<sup>4</sup>,  
<sup>1</sup>Japanese Red Cross Medical Center, Tokyo, JP, <sup>2</sup>Kurume University School of Medicine, Kurume, JP, <sup>3</sup>Japanese Red Cross Okayama Hospital, Okayama, JP, <sup>4</sup>Yokohama Municipal Citizen's Hospital, Yokohama, JP, <sup>5</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>6</sup>Mitsui Memorial Hospital, Tokyo, JP, <sup>7</sup>Kitasato University School of Medicine, Sagamihara, JP, <sup>8</sup>National Hospital Organization Tokyo National Hospital, Kiyose, JP, <sup>9</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, <sup>10</sup>National Cancer Center Research Institute, Tokyo, JO, <sup>11</sup>Kurume University, Kurume, JP

12:50 - 12:50

**1426P - Longitudinal plasma monitoring of subjects treated with EGFR-TKIs allows better understanding of evolution of acquired resistance and can inform optimal treatment strategies**

J. Palma<sup>1</sup>, P. Vitazka<sup>1</sup>, N. Tikoo<sup>1</sup>, A. Balasubramanyam<sup>2</sup>, L. Xi<sup>1</sup>, S. Yaung<sup>1</sup>, E. Kwok<sup>2</sup>, A. Lovejoy<sup>1</sup>, D. Klass<sup>1</sup>, M. Heibeck<sup>3</sup>, K. Probst<sup>3</sup>, A. Rehfeldt<sup>3</sup>, E. Meldgaard<sup>4</sup>, A. Madsen<sup>4</sup>, M. Clement<sup>4</sup>, B. Sorensen<sup>4</sup>, P. Meldgaard<sup>4</sup>, <sup>1</sup>F. Hoffmann LaRoche, Ltd, Pleasanton, US, <sup>2</sup>Roche Sequencing Solutions, Inc., Pleasanton, US, <sup>3</sup>Roche Sequencing Solutions, Inc., Potsdam, DE, <sup>4</sup>Aarhus University Hospital, Aarhus, DK

12:50 - 12:50

**1428P - Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315)**

F. Griesinger<sup>1</sup>, W. Eberhardt<sup>2</sup>, A. Nusch<sup>3</sup>, M. Reiser<sup>4</sup>, C. Bernhardt<sup>5</sup>, N. Marschner<sup>6</sup>, M. Jaenicke<sup>7</sup>, A. Fleitz<sup>8</sup>, L. Spring<sup>7</sup>, J. Sahlmann<sup>7</sup>, A. Karatas<sup>9</sup>, A. Hipper<sup>9</sup>, W. Weichert<sup>10</sup>, A. Rittmeyer<sup>11</sup>, H. Bischoff<sup>12</sup>, C. Waller<sup>13</sup>, M. Thomas<sup>14</sup>, <sup>1</sup>Pius Hospital, Oldenburg, DE, <sup>2</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>3</sup>Onkologische Praxis Velbert, Velbert, DE, <sup>4</sup>PIOH (Köln Zentrum) - Praxis Internistischer Onkologie und Hämatologie, Köln, DE, <sup>5</sup>Gemeinschaftspraxis für Hämatologie und Onkologie, Dortmund, DE, <sup>6</sup>Praxis für Interdisziplinäre Onkologie, Freiburg, DE, <sup>7</sup>iOMEDICO, Freiburg, DE, <sup>8</sup>iOMEDICO AG, Freiburg, DE, <sup>9</sup>AIO Studien gGmbH, Berlin, DE, <sup>10</sup>Technical University of Munich, München, DE, <sup>11</sup>LKI Lungenfachklinik Immenhausen, Immenhausen, DE, <sup>12</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>13</sup>Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg, DE, <sup>14</sup>Thoraxklinik, Heidelberg, DE

12:50 - 12:50

**1427P - Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Various Gene Alterations and Brain Metastases**

K. Chen<sup>1</sup>, Y. Fan<sup>2</sup>, Z. Huang<sup>2</sup>, Y. Xu<sup>2</sup>, X. Yu<sup>1</sup>, H. Wang<sup>1</sup>, <sup>1</sup>ZHEJIANG CANCER HOSPITAL, Hangzhou, CN, <sup>2</sup>Zhejiang cancer hospital, Hangzhou, CN

12:50 - 12:50

**1429P - Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients.**

M.H. Hong<sup>1</sup>, M.H. Kim<sup>2</sup>, S.-Y. Kim<sup>3</sup>, S.G. Heo<sup>4</sup>, H.-N. Kang<sup>4</sup>, C.-W. Park<sup>4</sup>, J.C. Barrett<sup>5</sup>, D. Stetson<sup>5</sup>, J. Chmielecki<sup>5</sup>, A. Markovets<sup>5</sup>, H.R. Kim<sup>6</sup>, B.C. Cho<sup>2</sup>, <sup>1</sup>Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>JE-UK Institute for Cancer Research, Gumi-City, KR, <sup>4</sup>JE-UK Institute for Cancer Research, Gumi-city, KR,



<sup>5</sup>AstraZeneca, Waltham, US, <sup>6</sup>Yonsei Cancer Center Yonsei University, Seoul, KR

- 12:50 - 12:50 **1430P - Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC).**  
M. Kushnir<sup>1</sup>, H. Winter<sup>1</sup>, C. Murias<sup>1</sup>, P. Bains<sup>1</sup>, C. Abbosh<sup>2</sup>, D. Papadatos-Pastos<sup>3</sup>, T. Newsome-Davis<sup>4</sup>, T. Ahmed<sup>5</sup>, C. Swanton<sup>6</sup>, M. Forster<sup>7</sup>, D. Moore<sup>7</sup>, P. Bennett<sup>8</sup>, I. Faull<sup>9</sup>, R. Lanman<sup>10</sup>, H.-T. Arkenau<sup>11</sup>, <sup>1</sup>Sarah Cannon Research Institute, London, GB, <sup>2</sup>St. James's University Hospital Leeds, Leeds, GB, <sup>3</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>4</sup>Chelsea and Westminster, London, GB, <sup>5</sup>University college hospital, London, GB, <sup>6</sup>The Francis Crick Institute, London, GB, <sup>7</sup>University College London Cancer Institute, London, GB, <sup>8</sup>Sarah Cannon Molecular Diagnostics, London, GB, <sup>9</sup>Guardant Health, Barcelona, ES, <sup>10</sup>Guardant Health, Redwood City, US, <sup>11</sup>Sarah Cannon Research Institute SCRI UK, London, GB
- 12:50 - 12:50 **1431P - TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC**  
P. Christopoulos<sup>1</sup>, M. Kirchner<sup>2</sup>, F. Bozorgmehr<sup>3</sup>, V. Endris<sup>2</sup>, M. Elsayed<sup>3</sup>, N. Magios<sup>3</sup>, A.-L. Volckmar<sup>2</sup>, R. Penzel<sup>2</sup>, F. Herth<sup>1</sup>, C. Heussel<sup>1</sup>, H. Winter<sup>1</sup>, T. Muley<sup>3</sup>, M. Meister<sup>3</sup>, J. Fischer<sup>4</sup>, S. Rieken<sup>5</sup>, F. Lasitschka<sup>5</sup>, H. Bischoff<sup>1</sup>, P. Schirmacher<sup>6</sup>, M. Thomas<sup>7</sup>, A. Stenzinger<sup>8</sup>, <sup>1</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>2</sup>Institute of Pathology Heidelberg, Heidelberg, DE, <sup>3</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>4</sup>Klinik Loewenstein GmbH Med Klinik II Onkologie, Loewenstein, DE, <sup>5</sup>Heidelberg University Hospital, Heidelberg, DE, <sup>6</sup>University of Heidelberg, Heidelberg, DE, <sup>7</sup>Thoraxklinik, Heidelberg, DE, <sup>8</sup>University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE
- 12:50 - 12:50 **1432P - Hybrid capture NGS reliably detects a spectrum of clinically significant genetic aberrations in both, primary diagnostics and the relapse scenario.**  
S. Schatz<sup>1</sup>, M. Falk<sup>1</sup>, R. Menon<sup>2</sup>, L. Heukamp<sup>3</sup>, J. Roeper<sup>4</sup>, F. Griesinger<sup>5</sup>, M. Tiemann<sup>6</sup>, <sup>1</sup>Hematopathology Hamburg, Hamburg, DE, <sup>2</sup>NEO New Oncology, Cologne, DE, <sup>3</sup>New Oncology, Köln, DE, <sup>4</sup>Pius Hospital Oldenburg, University of Oldenburg, Berlin, DE, <sup>5</sup>Pius Hospital, Oldenburg, DE, <sup>6</sup>Hematopathology Hamburg, Berlin, DE
- 12:50 - 12:50 **1433P - Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in advanced non-small cell lung cancer.**  
K. Adamowicz<sup>1</sup>, A. Romanowska<sup>2</sup>, R. Zaucha<sup>3</sup>, <sup>1</sup>Hospital Wejherowo Szpital Specjalistyczny im. Floriana Ceynowy w Wejherowie, Wejherowo, PL, <sup>2</sup>University Clinical Center, Gdansk, PL, <sup>3</sup>Medical University of Gdansk, Gdansk, PL
- 12:50 - 12:50 **1434P - A Phase II Study of Nedaplatin and nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer (KRS1302)**  
T. Sugiyama<sup>1</sup>, T. Kasai<sup>1</sup>, N. Koyama<sup>2</sup>, K. Kobayashi<sup>3</sup>, E. Hoshi<sup>4</sup>, M. Nakayama<sup>5</sup>, K. Mori<sup>6</sup>, <sup>1</sup>Tochigi Cancer Center, Utsunomiya, JP, <sup>2</sup>Tokyo Medical University Hachioji Medical Center, Tokyo, JP, <sup>3</sup>Saitama Medical University Internatl Medical Centre, Saitama, JP, <sup>4</sup>Saitama Cardiovascular and Respiratory Center, Kumagaya, JP, <sup>5</sup>Saitama Medical Center, Kawagoe, JP, <sup>6</sup>Tsuboi cancer center Hospital, Koriyama, JP

- 12:50 - 12:50 **1435P - Bevacizumab as first-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC) in patients aged over 65 years in France. Final results of the AVANTAGE study.**
- F. Lionel<sup>1</sup>, D. Perol<sup>2</sup>, P.-J. Souquet<sup>3</sup>, H. Le Caer<sup>4</sup>, E. Dansin<sup>5</sup>, C. Audigier Valette<sup>6</sup>, J.-L. Mouysset<sup>7</sup>, M.L. Uffredi<sup>8</sup>, M. Ionescu-Goga<sup>9</sup>, K. Veerabudun<sup>10</sup>, Y. Lelarge<sup>11</sup>, E. Fabre-Guillevin<sup>12</sup>, <sup>1</sup>L'Hopital Nord Ouest, Villefranche Sur Saone, FR, <sup>2</sup>Centre Léon Bérard, Lyon, FR, <sup>3</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>4</sup>Centre Hospitalier, Saint Briec, FR, <sup>5</sup>Centre Oscar Lambret, Lille, FR, <sup>6</sup>Hospital Sainte Musse, Toulon, FR, <sup>7</sup>Clinique Rambot-Provençale, Aix-en-Provence, FR, <sup>8</sup>Roche S.A.S., Boulogne-Billancourt, FR, <sup>9</sup>Roche S.A.S., Boulaogne-billancourt, FR, <sup>10</sup>aixial, boulogne-billancourt, FR, <sup>11</sup>Hays, Paris, FR, <sup>12</sup>Dr. Elizabeth Fabre-Guillevin, La Défense, FR
- 12:50 - 12:50 **1436P - Randomized phase 2 study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naïve advanced non-squamous non-small-cell lung cancer (CLEAR study)**
- R. Koyama<sup>1</sup>, H. Udagawa<sup>2</sup>, E. Sugiyama<sup>2</sup>, K. Komuta<sup>3</sup>, M. Mori<sup>4</sup>, T. Yokoyama<sup>5</sup>, T. Sasaki<sup>6</sup>, H. Saito<sup>7</sup>, H. Ishida<sup>8</sup>, H. Nakagawa<sup>9</sup>, A. Sekine<sup>10</sup>, A. Tamura<sup>11</sup>, M. Shingyoji<sup>12</sup>, K. Mizuno<sup>13</sup>, A. Nakamura<sup>14</sup>, A. Kinoshita<sup>15</sup>, T. Yamanaka<sup>16</sup>, K. Goto<sup>2</sup>, <sup>1</sup>Juntendo University Faculty of Medicine, Tokyo, JP, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>Osaka Police Hospital, Osaka, JP, <sup>4</sup>National Hospital Organization Toneyama National Hospital, Toyonaka, JP, <sup>5</sup>Kurashiki Central Hospital, Kurashiki, JP, <sup>6</sup>Asahikawa Medical University, Asahikawa, JP, <sup>7</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>8</sup>Showa University School of Medicine, Tokyo, JP, <sup>9</sup>National Hospital Organization Hirosaki Hospital, Hirosaki, JP, <sup>10</sup>Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, <sup>11</sup>National Hospital Organization Tokyo National Hospital, Tokyo, JP, <sup>12</sup>Chiba Cancer Center, Chiba, JP, <sup>13</sup>Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, JP, <sup>14</sup>Sendai Kousei Hospital, Sendai, JP, <sup>15</sup>Nagasaki Medical Center, Omura, JP, <sup>16</sup>Yokohama City University Hospital, Yokohama, JP
- 12:50 - 12:50 **1437P - Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)**
- R. Plummer<sup>1</sup>, N. Cook<sup>2</sup>, T. Arkenau<sup>3</sup>, J. Melear<sup>4</sup>, C. Redfern<sup>5</sup>, A. Spira<sup>6</sup>, K. Chung<sup>7</sup>, T. Haddad<sup>8</sup>, S. Ramalingam<sup>9</sup>, R. Wesolowski<sup>10</sup>, E. Dean<sup>11</sup>, T. Goddemeier<sup>12</sup>, M. Falk<sup>13</sup>, G. Shapiro<sup>14</sup>, <sup>1</sup>Northern Institute for Cancer Research University of Newcastle, Newcastle upon Tyne, GB, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>3</sup>Sarah Cannon Research Institute, London, GB, <sup>4</sup>US Oncology - Texas Oncology - Midtown, Austin, US, <sup>5</sup>Sharp Memorial Hospital, San Diego, US, <sup>6</sup>Virginia Cancer Specialists, Fairfax, US, <sup>7</sup>Greenville Health System, Greenville, US, <sup>8</sup>Mayo Clinic, Rochester, US, <sup>9</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>10</sup>The Ohio State University Comprehensive Cancer Center, Columbus, US, <sup>11</sup>The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB, <sup>12</sup>Merck KGaA, Darmstadt, DE, <sup>13</sup>Merck Germany, Darmstadt, DE, <sup>14</sup>Dana-Farber Cancer Institute, Boston, US
- 12:50 - 12:50 **1438P - A multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease**
- Y. Usui<sup>1</sup>, H. Kenmotsu<sup>2</sup>, K. Mori<sup>3</sup>, A. Ono<sup>2</sup>, K. Yoh<sup>1</sup>, T. Baba<sup>4</sup>, Y. Fujiwara<sup>5</sup>, O. Yamaguchi<sup>6</sup>, R. Ko<sup>7</sup>, H. Okamoto<sup>8</sup>, N. Yamamoto<sup>9</sup>, T. Ninomiya<sup>10</sup>, T. Ogura<sup>4</sup>, T. Kato<sup>11</sup>,

<sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>3</sup>Shizuoka Cancer Center Hospital, Nagaizumi, JP, <sup>4</sup>Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, <sup>5</sup>National Cancer Center Hospital, Tokyo, JP, <sup>6</sup>Saitama Medical University International Medical Center, Saitama, JP, <sup>7</sup>Juntendo University Graduate School of Medicine, Tokyo, JP, <sup>8</sup>Yokohama Municipal Citizen's Hospital, Yokohama, JP, <sup>9</sup>Wakayama Medical University, Wakayama, JP, <sup>10</sup>Okayama University, Okayama, JP, <sup>11</sup>Kanagawa Cancer Center, Yokohama, JP

12:50 - 12:50 **1439P - HALO 107-201: A Phase 1b, open-label, multicenter study of pegvorhyaluronidase alfa (PEGPH20) + docetaxel in patients (pts) with recurrent locally advanced or metastatic non-small-cell lung cancer (NSCLC)**

M. Baumgart<sup>1</sup>, M. Muhsin<sup>2</sup>, W. Wu<sup>3</sup>, N. Gabrail<sup>4</sup>, <sup>1</sup>University of Rochester Medical Center, Rochester, US, <sup>2</sup>halozyme Therapeutics, San Francisco, US, <sup>3</sup>Halozyne Therapeutics, Inc., San Diego, US, <sup>4</sup>Gabrail Cancer Center, Canton, US

12:50 - 12:50 **1440P - Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced Non-Small-Cell Lung Cancer (NSCLC) patients (pts) with squamous (sq) histological type.**

F. Grossi<sup>1</sup>, P. Jaskiewicz<sup>2</sup>, E. Pichon<sup>3</sup>, G. Czyzewicz<sup>4</sup>, D. Kowalski<sup>2</sup>, L. Ciuffreda<sup>5</sup>, R. Garcia Gomez<sup>6</sup>, S. Caruso<sup>7</sup>, J. Bosch Barrera<sup>8</sup>, C. Ta Thanh Minh<sup>9</sup>, S. Gautier<sup>10</sup>, H. Hervieu<sup>11</sup>, S. Henriët<sup>9</sup>, G. De Castro Jr.<sup>12</sup>, <sup>1</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>2</sup>The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, <sup>3</sup>CHRU Bretonneau, Tours, FR, <sup>4</sup>Szpital Specjalistyczny im. Jana Pawła II, Krakow, PL, <sup>5</sup>AOU S. Giovanni Battista - Molinette, Torino, IT, <sup>6</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>7</sup>CH de la Dracénie-Draguignan, Draguignan, FR, <sup>8</sup>Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona, ES, <sup>9</sup>Pierre Fabre Oncologie France, Boulogne-Billancourt, FR, <sup>10</sup>IRPF, Pierre Fabre, Toulouse, FR, <sup>11</sup>Pierre Fabre, Boulogne-Billancourt, FR, <sup>12</sup>ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR

12:50 - 12:50 **1441P - Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026**

Y. Kawashima<sup>1</sup>, T. Fukuhara<sup>2</sup>, N. Furuya<sup>3</sup>, H. Saito<sup>4</sup>, K. Watanabe<sup>2</sup>, S. Iwasawa<sup>5</sup>, Y. Tsunozuka<sup>6</sup>, O. Yamaguchi<sup>7</sup>, M. Okada<sup>8</sup>, K. Yoshimori<sup>9</sup>, I. Nakachi<sup>10</sup>, A. Gemma<sup>11</sup>, K. Azuma<sup>12</sup>, K. Hagiwara<sup>13</sup>, T. Nukiwa<sup>14</sup>, S. Morita<sup>15</sup>, K. Kobayashi<sup>16</sup>, M. Maemondo<sup>2</sup>, <sup>1</sup>Sendai Kousei Hospital, Sendai, JP, <sup>2</sup>Miyagi Cancer Center, Natori, JP, <sup>3</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>4</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>5</sup>Chiba University Graduate School of Medicine, Chiba, JP, <sup>6</sup>Ishikawa Prefectural Central Hospital, Ishikawa, JP, <sup>7</sup>Saitama Medical University International Medical Center, Saitama, JP, <sup>8</sup>Hiroshima University, Hiroshima, JP, <sup>9</sup>Director of Clinical Cancer Center Fukujuji Hospital.JATA, Kiyose, JP, <sup>10</sup>Saiseikai Utsunomiya Hospital, Utsunomiya, JP, <sup>11</sup>Nippon Medical School, Tokyo, JP, <sup>12</sup>kurume university school of medicine, Fukuoka, JP, <sup>13</sup>Jichi Medical University, Shimotsuke, JP, <sup>14</sup>Tohoku University, Sendai, JP, <sup>15</sup>Kyoto University Graduate School of Medicine 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JP, <sup>16</sup>Saitama Medical University Internatl Medical Centre, Saitama, JP

12:50 - 12:50 **1442P - Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): final analysis of the global Phase**



**III LUX-Lung 8 (LL8) trial**

G. Goss<sup>1</sup>, M. Cobo<sup>2</sup>, S. Lu<sup>3</sup>, K. Syrigos<sup>4</sup>, K.H. Lee<sup>5</sup>, E. Göker<sup>6</sup>, V. Georgoulas<sup>7</sup>, W. Li<sup>8</sup>, D. Isla<sup>9</sup>, A. Morabito<sup>10</sup>, Y.J. Min<sup>11</sup>, A. Ardizzoni<sup>12</sup>, A. Cseh<sup>13</sup>, S. Bender<sup>14</sup>, E. Felip<sup>15</sup>,  
<sup>1</sup>University of Ottawa, Ottawa, CA, <sup>2</sup>Hospital Carlos Haya, Malaga, ES, <sup>3</sup>Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>4</sup>Athens School of Medicine, Athens, GR, <sup>5</sup>Chungbuk National University College of Medicine, Cheongju, KR, <sup>6</sup>Ege University Faculty of Medicine, Izmir, TR, <sup>7</sup>University Hospital of Heraklion, Crete, GR, <sup>8</sup>the first hospital of Jilin University, changchun, CN, <sup>9</sup>Hospital Lozano Blesa, Zaragoza, ES, <sup>10</sup>Istituto Nazionale Tumori "Fondazione G.Pascale", Naples, IT, <sup>11</sup>Ulsan University Hospital, Ulsan, KR, <sup>12</sup>University Hospital, Parma, IT, <sup>13</sup>Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, AT, <sup>14</sup>Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, US, <sup>15</sup>Vall d' Hebron University Hospital, Barcelona, ES

12:50 - 12:50

**1443P - Real world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset.**

J.H. Kang<sup>1</sup>, B.C. Cho<sup>2</sup>, D.-W. Kim<sup>3</sup>, K. Park<sup>4</sup>, J.-S. Lee<sup>5</sup>, S.S. Yoo<sup>6</sup>, S.Y. Lee<sup>7</sup>, C.H. Kim<sup>8</sup>, S.H. Jang<sup>9</sup>, Y.-C. Kim<sup>10</sup>, H.-K. Yoon<sup>11</sup>, S.-W. Kim<sup>12</sup>, <sup>1</sup>Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, <sup>2</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>Seoul National University Hospital, seoul, KR, <sup>4</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>5</sup>Seoul National University Bundang Hospital, Gyeonggi-do, KR, <sup>6</sup>Kyungpook National University Hospital, Daegu, KR, <sup>7</sup>Korea University Guro Hospital, seoul, KR, <sup>8</sup>Korea Cancer Center Hospital, seoul, KR, <sup>9</sup>Hallym University Sacred Heart Hospital, Anyang-si, KR, <sup>10</sup>Chonnam National University Hwasun Hospital, Jeollanam-do, KR, <sup>11</sup>The Catholic University of Korea, Yeouido St. Mary's hospital, seoul, KR, <sup>12</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

12:50 - 12:50

**1444P - A randomized phase 2 trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)**

T. Stinchcombe<sup>1</sup>, P. Janne<sup>2</sup>, X. Wang<sup>3</sup>, E. Bertino<sup>4</sup>, J. Weiss<sup>5</sup>, L. Bazhenova<sup>6</sup>, L. Gu<sup>3</sup>, C. Lau<sup>2</sup>, C. Paweletz<sup>2</sup>, A. Jaslawski<sup>7</sup>, G. Gerstner<sup>8</sup>, M. Baggstrom<sup>9</sup>, S. Graziano<sup>10</sup>, J. Bearden, Iii<sup>11</sup>, E. Vokes<sup>12</sup>, <sup>1</sup>Duke Cancer Center, Durham, US, <sup>2</sup>Dana Farber Cancer Institute, Boston, US, <sup>3</sup>Duke University, Durham, US, <sup>4</sup>The Ohio State University James Cancer Hospital, Columbus, US, <sup>5</sup>University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>6</sup>Moore's UCSD Cancer Center, La Jolla, US, <sup>7</sup>St. Mary's Hospital, Green Bay, US, <sup>8</sup>Illinois CancerCare, P.C., Peoria, US, <sup>9</sup>Washington University School of Medicine, St. Louis, US, <sup>10</sup>SUNY Upstate Medical University, Syracuse, US, <sup>11</sup>Palmetto Hematology Oncology Associates, Spartanburg, US, <sup>12</sup>The University of Chicago Medical Centre, Chicago, US

12:50 - 12:50

**1445P - A phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group Trial NEJ027.**

T. Aiba<sup>1</sup>, Y. Minegishi<sup>2</sup>, O. Yamaguchi<sup>3</sup>, S. Kuyama<sup>4</sup>, S. Watanabe<sup>5</sup>, K. Usui<sup>6</sup>, M. Mori<sup>7</sup>, O. Hataji<sup>8</sup>, T. Nukiwa<sup>9</sup>, S. Morita<sup>10</sup>, K. Kobayashi<sup>11</sup>, A. Gemma<sup>2</sup>, <sup>1</sup>Sendai Kousei Hospital, Sendai, JP, <sup>2</sup>Nippon Medical School, Tokyo, JP, <sup>3</sup>Saitama Medical University International Medical Center, Saitama, JP, <sup>4</sup>National Hospital Organization Iwakuni Clinical Center, Iwakuni, Yamaguchi, JP, <sup>5</sup>Niigata University Medical & Dental Hospital, Niigata, JP, <sup>6</sup>NTT



Medical Center Tokyo, Tokyo, JP, <sup>7</sup>National Hospital Organization Toneyama National Hospital, Toyonaka, JP, <sup>8</sup>Matsusaka City Hospital, Matsusaka, JP, <sup>9</sup>Tohoku University, Sendai, JP, <sup>10</sup>Kyoto University Graduate School of Medicine 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JP, <sup>11</sup>Saitama Medical University Internatl Medical Centre, Saitama, JP

- 12:50 - 12:50 **1446P - Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: analysis of tyrosine kinase inhibitors sequence.**  
R. Flippot<sup>1</sup>, E. Auclin<sup>2</sup>, P. Biondani<sup>3</sup>, E. Le Rhun<sup>4</sup>, J. Adam<sup>1</sup>, D. Planchard<sup>1</sup>, C. Caramella<sup>5</sup>, C. Le Pechoux<sup>1</sup>, L. Lacroix<sup>1</sup>, A. Gazzah<sup>1</sup>, L. Mezquita Pérez<sup>5</sup>, B. Besse<sup>6</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Hopital European George Pompidou, Paris, FR, <sup>3</sup>Hôpital Paul Brousse, Villejuif, FR, <sup>4</sup>Roger Salengro Hospital, Lille, FR, <sup>5</sup>Gustave Roussy, Villejuif, FR, <sup>6</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:50 - 12:50 **1447P - Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts**  
J. Roeper<sup>1</sup>, M. Falk<sup>2</sup>, S. Schatz<sup>2</sup>, M. Tiemann<sup>3</sup>, C. Wesseler<sup>4</sup>, G. Wiest<sup>4</sup>, S. Sackmann<sup>5</sup>, D. Ukena<sup>5</sup>, L. Heukamp<sup>6</sup>, F. Griesinger<sup>7</sup>, <sup>1</sup>Pius Hospital Oldenburg, University of Oldenburg, Berlin, DE, <sup>2</sup>Hematopathology Hamburg, Hamburg, DE, <sup>3</sup>Hematopathology Hamburg, Berlin, DE, <sup>4</sup>Asklepios Klinik Harburg, Hamburg, DE, <sup>5</sup>Klinikum Bremen-Ost, Bremen, DE, <sup>6</sup>New Oncology, Köln, DE, <sup>7</sup>Pius Hospital, Oldenburg, DE
- 12:50 - 12:50 **1448P - Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss Cohort Study**  
S. Schmid<sup>1</sup>, D. Klingbiel<sup>2</sup>, S. Aeppli<sup>3</sup>, C. Britschgi<sup>4</sup>, O. Gautschi<sup>5</sup>, M. Pless<sup>6</sup>, S. Rothschild<sup>7</sup>, L. Wannesson De Nicola<sup>8</sup>, W.-D. Janthur<sup>9</sup>, D. Foerbs<sup>1</sup>, I. Demmer<sup>1</sup>, W. Jochum<sup>1</sup>, M. Früh<sup>10</sup>, <sup>1</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>2</sup>SAKK, Bern, CH, <sup>3</sup>Kantonsspital St. Gallen, Bern, CH, <sup>4</sup>Universitätsspital Zürich, Zürich, CH, <sup>5</sup>Cantonal Hospital Lucerne, Lucern, CH, <sup>6</sup>Kantonsspital Winterthur, Winterthur, CH, <sup>7</sup>Universitätsspital Basel, Basel, CH, <sup>8</sup>IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, <sup>9</sup>Kantonsspital Aarau ZOHT, Aarau, CH, <sup>10</sup>Cantonal Hospital St. Gallen, St. Gallen, CH
- 12:50 - 12:50 **1449P - Efficacy of Afatinib in the clinical practice - First results of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany**  
W. Brueckl<sup>1</sup>, E. Laack<sup>2</sup>, M. Reck<sup>3</sup>, F. Griesinger<sup>4</sup>, H. Schäfer<sup>5</sup>, C. Kortsik<sup>6</sup>, T. Gaska<sup>7</sup>, J. Rawluk<sup>8</sup>, S. Krüger<sup>9</sup>, K. Kokowski<sup>10</sup>, S. Budweiser<sup>11</sup>, A. Schueler<sup>12</sup>, S. Kiessling<sup>12</sup>, <sup>1</sup>Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nuremberg, DE, <sup>2</sup>Hämatologie-Onkologie Hamburg, Berlin, DE, <sup>3</sup>Krankenhaus Grosshansdorf, Grosshansdorf, DE, <sup>4</sup>Pius Hospital, Oldenburg, DE, <sup>5</sup>Klinikum Neuperlach-Staedtisches Klinikum Muenchen, Munich, DE, <sup>6</sup>KKM St.Hildegardis Krankenhaus, Mainz, DE, <sup>7</sup>Bruederkrankenhaus St. Josef, Paderborn, DE, <sup>8</sup>Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg, DE, <sup>9</sup>Florence-Nightingale-Hospital, Düsseldorf, DE, <sup>10</sup>Krankenhaus München Bogenhausen II Med. Abteilung, Munich, DE, <sup>11</sup>RoMed Clinical Centre, Rosenheim, DE, <sup>12</sup>Boehringer Ingelheim - Germany, Ingelheim am Rhein, DE

- 12:50 - 12:50 **1450P - Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small-cell lung cancer**  
B. Van Veggel<sup>1</sup>, A. Van Der Wekken<sup>2</sup>, S. Hashemi<sup>3</sup>, R. Cornelissen<sup>4</sup>, K. Monkhorst<sup>1</sup>, D. Heideman<sup>3</sup>, T. Radonic<sup>3</sup>, E. Smit<sup>5</sup>, E. Schuurin<sup>6</sup>, J. De Langen<sup>7</sup>, <sup>1</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>2</sup>University of Groningen, Groningen, NL, <sup>3</sup>VU University Medical Center, Amsterdam, NL, <sup>4</sup>Erasmus MC, Rotterdam, NL, <sup>5</sup>VU University Medical Centre, Amsterdam, NL, <sup>6</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>7</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL
- 12:50 - 12:50 **1451P - The characteristics and clinical outcome of metastatic NSCLC harboring uncommon EGFR mutation at Thailand's tertiary referral center.**  
J. Chantharasamee, N. Pongvarin, P. Danchaiwijitr, S. Techawatanawanna, Siriraj Hospital, Mahidol University, Bangkok, TH
- 12:50 - 12:50 **1452P - Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation**  
S. Viteri<sup>1</sup>, G.-C. Chang<sup>2</sup>, R. Chiari<sup>3</sup>, B.C. Cho<sup>4</sup>, F. Ciardiello<sup>5</sup>, G. Curigliano<sup>6</sup>, T. Hida<sup>7</sup>, D.H. Lee<sup>8</sup>, W. Lim<sup>9</sup>, C.-C. Lin<sup>10</sup>, A. Martinez<sup>11</sup>, H. Murakami<sup>12</sup>, I. Natsume<sup>13</sup>, M. Nishio<sup>14</sup>, L. Paz-Ares<sup>15</sup>, R. Soo<sup>16</sup>, V. Cattan<sup>17</sup>, E. Gandossi<sup>18</sup>, H. Heck<sup>17</sup>, K. Park<sup>19</sup>, <sup>1</sup>Instituto Universitario USP Dexeus, Barcelona, ES, <sup>2</sup>Taichung Veterans General Hospital, Taichung, TW, <sup>3</sup>Azienda Ospedaliera di Perugia S. Maria della Misericordia, Perugia, IT, <sup>4</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>5</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>6</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>7</sup>Department of Thoracic Oncology, Aichi, JP, <sup>8</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>9</sup>National Cancer Centre Singapore, Singapore, SG, <sup>10</sup>National Taiwan University Hospital, Taipei city, TW, <sup>11</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>12</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>13</sup>Yokosuka Kyosai Hospital, Yokosuka Kyosai, JP, <sup>14</sup>The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, <sup>15</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>16</sup>National University Hospital, Singapore, SG, <sup>17</sup>Servier, Suresnes, FR, <sup>18</sup>Servier France, Suresnes, FR, <sup>19</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR
- 12:50 - 12:50 **1453P - Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data**  
C. Escriu<sup>1</sup>, M. Sallam<sup>2</sup>, L. Del Carpio<sup>3</sup>, N. Tokaca<sup>4</sup>, L. Solway<sup>5</sup>, R. Shah<sup>6</sup>, A. Fouzia<sup>7</sup>, Q. Ghafoor<sup>5</sup>, S. Popat<sup>8</sup>, P. Postmus<sup>9</sup>, <sup>1</sup>Clatterbridge Cancer Center, Wirral, GB, <sup>2</sup>University of Liverpool, Liverpool, GB, <sup>3</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>4</sup>The Royal Marsden NHS Foundation Trust, London, GB, <sup>5</sup>University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, <sup>6</sup>Maidstone and Tunbridge Wells NHS Trust, Maidstone, GB, <sup>7</sup>The Clatterbridge Cancer Center, Merseyside, GB, <sup>8</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>9</sup>Leiden University Medical Center (LUMC), Leiden, NL
- 12:50 - 12:50 **1454P - EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Nationwide register-based cohort study in Sweden**

S. Bergström<sup>1</sup>, H. Nordahl Christensen<sup>2</sup>, F. Wiklund<sup>3</sup>, M. Bergqvist<sup>4</sup>, <sup>1</sup>Sjukhus Gavle, Gävle, SE, <sup>2</sup>AstraZeneca, Södertälje, SE, <sup>3</sup>Statisticon AB, Stockholm, SE, <sup>4</sup>Umeå University, Umeå, SE

12:50 - 12:50

**1455P - Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real World Data of 1354 patients with EGFR mutant NSCLC**

K. Ito<sup>1</sup>, K. Murotani<sup>2</sup>, A. Kubo<sup>3</sup>, E. Kunii<sup>4</sup>, H. Taniguchi<sup>5</sup>, J. Shindo<sup>6</sup>, K. Asada<sup>7</sup>, K. Imaizumi<sup>8</sup>, K. Tanaka<sup>9</sup>, N. Inui<sup>9</sup>, M. Okuno<sup>10</sup>, O. Hataji<sup>1</sup>, S. Hayai<sup>11</sup>, T. Abe<sup>6</sup>, T. Kimura<sup>11</sup>, T. Tsuda<sup>5</sup>, T. Yamaguchi<sup>12</sup>, Y. Oya<sup>12</sup>, T. Yoshida<sup>13</sup>, T. Hida<sup>14</sup>, <sup>1</sup>Matsusaka City Hospital, Matsusaka, JP, <sup>2</sup>ichi Medical University Hospital, Nagakute, JP, <sup>3</sup>Aichi Medical University School of Medicine, Nagakute, JP, <sup>4</sup>Nagoya City West Medical Center, Nagoya, JP, <sup>5</sup>Toyama Prefectural Central Hospital, Toyama, JP, <sup>6</sup>Ogaki Municipal Hospital, Ogaki, JP, <sup>7</sup>Sizuoka General Hospital, Sizuoka, JP, <sup>8</sup>Fujita Health University School of Medicine, Toyoake, JP, <sup>9</sup>Hamamatsu University School of Medicine, Hamamatsu, JP, <sup>10</sup>Aichi Cancer Center, Aichi Hospital, Okazaki, JP, <sup>11</sup>Tosei General Hospital, Seto, JP, <sup>12</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>13</sup>New York University, New York, US, <sup>14</sup>Department of Thoracic Oncology, Aichi, JP

12:50 - 12:50

**1456P - Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged >70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: preliminary results**

K. Reckamp<sup>1</sup>, P. Gilman<sup>2</sup>, B. Halmos<sup>3</sup>, M. Jahanzeb<sup>4</sup>, J. Mccann<sup>5</sup>, H. Paripati<sup>6</sup>, L. Seneviratne<sup>7</sup>, J. Wallace<sup>8</sup>, B. Rueter<sup>9</sup>, A. Esler<sup>10</sup>, E. Dowling<sup>9</sup>, M. Koczywas<sup>11</sup>, <sup>1</sup>City of Hope, Duarte, US, <sup>2</sup>Lankenau Medical Center, Wynnewood, US, <sup>3</sup>Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, US, <sup>4</sup>University of Miami, Deerfield Beach, US, <sup>5</sup>Baystate Regional Cancer Program, Springfield, US, <sup>6</sup>Mayo Clinic, Phoenix, US, <sup>7</sup>Los Angeles Cancer Network, Los Angeles, US, <sup>8</sup>The University of Chicago Medicine, Harvey, US, <sup>9</sup>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, US, <sup>10</sup>Syneos Health, Raleigh, US, <sup>11</sup>City of Hope Comprehensive Cancer Center, Duarte, US

12:50 - 12:50

**1457P - Is There a Difference in PFS or OS of T790M-Mutated NSCLC Patients Treated with Osimertinib either after Chemotherapy or Immediately after Previous Target Therapy?**

C.H. Lai<sup>1</sup>, M.-C. Lin<sup>2</sup>, Y.-H. Tsai<sup>2</sup>, C.-C. Wang<sup>2</sup>, <sup>1</sup>Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, TW, <sup>2</sup>Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung city, TW

12:50 - 12:50

**1458P - Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma**

X. Zheng, C. Huang, G. Lin, Fujian Cancer Hospital, Fuzhou, CN

12:50 - 12:50

**1459P - Which is better EGFR-TKI followed by osimertinib between afatinib and gefitinib/erlotinib?**

M. Tamiya<sup>1</sup>, A. Tamiya<sup>2</sup>, H. Suzuki<sup>3</sup>, K. Nakahama<sup>4</sup>, Y. Taniguchi<sup>2</sup>, K. Kunimasa<sup>5</sup>, M. Kimura<sup>5</sup>, T. Inoue<sup>5</sup>, K. Nishino<sup>6</sup>, T. Hirashima<sup>7</sup>, S. Atagi<sup>4</sup>, F. Imamura<sup>8</sup>, T. Kumagai<sup>5</sup>, <sup>1</sup>Osaka Prefectural Habikino Hospital, Habikino, JP, <sup>2</sup>Kinki-chuo Chest Medical Center, Sakai, JP, <sup>3</sup>Osaka Habikino Medical Center, Osaka, JP, <sup>4</sup>National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, JP, <sup>5</sup>Osaka International Cancer Institute,



Osaka, JP, <sup>6</sup>Osaka International Cancer Institute, Osaka, JP, <sup>7</sup>Osaka Habikino Medical Center, Habikino, JP, <sup>8</sup>Osaka International Cancer Institution, Osaka, JP

- 12:50 - 12:50 **1460P - Biopsy on Progression in EGFR Mutation Positive (EGFRm) Advanced Non-Small Cell Lung Cancer (aNSCLC) patients (pts) - A Canadian Experience.**  
Q.S.-C. Chu<sup>1</sup>, A. Agha<sup>2</sup>, N. Devost<sup>3</sup>, R. Walton<sup>3</sup>, S. Ghosh<sup>1</sup>, C. Ho<sup>4</sup>, <sup>1</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>2</sup>University of British Columbia, Vancouver, CA, <sup>3</sup>Astra Zeneca, Toronto, CA, <sup>4</sup>BC Cancer Research Center, Vancouver, CA
- 12:50 - 12:50 **1461P - ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC); European subset**  
M. Tiseo<sup>1</sup>, A. Santo<sup>2</sup>, M. Hochmair<sup>3</sup>, T. Geldart<sup>4</sup>, G. Metro<sup>5</sup>, E. Hanrahan<sup>6</sup>, K. Lamberg<sup>7</sup>, T. Moran<sup>8</sup>, C. Nyhus<sup>9</sup>, A. Paredes<sup>10</sup>, J. Vansteenkiste<sup>11</sup>, D. Vicente<sup>12</sup>, M. Miranda<sup>13</sup>, J. Rigas<sup>14</sup>, F. De Marinis<sup>15</sup>, <sup>1</sup>AOU di Parma, Parma, IT, <sup>2</sup>University of Verona, AOUI Verona, Verona, IT, <sup>3</sup>Otto Wagner Spital, Vienna, AT, <sup>4</sup>Royal Bournemouth Hospital, Bournemouth, GB, <sup>5</sup>Azienda Ospedaliera di Perugia S. Maria della Misericordia, Perugia, IT, <sup>6</sup>St Vincents University Hospital, Dublin, IE, <sup>7</sup>Uppsala University Hospital, Uppsala, SE, <sup>8</sup>ICO Badalona, Badalona, ES, <sup>9</sup>Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, <sup>10</sup>The Ohio State University Wexner Medical Center, Columbus, US, <sup>11</sup>University Hospitals Leuven, Leuven, BE, <sup>12</sup>Hospital Universitario Virgen Macarena, Seville, ES, <sup>13</sup>AstraZeneca, Cambridge, GB, <sup>14</sup>AstraZeneca, Gaithersburg, US, <sup>15</sup>Istituto Europeo di Oncologia, Milan, IT
- 12:50 - 12:50 **1462P - Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts).**  
R. Tay<sup>1</sup>, J. Chiramel<sup>2</sup>, E. Montague<sup>2</sup>, F. Wilson<sup>2</sup>, Y. Summers<sup>2</sup>, F. Blackhall<sup>2</sup>, R. Califano<sup>2</sup>, <sup>1</sup>Box Hill Hospital-Eastern health, Box Hill, AU, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB
- 12:50 - 12:50 **1463P - Updated results of M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- $\alpha$  and PD-L1, in second-line (2L) NSCLC**  
L. Paz-Ares<sup>1</sup>, T.M. Kim<sup>2</sup>, D. Vincente<sup>3</sup>, E. Felip<sup>4</sup>, D.H. Lee<sup>5</sup>, K. Lee<sup>6</sup>, C.-C. Lin<sup>7</sup>, M. Oncala<sup>8</sup>, M. Di Nicola<sup>9</sup>, R.M. Alvarez<sup>10</sup>, I. Dussault<sup>11</sup>, C. Helwig<sup>12</sup>, L. Ojalvo<sup>11</sup>, J. Gulley<sup>13</sup>, B.C. Cho<sup>14</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Hospital Universitario Virgen Macarena, Sevilla, ES, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>University of Ulsan College of Medicine, Seoul, KR, <sup>6</sup>Chungbuk National University, Chungcheongbukdo, KR, <sup>7</sup>National Taiwan University Hospital, Taipei city, TW, <sup>8</sup>Jesus Corral Virgen Del Rocio Hospital, Seville, ES, <sup>9</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>10</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>11</sup>EMD Serono, Billerica, US, <sup>12</sup>Merck KGaA, Darmstadt, DE, <sup>13</sup>National Cancer Institute, Bethesda, US, <sup>14</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
- 12:50 - 12:50 **1464P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: does choice of platinum affect outcomes?**  
D. Rodriguez Abreu<sup>1</sup>, M. Garassino<sup>2</sup>, E. Esteban<sup>3</sup>, G. Speranza<sup>4</sup>, E. Felip<sup>5</sup>, M. Domine<sup>6</sup>,



M. Hochmair<sup>7</sup>, S. Powell<sup>8</sup>, S. Cheng<sup>9</sup>, H. Bischoff<sup>10</sup>, N. Peled<sup>11</sup>, R. Hui<sup>12</sup>, M. Reck<sup>13</sup>, E. Garon<sup>14</sup>, M. Boyer<sup>15</sup>, F. Grossi<sup>16</sup>, R. Jennens<sup>17</sup>, J. Yang<sup>18</sup>, M.C. Pietanza<sup>19</sup>, S. Gadgeel<sup>20</sup>,  
<sup>1</sup>Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>Hospital Universitario Central de Asturias, Oviedo, ES, <sup>4</sup>Hôpital Charles Le Moyne, Greenfield Park, CA, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Instituto de Investigación Sanitaria- Fundación Jiménez Díaz, Madrid, ES, <sup>7</sup>Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Vienna, AT, <sup>8</sup>Sanford Health, Sioux Falls, US, <sup>9</sup>Sunnybrook Health Sciences Centre, Toronto, CA, <sup>10</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>11</sup>Soroka University Medical Center, Beer Sheva, IL, <sup>12</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>13</sup>Krankenhaus Grosshansdorf, Grosshansdorf, DE, <sup>14</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>15</sup>Chris O'Brien Lifehouse, Camperdown, AU, <sup>16</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>17</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>18</sup>Merck & Co., Inc., Kenilworth, US, <sup>19</sup>Merck & Co, Rahway, US, <sup>20</sup>University of Michigan, Ann Arbor, US

12:50 - 12:50

**1465P - Phase 1 Dose Escalation of Pembrolizumab Given Concurrently with Palliative Thoracic Radiotherapy (RT) for NSCLC**

R. Kumar<sup>1</sup>, D. Walder<sup>2</sup>, A. Pejanaute<sup>3</sup>, R. Gunapala<sup>3</sup>, J. Bhosle<sup>3</sup>, N. Yousef<sup>3</sup>, S. Popat<sup>3</sup>, F. Mcdonald<sup>3</sup>, I. Locke<sup>3</sup>, K. Harrington<sup>2</sup>, A. Tree<sup>2</sup>, S. Lalondrelle<sup>3</sup>, R. Huddart<sup>2</sup>, M. O'Brien<sup>2</sup>, M. Ahmed<sup>2</sup>, <sup>1</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>2</sup>The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, GB, <sup>3</sup>The Royal Marsden NHS Foundation Trust, London, GB

12:50 - 12:50

**1466P - Effects of antibiotic use during immunotherapy in metastatic non small cell lung cancer**

G. Galli<sup>1</sup>, M. Poggi<sup>2</sup>, G. Fucà<sup>3</sup>, M. Imbimbo<sup>2</sup>, C. Proto<sup>3</sup>, D. Signorelli<sup>2</sup>, M. Vitali<sup>3</sup>, N. Zilembo<sup>3</sup>, M. Ganzinelli<sup>2</sup>, F. De Braud<sup>2</sup>, M. Garassino<sup>1</sup>, G. Lo Russo<sup>2</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

12:50 - 12:50

**1467P - Efficacy and safety of nivolumab for cytotoxic chemotherapy unfit patients with advanced non-small cell lung cancer: A phase II study**

Y. Okuma<sup>1</sup>, S. Kitano<sup>2</sup>, K. Watanabe<sup>1</sup>, M. Yomota<sup>1</sup>, Y. Hosomi<sup>1</sup>, Y. Zenke<sup>3</sup>, N. Yamamoto<sup>2</sup>, <sup>1</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP

12:50 - 12:50

**1468P - GECP 1605/NIVEX TRIAL. Nivolumab in the real world: the SPANISH expanded access program experience in pretreated advanced NSCLC**

M. Majem Tarruella<sup>1</sup>, J. Campillo<sup>2</sup>, J.F. Grau Béjar<sup>3</sup>, E. Carcereny<sup>4</sup>, R. Bernabe Caro<sup>5</sup>, Y. Garcia<sup>6</sup>, A. Artal-Cortes<sup>7</sup>, M. González Cao<sup>8</sup>, P. Lianes<sup>9</sup>, A. Paredes Lario<sup>10</sup>, M. Sereno Moyano<sup>11</sup>, X. Mielgo Rubio<sup>12</sup>, J.A. Macias<sup>13</sup>, M. Provencio Pulla<sup>14</sup>, D. Rodriguez-Abreu<sup>15</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>2</sup>Hospital Virgen de la Arrixaca, Murcia, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Catalan Institute of Oncology, Badalona, ES, <sup>5</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES,

<sup>6</sup>Corporació Sanitaria Parc Taulí, Sabadell, ES, <sup>7</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>8</sup>QuironSalud Dexeus University Institute, IOR, Barcelona, ES, <sup>9</sup>Hospital de Mataró, Mataró, ES, <sup>10</sup>Hospital Donostia, San Sebastian, ES, <sup>11</sup>Hospital Infanta Sofia, Madrid, ES, <sup>12</sup>Hospital Universitario Fundación Alcorcón, Madrid, ES, <sup>13</sup>Hospital Morales Messeguer, Murcia, ES, <sup>14</sup>Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, ES, <sup>15</sup>Hospital Insular De Gran Canaria, Las Palmas, ES

12:50 - 12:50

**1469P - EVIDENS: An observational study of Nivolumab-treated patients in Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-world Setting: initial results on 1394 Patients (NCT03382496, BMS sponsored)**

A. Dixmier<sup>1</sup>, D. Debieuvre<sup>2</sup>, C. Raspaud<sup>3</sup>, J.B. Auliac<sup>4</sup>, N. Benoit<sup>5</sup>, P. Bombaron<sup>6</sup>, B. Asselain<sup>7</sup>, A. Dumont<sup>8</sup>, P. Lamoureux<sup>9</sup>, N. Goyard<sup>8</sup>, D. Moro-Sibilot<sup>10</sup>, M. Perol<sup>11</sup>, F. Barlesi<sup>12</sup>, C. Audigier Valette<sup>13</sup>, <sup>1</sup>C.H.R. Orleans - La Source, Orleans, FR, <sup>2</sup>Hopital Emile Muller, Mulhouse, FR, <sup>3</sup>Clinique Pasteur, Toulouse, FR, <sup>4</sup>CH François Quesnay, Mantes La Jolie, FR, <sup>5</sup>Clinique de l'Europe, Amiens, FR, <sup>6</sup>Hôpital privé Jean Mermoz, Lyon, FR, <sup>7</sup>Institut Curie GINECO, Paris, FR, <sup>8</sup>Bristol-Myers Squibb, Rueil-Malmaison, FR, <sup>9</sup>Bristol-Myers Squibb, Vandoeuvre les Nancy, FR, <sup>10</sup>Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, FR, <sup>11</sup>Centre Léon Bérard, Lyon, FR, <sup>12</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>13</sup>Hospital Sainte Musse, Toulon, FR

12:50 - 12:50

**1470P - Fractional polynomial network meta-analysis: a different approach to indirectly assess the comparative efficacy of 2L+ cancer immunotherapy (CIT) treatments for metastatic NSCLC**

C. Schulz<sup>1</sup>, P. Chu<sup>2</sup>, C. Berardo<sup>3</sup>, B. Karthuria<sup>2</sup>, J. Foo<sup>4</sup>, C. Morel<sup>4</sup>, C. Watkins<sup>5</sup>, M. Ballinger<sup>6</sup>, D. Gandara<sup>7</sup>, <sup>1</sup>University of Regensburg, Regensburg, DE, <sup>2</sup>F. Hoffman-La Roche Ltd., Basel, CH, <sup>3</sup>Home - Carmen Berardo, Oberwil, CH, <sup>4</sup>Mapi Group, Houten, NL, <sup>5</sup>Clarostat Consulting, Cheshire, GB, <sup>6</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>7</sup>University of California Davis Cancer Center, Sacramento, US

12:50 - 12:50

**1471P - Prior or Concurrent Radiotherapy and Nivolumab Immunotherapy in Non-Small Cell Lung Cancer**

G. Ratnayake<sup>1</sup>, M. Shankar<sup>2</sup>, K. Roberts<sup>3</sup>, R. Mason<sup>4</sup>, B. Hughes<sup>1</sup>, Z. Lwin<sup>1</sup>, V. Jain<sup>3</sup>, K. O'Byrne<sup>5</sup>, B. Chua<sup>1</sup>, <sup>1</sup>Royal Brisbane and Women's Hospital, Brisbane, AU, <sup>2</sup>Townsville Hospital, Townsville, AU, <sup>3</sup>Mater Adults Hospital, Brisbane, AU, <sup>4</sup>Princess Alexandra Hospital, Brisbane, AU, <sup>5</sup>Princess Alexandra Hospital, Woolloongabba, AU

12:50 - 12:50

**1472P - Immunotherapy in elderly patients (> 75 yrs) with advanced Non-Small-Cell Lung Cancer (NSCLC): a multicenter Italian experience.**

A. Luciani<sup>1</sup>, L. Toschi<sup>2</sup>, S. Fava<sup>3</sup>, D. Cortinovis<sup>4</sup>, V. Filipazzi<sup>5</sup>, A. Tuzi<sup>6</sup>, A. Marra<sup>4</sup>, S. Rossi<sup>2</sup>, A. Rossi<sup>7</sup>, M. Blasi<sup>8</sup>, M. Violati<sup>8</sup>, L. Sala<sup>4</sup>, F. Agustoni<sup>9</sup>, P. Bidoli<sup>10</sup>, S. Zonato<sup>1</sup>, D. Ferrari<sup>11</sup>, <sup>1</sup>Azienda Ospedaliera S. Paolo, Milan, IT, <sup>2</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>3</sup>Ospedale Civile di Legnano, Legnano, IT, <sup>4</sup>Azienda Ospedaliera S. Gerardo U.O. Oncologia Medica, Monza, IT, <sup>5</sup>Ospedale Luigi Sacco, Milano, IT, <sup>6</sup>Ospedale di Circolo Fondazione Macchi, Varese, IT, <sup>7</sup>Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT, <sup>8</sup>ASST Santi Paolo e Carlo, Milan, IT, <sup>9</sup>AO San Gerardo, Monza, IT, <sup>10</sup>San Gerardo dei Tintori Hospital, monza, IT, <sup>11</sup>azienda ospedaliera san paolo, milano, IT

12:50 - 12:50

**1473P - Immune checkpoint inhibitor efficacy and safety in elderly non-small**

**cell lung cancer patients**

T. Kubo<sup>1</sup>, H. Watanabe<sup>1</sup>, K. Ninomiya<sup>1</sup>, K. Kudo<sup>2</sup>, D. Minami<sup>3</sup>, E. Murakami<sup>4</sup>, N. Ochi<sup>5</sup>, T. Ninomiya<sup>6</sup>, D. Harada<sup>7</sup>, M. Yasugi<sup>8</sup>, E. Ichihara<sup>1</sup>, K. Ohashi<sup>1</sup>, K. Fujiwara<sup>3</sup>, K. Hotta<sup>9</sup>, M. Tabata<sup>1</sup>, Y. Maeda<sup>10</sup>, K. Kiura<sup>1</sup>, <sup>1</sup>Okayama University Hospital, Okayama, JP, <sup>2</sup>Iwakuni Medical Center, Iwakuni, JP, <sup>3</sup>Okayama Medical Center, Okayama, JP, <sup>4</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>5</sup>General Internal Medicine 4, Okayama, JP, <sup>6</sup>Okayama University, Okayama, JP, <sup>7</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>8</sup>Respiratory Medicine, Fukuyama, JP, <sup>9</sup>Okayama University Hospital, Okayama, JP, <sup>10</sup>Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JP

12:50 - 12:50 **1474P - Nivolumab in Non Small Cell Lung Cancer: French evaluation of use, current practices and medico economic approach**

F. Grude<sup>1</sup>, R. Corre<sup>2</sup>, T. Urban<sup>3</sup>, J. Bennouna<sup>4</sup>, G. De Chabot<sup>3</sup>, T. Chatellier<sup>5</sup>, F. Denis<sup>6</sup>, R. Descourt<sup>7</sup>, J.-Y. Douillard<sup>8</sup>, C. Ricordel<sup>2</sup>, O. Molinier<sup>9</sup>, F. Pinguet<sup>3</sup>, G. Robinet<sup>7</sup>, M. Travers<sup>10</sup>, B. Moiteaux<sup>11</sup>, D. Deniel Lagadec<sup>12</sup>, F. Marhuenda<sup>13</sup>, <sup>1</sup>Centre Paul Papin, Angers, FR, <sup>2</sup>CHU de Pontchaillou, Rennes, FR, <sup>3</sup>CHU Angers, Angers, FR, <sup>4</sup>CHU de Nantes, Nantes, FR, <sup>5</sup>Clinique Mutualiste de l'Estuaire, Saint Nazaire, FR, <sup>6</sup>Clinique Victor Hugo Le Mans, Le Mans, FR, <sup>7</sup>C.H.U. Brest - Hôpital Morvan, Brest, FR, <sup>8</sup>ESMO - European Society for Medical Oncology, Lugano - Viganello, CH, <sup>9</sup>Centre Hospitalier Du Mans, Le Mans, FR, <sup>10</sup>Université de Nantes, NANTES, FR, <sup>11</sup>university of Nantes, Nantes, FR, <sup>12</sup>CHRU BREST, BREST, FR, <sup>13</sup>ICO Paul Papin, ANGERS, FR

12:50 - 12:50 **1475P - Radiological identification of rapid progressions in advanced NSCLC patients treated with Nivolumab.**

P. Simões Da Rocha<sup>1</sup>, E. Ripoll<sup>2</sup>, A. Corbera<sup>2</sup>, M. Hardy-Werbin<sup>2</sup>, A.F. Fernandez-Alarza<sup>2</sup>, M. Orrillo<sup>2</sup>, Á. Taus<sup>2</sup>, E. Arriola<sup>2</sup>, <sup>1</sup>University Hospital del Mar, Barcelona, ES, <sup>2</sup>Hospital del Mar, Barcelona, ES

12:50 - 12:50 **1476P - Role of Immunotherapy (I) for advanced. pre-treated, non-squamous NSCLC (APNS-NSCLC). Preliminary data of a pooled analysis with network meta-analysis.**

C. Cherubini, M. Papi, L. Gianni, C. Gianni, S.V.L. Nicoletti, M. Fantini, L.A. Lazzari Agli, D. Tassinari, Ospedale Infermi, Rimini, IT

12:50 - 12:50 **1477P - Evaluation of Progression-Free Survival (PFS) and One-Year (1y) Survival as Surrogate Endpoints (SE) in Previously Treated Advanced Non-Small Cell Lung Cancer (adNSCLC) in the Era of Immuno-Oncology (IO)**

S. Zhao, Z. Zhang, T. Zhou, Y. Zhang, L. Zhang, Sun Yat-sen University Cancer Center, Guangzhou, CN

12:50 - 12:50 **1478P - Efficacy of second-line nivolumab after early time to progression on first-line cytotoxic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).**

T. Ota, K. Kirita, H. Udagawa, S. Umemura, S. Matsumoto, K. Yoh, S. Niho, K. Goto, National Cancer Center Hospital East, Kashiwa, JP

12:50 - 12:50 **1479P - First analysis of patients (p) with stage IV Non-Small Cell Lung Cancer (NSCLC) of the Thoracic Tumor Registry (RTT) of the Spanish Lung Cancer**



**Group (SLCG)**

E. Carcereny Costa<sup>1</sup>, D. Rodriguez-Abreu<sup>2</sup>, M. Guirado<sup>3</sup>, R. López-Castro<sup>4</sup>, B. Massutí<sup>5</sup>, J. Bosch Barrera<sup>6</sup>, E. Nogueron Martinez<sup>7</sup>, M.A. Sala Gonzalez<sup>8</sup>, M. Domine Gomez<sup>9</sup>, E. Del Barco Morillo<sup>10</sup>, S. Cerezo Gonzalez<sup>11</sup>, M. Dorta Suarez<sup>12</sup>, J. Casal Rubio<sup>13</sup>, C. Camps<sup>14</sup>, M.A. Muñoz<sup>15</sup>, R. De Las Peñas<sup>16</sup>, J.A. Ortega Dominguez<sup>17</sup>, J. Gonzalez-Larriba<sup>18</sup>, R. Bernabe Caro<sup>19</sup>, M. Provencio Pulla<sup>20</sup>, <sup>1</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>2</sup>Hospital Insular De Gran Canaria, Las Palmas, ES, <sup>3</sup>Hospital General Universitario de Elche, Elche, ES, <sup>4</sup>Hospital Universitario Clínico de Valladolid, Valladolid, ES, <sup>5</sup>Hospital General Universitario Alicante, Alicante, ES, <sup>6</sup>Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona, ES, <sup>7</sup>Complejo Hospitalario Universitario de Albacete, Albacete, ES, <sup>8</sup>HOSPITAL DE BASURTO, Vizcaya, ES, <sup>9</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>10</sup>COMPLEJO HOSPITALARIO UNIVERSITARIO DE SALAMANCA, SALAMANCA, ES, <sup>11</sup>Hospital General Mancha Centro, Alcazar de San Juan, ES, <sup>12</sup>Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, ES, <sup>13</sup>Hospital Meixoeiro, Vigo, ES, <sup>14</sup>Consorcio Hospital General Universitario de Valencia, Valencia, ES, <sup>15</sup>INSTITUTO VALENCIANO DE ONCOLOGIA, VALENCIA, ES, <sup>16</sup>Consorcio Hospitalario Provincial de Castellon, CASTELLON, ES, <sup>17</sup>Hospital Universitario Virgen de las Nieves, Granada, ES, <sup>18</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>19</sup>Hospital Universitario Virgen del Rocio, Sevilla, ES, <sup>20</sup>Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, ES

12:50 - 12:50

**1480P\_PR - Effects of physical exercise in non-operable lung cancer patients undergoing palliative treatment**

J. Wiskemann<sup>1</sup>, C. Titz<sup>1</sup>, M. Schmidt<sup>2</sup>, K. Steindorf<sup>2</sup>, C. Ulrich<sup>3</sup>, F. Herth<sup>4</sup>, C. Heussel<sup>4</sup>, H. Winter<sup>4</sup>, M. Steins<sup>5</sup>, S. Hummler<sup>4</sup>, M. Thomas<sup>5</sup>, <sup>1</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, <sup>2</sup>Deutsches Krebsforschungszentrum, Heidelberg, DE, <sup>3</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>4</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>5</sup>Thoraxklinik, Heidelberg, DE

12:50 - 12:50

**1481P - Extra-cost of brain metastases in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis**

N. Girard<sup>1</sup>, D. Cozzone<sup>2</sup>, L. De Léotoing<sup>3</sup>, C. Tournier<sup>3</sup>, A. Vainchtock<sup>3</sup>, B. Tehard<sup>2</sup>, A. Cortot<sup>4</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>Roche S.A.S - France, Boulogne-Billancourt, FR, <sup>3</sup>HEVA, Lyon, FR, <sup>4</sup>CHRU de Lille, Lille, FR

12:50 - 12:50

**1482P - Localablative treatment for synchronous oligometastatic lung cancer - a propensity score analysis of 180 patients**

N. Frost<sup>1</sup>, A. Tessmer<sup>2</sup>, A. Schmittel<sup>3</sup>, V. Van Laak<sup>4</sup>, S. Ochsenreither<sup>5</sup>, B. Temmesfeld-Wollbrück<sup>1</sup>, B. Schmidt<sup>4</sup>, N. Suttorp<sup>1</sup>, M. Witzenrath<sup>1</sup>, C. Grohe<sup>6</sup>, <sup>1</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>2</sup>Evangelische Lungenklinik Berlin-Buch, Berlin, DE, <sup>3</sup>Schwerpunkt Hamatologie und Onkologie - Berlin Facharzt für Innere Medizin, Berlin, DE, <sup>4</sup>DRK-Klinikum Berlin-Mitte, Berlin, DE, <sup>5</sup>Charité University of Medicine, Berlin, DE, <sup>6</sup>Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE

12:50 - 12:50

**1483P - Initial treatment in patients (pts) diagnosed with non-small cell lung cancer (NSCLC) in Denmark from 2005-2015: The SCAN-LEAF study**

J. Sørensen<sup>1</sup>, S. Ekman<sup>2</sup>, P. Horvat<sup>3</sup>, D. Layton<sup>3</sup>, J. Kim<sup>3</sup>, M. Rosenlund<sup>3</sup>, A. Juarez-



Garcia<sup>4</sup>, M. Daumont<sup>5</sup>, H. Jacobs<sup>6</sup>, L. Lacoïn<sup>7</sup>, O.T. Brustugun<sup>8</sup>, M. Planck<sup>9</sup>,  
<sup>1</sup>Rigshospitalet, Copenhagen, DK, <sup>2</sup>Karolinska University Hospital-Solna, Stockholm, SE,  
<sup>3</sup>IQVIA, London, GB, <sup>4</sup>Bristol-Myers Squibb, Uxbridge, GB, <sup>5</sup>Bristol-Myers Squibb, Braine  
L'Alleud, BE, <sup>6</sup>BMS, Uxbridge, GB, <sup>7</sup>Bristol-Myers Squibb, Princeton, US,  
<sup>8</sup>Radiumhospitalet, Oslo, NO, <sup>9</sup>Skane University Hospital-Lund, Lund, SE

12:50 - 12:50

**1484P - Treatment patterns in patients (pts) with stage IIIB-IV non-small cell lung cancer (NSCLC) in Sweden: The SCAN-LEAF study**

S. Ekman<sup>1</sup>, M. Planck<sup>2</sup>, J. Sørensen<sup>3</sup>, P. Horvat<sup>4</sup>, D. Layton<sup>4</sup>, J. Kim<sup>4</sup>, M. Rosenlund<sup>4</sup>, A. Juarez-Garcia<sup>5</sup>, M. Daumont<sup>6</sup>, H. Jacobs<sup>7</sup>, L. Lacoïn<sup>8</sup>, O.T. Brustugun<sup>9</sup>, <sup>1</sup>Karolinska University Hospital-Solna, Stockholm, SE, <sup>2</sup>Skane University Hospital-Lund, Lund, SE, <sup>3</sup>Rigshospitalet, Copenhagen, DK, <sup>4</sup>IQVIA, London, GB, <sup>5</sup>Bristol-Myers Squibb, Uxbridge, GB, <sup>6</sup>Bristol-Myers Squibb, Braine L'Alleud, BE, <sup>7</sup>BMS, Uxbridge, GB, <sup>8</sup>Bristol-Myers Squibb, Princeton, US, <sup>9</sup>Radiumhospitalet, Oslo, NO

12:50 - 12:50

**1485P - NSCLC with well controlled extra-cranial disease but uncontrolled brain metastases**

H.A. Jung<sup>1</sup>, K. Park<sup>2</sup>, J.-M. Sun<sup>3</sup>, S.H. Lee<sup>3</sup>, J.S. Ahn<sup>3</sup>, M.-J. Ahn<sup>3</sup>, S. Park<sup>2</sup>, <sup>1</sup>Dongtan Sacred Heart Hospital, Hwanseong-si, KR, <sup>2</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>3</sup>Samsung Medical Center, Seoul, KR

12:50 - 12:50

**1486P - Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): recursive partitioning analysis (RPA) model modification**

C. Salvador Coloma<sup>1</sup>, D. Lorente<sup>2</sup>, C. Escoin<sup>3</sup>, J. Mendez<sup>1</sup>, O. Juan-Vidal<sup>4</sup>, <sup>1</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>2</sup>HULa Fe, Valencia, ES, <sup>3</sup>Hospital La Ribera, Valencia, ES, <sup>4</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES

12:50 - 12:50

**1487P - LURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer**

K. Yoh<sup>1</sup>, T. Seto<sup>2</sup>, M. Satouchi<sup>3</sup>, M. Nishio<sup>4</sup>, N. Yamamoto<sup>5</sup>, H. Murakami<sup>6</sup>, N. Nogami<sup>7</sup>, S. Kuroda<sup>8</sup>, S. Nomura<sup>8</sup>, A. Sato<sup>8</sup>, K. Tsuchihara<sup>8</sup>, T. Kohno<sup>9</sup>, S. Matsumoto<sup>1</sup>, K. Goto<sup>1</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>3</sup>Hyogo Cancer Center, Hyogo, JP, <sup>4</sup>The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, <sup>5</sup>National Cancer Center Hospital, Tokyo, JP, <sup>6</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>7</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>8</sup>National Cancer Center, Kashiwa, JP, <sup>9</sup>National Cancer Center Research Institute, Tokyo, JP

12:50 - 12:50

**1488P - Vemurafenib in patients (pts) harboring BRAF V600 mutation. Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial.**

J. Mazières<sup>1</sup>, L. Montané<sup>2</sup>, F. Barlesi<sup>3</sup>, X. Quantin<sup>4</sup>, J. Trédaniel<sup>5</sup>, J. Le Treut<sup>6</sup>, V. Avrillon<sup>7</sup>, A. Lavolé<sup>8</sup>, V. Westeel<sup>9</sup>, F. Orsini Piocelle<sup>10</sup>, E. Pichon<sup>11</sup>, L. Thiberville<sup>12</sup>, C. Borel<sup>13</sup>, P. Renault<sup>14</sup>, M. Jaffro<sup>1</sup>, S. Collot<sup>1</sup>, G. Ferretti<sup>15</sup>, F. Legrand<sup>16</sup>, C. Mahier Ait Oukhatar<sup>17</sup>, J. Blay<sup>7</sup>, <sup>1</sup>Hospital Larrey, Toulouse, FR, <sup>2</sup>Léon Bérard Center, Lyon, FR, <sup>3</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>4</sup>Hopital Arnaud de Villeneuve, Montpellier, FR, <sup>5</sup>Hospital Groupe Paris Saint Joseph, Paris, FR, <sup>6</sup>CH du Pays d'Aix, Aix-en-Provence, FR, <sup>7</sup>Centre Léon Bérard, Lyon, FR, <sup>8</sup>Hospital Tenon, APHP, Paris, FR,

<sup>9</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>10</sup>Hospital center Annecy Gennevois, Pringy, FR, <sup>11</sup>CHRU Bretonneau, Tours, FR, <sup>12</sup>CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR, <sup>13</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>14</sup>Centre Hospitalier, Pau, FR, <sup>15</sup>Hospital Michallon, Grenoble, FR, <sup>16</sup>Institut National du Cancer, Boulogne-Billancourt, FR, <sup>17</sup>UNICANCER, Paris, FR

- 12:50 - 12:50 **1489P - Treatment Patterns and Overall Survival in Patients With BRAF-Mutated Metastatic Non-Small Cell Lung Cancer**  
R. Goyal<sup>1</sup>, A. Kron<sup>2</sup>, J. Wolf<sup>2</sup>, J. Mazieres<sup>3</sup>, C. Chouaid<sup>4</sup>, K. Davis<sup>1</sup>, M. Perrinjaquet<sup>5</sup>, S. Knoll<sup>6</sup>, <sup>1</sup>RTI Health Solutions, Research Triangle Park, US, <sup>2</sup>University Hospital Cologne, Kerpen, DE, <sup>3</sup>Hospital Larrey, Toulouse, FR, <sup>4</sup>Centre Hospitalier Intercommunal Créteil, Créteil, FR, <sup>5</sup>Navigant, London, GB, <sup>6</sup>Novartis Pharmaceuticals Corporation, East Hanover, US
- 12:50 - 12:50 **1490P - A prospective observational study of HER2 alterations in NSCLCs: HOT1303-A**  
T. Goda<sup>1</sup>, I. Kinoshita<sup>1</sup>, S. Oizumi<sup>2</sup>, K. Nakano<sup>3</sup>, T. Harada<sup>4</sup>, Y. Kawai<sup>5</sup>, J. Sakakibara-Konishi<sup>1</sup>, H. Yokouchi<sup>6</sup>, N. Morikawa<sup>7</sup>, N. Yamada<sup>8</sup>, S. Yamazaki<sup>9</sup>, S. Sugawara<sup>10</sup>, H. Asahina<sup>2</sup>, T. Amano<sup>2</sup>, Y. Hatanaka<sup>2</sup>, Y. Matsuno<sup>2</sup>, H. Nishihara<sup>2</sup>, H. Isobe<sup>11</sup>, M. Nishimura<sup>12</sup>, H. Dosaka-Akita<sup>13</sup>, <sup>1</sup>Hokkaido University, Sapporo, JP, <sup>2</sup>Hokkaido University Hospital, Sapporo, JP, <sup>3</sup>National Hospital Organization Hokkaido Cancer Center, Sapporo, JP, <sup>4</sup>JCHO Hokkaido Hospital, Sapporo, JP, <sup>5</sup>Oji General Hospital, Tomakomai, JP, <sup>6</sup>Fukushima Medical University, Fukushima, JP, <sup>7</sup>Iwate Medical University School of Medicine, Morioka, JP, <sup>8</sup>Iwamizawa Municipal General Hospital, Iwamizawa, JP, <sup>9</sup>Keiyukai Sapporo Hospital, Sapporo, JP, <sup>10</sup>Sendai Kousei Hospital, Sendai, JP, <sup>11</sup>KKR Sapporo Medical Center, sapporo, JP, <sup>12</sup>Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JP, <sup>13</sup>Private Practice, Sapporo, JP
- 12:50 - 12:50 **1491P - A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial**  
I. Kinoshita<sup>1</sup>, T. Goda<sup>1</sup>, K. Watanabe<sup>2</sup>, M. Maemondo<sup>2</sup>, S. Oizumi<sup>3</sup>, T. Amano<sup>3</sup>, Y. Hatanaka<sup>3</sup>, Y. Matsuno<sup>3</sup>, H. Nishihara<sup>3</sup>, H. Asahina<sup>3</sup>, T. Harada<sup>4</sup>, K. Goto<sup>5</sup>, H. Isobe<sup>6</sup>, M. Nishimura<sup>7</sup>, H. Dosaka-Akita<sup>8</sup>, <sup>1</sup>Hokkaido University, Sapporo, JP, <sup>2</sup>Miyagi Cancer Center, Natori, JP, <sup>3</sup>Hokkaido University Hospital, Sapporo, JP, <sup>4</sup>JCHO Hokkaido Hospital, Sapporo, JP, <sup>5</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>6</sup>KKR Sapporo Medical Center, sapporo, JP, <sup>7</sup>Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JP, <sup>8</sup>Private Practice, Sapporo, JP
- 12:50 - 12:50 **1492P - BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: results from a first-in-human, phase 1, dose-escalation study**  
X. Hu<sup>1</sup>, X. Zheng<sup>2</sup>, H. Mo<sup>1</sup>, X. Cui<sup>2</sup>, L. Ding<sup>3</sup>, F. Tan<sup>4</sup>, P. Hu<sup>2</sup>, Y. Shi<sup>1</sup>, <sup>1</sup>Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, CN, <sup>2</sup>Peking Union Medical College Hospital, Beijing, CN, <sup>3</sup>Bettapharma Pharmaceuticals Co.Ltd, Hangzhou, CN, <sup>4</sup>Bettapharma Pharmaceuticals Co.Ltd, Beijing, CN
- 12:50 - 12:50 **1493P - Clinical characteristics and outcomes of non-small cell lung cancer**

**(NSCLC) patients harboring MET exon 14 splice sites mutations.**

P. Jamme<sup>1</sup>, F. Escande<sup>2</sup>, C. Descarpentries<sup>2</sup>, M.C. Copin<sup>2</sup>, E. Dansin<sup>3</sup>, T. Vanparis<sup>4</sup>, D. Tulasne<sup>1</sup>, S. Baldacci<sup>5</sup>, Z. Kherrouche<sup>2</sup>, A. Cortot<sup>6</sup>, <sup>1</sup>Institut Pasteur de Lille, Lille, FR, <sup>2</sup>Centre biologie et pathologie, Chru Lille, Lille, FR, <sup>3</sup>Centre Oscar Lambret, Lille, FR, <sup>4</sup>centre hospitalier de Boulogne-sur-Mer, Boulogne-sur-Mer, FR, <sup>5</sup>Hopital Calmette, CHRU Lille, Lille, FR, <sup>6</sup>CHRU de Lille, Lille, FR

12:50 - 12:50 **1494P - Risk of lung cancer following pulmonary tuberculosis: A nationwide population-based cohort study, South Korea**

S.-S. Han<sup>1</sup>, J. Heo<sup>1</sup>, S.-J. Lee<sup>2</sup>, <sup>1</sup>Kangwon National University Hospital, Chuncheon, KR, <sup>2</sup>Kangwon National University, Chuncheon, KR

12:50 - 12:50 **1495P - Analysis of the relationship between heading N / L and survival in patients treated with Immunotherapy in lung cancer**

N. De Dios Alvare<sup>1</sup>, M. Costa Rivas<sup>1</sup>, S. Agraso Busto<sup>2</sup>, A. Alonso Herrero<sup>3</sup>, M.J. Villanueva Silva<sup>4</sup>, D. Pereiro Corbacho<sup>3</sup>, C. García Benito<sup>1</sup>, <sup>1</sup>Hospital Universitario Alvaro Cunqueiro, Vigo, ES, <sup>2</sup>Hospital Universitario Alvaro Cunqueiro, VIGO, ES, <sup>3</sup>hospital Universitario Alvaro Cunqueiro, vigo, ES, <sup>4</sup>Hospital Universitario Alvaro Cunqueiro, vigo, ES

12:50 - 12:50 **1496P - Intracranial Activity of Ensartinib in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC)**

H. Wakelee<sup>1</sup>, K. Reckamp<sup>2</sup>, T. Leal<sup>3</sup>, S. Patel<sup>4</sup>, G. Blumenschein<sup>5</sup>, E. Shum<sup>6</sup>, J. Nieva<sup>7</sup>, G. Oxnard<sup>8</sup>, R. Sanborn<sup>9</sup>, S. Waqar<sup>10</sup>, K. Zeman<sup>11</sup>, G. Dukart<sup>12</sup>, K. Harrow<sup>13</sup>, C. Liang<sup>12</sup>, A. Holzhausen<sup>12</sup>, L. Horn<sup>14</sup>, <sup>1</sup>Stanford Advanced Medicine Center, Stanford, US, <sup>2</sup>City of Hope, Duarte, US, <sup>3</sup>University of Wisconsin School of Medicine and Public Health, Madison, US, <sup>4</sup>UC San Diego Moores Cancer Center, La Jolla, US, <sup>5</sup>MD Anderson Cancer Center, Houston, US, <sup>6</sup>New York University, New York, US, <sup>7</sup>University of California, San Diego, San Diego, US, <sup>8</sup>Dana-Farber Cancer Institute, Boston, US, <sup>9</sup>Providence Cancer Institute, Portland, US, <sup>10</sup>Washington University Medical School, St. Louis, US, <sup>11</sup>Walter Reed National Military Medical Center, Bethesda, US, <sup>12</sup>Xcovery Holdings, Inc., Palm Beach Gardens, US, <sup>13</sup>Xcovery Holding Company, LLC, Palm Beach Gardens, US, <sup>14</sup>Vanderbilt Ingram Cancer Center, Nashville, US

12:50 - 12:50 **1497P - JNJ-61186372 (JNJ-372), an EGFR-cMET Bispecific Antibody, in Advanced Non-Small Cell Lung Cancer (NSCLC): An Update on Phase 1 Results**

B.C. Cho<sup>1</sup>, J.-S. Lee<sup>2</sup>, J.-Y. Han<sup>3</sup>, E.K. Cho<sup>4</sup>, E. Haura<sup>5</sup>, K.H. Lee<sup>6</sup>, J. Bauml<sup>7</sup>, R. Sanborn<sup>8</sup>, M. Curtis<sup>9</sup>, E. Attiyeh<sup>9</sup>, N. Haddish-Berhane<sup>9</sup>, K. Bae<sup>9</sup>, R. Knoblauch<sup>9</sup>, L. Sherman<sup>9</sup>, M. Lorenzi<sup>9</sup>, K. Park<sup>10</sup>, <sup>1</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>Seoul National University Bundang Hospital, Gyeonggi-do, KR, <sup>3</sup>National Cancer Center, Goyang, KR, <sup>4</sup>Gachon Univeristy Gil Medical Center, Incheon, KR, <sup>5</sup>H. Lee Moffitt Cancer Center, Tampa, US, <sup>6</sup>Chungbuk National University Hospital, Cheongju, KR, <sup>7</sup>Perelman School of Medicine at the University of Pennsylvania, Philadelphia, US, <sup>8</sup>Providence Cancer Institute, Portland, US, <sup>9</sup>Janssen Research & Development, Raritan, US, <sup>10</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR

12:50 - 12:50 **1498P - Optimal interval from preceding radiotherapy (RT) to enhance efficacy**



**of immune check point inhibitors (ICIs): consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC)**

H. Horinouchi<sup>1</sup>, Y. Matsumoto<sup>1</sup>, S. Murakami<sup>1</sup>, Y. Goto<sup>1</sup>, S. Kanda<sup>1</sup>, Y. Fujiwara<sup>1</sup>, N. Yamamoto<sup>1</sup>, Y. Nakayama<sup>2</sup>, Y. Ohe<sup>1</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Kanagawa Cancer Center, Yokohama, JP

12:50 - 12:50 **1499TiP - Tumor Treating Fields concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase 3 LUNAR study**

U. Weinberg<sup>1</sup>, O. Farber<sup>2</sup>, M. Giladi<sup>2</sup>, Z. Bomzon<sup>2</sup>, E. Kirson<sup>2</sup>, <sup>1</sup>Novocure, Luzern, CH, <sup>2</sup>Novocure, Haifa, IL

12:50 - 12:50 **1500TiP - eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients**

L. Horn<sup>1</sup>, Y.-L. Wu<sup>2</sup>, M. Reck<sup>3</sup>, H. Wakelee<sup>4</sup>, C. Liang<sup>5</sup>, K. Harrow<sup>6</sup>, V. Oertel<sup>5</sup>, T. Mok<sup>7</sup>, <sup>1</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>2</sup>Guangdong General Hospital, Guangzhou, CN, <sup>3</sup>Krankenhaus Grosshansdorf, Grosshansdorf, DE, <sup>4</sup>Stanford Advanced Medicine Center, Stanford, US, <sup>5</sup>Xcovery Holdings, Inc., Palm Beach Gardens, US, <sup>6</sup>Xcovery Holding Company, LLC, Palm Beach Gardens, US, <sup>7</sup>Chinese University of Hong Kong, Shatin, CN

12:50 - 12:50 **1501TiP - Afatinib (AFA) plus Bevacizumab (BEV) Combination after Osimertinib (OSIME) failure for advanced EGFR-mutant non-small cell lung cancer (NSCLC): a multicenter prospective single arm phase II study (ABCD-study)**

A. Hata<sup>1</sup>, N. Katakami<sup>2</sup>, K. Nishino<sup>3</sup>, M. Mori<sup>4</sup>, T. Yokoyama<sup>5</sup>, T. Kurata<sup>6</sup>, M. Tachihara<sup>7</sup>, N. Takase<sup>8</sup>, H. Daga<sup>9</sup>, T. Kijima<sup>10</sup>, S. Morita<sup>11</sup>, K. Sakai<sup>12</sup>, K. Nishio<sup>13</sup>, M. Satouchi<sup>14</sup>, S. Negoro<sup>8</sup>, <sup>1</sup>Institute of Biomedical Research and Innovation, Kobe, JP, <sup>2</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>3</sup>Osaka International Cancer Institute, Osaka, JP, <sup>4</sup>National Hospital Organization Toneyama National Hospital, Toyonaka, JP, <sup>5</sup>Kurashiki Central Hospital, Kurashiki, JP, <sup>6</sup>First Department of Internal Medicine, Kansai Medical University, Hirakata, JP, <sup>7</sup>Kobe University Hospital, Kobe, JP, <sup>8</sup>Takarazuka City Hospital, Takarazuka, JP, <sup>9</sup>Osaka City General Hospital, Osaka, JP, <sup>10</sup>Hyogo College of Medicine, Nishinomiya, JP, <sup>11</sup>Kyoto University Graduate School of Medicine 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JP, <sup>12</sup>Kindai University Faculty of Medicine, Osaka-sayama, JP, <sup>13</sup>Kinki University School of Medicine, Osaka, JP, <sup>14</sup>Hyogo Cancer Center, Hyogo, JP

12:50 - 12:50 **1502TiP - FOstering efficacy of anti-PD-1-treatment: nivolumab plus Radiotherapy in advanCED non-small cell lung cancer - the FORCE trial**

F. Bozorgmehr<sup>1</sup>, A. Hommertgen<sup>2</sup>, F. Lasitschka<sup>2</sup>, J. Krisam<sup>3</sup>, J. Debus<sup>2</sup>, J. Fischer<sup>4</sup>, M. Bischof<sup>5</sup>, A. Atmaca<sup>6</sup>, S. Wetzel<sup>7</sup>, M. Faehling<sup>8</sup>, D. Bottke<sup>9</sup>, C. Grohe<sup>10</sup>, W. Engel-Riedel<sup>11</sup>, E. Ingenhoff<sup>12</sup>, D. Heigener<sup>13</sup>, N. Reinmuth<sup>14</sup>, C. Schumann<sup>15</sup>, M. Wermke<sup>16</sup>, M. Thomas<sup>17</sup>, S. Rieken<sup>2</sup>, <sup>1</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>2</sup>Heidelberg University Hospital, Heidelberg, DE, <sup>3</sup>University of Heidelberg, Heidelberg, DE, <sup>4</sup>Klinik Loewenstein GmbH Med Klinik II Onkologie, Loewenstein, DE, <sup>5</sup>Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, Heilbronn, DE, <sup>6</sup>Nordwest-Krankenhaus, Frankfurt am Main, DE, <sup>7</sup>Krankenhaus Nordwest, Frankfurt am Main, DE, <sup>8</sup>Klinikum Esslingen, Esslingen, DE, <sup>9</sup>Hospital Esslingen, Esslingen, DE, <sup>10</sup>Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, <sup>11</sup>Krankenhaus Merheim, Köln, DE,



<sup>12</sup>City of Cologne Municipal Hospitals, Köln, DE, <sup>13</sup>Lungen Clinic Grosshansdorf, Grosshansdorf, DE, <sup>14</sup>Asklepios-Fachklinikum, Gauting, DE, <sup>15</sup>Klinikum Kempten-Oberallgaeu gGmbH, Kempten, DE, <sup>16</sup>University Hospital Carl-Gustav-Carus, Dresden, DE, <sup>17</sup>Thoraxklinik, Heidelberg, DE

- 12:50 - 12:50 **1503TiP - CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC**
- S. Gettinger<sup>1</sup>, T. Beck<sup>2</sup>, X. Yang<sup>3</sup>, B. Telivala<sup>4</sup>, D. Morgensztern<sup>5</sup>, V. Velcheti<sup>6</sup>, S. Ramalingam<sup>7</sup>, K. Schalper<sup>8</sup>, M. Dajee<sup>9</sup>, A. Ranck<sup>9</sup>, R. Yang<sup>9</sup>, D. Spiegel<sup>10</sup>, <sup>1</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>2</sup>Highlands Oncology Group, Fayetteville, US, <sup>3</sup>Bon Secours Saint Francis Cancer Center, Greenville, US, <sup>4</sup>Cancer Specialists of North Florida, Jacksonville, US, <sup>5</sup>Washington University School of Medicine, St. Louis, US, <sup>6</sup>Cleveland Clinic, Cleveland, US, <sup>7</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>8</sup>Yale Cancer Institute, New Haven, US, <sup>9</sup>Bristol-Myers Squibb, Princeton, US, <sup>10</sup>Sarah Cannon Research Institute, Nashville, US
- 12:50 - 12:50 **1504TiP - Nintedanib plus docetaxel in routine clinical practice: VARGADO - a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape**
- C. Grohe<sup>1</sup>, I. Zander<sup>2</sup>, K. Lüdtke-Heckenkamp<sup>3</sup>, W. Blau<sup>4</sup>, S. Krüger<sup>5</sup>, C. Franke<sup>6</sup>, H. Mueller-Huesmann<sup>7</sup>, W. Brückl<sup>8</sup>, N. Basara<sup>9</sup>, D. Ukena<sup>10</sup>, S. Lang<sup>11</sup>, J. Atz<sup>12</sup>, R. Kaiser<sup>12</sup>, <sup>1</sup>Evangelische Lungenklinik ELK Berlin Chest Hospital, Berlin, DE, <sup>2</sup>Dres. Zander und Buchholz, Hannover, DE, <sup>3</sup>MVZ Onkologie, Niels-Stensen-Kliniken GmbH, Osnabrück, DE, <sup>4</sup>Universitätsklinik Giessen, Giessen, DE, <sup>5</sup>Florence-Nightingale-Hospital, Duesseldorf, DE, <sup>6</sup>Facharztzentrum, Sonneberg, DE, <sup>7</sup>Bruederkrankenhaus St. Josef, Paderborn, DE, <sup>8</sup>Klinikum Nuernberg Nord, Nürnberg, DE, <sup>9</sup>St. Franziskus Hospital Malteserkrankenhaus, Flensburg, DE, <sup>10</sup>Klinikum Bremen-Ost, Bremen, DE, <sup>11</sup>SRH Wald-Klinikum Gera, Gera, DE, <sup>12</sup>Boehringer Ingelheim - Germany, Ingelheim am Rhein, DE
- 12:50 - 12:50 **1505TiP - A Phase III, Randomized, Open-Label, Multicenter Study of SHR-1210(Anti-PD-1 Antibody) in Combination with Pemetrexed and Carboplatin as First Line Therapy in Subjects with Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer**
- F. Wu<sup>1</sup>, G. Gao<sup>1</sup>, C. Zhou<sup>1</sup>, X. Kang<sup>2</sup>, Y. Zhou<sup>2</sup>, <sup>1</sup>Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, <sup>2</sup>Shanghai Hengrui Pharmaceutical Co.LTD, Shanghai, CN
- 12:50 - 12:50 **1506TiP - Phase 1 study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC**
- D. Planchard<sup>1</sup>, P. Janne<sup>2</sup>, H. Yu<sup>3</sup>, D. Moro-Sibilot<sup>4</sup>, T. Goldberg<sup>5</sup>, X. Gu<sup>5</sup>, J. Li<sup>5</sup>, J. McGill<sup>5</sup>, C. Yu<sup>5</sup>, E. Slosberg<sup>5</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Dana Farber Cancer Institute, Boston, US, <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>4</sup>Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, FR, <sup>5</sup>Daiichi Sankyo Inc., Basking Ridge, US
- 12:50 - 12:50 **1507TiP - Ultra-early response capturing in the treatment of non-squamous NSCLC using diffusion-weighted MRI: a prospective multicenter study.**

G. Heussel<sup>1</sup>, N. Batora<sup>2</sup>, M. Schneider<sup>1</sup>, P. Flechsig<sup>2</sup>, J. Krisam<sup>3</sup>, C. Wiedemann<sup>4</sup>, O. Sedlacek<sup>5</sup>, I. Fellhauer<sup>2</sup>, H.-U. Kauczor<sup>2</sup>, M. Thomas<sup>6</sup>, H. Golpon<sup>7</sup>, J. Vogel-Claussen<sup>8</sup>, A. Tufman<sup>9</sup>, J. Dinkel<sup>10</sup>, A. Guenther<sup>11</sup>, S. Janciauskiene<sup>8</sup>, H. Sueltmann<sup>12</sup>, M. Meister<sup>13</sup>, C. Heussel<sup>1</sup>, F. Bozorgmehr<sup>14</sup>, <sup>1</sup>Thoraxklinik at Heidelberg University Hospital; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE, <sup>2</sup>University Hospital Heidelberg; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE, <sup>3</sup>University of Heidelberg, Heidelberg, DE, <sup>4</sup>Thoraxklinik at Heidelberg University, Heidelberg, DE, <sup>5</sup>University Hospital Heidelberg; Division of Radiology, German Cancer Research Center (DKFZ); Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE, <sup>6</sup>Thoraxklinik, Heidelberg, DE, <sup>7</sup>Hannover Medical School; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover, DE, <sup>8</sup>Hannover Medical School; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, DE, <sup>9</sup>LMU Klinikum der Universität München, Munich, DE, <sup>10</sup>University of Munich (LMU); Comprehensive Pneumology Center (CPCM), Member of the German Center for Lung Research (DZL), Munich, DE, <sup>11</sup>Justus-Liebig University Giessen; Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, DE, <sup>12</sup>German Cancer Research Center (DKFZ); Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE, <sup>13</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>14</sup>Thoraxklinik Heidelberg, Heidelberg, DE

12:50 - 12:50

**1508TiP - Durvalumab in frail and elder patients with stage four NSCLC- the DURATION trial**

J. Kuon<sup>1</sup>, F. Bozorgmehr<sup>2</sup>, M. Schneider<sup>1</sup>, J. Krisam<sup>3</sup>, F. Lasitschka<sup>4</sup>, M. Serke<sup>5</sup>, W. Schuette<sup>6</sup>, N. Moosmann<sup>7</sup>, W. Gleiber<sup>8</sup>, M. Faehling<sup>9</sup>, M. Wermke<sup>10</sup>, P. Schuett<sup>11</sup>, M. Boesche<sup>12</sup>, V. Van Laak<sup>13</sup>, L. Fischer Von Weikersthal<sup>14</sup>, M. Ulmer<sup>15</sup>, C. Meyer Zum Büschenfelde<sup>16</sup>, J. Fischer<sup>17</sup>, M. Thomas<sup>1</sup>, <sup>1</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>2</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>3</sup>University of Heidelberg, Heidelberg, DE, <sup>4</sup>Heidelberg University Hospital, Heidelberg, DE, <sup>5</sup>Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH, Hemer, DE, <sup>6</sup>Hospital Martha-Maria Halle-Doelau, Halle, DE, <sup>7</sup>Hospital Barmherzige Brüder, Regensburg, DE, <sup>8</sup>University Hospital Frankfurt, Frankfurt, DE, <sup>9</sup>Klinikum Esslingen, Esslingen, DE, <sup>10</sup>University Hospital Carl-Gustav-Carus, Dresden, DE, <sup>11</sup>Onkologische Schwerpunktpraxis, Gütersloh, DE, <sup>12</sup>University of Greifswald, Greifswald, DE, <sup>13</sup>DRK-Klinikum Berlin-Mitte, Berlin, DE, <sup>14</sup>15Hospital St. Marien Amberg, Amberg, DE, <sup>15</sup>Hospital Ludwigsburg, ludwigsburg, DE, <sup>16</sup>St. Vincentius Hospital Karlsruhe, Karlsruhe, DE, <sup>17</sup>Klinik Loewenstein GmbH Med Klinik II Onkologie, Loewenstein, DE

12:50 - 12:50

**1509TiP - Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)**

Y. Elamin<sup>1</sup>, M. Antonoff<sup>1</sup>, C. Blakely<sup>2</sup>, M. Baggstorm<sup>3</sup>, T. Bivona<sup>4</sup>, X. Le<sup>1</sup>, A. Louie<sup>5</sup>, R. Doebele<sup>6</sup>, C. Rusthoven<sup>6</sup>, P. Lee<sup>2</sup>, R. Govindan<sup>3</sup>, S. Swisher<sup>7</sup>, V. Papadimitrakopoulou<sup>8</sup>, J. Heymach<sup>9</sup>, D. Gomez<sup>1</sup>, <sup>1</sup>UT MD Anderson Cancer Center, Houston, US, <sup>2</sup>University of California San Francisco, San Francisco, US, <sup>3</sup>Washington University in St. Louis, St. Louis, US, <sup>4</sup>University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, <sup>5</sup>London Health Science Centre, London, CA, <sup>6</sup>University of Colorado, Aurora, US, <sup>7</sup>The

University of Texas MD Anderson Cancer Center, Houston, US, <sup>8</sup>MD Anderson Cancer Center, Houston, US, <sup>9</sup>MD ANDERSON CANCER CENTER, HOUSTON, US

- 12:50 - 12:50 **1510TiP - The GATTO study: A phase I of the anti-EGFR Tomuzotuximab (TO) in combination with the anti-MUC1 Gatipotuzumab (GAT) in patients with EGFR positive solid tumors.**  
E. Garralda<sup>1</sup>, M. Van Hoef<sup>2</sup>, S. Ochsenreither<sup>3</sup>, L. Gianni<sup>4</sup>, D. Lorusso<sup>5</sup>, W. Fiedler<sup>6</sup>, U. Keilholz<sup>7</sup>, K. Klinghammer<sup>8</sup>, C. Dicke<sup>6</sup>, M. Kebenko<sup>6</sup>, I. Matos<sup>9</sup>, J. Tabernero<sup>10</sup>, F. Raspagliesi<sup>11</sup>, G. Del Conte<sup>12</sup>, B. Habel<sup>13</sup>, H. Baumeister<sup>13</sup>, A. Zurlo<sup>14</sup>, <sup>1</sup>Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>2</sup>Van Hoef Consulting, Belp, CH, <sup>3</sup>Charité University of Medicine, Berlin, DE, <sup>4</sup>IRCCS San Raffaele, Milan, IT, <sup>5</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>6</sup>University Medical Center Hamburg-Eppendorf, Hamburg, DE, <sup>7</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>8</sup>Charite Comprehensive Cancer Center, Berlin, DE, <sup>9</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>10</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES, <sup>11</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>12</sup>IRCCS San Raffaele Hospital, Milan, IT, <sup>13</sup>Glycotope, Berlin, DE, <sup>14</sup>Glycotope GmbH, Berlin, DE
- 12:50 - 12:50 **SCLC**
- 12:50 - 12:50 **1668P - A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who in participated US National Cancer Institute Cooperative Group studies**  
T. Stinchcombe<sup>1</sup>, W. Fan<sup>2</sup>, S. Schild<sup>3</sup>, E. Vokes<sup>4</sup>, J. Bogart<sup>5</sup>, Q.-T. Le<sup>6</sup>, C. Thomas, Jr.<sup>7</sup>, M. Edelman<sup>8</sup>, L. Horn<sup>9</sup>, R. Komaki<sup>10</sup>, H. Cohen<sup>1</sup>, A. Ganti<sup>11</sup>, H. Pang<sup>12</sup>, X. Wang<sup>13</sup>, <sup>1</sup>Duke Cancer Center, Durham, US, <sup>2</sup>Duke University, Durham, US, <sup>3</sup>Mayo Clinic Arizona, Scottsdale, US, <sup>4</sup>The University of Chicago Medical Centre, Chicago, US, <sup>5</sup>SUNY Upstate Medical University, Syracuse, US, <sup>6</sup>Stanford University School of Medicine, Stanford, US, <sup>7</sup>Oregon Health & Science University, Portland, US, <sup>8</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>9</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>10</sup>MD Anderson Cancer Center, Houston, US, <sup>11</sup>University of Nebraska Medical Center, Omaha, US, <sup>12</sup>Hong Kong University Li Ka Shing Faculty of Medicine, Hong Kong, CN, <sup>13</sup>Alliance Statistics and Data Center, Durham, US
- 12:50 - 12:50 **1669P - Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: A Retrospective Study of the Merseyside and Cheshire Cancer Network**  
M. Sallam<sup>1</sup>, H. Wong<sup>1</sup>, C. Escriu<sup>2</sup>, <sup>1</sup>The Clatterbridge Cancer Centre, Liverpool, GB, <sup>2</sup>Clatterbridge Cancer Center, Wirral, GB
- 12:50 - 12:50 **1670P - Timing of treatment in Small Cell Lung Cancer**  
S. Bhandari<sup>1</sup>, D. Pham<sup>1</sup>, C. Pinkston<sup>2</sup>, M. Oechsli<sup>1</sup>, G. Kloecker<sup>1</sup>, <sup>1</sup>Brown Cancer Center University of Louisville, Louisville, US, <sup>2</sup>School of Public Health, University of Louisville, Louisville, US



- 12:50 - 12:50 **1671P - Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy**  
J. Sorrentino<sup>1</sup>, A. Lai<sup>1</sup>, J. Weiss<sup>2</sup>, K. Dragnev<sup>3</sup>, T. Owonikoko<sup>4</sup>, S. Adler<sup>1</sup>, J. Antal<sup>5</sup>, R. Malik<sup>6</sup>, P. Roberts<sup>1</sup>, <sup>1</sup>G1 Therapeutics, Inc, Research Triangle Park, US, <sup>2</sup>University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>3</sup>Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, <sup>4</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>5</sup>G1 Therapeutics, Research Triangle Park, US, <sup>6</sup>G1 Therapeutics, Inc., Research Triangle park, US
- 12:50 - 12:50 **1672P - Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase 2 IMPULSE study**  
M. Thomas<sup>1</sup>, S. Ponce Aix<sup>2</sup>, A. Navarro Mendivil<sup>3</sup>, J. Riera Knorrenschild<sup>4</sup>, M. Schmidt<sup>5</sup>, E. Wiegert<sup>5</sup>, K. Kapp<sup>5</sup>, C. Mauri<sup>6</sup>, M. Domine Gomez<sup>7</sup>, J. Kollmeier<sup>8</sup>, P. Sadjadian<sup>9</sup>, K.-P. Fröhling<sup>10</sup>, R. Huber<sup>11</sup>, M. Wolf<sup>12</sup>, <sup>1</sup>Thoraxklinik, Heidelberg, DE, <sup>2</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>5</sup>Mologen AG, Berlin, DE, <sup>6</sup>University College London, London, GB, <sup>7</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>8</sup>HELIOS Klinikum Emil von Behring GmbH, Berlin, DE, <sup>9</sup>Johannes Weseling klinikum, Minden, DE, <sup>10</sup>Kath. Klinikum Koblenz-Montabaur, Koblenz, DE, <sup>11</sup>LMU Klinikum der Universität München, Munich, DE, <sup>12</sup>Klinik Kassel, Kassel, DE
- 12:50 - 12:50 **1673P - Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC (NABSTER TRIAL)**  
F. Gelsomino<sup>1</sup>, M. Tiseo<sup>2</sup>, F. Barbieri<sup>3</sup>, F. Riccardi<sup>4</sup>, L. Cavanna<sup>5</sup>, A. Frassoldati<sup>6</sup>, A. Delmonte<sup>7</sup>, L. Longo<sup>8</sup>, C. Dazzi<sup>9</sup>, S. Cinieri<sup>10</sup>, I. Colantonio<sup>11</sup>, M. Tognetto<sup>12</sup>, D. Baldari<sup>13</sup>, L. Tofani<sup>13</sup>, A. Ardizzoni<sup>14</sup>, <sup>1</sup>AOU Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>2</sup>AOU di Parma, Parma, IT, <sup>3</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>4</sup>Azienda Ospedaliera Cardarelli, Napoli, IT, <sup>5</sup>Azienda Ospedaliera Piacenza, Piacenza, IT, <sup>6</sup>Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, <sup>7</sup>Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola, IT, <sup>8</sup>AUSL of Modena, Carpi, IT, <sup>9</sup>AUSL of Romagna, Ravenna, IT, <sup>10</sup>Perrino Hospital, Brindisi, IT, <sup>11</sup>Hospital of Cuneo, Cuneo, IT, <sup>12</sup>Policlinico S.Orsola-Malpighi, Bologna, IT, <sup>13</sup>Istituto Toscano Tumori, Firenze, IT, <sup>14</sup>S.Orsola-Malpighi Hospital, Bologna, IT
- 12:50 - 12:50 **1674P - Safety of belotecan as second-line treatment for recurrent small cell lung cancer: a phase IIb randomized multicenter study**  
J.H. Kang<sup>1</sup>, H.T. Kim<sup>2</sup>, K.H. Lee<sup>3</sup>, D.-W. Kim<sup>4</sup>, S.-W. Kim<sup>5</sup>, H.R. Kim<sup>6</sup>, J.-H. Kim<sup>7</sup>, J.H. Choi<sup>8</sup>, H.J. An<sup>9</sup>, J.-S. Kim<sup>10</sup>, J.S. Jang<sup>11</sup>, B.-S. Kim<sup>12</sup>, <sup>1</sup>The Catholic University of Korea, Seoul, KP, <sup>2</sup>National Cancer Center, Goyang, KR, <sup>3</sup>Chungbuk University Hospital, Cheongju, KR, <sup>4</sup>Seoul National University Hospital, Seoul, KR, <sup>5</sup>Asan Medical Center, Seoul, KR, <sup>6</sup>Yonsei Cancer Center, Seoul, KR, <sup>7</sup>CHA Bundang Medical Center, Seongnam, KR, <sup>8</sup>Ajou University Hospital, Suwon, KR, <sup>9</sup>St. Vincent's Hospital, Suwon, KR, <sup>10</sup>Seoul National University Boramae Medical Center, Seoul, KR, <sup>11</sup>Chung-Ang University Hospital, Seoul, KR, <sup>12</sup>Veterans Health Service Medical Center, Seoul, KR
- 12:50 - 12:50 **1675P - Retrospective study of paclitaxel in advanced therapy lines in the**



**treatment of SCLC**

D. Von Eiff<sup>1</sup>, F. Bozorgmehr<sup>1</sup>, P. Christopoulos<sup>1</sup>, I. Chung<sup>1</sup>, D. Bernhardt<sup>2</sup>, S. Rieken<sup>2</sup>, S. Liersch<sup>3</sup>, T. Muley<sup>4</sup>, S. Kobinger<sup>5</sup>, M. Thomas<sup>6</sup>, M. Steins<sup>6</sup>, <sup>1</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>2</sup>Heidelberg University Hospital, Heidelberg, DE, <sup>3</sup>Thoraxklinik at Heidelberg University Hospital, Heidelberg, DE, <sup>4</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>5</sup>Thoraxklinik at Heidelberg University Hospital; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE, <sup>6</sup>Thoraxklinik, Heidelberg, DE

12:50 - 12:50 **1676P - Over-expression of Shh is prognostic marker in patients with extensive stage small cell lung cancer.**

S. Lim<sup>1</sup>, J. Kim<sup>1</sup>, S.Y. Park<sup>2</sup>, <sup>1</sup>Wonju Severance Christianity Hospital, Gangwon-do, KR, <sup>2</sup>Konyang University Hospital, Daejeon, KR

12:50 - 12:50 **1677P - UCHL1 has prognostic relevance and is a therapeutic target in high-grade neuroendocrine lung cancers**

Y. Shimada, T. Okano, T. Ohira, N. Ikeda, Tokyo Medical University Hospital, Tokyo, JP

12:50 - 12:50 **1678P - Robustness of DLL3 (SP347) Immunohistochemistry Assay for Detection of DLL3 Protein in Small Cell Lung Cancer**

C. Powell<sup>1</sup>, E. Elgabry<sup>1</sup>, B. Holmes<sup>1</sup>, D. Tyree<sup>1</sup>, R. Marati<sup>1</sup>, B. Admire<sup>1</sup>, T. Birdi<sup>1</sup>, A. Hanlon Newell<sup>2</sup>, B. Damadzadeh<sup>1</sup>, D. Dalvi<sup>1</sup>, R. Huang<sup>1</sup>, <sup>1</sup>Ventana Medical Systems, Inc., Tucson, US, <sup>2</sup>Roche Tissue Diagnostics - USA, Tucson, US

12:50 - 12:50 **1679P - Residential radon and small cell lung cancer. A systematic review.**

Á. Rodríguez Martínez<sup>1</sup>, A. Ruano Ravina<sup>2</sup>, M. Torres Duran<sup>3</sup>, <sup>1</sup>Complejo Hospitalario de Pontevedra, Pontevedra, ES, <sup>2</sup>University of Santiago de Compostela, Santiago de Compostela, ES, <sup>3</sup>Complejo Hospitalario de Vigo, Vigo, ES

12:50 - 12:50 **1680P - Nomogram for predicting the benefit of surgery for Stage IA-IIB Small-Cell Lung Cancer**

Y. Wang<sup>1</sup>, Z. Wang<sup>1</sup>, Q. Zheng<sup>2</sup>, <sup>1</sup>Beijing Cancer Hospital, Beijing, CN, <sup>2</sup>Peking University, Beijing, Beijing, CN

12:50 - 12:50 **Thoracic malignancies, other**

12:50 - 12:50 **1807P - STELLAR - Final results of a phase 2 trial of TTFIELDS with chemotherapy for first line treatment of pleural mesothelioma**

F. Grosso<sup>1</sup>, J. Aerts<sup>2</sup>, J. Madrzak<sup>3</sup>, R. Dziadziuszko<sup>4</sup>, R. Ramlau<sup>5</sup>, S. Cedres<sup>6</sup>, B. Hiddinga<sup>7</sup>, J. Van Meerbeeck<sup>8</sup>, M. Mencoboni<sup>9</sup>, D. Planchard<sup>10</sup>, A. Chella<sup>11</sup>, L. Crino<sup>12</sup>, M. Krzakowski<sup>13</sup>, G.L. Ceresoli<sup>14</sup>, <sup>1</sup>Ospedale di Alessandria, Alessandria, IT, <sup>2</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>3</sup>Medical University of Gdansk Clinical Hospital, Gdansk, PL, <sup>4</sup>Medical University of Gdansk, Gdansk, PL, <sup>5</sup>Medical University of Poznan, Poznan, PL, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>Antwerp University Hospital, Antwerp, BE, <sup>8</sup>U.Z.A. University Hospital Antwerp, Edegem, BE, <sup>9</sup>Ospedale Villa Scassi, Genova, IT, <sup>10</sup>Institut Gustave Roussy, Villejuif, FR, <sup>11</sup>Cisanello

University hospital Pisa, Pisa, IT, <sup>12</sup>Ospedale S. Maria della Misericordia, Perugia, IT,  
<sup>13</sup>The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL,  
<sup>14</sup>Humanitas Gavazzeni, Bergamo, IT

- 12:50 - 12:50 **1808P - Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and MisMatchRepair proteins expression in malignant mesothelioma**  
L. Losi<sup>1</sup>, F. Bertolini<sup>2</sup>, L. Scurani<sup>1</sup>, G. Guaitoli<sup>2</sup>, C. Baldessari<sup>2</sup>, A. Ambrosini Spaltro<sup>3</sup>, L. Botticelli<sup>1</sup>, A. Maiorana<sup>1</sup>, F. Barbieri<sup>2</sup>, S. Cascinu<sup>2</sup>, <sup>1</sup>University of Modena and Reggio Emilia, Modena, IT, <sup>2</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>3</sup>Universit of Modena and Reggio Emilia, Modena, IT
- 12:50 - 12:50 **1809P - Development and Validation of a Deep Learning Model using Biomarkers in Pleural Effusion for Prediction of Malignant Pleural Mesothelioma**  
S. Ikegaki<sup>1</sup>, Y. Kataoka<sup>1</sup>, T. Otsoshi<sup>2</sup>, T. Takemura<sup>3</sup>, M. Shimada<sup>3</sup>, <sup>1</sup>Hyogo Prefectural Amagasaki Hospital, Amagasaki, JP, <sup>2</sup>Kobe University Graduate School of Medicine, Kobe, JP, <sup>3</sup>Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, JP
- 12:50 - 12:50 **1810P - Elective nodal irradiation as adjuvant radiotherapy for advanced thymomas and thymic carcinomas**  
Y.J. Kim<sup>1</sup>, S.S. Kim<sup>2</sup>, S.Y. Song<sup>2</sup>, E.K. Choi<sup>2</sup>, <sup>1</sup>Kangwon National University Hospital, Chuncheon, KR, <sup>2</sup>Asan Medical Center, Seoul, KR
- 12:50 - 12:50 **1811P - Clinicopathological Features of Thymoma with the Expression of Programmed Death-Ligand 1**  
S. Hakiri<sup>1</sup>, T. Fukui<sup>1</sup>, S. Mori<sup>1</sup>, K. Kawaguchi<sup>1</sup>, S. Nakamura<sup>1</sup>, N. Ozeki<sup>1</sup>, T. Kato<sup>1</sup>, M. Goto<sup>1</sup>, Y. Yatabe<sup>2</sup>, K. Yokoi<sup>1</sup>, <sup>1</sup>Nagoya University, Graduate School of Medicine, Nagoya, JP, <sup>2</sup>Aichi Cancer Center Hospital, Nagoya, JP
- 12:50 - 12:50 **1812P - The impact of PD-L1, TGF- $\beta$  expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors**  
J. Duan<sup>1</sup>, X. Liu<sup>2</sup>, H. Chen<sup>3</sup>, H. Bai<sup>1</sup>, T. Xu<sup>4</sup>, S. Cai<sup>4</sup>, J. Wang<sup>5</sup>, <sup>1</sup>Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, CN, <sup>2</sup>Dong Ying People's Hospital, dongying, CN, <sup>3</sup>Peking University Cancer Hospital, beijing, CN, <sup>4</sup>3D medicines Inc., Shanghai, CN, <sup>5</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN
- 12:50 - 12:50 **1813P - Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic Large Cell Neuroendocrine Carcinoma (LCNEC)**  
B. Hermans<sup>1</sup>, J. Derks<sup>2</sup>, E. Thunissen<sup>3</sup>, R. Van Suylen<sup>4</sup>, M. Den Bakker<sup>5</sup>, H. Groen<sup>6</sup>, E. Smit<sup>7</sup>, R. Damhuis<sup>8</sup>, E. Van Den Broek<sup>9</sup>, P. Palga-Group<sup>9</sup>, C. Stallinga<sup>10</sup>, G. Roemen<sup>10</sup>, E. Speel<sup>10</sup>, A.-M. Dingemans<sup>2</sup>, <sup>1</sup>Academisch Ziekenhuis Maastricht (AZM), Maastricht, NL, <sup>2</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>3</sup>VU medical centre, Amsterdam, NL, <sup>4</sup>Jeroen Bosch Ziekenhuis, Den Bosch, NL, <sup>5</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>6</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>7</sup>Hospital Universitario, Madrid, ES, <sup>8</sup>Comprehensive Cancer Association, Utrecht, NL, <sup>9</sup>PALGA foundation, Houten, NL, <sup>10</sup>Maastricht University Medical Center, Maastricht, NL

- 12:50 - 12:50 **1814P - Computed tomography features of resected lung adenocarcinomas with spread through air spaces**  
Y. Yamada<sup>1</sup>, G. Toyokawa<sup>2</sup>, T. Tagawa<sup>1</sup>, T. Kamitani<sup>1</sup>, Y. Yamasaki<sup>1</sup>, F. Shoji<sup>3</sup>, K. Yamazaki<sup>3</sup>, S. Takeo<sup>3</sup>, Y. Oda<sup>1</sup>, <sup>1</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, <sup>2</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>3</sup>National Hospital Organization, Kyushu Medical Center, Fukuoka, JP
- 12:50 - 12:50 **1816P - Survival Outcomes for Patients with Lobectomy and Wedge Resection in Lung Cancer**  
S. Alshafie<sup>1</sup>, S. Ahmed<sup>2</sup>, <sup>1</sup>faculty of medicine suez canal university, Ismailia, EG, <sup>2</sup>Suez Canal University, Ismailia, EG
- 12:50 - 12:50 **1815P - Comparative Proteomic Analysis of Acetylation Profiles in Esophageal Squamous Carcinoma Cells**  
Y. Dai<sup>1</sup>, J. Li<sup>2</sup>, <sup>1</sup>Fujian Medical University, Fuzhou , Fujian, CN, <sup>2</sup>Fujian Cancer Hospital, Fuzhou, Fujian, CN
- 12:50 - 12:50 **1817TiP - SAKK 17/16: Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial.**  
Y. Metaxas<sup>1</sup>, A. Xyrafas<sup>2</sup>, M. Mark<sup>1</sup>, M. Pless<sup>3</sup>, M. Frueh<sup>4</sup>, P. Froesch<sup>5</sup>, M. Schneider<sup>2</sup>, C. Biaggi Rudolf<sup>2</sup>, F. Grosso<sup>6</sup>, R. Von Moos<sup>1</sup>, <sup>1</sup>Kantonsspital Graubünden, Chur, CH, <sup>2</sup>SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, <sup>3</sup>Kantonsspital Winterthur, Winterthur, CH, <sup>4</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>5</sup>IOSI Istituto Oncologico Svizzera Italiana, Locarno, CH, <sup>6</sup>Ospedale di Alessandria, Alessandria, IT
- 12:50 - 12:50 **1818TiP - Multicentre, double-blind, randomised Phase II study evaluating gemcitabine with or without Ramucirumab as II line treatment for MPM**  
M. Pagano<sup>1</sup>, F. Zanelli<sup>1</sup>, R. Gnani<sup>2</sup>, C. Bonelli<sup>1</sup>, M. Tiseo<sup>3</sup>, L. Boni<sup>4</sup>, G.L. Ceresoli<sup>5</sup>, P.A. Zucali<sup>6</sup>, F. Grosso<sup>7</sup>, G. Pasello<sup>8</sup>, F. Cappuzzo<sup>9</sup>, C. Pinto<sup>1</sup>, <sup>1</sup>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>2</sup>AUSL di Reggio Emilia-IRCCS, Reggio Emilia, IT, <sup>3</sup>AOU di Parma, Parma, IT, <sup>4</sup>clinical trial coordinating center, AOU careggi ,, firenze, IT, <sup>5</sup>Humanitas Gavazzeni, Bergamo, IT, <sup>6</sup>Humanitas Cancer Center Istituto Clinico Humanitas - IRCCS, Rozzano, IT, <sup>7</sup>Ospedale di Alessandria, Alessandria, IT, <sup>8</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>9</sup>Ospedale Civile di Ravenna - S.ta Maria delle Croci, Ravenna, IT
- 12:50 - 13:10 **Translational research**
- 13:10 - 13:10 **1838P - CANscript™ as a Patient-Derived Predictive Platform for individualizing Treatment in Lung Cancer**  
G. Babu<sup>1</sup>, K. Deepak<sup>2</sup>, B. Balakrishnan<sup>3</sup>, M. Biswas<sup>3</sup>, A. Prasath<sup>3</sup>, P. Radhakrishnan<sup>4</sup>, A. Chatterjee<sup>3</sup>, S. Thiyagarajan<sup>3</sup>, P. Chaudhuri<sup>3</sup>, P. Majumder<sup>4</sup>, <sup>1</sup>HCG Curie Centre of Oncology, Bangalore, IN, <sup>2</sup>Kidwai Memorial Institute of Oncology, Bangalore, IN, <sup>3</sup>Mitra Biotech, Bangalore, IN, <sup>4</sup>Mitra Biotech, Woburn, US

- 13:10 - 13:10 **1839P - Whole-exome cfDNA profiling captures the mutational signatures of metastatic breast cancer for monitoring disease evolution**  
R. Hastings<sup>1</sup>, M. Openshaw<sup>2</sup>, M. Vazquez<sup>3</sup>, D. Fernandez-Garcia<sup>2</sup>, D. Guttery<sup>2</sup>, K. Page<sup>2</sup>, B. Toghill<sup>2</sup>, A. Thomas<sup>2</sup>, S. Ahmed<sup>2</sup>, R. Toledo<sup>4</sup>, J. Shaw<sup>2</sup>, <sup>1</sup>University Hospitals of Leicester NHS trust, Leicester, GB, <sup>2</sup>University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB, <sup>3</sup>Barcelona Supercomputing Center, Barcelona, ES, <sup>4</sup>Barcelona, Barcelona, ES
- 13:10 - 13:10 **1840P - Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody**  
S. Brett<sup>1</sup>, S. Yadavilli<sup>2</sup>, L. Seestaller-Wehr<sup>2</sup>, S. Bhattacharya<sup>3</sup>, H. Jackson<sup>3</sup>, M. Bi<sup>3</sup>, J. Willoughby<sup>4</sup>, T. Zhang<sup>2</sup>, Y.-B. Liu<sup>2</sup>, Y.K. Katlinskaya<sup>2</sup>, H. Shi<sup>3</sup>, J. Jing<sup>3</sup>, A. Hahn<sup>3</sup>, S. Speller<sup>1</sup>, D. David Figueroa<sup>2</sup>, J. Yu<sup>2</sup>, D. Olive<sup>5</sup>, M. Cragg<sup>4</sup>, P. Mayes<sup>2</sup>, A. Hoos<sup>3</sup>, <sup>1</sup>GlaxoSmithKline GSK Stevenage - UK, Stevenage, GB, <sup>2</sup>GlaxoSmithKline, Colledgeville, US, <sup>3</sup>GlaxoSmithKline USA, Colledgeville, US, <sup>4</sup>University of Southampton, Southampton, GB, <sup>5</sup>Centre de Recherche en Cancérologie de Marseille (CRCM), Marseilles, FR
- 13:10 - 13:10 **1841P - Refining criteria of Hyperprogression (HPD) with Immune Checkpoint Inhibitors (ICIs) to improve clinical applicability.**  
I. Matos Garcia<sup>1</sup>, A. García Ruiz<sup>2</sup>, J. Martin-Liberal<sup>2</sup>, C. Hierro<sup>2</sup>, M. Ochoa De Olza Amat<sup>3</sup>, C. Viaplana<sup>3</sup>, G. Mur<sup>2</sup>, M. Vieito Villar<sup>4</sup>, I. Brana<sup>5</sup>, A. Azaro<sup>3</sup>, C. Perez<sup>2</sup>, V. Rodriguez Freixinos<sup>3</sup>, G. Argiles<sup>6</sup>, A.M. Antunes De Melo E Oliveira<sup>3</sup>, E. Felip<sup>3</sup>, E. Muñoz-Couselo<sup>7</sup>, J. Tabernero<sup>8</sup>, R. Dienstmann<sup>3</sup>, E. Garralda<sup>2</sup>, <sup>1</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>2</sup>Vall d' Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>5</sup>Vall D'Hebron Institute of Oncology, Barcelona, ES, <sup>6</sup>Vall d'Hebron Institute of Oncology, VHIO, Barcelona, ES, <sup>7</sup>Vall d'Hebron Hospital, Barcelona, ES, <sup>8</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES
- 13:10 - 13:10 **1842P - Foretinib circumvents the NTRK1 G667C mutation-associated entrectinib-resistance in the brain and liver metastases produced by NTRK1 fusion-positive tumor cells**  
S. Yano<sup>1</sup>, A. Nishiyama<sup>2</sup>, K. Kita<sup>2</sup>, S. Takeuchi<sup>2</sup>, <sup>1</sup>Kanazawa Medical University Hospital, Kanazawa, JP, <sup>2</sup>Kanazawa University, Kanazawa, JP
- 13:10 - 13:10 **1843P - Molecular alterations and matched treatment in older patients: results from the MOSCATO 01 trial.**  
P. Vuagnat<sup>1</sup>, C. Baldini<sup>1</sup>, L. Verlingue<sup>2</sup>, P. Martin Romano<sup>1</sup>, A. Varga<sup>1</sup>, A. Hollebecque<sup>1</sup>, S. Postel-Vinay<sup>3</sup>, A. Gazzah<sup>3</sup>, R. Bahleda<sup>4</sup>, A. Marabelle<sup>1</sup>, V. Ribrag<sup>1</sup>, S. Champiat<sup>1</sup>, J.-M. Michot<sup>3</sup>, J.-C. Soria<sup>5</sup>, C. Massard<sup>4</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>Private Practice, Paris, FR, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>5</sup>Medimmune, Gaithersburg, US
- 13:10 - 13:10 **1844P - Prognostic implications of mismatch repair deficiency in patients with early-stage colorectal and endometrial cancer**  
E. Fountzila<sup>1</sup>, V. Kotoula<sup>2</sup>, G. Pentherdoudakis<sup>3</sup>, K. Manousou<sup>3</sup>, E. Vrettou<sup>3</sup>, C. Poullos<sup>3</sup>,



C. Papadimitriou<sup>4</sup>, G. Raptou<sup>3</sup>, E. Pectasides<sup>5</sup>, G. Polychronidou<sup>1</sup>, G. Karayannopoulou<sup>3</sup>, S. Chrisafi<sup>3</sup>, P. Papakostas<sup>6</sup>, T. Makatsoris<sup>7</sup>, A. Psyrri<sup>8</sup>, E. Samantas<sup>9</sup>, M. Bobos<sup>3</sup>, C. Christodoulou<sup>10</sup>, D. Pectasides<sup>6</sup>, G. Fountzilas<sup>1</sup>, <sup>1</sup>Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, GR, <sup>2</sup>Aristotle University of Thessaloniky, Thessaloniki, GR, <sup>3</sup>Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, <sup>4</sup>Alexandra Hospital, Athens, GR, <sup>5</sup>Dana Farber Cancer Institute, Boston, US, <sup>6</sup>Hippokration General Hospital, Athens, GR, <sup>7</sup>University Hospital Patras, Patras, GR, <sup>8</sup>Attikon University Hospital, Athens, GR, <sup>9</sup>General Oncological Hospital of Kifisia "Agioi Anargyroi", Kifisia, GR, <sup>10</sup>Metropolitan Hospital, Athens, GR

13:10 - 13:10

**1845P - Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: results from two phase I trials**

M. Mau-Sorensen<sup>1</sup>, M. Van Bussel<sup>2</sup>, M. Kuipers<sup>3</sup>, D. Nielsen<sup>4</sup>, H. Verheul<sup>5</sup>, P. Aftimos<sup>6</sup>, M. De Jonge<sup>7</sup>, B. Van Triest<sup>8</sup>, J. Falkenius<sup>9</sup>, J. Debus<sup>10</sup>, E. Troost<sup>11</sup>, M. Samuels<sup>12</sup>, B. Sarholz<sup>13</sup>, V. Budach<sup>14</sup>, S. Goel<sup>15</sup>, G. Locatelli<sup>16</sup>, P. Geertsen<sup>17</sup>, <sup>1</sup>SKACCD - Rigshospitalet, Copenhagen, DK, <sup>2</sup>National Cancer Institute, Amsteram, NL, <sup>3</sup>Merck KGaA - Germany, Darmstadt, DE, <sup>4</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>5</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>6</sup>Institut Jules Bordet, Leuven, BE, <sup>7</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>8</sup>National Cancer Institute, Amsterdam, NL, <sup>9</sup>Karolinska University Hospital, Stockholm, SE, <sup>10</sup>Heidelberg University Hospital, Heidelberg, DE, <sup>11</sup>University Hospital Carl Gustav Carus and Faculty of Medicine of Technische Universität Dresden, Dresden, DE, <sup>12</sup>University of Miami, Miami, US, <sup>13</sup>Merck KGaA, Darmstadt, DE, <sup>14</sup>Klinik fuer Radioonkologie und Strahlentherapie Charite, Berlin, DE, <sup>15</sup>Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, <sup>16</sup>Merck Germany, Darmstadt, DE, <sup>17</sup>Herlev Hospital, University of Copenhagen, Herlev, DK

13:10 - 13:10

**1846P - Role of TP53 mutations in relation to response to anti-ALK agents in EML4-ALK-translocated NSCLC patients**

M. Canale<sup>1</sup>, A. Delmonte<sup>2</sup>, C. Dazzi<sup>3</sup>, A. Gamboni<sup>4</sup>, C. Casanova<sup>3</sup>, M. Papi<sup>5</sup>, M. Mariotti<sup>6</sup>, N. De Luigi<sup>7</sup>, M. Burgio<sup>7</sup>, G. Minuti<sup>8</sup>, D. Calistri<sup>1</sup>, M. Bonafè<sup>1</sup>, L. Crinò<sup>7</sup>, P. Ulivi<sup>1</sup>, <sup>1</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>2</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>3</sup>Umberto I Hospital, Lugo, IT, <sup>4</sup>Degli Infermi Hospital, Faenza, IT, <sup>5</sup>Ospedale Infermi, Rimini, IT, <sup>6</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - IRCCS, Meldola, IT, <sup>7</sup>Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST)- IRCCS, Meldola, IT, <sup>8</sup>Ospedali Riuniti Livorno, Livorno, IT

13:10 - 13:10

**1847P - Meta-enrichment analysis to identify a higher response patient population to S-1/Cisplatin for advanced gastric cancer**

M. Takeuchi<sup>1</sup>, M. Takeuchi<sup>2</sup>, H. Van Laarhoven<sup>3</sup>, X. Fang<sup>1</sup>, P. Pfeiffer<sup>4</sup>, J. Ajani<sup>5</sup>, <sup>1</sup>Kitasato University, tokyo, JP, <sup>2</sup>Keio University, Fujisawa, JP, <sup>3</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL, <sup>4</sup>Odense University Hospital, Odense C, DK, <sup>5</sup>MD Anderson Cancer Center, Houston, US

13:10 - 13:10

**1848P - Predictive significance of tumour angiogenic and anti-angiogenic VEGF-A splice variants in patients with metastatic colorectal cancer**

G. Pentheroudakis<sup>1</sup>, V. Kotoula<sup>2</sup>, G.-A. Koliou<sup>3</sup>, K. Papadopoulou<sup>3</sup>, E. Samantas<sup>4</sup>, T. Makatsoris<sup>5</sup>, V. Karavasilis<sup>2</sup>, D. Mauri<sup>6</sup>, I. Efstratiou<sup>3</sup>, D. Bafaloukos<sup>7</sup>, P. Papakostas<sup>8</sup>, A. Psyrris<sup>9</sup>, G. Papatsibas<sup>3</sup>, G. Zarkavelis<sup>1</sup>, A. Goussia<sup>3</sup>, I. Bompolaki<sup>3</sup>, G. Oikonomopoulos<sup>10</sup>, A. Christopoulou<sup>11</sup>, D. Pectasides<sup>8</sup>, G. Fountzilas<sup>12</sup>, <sup>1</sup>University Hospital of Ioannina, Ioannina, GR, <sup>2</sup>Aristotle University of Thessaloniky, Thessaloniki, GR, <sup>3</sup>Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, <sup>4</sup>General Oncological Hospital of Kifisia "Agiol Anargyroi", Kifisia, GR, <sup>5</sup>University Hospital Patras, Patras, GR, <sup>6</sup>General Hospital of Lamia, Lamia, GR, <sup>7</sup>Metropolitan Hospital, Athens, GR, <sup>8</sup>Hippokration General Hospital, Athens, GR, <sup>9</sup>Attikon University Hospital, Athens, GR, <sup>10</sup>Metropolitan Hospital of Athens, Piraeus, GR, <sup>11</sup>Hospital AG. Andreas, Patras, GR, <sup>12</sup>Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, GR

13:10 - 13:10 **1849P - ATR inhibition with radiation creates an inflammatory tumour microenvironment.**

M. Dillon<sup>1</sup>, K. Bergerhoff<sup>2</sup>, M. Pedersen<sup>2</sup>, H. Whittock<sup>2</sup>, E. Patin<sup>2</sup>, H. Smith<sup>2</sup>, J. Paget<sup>2</sup>, R. Patel<sup>2</sup>, G. Bozhanova<sup>2</sup>, S. Foo<sup>2</sup>, J. Campbell<sup>2</sup>, C. Ragulan<sup>2</sup>, E. Fontana<sup>3</sup>, A. Wilkins<sup>2</sup>, A. Sadanandam<sup>2</sup>, A. Melcher<sup>4</sup>, M. Mclaughlin<sup>2</sup>, K. Harrington<sup>1</sup>, <sup>1</sup>Institute of Cancer Research ICR, London, GB, <sup>2</sup>The Institute of Cancer Research, London, GB, <sup>3</sup>The Institute of Cancer Research, NG, GB, <sup>4</sup>Institute of Cancer Research, London, GB

13:10 - 13:10 **1850P - RNA-based analysis of anaplastic lymphoma kinase (ALK) fusions in non-small cell lung cancer (NSCLC) cases showing immunohistochemistry/fluorescence in-situ hybridisation (IHC/FISH) discordance**

C. Vollbrecht<sup>1</sup>, D. Lenze<sup>1</sup>, M. Hummel<sup>1</sup>, A. Lehmann<sup>1</sup>, M. Moebs<sup>1</sup>, N. Frost<sup>2</sup>, P. Jurmeister<sup>3</sup>, L. Schweizer<sup>3</sup>, U. Kellner<sup>4</sup>, M. Dietel<sup>3</sup>, M. Von Laffert<sup>3</sup>, <sup>1</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>2</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>3</sup>Charité - Universitätsmedizin Berlin corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, DE, <sup>4</sup>Johannes Wesling Klinikum Minden, Institute for Pathology, Minden, DE

13:10 - 13:10 **1851P - The combination of MEK inhibitor and anti PD-L1: effects on organoid models from NSCLC biopsies**

C.M. Della Corte<sup>1</sup>, G. Barra<sup>2</sup>, V. Ciaramella<sup>1</sup>, R. Di Liello<sup>1</sup>, M. Fasano<sup>3</sup>, F. Ciardiello<sup>1</sup>, F. Morgillo<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT, <sup>3</sup>AOU Policlinico Federico II, Napoli, IT

13:10 - 13:10 **1852P - Intraoperative Fluorescent Image-Guided Detection of Esophageal Cancer in Rabbit and Patient Specimens**

J. Rho<sup>1</sup>, Y.H. Quan<sup>1</sup>, B.H. Choi<sup>1</sup>, B.-M. Kim<sup>2</sup>, K.N. Han<sup>3</sup>, Y.H. Choi<sup>3</sup>, H.K. Kim<sup>3</sup>, <sup>1</sup>Korea University College of Medicine, Seoul, KR, <sup>2</sup>Korea University, Seoul, KR, <sup>3</sup>Korea University Guro Hospital, College of Medicine,, Seoul, KR

13:10 - 13:10 **1853P - Interaction Between Cancer Associated Fibroblasts and Cancer Cells Influence Immune Infiltrate and Is Modulated by Therapeutic Agents**

A. Rullan Iriarte<sup>1</sup>, E. Arwert<sup>2</sup>, E. Milford<sup>2</sup>, P. Chakravarty<sup>2</sup>, A. Melcher<sup>3</sup>, K. Harrington<sup>4</sup>, E. Sahai<sup>2</sup>, <sup>1</sup>Institut Catala de Oncologia, Barcelona, ES, <sup>2</sup>The Francis Crick Institute,

London, GB, <sup>3</sup>Institute of Cancer Research, London, GB, <sup>4</sup>The Institute of Cancer Research, London, GB

- 13:10 - 13:10 **1854P - Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer**  
T. Mizukami<sup>1</sup>, Y. Sunakawa<sup>1</sup>, H. Arai<sup>2</sup>, M. Chosokabe<sup>1</sup>, A. Doi<sup>2</sup>, Y. Horie<sup>2</sup>, M. Hirakawa<sup>2</sup>, O. Saji<sup>2</sup>, S. Naruki<sup>1</sup>, N. Izawa<sup>1</sup>, T. Ogura<sup>1</sup>, T. Tsuda<sup>1</sup>, T. Enomoto<sup>2</sup>, S. Mikami<sup>2</sup>, T. Fujino<sup>1</sup>, T. Otsubo<sup>2</sup>, T. Nakajima<sup>3</sup>, <sup>1</sup>St. Marianna University School of Medicine, Kanagawa, JP, <sup>2</sup>St. Marianna University School of Medicine, Kanagawa, JP, <sup>3</sup>St. Marianna University School of Medicine, Kawasaki city, JP
- 13:10 - 13:10 **1855P - CD5 and CD6: evaluation of their role as prognostic biomarkers in resectable non-small cell lung cancer**  
A. Moreno<sup>1</sup>, S. Calabuig Fariñas<sup>2</sup>, S. Gallach Garcia<sup>2</sup>, A. Fernando<sup>3</sup>, I. Simoes<sup>3</sup>, E. Carreras<sup>3</sup>, M. Consuegra-Fernández<sup>3</sup>, A. Blasco Cordellat<sup>2</sup>, A. Cunqueiro Tomas<sup>2</sup>, M. Martorell<sup>4</sup>, C. Camps<sup>5</sup>, F. Lozano<sup>6</sup>, R. Sirera Perez<sup>7</sup>, E. Jantus-Lewintre<sup>8</sup>, <sup>1</sup>Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, <sup>2</sup>Hospital General Universitario Valencia, Valencia, ES, <sup>3</sup>Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, <sup>4</sup>Dep. of Pathology, Hospital General Universitario de Valencia, Valencia, Spain; Dep. of Pathology, Universitat de València, Valencia, Spain, VALENCIA, ES, <sup>5</sup>Consortio Hospital General Universitario de Valencia, Valencia, ES, <sup>6</sup>Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain; Departament de Biomedicina, Facultat de Medicina, Universitat de Barcelona, Barcelona, ES, <sup>7</sup>No place of work provided, No City Provided, NA, <sup>8</sup>Departament de Biotecnologia, Universitat Politècnica de València, Valencia, ES
- 13:10 - 13:10 **1856P - Identification of the rational combination of two epigenetic inhibitors therapy in refractory AML using patient tumor derived ex vivo platform.**  
P. Majumder<sup>1</sup>, G. Babu<sup>2</sup>, C. Rajagowda<sup>2</sup>, S. Thiyagarajan<sup>3</sup>, M. Biswas<sup>3</sup>, P. Radhakrishnan<sup>1</sup>, P. Chaudhuri<sup>3</sup>, A. Chatterjee<sup>3</sup>, <sup>1</sup>Mitra Biotech, Woburn, US, <sup>2</sup>HCG Curie Centre of Oncology, Bangalore, IN, <sup>3</sup>Mitra Biotech, Bangalore, IN
- 13:10 - 13:10 **1857P - Tyrosine Kinase Inhibitors and acid-inhibitory drugs : strong concomitant dispensing and drug-drug interaction risk.**  
F. Grude<sup>1</sup>, C. Vigneau-Victorri<sup>2</sup>, D. Deniel Lagadec<sup>3</sup>, E. Michaud<sup>4</sup>, H. Bourgeois<sup>5</sup>, B. Forestier<sup>4</sup>, F. Marhuenda<sup>6</sup>, <sup>1</sup>Centre Paul Papin, Angers, FR, <sup>2</sup>Faculté de Médecine, Nantes, FR, <sup>3</sup>CHRU BREST, BREST, FR, <sup>4</sup>Regional Health Insurance, NANTES, FR, <sup>5</sup>Clinique Victor Hugo Le Mans, Le Mans, FR, <sup>6</sup>ICO Paul Papin, ANGERS, FR
- 13:10 - 13:10 **1858P - Intraoperative Detection of Resection Margin by Inhalation of ICG in Lung Cancer Preclinical Study**  
Y.H. Quan<sup>1</sup>, C.H. Oh<sup>2</sup>, D. Jung<sup>2</sup>, J.-Y. Lim<sup>2</sup>, B.H. Choi<sup>1</sup>, J. Rho<sup>1</sup>, Y. Choi<sup>3</sup>, K.N. Han<sup>4</sup>, J.-H. Park<sup>2</sup>, H.K. Kim<sup>4</sup>, Y.H. Choi<sup>4</sup>, <sup>1</sup>Korea University College of Medicine, Seoul, KR, <sup>2</sup>Korea Advanced Institute of Science and Technology, Daejeon, KR, <sup>3</sup>Korea University, Seoul, KR, <sup>4</sup>Korea University Guro Hospital, College of Medicine,, Seoul, KR
- 13:10 - 13:10 **1859P - Proteomic-based machine learning computational analysis discovered biomarkers of aberrant vesicle-exosomal trafficking to determine**



**chemotherapeutic responses in breast cancer**

H. Ryu<sup>1</sup>, D.H. Han<sup>2</sup>, K.-M. Lee<sup>2</sup>, K. Kim<sup>2</sup>, <sup>1</sup>Seoul National University Hospital (SNUH)-Yongon Campus, Seoul, KR, <sup>2</sup>Seoul National University Hospital, Seoul, KR

13:10 - 13:10

**1860P - CARCINOMA OF UNKNOWN ORIGIN: Deep Genomic profile helps to achieve an accurate diagnosis.**

A. Fernandez Díaz<sup>1</sup>, V. Iranzo Gonzalez-Cruz<sup>1</sup>, A.J. Cunqueiro Tomas<sup>1</sup>, C. Avila Andrade<sup>1</sup>, E. Jantus-Lewintre<sup>2</sup>, S. Calabuig Fariñas<sup>1</sup>, J.E. Ales<sup>3</sup>, M. Valero<sup>4</sup>, G. D'Errico<sup>5</sup>, R. Pazo Cid<sup>6</sup>, A. Gallego Martínez<sup>7</sup>, A. Viana<sup>8</sup>, S. Ponce Aix<sup>9</sup>, J.A. Pérez-Fidalgo<sup>10</sup>, A. Terradez<sup>11</sup>, A. Rodrigo<sup>11</sup>, L. Alvarez<sup>11</sup>, G. Beniuga<sup>12</sup>, M. Martorell<sup>13</sup>, C. Camps<sup>14</sup>, <sup>1</sup>Hospital General Universitario Valencia, Valencia, ES, <sup>2</sup>Departament de Biotecnologia, Universitat Politècnica de València, Valencia, ES, <sup>3</sup>Hospital Nuestra Señora de Sonsoles, AVILA, ES, <sup>4</sup>ONCOAVANZE, SEVILLA, ES, <sup>5</sup>Hospital Universitario Quirónsalud Madrid, MADRID, ES, <sup>6</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>7</sup>Hospital Universitario La Paz, Madrid, ES, <sup>8</sup>Hospital Nuestra Señora del Prado, TOLEDO, ES, <sup>9</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>10</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>11</sup>OncodNA S.A., Gosselies, BE, <sup>12</sup>Institute Pathology and Génétique, Charleroi, BE, <sup>13</sup>Dep. of Pathology, Hospital General Universitario de Valencia, Valencia, Spain; Dep. of Pathology, Universitat de València, Valencia, Spain, VALENCIA, ES, <sup>14</sup>Consorcio Hospital General Universitario de Valencia, Valencia, ES

13:10 - 13:10

**1861P - Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy.**

J. Lee<sup>1</sup>, S.Y. Lim<sup>2</sup>, A. Menzies<sup>3</sup>, M. Carlino<sup>4</sup>, A. Guminski<sup>5</sup>, K. Nahar<sup>3</sup>, D. Palmieri<sup>4</sup>, E. Breen<sup>2</sup>, R. Kefford<sup>6</sup>, R. Scolyer<sup>7</sup>, G. Long<sup>3</sup>, H. Rizos<sup>2</sup>, <sup>1</sup>Ogilvy PR Australia, Sydney, AU, <sup>2</sup>Macquarie University, Sydney, AU, <sup>3</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>4</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>5</sup>Royal North Shore Hospital, St Leonards, AU, <sup>6</sup>Macquarie University, Melanoma Institute Australia, Westmead Hospital, and The University of Sydney, Sydney, AU, <sup>7</sup>Royal Prince Alfred Hospital, Camperdown, AU

13:10 - 13:10

**1862P - A Phase 1 Trial of Vorolanib (X-82), a Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitor, in Patients (pts) with Advanced Solid Tumors**

J. Bendell<sup>1</sup>, K. Moore<sup>2</sup>, M. Patel<sup>3</sup>, C. Chua<sup>4</sup>, H.-T. Arkenau<sup>5</sup>, G. Dukart<sup>6</sup>, K. Harrow<sup>7</sup>, C. Liang<sup>6</sup>, <sup>1</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>2</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>3</sup>U Minnesota Medical School, Minneapolis, US, <sup>4</sup>Oncology Hematology Care, Inc., Blue Ash, US, <sup>5</sup>Sarah Cannon Research Institute SCRI UK, London, GB, <sup>6</sup>Xcovery Holdings, Inc., Palm Beach Gardens, US, <sup>7</sup>Xcovery Holding Company, LLC, Palm Beach Gardens, US

13:10 - 13:10

**1863P - Longitudinal analysis of circulating biomarkers to monitor advanced EGFR mutated (EGFR+) non-small cell lung cancer (NSCLC)**

P.N. Ding<sup>1</sup>, T. Becker<sup>2</sup>, V. Bray<sup>3</sup>, W. Chua<sup>3</sup>, Y.F. Ma<sup>4</sup>, A. Luk<sup>4</sup>, J. Po<sup>4</sup>, D. Lynch<sup>4</sup>, N. Caixeiro<sup>4</sup>, P. De Souza<sup>5</sup>, T. Roberts<sup>4</sup>, <sup>1</sup>Ingham Institute, Liverpool, AU, <sup>2</sup>Ingham Institute for Applied Medical Research, NSW, AU, <sup>3</sup>Concord Repatriation General Hospital, Concord, AU, <sup>4</sup>Ingham Institute for Applied Medical Research, Liverpool, AU, <sup>5</sup>St George Hospital Cancer Care Centre, Kogarah, AU



- 13:10 - 13:10 **1864P - Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information**  
T. Ettrich<sup>1</sup>, D. Schwerdel<sup>2</sup>, A. Dolnik<sup>1</sup>, F. Beuter<sup>1</sup>, T. Blätte<sup>1</sup>, S. Schmidt<sup>1</sup>, N. Stanescu-Siegmund<sup>1</sup>, J. Steinacker<sup>1</sup>, R. Marienfeld<sup>1</sup>, A. Kleger<sup>1</sup>, L. Bullinger<sup>1</sup>, T. Seufferlein<sup>1</sup>, A. Berger<sup>2</sup>, <sup>1</sup>Ulm Medical University, Ulm, DE, <sup>2</sup>University Medical Center Ulm, Ulm, DE
- 13:10 - 13:10 **1865P - Interactions of cancer stem cell and immune microenvironment in non-small cell lung cancer (NSCLC)**  
F. Zhang<sup>1</sup>, N. Dong<sup>2</sup>, S. Torres<sup>1</sup>, S. Calabuig Fariñas<sup>3</sup>, R. Sirera Perez<sup>4</sup>, M. Mosqueda<sup>1</sup>, E. Escorihuela<sup>5</sup>, E. Jantus-Lewintre<sup>5</sup>, C. Camps<sup>6</sup>, <sup>1</sup>Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, <sup>2</sup>Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, <sup>3</sup>Hospital General Universitario Valencia, Valencia, ES, <sup>4</sup>No place of work provided, No City Provided, NA, <sup>5</sup>Departament de Biotecnologia, Universitat Politècnica de València, Valencia, ES, <sup>6</sup>Consorcio Hospital General Universitario de Valencia, Valencia, ES
- 13:10 - 13:10 **1866P - Association of the rs1883832 variant of CD40 with NSCLC risk and overall survival**  
F.-I. Dimitrakopoulos<sup>1</sup>, A. Antonacopoulou<sup>2</sup>, A. Kottorou<sup>1</sup>, S. Marousi<sup>2</sup>, I. Koukourikou<sup>3</sup>, C. Scopa<sup>3</sup>, D. Dougenis<sup>3</sup>, V. Tzelepi<sup>3</sup>, H. Kalofonos<sup>2</sup>, <sup>1</sup>University Hospital Patras, Patras, GR, <sup>2</sup>University of Patras, Patras, GR, <sup>3</sup>University Hospital of Patras, Patras, GR
- 13:10 - 13:10 **1867P - Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer**  
S. Khakoo<sup>1</sup>, P. Carter<sup>2</sup>, N. Valeri<sup>3</sup>, R. Shaikh<sup>2</sup>, T. Jones<sup>2</sup>, R. Begum<sup>4</sup>, I. Rana<sup>5</sup>, S. Picchia<sup>5</sup>, M. Bali<sup>5</sup>, G. Brown<sup>1</sup>, A. Wotherspoon<sup>5</sup>, M. Terlizzo<sup>6</sup>, K. Von Loga<sup>5</sup>, I. Ahmed<sup>5</sup>, D. Watkins<sup>7</sup>, I. Chau<sup>1</sup>, N. Starling<sup>6</sup>, D. Tait<sup>6</sup>, M. Hubank<sup>1</sup>, D. Cunningham<sup>1</sup>, <sup>1</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>2</sup>The Institute of Cancer Research, Sutton, GB, <sup>3</sup>The Royal Marsden NHS Foundation Trust in Chelsea, London, GB, <sup>4</sup>The Francis Crick Institute, London, GB, <sup>5</sup>Royal Marsden Hospital NHS Foundation Trust, Sutton, GB, <sup>6</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>7</sup>Royal Marsden Hospital, Sutton, GB
- 13:10 - 13:10 **1868P - A Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients**  
F. Innocenti<sup>1</sup>, C. Jiang<sup>2</sup>, A. Sibley<sup>2</sup>, S. Denning<sup>1</sup>, A. Etheridge<sup>1</sup>, D. Watson<sup>2</sup>, D. Niedzwiecki<sup>3</sup>, A. Hatch<sup>2</sup>, H. Hurwitz<sup>3</sup>, A. Nixon<sup>3</sup>, Y. Furukawa<sup>4</sup>, M. Kubo<sup>5</sup>, D. Crona<sup>1</sup>, H. Kindler<sup>6</sup>, H. Mcleod<sup>7</sup>, M. Ratain<sup>6</sup>, K. Owzar<sup>2</sup>, <sup>1</sup>UNC-Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, US, <sup>2</sup>Duke Cancer Institute, Durham, US, <sup>3</sup>Duke University Medical Center, Durham, US, <sup>4</sup>RIKEN, Yokohama, US, <sup>5</sup>Riken, Kanagawa, JP, <sup>6</sup>The University of Chicago Medical Centre, Chicago, US, <sup>7</sup>Moffit Cancer Center, Tampa, US
- 13:10 - 13:10 **1869P - Effect of a combined treatment with iPS cells derived dendritic cells and proton beam irradiation in a murine subcutaneous melanoma model**  
Y. Wang<sup>1</sup>, L. Sun<sup>1</sup>, X. Li<sup>2</sup>, K. Tsuboi<sup>1</sup>, <sup>1</sup>University of Tsukuba, Tsukuba, Ibaraki, JP, <sup>2</sup>National Research Institute for Child Health and Development, Tokyo, JP

- 13:10 - 13:10 **1870P - Developing the liquid biopsy in gastroesophageal adenocarcinoma: Disease monitoring and detection of minimal residual disease**  
M. Openshaw, B. Ottolini, C. Richards, D. Guttery, J. Shaw, A. Thomas, University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB
- 13:10 - 13:10 **1871P - Survival from breast cancer in patients with BRCA1/2, CHEK2, NOD2 mutations and TP53 (c.[215G>C]) polymorphisms.**  
J. Huszno, Z. Kolosza, Maria Sklodowska Curie MSC Memorial Cancer Institute in Gliwice, Gliwice, PL
- 13:10 - 13:10 **1872P - Phase I pharmacological study of continuous chronomodulated capecitabine treatment**  
J. Roosendaal<sup>1</sup>, B. Jacobs<sup>2</sup>, D. Pluim<sup>2</sup>, H. Rosing<sup>3</sup>, B. Nuijen<sup>3</sup>, J. Beijnen<sup>3</sup>, A. Huitema<sup>3</sup>, J. Schellens<sup>2</sup>, S. Marchetti<sup>2</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>3</sup>The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, NL
- 13:10 - 13:10 **1873P - Head and Neck (HN) Primary Sarcomatoid Carcinoma (PSC) profile by High-throughput somatic mutation profiling.**  
V. Fallet<sup>1</sup>, R. Taouachi<sup>2</sup>, R. Saffroy<sup>3</sup>, A. Ben Lakhdar<sup>4</sup>, N. Rabbe<sup>1</sup>, F. André<sup>5</sup>, S. Temam<sup>6</sup>, A. Lemoine<sup>7</sup>, M. Wislez<sup>1</sup>, <sup>1</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>2</sup>Institut Curie, PSL Research University, Saint Cloud, FR, <sup>3</sup>AP-HP, GH Paris-Sud, Hôpital Paul Brousse / Platform Oncomolpath/INCA, Villejuif, FR, <sup>4</sup>Gustave Roussy Institute, Villejuif, FR, <sup>5</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>Hopital Paul Brousse, Villejuif, FR
- 13:10 - 13:10 **1874P - A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma**  
A. Berger<sup>1</sup>, T. Ettrich<sup>2</sup>, D. Schwerdel<sup>1</sup>, A. Reinacher-Schick<sup>3</sup>, H. Algül<sup>4</sup>, A.-O. König<sup>5</sup>, E. Gallmeier<sup>6</sup>, K. Wille<sup>7</sup>, S. Daum<sup>8</sup>, M. Geissler<sup>9</sup>, A. Tannapfel<sup>10</sup>, W. Uhl<sup>11</sup>, T. Seufferlein<sup>2</sup>, <sup>1</sup>University Medical Center Ulm, Ulm, DE, <sup>2</sup>Ulm Medical University, Ulm, DE, <sup>3</sup>Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE, <sup>4</sup>Klinikum rechts der Isar, Technische Universität München, München, DE, <sup>5</sup>Universitätsmedizin Göttingen, Göttingen, DE, <sup>6</sup>University of Marburg, Marburg, DE, <sup>7</sup>University Hospital Ruhr-University-Bochum, Minden, DE, <sup>8</sup>Charité University Medicine Berlin, Berlin, DE, <sup>9</sup>Klinikum Esslingen, Esslingen, DE, <sup>10</sup>Ruhr-Universität Bochum, Bochum, DE, <sup>11</sup>Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE
- 13:10 - 13:10 **1875P - Acquired chemoresistance of colorectal cancer (CRC) cells is accompanied by pro-invasive VEGF-signaling that can be attenuated by aflibercept**  
A. Larsen<sup>1</sup>, P. Van Dreden<sup>2</sup>, B. Chibaudel<sup>3</sup>, A. De Gramont<sup>4</sup>, G. Gerotziafas<sup>5</sup>, S. Thouroude<sup>6</sup>, <sup>1</sup>Hôpital Saint-Antoine, Paris, FR, <sup>2</sup>Diagnostica Stago (SAS), Gennevilliers, FR, <sup>3</sup>Institut hospitalier Franco-Britannique/ Franco-British Institute, Levallois-Perret, FR, <sup>4</sup>Institut hospitalier Franco-Britannique, Levallois-Perret, FR, <sup>5</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>6</sup>INSERM U938 and Université Pierre et Marie Curie (UPMC), Sorbonne Universités Paris, France, Paris, FR

- 13:10 - 13:10 **1876P - Actionable Mutations and Overall Survival in 3,211 Patients with Cancer: The Hellenic Cooperative Oncology Group Precision Medicine Initiative**  
E. Fountzila<sup>1</sup>, V. Kotoula<sup>2</sup>, G.-A. Koliou<sup>3</sup>, E. Giannoulatou<sup>4</sup>, H. Gogas<sup>5</sup>, C. Papadimitriou<sup>6</sup>, I. Tikas<sup>2</sup>, K. Papadopoulou<sup>3</sup>, F. Zagouri<sup>7</sup>, C. Christodoulou<sup>8</sup>, A. Koutras<sup>9</sup>, E. Razi<sup>10</sup>, P. Papakostas<sup>11</sup>, E. Samantas<sup>12</sup>, G. Aravantinos<sup>12</sup>, A. Psyrris<sup>13</sup>, D. Pectasides<sup>11</sup>, A. Futreal<sup>14</sup>, A.-M. Tsimberidou<sup>14</sup>, G. Fountzilas<sup>1</sup>, <sup>1</sup>Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, GR, <sup>2</sup>Aristotle University of Thessaloniky, Thessaloniki, GR, <sup>3</sup>Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, <sup>4</sup>Victor Chang Cardiac Research Institute, Darlinghurst, NSW, AU, <sup>5</sup>Laiko General Hospital of Athens, Athens, GR, <sup>6</sup>Alexandra Hospital, Athens, GR, <sup>7</sup>General Hospital Konstantopoulou-Agia Olga, Athens, GR, <sup>8</sup>Metropolitan Hospital, Athens, GR, <sup>9</sup>University Hospital Patras, Patras, GR, <sup>10</sup>Hygeia Hospital, Athens, GR, <sup>11</sup>Hippokration General Hospital, Athens, GR, <sup>12</sup>General Oncological Hospital of Kifisia "Agiou Anargyroi", Kifisia, GR, <sup>13</sup>Attikon University Hospital, Athens, GR, <sup>14</sup>MD Anderson Cancer Center, Houston, US
- 13:10 - 13:10 **1877P - DNA Repair genetic profiling in epithelial ovarian cancer: an opportunity for clinical improvement?**  
J. Assis<sup>1</sup>, S. Coelho<sup>1</sup>, A. Nogueira<sup>1</sup>, R. Pinto<sup>1</sup>, M. Brandao<sup>2</sup>, J. Dias<sup>1</sup>, S. Alves<sup>1</sup>, D. Pereira<sup>1</sup>, R. Medeiros<sup>1</sup>, <sup>1</sup>Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto, PT, <sup>2</sup>Institute Jules Bordet, Brussels, BE
- 13:10 - 13:10 **1878P - Strategy to improve the antitumor efficacy of dendritic cell-based nanovaccine under magnetic field control**  
O. Gorbach<sup>1</sup>, N. Khranovska<sup>1</sup>, O. Skachkova<sup>2</sup>, M. Inomistova<sup>1</sup>, I. Shumeiko<sup>1</sup>, V. Orel<sup>1</sup>, <sup>1</sup>National Cancer Institute of the MPH Ukraine, Kiev, UA, <sup>2</sup>National Cancer Institute of the MPH Ukraine of the MPH Ukraine, Kiev, UA
- 13:10 - 13:10 **1879P - Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in Squamous Cell Lung Cancer (SQLC) models.**  
A. Gkoutakos<sup>1</sup>, S. Pilotto<sup>2</sup>, M. Simbolo<sup>3</sup>, C. Vicentini<sup>3</sup>, A. Mafficini<sup>2</sup>, A. Del Curatolo<sup>3</sup>, A. Scarpa<sup>2</sup>, G. Tortora<sup>4</sup>, V. Corbo<sup>3</sup>, E. Bria<sup>5</sup>, <sup>1</sup>Ospedale Universitario Verona, Verona, IT, <sup>2</sup>AOU Integrata Verona "Borgo Roma", Verona, IT, <sup>3</sup>University and Hospital Trust of Verona, Verona, IT, <sup>4</sup>Università di Verona, Azienda Ospedaliera Universitaria Integrata, Verona, IT, <sup>5</sup>Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario Agostino Gemelli, Rome, IT
- 13:10 - 13:10 **1880P - Final results of the Phase 1 study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response.**  
L. Seitz, D. Ashok, M. Leleti, J. Powers, B. Rosen, D. Miles, E. Sharif, L. Jin, A. Park, S. Young, A. Rieger, U. Schindler, J. Karakunnel, M. Walters, Arcus Biosciences, Inc., Hayward, US
- 13:10 - 13:10 **1881P - An expression signature characterizes cancer stem cells from lung adenocarcinoma patients**  
A. Herreros Pomares<sup>1</sup>, S. Calabuig Fariñas<sup>2</sup>, J.D. De Maya<sup>3</sup>, E. Escorihuela<sup>4</sup>, E. Durendez-Saez<sup>5</sup>, A. Blasco Cordellat<sup>2</sup>, A. Navarro<sup>2</sup>, E. García-Del-Olmo<sup>2</sup>, R. Lucas<sup>6</sup>, R. Farràs<sup>3</sup>, E. Jantus-Lewintre<sup>4</sup>, C. Camps<sup>7</sup>, <sup>1</sup>Fundación de Investigación Hospital General



Universitario de Valencia, Valencia, ES, <sup>2</sup>Hospital General Universitario Valencia, Valencia, ES, <sup>3</sup>Centro de Investigación Príncipe Felipe, Valencia, ES, <sup>4</sup>Departament de Biotecnologia, Universitat Politècnica de València, Valencia, ES, <sup>5</sup>Molecular Oncology Laboratory, Fundación de Investigación Hospital General Universitario de Valencia, Spain., Valencia, ES, <sup>6</sup>Universitat de València, Valencia, ES, <sup>7</sup>Consorcio Hospital General Universitario de Valencia, Valencia, ES

- 13:10 - 13:10 **1882P - Development of primary human NSCLC patient derived xenograft and organoids models as a precision approach to tumor treatment**  
O.J. Juan Vidal<sup>1</sup>, C. Gandia<sup>2</sup>, J. Pardo-Sánchez<sup>2</sup>, M. Benet<sup>1</sup>, S. Aparisi<sup>3</sup>, S. Palanca<sup>1</sup>, E. Ansotegui<sup>1</sup>, C. Jordá<sup>1</sup>, J. Cerón<sup>1</sup>, N. Mancheño<sup>1</sup>, M. Sánchez-Céspedes<sup>4</sup>, A. Lahoz<sup>1</sup>, J. Carretero<sup>3</sup>, R. Farràs<sup>2</sup>, <sup>1</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>2</sup>Centro de Investigación Príncipe Felipe, Valencia, ES, <sup>3</sup>Universitat de Valencia, Valencia, ES, <sup>4</sup>Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES
- 13:10 - 13:10 **1883P - PBRM1 is a novel candidate low-penetrance familial cancer predisposition gene**  
I. Volodin<sup>1</sup>, V. Kozlova<sup>2</sup>, K. Anoshkin<sup>1</sup>, A. Tanas<sup>1</sup>, D. Zaletaev<sup>3</sup>, V. Strelnikov<sup>4</sup>, <sup>1</sup>Research Centre for Medical Genetics, Moscow, RU, <sup>2</sup>N.N. Blokhin Russian Research Center for Oncology, Moscow, RU, <sup>3</sup>Sechenov First Moscow State Medical University, Moscow, RU, <sup>4</sup>Institute of molecular medicine, Moscow, RU
- 13:10 - 13:10 **1884P - Liprin-alpha4 contributes to increased proliferation and decreased chemosensitivity under hypoxia for small cell lung cancer as a downstream mediator of HIF-1alpha**  
H. Onishi<sup>1</sup>, A. Yamasaki<sup>2</sup>, M. Kawamoto<sup>1</sup>, <sup>1</sup>Kyushu University Hospital, FUKUOKA, JP, <sup>2</sup>Kyushu University Hospital, Fukuoka, JP
- 13:10 - 13:10 **1885P - Precision Medicine for patients with rare cancers: an effective strategy within the prospective MOSCATO trial**  
M. Abdelshafy<sup>1</sup>, Y. El Dakdouki<sup>2</sup>, L. Verlingue<sup>3</sup>, A. Hollebecque<sup>1</sup>, L. Lacroix<sup>2</sup>, S. Postel-Vinay<sup>2</sup>, A. Varga<sup>1</sup>, R. Balheda<sup>4</sup>, J.-M. Michot<sup>2</sup>, A. Marabelle<sup>1</sup>, E. Rouleau<sup>5</sup>, E. Solary<sup>2</sup>, T. De Baere<sup>2</sup>, E. Angevin<sup>6</sup>, V. Ribrag<sup>1</sup>, S. Michiels<sup>1</sup>, F. André<sup>7</sup>, J.-Y. Scoazec<sup>8</sup>, J.-C. Soria<sup>9</sup>, C. Massard<sup>6</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Private Practice, Paris, FR, <sup>4</sup>Gustave Roussy, VILLEJUIF, FR, <sup>5</sup>Institut Curie, Paris, FR, <sup>6</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>7</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>8</sup>Gustave Roussy, University Paris-Saclay, Villejuif, FR, <sup>9</sup>Medimmune, Gaithersburg, US
- 13:10 - 13:10 **1886P - Streamlining Multi-omic and Artificial Intelligence Analysis Through Interrogative Biology and BAICis for Translational Precision Medicine Applications in Clinical Oncology**  
L. Rodrigues, M. Kiebish, G. Miller, L. Zhang, V. Vemulapalli, V. Vishnudas, R. Sarangarajan, N. Narain, V. Akmaev, BERG, LLC, Framingham, US
- 13:10 - 13:10 **1887P - Prediction of response to vemurafenib in BRAF V600E mutant cancers based on a network approach**  
R. Falcone<sup>1</sup>, P. Paci<sup>2</sup>, A. Verrienti<sup>1</sup>, G. Fiscon<sup>2</sup>, M. Sponziello<sup>1</sup>, F. Conte<sup>2</sup>, V. Pecce<sup>1</sup>, F.



Rosignolo<sup>3</sup>, G. Grani<sup>1</sup>, L. Lamartina<sup>1</sup>, V. Ramundo<sup>1</sup>, C. Durante<sup>1</sup>, L. Farina<sup>4</sup>, S. Filetti<sup>1</sup>,  
<sup>1</sup>Policlinico Umberto I, Rome, IT, <sup>2</sup>CNR, Rome, IT, <sup>3</sup>Policlinico Umberto I, Sapienza  
 University of Rome, Rome, IT, <sup>4</sup>Sapienza University of Rome, Rome, IT

13:10 - 13:10 **1888P - Improving value for cancer patients: A European study of outcomes in practice**

R. Hazarika<sup>1</sup>, T. Albrecht<sup>2</sup>, B. Beger<sup>3</sup>, D. Duplay<sup>4</sup>, L. Makaroff<sup>5</sup>, Z. Maravic<sup>6</sup>, R. Mortuza<sup>1</sup>,  
 V. Muthu<sup>7</sup>, K. Oliver<sup>8</sup>, R. Price<sup>9</sup>, M. Van Meerveld<sup>10</sup>, K. Steinmann<sup>11</sup>, A. Krukowska<sup>12</sup>, R.  
 Catena<sup>13</sup>, S. Wait<sup>13</sup>, V. Zilli<sup>13</sup>, T. Rosvall-Puplett<sup>14</sup>, <sup>1</sup>International Consortium for Health  
 Outcomes Measurement, London, GB, <sup>2</sup>National Institute of Public Health of Slovenia,  
 Ljubljana, SI, <sup>3</sup>The European CanCer Organisation, Brussels, BE, <sup>4</sup>Healtheo360, New  
 York, US, <sup>5</sup>European Cancer Patient Coalition, GB, <sup>6</sup>EuropaColon UK, Salisbury, GB,  
<sup>7</sup>Marivek Ltd, Epsom, GB, <sup>8</sup>International Brain Tumour Alliance, GB, <sup>9</sup>European CanCer  
 Organisation, GB, <sup>10</sup>MSD, GB, <sup>11</sup>Amgen (Europe) GmbH, GB, <sup>12</sup>Johnson & Johnson,  
 London, GB, <sup>13</sup>The Health Policy Partnership, London, GB, <sup>14</sup>Bristol-Myers Squibb  
 Belgium SA, Brussels, BE

13:10 - 13:10 **1889P - High-throughput screening of new drugs targeting lung CSCs**

H. Amado Labrador<sup>1</sup>, E. Jantus-Lewintre<sup>2</sup>, S. Calabuig Fariñas<sup>3</sup>, C. Aguilar-Gallardo<sup>4</sup>, J.  
 Murga<sup>5</sup>, E. Munera-Maravilla<sup>6</sup>, E. Durendez-Saez<sup>4</sup>, M. Mosqueda<sup>1</sup>, E. Escorihuela<sup>2</sup>, F.  
 Zhang<sup>1</sup>, E. Masiá<sup>7</sup>, N. Dong<sup>8</sup>, R. Guijarro<sup>9</sup>, C. Camps<sup>10</sup>, <sup>1</sup>Fundación de Investigación  
 Hospital General Universitario de Valencia, Valencia, ES, <sup>2</sup>Departament de Biotecnologia,  
 Universitat Politècnica de València, Valencia, ES, <sup>3</sup>Hospital General Universitario  
 Valencia, Valencia, ES, <sup>4</sup>Molecular Oncology Laboratory, Fundación de Investigación  
 Hospital General Universitario de Valencia, Spain., Valencia, ES, <sup>5</sup>Universidad Jaime I,  
 Castellón, Spain., Castellón, ES, <sup>6</sup>Fundación de Investigación Hospital General  
 Universitario de Valencia, Spain., Valencia, ES, <sup>7</sup>Centro de Investigación Príncipe Felipe,  
 Valencia, Spain., Valencia, ES, <sup>8</sup>Fundación de Investigación Hospital General  
 Universitario de Valencia, Valencia, ES, <sup>9</sup>Hospital General Universitario de Valencia,  
 Spain., Valencia, ES, <sup>10</sup>Consortio Hospital General Universitario de Valencia, Valencia,  
 ES

13:10 - 13:10 **1890TiP - RING observational trial to compare T790M mutation testing in blood by different methodologies**

B. Garcia-Pelaez<sup>1</sup>, E. Jantus Lewintre<sup>2</sup>, A. Romero<sup>3</sup>, M.-A. Molina<sup>4</sup>, A. Blasco Cordellat<sup>2</sup>,  
 C. Perez-Barrios<sup>5</sup>, R. Rosell<sup>6</sup>, C. Camps<sup>7</sup>, M. Provencio Pulla<sup>8</sup>, <sup>1</sup>QUIRON-DEXEUS  
 UNIVERSITY HOSPITAL, Barcelona, ES, <sup>2</sup>Hospital General Universitario Valencia,  
 Valencia, ES, <sup>3</sup>Private Practice, Majadahonda, ES, <sup>4</sup>Pangaea Biotech S.L., Barcelona, ES,  
<sup>5</sup>H. UNIV. PUERTA DE HIERRO-MAJADAHONDA, Majadahonda, ES, <sup>6</sup>Catalan Institute of  
 Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>7</sup>Consortio  
 Hospital General Universitario de Valencia, Valencia, ES, <sup>8</sup>Hospital Universitario Puerta  
 de Hierro - Majadahonda, Majadahonda, ES

**12:30 - 14:00**    **Type: Patient Advocacy Track**    **ICM - Room 5**  
**Title: Pillars of an effective healthcare system in Europe**  
 Chair(s): Ananda Plate, BE; Vlad Voiculescu, RO

12:30 - 12:45    **Key components of a well-functioning healthcare system**  
W. Quentin, European Observatory on Health Systems and Policies, Technische Universität Berlin, Berlin, DE

12:45 - 13:00    **Special focus on healthcare in CEE**  
V. Voiculescu, Romanian Health Observatory, Bucharest, RO

13:00 - 13:15    **Civic participation: How citizens shape the society they live in**  
G. Moro, FONDACA - Fondazione per la Cittadinanza Attiva, Roma, IT

13:15 - 14:00    **Discussion**

**12:30 - 13:00**    **Type: Special session**    **ICM - Foyer - Ground floor**  
**Title: Let's talk women's cancers**

12:30 - 12:34    **Welcome and Introduction**  
J. Browning, Filshie Browning Associates, Basel, CH

12:34 - 12:39    **Overview of Patient Guides: Focus on Ovarian Cancer Patient Guide**  
N. Colombo, Istituto Europeo di Oncologia, Milan, IT

12:39 - 12:44    **Additional perspective: Focus on Breast Cancer Patient Guide**  
E. Senkus-Konefka, Medical University of Gdansk, Gdansk, PL

12:44 - 12:49    **Oncology Nurse's perspective: Cervical Cancer Patient Guide; Shared decision-making; Lifestyle interventions**  
L. Bjerrum Thisted, Rigshospitalet, University of Copenhagen, Copenhagen, DK

12:49 - 12:54    **Patient Perspectives on Women's Cancers: Adoption of survivorship plan**  
K. Apostolidis, European Cancer Patient Coalition(ECPC), Brussels, BE

12:54 - 12:59    **Questions**

12:59 - 13:00    **Closing remarks**  
J. Browning, Filshie Browning Associates, Basel, CH

**13:00 - 14:30**    **Type: ESMO Colloquium**    **ICM - Room 1**  
**Title: ESMO COLLOQUIUM - Hepatocellular carcinoma treatment: Now, next and beyond**  
 Chair(s): Jean-Luc Raoul, FR

13:00 - 13:05    **Introduction**  
J.-L. Raoul, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR

13:05 - 13:30    **Pros and cons of loco-regional therapy options**  
C. Gomez Martin, University Hospital 12 De Octubre, Madrid, ES

13:30 - 13:55    **Transitioning to first line systemic treatment; Pros and Cons of initiating early systemic treatment?**  
L. Rimassa, Humanitas Clinical and Research Center, Rozzano, IT

13:55 - 14:20    **Moving beyond monotherapy in first line HCC: What will be the new standard for the expected clinical and patient outcomes?**  
A. Vogel, Medizinische Hochschule Hannover, Hannover, DE

14:20 - 14:30    **Summary and conclusion**  
J.-L. Raoul, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **ICM - Room 14b**  
**Title: Industry satellite symposium 14**

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **ICM - Room 13**  
**Title: Industry satellite symposium 15**

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall A1 - Room 15**  
**Title: Industry satellite symposium 16**

13:00 - 14:00    **Presentation 1**  
J. Cauwood, London, GB

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall A1 - Room 16**  
**Title: Industry satellite symposium 17**

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 23**  
**Title: Industry satellite symposium - EONS 1**

13:00 - 13:30    **Presentation 1**  
J. De Munter, Gent University Hospital, Gent, BE

13:30 - 14:00    **Presentation 2**  
J. Hippenmeyer, Amgen (Europe) - Switzerland, Zug, CH

14:00 - 14:30    **Presentation 3**  
A. Spiegel, Washington, US

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 20**  
**Title: Industry satellite symposium 18**

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 22**  
**Title: Industry satellite symposium 19**

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 19**  
**Title: Industry satellite symposium 20**

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 24**  
**Title: Industry satellite symposium - EONS 2**

13:00 - 13:20    **presentation 1**  
V. Biagioli, rome, IT

13:20 - 13:40    **presentation**  
C. Thomssen, Halle, DE

13:40 - 14:00    **presentation 3**  
C. Champeix, Brussels, BE

14:00 - 14:20    **presentation 4**  
M. Järvinen, Association of Cancer Patients in Finland, Helsinki, FI



**14:45 - 16:30** **Type: Educational session** **Hall A1 - Room 17**  
**Title: Novel therapies for small cell lung cancer**  
 Chair(s): Corinne Faivre-Finn, GB; Noemi Reguart Aransay, ES

14:45 - 15:10 **Genetic background of SCLC**  
C. Rudin, Memorial Sloan-Kettering Cancer Center, New York, US

15:10 - 15:35 **Radiotherapy in SCLC: Lessons to learn**  
C. Faivre-Finn, The Christie NHS Foundation Trust, Manchester, GB

15:35 - 16:00 **Targeted therapies in SCLC: What might we expect?**  
N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

16:00 - 16:25 **Immunotherapy in SCLC: Current status and future perspectives**  
S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

**14:45 - 16:05** **Type: Poster Discussion session** **ICM - Room 1**  
**Title: Poster Discussion session - Genitourinary tumours, non prostate**  
 Chair(s): Rob Jones, GB; Ignacio Duran, ES; Cristina Suarez, ES

14:45 - 14:45 **LBA33 - A Phase Ib/2 study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced Urothelial Cancer (UC)**  
C. Hoimes<sup>1</sup>, C. Albany<sup>2</sup>, J. Hoffman-Censits<sup>3</sup>, M. Fleming<sup>4</sup>, E. Trabulsi<sup>5</sup>, J. Picus<sup>6</sup>, C. Cary<sup>2</sup>, M. Koch<sup>2</sup>, R. Walling<sup>7</sup>, W. Kelly<sup>8</sup>, J. Godwin<sup>5</sup>, M. Cooney<sup>9</sup>, P. Fu<sup>10</sup>, A. Nelson<sup>9</sup>, K. Patel<sup>11</sup>, C. Eitman<sup>11</sup>, T. Breen<sup>12</sup>, A. Neal<sup>12</sup>, H. Kaimakliotis<sup>2</sup>, <sup>1</sup>Case Western Reserve University / University Hospitals, Cleveland, US, <sup>2</sup>Indiana University School of Medicine, Indianapolis, US, <sup>3</sup>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, <sup>4</sup>US Oncology Research / Virginia Oncology Associates, Norfolk, US, <sup>5</sup>Thomas Jefferson University Kimmel Cancer Center, Philadelphia, US, <sup>6</sup>Washington University School of Medicine, St. Louis, US, <sup>7</sup>Community Regional Cancer Center, Indianapolis, US, <sup>8</sup>Thomas Jefferson University, Philadelphia, US, <sup>9</sup>Case Western Reserve University School of Medicine / University Hospitals Seidman Cancer Center, Cleveland, US, <sup>10</sup>Case Western Reserve University School of Medicine, Cleveland, US, <sup>11</sup>University Hospitals of Cleveland Seidman Cancer Center, Cleveland, US, <sup>12</sup>Hoosier Cancer Research Network, Indianapolis, US

14:45 - 14:45 **865PD - RANGE, a phase 3, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): overall survival results**  
D. Petrylak<sup>1</sup>, C. Sternberg<sup>2</sup>, A. Drakaki<sup>3</sup>, R. De Wit<sup>4</sup>, H. Nishiyama<sup>5</sup>, A. Necchi<sup>6</sup>, D. Castellano Gauna<sup>7</sup>, A. Bamias<sup>8</sup>, K. Chi<sup>9</sup>, M. Van Der Heijden<sup>10</sup>, N. Matsubara<sup>11</sup>, S. Hussain<sup>12</sup>, A. Flechon<sup>13</sup>, B. Alekseev<sup>14</sup>, E. Yu<sup>15</sup>, R. Walgren<sup>16</sup>, F. Russo<sup>17</sup>, A. Zimmermann<sup>18</sup>, K. Bell-Mcguinn<sup>16</sup>, T. Powles<sup>19</sup>, <sup>1</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>2</sup>Azienda Ospedaliera S. Camillo Forlanini, Rome, IT, <sup>3</sup>UCLA Medical Center, Los Angeles, US, <sup>4</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>5</sup>University of Tsukuba, Tsukuba, JP, <sup>6</sup>Istituto Nazionale dei Tumori di

Milano - Fondazione IRCCS, Milan, IT, <sup>7</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>8</sup>University of Athens, Sotiria General Chest Diseases Hospital, Athens, GR, <sup>9</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>10</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>11</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>12</sup>Plymouth University, Plymouth, GB, <sup>13</sup>Centre Léon Bérard, Lyon, FR, <sup>14</sup>Herzen Cancer Research Institute, Moscow, RU, <sup>15</sup>University of Washington, Seattle, US, <sup>16</sup>Eli Lilly, Indianapolis, US, <sup>17</sup>Eli Lilly and Company, Florence, US, <sup>18</sup>Eli Lilly and Company, Indianapolis, US, <sup>19</sup>St. Bartholomew's Hospital, London, GB

14:45 - 14:45 **868PD - Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): prospective analysis from the GETUG-AFU 26 (NIVOREN) trial**

R. Flippot<sup>1</sup>, C. Dalban<sup>2</sup>, B. Laguerre<sup>3</sup>, D. Borchiellini<sup>4</sup>, G. Gravis<sup>5</sup>, S. Negrier<sup>2</sup>, C. Chevreau<sup>6</sup>, F. Joly<sup>7</sup>, L. Geoffrois<sup>8</sup>, S. Ladoire<sup>9</sup>, H. Mahammedi<sup>10</sup>, F. Tantot<sup>11</sup>, B. Escudier<sup>12</sup>, L. Albiges<sup>1</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Centre Léon Bérard, Lyon, FR, <sup>3</sup>Centre Eugene - Marquis, Rennes, FR, <sup>4</sup>CENTRE ANTOINE LACASSAGNE, NICE CEDEX 2, FR, <sup>5</sup>Institute Paoli Calmettes, Marseille, FR, <sup>6</sup>Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, <sup>7</sup>GINECO & Centre Francois Baclesse Caen, Caen, FR, <sup>8</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>9</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>10</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>11</sup>Unicancer, Paris, FR, <sup>12</sup>Gustave Roussy - Cancer Campus, Villejuif, FR

14:45 - 15:00 **Invited Discussant LBA33, 865PD and 868PD**

R. Jones, Beatson West of Scotland Cancer Centre, Glasgow, GB

15:00 - 15:10 **Q&A led by Discussant**

15:10 - 15:10 **866PD - Comprehensive biomarker analyses and updated results of PURE-01 study: neoadjuvant pembrolizumab (Pembro) in muscle-invasive urothelial bladder carcinoma (MIBC).**

A. Necchi<sup>1</sup>, A. Briganti<sup>2</sup>, D. Raggi<sup>3</sup>, R. Luciano<sup>2</sup>, M. Colecchia<sup>1</sup>, S. Massa<sup>1</sup>, P. Giannatempo<sup>3</sup>, R. Colombo<sup>2</sup>, A. Gallina<sup>2</sup>, R. Salvioni<sup>1</sup>, R. Mortarini<sup>1</sup>, F. Montorsi<sup>4</sup>, R. Madison<sup>5</sup>, S. Ali<sup>6</sup>, J. Ross<sup>7</sup>, J. Chung<sup>6</sup>, A. Anichini<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>IRCCS San Raffaele Hospital, Milan, IT, <sup>3</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>4</sup>IRCCS San Raffaele, Milan, IT, <sup>5</sup>Foundation Medicine, Cambridge, US, <sup>6</sup>Foundation Medicine, Inc., Cambridge, US, <sup>7</sup>SUNY Upstate Medical University, Syracuse, US

15:10 - 15:10 **867PD - Comprehensive genomic profiling (CGP) of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors (PMNSGCT)**

A. Necchi<sup>1</sup>, G. Bratslavsky<sup>2</sup>, R. Corona<sup>2</sup>, J. Chung<sup>3</sup>, S. Millis<sup>3</sup>, L. Gay<sup>4</sup>, J. Elvin<sup>3</sup>, J.-A. Vergilio<sup>3</sup>, S. Ramkissoon<sup>3</sup>, E. Severson<sup>3</sup>, S. Daniel<sup>3</sup>, J. Killian<sup>3</sup>, S. Ali<sup>3</sup>, A. Schrock<sup>3</sup>, V. Miller<sup>3</sup>, J. Ross<sup>5</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Upstate Medical University, Syracuse, US, <sup>3</sup>Foundation Medicine, Inc., Cambridge, US, <sup>4</sup>Foundation Medicine, Cambridge, US, <sup>5</sup>SUNY Upstate Medical University, Syracuse, US

15:10 - 15:25 **Invited Discussant 866PD and 867PD**

I. Duran, Hospital Universitario "Marqués de Valdecilla", Santander, ES

15:25 - 15:35 **Q&A led by Discussant**

15:35 - 15:35 **LBA34 - PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.**

T. Choueiri<sup>1</sup>, A. Flaifel<sup>2</sup>, W. Xie<sup>3</sup>, D. Braun<sup>1</sup>, M. Ficial<sup>2</sup>, R. Jennings<sup>2</sup>, A. Nassar<sup>1</sup>, B. Escudier<sup>4</sup>, D. George<sup>5</sup>, R. Motzer<sup>6</sup>, M. Morris<sup>6</sup>, T. Powles<sup>7</sup>, E. Wang<sup>8</sup>, Y. Huang<sup>1</sup>, G. Freeman<sup>1</sup>, S. Signoretti<sup>2</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>Brigham and Women's Hospital, Boston, US, <sup>3</sup>Dana Farber Cancer Institute, Boston, US, <sup>4</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>5</sup>Duke University Medical Center, Durham, US, <sup>6</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>7</sup>Barts Cancer Institute, London, GB, <sup>8</sup>Exelixis, Inc., South San Francisco, US

15:35 - 15:35 **869PD - Tumor molecular characteristics in patients (pts) with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) good (G) and intermediate/poor (I/P) risk**

B. Beuselinck<sup>1</sup>, A. Verbiest<sup>2</sup>, G. Couchy<sup>3</sup>, S. Job<sup>4</sup>, A. De Reyniès<sup>4</sup>, S. Caruso<sup>3</sup>, V. Verkarre<sup>5</sup>, N. Rioux-Leclercq<sup>6</sup>, P. Schöffski<sup>7</sup>, Y. Vano<sup>8</sup>, R.-T. Elaidi<sup>9</sup>, E. Lerut<sup>7</sup>, M. Albersen<sup>7</sup>, S. Oudard<sup>10</sup>, J. Zucman-Rossi<sup>11</sup>, <sup>1</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>2</sup>KU Leuven, Leuven, BE, <sup>3</sup>INSERM, Paris, FR, <sup>4</sup>La Ligue Contre Le Cancer, Paris, FR, <sup>5</sup>Hôpital Necker Enfants malades, Paris, FR, <sup>6</sup>CHU PONTCHAILLOU, RENNES, FR, <sup>7</sup>University Hospitals Leuven, Leuven, BE, <sup>8</sup>HEGP, Paris, FR, <sup>9</sup>ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, FR, <sup>10</sup>Hopital European George Pompidou, Paris, FR, <sup>11</sup>Université Paris Descartes, Paris, FR

15:35 - 15:35 **870PD - Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): results of a GETUG multicenter phase II trial (Axipap)**

S. Negrier<sup>1</sup>, N. Rioux-Leclercq<sup>2</sup>, A. Ravaud<sup>3</sup>, G. Gravis<sup>4</sup>, L. Geoffrois<sup>5</sup>, C. Chevreau<sup>6</sup>, F. Rolland<sup>7</sup>, E. Blanc<sup>1</sup>, C. Segura-Ferlay<sup>8</sup>, D. Perol<sup>1</sup>, M. Gross Goupil<sup>3</sup>, S. Dermeche<sup>4</sup>, A. Flechon<sup>1</sup>, L. Albiges<sup>9</sup>, B. Escudier<sup>10</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, FR, <sup>2</sup>CHU PONTCHAILLOU, RENNES, FR, <sup>3</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>4</sup>Institute Paoli Calmettes, Marseille, FR, <sup>5</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>6</sup>Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, <sup>7</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>8</sup>Centre Leon Bérard, Lyon, FR, <sup>9</sup>Institut Gustave Roussy, Villejuif, FR, <sup>10</sup>Gustave Roussy - Cancer Campus, Villejuif, FR

15:35 - 15:50 **Invited Discussant LBA34, 869PD and 870PD**

C. Suarez, Universitat Autònoma de Barcelona, Barcelona, ES

15:50 - 16:00 **Q&A led by Discussant**

**14:45 - 16:15**    **Type: Special session**    **Hall A1 - Room 16**  
**Title: Technologies of the future**  
 Chair(s): Alex A. Adjei, US; Udai Banerji, GB

14:45 - 15:15    **CRISPR**  
R. Bernards, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:15 - 15:45    **CAR T cells**  
M. Sadelain, Memorial Sloan Kettering Cancer Center, New York, US

15:45 - 16:15    **Oncolytic viruses**  
E. Galanis, Mayo Clinic, Rochester, US

**14:45 - 16:15**    **Type: Educational session**    **Hall A2 - Room 18**  
**Title: Adjuvant treatment in colon cancer: Standards and next steps**  
 Chair(s): Julien Taieb, FR; Volker Heinemann, DE

14:45 - 15:07    **Using the standards but when, for what, and for how long?**  
R. Labianca, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT

15:07 - 15:29    **Tumour biology: What have we learned from the preceding trials (and what is “ready for daily use”)?**  
J. Taieb, Hopital European George Pompidou, Paris, FR

15:29 - 15:51    **What are we doing with rare subtypes: Is the time right for treatment stratification?**  
C. Montagut, University Hospital del Mar, Barcelona, ES

15:51 - 16:13    **Monitoring “molecular residual disease” in colon cancer: Implications for the future**  
L. Diaz, Memorial Sloan Kettering Cancer Center, New York City, US

**14:45 - 16:05**    **Type: Poster Discussion session**    **ICM - Room 14b**  
**Title: Poster Discussion session - Melanoma and other skin tumours**  
 Chair(s): Georgina Long, AU; Jean Jacques Grob, FR; Susana Puig Sarda, ES

14:45 - 14:45    **LBA45 - Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy**  
G. Long<sup>1</sup>, M. Milhem<sup>2</sup>, A. Amin<sup>3</sup>, C. Hoimes<sup>4</sup>, T. Medina<sup>5</sup>, R. Conry<sup>6</sup>, C. Lao<sup>7</sup>, G. Daniels<sup>8</sup>, S. Reddy<sup>9</sup>, I. Mehmi<sup>10</sup>, R. Andtbacka<sup>11</sup>, M. Barve<sup>12</sup>, M. Shaheen<sup>13</sup>, T. Tueting<sup>14</sup>, M. Chisamore<sup>15</sup>, B. Xing<sup>16</sup>, A. Candia<sup>16</sup>, E. Gamelin<sup>16</sup>, R. Janssen<sup>16</sup>, A. Ribas<sup>17</sup>, <sup>1</sup>Melanoma



Institute Australia, University of Sydney, North Sydney, AU, <sup>2</sup>University of Iowa, Iowa City, US, <sup>3</sup>Levine Cancer Institute, Charlotte, US, <sup>4</sup>Case Western Reserve University / University Hospitals, Cleveland, US, <sup>5</sup>University of Colorado Cancer Center, Aurora, US, <sup>6</sup>UAB School of Medicine, Alabama, US, <sup>7</sup>University of Michigan Health System, Ann Arbor, US, <sup>8</sup>University of California, San Diego, San Diego, US, <sup>9</sup>Stanford University School of Medicine, Stanford, US, <sup>10</sup>West Virginia University, Morgantown, US, <sup>11</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>12</sup>Mary Crowley Cancer Research, Dallas, US, <sup>13</sup>University of Arizona Cancer Center North, Tucson, US, <sup>14</sup>University Hospital Madgeburg, Madgeburg, DE, <sup>15</sup>Merck & Co, Kenilworth, US, <sup>16</sup>Dynavax Technologies Corporation, Berkeley, US, <sup>17</sup>Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

14:45 - 14:45

**1245PD - Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a Multicenter, Phase 1/2 study**

A. Diab<sup>1</sup>, C. Haymaker<sup>2</sup>, C. Bernatchez<sup>2</sup>, R. Andtbacka<sup>3</sup>, M. Shaheen<sup>4</sup>, D. Johnson<sup>5</sup>, J. Markowitz<sup>6</sup>, I. Puzanov<sup>7</sup>, R. Murthy<sup>1</sup>, D. Johnson<sup>1</sup>, M. James<sup>1</sup>, S. Chunduru<sup>8</sup>, J. Geib<sup>8</sup>, S. Swann<sup>8</sup>, S. Rahimian<sup>8</sup>, P. Hwu<sup>1</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>4</sup>University of Arizona Cancer Center North, Tucson, US, <sup>5</sup>Vanderbilt University, Nashville, US, <sup>6</sup>Moffitt Cancer Center, Tampa, US, <sup>7</sup>Roswell Park Cancer Center, Buffalo, US, <sup>8</sup>Idera Pharmaceuticals, Exton, US

14:45 - 14:45

**1246PD - Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB-IVM1c melanoma: evidence for systemic effects in a phase 2, single-arm study**

H. Gogas<sup>1</sup>, I. Samoylenko<sup>2</sup>, D. Schadendorf<sup>3</sup>, R. Gutzmer<sup>4</sup>, J.J. Grob<sup>5</sup>, J. Sacco<sup>6</sup>, K. Gorski<sup>7</sup>, A. Anderson<sup>7</sup>, C. Liu<sup>7</sup>, J. Malvehy<sup>8</sup>, <sup>1</sup>Laiko General Hospital of Athens, Athens, GR, <sup>2</sup>N.N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>3</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>4</sup>Hannover Medical School, Hannover, DE, <sup>5</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>6</sup>Clatterbridge Cancer Center, Wirral, GB, <sup>7</sup>Amgen Inc., Thousand Oaks, US, <sup>8</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

14:45 - 14:45

**LBA46 - Phase 2 Study Comparing Pembrolizumab (PEM) with Intermittent/short-term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra).**

E. Rozeman<sup>1</sup>, K. Sikorska<sup>2</sup>, L. Grijpink-Ongering<sup>2</sup>, B. Heeres<sup>2</sup>, B. Van De Wiel<sup>2</sup>, A. Sari<sup>2</sup>, H. Mallo<sup>3</sup>, S. Adriaansz<sup>2</sup>, W. Uytterlinde<sup>2</sup>, J. Lijnsvelt<sup>2</sup>, L. Pronk<sup>1</sup>, J. Haanen<sup>2</sup>, J.W. De Groot<sup>4</sup>, S. Wilgenhof<sup>1</sup>, M. Vollenbergh<sup>2</sup>, J. Van Thienen<sup>2</sup>, C. Blank<sup>2</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup>Netherlands Cancer institute, Amsterdam, NL, <sup>4</sup>Isala Klinieken, Zwolle, NL

14:45 - 15:05

**Invited Discussant LBA45, 1245PD, 1246PD and LBA46**

S. Puig Sarda, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

15:05 - 15:15 **Q&A led by Discussant**

15:15 - 15:15 **LBA47 - Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)**

C. Lebbé<sup>1</sup>, N. Meyer<sup>2</sup>, L. Mortier<sup>3</sup>, I. Marquez-Rodas<sup>4</sup>, C. Robert<sup>5</sup>, P. Rutkowski<sup>6</sup>, A. Menzies<sup>7</sup>, T. Eigentler<sup>8</sup>, P. Ascierto<sup>9</sup>, M. Smylie<sup>10</sup>, M. Ajaz<sup>11</sup>, I.-M. Svane<sup>12</sup>, R. Gonzalez<sup>13</sup>, L. Rollin<sup>14</sup>, A. Saci<sup>15</sup>, E. Grigoryeva<sup>14</sup>, J. Pigozzo<sup>16</sup>, <sup>1</sup>Hôpital Saint-Louis, Paris, FR, <sup>2</sup>Toulouse III University - Paul Sabatier, Institut universitaire du Cancer and Toulouse University Hospital, Toulouse, FR, <sup>3</sup>Hopital Claude Huriez, Lille, FR, <sup>4</sup>General University Hospital Gregorio Marañón, Madrid, ES, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>Maria Sklodowska-Curie Institute - Oncology Center, Warszawa, PL, <sup>7</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>8</sup>Center for Dermatocology, Department of Dermatology, University Hospital Tuebingen, Tuebingen, DE, <sup>9</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>10</sup>Cross Cancer Institute, Edmonton, CA, <sup>11</sup>Royal Surrey County Hospital, University of Surrey, Guildford, GB, <sup>12</sup>Herlev Hospital, Herlev, DK, <sup>13</sup>University of Colorado Cancer Center, Denver, US, <sup>14</sup>Bristol-Myers Squibb, Princeton, US, <sup>15</sup>Bristol Myers Squibb, Plainsboro, US, <sup>16</sup>Istituto Oncologico Veneto-IRCCS, Padua, IT

15:15 - 15:15 **1247PD - Phase II multicenter, single arm, open label study of Nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma. GEM1402.NCT02626962**

J.M. Piulats Rodriguez<sup>1</sup>, L. De La Cruz Merino<sup>2</sup>, E. Espinosa<sup>3</sup>, L. Alonso Carrión<sup>4</sup>, S. Martin Algarra<sup>5</sup>, R. López-Castro<sup>6</sup>, M.T. Curiel García<sup>7</sup>, D. Rodriguez Abreu<sup>8</sup>, A. Rullan Iriarte<sup>9</sup>, A. Berrocal Jaime<sup>10</sup>, <sup>1</sup>Institut Catala d'Oncologia (ICO), Barcelona, ES, <sup>2</sup>Hospital Universitario Virgen Macarena, Sevilla, ES, <sup>3</sup>Hospital Universitario La Paz, Madrid, ES, <sup>4</sup>ljalonso@uma.es, Málaga, ES, <sup>5</sup>Clínica Universitaria de Navarra, Navarra, ES, <sup>6</sup>Hospital Universitario Clínico de Valladolid, Valladolid, ES, <sup>7</sup>Hospital Universitario Clínico de Santiago, Santiago de Compostela, ES, <sup>8</sup>Hospital Insular de Canarias, Las Palmas de Gran Canarias, ES, <sup>9</sup>Institut Catala de Oncologia, Barcelona, ES, <sup>10</sup>Hospital General Universitario Valencia, Valencia, ES

15:15 - 15:25 **Invited Discussant LBA47 and 1247PD**

G. Long, Melanoma Institute Australia, University of Sydney, North Sydney, AU

15:25 - 15:35 **Q&A led by Discussant**

15:35 - 15:35 **1248PD - Efficacy of Pembrolizumab (Pembro) in Patients (Pts) With Advanced Melanoma with Stable Brain Metastases (BM) at Baseline: A Pooled Retrospective Analysis**

O. Hamid<sup>1</sup>, A. Ribas<sup>2</sup>, A. Daud<sup>3</sup>, M. Butler<sup>4</sup>, M. Carlino<sup>5</sup>, W.-J. Hwu<sup>6</sup>, G. Long<sup>7</sup>, K. Ancell<sup>8</sup>, F.S. Hodi<sup>9</sup>, N. Khushalani<sup>10</sup>, C. Blank<sup>11</sup>, C. Loquai<sup>12</sup>, J. Lin<sup>13</sup>, S. Diede<sup>13</sup>, C. Robert<sup>14</sup>, <sup>1</sup>The Angeles Clinic and Research Institute, Los Angeles, US, <sup>2</sup>Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, <sup>3</sup>University of California, San Francisco, San

Francisco, US, <sup>4</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>5</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>6</sup>MD Anderson Cancer Center, Houston, US, <sup>7</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>8</sup>Vanderbilt-Ingram Cancer Center, Nashville, US, <sup>9</sup>Dana-Farber Cancer Institute, Boston, US, <sup>10</sup>Moffitt Cancer Center, Tampa, US, <sup>11</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>12</sup>University Medical Center Mainz, Mainz, DE, <sup>13</sup>Merck & Co., Inc., Kenilworth, US, <sup>14</sup>Institut Gustave Roussy, Villejuif, FR

15:35 - 15:35

**1249PD - Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase.**

C. Allayous<sup>1</sup>, B. Oriano<sup>2</sup>, S. Dalle<sup>3</sup>, L. Mortier<sup>4</sup>, M.-T. Leccia<sup>5</sup>, B. Guillot<sup>6</sup>, G. Jeudy<sup>7</sup>, C. Dutriaux<sup>8</sup>, J.-P. Lacour<sup>9</sup>, P. Saiag<sup>10</sup>, F. Brunet-Possenti<sup>11</sup>, J. De Quatrebarbes<sup>12</sup>, P.-E. Stoeber<sup>13</sup>, D. Legoupil<sup>14</sup>, M. Beylot-Barry<sup>15</sup>, T. Lesimple<sup>16</sup>, F. Aubin<sup>17</sup>, A. Ballon<sup>18</sup>, R. Porcher<sup>19</sup>, C. Lebbe<sup>18</sup>, <sup>1</sup>Hôpital St. Louis, Paris, FR, <sup>2</sup>AP-HP Hotel-Dieu, Paris, FR, <sup>3</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>4</sup>Hopital Claude Huriez, Lille, FR, <sup>5</sup>CHU Grenoble - Hopital Michallon, La Tronche, FR, <sup>6</sup>CHU de Montpellier, Montpellier, FR, <sup>7</sup>Dijon university hospital, Dijon, FR, <sup>8</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>9</sup>Archet hospital, CHU Nice, Nice, FR, <sup>10</sup>Hopital Ambroise Pare, Boulogne-Billancourt, FR, <sup>11</sup>AP-HP Bichat hospital, Paris, FR, <sup>12</sup>CH Annecy Genevois, Annecy, FR, <sup>13</sup>Nimes hospital, Nimes, FR, <sup>14</sup>Brest hospital, Brest, FR, <sup>15</sup>Bordeaux Saint-André hospital, Bordeaux, FR, <sup>16</sup>Eugene Marquis Center, Rennes, FR, <sup>17</sup>Besançon hospital, Besançon, FR, <sup>18</sup>AP-HP, Saint-Louis hospital, Paris, FR, <sup>19</sup>AP-HP, Hotel-Dieu hospital, Paris, FR

15:35 - 15:45

**Invited Discussant 1248PD and 1249PD**

J.J. Grob, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR

15:45 - 15:55

**Q&A led by Discussant**

14:45 - 16:15

**Type: Educational session**  
**Title: Precision medicine with chemotherapy**  
Chair(s): Stephen Taylor, GB; Anton Berns, NL

**Hall B3 - Room 20**

14:45 - 15:10

**Precision medicine with conventional therapies in ovarian cancer**

S. Taylor, Manchester University, Manchester, GB

15:10 - 15:35

**Functional selection assays for precision therapy in breast cancer**

R. Kanaar, Erasmus University Medical Center, Rotterdam, NL

15:35 - 16:00

**Therapy, response and resistance in breast cancer**

E. Gogola, Amsterdam, NL

16:00 - 16:15

**Discussion**

**14:45 - 16:15**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Patient safety**  
 Chair(s): Cristina Lacerda, GB

14:45 - 15:00    **Patient safety as a current concern for health systems in Europe**  
D. Schwappach, University of Bern, Bern, CH

15:00 - 15:15    **Cancer's a risky business: Risk assessment in oncology nursing**  
J. Richmond, Letterkenny General Hospital, Letterkenny, IE

15:15 - 15:30    **Safety in the era of oral chemotherapy**  
L. Iacorossi, Universita La Sapienza, Rome, IT

15:30 - 15:45    **Safety outside of cancer centres: The rise of oral chemotherapy and the safety needs of patients**  
C. Oakley, Guy's and St. Thomas' Hospital NHS Trust, London, GB

15:45 - 16:15    **Discussion**

**14:45 - 16:15**    **Type: Special session**    **ICM - Room 14a**  
**Title: The way to assure sustainable, accessible and affordable cancer care within National Cancer Control Plans (NCCP)**  
 Chair(s): Giuseppe Curigliano, IT; Lisa Stevens, US

14:45 - 14:50    **Introduction**  
L. Stevens, National Cancer Institute, Rockville, US

14:50 - 15:05    **To have an NCCP or not: That is issue and where should we begin?**  
A. Eniu, Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, RO

15:05 - 15:20    **Profile from Central Europe - Czech Republic**  
T. Svoboda, University Hospital Plzen, Plzen, CZ

15:20 - 15:35    **Kazakhstan: National Cancer Control Plan update on progress made in 2017 - 2018**  
D. Kaidarova, Kazakh Reserch Institute of Oncology & Radiology, Almaty, KZ

15:35 - 15:50    **Belarus: National Cancer Control Plan update on progress made in 2017 - 2018**  
S. Krasny, N.N. Alexandrov Research Institute, Minsk, BY

15:50 - 16:15    **Interactive Q&A/Wrap up**  
G. Curigliano, Istituto Europeo di Oncologia, Milan, IT



**15:00 - 16:00** **Type: Young Oncologist session** **B11**  
**Title: YO Medical students: ESMO for medical students and young physicians**  
 Chair(s): Andrés Cervantes, ES; Anna Sophie Berghoff, AT

15:00 - 15:20 **ESMO-ESO Medical Students Course**  
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:20 - 15:40 **How to prepare and present your first poster at a congress**  
A.S. Berghoff, Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

15:40 - 16:00 **Guided poster walk**

**15:00 - 16:00** **Type: Multidisciplinary interactive sessions** **ICM - Room 13**  
**Title: Prevention and management in long term chronic cancer care**  
 Chair(s): Annie Young, GB

15:00 - 15:10 **Case presentation on venous thromboembolism and pain**  
M. Ozturk, Marmara University Hospital, Istanbul, TR

15:10 - 15:25 **VTE**  
A. Young, University of Warwick, Coventry, GB

15:25 - 15:40 **Pain**  
A. Caraceni, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:40 - 16:00 **Discussion**

**15:00 - 16:15** **Type: Poster Discussion session** **Hall A1 - Room 15**  
**Title: Poster Discussion session - Breast cancer, early stage**  
 Chair(s): Hervé Bonnefoi, FR; Marc van de Vijver, NL; Veronique Dieras, FR

15:00 - 15:00 **LBA13 - Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial**  
O. Gluz<sup>1</sup>, U. Nitz<sup>1</sup>, C. Liedtke<sup>2</sup>, M. Christgen<sup>3</sup>, E.-M. Grischke<sup>4</sup>, H. Forstbauer<sup>5</sup>, M. Braun<sup>6</sup>, M. Warm<sup>7</sup>, J. Hackmann<sup>8</sup>, C. Uleer<sup>9</sup>, B. Aktas<sup>10</sup>, C. Schumacher<sup>11</sup>, C. Lindner<sup>12</sup>, S. Kümmel<sup>13</sup>, R. Kates<sup>14</sup>, J. Potenberg<sup>15</sup>, P. Staib<sup>16</sup>, R. Wuerstlein<sup>17</sup>, H. Kreipe<sup>3</sup>, N. Harbeck<sup>18</sup>, <sup>1</sup>Evang. Krankenhaus "Bethesda" Klinik, Mönchengladbach, DE, <sup>2</sup>University Clinics Charité, Berlin, DE, <sup>3</sup>Medical School Hannover, Hannover, DE, <sup>4</sup>University Clinics Tuebingen, Tuebingen, DE, <sup>5</sup>Praxisnetzwerk Onkologie, Troisdorf, DE, <sup>6</sup>RED CROSS HOSPITAL MUNICH, Munich, DE, <sup>7</sup>City Hospital Holweide, Cologne, DE, <sup>8</sup>Marien

Hospital, Witten, DE, <sup>9</sup>Practice of Gynecology and Oncology, Hildesheim, DE, <sup>10</sup>University Clinics, Leipzig, DE, <sup>11</sup>St. Elisabeth Krankenhaus Hohenlind, Köln, DE, <sup>12</sup>Charité University Clinics, Berlin, DE, <sup>13</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>14</sup>REK Consulting, Otterfing, DE, <sup>15</sup>Ev. Waldkrankenhaus, Berlin, DE, <sup>16</sup>St. Antonius Hospital Klinik für Hämatologie/Onkologie, Eschweiler, DE, <sup>17</sup>Ludwig Maximilians University - Grosshadern, München, DE, <sup>18</sup>Ludwig Maximilians University - Grosshadern, Munich, DE

15:00 - 15:00

**LBA14\_PR - The HOBEO-2 multicenter randomized phase 3 trial in premenopausal patients with hormone-receptor positive early breast cancer comparing Triptorelin plus either Tamoxifen or Letrozole or Letrozole + Zoledronic acid.**

F. Perrone<sup>1</sup>, M. De Laurentiis<sup>1</sup>, S. De Placido<sup>2</sup>, M. Orditura<sup>3</sup>, S. Cinieri<sup>4</sup>, F. Riccardi<sup>5</sup>, A.S. Ribecco<sup>6</sup>, C. Putzu<sup>7</sup>, L. Del Mastro<sup>8</sup>, E. Rossi<sup>9</sup>, B. Daniele<sup>10</sup>, A.M. Mosconi<sup>11</sup>, F. Di Rella<sup>1</sup>, G. Landi<sup>1</sup>, F. Nuzzo<sup>1</sup>, C. Pacilio<sup>1</sup>, R. Lauria<sup>12</sup>, L. Arenare<sup>1</sup>, M.C. Piccirillo<sup>1</sup>, C. Gallo<sup>3</sup>, <sup>1</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>2</sup>AOU Policlinico Federico II, Napoli, IT, <sup>3</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>4</sup>Perrino Hospital, Brindisi, IT, <sup>5</sup>Ospedale Cardarelli, Napoli, IT, <sup>6</sup>Ospedale S. Giovanni di Dio, Firenze, IT, <sup>7</sup>Università di Sassari, Sassari, IT, <sup>8</sup>IRCCS AOU San Martino - IST- Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>9</sup>Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT, <sup>10</sup>Azienda Ospedaliera G. Rummo, Benevento, IT, <sup>11</sup>Azienda Ospedaliera di Perugia S. Maria della Misericordia, Perugia, IT, <sup>12</sup>Private Practice, Pozzuoli, IT

15:00 - 15:00

**188PD - Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)**

M. Untch<sup>1</sup>, C. Jackisch<sup>2</sup>, A. Schneeweiss<sup>3</sup>, S. Schmatloch<sup>4</sup>, B. Aktas<sup>5</sup>, C. Denkert<sup>6</sup>, C. Schem<sup>7</sup>, H. Wiebringhaus<sup>8</sup>, S. Kümmel<sup>9</sup>, K. Rhiem<sup>10</sup>, M. Warm<sup>11</sup>, P.A. Fasching<sup>12</sup>, M. Just<sup>13</sup>, C. Hanusch<sup>14</sup>, J. Hackmann<sup>15</sup>, J.-U. Blohmer<sup>16</sup>, J. Furlanetto<sup>17</sup>, V. Nekljudova<sup>17</sup>, G. Von Minckwitz<sup>17</sup>, S. Loibl<sup>17</sup>, <sup>1</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>2</sup>Klinikum Offenbach GmbH, Offenbach, DE, <sup>3</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>4</sup>Elisabeth Krankenhaus, Kassel, DE, <sup>5</sup>University Clinics, Leipzig, DE, <sup>6</sup>Charite Berlin Mitte, Berlin, DE, <sup>7</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>8</sup>St. Barbara-Klinik, Hamm, DE, <sup>9</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>10</sup>University Hospital Cologne, Cologne, DE, <sup>11</sup>City Hospital Holweide, Cologne, DE, <sup>12</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>13</sup>Onkologische Schwerpunktpraxis, Bielefeld, DE, <sup>14</sup>Rotkreuzklinikum, Munich, DE, <sup>15</sup>Marien Hospital, Witten, DE, <sup>16</sup>St. Gertrauden-Krankenhaus, Berlin, DE, <sup>17</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

15:00 - 15:15

**Invited Discussant LBA13, LBA14\_PR and 188PD**

H. Bonnefoi, Institut Bergonié, Bordeaux, FR

15:15 - 15:25

**Q&A led by Discussant**

- 15:25 - 15:25 **189PD - Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04)**
- A. Van Rossum<sup>1</sup>, M. Hoogstraat<sup>2</sup>, M. Opdam<sup>2</sup>, H. Horlings<sup>3</sup>, L. Wessels<sup>2</sup>, R. Kerkhoven<sup>2</sup>, A. Van Leeuwen - Stok<sup>4</sup>, H. Oosterkamp<sup>5</sup>, M. Kok<sup>6</sup>, S. Linn<sup>1</sup>, <sup>1</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>3</sup>The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NL, <sup>4</sup>BOOG Study Center, Amsterdam, NL, <sup>5</sup>Medisch Centrum Haaglanden Westeinde Hospital, The Hague, NL, <sup>6</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL
- 15:25 - 15:25 **190PD - Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies**
- G. Bianchini<sup>1</sup>, J. Parker<sup>2</sup>, L. Carey<sup>3</sup>, C. Perou<sup>4</sup>, L. Sica<sup>1</sup>, A. Prat<sup>5</sup>, T. Pieńkowski<sup>6</sup>, Y.-H. Im<sup>7</sup>, G. Bianchi<sup>8</sup>, T. Ling-Ming<sup>9</sup>, M.-C. Liu<sup>10</sup>, A. Lluch<sup>11</sup>, V. Semiglazov<sup>12</sup>, J. De La Haba-Rodriguez<sup>13</sup>, D.-Y. Oh<sup>14</sup>, B. Poirier<sup>15</sup>, J. Pedrini<sup>16</sup>, P. Valagussa<sup>17</sup>, L. Gianni<sup>1</sup>, <sup>1</sup>IRCCS San Raffaele, Milan, IT, <sup>2</sup>UNC-Chapel Hill, Chapel Hill, US, <sup>3</sup>UNC - Lineberger Cancer Center, Chapel Hill, US, <sup>4</sup>University of North Carolina - Chapel Hill, Chapel Hill, US, <sup>5</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>6</sup>Radomskie Centrum Onkologii, Radom, PL, <sup>7</sup>Samsung Medical Center, Seoul, KR, <sup>8</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>9</sup>Taipei Veterans Hospital, Taipei, TW, <sup>10</sup>Koo Foundation Sun Yat-Sen Cancer Center, Taipei, TW, <sup>11</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>12</sup>14NN Petrov Research Institute of Oncology, St Petersburg, RU, <sup>13</sup>Hospital Reina Sofia, Cordoba, ES, <sup>14</sup>Seoul National University Hospital, Seoul, KR, <sup>15</sup>Centre des maladies du sein, Hôpital du Saint-Sacrement, Québec, CA, <sup>16</sup>Hospital Ernesto Dornelles, Porto Alegre, BR, <sup>17</sup>Fondazione Michelangelo, Milan, IT
- 15:25 - 15:40 **Invited Discussant 189PD and 190PD**
- M. Van De Vijver, The Netherlands Cancer Institute, Amsterdam, NL
- 15:40 - 15:50 **Q&A led by Discussant**
- 15:50 - 15:50 **191PD\_PR - 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio**
- P.F. Conte<sup>1</sup>, V. Guarneri<sup>1</sup>, G. Bisagni<sup>2</sup>, F. Piacentini<sup>3</sup>, A. Brandes<sup>4</sup>, L. Cavanna<sup>5</sup>, F. Giotta<sup>6</sup>, M. Aieta<sup>7</sup>, V. Gebbia<sup>8</sup>, A. Frassoldati<sup>9</sup>, A. Musolino<sup>10</sup>, O. Garrone<sup>11</sup>, C. Taverniti<sup>12</sup>, A. Rimanti<sup>10</sup>, S. Sarti<sup>13</sup>, D. Rubino<sup>14</sup>, A. Bologna<sup>2</sup>, R. Vicini<sup>15</sup>, S. Balduzzi<sup>15</sup>, R. D'Amico<sup>15</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>3</sup>Azienda Ospedaliera - Universitaria Policlinico di Modena, Modena, IT, <sup>4</sup>Ospedale Bellaria, Bologna, IT, <sup>5</sup>Azienda Ospedaliera Piacenza, Piacenza, IT, <sup>6</sup>Istituto Oncologico Bari, Bari, IT, <sup>7</sup>Centro di Riferimento Oncologico Basilicata IRCCS, Rionero in Vulture, IT, <sup>8</sup>Ospedale La Maddalena, Palermo, IT, <sup>9</sup>Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, <sup>10</sup>Azienda Ospedaliera di Parma, Parma, IT, <sup>11</sup>Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, <sup>12</sup>AOU città della salute e della scienza di Torino, Torino, IT, <sup>13</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>14</sup>AOU

Policlinico Sant'Orsola Malpighi, Bologna, IT, <sup>15</sup>University Hospital of Modena and Reggio Emilia, Modena, IT

15:50 - 15:50 **192PD - Randomized Trial of Lisinopril or Carvedilol for the Prevention of Cardiotoxicity in Patients with Early Stage HER2-Positive Breast Cancer Receiving Trastuzumab**  
P. Munster<sup>1</sup>, J. Krischer<sup>2</sup>, R. Tamura<sup>2</sup>, L. Bello-Matricaria<sup>2</sup>, A. Fink<sup>2</sup>, W. Mccaskill-Stevens<sup>3</sup>, M. Guglin<sup>4</sup>, <sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>University of South Florida, Tampa, US, <sup>3</sup>National Cancer Institute Div. Cancer Treatment, Rockville, US, <sup>4</sup>University of Kentucky, Lexington, US

15:50 - 16:05 **Invited Discussant 191PD and 192PD**  
V. Dieras, Centre Eugene - Marquis, Rennes, FR

16:05 - 16:15 **Q&A led by Discussant**

**15:00 - 16:15 Type: Poster Discussion session Hall B3 - Room 23**  
**Title: Poster Discussion session - Head and neck cancers**  
 Chair(s): Marco Merlano, IT; Hisham Mehanna, GB; Esat Mahmut Ozsahin, CH

15:00 - 15:00 **1047PD - Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): Post Hoc Analyses of Treatment Options From the Phase 3 KEYNOTE-040 Trial**  
C. Le Tourneau<sup>1</sup>, E. Cohen<sup>2</sup>, K. Harrington<sup>3</sup>, J. Dinis<sup>4</sup>, L. Licitra<sup>5</sup>, M.-J. Ahn<sup>6</sup>, A. Soria<sup>7</sup>, J.-P. Machiels<sup>8</sup>, N. Mach<sup>9</sup>, R. Mehra<sup>10</sup>, B. Burtness<sup>11</sup>, P. Zhang<sup>12</sup>, J. Cheng<sup>13</sup>, R. Swaby<sup>12</sup>, D. Soulières<sup>14</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>University of California San Diego, La Jolla, US, <sup>3</sup>The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, GB, <sup>4</sup>Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PT, <sup>5</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, IT, <sup>6</sup>Samsung Medical Center, Seoul, KR, <sup>7</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>8</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>9</sup>Hôpitaux Universitaires de Genève - HUG, Geneva, CH, <sup>10</sup>Fox Chase Cancer Center (currently at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA), Philadelphia, US, <sup>11</sup>Yale University School of Medicine, New Haven, US, <sup>12</sup>Merck & Co., Inc., Kenilworth, US, <sup>13</sup>Merck & Co Inc, North Wales, US, <sup>14</sup>Centre Hospitalier de l'Université de Montréal, Montréal, CA

15:00 - 15:00 **1049PD - Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)**  
J. Fayette<sup>1</sup>, G. Lefebvre<sup>2</sup>, M. Posner<sup>3</sup>, J. Bauman<sup>4</sup>, S. Salas<sup>5</sup>, C. Even<sup>6</sup>, E. Saada-Bouزيد<sup>7</sup>, T. Seiwert<sup>8</sup>, D. Colevas<sup>9</sup>, F. Calmels<sup>10</sup>, R. Zerbib<sup>10</sup>, A. Boyer Chamard<sup>10</sup>, R. Cohen<sup>11</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, FR, <sup>2</sup>Centre Oscar Lambret, Lille, FR, <sup>3</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, <sup>4</sup>Fox Case Cancer Center, Philadelphia, US, <sup>5</sup>CHU La Timone Adultes, Marseille, FR, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>Hopital Lacassagne, Nice, FR, <sup>8</sup>The University of Chicago Medical Centre, Chicago, US, <sup>9</sup>Stanford University Medical Center, Stanford, US, <sup>10</sup>Innate



Pharma, Marseille, FR, <sup>11</sup>Abramson Cancer Center, Philadelphia, US

15:00 - 15:00

**1050PD - Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)**

E. Cohen<sup>1</sup>, A. Algazi<sup>2</sup>, D. Laux<sup>3</sup>, D. Wong<sup>4</sup>, A. Amin<sup>5</sup>, L. Nabell<sup>6</sup>, M. Chisamore<sup>7</sup>, E. Gamelin<sup>8</sup>, R. Janssen<sup>8</sup>, S. Bishnoi<sup>9</sup>, <sup>1</sup>The University of Chicago Medical Centre, Chicago, US, <sup>2</sup>UCSF Medical Center at Mount Zion, San Francisco, US, <sup>3</sup>University of Iowa, Iowa City, US, <sup>4</sup>UCLA - School of Medicine, Los Angeles, US, <sup>5</sup>Levine Cancer Institute, Charlotte, US, <sup>6</sup>University of Alabama at Birmingham, Birmingham, US, <sup>7</sup>Merck & Co, Kenilworth, US, <sup>8</sup>Dynavax Technologies Corporation, Berkeley, US, <sup>9</sup>Adelaide Cancer Center, Kurralta Park, AU

15:00 - 15:15

**Invited Discussant 1047PD, 1049PD and 1050PD**

M. Merlano, Azienda Ospedaliera St. Croce e Carle, Cuneo, IT

15:15 - 15:25

**Q&A led by Discussant**

15:25 - 15:25

**1051PD - Comparison of Patient Populations Identified by Different PD-L1 Assays in Head and Neck Squamous Cell Carcinoma (HNSCC)**

M. Scott<sup>1</sup>, S. Wildsmith<sup>1</sup>, M. Ratcliffe<sup>2</sup>, H. Al-Masri<sup>3</sup>, P. Scorer<sup>4</sup>, C. Barker<sup>5</sup>, M. Rebelatto<sup>6</sup>, J. Walker<sup>7</sup>, <sup>1</sup>Astrazeneca, Cambridge, GB, <sup>2</sup>Astrazeneca, Macclesfield, GB, <sup>3</sup>Hematogenix, Tinley Park, US, <sup>4</sup>Precision Medicine Laboratories, Precision Medicine and Genomics, Cambridge, GB, <sup>5</sup>AstraZeneca, Little Chesterford, GB, <sup>6</sup>MedImmune, Gaithersburg, US, <sup>7</sup>AstraZeneca Netherlands, Zoetermeer, NL

15:25 - 15:25

**1052PD - Predictor of Effectiveness of Treatment Intensification on Overall Survival in Head and Neck Cancer (HNC)**

K. Zakeri<sup>1</sup>, F. Rotolo<sup>2</sup>, B. Lacas<sup>2</sup>, L. Vitzthum<sup>3</sup>, Q.-T. Le<sup>4</sup>, V. Gregoire<sup>5</sup>, J. Overgaard<sup>6</sup>, J. Tobias<sup>7</sup>, B. Zackrisson<sup>8</sup>, M. Parmar<sup>9</sup>, B. Burtness<sup>10</sup>, M.G. Ghi<sup>11</sup>, G. Sanguineti<sup>12</sup>, B. O'Sullivan<sup>13</sup>, C. Fortpied<sup>14</sup>, J. Bourhis<sup>15</sup>, H. Shen<sup>3</sup>, J. Harris<sup>16</sup>, J.-P. Pignon<sup>17</sup>, L. Mell<sup>18</sup>, <sup>1</sup>Moore's UCSD Cancer Center, La Jolla, US, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>University of California San Diego, La Jolla, US, <sup>4</sup>Stanford University School of Medicine, Stanford, US, <sup>5</sup>Leon Berard Cancer Center, Lyon, FR, <sup>6</sup>Aarhus University Hospital, Aarhus C, DK, <sup>7</sup>University College Hospital, London, GB, <sup>8</sup>Umeå University, Umeå, SE, <sup>9</sup>MRC Clinical Trials Unit at UCL, London, GB, <sup>10</sup>Yale University School of Medicine, New Haven, US, <sup>11</sup>Ospedale dell'Angelo di Mestre, Venezia, IT, <sup>12</sup>IRCCS Regina Elena National Cancer Institute, Rome, IT, <sup>13</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>14</sup>EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, <sup>15</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>16</sup>NRG Oncology, Philadelphia, US, <sup>17</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>18</sup>University of California, San Diego, US

15:25 - 15:25

**1053PD - Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC)**

S. Cavaliere<sup>1</sup>, L. De Cecco<sup>2</sup>, G. Calareso<sup>2</sup>, M. Silva<sup>3</sup>, S. Gazzani<sup>3</sup>, M. Bologna<sup>4</sup>, I. Nauta<sup>5</sup>, F. Wesseling<sup>6</sup>, L. Lopez Perez<sup>7</sup>, R. Shefi<sup>8</sup>, V. Tountopoulos<sup>9</sup>, G. Fico<sup>7</sup>, K. Scheckenbach<sup>10</sup>, R. Brakenhoff<sup>5</sup>, F. Hoebbers<sup>6</sup>, S. Canevari<sup>2</sup>, T. Poli<sup>3</sup>, L. Licitra<sup>11</sup>, L. Mainardi<sup>4</sup>, B. Bd2Decide Consortium<sup>12</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>University of Parma and Azienda Ospedaliero Universitaria di Parma, Parma, IT, <sup>4</sup>Politecnico di Milano, Milan, IT, <sup>5</sup>VU University Medical Center Amsterdam, Amsterdam, NL, <sup>6</sup>Maastricht University Medical Centre, Maastricht, NL, <sup>7</sup>LifeSTech, Madrid, ES, <sup>8</sup>All in Image, Israel, IL, <sup>9</sup>Innovation Lab, Athens, GR, <sup>10</sup>Universitätsklinikum Düsseldorf, Düsseldorf, DE, <sup>11</sup>Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, IT, <sup>12</sup>BD2Decide, Parma, IT

15:25 - 15:40 **Invited Discussant 1051PD, 1052PD and 1053PD**

H. Mehanna, The University of Birmingham Institute for Cancer Studies, Birmingham, GB

15:40 - 15:50 **Q&A led by Discussant**

15:50 - 15:50 **1054PD - Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT) versus conventional chemo-radiotherapy for locally advanced (LA) head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial**

Y. Tao<sup>1</sup>, A. Auperin<sup>2</sup>, P. Blanchard<sup>1</sup>, M. Alfonsi<sup>3</sup>, X.-S. Sun<sup>4</sup>, M. Rives<sup>5</sup>, Y. Pointreau<sup>6</sup>, J. Castelli<sup>7</sup>, P. Graff<sup>5</sup>, S. Wong Hee Kam<sup>8</sup>, J. Thariat<sup>9</sup>, O. Veresezan<sup>10</sup>, A. Cornely<sup>1</sup>, O. Casiraghi<sup>11</sup>, M. Lapeyre<sup>12</sup>, J. Bourhis<sup>13</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Gustave Roussy Cancer Campus, Villejuif, FR, <sup>3</sup>Clinique Sainte Catherine, avignon, FR, <sup>4</sup>Hopital Nord Franche-Comté de Montbéliard & CHRU de Besançon, Montbéliard, FR, <sup>5</sup>Institut Claudius Régaud, Toulouse, FR, <sup>6</sup>Centre Jean Bernard, Le Mans, FR, <sup>7</sup>Centre Eugène Marquis, Rennes, FR, <sup>8</sup>AP-HM Hôpital de la Timone, Marseille, FR, <sup>9</sup>Centre François Baclesse, Caen, FR, <sup>10</sup>Centre Henri Becquerel, Rouen, FR, <sup>11</sup>Institut Gustave Roussy, Villejuif, FR, <sup>12</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>13</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

15:50 - 15:50 **1055PD - Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).**

G. Koutsodontis<sup>1</sup>, G. Papaxoinis<sup>2</sup>, I. Kotsantis<sup>1</sup>, P. Oikonomopoulou<sup>1</sup>, A. Strati<sup>3</sup>, C. Avgerinou<sup>1</sup>, N. Spathas<sup>1</sup>, E. Kirodimos<sup>4</sup>, O. Tsavaris<sup>1</sup>, E. Maratou<sup>5</sup>, L. Hoxhallari<sup>1</sup>, M. Anastasiou<sup>1</sup>, M. Prevezanou<sup>1</sup>, E. Lianidou<sup>3</sup>, A. Psyrris<sup>1</sup>, <sup>1</sup>Attikon University Hospital, Athens, GR, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>3</sup>Lab of Analytical Chemistry, University of Athens, Athens, GR, <sup>4</sup>Hippokration General Hospital, University of Athens, Athens, GR, <sup>5</sup>Prevention and Treatment of Diabetes Mellitus and its Complications (H.N.D.C), Athens, GR

15:50 - 15:50 **1056PD - Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression**

M. Joerger<sup>1</sup>, S. Takahashi<sup>2</sup>, C.M. Sayehli<sup>3</sup>, S. Slosarczyk<sup>4</sup>, A. Navarro Mendivil<sup>5</sup>, P. Cassier<sup>6</sup>, H. Nogai<sup>7</sup>, C. Zhang<sup>8</sup>, F. Sei<sup>8</sup>, S. Bender<sup>9</sup>, P. Ellinghaus<sup>9</sup>, M. Tahara<sup>10</sup>,

<sup>1</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>2</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>3</sup>University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), Würzburg, DE, <sup>4</sup>Universität Würzburg, Wuerzburg, DE, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Centre Léon Bérard, Lyon, FR, <sup>7</sup>Bayer AG, Berlin, DE, <sup>8</sup>Bayer Yakuhin, Osaka, JP, <sup>9</sup>Bayer Pharma AG - Aprath Site, Wuppertal, DE, <sup>10</sup>National Cancer Center Hospital East, Kashiwa, JP

15:50 - 16:05 **Invited Discussant 1054PD, 1055PD and 1056PD**  
E.M. Ozsahin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

16:05 - 16:15 **Q&A led by Discussant**

**15:00 - 16:15 Type: Poster Discussion session** **Hall B3 - Room 22**  
**Title: Poster Discussion session - Developmental therapeutics / investigational immunotherapy**

Chair(s): Maria Grazia Daidone, IT; Boon-Cher Goh, SG; Christian Dittrich, AT

15:00 - 15:00 **LBA15 - Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas**

K. Harrington<sup>1</sup>, J. Brody<sup>2</sup>, M. Ingham<sup>3</sup>, J. Strauss<sup>4</sup>, S. Cemerski<sup>5</sup>, M. Wang<sup>6</sup>, A. Tse<sup>6</sup>, A. Khilnani<sup>6</sup>, A. Marabelle<sup>7</sup>, T. Golan<sup>8</sup>, <sup>1</sup>Institute of Cancer Research ICR, London, GB, <sup>2</sup>The Mount Sinai Hospital, New York, US, <sup>3</sup>Columbia University Medical Center, New York, US, <sup>4</sup>Mary Crowley Medical Research Center, Dallas, US, <sup>5</sup>Merck Research Laboratories, Boston, US, <sup>6</sup>Merck & Co., Inc., Kenilworth, US, <sup>7</sup>Gustave Roussy, Villejuif, FR, <sup>8</sup>Chaim Sheba Medical Center, Ramat Gan, IL

15:00 - 15:00 **LBA16 - Phase 1/2, Multicenter, Open-Label Study of Intratumoral/Intralesional Administration of the Retinoic Acid-Inducible Gene I (RIG-I) Activator MK-4621 in Patients With Advanced or Recurrent Tumors**

M. Middleton<sup>1</sup>, M. Wermke<sup>2</sup>, E. Calvo<sup>3</sup>, E. Chartash<sup>4</sup>, H. Zhou<sup>5</sup>, X. Zhao<sup>5</sup>, M. Niewel<sup>6</sup>, K. Dobrenkov<sup>4</sup>, V. Moreno<sup>7</sup>, <sup>1</sup>Churchill Hospital University of Oxford, Oxford, GB, <sup>2</sup>University Hospital Carl-Gustav-Carus, Dresden, DE, <sup>3</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>4</sup>MSD-Merck Sharp & Dohme, Kenilworth, US, <sup>5</sup>Merck & Co., Inc, Kenilworth, US, <sup>6</sup>Rigontec GMBH, Planegg, DE, <sup>7</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES

15:00 - 15:00 **412PD - Clinical activity, safety, and PK/PD from a Phase 1 study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)**

I. Melero<sup>1</sup>, E. Castanon Alvarez<sup>1</sup>, M. Mau-Sorensen<sup>2</sup>, U. Lassen<sup>3</sup>, M. Lolkema<sup>4</sup>, D. Robbrecht<sup>5</sup>, C. Gomez-Roca<sup>6</sup>, J. Martin-Liberal<sup>7</sup>, J. Tabernero<sup>8</sup>, W. Ros<sup>9</sup>, S. Ahmed<sup>10</sup>, N. Isambert<sup>11</sup>, H. Piper Lepoutre<sup>12</sup>, C. Boetsch<sup>12</sup>, J. Charo<sup>13</sup>, S. Evers<sup>12</sup>, V. Teichgräber<sup>14</sup>, J. Schellens<sup>15</sup>, <sup>1</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>2</sup>SKACCD - Rigshospitalet, Copenhagen, DK, <sup>3</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>4</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>5</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>6</sup>Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR,



<sup>7</sup>Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>8</sup>Vall d`Hebron University Hospital. Vall d`Hebron Institute of Oncology VHIO., Barcelona, ES, <sup>9</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>10</sup>University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB, <sup>11</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>12</sup>Roche Innovation Center Basel, Basel, CH, <sup>13</sup>Roche Innovation Center Zurich, Schlieren, CH, <sup>14</sup>Roche Glycart AG - Switzerland, Schlieren, CH, <sup>15</sup>The Netherlands Cancer Institute, Amsterdam, NL

15:00 - 15:00 **413PD - Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma**

M. Krebs<sup>1</sup>, J. Lopez<sup>2</sup>, A. El-Khoueiry<sup>3</sup>, Y.-J. Bang<sup>4</sup>, S. Postel-Vinay<sup>5</sup>, W. Abidah<sup>6</sup>, S.-A. Im<sup>4</sup>, L. Khoja<sup>7</sup>, N. Standifer<sup>8</sup>, G. Jones<sup>9</sup>, P. Marco-Casanova<sup>9</sup>, P. Frewer<sup>7</sup>, A. Berges<sup>7</sup>, A. Cheung<sup>7</sup>, C. Stephens<sup>7</sup>, B. Felicetti<sup>7</sup>, E. Dean<sup>7</sup>, A. Pierce<sup>7</sup>, S. Hollingsworth<sup>7</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>The Royal Marsden Hospital, London, GB, <sup>3</sup>Norris cancer centre, Los Angeles, US, <sup>4</sup>Seoul National University Hospital, Seoul, KR, <sup>5</sup>Institute Gustav Roussy, Paris, FR, <sup>6</sup>Memorial Sloan Kettering Hospital, New York, US, <sup>7</sup>AstraZeneca UK, Melbourn, GB, <sup>8</sup>medimmune plc, san francisco, US, <sup>9</sup>AstraZeneca UK, cambridge, GB

15:00 - 15:20 **Invited Discussant LBA15, LBA16, 412PD and 413PD**

M.G. Daidone, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:20 - 15:30 **Q&A led by Discussant**

15:30 - 15:30 **414PD - Phase 1 Study of the CTLA-4 Inhibitor MK-1308 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors**

B.C. Cho<sup>1</sup>, R. Perets<sup>2</sup>, J. Bar<sup>3</sup>, M.-J. Ahn<sup>4</sup>, D.-W. Kim<sup>5</sup>, K. Yoh<sup>6</sup>, A. Nagrial<sup>7</sup>, D. Spigel<sup>8</sup>, D.H. Lee<sup>9</sup>, M. Gutierrez<sup>10</sup>, D. Kotasek<sup>11</sup>, S. Siddiqi<sup>12</sup>, A. Chain<sup>12</sup>, B. Butts<sup>12</sup>, Y. Zhang<sup>12</sup>, X. Li<sup>12</sup>, J. Cyrus<sup>12</sup>, A. Tse<sup>12</sup>, R. Altura<sup>12</sup>, D. Rasco<sup>13</sup>, <sup>1</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>Rambam Medical Center, Haifa, IL, <sup>3</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>4</sup>Samsung Medical Center, Seoul, KR, <sup>5</sup>Seoul National University Hospital, Seoul, KR, <sup>6</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>7</sup>Blacktown Hospital and University of Sydney, Sydney, AU, <sup>8</sup>Sarah Cannon Research Institute, Nashville, US, <sup>9</sup>University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, <sup>10</sup>Hackensack University Medical Center, Hackensack, US, <sup>11</sup>Adelaide Cancer Centre, Adelaide, AU, <sup>12</sup>Merck & Co., Inc., Kenilworth, US, <sup>13</sup>START, San Antonio, US

15:30 - 15:30 **415PD - Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors.**

J. Medioni<sup>1</sup>, M. Brizard<sup>2</sup>, L. Teixeira<sup>3</sup>, L. Doucet<sup>3</sup>, Z. Ghrieb<sup>3</sup>, A. Angelergues<sup>2</sup>, S. Oudard<sup>2</sup>, S. Culine<sup>3</sup>, O. Adotevi<sup>4</sup>, C. Laheurte<sup>4</sup>, M.-A. Dragon-Durey<sup>5</sup>, P. Laurent-Puig<sup>6</sup>, J.-J. Kiladjian<sup>3</sup>, V. Doppler<sup>7</sup>, B. Souttou<sup>7</sup>, S. Wain-Hobson<sup>7</sup>, R. Defrance<sup>8</sup>, T. Huet<sup>7</sup>, P. Langlade-Demoyen<sup>7</sup>, <sup>1</sup>Gh Diaconesses Croix Saint-Simon, Paris, FR, <sup>2</sup>Hopital European George Pompidou, Paris, FR, <sup>3</sup>Hôpital St. Louis, Paris, FR, <sup>4</sup>UMR1098, Besançon, FR,



<sup>5</sup>Hôpital Européen Georges Pompidou, Paris, FR, <sup>6</sup>Paris Descartes University, Paris, FR,  
<sup>7</sup>Invectys, Paris, FR, <sup>8</sup>Ipsen Pharma France, Boulogne-Billancourt, FR

- 15:30 - 15:30 **416PD - Final Results from a Phase I Clinical Trial Evaluating the Safety, Immunogenicity, and Anti-Tumor Activity of SNS-301 in Men with Biochemically Relapsed Prostate Cancer**  
L. Nordquist<sup>1</sup>, H. Ghanbari<sup>2</sup>, J. Elist<sup>3</sup>, J. Oliver<sup>4</sup>, W. Gannon<sup>5</sup>, A. Shahlaee<sup>2</sup>, S. Fuller<sup>2</sup>, N. Shore<sup>6</sup>, <sup>1</sup>Urology Cancer Center and GU Research Network, Omaha, US, <sup>2</sup>Sensei Biotherapeutics, Gaithersburg, US, <sup>3</sup>Dr. James J. Elist, Beverley Hills, US, <sup>4</sup>Accelovance, Raleigh, US, <sup>5</sup>Capital City Technical Consulting, Washington, US, <sup>6</sup>Medical Director, Myrtu Beach, US
- 15:30 - 15:45 **Invited Discussant 414PD, 415PD and 416PD**  
B.-C. Goh, National University Hospital, Singapore, SG
- 15:45 - 15:55 **Q&A led by Discussant**
- 15:55 - 15:55 **417PD - Combination Therapy Optimization in Gastrointestinal Cancers using Multi-omic Molecular Profiling**  
M.C. Monge Bonilla<sup>1</sup>, E. Blais<sup>2</sup>, W. Chen<sup>3</sup>, M. Pishvain<sup>4</sup>, E. Petricoin<sup>2</sup>, J. Marshall<sup>5</sup>, <sup>1</sup>NCI/NIH, Bethesda, US, <sup>2</sup>Perthera, McLean, US, <sup>3</sup>Caris Life Sciences, Irving, US, <sup>4</sup>Georgetown University Hospital, Washington, US, <sup>5</sup>Georgetown University Hospital, Washington DC, US
- 15:55 - 15:55 **418PD - NCI-MATCH Arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss**  
F. Janku<sup>1</sup>, O. Jegede<sup>2</sup>, S. Puhalla<sup>3</sup>, P. Konstantinopoulos<sup>4</sup>, F. Meric-Bernstam<sup>5</sup>, E. Mitchell<sup>6</sup>, J. Zwiebel<sup>7</sup>, L. Mcshane<sup>7</sup>, S. Li<sup>2</sup>, L. Rubinstein<sup>7</sup>, L. Doyle<sup>7</sup>, D. Patton<sup>7</sup>, B. Conley<sup>7</sup>, P. O'Dwyer<sup>8</sup>, L. Harris<sup>7</sup>, C. Arteaga<sup>9</sup>, P. Williams<sup>10</sup>, S. Hamilton<sup>5</sup>, A. Chen<sup>11</sup>, K. Flaherty<sup>12</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>Dana Farber Cancer Institute, Boston, US, <sup>3</sup>The University of Pittsburgh, Pittsburgh, US, <sup>4</sup>Dana-Farber Cancer Institute, Boston, US, <sup>5</sup>MD Anderson Cancer Center, Houston, US, <sup>6</sup>Kimmel Cancer Center-Thomas Jefferson University, Philadelphia, US, <sup>7</sup>National Cancer Institute, Bethesda, US, <sup>8</sup>ECOG-ACRIN, Philadelphia, US, <sup>9</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>10</sup>Frederick National Laboratory for Cancer Research, Frederick, US, <sup>11</sup>Center for Cancer Research-National Cancer Institute, Bethesda, US, <sup>12</sup>Massachusetts General Hospital, Boston, US
- 15:55 - 16:05 **Invited Discussant 417PD and 418PD**  
C. Dittrich, Angewandte Krebsforschung - Institution für Translationale Forschung Wien (ACR-ITR VIENNA), Vienna, AT
- 16:05 - 16:15 **Q&A led by Discussant**

**15:00 - 16:00** **Type: Poster Discussion session** **Hall B4 - Room 19**  
**Title: Poster Discussion session - Translational research 1**  
 Chair(s): Laura Mezquita Pérez, FR; Rodrigo Dienstmann, ES

- 15:00 - 15:00 **53PD - Association of PD-L1 expression with prognosis among patients with 10 select cancers**  
T. Steiniche<sup>1</sup>, M. Ladekarl<sup>2</sup>, J. Bæhr Georgsen<sup>1</sup>, S. Andreasen<sup>3</sup>, M. Busch-Sørensen<sup>4</sup>, W. Zhou<sup>5</sup>, S. Pruitt<sup>6</sup>, A. Joe<sup>6</sup>, K.-L. Liaw<sup>6</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Aarhus University Hospital, Aarhus C, DK, <sup>3</sup>Copenhagen University Hospital, Copenhagen, DK, <sup>4</sup>MSD Denmark, Copenhagen, DK, <sup>5</sup>Merck & Co Inc, North Wales, US, <sup>6</sup>Merck & Co., Inc., Kenilworth, US
- 15:00 - 15:00 **54PD - Pre-treatment CD4 senescent T cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non small cell lung cancer, and correlates with risk of hyperprogression**  
M. Zuazo<sup>1</sup>, H. Arasanz<sup>2</sup>, M. Gato-Cañas<sup>3</sup>, G. Fernández-Hinojal<sup>2</sup>, B. Hernández-Marín<sup>2</sup>, M. Martínez-Aguillo<sup>2</sup>, M. Ibáñez-Vea<sup>1</sup>, M.J. Lecumberri Biurrun<sup>2</sup>, Á. Fernández De Lascoiti<sup>2</sup>, R. Vera<sup>2</sup>, G. Kochan<sup>1</sup>, D. Escors<sup>1</sup>, <sup>1</sup>Navarrabiomed, Pamplona, ES, <sup>2</sup>Complejo Hospitalario de Navarra, Pamplona, ES, <sup>3</sup>Navarrabiomed / Fundación Miguel Servet, Pamplona, ES
- 15:00 - 15:00 **55PD - Identification of biological axes associated with stage II/III CRC recurrence risk and outcome after adjuvant therapy revealed a T-effector-independent prognostic role for granzyme B.**  
M. Das Thakur<sup>1</sup>, A. Udyavar<sup>1</sup>, T. Sandmann<sup>2</sup>, C. Li<sup>1</sup>, L. Bosch<sup>3</sup>, W. O'Gorman<sup>1</sup>, Y. Li<sup>1</sup>, A. Au-Yeung<sup>1</sup>, C. Takahashi<sup>1</sup>, R. Bourgon<sup>1</sup>, A. Daemen<sup>1</sup>, P. Hegde<sup>1</sup>, C. Bais<sup>1</sup>, <sup>1</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>2</sup>Denali Therapeutics, SSF, US, <sup>3</sup>Netherlands Cancer Institute, Amsterdam, NL
- 15:00 - 15:00 **56PD - Analytic Validation of Tumor Mutational Burden as a Companion Diagnostic for Combination Immunotherapy in Non-Small Cell Lung Cancer**  
D. Fabrizio<sup>1</sup>, C. Milbury<sup>1</sup>, W.-K. Yip<sup>1</sup>, L. Ramamurthy<sup>1</sup>, X. Bai<sup>1</sup>, V. Pattani<sup>1</sup>, P. Maness<sup>1</sup>, A. Cowen<sup>1</sup>, K. Fedorchak<sup>1</sup>, P. Ma<sup>1</sup>, G. Frampton<sup>2</sup>, C. Connelly<sup>1</sup>, Y. Li<sup>1</sup>, <sup>1</sup>Foundation Medicine, Cambridge, US, <sup>2</sup>Foundation Medicine, Inc., Cambridge, US
- 15:00 - 15:00 **57PD - Tumor mutational burden and prognosis across pan-cancers**  
H. Ding<sup>1</sup>, J. Zhao<sup>2</sup>, Y. Zhang<sup>2</sup>, G. Wang<sup>2</sup>, S. Cai<sup>2</sup>, F. Qiu<sup>3</sup>, <sup>1</sup>Affiliated People Hospital of Jiangsu University, Zhenjiang, CN, <sup>2</sup>Shanghai 3D Medicines.Inc, Shanghai, CN, <sup>3</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN
- 15:00 - 15:20 **Invited Discussant 53PD, 54PD, 55PD, 56PD and 57PD**  
L. Mezquita Pérez, Gustave Roussy, Villejuif, FR
- 15:20 - 15:30 **Q&A led by Discussant**
- 15:30 - 15:30 **58PD - Pan-Cancer Analysis of RET Fusions (FN) and Rearrangements (RE) By**

**Genomic Profiling of 158,360 Tumors**

L. Gay<sup>1</sup>, D. Pavlick<sup>1</sup>, S. Ramkissoon<sup>2</sup>, S. Daniel<sup>2</sup>, J. Killian<sup>2</sup>, J.-A. Vergilio<sup>2</sup>, E. Severson<sup>2</sup>, G. Frampton<sup>2</sup>, J. Elvin<sup>2</sup>, J. Ross<sup>3</sup>, <sup>1</sup>Foundation Medicine, Cambridge, US, <sup>2</sup>Foundation Medicine, Inc., Cambridge, US, <sup>3</sup>SUNY Upstate Medical University, Syracuse, US

15:30 - 15:30 **59PD - Final analysis of serum biomarkers in patients (pts) from the phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]**

R. Finn<sup>1</sup>, M. Kudo<sup>2</sup>, A.-L. Cheng<sup>3</sup>, L. Wyrwicz<sup>4</sup>, R. Ngan<sup>5</sup>, J.F. Blanc<sup>6</sup>, A. Baron<sup>7</sup>, A. Vogel<sup>8</sup>, M. Ikeda<sup>9</sup>, F. Piscaglia<sup>10</sup>, K.-H. Han<sup>11</sup>, S. Qin<sup>12</sup>, Y. Minoshima<sup>13</sup>, M. Kanekiyo<sup>14</sup>, M. Ren<sup>15</sup>, R. Dairiki<sup>14</sup>, T. Tamai<sup>15</sup>, C. Dutcus<sup>16</sup>, Y. Funahashi<sup>17</sup>, T.R.J. Evans<sup>18</sup>, <sup>1</sup>UCLA - School of Medicine, Los Angeles, US, <sup>2</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>3</sup>National Taiwan University Hospital, Taipei, TW, <sup>4</sup>Centrum Onkologii - Instytut, Warsaw, PL, <sup>5</sup>Queen Elizabeth Hospital, Kowloon, HK, <sup>6</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>7</sup>California Pacific, San Francisco, US, <sup>8</sup>Hannover Medical, Hannover, US, <sup>9</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>10</sup>University of Bologna, Bologna, IT, <sup>11</sup>Yonsei University, Seoul, KP, <sup>12</sup>81 Hospital, Nanjing, CN, <sup>13</sup>Eisai Co., Ltd. Tsukuba Research Laboratories, Tsukuba-shi, JP, <sup>14</sup>Eisai Co., Ltd., Ibaraki, JP, <sup>15</sup>Eisai, Woodcliff Lake, US, <sup>16</sup>Eisai Inc, Woodcliff Lake, US, <sup>17</sup>Eisai Inc., Andover, US, <sup>18</sup>Beatson Institute for Cancer Research, Glasgow, GB

15:30 - 15:30 **60PD - Colon Cancer Molecular Subtype IntraTumoral Heterogeneity and its prognostic impact : An Extensive Molecular Analysis of the PETACC-8**

P. Laurent-Puig<sup>1</sup>, L. Marisa<sup>2</sup>, M. Ayadi<sup>2</sup>, Y. Blum<sup>2</sup>, R. Balogoun<sup>1</sup>, C. Pilati<sup>1</sup>, K. Le Malicot<sup>3</sup>, C. Lepage<sup>4</sup>, J.F. Emile<sup>5</sup>, R. Salazar<sup>6</sup>, D. Aust<sup>7</sup>, A. Duval<sup>8</sup>, J. Selves<sup>9</sup>, D. Guenot<sup>10</sup>, G. Milano<sup>11</sup>, J.-F. Seitz<sup>12</sup>, J. Taieb<sup>13</sup>, V. Boige<sup>14</sup>, A. De Reyniès<sup>15</sup>, <sup>1</sup>Paris Descartes University, Paris, FR, <sup>2</sup>Ligue Nationale contre le cancer, Paris, FR, <sup>3</sup>FFCD-, Dijon, FR, <sup>4</sup>CHU Dijon, Dijon, FR, <sup>5</sup>Hopital Ambroise Pare, Boulogne-Billancourt, FR, <sup>6</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>7</sup>Universitätsklinikum Dresden, Dresden, DE, <sup>8</sup>INSERM UMR1102, Paris, FR, <sup>9</sup>Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, FR, <sup>10</sup>Strasbourg university, Strasbourg, FR, <sup>11</sup>Centre antoine Lacassagne, Nice, FR, <sup>12</sup>CHU La Timone Enfants, Marseille, FR, <sup>13</sup>Hopital European George Pompidou, Paris, FR, <sup>14</sup>Institut Gustave Roussy, Villejuif, FR, <sup>15</sup>La Ligue Contre Le Cancer, Paris, FR

15:30 - 15:30 **61PD - Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3**

M. Berger<sup>1</sup>, S. Stintzing<sup>2</sup>, V. Heinemann<sup>2</sup>, S. Cao<sup>3</sup>, D. Yang<sup>3</sup>, Y. Miyamoto<sup>1</sup>, M. Suenaga<sup>4</sup>, D.L. Hanna<sup>1</sup>, S. Soni<sup>1</sup>, A. Puccini<sup>5</sup>, R. Tokunaga<sup>1</sup>, M. Naseem<sup>1</sup>, F. Battaglin<sup>1</sup>, M. Mckane<sup>1</sup>, W. Zhang<sup>1</sup>, H.-J. Lenz<sup>1</sup>, <sup>1</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>2</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>3</sup>University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, US, <sup>4</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>5</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

15:30 - 15:30 **1831PD - Molecular differences between colorectal cancers with mutations in histone modifiers genes vs wild-type (WT) tumors.**

A. Puccini<sup>1</sup>, K. Poorman<sup>2</sup>, R. Goldberg<sup>3</sup>, A. Shields<sup>4</sup>, M. Winerip<sup>2</sup>, W.M. Korn<sup>2</sup>, M. Berger<sup>5</sup>, R. Tokunaga<sup>5</sup>, M. Naseem<sup>5</sup>, F. Battaglin<sup>5</sup>, W. Zhang<sup>6</sup>, S. Soni<sup>5</sup>, J. Hwang<sup>7</sup>, P. Philip<sup>4</sup>, J. Marshall<sup>8</sup>, H.-J. Lenz<sup>5</sup>, <sup>1</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>2</sup>Caris Life Sciences, Phoenix, US, <sup>3</sup> , SG, <sup>4</sup>Karmanos Cancer Institute, Detroit, US, <sup>5</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>6</sup>University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, US, <sup>7</sup>Levine Cancer Institute, Carolinas HealthCare System, Charlotte, US, <sup>8</sup>Georgetown University Hospital, Washington DC, US

15:30 - 15:50 **Invited Discussant 58PD, 59PD, 60PD, 61PD and 1831PD**  
R. Dienstmann, Vall d'Hebron University Hospital, Barcelona, ES

15:50 - 16:00 **Q&A led by Discussant**

<b>16:30 - 18:00</b>	<b>Type: Educational session</b> <b>Title: Multimodality approaches to hepatobiliary cancers</b> Chair(s): Eileen O'Reilly, US; Ann-Lii Cheng, TW	<b>ICM - Room 1</b>
----------------------	---	---------------------

16:30 - 16:55 **Locoregional treatment of HCC**  
J. Ricke, LMU Klinikum der Universität München, Munich, DE

16:55 - 17:20 **Systemic treatment of HCC in the era of immunotherapy**  
B. Daniele, Azienda Ospedaliera G. Rummo, Benevento, IT

17:20 - 17:45 **Targeted therapy for biliary cancer**  
E. O'Reilly, Memorial Sloan-Kettering Cancer Center, New York, US

17:45 - 18:00 **Discussion**



**16:30 - 18:00** **Type: Special Symposium** **Hall A1 - Room 15**  
**Title: Epigenetic alterations and potential clinical implications in sarcomas and other rare tumours**  
 Chair(s): Olivier Mir, FR; Susan Chi, US

16:30 - 16:35 **Introduction**  
O. Mir, Institut Gustave Roussy, Villejuif, FR

16:35 - 16:55 **Epigenetic insights into Ewing sarcoma**  
O. Delattre, Institut Curie, Paris, FR

16:55 - 17:15 **Epigenetic insights into midline carcinoma**  
C. French, Brigham and Women's Hospital, Boston, US

17:15 - 17:35 **Epigenetic insights into rhabdoid tumours**  
S. Chi, Dana-Farber Cancer Institute, Boston, US

17:35 - 17:55 **Epigenetic insights into epithelioid sarcomas**  
O. Mir, Institut Gustave Roussy, Villejuif, FR

17:55 - 18:00 **Conclusions and clinical perspectives**  
S. Chi, Dana-Farber Cancer Institute, Boston, US

**16:30 - 18:20** **Type: Proffered Paper session** **Hall A2 - Room 18**  
**Title: Presidential Symposium 1**  
 Chair(s): Josep Tabernero, ES; Andrés Cervantes, ES

16:30 - 16:45 **LBA1\_PR - IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)**

P. Schmid<sup>1</sup>, S. Adams<sup>2</sup>, H. Rugo<sup>3</sup>, A. Schneeweiss<sup>4</sup>, C. Barrios<sup>5</sup>, H. Iwata<sup>6</sup>, V. Dieras<sup>7</sup>, R. Hegg<sup>8</sup>, S.-A. Im<sup>9</sup>, G. Wright<sup>10</sup>, V. Henschel<sup>11</sup>, L. Molinero<sup>12</sup>, S. Chui<sup>13</sup>, R. Funke<sup>12</sup>, A. Husain<sup>12</sup>, E. Winer<sup>14</sup>, S. Loi<sup>15</sup>, L. Emens<sup>16</sup>, <sup>1</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>2</sup>New York University Langone Medical Center, New York, US, <sup>3</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>4</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>5</sup>PUCRS School of Medicine, Porto Alegre, BR, <sup>6</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>7</sup>Centre Eugene - Marquis, Rennes, FR, <sup>8</sup>Gynecological Clinical Service School of Medicine, Univ. Sao Paulo, Sao Paulo, BR, <sup>9</sup>Seoul National University Hospital, Seoul, KR, <sup>10</sup>Florida Cancer Specialists & Research Institute, New Port Richey, US, <sup>11</sup>Roche, Basel, CH, <sup>12</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>13</sup>Genentech, Inc., South San Francisco, US, <sup>14</sup>Dana-Farber Cancer Institute, Boston, US, <sup>15</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>16</sup>Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, US

16:45 - 17:00

**Invited discussant**

G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

17:00 - 17:15

**LBA2\_PR - Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3**

M. Cristofanilli<sup>1</sup>, D. Slamon<sup>2</sup>, J. Ro<sup>3</sup>, I. Bondarenko<sup>4</sup>, S.-A. Im<sup>5</sup>, N. Masuda<sup>6</sup>, M. Colleoni<sup>7</sup>, A. Demichele<sup>8</sup>, S. Loi<sup>9</sup>, S. Verma<sup>10</sup>, H. Iwata<sup>11</sup>, N. Harbeck<sup>12</sup>, S. Loibl<sup>13</sup>, F. André<sup>14</sup>, K. Puyana Theall<sup>15</sup>, X. Huang<sup>16</sup>, C. Giorgetti<sup>17</sup>, C. Huang Bartlett<sup>18</sup>, N. Turner<sup>19</sup>, <sup>1</sup>Feinberg School of Medicine, Northwestern University, Chicago, US, <sup>2</sup>UCLA - School of Medicine, Los Angeles, US, <sup>3</sup>National Cancer Center, Goyang-si, KR, <sup>4</sup>City Multiple-Discipline Clinical Hospital #4, Dnipropetrovsk, UA, <sup>5</sup>Seoul National University Hospital, Seoul, KR, <sup>6</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>7</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>University of Pennsylvania, Philadelphia, US, <sup>9</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>10</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>11</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>12</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>13</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>14</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>15</sup>Pfizer Inc, Cambridge, US, <sup>16</sup>Pfizer Inc, San Diego, US, <sup>17</sup>Pfizer Inc, Milan, IT, <sup>18</sup>Pfizer Inc, Collegeville, US, <sup>19</sup>Royal Marsden Hospital and Institute of Cancer Research, London, GB

17:15 - 17:30

**Invited Discussant**

F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT

17:30 - 17:45

**LBA3\_PR - Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial**

F. André<sup>1</sup>, E. Ciruelos<sup>2</sup>, G. Rubovszky<sup>3</sup>, M. Campone<sup>4</sup>, S. Loibl<sup>5</sup>, H. Rugo<sup>6</sup>, H. Iwata<sup>7</sup>, P. Conte<sup>8</sup>, I. Mayer<sup>9</sup>, B. Kaufman<sup>10</sup>, T. Yamashita<sup>11</sup>, Y.-S. Lu<sup>12</sup>, K. Inoue<sup>13</sup>, M. Takahashi<sup>14</sup>, Z. Pápai<sup>15</sup>, A.-S. Longin<sup>16</sup>, D. Mills<sup>17</sup>, C. Wilke<sup>17</sup>, S. Hirawat<sup>18</sup>, D. Juric<sup>19</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>3</sup>National Institute of Oncology Hungary, Budapest, HU, <sup>4</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>5</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>6</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>7</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>8</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>9</sup>Vanderbilt-Ingram Cancer Center, Nashville, US, <sup>10</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>11</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>12</sup>National Taiwan University Hospital, Taipei, TW, <sup>13</sup>Saitama Cancer Center, Kitadachi Ina, JP, <sup>14</sup>Hokkaido Cancer Center, Sapporo, JP, <sup>15</sup>Duna Medical Center, Budapest, HU, <sup>16</sup>Novartis Pharma S.A.S, Paris, FR, <sup>17</sup>Novartis Pharma AG, Basel, CH, <sup>18</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>19</sup>Massachusetts General Hospital, Boston, US

17:45 - 18:00

**2830\_PR - Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer**

Z. Jiang<sup>1</sup>, W. Li<sup>2</sup>, X. Hu<sup>3</sup>, Q. Zhang<sup>4</sup>, T. Sun<sup>5</sup>, S. Cui<sup>6</sup>, S. Wang<sup>7</sup>, Q. Ouyang<sup>8</sup>, Y. Yin<sup>9</sup>, C. Geng<sup>10</sup>, Z. Tong<sup>11</sup>, Y. Cheng<sup>12</sup>, Y. Pan<sup>13</sup>, Y. Sun<sup>14</sup>, H. Wang<sup>15</sup>, T. Ouyang<sup>16</sup>, K. Gu<sup>17</sup>, J. Feng<sup>18</sup>, X. Wang<sup>19</sup>, <sup>1</sup>307th Hospital of PLA (AMMS China), Beijing, CN, <sup>2</sup>the first hospital

of Jilin University, changchun, CN, <sup>3</sup>fudan university shanghai cancer center, shanghai, CN, <sup>4</sup>harbin medical university cancer hospital, harbin, CN, <sup>5</sup>liaoning cancer hospital, shenyang, CN, <sup>6</sup>henan cancer hospital, zhengzhou, CN, <sup>7</sup>sun yat-sen university cancer center, guangzhou, CN, <sup>8</sup>hunan cancer hospital, changsha, CN, <sup>9</sup>jiangsu province hospital, nanjing, CN, <sup>10</sup>tumor hospital of hebei province, shijiazhuang, CN, <sup>11</sup>tianjin medical university cancer hospital, tianjin, CN, <sup>12</sup>jilin cancer hospital, changchun, CN, <sup>13</sup>anhui province hospital, hefei, CN, <sup>14</sup>jinan cancer hospital, jinan, CN, <sup>15</sup>the third hospital of nanchang, nanchang, CN, <sup>16</sup>beijing cancer hospital, beijing, CN, <sup>17</sup>the first affiliated hospital of anhui medical university, hefei, CN, <sup>18</sup>jiangsu cancer hospital, nanjing, CN, <sup>19</sup>zhejiang cancer hospital, hangzhou, CN

18:00 - 18:20 **Invited discussant**

R. Dent, National Cancer Centre Singapore, Singapore, SG

**16:30 - 17:45 Type: Poster Discussion session Hall B3 - Room 23**

**Title: Poster Discussion session - CNS tumours**

Chair(s): Michael Weller, CH; Priscilla Brastianos, US; Frank Winkler, DE

16:30 - 16:30 **376PD - Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors.**

J.C. Benítez Montañez<sup>1</sup>, M. Vieito Villar<sup>2</sup>, C. Hierro<sup>3</sup>, M. Gonzalez Rodriguez<sup>3</sup>, I. Matos<sup>4</sup>, I. Braña Garcia<sup>4</sup>, C. Suarez Rodriguez<sup>4</sup>, E.A. Martinez Saez<sup>4</sup>, M.C. Perez-Gago<sup>3</sup>, R. Morales-Barrera<sup>5</sup>, C. Ortiz<sup>4</sup>, C. Suarez<sup>6</sup>, X. Maldonado<sup>4</sup>, F. Martinez-Ricarte<sup>4</sup>, C. Auger<sup>7</sup>, A. Azaro<sup>4</sup>, R. Dienstmann<sup>4</sup>, J. Carles<sup>8</sup>, E. Garralda<sup>3</sup>, <sup>1</sup>Hospital Mutua de Terrassa, Terrassa, ES, <sup>2</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>3</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Barcelona, ES, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>Hospital Vall d'Hebron, Barcelona, ES, <sup>8</sup>Vall Hebron Institute of Oncology, Barcelona, ES

16:30 - 16:30 **377PD - Multiplex digital PCR for the diagnostic of pilocytic astrocytoma and glioneuronal tumors**

F. Fina<sup>1</sup>, D. Henaff<sup>2</sup>, A. Bresson<sup>2</sup>, V. Juline<sup>2</sup>, A. Romain<sup>3</sup>, C. Carole<sup>4</sup>, D. Figarella-Branger<sup>3</sup>, <sup>1</sup>DT plateforme d'oncogénétique somatique, Marseille, FR, <sup>2</sup>ID solutions, Grabels, FR, <sup>3</sup>APHM, Marseille, FR, <sup>4</sup>Aix-Marseille Univ., Marseille, FR

16:30 - 16:40 **Invited Discussant 376PD and 377PD**

M. Weller, University Hospital and University of Zurich, Zurich, CH

16:40 - 16:50 **Q&A led by Discussant**

16:50 - 16:50 **378PD - Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases**

C. Wipfel<sup>1</sup>, A. Starzer<sup>1</sup>, A.S. Berghoff<sup>1</sup>, E. Bergen<sup>1</sup>, P. Wolf<sup>1</sup>, G. Widhalm<sup>1</sup>, J. Frischer<sup>1</sup>, B. Gatterbauer<sup>1</sup>, C. Marosi<sup>1</sup>, K. Dieckmann<sup>1</sup>, R. Bartsch<sup>1</sup>, M. Preusser<sup>2</sup>, <sup>1</sup>Medizinische

Universitaet Wien (Medical University of Vienna), Vienna, AT, <sup>2</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

- 16:50 - 16:50 **379PD - Androgen receptor expression in breast cancer brain metastases**  
E. Bergen<sup>1</sup>, A.S. Berghoff<sup>2</sup>, U. Rajky<sup>3</sup>, M. Rudas<sup>2</sup>, Z. Bago-Horvath<sup>4</sup>, R. Exner<sup>1</sup>, K. Dieckmann<sup>2</sup>, G. Widhalm<sup>2</sup>, M. Gnant<sup>1</sup>, C. Zielinski<sup>1</sup>, G. Steger<sup>1</sup>, M. Preusser<sup>1</sup>, R. Bartsch<sup>2</sup>, <sup>1</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>2</sup>Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, <sup>3</sup>Medical University of Vienna, Vienna, AT, <sup>4</sup>Vienna General Hospital (AKH) - Medical University of Vienna, Vienna, AT
- 16:50 - 17:00 **Invited Discussant 378PD and 379PD**  
P. Brastianos, Massachusetts General Hospital, Boston, US
- 17:00 - 17:10 **Q&A led by Discussant**
- 17:10 - 17:10 **380PD - Understanding Biological Activity, Tumor Response and Pseudoprogression in a Phase-2b Study of MDNA55 in Adults with Recurrent or Progressive Glioblastoma (GB)**  
M. Bexon<sup>1</sup>, A. Achrol<sup>2</sup>, K. Bankiewicz<sup>3</sup>, A. Brenner<sup>4</sup>, N. Butowski<sup>5</sup>, S. Kesari<sup>2</sup>, F. Merchant<sup>6</sup>, R. Merchant<sup>6</sup>, D. Randazzo<sup>7</sup>, M. Vogelbaum<sup>8</sup>, M. Zabek<sup>9</sup>, J. Sampson<sup>7</sup>, <sup>1</sup>Bexon Clinical Consulting, Basel, CH, <sup>2</sup>Pacific Neurosciences Institute, Santa Monica, US, <sup>3</sup>University of California San Francisco, San Francisco, US, <sup>4</sup>University of Texas Health San Antonio, San Antonio, US, <sup>5</sup>UCSF, San Francisco, US, <sup>6</sup>Medicenna BioPharma, Houston, US, <sup>7</sup>Duke University Medical Center, Durham, US, <sup>8</sup>Cleveland Clinic, Cleveland, US, <sup>9</sup>Mazovian Brodnowski Hospital, Warsaw, PL
- 17:10 - 17:10 **381PD - Comprehensive Geriatric Assessment (CGA) for outcome prediction in elderly patients (PTS) with glioblastoma (GBM): a mono-institutional experience**  
G. Lombardi<sup>1</sup>, E. Bergo<sup>1</sup>, L. Bellu<sup>1</sup>, M. Caccese<sup>2</sup>, A. Lettiero<sup>3</sup>, G. Tierno<sup>3</sup>, A. Pambuku<sup>1</sup>, A. Brunello<sup>1</sup>, V. Zagonel<sup>4</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>University of Verona, AOUI Verona, Verona, IT, <sup>3</sup>Veneto Institute of Oncology IOV - IRCCS, Padua, IT, <sup>4</sup>Istituto Oncologico Veneto-IRCCS, padova, IT
- 17:10 - 17:10 **382PD - Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma**  
J. Simões<sup>1</sup>, N. Tavares<sup>2</sup>, C. Borges<sup>3</sup>, S. Meireles<sup>3</sup>, C. Fernandes<sup>3</sup>, A. Costa<sup>3</sup>, C. Caeiro<sup>3</sup>, M. Damasceno<sup>3</sup>, <sup>1</sup>Hospital de S. João, Porto, PT, <sup>2</sup>HSJ - Hospital de São João, EPE, Porto, PT, <sup>3</sup>Centro Hospitalar de São João, EPE, Porto, PT
- 17:10 - 17:25 **Invited Discussant 380PD, 381PD and 382PD**  
F. Winkler, University Hospital of Heidelberg, Heidelberg, DE
- 17:25 - 17:35 **Q&A led by Discussant**



**16:30 - 18:00**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: EONS-ESO: How to stay resilient and lead cancer services successfully**  
 Chair(s): Daniel Kelly, GB

16:30 - 16:45    **Leading the multiprofessional team**  
E. Karlsson, Umea University, Umea, SE

16:45 - 17:00    **Leadership from research to an organisational level**  
T. Wiseman, Royal Marsden Hospital NHS Foundation Trust, London, GB

17:00 - 17:15    **Safe staffing**  
L. Smeds Alenius, Karolinska Institutet Innovations AB, Stockholm, SE

17:15 - 17:30    **CN1 - Evaluation of An Education Programme on Compassion Fatigue: Turkish Oncology-Haematology Nurses' Perspectives**  
T. Pehlivan<sup>1</sup>, P. Güner<sup>2</sup>, <sup>1</sup>Koc University Hospital (Koç Üniversitesi Hastanesi), Istanbul, TR, <sup>2</sup>Koc University Hospital, Istanbul, TR

17:30 - 17:45    **CN25 - Professional Grief in nurses exposed to patient deaths: the reality of a Portuguese Institute of Oncology.**  
B. Grube, Copenhagen, DK

17:45 - 18:00    **Discussion**

**16:45 - 17:45**    **Type: Poster Discussion session**    **ICM - Room 14b**  
**Title: Poster discussion session - Immunotherapy of cancer 1**  
 Chair(s): John Haanen, NL; Ulrich Keilholz, DE

16:45 - 16:45    **1131PD - Preliminary results of Phase 1/2 study of SENL-B19 chimeric antigen receptor T cell therapy in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r-ALL)**  
F. Ma<sup>1</sup>, J. Li<sup>2</sup>, J. Ren<sup>1</sup>, X. Zhang<sup>1</sup>, F. Wang<sup>1</sup>, X. Guo<sup>1</sup>, J. Zhang<sup>1</sup>, D. Wang<sup>3</sup>, Q. Liu<sup>4</sup>, J. Luo<sup>1</sup>,  
<sup>1</sup>The second hospital of hebei medical University, Shijiazhuang, CN, <sup>2</sup>Hebei Senlang Biotech. Co Ltd, Shijiazhuang, CN, <sup>3</sup>Harrison International Peace Hospital, shijiazhuang, CN, <sup>4</sup>The first hospital of hebei medical University, Shijiazhuang, CN

16:45 - 16:45    **LBA38 - Safety and Anti-Tumor Effects of MAGE-A10c796 TCR T-cells in Two Clinical Trials**  
V. Lam<sup>1</sup>, D. Hong<sup>2</sup>, J. Heymach<sup>3</sup>, G. Blumenschein<sup>4</sup>, M. Butler<sup>5</sup>, M. Johnson<sup>6</sup>, B. Creelan<sup>7</sup>, J. Gainor<sup>8</sup>, R. Govindan<sup>9</sup>, R. Mudad<sup>10</sup>, J. Neal<sup>11</sup>, F. Brophy<sup>12</sup>, F. Fang<sup>13</sup>, N. Hyland<sup>12</sup>, T. Holdich<sup>14</sup>, T. Trivedi<sup>12</sup>, E. Norry<sup>12</sup>, R. Amado<sup>13</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, houston, US, <sup>2</sup>The University of Texas M. D. Anderson Cancer Center,

Houston, US, <sup>3</sup>MD ANDERSON CANCER CENTER, HOUSTON, US, <sup>4</sup>MD Anderson Cancer Center, Houston, US, <sup>5</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>6</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>7</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, <sup>8</sup>Massachusetts General Hospital, Boston, US, <sup>9</sup>Washington University in St. Louis, St. Louis, US, <sup>10</sup>University of Miami, Miami, US, <sup>11</sup>Stanford University Medical Center, Stanford, US, <sup>12</sup>Adaptimmune, Philadelphia, US, <sup>13</sup>Adaptimmune LLC, Philadelphia, US, <sup>14</sup>Adaptimmune Ltd, Abingdon, GB

16:45 - 16:45

**1132PD - Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients**

T. Borch<sup>1</sup>, R. Andersen<sup>1</sup>, M.A. Rana<sup>1</sup>, P. Kongsted<sup>1</sup>, M. Pedersen<sup>1</sup>, M. Nielsen<sup>1</sup>, J. Kjeldsen<sup>1</sup>, A. Kverneland<sup>1</sup>, C. Lorentzen<sup>1</sup>, Ö. Met<sup>1</sup>, M. Donia<sup>1</sup>, I.-M. Svane<sup>2</sup>, <sup>1</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>2</sup>Herlev Hospital, Herlev, DK

16:45 - 17:05

**Invited Discussant 1131PD, LBA38 and 1132PD**

J. Haanen, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

17:05 - 17:15

**Q&A led by Discussant**

17:15 - 17:15

**LBA39 - Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors**

I. Marquez Rodas<sup>1</sup>, F. Longo<sup>2</sup>, M. Rodriguez-Ruiz<sup>3</sup>, A. Calles<sup>1</sup>, J.L. Pérez-Gracia<sup>4</sup>, A. Gomez-Rueda<sup>2</sup>, S. Lopez-Tarruella<sup>5</sup>, M. Ponz-Sarvisé<sup>6</sup>, R.M. Alvarez<sup>7</sup>, A. Soria<sup>2</sup>, E. De-Miguel<sup>1</sup>, J. Gayarre<sup>1</sup>, M.A. Aznar<sup>8</sup>, A. Calvo<sup>1</sup>, P. Lopez-Casas<sup>9</sup>, D. Tersago<sup>9</sup>, M. Quintero<sup>9</sup>, S. Martin-Algarra<sup>3</sup>, M. Martín<sup>5</sup>, I. Melero<sup>6</sup>, <sup>1</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>2</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>3</sup>Clinica Universidad de Navarra, Pamplona, ES, <sup>4</sup>Clínica Universitaria de Navarra, Pamplona, ES, <sup>5</sup>Universidad Complutense, Madrid, ES, <sup>6</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>7</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>8</sup>CIMA, Pamplona, ES, <sup>9</sup>Bioncotech Therapeutics, Valencia, ES

17:15 - 17:15

**LBA40 - Phase 1b KEYNOTE-200. A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients**

C. Rudin<sup>1</sup>, H. Pandha<sup>2</sup>, S. Gupta<sup>3</sup>, M. Zibelman<sup>4</sup>, W. Akerley<sup>3</sup>, D. Day<sup>5</sup>, A. Hill<sup>6</sup>, R. Sanborn<sup>7</sup>, S. O'Day<sup>8</sup>, T. Clay<sup>9</sup>, G. Wright<sup>10</sup>, R. Jennens<sup>11</sup>, D. Gerber<sup>12</sup>, J. Rosenberg<sup>1</sup>, C. Ralph<sup>13</sup>, D. Campbell<sup>14</sup>, B. Curti<sup>7</sup>, E. Schmidt<sup>15</sup>, M. Grose<sup>16</sup>, D. Shafren<sup>17</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>Royal Surrey County Hospital, Surrey, GB, <sup>3</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>4</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>5</sup>Monash Health, Melbourne, AU, <sup>6</sup>Tasman Oncology Research, Southport, AU, <sup>7</sup>Providence Cancer Institute, Portland, US, <sup>8</sup>John Wayne Cancer Institute, Santa Monica, US, <sup>9</sup>St. John of God, Subiaco, AU, <sup>10</sup>St. Vincent's Hospital Melbourne, Fitzroy, AU, <sup>11</sup>Epworth Healthcare, Richmond, AU, <sup>12</sup>UT Southwestern, Dallas, US, <sup>13</sup>St. James University Hospital, Leeds, GB, <sup>14</sup>Barwon Health Hospital, Geelong, AU, <sup>15</sup>Merck Research Laboratories, North Wales, US, <sup>16</sup>Viralytics Limited, Sydney, AU, <sup>17</sup>Viralytics,

Limited, Sydney, AU

- 17:15 - 17:15 **1133PD - A Phase 2a Trial to Assess the Safety and Efficacy of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)**  
M. Hidalgo<sup>1</sup>, R. Epelbaum<sup>2</sup>, B. Wolpin<sup>3</sup>, S. Stemmer<sup>4</sup>, R. Geva<sup>5</sup>, T. Golan<sup>6</sup>, E. Borazanci<sup>7</sup>, M. Borad<sup>8</sup>, K. Pedersen<sup>9</sup>, J.O. Park<sup>10</sup>, R. Ramirez<sup>11</sup>, A. Peled<sup>12</sup>, T. Lustig<sup>13</sup>, O. Bohana Kashtan<sup>13</sup>, O. Rosenfeld<sup>13</sup>, E. Sorani<sup>13</sup>, K. Schlienger<sup>14</sup>, A. Vainstein Haras<sup>15</sup>, D. Von Hoff<sup>16</sup>, <sup>1</sup>Beth Israel Deaconess Med. Center, Boston, US, <sup>2</sup>Rambam Health Care Center, Haifa, IL, <sup>3</sup>Dana Farber Cancer Institute, Boston, US, <sup>4</sup>Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, <sup>5</sup>Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, <sup>6</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>7</sup>Honor Health/TGen, Scottsdale, US, <sup>8</sup>Mayo Clinic Cancer Center, Scottsdale, US, <sup>9</sup>Washington University School of Medicine, St Louis, US, <sup>10</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>11</sup>Ochsner Medical Centre, Jefferson, US, <sup>12</sup>Hebrew University of Jerusalem, Jerusalem, IL, <sup>13</sup>BioLineRx Ltd, Modi'in, IL, <sup>14</sup>Merck & Co, Rahway, US, <sup>15</sup>No place of work provided, No City Provided, NA, <sup>16</sup>NDA Consulting Corp., Scottsdale, US
- 17:15 - 17:15 **1134PD - A Phase 1a/2b Trial of the CXCR4 Inhibitor X4P-001 and Nivolumab for Advanced Renal Cell Carcinoma (RCC) that is Unresponsive to Nivolumab Monotherapy**  
T. Choueiri<sup>1</sup>, M. Atkins<sup>2</sup>, T. Rose<sup>3</sup>, R. Alter<sup>4</sup>, E. Tsiroyannis<sup>5</sup>, K. Niland<sup>5</sup>, Y. Wang<sup>5</sup>, S. Parasuraman<sup>5</sup>, L. Gan<sup>5</sup>, D. Mcdermott<sup>6</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>Georgetown Lombardi Comprehensive Cancer Center, Washington, US, <sup>3</sup>University of North Carolina School of Medicine, Chapel Hill, US, <sup>4</sup>The John Theurer Cancer Center, Hackensack, US, <sup>5</sup>X4 Pharmaceuticals, Cambridge, US, <sup>6</sup>Beth Israel Deaconess Med. Center, Boston, US
- 17:15 - 17:35 **Invited Discussant LBA39, LBA40, 1133PD and 1134PD**  
U. Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE
- 17:35 - 17:45 **Q&A led by Discussant**

<b>16:45 - 17:45</b>	<b>Type: Multidisciplinary interactive sessions</b> <b>Title: Management of brain metastases in patients with oncogene drivers</b> Chair(s): Daniel Shao Weng Tan, SG	<b>ICM - Room 13</b>
16:45 - 16:50	<b>Case 1: ALK positive patient with brain oligo-metastasis</b> <u>D.S.W. Tan</u> , National Cancer Center Singapore, Singapore, SG	
16:50 - 17:00	<b>Neurosurgeons' perspective on patient selection</b> <u>C. Watts</u> , University Hospital Birmingham, Edgbaston, GB	
17:00 - 17:10	<b>Discussion</b>	
17:10 - 17:15	<b>Case 2: First presentation of multiple brain mets EGFR mutant NSCLC</b> <u>D. De Ruyscher</u> , Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL	
17:15 - 17:25	<b>Key considerations from the viewpoint of radiation oncologist</b> <u>D. De Ruyscher</u> , Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL	
17:25 - 17:35	<b>Emerging TKI strategies to tackle brain mets</b> <u>D.S.W. Tan</u> , National Cancer Center Singapore, Singapore, SG	
17:35 - 17:45	<b>Discussion</b>	



**16:45 - 17:45**    **Type: Special session**    **Hall A1 - Room 16**  
**Title: Molecular tumour board and drug access**  
 Chair(s): Teresa Troiani, IT

16:45 - 16:55    **How to select targeted agents for molecular aberrations**  
R. Dienstmann, Vall d'Hebron University Hospital, Barcelona, ES

16:55 - 17:05    **Integration of new technology in the identification of molecular targets**  
I. Wistuba, The University of Texas MD Anderson Cancer Center, Houston, US

17:05 - 17:15    **Identifying actionable targets**  
Y. Shyr, Vanderbilt University School of Medicine, New York, US

17:15 - 17:25    **Industry reaction to new scientific insights**  
S. Galbraith, Astrazeneca, Macclesfield, GB

17:25 - 17:45    **Discussion**

**18:00 - 19:30**    **Type: Patient Advocacy Track**    **ICM - Room 5**  
**Title: Cancer prevention**  
 Chair(s): Fredrik Johansson, SE; Gilberto Morgan, SE

18:00 - 18:15    **Why we are losing the war on cancer**  
C. Leaf, Fortune Magazine, New York, US

18:15 - 18:30    **Tobacco control: Saving lives and driving development**  
G. Morgan, Skane University Hospital, Lund, SE

18:30 - 18:45    **Behavioural aspects of health-related prevention measures**  
A. Leppänen, Regional Cancer Center Stockholm Gotland, Stockholm, SE

18:45 - 19:00    **Cancer awareness and screening: The challenges**  
Z. Maravic, EuropaColon UK, Salisbury, GB

19:00 - 19:30    **Discussion**

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 1**  
**Title: Industry satellite symposium 21**

**18:30 - 20:00**    **Type: ESMO Colloquium**    **ICM - Room 14b**  
**Title: ESMO COLLOQUIUM - Systemic therapies in unresectable hepatocellular carcinoma (HCC): 1st and later lines**  
 Chair(s): Peter Galle, DE

18:30 - 18:35    **Introduction**  
P. Galle, Universitätsmedizin Mainz, Mainz, DE

18:35 - 18:55    **Targets Biology in HCC**  
J.-L. Raoul, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR

18:55 - 19:15    **Targeted agents in unresectable HCC: a review of results in 1st and 2nd line**  
L. Rimassa, Humanitas Clinical and Research Center, Rozzano, IT

19:15 - 19:35    **Emerging Immunotherapy in unresectable HCC**  
B. Sangro, Clinica Universidad de Navarra, Pamplona, ES

19:35 - 19:55    **Future systemic treatments: new agents, targeted drug-combination, immune-drug combination?**  
J. Bruix, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, ES

19:55 - 20:00    **Conclusion**  
P. Galle, Universitätsmedizin Mainz, Mainz, DE

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 13**  
**Title: Industry satellite symposium 23**

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall A1 - Room 15**  
**Title: Industry satellite symposium 24**

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall A1 - Room 16**  
**Title: Industry satellite symposium 25**

18:30 - 18:50    **Presentation 1**  
A. Grothey<sup>1</sup>, H.-J. Lenz<sup>2</sup>, M. Ducreux<sup>3</sup>, C. Verslype<sup>4</sup>, <sup>1</sup>West Cancer Center, Germantown, US, <sup>2</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>3</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>4</sup>University Hospitals Leuven, Leuven, BE

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 23**  
**Title: Industry satellite symposium - EONS 3**

18:30 - 18:50    **presentation**

A. Charalambous<sup>1</sup>, P. Crombez<sup>2</sup>, M. Davies<sup>3</sup>, T. Wiseman<sup>4</sup>, J. Koldenhof<sup>5</sup>, <sup>1</sup>Cyprus University of Technology - Nursing Science, Limassol, CY, <sup>2</sup>Jules Bordet, Brussel, BE, <sup>3</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>4</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>5</sup>UMC - University Medical Center Utrecht, Utrecht, NL

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 20**  
**Title: Industry satellite symposium 26**

18:30 - 18:50    **Presentation**

I. Pabinger-Fasching<sup>1</sup>, P. Wells<sup>2</sup>, A.J. Muñoz<sup>3</sup>, A. Cohen<sup>4</sup>, G. Agnelli<sup>5</sup>, <sup>1</sup> Viena, AT, <sup>2</sup> Montreal, CA, <sup>3</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>4</sup> London, GB, <sup>5</sup> Rome, IT

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 19**  
**Title: Industry satellite symposium 27**

18:30 - 20:00    **presentation**

J. Sparano<sup>1</sup>, F. Penault-Llorca<sup>2</sup>, U. Nitz<sup>3</sup>, <sup>1</sup>Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, <sup>2</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>3</sup>Evang. Krankenhaus "Bethesda" Klinik, Mönchengladbach, DE

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 24**  
**Title: Industry satellite symposium - EONS 4**

18:30 - 18:50    **presentation 1**

J. Wall, Stockholm, SE

18:50 - 19:10    **presentation 2**

S. Esienberg, Seattle, US

19:10 - 19:30    **presentation 3**

L.-L. Aruväli, Tartu University Hospital, Tartu, EE

19:30 - 19:50    **presentation 4**

G. Knötgen, Berlin, DE

21.10.2018

**08:00 - 09:00**    **Type: Controversy Session**    **Hall A1 - Room 15**  
**Title: Should oligosymptomatic brain metastasis patients without oncogene addiction receive upfront systemic therapy?**  
 Chair(s): Matthias Preusser, AT

08:00 - 08:10    **Introduction and 1st vote**  
M. Preusser, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

08:10 - 08:30    **Pro**  
P. Brastianos, Massachusetts General Hospital, Boston, US

08:30 - 08:50    **Contra**  
S. Combs, Klinikum rechts der Isar TUM, Munich, DE

08:50 - 09:00    **2nd vote and conclusions**  
M. Preusser, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

**08:00 - 09:00**    **Type: Challenge Your Expert (CYE) session**    **Hall A1 - Room 16**  
**Title: The right time for discontinuing immunotherapy**  
 Chair(s): Jean-Charles Soria, US

08:00 - 08:10    **The right time for discontinuing immunotherapy**  
J. Weber, NYU Langone Medical Center, New York, US

08:10 - 09:00    **Discussion led by**  
J.-C. Soria, Medimmune, Gaithersburg, US

**08:00 - 09:00**    **Type: Challenge Your Expert (CYE) session**    **Hall B3 - Room 21**  
**Title: Challenging germ cell tumour patients**  
 Chair(s): Kirsten Gedske Daugaard, DK

08:00 - 08:10    **Challenging germ cell tumour patients**  
J. Gietema, University Hospital Groningen (UMCG), Groningen, NL

08:10 - 09:00    **Discussion led by**  
K.G. Daugaard, Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK



**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 23**  
**Title: Multiscale tumor heterogeneity: Clinical implications**  
 Chair(s): Nicola Normanno, IT

08:00 - 08:10 **Multiscale tumor heterogeneity: Clinical implications**  
E. Mardis, The Genome Institute at Washington University, St. Louis, US

08:10 - 09:00 **Discussion led by**  
N. Normanno, Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 20**  
**Title: Personalised breast cancer medicine: Should all patients have whole genome sequencing?**  
 Chair(s): Fabrice André, FR

08:00 - 08:10 **Personalised breast cancer medicine: Should all patients have whole genome sequencing?**  
C. Caldas, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

08:10 - 09:00 **Discussion led by**  
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 22**  
**Title: Small bowel adenocarcinomas**  
 Chair(s): Stefano Cascinu, IT

08:00 - 08:10 **Small bowel adenocarcinomas**  
T. Aparicio, Hôpital Avicenne, Bobigny, FR

08:10 - 09:00 **Discussion led by**  
S. Cascinu, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT

**08:00 - 09:00**    **Type: Special session**    **Hall B4 - Room 19**  
**Title: Special session: Summary of the ESMO-ESGO consensus conference on ovarian cancer**  
 Chair(s): Cristiana Sessa, CH

08:00 - 08:20    **Title to be defined**  
N. Colombo, Istituto Europeo di Oncologia, Milan, IT

08:20 - 08:40    **Title to be defined**  
J. Ledermann, University College London Cancer Institute, London, GB

08:40 - 09:00    **Q&A**

**08:00 - 09:00**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Self-care for young cancer nurses**  
 Chair(s): Sara Parreira, PT

08:00 - 08:20    **Compassion fatigue, burn-out, resilience and balance: What does it entail?**  
S. Parreira, Hospital CUF Infante Santo, Lisbon, PT

08:20 - 08:40    **Compassion fatigue, burn-out, resilience and balance: How can cancer nurses support each other?**  
L.-L. Aruväli, Tartu University Hospital, Tartu, EE

08:40 - 09:00    **Discussion**

**08:00 - 09:00**    **Type: Challenge Your Expert (CYE) session**    **ICM - Room 14a**  
**Title: Follicular and other indolent lymphomas**  
 Chair(s): Martin Dreyling, DE

08:00 - 08:10    **Follicular and other indolent lymphomas**  
M. Ghielmini, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

08:10 - 09:00    **Discussion led by**  
M. Dreyling, Ludwig Maximilians University - Grosshadern, Munich, DE

**08:15 - 09:00**    **Type: Keynote lecture**    **Hall A1 -**  
**Title: How do we manipulate the tumour microenvironment for**    **Room 17**  
**immunotherapy?**  
Chair(s): George Coukos, CH

08:15 - 09:00    **How do we manipulate the tumour microenvironment for immunotherapy?**  
T. Gajewski, The University of Chicago, Chicago, US

**09:10 - 10:45**    **Type: Special session**    **ICM - Room 14a**  
**Title: Practicing oncologists and rare tumours**  
 Chair(s): Stefan Rauh, LU; George Pentheroudakis, GR

09:10 - 09:10    **Is there still a Cancer of Unknown Primary (CUP) in 2018? Who will mostly guide your decision: Your genetician, pathologist, radiologist, or your “gut feeling”?**  
G. Lakatos, Szent Laszlo Korhaz, Budapest, HU

09:10 - 09:15    **Clinical case presentation**  
G. Lakatos, Szent Laszlo Korhaz, Budapest, HU

09:15 - 09:38    **Do clinical and “standard” pathological decision parameters dominate the treatment algorithms, or do we rely on the genetic signature?**  
G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR

09:38 - 09:38    **Adjuvant treatment of GIST: Who should benefit? Is there a need for referral?**  
M. Karamouzis, School of Medicine, University of Athens, Kolonaki, GR

09:38 - 09:43    **Clinical case presentation**  
M. Karamouzis, School of Medicine, University of Athens, Kolonaki, GR

09:43 - 10:06    **State of Art: Recommendation for adjuvant treatment in GIST**  
A. Le Cesne, Gustave Roussy - Cancer Campus, Villejuif, FR

10:06 - 10:06    **Rare tumours with recent treatment progresses**  
S. Rauh, Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU

10:06 - 10:11    **New treatment options in NET (incl combined radio nuclides**  
S. Rauh, Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU

10:11 - 10:34    **Should nuclear medicine be a mandatory treatment option for NET’s in 2018?**  
A. Beer, Ulm Medical University, Ulm, DE

10:34 - 10:40    **Closing remarks: The role of the PO in rare tumor management / Management issues of rare cancer from a community oncology point of view**  
S. Rauh, Centre Hospitalier Emile Mayrisch CHEM, Esch sur Alzette, LU

**09:15 - 10:55**    **Type: Proffered Paper session**    **Hall A1 - Room 17**  
**Title: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies**  
 Chair(s): Enriqueta Felip, ES; Pieter Postmus, NL

09:15 - 09:30    **LBA48\_PR - CTONG 1103 : Erlotinib versus Gemcitabine plus Cisplatin as Neo-adjuvant Treatment for Stage IIIA -N2 EGFR-mutation Non-small-cell lung cancer (EMERGING): a Randomised Study**



W.-Z. Zhong<sup>1</sup>, Y.-L. Wu<sup>1</sup>, K.-N. Chen<sup>2</sup>, C. Chen<sup>3</sup>, C.-D. Gu<sup>4</sup>, Q. Wang<sup>5</sup>, J. Wang<sup>6</sup>, W. Mao<sup>7</sup>, G.-B. Qiao<sup>8</sup>, Y. Cheng<sup>9</sup>, L. Xu<sup>10</sup>, C.-L. Wang<sup>11</sup>, M.-W. Chen<sup>12</sup>, X.-N. Yang<sup>1</sup>, H.-J. Chen<sup>1</sup>, H.-H. Yang<sup>1</sup>, J.-J. Yang<sup>13</sup>, Q. Zhou<sup>13</sup>, <sup>1</sup>Guangdong General Hospital, Guangzhou, CN, <sup>2</sup>Beijing Cancer Hospital, Beijing, CN, <sup>3</sup>Fujian Medical University Union Hospital, Fuzhou, CN, <sup>4</sup>The 1st hospital affiliated Dalian Medical University, Dalian, CN, <sup>5</sup>Fudan University Affiliated Zhongshan Hospital, Shanghai, CN, <sup>6</sup>The People's Hospital of Peking University, Beijing, CN, <sup>7</sup>Department of Thoracic Surgery, Hangzhou, CN, <sup>8</sup>Thoracic Surgery department, Guangzhou, CN, <sup>9</sup>Jilin Provincial Cancer Hospital, Changchun, CN, <sup>10</sup>Jiangsu Cancer Hospital, Nanjing, CN, <sup>11</sup>Tianjin Cancer Hospital, Tianjin, CN, <sup>12</sup>The 1st hospital affiliated Xi'an Jiaotong University, Xi'an, CN, <sup>13</sup>Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

09:30 - 09:45 **LBA49 - Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)**

T. Cascone<sup>1</sup>, W. William<sup>2</sup>, A. Weissferdt<sup>3</sup>, C. Leung<sup>3</sup>, L. Federico<sup>3</sup>, C. Haymaker<sup>3</sup>, C. Bernatchez<sup>3</sup>, F. Fossella<sup>3</sup>, F. Mott<sup>3</sup>, V. Papadimitrakopoulou<sup>2</sup>, L. Byers<sup>4</sup>, V. Lam<sup>5</sup>, M. Godoy<sup>3</sup>, B. Carter<sup>3</sup>, J. Lee<sup>2</sup>, A. Vaporciyan<sup>3</sup>, D. Gibbons<sup>4</sup>, S. Swisher<sup>3</sup>, J. Heymach<sup>4</sup>, B. Sepesi<sup>3</sup>, <sup>1</sup>UT MD Anderson Cancer Center, Houston, US, <sup>2</sup>MD Anderson Cancer Center, Houston, US, <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>4</sup>MD ANDERSON CANCER CENTER, HOUSTON, US, <sup>5</sup>The University of Texas MD Anderson Cancer Center, Houston, US

09:45 - 10:00 **Invited Discussant LBA48\_PR and LBA49**

S. Ramalingam, Emory University Winship Cancer Institute, Atlanta, US

10:00 - 10:15 **16640 - A randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 Trial**

J.-L. Pujol<sup>1</sup>, L. Greillier<sup>2</sup>, C. Audigier Valette<sup>3</sup>, D. Moro-Sibilot<sup>4</sup>, L. Uwer<sup>5</sup>, J. Hureauux<sup>6</sup>, L. Thiberville<sup>7</sup>, D. Carmier<sup>8</sup>, J. Madelaine<sup>9</sup>, J. Otto<sup>10</sup>, V. Gounant<sup>11</sup>, P. Merle<sup>12</sup>, P. Mourlanette<sup>13</sup>, O. Molinier<sup>14</sup>, P. Renault<sup>15</sup>, J. Mazieres<sup>16</sup>, M. Antoine<sup>17</sup>, A. Langlais<sup>18</sup>, F. Morin<sup>19</sup>, P.-J. Souquet<sup>20</sup>, <sup>1</sup>Hopital Arnaud de Villeneuve, Montpellier, FR, <sup>2</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>3</sup>Hopital Sainte Musse, Toulon, FR, <sup>4</sup>Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, FR, <sup>5</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>6</sup>CHU Angers, Angers, FR, <sup>7</sup>CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR, <sup>8</sup>CHRU Bretonneau, Tours, FR, <sup>9</sup>CHU de Caen, Caen, FR, <sup>10</sup>Centre Antoine Lacassagne, Nice, FR, <sup>11</sup>Hopital Bichat Claude Bernard, Paris, FR, <sup>12</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>13</sup>Clinique des Cedres, Cornebarrieu, FR, <sup>14</sup>Centre Hospitalier Du Mans, Le Mans, FR, <sup>15</sup>Centre Hospitalier, Pau, FR, <sup>16</sup>Hopital Larrey, Toulouse, FR, <sup>17</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>18</sup>IFCT, Paris, FR, <sup>19</sup>French Cooperative Thoracic Intergroup, Paris, FR, <sup>20</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR

10:15 - 10:27 **Invited Discussant 16640 and 13630**

J. Vansteenkiste, University Hospitals Leuven, Leuven, BE

10:27 - 10:42 **13630 - Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC**

C. Faivre-Finn<sup>1</sup>, D. Spigel<sup>2</sup>, S. Senan<sup>3</sup>, C. Langer<sup>4</sup>, D. Raben<sup>5</sup>, B. Perez<sup>6</sup>, M. Özgüroğlu<sup>7</sup>, D. Daniel<sup>8</sup>, A. Villegas<sup>9</sup>, D. Vicente<sup>10</sup>, R. Hui<sup>11</sup>, S. Murakami<sup>12</sup>, L. Paz-Ares<sup>13</sup>, L. Poole<sup>14</sup>, C. Wadsworth<sup>15</sup>, P. Dennis<sup>16</sup>, S. Antonia<sup>6</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Sarah Cannon Research Institute, Nashville, US, <sup>3</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>4</sup>University of Pennsylvania, Philadelphia, US, <sup>5</sup>University of Colorado, Denver, US, <sup>6</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, <sup>7</sup>Istanbul University Cerrahpasa School of Medicine, Istanbul, TR, <sup>8</sup>Tennessee Oncology, Chattanooga, US, <sup>9</sup>Cancer Specialists of North Florida, Jacksonville, US, <sup>10</sup>Hospital Universitario Virgen Macarena, Seville, ES, <sup>11</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>12</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>13</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>14</sup>AstraZeneca, Cambridge, GB, <sup>15</sup>Astrazeneca, Macclesfield, GB, <sup>16</sup>Astra Zeneca, New York, US

10:42 - 10:54 **Invited discussant 13630**

N. Rizvi, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

**09:15 - 10:45** **Type: Special Symposium** **Hall A2 - Room 18**  
**Title: Precision cancer medicine in metastatic colorectal cancer**  
 Chair(s): Tim Maughan, GB; Aurelien Marabelle, FR

09:15 - 09:20 **Introduction**  
A. Marabelle, Gustave Roussy, Villejuif, FR

09:20 - 09:40 **Pathological subgroups and molecular characterisation**  
S. Tejpar, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

09:40 - 10:00 **Cell free tumour DNA: Yet a role in treatment monitoring of mCRC?**  
K.-L. Spindler, Aarhus University Hospital, Aarhus, DK

10:00 - 10:20 **Novel therapeutic approaches for specific (rare) subtypes**  
T. Maughan, Oxford Institute for Radiation Oncology, Oxford, GB

10:20 - 10:40 **Immunotherapy: Checkpoint inhibitors and beyond**  
A. Marabelle, Gustave Roussy, Villejuif, FR

10:40 - 10:45 **Conclusions and perspectives**  
T. Maughan, Oxford Institute for Radiation Oncology, Oxford, GB

**09:15 - 10:30** **Type: Poster Discussion session** **ICM - Room 1**  
**Title: Poster Discussion session - Breast cancer, metastatic**  
 Chair(s): Lisa Carey, US; Alessandra Gennari, IT; Caroline Schroeder, NL

09:15 - 09:15 **293PD\_PR - Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-**

**negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b ComPLEEment-1 trial**

C. Zamagni<sup>1</sup>, M. Campone<sup>2</sup>, I. Kudryavcev<sup>3</sup>, U. Brown-Glaberman<sup>4</sup>, P. Cottu<sup>5</sup>, A. Ring<sup>6</sup>, J. Lu<sup>7</sup>, M. Martín<sup>8</sup>, M. De Laurentiis<sup>9</sup>, K. Zhou<sup>10</sup>, J. Wu<sup>10</sup>, L. Menon<sup>10</sup>, H. Azim<sup>11</sup>, <sup>1</sup>AOU Policlinico S. Orsola-Malpighi, F. Addarii, Bologna, IT, <sup>2</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>3</sup>Kaluga regional clinical cancer center, Kaluga, RU, <sup>4</sup>University of New Mexico Cancer Center, Albuquerque, US, <sup>5</sup>Institut Curie, Paris, FR, <sup>6</sup>The Royal Marsden NHS Foundation Trust, Surrey, GB, <sup>7</sup>University of Southern California, Los Angeles, US, <sup>8</sup>Universidad Complutense, Madrid, ES, <sup>9</sup>Istituto Nazionale Tumori "Fondazione G. Pascale", Napoli, IT, <sup>10</sup>Novartis Pharmaceuticals, East Hanover, US, <sup>11</sup>Cairo Oncology Center Cairo University-CairoCure, Cairo, EG

09:15 - 09:15

**294PD\_PR - Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program**

J. Sirieix<sup>1</sup>, J. Fraisse<sup>2</sup>, S. Mathoulin-Pelissier<sup>3</sup>, M. Leheurteur<sup>4</sup>, L. Vanlemmens<sup>5</sup>, C. Jouannaud<sup>6</sup>, V. Dieras<sup>7</sup>, C. Levy<sup>8</sup>, F. Dalenc<sup>9</sup>, M.-A. Mouret-Reynier<sup>10</sup>, T. Petit<sup>11</sup>, B. Coudert<sup>12</sup>, E. Brain<sup>13</sup>, B. Pistilli<sup>14</sup>, J.-M. Ferrero<sup>15</sup>, A. Gonçalves<sup>16</sup>, L. Uwer<sup>17</sup>, S. Gourgou<sup>18</sup>, J.-S. Frenel<sup>19</sup>, <sup>1</sup>CHRU Bretonneau, Tours, FR, <sup>2</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>3</sup>Institut Bergonié, Bordeaux, FR, <sup>4</sup>Centre Henri Becquerel, Rouen, FR, <sup>5</sup>Centre Oscar Lambret, Lille, FR, <sup>6</sup>Institut Jean Godinot, Reims, FR, <sup>7</sup>Centre Eugene - Marquis, Rennes, FR, <sup>8</sup>Centre Francois Baclesse, Caen, FR, <sup>9</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>10</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>11</sup>GINECO & Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, FR, <sup>12</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>13</sup>Institut Curie, Paris & Saint-Cloud, FR, <sup>14</sup>Gustave Roussy, Villejuif, FR, <sup>15</sup>Centre Antoine Lacassagne, Nice, FR, <sup>16</sup>Institute Paoli Calmettes, Marseille, FR, <sup>17</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>18</sup>Institut du Cancer de Montpellier, Montpellier, FR, <sup>19</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR

09:15 - 09:15

**273PD\_PR - Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients**

M. Reinisch<sup>1</sup>, S. Seiler<sup>2</sup>, T. Hauzenberger<sup>3</sup>, S. Schmatloch<sup>4</sup>, H.-J. Strittmatter<sup>5</sup>, D.-M. Zahm<sup>6</sup>, C. Thode<sup>7</sup>, C. Jackisch<sup>8</sup>, D. Strik<sup>9</sup>, V. Moebus<sup>10</sup>, T. Reimer<sup>11</sup>, B. Sinn<sup>12</sup>, E. Stickeler<sup>13</sup>, F. Marme<sup>14</sup>, W. Janni<sup>15</sup>, A. Kamischke<sup>16</sup>, C. Rudlowski<sup>17</sup>, V. Nekljudova<sup>2</sup>, G. Von Minckwitz<sup>2</sup>, S. Loibl<sup>2</sup>, <sup>1</sup>Kliniken Essen-Mitte, Essen, DE, <sup>2</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>3</sup>Klinikum St. Marien, Amberg, DE, <sup>4</sup>Elisabeth Krankenhaus, Kassel, DE, <sup>5</sup>Reims-Murr-Hospital GmbH, Winnenden, DE, <sup>6</sup>SRH Wald-Klinikum, Gera, DE, <sup>7</sup>amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Göttingen, DE, <sup>8</sup>Klinikum Offenbach GmbH, Offenbach, DE, <sup>9</sup>Endokrinologikum, Berlin, DE, <sup>10</sup>Klinikum Frankfurt Höchst, Academic Hospital of the Goethe University Frankfurt, Frankfurt, DE, <sup>11</sup>University of Rostock, Rostock, DE, <sup>12</sup>Charité-Universitätsmedizin, Berlin, DE, <sup>13</sup>Uniklinik RWTH, Aachen, DE, <sup>14</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, <sup>15</sup>Universitätsklinikum, Ulm, DE, <sup>16</sup>MVZ Kinderwunsch und Hormonzentrum, Münster, DE, <sup>17</sup>Evangelisches Krankenhaus, Bergisch Gladbach, DE



- 09:15 - 09:30 **Invited Discussant 293PD, 294PD and 273PD**  
C. Schroeder, University Hospital Groningen (UMCG), Groningen, NL
- 09:30 - 09:40 **Q&A led by Discussant**
- 09:40 - 09:40 **285PD - Balixafortide (a novel CXCR4 inhibitor) and Eribulin in HER2-neg Metastatic Breast Cancer (MBC) patients (pts): a Phase I trial**  
J. Cortes Castan<sup>1</sup>, M. Martín<sup>2</sup>, S. Pernas Simon<sup>3</sup>, P. Gomez Pardo<sup>1</sup>, S. Lopez-Tarruella<sup>2</sup>, M. Gil Martin<sup>4</sup>, L. Manso<sup>5</sup>, E. Ciruelos<sup>6</sup>, J.A. Perez Fidalgo<sup>7</sup>, C. Hernando<sup>7</sup>, F. Ademuyiwa<sup>8</sup>, K. Weilbaecher<sup>8</sup>, I. Mayer<sup>9</sup>, T. Pluard<sup>10</sup>, M. Martinez Garcia<sup>11</sup>, L. Vahdat<sup>12</sup>, A. Wach<sup>13</sup>, D. Barker<sup>14</sup>, B. Romagnoli<sup>13</sup>, P. Kaufman<sup>15</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>Universidad Complutense, Madrid, ES, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>Institut Català d'Oncologia L'Hospitalet-Barcelona, Barcelona, ES, <sup>5</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>6</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>7</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>8</sup>Washington University, St Louis, US, <sup>9</sup>Vanderbilt-Ingram Cancer Center, Nashville, US, <sup>10</sup>St Luke's Cancer Institute, Kansas city, US, <sup>11</sup>University Hospital del Mar, Barcelona, ES, <sup>12</sup>Weill Medical college, New York, US, <sup>13</sup>Polyphor Ltd, Allschwil, CH, <sup>14</sup>Polyphor AG, Allschwil, CH, <sup>15</sup>Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US
- 09:40 - 09:40 **286PD - Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratumab vedotin-treated advanced breast cancer patients**  
J. Specht<sup>1</sup>, L. Pusztai<sup>2</sup>, A. Forero-Torres<sup>3</sup>, M. Mita<sup>4</sup>, A. Weise<sup>5</sup>, I. Krop<sup>6</sup>, A. Grosse-Wilde<sup>7</sup>, Z. Wang<sup>7</sup>, M. Li<sup>7</sup>, S. Hengel<sup>7</sup>, P. Garfin<sup>7</sup>, G. Means<sup>7</sup>, M. Onsum<sup>7</sup>, S. Modi<sup>8</sup>, <sup>1</sup>University of Washington, Seattle, US, <sup>2</sup>Yale School of Medicine, New Haven, US, <sup>3</sup>University of Alabama at Birmingham, Birmingham, US, <sup>4</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>5</sup>Karmonas Cancer Institute, Detroit, US, <sup>6</sup>Dana FARber Cancer Institute, Boston, US, <sup>7</sup>Seattle Genetics, Bothell, US, <sup>8</sup>Memorial Sloan-Kettering Cancer Center, New York City, US
- 09:40 - 09:40 **287PD - Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients**  
M.-S. Dai<sup>1</sup>, T.-Y. Chao<sup>2</sup>, T.-C. Chao<sup>3</sup>, C.-F. Chiu<sup>4</sup>, Y.-S. Lu<sup>5</sup>, H.-S. Shiah<sup>6</sup>, Y.-Y. Wu<sup>1</sup>, G. Gerald Fetterly<sup>7</sup>, N. Hung<sup>7</sup>, D.L. Cutler<sup>7</sup>, R. Kwan<sup>7</sup>, D. Douglas Kramer<sup>7</sup>, W.-K. Chan<sup>7</sup>, T. Hung<sup>8</sup>, <sup>1</sup>Tri-Service General Hospital, National Defense Medical Center, Taipei, TW, <sup>2</sup>Taipei Medical University- Shuang Ho Hospital, No. 291, Zhongzheng Rd., Zhonghe District, New Taipei City, 23561, NewTaipei, TW, <sup>3</sup>Taipei Veterans General Hospital, Taipei, Taipei, TW, <sup>4</sup>China Medical University Hospital, Tai-Chung, TW, <sup>5</sup>National Taiwan University Hospital, Taipei, TW, <sup>6</sup>Taipei Medical University Hospital, Taipei, TW, <sup>7</sup>Athenex, New York, US, <sup>8</sup>Zenith Technology Corporation Limited, Dunedin, NZ
- 09:40 - 09:55 **Invited Discussant 285PD, 286PD and 287PD**  
A. Gennari, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, IT



09:55 - 10:05 **Q&A led by Discussant**

10:05 - 10:05 **288PD - PERNETTA - A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)**

J. Huober<sup>1</sup>, P. Weder<sup>2</sup>, C. Veyret<sup>3</sup>, B. Thürlimann<sup>2</sup>, A. Xyrafas<sup>4</sup>, L. Vanlemmens<sup>5</sup>, S. Guiu<sup>6</sup>, E. Brain<sup>7</sup>, J. Grenier<sup>8</sup>, F. Dalenc<sup>9</sup>, C. Levy<sup>10</sup>, A.M. Savoye<sup>11</sup>, A. Müller<sup>12</sup>, V. Membrez-Antonioli<sup>13</sup>, M.A. Gerard<sup>4</sup>, J. Lemonnier<sup>14</sup>, H. Hawle<sup>4</sup>, E. Boven<sup>15</sup>, H. Bonnefoi<sup>16</sup>,  
<sup>1</sup>Universitaetsfrauenklinik Ulm, Ulm, DE, <sup>2</sup>Cantonal hospital St. Gallen, St. Gallen, CH, <sup>3</sup>Centre Henri Becquerel, Rouen, FR, <sup>4</sup>SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, <sup>5</sup>Centre Oscar Lambret, Lille, FR, <sup>6</sup>Reginal cancer institute, Montpellier, FR, <sup>7</sup>Institut Curie, Paris & Saint-Cloud, FR, <sup>8</sup>Institut Ste Catherine, Avignon, FR, <sup>9</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>10</sup>Centre Francois Baclesse, Caen, FR, <sup>11</sup>Institut Jean Godinot, Reims, FR, <sup>12</sup>Kantonsspital Winterthur, Winterthur, CH, <sup>13</sup>Hôpital Régional Sion-Hérens-Conthey, Site de Champsec Centre du Cancer Lausanne, Sion, CH, <sup>14</sup>Unicancer, Paris, FR, <sup>15</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>16</sup>Institut Bergonié, Bordeaux, FR

10:05 - 10:05 **289PD - Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): results from the multicohort phase II FINESSE trial**

R. Hui<sup>1</sup>, A. Pearson<sup>2</sup>, J. Cortes Castan<sup>3</sup>, C. Campbell<sup>4</sup>, C. Poirot<sup>5</sup>, H. Azim Jr.<sup>6</sup>, D. Fumagalli<sup>7</sup>, M. Lambertini<sup>7</sup>, F. Daly<sup>4</sup>, A. Arahmani<sup>8</sup>, J. Perez-Garcia<sup>9</sup>, P. Aftimos<sup>7</sup>, P. Bedard<sup>10</sup>, L. Xuereb<sup>5</sup>, S. Loibl<sup>11</sup>, S. Loi<sup>12</sup>, M.-J. Pierrat<sup>5</sup>, N. Turner<sup>13</sup>, F. André<sup>14</sup>, G. Curigliano<sup>15</sup>,  
<sup>1</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>2</sup>The Institute of Cancer Research, London, GB, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Frontier Science Scotland, Kingussie, GB, <sup>5</sup>Institut de Recherches Internationales Servier, Suresnes, FR, <sup>6</sup>American University of Beirut, Beirut, LB, <sup>7</sup>Institute Jules Bordet, Brussels, BE, <sup>8</sup>Breast International Group, Brussels, BE, <sup>9</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>10</sup>Princess Margaret Hospital, Toronto, CA, <sup>11</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>12</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>13</sup>Royal Marsden Hospital and Institute of Cancer Research, London, GB, <sup>14</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>15</sup>Istituto Europeo di Oncologia, Milan, IT

10:05 - 10:20 **Invited Discussant 288PD, 289PD and one LBA TBC**

L. Carey, UNC - Lineberger Cancer Center, Chapel Hill, US

10:20 - 10:30 **Q&A led by Discussant**

<b>09:15 - 10:30</b>	<b>Type: Poster Discussion session</b> <b>Title: Poster Discussion session - Genitourinary tumours, prostate</b> Chair(s): Joaquin Mateo, ES; Joe O'Sullivan, GB; Aristotelis Bamias, GR	<b>ICM - Room 14b</b>
----------------------	--	-----------------------

09:15 - 09:15 **793PD - Preliminary results from TRITON2: a phase 2 study of rucaparib in**

**patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations**

W. Abida<sup>1</sup>, A. Bryce<sup>2</sup>, N. Vogelzang<sup>3</sup>, R. Amato<sup>4</sup>, I. Percent<sup>5</sup>, J. Shapiro<sup>6</sup>, R. Mcdermott<sup>7</sup>, A. Hussain<sup>8</sup>, A. Patnaik<sup>9</sup>, D. Petrylak<sup>10</sup>, C. Ryan<sup>11</sup>, T. Stanton<sup>12</sup>, J. Zhang<sup>13</sup>, A. Simmons<sup>14</sup>, D. Despain<sup>15</sup>, M. Collins<sup>15</sup>, T. Golsorski<sup>15</sup>, H. Scher<sup>16</sup>, S. Chowdhury<sup>17</sup>,  
<sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>Mayo Clinic Cancer Center, Phoenix, US, <sup>3</sup>US Oncology Research c/o Comprehensive Cancer Crts of NV, Las Vegas, US, <sup>4</sup>UTHealth-Memorial Hermann Cancer Center, Houston, US, <sup>5</sup>Florida Cancer Specialists, Port Charlotte, US, <sup>6</sup>Cabrini Health, Malvern, AU, <sup>7</sup>AMNCH Adelaide and Meath Hospital, Dublin, IE, <sup>8</sup>University of Maryland Greenebaum Cancer Center, Baltimore, US, <sup>9</sup>The University of Chicago, Chicago, US, <sup>10</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>11</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>12</sup>University of Minnesota, Minneapolis, US, <sup>13</sup>H. Lee Moffitt Cancer Center, Tampa, US, <sup>14</sup>Clovis Oncology, San Francisco, US, <sup>15</sup>Clovis Oncology, Inc., Boulder, US, <sup>16</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>17</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB

09:15 - 09:15 **794PD - Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors**

S. Ali<sup>1</sup>, J. Chung<sup>2</sup>, N. Dewal<sup>1</sup>, L. Gay<sup>2</sup>, Y. He<sup>1</sup>, E. Sokol<sup>1</sup>, S. Millis<sup>1</sup>, J. Killian<sup>1</sup>, A. Schrock<sup>1</sup>, S. Pal<sup>3</sup>, V. Miller<sup>1</sup>, J. Ross<sup>4</sup>, N. Agarwal<sup>5</sup>,  
<sup>1</sup>Foundation Medicine, Inc., Cambridge, US, <sup>2</sup>Foundation Medicine, Cambridge, US, <sup>3</sup>City of Hope, Duarte, US, <sup>4</sup>SUNY Upstate Medical University, Syracuse, US, <sup>5</sup>Huntsman Cancer Institute, Salt Lake City, US

09:15 - 09:15 **795PD - Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)**

S. Chowdhury<sup>1</sup>, R. Mcdermott<sup>2</sup>, J.M. Piulats<sup>3</sup>, J. Shapiro<sup>4</sup>, I. Mejlholm<sup>5</sup>, D. Morris<sup>6</sup>, P. Ostler<sup>7</sup>, A. Hussain<sup>8</sup>, I. Dumbadze<sup>9</sup>, E. Goldfischer<sup>10</sup>, E. Pintus<sup>11</sup>, A. Benjelloun<sup>12</sup>, M. Gross<sup>13</sup>, S. Tejwani<sup>14</sup>, G. Chatta<sup>15</sup>, A. Font<sup>16</sup>, A. Loehr<sup>17</sup>, A. Simmons<sup>18</sup>, S. Watkins<sup>19</sup>, W. Abida<sup>20</sup>,  
<sup>1</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>2</sup>AMNCH Adelaide and Meath Hospital, Dublin, IE, <sup>3</sup>Catalan Institute of Oncology, Barcelona, ES, <sup>4</sup>Cabrini Health, Malvern, AU, <sup>5</sup>Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, <sup>6</sup>Urology Associates Clinical Research, Nashville, US, <sup>7</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>8</sup>University of Maryland Greenebaum Cancer Center, Baltimore, US, <sup>9</sup>The Urology Group, Cincinnati, US, <sup>10</sup>Premier Medical Group of the Hudson Valley, Poughkeepsie, US, <sup>11</sup>Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB, <sup>12</sup>Dr. Leon Richard Oncology Centre, Moncton, CA, <sup>13</sup>University of Southern California, Los Angeles, US, <sup>14</sup>Henry Ford Hospital, Detroit, US, <sup>15</sup>Roswell Park Comprehensive Cancer Center, Buffalo, US, <sup>16</sup>Catalan Institute of Oncology (ICO) - Germans Trias i Pujol Hospital, Badalona, ES, <sup>17</sup>Clovis Oncology, Boulder, US, <sup>18</sup>Clovis Oncology, San Francisco, US, <sup>19</sup>Clovis Oncology, Cambridge, GB, <sup>20</sup>Memorial Sloan Kettering Cancer Center, New York, US

09:15 - 09:30 **Invited Discussant 793PD, 794PD and 795PD**

J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

09:30 - 09:40 **Q&A led by Discussant**

- 09:40 - 09:40 **796PD - Detection of circulating tumor DNA in de novo metastatic castrate sensitive prostate cancer**  
W. Struss<sup>1</sup>, G. Vandekerkhove<sup>1</sup>, M. Annala<sup>1</sup>, K. Chi<sup>2</sup>, M. Gleave<sup>3</sup>, A. Wyatt<sup>4</sup>, <sup>1</sup>Vancouver Prostate Centre-Vancouver General Hospital, Vancouver, CA, <sup>2</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>3</sup>University of British Columbia Faculty of Medicine, Vancouver, CA, <sup>4</sup>Vancouver Prostate Centre, Vancouver, CA
- 09:40 - 09:40 **797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)**  
N. Matsubara<sup>1</sup>, K. Chi<sup>2</sup>, M. Ozguroglu<sup>3</sup>, A. Rodriguez Antolin<sup>4</sup>, S. Feyerabend<sup>5</sup>, L. Fein<sup>6</sup>, B. Alekseev<sup>7</sup>, G. Sulur<sup>8</sup>, A. Protheroe<sup>9</sup>, S. Li<sup>10</sup>, S. Mundle<sup>11</sup>, P. De Porre<sup>12</sup>, N. Tran<sup>13</sup>, K. Fazazi<sup>14</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, Chiba, JP, <sup>2</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>3</sup>University Of Istanbul Cerrahpasa Medical Faculty, Istanbul, TR, <sup>4</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>5</sup>University of Tübingen, Tübingen, DE, <sup>6</sup>Institute of Oncology Rosario, Rosario, AR, <sup>7</sup>Herzen Cancer Research Institute, Moscow, RU, <sup>8</sup>Janssen Pharmaceutical, Beijing, CN, <sup>9</sup>Churchill Hospital University of Oxford, Oxford, GB, <sup>10</sup>Janssen Research & Development, Los Angeles, US, <sup>11</sup>Janssen Research & Development, Raritan, US, <sup>12</sup>Janssen R&D BE, Beerse, BE, <sup>13</sup>Janssen R&D, Los Angeles, US, <sup>14</sup>Institut Gustave Roussy, Villejuif, FR
- 09:40 - 09:55 **Invited Discussant 796PD and 797PD**  
J. O'Sullivan, Belfast City Hospital Northern Ireland Cancer Centre, School of Medicine, Dentistry & Biomedical Science, Belfast, GB
- 09:55 - 10:05 **Q&A led by Discussant**
- 10:05 - 10:05 **798PD - In-depth assessment of metastatic prostate cancer with high tumour mutational burden**  
N. Mehra<sup>1</sup>, J. Van Riet<sup>2</sup>, M. Smits<sup>1</sup>, H. Westdorp<sup>1</sup>, M. Gorris<sup>3</sup>, T. Van Ee<sup>3</sup>, M. Van Der Doelen<sup>1</sup>, I. Van Oort<sup>1</sup>, M. Sedelaar<sup>1</sup>, J. Textor<sup>1</sup>, E. Cuppen<sup>4</sup>, K. Grunberg<sup>1</sup>, M. Ligtenberg<sup>1</sup>, W. Zwart<sup>5</sup>, A. Bergman<sup>5</sup>, H. Van De Werken<sup>2</sup>, J. Schalken<sup>1</sup>, I. De Vries<sup>3</sup>, M. Lolkema<sup>6</sup>, W. Gerritsen<sup>1</sup>, <sup>1</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>2</sup>Erasmus Medical Center, Rotterdam, NL, <sup>3</sup>Radboud Institute for Molecular Life Sciences, Nijmegen, NL, <sup>4</sup>University Medical Center Utrecht, Utrecht, NL, <sup>5</sup>Division of Internal Medicine (MOD) and Oncogenomics, Amsterdam, NL, <sup>6</sup>Erasmus University Medical Center, Rotterdam, NL
- 10:05 - 10:05 **799PD - Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)**  
S. Tagawa, S. Vallabhajosula, Y. Jhanwar, A. Hackett, C. Oromendia, M. Naiz, S. Goldsmith, D.M. Nanus, H. Beltran, A. Molina, B. Faltas, J. Sreekumar, J. Babich, K. Ballman, N. Bander, Weill Cornell Medical College, New York, US

10:05 - 10:20 **Invited Discussant 798PD and 799PD**  
A. Bamias, University of Athens, Sotiria General Chest Diseases Hospital, Athens, GR

10:20 - 10:30 **Q&A led by Discussant**

<b>09:15 - 10:45</b>	<b>Type: Special Symposium</b> <b>Title: Modern tools to optimise therapy for patients with head and neck cancer</b> Chair(s): Amanda Psyrris, GR; Christophe Le Tourneau, FR	<b>ICM - Room 13</b>
----------------------	---	--------------------------

09:15 - 09:20 **Introduction**  
A. Psyrris, Attikon University Hospital, Athens, GR

09:20 - 09:40 **Biomarkers and next generation sequencing**  
B. Solomon, Peter MacCallum Cancer Center, Melbourne, AU

09:40 - 10:00 **Optimising response to immunotherapy using combinations in the recurrent/metastatic setting**  
A. Psyrris, Attikon University Hospital, Athens, GR

10:00 - 10:20 **Taking the next step - immunotherapy in the curative setting**  
E. Cohen, The University of Chicago Medical Centre, Chicago, US

10:20 - 10:40 **Response assessment and endpoint selection for immunotherapy studies**  
S. Faivre, Hôpitaux Paris Centre AP-HP, Paris, FR

10:40 - 10:45 **Conclusions and perspectives**  
C. Le Tourneau, Institut Curie, Paris, FR



**09:15 - 10:45**    **Type: Educational session**    **Hall B3 - Room 21**  
**Title: Opportunities in clinic trial design in the era of genomics and immuno-oncology**  
 Chair(s): Christian Rolfo, US; Allan Jordan, GB

09:15 - 09:40    **Integration of biomarkers into drug development**  
C. Rolfo, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, US

09:40 - 10:05    **Novel pre-clinical models to design drug combinations**  
J. Hoffmann, EPO Experimental Pharmacology & Oncology Berlin-Buch, Berlin, DE

10:05 - 10:30    **Role of artificial intelligence in drug development**  
M. Kris, Memorial Sloan Kettering Cancer Center, New York, US

10:30 - 10:45    **Discussion**

**09:15 - 10:45**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Symptom management: Clinical aspects and implementation**  
 Chair(s): Karin Jordan, DE; Wendy Oldenmenger, NL

09:15 - 09:35    **Guidelines on peripheral neuropathy**  
K. Jordan, University of Heidelberg, Heidelberg, DE

09:35 - 09:55    **Patient-centered care and self-management**  
M. Piredda, Policlinico Universitario Campus Bio-Medico, Rome, IT

09:55 - 10:15    **Essentials of optimal pain management**  
J. Wood, Royal Marsden Hospital NHS Foundation Trust, London, GB

10:15 - 10:35    **Oral cryotherapy for the prevention of oral mucositis**  
M. Hellberg-Nägele, Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg im Breisgau, DE

10:35 - 10:45    **Discussion**

**09:30 - 10:30** **Type: Controversy Session** **Hall A1 - Room 15**  
**Title: Identification of ultra-rare, life-saving molecular subtypes of cancer - NGS for everyone, some or none?**  
 Chair(s): George Demetri, US

09:30 - 09:40 **Introduction and 1st vote**  
G. Demetri, Dana-Farber Cancer Institute, Boston, US

09:40 - 10:00 **Yes**  
E. Wardelmann, University Hospital Muenster-Gerhard Domagk Institute of Pathology, Münster, DE

10:00 - 10:20 **No**  
S. Sleijfer, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

10:20 - 10:30 **2nd vote and conclusions**  
G. Demetri, Dana-Farber Cancer Institute, Boston, US

**09:30 - 10:30** **Type: Special session** **Hall A1 - Room 16**  
**Title: Integration of immunotherapy with disease entities**  
 Chair(s): Ulrich Keilholz, DE

09:30 - 09:50 **Head and neck**  
U. Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE

09:50 - 10:10 **Lung cancer**  
S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

10:10 - 10:30 **Lymphoma**  
C. Arber Barth, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

**09:30 - 10:30**    **Type: Challenge Your Expert (CYE) session**    **Hall B3 - Room 23**  
**Title: Challenges in the treatment of early stage ovarian cancer**  
 Chair(s): Jonathan Ledermann, GB

09:30 - 09:30    **Session DOI**

09:30 - 09:40    **Challenges in the treatment of early stage ovarian cancer**  
C. Marth, University Hospital Innsbruck, Innsbruck, AT

09:40 - 10:30    **Discussion led by**  
J. Ledermann, University College London Cancer Institute, London, GB

**09:30 - 10:35**    **Type: Multidisciplinary interactive sessions**    **Hall B3 - Room 20**  
**Title: Dissecting mediastinal grey zone lymphomas**  
 Chair(s): Maurizio Martelli, IT

09:30 - 09:30    **Session DOI**

09:30 - 09:35    **Case presentation**  
M. Martelli, Sapienza - Università di Roma, Roma, IT

09:35 - 09:45    **The pathologist's perspective**  
T. Molina, Université Paris Descartes, Paris, FR

09:45 - 09:55    **The haematologist's perspective**  
M. Martelli, Sapienza - Università di Roma, Roma, IT

09:55 - 10:05    **The radiation oncologist's perspective**  
A. Filippi, Fondazione IRCCS Policlinico San Matteo, Pavia, IT

10:05 - 10:35    **Discussion**

**09:30 - 10:30**    **Type: Special session**    **Hall B3 - Room 22**  
**Title: Using population data evidence to support policy decisions in cancer**  
 Chair(s): Andrew Briggs, GB; Bengt Jönsson, SE

09:30 - 09:30    **Session DOI**

09:30 - 09:45    **The role of evidence in alternative frameworks for the valuation of oncology treatments**

B. Jönsson, Stockholm school of economics, Stockholm, SE

09:45 - 10:00    **Using real world data for decision-making in R&D and health technology assessment**

A. Forsythe, Purple Squirrel Economics, New York, US

10:00 - 10:15    **Using RWE to identify gaps in the provision of effective - and cost-effective - care**

A. Briggs, University of Glasgow, Glasgow, GB

10:15 - 10:30    **Discussion**

**10:45 - 12:45**    **Type: Clinical Practice Guidelines**    **Hall A1 - Room 15**  
**Title: ESMO Clinical Practice Guidelines 1**  
 Chair(s): George Pentheroudakis, GR; Cristiana Sessa, CH

10:45 - 10:45    **Session DOI**

10:45 - 10:55    **Introduction**

G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR

10:55 - 11:05    **Questionnaire**

C. Sessa, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

11:05 - 11:15    **Gastroenteropancreatic neuroendocrine tumours**

J. Hadoux, Gustave Roussy Institut de Cancérologie, Villejuif, FR

11:15 - 11:25    **Discussant**

A. Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

11:25 - 11:30    **Q&A**



- 11:30 - 11:40 **Mantle cell lymphoma**  
M. Jerkeman, Skane University Hospital, Lund, SE
- 11:40 - 11:50 **Discussant**  
M. Dreyling, Ludwig Maximilians University - Grosshadern, Munich, DE
- 11:50 - 11:55 **Q&A**
- 11:55 - 12:05 **Rectal cancer**  
F. Scialfani, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 12:05 - 12:15 **Discussant**  
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES
- 12:15 - 12:20 **Q&A**
- 12:20 - 12:30 **Metastatic NSCLC**  
M. Früh, Cantonal Hospital St. Gallen, St. Gallen, CH
- 12:30 - 12:40 **Discussant**  
P. Janne, Dana Farber Cancer Institute, Boston, US
- 12:40 - 12:45 **Q&A**

**11:00 - 12:30**    **Type: Special Symposium**    **Hall A2 - Room 18**  
**Title: Safe de-escalation of therapy in the management of early breast cancer**  
 Chair(s): Charlotte Coles, GB; Emiel Rutgers, NL

11:00 - 11:00    **Session DOI**

11:00 - 11:05    **Introduction**

C. Coles, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

11:05 - 11:25    **Chemotherapy or not: How do you decide?**

S. Delaloge, Gustave Roussy, Villejuif, FR

11:25 - 11:45    **Duration of targeted therapy for HER2 and for hormone therapy**

H. Earl, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

11:45 - 12:05    **Minimising surgical management of early breast cancer**

E. Rutgers, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

12:05 - 12:25    **Biomarker-guided radiotherapy in the management of early breast cancer**

T. Whelan, McMaster University, Hamilton, CA

12:25 - 12:30    **Conclusions and perspectives**

E. Rutgers, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

**11:00 - 12:30**    **Type: Educational session**    **ICM - Room 1**  
**Title: The critical need of a multidisciplinary approach for the treatment of prostate cancer**  
 Chair(s): Silke Gillessen, GB; Chris Parker, GB

11:00 - 11:00    **Session DOI**

11:00 - 11:25    **Update on diagnosis and treatment of localised prostate cancer**  
M. Emberton, University College London Hospital, London, GB

11:25 - 11:50    **Oligometastatic disease**  
A. Bossi, Gustave Roussy Institut de Cancérologie, Villejuif, FR

11:50 - 12:15    **What is new in metastatic castration resistant prostate cancer (CRPC)?**  
R. De Wit, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

12:15 - 12:30    **Discussion**

**11:00 - 12:30**    **Type: Educational session**    **ICM - Room 14b**  
**Title: Optimal antineoplastic therapy and supportive care of elderly cancer patients**  
 Chair(s): Jorn Herrstedt, DK; Stein Kaasa, NO

11:00 - 11:00    **Session DOI**

11:00 - 11:02    **Introduction**  
J. Herrstedt, University Hospital Zealand, Roskilde, DK

11:02 - 11:27    **Anticancer therapy-induced dose-limiting toxicity in elderly cancer patients**  
K. Jordan, University of Heidelberg, Heidelberg, DE

11:27 - 11:52    **Importance of maintaining dose density and dose intensity**  
J. Herrstedt, University Hospital Zealand, Roskilde, DK

11:52 - 12:17    **Immunotherapy in the elderly**  
M. Aapro, Clinique de Genolier, Genolier, CH

12:17 - 12:30    **Discussion**

**11:00 - 12:30**    **Type: Special Symposium**    **ICM - Room 13**  
**Title: Novel therapies for brain tumors**  
 Chair(s): Michael Weller, CH; Joerg-Christian Tonn, DE

11:00 - 11:00    **Session DOI**

11:00 - 11:05    **Introduction**

J.-C. Tonn, Ludwig Maximilians University - Grosshadern, Munich, DE

11:05 - 11:20    **Immunotoxins for gliomas**

M. Van Den Bent, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

11:20 - 11:35    **Update on vaccination strategies for gliomas**

M. Weller, Universitätsspital Zürich, Zürich, CH

11:35 - 11:50    **Immune check-point inhibitors in brain tumors**

A.S. Berghoff, Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

11:50 - 12:05    **Genomically targeted therapies in neuro-oncology**

W. Wick, University of Heidelberg, Heidelberg, DE

12:05 - 12:20    **Targeted therapies of pediatric brain tumors**

D. Hargrave, Great Ormond Street Hospital for Children NHS Foundation Trust, London, GB

12:20 - 12:30    **Conclusions and clinical perspectives**

M. Weller, Universitätsspital Zürich, Zürich, CH



**11:00 - 12:30**    **Type: Special session**    **Hall A1 - Room 16**  
**Title: Integrating radiation in immunotherapy schemes**  
 Chair(s): Fernanda Herrera, CH; Ulrich Keilholz, DE

11:00 - 11:00    **Session DOI**

11:00 - 11:05    **Introduction**

U. Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE

11:05 - 11:25    **Abscopal effect of radiotherapy with checkpoint inhibitors**

C. Chargari, Paris, FR

11:25 - 11:45    **Manipulating the tumour microenvironment through radiation**

S. Demaria, Weill Cornell Medical College, New York, US

11:45 - 12:05    **Radiation dose to harness the immune system**

F. Herrera, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

12:05 - 12:25    **Checkpoint inhibitors plus radiotherapy to increase cure rates in head and neck cancer**

K. Harrington, Institute of Cancer Research ICR, London, GB

12:25 - 12:30    **Conclusions and perspectives**

F. Herrera, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

**11:00 - 12:30**    **Type: Proffered Paper session**    **Hall B3 - Room 22**  
**Title: Proffered paper session - Developmental therapeutics**  
 Chair(s): Alex A. Adjei, US; Allan Jordan, GB

11:00 - 11:00    **Session DOI**

11:00 - 11:12    **4080 - Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL**

L. Bazhenova<sup>1</sup>, R. Carvajal<sup>2</sup>, B.C. Cho<sup>3</sup>, K. Eaton<sup>4</sup>, S. Goel<sup>5</sup>, R. Heist<sup>6</sup>, M. Ingham<sup>2</sup>, D. Wang<sup>7</sup>, T. Werner<sup>8</sup>, S. Neuteboom<sup>9</sup>, D. Potvin<sup>9</sup>, I. Chen<sup>9</sup>, J. Christensen<sup>9</sup>, R. Chao<sup>9</sup>, A. Alva<sup>10</sup>, <sup>1</sup>Moore's UCSD Cancer Center, La Jolla, US, <sup>2</sup>Columbia University Medical Center, New York, US, <sup>3</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>4</sup>University of Washington Medical Center, Seattle, US, <sup>5</sup>Montefiore Medical Center (East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, <sup>6</sup>Massachusetts General Hospital, Boston, US, <sup>7</sup>Henry Ford Hospital, Detroit, US, <sup>8</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>9</sup>Mirati Therapeutics, Inc., San Diego, US, <sup>10</sup>Cancer Center, Univ. of Michigan, Ann Arbor, US

- 11:12 - 11:24 **4090 - Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach**  
U. Lassen<sup>1</sup>, C. Albert<sup>2</sup>, S. Kummar<sup>3</sup>, C. Van Tilburg<sup>4</sup>, S. Dubois<sup>5</sup>, B. Georger<sup>6</sup>, L. Mascarenhas<sup>7</sup>, N. Federman<sup>8</sup>, R. Schilder<sup>9</sup>, F. Doz<sup>10</sup>, J. Berlin<sup>11</sup>, D.-Y. Oh<sup>12</sup>, S. Bielack<sup>13</sup>, R. Mcdermott<sup>14</sup>, D.S.W. Tan<sup>15</sup>, S. Cruickshank<sup>16</sup>, N. Ku<sup>16</sup>, M. Cox<sup>16</sup>, A. Drilon<sup>17</sup>, D. Hong<sup>18</sup>, <sup>1</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>2</sup>Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, US, <sup>3</sup>Stanford University School of Medicine, Stanford, US, <sup>4</sup>Universitätsklinikums Heidelberg, Heidelberg, DE, <sup>5</sup>Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, US, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, US, <sup>8</sup>University of California, Los Angeles, Los Angeles, US, <sup>9</sup>Thomas Jefferson University, Philadelphia, US, <sup>10</sup>Institut Curie, Paris, FR, <sup>11</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>12</sup>Seoul National University Hospital, Seoul, KR, <sup>13</sup>Klinikum Stuttgart - Olgahospital, Stuttgart, DE, <sup>14</sup>AMNCH Adelaide and Meath Hospital, Dublin, IE, <sup>15</sup>National Cancer Center Singapore, Singapore, SG, <sup>16</sup>Loxo Oncology, South San Francisco, US, <sup>17</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>18</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US
- 11:24 - 11:36 **LBA17 - Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive (NTRK-fp) Tumors: Pooled Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001**  
G. Demetri<sup>1</sup>, L. Paz-Ares<sup>2</sup>, A. Farago<sup>3</sup>, S. Liu<sup>4</sup>, S. Chawla<sup>5</sup>, D. Tosi<sup>6</sup>, E. Kim<sup>7</sup>, C. Blakely<sup>8</sup>, J. Krauss<sup>9</sup>, D. Sigal<sup>10</sup>, L. Bazhenova<sup>11</sup>, T. John<sup>12</sup>, B. Besse<sup>13</sup>, J. Wolf<sup>14</sup>, T. Seto<sup>15</sup>, E. Chow-Maneval<sup>16</sup>, P. Multani<sup>17</sup>, A. Johnson<sup>18</sup>, B. Simmons<sup>19</sup>, R. Doebele<sup>20</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>3</sup>Massachusetts General Hospital, Boston, US, <sup>4</sup>Georgetown University, Washington, US, <sup>5</sup>Sarcoma Oncology Center, Santa Monica, US, <sup>6</sup>Institut du Cancer de Montpellier, Montpellier, FR, <sup>7</sup>Levine Cancer Institute, Charlotte, US, <sup>8</sup>University of California San Francisco, San Francisco, US, <sup>9</sup>Michigan Medicine, Ann Arbor, US, <sup>10</sup>Scripps Clinic, La Jolla, US, <sup>11</sup>Moore's UCSD Cancer Center, La Jolla, US, <sup>12</sup>Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, AU, <sup>13</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>14</sup>University Hospital Cologne, Cologne, DE, <sup>15</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>16</sup>Ignitya, San Diego, GB, <sup>17</sup>Ignitya, San Diego, US, <sup>18</sup>Ignitya, San Diego, US, <sup>19</sup>Genentech (Roche), South San Francisco, US, <sup>20</sup>University of Colorado, Aurora, US
- 11:36 - 11:51 **Invited Discussant 4080, 4090 and LBA17**  
A. Jordan, Cancer Research UK Manchester Institute, Manchester, GB
- 11:51 - 12:03 **4100 - First-in-Human, First-in-Class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors**  
E. Calvo<sup>1</sup>, P. Aftimos<sup>2</sup>, A. Azaro<sup>3</sup>, M.J. De Miguel<sup>1</sup>, C. Jungels<sup>2</sup>, J. Zeron-Medina Cuairan<sup>3</sup>, P. Nuciforo<sup>3</sup>, P. Ehmer<sup>4</sup>, A. Martin<sup>5</sup>, H. Bender<sup>5</sup>, K. Dembowski<sup>5</sup>, <sup>1</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>2</sup>Institute Jules Bordet, Brussels, BE, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Pharmacelsus GmbH, Saarbrücken, DE, <sup>5</sup>amcure GmbH, Eggenstein-Leopoldshafen, DE

12:03 - 12:15 **4110 - Initial results from a phase 1/2a trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer**

J. Hilton<sup>1</sup>, M. Cristea<sup>2</sup>, M. Voskoboynik<sup>3</sup>, S. Postel-Vinay<sup>4</sup>, W. Edenfield<sup>5</sup>, A. Gavai<sup>6</sup>, S. Wee<sup>6</sup>, N. Srivastava<sup>6</sup>, A. Klippel<sup>7</sup>, D. Jackson<sup>6</sup>, A. Apfel<sup>6</sup>, S. Chasalow<sup>6</sup>, D. Williams<sup>6</sup>, M. Donovan<sup>6</sup>, B. Fischer<sup>7</sup>, S. Khaldoyanidi<sup>6</sup>, J. Diamond<sup>8</sup>, <sup>1</sup>The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, <sup>2</sup>City of Hope, Duarte, US, <sup>3</sup>Alfred Hospital, Prahran, AU, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR, <sup>5</sup>GHS Cancer Institute, Greenville Health System, Greenville, US, <sup>6</sup>Bristol-Myers Squibb, Princeton, US, <sup>7</sup>Bristol-Myers Squibb Company, Lawrenceville, US, <sup>8</sup>University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US

12:15 - 12:30 **Invited Discussant 4100 and 4110**

U. Banerji, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

**11:00 - 12:30 Type: Proffered Paper session Hall B4 - Room 19**  
**Title: Proffered paper session - Haematological malignancies**  
 Chair(s): Marco Ladetto, IT; Maria-Victoria Mateos, ES

11:00 - 11:00 **Session DOI**

11:00 - 11:15 **10060 - Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: combined analysis from phase I and II studies**

D. Healy<sup>1</sup>, P. Zinzani<sup>2</sup>, A. Santoro<sup>3</sup>, L. Mollica<sup>4</sup>, G. Follows<sup>5</sup>, K. Bouabdallah<sup>6</sup>, F. Morschhauser<sup>7</sup>, A. Patnaik<sup>8</sup>, L. Huang<sup>9</sup>, F. Hiemeyer<sup>10</sup>, A. Benson<sup>11</sup>, I. Genvesse<sup>10</sup>, J. Garcia-Vargas<sup>12</sup>, B. Childs<sup>1</sup>, M. Dreyling<sup>13</sup>, <sup>1</sup>Bayer HealthCare Pharmaceutical, New York, US, <sup>2</sup>University of Bologna, Bologna, IT, <sup>3</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>4</sup>Hôpital Maisonneuve-Rosemont-Montreal, Montreal, CA, <sup>5</sup>Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital, Cambridge, GB, <sup>6</sup>University Hospital of Bordeaux, Pessac, FR, <sup>7</sup>CHRU - Hôpital Claude Huriez, Lille, FR, <sup>8</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>9</sup>Bayer HealthCare Pharmaceuticals, Whippany, US, <sup>10</sup>Bayer AG, Berlin, DE, <sup>11</sup>Bayer HealthCare, Whippany, US, <sup>12</sup>Bayer HealthCare Pharmaceuticals USA, Whippany, US, <sup>13</sup>Ludwig Maximilians University - Grosshadern, Munich, DE

11:15 - 11:30 **10040 - Final Overall Survival Results of Frontline Bortezomib plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) vs R-CHOP in Transplantation-ineligible Patients (Pts) with Newly Diagnosed Mantle-Cell Lymphoma (MCL): A Randomized, Open-Label, Phase 3 (LYM-3002) Study**

F. Cavalli<sup>1</sup>, J. Jin<sup>2</sup>, H. Pylypenko<sup>3</sup>, G. Verhoef<sup>4</sup>, N. Siritanaratkul<sup>5</sup>, J. Drach<sup>6</sup>, M. Raderer<sup>7</sup>, J. Mayer<sup>8</sup>, J. Pereira<sup>9</sup>, G. Tumyan<sup>10</sup>, R. Okamoto<sup>11</sup>, S. Nakahara<sup>12</sup>, P. Hu<sup>13</sup>, C. Appiani<sup>14</sup>, S. Nemat<sup>15</sup>, T. Robak<sup>16</sup>, M. Ghielmini<sup>1</sup>, <sup>1</sup>IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, <sup>2</sup>The First Affiliated Hospital of Zhejiang, Zhejiang, CN, <sup>3</sup>Cherkassy Regional Oncology Dispensary, Cherkassy, UA, <sup>4</sup>University Hospital Leuven, Leuven, BE, <sup>5</sup>Mahidol University, Bangkok, TH, <sup>6</sup>Allgemeines Krankenhaus der Stadt Wien, Vienna, AT, <sup>7</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>8</sup>Internal Haemato-oncology Department FN Brno, Brno, CZ, <sup>9</sup>Hospital Das Clinicas Da

Faculdade, São Paulo, BR, <sup>10</sup>N.N. Blokhin Academy Of Medical Science, Moscow, RU, <sup>11</sup>Tokyo Metropolitan - Komagome Hospital, Chiba, JP, <sup>12</sup>Janssen Pharmaceutical, K.K., Tokyo, JP, <sup>13</sup>Janssen Research & Development, LLC., Raritan, US, <sup>14</sup>Janssen Research & Development, LLC, Titusville, US, <sup>15</sup>Janssen Research & Development, LLC, High Wycombe, GB, <sup>16</sup>Medical University of Lodz, Lodz, PL

11:30 - 11:45 **10050 - A Revised International Prognostic Score System for Waldenström's Macroglobulinemia**

M. Gavriatopoulou<sup>1</sup>, E. Kastritis<sup>2</sup>, P. Morel<sup>3</sup>, A. Duhamel<sup>4</sup>, M. Kyrtsolis<sup>5</sup>, E. Durot<sup>4</sup>, A. Symeonidis<sup>6</sup>, K. Laribi<sup>7</sup>, E. Hatjiharisi<sup>8</sup>, L. Ysebaert<sup>9</sup>, A. Vassou<sup>10</sup>, N. Giannakoulas<sup>11</sup>, G. Merlini<sup>12</sup>, P. Repousis<sup>13</sup>, M. Varettoni<sup>14</sup>, E. Michalis<sup>15</sup>, B. Hivert<sup>14</sup>, M. Michalis<sup>16</sup>, V. Leblond<sup>14</sup>, M. Dimopoulos<sup>1</sup>, <sup>1</sup>Alexandra Hospital, Athens, GR, <sup>2</sup>Alexandra Hospital, ATHENS, GR, <sup>3</sup>Centre Hospitalier de Lens, Lens, FR, <sup>4</sup>Univ. Lille, CHU Lille, EA2694 - Santé publique : épidémiologie et qualité des soins, F59000 Lille, France, LILLE, FR, <sup>5</sup>laikon hospital, Athens, GR, <sup>6</sup>patras general hospital, patras, GR, <sup>7</sup> Le Mans, FR, <sup>8</sup>IPPOKRATEION HOSPITAL, THESSALONIKI, GR, <sup>9</sup>Institut Claudius Regaud - IUCT Oncopole, Toulouse, FR, <sup>10</sup>Aktina s.a, Chalandri, GR, <sup>11</sup>larissa general hospital, larissa, GR, <sup>12</sup>PAVIA HOSPITAL, PAVIA, IT, <sup>13</sup>METAKSA HOSPITAL, Athens, GR, <sup>14</sup>French Innovative Leukemia Organization, LILLE, FR, <sup>15</sup>genikon kratikon hospital, Athens, GR, <sup>16</sup>leukosia general hospital, leukosia, CY

11:45 - 12:05 **Invited Discussant 10040, 10050 and 10060**

C. Buske, Ulm Medical University, Ulm, DE

12:05 - 12:20 **10070 - Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry**

R. Abonour<sup>1</sup>, R. Rifkin<sup>2</sup>, C. Gasparetto<sup>3</sup>, K. Toomey<sup>4</sup>, B. Durie<sup>5</sup>, J. Hardin<sup>6</sup>, H. Terebelo<sup>7</sup>, S. Jagannath<sup>8</sup>, M. Narang<sup>9</sup>, S. Ailawadhi<sup>10</sup>, S. Srinivasan<sup>11</sup>, A. Kitali<sup>11</sup>, A. Agarwal<sup>11</sup>, L. Wagner<sup>12</sup>, <sup>1</sup>Indiana University, Indianapolis, US, <sup>2</sup>Mountain Cancer Centers US Oncology, Denver, US, <sup>3</sup>Duke University Medical Centre, Durham, US, <sup>4</sup>Steeplechase Cancer Center, Somerville, US, <sup>5</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>6</sup>University of South Carolina, Columbia, US, <sup>7</sup>Providence Cancer Institute,, Novi, US, <sup>8</sup>Mount Sinai Hospital, New York, US, <sup>9</sup>US Oncology Research, Columbia, US, <sup>10</sup>Mayo Clinic, Jacksonville, US, <sup>11</sup>Celgene Corporation, Summit, US, <sup>12</sup>Wake Forest University School of Medicine, Winston-Salem, US

12:20 - 12:30 **Invited Discussant 10070**

M.-V. Mateos, University Hospital of Salamanca, Salamanca, ES



**11:00 - 12:00**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Symptom management**  
 Chair(s): Patrick Jahn, DE

11:00 - 11:00    **Session DOI**

11:00 - 11:15    **CN26 - The Cost of Survival: A Mixed-Method Exploration of Healthcare-Related Factors Predicting Colorectal Cancer Survivors' Quality of Life**

A. Drury<sup>1</sup>, S. Payne<sup>2</sup>, A.-M. Brady<sup>3</sup>, <sup>1</sup>Trinity College Dublin, Dublin, IE, <sup>2</sup>Lancaster University, YG, GB, <sup>3</sup>Trinity College Dublin, T, IE

11:15 - 11:30    **CN53 - Rectal cancer survivorship: the struggle of the low anterior resection syndrome (LARS)**

E. Pape<sup>1</sup>, P. Pattyn<sup>1</sup>, A. Van Hecke<sup>2</sup>, N. Somers<sup>2</sup>, D. Van De Putte<sup>3</sup>, W. Ceelen<sup>3</sup>, E. Van Daele<sup>3</sup>, W. Willaert<sup>3</sup>, Y. Van Nieuwenhove<sup>3</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>Ghent University, Ghent, BE, <sup>3</sup>Ghent University Hospital, Gent, BE

11:30 - 11:45    **CN54 - Nurse-led approaches to self-management of symptoms in routine Swiss outpatient care: a qualitative exploration**

K. Ribl<sup>1</sup>, M. Bana<sup>2</sup>, S. Peters<sup>3</sup>, S. Kropf-Straub<sup>4</sup>, E. Näf<sup>5</sup>, S. Zürcher<sup>4</sup>, M. Eicher<sup>6</sup>, <sup>1</sup>IBCSG International Breast Cancer Study Group, Bern, CH, <sup>2</sup>HES-SO University of Applied Sciences and Arts Western Switzerland, Fribourg, Fribourg, CH, <sup>3</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>4</sup>Hospital Group Lindenhof, Berne, Bern, CH, <sup>5</sup>Solothurner Spitäler AG, Olten und Solothurn, Solothurn, CH, <sup>6</sup>University of Lausanne, Lausanne, CH

11:45 - 12:00    **CN27 - The influence of social networks on cancer survivors' self-management support: A survey analysis**

G. Howard-Jones<sup>1</sup>, A. Richardson<sup>2</sup>, I. Vassilev<sup>3</sup>, D. Fenlon<sup>4</sup>, S. Ewings<sup>3</sup>, <sup>1</sup>Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB, <sup>2</sup>University Hospital Southampton Foundation Trust, Southampton, GB, <sup>3</sup>University of Southampton, Southampton, GB, <sup>4</sup>Swansea University, Swansea, GB

**11:00 - 11:45**    **Type: Young Oncologist session**    **ICM - Room 14a**  
**Title: YO Brunch 2: Breaking bad news: How to deal with end-of-life discussions**  
 Chair(s): Mila Petrova, BG; Mehmet Akif Ozturk, TR

11:00 - 11:00    **Session DOI**

11:00 - 11:15    **Breaking bad news: How to deal with end-of-life discussions**

E. Masel, Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

**11:10 - 12:40**    **Type: Proffered Paper session**    **Hall A1 - Room**

**Title: Proffered paper session - Gastrointestinal tumours, non colorectal**

17

Chair(s): Yoon-Koo Kang, KR; Florian Lordick, DE

11:10 - 11:10 **Session DOI**11:10 - 11:25 **LBA25 - TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer**

H.-T. Arkenau<sup>1</sup>, J. Taberero<sup>2</sup>, K. Shitara<sup>3</sup>, M. Dvorkin<sup>4</sup>, W. Mansoor<sup>5</sup>, A. Prokharau<sup>6</sup>, M. Alsina<sup>7</sup>, M. Ghidini<sup>8</sup>, C. Faustino<sup>9</sup>, V. Gorbunova<sup>10</sup>, E. Zhavrid<sup>11</sup>, K. Nishikawa<sup>12</sup>, A. Hosokawa<sup>13</sup>, D. Ganea<sup>14</sup>, Ş. Yalçın<sup>15</sup>, G. Beretta<sup>16</sup>, R. Winkler<sup>17</sup>, L. Makris<sup>18</sup>, T. Doi<sup>19</sup>, D. Ilson<sup>20</sup>, <sup>1</sup>Sarah Cannon Research Institute SCRI UK, London, GB, <sup>2</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES, <sup>3</sup>National Cancer Center, Kashiwa-city, Chiba, JP, <sup>4</sup>Omsk Regional Clinical Centre of Oncology, Omsk, Omsk Region, RU, <sup>5</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>6</sup>Minsk City Clinical Oncology Dispensary, Minsk, BY, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Istituti Ospitalieri di Cremona, Cremona, IT, <sup>9</sup>Instituto Português de Oncologia do Porto, Porto, PT, <sup>10</sup>N.N.Blokhin Russian Cancer Research Center, Moscow, RU, <sup>11</sup>N.N. Alexandrov Research Institute, Minsk, BY, <sup>12</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>13</sup>University of Toyoma, Toyoma, JP, <sup>14</sup>Spitalul Judetean de Urgenta Sfantul Ioan cel Nou Suceava, Suceava, RO, <sup>15</sup>Hacettepe University, Ankara, TR, <sup>16</sup>Humanitas Gavazzeni, Bergamo, IT, <sup>17</sup>Taiho Oncology, Inc., Princeton, US, <sup>18</sup>Stathmi Inc., New Hope, US, <sup>19</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>20</sup>Memorial Sloan Kettering Cancer Center, New York, US

11:25 - 11:37 **Invited Discussant LBA25**Y.-K. Kang, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR11:37 - 11:52 **6150 - Randomized phase III study of Gemcitabine, Cisplatin plus S-1 (GCS) versus Gemcitabine, Cisplatin (GC) for Advanced Biliary Tract Cancer (KHBO1401-MITSUBA)**

D. Sakai<sup>1</sup>, M. Kanai<sup>2</sup>, S. Kobayashi<sup>3</sup>, H. Eguchi<sup>4</sup>, H. Baba<sup>5</sup>, S. Seo<sup>6</sup>, A. Taketomi<sup>7</sup>, T. Takayama<sup>8</sup>, H. Yamaue<sup>9</sup>, C. Ishioka<sup>10</sup>, M. Sho<sup>11</sup>, Y. Takeyama<sup>12</sup>, J. Fujimoto<sup>13</sup>, M. Toyoda<sup>14</sup>, J. Shimizu<sup>15</sup>, T. Goto<sup>16</sup>, K. Yoshimura<sup>17</sup>, E. Hatano<sup>13</sup>, H. Nagano<sup>18</sup>, T. Ioka<sup>19</sup>, <sup>1</sup>Osaka University, Osaka, JP, <sup>2</sup>Kyoto University Hospital, Kyoto, JP, <sup>3</sup>Osaka University Graduate School of Medicine, Osaka, JP, <sup>4</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>5</sup>Kumamoto University, Kumamoto, JP, <sup>6</sup>Kyoto University Graduate School of Medicine, Kyoto, JP, <sup>7</sup>Graduate School of Medicine, Hokkaido University, Sapporo, JP, <sup>8</sup>Nihon University School of Medicine, Itabashi-ku, JP, <sup>9</sup>Wakayama Medical University, Wakayama, JP, <sup>10</sup>Institute of Development, Aging Cancer, Tohoku University, Sendai, JP, <sup>11</sup>Nara Medical University, Nara, JP, <sup>12</sup>Department of Surgery, Osaka-sayama, JP, <sup>13</sup>Hyogo College of Medicine, Nishinomiya, JP, <sup>14</sup>Kobe University Hospital, Kobe, JP, <sup>15</sup>Osaka Rosai Hospital, Osaka, JP, <sup>16</sup>Asahikawa Medical University, Asahikawa, JP, <sup>17</sup>Kanazawa University, Kanazawa, JP, <sup>18</sup>Yamaguchi University Graduate School of Medicine, Yamaguchi, JP, <sup>19</sup>Osaka International Cancer Institution, Osaka, JP

11:52 - 12:04 **Invited Discussant 6150**

J. Valle, The Christie NHS Foundation Trust, Manchester, GB

12:04 - 12:19

**LBA26 - Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)**

M. Pishvaian<sup>1</sup>, M. Lee<sup>2</sup>, B.-Y. Ryoo<sup>3</sup>, S. Stein<sup>4</sup>, K.-H. Lee<sup>5</sup>, W. Verret<sup>6</sup>, J. Spahn<sup>6</sup>, H. Shao<sup>7</sup>, B. Liu<sup>6</sup>, K. Iizuka<sup>6</sup>, C.-H. Hsu<sup>8</sup>, <sup>1</sup>Georgetown University, Washington, US, <sup>2</sup>UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>3</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Yale School of Medicine, New Haven, US, <sup>5</sup>Seoul National University Hospital, Seoul, KR, <sup>6</sup>Genentech, South San Francisco, US, <sup>7</sup>F. Hoffmann-La Roche Ltd, Beijing, CN, <sup>8</sup>National Taiwan University Hospital, Taiwan, TW

12:19 - 12:34

**LBA27 - A Randomized Multicentered Phase 2 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects with Advanced Hepatocellular Carcinoma (HCC) who Failed or Intolerable to Prior Systemic Treatment**

S. Qin<sup>1</sup>, Z. Ren<sup>2</sup>, Z. Meng<sup>3</sup>, Z. Chen<sup>4</sup>, X. Chai<sup>5</sup>, J. Xiong<sup>6</sup>, Y. Bai<sup>7</sup>, L. Yang<sup>8</sup>, H. Zhu<sup>9</sup>, W. Fang<sup>10</sup>, X. Lin<sup>11</sup>, X. Chen<sup>12</sup>, E. Li<sup>13</sup>, Y. Xia<sup>14</sup>, J. Zou<sup>14</sup>, <sup>1</sup>Nanjing Chinese Medicine University Oncology, Nanjing, CN, <sup>2</sup>Zhongshan Hospital, Fudan University, Shanghai, CN, <sup>3</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>4</sup>2nd Hospital of Anhui Medical University, Hefei, CN, <sup>5</sup>Hunan Cancer Hospital, Changsha, CN, <sup>6</sup>The First Affiliated Of Nanchang University, Nanchang, CN, <sup>7</sup>3rd Affiliated Hospital of Harbin Medical University, Harbin, CN, <sup>8</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>9</sup>West China Hospital, Chengdu, CN, <sup>10</sup>1st Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, <sup>11</sup>Fujian Medical University Union Hospital, Fuzhou, CN, <sup>12</sup>Guangdong General Hospital, Guangzhou, CN, <sup>13</sup>First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), Xi'an, CN, <sup>14</sup>Jiangsu Hengrui Medicine Co. LTD, Shanghai, CN

12:34 - 12:46

**Invited Discussant LBA26 and LBA27**

M. Ducreux, Gustave Roussy Cancer Campus Grand Paris, Villejuif, FR

**11:10 - 12:15**    **Type: Multidisciplinary interactive sessions**    **Hall B3 - Room 23**  
**Title: Multidisciplinary perspectives in stage I-II NSCLC management**  
Chair(s): Enriqueta Felip, ES

11:10 - 11:10    **Session DOI**

11:10 - 11:15    **Case presentation on stage**  
E. Felip, Vall d' Hebron University Hospital, Barcelona, ES

11:15 - 11:25    **The role of medical oncology**  
E. Felip, Vall d' Hebron University Hospital, Barcelona, ES

11:25 - 11:35    **The role of radiotherapy**  
  
S. Senan, Vrije University Medical Centre (VUMC), Amsterdam, NL

11:35 - 11:45    **The role of surgery**  
W. Weder, University Hospital Zürich, Zurich, CH

11:45 - 12:15    **Discussion**



**11:10 - 12:15** **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 20**  
**Title: Pre-op/neoadjuvant treatments in sarcomas: “Think twice before you open it”**  
 Chair(s): Paolo G. Casali, IT

11:10 - 11:10 **Session DOI**

11:10 - 11:15 **Case presentation**

P.G. Casali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

11:15 - 11:25 **The surgeon’s perspective**

P. Rutkowski, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL

11:25 - 11:35 **The radiation oncologist’s perspective**

A. Miah, Royal Marsden Hospital NHS Foundation Trust, London, GB

11:35 - 11:45 **The medical oncologist’s perspective**

A. Le Cesne, Gustave Roussy - Cancer Campus, Villejuif, FR

11:45 - 12:15 **Discussion**

**11:15 - 12:15** **Type: Poster Discussion session** **Hall B3 - Room 21**  
**Title: Poster Discussion session - Translational research 2**  
 Chair(s): Giampaolo Tortora, IT; Gert Attard, GB

11:15 - 11:15 **Session DOI**

11:15 - 11:15 **62PD - Could plasma EBV DNA kinetics predict long-term disease-free survival in metastatic nasopharyngeal carcinoma?**

L. Guoying, H. Liang, W.-X. Xia, Y.-Q. Xiang, X. Lv, X. Guo, Y.-H. Yu, S.-H. Lv, K.-Y. Liu, W.-Z. Qiu, X.-J. Huang, W.-Z. Li, Sun Yat-sen University Cancer Center, Guangzhou, CN

11:15 - 11:15 **63PD - Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials**

B. Holt<sup>1</sup>, D. Micklem<sup>1</sup>, A. Brown<sup>2</sup>, M. Yule<sup>2</sup>, J. Lorens<sup>3</sup>, <sup>1</sup>BerGenBio ASA, Oxford, GB, <sup>2</sup>BerGenBio ASA, Bergen, NO, <sup>3</sup>University of Bergen, Bergen, NO

11:15 - 11:15 **64PD - Identification and Validation of a 23-Gene Expression Signature for Subtype Classification of Medulloblastoma**

Q. Xu<sup>1</sup>, Q. Wang<sup>2</sup>, J. Chen<sup>3</sup>, C. Chen<sup>3</sup>, Y. Sun<sup>3</sup>, L. Chen<sup>4</sup>, Q. Ye<sup>5</sup>, X. Du<sup>2</sup>, <sup>1</sup>Institute of

Machine Learning and Systems Biology, College of Electronics and Information Engineering, Shanghai, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>3</sup>Canhelp Genomics, Hangzhou, CN, <sup>4</sup>Xuzhou Medical University, Xuzhou, CN, <sup>5</sup>Nanjing Drum Tower Hospital, Nanjing, CN

- 11:15 - 11:15 **1832PD - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)**  
A. Hollebecque<sup>1</sup>, J. De Bono<sup>2</sup>, R. Plummer<sup>3</sup>, N. Isambert<sup>4</sup>, P. Martin-Romano<sup>5</sup>, E. Baudin<sup>5</sup>, S. Mora<sup>6</sup>, A. Harding<sup>7</sup>, A. Nguyen<sup>8</sup>, E. Filvaroff<sup>9</sup>, M. Lamba<sup>10</sup>, K. Liu<sup>10</sup>, J. De Alvaro<sup>11</sup>, J. Dimartino<sup>8</sup>, M. Zuraek<sup>8</sup>, Z. Nikolova<sup>6</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>The Institute of Cancer Research and Royal Marsden, London, GB, <sup>3</sup>Northern Institute for Cancer Research University of Newcastle, Newcastle upon Tyne, GB, <sup>4</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>Celgene Institute Translational Research Europe-CITRE, Sevilla, ES, <sup>7</sup>Celgene Ltd, Uxbridge, GB, <sup>8</sup>Celgene Corporation, South San Francisco, US, <sup>9</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>10</sup>Celgene Corporation, Summit, US, <sup>11</sup>Chiltern International, Algeciras, ES
- 11:15 - 11:15 **1833PD - Lack of efficiency of Precision Oncology with target-based investigational treatments for patients in Early Phase clinical trials based on pre-screened molecular alterations**  
B. Doger De Spéville<sup>1</sup>, V. Moreno<sup>2</sup>, T. Hernandez<sup>2</sup>, V. Boni<sup>3</sup>, M.J. De Miguel<sup>3</sup>, F. Rojo<sup>2</sup>, F. Lopez-Rios<sup>3</sup>, E. Calvo<sup>3</sup>, <sup>1</sup>Fundación Jiménez Díaz, Madrid, ES, <sup>2</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>3</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES
- 11:15 - 11:35 **Invited Discussant 62PD, 63PD, 64PD, 1832PD and 1833PD**  
G. Tortora, Fondazione Policlinico Universitario Gemelli -IRCCS Rome, Rome, IT
- 11:35 - 11:45 **Q&A led by Discussant**
- 11:45 - 11:45 **65PD - High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4**  
B. Higgs, MedImmune, Gaithersburg, US
- 11:45 - 11:45 **1834PD - Genomic profile and T cell receptor repertoire of lung adenosquamous carcinomas**  
G. Lin<sup>1</sup>, C. Li<sup>1</sup>, W.-Z. Fang<sup>2</sup>, W. Chen<sup>3</sup>, C. Huang<sup>1</sup>, <sup>1</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>2</sup>Fuzhou General Hospital, Fuzhou, CN, <sup>3</sup>Geneplus-Beijing Institute, Fuzhou, CN
- 11:45 - 11:45 **1835PD - Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low**  
M. Salem<sup>1</sup>, A. Puccini<sup>2</sup>, A. Grothey<sup>3</sup>, J. Xiu<sup>4</sup>, R. Goldberg<sup>5</sup>, E. Kim<sup>6</sup>, W.M. Korn<sup>7</sup>, H.-J. Lenz<sup>8</sup>, D. Raghavan<sup>9</sup>, J. Marshall<sup>10</sup>, M. Hall<sup>11</sup>, <sup>1</sup>Lombardi Cancer Center Georgetown University, Washington DC, US, <sup>2</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la

Ricerca sul Cancro, Genova, IT, <sup>3</sup>West Cancer Center, Germantown, US, <sup>4</sup>Mayo Clinic Cancer Center, Phoenix, US, <sup>5</sup>, SG, <sup>6</sup>Levine Cancer Institute, Atrium Health, Charlotte, US, <sup>7</sup>Caris Life Sciences, Phoenix, US, <sup>8</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>9</sup>Carolinas HealthCare System, Charlotte, US, <sup>10</sup>Georgetown University Hospital, Washington DC, US, <sup>11</sup>Fox Chase Cancer Center, Philadelphia, US

11:45 - 11:45 **1836PD - Representative Sequencing: profiling extreme tumor diversity**  
K. Litchfield<sup>1</sup>, L. Au<sup>1</sup>, C. Swanton<sup>1</sup>, S. Turajlic<sup>2</sup>, <sup>1</sup>The Francis Crick Institute, London, GB, <sup>2</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB

11:45 - 11:45 **1837PD - Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC)**  
J.L. Perez Gracia<sup>1</sup>, M.J. Pajares<sup>2</sup>, J.P. Fusco<sup>3</sup>, M. Andueza<sup>4</sup>, V. Segura<sup>2</sup>, M.I. Mora<sup>4</sup>, E. Guruceaga<sup>5</sup>, R. Sanchez Bayona<sup>3</sup>, A. Gurrpide<sup>4</sup>, J.M. Lopez-Picazo<sup>4</sup>, I. Gil-Bazo<sup>3</sup>, J.P. De Torres<sup>4</sup>, J. Zulueta<sup>4</sup>, R. Pio<sup>2</sup>, I. Melero<sup>3</sup>, M. Sanmamed<sup>6</sup>, M. Rodriguez-Ruiz<sup>4</sup>, A. Gonzalez Neira<sup>7</sup>, L. Montuenga<sup>8</sup>, A. Patiño-Garcia<sup>4</sup>, <sup>1</sup>Clinica Universidad de Navarra, Salamanca, ES, <sup>2</sup>Universidad de Navarra, Pamplona, ES, <sup>3</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>4</sup>Clinica Universidad de Navarra, Pamplona, ES, <sup>5</sup>Universidad de Navarra, eguruce@unav.es, ES, <sup>6</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>7</sup>CNIO, Madrid, ES, <sup>8</sup>Complejo Hospitalario de Navarra, Pamplona, ES

11:45 - 12:05 **Invited Discussant 1834PD, 1835PD, 1836PD and 1837PD**  
G. Attard, The Institute of Cancer Research (Sutton Site), Sutton, GB

12:05 - 12:15 **Q&A led by Discussant**

**12:00 - 13:00 Type: Poster Display session Title: EONS Poster display Hall B4 - Room 24**

12:00 - 12:00 **CN5 - Patients - power sources for cancer nurses**  
C. Beisel, University Hospital Heidelberg, Heidelberg, DE

12:00 - 12:00 **CN6 - BRAF/MEK-inhibition for patients with metastatic melanoma: towards patient-centered care**  
J. Koldenhof<sup>1</sup>, S. Vervoort<sup>2</sup>, C. Nierop<sup>3</sup>, K. Suijkerbuijk<sup>4</sup>, <sup>1</sup>UMC - University Medical Center Utrecht, Utrecht, NL, <sup>2</sup>University Medical Center Utrecht, Utrecht, NL, <sup>3</sup>HU University of Applied sciences, Utrecht, NL, <sup>4</sup>University Hospital Utrecht, Utrecht, NL

12:00 - 12:00 **CN7 - Perceptions of Rural Nurses Extending Their Role to Administer Chemotherapy**  
Q. Alnasser<sup>1</sup>, K. Cameron<sup>2</sup>, J. Prouse<sup>3</sup>, <sup>1</sup>King Faisal Specialist Hospital and Research Center, Riyadh, SA, <sup>2</sup>King Faisal Specialist Hospital & Research Center, Riyadh, SA, <sup>3</sup>Royal Adelaide Hospital, Adelaide, AU

- 12:00 - 12:00 **CN8 - AYA cancer nursing - An emerging sub-speciality - the first book about AYA cancer nursing, edited and authored by nurses.**  
S. Smith, Aarhus University Hospital, Aarhus C, DK
- 12:00 - 12:00 **CN9 - Nurse led follow-up for CML patients on oral cancer treatment**  
S. De Wilde<sup>1</sup>, J. De Munter<sup>2</sup>, M. Quaghebeur<sup>2</sup>, D. Mazure<sup>2</sup>, A. De Pauw<sup>2</sup>, B. Casteels<sup>2</sup>,  
<sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University hospital Ghent, Gent, BE
- 12:00 - 12:00 **CN10 - Introducing a new role in cancer care, Coordinating Contact Nurses - patient-reported evaluation.**  
B. Westman<sup>1</sup>, H. Ullgren<sup>2</sup>, L. Sharp<sup>1</sup>, <sup>1</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE, <sup>2</sup>Karolinska University Hospital-Solna, Stockholm, SE
- 12:00 - 12:00 **CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: preliminary study.**  
E. Mahía<sup>1</sup>, G. Simó<sup>1</sup>, E. Heras<sup>2</sup>, M. Pascual<sup>2</sup>, F. Cobo<sup>1</sup>, J. Pujadas<sup>1</sup>, S. Albiol<sup>3</sup>, <sup>1</sup>Servei Andorra Atenció Sanitaria, Escaldes-Engordany, AD, <sup>2</sup>Servei Andorra Atencio Sanitaria, Escaldes-Engordany, AD, <sup>3</sup>Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, AD
- 12:00 - 12:00 **CN12 - Systemic Anticancer Therapy Administration Safety**  
S. Toland<sup>1</sup>, A. Simons<sup>2</sup>, <sup>1</sup>Birmingham City University, Birmingham, GB, <sup>2</sup>Birmingham City University, Birmingham city university, GB
- 12:00 - 12:00 **CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: the role of the nurse practitioner for early recognition and management**  
C. Roth, M. Labots, A. Eertwegh, Vrije University Medical Centre (VUMC), Amsterdam, NL
- 12:00 - 12:00 **CN14 - Experiences from a new advanced cancer nursing role in Sweden, an analysis based on EONS Cancer Nursing Education Framework using the Delphi method**  
H. Ullgren, Karolinska University Hospital-Solna, Stockholm, SE
- 12:00 - 12:00 **CN15 - Opinions and Experiences of Patients Receiving Oral Chemotherapy: A Qualitative Study**  
S. Kutlutürkan<sup>1</sup>, Ö. Yurtal<sup>1</sup>, K. Kirca<sup>2</sup>, <sup>1</sup>Gazi Üniversitesi, Ankara, TR, <sup>2</sup>Kırıkkale Üniversitesi, Kırıkkale, TR
- 12:00 - 12:00 **CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for Adolescents and Young Adults (AYAs) with an hematological disease**  
J. De Munter<sup>1</sup>, S. De Wilde<sup>1</sup>, M. Quaghebeur<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University hospital Ghent, Gent, BE



- 12:00 - 12:00 **CN17 - Standardising the psychosocial assessment of oncological patients at Donostia University Hospital**  
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria, Hospital Donostia, San Sebastian, ES
- 12:00 - 12:00 **CN18 - Are there differences between nurses' and patients' perceptions of cancer patients' quality of life in Greece?**  
M. Lavdaniti<sup>1</sup>, E. Gogou<sup>1</sup>, G.-C. Karagiannidou<sup>1</sup>, M. Delibaltidou<sup>1</sup>, E. Zioga<sup>1</sup>, K. Marmara<sup>2</sup>, E. Fradelos<sup>1</sup>, <sup>1</sup>Alexander Technological Educational Institute, Thessaloniki, GR, <sup>2</sup>Alexander Technological Educational Institute, thessaloniki, GR
- 12:00 - 12:00 **CN19 - How an empowerment program can touch cancer survivor's life by improving posttraumatic growth?**  
Y.S. Uzar Ozcetin, Hacettepe University Faculty of Nursing, Ankara, TR
- 12:00 - 12:00 **CN20 - Organising a general oncology nursing outpatient clinic**  
C. Lundgren<sup>1</sup>, A. Lagerquist<sup>1</sup>, M. Högman<sup>2</sup>, U. Östlund<sup>3</sup>, <sup>1</sup>Sjukhus Gävle, Gävle, SE, <sup>2</sup>Uppsala University, Uppsala, SE, <sup>3</sup>Region Gävleborg, Gävle, SE
- 12:00 - 12:00 **CN21 - Job content of advanced practice nurses in Flanders**  
E. Decoene<sup>1</sup>, A. Van Hecke<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University Ghent, Gent, BE
- 12:00 - 12:00 **CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professionals self-efficacy when supporting parents newly diagnosed with cancer who have dependent children**  
C. Semple<sup>1</sup>, E. Mccaughan<sup>2</sup>, <sup>1</sup>Ulster University / South Eastern Health and Social Care Trust, Belfast, GB, <sup>2</sup>Ulster University, Coleraine, GB
- 12:00 - 12:00 **CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals**  
J. Bird<sup>1</sup>, M. Nolan<sup>2</sup>, S. Danson<sup>3</sup>, <sup>1</sup>Weston Park Hospital Cancer Research Centre, Sheffield, GB, <sup>2</sup>University of Sheffield, Sheffield, GB, <sup>3</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB
- 12:00 - 12:00 **CN24 - Assessing the effect of telephone support on patients with myeloma Multiple (MM) in The Catalan Oncology Institut in Girona**  
C. Puigmarti, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona, ES
- 12:00 - 12:00 **CN28 - Transmural collaborative care in oncology: Experiences of general practitioners**  
M. Daem<sup>1</sup>, E. Van Roekeghem<sup>2</sup>, M. Grypdonck<sup>2</sup>, P. Pype<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>Ghent University, Ghent, BE

- 12:00 - 12:00 **CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: a systematic review**  
S. Colomer-Lahiguera<sup>1</sup>, D. Bryant-Lukosius<sup>2</sup>, S. Rietkoetter<sup>2</sup>, L. Martelli<sup>2</sup>, K. Ribic<sup>3</sup>, A. Orcurto<sup>1</sup>, R. Juergens<sup>4</sup>, M. Eicher<sup>5</sup>, <sup>1</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>2</sup>McMaster University, Hamilton, CA, <sup>3</sup>IBCSG International Breast Cancer Study Group, Bern, CH, <sup>4</sup>Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, CA, <sup>5</sup>University of Lausanne, Lausanne, CH
- 12:00 - 12:00 **CN30 - Laryngectomized patients caregivers' life experience: a phenomenological study**  
V. Bressan<sup>1</sup>, E. Dri<sup>1</sup>, S. Stevanin<sup>2</sup>, L. Cadorin<sup>3</sup>, A. Rizzuto<sup>4</sup>, G. Bulfone<sup>1</sup>, L. Ghirotto<sup>5</sup>, <sup>1</sup>University of Udine, Udine, IT, <sup>2</sup>Veneto Region, Venice, IT, <sup>3</sup>National Cancer Institute CRO Aviano, Aviano, IT, <sup>4</sup>Udine University Hospital, Udine, IT, <sup>5</sup>Azienda Santa Maria Nuova-IRCCS, Reggio Emilia, IT
- 12:00 - 12:00 **CN31 - Comparing nurses' and patients' research priorities in cancer care: A mixed methods systematic review**  
L. Cadorin<sup>1</sup>, I. Truccolo<sup>2</sup>, V. Bressan<sup>3</sup>, N. Suter<sup>4</sup>, <sup>1</sup>Cro, Pordenone, IT, <sup>2</sup>CRO Aviano National Cancer Institute, Aviano, IT, <sup>3</sup>University of Udine, Udine, IT, <sup>4</sup>CRO Aviano National Cancer Institute, Pordenone, IT
- 12:00 - 12:00 **CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy**  
A. Psychogyiou, S. Katsaragakis, C. Lemonidou, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:00 - 12:00 **CN33 - A new beginning of collaboration - the Danish Cancer Nursing Research Network**  
K. Dieperink<sup>1</sup>, M. Kjerholt<sup>2</sup>, P. Riis Olsen<sup>3</sup>, <sup>1</sup>Odense University Hospital, Odense C, DK, <sup>2</sup>Sjællands Universitets Hospital, Roskilde, DK, <sup>3</sup>Aarhus University Hospital, Aarhus, DK
- 12:00 - 12:00 **CN34 - Individual network meetings in cancer care - From young people with cancer to adults with brain tumours**  
P. Riis Olsen, Aarhus University Hospital, Aarhus, DK
- 12:00 - 12:00 **CN35 - Does being cancer patient or family caregiver of cancer patient effect bone marrow donation awareness?**  
G. Bagcivan<sup>1</sup>, N. Ozen<sup>2</sup>, D. Bayrak<sup>3</sup>, F.I. Cinar<sup>4</sup>, <sup>1</sup>Gulhane Training and Reseach Hospital, Ankara, TR, <sup>2</sup>Istinye University, Istanbul, TR, <sup>3</sup>Cankiri Karatekin University, Cankiri, TR, <sup>4</sup>University of Health Sciences, Ankara, TR
- 12:00 - 12:00 **CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment**  
C. Johnston<sup>1</sup>, M. Tanay<sup>2</sup>, <sup>1</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>2</sup>King's College London, London, GB
- 12:00 - 12:00 **CN37 - Evaluation of support and information needs for patients with cancer in a**

**Phase I trials unit.**

S. Stapleton<sup>1</sup>, L. O'Leary<sup>1</sup>, M. Van Zyl<sup>2</sup>, J. Hanwell<sup>1</sup>, T. Wiseman<sup>3</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>3</sup>The Royal Marsden NHS Foundation Trust, London, GB

- 12:00 - 12:00 **CN38 - Dignity of Greek patients with advanced cancer: a cross-sectional study**  
S. Katsaragakis, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:00 - 12:00 **CN39 - Development and implementation of national guidelines on lifestyle issues and cancer -Report from an on-going quality improvement project**  
K. Vuollet Karlsson<sup>1</sup>, C. Landegren<sup>2</sup>, B. Westman<sup>2</sup>, <sup>1</sup>Norrlands universitetssjukhus, Umea, SE, <sup>2</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:00 - 12:00 **CN40 - Developing a Patient Reported Experience Measure (PREM) in Secondary Breast Cancer (SBC)**  
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke, The Christie NHS Foundation Trust, Manchester, GB
- 12:00 - 12:00 **CN41 - Cancer situation in sub-Saharan Countries: development of educational, diagnosis and treatment plans.**  
J. De La Torre-Montero<sup>1</sup>, N. Gil-Gómez<sup>2</sup>, J. Ribes Bernal<sup>3</sup>, N. Domenech Climent<sup>4</sup>, A. Ojer Perea<sup>5</sup>, P. Beorlegui Murillo<sup>5</sup>, J.M. Gavala Arjona<sup>6</sup>, R. Cumplido Corbacho<sup>7</sup>, I. Magallon Pedrera<sup>8</sup>, M.A. Peñuelas Saiz<sup>8</sup>, <sup>1</sup>SPANISH SOCIETY OF ONCOLOGY NURSING, Madrid, ES, <sup>2</sup>HOSPITAL QUIRÓN MADRID, MADRID, ES, <sup>3</sup>HOSPITAL CLINIC, BARCELONA, ES, <sup>4</sup>HOSPITAL VIRGEN DE LOS LIRIOS, ALCOY, ES, <sup>5</sup>CLINICA UNIVERSITARIA DE NAVARRA, PAMPLONA, ES, <sup>6</sup>HOSPITAL SON ESPASES, PALMA DE MALLORCA, ES, <sup>7</sup>HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLE, ES, <sup>8</sup>Hospital Universitari Vall d'Hebron, BARCELONA, ES
- 12:00 - 12:00 **CN42 - The Gastrointestinal and Lymphoma unit Lead Nurse Research role in Royal Marsden Hospital.**  
J. Duncan<sup>1</sup>, V. Michalarea<sup>2</sup>, T. Coyne<sup>1</sup>, J. Thomas<sup>1</sup>, D. Cunningham<sup>2</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 12:00 - 12:00 **CN43 - Patients' learning and participation in their breast cancer care**  
L. Boman<sup>1</sup>, K. Sandelin<sup>2</sup>, Y. Wengström<sup>3</sup>, C. Silén<sup>1</sup>, <sup>1</sup>Karolinska Institute, Stockholm, SE, <sup>2</sup>Karolinska Institutet - Dept of Oncology-Pathology, Stockholm, SE, <sup>3</sup>Karolinska Institutet, Huddinge, SE
- 12:00 - 12:00 **CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration.**  
S.Y. Oh<sup>1</sup>, J.M. Lee<sup>1</sup>, J.W. Kim<sup>1</sup>, S.H. Kim<sup>1</sup>, J.M. Park<sup>1</sup>, G.Y. Yeo<sup>1</sup>, J.E. Hyun<sup>1</sup>, J.-H. Park<sup>2</sup>, <sup>1</sup>Asan Medical Center, Seoul, KR, <sup>2</sup>Ajou Univ. Hospital, Suwon, KR

- 12:00 - 12:00 **CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy**  
A. Frade, S. Miguel, Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P.E., LISBOA, PT
- 12:00 - 12:00 **CN46 - Safe navigation of CARs in a changing landscape**  
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB
- 12:00 - 12:00 **CN47 - Patients' interpretations and experiences of participation in cancer care**  
J. Jackson, J. Rundgren, Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:00 - 12:00 **CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab**  
M. Qiu<sup>1</sup>, Y. Chen<sup>2</sup>, B.-L. Zhang<sup>2</sup>, X.-Y. Wang<sup>2</sup>, <sup>1</sup>West China Hospital, Sichuan University, Chengdu, Sichuan Province, CN, <sup>2</sup>West China Hospital, Chengdu, CN
- 12:00 - 12:00 **CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care**  
J. De Munter<sup>1</sup>, P. Crombez<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>Jules Bordet, Brussel, BE
- 12:00 - 12:00 **CN50 - Overview of an Acute Oncology Service in A UK Cancer Centre**  
M. Foulkes, Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB
- 12:00 - 12:00 **CN51 - The development and evaluation of an online oncology portal**  
J. De Munter<sup>1</sup>, E. Decoene<sup>2</sup>, A. Van Hecke<sup>3</sup>, <sup>1</sup>Ghent University Hospital, Ghent, BE, <sup>2</sup>Gent University Hospital, Ghent, BE, <sup>3</sup>University Ghent, Ghent, BE
- 12:00 - 12:00 **CN52 - Pilot Study - Nurses' Role in Management of Cutaneous Toxicity in Patients with Targeted Therapies Anti EGFR-Is' Treatment.**  
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso, Istituto Oncologico Veneto IRCCS, Padova, IT
- 12:00 - 12:00 **CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?**  
D. Oliva<sup>1</sup>, F. Lewin<sup>1</sup>, N. Lewin<sup>2</sup>, M. Nilsson<sup>3</sup>, M. Strandéus<sup>1</sup>, B.-Å. Andersson<sup>2</sup>, L. Sharp<sup>4</sup>, <sup>1</sup>County Hospital Ryhov, Jönköping, SE, <sup>2</sup>Laboratory Medicine, Jönköping, SE, <sup>3</sup>Futurum - , Jönköping, SE, <sup>4</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:00 - 12:00 **CN58 - Effect of Aromatherapy Massage on Chemotherapy-Induced Peripheral Neuropathic Pain and Fatigue in Patients Receiving Oxaliplatin**  
N. Izgu<sup>1</sup>, L. Ozdemir<sup>2</sup>, F. Bugdayci Basal<sup>3</sup>, <sup>1</sup>Hacettepe University Faculty of Nursing, Ankara, TR, <sup>2</sup>Hacettepe University, Ankara, TR, <sup>3</sup>Ataturk Egitim ve Arastirma Hastanesi tibbi onkoloji klinik, Izmir, TR



- 12:00 - 12:00 **CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital**  
C. Palassari, S. Katsaragakis, J. Kaklamanos, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:00 - 12:00 **CN60 - The experience of dysgeusia in allogenic hematopoietic cell transplantation survivors: a qualitative study**  
D. Bomben<sup>1</sup>, A. Bin<sup>2</sup>, M. Venturini<sup>1</sup>, T. Bulfone<sup>1</sup>, L. Ghirotto<sup>3</sup>, V. Bressan<sup>1</sup>, <sup>1</sup>University of Udine, Udine, IT, <sup>2</sup>Udine University Hospital, Udine, IT, <sup>3</sup>Azienda Santa Maria Nuova-IRCCS, Reggio Emilia, IT
- 12:00 - 12:00 **CN61 - "It may not affect you" -- Lived experiences and support needs of women who developed peripheral neuropathy following chemotherapy treatment for cancer.**  
M. Tanay<sup>1</sup>, J. Armes<sup>2</sup>, <sup>1</sup>King's College London, London, GB, <sup>2</sup>University of Surrey, Surrey, GB
- 12:00 - 12:00 **CN62 - App about chemotherapy - helping the patient with cancer**  
B. Espersen, Aarhus University Hospital, Aarhus, DK
- 12:00 - 12:00 **CN63 - Usability Test For a CINV Diary Application For Smartphones at Oncology Nursing**  
P. Fernández- Ortega<sup>1</sup>, Y. Escobar<sup>2</sup>, E. Trigoso<sup>3</sup>, R. Blat<sup>4</sup>, M. Cantero<sup>2</sup>, A. Alvarez<sup>5</sup>, <sup>1</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>2</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>3</sup>Hospital La Fé, Valencia, ES, <sup>4</sup>Hospital Mar Parc Salut, Barcelona, ES, <sup>5</sup>Hospital de Leon, Leon, ES
- 12:00 - 12:00 **CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the Memorial Symptom Assessment Scale**  
D. Palitzika<sup>1</sup>, E. Fradelos<sup>1</sup>, V. Alikari<sup>1</sup>, P. Charitopoulos<sup>1</sup>, E. Zioga<sup>1</sup>, S. Zyga<sup>2</sup>, M. Lavdaniti<sup>1</sup>, <sup>1</sup>Alexander Technological Educational Institute, Thessaloniki, GR, <sup>2</sup>University of Peloponnesus, Thessaloniki, GR
- 12:00 - 12:00 **CN65 - How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool "Onco'nect®"**  
M. Belhadji<sup>1</sup>, E. Kempf<sup>2</sup>, A. Lebel<sup>2</sup>, A. Guillemin<sup>2</sup>, H. BouSSION<sup>3</sup>, C. Joly<sup>2</sup>, I. Baumgaertner<sup>4</sup>, E. Assaf<sup>5</sup>, C. Saldana<sup>4</sup>, B. Rousseau<sup>4</sup>, C. Tournigand<sup>4</sup>, <sup>1</sup>Université Paris-Est Créteil Val de Marne, Faculté de Médecine, Créteil, FR, <sup>2</sup>Hôpital Henri Mondor, AP-HP, Créteil, FR, <sup>3</sup>Assistance Publique - Hôpitaux De Paris, Paris, FR, <sup>4</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>5</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR
- 12:00 - 12:00 **CN66 - Medical makeup in cancer patients and its impact in their quality of life**  
R. Lechou, M. Lavdaniti, Alexander Technological Educational Institute, Thessaloniki, GR

**12:30 - 14:00**    **Type: Patient Advocacy Track**    **ICM - Room 5**  
**Title: The cancer drugs we need: Incentivising innovation in cancer**  
 Chair(s): Bettina Ryll, SE; Charlotte Roffiaen, FR

12:30 - 12:30    **Session DOI**

12:30 - 12:45    **Shaping policies to drive innovation in cancer**  
R. Sullivan, Institute of cancer policy, London, GB

12:45 - 13:00    **Incentivising innovation**  
J. Scannell, UBS, London, GB

13:00 - 13:15    **Patient advocate driving innovation**  
B. Ryll, Melanoma Patient network Europe, Uppsala, SE

13:15 - 14:00    **Discussion**

**12:45 - 13:45**    **Type: Poster Display session**    **Hall A3 - Poster Area**  
**Title: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal &&**    **Networking Hub**

12:45 - 12:45    **Basic science**

12:45 - 12:45    **6P - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome**  
E. Llabres Valenti, A. Sanchez De Abajo, J. Brenes Castro, A. Ramchandani Vaswani, A. Gómez De Liaño, A. Hernández, M. Cejuela, J. Rodriguez Garcia, E. González, E. Vicente, Hospital Universitario Insular de Gran Canaria, Las Palmas, ES

12:45 - 12:45    **7P - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender**  
J.B. Ramirez Sabio<sup>1</sup>, J.V. Sorlí<sup>2</sup>, I. González-Monje<sup>2</sup>, C. Ortega-Azorín<sup>2</sup>, Ó. Coltell<sup>3</sup>, D. Corella<sup>2</sup>, <sup>1</sup>Hospital de Sagunt, Sagunt, ES, <sup>2</sup>Universitat de València, Valencia, ES, <sup>3</sup>Universitat Jaume I, Castellón, ES

12:45 - 12:45    **8P - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population**  
J.B. Ramirez Sabio<sup>1</sup>, J.V. Sorlí<sup>2</sup>, C. Ortega-Azorín<sup>2</sup>, J.A. Pérez-Fidalgo<sup>3</sup>, E.M. Asensio<sup>2</sup>, D. Corella<sup>2</sup>, <sup>1</sup>Hospital de Sagunt, Sagunt, ES, <sup>2</sup>Universitat de València, Valencia, ES, <sup>3</sup>Hospital Clínico Universitario de Valencia, Valencia, ES

- 12:45 - 12:45 **9P - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer**  
S. Shahid Sales<sup>1</sup>, M. Mehramiz<sup>2</sup>, S.A. Aledavood<sup>3</sup>, M. Joudi Mashhad<sup>4</sup>, S. Ahmadi Simab<sup>5</sup>, A. Avan<sup>6</sup>, <sup>1</sup>OMID Hospital Mashhad University of Medical Sciences, Mashhad, IR, <sup>2</sup>Metabolic Syndrome Research Center, Mashhad, IR, <sup>3</sup>Mashhad University of Medical Sciences, mashhad, IR, <sup>4</sup>Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, IR, <sup>5</sup>Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Mashhad, IR, <sup>6</sup>School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR
- 12:45 - 12:45 **10P - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR**  
K. Bakshi, Shiv Nadar University, Greater Noida, UP, IN
- 12:45 - 12:45 **11P - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma**  
H. Jo, S. Hwang, M. Lee, Incheon University, Incheon, KR
- 12:45 - 12:45 **12P - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System**  
Y. Ge<sup>1</sup>, C. Ma<sup>2</sup>, L. Tao<sup>1</sup>, M.F. Han<sup>1</sup>, L. Ma<sup>3</sup>, G. Li<sup>4</sup>, L.M. Ma<sup>3</sup>, Q. Lu<sup>2</sup>, Z. Wu<sup>3</sup>, P.F. Yu<sup>3</sup>, Y.F. Yang<sup>3</sup>, Y.Y. Ma<sup>2</sup>, B.B. Song<sup>3</sup>, W. Gao<sup>3</sup>, <sup>1</sup>Anhu Fuyang No.2 People's Hospital, Fuyang, CN, <sup>2</sup>American Intelligent Health, Bellevue, US, <sup>3</sup>Beijing Yiwang Data Technology, Beijing, CN, <sup>4</sup>Fu Wai Hospital, Beijing, CN
- 12:45 - 12:45 **13P - Measuring the Efficiency of Cancer Care in Europe**  
R. Althin<sup>1</sup>, R. Färe<sup>2</sup>, S. Grosskopf<sup>2</sup>, B. Jönsson<sup>3</sup>, N. Wilking<sup>4</sup>, <sup>1</sup>The Swedish Institute for Health Economics, Lund, SE, <sup>2</sup>Oregon State, Corvallis, US, <sup>3</sup>Stockholm school of economics, Stockholm, SE, <sup>4</sup>Skane University Hospital, Lund, SE
- 12:45 - 12:45 **14P - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients**  
C.-Y. Yang<sup>1</sup>, C.-H. Lin<sup>2</sup>, J.-K. Jiang<sup>3</sup>, <sup>1</sup>Taipei City Hospital, Taipei, TW, <sup>2</sup>Institute of Microbiology and Immunology, Taipei, TW, <sup>3</sup>Department of Surgery, Taipei, TW
- 12:45 - 12:45 **15P - \_lonality of uterine carcinosarcoma as a factor of clinical prognosis.**  
N. Levitskaya<sup>1</sup>, O. Vostriukhina<sup>2</sup>, I. Poddubnaia<sup>3</sup>, <sup>1</sup>Russian Medical Academy of Postgraduate Education, Moscow, RU, <sup>2</sup>Petersburg nuclear physics institute named by B.P.Konstantinov, Russia, Leningradskaya Oblast, Gatchina, mkr. Orlova roshcha., RU, <sup>3</sup>Russian Medical Academy of Continuous Vocational Training, Moscow, RU
- 12:45 - 12:45 **16P - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer**  
A. Moilanen<sup>1</sup>, J. Lindqvist<sup>2</sup>, M. Björkman<sup>2</sup>, R. Riikonen<sup>2</sup>, D. Nicorici<sup>2</sup>, E. Mattila<sup>2</sup>, C. Abbineni<sup>3</sup>, M. Jaleel<sup>3</sup>, J. Eriksson<sup>4</sup>, P. Kallio<sup>2</sup>, <sup>1</sup>Orion Corporate, Orion Pharma, Turku, FI, <sup>2</sup>Orion Pharma, Espoo, FI, <sup>3</sup>Aurigene Discovery Technologies Limited, Bangalore, IN,

<sup>4</sup>Åbo Akademi University, Turku, FI

- 12:45 - 12:45 **17P - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.**  
R. Dubianski<sup>1</sup>, E. Sarnowska<sup>2</sup>, M. Leszczynski<sup>3</sup>, S. Kubala<sup>4</sup>, W. Olszewski<sup>2</sup>, N. Rusetska<sup>5</sup>, A. Jagiello-Gruszczyńska<sup>2</sup>, R. Konopinski<sup>3</sup>, T. Sarnowski<sup>6</sup>, J. Siedlecki<sup>5</sup>, Z. Nowecki<sup>2</sup>, <sup>1</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>2</sup>The Maria Skłodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, <sup>3</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, PL, <sup>4</sup>Institute of Biochemistry and Biophysics PAS, Warszawa, PL, <sup>5</sup>Marii Skłodowska-Curie Cancer Center, Warsaw, PL, <sup>6</sup>Institute of Biochemistry and Biophysics PAS, Warsaw, PL
- 12:45 - 12:45 **18P - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.**  
P.P. Vitiello, C. Cardone, D. Ciardiello, V. Belli, N. Matrone, C. Borrelli, L. Poliero, V. De Falco, E. Giunta, P. Vitale, N. Zanaletti, G. Tirino, T. Troiani, F. Ciardiello, E. Martinelli, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 12:45 - 12:45 **19P - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.**  
X. Fu<sup>1</sup>, M. Liu<sup>1</sup>, S. Qu<sup>1</sup>, J. Ma<sup>1</sup>, Y. Zhang<sup>1</sup>, T. Shi<sup>1</sup>, H. Wen<sup>1</sup>, Y. Yang<sup>2</sup>, S. Wang<sup>1</sup>, J. Wang<sup>1</sup>, K. Nan<sup>1</sup>, Y. Yao<sup>1</sup>, T. Tian<sup>1</sup>, <sup>1</sup>First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), Xi'an, CN, <sup>2</sup>Shaanxi Provincial People's Hospital, Xi'an, CN
- 12:45 - 12:45 **20P - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women**  
J.B. Ramirez Sabio<sup>1</sup>, J.V. Sorlí<sup>2</sup>, R. Barragán<sup>2</sup>, F.-C. Rebeca<sup>2</sup>, E.M. Asensio<sup>2</sup>, D. Corella<sup>2</sup>, <sup>1</sup>Hospital de Sagunt, Sagunt, ES, <sup>2</sup>Universitat de València, Valencia, ES
- 12:45 - 12:45 **21P - Cisplatin in NIPEC or HIPEC?**  
I. Alvovsky<sup>1</sup>, V. Beshpalov<sup>2</sup>, G. Kireeva<sup>2</sup>, <sup>1</sup>St. Petersburg Clinical and Scientific Oncological Center, Saint-Petersburg, RU, <sup>2</sup>N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU
- 12:45 - 12:45 **22P - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment**  
M. Hirai<sup>1</sup>, Y. Kobayashi<sup>2</sup>, M. Miyazawa<sup>2</sup>, H. Kitahara<sup>2</sup>, S. Kawashiri<sup>2</sup>, H. Nakamura<sup>2</sup>, <sup>1</sup>Kanazawa University, Kanazawa, JP, <sup>2</sup>Kanazawa University Hospital, Kanazawa, JP
- 12:45 - 12:45 **24P - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis**  
P. Sriskandarajah<sup>1</sup>, K. Macleod<sup>2</sup>, N. Carragher<sup>2</sup>, M. Kaiser<sup>3</sup>, S. Whittaker<sup>3</sup>, <sup>1</sup>Private Practice, Orpington, GB, <sup>2</sup>Edinburgh Cancer Research Centre, Edinburgh, GB, <sup>3</sup>Institute of Cancer Research, Sutton, GB



- 12:45 - 12:45 **25P - Functional inhibition of TGF- $\beta$  in colorectal cancer cells and its interaction with AXL receptor**  
D. Ciardiello<sup>1</sup>, G. Martini<sup>2</sup>, N. Matrone<sup>1</sup>, V. Belli<sup>1</sup>, P.P. Vitiello<sup>1</sup>, C. Cardone<sup>1</sup>, V. Ciaramella<sup>1</sup>, G. Barra<sup>3</sup>, L. Poliero<sup>1</sup>, C. Borrelli<sup>1</sup>, T. Troiani<sup>1</sup>, D. Melisi<sup>4</sup>, F. Morgillo<sup>1</sup>, E. Giunta<sup>1</sup>, V. De Falco<sup>1</sup>, F. Ciardiello<sup>1</sup>, E. Martinelli<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>Vall D'Hebron institute o, Barcelona, ES, <sup>3</sup>AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT, <sup>4</sup>AOU Integrata Verona "Borgo Roma", Verona, IT
- 12:45 - 12:45 **26P - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma**  
H. Arasanz<sup>1</sup>, M. Gato-Cañas<sup>2</sup>, M. Zuazo<sup>3</sup>, M. Ibáñez-Vea<sup>3</sup>, G. Fernández-Hinojal<sup>1</sup>, J. Fernandez-Irigoyen<sup>3</sup>, E. Santamaria<sup>3</sup>, G. Kochan<sup>3</sup>, R. Vera<sup>1</sup>, D. Escors<sup>3</sup>, <sup>1</sup>Complejo Hospitalario de Navarra, Pamplona, ES, <sup>2</sup>Navarrabiomed / Fundación Miguel Servet, Pamplona, ES, <sup>3</sup>Navarrabiomed, Pamplona, ES
- 12:45 - 12:45 **27P - Lymphocytes express receptor tyrosine kinases in patients with renal cell carcinoma and healthy donors**  
I. Tsimafeyeu<sup>1</sup>, M. Volkova<sup>2</sup>, A. Olshanskaia<sup>2</sup>, G. Raskin<sup>3</sup>, S. Aschuba<sup>2</sup>, Y. Khochenkova<sup>2</sup>, A. Bondarenko<sup>4</sup>, D. Khochenkov<sup>2</sup>, <sup>1</sup>Russian Society of Clinical Oncology, Moscow, RU, <sup>2</sup>N.N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>3</sup>A.M. Granov Russian Scientific Centre of Radiology and Surgical Technologies, Saint-Petersburg, RU, <sup>4</sup>I.M. Sechenov First Moscow State Medical University, Moscow, RU
- 12:45 - 12:45 **28P - Oncogenes analysis using GO-based clustering**  
D. Babenko, Y. Babenko, Karaganda State Medical University, Karaganda, KZ
- 12:45 - 12:45 **29P - PNU-74654 enhances the antiproliferative effects of 5-FU in breast cancer and antagonizes thrombin induced cell growth via the Wnt Pathway**  
S. Shahid Sales<sup>1</sup>, A. Avan<sup>2</sup>, F. Rahmani<sup>3</sup>, S.M. Hassanian<sup>4</sup>, M. Hashemzahi<sup>2</sup>, F. Amerizadeh<sup>2</sup>, G. A. Ferns<sup>5</sup>, M. Khazaei<sup>6</sup>, <sup>1</sup>OMID Hospital Mashhad University of Medical Sciences, Mashhad, IR, <sup>2</sup>School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR, <sup>3</sup>Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., mashhad, IR, <sup>4</sup>Metabolic syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., mashhad, IR, <sup>5</sup>Brighton & Sussex Medical School, Falmer, GB, <sup>6</sup>Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR
- 12:45 - 12:45 **30P - P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer**  
M. Iida<sup>1</sup>, M. Nakamura<sup>2</sup>, E. Tokuda<sup>2</sup>, T. Niwa<sup>1</sup>, T. Ishida<sup>1</sup>, S.-I. Hayashi<sup>1</sup>, <sup>1</sup>Tohoku University Hospital, Sendai, JP, <sup>2</sup>Tohoku University, Sendai, JP
- 12:45 - 12:45 **31P - Overexpression of NAMPT in adult T-cell leukemia/lymphoma patients and anti-tumor activity of a NAMPT inhibitor in vivo**  
T. Kozako<sup>1</sup>, T. Ohsugi<sup>2</sup>, M. Yoshimitsu<sup>3</sup>, Y.-I. Uchida<sup>3</sup>, K. Ishitsuka<sup>3</sup>, K. Naho<sup>4</sup>, A. Aikawa<sup>4</sup>, S.-I. Honda<sup>4</sup>, <sup>1</sup>Fukuoka University School of Medicine, Fukuoka, JP, <sup>2</sup>Rakuno Gakuen

University, Ebethu, JP, <sup>3</sup>Kagoshima University,, Kagoshima, JP, <sup>4</sup>Fukuoka University, FUKUOKA, JP

- 12:45 - 12:45 **32P - 9-ING-41, a clinically relevant inhibitor of Glycogen Synthase Kinase-3 (GSK-3), is active pre-clinically in human bladder and renal cell cancers**  
H. Kuroki<sup>1</sup>, T. Anraku<sup>1</sup>, V. Bilim<sup>1</sup>, M. Tasaki<sup>1</sup>, D. Schmitt<sup>2</sup>, A. Mazar<sup>3</sup>, A. Ugolkov<sup>4</sup>, Y. Tomita<sup>1</sup>, <sup>1</sup>Niigata University Medical and Dental Hospital, Niigata, JP, <sup>2</sup>Actuate Therapeutics, Fort Worth, US, <sup>3</sup>Monopar Therapeutics, Wilmette, US, <sup>4</sup>Feinberg School of Medicine, Northwestern University, Chicago, US
- 12:45 - 12:45 **33P - A new natural compound identified with metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab**  
V. De Falco, E. Giunta, V. Belli, N. Matrone, S. Napolitano, E. Martinelli, P. Vitale, N. Zanaletti, M. Terminiello, P.P. Vitiello, F. Ciardiello, T. Troiani, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 12:45 - 12:45 **34P - Multiple Myeloma Metal Levels and Proteasome Activity**  
K.U. Stumpf<sup>1</sup>, H. Einsele<sup>2</sup>, T. Nekova<sup>2</sup>, <sup>1</sup>Institute of Mineral Analysis, Würzburg, DE, <sup>2</sup>University Hospital Wuerzburg, Würzburg, DE
- 12:45 - 12:45 **35P - A translational drug-screening tool for interrogating the effect of anti-TGF-<sub>β</sub> therapy on fibroblast activity and the desmoplastic reaction**  
N. Nissen, N. Willumsen, N. Gudmann, S. Rønnow, M. Karsdal, D. Leeming, J. Sand, Nordic Bioscience A/S, Herlev, DK
- 12:45 - 12:45 **36P - Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors**  
H. Kitahara, Y. Kobayashi, M. Hirai, S. Kawashiri, H. Nakamura, Kanazawa University Hospital, Kanazawa, JP
- 12:45 - 12:45 **37P - Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of Smad4 in lung cancer cell lines.**  
K. Takahashi<sup>1</sup>, S. Nishikawa<sup>2</sup>, R. Miyata<sup>1</sup>, M. Noguchi<sup>1</sup>, H. Ishikawa<sup>1</sup>, Y. Yutaka<sup>1</sup>, D. Nakajima<sup>1</sup>, M. Hamaji<sup>1</sup>, A. Ohsumi<sup>1</sup>, T. Menju<sup>1</sup>, F. Chen-Yoshikawa<sup>1</sup>, T. Sato<sup>1</sup>, M. Sonobe<sup>1</sup>, H. Date<sup>1</sup>, <sup>1</sup>Kyoto University-Graduate school of medicine, Kyoto, JP, <sup>2</sup>Kyoto University Graduate School, Kyoto, JP
- 12:45 - 12:45 **38P - Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro**  
A. Cortez, K. Kujawa, P. Tudrej, K. Lisowska, Maria Skłodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, PL
- 12:45 - 12:45 **39P - MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1**  
L. Qiu, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN

- 12:45 - 12:45 **40P - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1**  
X. Wang<sup>1</sup>, X. Che<sup>2</sup>, Y. Fan<sup>2</sup>, M. Bai<sup>2</sup>, X. Qu<sup>2</sup>, <sup>1</sup>The first hospital of China medical university, Shenyang, CN, <sup>2</sup>the first hospital of china medical university, shenyang, CN
- 12:45 - 12:45 **41P - Risk prediction of metastasis through study of circulating tumor cells**  
P. Apostolou<sup>1</sup>, I. Papatirou<sup>2</sup>, <sup>1</sup>Research Genetic Cancer Centre Ltd, Filotas, GR, <sup>2</sup>Research Genetic Cancer Centre S.A., Florina, GR
- 12:45 - 12:45 **42P - First step to metastasis: miRNAome abnormalities impair cell-cell adhesion and facilitate detachment of breast cancer cells**  
V. Halytskiy, Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiev, UA
- 12:45 - 12:45 **43P - Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment**  
A. Tsidulko<sup>1</sup>, C. Bezier<sup>2</sup>, G. De La Bourdonnaye<sup>3</sup>, A. Suhovskih<sup>4</sup>, G. Kazanskaya<sup>5</sup>, S. Aidagulova<sup>6</sup>, E. Grigorieva<sup>1</sup>, <sup>1</sup>Institute of Molecular Biology and Biophysics SB RAMS, Novosibirsk, RU, <sup>2</sup>Pierre et Marie Curie University, Paris, FR, <sup>3</sup>National Institute for Applied Sciences, Toulouse, FR, <sup>4</sup>Novosibirsk State University, Novosibirsk, RU, <sup>5</sup>Meshalkin National Medical Research Center, Novosibirsk, RU, <sup>6</sup>Novosibirsk State Medical University, Novosibirsk, RU
- 12:45 - 12:45 **44P - Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro**  
D. Albert Bellver<sup>1</sup>, R. Gil-Benso<sup>2</sup>, A. Martínez<sup>3</sup>, T. San-Miguel<sup>2</sup>, L. Muñoz-Hidalgo<sup>2</sup>, A. Carratalá<sup>2</sup>, D. Gozalbo<sup>3</sup>, C. López-Ginés<sup>2</sup>, M. Cerdá-Nicolás<sup>2</sup>, M.L. Gil<sup>3</sup>, J. Megías<sup>2</sup>, <sup>1</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>2</sup>University of Valencia, Valencia, ES, <sup>3</sup>University of Valencia, Burjassot, ES
- 12:45 - 12:45 **45P - 5-Fluorouracil induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients**  
Z. Min<sup>1</sup>, F. Yibo<sup>2</sup>, C. Xiaofang<sup>2</sup>, H. Kezuo<sup>2</sup>, Q. Xiujuan<sup>2</sup>, <sup>1</sup>1st Affiliated Hospital of China Medical University, Shenyang, CN, <sup>2</sup>the First Hospital of China Medical University, Shenyang, CN
- 12:45 - 12:45 **46P - Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?**  
F. Kohutek<sup>1</sup>, B. Bystricky<sup>1</sup>, M. Kohutekova<sup>2</sup>, <sup>1</sup>Faculty Hospital TN, Trencin, SK, <sup>2</sup>Faculty Hospital Trencin, Trencin, SK
- 12:45 - 12:45 **47P - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)**  
S. Wanandi<sup>1</sup>, G. Wideani<sup>2</sup>, M. Zainuri<sup>2</sup>, R. Putri<sup>3</sup>, E. Bachtiar<sup>4</sup>, S. Jusman<sup>2</sup>, <sup>1</sup>Faculty of Medicine, Universitas Indonesia (FMUI), Jakarta, ID, <sup>2</sup>Faculty of Medicine, Universitas

Indonesia, Jakarta, ID, <sup>3</sup>National Institute of Health Research and Development, Ministry of Health, Indonesia, Jakarta, ID, <sup>4</sup>Faculty of Dentistry, Universitas Indonesia, Jakarta, ID

12:45 - 12:45 **48P - Estrogen-related receptor \_ as a potential molecular target for endometrial cancer therapy**

T. Kokabu, T. Mori, H. Matsushima, Y. Tarumi, K. Yoriki, H. Kuroboshi, M. Sawada, S. Umemura, J. Kitawaki, Kyoto Prefectural University of Medicine, Kyoto, JP

12:45 - 12:45 **49P - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies**

J. Gaudreault<sup>1</sup>, A. Schmidt<sup>1</sup>, P. Altevogt<sup>2</sup>, G. Spohn<sup>1</sup>, <sup>1</sup>Elthera AG, Schlieren, CH, <sup>2</sup>DKFZ, Heidelberg, DE

12:45 - 12:45 **Tumour biology and pathology**

12:45 - 12:45 **451P - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma**

A. Jouinot<sup>1</sup>, B. Royer<sup>2</sup>, S. Moeung<sup>3</sup>, E. Chatelut<sup>3</sup>, A. Bellesoeur<sup>1</sup>, G. Assié<sup>4</sup>, A. Thomas-Schoemann<sup>4</sup>, J. Bertherat<sup>4</sup>, F. Goldwasser<sup>1</sup>, B. Blanchet<sup>4</sup>, <sup>1</sup>Hôpital Cochin, Paris, FR, <sup>2</sup>CHU Besancon, Besancon, FR, <sup>3</sup>Université de Toulouse, INSERM, Centre de Recherches en Cancérologie de Toulouse, Toulouse, FR, <sup>4</sup>Cochin Hospital, Paris Descartes University, AP-HP, Paris, FR

12:45 - 12:45 **Gastrointestinal tumours, colorectal**

12:45 - 12:45 **463P - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study**

J.M. O'Connor<sup>1</sup>, M. Ducreux<sup>2</sup>, L.N. Petersen<sup>3</sup>, L. Öhler<sup>4</sup>, F. Bergamo<sup>5</sup>, J.-P. Metges<sup>6</sup>, J.W. De Groot<sup>7</sup>, J.-Y. Wang<sup>8</sup>, B. García Paredes<sup>9</sup>, E. Dochy<sup>10</sup>, S. Fiala-Buskies<sup>11</sup>, A. Cervantes<sup>12</sup>, A. Falcone<sup>13</sup>, <sup>1</sup>Institute Alexander Fleming, Buenos Aires, AR, <sup>2</sup>Gustave Roussy Cancer Campus Grand Paris, Villejuif, FR, <sup>3</sup>Rigshospitalet, Copenhagen, DK, <sup>4</sup>St. Josef Krankenhaus, Vienna, AT, <sup>5</sup>Veneto Institute of Oncology IOV - IRCCS, Padula, IT, <sup>6</sup>CHU de Brest - Hôpital Morvan, Brest, FR, <sup>7</sup>Isala, Zwolle, NL, <sup>8</sup>Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, TW, <sup>9</sup>Hospital Clínico San Carlos, Madrid, ES, <sup>10</sup>TBC, TBC, US, <sup>11</sup>Bayer AG, Wuppertal, DE, <sup>12</sup>University Hospital of Valencia, Valencia, ES, <sup>13</sup>University of Pisa, Pisa, IT

12:45 - 12:45 **464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study**

J. Taieb<sup>1</sup>, A. Falcone<sup>2</sup>, S. Lonardi<sup>3</sup>, T. Price<sup>4</sup>, J.-B. Bachet<sup>5</sup>, L. Wyrwicz<sup>6</sup>, F. Ciardiello<sup>7</sup>, M. Becquart<sup>8</sup>, N. Mounedji<sup>8</sup>, E. Van Cutsem<sup>9</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>University of Pisa, Pisa, IT, <sup>3</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>4</sup>Queen Elizabeth Hospital, Woodville, AU, <sup>5</sup>Groupe Hospitalier Pitié Salpêtrière, Paris, FR,



<sup>6</sup>Centrum Onkologii-Instytut im. M. Skłodowskiej Curie, Warszawa, PL, <sup>7</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>8</sup>Servier, Suresnes, FR, <sup>9</sup>University Hospitals Leuven, Leuven, BE

12:45 - 12:45

**465P - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study**

T. Kawakami<sup>1</sup>, K. Yamazaki<sup>1</sup>, E. Oki<sup>2</sup>, M. Shimokawa<sup>3</sup>, N. Takahashi<sup>4</sup>, M. Yokota<sup>5</sup>, S. Tokunaga<sup>6</sup>, T. Esaki<sup>7</sup>, M. Gamoh<sup>8</sup>, A. Maeda<sup>9</sup>, Y. Tsuji<sup>10</sup>, A. Sakai<sup>11</sup>, K. Hatanaka<sup>12</sup>, Y. Shimada<sup>13</sup>, M. Shiozawa<sup>14</sup>, Y. Komatsu<sup>15</sup>, H. Okuda<sup>16</sup>, M. Ohue<sup>17</sup>, Y. Maehara<sup>18</sup>, <sup>1</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>2</sup>Kyushu University Hospital, Fukuoka, JP, <sup>3</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>4</sup>Saitama Cancer Centr, Saitama, JP, <sup>5</sup>Kurashiki Central Hospital, Kurashiki, JP, <sup>6</sup>Osaka City General Hospital, Osaka, JP, <sup>7</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>8</sup>Osaki Citizen Hospital, Osaki, JP, <sup>9</sup>Ogaki Municipal Hospital, Ogaki, JP, <sup>10</sup>KKR Tonan Hospital, Sapporo, JP, <sup>11</sup>Hyogo cancer center, Akashi, JP, <sup>12</sup>Hakodate Municipal Hospital, Hakodate, JP, <sup>13</sup>Kochi Health Sciences Center, Kochi, JP, <sup>14</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>15</sup>Hokakido University Cancer Center, Sapporo, JP, <sup>16</sup>Keiyukai Sapporo Hospital, Sapporo, JP, <sup>17</sup>Osaka International Cancer Institute, Osaka, JP, <sup>18</sup>Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JP

12:45 - 12:45

**466P - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD**

T. Aparicio<sup>1</sup>, A. Darut Jouve<sup>2</sup>, F. Khemissa<sup>3</sup>, C. Montérymard<sup>4</sup>, P. Artru<sup>5</sup>, L. Cany<sup>6</sup>, O. Romano<sup>7</sup>, B. Valenza<sup>8</sup>, C. Le Foll<sup>9</sup>, C. Delbaldo<sup>10</sup>, C. Falandry<sup>11</sup>, M. Duluc<sup>12</sup>, Y. Rinaldi<sup>13</sup>, J.L. Legoux<sup>14</sup>, M. Ben Abdelghani<sup>15</sup>, E. Assenat<sup>16</sup>, M. Dhooge<sup>17</sup>, D. Smith<sup>18</sup>, G. Des Guetz<sup>1</sup>, C. Lepage<sup>19</sup>, <sup>1</sup>Hôpital Avicenne, Bobigny, FR, <sup>2</sup>Clinique Clement Drevon, Dijon, FR, <sup>3</sup>CH Perpignan, Hôpital Saint Jean, Perpignan, FR, <sup>4</sup>FFCD-, Dijon, FR, <sup>5</sup>Hôpital privé Jean Mermoz, Lyon, FR, <sup>6</sup>Polyclinique Francheville, PERIGUEUX, FR, <sup>7</sup>Hôpital Privé de la Louvière, Lille, FR, <sup>8</sup>CHI de Fréjus - Saint-Raphaël, Fréjus, FR, <sup>9</sup>CH Marne La Vallée - Jossigny, JOSSIGNY, FR, <sup>10</sup>Dr. Catherine Delbaldo, La Défense, FR, <sup>11</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>12</sup>CHU La Timone Adultes, Marseille, FR, <sup>13</sup>Hôpital Européen Marseille, MARSEILLE, FR, <sup>14</sup>C.H.R. Orleans - La Source, Orleans, FR, <sup>15</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>16</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>17</sup>Hôpital Cochin, PARIS, FR, <sup>18</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>19</sup>CHU Dijon, Dijon, FR

12:45 - 12:45

**467P - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer**

T. Masuishi<sup>1</sup>, T. Suzuki<sup>2</sup>, Y. Sukawa<sup>2</sup>, C. Imamura<sup>2</sup>, H. Satake<sup>3</sup>, Y. Kumekawa<sup>4</sup>, S. Funakoshi<sup>5</sup>, M. Kotaka<sup>6</sup>, Y. Horie<sup>7</sup>, S. Kawai<sup>8</sup>, H. Okuda<sup>9</sup>, T. Terazawa<sup>10</sup>, C. Kondoh<sup>11</sup>, K. Kato<sup>12</sup>, K. Yoshimura<sup>13</sup>, H. Ishikawa<sup>14</sup>, Y. Hamamoto<sup>2</sup>, N. Boku<sup>15</sup>, T. Kanai<sup>2</sup>, H. Takaishi<sup>2</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>Keio University School of Medicine, Tokyo, JP, <sup>3</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>4</sup>Saitama cancer Center, Saitama, JP, <sup>5</sup>Tokyo Saiseikai Central Hospital, Tokyo, JP, <sup>6</sup>Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, <sup>7</sup>St Marianna University School of Medicine, Kawasaki city, JP, <sup>8</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>9</sup>Keiyukai Sapporo Hospital, Sapporo, JP, <sup>10</sup>Osaka Medical College, Takatsuki, JP, <sup>11</sup>Toranomon Hospital, Tokyo, JP, <sup>12</sup>National Cancer Center Hospital, Tokyo, JP, <sup>13</sup>Kanazawa University, Kanazawa, JP, <sup>14</sup>Kyoto Prefectural

University of Medicine, Kyoto, JP, <sup>15</sup>St. Marianna University School of Medicine, Kawasaki, JP

- 12:45 - 12:45 **468P - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis**  
K. Kopeckova<sup>1</sup>, R. Chloupkova<sup>2</sup>, B. Melichar<sup>3</sup>, Z. Linke<sup>1</sup>, L. Petruzelka<sup>4</sup>, J. Finek<sup>5</sup>, O. Fiala<sup>5</sup>, J. Tomasek<sup>6</sup>, I. Kiss<sup>7</sup>, J. Prausova<sup>1</sup>, T. Buchler<sup>8</sup>, <sup>1</sup>Fakultni Nemocnice V Motole, Prague, CZ, <sup>2</sup>Masaryk University Brno, Brno, CZ, <sup>3</sup>University Hospital Olomouc, Olomouc, CZ, <sup>4</sup>General Faculty Hospital, VFN Charles University, Prague, CZ, <sup>5</sup>University Hospital Plzen, Plzen, CZ, <sup>6</sup>Faculty of Medicine, Brno, CZ, <sup>7</sup>Masaryk Memorial Cancer Institute, Brno, CZ, <sup>8</sup>Thomayer University Hospital, Prague, CZ
- 12:45 - 12:45 **469P - The Combination of TAS-102 and Bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)**  
H. Kamiyama<sup>1</sup>, Y. Yoshida<sup>2</sup>, H. Yoshida<sup>3</sup>, C. Kosugi<sup>4</sup>, K. Ishibashi<sup>5</sup>, K. Ihara<sup>6</sup>, M. Takahashi<sup>1</sup>, H. Kuramochi<sup>7</sup>, A. Fukazawa<sup>8</sup>, H. Sonoda<sup>9</sup>, K. Yoshimatsu<sup>10</sup>, A. Matsuda<sup>11</sup>, S. Yamaguchi<sup>6</sup>, H. Ishida<sup>12</sup>, S. Hasegawa<sup>2</sup>, T. Yamada<sup>13</sup>, K. Sakamoto<sup>14</sup>, K. Koda<sup>4</sup>, <sup>1</sup>Juntendo University Hospital, Tokyo, JP, <sup>2</sup>Fukuoka University School of Medicine, FUKUOKA, JP, <sup>3</sup>Nippon Medical School, Tokyo, JP, <sup>4</sup>Teikyo University Chiba Medical Center, Ichihara, JP, <sup>5</sup>Saitama Medical Center, Saitama Medical University, Saitama, JP, <sup>6</sup>Dokkyo Medical University, Tochigi, JP, <sup>7</sup>Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, JP, <sup>8</sup>Iwata City Hospital, Shizuoka, JP, <sup>9</sup>Kyoto First Red Cross Hospital (Kyoto Daiichi Sekijyuji Byoin), Kyoto, JP, <sup>10</sup>Tokyo Women's Medical University, Tokyo, JP, <sup>11</sup>Nippon Medical School Chiba Hokusoh Hospital, Inzai, JP, <sup>12</sup>Saitama Medical University, Saitama, JP, <sup>13</sup>Nippon Medical School Main Hospital, Tokyo, JP, <sup>14</sup>Juntendo University School of Medicine, Tokyo, JP
- 12:45 - 12:45 **470P - Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)**  
A. Calvo Ferrandiz<sup>1</sup>, L. Dahan<sup>2</sup>, A. Hollebecque<sup>3</sup>, G. Prager<sup>4</sup>, T. Andre<sup>5</sup>, G. Argiles Martinez<sup>6</sup>, R. Bordonaro<sup>7</sup>, A. Stein<sup>8</sup>, G. Tortora<sup>9</sup>, C. Leger<sup>10</sup>, N. Amellal<sup>11</sup>, J. Tabernero<sup>12</sup>, <sup>1</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>2</sup>CHU La Timone Enfants, Marseille, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>5</sup>Sorbonne Université et Hôpital Saint-Antoine, Paris, FR, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>Azienda Ospedaliera ARNAS Garibaldi, Catania, IT, <sup>8</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>9</sup>Fondazione Policlinico Universitario Gemelli -IRCCS Rome, Rome, IT, <sup>10</sup>Servier France, Suresnes, FR, <sup>11</sup>Servier, Suresnes, FR, <sup>12</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES
- 12:45 - 12:45 **471P - A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study**  
M. Suenaga<sup>1</sup>, T. Wakatsuki<sup>1</sup>, M. Ogura<sup>1</sup>, T. Ichimura<sup>1</sup>, E. Shinozaki<sup>1</sup>, I. Nakayama<sup>1</sup>, H. Osumi<sup>1</sup>, Y. Ota<sup>1</sup>, K. Chin<sup>1</sup>, T. Mashima<sup>2</sup>, H. Seimiya<sup>2</sup>, D. Takahari<sup>1</sup>, K. Yamaguchi<sup>1</sup>, <sup>1</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>2</sup>Cancer Chemotherapy Center of JFCR, Tokyo, JP

- 12:45 - 12:45 **472P - Sidedness of the Primary Tumor on the Effect of TAS-102 for Refractory metastatic colorectal cancer**  
S. Ueda<sup>1</sup>, Y. Tsuboguchi<sup>2</sup>, Y. Nakatani<sup>3</sup>, A. Tsuya<sup>2</sup>, S.-I. Nishina<sup>4</sup>, K. Akiyoshi<sup>2</sup>, S. Okazaki<sup>5</sup>, S. Tokunaga<sup>2</sup>, H. Daga<sup>2</sup>, <sup>1</sup>Kinki University School of Medicine Nara Hospital, Nara, JP, <sup>2</sup>Osaka City General Hospital, Osaka, JP, <sup>3</sup>Osaka City General Hospital, Osaka, JP, <sup>4</sup>Ako central hospital, Ako-city, JP, <sup>5</sup>Kyoto Medical Center, Kyoto, JP
- 12:45 - 12:45 **473P - Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib**  
F. De Man<sup>1</sup>, K. Husaarts<sup>2</sup>, M. De With<sup>2</sup>, E. Oomen-De Hoop<sup>2</sup>, H. Van Halteren<sup>3</sup>, N. Van Der Burg-De Graauw<sup>4</sup>, F. Eskens<sup>2</sup>, T. Van Gelder<sup>1</sup>, R. Van Leeuwen<sup>1</sup>, R. Mathijssen<sup>2</sup>, <sup>1</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>2</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>3</sup>Admiraal de Ruijter Hospital, Vlissingen, NL, <sup>4</sup>Bravis Hospital, Roosendaal, NL
- 12:45 - 12:45 **474P - A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.**  
T. Seufferlein<sup>1</sup>, L. Lausser<sup>2</sup>, A. Stein<sup>3</sup>, G. Prager<sup>4</sup>, S. Kasper<sup>5</sup>, M. Niedermeier<sup>6</sup>, L. Müller<sup>7</sup>, S. Kubicka<sup>8</sup>, A.-O. König<sup>9</sup>, P. Büchner-Steudel<sup>10</sup>, K. Wille<sup>11</sup>, L. Perkhofer<sup>1</sup>, A. Hann<sup>2</sup>, A. Berger<sup>12</sup>, D. Arnold<sup>13</sup>, H. Kestler<sup>2</sup>, T. Ettrich<sup>1</sup>, <sup>1</sup>Ulm Medical University, Ulm, DE, <sup>2</sup>Ulm University, Ulm, DE, <sup>3</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>4</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>5</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>6</sup>Private Practice - Dr. Michael Niedermeier, Memmingen, DE, <sup>7</sup>Onkologie UnterEms, Leer, DE, <sup>8</sup>Klinikum am Steinenberg Reutlingen, Reutlingen, DE, <sup>9</sup>Universitätsmedizin Göttingen, Göttingen, DE, <sup>10</sup>Martin-Luther-University Halle-Wittenberg, Halle, DE, <sup>11</sup>University Hospital Ruhr-University-Bochum, Minden, DE, <sup>12</sup>Martin Luther Universität Halle-Wittenberg, Halle, DE, <sup>13</sup>Asklepios Klinik Altona, Hamburg, DE
- 12:45 - 12:45 **475P - Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer**  
M. Nakamura<sup>1</sup>, A. Takashima<sup>2</sup>, T. Denda<sup>3</sup>, M. Gamoh<sup>4</sup>, I. Iwanaga<sup>5</sup>, Y. Komatsu<sup>6</sup>, M. Takahashi<sup>7</sup>, H. Ohori<sup>4</sup>, T. Sekikawa<sup>8</sup>, M. Tsuda<sup>9</sup>, Y. Kobayashi<sup>10</sup>, Y. Miyamoto<sup>11</sup>, M. Kotake<sup>12</sup>, C. Ishioka<sup>7</sup>, K. Shimada<sup>13</sup>, A. Sato<sup>14</sup>, S. Yuki<sup>6</sup>, S. Morita<sup>15</sup>, S. Takahashi<sup>16</sup>, T. Yamaguchi<sup>17</sup>, <sup>1</sup>Aizawa Hospital, Matsumoto, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>Chiba Cancer Center Hospital, Chiba, JP, <sup>4</sup>Osaki Citizen Hospital, Osaki, JP, <sup>5</sup>Kitami Red Cross Hospital, Kitami, JP, <sup>6</sup>Hokkaido University Hospital, Sapporo, JP, <sup>7</sup>Institute of Development, Aging Cancer, Tohoku University, Sendai, JP, <sup>8</sup>Showa University Fujigaoka Hospital, Kanagawa, JP, <sup>9</sup>Hyogo Cancer Center, Hyogo, JP, <sup>10</sup>Kushiro Rosai Hospital, Kushiro, JP, <sup>11</sup>Kumamoto University, Kumamoto, JP, <sup>12</sup>Kouseiren Takaoka Hospital, Toyama, JP, <sup>13</sup>Showa University Kouto-Toyosu Hospital, Tokyo, JP, <sup>14</sup>Hirosaki University Graduate School of Medicine, Aomori, JP, <sup>15</sup>Kyoto University Graduate School of Medicine, Kyoto, JP, <sup>16</sup>Tohoku University Hospital, Sendai, JP, <sup>17</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP



- 12:45 - 12:45 **476P - Aflibercept in combination with Irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients : a phase II multicentric study.**  
A. Lapeyre-Prost<sup>1</sup>, S. Pernot<sup>1</sup>, J. Sigrand<sup>2</sup>, F. Mary<sup>3</sup>, K. Le Malicot<sup>4</sup>, T. Aparicio<sup>3</sup>, L. Dahan<sup>5</sup>, F.-X. Caroli-Bosc<sup>6</sup>, T. Lecomte<sup>7</sup>, S. Racine Doat<sup>8</sup>, L. Marthey<sup>9</sup>, J. Desrame<sup>10</sup>, C. Lepage<sup>11</sup>, J. Taieb<sup>1</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>CHU La Timone, Marseille, FR, <sup>3</sup>Hôpital Avicenne, Bobigny, FR, <sup>4</sup>FFCD-, Dijon, FR, <sup>5</sup>CHU La Timone Enfants, Marseille, FR, <sup>6</sup>CHU Angers, Angers, FR, <sup>7</sup>CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, <sup>8</sup>Groupe Hospitalier Pitié Salpetriere, Paris, FR, <sup>9</sup>CHU de Bicêtre, Le Kremlin Bicetre, FR, <sup>10</sup>Hôpital privé Jean Mermoz, Lyon, FR, <sup>11</sup>CHU Dijon, Dijon, FR
- 12:45 - 12:45 **477P - Folfiri-Aflibercept vs Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.**  
A. Ottaiano<sup>1</sup>, M. Capozzi<sup>2</sup>, C. De Divitiis<sup>2</sup>, A. Cassata<sup>2</sup>, A. De Stefano<sup>2</sup>, S. Tafuto<sup>1</sup>, A. Avallone<sup>1</sup>, G. Nasti<sup>1</sup>, <sup>1</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>2</sup>Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", Naples, IT
- 12:45 - 12:45 **478P - In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?**  
E. Mata Velasco<sup>1</sup>, E. González-Flores<sup>2</sup>, I. Juez Martel<sup>3</sup>, V. Alonso<sup>4</sup>, P. Iranzo Gomez<sup>5</sup>, N. Martinez Lago<sup>6</sup>, C. Lopez<sup>7</sup>, J. Cabrera Romero<sup>8</sup>, M.J. Safont Aguilera<sup>9</sup>, A. Ruiz Casado<sup>10</sup>, M. Salgado Fernandez<sup>11</sup>, B. González Astorga<sup>12</sup>, P. Escudero<sup>5</sup>, F. Rivera Herrero<sup>13</sup>, C. Pericay Pijaume<sup>8</sup>, R. Vera<sup>1</sup>, <sup>1</sup>Complejo Hospitalario de Navarra, Pamplona, ES, <sup>2</sup>Hospital Universitario Virgen de las Nieves, Granada, ES, <sup>3</sup>Hospital Universitario de Fuenlabrada, Madrid, ES, <sup>4</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>5</sup>Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, <sup>6</sup>Hospital Universitario a Coruna, A Coruna, ES, <sup>7</sup>Marques de Valdecilla University Hospital, Santander, ES, <sup>8</sup>Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES, <sup>9</sup>Hospital General Universitario Valencia, Valencia, ES, <sup>10</sup>Hospital Puerta de Hierro, Majadahonda, ES, <sup>11</sup>Complejo Hospitalario De Ourense, Ourense, ES, <sup>12</sup>Hospital Universitario San Cecilio, Granada, ES, <sup>13</sup>Hospital Universitario Marques de Valdecilla, Santander, ES
- 12:45 - 12:45 **479P - A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer. The AIRS study**  
M. Honda<sup>1</sup>, C. Matsuda<sup>2</sup>, C. Tanaka<sup>3</sup>, K. Kondo<sup>4</sup>, T. Takahashi<sup>5</sup>, C. Kosugi<sup>6</sup>, Y. Tokunaga<sup>7</sup>, H. Takemoto<sup>8</sup>, H. Kim<sup>9</sup>, J. Sakamoto<sup>10</sup>, K. Oba<sup>11</sup>, H. Mishima<sup>12</sup>, <sup>1</sup>Fukushima Medical University, Fukushima, JP, <sup>2</sup>Osaka University, Osaka, JP, <sup>3</sup>Gifu Prefectural General Medical Center, Gifu, JP, <sup>4</sup>National Hospital Organization, Nagoya Medical Center, Nagoya, JP, <sup>5</sup>Gifu University Graduate School of Medicine, Gifu, JP, <sup>6</sup>Teikyo University Chiba Medical Center, Ichihara, JP, <sup>7</sup>Kyoto Japan Post Hospital, Kyoto, JP, <sup>8</sup>Kinki Central Hospital, Osaka, JP, <sup>9</sup>Rinku General Medical Center, Izumisano, JP, <sup>10</sup>Tokai Central Hospital, Kakamigahara, JP, <sup>11</sup>The University of Tokyo School of Public Health, Tokyo, JP, <sup>12</sup>Aichi Medical University, Nagakute, JP
- 12:45 - 12:45 **480P - The safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective**



**study**

T. Ogata<sup>1</sup>, H. Satake<sup>1</sup>, M. Ogata<sup>1</sup>, Y. Hatachi<sup>1</sup>, M. Hamada<sup>2</sup>, H. Yasui<sup>1</sup>, <sup>1</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>2</sup>Kansai Medical University Hospital, Hirakata, JP

12:45 - 12:45 **481P - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial**

H. Osawa<sup>1</sup>, E. Shinozaki<sup>2</sup>, M. Nakamura<sup>3</sup>, Y. Ohhara<sup>4</sup>, Y. Shindo<sup>5</sup>, M. Shiozawa<sup>6</sup>, H. Uetake<sup>7</sup>, H. Matsumoto<sup>8</sup>, N. Ureshino<sup>9</sup>, H. Satake<sup>10</sup>, T. Kobayashi<sup>11</sup>, T. Suto<sup>12</sup>, S. Kitano<sup>13</sup>, Y. Ohashi<sup>14</sup>, K. Uemura<sup>15</sup>, K. Yamaguchi<sup>2</sup>, <sup>1</sup>Edogawa Hospital, Tokyo, JP, <sup>2</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>3</sup>Aizawa Hospital, Matsumoto, JP, <sup>4</sup>Sapporo Medical Center, Sapporo, JP, <sup>5</sup>Nakadori General Hospital, Akita, JP, <sup>6</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>7</sup>Tokyo Medical and Dental University, Tokyo, JP, <sup>8</sup>Tokyo Metropolitan Komagome Hospital, Tokyo, JP, <sup>9</sup>Saga-Ken Medical Center Koseikan, Saga, JP, <sup>10</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>11</sup>Kyorin University Faculty of Medicine, Mitaka, JP, <sup>12</sup>Yamagata Prefectural Central Hospital, Yamagata, JP, <sup>13</sup>Osaka University, Osaka, JP, <sup>14</sup>Chuo University, Tokyo, JP, <sup>15</sup>The University of Tokyo, Tokyo, JP

12:45 - 12:45 **482P - RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer**

T. Rich<sup>1</sup>, K. Clifton<sup>2</sup>, A. Grothey<sup>3</sup>, A. Hendifar<sup>4</sup>, D. Henry<sup>5</sup>, Y. Kagawa<sup>6</sup>, Y. Nakamura<sup>7</sup>, W. Okamoto<sup>7</sup>, B. Tan<sup>8</sup>, G. Sherrill<sup>9</sup>, T. Yoshino<sup>7</sup>, V. Raymond<sup>1</sup>, Y. Shiotsu<sup>1</sup>, R. Lanman<sup>1</sup>, V. Morris<sup>2</sup>, <sup>1</sup>Guardant Health, Redwood City, US, <sup>2</sup>MD Anderson Cancer Center, Houston, US, <sup>3</sup>West Cancer Center, Germantown, US, <sup>4</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>5</sup>University of Pennsylvania, Philadelphia, US, <sup>6</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>7</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>8</sup>University of Washington, Saint Louis, US, <sup>9</sup>Cone Health Cancer Center, Greensboro, US

12:45 - 12:45 **483P - A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3**

Y. Sunakawa<sup>1</sup>, S. Stintzing<sup>2</sup>, S. Cao<sup>3</sup>, J. Luecke<sup>4</sup>, D. Thompson<sup>4</sup>, M. Moran<sup>5</sup>, S. Astrow<sup>6</sup>, J. Hsiang<sup>5</sup>, C. Stephens<sup>5</sup>, W. Zhang<sup>3</sup>, A. Tsuji<sup>7</sup>, T. Takahashi<sup>8</sup>, T. Denda<sup>9</sup>, K. Shimada<sup>10</sup>, M. Kochi<sup>11</sup>, M. Takeuchi<sup>12</sup>, M. Fujii<sup>11</sup>, W. Ichikawa<sup>8</sup>, V. Heinemann<sup>2</sup>, H.-J. Lenz<sup>13</sup>, <sup>1</sup>St.Marianna University School of Medicine, Kanagawa, JP, <sup>2</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>3</sup>University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, US, <sup>4</sup>HTG Molecular Diagnostics Inc., Tucson, US, <sup>5</sup>Cancer Genetics, Inc., Los Angeles, US, <sup>6</sup>Kite, a Gilead Company, Santa Monica, US, <sup>7</sup>Kagawa University Hospital, Kagawa, JP, <sup>8</sup>Showa University Fujigaoka Hospital, Yokohama, JP, <sup>9</sup>Chiba Cancer Center Hospital, Chiba, JP, <sup>10</sup>Showa University Kouto-Toyosu Hospital, Tokyo, JP, <sup>11</sup>Nihon University School of Medicine, Tokyo, JP, <sup>12</sup>Kitasato University, Tokyo, JP, <sup>13</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US

12:45 - 12:45 **484P - Retrospective RAS Analysis of the EPIC Trial: Cetuximab Plus Irinotecan vs Irinotecan in Patients (pts) With Second-Line Metastatic Colorectal Cancer (mCRC)**

A. Sobrero<sup>1</sup>, H.-J. Lenz<sup>2</sup>, C. Eng<sup>3</sup>, W. Scheithauer<sup>4</sup>, G. Middleton<sup>5</sup>, W. Chen<sup>6</sup>, R. Esser<sup>7</sup>, J.

Nippgen<sup>8</sup>, H. Burris<sup>9</sup>, <sup>1</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>2</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>3</sup>M. D. Anderson Cancer Center, Houston, US, <sup>4</sup>Medical University of Vienna, Vienna, AT, <sup>5</sup>University of Birmingham, Birmingham, GB, <sup>6</sup>EMD Serono, Beijing, CN, <sup>7</sup>Merck KGaA, Darmstadt, DE, <sup>8</sup>Merck Germany, Darmstadt, DE, <sup>9</sup>Sarah Cannon Research Institute, Nashville, US

12:45 - 12:45

**485P - Withholding Anti-EGFR: Impact on Outcome of RAS wild-type metastatic Colorectal Tumors (WAIT OR ACT): a multicentric AGEO study**

L.-J. Palmieri<sup>1</sup>, L. Mineur<sup>2</sup>, D. Tougeron<sup>3</sup>, B. Rousseau<sup>4</sup>, V. Granger<sup>5</sup>, J.-M. Gornet<sup>6</sup>, D. Smith<sup>7</sup>, A. Lievre<sup>8</sup>, M.P. Galais<sup>9</sup>, S. Racine Doat<sup>10</sup>, S. Pernot<sup>11</sup>, A.L. Bignon Bretagne<sup>12</sup>, J.-P. Metges<sup>13</sup>, N. Baba-Hamed<sup>14</sup>, M. Hassine<sup>15</sup>, S. Obled<sup>16</sup>, C. Vitellius<sup>17</sup>, O. Bouche<sup>18</sup>, D. Vernerey<sup>19</sup>, R. Coriat<sup>1</sup>, <sup>1</sup>Hôpital Cochin, Paris, FR, <sup>2</sup>Institut Ste Catherine, Avignon, FR, <sup>3</sup>CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR, <sup>4</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>5</sup>Centre Hospitalier Universitaire Grenoble, Grenoble, FR, <sup>6</sup>Hôpital St. Louis, Paris, FR, <sup>7</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>8</sup>CHU de Pontchaillou, Rennes, FR, <sup>9</sup>Centre Francois Baclesse, Caen, FR, <sup>10</sup>Groupe Hospitalier Pitié Salpêtrière, Paris, FR, <sup>11</sup>Hopital European George Pompidou, Paris, FR, <sup>12</sup>CHU de Caen, Caen, FR, <sup>13</sup>C.H.U. Brest - Hôpital Morvan, Brest, FR, <sup>14</sup>Groupe Hospitalier Paris Saint-Joseph, PARIS, FR, <sup>15</sup>CHU de Rouen - Hôpital Charle Nicolle, Rouen, FR, <sup>16</sup>Centre Hospitalier Universitaire Nimes, Nimes, FR, <sup>17</sup>CHU Angers, Angers, FR, <sup>18</sup>CHU de Reims - Hôpital Robert Debré, Reims, FR, <sup>19</sup>CHU Besançon, Hôpital Jean Minjot, Besançon, FR

12:45 - 12:45

**486P - Prospective biomarker study in advanced RAS wild-type colorectal cancer. POSIBA trial.**

X. García Albéniz<sup>1</sup>, V. Alonso<sup>2</sup>, P. Escudero<sup>3</sup>, M. Méndez<sup>4</sup>, J. Gallego Plazas<sup>5</sup>, J.R. Rodriguez<sup>6</sup>, A. Salud Salvia<sup>7</sup>, J. Fernández-Plana<sup>8</sup>, H. Manzano Alemany<sup>9</sup>, M. Zanui<sup>10</sup>, E. Falcó<sup>11</sup>, J. Feliu Batlle<sup>12</sup>, M. Gil-Raga<sup>13</sup>, C. Fernández-Martos<sup>14</sup>, U. Bohn Sarmiento<sup>15</sup>, M.C. Alonso López<sup>16</sup>, V. Calderero Aragón<sup>17</sup>, F. Rojo<sup>18</sup>, M. Cuatrecasas<sup>19</sup>, J. Maurel<sup>20</sup>, <sup>1</sup>Harvard T.H. Chan School of Public Health, Boston, US, <sup>2</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>3</sup>Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, <sup>4</sup>Hospital de Móstoles, Móstoles, ES, <sup>5</sup>Hospital General Universitario de Elche, Elche, ES, <sup>6</sup>Hospital Infanta Cristina, Madrid, ES, <sup>7</sup>Hospital Arnau de Vilanova, Lleida, ES, <sup>8</sup>Hospital Mútua de Terrasa, Terrasa, Barcelona, ES, <sup>9</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>10</sup>Hospital de Mataró, Mataró, ES, <sup>11</sup>Hospital Son Llàtzer, Palma, ES, <sup>12</sup>Hospital Universitario La Paz, Madrid, ES, <sup>13</sup>Hospital de Sagunto, Sagunto, ES, <sup>14</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>15</sup>Hospital de Gran Canaria Dr. Negrin, Las Palmas, ES, <sup>16</sup>Complejo Hospitalario Universitario de Albacete, Albacete, ES, <sup>17</sup>Hospital de Barbastro, Barbastro, ES, <sup>18</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>19</sup>Hospital Clínic de Barcelona, Barcelona, ES, <sup>20</sup>Hospital Clínic of Barcelona, Barcelona, ES

12:45 - 12:45

**487P - Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC). A retrospective analysis of the randomized phase I/II Poseidon study.**

R. Laeufle<sup>1</sup>, D. Arnold<sup>2</sup>, S. Kopetz<sup>3</sup>, J. Straub<sup>4</sup>, R. Bruns<sup>4</sup>, G. Massimini<sup>4</sup>, R. Debenedetto<sup>5</sup>, R. Linke<sup>5</sup>, E. Elez Fernandez<sup>6</sup>, J. Tabernero<sup>7</sup>, <sup>1</sup>SFJ Pharmaceuticals, Pleasanton, US, <sup>2</sup>Asklepios Klinik Altona, Hamburg, DE, <sup>3</sup>MD Anderson Cancer Center,

Houston, US, <sup>4</sup>Merck KGaA, Darmstadt, DE, <sup>5</sup>SFJ-Pharmaceuticals, Inc., Pleasanton, US, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES

12:45 - 12:45

**488P - Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial.**

Y. Emi<sup>1</sup>, T. Yamanaka<sup>2</sup>, K. Muro<sup>3</sup>, H. Uetake<sup>4</sup>, E. Oki<sup>5</sup>, T. Takahashi<sup>6</sup>, Y. Katayose<sup>7</sup>, K. Yoshida<sup>8</sup>, M. Sakamoto<sup>9</sup>, S. Aishima<sup>10</sup>, K. Ishida<sup>11</sup>, J. Imura<sup>12</sup>, M. Unno<sup>13</sup>, I. Hyodo<sup>14</sup>, N. Tomita<sup>15</sup>, K. Sugihara<sup>4</sup>, Y. Maehara<sup>16</sup>, <sup>1</sup>Saiseikai Fukuoka General Hospital, FUKUOKA, JP, <sup>2</sup>Yokohama City University Hospital, Yokohama, JP, <sup>3</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>4</sup>Tokyo Medical and Dental University, Tokyo, JP, <sup>5</sup>Kyushu University Hospital, Fukuoka, JP, <sup>6</sup>Gifu University Graduate School of Medicine, Gifu, JP, <sup>7</sup>Tohoku Rosai Hospital, Sendai, JP, <sup>8</sup>Gifu University Hospital, Gifu, JP, <sup>9</sup>Keio University School of Medicine, Tokyo, JP, <sup>10</sup>Saga University, Saga, JP, <sup>11</sup>Iwate Medical University, Morioka, JP, <sup>12</sup>University of Toyama, Toyama, JP, <sup>13</sup>Tohoku University Hospital, Sendai, JP, <sup>14</sup>University of Tsukuba, Tsukuba, JP, <sup>15</sup>Hyogo College of Medicine, Nishinomiya, JP, <sup>16</sup>Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JP

12:45 - 12:45

**489P - Verification of guideline conform mCRC treatment with EGFR inhibitors with real-world evidence data from EU5 countries**

L. Hoyer, N. Schmidt, IMS Health GmbH & Co. OHG, Frankfurt am Main, DE

12:45 - 12:45

**491P - Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: a retrospective registry-based analysis**

T. Buchler<sup>1</sup>, O. Fiala<sup>2</sup>, V. Veskrnova<sup>3</sup>, R. Chloupkova<sup>4</sup>, A. Poprach<sup>5</sup>, I. Kiss<sup>5</sup>, K. Kopeckova<sup>6</sup>, L. Dusek<sup>4</sup>, L. Slavicek<sup>7</sup>, M. Kohoutek<sup>8</sup>, J. Finek<sup>2</sup>, M. Svoboda<sup>5</sup>, J. Dvorak<sup>1</sup>, L. Petruzelka<sup>9</sup>, B. Melichar<sup>10</sup>, <sup>1</sup>Thomayer University Hospital, Prague, CZ, <sup>2</sup>University Hospital Plzen, Plzen, CZ, <sup>3</sup>First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, CZ, <sup>4</sup>Masaryk University Brno, Brno, CZ, <sup>5</sup>Masaryk Memorial Cancer Institute, Brno, CZ, <sup>6</sup>Fakultni Nemocnice V Motole, Prague, CZ, <sup>7</sup>Hospital Jihlava, Jihlava, CZ, <sup>8</sup>Krajska Nemocnice T. Bati, a.s. (T. Batas Regional Hospital), Zlin, CZ, <sup>9</sup>General Faculty Hospital, VFN Charles University, Prague, CZ, <sup>10</sup>University Hospital Olomouc, Olomouc, CZ

12:45 - 12:45

**492P - A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial)**

Y. Nishioka<sup>1</sup>, K. Hasegawa<sup>2</sup>, A. Saiura<sup>3</sup>, M. Oba<sup>2</sup>, J. Yamamoto<sup>4</sup>, Y. Nomura<sup>5</sup>, T. Takayama<sup>6</sup>, Y. Hashiguchi<sup>7</sup>, M. Shibasaki<sup>8</sup>, H. Sakamoto<sup>9</sup>, S. Yamagata<sup>10</sup>, N. Aoyanagi<sup>11</sup>, H. Kaneko<sup>12</sup>, H. Koyama<sup>13</sup>, S. Miyagawa<sup>14</sup>, Y. Mise<sup>3</sup>, E. Shinozaki<sup>3</sup>, S. Yoshida<sup>2</sup>, H. Nozawa<sup>1</sup>, N. Kokudo<sup>1</sup>, <sup>1</sup>Tokyo University Hospital, Tokyo, JP, <sup>2</sup>The University of Tokyo Graduate School of Medicine, Tokyo, JP, <sup>3</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>4</sup>National Defence Medical College, Tokorozawa, JP, <sup>5</sup>Asahi General Hospital, Chiba, JP, <sup>6</sup>Nihon University School of Medicine, Itabashi-ku, JP, <sup>7</sup>Teikyo University School of Medicine, Tokyo, JP, <sup>8</sup>JCHO Tokyo Yamate Medical Center, Tokyo, JP, <sup>9</sup>Saitama Cancer



Center, Saitama, JP, <sup>10</sup>JCHO Tokyo Shinjuku Medical Center, Tokyo, JP, <sup>11</sup>Kohnodai Hospital, National Center for Global-Health and Medicine, Chiba, JP, <sup>12</sup>Toho University Faculty of Medicine, Tokyo, JP, <sup>13</sup>JCHO Tokyo Takanawa Hospital, Tokyo, JP, <sup>14</sup>Shinshu University, School of Medicine, Matsumoto, JP

12:45 - 12:45 **493P - Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer**

E. Oki<sup>1</sup>, H. Samura<sup>2</sup>, H. Okumura<sup>3</sup>, T. Ohchi<sup>4</sup>, H. Orita<sup>5</sup>, K. Kobayashi<sup>6</sup>, T. Kinjo<sup>7</sup>, S. Mori<sup>8</sup>, T. Touyama<sup>9</sup>, K. Ohgaki<sup>10</sup>, H. Kawanaka<sup>11</sup>, A. Makiyama<sup>12</sup>, N. Ureshino<sup>13</sup>, M. Kotaka<sup>14</sup>, T. Shimose<sup>15</sup>, H. Saeki<sup>16</sup>, T. Nishimaki<sup>7</sup>, H. Baba<sup>17</sup>, Y. Maehara<sup>18</sup>, <sup>1</sup>Kyushu University Hospital, FUKUOKA, JP, <sup>2</sup>Urazoe General Hospital, Okinawa, JP, <sup>3</sup>Kagoshima kouseiren hospital, Kagoshima, JP, <sup>4</sup>Social Insurance Tagawa Hospital, Kurume, JP, <sup>5</sup>NAKATSU MUNICIPAL HOSPITAL, Nakatsu, JP, <sup>6</sup>Nagasaki University Hospital, Nagasaki, JP, <sup>7</sup>Ryukyu University, Okinawa, JP, <sup>8</sup>Kagoshima University, Kagoshima, JP, <sup>9</sup>Nakagami Hospital, Okinawa, JP, <sup>10</sup>Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, FUKUOKA, JP, <sup>11</sup>National Beppu Medical Center, Beppu, JP, <sup>12</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>13</sup>Saga-Ken Medical Center Koseikan, Saga, JP, <sup>14</sup>Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, <sup>15</sup>Clinical Research Support Center Kyushu, Fukuoka, JP, <sup>16</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, <sup>17</sup>Kumamoto University, Kumamoto, JP, <sup>18</sup>Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JP

12:45 - 12:45 **494P - A multi-institutional randomized phase II study on the timing of Oxaliplatin plus 5-Fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR Study.**

P. Kavan<sup>1</sup>, I. Barrera<sup>2</sup>, L. Azoulay<sup>2</sup>, A.-G. Martin<sup>3</sup>, C. Vasilevsky<sup>2</sup>, M. Boutros<sup>2</sup>, E. Ferland<sup>4</sup>, G. Batist<sup>5</sup>, T. Vuong<sup>2</sup>, <sup>1</sup>Jewish General Hospital McGill University, Montreal, CA, <sup>2</sup>Jewish General Hospital, TE, CA, <sup>3</sup>CHU de Quebec Laval, Montreal, CA, <sup>4</sup>CHUM, Montreal, CA, <sup>5</sup>Jewish General Hospital, Montreal, CA

12:45 - 12:45 **495P - Tumor Regression Grading After Preoperative Hyperfractionated Radiotherapy/ Chemoradiotherapy for Locally Advanced Rectal Cancers: A Phase III Clinical Study**

A. Idasiak, K. Galwas-Kliber, K. Behrendt, I. Wziętek, M. Zeman, E. Stobiecka, E. Chmielik, T. Dworzecki, R. Suwiński, Maria Skłodowska Curie MSC Memorial Cancer Institute in Gliwice, Gliwice, PL

12:45 - 12:45 **496P - Short-Term radiotherapy plus chemotherapy versus Long-term chemoradiotherapy in Locally Advanced Rectal cancer (STELLAR): a planned interim analysis**

J. Jin<sup>1</sup>, Y. Tang<sup>2</sup>, S. Liu<sup>3</sup>, Y. Zhu<sup>4</sup>, W. Wang<sup>5</sup>, G. Li<sup>6</sup>, X. Wang<sup>7</sup>, J. Wang<sup>8</sup>, J. Yang<sup>9</sup>, S. Li<sup>10</sup>, N. Li<sup>10</sup>, W. Liu<sup>10</sup>, Y. Li<sup>10</sup>, Y. Chi<sup>2</sup>, A. Zhou<sup>11</sup>, J. Huang<sup>10</sup>, X. Wang<sup>10</sup>, L. Jiang<sup>10</sup>, J. Jiang<sup>10</sup>, S. Zou<sup>10</sup>, <sup>1</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, <sup>2</sup>Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN, <sup>3</sup>Jilin Provincial Cancer Hospital, Changchun, CN, <sup>4</sup>Zhejiang Provincial Cancer Hospital, Hangzhou, CN, <sup>5</sup>Guizhou Provincial Cancer Hospital, Guiyang, CN, <sup>6</sup>Beijing Hospital, Beijing, CN, <sup>7</sup>West China Hospital, Sichuan University,



Chengdu, CN, <sup>8</sup>Hebei Provincial Cancer Hospital, Shijiazhuang, CN, <sup>9</sup>Sichuan Provincial Cancer Hospital, Chengdu, CN, <sup>10</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CN, <sup>11</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

- 12:45 - 12:45 **497P - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Analysis from two prospective trials**  
J. Zhang, Y. Deng, Z. Wu, H. Hu, Y. Cai, J. Ling, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
- 12:45 - 12:45 **498P - Phase 1/2 study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3).**  
A. Budillon<sup>1</sup>, P. Delrio<sup>1</sup>, B. Pecori<sup>1</sup>, F. Tatangelo<sup>1</sup>, E. Di Gennaro<sup>1</sup>, C. Romano<sup>1</sup>, V. D'Angelo<sup>1</sup>, P. Marone<sup>1</sup>, C. Granata<sup>1</sup>, E. Cavalacanti<sup>1</sup>, A. De Stefano<sup>1</sup>, U. Pace<sup>1</sup>, F. Bianco<sup>1</sup>, A. Petrillo<sup>2</sup>, S. Lastoria<sup>2</sup>, G. Botti<sup>1</sup>, P. Muto<sup>1</sup>, F. Perrone<sup>1</sup>, M.C. Piccirillo<sup>1</sup>, A. Avallone<sup>1</sup>, <sup>1</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>2</sup>Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", Naples, IT
- 12:45 - 12:45 **499P - A classifier of 53BP1, immune score and texture analysis of MRI images can predict pathological response to chemoradiotherapy in locally advanced rectal cancer**  
H. Ma<sup>1</sup>, J. Yao<sup>1</sup>, A. Huang<sup>2</sup>, Y. Xiao<sup>1</sup>, L. Fan<sup>1</sup>, <sup>1</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>2</sup>Cancer Center Union Hospital, Wuhan, CN
- 12:45 - 12:45 **500P - Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy**  
A. Cercek<sup>1</sup>, G. Dos Santos Fernandes<sup>2</sup>, C. Roxburgh<sup>3</sup>, S. Ng<sup>4</sup>, R. Yaeger<sup>4</sup>, N. Segal<sup>4</sup>, K. Ganesh<sup>5</sup>, D. Reidy<sup>6</sup>, J.J. Smith<sup>4</sup>, G. Nash<sup>4</sup>, J. Guillem<sup>4</sup>, P. Paty<sup>4</sup>, J. Shia<sup>2</sup>, J. Garcia-Aguilar<sup>4</sup>, L. Diaz<sup>7</sup>, C. Crane<sup>1</sup>, K. Goodman<sup>3</sup>, L. Saltz<sup>1</sup>, M. Weiser<sup>4</sup>, Z. Stadler<sup>2</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>3</sup>MSKCC, New York, US, <sup>4</sup>MSKCC, New York, US, <sup>5</sup>MSK, New York, US, <sup>6</sup>MSKCC, New York, US, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York City, US
- 12:45 - 12:45 **501P - Outcomes of Chemoradiotherapy plus Local Excision in Patients with Clinical T1 or T2, N0 Rectal Cancer**  
T. Suzuki<sup>1</sup>, S. Sadahiro<sup>2</sup>, T. Ogimi<sup>1</sup>, H. Miyakita<sup>2</sup>, G. Saito<sup>1</sup>, K. Okada<sup>2</sup>, A. Tanaka<sup>2</sup>, <sup>1</sup>Tokai University School of Medicine Isehara Campus, Isehara, JP, <sup>2</sup>Tokai University School of Medicine, Isehara, JP
- 12:45 - 12:45 **502P - Comparison of Immune Microenvironment between Different Neoadjuvant Radiotherapy Regimens for Rectal Cancer**  
J. Wu<sup>1</sup>, Q. Peng<sup>2</sup>, J. Li<sup>1</sup>, L. Tang<sup>2</sup>, Y. Huang<sup>2</sup>, X. Zhang<sup>3</sup>, <sup>1</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>2</sup>Fujian Medical University Cancer Hospital, Fuzhou, Fujian, CN, <sup>3</sup>Fujian Medical University Cancer Hospital, Fuzhou, CN

- 12:45 - 12:45 **503P - Prognostic factors of chemo-radiotherapy efficacy in patients with locally-advanced rectal cancer**  
M. Fedyanin<sup>1</sup>, A. Tryakin<sup>2</sup>, I. Pokataev<sup>1</sup>, A. Bulanov<sup>3</sup>, O. Sekhina<sup>1</sup>, D. Chekini<sup>1</sup>, S. Gordeev<sup>4</sup>, V. Aliev<sup>4</sup>, D. Kuzmichev<sup>4</sup>, Z. Mamedli<sup>4</sup>, Y. Barsukov<sup>4</sup>, V. Glebovskaya<sup>4</sup>, S. Tkachev<sup>4</sup>, M. Chernykh<sup>4</sup>, N. Kozlov<sup>4</sup>, S. Tjulandin<sup>2</sup>, <sup>1</sup>N. N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>2</sup>N.N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>3</sup>No place of work provided Iran, Teheran, IR, <sup>4</sup>Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» of the Ministry of Health of the Russian Federation., Moscow, RU
- 12:45 - 12:45 **504P - Association of Systemic and Local Inflammation with Prognosis in Rectal Cancer Treated with Neoadjuvant Radiotherapy**  
J. Li<sup>1</sup>, X. Zhang<sup>2</sup>, Y. Huang<sup>3</sup>, L. Tang<sup>3</sup>, Q. Peng<sup>3</sup>, J. Wu<sup>3</sup>, <sup>1</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>2</sup>Fujian Medical University Cancer Hospital, Fuzhou, CN, <sup>3</sup>Fujian Medical University Cancer Hospital, Fuzhou , Fujian, CN
- 12:45 - 12:45 **505P - Early prediction of histopathological response by PET/CT after two weeks of neoadjuvant chemoradiotherapy for rectal cancer: Wishful thinking or reality?**  
Y. Kundel<sup>1</sup>, G. Natalia<sup>2</sup>, H. Berenshtain<sup>2</sup>, J. Prus<sup>3</sup>, B. Brenner<sup>3</sup>, <sup>1</sup>Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, <sup>2</sup>Rabin Medical Center Beilinson Campus, Petah Tikva, IL, <sup>3</sup>Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tiqva, IL
- 12:45 - 12:45 **506P - Association between obesity and efficacy of chemoradiotherapy in rectal cancer patients**  
C. Diaz Romero<sup>1</sup>, R. Calderillo<sup>2</sup>, M. Herrera-Martínez<sup>3</sup>, R. Erika<sup>1</sup>, J.M. Flores Castro<sup>1</sup>, <sup>1</sup>Instituto Nacional de Cancerologia - Mexico, Ciudad de México, MX, <sup>2</sup>Instituto Nacional de Cancerologia - Mexico, MEXICO, MX, <sup>3</sup>Instituto Nacional de Cancerologia-Mexico, Mexico City, MX
- 12:45 - 12:45 **507P - Treatment Outcomes of Patients with Localized Anal Squamous Cell Carcinoma and HIV Infection: Systematic Review and Meta-Analysis**  
M. Camandaroba<sup>1</sup>, R. Riechelmann<sup>1</sup>, V. Silva<sup>1</sup>, C. Mello<sup>1</sup>, R. Araujo<sup>2</sup>, <sup>1</sup>A. C. Camargo Cancer Center, Sao Paulo, BR, <sup>2</sup>Hospital do Cancer de Barretos, -, BR
- 12:45 - 12:45 **508P - p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal - A single center retrospective analysis in Japan**  
R. Takahashi, T. Wakatsuki, N. Yamamoto, S. Taguchi, E. Shinozaki, H. Osumi, M. Ogura, T. Ichimura, D. Takahari, M. Suenaga, K. Chin, M. Oguchi, M. Ueno, K. Yamaguchi, Cancer Institute Hospital of JFCR, Tokyo, JP
- 12:45 - 12:45 **509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis**  
D. Modest<sup>1</sup>, V. Heinemann<sup>1</sup>, G. Folprecht<sup>2</sup>, T. Denecke<sup>3</sup>, J. Pratschke<sup>3</sup>, H. Lang<sup>4</sup>, M. Bemelmans<sup>5</sup>, T. Becker<sup>6</sup>, M. Rentsch<sup>7</sup>, D. Seehofer<sup>8</sup>, C. Bruns<sup>9</sup>, B. Gebauer<sup>3</sup>, S. Held<sup>10</sup>, U. Neumann<sup>11</sup>, I. Ricard<sup>12</sup>, <sup>1</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>2</sup>Universitätsklinikum Dresden, Dresden, DE, <sup>3</sup>Charite, Berlin, DE, <sup>4</sup>Uniklinik Mainz,

Mainz, DE, <sup>5</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>6</sup>Uniklinikum Schleswig-Holstein, Kiel, DE, <sup>7</sup>LMU Großhadern, München, DE, <sup>8</sup>Uniklinik Leipzig, Leipzig, DE, <sup>9</sup>Uniklinik Köln, Köln, DE, <sup>10</sup>Clinassess, Leverkusen, DE, <sup>11</sup>Universitätsklinikum Aachen (UKA), Aachen, DE, <sup>12</sup>IBE München, München, DE

- 12:45 - 12:45 **510P - Targeted therapies in conversion therapy in mCRC: A systematic review and meta-analysis**  
B. Xing<sup>1</sup>, B. Cui<sup>2</sup>, Z. Gu<sup>3</sup>, H. Peng<sup>4</sup>, <sup>1</sup>3rd Xiangya Hospital of Central South University, Changsha, CN, <sup>2</sup>3rd Affiliated Hospital of Harbin Medical University, Harbin, CN, <sup>3</sup>Merck Serono Co. Ltd, Darmstadt, DE, <sup>4</sup>Peking University Cancer Hospital, Beijing, CN
- 12:45 - 12:45 **511P - Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): a post hoc analysis of the WJOG4407G phase III study**  
A. Hosokawa<sup>1</sup>, K. Yamazaki<sup>2</sup>, C. Matsuda<sup>3</sup>, S. Ueda<sup>4</sup>, H. Fujii<sup>5</sup>, E. Baba<sup>6</sup>, S. Okamura<sup>7</sup>, M. Tsuda<sup>8</sup>, T. Tamura<sup>9</sup>, K. Shinozaki<sup>10</sup>, T. Tsushima<sup>2</sup>, T. Tsuda<sup>11</sup>, T. Shirakawa<sup>12</sup>, H. Yamashita<sup>13</sup>, S. Morita<sup>14</sup>, K. Muro<sup>15</sup>, <sup>1</sup>University of Miyazaki, Miyazaki, JP, <sup>2</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>3</sup>Osaka General Medical Center, Osaka, JP, <sup>4</sup>Kindai University Nara Hospital, Nara, JP, <sup>5</sup>Jichi Medical University, Shimotsuke, JP, <sup>6</sup>Kyushu University Hospital, Fukuoka, JP, <sup>7</sup>Suita Municipal Hospital, Suita, JP, <sup>8</sup>Hyogo Cancer Center, Hyogo, JP, <sup>9</sup>Kindai University Faculty of Medicine, Osakasayama, JP, <sup>10</sup>Hiroshima Prefectural Hospital, Hiroshima, JP, <sup>11</sup>St Marianna University School of Medicine, Kawasaki, JP, <sup>12</sup>Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JP, <sup>13</sup>National Hospital Organization Okayama Medical Center, Okayama, JP, <sup>14</sup>Kyoto University Graduate School of Medicine, Kyoto, JP, <sup>15</sup>Aichi Cancer Center Hospital, Nagoya, JP
- 12:45 - 12:45 **512P - KRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients**  
M. Domenech Viñolas<sup>1</sup>, C. Santos<sup>2</sup>, J. Pérez<sup>3</sup>, M. Varela<sup>4</sup>, M. Martinez Villacampa<sup>2</sup>, A. Teule<sup>5</sup>, J. Ruffinelli Rodriguez<sup>1</sup>, N. Mulet Margalef<sup>1</sup>, G. Soler<sup>2</sup>, A. Ortega<sup>3</sup>, M. Bergamino<sup>6</sup>, X. Sanjuan<sup>4</sup>, J. Torras<sup>4</sup>, E. Ramos<sup>4</sup>, R. Salazar<sup>1</sup>, <sup>1</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>2</sup>Institut Catala de Oncologia, Barcelona, ES, <sup>3</sup>Catalan Institute of Oncology, Hospitalet de Llobregat, ES, <sup>4</sup>Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, <sup>5</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>6</sup>Institut Catala d'Oncologia (ICO), Barcelona, ES
- 12:45 - 12:45 **513P - Impact of response to preoperative chemotherapy on the outcome of pulmonary metastasectomy for colorectal cancer: Results of a retrospective multicenter study**  
T. Okumura<sup>1</sup>, N. Boku<sup>2</sup>, T. Hishida<sup>3</sup>, Y. Ohde<sup>4</sup>, Y. Sakao<sup>5</sup>, K. Yoshiya<sup>6</sup>, M. Higashiyama<sup>7</sup>, K. Kameyama<sup>8</sup>, H. Adachi<sup>9</sup>, K. Shiomi<sup>10</sup>, M. Kanzaki<sup>11</sup>, M. Yoshimura<sup>12</sup>, M. Matsuura<sup>13</sup>, Y. Hata<sup>14</sup>, F. Chen<sup>15</sup>, K. Yoshida<sup>16</sup>, H. Sasaki<sup>17</sup>, I. Hyodo<sup>18</sup>, K. Mori<sup>19</sup>, H. Kondo<sup>20</sup>, <sup>1</sup>Teikyo University School Of Medicine, University Hospital Mizonokuchi, Kawasaki, JP, <sup>2</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>3</sup>Keio University, Tokyo, JP, <sup>4</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>5</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>6</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>7</sup>Osaka International Cancer, Osaka, JP, <sup>8</sup>Kurashiki Central Hospital, Okayama, JP, <sup>9</sup>Hokkaido Cancer Center, Hokkaido, JP, <sup>10</sup>Kitasato University School of Medicine, Kanagawa, JP, <sup>11</sup>Tokyo Women's Medical



University, Tokyo, JP, <sup>12</sup>Hyogo Cancer Center, Hyogo, JP, <sup>13</sup>Hiroshima City Hospital, Hiroshima, JP, <sup>14</sup>Toho University School of Medicine, Tokyo, JP, <sup>15</sup>Kyoto University Graduate School of Medicine, Kyoto, JP, <sup>16</sup>Shinshu University School of Medicine, Nagano, JP, <sup>17</sup>Nagoya City University Graduate School of Medical Sciences, Nagoya, JP, <sup>18</sup>University of Tsukuba, Tsukuba, JP, <sup>19</sup>Shizuoka Cancer Center Hospital, Nagaizumi, JP, <sup>20</sup>Kyorin University, Tokyo, JP

12:45 - 12:45 **514P - Long-term Outcomes with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Carcinomatosis: 10-Year Experience in a Developing Country**

F. Arias<sup>1</sup>, E. Londoño-Schimmer<sup>1</sup>, J. Otero<sup>1</sup>, C.E. Cétares<sup>1</sup>, G.E. Herrera<sup>1</sup>, M. Mora<sup>1</sup>, P. Rodriguez<sup>1</sup>, M. Mejía<sup>1</sup>, J.D. Guerra<sup>2</sup>, A. Ruiz-Patiño<sup>3</sup>, A. Cardona Zorrilla<sup>4</sup>, <sup>1</sup>Fundacion Santa Fe de Bogota, Bogota, CO, <sup>2</sup>Universidad de los Andes, Bogota, CO, <sup>3</sup>Hospital Universitario San Ignacio-Pontificia Universidad Javeriana, Bogotá, CO, <sup>4</sup>Fundacion Sta Fe de Bogota Instituto de Oncologia, Bogotá, CO

12:45 - 12:45 **515P - Clinical impact of 18F-FDG-PET/CT (PET) in patients (P) with oligometastatic disease (OMD) at a skin and gastrointestinal tumour section.**

J.I. Garcia-Mosquera<sup>1</sup>, L. Layos Romero<sup>1</sup>, C. Buges<sup>1</sup>, S. España Fernandez<sup>1</sup>, S. Chen<sup>1</sup>, J.M. Velarde<sup>1</sup>, E. Felip<sup>2</sup>, C. Erasun Lecuona<sup>3</sup>, L. Angelats<sup>1</sup>, M. Cucurull Salamero<sup>1</sup>, J.L. Manzano<sup>1</sup>, <sup>1</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>2</sup>Germans Trias i Pujol Hospital, Catalan Institute of Oncology (ICO)-Badalona, Badalona, ES, <sup>3</sup>Institut Catala de Oncologia, Barcelona, ES

12:45 - 12:45 **516P - Simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis**

Y. Xu, Fudan University Shanghai Cancer Center, Shanghai, CN

12:45 - 12:45 **517P - Clinical factors are unable to accurately predict the absence of benefit of surgery in patients operated for resection of colorectal liver metastasis**

A. Bohlok<sup>1</sup>, H. Tessely<sup>2</sup>, E. Naets<sup>2</sup>, F. Bouazza<sup>1</sup>, D. Germanova<sup>3</sup>, J.L. Van Laethem<sup>3</sup>, A. Hendlisz<sup>4</sup>, V. Lucidi<sup>3</sup>, V. Donckier<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Institut Jules Bordet, Bruxelles, BE, <sup>3</sup>Erasmus University Hospital ULB, Brussels, BE, <sup>4</sup>Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BE

12:45 - 12:45 **518P - Hepatic arterial infusion (HAI) of oxaliplatin with capecitabine in first line treatment of patients (pts) with liver limited metastases from colorectal cancer (LLmCRC).**

B. Vittrup<sup>1</sup>, H. Nørgaard<sup>1</sup>, M. Bergenfeldt<sup>2</sup>, F.O. Larsen<sup>3</sup>, E. Høgdall<sup>4</sup>, J. Johansen<sup>3</sup>, J. Sidenius Johansen<sup>3</sup>, H. Hermann<sup>5</sup>, D. Nielsen<sup>3</sup>, <sup>1</sup>Herlev Hospital, Herlev, DK, <sup>2</sup>Herlev Hospital and Skåne Hospital, Herlev, DK, <sup>3</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>4</sup>Herlev Hospital, Copenhagen, DK, <sup>5</sup>Herlev anf Gentofte Hospital, Herlev, DK

12:45 - 12:45 **519P - Microsatellite instability is associated with distinct clinical and molecular characteristics in early colon cancer: Analysis of a molecular registry of the AIO colorectal study group - Colopredict Plus**

A. Reinacher-Schick<sup>1</sup>, H. Juetten<sup>2</sup>, S. Noepel-Duenebacke<sup>3</sup>, D. Arnold<sup>4</sup>, N. Basara<sup>5</sup>, H.



Boehner<sup>6</sup>, T. Dahm<sup>7</sup>, I. Feder<sup>2</sup>, T. Herzog<sup>7</sup>, W. Hiller<sup>8</sup>, L. Mueller<sup>9</sup>, L. Engel<sup>10</sup>, M. Senkal<sup>11</sup>, C. Teschendorf<sup>6</sup>, G. Trenn<sup>12</sup>, B. Verdoodt<sup>2</sup>, H. Wolters<sup>13</sup>, W. Uhl<sup>7</sup>, A. Tannapfel<sup>2</sup>, <sup>1</sup>Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE, <sup>2</sup>Ruhr-Universität Bochum, Bochum, DE, <sup>3</sup>St. Josef-Hospital Bochum, Bochum, DE, <sup>4</sup>Asklepios Klinik Altona, Hamburg, DE, <sup>5</sup>St. Franziskus Hospital Malteserkrankenhaus, Flensburg, DE, <sup>6</sup>Katholisches Krankenhaus Dortmund West, Dortmund, DE, <sup>7</sup>Katholisches Klinikum Bochum - St. Josef-Hospital, Bochum, DE, <sup>8</sup>Klinikum Lippe GmbH, Detmold, DE, <sup>9</sup>Onkologische Schwerpunktpraxis Leer-Emden, Leer, DE, <sup>10</sup>Klinikum Nürnberg Nord, Nürnberg, DE, <sup>11</sup>Marien Hospital Witten, Witten, DE, <sup>12</sup>Knappschaftskrankenhaus Bottrop Medizinische Klinik, Bottrop, DE, <sup>13</sup>St.-Josefs-Hospital Dortmund-Hoerde, Dortmund, DE

12:45 - 12:45

**520P - Prognostic impact of MSI and 18qLOH in stage II colon cancer: A prospective biomarker study in the SACURA trial**

T. Ishikawa<sup>1</sup>, M. Ishiguro<sup>1</sup>, E. Nakatani<sup>2</sup>, H. Ueno<sup>3</sup>, H. Uetake<sup>1</sup>, K. Murotani<sup>4</sup>, S. Matsui<sup>5</sup>, N. Tomita<sup>6</sup>, Y. Shimada<sup>7</sup>, K. Takahashi<sup>8</sup>, K. Kotake<sup>9</sup>, M. Watanabe<sup>10</sup>, H. Mochizuki<sup>3</sup>, S. Teramukai<sup>11</sup>, K. Sugihara<sup>1</sup>, <sup>1</sup>Tokyo Medical and Dental University, Tokyo, JP, <sup>2</sup>Translational Research Informatics Center, Foundation for Biomedical Research and Innovation at Kobe, Kobe, JP, <sup>3</sup>National Defense Medical College, Saitama, JP, <sup>4</sup>ichi Medical University Hospital, Nagakute, JP, <sup>5</sup>Nagoya University, Aichi, JP, <sup>6</sup>Hyogo College of Medicine, Hyogo, JP, <sup>7</sup>Kochi Health Sciences Center, Kochi, JP, <sup>8</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, <sup>9</sup>Tochigi Cancer Center, Tochigi, JP, <sup>10</sup>Kitasato University School of Medicine, Kanagawa, JP, <sup>11</sup>Kyoto Prefectural University of Medicine, Kyoto, JP

12:45 - 12:45

**521P - miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: a retrospective analysis of the PETACC-8 trial.**

Y. Gaston Mathe<sup>1</sup>, S. Martin-Lannerée<sup>2</sup>, C. Vazart<sup>2</sup>, K. Fontaine<sup>2</sup>, C. Mulo<sup>3</sup>, A. Caumont<sup>4</sup>, F. Montestruc<sup>4</sup>, K. Le Malicot<sup>5</sup>, C. Lepage<sup>6</sup>, J. Taieb<sup>7</sup>, P. Laurent-Puig<sup>8</sup>, <sup>1</sup>YGM Consult SAS, Paris, FR, <sup>2</sup>IntegraGen, Evry, FR, <sup>3</sup>INSERM, Paris, FR, <sup>4</sup>eXYSTAT, Malakoff, FR, <sup>5</sup>FFCD-, Dijon, FR, <sup>6</sup>CHU Dijon, Dijon, FR, <sup>7</sup>Hopital European George Pompidou, Paris, FR, <sup>8</sup>Paris Descartes University, Paris, FR

12:45 - 12:45

**522P - Prognostic value of neutrophil-lymphocyte ratio in resected high risk colorectal cancer: an analysis of adjuvant TOSCA trial**

F. Petrelli<sup>1</sup>, G. Rosati<sup>2</sup>, M. Banzi<sup>3</sup>, M.G. Zampino<sup>4</sup>, N. Pella<sup>5</sup>, M. Di Bartolomeo<sup>6</sup>, E. Maiello<sup>7</sup>, P. Bidoli<sup>8</sup>, D. Ferrari<sup>9</sup>, L. Rimassa<sup>10</sup>, R. Labianca<sup>11</sup>, M. Scartozzi<sup>12</sup>, S. Lonardi<sup>13</sup>, S. De Placido<sup>14</sup>, A. Zaniboni<sup>15</sup>, A. Sobrero<sup>16</sup>, L. Frassinetti<sup>17</sup>, N. Silvestris<sup>18</sup>, D. Corsi<sup>19</sup>, F. Galli<sup>20</sup>, S. Barni<sup>21</sup>, <sup>1</sup>Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, IT, <sup>2</sup>ospedale San Carlo, Potenza, IT, <sup>3</sup>arcispedale santa maria nuova-IRCCS, reggio emilia, IT, <sup>4</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>5</sup>Azienda Ospedaliero Universitaria Santa Maria della Misericordia, udine, IT, <sup>6</sup>Fondazione IRCCS, Milan, IT, <sup>7</sup>Hospital Casa Sollievo della Sofferenza-IRCCS, san giovanni rotondo, IT, <sup>8</sup>San Gerardo dei Tintori Hospital, monza, IT, <sup>9</sup>azienda ospedaliera san paolo, milano, IT, <sup>10</sup>Humanitas Clinical and Research Center, Rozzano, IT, <sup>11</sup>Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, <sup>12</sup>University Hospital and University of Cagliari, cagliari, IT, <sup>13</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>14</sup>AOU Policlinico Federico II, Napoli, IT, <sup>15</sup>casa di cura poliambulanza, brescia, IT, <sup>16</sup>IRCCS Ospedale San Martino IST, Genoa, IT, <sup>17</sup>Istituto

Tumori della Romagna I.R.S.T., Meldola, IT, <sup>18</sup>Ospedale Oncologico "Giovanni Paolo II"-IRCCS, bari, IT, <sup>19</sup>Ospedale S.Giovanni Calibita FBF, roma, IT, <sup>20</sup>IRCCS laboratorio ricerche farmacologiche Mario Negri, milano, IT, <sup>21</sup>ASST Bergamo Ovest, treviglio, IT

- 12:45 - 12:45 **523P - Distribution of lymph node metastases can have an impact on survival benefit of oxaliplatin-containing chemotherapy in stage III colon cancer**  
Y. Chae<sup>1</sup>, J.G. Kim<sup>2</sup>, J.H. Baek<sup>3</sup>, S.J. Lee<sup>2</sup>, D.W. Baek<sup>2</sup>, B.W. Kang<sup>2</sup>, <sup>1</sup>Kyungpook National University Medical Center, Daegu, KR, <sup>2</sup>Kyungpook National University Hospital, Daegu, KR, <sup>3</sup>Ulsan University Hospital, Ulsan, KR
- 12:45 - 12:45 **524P - Implications of Thymidylate Synthase gene polymorphisms, KRAS and BRAF mutations in the survival of patients with colorectal cancer treated with adjuvant chemotherapy**  
A. Ntavatzikos, A. Spathis, P. Patapis, G. Peros, I. Panayiotides, I. Papadopoulos, A. Koumariou, Attikon University Hospital, Athens, GR
- 12:45 - 12:45 **525P\_PR - Profile of individuals who never undergo colorectal cancer screening**  
J. Viguier<sup>1</sup>, J.F. Morère<sup>2</sup>, S. Couraud<sup>3</sup>, M. Roupert<sup>4</sup>, C. Touboul<sup>5</sup>, C. Lhomel<sup>6</sup>, L. Greillier<sup>7</sup>, T. De La Motte Rouge<sup>8</sup>, F. Eisinger<sup>9</sup>, <sup>1</sup>Institut National du Cancer, Boulogne-Billancourt, FR, <sup>2</sup>Hôpital Paul Brousse, Villejuif, FR, <sup>3</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>4</sup>Hôpital Universitaire Pitié-Salpêtrière, Paris, FR, <sup>5</sup>Kantar Health, Paris, FR, <sup>6</sup>Products Roche - France, Neuilly-sur-Seine, FR, <sup>7</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>8</sup>Centre Eugene - Marquis, Rennes, FR, <sup>9</sup>Institute Paoli Calmettes, Marseille, FR
- 12:45 - 12:45 **526P - Results of the national organised colorectal cancer screening program with FIT in Paris**  
A. Pellat<sup>1</sup>, R. Coriat<sup>2</sup>, S. Chaussade<sup>2</sup>, <sup>1</sup>Hôpital Saint-Antoine, Paris, FR, <sup>2</sup>Hôpital Cochin, Paris, FR
- 12:45 - 12:45 **527P - Screening strategy of Lynch syndrome for Chinese colorectal cancer patients with MLH1-immunoloss**  
W. Wang<sup>1</sup>, L. Dong<sup>1</sup>, S. Zou<sup>2</sup>, N. Lu<sup>2</sup>, <sup>1</sup>Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>2</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CN
- 12:45 - 12:45 **528P - Early detection of colorectal cancer using breath biomarkers: Preliminary study**  
G. Woodfield<sup>1</sup>, I. Belluomo<sup>1</sup>, H. Panesar<sup>1</sup>, G.P. Lin<sup>1</sup>, P. Boshier<sup>1</sup>, A. Romano<sup>1</sup>, J. Martin<sup>2</sup>, C. Groves<sup>3</sup>, B. Saunders<sup>4</sup>, W. Atkin<sup>1</sup>, G. Hanna<sup>1</sup>, <sup>1</sup>Imperial College London, London, GB, <sup>2</sup>Imperial College Healthcare NHS Trust, London, GB, <sup>3</sup>St George's Healthcare NHS Trust, London, GB, <sup>4</sup>St Mark's Hospital, London, GB
- 12:45 - 12:45 **529P - Survival of stage IV colorectal cancer: interaction of cancer location, microsatellite instability and KRAS mutation.**  
J. Uhlig<sup>1</sup>, S. Stein<sup>1</sup>, J. Lacy<sup>2</sup>, C. Fuchs<sup>2</sup>, H. Kim<sup>3</sup>, <sup>1</sup>Yale School of Medicine, New Haven,

US, <sup>2</sup>Yale University, New Haven, US, <sup>3</sup>Yale School of Medicine - Interventional Radiology Yale Cancer Center, New Haven, US

12:45 - 12:45

**530P - Influence of primary tumour sidedness on survival after upfront primary tumour resection (PTR) in synchronous metastatic colon cancer (mCC)**

K. Van Rooijen<sup>1</sup>, S. Kurk<sup>2</sup>, D. Van Der Kruijssen<sup>1</sup>, S. Elias<sup>3</sup>, A. May<sup>1</sup>, A. Cats<sup>4</sup>, G.-J. Creemers<sup>5</sup>, F. Erdkamp<sup>6</sup>, O. Loosveld<sup>7</sup>, C. Rodenburg<sup>8</sup>, P. Tanis<sup>9</sup>, G. Vink<sup>10</sup>, J. De Wilt<sup>11</sup>, C. Punt<sup>12</sup>, M. Koopman<sup>1</sup>, <sup>1</sup>University Hospital Utrecht, Utrecht, NL, <sup>2</sup>University Medical Center Utrecht, Utrecht, NL, <sup>3</sup>Julius Center of Health Academy, Utrecht, NL, <sup>4</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>5</sup>Catharina Hospital Eindhoven, Eindhoven, NL, <sup>6</sup>Zuyderland Medical Center-Sittard-Geleen, Sittard, NL, <sup>7</sup>Amphia Ziekenhuis-location Molengracht, Breda, NL, <sup>8</sup>Meander Medical Center, Amersfoort, NL, <sup>9</sup>Academic Medical Center, Amsterdam, NL, <sup>10</sup>Netherlands Comprehensive Cancer Organisation, Utrecht, NL, <sup>11</sup>University Medical Center St Radboud, Nijmegen, NL, <sup>12</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL

12:45 - 12:45

**531P - The Clinical Features and Genomic Landscape of Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) in Patients with Colorectal Cancer**

M.-H. Chen<sup>1</sup>, S.-C. Chang<sup>2</sup>, P.-C. Lin<sup>3</sup>, S.-H. Yang<sup>1</sup>, C.-C. Lin<sup>1</sup>, Y.-T. Lan<sup>1</sup>, H.-H. Lin<sup>1</sup>, C.-H. Lin<sup>4</sup>, W.-Y. Liang<sup>1</sup>, W.-S. Chen<sup>1</sup>, J.-K. Jiang<sup>5</sup>, J.-K. Lin<sup>5</sup>, <sup>1</sup>Taipei Veterans General Hospital, Taipei, TW, <sup>2</sup>National Yang-Ming University, Taipei, TW, <sup>3</sup>University of Taipei, Taipei, TW, <sup>4</sup>National Health Research Institutes, Taipei, TW, <sup>5</sup>Department of Surgery, Taipei, TW

12:45 - 12:45

**532P - Identification of positively and negatively selected driver gene mutations associated with colorectal cancer with microsatellite instability**

V. Jonchere<sup>1</sup>, L. Marisa<sup>2</sup>, M. Greene<sup>3</sup>, A. Guilloux<sup>4</sup>, A. Collura<sup>1</sup>, A. De Reynies<sup>2</sup>, A. Duval<sup>5</sup>, <sup>1</sup>Hôpital Saint-Antoine, Paris, FR, <sup>2</sup>Ligue Nationale contre le cancer, Paris, FR, <sup>3</sup>INSERM, Paris, FR, <sup>4</sup>Evry University, Évry, FR, <sup>5</sup>INSERM UMR1102, Paris, FR

12:45 - 12:45

**533P - Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients**

T. Nagasaka<sup>1</sup>, A. Nyuya<sup>1</sup>, H. Tanioka<sup>2</sup>, Y. Katata<sup>2</sup>, M. Yokota<sup>3</sup>, F. Taniguchi<sup>4</sup>, T. Kawai<sup>1</sup>, Y. Mori<sup>1</sup>, K. Shigeyasu<sup>1</sup>, M. Okawaki<sup>2</sup>, M. Yamamura<sup>2</sup>, Y. Umeda<sup>1</sup>, A. Tsuruta<sup>2</sup>, T. Ueno<sup>2</sup>, Y. Yamaguchi<sup>2</sup>, <sup>1</sup>Okayama University Hospital, Okayama, JP, <sup>2</sup>Kawasaki Medical School Hospital, Kurashiki, JP, <sup>3</sup>Kurashiki Central Hospital, Kurashiki, JP, <sup>4</sup>Iwakuni Clinical Hospital, Iwakuni, JP

12:45 - 12:45

**534P - Patterns of Germline and Somatic Mutations in 16 Mismatch Repair associated genes analyzed with Next Generation Sequencing(NGS) in Colorectal Cancer with EMAST(+) and/or MSI-high**

S.-C. Chang<sup>1</sup>, P.-C. Lin<sup>2</sup>, C.-C. Lin<sup>1</sup>, J.-K. Lin<sup>3</sup>, Y.-T. Lan<sup>1</sup>, J.-K. Jiang<sup>3</sup>, S.-H. Yang<sup>1</sup>, C.-H. Lin<sup>4</sup>, W.-S. Chen<sup>1</sup>, <sup>1</sup>Taipei Veterans General Hospital, Taipei, TW, <sup>2</sup>University of Taipei, Taipei, TW, <sup>3</sup>Department of Surgery, Taipei, TW, <sup>4</sup>National Health Research Institutes, Taipei, TW

12:45 - 12:45



**535P - Lower Tumor Mutational Burden (TMB) and Hepatic Metastases May Predict for Lack of Response to PD-1 Blockade in MSI-H Metastatic Colorectal Cancer (MCRC)**

I. Amanam<sup>1</sup>, J. Chao<sup>1</sup>, D. Lim<sup>1</sup>, S. Rahmanuddin<sup>1</sup>, A. Schrock<sup>2</sup>, S. Ali<sup>2</sup>, C. Lau<sup>1</sup>, D. Chevalier<sup>1</sup>, E. Harris<sup>1</sup>, J. Saluja<sup>1</sup>, C. Wang<sup>1</sup>, M. Fakih<sup>1</sup>, <sup>1</sup>City of Hope, Duarte, US, <sup>2</sup>Foundation Medicine, Inc., Cambridge, US

12:45 - 12:45 **536P - Comparison of microsatellite status detections in colorectal carcinoma**

M. Chen<sup>1</sup>, L. Yu<sup>1</sup>, B. Liu<sup>2</sup>, X. Qian<sup>2</sup>, M. Yang<sup>1</sup>, <sup>1</sup>Nanjing Drum Tower Hospital Nanjing University - The Affiliated Hospital of Nanjing University Medical School, Nanjing, CN, <sup>2</sup>Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, CN

12:45 - 12:45 **537P - Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy**

R. Cohen<sup>1</sup>, E. Hain<sup>2</sup>, O. Buhard<sup>2</sup>, A. Guilloux<sup>3</sup>, A. Bardier<sup>4</sup>, R. Kaci<sup>5</sup>, P. Bertheau<sup>6</sup>, F. Renaud<sup>7</sup>, F. Bibeau<sup>8</sup>, J.-F. Fléjou<sup>9</sup>, T. André<sup>1</sup>, M. Svrcek<sup>9</sup>, A. Duval<sup>10</sup>, <sup>1</sup>Hôpital Saint-Antoine, Paris, FR, <sup>2</sup>Sorbonne Université, INSERM, Unité Mixte de Recherche Scientifique 938 and SIRIC CURAMUS, Paris, FR, <sup>3</sup>Evry University, Évry, FR, <sup>4</sup>AP-HP, hôpital Pitié Salpêtrière, Paris, FR, <sup>5</sup>AP-HP, hôpital Lariboisière, Paris, FR, <sup>6</sup>AP-HP, hôpital Saint-Louis, Paris, FR, <sup>7</sup>CHU Lille, Lille, FR, <sup>8</sup>CHU de Caen, Caen, FR, <sup>9</sup>Sorbonne Université, AP-HP, hôpital Saint-Antoine, Paris, FR, <sup>10</sup>INSERM UMR1102, Paris, FR

12:45 - 12:45 **538P - The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection**

S.-H. Cho<sup>1</sup>, H.-J. Shim<sup>1</sup>, J.E. Hwang<sup>1</sup>, W.-K. Bae<sup>1</sup>, I.J. Chung<sup>2</sup>, <sup>1</sup>Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, <sup>2</sup>Chonnam National University Hwasun Hospital, Hwasun, KR

12:45 - 12:45 **539P - Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor-infiltrating immune cell composition**

J. Berntsson<sup>1</sup>, J. Eberhard<sup>2</sup>, B. Nodin<sup>3</sup>, A. Larsson<sup>1</sup>, K. Jirstrom<sup>4</sup>, <sup>1</sup>Lund University-Institution of Clinical Sciences-Oncology and Pathology, Lund, SE, <sup>2</sup>Skane University Hospital, Lund, SE, <sup>3</sup>Clinical Sciences, Lund, SE, <sup>4</sup>Lund University, Lund, SE

12:45 - 12:45 **540P - Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: prognostic role evaluation and cut-off definition**

D. Basile<sup>1</sup>, S. Garattini<sup>2</sup>, G. Pelizzari<sup>3</sup>, F. Cortiula<sup>2</sup>, L. Gerratana<sup>4</sup>, M. Cattaneo<sup>5</sup>, C. Corvaja<sup>1</sup>, A. Parnofiello<sup>5</sup>, V. Andreotti<sup>5</sup>, E. Bertoli<sup>3</sup>, C. Lisanti<sup>3</sup>, D. Iacono<sup>3</sup>, M. Casagrande<sup>5</sup>, G. Cardellino<sup>6</sup>, G. Miolo<sup>7</sup>, N. Pella<sup>8</sup>, G. Aprile<sup>9</sup>, A. Buonadonna<sup>1</sup>, G. Fasola<sup>3</sup>, F. Puglisi<sup>1</sup>, <sup>1</sup>CRO di Aviano, Aviano, IT, <sup>2</sup>University of Udine, Udine, IT, <sup>3</sup>Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, <sup>4</sup>AOU Santa Maria della Misericordia, Udine, IT, <sup>5</sup>ASUIUD Azienda Ospedaliero-Universitaria di Udine, Udine, IT, <sup>6</sup>Udine University and General Hospital, Udine, IT, <sup>7</sup>CRO National Cancer Institute, Aviano, IT, <sup>8</sup>Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Udine, IT, <sup>9</sup>ULSS 8 Berica - Vicenza, Vicenza, IT



- 12:45 - 12:45 **541P - Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis**  
H. Osumi<sup>1</sup>, E. Shinozaki<sup>1</sup>, H. Zembutsu<sup>2</sup>, Y. Takeda<sup>1</sup>, T. Wakatsuki<sup>1</sup>, T. Ichimura<sup>1</sup>, Y. Ota<sup>1</sup>, I. Nakayama<sup>1</sup>, M. Ogura<sup>1</sup>, M. Suenaga<sup>1</sup>, D. Takahari<sup>1</sup>, K. Chin<sup>1</sup>, A. Saiura<sup>1</sup>, S. Takahashi<sup>1</sup>, T. Noda<sup>2</sup>, K. Yamaguchi<sup>1</sup>, <sup>1</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>2</sup>Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, JP
- 12:45 - 12:45 **542P - Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer**  
E. Van Cutsem<sup>1</sup>, K. Lesniewski-Kmak<sup>2</sup>, M. Saunders<sup>3</sup>, H. Wasan<sup>4</sup>, G. Argiles<sup>5</sup>, C. Borg<sup>6</sup>, G.-J. Creemers<sup>7</sup>, M. Fedyanin<sup>8</sup>, R. Glynn-Jones<sup>9</sup>, P. Pfeiffer<sup>10</sup>, C. Punt<sup>11</sup>, D. Stroyakovskiy<sup>12</sup>, A. Ten Tije<sup>13</sup>, A. Van De Wouw<sup>14</sup>, V. Cattan<sup>15</sup>, G. Desachy<sup>16</sup>, N. Amellal<sup>15</sup>, V. Moiseyenko<sup>17</sup>, <sup>1</sup>University Hospitals Leuven, Leuven, BE, <sup>2</sup>Szpital Morski, Gdynia, PL, <sup>3</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>4</sup>Imperial College London - Hammersmith Hospital, London, GB, <sup>5</sup>Vall d'Hebron Institute of Oncology, VHIO, Barcelona, ES, <sup>6</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>7</sup>Catharina Hospital Eindhoven, Eindhoven, NL, <sup>8</sup>N. N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>9</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>10</sup>Odense University Hospital, Odense C, DK, <sup>11</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL, <sup>12</sup>Moscow City Oncology Hospital No. 62, Moscow, RU, <sup>13</sup>Amphia Ziekenhuis-location Molengracht, Breda, NL, <sup>14</sup>VieCuri MC, Venlo, NL, <sup>15</sup>Servier, Suresnes, FR, <sup>16</sup>Instut de recherches internationales Servier, Suresnes, FR, <sup>17</sup>Petrov Research Institute of Oncology, Saint Petersburg, RU
- 12:45 - 12:45 **543P - Gene mutation status in circulating tumor DNA (ctDNA) and 1st-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation**  
Y. Sunakawa<sup>1</sup>, J. Usher<sup>2</sup>, H. Satake<sup>3</sup>, Y. Jaimes<sup>2</sup>, Y. Miyamoto<sup>4</sup>, M. Nakamura<sup>5</sup>, M. Kataoka<sup>6</sup>, M. Shiozawa<sup>7</sup>, A. Takagane<sup>8</sup>, T. Terazawa<sup>9</sup>, T. Watanabe<sup>10</sup>, K. Ishigure<sup>11</sup>, C. Tanaka<sup>12</sup>, T. Sekikawa<sup>13</sup>, M. Takeuchi<sup>14</sup>, M. Fujii<sup>15</sup>, K. Danenberg<sup>2</sup>, P. Danenberg<sup>16</sup>, H.-J. Lenz<sup>17</sup>, W. Ichikawa<sup>18</sup>, <sup>1</sup>St.Marianna University School of Medicine, Kanagawa, JP, <sup>2</sup>Liquid Genomics, Inc., Culver City, US, <sup>3</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>4</sup>Kumamoto University, Kumamoto, JP, <sup>5</sup>Aizawa Hospital, Matsumoto, JP, <sup>6</sup>National Hospital Organization Nagoya Medical Center, Nagoya, JP, <sup>7</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>8</sup>Hakodate Goryoukaku Hospital, Hakodate, JP, <sup>9</sup>Osaka Medical College, Takatsuki, JP, <sup>10</sup>Himeji Red Cross Hospital, Himeji, JP, <sup>11</sup>Konan Kosei Hospital, Konan, JP, <sup>12</sup>3) Gifu Prefectural General Medical Center, Gifu, JP, <sup>13</sup>Showa University Fujigaoka Hospital, Kanagawa, JP, <sup>14</sup>Kitasato University, Tokyo, JP, <sup>15</sup>Nihon University School of Medicine, Tokyo, JP, <sup>16</sup>University of Southern California, Los Angeles, US, <sup>17</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>18</sup>Showa University Fujigaoka Hospital, Yokohama, JP
- 12:45 - 12:45 **544P - ctDNA assays identify alterations in RAS, EGFR, and cMET that are unique to RAS-WT patients progressing on anti-EGFR therapy**  
R. Gupta, D. Chevalier, J. Saluja, C. Lau, C. Wang, M. Fakih, City of Hope, Duarte, US
- 12:45 - 12:45 **545P - Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus**

**anti-EGFR therapy. Combined analysis of two prospective clinical trials**

C. Montagut<sup>1</sup>, V. Alonso<sup>2</sup>, P. Escudero<sup>3</sup>, C. Fernández-Martos<sup>4</sup>, A. Salud Salvia<sup>5</sup>, M. Méndez<sup>6</sup>, J. Gallego Plazas<sup>7</sup>, J.R. Rodriguez<sup>8</sup>, M. Martín-Richard<sup>9</sup>, J. Fernández-Plana<sup>10</sup>, J. Aparicio<sup>11</sup>, J. Feliu Batlle<sup>12</sup>, X. García De Albéniz<sup>13</sup>, F. Rojo<sup>14</sup>, V. Fernández<sup>15</sup>, B. Claes<sup>16</sup>, G. Maertens<sup>16</sup>, E. Sablon<sup>16</sup>, B. Jacobs<sup>17</sup>, J. Maurel<sup>18</sup>, <sup>1</sup>Hospital del Mar, Barcelona, ES, <sup>2</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>3</sup>Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, <sup>4</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>5</sup>Hospital Arnau de Vilanova, Lleida, ES, <sup>6</sup>Hospital de Móstoles, Móstoles, ES, <sup>7</sup>Hospital General Universitario de Elche, Elche, ES, <sup>8</sup>Hospital Infanta Cristina, Madrid, ES, <sup>9</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>10</sup>Hospital Mútua de Terrasa, Terrasa, Barcelona, ES, <sup>11</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>12</sup>Hospital Universitario La Paz, Madrid, ES, <sup>13</sup>Harvard T.H. Chan School of Public Health, Boston (MA), US, Boston, US, <sup>14</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>15</sup>Idibaps, Barcelona, ES, <sup>16</sup>Biocartis, Mechelen, BE, <sup>17</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>18</sup>Hospital Clínic of Barcelona, Barcelona, ES

12:45 - 12:45

**546P - First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts). PERSEIDA study**

P. García Alfonso<sup>1</sup>, M. Valladares-Ayerbes<sup>2</sup>, J. Muñoz Luengo<sup>3</sup>, P. Pimentel<sup>4</sup>, J.M. Viéitez<sup>5</sup>, J.J. Cruz Hernandez<sup>6</sup>, M. Llanos<sup>7</sup>, C. Garcia Girón<sup>8</sup>, A. Salud Salvia<sup>9</sup>, A. Lloansí Vila<sup>10</sup>, <sup>1</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>2</sup>University Hospital Reina Sofia. CIBERONC Instituto de Salud Carlos III, Córdoba, ES, <sup>3</sup>Hospital San Pedro de Alcántara, Cáceres, ES, <sup>4</sup>Hospital Santa Lucia, Cartagena, ES, <sup>5</sup>Hospital Central de Asturias, Oviedo, ES, <sup>6</sup>Hospital Universitario de Salamanca, Salamanca, ES, <sup>7</sup>Hospital Universitario de Canarias, Santa Cruz de Tenerife, ES, <sup>8</sup>Hospital Universitario de Burgos, Burgos, ES, <sup>9</sup>Hospital Arnau de Vilanova, Lleida, ES, <sup>10</sup>Amgen S.A., Barcelona, ES

12:45 - 12:45

**547P - Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response**

J. Zhou<sup>1</sup>, C. Bai<sup>2</sup>, Z. Sun<sup>2</sup>, Y. Cheng<sup>2</sup>, N. Jia<sup>1</sup>, Y. Zhou<sup>2</sup>, <sup>1</sup>PUMCH, Beijing, CN, <sup>2</sup>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

12:45 - 12:45

**548P - Cross-Platform Comparison of NGS and MALDI-TOF for Detecting RAS/RAF/PIK3CA Mutations in Circulating Tumor DNA from metastatic Colorectal Cancer Patient Plasma**

L. Liang<sup>1</sup>, B.-L. Wang<sup>2</sup>, Q. Yu<sup>2</sup>, T.-S. Liu<sup>1</sup>, W. Guo<sup>1</sup>, <sup>1</sup>Zhongshan Hospital, Fudan University, Shanghai, CN, <sup>2</sup>Zhongshan Hospital, Shanghai, CN

12:45 - 12:45

**549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type "window of opportunity"**

P. Gazzaniga<sup>1</sup>, C. Raimondi<sup>2</sup>, F. Urbano<sup>2</sup>, E. Cortesi<sup>3</sup>, <sup>1</sup>sapienza university of rome, Roma, IT, <sup>2</sup>Sapienza Univeristy of Rome, roma, IT, <sup>3</sup>Policlinico Umberto I, roma, IT

12:45 - 12:45

**550P - Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay**

A. Vivancos<sup>1</sup>, E. Aranda Aguilar<sup>2</sup>, M. Benavides<sup>3</sup>, E. Elez Fernandez<sup>1</sup>, M. Toledano<sup>2</sup>, M.

Alvarez<sup>3</sup>, E. Diaz Rubio<sup>4</sup>, A. Gómez-España<sup>2</sup>, V. Garcia-Barberan<sup>4</sup>, M. Chica-Parrao<sup>5</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>3</sup>Hospital Regional Universitario Carlos Haya, Malaga, ES, <sup>4</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>5</sup>Hospital Universitario Virgen de la Victoria, Malaga, ES

- 12:45 - 12:45 **551P - Non-invasive genotyping and monitoring of tumor evolution in locally advanced rectal cancer (LARC) patients using circulating tumor DNA (ctDNA)**  
S. Toomey<sup>1</sup>, A. Sartori<sup>2</sup>, D. Irwin<sup>3</sup>, S. Hummel<sup>4</sup>, A. Carr<sup>1</sup>, C.L. Lee<sup>5</sup>, P. Armstrong<sup>1</sup>, A. Farrelly<sup>6</sup>, S. El-Masry<sup>7</sup>, D. Mcnamara<sup>8</sup>, P. Morris<sup>8</sup>, L. Grogan<sup>8</sup>, O. Breathnach<sup>8</sup>, L. O'Sullivan<sup>9</sup>, S. Bradshaw<sup>10</sup>, A. Rashed<sup>11</sup>, R. Smyth<sup>1</sup>, J. Workman<sup>1</sup>, B. O'Neill<sup>12</sup>, B. Hennessy<sup>8</sup>, <sup>1</sup>Royal College of Surgeons in Ireland, Dublin, IE, <sup>2</sup>Agena Biosciences, Hamburg, DE, <sup>3</sup>Agena Biosciences, Brisbane, AU, <sup>4</sup>Agena Biosciences, San Diego, US, <sup>5</sup>St Vincents University Hospital, Dublin, IE, <sup>6</sup>Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, IE, <sup>7</sup>Our Lady of Lourdes Hospital, Drogheda, Drogheda, IE, <sup>8</sup>Beaumont Hospital, Dublin, IE, <sup>9</sup>Cancer Trials Ireland, Dublin, IE, <sup>10</sup>St Luke's Radiation Oncology Network, Dublin, IE, <sup>11</sup>Our Lady of Lourdes Hospital, Drogheda, IE, <sup>12</sup>St. Luke's Radiation Oncology Network, Dublin, IE
- 12:45 - 12:45 **552P - Circulating tumor DNA by next generation sequencing as a prognostic and predictive biomarker in metastatic colorectal cancer**  
N. Jia<sup>1</sup>, L. Chang<sup>2</sup>, X. Dou<sup>3</sup>, M. Guan<sup>3</sup>, Y. Shao<sup>3</sup>, N. Li<sup>3</sup>, Y. Cheng<sup>3</sup>, H. Ying<sup>3</sup>, Z. Sun<sup>3</sup>, Y. Zhou<sup>3</sup>, L. Zhao<sup>3</sup>, J. Zhou<sup>3</sup>, C. Bai<sup>3</sup>, <sup>1</sup>PUMCH, Beijing, CN, <sup>2</sup>Geneplus-Beijing, Beijing, CN, <sup>3</sup>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 12:45 - 12:45 **553P - Dynamic monitoring of KRAS, NRAS, BRAF and PIK3CA mutations in circulating cell-free DNA for metastatic colorectal cancer patients treated with cetuximab**  
L. Liu, Z. Tong, C. Yan, H. Zhang, W. Jiang, Y. Zheng, P. Zhao, W. Fang, 1st Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN
- 12:45 - 12:45 **554P - KRAS-dependent and independent mechanisms of progressive disease (PD) in colorectal cancer (CRC) patients (pts) with liver metastases (LM) while monitoring on circulating cell free DNA (cfDNA)**  
A. Kirov<sup>1</sup>, Z. Mihaylova<sup>2</sup>, V. Petrova<sup>2</sup>, T. Todorov<sup>3</sup>, D. Petkova<sup>2</sup>, A. Garev<sup>2</sup>, A. Todorova-Georgieva<sup>3</sup>, <sup>1</sup>Medical University Sofia, Sofia, BG, <sup>2</sup>Military Medical Academy, Sofia, BG, <sup>3</sup>Genetic Medico-Diagnostic Laboratory Genica, Sofia, BG
- 12:45 - 12:45 **555P - Correlation between ctDNA methylation and CEA in colorectal cancer**  
W. Tang<sup>1</sup>, H.-X. An<sup>2</sup>, D. Zhou<sup>2</sup>, M. Cai<sup>2</sup>, R. Zeng<sup>2</sup>, X.-J. Lv<sup>3</sup>, L. Chen<sup>2</sup>, F. Ye<sup>2</sup>, Y. Zhang<sup>4</sup>, <sup>1</sup>The 1st Affiliated Hospital of Xiamen University, Xiamen, CN, <sup>2</sup>Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, CN, <sup>3</sup>Xiamen Humanity Hospital Xiamen University, Xiamen, CN, <sup>4</sup>Xiang'an Hospital of Xiamen University, Xiamen, CN
- 12:45 - 12:45 **556P - Cell free DNA and Hepatic Arterial Infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases.**



A. Boysen<sup>1</sup>, J. Schou<sup>2</sup>, B. Jensen<sup>2</sup>, D. Nielsen<sup>2</sup>, B. Sørensen<sup>1</sup>, J. Johansen<sup>2</sup>, K.-L. Spindler<sup>1</sup>,  
<sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Herlev and Gentofte Hospital, Herlev, DK

12:45 - 12:45

**557P - Metastatic colorectal signet-ring cell carcinoma : clinical, histological and molecular description from an AGEO French multicenter retrospective cohort**

M. Allart-Sava<sup>1</sup>, F. Le Roy<sup>2</sup>, S. Kim<sup>3</sup>, D. Sefrioui<sup>4</sup>, C. Mariette<sup>5</sup>, A. Zaanan<sup>6</sup>, B. Rousseau<sup>7</sup>, M. Ben Abdelghani<sup>8</sup>, C. De La Fouchardière<sup>9</sup>, W. Cacheux<sup>10</sup>, R. Legros<sup>11</sup>, S. Louafi<sup>12</sup>, D. Tougeron<sup>13</sup>, N. Fares<sup>14</sup>, G. Roquin<sup>15</sup>, A.L. Bignon Bretagne<sup>16</sup>, M. Maillet<sup>17</sup>, B. Tchoundjeu<sup>18</sup>, A. Pozet<sup>19</sup>, V. Hautefeuille<sup>1</sup>, <sup>1</sup>CHU Amiens-Picardie Site Nord, Amiens, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>CHU Besançon, Hôpital Jean Minjot, Besançon, FR, <sup>4</sup>CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR, <sup>5</sup>C.H.U. Claude Huriez, Lille, FR, <sup>6</sup>Hopital European George Pompidou, Paris, FR, <sup>7</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>8</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>9</sup>Centre Léon Berard, LYON, FR, <sup>10</sup>Hôpital René Huguenin - Institut Curie, St. Cloud, FR, <sup>11</sup>CHU, Limoges, FR, <sup>12</sup>Centre Hospitalier de Longjumeau, Longjumeau, FR, <sup>13</sup>CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR, <sup>14</sup>CHU, Toulouse, FR, <sup>15</sup>CHU Angers, Angers, FR, <sup>16</sup>CHU de Caen, Caen, FR, <sup>17</sup>Hopital Saint-Louis, Paris, FR, <sup>18</sup>CHU, Orléans, FR, <sup>19</sup>CHU, Besançon, FR

12:45 - 12:45

**558P - The combination of trifluridine/tipiracil and oxaliplatin induces immunogenic cell death in microsatellite stable colorectal cancer**

F. Ghiringhelli<sup>1</sup>, E. Limagne<sup>2</sup>, M. Thibaudin<sup>2</sup>, L. Nuttin<sup>2</sup>, A. Spill<sup>2</sup>, V. Derangere<sup>2</sup>, V. Cattan<sup>3</sup>, E. Peranzoni<sup>4</sup>, N. Amellal<sup>3</sup>, <sup>1</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>2</sup>Centre Georges-François Leclerc, Dijon, FR, <sup>3</sup>Servier, Suresnes, FR, <sup>4</sup>Instut de recherches Servier, Croissy, FR

12:45 - 12:45

**559P - Distribution of Endocrine Tumor Marker-positive Cells in Adenocarcinoma Tissue Between Right-sided and Left-sided Colon Cancer**

T. Ogimi<sup>1</sup>, S. Sadahiro<sup>1</sup>, H. Miyakita<sup>1</sup>, G. Saito<sup>1</sup>, K. Okada<sup>2</sup>, A. Tanaka<sup>2</sup>, T. Suzuki<sup>1</sup>, H. Kajiwara<sup>2</sup>, <sup>1</sup>Tokai University School of Medicine Isehara Campus, Isehara, JP, <sup>2</sup>Tokai University School of Medicine, Isehara, JP

12:45 - 12:45

**560P - Prospective DPYD testing in colorectal cancer patients in a realworld UK population**

B. Eccles<sup>1</sup>, A. Harle<sup>2</sup>, S. Pullinger<sup>3</sup>, C. Holling<sup>2</sup>, A. Ingram<sup>4</sup>, S. Stark<sup>3</sup>, M. Bunce<sup>3</sup>, G. Melville<sup>2</sup>, J. Gibbins<sup>4</sup>, N. Calcutt<sup>4</sup>, T. Hickish<sup>5</sup>, M. Flubacher<sup>2</sup>, T. Marinaki<sup>6</sup>, <sup>1</sup>Poole hospital NHS Foundation Trust, Poole, GB, <sup>2</sup>Poole Hospital NHS Foundation Trust, Poole, GB, <sup>3</sup>Royal Bournemouth Hospital, Bournemouth, GB, <sup>4</sup>Dorchester County Hospital, Dorchester, GB, <sup>5</sup>Royal Bournemouth Hospital and University, Bournemouth, GB, <sup>6</sup>St Thomas Hospital, London, GB

12:45 - 12:45

**561P - Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers**

C. Lunenburg<sup>1</sup>, L. Henricks<sup>2</sup>, E. Dreussi<sup>3</sup>, F. Peters<sup>1</sup>, M. Fiocco<sup>4</sup>, D. Meulendijks<sup>5</sup>, G. Toffoli<sup>3</sup>, H.-J. Guchelaar<sup>6</sup>, J. Swen<sup>6</sup>, E. Cecchin<sup>3</sup>, J. Schellens<sup>2</sup>, H. Gelderblom<sup>1</sup>, <sup>1</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>2</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>3</sup>National Cancer Institute, Aviano, IT, <sup>4</sup>Leiden University Medical



Centre, Leiden, NL, <sup>5</sup>CBG-MEB, Utrecht, NL, <sup>6</sup>Leiden University Medical Center, Leiden, NL

12:45 - 12:45

**562P - Determination of DPYD polymorphisms before treatment with chemotherapy with a pyrimidine. Should we continue doing it?**

C. Avila Andrade<sup>1</sup>, A.J. Cunqueiro Tomas<sup>1</sup>, A.B. Fernandez Diaz<sup>1</sup>, M. Meri Abad<sup>1</sup>, L.D. Condori Farfan<sup>1</sup>, I. Shaheen<sup>1</sup>, S. Cervantes Garcia<sup>2</sup>, M.J. Safont Aguilera<sup>1</sup>, V. Iranzo Gonzalez-Cruz<sup>1</sup>, V. Sforza<sup>3</sup>, C. Caballero<sup>4</sup>, M.C. Godes De Bremond<sup>1</sup>, M. Gil<sup>1</sup>, F.D.A. Aparisi Aparisi<sup>5</sup>, A. Blasco Cordellat<sup>1</sup>, A. Berrocal Jaime<sup>1</sup>, I. Ferrer Bolufer<sup>2</sup>, M. Lobo De Mena<sup>1</sup>, G. Marcaida Benito<sup>2</sup>, C. Camps<sup>6</sup>, <sup>1</sup>Hospital General Universitario Valencia, Valencia, ES, <sup>2</sup>Hospital General Universitario Valencia, VALENCIA, ES, <sup>3</sup>Università degli Studi della Campania Luigi Vanvitelli, Naples, IT, <sup>4</sup>Hospital General, València, ES, <sup>5</sup>Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES, <sup>6</sup>Consortio Hospital General Universitario de Valencia, Valencia, ES

12:45 - 12:45

**563P - Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer**

T. Yoshino<sup>1</sup>, H. Iwata<sup>2</sup>, K. Tamura<sup>3</sup>, S. Takahashi<sup>4</sup>, C. Redfern<sup>5</sup>, S. Modi<sup>6</sup>, T. Doi<sup>1</sup>, H. Kawakami<sup>7</sup>, H. Taniguchi<sup>2</sup>, A. Takashima<sup>3</sup>, K. Yamaguchi<sup>4</sup>, J. Fisher<sup>8</sup>, B. Li<sup>6</sup>, K. Saito<sup>9</sup>, Y. Fujisaki<sup>9</sup>, M. Sugihara<sup>9</sup>, J. Tsurutani<sup>10</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>3</sup>National Cancer Center Hospital, Tokyo, JP, <sup>4</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>5</sup>Sharp Memorial Hospital, San Diego, US, <sup>6</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>7</sup>Kindai University Faculty of Medicine, Osakasayama, JP, <sup>8</sup>Sharp HealthCare, San Diego, US, <sup>9</sup>Daiichi Sankyo Co., Ltd, Tokyo, JP, <sup>10</sup>Kindai University School of Medicine, Osaka, JP

12:45 - 12:45

**564P - TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer - final results from the randomized phase II trial of the AIO**

T. Ettrich<sup>1</sup>, A. Berger<sup>2</sup>, T. Decker<sup>3</sup>, R.D. Hofheinz<sup>4</sup>, V. Heinemann<sup>5</sup>, T. Hoffmann<sup>6</sup>, H. Hebart<sup>7</sup>, T. Herrmann<sup>8</sup>, C.-V. Hannig<sup>9</sup>, P. Büchner-Steudel<sup>10</sup>, H. Bartholomäus<sup>11</sup>, M. Güthle<sup>11</sup>, L. Perkhofer<sup>1</sup>, T. Seufferlein<sup>1</sup>, <sup>1</sup>Ulm Medical University, Ulm, DE, <sup>2</sup>Martin Luther Universität Halle-Wittenberg, Halle, DE, <sup>3</sup>Onkologie Ravensburg, Ravensburg, DE, <sup>4</sup>Universitätsklinikum Mannheim, Mannheim, DE, <sup>5</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>6</sup>Klinikum Weimar, Weimar, DE, <sup>7</sup>Klinikum Schwäbisch Gmünd Stauferklinik, Mutlangen, DE, <sup>8</sup>Westküstenklinikum Heide Medizinische Klinik, Heide, DE, <sup>9</sup>Schwerpunktpraxis Haematologie / Onkologie, Bottrop, DE, <sup>10</sup>Martin-Luther-University Halle-Wittenberg, Halle, DE, <sup>11</sup>Ulm University, Ulm, DE

12:45 - 12:45

**565P - Dose finding and safety study of Reovirus (Reo) with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final results**

S. Goel<sup>1</sup>, A. Ocean<sup>2</sup>, R. Parakrama<sup>1</sup>, M. Ghalib<sup>1</sup>, I. Chaudhary<sup>1</sup>, U. Shah<sup>1</sup>, M. Coffey<sup>3</sup>, E. Kaledzi<sup>1</sup>, R. Maitra<sup>1</sup>, <sup>1</sup>Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, <sup>2</sup>New York Presbyterian-Weill Cornell Medical Center, New York, US, <sup>3</sup>Oncolytics, Calgary, CA

12:45 - 12:45

**566P - A first-in-human phase 1 study of GC1118, a novel monoclonal antibody**

**inhibiting epidermal growth factor receptor (EGFR), in patients with colorectal cancer and gastric/GEJ cancer**

D.-Y. Oh<sup>1</sup>, K.-W. Lee<sup>2</sup>, S.-W. Han<sup>1</sup>, J.W. Kim<sup>2</sup>, J.-W. Shin<sup>3</sup>, S.-J. Jo<sup>1</sup>, N.H. Kim<sup>4</sup>, A. Woo<sup>5</sup>, J. Won<sup>6</sup>, S. Hahn<sup>1</sup>, H. Lee<sup>1</sup>, W.H. Kim<sup>1</sup>, Y.-J. Bang<sup>1</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>3</sup>Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, KR, <sup>4</sup>Green Cross Corp., Yongin, KR, <sup>5</sup>Green Cross Corporation, Yongin, KR, <sup>6</sup>MOGAM Institute for Biomedical Research, Gyeonggi-do, KR

12:45 - 12:45

**567P - Results of a phase I study of andeciximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer**

H.-J. Lenz<sup>1</sup>, H. Park<sup>2</sup>, M. Shah<sup>3</sup>, J. Berlin<sup>4</sup>, D. Bruetman<sup>5</sup>, J. Chaves<sup>6</sup>, M. Gordon<sup>7</sup>, R. Patel<sup>8</sup>, A. Starodub<sup>9</sup>, J. Liu<sup>10</sup>, C. Baker Brachmann<sup>10</sup>, P. Bhargava<sup>10</sup>, Z. Wainberg<sup>11</sup>, J. Bendell<sup>12</sup>, <sup>1</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>2</sup>Washington University, St. Louis, US, <sup>3</sup>Weill Cornell Medicine/ New York Presbyterian Hospital, New York, US, <sup>4</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>5</sup>Goshen Center for Cancer Care, Goshen, US, <sup>6</sup>Northwest Medical Specialties PLLC, Tacoma, US, <sup>7</sup>HonorHealth Virginia G Piper Cancer Care Network, Scottsdale, US, <sup>8</sup>Comprehensive Blood and Cancer Center, Bakersfield, US, <sup>9</sup>Indiana University Health Goshen Hospital, Goshen, US, <sup>10</sup>Gilead Science, Foster City, US, <sup>11</sup>UCLA Medical Center, Los Angeles, US, <sup>12</sup>Sarah Cannon Research Institute, Nashville, US

12:45 - 12:45

**568P - A Phase 2 study of Pemetrexed and Erlotinib for Metastatic Colorectal Cancer Refractory to Standard Chemotherapy**

S.-H. Beom<sup>1</sup>, K.-W. Lee<sup>2</sup>, S.-H. Cho<sup>3</sup>, Y.S. Park<sup>4</sup>, T.W. Kim<sup>5</sup>, K.H. Lee<sup>6</sup>, M. Jung<sup>7</sup>, S.J. Shin<sup>8</sup>, J.B. Ahn<sup>9</sup>, <sup>1</sup>Yonsei University, Seoul, KR, <sup>2</sup>Seoul National University Bundang Hospital, Seoul, KR, <sup>3</sup>Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, <sup>4</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>5</sup>University of Ulsan, Seoul, KR, <sup>6</sup>Department of Internal Medicine, Daegu, KR, <sup>7</sup>Yonsei Cancer Center, Seoul, KR, <sup>8</sup>Yonsei University College of Medicine, Seoul, KR, <sup>9</sup>Yonsei University College of Medicine Department of Internal Medicine, Seoul, KR

12:45 - 12:45

**569P - ISO-CC-005; a phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin \_ bevacizumab in patients with metastasizing colorectal cancer**

G. Carlsson<sup>1</sup>, T.K. Guren<sup>2</sup>, J. Haux<sup>3</sup>, P. Pfeiffer<sup>4</sup>, H. Taflin<sup>1</sup>, D. Mavroudis<sup>5</sup>, V. Georgoulas<sup>6</sup>, C. Papadimitriou<sup>7</sup>, N. Kentepozidis<sup>8</sup>, D. Boumpas<sup>9</sup>, L. Skintemo<sup>10</sup>, K. Ganlöv<sup>10</sup>, B. Gustavsson<sup>11</sup>, <sup>1</sup>Sahlgrenska University Hospital, Gothenburg, SE, <sup>2</sup>Oslo University Hospital, Oslo, NO, <sup>3</sup>Skaraborg Hospital, Skövde, SE, <sup>4</sup>Odense University Hospital, Odense C, DK, <sup>5</sup>University General Hospital, Heraklion, GR, <sup>6</sup>University Hospital of Heraklion, Heraklion, GR, <sup>7</sup>Alexandra Hospital, Athens, GR, <sup>8</sup>251 Hellenic Airforce General Hospital, Athens, GR, <sup>9</sup>University Hospital Attikon, Chaidari Athens, GR, <sup>10</sup>Isofol Medical AB, Gothenburg, SE, <sup>11</sup>University of Gothenburg, Goteborg, SE

12:45 - 12:45

**570P - Detection of frailty in elderly colorectal cancer patients: is G8 a good screening tool?**

J. Ruffinelli Rodriguez<sup>1</sup>, G. Soler<sup>2</sup>, R. Legido<sup>2</sup>, M. Martinez Villacampa<sup>2</sup>, F. Perez<sup>2</sup>, B. Pardo-Burdalo<sup>3</sup>, J. Marín<sup>1</sup>, I. Morilla Ruiz<sup>2</sup>, L. Heras Lopez<sup>4</sup>, S. Vazquez<sup>2</sup>, S. Recalde<sup>1</sup>, M. Plana Serrahima<sup>2</sup>, C. Santos<sup>2</sup>, N. Mulet Margalef<sup>1</sup>, A. Teule<sup>5</sup>, R. Salazar<sup>1</sup>, M. Galan<sup>1</sup>, J. Saldaña<sup>2</sup>, <sup>1</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>2</sup>Institut Català de Oncologia, Barcelona, ES, <sup>3</sup>Institut Català Oncologia-Hospital Duran i Reynals, Barcelona, ES, <sup>4</sup>ICO, Barcelona, ES, <sup>5</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES

- 12:45 - 12:45 **571P - Interim Results from a Real World European Survey on the Unmet Needs of Patients Living with Metastatic Colorectal Cancer (mCRC)**  
Z. Maravic<sup>1</sup>, J. Borrás<sup>2</sup>, E. Espin Basany<sup>3</sup>, Á. Petrányi<sup>4</sup>, Z. Kapitány<sup>5</sup>, P. Rakonczai<sup>6</sup>, A. Benedict<sup>7</sup>, N. Muszbek<sup>8</sup>, <sup>1</sup>EuropaColon UK, Salisbury, GB, <sup>2</sup>Hospital Duran i Reynals, Barcelona, ES, <sup>3</sup>Hospital Valle de Hebron, Universitat Autònoma de Barcelona, Barcelona, ES, <sup>4</sup>Egyesített Szent István és Szent László Kórház, Budapest, HU, <sup>5</sup>Semmelweis University Faculty of Health Sciences, Budapest, HU, <sup>6</sup>Evidera, Budapest, HU, <sup>7</sup>Evidera Inc., Budapest, HU, <sup>8</sup>Evidera (European Headquarter), London, GB
- 12:45 - 12:45 **572P - Socioeconomic discrepancies in survival of stage IV colorectal cancer.**  
H. Kim<sup>1</sup>, J. Uhlig<sup>2</sup>, S. Stein<sup>2</sup>, L. Jill<sup>2</sup>, C. Fuchs<sup>3</sup>, <sup>1</sup>Yale School of Medicine - Interventional Radiology Yale Cancer Center, New Haven, US, <sup>2</sup>Yale School of Medicine, New Haven, US, <sup>3</sup>Yale University, New Haven, US
- 12:45 - 12:45 **573P - Influence of not having children on mortality in patients with metastatic (mCRC) colorectal cancer.**  
S. Ahmed<sup>1</sup>, T. Baig<sup>2</sup>, A. Zaidi<sup>1</sup>, H. Chalchal<sup>3</sup>, K. Haider<sup>1</sup>, T. Asif<sup>1</sup>, N. Iqbal<sup>1</sup>, <sup>1</sup>Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, CA, <sup>2</sup>University of Saskatchewan, Saskatoon, CA, <sup>3</sup>Allan Blair Cancer Center, Regina, CA
- 12:45 - 12:45 **574P - Interim Quality of Life Results from a Real World European Survey on the Unmet Needs of Patients Living with Metastatic Colorectal Cancer (mCRC)**  
Z. Maravic<sup>1</sup>, L. Wyrwicz<sup>2</sup>, B. Karczmarek-Borowska<sup>3</sup>, A. Horvath<sup>4</sup>, A. Ruiz Casado<sup>5</sup>, A. Carrato Mena<sup>6</sup>, N. Muszbek<sup>7</sup>, P. Rakonczai<sup>8</sup>, <sup>1</sup>EuropaColon UK, Salisbury, GB, <sup>2</sup>Centrum Onkologii-Instytut im. M. Skłodowskiej Curie, Warszawa, PL, <sup>3</sup>Provincial Specialized Hospital in Rzeszów, Rzeszow, PL, <sup>4</sup>Semmelweis University Kutvolgyi Clinical Center, Budapest, HU, <sup>5</sup>Hospital Puerta de Hierro, Majadahonda, ES, <sup>6</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>7</sup>Evidera (European Headquarter), London, GB, <sup>8</sup>Evidera, Budapest, HU
- 12:45 - 12:45 **575P - Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL) + FOLFIRI - Efficacy according to age group <65 and >65 years**  
R.D. Hofheinz<sup>1</sup>, H.-G. Derigs<sup>2</sup>, G. Piringer<sup>3</sup>, R. Von Moos<sup>4</sup>, <sup>1</sup>Universitätsklinikum Mannheim, Mannheim, DE, <sup>2</sup>Klinikum Frankfurt Höchst, Frankfurt a. M., DE, <sup>3</sup>Klinikum Wels-Grieskirchen GmbH, Wels, AT, <sup>4</sup>Kantonsspital Graubünden, Chur, CH
- 12:45 - 12:45 **576P - Inhibitory effect of a synthetic bioresorbable adhesion membrane on small bowel obstruction (SBO) in patients undergoing elective surgery for colon cancer: A randomized controlled trial**



G. Saito<sup>1</sup>, S. Sadahiro<sup>1</sup>, H. Miyakita<sup>1</sup>, K. Okada<sup>2</sup>, A. Tanaka<sup>2</sup>, T. Suzuki<sup>1</sup>, <sup>1</sup>Tokai University School of Medicine Isehara Campus, Isehara, JP, <sup>2</sup>Tokai University School of Medicine, Isehara, JP

- 12:45 - 12:45 **577P - Short- and Long-term Outcomes of High Tie versus Low Tie with Lymph Node Dissection around the Inferior Mesenteric Artery in Sigmoid Colon or Rectal Cancer Surgery**  
X. Li, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:45 - 12:45 **578P - Mesenteric Vs. Antimesenteric Colorectal Cancer. A Single Center Study.**  
K.H. Lee<sup>1</sup>, W.R. Kim<sup>2</sup>, J.W. Kim<sup>3</sup>, <sup>1</sup>Bundang Cha Medical Center, Seongnam, KR, <sup>2</sup>CHA Bundang Medical Center, Seongnam, KR, <sup>3</sup>Cha university, Gyunggi, KR
- 12:45 - 12:45 **579P - The SLICE study: the prognostic role of viSceraL fat In metastatic Colorectal canCEr**  
D. Basile<sup>1</sup>, C. Lisanti<sup>2</sup>, M. Borghi<sup>3</sup>, M. Bartoletti<sup>4</sup>, L. Gerratana<sup>5</sup>, L. Bortot<sup>4</sup>, G. Pelizzari<sup>2</sup>, C. Corvaja<sup>1</sup>, E. Ongaro<sup>6</sup>, S. Garattini<sup>4</sup>, V. Fanotto<sup>7</sup>, A. Parnofiello<sup>6</sup>, F. Cortiula<sup>4</sup>, M. Cattaneo<sup>6</sup>, V. Andreotti<sup>6</sup>, E. Bertoli<sup>2</sup>, M. Guardascione<sup>3</sup>, G. Miolo<sup>3</sup>, F. Puglisi<sup>1</sup>, A. Buonadonna<sup>1</sup>, <sup>1</sup>CRO di Aviano, Aviano, IT, <sup>2</sup>Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, <sup>3</sup>CRO National Cancer Institute, Aviano, IT, <sup>4</sup>University of Udine, Udine, IT, <sup>5</sup>AOU Santa Maria della Misericordia, Udine, IT, <sup>6</sup>ASUIUD Azienda Ospedaliero-Universitaria di Udine, udine, IT, <sup>7</sup>University Hospital of Udine, Udine, IT
- 12:45 - 12:45 **580P - Safety and Outcomes of Self-expandable Metal Stents (SEMS) versus Emergency Surgery for Acute Colonic Obstruction in Metastatic Colon Cancer patients treated with Bevacizumab (BV)**  
V. Pacheco-Barcia<sup>1</sup>, R. Mondéjar Solís<sup>1</sup>, O. Martínez-Sáez<sup>2</sup>, F. Longo<sup>3</sup>, E. Bermejo<sup>4</sup>, J.A. Moreno<sup>1</sup>, C. Marin<sup>4</sup>, A. Correa<sup>4</sup>, R. Maqueda<sup>4</sup>, J. Rogado<sup>1</sup>, A. García De Paredes<sup>3</sup>, E. Rodriguez De Santiago<sup>3</sup>, V. Pachón Olmos<sup>2</sup>, R. Ferreiro Monteagudo<sup>2</sup>, M. Rodriguez Garrote<sup>2</sup>, A. Carrato Mena<sup>3</sup>, O. Donnay<sup>1</sup>, E. Martin Perez<sup>4</sup>, C. Santander<sup>1</sup>, R. Colomer Bosch<sup>1</sup>, <sup>1</sup>Hospital Universitario de La Princesa, Madrid, ES, <sup>2</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>3</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>4</sup>Hospital Universitario La Princesa, Madrid, ES
- 12:45 - 12:45 **581P - Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed Pseudomyxoma Peritonei**  
A. Raimondi<sup>1</sup>, S. Corallo<sup>1</sup>, M. Niger<sup>2</sup>, M. Antista<sup>3</sup>, G. Randon<sup>1</sup>, F. Morano<sup>1</sup>, C. Cremolini<sup>4</sup>, M. Di Bartolomeo<sup>5</sup>, F.G. De Braud<sup>1</sup>, F. Pietrantonio<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>AOU Policlinico "Paolo Giaccone", Palermo, IT, <sup>4</sup>Azienda Ospedaliera Universitaria S.Chiara, Pisa, IT, <sup>5</sup>Fondazione IRCCS, Milan, IT
- 12:45 - 12:45 **582P - Utility of Carcinoembryonic Antigen (CEA) in Appendiceal carcinoma**  
A. Karippot<sup>1</sup>, S. Groover<sup>2</sup>, J. Ai<sup>3</sup>, S. Nambiar<sup>1</sup>, <sup>1</sup>cancer tretment centers of america, Tulsa, US, <sup>2</sup>Oklahoma State University Center for Health Sciences, Tulsa, US, <sup>3</sup>Cancer Treatment Centers of America, Tulsa, US



- 12:45 - 12:45 **583P - Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients. Subgroup analysis from the adjuvant TOSCA trial**  
S. Barni<sup>1</sup>, G. Rosati<sup>2</sup>, V. Zagonel<sup>3</sup>, N. Pella<sup>4</sup>, M. Banzi<sup>5</sup>, M.G. Zampino<sup>6</sup>, M. Di Bartolomeo<sup>7</sup>, L. Rimassa<sup>8</sup>, P. Marchetti<sup>9</sup>, E. Maiello<sup>10</sup>, F. Artioli<sup>11</sup>, D. Ferrari<sup>12</sup>, R. Labianca<sup>13</sup>, P. Bidoli<sup>14</sup>, A. Zaniboni<sup>15</sup>, A. Sobrero<sup>16</sup>, V. Iaffaioli<sup>17</sup>, S. De Placido<sup>18</sup>, L. Frassinetti<sup>19</sup>, F. Galli<sup>20</sup>, F. Petrelli<sup>21</sup>, <sup>1</sup>ASST Bergamo Ovest, treviglio, IT, <sup>2</sup>ospedale San Carlo, Potenza, IT, <sup>3</sup>Istituto Oncologico Veneto-IRCCS, padova, IT, <sup>4</sup>Azienda Ospedaliero Universitaria Santa Maria della Misericordia, udine, IT, <sup>5</sup>arcispedale santa maria nuova-IRCCS, reggio emilia, IT, <sup>6</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>7</sup>Fondazione IRCCS, Milan, IT, <sup>8</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>9</sup>Azienda Ospedaliera St. Andrea, Roma, IT, <sup>10</sup>Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, <sup>11</sup>ospedale Ramazzini, carpi, IT, <sup>12</sup>azienda ospedaliera san paolo, milano, IT, <sup>13</sup>Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, <sup>14</sup>San Gerardo dei Tintori Hospital, monza, IT, <sup>15</sup>casa di cura poliambulanza, brescia, IT, <sup>16</sup>IRCCS Ospedale San Martino IST, Genoa, IT, <sup>17</sup>National Cancer Institute, IRCCS Foundation Pascale, napoli, IT, <sup>18</sup>AOU Policlinico Federico II, Napoli, IT, <sup>19</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>20</sup>IRCCS istituto ricerche farmacologiche Mario Negri, milano, IT, <sup>21</sup>Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, IT
- 12:45 - 12:45 **584P - The clinical utility of early follow-up computed tomography in patients with stage II-III colorectal cancer receiving oxaliplatin-based chemotherapy**  
Y. Lee<sup>1</sup>, S.Y. Kim<sup>1</sup>, J.E. Kim<sup>2</sup>, Y.S. Hong<sup>1</sup>, T.W. Kim<sup>3</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KR, <sup>3</sup>University of Ulsan, Seoul, KR
- 12:45 - 12:45 **585P - Clinical Benefit of Whole Genome and Transcriptome Analysis (WGTA) in Metastatic Colorectal Cancer (MCRC): Results from the Personalized Oncogenomics Program (POG)**  
S. Liu<sup>1</sup>, J. Loree<sup>2</sup>, D. Renouf<sup>2</sup>, M. Jones<sup>3</sup>, S. Yip<sup>3</sup>, M. Marra<sup>1</sup>, S. Jones<sup>1</sup>, J. Nelson<sup>1</sup>, J. Laskin<sup>2</sup>, H. Lim<sup>2</sup>, S. Gill<sup>2</sup>, <sup>1</sup>BC Cancer Agency, Vancouver, CA, <sup>2</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>3</sup>BC Genome Science Centre, Vancouver, CA
- 12:45 - 12:45 **586P - Sequencing of KRAS and NRAS in 1501 colorectal carcinomas reveals significant share of mutations, which are not included in common diagnostic kits**  
E. Imyanitov<sup>1</sup>, N. Mitiushkina<sup>1</sup>, E. Kuligina<sup>2</sup>, M. Holmatov<sup>1</sup>, G. Yanus<sup>1</sup>, I. Demidova<sup>3</sup>, T. Kekeeva<sup>4</sup>, M. Gordiev<sup>5</sup>, E. Kharitonova<sup>6</sup>, I. Tsimafeyeu<sup>6</sup>, S. Tjulandin<sup>7</sup>, <sup>1</sup>N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, <sup>2</sup>Research Institute of Oncology named after NN Petrov, Saint Petersburg, RU, <sup>3</sup>Moscow City Oncology Hospital No. 62, Moscow, RU, <sup>4</sup>Medical and Rehabilitation Center, Moscow, RU, <sup>5</sup>Tatarstan Cancer Center, Kazan, RU, <sup>6</sup>Russian Society of Clinical Oncology, Moscow, RU, <sup>7</sup>N. N. Blokhin Russian Cancer Research Center, Moscow, RU
- 12:45 - 12:45 **587P - Patterns of care and of biomolecular characterization of Right, Transverse, and Left Colorectal Cancer from real-life evidence in Asia Pacific and European countries**  
E. Mari<sup>1</sup>, S. Mpima<sup>2</sup>, F. Guglielmetti<sup>3</sup>, P. Nasuti<sup>2</sup>, <sup>1</sup>IQVIA Italy, Milan, IT, <sup>2</sup>IQVIA, London, GB, <sup>3</sup>Quintiles SpA - Italy, Cassina De' Pecchi, IT

- 12:45 - 12:45 **588P - The role of primary tumour location in the recurrence rate of metachronous metastasis of colon cancer**  
M. Rimini<sup>1</sup>, C. Bardasi<sup>2</sup>, F. Gelsomino<sup>3</sup>, K. Andrikou<sup>3</sup>, C. Santini<sup>2</sup>, G. Orsi<sup>4</sup>, M. Salati<sup>1</sup>, M.L. Riggi<sup>4</sup>, S. Pipitone<sup>1</sup>, S. Cascinu<sup>1</sup>, A. Spallanzani<sup>3</sup>, <sup>1</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>2</sup>University of Modena and Reggio Emilia, Modena, IT, <sup>3</sup>University Hospital of Modena, Modena, IT, <sup>4</sup>Modena Cancer Center,, modena, IT
- 12:45 - 12:45 **589P - The prognostic value of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status in left- and right-sided metastatic colorectal cancer (mCRC): a Belgian population-based study.**  
K. Janssens<sup>1</sup>, G. Van Camp<sup>2</sup>, K. Op De Beeck<sup>3</sup>, E. Franssen<sup>3</sup>, F. Calay<sup>4</sup>, N. Van Damme<sup>4</sup>, M. Peeters<sup>2</sup>, <sup>1</sup>University of Antwerp, Antwerp, BE, <sup>2</sup>U.Z.A. University Hospital Antwerp, Edegem, BE, <sup>3</sup>University of Antwerp, Edegem, BE, <sup>4</sup>Belgian cancer registry, Sint-Joosten-Node, BE
- 12:45 - 12:45 **590P - Increase in tumor-infiltrating FoxP3-positive regulatory T cells in left-sided colorectal cancer tissues after preoperative oral uracil and tegafur/leucovorin chemotherapy**  
S. Sadahiro<sup>1</sup>, T. Suzuki<sup>1</sup>, A. Tanaka<sup>2</sup>, K. Okada<sup>2</sup>, G. Saito<sup>1</sup>, H. Miyakita<sup>2</sup>, H. Kajiwara<sup>2</sup>, H. Nagase<sup>3</sup>, <sup>1</sup>Tokai University School of Medicine Isehara Campus, Isehara, JP, <sup>2</sup>Tokai University School of Medicine, Isehara, JP, <sup>3</sup>Taiho Pharmaceutical Co.,Ltd, Tokushima, JP
- 12:45 - 12:45 **591P - Comparing Metastatic (M) Young Onset (YO) Colorectal Cancer (CRC) with Average Onset (AO): Are They Do They Differ Clinical and Genetically?**  
G. Dos Santos Fernandes<sup>1</sup>, W. Chatila<sup>1</sup>, R. Yaeger<sup>1</sup>, R. Mendelsohn<sup>1</sup>, Z. Stadler<sup>1</sup>, N. Segal<sup>2</sup>, A. Varghese<sup>3</sup>, D. Reidy<sup>4</sup>, L. Diaz<sup>5</sup>, J. Shia<sup>1</sup>, E. Vakiani<sup>1</sup>, J. Hechtman<sup>1</sup>, N. Schultz<sup>1</sup>, M. Berger<sup>1</sup>, D. Hyman<sup>3</sup>, D. Solit<sup>1</sup>, L. Saltz<sup>2</sup>, J. Garcia Aguilar<sup>1</sup>, A. Cercek<sup>2</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>MSKCC, New York, US, <sup>4</sup>MSKCC, NEw York, US, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York City, US
- 12:45 - 12:45 **592P - Impact of Charlson comorbidity index on survival of octogenarian patients with colorectal cancer.**  
E. Inga Saavedra<sup>1</sup>, J.R. Rodriguez<sup>2</sup>, E. Casaut Lora<sup>3</sup>, A. Gonzalez-Haba<sup>1</sup>, V. Serrano Pecos<sup>1</sup>, M.F. Martinez Barragan<sup>1</sup>, E. Blanco<sup>1</sup>, J. Gomez-Ulla<sup>1</sup>, <sup>1</sup>Hospital Infanta Cristina, Badajoz, ES, <sup>2</sup>Hospital Infanta Cristina, Madrid, ES, <sup>3</sup>HOSPITAL PERPETUO SOCORRO, Badajoz, ES
- 12:45 - 12:45 **593P - The SENECA study: prognostic role of Serum biomarkErs iN Elderly metastatic Colorectal cAncer patients.**  
C. Lisanti<sup>1</sup>, D. Basile<sup>2</sup>, S. Garattini<sup>2</sup>, G. Pelizzari<sup>1</sup>, A. Parnofiello<sup>3</sup>, F. Cortiula<sup>1</sup>, E. Ongaro<sup>3</sup>, M. Cattaneo<sup>3</sup>, C. Corvaja<sup>4</sup>, V. Andreotti<sup>3</sup>, M. Bartoletti<sup>2</sup>, M. Casagrande<sup>3</sup>, D. Iacono<sup>1</sup>, M. Bonotto<sup>3</sup>, P. Ermacora<sup>3</sup>, N. Pella<sup>5</sup>, A. Buonadonna<sup>4</sup>, F. Puglisi<sup>4</sup>, G. Fasola<sup>1</sup>, G. Miolo<sup>6</sup>, <sup>1</sup>Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, <sup>2</sup>University of Udine, Udine, IT, <sup>3</sup>ASUIUD Azienda Ospedaliero-Universitaria di Udine, udine, IT, <sup>4</sup>CRO di Aviano, Aviano, IT, <sup>5</sup>Azienda Ospedaliero Universitaria Santa Maria della Misericordia, udine, IT, <sup>6</sup>CRO National Cancer Institute, Aviano, IT

- 12:45 - 12:45 **594P - Determinants of oncologist's choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer**  
S.K. Garattini<sup>1</sup>, M. Bonotto<sup>2</sup>, L. Porcu<sup>2</sup>, E. Ongaro<sup>2</sup>, D. Basile<sup>3</sup>, F. Cortiula<sup>1</sup>, G. Pelizzari<sup>1</sup>, M. Cattaneo<sup>2</sup>, A. Parnofiello<sup>2</sup>, V. Andreotti<sup>2</sup>, C. Corvaja<sup>3</sup>, G. Cardellino<sup>4</sup>, P. Ermacora<sup>2</sup>, M. Casagrande<sup>2</sup>, D. Iacono<sup>1</sup>, N. Pella<sup>5</sup>, A. Buonadonna<sup>3</sup>, A. Minisini<sup>2</sup>, F. Puglisi<sup>3</sup>, G. Fasola<sup>1</sup>, <sup>1</sup>Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, <sup>2</sup>ASUIUD Azienda Ospedaliero-Universitaria di Udine, Udine, IT, <sup>3</sup>CRO di Aviano, Aviano, IT, <sup>4</sup>Udine University and General Hospital, Udine, IT, <sup>5</sup>Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Udine, IT
- 12:45 - 12:45 **596P - Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models**  
V. Belli<sup>1</sup>, N. Matrone<sup>1</sup>, S. Napolitano<sup>1</sup>, E. Martinelli<sup>1</sup>, M. Castellone<sup>2</sup>, L. Trusolino<sup>3</sup>, E. Giunta<sup>1</sup>, V. De Falco<sup>1</sup>, N. Zanaletti<sup>1</sup>, P.P. Vitiello<sup>1</sup>, D. Ciardiello<sup>1</sup>, M. Terminiello<sup>1</sup>, F. Ciardiello<sup>1</sup>, T. Troiani<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>CNR, Napoli, IT, <sup>3</sup>IRCCS Istituto di Candiolo, Candiolo, IT
- 12:45 - 12:45 **597P - Predictive value of in-vitro testing anti-cancer therapy sensitivity on 3D micro-tumors (tumoroids) from patients with metastatic colorectal cancer - a feasibility study**  
L.H. Jensen<sup>1</sup>, C. Dam<sup>2</sup>, G. Hagel<sup>3</sup>, C. Hansen<sup>2</sup>, H. Harling<sup>4</sup>, B. Havelund<sup>1</sup>, A. Jakobsen<sup>1</sup>, J. Lindebjerg<sup>2</sup>, S. Rafaelsen<sup>2</sup>, O. Thastrup<sup>5</sup>, T. Hansen<sup>2</sup>, <sup>1</sup>Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, <sup>2</sup>Institute of Regional Health Research, University of Southern Denmark, Vejle, DK, <sup>3</sup>cureX, Copenhagen, DK, <sup>4</sup>Bispebjerg Hospital, Copenhagen, DK, <sup>5</sup>University of Copenhagen - Department of Drug Design and Pharmacology, Copenhagen, DK
- 12:45 - 12:45 **598P - Macrophage migration inhibitory factor overexpression is a mechanism of acquired resistance to anti-EGFR inhibitor cetuximab in human colorectal cancer cell line**  
N. Matrone, A. Chambery, R. Russo, P.V. Pedone, V. Belli, S. Napolitano, E. Martinelli, E. Giunta, V. De Falco, N. Zanaletti, P. Vitale, M. Terminiello, C. Cardone, F. Ciardiello, T. Troiani, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 12:45 - 12:45 **599P - Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): results of a placebo-controlled, randomized, double-blind phase 2 study**  
T. Kato<sup>1</sup>, M. Kotaka<sup>2</sup>, H. Satake<sup>3</sup>, A. Makiyama<sup>4</sup>, Y. Tsuji<sup>5</sup>, K. Shinozaki<sup>6</sup>, T. Fujiwara<sup>7</sup>, T. Mizushima<sup>8</sup>, Y. Harihara<sup>9</sup>, N. Nagata<sup>10</sup>, N. Kurihara<sup>11</sup>, Y. Kagawa<sup>12</sup>, G. Kusakawa<sup>13</sup>, T. Sakai<sup>14</sup>, Y. Uchida<sup>14</sup>, M. Takamoto<sup>13</sup>, S. Asami<sup>14</sup>, M. Ando<sup>15</sup>, Y. Saito<sup>16</sup>, I. Hyodo<sup>17</sup>, <sup>1</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>2</sup>Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, <sup>3</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>4</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>5</sup>KKR Tonan Hospital, Sapporo, JP, <sup>6</sup>Hiroshima Prefectural Hospital, Hiroshima, JP, <sup>7</sup>Okayama University Hospital, Okayama, JP, <sup>8</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>9</sup>NTT Medical Center Tokyo, Tokyo, JP, <sup>10</sup>Kitakyushu General Hospital, Kitakyushu, JP, <sup>11</sup>Nerima General Hospital, Tokyo, JP, <sup>12</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>13</sup>Asahi kasei



pharma corporation, Tokyo, JP, <sup>14</sup>Asahi Kasei, Tokyo, JP, <sup>15</sup>Nagoya University Hospital, Nagoya, JP, <sup>16</sup>Shimane University Faculty of Medicine, Izumo, JP, <sup>17</sup>University of Tsukuba, Tsukuba, JP

- 12:45 - 12:45 **600P - Development of a Nomogram for Predicting Survival in Microsatellite Stable Patients with Resected Colorectal Cancer**  
Y. Li<sup>1</sup>, J. Peng<sup>1</sup>, T. Hou<sup>2</sup>, H. Han-Zhang<sup>2</sup>, H. Liu<sup>2</sup>, J. Xiang<sup>2</sup>, L. Zhang<sup>2</sup>, X. Ma<sup>1</sup>, D. Huang<sup>1</sup>, S. Cai<sup>1</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Burning Rock Biotech, Guangzhou, CN
- 12:45 - 12:45 **601P - Germline mutations in Chinese colorectal cancer patients with mismatch repair deficiency**  
Y. Yuan<sup>1</sup>, L. Zhu<sup>2</sup>, D. Xu<sup>3</sup>, C. Liu<sup>4</sup>, X. Mao<sup>4</sup>, <sup>1</sup>2nd Affiliated Hospital of Zhejiang University University School of Medicine, Hangzhou, CN, <sup>2</sup>The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, <sup>3</sup>2nd Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, <sup>4</sup>Burning Rock Biotech, Guangzhou, CN
- 12:45 - 12:45 **602P - Kynurenine 3-monooxygenase as a potential biomarker for colorectal cancer**  
C.-Y. Liu<sup>1</sup>, C.-H. Lee<sup>1</sup>, J.-L. Chen<sup>1</sup>, T.-T. Huang<sup>1</sup>, S.-H. Yang<sup>1</sup>, J.-K. Jiang<sup>2</sup>, W.-S. Chen<sup>1</sup>, K.-D. Lee<sup>3</sup>, H.-W. Teng<sup>1</sup>, <sup>1</sup>Taipei Veterans General Hospital, Taipei, TW, <sup>2</sup>Department of Surgery, Taipei, TW, <sup>3</sup>Taipei Medical University Hospital, Taipei, TW
- 12:45 - 12:45 **603TiP - Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer (ICAR)**  
J. Souza, R. Araujo, M. Valadão, C. Carrara, M. Barbosa, R. Guimarães, J. Carvalho, G. Kovalski, I. Small, A. Marins, A.P. Victorino, R. Gil, J.P. Jesus, L.H. De Araujo, A. De Melo, INCA - Instituto Nacional de Cancer, Rio de Janeiro, BR
- 12:45 - 12:45 **604TiP - Phase II study of surgery after S-1 + oxaliplatin + bevacizumab therapy for unresectable rectal cancer by organ-preserved TME**  
T. Yoshida<sup>1</sup>, T. Miura<sup>2</sup>, Y. Sakamoto<sup>1</sup>, H. Morohashi<sup>1</sup>, H. Fujita<sup>1</sup>, K. Sato<sup>1</sup>, K. Hakamada<sup>1</sup>, <sup>1</sup>Hirosaki University Hospital, Hirosaki, JP, <sup>2</sup>Hirosaki Hospital, Hirosaki, JP
- 12:45 - 12:45 **605TiP - Phase II study of resection of primary colorectal cancer and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + Bevacizumab(Bmab) therapy and adjuvant S-1 chemotherapy**  
T. Miura<sup>1</sup>, H. Morohashi<sup>1</sup>, Y. Sakamoto<sup>2</sup>, T. Yoshida<sup>2</sup>, K. Sato<sup>2</sup>, K. Ishido<sup>2</sup>, D. Kudo<sup>2</sup>, N. Kimura<sup>2</sup>, K. Hakamada<sup>2</sup>, <sup>1</sup>Hirosaki Hospital, Hirosaki, JP, <sup>2</sup>Hirosaki University Hospital, Hirosaki, JP
- 12:45 - 12:45 **606TiP - Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G**  
Y. Kito<sup>1</sup>, T. Yamada<sup>2</sup>, T. Matsumoto<sup>3</sup>, H. Yasui<sup>4</sup>, K. Murata<sup>5</sup>, A. Makiyama<sup>6</sup>, H. Hara<sup>7</sup>, E. Baba<sup>8</sup>, K. Nishio<sup>9</sup>, K. Yoshimura<sup>10</sup>, S. Hironaka<sup>11</sup>, K. Muro<sup>12</sup>, K. Yamazaki<sup>13</sup>, <sup>1</sup>Ishikawa



Prefectural Central Hospital, Kanazawa, JP, <sup>2</sup>University of Tsukuba Hospital, Tsukuba, Ibaraki, JP, <sup>3</sup>Himeji Red Cross Hospital, Himeji Hyogo Pref, JP, <sup>4</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>5</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>6</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>7</sup>Saitama Cancer Center, Ina, JP, <sup>8</sup>Kyushu University Hospital, FUKUOKA, JP, <sup>9</sup>Kinki University School of Medicine, Osaka, JP, <sup>10</sup>Kanazawa University, Kanazawa, JP, <sup>11</sup>Oita University Faculty of Medicine, Yufu, JP, <sup>12</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>13</sup>Shizuoka Cancer Center, Shizuoka, JP

12:45 - 12:45

**607TiP - BIG BANG study: A Multicenter Phase II Study of the MEK Inhibitor Binimetinib + BRAF Inhibitor Encorafenib + Anti-EGFR Antibody Cetuximab in Patients with BRAF Non-V600E Mutated Metastatic Colorectal Cancer (EPOC 1703)**

D. Kotani<sup>1</sup>, H. Bando<sup>1</sup>, T. Masuishi<sup>2</sup>, Y. Komatsu<sup>3</sup>, K. Yamaguchi<sup>4</sup>, T. Nakajima<sup>5</sup>, T. Satoh<sup>6</sup>, T. Nishina<sup>7</sup>, T. Esaki<sup>8</sup>, S. Nomura<sup>1</sup>, S. Sakamoto<sup>1</sup>, S. Iida<sup>1</sup>, S. Matsuda<sup>1</sup>, M. Yonemura<sup>1</sup>, N. Fuse<sup>1</sup>, A. Sato<sup>9</sup>, S. Fujii<sup>9</sup>, H. Ebi<sup>10</sup>, A. Ohtsu<sup>1</sup>, T. Yoshino<sup>1</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>3</sup>Hokkaido University Cancer Center, Sapporo, JP, <sup>4</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>5</sup>St Marianna University School of Medicine, Kawasaki city, JP, <sup>6</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>7</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>8</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>9</sup>National Cancer Center, Kashiwa, JP, <sup>10</sup>Aichi Cancer Center Research Institute, Nagoya, JP

12:45 - 12:45

**608TiP - BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701).**

T. Masuishi<sup>1</sup>, H. Taniguchi<sup>1</sup>, D. Kotani<sup>2</sup>, H. Bando<sup>2</sup>, Y. Komatsu<sup>3</sup>, K. Yamaguchi<sup>4</sup>, T. Nakajima<sup>5</sup>, T. Satoh<sup>6</sup>, T. Nishina<sup>7</sup>, T. Esaki<sup>8</sup>, M. Wakabayashi<sup>9</sup>, S. Nomura<sup>2</sup>, S. Sakamoto<sup>2</sup>, H. Ono<sup>2</sup>, N. Hirano<sup>2</sup>, N. Fujishiro<sup>2</sup>, N. Fuse<sup>2</sup>, A. Sato<sup>9</sup>, A. Ohtsu<sup>2</sup>, T. Yoshino<sup>2</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>Hokkaido University Hospital, Sapporo, JP, <sup>4</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>5</sup>St Marianna University School of Medicine, Kawasaki city, JP, <sup>6</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>7</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>8</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>9</sup>National Cancer Center, Kashiwa, JP

12:45 - 12:45

**609TiP - Intermittent or continuous Panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): a randomized phase 2 trial (IMPROVE)**

A. De Stefano<sup>1</sup>, G. Nasti<sup>1</sup>, A. Febbraro<sup>2</sup>, G. Rosati<sup>3</sup>, F. Giuliani<sup>4</sup>, D. Santini<sup>5</sup>, G. Aprile<sup>6</sup>, M. Scartozzi<sup>7</sup>, F. Silvestris<sup>8</sup>, G. Luppi<sup>9</sup>, I. Lolli<sup>10</sup>, C. Mastroianni<sup>11</sup>, S. Leo<sup>12</sup>, V. Montesarchio<sup>13</sup>, C. Gridelli<sup>14</sup>, C. Pozzo<sup>15</sup>, E. Sperti<sup>16</sup>, D. Giannarelli<sup>17</sup>, A. Budillon<sup>18</sup>, A. Avallone<sup>1</sup>, <sup>1</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>2</sup>Ospedale "Sacro Cuore di Gesù" Fatebenefratelli, Benevento, IT, <sup>3</sup>ospedale San Carlo, Potenza, IT, <sup>4</sup>ISTITUTO TUMORI GIOVANNI PAOLO II, Bari, IT, <sup>5</sup>Campus Bio-Medico di Roma, Rome, IT, <sup>6</sup>ULSS 8 Berica - Vicenza, Vicenza, IT, <sup>7</sup>University Hospital and University of Cagliari, Cagliari, IT, <sup>8</sup>Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, IT, <sup>9</sup>Private Practice, Modena, IT, <sup>10</sup>IRCCS Saverio de Bellis, Castellana Grotte, IT, <sup>11</sup>Azienda Ospedaliera di Cosenza, Cosenza, IT, <sup>12</sup>Ospedale Vito Fazzi, Lecce, IT, <sup>13</sup>Azienda Ospedaliera Dei Colli-Monaldi, Napoli, IT, <sup>14</sup>Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT, <sup>15</sup>Università Cattolica del Sacro Cuore, Rome, IT, <sup>16</sup>Ordine Mauriziano Hospital, Turin, IT, <sup>17</sup>IFO Regina Elena Roma, Roma, IT,

<sup>18</sup>Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", Naples, IT

- 12:45 - 12:45 **610TiP - Preoperative Nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): a window-of-opportunity study (NICOLE)**  
A. Avallone<sup>1</sup>, P. Delrio<sup>2</sup>, G. Nasti<sup>1</sup>, A. Cassata<sup>2</sup>, L. Silvestro<sup>2</sup>, A. De Stefano<sup>2</sup>, S. Lastoria<sup>2</sup>, R. Casaretti<sup>2</sup>, C. Romano<sup>2</sup>, A. Ottaiano<sup>1</sup>, E. Di Gennaro<sup>2</sup>, A. Nappi<sup>2</sup>, P. Maiolino<sup>2</sup>, E. Cavalcanti<sup>2</sup>, A. Petrillo<sup>2</sup>, F. Tatangelo<sup>2</sup>, D. Giannarelli<sup>3</sup>, J. Galon<sup>4</sup>, P. Ascierto<sup>1</sup>, A. Budillon<sup>2</sup>, <sup>1</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>2</sup>Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", Naples, IT, <sup>3</sup>IFO Regina Elena Roma, Roma, IT, <sup>4</sup>National Institute of Health and Medical Research, Paris, FR
- 12:45 - 12:45 **611TiP - AVEVAC. A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients. (GEMCAD 16-02)**  
M. Español Rego<sup>1</sup>, V. Alonso<sup>2</sup>, J. Aparicio<sup>3</sup>, E. Elez Fernandez<sup>4</sup>, P. Escudero<sup>5</sup>, C. Fernández-Martos<sup>6</sup>, N. Rodríguez<sup>7</sup>, A. Ruiz Casado<sup>8</sup>, J. Cid<sup>1</sup>, R. Cabezón<sup>1</sup>, M. Lozano<sup>1</sup>, A. Ginés<sup>1</sup>, L. Bianchi<sup>1</sup>, J. Garcia-Corbacho<sup>9</sup>, X. García De Albéniz<sup>10</sup>, J. Maurel<sup>1</sup>, D. Benitez Ribas<sup>1</sup>, <sup>1</sup>Hospital Clínic of Barcelona, Barcelona, ES, <sup>2</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>3</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, <sup>6</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>7</sup>H. U. Fundación Alcorcón, Madrid, ES, <sup>8</sup>Hospital Puerta de Hierro, Majadahonda, ES, <sup>9</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>10</sup>Harvard T.H. Chan School of Public Health, Boston (MA), US, Boston, US
- 12:45 - 12:45 **612TiP - Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer**  
A. Flament<sup>1</sup>, A. Hendlisz<sup>2</sup>, L. Shaza<sup>2</sup>, S. Aspeslagh<sup>2</sup>, M. Vouche<sup>2</sup>, V. Donckier<sup>2</sup>, A. Awada<sup>2</sup>, J.-P. Machiels<sup>3</sup>, M. Van Den Eynde<sup>3</sup>, J.-L. Canon<sup>4</sup>, J. Carrasco<sup>4</sup>, C. Lonzé<sup>1</sup>, F. Lehmann<sup>1</sup>, <sup>1</sup>Celyad SA, Mont Saint Guibert, BE, <sup>2</sup>Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BE, <sup>3</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>4</sup>Grand Hopital de Charleroi Site Notre Dame, Charleroi, BE
- 12:45 - 12:45 **613TiP - Serum levels of interleukin 8 (IL-8) and other cytokines as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic colo-rectal cancer patients: the FLIBER study**  
C. Buonerba<sup>1</sup>, S. Vecchiarelli<sup>2</sup>, F. Cappuzzo<sup>2</sup>, <sup>1</sup>AOU Policlinico Federico II, Napoli, IT, <sup>2</sup>Ospedale Civile di Ravenna - S.ta Maria delle Croci, Ravenna, IT
- 12:45 - 12:45 **614TiP - UCGI 28 Panirinox : a randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis.**  
T. Mazard<sup>1</sup>, F. Ghiringhelli<sup>2</sup>, C. Mollevi<sup>1</sup>, E. Assenat<sup>3</sup>, C. Gavaille<sup>4</sup>, D. Smith<sup>5</sup>, V. Pezzella<sup>6</sup>, R. Meddeb<sup>7</sup>, B. Pastor<sup>1</sup>, M. Ychou<sup>1</sup>, A. Thierry<sup>1</sup>, <sup>1</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>2</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>3</sup>CHU Saint Eloi, Montpellier, FR, <sup>4</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>5</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR,

<sup>6</sup>UNICANCER, PARIS cedex, FR, <sup>7</sup>IRCM, Montpellier, FR

12:45 - 12:45 **Gastrointestinal tumours, non-colorectal**

12:45 - 12:45 **627P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer.**

K. Kato<sup>1</sup>, T. Kojima<sup>2</sup>, H. Saeki<sup>3</sup>, H. Hara<sup>4</sup>, T. Kajiwara<sup>5</sup>, S. Hironaka<sup>6</sup>, H. Nakatsumi<sup>7</sup>, S. Kadowaki<sup>8</sup>, Y. Kagawa<sup>9</sup>, T. Esaki<sup>10</sup>, T. Moriwaki<sup>11</sup>, T. Kobayashi<sup>12</sup>, N. Izawa<sup>13</sup>, S. Nomura<sup>14</sup>, T. Kuwata<sup>14</sup>, S. Fujii<sup>15</sup>, W. Okamoto<sup>14</sup>, K. Shitara<sup>14</sup>, A. Ohtsu<sup>14</sup>, T. Yoshino<sup>14</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>National Cancer Center Hospital East, Kashiwa-shi, JP, <sup>3</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, <sup>4</sup>Saitama Cancer Center, Ina, JP, <sup>5</sup>National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, <sup>6</sup>Chiba Cancer Center, Chiba, JP, <sup>7</sup>Hokkaido University Hospital, Sapporo, JP, <sup>8</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>9</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>10</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>11</sup>University of Tsukuba, Tsukuba, JP, <sup>12</sup>Kyorin University Faculty of Medicine, Mitaka, JP, <sup>13</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>14</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>15</sup>National Cancer Center, Kashiwa, JP

12:45 - 12:45 **628P - Signal transduction pathway activity during neoadjuvant treatment in esophageal adenocarcinomas**

A. Creemers<sup>1</sup>, S. Meijer<sup>1</sup>, M. Stoffels<sup>2</sup>, G. Hooijer<sup>1</sup>, L. Holtzer<sup>2</sup>, H. Van Ooijen<sup>2</sup>, A. Van Brussel<sup>2</sup>, E. Aussems-Custers<sup>2</sup>, M. Van Berge Henegouwen<sup>3</sup>, M. Hulshof<sup>1</sup>, K. Krishnadath<sup>1</sup>, A. Van De Stolpe<sup>4</sup>, M. Bijlsma<sup>1</sup>, H. Van Laarhoven<sup>5</sup>, <sup>1</sup>Academic Medical Center (AMC), Amsterdam, NL, <sup>2</sup>Philips Research, Eindhoven, NL, <sup>3</sup>Academic Medical Center, Amsterdam, NL, <sup>4</sup>Philips, Eindhoven, NL, <sup>5</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL

12:45 - 12:45 **629P - Hypoxia Gene Expression Defines a Poor Prognostic Sub-group in Oesophageal Adenocarcinoma**

R. Douglas<sup>1</sup>, C. Mckinney<sup>2</sup>, L. Stevenson<sup>2</sup>, L. Cairns<sup>2</sup>, R. Kennedy<sup>2</sup>, J. Blayney<sup>2</sup>, R. Turkington<sup>2</sup>, <sup>1</sup>Centre for Cancer Research and Cell Biology, Belfast, GB, <sup>2</sup>Health Science Building, Belfast, GB

12:45 - 12:45 **630P - Neoadjuvant radio-chemotherapy for esophageal cancer: a multicenter european study comparing PACLITAXEL/CARBOPLATIN , 5FU/CISPLATIN and FOLFOX.**

P. Allemann<sup>1</sup>, S. Mantziari<sup>1</sup>, M. Winiker<sup>1</sup>, A. Wagner<sup>1</sup>, A. Digkila<sup>1</sup>, M. Van Berge Henegouwen<sup>2</sup>, S. Gisbertz<sup>2</sup>, A. Slaman<sup>2</sup>, R. Van Hillegersberg<sup>3</sup>, J. Ruurda<sup>3</sup>, H. Brenkman<sup>3</sup>, M. Nilsson<sup>4</sup>, K. Satoshi<sup>4</sup>, G. Piessen<sup>5</sup>, D. Collet<sup>6</sup>, C. Gronnier<sup>6</sup>, N. Carrere<sup>7</sup>, A. Marinho<sup>7</sup>, N. Demartines<sup>1</sup>, M. Schafer<sup>1</sup>, <sup>1</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>2</sup>Academic Medical Center, Amsterdam, NL, <sup>3</sup>University Medical Center Utrecht, Utrecht, NL, <sup>4</sup>Karolinska Institute, Huddinge, SE, <sup>5</sup>C.H.U. Claude Huriez, Lille, FR, <sup>6</sup>University Hospital Bordeaux, Bordeaux, FR, <sup>7</sup>CHU Toulouse, Toulouse, FR



- 12:45 - 12:45 **631P - Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy**
- A. Barbour<sup>1</sup>, S. Brosda<sup>2</sup>, B. Wijnhoven<sup>3</sup>, S. Van Hootgem<sup>3</sup>, J. Lanschot<sup>3</sup>, S. Barbour<sup>4</sup>, S. Lagarde<sup>3</sup>, L. Krause<sup>5</sup>, D. Pryor<sup>1</sup>, J. Thomas<sup>1</sup>, E. Walpole<sup>1</sup>, A. Van Der Gaast<sup>6</sup>, M. Smithers<sup>1</sup>, <sup>1</sup>Princess Alexandra Hospital, Woolloongabba, AU, <sup>2</sup>Diamantina Institute, Woolloongabba, AU, <sup>3</sup>Erasmus Medical Center, Rotterdam, NL, <sup>4</sup>Greenslopes Private Hospital, Greenslopes, AU, <sup>5</sup>The University of Queensland, Woolloongabba, AU, <sup>6</sup>Erasmus University Medical Center, Rotterdam, NL
- 12:45 - 12:45 **632P - induction chemotherapy for locally advanced esophageal cancer**
- G. Harada<sup>1</sup>, R. Bonadio<sup>2</sup>, F. De Araújo<sup>2</sup>, C. Victor<sup>2</sup>, F. Takeda<sup>2</sup>, R. Sallum<sup>2</sup>, U. Junior<sup>2</sup>, I. Cecconello<sup>2</sup>, T. De Castria<sup>2</sup>, <sup>1</sup>Instituto do Cncer do Estado de Sao Paulo, Sao Paulo, BR, <sup>2</sup>ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR
- 12:45 - 12:45 **633P - The role of comprehensive evaluation for clinical complete response in predicting pathologic complete response in patients treated with neoadjuvant chemoradiation for esophageal squamous cell carcinoma (ESCC)**
- H.-S. Im<sup>1</sup>, J. Kang<sup>1</sup>, Y.-H. Kim<sup>2</sup>, H.R. Kim<sup>2</sup>, J.H. Kim<sup>2</sup>, H.-Y. Jung<sup>1</sup>, G.-H. Lee<sup>2</sup>, H.J. Song<sup>2</sup>, D.H. Kim<sup>2</sup>, K.D. Choi<sup>2</sup>, J.H. Lee<sup>2</sup>, J.Y. Ahn<sup>2</sup>, J.-S. Ryu<sup>2</sup>, K.-J. Cho<sup>2</sup>, S.-B. Kim<sup>3</sup>, S.R. Park<sup>1</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, seoul, KR, <sup>3</sup>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 12:45 - 12:45 **634P - Prognostic impact of inflammation-based scores in esophageal cancer patients achieving pathologic complete response after neoadjuvant chemoradiotherapy followed by surgery**
- J. Kang<sup>1</sup>, H.-S. Im<sup>2</sup>, Y.-H. Kim<sup>2</sup>, H.R. Kim<sup>2</sup>, J.H. Kim<sup>2</sup>, H.-Y. Jung<sup>2</sup>, G.-H. Lee<sup>2</sup>, H.J. Song<sup>2</sup>, D.H. Kim<sup>2</sup>, K.D. Choi<sup>2</sup>, J.H. Lee<sup>2</sup>, J.Y. Ahn<sup>2</sup>, J.-S. Ryu<sup>2</sup>, K.-J. Cho<sup>2</sup>, S.-B. Kim<sup>3</sup>, S.R. Park<sup>2</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, seoul, KR, <sup>3</sup>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 12:45 - 12:45 **635P - Association of sarcopenia with dose-limiting toxicities and survival in oesophageal adenocarcinoma treated with neoadjuvant chemotherapy**
- J. Weaver<sup>1</sup>, C. Cipriano<sup>1</sup>, A. Mcwilliam<sup>2</sup>, Z. Kordatou<sup>1</sup>, M. Abraham<sup>1</sup>, T. Germetaki<sup>1</sup>, G. Papaxoinis<sup>1</sup>, W. Mansoor<sup>1</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>University of Manchester, Manchester, GB
- 12:45 - 12:45 **636P - Survival Benefit of Re-irradiation in Esophageal Cancer Patients with Locoregional Recurrence: A Propensity Score Matched Analysis**
- K. Xiangquan<sup>1</sup>, Y. Huang<sup>2</sup>, B. Zheng<sup>2</sup>, Q. Zhuang<sup>2</sup>, X. Zhang<sup>3</sup>, L. Tang<sup>2</sup>, J. Li<sup>4</sup>, J. Wu<sup>2</sup>, <sup>1</sup>Tumor Hospital of Fujian Province, Fuzhou, CN, <sup>2</sup>Fujian Medical University Cancer Hospital, Fuzhou , Fujian, CN, <sup>3</sup>Fujian Medical University Cancer Hospital, Fuzhou, CN, <sup>4</sup>Fujian Cancer Hospital, Fuzhou, CN
- 12:45 - 12:45 **637P - Magnetic resonance imaging in oesophageal (oes) cancer: results from**



**the ST03 MRI substudy**

M. Davidson<sup>1</sup>, M. Nankivell<sup>2</sup>, D. Cunningham<sup>3</sup>, N. Starling<sup>1</sup>, D.-M. Koh<sup>1</sup>, G. Brown<sup>3</sup>, W. Allum<sup>1</sup>, A. Wotherspoon<sup>4</sup>, E. Smyth<sup>5</sup>, L. Ly<sup>2</sup>, N. Kleovoulou<sup>2</sup>, R. Langley<sup>2</sup>, A. Riddell<sup>1</sup>,  
<sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>University College London, London, GB, <sup>3</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>4</sup>Royal Marsden Hospital NHS Foundation Trust, Sutton, GB, <sup>5</sup>The Francis Crick Institute, London, GB

12:45 - 12:45

**638P - Prognostic Value of Pretreatment Diffusion Weighted Magnetic Resonance Imaging based Texture in Concurrent Chemo-radiotherapy of Esophageal Squamous Cell Cancer**

B. Li<sup>1</sup>, Z. Li<sup>2</sup>, C. Han<sup>3</sup>, <sup>1</sup>Cancer Hospital and Institute of Shandong, Jinan, CN, <sup>2</sup>Shandong Cancer Hospital, Jinan, CN, <sup>3</sup>Hebei Cancer Hospital, Shijiazhuang, CN

12:45 - 12:45

**639P - Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?**

S. Nagasawa<sup>1</sup>, T. Ogata<sup>1</sup>, K. Hara<sup>1</sup>, Y. Shimoda<sup>1</sup>, M. Nakazono<sup>1</sup>, Y. Kumazu<sup>1</sup>, T. Hayashi<sup>1</sup>, T. Yamada<sup>1</sup>, Y. Rino<sup>2</sup>, M. Masuda<sup>2</sup>, T. Yoshikawa<sup>1</sup>, T. Oshima<sup>1</sup>, <sup>1</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>2</sup>Yokohama City University, Yokohama, JP

12:45 - 12:45

**640P - A model using computed tomography-based compactness to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma**

Q. Wang<sup>1</sup>, B. Cao<sup>2</sup>, J. Chen<sup>3</sup>, T. Li<sup>1</sup>, J. Lang<sup>1</sup>, Z. Xiao<sup>4</sup>, <sup>1</sup>Sichuan Cancer Hospital & Institute, Chengdu, CN, <sup>2</sup>Sichuan Cancer Hospital & Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, CN, <sup>3</sup>Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, China, Fuzhou, CN, <sup>4</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Beijing, CN

12:45 - 12:45

**641P - Clinical significance of 18F-fluorodeoxyglucose-positron emission tomography-positive lymph nodes to outcomes of trimodal therapy for esophageal squamous cell carcinoma**

Y. Hamai<sup>1</sup>, M. Emi<sup>1</sup>, Y. Ibuki<sup>1</sup>, M. Okada<sup>2</sup>, <sup>1</sup>Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JP, <sup>2</sup>Hiroshima University, Hiroshima, JP

12:45 - 12:45

**642P - Phase 1 study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor- $\alpha$  (TGF- $\alpha$ ) and PD-L1**

C.-C. Lin<sup>1</sup>, T. Doi<sup>2</sup>, K. Muro<sup>3</sup>, M.-M. Hou<sup>4</sup>, T. Esaki<sup>5</sup>, H. Hara<sup>6</sup>, H.-C. Chung<sup>7</sup>, M. Osada<sup>8</sup>, C. Helwig<sup>9</sup>, S. Kondo<sup>10</sup>, <sup>1</sup>National Taiwan University Hospital, Taipei city, TW, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>4</sup>Chang Gung Memorial Hospital-Linkou, Taoyuan, TW, <sup>5</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>6</sup>Saitama Cancer Center, Ina, JP, <sup>7</sup>Severance Hospital, Seoul, KR, <sup>8</sup>Merck Serono, Tokyo, JP, <sup>9</sup>Merck KGaA, Darmstadt, DE, <sup>10</sup>National Cancer Center Hospital, Tokyo, JP

- 12:45 - 12:45 **643P - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ , in patients with post-platinum esophageal adenocarcinoma (EAC): preliminary results from a phase 1 cohort**  
B. Tan<sup>1</sup>, A. Khattak<sup>2</sup>, E. Felip<sup>3</sup>, K. Kelly<sup>4</sup>, P. Rich<sup>5</sup>, D. Wang<sup>6</sup>, C. Helwig<sup>7</sup>, I. Dussault<sup>8</sup>, L. Ojalvo<sup>8</sup>, N. Isambert<sup>9</sup>, <sup>1</sup>Washington University School of Medicine, Saint Louis, US, <sup>2</sup>Fiona Stanley Hospital, Murdoch, AU, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>University of California Davis Cancer Center, Sacramento, US, <sup>5</sup>Cancer Treatment Centers of America Lung Cancer Institute, Newnan, US, <sup>6</sup>Henry Ford Hospital, Detroit, US, <sup>7</sup>Merck KGaA, Darmstadt, DE, <sup>8</sup>EMD Serono, Billerica, US, <sup>9</sup>Centre Georges-François Leclerc, Dijon, FR
- 12:45 - 12:45 **644P - The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Pancreatic Cancer.**  
N. Izawa<sup>1</sup>, C. Morizane<sup>2</sup>, H. Takahashi<sup>3</sup>, M. Ueno<sup>4</sup>, Y. Kawamoto<sup>5</sup>, N. Okano<sup>6</sup>, S. Shimizu<sup>7</sup>, K. Sudo<sup>8</sup>, S. Itoh<sup>9</sup>, A. Asagi<sup>10</sup>, Y. Kagawa<sup>11</sup>, K. Kamata<sup>12</sup>, T. Kudo<sup>13</sup>, S. Nomura<sup>3</sup>, T. Kuwata<sup>3</sup>, S. Fujii<sup>14</sup>, W. Okamoto<sup>3</sup>, K. Shitara<sup>3</sup>, A. Ohtsu<sup>3</sup>, T. Yoshino<sup>3</sup>, <sup>1</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>5</sup>Hokkaido University Hospital, Sapporo, JP, <sup>6</sup>Kyorin university Hospital, Tokyo, JP, <sup>7</sup>Saitama Cancer Center, Kitaadachigun, JP, <sup>8</sup>Chiba Cancer Center, Chiba, JP, <sup>9</sup>Kyushu University Hospital, Fukuoka, JP, <sup>10</sup>Shikoku Cancer Center, yona, JP, <sup>11</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>12</sup>Kindai University Faculty of Medicine, ina, JP, <sup>13</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>14</sup>National Cancer Center, Kashiwa, JP
- 12:45 - 12:45 **645P - Spatial Genomic Heterogeneity from Multi-Region Endoscopic Biopsies in Primary Gastric Cancer: Implications for Precision Therapy**  
S. Klempner<sup>1</sup>, J. Chao<sup>2</sup>, K. Kim<sup>3</sup>, K.-M. Kim<sup>3</sup>, S.-T. Kim<sup>3</sup>, J. Lee<sup>3</sup>, H. Lee<sup>3</sup>, <sup>1</sup>The Angeles Clinic and Research Institute, Los Angeles, US, <sup>2</sup>City of Hope, Duarte, US, <sup>3</sup>Samsung Medical Center, Seoul, KR
- 12:45 - 12:45 **646P - EGFR amplification (amp) and survival in the REAL-3 trial**  
E. Smyth<sup>1</sup>, K. Kouvelakis<sup>2</sup>, D. Cunningham<sup>2</sup>, J.C. Hahne<sup>3</sup>, C. Peckitt<sup>2</sup>, G. Vlachogiannis<sup>4</sup>, D. Watkins<sup>5</sup>, S. Rao<sup>2</sup>, N. Starling<sup>2</sup>, S.H. Wilson<sup>4</sup>, T. Wadell<sup>6</sup>, A. Okines<sup>2</sup>, T. Crosby<sup>7</sup>, W. Mansoor<sup>6</sup>, J. Wadsley<sup>8</sup>, G. Middleton<sup>9</sup>, A. Wotherspoon<sup>10</sup>, I. Chau<sup>4</sup>, N. Valeri<sup>3</sup>, <sup>1</sup>The Francis Crick Institute, London, GB, <sup>2</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>3</sup>The Royal Marsden NHS Foundation Trust in Chelsea, London, GB, <sup>4</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>5</sup>Royal Marsden Hospital, Sutton, GB, <sup>6</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>7</sup>Velindre Cancer Centre, Cardiff, GB, <sup>8</sup>Weston Park Hospital Cancer Research Centre, Sheffield, GB, <sup>9</sup>University of Birmingham, Birmingham, GB, <sup>10</sup>Royal Marsden Hospital NHS Foundation Trust , Sutton, GB
- 12:45 - 12:45 **647P - The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy**  
M. Skupinska<sup>1</sup>, M. Jesiotr<sup>2</sup>, P. Chrom<sup>3</sup>, A. Mroz<sup>4</sup>, S. Cierniak<sup>2</sup>, M. Winiarek<sup>4</sup>, L. Wyrwicz<sup>5</sup>, J. Pieczykolan<sup>6</sup>, M. Wieczorek<sup>7</sup>, A. Stanczak<sup>1</sup>, L. Bodnar<sup>3</sup>, <sup>1</sup>Celon Pharma, Warsaw, PL, <sup>2</sup>Military Institute of Medicine, Warsaw, PL, <sup>3</sup>Military Medical Institute, Warsaw, PL, <sup>4</sup>M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, PL, <sup>5</sup>The

Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, <sup>6</sup>Celon Pharma, Lomianki, PL, <sup>7</sup>Celon Pharma S.A., Lomianki, PL

- 12:45 - 12:45 **648P - Changes in CpG methylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A in gastric adenocarcinoma**  
N. Timoshkina<sup>1</sup>, O. Kit<sup>1</sup>, D. Vodolazhskiy<sup>2</sup>, N. Soldatkina<sup>2</sup>, Y. Gevorkyan<sup>1</sup>, N. Samoylenko<sup>1</sup>, D. Kharagezov<sup>1</sup>, M. Duritskiy<sup>1</sup>, A. Dashkov<sup>1</sup>, D. Kaymakchi<sup>1</sup>, D. Petrov<sup>1</sup>, S. Ilchenko<sup>2</sup>, V. Sustretov<sup>1</sup>, L. Vladimirova<sup>1</sup>, <sup>1</sup>Rostov Research Institute of Oncology, Rostov-on-Don, RU, <sup>2</sup>Rostov Research Oncology Institute, Rostov-on-Don, RU
- 12:45 - 12:45 **649P - The level of somatic mutations as an indicator of overall survival in gastric cancer**  
T. Kekeeva<sup>1</sup>, A. Tanas<sup>2</sup>, L. Khashimov<sup>3</sup>, V. Lyadov<sup>4</sup>, Y. Andreeva<sup>5</sup>, G. Frank<sup>5</sup>, L. Zavalishina<sup>5</sup>, D. Zaletaev<sup>6</sup>, V. Strelnikov<sup>7</sup>, <sup>1</sup>Medical and Rehabilitation Center, Moscow, RU, <sup>2</sup>Research Centre for Medical Genetics, Moscow, RU, <sup>3</sup>Russian Medical Academy of Postgraduate Education, Moscow, RU, <sup>4</sup>Treatment and Rehabilitation Center, Moscow, RU, <sup>5</sup>Russian Medical Academy of Continuous Professional Education, Moscow, RU, <sup>6</sup>Sechenov First Moscow State Medical University, Moscow, RU, <sup>7</sup>Institute of molecular medicine, Moscow, RU
- 12:45 - 12:45 **650P - mechanisms of G9a on promoting tumor invasion and metastasis of gastric cancer**  
B. Liu, L. Hu, Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN
- 12:45 - 12:45 **651P - Prospective Observation: Clinicopathological Features and Clinical Utility of Plasma Epstein-Barr Virus DNA Load of Epstein-Barr Virus-associated Gastric Carcinoma**  
M.-Z. Qiu, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:45 - 12:45 **652P - Is standard adjuvant chemotherapy effective in patients with Epstein-Barr virus associated gastric cancer?**  
J.G. Kim<sup>1</sup>, Y. Chae<sup>2</sup>, J.H. Baek<sup>3</sup>, B.W. Kang<sup>1</sup>, <sup>1</sup>Kyungpook National University Hospital, Daegu, KR, <sup>2</sup>Kyungpook National University Medical Center, Daegu, KR, <sup>3</sup>Ulsan University Hospital, Ulsan, KR
- 12:45 - 12:45 **653P - PD-L1 Expression and T-Cell Inflamed Gene Expression Profile (GEP) in Korean and US Patients (pts) With Advanced Gastric Cancer (GC)**  
S.Y. Rha<sup>1</sup>, G. Ku<sup>2</sup>, H.S. Kim<sup>3</sup>, H.C. Chung<sup>3</sup>, F.G. Amlashi<sup>4</sup>, D. Maru<sup>4</sup>, C. Fein<sup>2</sup>, L. Tang<sup>2</sup>, M. Savage<sup>5</sup>, W. Zhou<sup>5</sup>, T. Wu<sup>5</sup>, S. Peter<sup>6</sup>, D. Kelsen<sup>7</sup>, J. Ajani<sup>4</sup>, <sup>1</sup>Yonsei Cancer Center, Seoul, KR, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Merck & Co., Inc., Kenilworth, US, <sup>6</sup>Merck & Co Inc, North Wales, US, <sup>7</sup>Merck & Co., Inc., New York, US
- 12:45 - 12:45 **654P - Relationship between immune related molecules and chemosensitivity and prognosis in gastric cancer**



T. Hagi<sup>1</sup>, Y. Kurokawa<sup>2</sup>, T. Hashimoto<sup>2</sup>, Y. Miyazaki<sup>2</sup>, T. Takahashi<sup>2</sup>, K. Tanaka<sup>1</sup>, T. Makino<sup>1</sup>, M. Yamasaki<sup>1</sup>, K. Nakajima<sup>1</sup>, M. Mori<sup>1</sup>, Y. Doki<sup>1</sup>, <sup>1</sup>Osaka University Graduate School of Medicine, Osaka, JP, <sup>2</sup>Osaka University Graduate School of Medicine, Suita, JP

12:45 - 12:45 **655P - Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma**

C. Siesing<sup>1</sup>, M. Svensson<sup>2</sup>, C. Hedner<sup>1</sup>, B. Nodin<sup>3</sup>, D. Borg<sup>4</sup>, K. Jirstrom<sup>5</sup>, <sup>1</sup>Lund University-Institution of Clinical Sciences-Oncology and Pathology, Lund, SE, <sup>2</sup>Skane University Hospital-Lund, Lund, SE, <sup>3</sup>Clinical Sciences, Lund, SE, <sup>4</sup>Lund University, Faculty of Medicine, Lund, SE, <sup>5</sup>Lund University, Lund, SE

12:45 - 12:45 **656P - Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: an exploratory analysis of JCOG1302A**

Y. Sato<sup>1</sup>, J. Mizusawa<sup>2</sup>, K. Nakamura<sup>2</sup>, T. Fukagawa<sup>3</sup>, H. Katai<sup>4</sup>, S. Haruta<sup>5</sup>, M. Yamada<sup>6</sup>, M. Takagi<sup>7</sup>, S. Tamura<sup>8</sup>, T. Yoshimura<sup>9</sup>, T. Inada<sup>10</sup>, N. Hirabayashi<sup>11</sup>, I. Wada<sup>12</sup>, Y. Kodera<sup>13</sup>, M. Tokunaga<sup>14</sup>, T. Yoshikawa<sup>15</sup>, N. Boku<sup>16</sup>, T. Sano<sup>17</sup>, M. Sasako<sup>18</sup>, M. Terashima<sup>14</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, Japan, Tokyo, JP, <sup>2</sup>National Cancer Center, Tokyo, JP, <sup>3</sup>Teikyo University Hospital, Tokyo, JP, <sup>4</sup>National Cancer Center Hospital, Tokyo, JP, <sup>5</sup>Toranomon Hospital, Tokyo, JP, <sup>6</sup>Gifu Municipal Hospital, Gifu, JP, <sup>7</sup>Shizuoka General Hospital, Shizuoka, JP, <sup>8</sup>Yao Municipal Hospital, Osaka, JP, <sup>9</sup>Tenri Hospital, Tokyo, JP, <sup>10</sup>Tochigi Cancer Center, Tochigi, JP, <sup>11</sup>Hiroshima City Asa Hospital, Hiroshima, JP, <sup>12</sup>Tokyo Metropolitan Bokutoh Hospital, Tokyo, JP, <sup>13</sup>Nagoya University Graduate School of Medicine, Nagoya, JP, <sup>14</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>15</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>16</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>17</sup>Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, <sup>18</sup>Hyogo College of Medicine, Nishinomiya, JP

12:45 - 12:45 **657P - Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?**

K. Hara<sup>1</sup>, T. Hayashi<sup>1</sup>, Y. Shimoda<sup>1</sup>, M. Nakazono<sup>1</sup>, S. Nagasawa<sup>1</sup>, Y. Kumazu<sup>1</sup>, T. Yamada<sup>1</sup>, Y. Rino<sup>2</sup>, M. Masuda<sup>2</sup>, T. Ogata<sup>1</sup>, T. Oshima<sup>1</sup>, T. Yoshikawa<sup>1</sup>, <sup>1</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>2</sup>Yokohama City University, Yokohama, JP

12:45 - 12:45 **658P - Patient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA)**

R. Morlock<sup>1</sup>, M. Krukas-Hampel<sup>2</sup>, Ö. Türeci<sup>3</sup>, <sup>1</sup>Astellas Pharma Global Development, Inc., Northbrook, US, <sup>2</sup>IQVIA Global Consulting Services, New York, US, <sup>3</sup>Cluster for Individualized Immune Intervention, Mainz, DE

12:45 - 12:45 **659P - Avelumab (anti-PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated results from the phase 1b JAVELIN Solid Tumor JPN trial**

T. Doi<sup>1</sup>, S. Iwasa<sup>2</sup>, K. Muro<sup>3</sup>, T. Satoh<sup>4</sup>, S. Hironaka<sup>5</sup>, T. Esaki<sup>6</sup>, T. Nishina<sup>7</sup>, H. Hara<sup>8</sup>, N. Machida<sup>9</sup>, Y. Komatsu<sup>10</sup>, Y. Shimada<sup>11</sup>, S. Otsu<sup>12</sup>, S. Shimizu<sup>13</sup>, V. Chand<sup>14</sup>, M. Watanabe<sup>13</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>4</sup>Osaka University



Graduate School of Medicine, Suita, JP, <sup>5</sup>Chiba Cancer Center, Chiba, JP, <sup>6</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>7</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>8</sup>Saitama Cancer Center, Ina, JP, <sup>9</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>10</sup>Hokkaido University Hospital, Sapporo, JP, <sup>11</sup>Kochi Health Sciences Center, Kochi, JP, <sup>12</sup>Oita University Hospital, Oita, JP, <sup>13</sup>Merck Serono Co., Ltd, Tokyo, JP, <sup>14</sup>EMD Serono, Inc, Billerica, US

12:45 - 12:45

**660P - Safety and Efficacy of a DKK1 Inhibitor (DKN-01) in Combination with Pembrolizumab (P) in Patients (Pts) with Advanced Gastroesophageal (GE) Malignancies**

S. Klempner<sup>1</sup>, J. Bendell<sup>2</sup>, V. Meucci Villaflor<sup>3</sup>, L. Tenner<sup>4</sup>, S. Stein<sup>5</sup>, C. Sirard<sup>6</sup>, W. Newman<sup>6</sup>, M. Kagey<sup>6</sup>, K. Schlienger<sup>7</sup>, J. Strickler<sup>8</sup>, <sup>1</sup>The Angeles Clinic and Research Institute, Los Angeles, US, <sup>2</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>3</sup>Northwestern University Feinberg School of Medicine, Chicago, US, <sup>4</sup>University of Texas Health Science Center, San Antonio, US, <sup>5</sup>Yale School of Medicine, New Haven, US, <sup>6</sup>Leap Therapeutics, Inc., Cambridge, US, <sup>7</sup>Merck & Co, Rahway, US, <sup>8</sup>Duke University Medical Center, Durham, US

12:45 - 12:45

**661P - Updated results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ , in patients with pretreated recurrent or refractory gastric cancer**

Y.-J. Bang<sup>1</sup>, T. Doi<sup>2</sup>, S. Kondo<sup>3</sup>, H.C. Chung<sup>4</sup>, K. Muro<sup>5</sup>, I. Dussault<sup>6</sup>, C. Helwig<sup>7</sup>, M. Osada<sup>8</sup>, Y.-K. Kang<sup>9</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>National Cancer Center Hospital, Tokyo, JP, <sup>4</sup>Yonsei University College of Medicine, Seoul, KR, <sup>5</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>6</sup>EMD Serono, Billerica, US, <sup>7</sup>Merck KGaA, Darmstadt, DE, <sup>8</sup>Merck Serono, Tokyo, JP, <sup>9</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

12:45 - 12:45

**662P - Biomarker-Guided Enrichment of the Antitumor Activity of Margetuximab (M) plus Pembrolizumab (P) in Patients with Advanced HER2+ Gastric Adenocarcinoma (GEA)**

D. Catenacci<sup>1</sup>, H. Park<sup>2</sup>, H. Uronis<sup>3</sup>, Y.-K. Kang<sup>4</sup>, M. Ng<sup>5</sup>, P. Gold<sup>6</sup>, J. Lacy<sup>7</sup>, P. Enzinger<sup>8</sup>, S. Park<sup>9</sup>, K.-W. Lee<sup>10</sup>, J. Yen<sup>11</sup>, J. Odegaard<sup>11</sup>, A. Franovic<sup>11</sup>, J. Baughman<sup>12</sup>, J. Muth<sup>13</sup>, A. Wynter-Horton<sup>13</sup>, T. Wu<sup>13</sup>, J. Wigginton<sup>13</sup>, J. Davidson-Moncada<sup>13</sup>, Y.-J. Bang<sup>14</sup>, <sup>1</sup>The University of Chicago Medical Centre, Chicago, US, <sup>2</sup>Washington University, St. Louis, US, <sup>3</sup>Duke University Medical Center, Durham, US, <sup>4</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>5</sup>National Cancer Centre (NCC), Singapore, Singapore, SG, <sup>6</sup>Swedish Medical Center, Seattle, US, <sup>7</sup>Yale School of Medicine, New Haven, US, <sup>8</sup>Dana-Farber Cancer Institute, Boston, US, <sup>9</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>10</sup>Seoul National University Bundang Hospital, Seoul, KR, <sup>11</sup>Guardant Health, Redwood City, US, <sup>12</sup>MacroGenics, Inc., Brisbane, US, <sup>13</sup>MacroGenics, Inc., Rockville, US, <sup>14</sup>Seoul National University Hospital, Seoul, KR

12:45 - 12:45

**663P - HER2 alterations is associated with higher tumor mutation burden in gastric cancer**

B. Wei<sup>1</sup>, Z. Li<sup>2</sup>, Q. Han<sup>3</sup>, X. Xing<sup>4</sup>, Y. Hao<sup>5</sup>, J. Zhou<sup>6</sup>, Y. Zhang<sup>7</sup>, S. Cai<sup>7</sup>, Y. Gu<sup>8</sup>, <sup>1</sup>The Third affiliated hospital, Sun Yat-Sen University, Guangzhou, CN, <sup>2</sup>Beijing Cancer Hospital, Beijing, CN, <sup>3</sup>The General Hospital of People's Liberation Army(301 hospital), Beijing, CN, <sup>4</sup>Cancer Hospital of China Medical University, Liaoning Cancer Hospital and

Institute, Shengyang, CN, <sup>5</sup>Southwest Hospital, Chongqing, CN, <sup>6</sup>Peking University People's Hospital, Beijing, CN, <sup>7</sup>3D Medicines Co., Ltd, Shanghai, CN, <sup>8</sup>Jiangsu Province Hospital, Nanjing, CN

- 12:45 - 12:45 **664P - Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)**  
M. Alsina Maqueda<sup>1</sup>, A. Varga<sup>2</sup>, A. Amatu<sup>3</sup>, J. Schellens<sup>4</sup>, P. Witteveen<sup>5</sup>, V. Boni<sup>6</sup>, V. Moreno<sup>7</sup>, K. Bol<sup>8</sup>, A. Lourbakos<sup>8</sup>, M. Magin Ferrer<sup>8</sup>, E. Wasserman<sup>9</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>Gustave Roussy, Villejuif, FR, <sup>3</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, <sup>4</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>5</sup>UMC - University Medical Center Utrecht, Utrecht, NL, <sup>6</sup>START Madrid-CIOCC HM Hospital Sanchinarro, Madrid, ES, <sup>7</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>8</sup>Merus NV, Utrecht, NL, <sup>9</sup>Merus, Cambridge, US
- 12:45 - 12:45 **665P - NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer**  
V. Gambardella<sup>1</sup>, F. Gimeno-Valiente<sup>2</sup>, N. Tarazona Llaveró<sup>1</sup>, T. Fleitas Kanonnikoff<sup>2</sup>, P. Tolosa<sup>3</sup>, M. Belda Moscardó<sup>2</sup>, B. Garcia-Mico<sup>2</sup>, M. Huerta<sup>2</sup>, S. Roselló<sup>2</sup>, D. Roda<sup>2</sup>, A. Cervantes<sup>1</sup>, J. Castillo<sup>2</sup>, <sup>1</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>2</sup>Biomedical Research Institute INCLIVA, Valencia, ES, <sup>3</sup>Hospital Clinico Universitario de Valencia. INCLIVA., Valencia, ES
- 12:45 - 12:45 **666P - Discordance between HER2 Expression status in Primary Tumor and Matched Malignant Ascites in Gastric Adenocarcinoma**  
Y. Yang<sup>1</sup>, H. Kim<sup>2</sup>, S.-M. Son<sup>2</sup>, H.S. Han<sup>2</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>Chungbuk National University Hospital, Cheongju-si, KR
- 12:45 - 12:45 **667P - A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).**  
K. Chin<sup>1</sup>, A. Takashima<sup>2</sup>, K. Minashi<sup>3</sup>, S. Kadowaki<sup>4</sup>, T. Nishina<sup>5</sup>, T. Nakajima<sup>6</sup>, K. Amagai<sup>7</sup>, N. Machida<sup>8</sup>, M. Gotoh<sup>9</sup>, K. Taku<sup>10</sup>, N. Ishizuka<sup>1</sup>, D. Takahari<sup>1</sup>, <sup>1</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>Chiba Cancer Center, Chiba, JP, <sup>4</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>5</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>6</sup>St Marianna University School of Medicine, Kawasaki city, JP, <sup>7</sup>Ibaraki Prefectural Central Hospital, Kasama, JP, <sup>8</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>9</sup>Osaka Medical College, Takatsuki, JP, <sup>10</sup>Shizuoka Prefectural Hospital, Shizuoka, JP
- 12:45 - 12:45 **668P - Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B**  
S. Yuki<sup>1</sup>, K. Shinozaki<sup>2</sup>, T. Kashiwada<sup>3</sup>, T. Kusumoto<sup>4</sup>, M. Iwatsuki<sup>5</sup>, H. Satake<sup>6</sup>, S. Tokunaga<sup>7</sup>, Y. Emi<sup>8</sup>, A. Makiyama<sup>9</sup>, Y. Kawamoto<sup>1</sup>, Y. Komatsu<sup>1</sup>, M. Shimokawa<sup>10</sup>, H. Saeki<sup>11</sup>, E. Oki<sup>7</sup>, H. Baba<sup>5</sup>, Y. Maehara<sup>12</sup>, <sup>1</sup>Hokkaido University Hospital, Sapporo, JP, <sup>2</sup>Hiroshima Prefectural Hospital, Hiroshima, JP, <sup>3</sup>Saga Univ Faculty of Medicine-Nabeshima, Saga, JP, <sup>4</sup>National Kyushu Medical Center, Fukuoka, JP, <sup>5</sup>Kumamoto

University, Kumamoto, JP, <sup>6</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>7</sup>Kyushu University Hospital, Fukuoka, JP, <sup>8</sup>Saiseikai Fukuoka General Hospital, FUKUOKA, JP, <sup>9</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>10</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>11</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, <sup>12</sup>Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JP

12:45 - 12:45

**669P - Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ).**

N. Martinez Lago<sup>1</sup>, S. Candamio Folgar<sup>2</sup>, C. Grande Ventura<sup>3</sup>, M. Salgado Fernandez<sup>4</sup>, J. De La Camara Gomez<sup>5</sup>, J.C. Méndez Méndez<sup>6</sup>, D. Arias Ron<sup>4</sup>, F. Vazquez<sup>7</sup>, M. Reboredo Lopez<sup>1</sup>, Y. Vidal Insua<sup>2</sup>, B. Graña Suarez<sup>1</sup>, M. Jorge Fernandez<sup>3</sup>, M.E. Brozos Vazquez<sup>8</sup>, M.L. Pellon Augusto<sup>5</sup>, J. Prato Varela<sup>1</sup>, P. Gonzalez Villarroya<sup>3</sup>, A. Fernandez Montes<sup>9</sup>, <sup>1</sup>Hospital Universitario a Coruna, A Coruna, ES, <sup>2</sup>University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, ES, <sup>3</sup>Hospital Universitario Alvaro Cunqueiro, Vigo, ES, <sup>4</sup>Complejo Hospitalario De Ourense, Ourense, ES, <sup>5</sup>Complejo Hospitalario Universitario de Ferrol, Ferrol, ES, <sup>6</sup>Centro Oncológico de Galicia, A Coruña, ES, <sup>7</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>8</sup>Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, ES, <sup>9</sup>Complejo Hospitalario Universitario de Ourense, Ourense, ES

12:45 - 12:45

**670P - Phase II study of S-1 and Oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)**

K. Kobayashi<sup>1</sup>, M. Iwatsuki<sup>2</sup>, H. Orita<sup>3</sup>, S. Hidaka<sup>4</sup>, T. Arigami<sup>5</sup>, T. Kusumoto<sup>6</sup>, H. Satake<sup>7</sup>, E. Oki<sup>8</sup>, K. Satoshi<sup>9</sup>, K. Tobimatsu<sup>10</sup>, M. Shimokawa<sup>11</sup>, H. Saeki<sup>12</sup>, A. Makiyama<sup>13</sup>, Y. Kakeji<sup>14</sup>, S. Natsugoe<sup>15</sup>, H. Baba<sup>2</sup>, S. Eguchi<sup>16</sup>, Y. Maehara<sup>17</sup>, <sup>1</sup>Nagasaki University Hospital, Nagasaki, JP, <sup>2</sup>Kumamoto University, Kumamoto, JP, <sup>3</sup>NAKATSU MUNICIPAL HOSPITAL, Nakatsu, JP, <sup>4</sup>Graduate school of biomedical sciences, Nagasaki University, Nagasaki, JP, <sup>5</sup>Department of Onco-biological Surgery, Kagoshima, JP, <sup>6</sup>National Kyushu Medical Center, Fukuoka, JP, <sup>7</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>8</sup>Kyushu University Hospital, Fukuoka, JP, <sup>9</sup>Karolinska Institute, Huddinge, SE, <sup>10</sup>Kobe University Graduate School of Medicine, Kobe, JP, <sup>11</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>12</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, <sup>13</sup>National Kyushu Cancer Center, FUKUOKA, JP, <sup>14</sup>Graduate School of Medicine, Kobe University, Kobe, JP, <sup>15</sup>Kagoshima University, Kagoshima, JP, <sup>16</sup>Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JP, <sup>17</sup>Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, JP

12:45 - 12:45

**671P - A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)**

R. Kawabata<sup>1</sup>, T. Terazawa<sup>2</sup>, J. Matsuyama<sup>3</sup>, S. Endo<sup>4</sup>, O. Shiraishi<sup>5</sup>, S. Fujita<sup>6</sup>, Y. Akamaru<sup>7</sup>, H. Taniguchi<sup>8</sup>, M. Tatsumi<sup>9</sup>, M. Gotoh<sup>2</sup>, S.-W. Lee<sup>2</sup>, Y. Kurokawa<sup>10</sup>, T. Shimokawa<sup>11</sup>, D. Sakai<sup>12</sup>, T. Kato<sup>13</sup>, K. Fujitani<sup>14</sup>, T. Satoh<sup>10</sup>, <sup>1</sup>Osaka Rosai Hospital, Sakai, JP, <sup>2</sup>Osaka Medical College, Takatsuki, JP, <sup>3</sup>Yao Municipal Hospital, Yao, JP, <sup>4</sup>Higashiosaka City General Hospital, Higashiosaka, JP, <sup>5</sup>Kindai University, Osakasayama, JP, <sup>6</sup>NTT West Osaka Hospital, Osaka, JP, <sup>7</sup>Ikeda Municipal Hospital, Ikeda, JP, <sup>8</sup>Minoh City, Minoh, JP, <sup>9</sup>Hoshigaoka Medical Center, Hirakata, JP, <sup>10</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>11</sup>Wakayama Medical University, Wakayama, JP, <sup>12</sup>Osaka



University, Osaka, JP, <sup>13</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>14</sup>Osaka General Medical Center, Osaka, JP

- 12:45 - 12:45 **672P - Comparison of preoperative neoadjuvant chemotherapy (SOX) with different courses of treatment on the patients with advanced gastric cancer**  
X. Wang, Military General Hospital of Beijing (PLA), Beijing, CN
- 12:45 - 12:45 **673P - Phase II trial of neoadjuvant therapy using apatinib plus SOX regimen in locally advanced gastric cancer: updated results**  
Y. Zheng<sup>1</sup>, X. Yang<sup>2</sup>, H. Shi<sup>2</sup>, Z. Yang<sup>2</sup>, C. Yan<sup>2</sup>, Z. Ni<sup>2</sup>, M. Li<sup>2</sup>, B.K. Sah<sup>2</sup>, W. Liu<sup>2</sup>, W. Xu<sup>2</sup>, X. Yao<sup>2</sup>, Z. Zhu<sup>2</sup>, M. Yan<sup>2</sup>, Z. Zhu<sup>2</sup>, C. Li<sup>2</sup>, <sup>1</sup>Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>2</sup>Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai, CN
- 12:45 - 12:45 **674P - The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis**  
T. Van Den Ende<sup>1</sup>, E. Ter Veer<sup>1</sup>, M. Machiels<sup>1</sup>, R. Mali<sup>1</sup>, F. Abe Nijenhuis<sup>1</sup>, L. Waal<sup>1</sup>, M. Laarman<sup>1</sup>, S. Gisbertz<sup>2</sup>, M. Hulshof<sup>1</sup>, M. Van Oijen<sup>1</sup>, H. Van Laarhoven<sup>3</sup>, <sup>1</sup>Academic Medical Center (AMC), Amsterdam, NL, <sup>2</sup>Academic Medical Center, Amsterdam, NL, <sup>3</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL
- 12:45 - 12:45 **675P - Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA)**  
E. Obarevich<sup>1</sup>, N. Besova<sup>1</sup>, E. Trusilova<sup>1</sup>, V. Gorbunova<sup>2</sup>, <sup>1</sup>N. N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>2</sup>N.N.Blokhin Russian Cancer Research Center, Moscow, RU
- 12:45 - 12:45 **676P - Efficacy and safety for apatinib combined with oxaliplatin and S1 in initially treated metastatic gastric cancer ----- a single-center observational study**  
J. Peng<sup>1</sup>, L. Peng<sup>2</sup>, H. Wu<sup>2</sup>, K. Wu<sup>2</sup>, W. Chen<sup>2</sup>, C. Xie<sup>2</sup>, J. Xu<sup>2</sup>, X. Zhang<sup>2</sup>, D. Chen<sup>2</sup>, S. Cai<sup>2</sup>, Y. He<sup>2</sup>, <sup>1</sup>1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, <sup>2</sup>the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
- 12:45 - 12:45 **677P - Afatinib in combination with cisplatin and 5-fluorouracil (5-FU) as first line treatment in inoperable gastric and gastro-esophageal junction (GEJ) cancer. A phase II study by the Hellenic Cooperative Oncology Group.**  
T. Makatsoris<sup>1</sup>, E. Samantas<sup>2</sup>, K. Manousou<sup>3</sup>, V. Karavasilis<sup>4</sup>, G. Aravantinos<sup>2</sup>, D. Tryfonopoulos<sup>5</sup>, A. Psyrri<sup>6</sup>, D. Pectasides<sup>7</sup>, E. Pazarli<sup>8</sup>, C. Petraki<sup>8</sup>, A. Tsipoura<sup>8</sup>, I. Kaklamanos<sup>8</sup>, G. Fountzilas<sup>9</sup>, G. Pentheroudakis<sup>10</sup>, <sup>1</sup>University Hospital Patras, Patras, GR, <sup>2</sup>General Oncological Hospital of Kifisia "Agioli Anargyroi", Kifisia, GR, <sup>3</sup>Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, <sup>4</sup>Aristotle University of Thessaloniky, Thessaloniky, GR, <sup>5</sup>Agios Savvas Regional Cancer Hospital, Athens, GR, <sup>6</sup>Attikon University Hospital, Athens, GR, <sup>7</sup>Hippokration General Hospital, Athens, GR, <sup>8</sup>Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, <sup>9</sup>Papageorgiou Hospital Aristotle University of Thessaloniky, Thessaloniky, GR, <sup>10</sup>University Hospital of Ioannina, Ioannina, GR



GR

12:45 - 12:45

**678P - Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer**

K.-W. Lee<sup>1</sup>, J.W. Kim<sup>2</sup>, J.G. Kim<sup>3</sup>, B.W. Kang<sup>4</sup>, I.J. Chung<sup>5</sup>, Y.S. Hong<sup>6</sup>, T.-Y. Kim<sup>7</sup>, K.H. Lee<sup>8</sup>, D.Y. Zang<sup>9</sup>, Y.H. Ko<sup>10</sup>, E.-K. Song<sup>11</sup>, J.H. Baek<sup>12</sup>, D. Koo<sup>4</sup>, S.Y. Oh<sup>13</sup>, H. Cho<sup>14</sup>,  
1Seoul National University Bundang Hospital, Seoul, KR, 2Seoul National University Bundang Hospital, Seongnam, KR, 3Kyungpook National University School of Medicine, Daegu, KR, 4Kyungpook National University Hospital, Daegu, KR, 5Chonnam National University Hwasun Hospital, Hwasun, KR, 6The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, KR, 7Department of Internal Medicine, Seoul, KR, 8Department of Internal Medicine, Daegu, KR, 9Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KR, 10Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, KR, 11Chonbuk National University Medical School, Jeonju, KR, 12Ulsan University Hospital, Ulsan, KR, 13Pusan National University Yangsan Hospital, Yangsan, KR, 14Sanofi Korea, Seoul, KR

12:45 - 12:45

**679P - Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer**

K. Nishikawa<sup>1</sup>, W. Koizumi<sup>2</sup>, A. Tsuburaya<sup>3</sup>, T. Yamanaka<sup>4</sup>, S. Morita<sup>5</sup>, K. Fujitani<sup>6</sup>, Y. Akamaru<sup>7</sup>, K. Shimada<sup>8</sup>, H. Hosaka<sup>9</sup>, N. Nakayama<sup>10</sup>, Y. Miyashita<sup>11</sup>, T. Tsujinaka<sup>12</sup>, J. Sakamoto<sup>13</sup>,  
1National Hospital Organization Osaka National Hospital, Osaka, JP, 2Kitasato University School of Medicine, Kanagawa, JP, 3Yokohama City University Medical Center, Yokohama, JP, 4Yokohama City University Hospital, Yokohama, JP, 5Kyoto University Graduate School of Medicine 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JP, 6Osaka General Medical Center, Osaka, JP, 7Ikeda Municipal Hospital, Ikeda, JP, 8Showa University Kouto-Toyosu Hospital, Tokyo, JP, 9Gunma Prefectural Cancer Center, Ohta, JP, 10Kanagawa Cancer Center, Yokohama, JP, 11Epidemiological & Clinical Research Information Network, Okazaki, JP, 12Kaizuka City Hospital, Kaizuka, JP, 13Tokai Central Hospital, Kakamigahara, JP

12:45 - 12:45

**680P - A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients With Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)**

K.-W. Lee<sup>1</sup>, C.H. Maeng<sup>2</sup>, T.-Y. Kim<sup>3</sup>, D.Y. Zang<sup>4</sup>, Y.H. Kim<sup>5</sup>, I.G. Hwang<sup>6</sup>, S.C. Oh<sup>7</sup>, J.S. Chung<sup>8</sup>, H.S. Song<sup>9</sup>, J.W. Kim<sup>1</sup>, S.J. Jeong<sup>2</sup>, J.Y. Cho<sup>10</sup>,  
1Seoul National University Bundang Hospital, Seoul, KR, 2Kyung Hee University Hospital, Seoul, KR, 3Department of Internal Medicine, Seoul, KR, 4Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KR, 5Korea University Anam Hospital, Korea University College of Medicine, Seoul, KR, 6Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, KR, 7Korea University Guro Hospital, College of Medicine, Korea University, Seoul, KR, 8Pusan National University Hospital, College of Medicine Pusan National University, Busan, KR, 9Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, KR, 10Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR

12:45 - 12:45

**681P - Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study**

T. Masuishi<sup>1</sup>, S. Kadowaki<sup>1</sup>, H. Hirano<sup>2</sup>, S. Kawai<sup>3</sup>, T. Yamada<sup>4</sup>, T. Moriwaki<sup>4</sup>, N. Machida<sup>3</sup>, N. Boku<sup>5</sup>, K. Muro<sup>1</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>4</sup>University of Tsukuba, Tsukuba, JP, <sup>5</sup>St. Marianna University School of Medicine, Kawasaki, JP

12:45 - 12:45

**682P - Identification of patients who benefit from apatinib in advanced gastric cancer: data derived from a real world study**

J. Feng<sup>1</sup>, B. Shen<sup>1</sup>, H. Jiang<sup>2</sup>, L. Wang<sup>3</sup>, J. Qian<sup>4</sup>, Y. Shu<sup>5</sup>, P. Chen<sup>6</sup>, G. Mao<sup>7</sup>, B. Liu<sup>8</sup>, X. Zhang<sup>9</sup>, C. Liu<sup>10</sup>, J. Wu<sup>11</sup>, X. Li<sup>12</sup>, W. Cai<sup>13</sup>, W. Shen<sup>14</sup>, Q. Wang<sup>15</sup>, J. He<sup>16</sup>, D. Hua<sup>17</sup>, Z. Zhang<sup>18</sup>, Y. Zhang<sup>19</sup>, <sup>1</sup>Jiangsu Cancer Hospital, Nanjing, CN, <sup>2</sup>Changzhou No.2 People's Hospital, Changzhou, CN, <sup>3</sup>Bayi Hospital of People's Liberation Army, Nanjing, CN, <sup>4</sup>Suzhou Municipal Hospital, Suzhou, CN, <sup>5</sup>Jiangsu Province hospital, Nanjing, CN, <sup>6</sup>Yancheng City No.1 People's Hospital, Yancheng, CN, <sup>7</sup>Affiliated Hospital Of Nantong University, Nantong, CN, <sup>8</sup>Nanjing Drum Tower Hospital, Nanjing, CN, <sup>9</sup>Northern Jiangsu People's Hospital, Yangzhou, CN, <sup>10</sup>Wuxi People's Hospital, Wuxi, CN, <sup>11</sup>The First People's Hospital of Changzhou, Changzhou, CN, <sup>12</sup>Affiliated Hospital of Jiangsu University, Zhenjiang, CN, <sup>13</sup>The First People's Hospital of Wujiang, Wujiang, CN, <sup>14</sup>The First People's Hospital of Kunshan, Kunshan, CN, <sup>15</sup>Jiangyin People's Hospital, Jiangyin, CN, <sup>16</sup>Huai'an First People's Hospital, Huai'an, CN, <sup>17</sup>Affiliated Hospital, Jiangnan University, Wuxi, CN, <sup>18</sup>Changshu No.2 People's Hospital, Changshu, CN, <sup>19</sup>Jiangning People's Hospital, Nanjing, CN

12:45 - 12:45

**683P - A real world study of apatinib treatment in gastric cancer: current status and clinical benefit**

G. Sun<sup>1</sup>, D. Li<sup>2</sup>, Z. Ning<sup>3</sup>, Y. He<sup>3</sup>, J. Chang<sup>4</sup>, F. Zhang<sup>5</sup>, C. Jiang<sup>6</sup>, Y. Cheng<sup>7</sup>, L. Xia<sup>8</sup>, B. Hu<sup>9</sup>, C. Yu<sup>10</sup>, Z. Wang<sup>6</sup>, D. Wang<sup>11</sup>, G. Wang<sup>12</sup>, Y. Zhao<sup>2</sup>, J. Wang<sup>13</sup>, H. Liang<sup>2</sup>, M. Xiong<sup>10</sup>, W. Peng<sup>10</sup>, H. Qian<sup>14</sup>, <sup>1</sup>1st Hospital Affiliated to Anhui Medical University, Hefei, CN, <sup>2</sup>Lu'an People's Hospital, Lu'an, CN, <sup>3</sup>Anhui Provincial People's Hospital, Hefei, CN, <sup>4</sup>the First Affiliated Hospital of Anhui Medical University, Hefei, CN, <sup>5</sup>Maanshan Municipal People's Hospital, Maanshan, CN, <sup>6</sup>The First Affiliated Tumor Hospital of Bengbu Medical College, Bengbu, CN, <sup>7</sup>The Second Hospital of Anhui Medical University, Hefei, CN, <sup>8</sup>Anhui Provincial Hospital of Traditional Chinese Medicine, Hefei, CN, <sup>9</sup>Anhui Provincial Hospital, Hefei, CN, <sup>10</sup>The First Affiliated Hospital of Anhui Medical University, Hefei, CN, <sup>11</sup>Wanbei Coal-electricity Group General Hospital, Suzhou, CN, <sup>12</sup>Tongling People's Hospital, Tongling, CN, <sup>13</sup>The PLA Navy Anqing Hospital, Anqing, CN, <sup>14</sup>Fuyang Cancer Hospital, Fuyang, CN

12:45 - 12:45

**684P - An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake**

S. Kadowaki<sup>1</sup>, H. Ishigami<sup>2</sup>, K. Muro<sup>1</sup>, S. Yoshida<sup>3</sup>, Y. Hirono<sup>4</sup>, T. Tomita<sup>5</sup>, H. Yabusaki<sup>6</sup>, T. Kusumoto<sup>7</sup>, M. Ota<sup>8</sup>, Y. Kodera<sup>9</sup>, Y. Tsuji<sup>10</sup>, A. Hidemura<sup>11</sup>, O. Hachiya<sup>12</sup>, K. Oba<sup>13</sup>, J. Kitayama<sup>14</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>The University of Tokyo, Tokyo, JP, <sup>3</sup>The University of Tokyo Graduate School of Medicine, Tokyo, JP, <sup>4</sup>University of Fukui, Yoshida-gun, JP, <sup>5</sup>Hyogo College of Medicine, Nishinomiya, JP, <sup>6</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>7</sup>National Kyushu Medical Center, Fukuoka, JP, <sup>8</sup>National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, <sup>9</sup>Nagoya University Graduate School of Medicine, Nagoya, JP, <sup>10</sup>KKR Tonan Hospital, Sapporo, JP, <sup>11</sup>Kantorosai Hospital, Kawasaki, JP, <sup>12</sup>Yamagata University, Yamagata, JP, <sup>13</sup>The University of Tokyo

School of Public Health, Tokyo, JP, <sup>14</sup>Jichi Medical University Hospital, Shimotsuke, JP

- 12:45 - 12:45 **685P - Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese Phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer.**
- M. Takeuchi<sup>1</sup>, W. Ichikawa<sup>2</sup>, K. Shitara<sup>3</sup>, Y. Sunakawa<sup>4</sup>, K. Oba<sup>5</sup>, W. Koizumi<sup>6</sup>, Y. Sakata<sup>7</sup>, H. Furukawa<sup>8</sup>, M. Takeuchi<sup>9</sup>, M. Fujii<sup>10</sup>, <sup>1</sup>Keio University, Fujisawa, JP, <sup>2</sup>Showa University Fujigaoka Hospital, Yokohama, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>St.Marianna University School of Medicine, Kanagawa, JP, <sup>5</sup>The University of Tokyo School of Public Health, Tokyo, JP, <sup>6</sup>Kitasato University School of Medicine, Kanagawa, JP, <sup>7</sup>Misawa City Hospital, Misawa, JP, <sup>8</sup>Department of Surgery, Kindai University Faculty, Osaka-Sayama, JP, <sup>9</sup>Kitasato University, Tokyo, JP, <sup>10</sup>Nihon University School of Medicine, Tokyo, JP
- 12:45 - 12:45 **686P - Immune gene expression profiling (GEP) of resected gastric adenocarcinomas (GAs) to identify biomarkers associated with immune checkpoint inhibitor (ICPI) response in early stage disease**
- J. Chao<sup>1</sup>, H. Yin<sup>1</sup>, J. Lee<sup>2</sup>, S. Klempner<sup>3</sup>, R. Pillai<sup>1</sup>, <sup>1</sup>City of Hope, Duarte, US, <sup>2</sup>Samsung Medical Center, Seoul, KR, <sup>3</sup>The Angeles Clinic and Research Institute, Los Angeles, US
- 12:45 - 12:45 **687P - Significant prognostic markers related to lymphocytes in gastric cancer**
- T. Hashimoto, Y. Kurokawa, T. Takahashi, Y. Miyazaki, K. Tanaka, T. Makino, M. Yamasaki, K. Nakajima, M. Mori, Y. Doki, Osaka University Graduate School of Medicine, Suita, JP
- 12:45 - 12:45 **688P - Correlation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: looking for prognostic biomarkers**
- M. Ratti<sup>1</sup>, N. Valeri<sup>2</sup>, J.C. Hahne<sup>2</sup>, A. Lampis<sup>2</sup>, M. Ghidini<sup>1</sup>, G. Tomasello<sup>1</sup>, G. Tanzi<sup>1</sup>, L. Toppo<sup>1</sup>, C. Pizzo<sup>1</sup>, B. Donida<sup>1</sup>, C. Senti<sup>1</sup>, M. Salati<sup>3</sup>, M. Trombatore<sup>1</sup>, M. Fassan<sup>4</sup>, R. Passalacqua<sup>1</sup>, <sup>1</sup>Istituti Ospitalieri di Cremona, Cremona, IT, <sup>2</sup>The Royal Marsden NHS Foundation Trust in Chelsea, London, GB, <sup>3</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>4</sup>University of Padova, Padova, IT
- 12:45 - 12:45 **689P - Neutrophil-lymphocyte ratio (NLR) as an important prognostic factor for paclitaxel as a second line chemotherapy in advanced gastric cancer (AGC): Results from phase 3 DREAM study**
- M.-H. Ryu<sup>1</sup>, J.H. Kim<sup>1</sup>, S.C. Oh<sup>2</sup>, S. Park<sup>3</sup>, J.G. Kim<sup>4</sup>, J.W. Kim<sup>5</sup>, S.-H. Cho<sup>6</sup>, K.-E. Yoon<sup>7</sup>, Y.-K. Kang<sup>8</sup>, <sup>1</sup>Asan Medical Center, Seoul, KR, <sup>2</sup>Korea University Guro Hospital, College of Medicine, Korea University, Seoul, KR, <sup>3</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>4</sup>Kyungpook National University Medical Center, Daegu, KR, <sup>5</sup>Seoul National University Bundang Hospital, Seoul, KR, <sup>6</sup>Chonnam National University Hwasun Hospital, Hwasun, KR, <sup>7</sup>Daehwa Pharmaceutical, Co., Ltd., Seoul, KR, <sup>8</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 12:45 - 12:45 **690P - Combination versus single-agent as palliative chemotherapy for gastric cancer: significance of age and platelet-to-lymphocyte ratio**
- M.S. Ahn<sup>1</sup>, Y.W. Choi<sup>2</sup>, H. Lee<sup>3</sup>, S.Y. Kang<sup>2</sup>, J.-H. Choi<sup>4</sup>, <sup>1</sup>Ajou University Hospital School



of Medicine, Suwon, KR, <sup>2</sup>Ajou University School of Medicine, Suwon, KR, <sup>3</sup>School of Medicine Chungnam National University and Chungnam National University Hospital, Suwon, KR, <sup>4</sup>Ajou University School of Medicine-AMGP, Suwon, KR

- 12:45 - 12:45 **691P - Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial**  
A. Slagter<sup>1</sup>, K. Sikorska<sup>2</sup>, C. Grootsholten<sup>3</sup>, H. Van Laarhoven<sup>4</sup>, H. Boot<sup>2</sup>, E. Meershoek-Klein Kranenbarg<sup>5</sup>, C. Van De Velde<sup>6</sup>, N. Van Grieken<sup>7</sup>, E. Jansen<sup>1</sup>, M. Verheij<sup>8</sup>, A. Cats<sup>2</sup>, <sup>1</sup>NKI-AVL, Amsterdam, NL, <sup>2</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>4</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL, <sup>5</sup>Leiden University Medical Center, Leiden, NL, <sup>6</sup>Prof. Cornelis van de Velde, Amsterdam, NL, <sup>7</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>8</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL
- 12:45 - 12:45 **692P - The difference of risk factor for gastric cancer surgery between elderly and non-elderly patients.**  
T. Hayashi<sup>1</sup>, T. Oshima<sup>1</sup>, K. Hara<sup>1</sup>, Y. Shimoda<sup>1</sup>, M. Nakazono<sup>1</sup>, S. Nagasawa<sup>1</sup>, Y. Kumazu<sup>1</sup>, T. Yamada<sup>1</sup>, Y. Rino<sup>2</sup>, M. Masuda<sup>2</sup>, T. Ogata<sup>1</sup>, T. Yoshikawa<sup>1</sup>, <sup>1</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>2</sup>Yokohama City University, Yokohama, JP
- 12:45 - 12:45 **693P - Gastric Cancer In Young Patients**  
M.M. Seker<sup>1</sup>, A. Bahceci<sup>2</sup>, T. Kacan<sup>2</sup>, <sup>1</sup>Ozel Bayindir Hospital, Ankara, TR, <sup>2</sup>Cumhuriyet University Faculty of Medicine, Sivas, TR
- 12:45 - 12:45 **694P - Differences in presentation and outcomes among young and old patients with gastric cancer**  
M. Al Otaibi<sup>1</sup>, J. Al Barak<sup>2</sup>, J. Al Abbad<sup>1</sup>, A. Akbar<sup>1</sup>, <sup>1</sup>Kuwait Cancer Control Centre Al Sabah Hospital, Shuwaikh, KW, <sup>2</sup>Kuwait Cancer Control center, Kuwait, KW
- 12:45 - 12:45 **695P - Prospective Observational Cohort study of Oesophagogastric cancer Patients (POCOP): a Dutch nationwide cohort**  
I.J. Van Kleeff<sup>1</sup>, L. Van De Poll-Franse<sup>2</sup>, R. Verhoeven<sup>3</sup>, M. Slingerland<sup>4</sup>, J. Ruurda<sup>5</sup>, J. Heisterkamp<sup>6</sup>, C. Rosman<sup>7</sup>, J.W. De Groot<sup>8</sup>, E. Kouwenhoven<sup>9</sup>, M. Van Dijk<sup>10</sup>, E. De Graaf<sup>11</sup>, T. Van Voorthuizen<sup>12</sup>, F. Daams<sup>13</sup>, S. Lagarde<sup>14</sup>, G. Nieuwenhuijzen<sup>15</sup>, J. Vincent<sup>16</sup>, M. Van Berge Henegouwen<sup>17</sup>, M. Van Oijen<sup>1</sup>, M. Sprangers<sup>1</sup>, H. Van Laarhoven<sup>18</sup>, <sup>1</sup>Academic Medical Center (AMC), Amsterdam, NL, <sup>2</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>3</sup>Netherlands Comprehensive Cancer Organisation, Utrecht, NL, <sup>4</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>5</sup>University Medical Center Utrecht, Utrecht, NL, <sup>6</sup>Elisabeth-Tweesteden Hospital, Tilburg, NL, <sup>7</sup>Radboud University Medical Center, Nijmegen, NL, <sup>8</sup>Isala Hospital, Zwolle, NL, <sup>9</sup>HospitalGroup Twente (ZGT), Almelo, NL, <sup>10</sup>ZorgSaam Hospital, Terneuzen, NL, <sup>11</sup>Reinier de Graaf Hospital, Delft, NL, <sup>12</sup>Rijnstate Hospital, Arnhem, NL, <sup>13</sup>VU Medical Center, Amsterdam, NL, <sup>14</sup>Erasmus Medical Center, Rotterdam, NL, <sup>15</sup>Catharina Cancer Institute, Catharina Hospital, Eindhoven, NL, <sup>16</sup>Elkerliekziekenhuis, Helmond, NL, <sup>17</sup>Academic Medical Center, Amsterdam, NL, <sup>18</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL



- 12:45 - 12:45 **1656P - Should we consider altering our patterns of care for elderly sarcoma patients?**  
S. Vari<sup>1</sup>, C. Zoccali<sup>2</sup>, V. Anelli<sup>2</sup>, A. Annovazzi<sup>2</sup>, M.G. Petrongari<sup>2</sup>, G. Maggi<sup>2</sup>, D. Giannarelli<sup>3</sup>, N. Salducca<sup>2</sup>, L. Favale<sup>2</sup>, M. Zeuli<sup>2</sup>, R. Biagini<sup>2</sup>, A. Latini<sup>2</sup>, W. Faltyn<sup>2</sup>, M. Anza<sup>2</sup>, R. Covelto<sup>2</sup>, J. Baldi<sup>2</sup>, D. Pellegrini<sup>4</sup>, E. Checcucci<sup>5</sup>, F. Cognetti<sup>6</sup>, V. Ferraresi<sup>4</sup>,  
<sup>1</sup>St. Bartholomew's Hospital, London, GB, <sup>2</sup>IRCCS-Regina Elena National Cancer Institute, Rome, IT, <sup>3</sup>IFO Regina Elena Roma, Roma, IT, <sup>4</sup>Istituto Regina Elena, Roma, IT, <sup>5</sup>IRCCS-Regina Elena National Cancer Institute, Roma, IT, <sup>6</sup>Istituto Nazionale Tumori Regina Elena, Rome, IT
- 12:45 - 12:45 **697P - A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma**  
A.-L. Cheng<sup>1</sup>, C.-J. Yen<sup>2</sup>, T. Okusaka<sup>3</sup>, M. Ikeda<sup>4</sup>, C.-H. Hsu<sup>5</sup>, S.-Y. Wu<sup>2</sup>, C. Morizane<sup>3</sup>, Y. Hashimoto<sup>4</sup>, K. Ueshima<sup>6</sup>, T. Ohtomo<sup>7</sup>, T. Tanaka<sup>7</sup>, M. Kudo<sup>6</sup>,  
<sup>1</sup>National Taiwan University Hospital, Taipei, TW, <sup>2</sup>National Cheng Kung University Hospital, Tainan, TW, <sup>3</sup>National Cancer Center Hospital, Tokyo, JP, <sup>4</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>5</sup>National Taiwan University Hospital, Taiwan, TW, <sup>6</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>7</sup>Chugai Pharmaceutical Co., Ltd., Tokyo, JP
- 12:45 - 12:45 **698P - Phase 2 efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)**  
T. Decaens<sup>1</sup>, C. Barone<sup>2</sup>, E. Assenat<sup>3</sup>, M. Wermke<sup>4</sup>, A. Fasolo<sup>5</sup>, P. Merle<sup>6</sup>, J.F. Blanc<sup>7</sup>, V. Grando<sup>8</sup>, R. Bruns<sup>9</sup>, J. Straub<sup>9</sup>, C. Zhao<sup>10</sup>, S. Faivre<sup>11</sup>,  
<sup>1</sup>CHU de Grenoble, La Tronche, FR, <sup>2</sup>Policlinico Universitario A. Gemelli, Roma, IT, <sup>3</sup>CHU Saint Eloi, Montpellier, FR, <sup>4</sup>University Hospital Carl-Gustav-Carus, Dresden, DE, <sup>5</sup>IRCCS San Raffaele, Milan, IT, <sup>6</sup>Centre Hospitalier de la Croix Rousse, Lyon, FR, <sup>7</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>8</sup>Jean Verdier Hospital, Bondy, FR, <sup>9</sup>Merck KGaA, Darmstadt, DE, <sup>10</sup>EMD Serono Inc, Billerica, US, <sup>11</sup>Hopital Beaujon, Clichy, FR
- 12:45 - 12:45 **699P - Real-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma**  
S.E. Yoon<sup>1</sup>, J.Y. Hur<sup>1</sup>, K.K. Lee<sup>1</sup>, S.J. Lee<sup>1</sup>, J. Lee<sup>2</sup>, S. Paik<sup>2</sup>, H.Y. Lim<sup>1</sup>,  
<sup>1</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>2</sup>Samsung Medical Center, Seoul, KR
- 12:45 - 12:45 **700P - Stemness in hepatocellular carcinoma reduced by inhibition of WEE1 expression**  
K.U. Park<sup>1</sup>, M.J. Ko<sup>2</sup>, H.M. Ryoo<sup>3</sup>, Y.-H. Lee<sup>2</sup>,  
<sup>1</sup>Dongsan Medical Center Kemyung University Hospital, Daegu, KR, <sup>2</sup>Keimyung University School of Medicine, Daegu, KR, <sup>3</sup>Daegu Catholic University, Daegu, KR
- 12:45 - 12:45 **701P - Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC)**  
K. Köchert<sup>1</sup>, G. Meinhardt<sup>2</sup>, J. Bruix<sup>3</sup>, M. Teufel<sup>4</sup>,  
<sup>1</sup>Bayer Pharma AG, Berlin, DE, <sup>2</sup>Clinical

Development Oncology, Whippany, US, <sup>3</sup>University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, ES, <sup>4</sup>Bayer HealthCare Pharmaceuticals, Whippany, US

12:45 - 12:45

**702P - Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)**

R. Kelley<sup>1</sup>, A. El-Khoueiry<sup>2</sup>, T. Meyer<sup>3</sup>, L. Rimassa<sup>4</sup>, P. Merle<sup>5</sup>, S. Chan<sup>6</sup>, A. Tran<sup>6</sup>, F. Parnis<sup>7</sup>, V. Tam<sup>8</sup>, S. Cattan<sup>9</sup>, D. Markby<sup>10</sup>, D. Clary<sup>10</sup>, A.-L. Cheng<sup>11</sup>, G. Abou-Alfa<sup>12</sup>, <sup>1</sup>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, US, <sup>2</sup>USC/Norris Comprehensive Cancer Center, Los Angeles, US, <sup>3</sup>University College London Cancer Institute, London, GB, <sup>4</sup>Humanitas Cancer Center, Milan, IT, <sup>5</sup>Centre Hospitalier de la Croix Rouse, Lyon, FR, <sup>6</sup>The Chinese University of Hong Kong, Shatin, Hong Kong, CN, <sup>7</sup>Adelaide Cancer Centre, Adelaide University, Kurrulta Park, AU, <sup>8</sup>University of Calgary, Calgary, CA, <sup>9</sup>CHRU Lille, Lille, FR, <sup>10</sup>Exelixis Inc., San Francisco, US, <sup>11</sup>National Taiwan University Hospital, Taipei, TW, <sup>12</sup>Memorial Sloan Kettering Cancer Center, New York, US

12:45 - 12:45

**703P - Assessment of disease burden in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)**

J.F. Blanc<sup>1</sup>, T. Meyer<sup>2</sup>, A.-L. Cheng<sup>3</sup>, A. El-Khoueiry<sup>4</sup>, I. Cicin<sup>5</sup>, Y. Chen<sup>6</sup>, L. Bolondi<sup>7</sup>, V. Dadduzio<sup>8</sup>, A. Baron<sup>9</sup>, Z.-Z. Lin<sup>3</sup>, J. Adriani<sup>10</sup>, R. Kelly<sup>11</sup>, G. Abou-Alfa<sup>12</sup>, <sup>1</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>2</sup>University College London Cancer Institute, London, GB, <sup>3</sup>National Taiwan University Hospital, Taipei, TW, <sup>4</sup>USC/Norris Comprehensive Cancer Center, Los Angeles, US, <sup>5</sup>Trakya University Faculty of Medicine, Edirne, TR, <sup>6</sup>Department of Medical Oncology, Tainan, TW, <sup>7</sup>Department of Medical and Surgical Sciences, Bologna, IT, <sup>8</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>9</sup>California Pacific Medical Center, San Francisco, US, <sup>10</sup>Exelixis, Inc, San Francisco, US, <sup>11</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>12</sup>Memorial Sloan Kettering Cancer Center, New York, US

12:45 - 12:45

**704P - Outcomes by prior transarterial chemoembolization (TACE) in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)**

T. Yau<sup>1</sup>, A.-L. Cheng<sup>2</sup>, T. Meyer<sup>3</sup>, B.-Y. Ryoo<sup>4</sup>, J.-W. Park<sup>5</sup>, H.-J. Klumpen<sup>6</sup>, H.Y. Lim<sup>7</sup>, S. Kim<sup>8</sup>, J. Knox<sup>9</sup>, M. Patel<sup>10</sup>, A. El-Khoueiry<sup>11</sup>, R. Kelley<sup>12</sup>, G. Abou-Alfa<sup>13</sup>, <sup>1</sup>Queen Mary Hospital, Hong Kong, CN, <sup>2</sup>National Taiwan University Hospital, Taipei, TW, <sup>3</sup>University College London Cancer Institute, London, GB, <sup>4</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>5</sup>National Cancer Center, Goyang-si, KR, <sup>6</sup>Academic Medical Center, Amsterdam, NL, <sup>7</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>8</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>9</sup>Princess Margaret Hospital, Toronto, CA, <sup>10</sup>Exelixis, Inc., South San Francisco, US, <sup>11</sup>USC/Norris Comprehensive Cancer Center, Los Angeles, US, <sup>12</sup>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, US, <sup>13</sup>Memorial Sloan Kettering Cancer Center, New York, US

12:45 - 12:45

**705P - Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib**

L. Fonseca<sup>1</sup>, A. Díaz<sup>2</sup>, V. Sapena<sup>2</sup>, Á. Díaz-González<sup>2</sup>, L. Boix<sup>2</sup>, M. Sanduzzi-Zamparelli<sup>2</sup>, C. Fuster<sup>2</sup>, N. Llarch<sup>2</sup>, G. Iserte<sup>2</sup>, F. Torres<sup>2</sup>, J. Bruix<sup>3</sup>, M. Reig<sup>2</sup>, <sup>1</sup>ICESP - Instituto do Câncer do Estado de São Paulo, São Paulo, BR, <sup>2</sup>Hospital Clínic of Barcelona. IDIBAPS. CIBERehd, Barcelona, ES, <sup>3</sup>University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, ES

- 12:45 - 12:45 **706P - Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database**
- D. Meyers<sup>1</sup>, R. Lee-Ying<sup>2</sup>, M. Alghamdi<sup>2</sup>, H.-W. Sim<sup>3</sup>, V. Zaborska<sup>4</sup>, Y.-J. Ko<sup>5</sup>, T. Raycraft<sup>4</sup>, E. Batuyong<sup>2</sup>, W. Cheung<sup>6</sup>, H. Samawi<sup>2</sup>, J. Davies<sup>4</sup>, V. Tam<sup>7</sup>, <sup>1</sup>Faculty of Medicine, University of Calgary, Calgary, CA, <sup>2</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>3</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>4</sup>University of British Columbia, Vancouver, CA, <sup>5</sup>Odette Cancer Centre, Toronto, CA, <sup>6</sup>Alberta Health Services, Calgary, CA, <sup>7</sup>University of Calgary, Calgary, CA
- 12:45 - 12:45 **707P - Efficacy and safety of sorafenib (SFN) in elderly patients with hepatocellular carcinoma (HCC)**
- L. Gomes Da Fonseca<sup>1</sup>, G. Nader Marta<sup>2</sup>, M.I. Braghiroli<sup>1</sup>, P. M. Hoff<sup>1</sup>, J. Sabbaga<sup>1</sup>, <sup>1</sup>ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR, <sup>2</sup>ICESP (Cancer Institute of Sao Paulo State), Sao Paulo, BR
- 12:45 - 12:45 **708P - Relationship between change in  $\alpha$ -fetoprotein (AFP) and patient (pt) survival in hepatocellular carcinoma (HCC): a real-world electronic medical records (EMR) database study**
- L. Hess<sup>1</sup>, Z. Cui<sup>2</sup>, T. Sugihara<sup>3</sup>, Y. Fang<sup>3</sup>, A. Girvan<sup>2</sup>, P. Abada<sup>1</sup>, <sup>1</sup>Eli Lilly, Indianapolis, US, <sup>2</sup>Eli Lilly and Company, Indianapolis, US, <sup>3</sup>Syneos Health, Indianapolis, US
- 12:45 - 12:45 **709P - Antiviral Therapy Improves Outcomes after Radiofrequency Ablation for HBV-related Hepatocellular Carcinoma: A Propensity Score Matching Analysis**
- K. Wang, F. Shen, J. Liu, Z. Yan, J. Li, Y. Xia, L. Shi, G. Qian, Z. Lu, Y. Chen, X. Wan, M. Wu, Y. Zhang, Eastern Hepatobiliary Surgical Hospital(EHSH),2nd Military Medical University, Shanghai, CN
- 12:45 - 12:45 **710P - Practice Patterns and Deterioration of Liver Function after Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): Final Analysis of OPTIMIS in Europe and Canada**
- J.-L. Raoul<sup>1</sup>, T. Decaens<sup>2</sup>, K. Burak<sup>3</sup>, J. Koskinas<sup>4</sup>, G.E. Villadsen<sup>5</sup>, A. Heurgue-Berlot<sup>6</sup>, I. Bayh<sup>7</sup>, A.-L. Cheng<sup>8</sup>, M. Kudo<sup>9</sup>, H.C. Lee<sup>10</sup>, K. Nakajima<sup>11</sup>, M. Peck-Radosavljevic<sup>12</sup>, <sup>1</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>2</sup>CHU Grenoble Alpes, Grenoble, FR, <sup>3</sup>Cumming School of Medicine, University of Calgary, Calgary, CA, <sup>4</sup>Medical School of Athens, Hippokration Hospital, Athens, GR, <sup>5</sup>Aarhus University Hospital, Aarhus, DK, <sup>6</sup>Centre Hospitalier Universitaire Reims, Reims, FR, <sup>7</sup>SBU Oncology, Pharmaceuticals, Wuppertal, DE, <sup>8</sup>National Taiwan University Hospital, Taipei, TW, <sup>9</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>10</sup>Asan Medical Center, Seoul, KR, <sup>11</sup>Bayer HealthCare Pharmaceuticals, Whippany, US, <sup>12</sup>Medical University of Vienna/Klinikum Klagenfurt am Wörthersee, Vienna/Klagenfurt, AT
- 12:45 - 12:45 **711P - Hepatocellular carcinoma and liver metastasis treated by hafnium oxide**



**nanoparticles activated by stereotactic body radiation therapy**

M. Pracht<sup>1</sup>, E. Chajon<sup>1</sup>, T. De Baere<sup>2</sup>, F. Nguyen<sup>2</sup>, J.-P. Bronowicki<sup>3</sup>, V. Vendrely<sup>4</sup>, A.-S. Baumann<sup>5</sup>, V. Croisé-Laurent<sup>6</sup>, E. Rio<sup>7</sup>, Y. Rolland<sup>8</sup>, S. Le Sourd<sup>1</sup>, P. Gustin<sup>2</sup>, C. Perret<sup>7</sup>, F. Mornex<sup>9</sup>, D. Peiffert<sup>5</sup>, P. Merle<sup>10</sup>, E. Deutsch<sup>2</sup>, <sup>1</sup>Centre Eugene - Marquis, Rennes, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>CHU Brabois, Vandoeuvre les Nancy, FR, <sup>4</sup>Centre Hospitalier Universitaire de Bordeaux, Bordeaux, FR, <sup>5</sup>Institut de Cancérologie de Lorraine, Nancy, FR, <sup>6</sup>Hôpital de Brabois, Vandoeuvre lès Nancy, FR, <sup>7</sup>Institut de cancérologie de l'Ouest, Nantes, FR, <sup>8</sup>Centre Eugène Marquis, Rennes, FR, <sup>9</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>10</sup>Centre Hospitalier de la Croix Rouse, Lyon, FR

12:45 - 12:45 **712P - Molecular profiling of PDAC and response to chemotherapy: an update from the COMPASS trial**

G. O'Kane<sup>1</sup>, S. Fischer<sup>1</sup>, R. Denroche<sup>2</sup>, G.H. Jang<sup>2</sup>, A. Zhang<sup>2</sup>, A. Dodd<sup>1</sup>, H. Albaba<sup>1</sup>, S. Moura<sup>1</sup>, S. Holter<sup>3</sup>, K. Aung<sup>1</sup>, R. Grant<sup>1</sup>, P. Krzyzanowski<sup>2</sup>, E. Elimova<sup>1</sup>, N. Dhani<sup>1</sup>, D. Hedley<sup>1</sup>, F. Notta<sup>2</sup>, J. Wilson<sup>2</sup>, S. Gallinger<sup>1</sup>, J. Knox<sup>1</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>Ontario institute for Cancer Research, Toronto, CA, <sup>3</sup>Mount Sinai Hospital, Toronto, CA

12:45 - 12:45 **713P - Analysis of BRCAness with MLPA in pancreatic ductal adenocarcinoma patients using FFPE sample obtained via EUS-FNAB**

K. Okuwaki<sup>1</sup>, H. Imaizumi<sup>2</sup>, H. Masutani<sup>1</sup>, T. Yoshida<sup>1</sup>, M. Kida<sup>1</sup>, T. Iwai<sup>1</sup>, H. Yamauchi<sup>1</sup>, T. Kaneko<sup>1</sup>, R. Hasegawa<sup>1</sup>, E. Miyata<sup>1</sup>, K. Adachi<sup>1</sup>, M. Tadehara<sup>1</sup>, W. Koizumi<sup>3</sup>, <sup>1</sup>Kitasato University School of Medicine, Sagamihara, JP, <sup>2</sup>Japan Community Health care Organization, Sagamino Hospital, Sagamihara, JP, <sup>3</sup>Kitasato University School of Medicine, Kanagawa, JP

12:45 - 12:45 **714P - Repeated mutKRAS ctDNA measurements in patients with advanced pancreatic cancer patients: kinetics, response prediction and therapy monitoring in comparison to protein-based tumor markers**

S. Kruger<sup>1</sup>, V. Heinemann<sup>1</sup>, C. Ross<sup>2</sup>, F. Diehl<sup>2</sup>, S. Ormanns<sup>1</sup>, S. Liebmann<sup>3</sup>, C. Westphalen<sup>4</sup>, M. Haas<sup>1</sup>, A. Jung<sup>3</sup>, T. Kirchner<sup>1</sup>, M. Von Bergwelt-Baildon<sup>5</sup>, S. Holdenrieder<sup>6</sup>, S. Boeck<sup>1</sup>, <sup>1</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>2</sup>Sysmex Inostics GmbH, Hamburg, DE, <sup>3</sup>Ludwig Maximilians University, Munich, DE, <sup>4</sup>University Hospital, LMU Munich, Munich, DE, <sup>5</sup>LMU Klinikum der Universität München, Munich, DE, <sup>6</sup>Technical University of Munich, Munich, DE

12:45 - 12:45 **715P - Clinical utility of plasma cell-free DNA in patients with pancreatic cancer.**

I. Chen<sup>1</sup>, K. Wind<sup>2</sup>, C. Dehlendorff<sup>3</sup>, B. Sørensen<sup>2</sup>, B. Vittrup<sup>4</sup>, A. Johansen<sup>1</sup>, P. Pfeiffer<sup>5</sup>, J. Bjerregaard<sup>5</sup>, S. Bojesen<sup>1</sup>, S. Nielsen<sup>1</sup>, N. Holländer<sup>6</sup>, M. Yilmaz<sup>7</sup>, L. Rasmussen<sup>7</sup>, N. Pallisgaard<sup>8</sup>, J. Johansen<sup>1</sup>, K.-L. Spindler<sup>2</sup>, <sup>1</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>2</sup>Aarhus University Hospital, Aarhus, DK, <sup>3</sup>Danish Cancer Society Research Center, Copenhagen, DK, <sup>4</sup>Herlev Hospital, Herlev, DK, <sup>5</sup>Odense University Hospital, Odense C, DK, <sup>6</sup>Zealand University Hospital, Naetved, DK, <sup>7</sup>Aalborg University Hospital, Aalborg, DK, <sup>8</sup>Roskilde Hospital, Roskilde, DK

12:45 - 12:45 **716P - Cell free Tumor-DNA can predict treatment outcome in advanced PDAC**

S. Payr<sup>1</sup>, J. Beck<sup>2</sup>, U. König<sup>1</sup>, M. Brunner<sup>1</sup>, J. Gaedcke<sup>1</sup>, A. Azizian<sup>1</sup>, M. Ghadimi<sup>1</sup>, V.



Ellenrieder<sup>1</sup>, E. Schütz<sup>2</sup>, A.-O. König<sup>1</sup>, <sup>1</sup>Universitätsmedizin Göttingen, Göttingen, DE, <sup>2</sup>Chronix Biomedical GmbH, Göttingen, DE

12:45 - 12:45

**717P - Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Ductal Adenocarcinoma Patients Treated with FOLFIRINOX**

A. Sehdev<sup>1</sup>, O. Gbolahan<sup>2</sup>, B. Hancock<sup>2</sup>, M. Stanley<sup>2</sup>, S. Shahda<sup>3</sup>, J. Wan<sup>2</sup>, H. Wu<sup>2</sup>, M. Radovich<sup>2</sup>, B. O'Neil<sup>4</sup>, <sup>1</sup>Indiana University Simon Cancer Center, Indianapolis, US, <sup>2</sup>Indiana University, Indianapolis, US, <sup>3</sup>Indiana University Melvin Bren Simon Cancer Center, Indianapolis, US, <sup>4</sup>Indiana University School of Medicine, Indianapolis, US

12:45 - 12:45

**718P - A three-gene signature to predict lymph node metastasis of pancreatic cancer**

C. Liang, X. Yu, Fudan University Shanghai Cancer Center, Shanghai, CN

12:45 - 12:45

**719P - Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: an explorative randomized AIO phase II trial (ACCEPT)**

M. Haas<sup>1</sup>, D. Waldschmidt<sup>2</sup>, M. Stahl<sup>3</sup>, A. Reinacher-Schick<sup>4</sup>, J. Freiberg-Richter<sup>5</sup>, F. Kaiser<sup>6</sup>, S. Kanzler<sup>7</sup>, N. Frickhofen<sup>8</sup>, T. Seufferlein<sup>9</sup>, T. Dechow<sup>10</sup>, R. Mahlberg<sup>11</sup>, P. Malfertheiner<sup>12</sup>, G. Illerhaus<sup>13</sup>, S. Kubicka<sup>14</sup>, S. Held<sup>15</sup>, C. Westphalen<sup>16</sup>, S. Kruger<sup>1</sup>, S. Boeck<sup>1</sup>, V. Heinemann<sup>1</sup>, <sup>1</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>2</sup>University of Cologne, Cologne, DE, <sup>3</sup>Kliniken Essen-Mitte, Essen, DE, <sup>4</sup>Ruhr University Bochum, Bochum, DE, <sup>5</sup>Practice for, Dresden, DE, <sup>6</sup>VK&K, Landshut, DE, <sup>7</sup>Leopoldina Krankenhaus Schweinfurt, Schweinfurt, DE, <sup>8</sup>HSK Dr. Horst Schmidt Klinik Internal Medizin 3, Wiesbaden, DE, <sup>9</sup>Ulm Medical University, Ulm, DE, <sup>10</sup>Onkologie-Ravensburg, Ravensburg, DE, <sup>11</sup>Klinikum Mutterhaus der Borromäerinnen, Trier, DE, <sup>12</sup>Otto von Guericke University Magdeburg, Magdeburg, DE, <sup>13</sup>Klinikum Stuttgart, Stuttgart, DE, <sup>14</sup>Klinikum am Steinenberg Reutlingen, Reutlingen, DE, <sup>15</sup>Clinassess, Leverkusen, DE, <sup>16</sup>University Hospital, LMU Munich, Munich, DE

12:45 - 12:45

**720P - SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): results of Stage 1 - the non-randomised dose-finding component**

S. Mukherjee<sup>1</sup>, P. Virdee<sup>2</sup>, R. Shaw<sup>3</sup>, J. Bridgewater<sup>4</sup>, G. Radhakrishna<sup>5</sup>, S. Falk<sup>6</sup>, M. Scott-Brown<sup>7</sup>, V. Strauss<sup>2</sup>, C. Brooks<sup>3</sup>, R. Gillmore<sup>8</sup>, N. Patel<sup>9</sup>, B. Tranter<sup>10</sup>, P. Parsons<sup>10</sup>, D. Sebag-Montefiore<sup>11</sup>, M. Hawkins<sup>1</sup>, P. Corrie<sup>12</sup>, T. Maughan<sup>13</sup>, <sup>1</sup>Oxford Institute for Radiation Oncology, Oxford, GB, <sup>2</sup>Oxford University, Oxford, GB, <sup>3</sup>Oncology Clinical Trials Office, Oxford, GB, <sup>4</sup>University College London Hospitals, London, GB, <sup>5</sup>Christie NHS Foundation Trust, Manchester, GB, <sup>6</sup>Bristol University Hospitals NHS Foundation Trust, Bristol, GB, <sup>7</sup>University Hospitals Coventry and Warwickshire, Coventry, GB, <sup>8</sup>Royal Free London NHS Foundation Trust, London, GB, <sup>9</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, GB, <sup>10</sup>Velindre NHS University Trust, Cardiff, GB, <sup>11</sup>University of Leeds, Leeds, GB, <sup>12</sup>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, <sup>13</sup>University of Oxford, Oxford, GB

12:45 - 12:45

**721P - A phase 1 study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer.**

E. Miyata<sup>1</sup>, K. Okuwaki<sup>1</sup>, H. Imaizumi<sup>2</sup>, M. Kida<sup>1</sup>, T. Iwai<sup>1</sup>, H. Yamauchi<sup>1</sup>, T. Kaneko<sup>1</sup>, R. Hasegawa<sup>1</sup>, K. Adachi<sup>1</sup>, M. Tadehara<sup>1</sup>, W. Koizumi<sup>3</sup>, <sup>1</sup>Kitasato University School of Medicine, Sagamihara, JP, <sup>2</sup>Japan Community Health care Organization, Sagamino Hospital, Sagamihara, JP, <sup>3</sup>Kitasato University School of Medicine, Kanagawa, JP

12:45 - 12:45 **722P - Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer**

J. Taieb<sup>1</sup>, J.M. Phelip<sup>2</sup>, Y. Rinaldi<sup>3</sup>, E. Barbier<sup>4</sup>, O. Bouche<sup>5</sup>, F. Khemissa Akouz<sup>6</sup>, A. Grattet<sup>7</sup>, C. Petorin<sup>8</sup>, L. Miglianico<sup>9</sup>, D. Malka<sup>10</sup>, H. Laharie Mineur<sup>11</sup>, C. Rebischung<sup>12</sup>, C. Lepage<sup>13</sup>, E. Francois<sup>14</sup>, L. Dahan<sup>15</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>CHU University hospital of St Etienne, St. Etienne, FR, <sup>3</sup>Hôpital Européen Marseille, MARSEILLE, FR, <sup>4</sup>FFCD-, Dijon, FR, <sup>5</sup>CHU de Reims - Hôpital Robert Debré, Reims, FR, <sup>6</sup>CH Perpignan, Hôpital Saint Jean, Perpignan, FR, <sup>7</sup>Clinique Pasteur, Toulouse, FR, <sup>8</sup>CHU Estaing, Clermont-Ferrand, FR, <sup>9</sup>CHP Saint-Grégoire, St. Grégoire, FR, <sup>10</sup>Institut Gustave Roussy, Villejuif, FR, <sup>11</sup>Clinique Tivoli Ducos, Bordeaux, FR, <sup>12</sup>CHU Grenoble - Hopital Michallon, La Tronche, FR, <sup>13</sup>CHU Dijon, Dijon, FR, <sup>14</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>15</sup>CHU La Timone Enfants, Marseille, FR

12:45 - 12:45 **723P - First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe**

J. Taieb<sup>1</sup>, A. Carrato<sup>2</sup>, B. Westphalen<sup>3</sup>, D. Melisi<sup>4</sup>, G. Prager<sup>5</sup>, T. Macarulla Mercade<sup>6</sup>, Å. Mellbring<sup>7</sup>, N. D'Esquermes<sup>8</sup>, A. Ferreras<sup>8</sup>, F. De Jong<sup>9</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>Ramón y Cajal University Hospital, Madrid, ES, <sup>3</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>4</sup>AOU Integrata Verona "Borgo Roma", Verona, IT, <sup>5</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>6</sup>Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>7</sup>Shire, Stockholm, SE, <sup>8</sup>Genactis, Mougins, FR, <sup>9</sup>Private Practice - Mr. Floris de Jong, Basel, CH

12:45 - 12:45 **724P - Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)**

E.G. Chiorean<sup>1</sup>, W. Cheung<sup>2</sup>, G. Giordano<sup>3</sup>, G. Kim<sup>4</sup>, S.-E. Al-Batran<sup>5</sup>, <sup>1</sup>University of Washington, Seattle, US, <sup>2</sup>Alberta Health Services, Calgary, CA, <sup>3</sup>IRRCs Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, <sup>4</sup>21st Century Oncology, Jacksonville, US, <sup>5</sup>Nordwest-Krankenhaus, Frankfurt am Main, DE

12:45 - 12:45 **725P - Efficacy and safety of Nab-Paclitaxel plus Gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis**

K. Lee<sup>1</sup>, I. Hwang<sup>2</sup>, J. Kang<sup>2</sup>, C. Yoo<sup>2</sup>, K.-P. Kim<sup>2</sup>, J.H. Jeong<sup>2</sup>, H.-M. Chang<sup>3</sup>, B.-Y. Ryoo<sup>2</sup>, <sup>1</sup>Asan Medical Center, Seoul, KR, <sup>2</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>3</sup>Asan Medical Center, Seoul, KP

12:45 - 12:45 **726P - FOLFIRINOX for recurrent pancreatic cancer after resection: nationwide multicenter observational study by Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)**

S. Morinaga<sup>1</sup>, M. Takita<sup>1</sup>, A. Yoshizawa<sup>1</sup>, K. Kamei<sup>2</sup>, S. Nakamori<sup>3</sup>, S. Ishihara<sup>4</sup>, H. Kuramochi<sup>5</sup>, Y. Yokoyama<sup>6</sup>, T. Uchiyama<sup>7</sup>, G. Murohisa<sup>8</sup>, M. Kobayashi<sup>9</sup>, A. Todaka<sup>10</sup>, A. Fukutomi<sup>10</sup>, <sup>1</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>2</sup>Kinki University Faculty of Medicine, Osakasakai, JP, <sup>3</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>4</sup>Fujita Health University, Toyoake, JP, <sup>5</sup>Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, JP, <sup>6</sup>Nagoya University Hospital, Nagoya, JP, <sup>7</sup>Kikugawa General Hospital, Kikugawa, JP, <sup>8</sup>Seirei Hamamatsu General Hospital, Hamamatsu, JP, <sup>9</sup>Pharma Valley Center, Shizuoka, JP, <sup>10</sup>Shizuoka Cancer Center, Shizuoka, JP

12:45 - 12:45

**727P - A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer**

S.J. Lee<sup>1</sup>, D.-Y. Oh<sup>2</sup>, J.-H. Kang<sup>3</sup>, H.J. Choi<sup>4</sup>, M.A. Lee<sup>5</sup>, S.Y. Oh<sup>6</sup>, S.-T. Kim<sup>7</sup>, Y.S. Park<sup>1</sup>, B.-Y. Ryu<sup>8</sup>, J.O. Park<sup>1</sup>, <sup>1</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Gyeongsang National University School of Medicine, Jinju, Jinju, KR, <sup>4</sup>Yonsei University College of Medicine Department of Internal Medicine, Seoul, KR, <sup>5</sup>Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, <sup>6</sup>Dong-A University College of Medicine, Busan, KR, <sup>7</sup>Samsung Medical Center, Seoul, KR, <sup>8</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

12:45 - 12:45

**728P - Nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A pooled meta-analysis**

Y. Zhang<sup>1</sup>, S. Shi<sup>2</sup>, X. Yu<sup>3</sup>, <sup>1</sup>The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, <sup>2</sup>Fudan University Shanghai Cancer, Shanghai, CN, <sup>3</sup>Fudan University Shanghai Cancer Center, Shanghai, CN

12:45 - 12:45

**729P - Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)**

I. Hwang<sup>1</sup>, J. Kang<sup>1</sup>, C. Yoo<sup>1</sup>, J.H. Jeong<sup>1</sup>, K.-P. Kim<sup>1</sup>, H.-M. Chang<sup>2</sup>, B.-Y. Ryoo<sup>1</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KP

12:45 - 12:45

**730P - A Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 (PAG) and Rivaroxaban for Advanced Pancreatic Adenocarcinoma: Interim Safety and Efficacy Analysis**

K. Yu<sup>1</sup>, S. Mantha<sup>1</sup>, C. Tjan<sup>1</sup>, E. Kaufmann<sup>1</sup>, R. Brenner<sup>1</sup>, M. Lowery<sup>1</sup>, G. Ku<sup>1</sup>, N. Raj<sup>2</sup>, M. Shcherba<sup>1</sup>, Z. Goldberg<sup>1</sup>, J. Li<sup>1</sup>, A. Zervoudakis<sup>1</sup>, A. Hamilton<sup>1</sup>, E. Won<sup>1</sup>, R. Do<sup>1</sup>, E. O'Reilly<sup>3</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, New York, US, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York, US

12:45 - 12:45

**731P - Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)**

H. Takahashi<sup>1</sup>, C. Morizane<sup>2</sup>, S. Nomura<sup>1</sup>, N. Okano<sup>3</sup>, M. Tsuda<sup>4</sup>, N. Mizuno<sup>5</sup>, H. Satake<sup>6</sup>, K. Tsuji<sup>7</sup>, K. Shioji<sup>8</sup>, H. Ishii<sup>9</sup>, K. Yasui<sup>10</sup>, H. Miyakawa<sup>11</sup>, A. Ishiguro<sup>12</sup>, T. Ogura<sup>13</sup>, M. Ueno<sup>14</sup>, A. Ikeda<sup>15</sup>, T. Terashima<sup>16</sup>, M. Ikeda<sup>1</sup>, T. Okusaka<sup>2</sup>, J. Furuse<sup>3</sup>, <sup>1</sup>National Cancer



Center Hospital East, Kashiwa, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>Kyorin university Hospital, Tokyo, JP, <sup>4</sup>Hyogo Cancer Center, Hyogo, JP, <sup>5</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>6</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>7</sup>Ishikawa Prefectural Central Hospital, Kanazawa, JP, <sup>8</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>9</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>10</sup>Kyoto Prefectural University of Medicine, Kyoto, JP, <sup>11</sup>Sapporo Kosei General Hospital, kyoto, JP, <sup>12</sup>Teine Keijinkai Hospital, Sapporo, JP, <sup>13</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>14</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>15</sup>Kobe University Graduate School of Medicine, Kobe, JP, <sup>16</sup>Kanazawa University, Kanazawa, JP

12:45 - 12:45

**732P - GEMOX plus hypofractionated radiotherapy for unresectable locally advanced pancreatic cancer: results from a phase 2 study.**

A. Passardi<sup>1</sup>, E. Scarpi<sup>2</sup>, E. Neri<sup>3</sup>, E. Parisi<sup>4</sup>, G. Ghigi<sup>4</sup>, G. Ercolani<sup>5</sup>, A. Gardini<sup>6</sup>, G. La Barba<sup>6</sup>, F. Pagan<sup>4</sup>, A. Casadei Gardini<sup>1</sup>, L. Frassinetti<sup>1</sup>, F. Ferroni<sup>4</sup>, M. Valgiusti<sup>4</sup>, S. Darwish<sup>7</sup>, A. Romeo<sup>4</sup>, <sup>1</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>2</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>3</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, MELDOLA, IT, <sup>4</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, meldola, IT, <sup>5</sup>University of Bologna, Bologna, IT, <sup>6</sup>Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, IT, <sup>7</sup>Tanta University Hospital, tanta, EG

12:45 - 12:45

**733P - NAPOLI-1 phase 3 trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)**

T. Macarulla Mercade<sup>1</sup>, G. Bodoky<sup>2</sup>, J. Siveke<sup>3</sup>, K.-H. Lee<sup>4</sup>, J. Chen<sup>5</sup>, B. Mirakhur<sup>6</sup>, A. Dean<sup>7</sup>, L.-T. Chen<sup>8</sup>, F. De Jong<sup>9</sup>, <sup>1</sup>Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>2</sup>St. László Hospital, Budapest, HU, <sup>3</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>4</sup>Seoul National University Hospital, Seoul, KR, <sup>5</sup>Shire plc, Cambridge, US, <sup>6</sup>Ipsen Biopharmaceuticals, Inc., Basking Ridge, US, <sup>7</sup>Saint John of God Hospital Subiaco, Subiaco, AU, <sup>8</sup>National Health Research Institutes, Tainan, TW, <sup>9</sup>Private Practice - Mr. Floris de Jong, Basel, CH

12:45 - 12:45

**734P - Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1**

L.-T. Chen<sup>1</sup>, T. Macarulla<sup>2</sup>, J. Blanc<sup>3</sup>, B. Mirakhur<sup>4</sup>, F. De Jong<sup>5</sup>, B. Belanger<sup>4</sup>, T. Bekaii-Saab<sup>6</sup>, J. Siveke<sup>7</sup>, <sup>1</sup>National Health Research Institutes, Tainan, TW, <sup>2</sup>Vall d'Hebron University Hospital (HUVH), Barcelona, ES, <sup>3</sup>Groupe Hospitalier Hau-Lévêque, Pessac, FR, <sup>4</sup>Ipsen Biopharmaceuticals, Inc., Basking Ridge, US, <sup>5</sup>Shire GmbH, ZUG, CH, <sup>6</sup>Division of Hematology/Medical Oncology, Mayo Clinic, Phoenix, US, <sup>7</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

12:45 - 12:45

**735P - Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics**

D. Ahn<sup>1</sup>, A. Barzi<sup>2</sup>, R. Miksad<sup>3</sup>, A. Surinach<sup>4</sup>, F. Corvino<sup>4</sup>, A. Valderrama<sup>5</sup>, K. Mamlouk<sup>5</sup>, S. Pulgar<sup>5</sup>, T. Bekaii-Saab<sup>1</sup>, <sup>1</sup>Mayo Clinic, Phoenix, US, <sup>2</sup>University of Southern California, Los Angeles, US, <sup>3</sup>Flatiron Health, New York, US, <sup>4</sup>Genesis Research, Hoboken, US, <sup>5</sup>Ipsen Biopharmaceutical, Basking Ridge, US



- 12:45 - 12:45 **736P - Multicenter, Phase II Trial of Biweekly S-1, Leucovorin (LV), Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma (mPDAC): Final Report of TCOG T1211 Study**  
N.-J. Chiang<sup>1</sup>, K.K. Tsai<sup>1</sup>, J.-S. Chen<sup>2</sup>, S.-H. Yang<sup>3</sup>, H.-H. Hsiao<sup>4</sup>, Y.-S. Shan<sup>5</sup>, L.-T. Chen<sup>1</sup>,  
<sup>1</sup>National Health Research Institutes, Tainan, TW, <sup>2</sup>Chung Gung University, Tao Yuan, TW,  
<sup>3</sup>National Taiwan University Hospital, Taipei, TW, <sup>4</sup>Kaohsiung Medical University Hospital, Kaohsiung, TW, <sup>5</sup>National Cheng Kung University, Tainan, TW
- 12:45 - 12:45 **737P - A phase II trial of gemcitabine, S-1 and LV combination therapy in patients with advanced pancreatic cancer**  
K. Saito<sup>1</sup>, Y. Nakai<sup>1</sup>, H. Isayama<sup>2</sup>, K. Ishigaki<sup>1</sup>, T. Saito<sup>1</sup>, N. Takahara<sup>1</sup>, S. Mizuno<sup>1</sup>, H. Kogure<sup>1</sup>, K. Koike<sup>1</sup>, <sup>1</sup>The University of Tokyo Graduate School of Medicine, Tokyo, JP, <sup>2</sup>Juntendo University, Tokyo, JP
- 12:45 - 12:45 **738P - Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer**  
Y. Sunakawa<sup>1</sup>, H. Arai<sup>2</sup>, N. Izawa<sup>3</sup>, T. Mizukami<sup>3</sup>, Y. Horie<sup>4</sup>, A. Doi<sup>3</sup>, M. Hirakawa<sup>4</sup>, T. Ogura<sup>3</sup>, T. Tsuda<sup>3</sup>, T. Nakajima<sup>4</sup>, <sup>1</sup>St.Marianna University School of Medicine, Kanagawa, JP, <sup>2</sup>St.Marianna University School of Medicine, Kawasaki, JP, <sup>3</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>4</sup>St Marianna University School of Medicine, Kawasaki city, JP
- 12:45 - 12:45 **739P - Quality of Life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: results of the large QoL study AIO-QoliXane/PARAGON**  
C. Schönherr<sup>1</sup>, T. Götze<sup>2</sup>, G. Zur Hausen<sup>2</sup>, A. Reichart<sup>3</sup>, C. Pauligk<sup>2</sup>, R. Schlag<sup>4</sup>, G. Siegler<sup>5</sup>, S. Dörfel<sup>6</sup>, A. Aldaoud<sup>7</sup>, L. Hahn<sup>8</sup>, J. Schubert<sup>9</sup>, M.-O. Zahn<sup>10</sup>, H.-G. Höffkes<sup>11</sup>, M. Reiser<sup>12</sup>, M. Koenigsmann<sup>13</sup>, W. Blau<sup>14</sup>, O. Waidmann<sup>15</sup>, N. Homann<sup>16</sup>, J. Trojan<sup>15</sup>, S.-E. Al-Batran<sup>2</sup>, <sup>1</sup>IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt, DE, <sup>2</sup>Nordwest-Krankenhaus, Frankfurt am Main, DE, <sup>3</sup>Krankenhaus Nordwest gGmbH, Frankfurt am Main, DE, <sup>4</sup>Hämatonkologische Praxis Dr. R. Schlag, Berlin, DE, <sup>5</sup>Klinikum Nuernberg Nord, Nürnberg, DE, <sup>6</sup>Onkozentrum Dresden, Dresden, DE, <sup>7</sup>Gemeinschaftspraxis, Leipzig, DE, <sup>8</sup>Dokusan Gesellschaft für med. Studien, Herne, DE, <sup>9</sup>Elblandklinik, Riesa, DE, <sup>10</sup>MVZ Onkologische Kooperation Harz, Goslar, DE, <sup>11</sup>MVZ Osthessen, Fulda, DE, <sup>12</sup>PIOH (Köln Zentrum) - Praxis Internistischer Onkologie und Hämatologie, Köln, DE, <sup>13</sup>MediProjekt Hannover, Hannover, DE, <sup>14</sup>Universitätsklinik Giessen, Giessen, DE, <sup>15</sup>Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>16</sup>Klinikum Wolfsburg, Wolfsburg, DE
- 12:45 - 12:45 **740P - Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC**  
G. Chiritescu<sup>1</sup>, K. Dumon<sup>1</sup>, C. Verslype<sup>1</sup>, G. Houbiers<sup>2</sup>, M. Peeters<sup>3</sup>, J. Janssens<sup>4</sup>, D. Van Daele<sup>5</sup>, S. Laurent<sup>6</sup>, J. Arts<sup>7</sup>, K. Hendrickx<sup>8</sup>, I. Borbath<sup>9</sup>, M. Ferrante<sup>10</sup>, F. Bastin<sup>11</sup>, J.-C. Goeminne<sup>12</sup>, J.-L. Van Laethem<sup>13</sup>, E. Vanderstraeten<sup>14</sup>, J. Decaestecker<sup>15</sup>, W. Van Vaerenbergh<sup>16</sup>, B. Delhougne<sup>17</sup>, E. Van Cutsem<sup>1</sup>, <sup>1</sup>University Hospitals Leuven, Leuven, BE, <sup>2</sup>Centre Hospitalier Chrétien (CHC), Liège, BE, <sup>3</sup>U.Z.A. University Hospital Antwerp, Edegem, BE, <sup>4</sup>A.Z. Turnhout, Turnhout, BE, <sup>5</sup>CHU Sart-Tilman, Liege, BE, <sup>6</sup>UZ Gent,

Gent, BE, <sup>7</sup>AZ Sint Lucas, Brugge, BE, <sup>8</sup>Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, BE, <sup>9</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>10</sup>A.Z. Sint Maarten, Mechelen, BE, <sup>11</sup>CHIREC Parc Léopold Clinic, Brussels, BE, <sup>12</sup>Clinique Ste Elisabeth, Namur, BE, <sup>13</sup>Erasmus University Hospital-(Universite Libre de Bruxelles), Brussels, BE, <sup>14</sup>A.Z. Maria Middelaers, Gent, BE, <sup>15</sup>AZ Delta campus Wilgenstraat, Roeselare, BE, <sup>16</sup>Heilig Hart Ziekenhuis, Lier, BE, <sup>17</sup>CHR Citadelle, Liege, BE

12:45 - 12:45

**741P - Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): a systematic literature review (SLR)**

T. Macarulla Mercade<sup>1</sup>, A. Hendifar<sup>2</sup>, C.-P. Li<sup>3</sup>, M. Reni<sup>4</sup>, H. Riess<sup>5</sup>, M. Tempero<sup>6</sup>, A. Dueck<sup>7</sup>, M. Botteman<sup>8</sup>, C. Deshpande<sup>8</sup>, E. Lucas<sup>8</sup>, D.-Y. Oh<sup>9</sup>, <sup>1</sup>Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>3</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>4</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>5</sup>Charite Berlin Mitte, Berlin, DE, <sup>6</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>7</sup>Mayo Clinic, Phoenix, US, <sup>8</sup>Pharmerit International, Inc, Bethesda, US, <sup>9</sup>Seoul National University Hospital, Seoul, KR

12:45 - 12:45

**742P - Outcome Following Centralisation of Pancreatic Cancer Care in Ireland**

R. Abdul Rahman<sup>1</sup>, M. Moriarty<sup>2</sup>, G. Mcvey<sup>2</sup>, P. Ridgway<sup>3</sup>, D. Maguire<sup>3</sup>, E. Hoti<sup>3</sup>, J. Geoghegan<sup>3</sup>, K. Conlon<sup>3</sup>, R. Mcdermott<sup>1</sup>, <sup>1</sup>AMNCH Adelaide and Meath Hospital, Dublin, IE, <sup>2</sup>St. Luke's Hospital, Rathgar, IE, <sup>3</sup>St Vincents University Hospital, Dublin, IE

12:45 - 12:45

**743P - Initial treatment and survival in a national unselected Danish cohort of 4161 patients with pancreatic cancer.**

L. Rasmussen<sup>1</sup>, B. Vittrup<sup>2</sup>, M. Ladekar<sup>3</sup>, P. Pfeiffer<sup>4</sup>, M. Yilmaz<sup>1</sup>, L. Poulsen<sup>1</sup>, K. Østerlind<sup>5</sup>, H. Skuladottir<sup>6</sup>, C. Hansen<sup>7</sup>, M. Mortensen<sup>8</sup>, F. Mortensen<sup>9</sup>, M. Sall<sup>1</sup>, U. Falkmer<sup>10</sup>, C. Frstrup<sup>11</sup>, <sup>1</sup>Aalborg University Hospital, Aalborg, DK, <sup>2</sup>Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, DK, <sup>3</sup>Aarhus University Hospital, Aarhus C, DK, <sup>4</sup>Odense University Hospital, Odense C, DK, <sup>5</sup>North Sealand Hospital, Hillerød, DK, <sup>6</sup>Regional Hospital West Jutland, Herning, DK, <sup>7</sup>Rigshospitalet, Copenhagen University Hospital, Copenhagen, DK, <sup>8</sup>Odense Pancreas Center (OPAC), Odense University Hospital, Odense, DK, <sup>9</sup>Aarhus University Hospital, Aarhus, DK, <sup>10</sup>Clinical Cancer Research Center, Aalborg University Hospital; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, DK, <sup>11</sup>Danish Pancreatic Cancer Database; Odense University Hospital, Odense, DK

12:45 - 12:45

**744P - Trends of care of non-metastatic pancreas cancer patients in Ireland.**

R. Abdul Rahman<sup>1</sup>, G. Mcvey<sup>2</sup>, M. Moriarty<sup>2</sup>, D. Maguire<sup>3</sup>, E. Hoti<sup>3</sup>, P. Ridgway<sup>3</sup>, K. Conlon<sup>3</sup>, J. Geoghegan<sup>3</sup>, R. Mcdermott<sup>1</sup>, <sup>1</sup>AMNCH Adelaide and Meath Hospital, Dublin, IE, <sup>2</sup>St. Luke's Hospital, Rathgar, IE, <sup>3</sup>St Vincents University Hospital, Dublin, IE

12:45 - 12:45

**745P - Anti-hypertensive medication, sRAGE, and risk of pancreatic cancer: results from the Women's Health Initiative Study**

Z. Wang<sup>1</sup>, D. White<sup>2</sup>, L. Chen<sup>2</sup>, E. Whitsel<sup>3</sup>, P. Richardson<sup>2</sup>, J. Garcia<sup>4</sup>, H. El-Serag<sup>2</sup>, L. Jiao<sup>2</sup>, <sup>1</sup>Baylor College of Medicine, Houston, US, <sup>2</sup>Michael E. DeBakey VA Medical

Center, Houston, US, <sup>3</sup>University of North Carolina at Chapel Hill, Chapel Hill, US,  
<sup>4</sup>University of Washington, Seattle, US

- 12:45 - 12:45 **746P - Usefulness of the first screening using apolipoprotein A2 isoforms as the enrichment strategy for pancreatic cancer and its risk diseases**  
Y. Sato<sup>1</sup>, T. Kobayashi<sup>1</sup>, S. Nishiumi<sup>1</sup>, S. Okaya<sup>2</sup>, M. Yoshida<sup>1</sup>, Y. Kodama<sup>1</sup>, K. Nagashima<sup>3</sup>, K. Honda<sup>4</sup>, <sup>1</sup>Kobe University Graduate School of Medicine, Kobe, JP, <sup>2</sup>National Cancer Center Research Institute, Tokyo, JP, <sup>3</sup>The Institute of Statistical Mathematics., Tokyo, JP, <sup>4</sup>National Cancer Center Hospital, Tokyo, JP
- 12:45 - 12:45 **747P - Survival-associated factors and a prognostic nomogram in resected pancreatic cancer: A large international population-based cohort study**  
L. Huang<sup>1</sup>, Y. Balavarca<sup>2</sup>, L. Van Der Geest<sup>3</sup>, V. Lemmens<sup>3</sup>, L. Van Eycken<sup>4</sup>, H. De Schutter<sup>5</sup>, T. Johannesen<sup>6</sup>, V. Zadnik<sup>7</sup>, M. Primic-Žakelj<sup>7</sup>, M. Mägi<sup>8</sup>, R. Grützmänn<sup>9</sup>, M. Besselink<sup>10</sup>, P. Schrotz-King<sup>2</sup>, H. Brenner<sup>2</sup>, L. Jansen<sup>1</sup>, <sup>1</sup>German Cancer Research Center, Heidelberg, DE, <sup>2</sup>German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, DE, <sup>3</sup>Netherlands Cancer Registry (NCR), Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, NL, <sup>4</sup>Belgian Cancer Registry (BCR), Brussels, BE, <sup>5</sup>Belgian Cancer Registry, Brussels, BE, <sup>6</sup>The Cancer Registry of Norway (CRN), Oslo, NO, <sup>7</sup>Institute of Oncology Ljubljana, Ljubljana, SI, <sup>8</sup>National Institute for Health Development, Tallinn, EE, <sup>9</sup>Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, DE, <sup>10</sup>Cancer Center Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, NL
- 12:45 - 12:45 **748P - Predicting Survival of Pancreatic Cancer Using Supervised Machine Learning**  
M. Osman, Zagazig University Faculty of Medicine, Zagazig, EG
- 12:45 - 12:45 **749P - The prognostic value of the Modified Glasgow Prognostic Score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)**  
L.-T. Chen<sup>1</sup>, T. Macarulla<sup>2</sup>, B. Belanger<sup>3</sup>, B. Mirakhor<sup>4</sup>, F. De Jong<sup>5</sup>, J. Siveke<sup>6</sup>, <sup>1</sup>National Health Research Institutes, Tainan, TW, <sup>2</sup>Vall d'Hebron University Hospital (HUVH), Barcelona, ES, <sup>3</sup>Ipsen Biopharmaceuticals, Inc., Cambridge, US, <sup>4</sup>Ipsen Biopharmaceuticals, Inc., Basking Ridge, US, <sup>5</sup>Shire GmbH, ZUG, CH, <sup>6</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
- 12:45 - 12:45 **750P - Prognostic Value of the Neutrophil-Lymphocyte Ratio and CA 19-9 in Predicting Survival in Patients with Metastatic Pancreatic Cancer**  
I. Dede<sup>1</sup>, M. Cetin<sup>2</sup>, S. Cetin<sup>3</sup>, <sup>1</sup>Mustafa Kemal University Faculty of Medicine, Hatay, TR, <sup>2</sup>Mustafa Kemal University, Antakya- Hatay, TR, <sup>3</sup>Ondokuzmayis University, samsun, TR
- 12:45 - 12:45 **751P - Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC)**  
R. Pihlak<sup>1</sup>, R. Almond<sup>1</sup>, P. Srivastava<sup>2</sup>, H. Raja<sup>2</sup>, R. Broadbent<sup>1</sup>, L. Hopewell<sup>1</sup>, C.



Higham<sup>1</sup>, A. Lamarca<sup>1</sup>, R. Hubner<sup>1</sup>, J. Valle<sup>1</sup>, M. Mcnamara<sup>1</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>University Manchester, Manchester, GB

12:45 - 12:45

**752P - Clinical utility of serum type III collagen in patients with pancreatic carcinoma.**

I. Chen<sup>1</sup>, N. Willumsen<sup>2</sup>, C. Dehlendorff<sup>3</sup>, A. Johansen<sup>1</sup>, B. Vittrup<sup>4</sup>, M. Krüger<sup>1</sup>, P. Pfeiffer<sup>5</sup>, J. Bjerregaard<sup>5</sup>, S. Bojesen<sup>1</sup>, S. Nielsen<sup>1</sup>, N. Holländer<sup>6</sup>, M. Yilmaz<sup>7</sup>, L. Rasmussen<sup>7</sup>, M. Karsdal<sup>2</sup>, J. Johansen<sup>1</sup>, <sup>1</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>2</sup>Nordic Bioscience A/S, Herlev, DK, <sup>3</sup>Danish Cancer Society Research Center, Copenhagen, DK, <sup>4</sup>Herlev Hospital, Herlev, DK, <sup>5</sup>Odense University Hospital, Odense C, DK, <sup>6</sup>Zealand University Hospital, Naetved, DK, <sup>7</sup>Aalborg University Hospital, Aalborg, DK

12:45 - 12:45

**753P - Venous thromboembolism in Asian patients with pancreatic cancer who underwent palliative chemotherapy: low prevalence, but a poor prognostic factor for early onset**

W.-C. Chou<sup>1</sup>, J.-S. Chen<sup>2</sup>, Y.-Y. Chen<sup>3</sup>, C.-H. Lu<sup>4</sup>, P.-H. Chang<sup>5</sup>, <sup>1</sup>Chang Gung Memorial Hospital-Linkou, Taoyuan, TW, <sup>2</sup>Chang Gung Memorial Hospital-Taipei, Taipei city, TW, <sup>3</sup>Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, TW, <sup>4</sup>Chiayi Chang Gung Memorial Hospital, Puzi City, TW, <sup>5</sup>Keelung Chang Gung Memorial Hospital, Keelung, TW

12:45 - 12:45

**754P - Targeted Therapy based on the Genetic Alterations Prolongs the Progression-free Survival of Patients with Advanced Biliary Tract Cancer**

F. Feng<sup>1</sup>, Q. Cheng<sup>1</sup>, D. Zhang<sup>2</sup>, B. Li<sup>1</sup>, H. Qin<sup>2</sup>, C. Xu<sup>1</sup>, M. Han<sup>2</sup>, Y. Yu<sup>1</sup>, Z. Li<sup>1</sup>, J.-Y. Li<sup>2</sup>, Z. Qiu<sup>1</sup>, L. Xiong<sup>2</sup>, C. Liu<sup>1</sup>, F. Li<sup>2</sup>, B. Yi<sup>1</sup>, X. Jiang<sup>1</sup>, <sup>1</sup>Eastern Hepatobiliary Surgical Hospital(EHSH), <sup>2</sup>nd Military Medical University, Shanghai, CN, <sup>3</sup>D Medicine Inc., Shanghai, China., Shanghai, CN

12:45 - 12:45

**755P - Evaluation of genetic alterations in biliary tract cancer using targeted exome sequencing.**

H. Chae<sup>1</sup>, C. Yoo<sup>1</sup>, D. Kim<sup>1</sup>, J.H. Jung<sup>1</sup>, H.-M. Chang<sup>2</sup>, B.-Y. Ryoo<sup>1</sup>, K.-P. Kim<sup>1</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KP

12:45 - 12:45

**756P - Interim results of fight-202, a phase 2, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations**

A. Hollebecque<sup>1</sup>, M. Borad<sup>2</sup>, V. Sahai<sup>3</sup>, D. Catenacci<sup>4</sup>, A. Murphy<sup>5</sup>, G. Vaccaro<sup>6</sup>, A. Paulson<sup>7</sup>, D.-Y. Oh<sup>8</sup>, L. Féliz<sup>9</sup>, C. Lihou<sup>10</sup>, H. Zhen<sup>10</sup>, G. Abou-Alfa<sup>11</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>Mayo Clinic Cancer Center, Scottsdale, US, <sup>3</sup>University of Michigan, Ann Arbor, US, <sup>4</sup>The University of Chicago Medical Centre, Chicago, US, <sup>5</sup>Johns Hopkins University, Baltimore, US, <sup>6</sup>Oregon Health & Science University, Portland, US, <sup>7</sup>Texas Oncology, P.A., U.S. Oncology Research Network, Woodlands, US, <sup>8</sup>Seoul National University Hospital, Seoul, KR, <sup>9</sup>Incyte Corporation, Geneva, CH, <sup>10</sup>Incyte, Willmington, US, <sup>11</sup>Memorial Sloan-Kettering Cancer Center, New York, US

12:45 - 12:45

**757P - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1**



**and TGF- $\alpha$ , in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase 1 trial**

C. Yoo<sup>1</sup>, D.-Y. Oh<sup>2</sup>, H.J. Choi<sup>3</sup>, M. Kudo<sup>4</sup>, M. Ueno<sup>5</sup>, S. Kondo<sup>6</sup>, L.-T. Chen<sup>7</sup>, M. Osada<sup>8</sup>, C. Helwig<sup>9</sup>, I. Dussault<sup>10</sup>, M. Ikeda<sup>11</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Yonsei University College of Medicine Department of Internal Medicine, Seoul, KR, <sup>4</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>5</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>6</sup>National Cancer Center Hospital, Tokyo, JP, <sup>7</sup>National Health Research Institutes, Tainan, TW, <sup>8</sup>Merck Serono, Tokyo, JP, <sup>9</sup>Merck KGaA, Darmstadt, DE, <sup>10</sup>EMD Serono, Billerica, US, <sup>11</sup>National Cancer Center Hospital East, Kashiwa, JP

**12:45 - 12:45 758P - A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08)**

M. Mcnamara<sup>1</sup>, J. Bridgewater<sup>2</sup>, D. Palmer<sup>3</sup>, H. Wasan<sup>4</sup>, W.D. Ryder<sup>1</sup>, C. Gnanaranjan<sup>5</sup>, E. Ghazaly<sup>6</sup>, T.R.J. Evans<sup>7</sup>, J. Valle<sup>1</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>University College London Hospitals, London, GB, <sup>3</sup>Clatterbridge Cancer Centre, Liverpool, GB, <sup>4</sup>Imperial College London - Hammersmith Hospital, London, GB, <sup>5</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>6</sup>Barts Cancer Centre, London, GB, <sup>7</sup>Beatson Institute for Cancer Research, Glasgow, GB

**12:45 - 12:45 759P - Phase II Study of Evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer**

J.S. Yoon, K.-H. Lee, G.J. Cheon, Y.-J. Bang, D.-Y. Oh, Seoul National University Hospital, Seoul, KR

**12:45 - 12:45 760P - PhotoChemical Internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma - results from a phase I dose escalation trial**

J. Trojan<sup>1</sup>, R. Sturgess<sup>2</sup>, D. Harrison Palmer<sup>3</sup>, B. Neu<sup>4</sup>, S. Kasper<sup>5</sup>, A. Dechene<sup>5</sup>, C. Jürgensen<sup>6</sup>, J. Schirra<sup>7</sup>, R. Jakobs<sup>8</sup>, A. Högset<sup>9</sup>, L. Finnesand<sup>9</sup>, H. Olivecrona<sup>9</sup>, <sup>1</sup>Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>2</sup>University Hospital Aintree, Liverpool, GB, <sup>3</sup>University of Liverpool Cancer Research UK Centre, London, GB, <sup>4</sup>Krankenhaus Landshut-Achdorf, Landshut, DE, <sup>5</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>6</sup>Medizinische Klinik, Berlin, DE, <sup>7</sup>Klinikum der Ludwig-Maximilians-Universität, Munich, DE, <sup>8</sup>Klinikum Ludwigshafen, Ludwigshafen, DE, <sup>9</sup>PCI Biotech AS, Oslo, NO

**12:45 - 12:45 761P - FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)**

A. Ulusakarya<sup>1</sup>, W. Karray<sup>1</sup>, J. Abdou<sup>1</sup>, A. Karaboué<sup>1</sup>, M. Haydar<sup>1</sup>, S. Krimi<sup>1</sup>, Y. Gumus<sup>1</sup>, W. Almohamad<sup>1</sup>, E. Goldschmidt<sup>2</sup>, P. Biondani<sup>1</sup>, J.F. Morère<sup>1</sup>, <sup>1</sup>Hôpital Paul Brousse, Villejuif, FR, <sup>2</sup>AP-HP, Hôpital Paul Brousse, Villejuif, FR

**12:45 - 12:45 763P - Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis**

S. Yadav<sup>1</sup>, H. Xie<sup>1</sup>, I. Riaz<sup>1</sup>, P. Sharma<sup>2</sup>, A. Mahipal<sup>3</sup>, R. Mcwilliams<sup>1</sup>, <sup>1</sup>Mayo Clinic, Rochester, US, <sup>2</sup>Bridgeport Hospital, Yale New Haven Health System, Bridgeport, US, <sup>3</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US

- 12:45 - 12:45 **762P - A randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208)**
- H. Terajima<sup>1</sup>, S. Kobayashi<sup>2</sup>, H. Nagano<sup>3</sup>, A. Tomokuni<sup>4</sup>, K. Gotoh<sup>2</sup>, D. Sakai<sup>5</sup>, E. Hatano<sup>6</sup>, S. Seo<sup>7</sup>, Y. Uchida<sup>1</sup>, T. Ajiki<sup>8</sup>, H. Satake<sup>9</sup>, K. Kamei<sup>10</sup>, T. Tohyama<sup>11</sup>, T. Hirose<sup>12</sup>, I. Ikai<sup>13</sup>, S. Morita<sup>14</sup>, T. Ioka<sup>15</sup>, <sup>1</sup>Kitano Hospital The Tazuke Kofu Kai Medical Research Institute, Osaka, JP, <sup>2</sup>Osaka University Graduate School of Medicine, Osaka, JP, <sup>3</sup>Yamaguchi University Graduate School of Medicine, Yamaguchi, JP, <sup>4</sup>Osaka International Cancer Institute, Osaka, JP, <sup>5</sup>Osaka University, Osaka, JP, <sup>6</sup>Hyogo College of Medicine, Nishinomiya, JP, <sup>7</sup>Kyoto University Graduate School of Medicine, Kyoto, JP, <sup>8</sup>Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe, JP, <sup>9</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>10</sup>Kinki University Faculty of Medicine, Osakasakai, JP, <sup>11</sup>Ehime University Graduate School of Medicine, Touon, JP, <sup>12</sup>Otsu Red Cross Hospital, Otsu, JP, <sup>13</sup>National Hospital Organization Kyoto Medical Center, Kyoto, JP, <sup>14</sup>Kyoto University Graduate School of Medicine 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JP, <sup>15</sup>Osaka International Cancer Institution, Osaka, JP
- 12:45 - 12:45 **764P - Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): outcomes and safety from a multicenter Italian experience**
- V. Dadduzio<sup>1</sup>, M. Rizzato<sup>1</sup>, G. Ramondo<sup>1</sup>, C. Vivaldi<sup>2</sup>, M. Milella<sup>3</sup>, G. Brandi<sup>4</sup>, S. Cereda<sup>5</sup>, S. Murgioni<sup>1</sup>, G. Cardellino<sup>6</sup>, R. Filippi<sup>7</sup>, D. Santini<sup>8</sup>, G. Pasquini<sup>9</sup>, R. Intini<sup>1</sup>, V. Vaccaro<sup>3</sup>, A. Palloni<sup>4</sup>, M. Reni<sup>10</sup>, G. Musettini<sup>11</sup>, E. Gringeri<sup>12</sup>, C. Aliberti<sup>1</sup>, V. Zagone<sup>13</sup>, <sup>1</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>Azienda Ospedaliera Universitaria Pisana, Pisa, IT, <sup>3</sup>Istituto Nazionale Tumori Regina Elena, Rome, IT, <sup>4</sup>Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>5</sup>San Raffaele Scientific Institute, Milano, IT, <sup>6</sup>Udine University and General Hospital, Udine, IT, <sup>7</sup>Università degli Studi di Torino, Torino, IT, <sup>8</sup>Campus Bio-Medico di Roma, Rome, IT, <sup>9</sup>University of Pisa, Pisa, Italy, Pisa, IT, <sup>10</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>11</sup>Azienda Ospedaliera Universitaria S. Chiara, Pisa, IT, <sup>12</sup>Padua University Hospital, Padova, IT, <sup>13</sup>Istituto Oncologico Veneto-IRCCS, padova, IT
- 12:45 - 12:45 **765P - Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations**
- C. Neuzillet<sup>1</sup>, A. Casadei Gardini<sup>2</sup>, B. Brieu<sup>3</sup>, C. Vivaldi<sup>4</sup>, C. Smolenschi<sup>5</sup>, G. Brandi<sup>6</sup>, D. Tougeron<sup>7</sup>, R. Filippi<sup>8</sup>, A. Vienot<sup>9</sup>, N. Silvestris<sup>10</sup>, A.-L. Pointet<sup>11</sup>, S. Murgioni<sup>12</sup>, B. Rousseau<sup>13</sup>, M. Scartozzi<sup>14</sup>, L. Dahan<sup>15</sup>, T. Boussaha<sup>16</sup>, S. Cruz<sup>17</sup>, A. Meurisse<sup>18</sup>, A. Lievre<sup>19</sup>, D. Vernerey<sup>18</sup>, <sup>1</sup>Hôpital Beaujon, Clichy, FR, <sup>2</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>3</sup>Hôpital Cochin, Paris, FR, <sup>4</sup>Azienda Ospedaliera Universitaria Pisana, Pisa, IT, <sup>5</sup>Gustave Roussy Institute, Villejuif, FR, <sup>6</sup>Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>7</sup>CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR, <sup>8</sup>Università degli Studi di Torino, Torino, IT, <sup>9</sup>Besançon University Hospital, Besançon, FR, <sup>10</sup>Ospedale Oncologico "Giovanni Paolo II"- IRCCS, bari, IT, <sup>11</sup>Hopital European George Pompidou, Paris, FR, <sup>12</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>13</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>14</sup>University Hospital and University of Cagliari, cagliari, IT, <sup>15</sup>CHU La Timone Enfants, Marseille, FR, <sup>16</sup>Centre Multidisciplinaire d'Oncologie-CePo, Lausanne, CH, <sup>17</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>18</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>19</sup>CHU de Pontchaillou, Rennes, FR

- 12:45 - 12:45 **766P - Prognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)**  
J. Hyung<sup>1</sup>, C. Yoo<sup>1</sup>, K.-P. Kim<sup>1</sup>, B.J. Kim<sup>1</sup>, J.H. Jeong<sup>1</sup>, H.-M. Chang<sup>2</sup>, B.-Y. Ryoo<sup>1</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KP
- 12:45 - 12:45 **767P - Predictive factors of outcome in patients with advanced biliary tract cancer receiving Gemcitabine plus Cisplatin as first-line chemotherapy**  
Y. Suzuki, M. Kan, G. Kimura, K. Umemoto, K. Watanabe, M. Sasaki, H. Takahashi, Y. Hashimoto, H. Imaoka, I. Ohno, S. Mitsunaga, M. Ikeda, National Cancer Center Hospital East, Kashiwa, JP
- 12:45 - 12:45 **768P - Nomograms predicting survival of patients with advanced or recurrent biliary tract cancer receiving a first-line chemotherapy.**  
N. Takahara<sup>1</sup>, Y. Nakai<sup>2</sup>, K. Saito<sup>2</sup>, M. Sato<sup>2</sup>, H. Ooyama<sup>2</sup>, S. Kanai<sup>2</sup>, T. Suzuki<sup>2</sup>, T. Sato<sup>2</sup>, R. Hakuta<sup>2</sup>, K. Ishigaki<sup>2</sup>, T. Takeda<sup>2</sup>, S. Mizuno<sup>2</sup>, H. Kogure<sup>2</sup>, M. Tada<sup>2</sup>, K. Koike<sup>2</sup>, <sup>1</sup>Tokyo University Hospital, Tokyo, JP, <sup>2</sup>The University of Tokyo Graduate School of Medicine, Tokyo, JP
- 12:45 - 12:45 **769P - Stromal progesterone receptor expression and long-term survival in patients with resected periampullary adenocarcinoma**  
G. Andersson<sup>1</sup>, S. Olsson-Hau<sup>2</sup>, S. Lundgren<sup>1</sup>, M. Heby<sup>3</sup>, B. Nodin<sup>3</sup>, K. Jirstrom<sup>4</sup>, <sup>1</sup>Lund University-Institution of Clinical Sciences-Oncology and Pathology, Lund, SE, <sup>2</sup>of Clinical Sciences, Lund, SE, <sup>3</sup>Clinical Sciences, Lund, SE, <sup>4</sup>Lund University, Lund, SE
- 12:45 - 12:45 **770P - A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht).**  
M. Salati<sup>1</sup>, F. Caputo<sup>2</sup>, A. Spallanzani<sup>2</sup>, M. Rimini<sup>2</sup>, F. Gelsomino<sup>2</sup>, K. Andrikou<sup>2</sup>, S. Cascinu<sup>2</sup>, <sup>1</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>2</sup>University Hospital of Modena, Modena, IT
- 12:45 - 12:45 **771P - “The German- Registry” of Incidental gallbladder cancer and the GAIN-phase III trial- transformation from a registry to treatment platform due to a trial in trial concept**  
T. Götze<sup>1</sup>, V. Paolucci<sup>2</sup>, S.-E. Al-Batran<sup>1</sup>, <sup>1</sup>Nordwest-Krankenhaus, Frankfurt am Main, DE, <sup>2</sup>Ketteler- Krankenhaus, Offenbach, DE
- 12:45 - 12:45 **772P - ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort**  
T. Aparicio<sup>1</sup>, S. Manfredi<sup>2</sup>, D. Tougeron<sup>3</sup>, J. Henriques<sup>4</sup>, O. Bouche<sup>5</sup>, D. Pezet<sup>6</sup>, G. Piessen<sup>7</sup>, R. Coriat<sup>8</sup>, A. Zaanani<sup>9</sup>, J.L. Legoux<sup>10</sup>, E. Terrebone<sup>11</sup>, M. Pocard<sup>12</sup>, J.-M. Gornet<sup>13</sup>, D. Vernerey<sup>4</sup>, P. Afchain<sup>14</sup>, <sup>1</sup>Hôpital Avicenne, Bobigny, FR, <sup>2</sup>CHU de Pontchaillou, Rennes, FR, <sup>3</sup>CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR, <sup>4</sup>CHU



Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>5</sup>CHU de Reims - Hôpital Robert Debré, Reims, FR, <sup>6</sup>CHU de Clermont Ferrand, Clermont ferrand, FR, <sup>7</sup>C.H.U. Claude Huriez, Lille, FR, <sup>8</sup>Hôpital Cochin, Paris, FR, <sup>9</sup>Hopital European George Pompidou, Paris, FR, <sup>10</sup>C.H.R. Orleans - La Source, Orleans, FR, <sup>11</sup>CHU Haut Lévêque, Pessac, FR, <sup>12</sup>CHU Lariboisière, Paris, FR, <sup>13</sup>Hôpital St. Louis, Paris, FR, <sup>14</sup>CHU Saint Antoine, Paris, FR

12:45 - 12:45 **773P - Impact of the Number of Nodes Examined on Survival in Node Negative Small Bowel Adenocarcinoma - A SEER Database Analysis**

M. Thiessen, P. Tang, R. Lee-Ying, J. Monzon, Tom Baker Cancer Centre, Calgary, CA

12:45 - 12:45 **774P - The role of adjuvant therapy in resectable SBA: a different clinicians attitude with a relevant impact on outcome.**

G. Orsi<sup>1</sup>, K. Andrikou<sup>2</sup>, F. Bergamo<sup>3</sup>, F. Nappo<sup>4</sup>, C. Manai<sup>3</sup>, A. Passardi<sup>5</sup>, M. Puzzoni<sup>6</sup>, S. Vallarelli<sup>7</sup>, M. Libertini<sup>8</sup>, M.L. Riggi<sup>1</sup>, G. Pugliese<sup>9</sup>, A. Zaniboni<sup>10</sup>, M. Schirripa<sup>4</sup>, L. Procaccio<sup>4</sup>, N. Silvestris<sup>11</sup>, M. Scartozzi<sup>12</sup>, A. Casadei Gardini<sup>5</sup>, V. Zagonel<sup>13</sup>, S. Cascinu<sup>9</sup>, <sup>1</sup>Modena Cancer Center,, modena, IT, <sup>2</sup>AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, <sup>3</sup>Veneto Institute of Oncology IOV - IRCCS, Padula, IT, <sup>4</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>5</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>6</sup>Department of Medical Oncology, cagliari, IT, <sup>7</sup>Medical Oncology Unit, National Cancer Research Centre, bari, IT, <sup>8</sup>Oncology Department, brescia, IT, <sup>9</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>10</sup>casa di cura poliambulanza, brescia, IT, <sup>11</sup>Ospedale Oncologico "Giovanni Paolo II"- IRCCS, bari, IT, <sup>12</sup>University Hospital and University of Cagliari, cagliari, IT, <sup>13</sup>Istituto Oncologico Veneto-IRCCS, padova, IT

12:45 - 12:45 **775TiP - A Phase 3, Randomized, Open-Label Study to Compare the Efficacy of Tislelizumab Versus Chemotherapy as Second-Line Therapy for Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)**

L. Shen<sup>1</sup>, J. Ajani<sup>2</sup>, S.-B. Kim<sup>3</sup>, E. Van Cutsem<sup>4</sup>, B. Guo<sup>5</sup>, J. Song<sup>6</sup>, V. Paton<sup>7</sup>, K. Kato<sup>8</sup>, <sup>1</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>2</sup>The University of Texas, MD Anderson Cancer Center, Huston, US, <sup>3</sup>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Leuven Cancer Institute, University Hospitals Leuven, Leuven, BE, <sup>5</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>6</sup>BeiGene USA, Inc., Fort Lee, US, <sup>7</sup>BeiGene USA, Inc., Oakland, US, <sup>8</sup>National Cancer Center Hospital, Tokyo, JP

12:45 - 12:45 **776TiP - Global Phase 3 Study of Tislelizumab Versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC): A Trial-in-Progress**

S. Qin<sup>1</sup>, R. Finn<sup>2</sup>, M. Kudo<sup>3</sup>, T. Meyer<sup>4</sup>, A. Vogel<sup>5</sup>, M. Ducreux<sup>6</sup>, T. Macarulla<sup>7</sup>, G. Tomasello<sup>8</sup>, F. Boisserie<sup>9</sup>, J. Hou<sup>10</sup>, C. Li<sup>11</sup>, J. Song<sup>9</sup>, A. Zhu<sup>12</sup>, <sup>1</sup>People's Liberation Army (PLA) 81 Hospital, Nanjing, CN, <sup>2</sup>UCLA - School of Medicine, Los Angeles, US, <sup>3</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>4</sup>University College London Cancer Institute, London, GB, <sup>5</sup>Medizinische Hochschule Hannover, Hannover, DE, <sup>6</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>7</sup>Vall d'Hebron University Hospital (HUVH), Barcelona, ES, <sup>8</sup>Istituti Ospitalieri di Cremona, Cremona, IT, <sup>9</sup>BeiGene USA, Inc., Fort Lee, US, <sup>10</sup>BeiGene USA, Inc., Emeryville, US, <sup>11</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>12</sup>Massachusetts General Hospital, Boston, US



- 12:45 - 12:45 **777TiP - A Phase 3, Double-Blind, Randomized Study of Pamiparib Versus Placebo as Maintenance Therapy in Patients With Inoperable, Locally Advanced, or Metastatic Gastric Cancer that Responded to Platinum-Based First-Line Chemotherapy**
- F. Ciardiello<sup>1</sup>, Y.-J. Bang<sup>2</sup>, J. Bendell<sup>3</sup>, A. Cervantes<sup>4</sup>, R. Brachmann<sup>5</sup>, K. Zhang<sup>6</sup>, M. Raponi<sup>6</sup>, H. Farin<sup>7</sup>, L. Shen<sup>8</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>4</sup>Instituto de Investigación Sanitaria INCLIVA, Valencia, ES, <sup>5</sup>BeiGene USA, Inc., Emeryville, CA, Emeryville, US, <sup>6</sup>BeiGene USA, Inc., Emeryville, US, <sup>7</sup>BeiGene USA, Inc., Cambridge, US, <sup>8</sup>Beijing Cancer Hospital, Beijing, CN
- 12:45 - 12:45 **778TiP - Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastatic EsophagoGastric Adenocarcinoma (EGA) - the randomized phase 2 INTEGA trial (AIO STO 0217)**
- E. Goekkurt<sup>1</sup>, M. Binder<sup>2</sup>, S. Lorenzen<sup>3</sup>, P. Thuss-Patience<sup>4</sup>, S.-E. Al-Batran<sup>5</sup>, A. Hinke<sup>6</sup>, S. Hegewisch-Becker<sup>1</sup>, S. Nilsson<sup>2</sup>, C. Bokemeyer<sup>7</sup>, A. Stein<sup>7</sup>, <sup>1</sup>Hämatologisch-Onkologische Praxis Eppendorf, Hamburg, DE, <sup>2</sup>University Medical Center HH-Eppendorf, Hamburg, DE, <sup>3</sup>Rechts der Isar Hospital, TUM, Munich, DE, <sup>4</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>5</sup>Nordwest-Krankenhaus, Frankfurt am Main, DE, <sup>6</sup>CCRC, Berlin, DE, <sup>7</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
- 12:45 - 12:45 **779TiP - TRIANgLE study (JCOG1510): A phase III study of tri-modality combination therapy with induction docetaxel (DOC), cisplatin (CDDP), 5-fluorouracil (FU) (DCF) vs definitive chemoradiotherapy (dCRT) for locally advanced unresectable squamous cell carcinoma (SCC) of the thoracic esophagus**
- H. Daiko<sup>1</sup>, H. Hara<sup>2</sup>, H. Ogawa<sup>3</sup>, K. Hori<sup>4</sup>, J. Mizusawa<sup>5</sup>, S. Ozawa<sup>6</sup>, M. Takagi<sup>7</sup>, M. Tanaka<sup>8</sup>, H. Baba<sup>9</sup>, Y. Shirakawa<sup>10</sup>, M. Tsuda<sup>11</sup>, S. Nakagawa<sup>12</sup>, H. Takeuchi<sup>13</sup>, T. Abe<sup>14</sup>, Y. Ito<sup>15</sup>, T. Kojima<sup>4</sup>, T. Kadota<sup>1</sup>, H. Fukuda<sup>5</sup>, K. Kato<sup>1</sup>, Y. Kitagawa<sup>16</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Saitama Cancer Center, Ina, JP, <sup>3</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>4</sup>National Cancer Center Hospital East, Kashiwa-shi, JP, <sup>5</sup>National Cancer Center, Tokyo, JP, <sup>6</sup>Tokai University School of Medicine, Kanagawa, JP, <sup>7</sup>Shizuoka General Hospital, Shizuoka, JP, <sup>8</sup>Osaka City General Hospital, Osaka, JP, <sup>9</sup>Kumamoto University, Kumamoto, JP, <sup>10</sup>Okayama University Hospital, Okayama, JP, <sup>11</sup>Hyogo Cancer Center, Hyogo, JP, <sup>12</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>13</sup>Hamamatsu University School of Medicine, Hamamatsu, JP, <sup>14</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>15</sup>Showa University School of Medicine, Tokyo, JP, <sup>16</sup>Keio University School of Medicine, Tokyo, JP
- 12:45 - 12:45 **780TiP - Phase II trial of perioperative PD-L1 inhibition with Avelumab and mDCF chemotherapy for Resectable Locally Advanced Gastric And Esophago-Gastric Adenocarcinoma**
- T. Alcindor<sup>1</sup>, A. Awan<sup>1</sup>, T. Opu<sup>1</sup>, J. Asselah<sup>1</sup>, M. Vanhuyse<sup>2</sup>, C. Mueller<sup>3</sup>, L. Ferri<sup>3</sup>, <sup>1</sup>McGill University Health Centre - Glen Site, Montreal, CA, <sup>2</sup>Cedars Cancer Center, Montreal, CA, <sup>3</sup>The McGill University Health Centre - Glen Site, Montreal, CA
- 12:45 - 12:45 **781TiP - PRODIGE 29-UCGI 26(NEOPAN): A Randomised trial of chemotherapy**

**with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC).**

M. Ducreux<sup>1</sup>, R. Desgrippes<sup>2</sup>, M. Texier<sup>3</sup>, F. Di Fiore<sup>4</sup>, P. Vanelslander<sup>5</sup>, O. Capitain<sup>6</sup>, R. Guimbaud<sup>7</sup>, J. Forestier<sup>8</sup>, F. El Hajbi<sup>9</sup>, P. Follana<sup>10</sup>, A. Parzy<sup>11</sup>, N. Baba Hamed<sup>12</sup>, Y. Rinaldi<sup>13</sup>, T. Brotelle<sup>14</sup>, J.-P. Pignon<sup>3</sup>, C. Jouffroy<sup>15</sup>, L. Dahan<sup>16</sup>, O. Bouche<sup>17</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>C.H. Broussais, St. Malo, FR, <sup>3</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>4</sup>CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR, <sup>5</sup>Hospital Saint Claude, Saint Quentin, FR, <sup>6</sup>Centre Paul Papin, Angers, FR, <sup>7</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>8</sup>Hôpital Edouard Herriot, Lyon, FR, <sup>9</sup>Centre Oscar Lambret, Lille, FR, <sup>10</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>11</sup>Centre Francois Baclesse, Caen, FR, <sup>12</sup>Hopital St. Joseph, Paris, FR, <sup>13</sup>Hôpital Européen Marseille, MARSEILLE, FR, <sup>14</sup>Centre Hospitalier Henri Duffaut, Avignon, FR, <sup>15</sup>UNICANCER, Paris, FR, <sup>16</sup>CHU La Timone Enfants, Marseille, FR, <sup>17</sup>CHU de Reims - Hôpital Robert Debré, Reims, FR

12:45 - 12:45

**782TiP - Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: the randomised Phase III study IMbrave150**

M. Ducreux<sup>1</sup>, A.-L. Cheng<sup>2</sup>, S. Qin<sup>3</sup>, A. Zhu<sup>4</sup>, M. Ikeda<sup>5</sup>, T.-Y. Kim<sup>6</sup>, D.-Z. Xu<sup>7</sup>, W. Verret<sup>8</sup>, J. Liu<sup>7</sup>, R. Finn<sup>9</sup>, P. Galle<sup>10</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>National Taiwan University Hospital, Taipei, TW, <sup>3</sup>People's Liberation Army Cancer Center, Nanjing, CN, <sup>4</sup>Massachusetts General Hospital, Boston, US, <sup>5</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>6</sup>Seoul National University College of Medicine, Seoul, KR, <sup>7</sup>Hoffman-La Roche Ltd., Shanghai, CN, <sup>8</sup>Genentech, South San Francisco, US, <sup>9</sup>UCLA - School of Medicine, Los Angeles, US, <sup>10</sup>Universitätsmedizin Mainz, Mainz, DE

12:45 - 12:45

**783TiP - CA209-9DX: Phase 3, Randomized, Double-Blind Study of Adjuvant Nivolumab vs Placebo for Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence after Curative Resection or Ablation**

M. Jimenez Exposito<sup>1</sup>, M. Akce<sup>2</sup>, J. Montero Alvarez<sup>3</sup>, E. Assenat<sup>4</sup>, L. Balart<sup>5</sup>, A. Baron<sup>6</sup>, T. Decaens<sup>7</sup>, A. Heurgue-Berlot<sup>8</sup>, A. Martin<sup>9</sup>, S. Paik<sup>10</sup>, V. Poulart<sup>11</sup>, A. Sehbai<sup>12</sup>, N. Takemura<sup>13</sup>, J.-H. Yoon<sup>14</sup>, <sup>1</sup>Bristol-Myers Squibb, Princeton, US, <sup>2</sup>Winship Cancer Institute of Emory University, Atlanta, US, <sup>3</sup>Hospital Universitario Reina Sofia, Cordoba, ES, <sup>4</sup>CHU de Montpellier - Hospital Saint Eloi, Montpellier, FR, <sup>5</sup>Tulane Medical Center, Tulane University health Sciences Center, New Orleans, US, <sup>6</sup>California Pacific, San Francisco, US, <sup>7</sup>CHU Grenoble Alpes, Grenoble, FR, <sup>8</sup>Centre Hospitalier Universitaire Reims, Reims, FR, <sup>9</sup>Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz, Madrid, ES, <sup>10</sup>Samsung Medical Center, Seoul, KR, <sup>11</sup>Bristol-Myers Squibb, Braine-l'Alleud, BE, <sup>12</sup>Pinnacle Research Group, Llc, Anniston, US, <sup>13</sup>Tokyo National Center for Global Health and Medicine, Tokyo, JP, <sup>14</sup>Seoul National University Hospital, Seoul, KR

12:45 - 12:45

**784TiP - Phase 3 KEYNOTE-585 Study of Chemotherapy (Chemo) + Pembrolizumab (Pembro) vs Chemo + Placebo as Neoadjuvant/Adjuvant Treatment for Patients (Pts) With Gastric or Gastroesophageal Junction (G/GEJ) Cancer**

Y.-J. Bang<sup>1</sup>, E. Van Cutsem<sup>2</sup>, C. Fuchs<sup>3</sup>, A. Ohtsu<sup>4</sup>, J. Tabernero<sup>5</sup>, D. Ilson<sup>6</sup>, W.J. Hyung<sup>7</sup>, V.E. Strong<sup>6</sup>, T.O. Goetze<sup>8</sup>, T. Yoshikawa<sup>9</sup>, L. Tang<sup>6</sup>, P.M.T. Hwang<sup>10</sup>, D. Adelberg<sup>11</sup>, K. Shitara<sup>4</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, BE, <sup>3</sup>Yale University, New Haven, US, <sup>4</sup>National Cancer Center Hospital East, Chiba, JP, <sup>5</sup>Vall d'Hebron University Hospital, Vall

d'Hebron Institute of Oncology VHIO., Barcelona, ES, <sup>6</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>7</sup>Yonsei Cancer Hospital, Yonsei University Health System, Seoul, KR, <sup>8</sup>Institute of Clinical Cancer Research, UCT University Cancer Center, Frankfurt, DE, <sup>9</sup>Kanagawa Cancer Center, Kanagawa, JP, <sup>10</sup>Merck & Co., Inc., New York, US, <sup>11</sup>Merck & Co., Inc., Kenilworth, US

12:45 - 12:45

**785TiP - Phase 3 KEYNOTE-590 Study of Chemotherapy + Pembrolizumab Versus Chemotherapy + Placebo as First-Line Therapy for Patients (Pts) With Advanced Esophageal or Esophagogastric Junction (E/EGJ) Cancer**

K. Kato<sup>1</sup>, M. Shah<sup>2</sup>, P. Enzinger<sup>3</sup>, J. Bennouna<sup>4</sup>, L. Shen<sup>5</sup>, A. Adenis<sup>6</sup>, J.-M. Sun<sup>7</sup>, B.C. Cho<sup>8</sup>, M. Ozguroglu<sup>9</sup>, T. Kojima<sup>10</sup>, V. Kostorov<sup>11</sup>, C. Hierro<sup>12</sup>, Y. Zhu<sup>13</sup>, S. Shah<sup>13</sup>, P. Bhagia<sup>13</sup>, T. Doi<sup>14</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Weill Cornell Medicine/ New York Presbyterian Hospital, New York, US, <sup>3</sup>Dana-Farber Cancer Institute, Boston, US, <sup>4</sup>University Hospital of Nantes, Nantes, FR, <sup>5</sup>Beijing Cancer Hospital, Beijing, CN, <sup>6</sup>Institut du Cancer de Montpellier, Montpellier, FR, <sup>7</sup>Samsung Medical Center, Seoul, KR, <sup>8</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>9</sup>University Of Istanbul Cerrahpasa Medical Faculty, Istanbul, TR, <sup>10</sup>National Cancer Center Hospital East, Kashiwa-shi, JP, <sup>11</sup>Leningrad Regional Oncology Dispensary, Saint Petersburg, RU, <sup>12</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>13</sup>Merck & Co., Inc., Kenilworth, US, <sup>14</sup>National Cancer Center Hospital East, Kashiwa, JP

12:45 - 12:45

**786TiP - Prospective multicenter feasibility study of laparoscopic sentinel basin dissection after endoscopic submucosal dissection for early gastric cancer.**

K.W. Ryu<sup>1</sup>, B.W. Eom<sup>1</sup>, H.M. Yoon<sup>1</sup>, Y.-W. Kim<sup>1</sup>, J.S. Min<sup>2</sup>, G.S. Cho<sup>3</sup>, I. Cho<sup>3</sup>, Y.J. Lee<sup>4</sup>, J.-H. Park<sup>4</sup>, H. Hur<sup>5</sup>, Y.K. Park<sup>6</sup>, O. Jeong<sup>6</sup>, M.R. Jung<sup>6</sup>, J.H. Lee<sup>7</sup>, J.Y. An<sup>7</sup>, <sup>1</sup>National Cancer Center, Gyeonggi-do, KR, <sup>2</sup>Dongnam Institute of Radiological and Medical Sciences, Cancer Center, Busan, KR, <sup>3</sup>Soonchunhyang University College of Medicine, Bucheon, KR, <sup>4</sup>Gyeongsang National University, Jinju, KR, <sup>5</sup>Ajou University School of Medicine, Suwon, KR, <sup>6</sup>Chonnam National University Hwasun Hospital, Hwasun, KR, <sup>7</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR

12:45 - 12:45

**787TiP - A phase III study of adjuvant docetaxel, capecitabine and oxaliplatin triplet vs capecitabine and oxaliplatin doublet in patients with curatively resected stage IIIB or IV(M0) (AJCC 6th ed) gastric adenocarcinoma (TRIUMPH, KCSG ST14-05)**

M.-H. Ryu<sup>1</sup>, D.Y. Zang<sup>2</sup>, K.-W. Lee<sup>3</sup>, B.Y. Shim<sup>4</sup>, M.H. Lee<sup>5</sup>, S.Y. Rha<sup>6</sup>, Y.-K. Kang<sup>7</sup>, <sup>1</sup>Asan Medical Center, Seoul, KR, <sup>2</sup>Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KR, <sup>3</sup>Seoul National University Bundang Hospital, Seoul, KR, <sup>4</sup>St. Vincent's Hospital, Suwon, KR, <sup>5</sup>Inha University Hospital, Incheon, KR, <sup>6</sup>Yonsei Cancer Center, Seoul, KR, <sup>7</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR

12:45 - 12:45

**788TiP - ACELARATE - A randomised Phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma**

D. Harrison Palmer<sup>1</sup>, P. Ross<sup>2</sup>, P. Silcocks<sup>3</sup>, W. Greenhalf<sup>3</sup>, O. Faluyi<sup>4</sup>, Y.T. Ma<sup>5</sup>, J. Wadsley<sup>6</sup>, C. Rawcliffe<sup>3</sup>, J. Neoptolemos<sup>7</sup>, J. Valle<sup>8</sup>, H. Wasan<sup>9</sup>, N. Starling<sup>10</sup>, K. Patel<sup>11</sup>, J. Bridgewater<sup>12</sup>, <sup>1</sup>University of Liverpool Cancer Research UK Centre, London, GB, <sup>2</sup>Guy's



and St Thomas' NHS Foundation Trust, London, GB, <sup>3</sup>University of Liverpool, Liverpool, GB, <sup>4</sup>Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, GB, <sup>5</sup>University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, <sup>6</sup>Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, GB, <sup>7</sup>University of Heidelberg, Heidelberg, DE, <sup>8</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>9</sup>Imperial College Healthcare NHS Trust, London, GB, <sup>10</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>11</sup>Churchill Hospital, Oxford, GB, <sup>12</sup>University College London Hospitals, London, GB

12:45 - 12:45

**789TiP - HALO 109-301: Phase 3, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high Stage IV pancreatic ductal adenocarcinoma (PDA)**

E. Van Cutsem<sup>1</sup>, P. Corrie<sup>2</sup>, M. Ducreux<sup>3</sup>, D. Sigal<sup>4</sup>, V. Sahai<sup>5</sup>, D.-Y. Oh<sup>6</sup>, A. Bullock<sup>7</sup>, Y.-J. Bang<sup>6</sup>, A. Baron<sup>8</sup>, A. Hendifar<sup>9</sup>, C.-P. Li<sup>10</sup>, P. Philip<sup>11</sup>, M. Reni<sup>12</sup>, M. Zalupski<sup>5</sup>, L. Zheng<sup>13</sup>, C. Berman<sup>14</sup>, D. Chondros<sup>15</sup>, M. Tempero<sup>16</sup>, <sup>1</sup>Leuven Cancer Institute, University Hospitals Leuven, Leuven, BE, <sup>2</sup>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, <sup>3</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>4</sup>Scripps Clinic, La Jolla, US, <sup>5</sup>University of Michigan, Ann Arbor, US, <sup>6</sup>Seoul National University Hospital, Seoul, KR, <sup>7</sup>Beth Israel Deaconess Medical Center, Boston, US, <sup>8</sup>California Pacific, San Francisco, US, <sup>9</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>10</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>11</sup>Karmanos Cancer Institute, Detroit, US, <sup>12</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>13</sup>Johns Hopkins University, Baltimore, US, <sup>14</sup>Halozyme Therapeutics, Inc, San Diego, US, <sup>15</sup>Halozyme Therapeutics, Inc., San Diego, US, <sup>16</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

12:45 - 12:45

**790TiP - A Phase 2 Clinical Investigation of BPM31510-IV (Ubidecarenone) in patients with advanced Pancreatic Cancer**

A. Niewiarowska<sup>1</sup>, D. Lucius<sup>2</sup>, R. Sarangarajan<sup>2</sup>, N. Narain<sup>2</sup>, R. Ramanathan<sup>3</sup>, P. Ritch<sup>4</sup>, J. Strauss<sup>5</sup>, M. Kundranda<sup>6</sup>, D. Propper<sup>7</sup>, <sup>1</sup>Vita Medical Associates, Bethlehem, US, <sup>2</sup>BERG, LLC, Framingham, US, <sup>3</sup>Mayo Clinic Cancer Center, Scottsdale, US, <sup>4</sup>Medical College of Wisconsin, Milwaukee, US, <sup>5</sup>Mary Crowley Medical Research Center, Dallas, US, <sup>6</sup>Banner MD Anderson Cancer Center, Gilbert, US, <sup>7</sup>St. Bartholomew's Hospital, London, GB

12:45 - 12:45

**1936P - Survival effect of lncRNA-X expression in EGFR-mutant adenocarcinoma**

Y. Nakano<sup>1</sup>, K. Isobe<sup>1</sup>, A. Kakimoto<sup>1</sup>, H. Kobayashi<sup>1</sup>, K. Kaburaki<sup>1</sup>, G. Sano<sup>1</sup>, S. Sakamoto<sup>1</sup>, Y. Takai<sup>1</sup>, N. Tochigi<sup>1</sup>, T. Mikami<sup>2</sup>, A. Iyoda<sup>1</sup>, S. Homma<sup>1</sup>, <sup>1</sup>Toho university Medical Center Oomori Hospital, Tokyo, JP, <sup>2</sup>Toho University School of Medicine, Tokyo, JP

12:45 - 12:45

**Head and neck cancer**

12:45 - 12:45

**1057P - Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): an observational study (ENCORE)**

C. Le Tourneau<sup>1</sup>, M. Ghiani<sup>2</sup>, M. Cau<sup>3</sup>, R. Depenni<sup>4</sup>, G. Ronzino<sup>5</sup>, P. Bonomo<sup>6</sup>, V.



Montesarchio<sup>7</sup>, L. Leo<sup>8</sup>, J. Schulten<sup>9</sup>, D. Messinger<sup>10</sup>, A. Sbrana<sup>11</sup>, M.G. Ghi<sup>12</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>Azienda Ospedaliera Brotzu, Cagliari, IT, <sup>3</sup>Medical Oncology Department, Cagliari, IT, <sup>4</sup>Università degli Studi di Modena e Reggio Emilia, Modena, IT, <sup>5</sup>Ospedale "Vito Fazzi", Lecce, IT, <sup>6</sup>Azienda Ospedaliero-Universitaria Careggi, Florence, IT, <sup>7</sup>Azienda Ospedaliera Dei Colli-Monaldi, Napoli, IT, <sup>8</sup>Ospedale Monaldi-Azienda Ospedaliera dei Colli, Naples, IT, <sup>9</sup>Merck KGaA, Darmstadt, DE, <sup>10</sup>Prometris GmbH, Mannheim, DE, <sup>11</sup>Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, <sup>12</sup>Ospedale dell'Angelo di Mestre, Venezia, IT

12:45 - 12:45

**1058P - Elderly patients with locally advanced head and neck squamous cell carcinoma treated with NBTXR3 nanoparticles activated by radiotherapy: a phase I trial.**

C. Le Tourneau<sup>1</sup>, V. Calugaru<sup>1</sup>, V. Moreno<sup>2</sup>, X. Mirabel<sup>3</sup>, B. Dodger<sup>2</sup>, E. Calvo<sup>4</sup>, T. Jouffroy<sup>1</sup>, J. Rodriguez<sup>1</sup>, A. Chilles<sup>1</sup>, M. Yemi<sup>1</sup>, C. Hoffmann<sup>1</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>3</sup>Oscar Lambret Center, Lille, FR, <sup>4</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES

12:45 - 12:45

**1059P - Long lasting responses to adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma**

S. Secondino<sup>1</sup>, P. Bossi<sup>2</sup>, A. Gurrado<sup>3</sup>, S. Basso<sup>3</sup>, I. Imarisio<sup>1</sup>, A. Pagani<sup>3</sup>, M. Zecca<sup>3</sup>, I. Pisani<sup>3</sup>, J. Bagnarino<sup>3</sup>, M. Casanova<sup>4</sup>, C. Bergamini<sup>5</sup>, C. Perotti<sup>3</sup>, L. Licitra<sup>2</sup>, P. Comoli<sup>3</sup>, P. Pedrazzoli<sup>3</sup>, <sup>1</sup>Ospedale San Matteo, Pavia, IT, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>Fondazione IRCCS Policlinico San Matteo, Pavia, IT, <sup>4</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>5</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

12:45 - 12:45

**1060P - Radiotherapy Alone for Human Papillomavirus-Related Locally Advanced Oropharyngeal Squamous Cell Carcinoma: a Single-Arm, Phase 2 Study**

N. Takemoto<sup>1</sup>, M. Suzuki<sup>2</sup>, Y. Seo<sup>2</sup>, K. Ogawa<sup>2</sup>, H. Inohara<sup>3</sup>, <sup>1</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>2</sup>Osaka University Graduate School of Medicine, Osaka, JP, <sup>3</sup>Osaka University, Osaka, JP

12:45 - 12:45

**1061P - Molecular screening in advanced cancer patients with head and neck cancers: a retrospective analysis of MOSCATO-01 trial.**

A. Houessinon<sup>1</sup>, L. Verlingue<sup>2</sup>, A. Hollebecque<sup>3</sup>, C. Even<sup>4</sup>, L. Lacroix<sup>4</sup>, S. Postel-Vinay<sup>4</sup>, A. Varga<sup>3</sup>, Y. El Dakdouki<sup>4</sup>, R. Balheda<sup>5</sup>, J.-M. Michot<sup>4</sup>, A. Gazzah<sup>4</sup>, A. Marabelle<sup>3</sup>, S. Michiels<sup>3</sup>, E. Rouleau<sup>6</sup>, I. Breuskin<sup>4</sup>, T. De Baere<sup>4</sup>, E. Angevin<sup>7</sup>, J.-Y. Scoazec<sup>8</sup>, J.-C. Soria<sup>9</sup>, C. Massard<sup>7</sup>, <sup>1</sup>CHU Amiens-Picardie Site Sud, Amiens, FR, <sup>2</sup>Private Practice, Paris, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR, <sup>5</sup>Gustave Roussy, VILLEJUIF, FR, <sup>6</sup>Institut Curie, Paris, FR, <sup>7</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>8</sup>Gustave Roussy, University Paris-Saclay, Villejuif, FR, <sup>9</sup>Medimmune, Gaithersburg, US

12:45 - 12:45

**1062P - Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma**

H.-F. Kao, R.-L. Hong, National Taiwan University Hospital, Taipei, TW

- 12:45 - 12:45 **1063P - A Multicenter Phase II Trial of Paclitaxel, Carboplatin and Cetuximab (PCE) followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN)**
- T. Enokida<sup>1</sup>, T. Ogawa<sup>2</sup>, A. Homma<sup>3</sup>, K. Okami<sup>4</sup>, S. Minami<sup>5</sup>, S. Iwae<sup>6</sup>, A. Nakanome<sup>7</sup>, Y. Shimizu<sup>8</sup>, A. Motegi<sup>1</sup>, D. Maki<sup>4</sup>, Y. Ueda<sup>1</sup>, T. Fujisawa<sup>1</sup>, S. Nomura<sup>1</sup>, S. Okano<sup>1</sup>, M. Tahara<sup>1</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Tohoku University School of Medicine, Sendai, JP, <sup>3</sup>Hokkaido University Graduate School of Medicine, Sapporo, JP, <sup>4</sup>Tokai University, Isehara, JP, <sup>5</sup>National Hospital Organization Tokyo Medical Center, Tokyo, JP, <sup>6</sup>Hyogo Cancer Center, Akashi, JP, <sup>7</sup>Tohoku University Hospital, Sendai, JP, <sup>8</sup>Hokkaido University Hospital, Sapporo, JP
- 12:45 - 12:45 **1064P - Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study**
- M. Hecht<sup>1</sup>, D. Hahn<sup>2</sup>, P. Wolber<sup>3</sup>, M. Hautmann<sup>4</sup>, D. Reichert<sup>5</sup>, J. Weniger<sup>6</sup>, C. Belka<sup>7</sup>, T. Bergmann<sup>8</sup>, T. Göhler<sup>9</sup>, M. Welslau<sup>10</sup>, D. Hofmann<sup>11</sup>, R. Fiektkau<sup>12</sup>, <sup>1</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>2</sup>Klinikum Stuttgart - Katharinenhospital Klinik f. Onkologie, Stuttgart, DE, <sup>3</sup>Universitätsklinikum Köln, Köln, DE, <sup>4</sup>Universitätsklinikum Regensburg, Regensburg, DE, <sup>5</sup>Medizinische Studiengesellschaft NORD-WEST GmbH, Westerstede, DE, <sup>6</sup>Gemeinschaftspraxis Dres. Weniger, Bittrich, Schütze, Erfurt, DE, <sup>7</sup>University of Munich, Munich, DE, <sup>8</sup>SRH Wald-Klinikum Gera GmbH, Gera, DE, <sup>9</sup>Onkozentrum Dresden/Freiberg, Dresden, DE, <sup>10</sup>Klinikum Aschaffenburg, Aschaffenburg, DE, <sup>11</sup>Merck Serono GmbH, Darmstadt, DE, <sup>12</sup>Universitätsklinikum Erlangen, Erlangen, DE
- 12:45 - 12:45 **1065P - TOPNIVO - A safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): first results on behalf of the Unicancer Head&Neck Group and the GORTEC.**
- C. Even<sup>1</sup>, A. Daste<sup>2</sup>, E. Saada-Bouزيد<sup>3</sup>, J. Fayette<sup>4</sup>, M.-C. Kaminsky-Forrett<sup>5</sup>, S. Zanetta<sup>6</sup>, A. Prevost<sup>7</sup>, G. Lefebvre<sup>8</sup>, C. Borel<sup>9</sup>, D. Cupissol<sup>10</sup>, F. Huguet<sup>11</sup>, J.-P. Delord<sup>12</sup>, N. Baste Rotllan<sup>13</sup>, J. Delaye<sup>14</sup>, I. Jallut<sup>14</sup>, N. Vintonenko<sup>15</sup>, J. Bourhis<sup>16</sup>, J. Guigay<sup>17</sup>, M. Texier<sup>18</sup>, A. Auperin<sup>19</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>3</sup>Hopital Lacassagne, Nice, FR, <sup>4</sup>Centre Léon Bérard, Lyon, FR, <sup>5</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>6</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>7</sup>Institut Jean Godinot, REIMS, FR, <sup>8</sup>Centre Oscar Lambret, Lille, FR, <sup>9</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>10</sup>Laboratoire de Radio-Analyse du C.R.L.C., Montpellier, FR, <sup>11</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>12</sup>Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, <sup>13</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>14</sup>Unicancer, Paris, FR, <sup>15</sup>GORTEC, TOURS, FR, <sup>16</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>17</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>18</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>19</sup>Gustave Roussy Cancer Campus, Villejuif, FR
- 12:45 - 12:45 **1066P - A Phase II Trial of Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck**
- Y. Imamura<sup>1</sup>, N. Kiyota<sup>1</sup>, K. Tanaka<sup>2</sup>, H. Hayashi<sup>3</sup>, I. Ota<sup>4</sup>, K. Nario<sup>4</sup>, S. Hirano<sup>5</sup>, A. Arai<sup>5</sup>,

S. Iwae<sup>6</sup>, T. Onoe<sup>6</sup>, S. Minami<sup>7</sup>, T. Shimada<sup>8</sup>, K. Yane<sup>9</sup>, T. Yamazaki<sup>10</sup>, Y. Nagatani<sup>1</sup>, M. Toyoda<sup>1</sup>, N. Otsuki<sup>1</sup>, K.-I. Nibu<sup>1</sup>, H. Minami<sup>1</sup>, <sup>1</sup>Kobe University Hospital, Kobe, JP, <sup>2</sup>Kinki University School of Medicine, Osaka, JP, <sup>3</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>4</sup>Nara Medical University, Kashihara, JP, <sup>5</sup>Kyoto Prefectural University of Medicine, Kyoto, JP, <sup>6</sup>Hyogo Cancer Center, Akashi, JP, <sup>7</sup>National Hospital Organization Tokyo Medical Center, Tokyo, JP, <sup>8</sup>National Hospital Organization Tokyo Medical Center, Meguro, JP, <sup>9</sup>Nara Hospital, Faculty of Medicine, Kindai University, Nara, JP, <sup>10</sup>Miyagi Cancer Center, Natori, JP

12:45 - 12:45 **1067P - Multicenter Phase II Trial of nab-paclitaxel and Cisplatin (AP) followed by Chemoradiation Therapy (CRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)**

D. Adkins<sup>1</sup>, J. Ley<sup>1</sup>, H. Gay<sup>1</sup>, M. Daly<sup>1</sup>, R. Jackson<sup>1</sup>, J. Rich<sup>1</sup>, P. Pipkorn<sup>1</sup>, R. Paniello<sup>1</sup>, K. Trinkaus<sup>1</sup>, P. Neupane<sup>2</sup>, J. Zevallos<sup>1</sup>, W. Thorstad<sup>1</sup>, P. Oppelt<sup>1</sup>, <sup>1</sup>Washington University School of Medicine, St. Louis, US, <sup>2</sup>University of Kansas Cancer Center, Fairway, US

12:45 - 12:45 **1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib - randomized phase II study versus single agent MTX.**

J. Ham<sup>1</sup>, E. Meerten<sup>2</sup>, E. Fiets<sup>3</sup>, F. Jeurissen Mc Haaglanden<sup>4</sup>, M. Slingerland<sup>5</sup>, W. Van Der Graaf<sup>6</sup>, C. Van Herpen<sup>1</sup>, L. Beerepoot<sup>7</sup>, <sup>1</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>2</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>3</sup>Medical Center Leeuwarden, Leeuwarden, NL, <sup>4</sup>Medisch Centrum Haaglanden, locatie Westeinde, Den Haag, NL, <sup>5</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>6</sup>Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, <sup>7</sup>St. Elisabeth Hospital, Tilburg, NL

12:45 - 12:45 **1069P - Phase II study of biweekly TPFL induction chemotherapy for locally advanced squamous cell carcinoma of head and neck**

C.Y. Hsieh, M.Y. Lein, C.-H. Hua, China Medical University Hospital., Taichung city, TW

12:45 - 12:45 **1070P - Evaluate the Role of Induction Chemotherapy in the Treatment of Stage II Nasopharyngeal Carcinoma in Intensity Modulated Radiotherapy Era**

T. Jin, P.-J. Li, Zhejiang Cancer Hospital, Hangzhou, CN

12:45 - 12:45 **1071P - Phase 2 study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): final results**

R. Mesia Nin<sup>1</sup>, P. Bossi<sup>2</sup>, A. Hansen<sup>3</sup>, C. Hsieh<sup>4</sup>, L. Licitra<sup>2</sup>, E.H. Tan<sup>5</sup>, P. Chen<sup>6</sup>, J. Miller<sup>7</sup>, L. Siu<sup>8</sup>, R. Haddad<sup>9</sup>, <sup>1</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>4</sup>China Medical University Hospital, Taichung, TW, <sup>5</sup>National Cancer Center, Singapore, SG, <sup>6</sup>Celgene Corporation, Summit, US, <sup>7</sup>Celgene - USA, Basking Ridge, US, <sup>8</sup>Princess Margaret Hospital, Toronto, CA, <sup>9</sup>Dana-Farber Cancer Institute, Boston, US

12:45 - 12:45 **1072P - Concurrent cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy for p16-positive, locally advanced oropharyngeal cancer: A meta-analysis**



P. Suton<sup>1</sup>, M. Skelin<sup>2</sup>, I. Luksic<sup>3</sup>, <sup>1</sup>University Hospital for Tumors, University Hospital Center Sestre Milosrdnice, Zagreb, HR, <sup>2</sup>OB General Hospital Sibenik, Sibenik, HR, <sup>3</sup>University Hospital Dubrava, Zagreb, HR

- 12:45 - 12:45 **1073P - Survival benefit of adjuvant chemotherapy VS active surveillance in locally advanced nasopharyngeal carcinoma, a multicenter retrospective study**  
P. Danchaivijitr<sup>1</sup>, A. Dechaphunkul<sup>2</sup>, C. Paoin<sup>1</sup>, J. Setakornnukul<sup>1</sup>, T. Dechaphunkul<sup>3</sup>, R. Jiratrachu<sup>4</sup>, S. Niyomnaitham<sup>1</sup>, B. Suktitipat<sup>1</sup>, C. Sookthon<sup>5</sup>, P. Pattaranutaporn<sup>5</sup>, C. Jiarpinitnun<sup>5</sup>, N. Ngamphaiboon<sup>5</sup>, <sup>1</sup>Siriraj Hospital, Mahidol University, Bangkok, TH, <sup>2</sup>Prince of Songkla University, Sonckhla, TH, <sup>3</sup>Songkhlanagerind Hospital, Songkla, TH, <sup>4</sup>Songkhlanagerind Hospital, Hat Yai, TH, <sup>5</sup>Ramathibodi Hospital, Bangkok, TH
- 12:45 - 12:45 **1074P - Paclitaxel in combination with anti-EGFR therapy as induction chemotherapy for patients unfit for cisplatin with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)**  
J. Marín<sup>1</sup>, M. Oliva Bernal<sup>2</sup>, M. Plana Serrahima<sup>2</sup>, M. Ferrer<sup>3</sup>, N. Vilariño Quintela<sup>4</sup>, S. Vazquez<sup>2</sup>, E. Vilajosana<sup>2</sup>, A. Lozano<sup>2</sup>, J. Nogués<sup>5</sup>, A. Mari<sup>5</sup>, O. Bermejo<sup>5</sup>, R. Mesia Nin<sup>6</sup>, M. Taberna Sanz<sup>1</sup>, <sup>1</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>2</sup>Institut Catala de Oncologia, Barcelona, ES, <sup>3</sup>Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES, <sup>4</sup>University Hospital del Mar, Barcelona, ES, <sup>5</sup>Hospital Universitari de Bellvitge, Barcelona, ES, <sup>6</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES
- 12:45 - 12:45 **1075P - Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastatic head and neck squamous cell (PR R/M HNSCC) patients (pts):real-life experience.**  
G. Bruixola<sup>1</sup>, J. Caballero Daroqui<sup>2</sup>, A.J. Cunqueiro Tomas<sup>3</sup>, S. Sandiego<sup>4</sup>, J. García Sánchez<sup>5</sup>, S. Blasco<sup>6</sup>, S. Ochendusko<sup>7</sup>, A. Iranzo<sup>8</sup>, J. Lavernia<sup>4</sup>, A. Berrocal Jaime<sup>3</sup>, M. Pastor Borgoñón<sup>2</sup>, <sup>1</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>2</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>3</sup>Hospital General Universitario Valencia, Valencia, ES, <sup>4</sup>Instituto Valenciano de Oncología, València, ES, <sup>5</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>6</sup>Hospital de Sagunto, Valencia, ES, <sup>7</sup>Hospital Dr. Peset Aleixandre, Valencia, ES, <sup>8</sup>Hospital Clinico Universitario de Valencia - INCLIVA, Valencia, ES
- 12:45 - 12:45 **1076P - Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) receiving concurrent chemoradiotherapy (CCRT) : A multicenter retrospective study**  
A. Dechaphunkul<sup>1</sup>, P. Danchaivijitr<sup>2</sup>, R. Jiratrachu<sup>1</sup>, T. Dechaphunkul<sup>3</sup>, C. Sookthon<sup>4</sup>, C. Jiarpinitnun<sup>4</sup>, C. Paoin<sup>2</sup>, J. Setakornnukul<sup>2</sup>, S. Niyomnaitham<sup>2</sup>, B. Suktitipat<sup>2</sup>, P. Pattaranutaporn<sup>4</sup>, N. Ngamphaiboon<sup>4</sup>, <sup>1</sup>Songkhlanagerind Hospital, Hat Yai, TH, <sup>2</sup>Siriraj Hospital, Mahidol University, Bangkok, TH, <sup>3</sup>Songkhlanagerind Hospital, Songkla, TH, <sup>4</sup>Ramathibodi Hospital, Bangkok, TH
- 12:45 - 12:45 **1077P - Comparison of Concurrent Chemoradiation Therapy Plus Induction Chemotherapy with Cisplatin, Fluorouracil and Docetaxel Versus Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma.**  
Z. Zeng<sup>1</sup>, R. Yan<sup>1</sup>, L. Tu<sup>1</sup>, Y. Wang<sup>1</sup>, P. Chen<sup>2</sup>, F. Luo<sup>1</sup>, L. Liu<sup>1</sup>, <sup>1</sup>West China Hospital,



Sichuan University, Chengdu, CN, 2Sichuan University, Chengdu, CN

- 12:45 - 12:45 **1078P - Genomic Profiling and Matched Therapy for recurrent or metastatic malignant salivary gland tumors**  
E. Malone<sup>1</sup>, R. Jang<sup>2</sup>, A. Spreafico<sup>2</sup>, I. Weinreb<sup>3</sup>, S. Jennings<sup>2</sup>, L. Siu<sup>4</sup>, A. Hansen<sup>2</sup>,  
<sup>1</sup>Beaumont Hospital, Dublin, IE, <sup>2</sup>Princess Margaret Cancer Center, Toronto, CA,  
<sup>3</sup>University of Toronto, Toronto, CA, <sup>4</sup>Princess Margaret Hospital, Toronto, CA
- 12:45 - 12:45 **1079P - Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma**  
W. Boxtel<sup>1</sup>, I. Van Engen-Van Grunsven<sup>1</sup>, D. Van Strijp<sup>2</sup>, J.B.A. Van Zon<sup>3</sup>, M. Ligtenberg<sup>4</sup>,  
G. Verhaegh<sup>1</sup>, J. Schalken<sup>4</sup>, S. Neerken<sup>5</sup>, A. Van De Stolpe<sup>3</sup>, C. Van Herpen<sup>4</sup>,  
<sup>1</sup>Radboudumc, Nijmegen, NL, <sup>2</sup>Philips Research, Eindhoven, NL, <sup>3</sup>Philips, Eindhoven,  
NL, <sup>4</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>5</sup>Philips Healthcare,  
Eindhoven, NL
- 12:45 - 12:45 **1080P - Prognostics factors in Adenoid Cystic Carcinoma of the Head and Neck (ACCHN): retrospective study of 15 years**  
P. Nejo<sup>1</sup>, R. Conde<sup>2</sup>, S. Esteves<sup>2</sup>, M.T. Alexandre<sup>3</sup>, M. Ferreira<sup>1</sup>, E. Netto<sup>3</sup>, J. Santos<sup>1</sup>, M.  
Magalhães<sup>1</sup>, A. Moreira<sup>3</sup>, <sup>1</sup>Instituto Português de Oncologia de Lisboa Francisco Gentil,  
E.P.E., Lisbon, PT, <sup>2</sup>Instituto Português de Oncologia de Lisboa, lisbon, PT, <sup>3</sup>Instituto  
Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon, PT
- 12:45 - 12:45 **1081P - Molecular analysis of NRAS, BRAF, C-KIT, ROS1, ALK and RET alterations in serial biopsies in sinonasal mucosal melanoma**  
G. Anguera Palacios<sup>1</sup>, L. Del Carpio<sup>1</sup>, M.-A. Molina<sup>2</sup>, C. Aguado<sup>2</sup>, J.R. Gras-Cabrero<sup>3</sup>, X.  
Leon<sup>3</sup>, M. Gonzalez-Cao<sup>4</sup>, N. Karachaliou<sup>5</sup>, A. Mozos<sup>3</sup>, A. Gonzalez<sup>3</sup>, A. Barnadas<sup>1</sup>, R.  
Rosell<sup>6</sup>, M. Majem<sup>1</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>2</sup>Pangaea  
Biotech S.L., Barcelona, ES, <sup>3</sup>Hospital de la Santa Creu i Sant Pau and Universitat  
Autònoma de Barcelona, Barcelona, ES, <sup>4</sup>Quirón Dexeus University Hospital, Barcelona,  
ES, <sup>5</sup>Institute of Oncology Rosell, Barcelona, ES, <sup>6</sup>Catalan Institute of Oncology,  
Badalona, ES
- 12:45 - 12:45 **1082P - Programmed Death-Ligand 1 (PD-L1) Expression and HPV-associated p16 in Oropharyngeal Squamous Cell Carcinoma (OSCC) treated with primary curative radiotherapy (RT)**  
T. Steiniche<sup>1</sup>, J. Eriksen<sup>1</sup>, J. Lilja-Fischer<sup>1</sup>, J. Georgsen<sup>1</sup>, P.-T. Vo<sup>2</sup>, M. Busch-Sørensen<sup>3</sup>, D.  
Chirovsky<sup>2</sup>, J. Cheng<sup>4</sup>, D. Aurora-Garg<sup>3</sup>, R. Swaby<sup>5</sup>, J. Overgaard<sup>1</sup>, <sup>1</sup>Aarhus University  
Hospital, Aarhus C, DK, <sup>2</sup>MSD - Merck & Co USA, Kenilworth, US, <sup>3</sup>Merck & Co., Inc.,  
Kenilworth, US, <sup>4</sup>Merck & Co Inc, North Wales, US, <sup>5</sup>Merck & Co., Inc., Kenilworth, US
- 12:45 - 12:45 **1083P - Dynamics of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC)**  
A. Grages<sup>1</sup>, S. Jeske<sup>1</sup>, L. Puntigam<sup>1</sup>, C. Brunner<sup>1</sup>, J. Kraus<sup>2</sup>, H. Kestler<sup>2</sup>, J. Döscher<sup>1</sup>, T.  
Hoffmann<sup>1</sup>, P. Schuler<sup>1</sup>, S. Laban<sup>1</sup>, <sup>1</sup>University Medical Center Ulm, Ulm, DE, <sup>2</sup>Ulm  
University, Ulm, DE

- 12:45 - 12:45 **1084P - Multiobjective optimization reveals distinct cancer-testis antigen patterns by primary site and Human Papilloma Virus status in head and neck squamous cell carcinoma**  
S. Laban<sup>1</sup>, G. Völkel<sup>2</sup>, J. Ezic<sup>1</sup>, T. Hoffmann<sup>1</sup>, H.-G. Rammensee<sup>3</sup>, J. Döscher<sup>1</sup>, P. Schuler<sup>1</sup>, C. Brunner<sup>1</sup>, J. Kraus<sup>2</sup>, H. Kestler<sup>2</sup>, <sup>1</sup>University Medical Center Ulm, Ulm, DE, <sup>2</sup>Ulm University, Ulm, DE, <sup>3</sup>University of Tübingen, Tübingen, DE
- 12:45 - 12:45 **1085P - The use of HPV16-E5, EGFR and pEGFR as prognostic biomarkers for oropharyngeal cancer patients**  
M. Taberna<sup>1</sup>, M. Torres<sup>1</sup>, M. Alejo<sup>2</sup>, M. Mena<sup>1</sup>, S. Tous<sup>1</sup>, S. Marquez<sup>1</sup>, M.A. Pavon<sup>1</sup>, X. Leon<sup>3</sup>, J. Garcia<sup>3</sup>, M. Guix<sup>4</sup>, R. Hijano<sup>4</sup>, T. Bonfill<sup>5</sup>, A. Aguilà<sup>5</sup>, A. Lozano<sup>6</sup>, R. Mesia Nin<sup>7</sup>, L. Alemany<sup>1</sup>, I.G. Bravo<sup>8</sup>, <sup>1</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>2</sup>Hospital General de Hospitalet, L'hospitalet de Llobregat, ES, <sup>3</sup>Hospital de Sant Pau, Barcelona, ES, <sup>4</sup>Hospital del Mar, Barcelona, ES, <sup>5</sup>Hospital Parc Taulí, Barcelona, ES, <sup>6</sup>Institut Catala de Oncologia, Barcelona, ES, <sup>7</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>8</sup>National Center for Scientific Research (UMR CNRS IRD UM), Montpellier, FR
- 12:45 - 12:45 **1086P - Combined analysis of gene expression profiles in 2 preoperative trials with afatinib and cetuximab in head and neck squamous cell carcinoma**  
P. Bossi<sup>1</sup>, S. Schmitz<sup>2</sup>, J.-P. Machiels<sup>2</sup>, L. Licitra<sup>1</sup>, C. Fortpied Lefevre<sup>3</sup>, C. Caballero<sup>3</sup>, S. Canevari<sup>4</sup>, L. De Cecco<sup>4</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>3</sup>EORTC, Brussels, BE, <sup>4</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 12:45 - 12:45 **1087P - Association of LIPI Score with Immune Checkpoint Inhibitors (ICI) outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck (R/M SCCHN) patients (pts).**  
R.G. Herrera Gomez<sup>1</sup>, L. Mezquita Pérez<sup>2</sup>, E. Auclin<sup>3</sup>, K. Saleh<sup>4</sup>, N. Baste Rotllan<sup>5</sup>, M. Jacobs<sup>4</sup>, S. Bursuc<sup>6</sup>, L. Mayache Badis<sup>4</sup>, F.R. Ferrand<sup>7</sup>, O. Casiraghi<sup>4</sup>, S. Temam<sup>4</sup>, I. Breuskin<sup>4</sup>, Y. Tao<sup>4</sup>, B. Besse<sup>8</sup>, C. Even<sup>4</sup>, <sup>1</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>2</sup>Gustave Roussy, Villejuif, FR, <sup>3</sup>Hopital European George Pompidou, Paris, FR, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Iasi Regional Oncology Institute, Iasi, RO, <sup>7</sup>Bégin Military Teaching Hospital, Saint-Mandé, FR, <sup>8</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:45 - 12:45 **1088P - Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma(R/M HNSCC) treated with Pembrolizumab in the INSPIRE study**  
M. Oliva Bernal<sup>1</sup>, S. Lien<sup>2</sup>, B. Wang<sup>2</sup>, S.C. Yang<sup>3</sup>, A. Spreafico<sup>4</sup>, R. Jang<sup>4</sup>, S. Elston<sup>5</sup>, S. Jennings<sup>4</sup>, H. Jiang<sup>6</sup>, B. Haibe-Kains<sup>2</sup>, T. Pugh<sup>7</sup>, P. Ohashi<sup>8</sup>, L. Siu<sup>5</sup>, A. Hansen<sup>4</sup>, <sup>1</sup>Institut Catala de Oncologia, Barcelona, ES, <sup>2</sup>Princess Margaret Cancer centre, University of Toronto, Toronto, CA, <sup>3</sup>Princess Margaret Cancer Centre, University of Toronto, Toronto, CA, <sup>4</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>5</sup>Princess Margaret Hospital, Toronto, CA, <sup>6</sup>University Health Network, Toronto, CA, <sup>7</sup>Princess Margaret Cancer Centre, University Health Network, Toronto, CA, <sup>8</sup>Campbell Family Institute for Cancer Research, University Health Network, Toronto, CA

- 12:45 - 12:45 **1089P - C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer**  
M.-C. Lin<sup>1</sup>, P.-H. Chien<sup>1</sup>, H.-Y. Wu<sup>2</sup>, S.-T. Chen<sup>2</sup>, H.-F. Juan<sup>2</sup>, N.-Y. Lin<sup>2</sup>, P.-J. Lou<sup>1</sup>, M.-C. Huang<sup>2</sup>, <sup>1</sup>National Taiwan University Hospital, Taipei, TW, <sup>2</sup>National Taiwan University, Taipei, TW
- 12:45 - 12:45 **1090P - Frequency of PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma (HNSCC) in Southern Thailand.**  
P. Thongwatchara<sup>1</sup>, P. Thongsuksai<sup>2</sup>, T. Dechaphunkul<sup>1</sup>, A. Dechaphunkul<sup>3</sup>,  
<sup>1</sup>Songkhlanagarind Hospital, Songkla, TH, <sup>2</sup>Songkhlanagarind Hospital, Songkhla, TH, <sup>3</sup>Prince of Songkla University, Songkhla, TH
- 12:45 - 12:45 **1091P - Comparison between the 7th and the proposed 8th editions of the UICC staging system for nasopharyngeal carcinoma patients without cervical lymph node metastasis: a retrospective analysis**  
C. Hu, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:45 - 12:45 **1092P - Validation of the Clinical AJCC/UICC TNM 8th Edition for Human Papillomavirus Related Oropharyngeal Squamous Cell Carcinoma**  
S. Deschuymer<sup>1</sup>, R. Dok<sup>2</sup>, A. Laenen<sup>3</sup>, E. Hauben<sup>4</sup>, S. Nuyts<sup>5</sup>, <sup>1</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>2</sup>KU Leuven - University of Leuven, Leuven, BE, <sup>3</sup>KU Leuven University, Leuven, BE, <sup>4</sup>University Hospitals Leuven, Leuven, BE, <sup>5</sup>KU Leuven - University Hospitals Leuven, Leuven, BE
- 12:45 - 12:45 **1093P - Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)**  
K. Xu<sup>1</sup>, A. Lo<sup>2</sup>, V. Chin<sup>1</sup>, C. Gzell<sup>3</sup>, C. O'Connor<sup>3</sup>, D. Forstner<sup>3</sup>, R. Gallagher<sup>1</sup>, R. Bova<sup>1</sup>, J. Crawford<sup>1</sup>, R. Harvey<sup>1</sup>, A. Lochhead<sup>4</sup>, P. Earls<sup>5</sup>, M. Qiu<sup>5</sup>, E. Hsu<sup>6</sup>, G. Bigg-Wither<sup>6</sup>, L. Chan<sup>6</sup>, H. Bao<sup>6</sup>, P. Foltyn<sup>6</sup>, H.-W. Sim<sup>1</sup>, A. Prawira<sup>7</sup>, <sup>1</sup>The Kinghorn Cancer Centre, Darlinghurst, AU, <sup>2</sup>The University of New South Wales, Sydney, AU, <sup>3</sup>Genesis Cancer Care, Darlinghurst, AU, <sup>4</sup>Southern IML Pathology, Wollongong, AU, <sup>5</sup>St Vincent's Pathology, Darlinghurst, AU, <sup>6</sup>St Vincent's Hospital, Darlinghurst, AU, <sup>7</sup>The Kinghorn Cancer Centre, Darlinghurst, CA
- 12:45 - 12:45 **1094P - Clinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy.**  
P. Bossi<sup>1</sup>, R. Depenni<sup>2</sup>, M. Cossu Rocca<sup>3</sup>, D. Ferrari<sup>4</sup>, G. Azzarello<sup>5</sup>, M. Alù<sup>6</sup>, F. Nolè<sup>7</sup>, C. Codecà<sup>4</sup>, G. Boscolo<sup>8</sup>, M. Piccininni<sup>9</sup>, S. Cavalieri<sup>1</sup>, G. Pugliese<sup>10</sup>, L. Licitra<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Modena Cancer Center, Modena, IT, <sup>3</sup>Istituto Europeo di Oncologia, Milano, IT, <sup>4</sup>azienda ospedaliera san paolo, milano, IT, <sup>5</sup>Mirano Hospital, Mirano, IT, <sup>6</sup>Arnas Civico, Palermo, IT, <sup>7</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>Unita Locale Socio Sanitaria 13 P.O Mirano, Mirano, IT, <sup>9</sup>University of Bari "Aldo Moro", Bari, IT, <sup>10</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT

- 12:45 - 12:45 **1095P - Prognostic value of MRI-derived residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma and a nomogram for the prediction of it**  
W.-Z. Li<sup>1</sup>, H. Liang<sup>1</sup>, X. Lv<sup>1</sup>, L.-R. Ke<sup>1</sup>, Y.-F. Ye<sup>2</sup>, Y.-H. Yu<sup>1</sup>, W.-Z. Qiu<sup>1</sup>, G.-Y. Liu<sup>1</sup>, X.-J. Huang<sup>1</sup>, K.-Y. Liu<sup>1</sup>, S.-H. Lv<sup>1</sup>, X. Guo<sup>1</sup>, Y.-Q. Xiang<sup>1</sup>, W.-X. Xia<sup>1</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Sun Yat-Sen Memorial Hospital, Guangzhou, CN
- 12:45 - 12:45 **1096P - Proteomic Comparison Based on 18FDG-PET/CT Defined Metabolic Tumor Volume in Non-metastatic Nasopharyngeal Carcinoma**  
C. Chen<sup>1</sup>, L. Li<sup>2</sup>, Z. Fei<sup>1</sup>, J. Wang<sup>2</sup>, T. Chen<sup>2</sup>, <sup>1</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>2</sup>Fujian Cancer Hospital, Fujian Medical University, Fuzhou, CN
- 12:45 - 12:45 **1097P - Prognostic value of metabolic tumor volume in recurrent and/or metastatic head and neck squamous cell carcinoma treated with platinum-based chemotherapy.**  
M. Suzuki<sup>1</sup>, N. Takemoto<sup>2</sup>, T. Fukuzumi<sup>1</sup>, M. Yamamoto<sup>1</sup>, S. Otozai<sup>3</sup>, T. Yoshii<sup>3</sup>, T. Fujii<sup>3</sup>, H. Inohara<sup>4</sup>, <sup>1</sup>Osaka University Graduate School of Medicine, Osaka, JP, <sup>2</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>3</sup>Osaka International Cancer Institute, Osaka, JP, <sup>4</sup>Osaka University, Osaka, JP
- 12:45 - 12:45 **1098P - The prognostic value of early tumor response in metastatic nasopharyngeal carcinoma patients treated with first-line chemotherapy**  
W.-X. Xia, L. Guoying, X. Lv, S.-H. Lv, X.-J. Huang, W.-Z. Qiu, H. Liang, W.-Z. Li, K.-Y. Liu, Y.-H. Yu, Y.-Q. Xiang, X. Guo, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:45 - 12:45 **1099P - Potential clinical management changes in patients harboring locally advanced squamous-cell carcinoma of head and neck by incorporating pre and post chemoradiotherapy 18.FDG PET/CT: A prospective trial.**  
U. Nicolau, A.C. Queiroz, T. Felismino, E. Lima, V.H. Jesus, L. Cezana, M. Alves, A.C. Pellizzon, P. Pinto, G. Porto, G. Carvalho, C.A. Pinto, V. Silva, A. Guimarães, T. Oliveira, M. Ikeda, T. Paiva Jr, P. Bes, L.P. Kowalski, A. C. Camargo Cancer Center, Sao Paulo, BR
- 12:45 - 12:45 **1100P - Patterns of Local Failures and Suggestions for Reduction of Clinical Target Volume for Nasopharyngeal Carcinoma Patients Without Cervical Lymph Node Metastasis**  
C. Hu, Y. Li, Fudan University Shanghai Cancer Center, Shanghai, CN
- 12:45 - 12:45 **1101P - Target delineation and dose prescription for adaptive replanned intensity-modulated radiotherapy in nasopharyngeal carcinoma.**  
X. Huan, Sun Yat-sen University Cancer Center, Guangzhou, CN
- 12:45 - 12:45 **1102P - Significance of Pretreatment F-18 FDG PET/CT Parameters in Nasopharyngeal Carcinoma Treated with Intensity-modulated Radiation Therapy**  
Y. Huang<sup>1</sup>, C. Chen<sup>2</sup>, Y. Li<sup>1</sup>, X. Qiu<sup>1</sup>, T. Chen<sup>1</sup>, <sup>1</sup>Fujian Cancer Hospital, Fujian Medical University, Fuzhou, CN, <sup>2</sup>Fujian Cancer Hospital, Fuzhou, CN
- 12:45 - 12:45 **1103P - Sentinel lymph node biopsy for clinically N0 oral squamous cell carcinoma**



H. Goda, K.-I. Nakashiro, Ehime University Graduate School of Medicine, Ehime, JP

- 12:45 - 12:45 **1104P - An insight on Head and neck cancer management in China**  
Y. Xiaoshi<sup>1</sup>, D. Weiyi<sup>2</sup>, <sup>1</sup>11st Affiliated Hospital of China Medical University, Shenyang, CN, <sup>2</sup>Stomatology Hospital of China Medical University, Shenyang, CN
- 12:45 - 12:45 **1105P - Real-world outcomes and costs in patients with recurrent or metastatic squamous cell carcinoma of the head and neck**  
A. Lafuma<sup>1</sup>, F.-E. Cotté<sup>2</sup>, C. Le Tourneau<sup>3</sup>, C. Emery<sup>1</sup>, A.-F. Gaudin<sup>2</sup>, E. Torreton<sup>1</sup>, J. Gourmelen<sup>4</sup>, J. Bonastre<sup>5</sup>, <sup>1</sup>Cemka-Eval, Bourg-la-Reine, FR, <sup>2</sup>Bristol-Myers Squibb, Rueil-Malmaison, FR, <sup>3</sup>Institut Curie, Paris, FR, <sup>4</sup>INSERM, Villejuif, FR, <sup>5</sup>Gustave Roussy, Villejuif, FR
- 12:45 - 12:45 **1106P - Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): results from an EORTC led survey**  
S. Oosting<sup>1</sup>, I. Desideri<sup>2</sup>, D. Staelens<sup>3</sup>, C. Caballero<sup>3</sup>, S. Tribius<sup>4</sup>, C. Simon<sup>5</sup>, S. Singer<sup>6</sup>, V. Gregoire<sup>7</sup>, C. Fortpied<sup>3</sup>, A. Luciani<sup>8</sup>, <sup>1</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>2</sup>Università di Firenze- Dipartimento di Patologia e Oncologia Sperimentali, Firenze, IT, <sup>3</sup>EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, <sup>4</sup>Asklepios Klinik St. Georg, Hamburg, DE, <sup>5</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>6</sup>University Medical Center Mainz, Mainz, DE, <sup>7</sup>Leon Berard Cancer Center, Lyon, FR, <sup>8</sup>Azienda Ospedaliera S. Paolo, Milan, IT
- 12:45 - 12:45 **1107P - The importance of comorbidity assessment in patients with oral squamous cell carcinoma (OSCC). Could the Adult Comorbidity Evaluation - 27 (ACE-27) provide an additional information?**  
U. Jarrod Ferrer<sup>1</sup>, S. Blanco Sanfrutos<sup>1</sup>, M. Gavin Clavero<sup>1</sup>, T. Uson Bouthelie<sup>1</sup>, B. Nadal Cristobal<sup>1</sup>, I. Moral Saez<sup>1</sup>, I. Pajares Bernad<sup>1</sup>, A. Cisneros Gimeno<sup>2</sup>, J. Martinez Trufero<sup>1</sup>, <sup>1</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>2</sup>University of Zaragoza, Zaragoza, ES
- 12:45 - 12:45 **1108P - Can concomitant diseases predict the compliance with cisplatin plus RT in patients with LA SCCHN? An exploratory endpoint analysis of the COMPLY trial.**  
J. Dunst<sup>1</sup>, G. Hildebrandt<sup>2</sup>, M. Becker-Schiebe<sup>3</sup>, T. Kuhnt<sup>4</sup>, F. Weykamp<sup>5</sup>, F. Martucci<sup>6</sup>, D. Vordermark<sup>7</sup>, M. Pless<sup>8</sup>, D. Hofmann<sup>9</sup>, V. Bühler<sup>10</sup>, S. Rothschild<sup>11</sup>, <sup>1</sup>Universitätsklinikum Schleswig-Holstein, Kiel, DE, <sup>2</sup>Universitätsklinikum Rostock, Rostock, DE, <sup>3</sup>Klinikum Braunschweig, Braunschweig, DE, <sup>4</sup>Universitätsklinikum Leipzig, Leipzig, DE, <sup>5</sup>Universitätsklinikum Heidelberg, Heidelberg, DE, <sup>6</sup>IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, <sup>7</sup>Universitätsklinikum Halle/Saale, Halle/Saale, DE, <sup>8</sup>Kantonsspital Winterthur, Winterthur, CH, <sup>9</sup>Merck Serono GmbH, Darmstadt, DE, <sup>10</sup>Merck (Schweiz) AG, Zug, CH, <sup>11</sup>Universitätsspital Basel, Basel, CH
- 12:45 - 12:45 **1109P - Comparison of acute hematologic and renal toxicities in two chemotherapy schedules of cisplatin for epithelial cell carcinoma of head and neck**  
A. Ameri<sup>1</sup>, S. Norouzi<sup>1</sup>, A. Sourati<sup>1</sup>, K. Novin<sup>1</sup>, S. Azghandi<sup>2</sup>, <sup>1</sup>Imam Hossein Hospital, Teheran, IR, <sup>2</sup>Shohada Tajrish Hospital, Teheran, IR

- 12:45 - 12:45 **1110P - Patient reports of mouth symptoms after radiotherapy treatment for head and neck cancer: an international survey.**  
C. Curtis<sup>1</sup>, A. Nicotera<sup>2</sup>, C. Griseri<sup>2</sup>, H. Roddam<sup>2</sup>, <sup>1</sup>The Swallows Head and Neck Cancer Support Group, Blackpool, GB, <sup>2</sup>University of Central Lancashire, Preston, GB
- 12:45 - 12:45 **1111P - Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer.**  
H. Shirasu, T. Yokota, K. Fushiki, H. Inoue, M. Shibata, M. Furuta, T. Kawakami, S. Kawai, S. Hamauchi, A. Todaka, T. Tsushima, N. Machida, K. Yamazaki, A. Fukutomi, Y. Onozawa, H. Yasui, Shizuoka Cancer Center, Shizuoka, JP
- 12:45 - 12:45 **1112P - Nutritional Support Dependence after Curative Chemoradiotherapy in Head and Neck Cancer: a Supplementary Analysis of a Phase II Trial (JCOG0706S1)**  
Y. Imamura<sup>1</sup>, N. Kiyota<sup>1</sup>, T. Akimoto<sup>2</sup>, G. Ogawa<sup>3</sup>, J. Eba<sup>4</sup>, S. Minami<sup>5</sup>, Y. Hasegawa<sup>6</sup>, S. Iwae<sup>7</sup>, N. Monden<sup>8</sup>, K. Matsuura<sup>9</sup>, H. Fujii<sup>10</sup>, Y. Onozawa<sup>11</sup>, A. Homma<sup>12</sup>, R. Hayashi<sup>2</sup>, M. Tahara<sup>2</sup>, <sup>1</sup>Kobe University Hospital, Kobe, JP, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>National Cancer Center Hospital East, Tokyo, JP, <sup>4</sup>National Cancer Center, Tokyo, JP, <sup>5</sup>National Hospital Organization Tokyo Medical Center, Tokyo, JP, <sup>6</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>7</sup>Hyogo Cancer Center, Akashi, JP, <sup>8</sup>National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, <sup>9</sup>Miyagi Cancer Center, Natori, JP, <sup>10</sup>Jichi Medical University, Shimotsuke, JP, <sup>11</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>12</sup>Hokkaido University, Sapporo, JP
- 12:45 - 12:45 **1113P - The retrospective analysis of nephrotoxicity for cisplatin dose of CRT compared 100 mg/m<sup>2</sup> to 80 mg/m<sup>2</sup> for head and neck cancer (HNC) patients**  
T. Oguri<sup>1</sup>, K. Nakano<sup>2</sup>, N. Fukuda<sup>3</sup>, K. Kawaguchi<sup>2</sup>, T. Urasaki<sup>2</sup>, M. Nishizawa<sup>2</sup>, M. Yunokawa<sup>2</sup>, M. Ono<sup>2</sup>, S. Taira<sup>2</sup>, J. Tomomatsu<sup>2</sup>, T. Toshiyasu<sup>2</sup>, H. Mitani<sup>2</sup>, S. Takahashi<sup>4</sup>, <sup>1</sup>Nagoya University, Graduate School of Medicine, Nagoya, JP, <sup>2</sup>The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, <sup>3</sup>The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, JP, <sup>4</sup>Cancer Institute Hospital of JFCR, Tokyo, JP
- 12:45 - 12:45 **1114P - Comparison of Treatment Outcomes and Tolerability of Patients with Recurrent (R) Nasopharyngeal Carcinoma (NPC) and Metastatic Disease at Diagnosis (M1) : A Retrospective Analysis**  
C. Sookthon, P. Pattaranutaporn, C. Jiarpinitnun, N. Ngamphaiboon, Ramathibodi Hospital, Bangkok, TH
- 12:45 - 12:45 **1115P - Impact of the multidisciplinary approach on the survival of squamous head and neck cancer in our institution.**  
M.J. Martínez-Ortiz<sup>1</sup>, Á. Martínez-Ortiz<sup>1</sup>, G. Marín-Zafra<sup>1</sup>, P. Cerezuela-Fuentes<sup>1</sup>, J. Balsalobre<sup>2</sup>, J.A. Díaz-Manzano<sup>3</sup>, J. Trujillo-Santos<sup>1</sup>, M.T. García-García<sup>1</sup>, <sup>1</sup>Hospital Universitario Santa Lucia, Cartagena, ES, <sup>2</sup>Hospital Universitario Virgen de la Arrixaca, Murcia, ES, <sup>3</sup>HCUV Arrixaca, El Palmar (Murcia), ES
- 12:45 - 12:45 **1116TiP - A randomized phase III study to evaluate the value of the omission of**

**prophylactic neck dissection for stage I/II tongue cancer (RESPOND: JCOG1601)**

N. Hanai<sup>1</sup>, T. Asakage<sup>2</sup>, N. Kiyota<sup>3</sup>, A. Homma<sup>4</sup>, N. Monden<sup>5</sup>, H. Fukushima<sup>6</sup>, T. Fujii<sup>7</sup>, T. Ogawa<sup>8</sup>, K. Tanaka<sup>9</sup>, J. Mizusawa<sup>10</sup>, J. Eba<sup>10</sup>, R. Hayashi<sup>11</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, JP, <sup>3</sup>Kobe University Hospital, Kobe, JP, <sup>4</sup>Hokkaido University, Sapporo, JP, <sup>5</sup>National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, <sup>6</sup>Cancer Institute Hospital, Tokyo, JP, <sup>7</sup>Osaka International Cancer Institute, Osaka, JP, <sup>8</sup>Tohoku University Graduate School of Medicine, Sendai, JP, <sup>9</sup>National Cancer Center Hospital, Tokyo, JP, <sup>10</sup>National Cancer Center, Tokyo, JP, <sup>11</sup>National Cancer Center Hospital East, Kashiwa, JP

12:45 - 12:45

**1117TiP - IMvoke010: Randomized Phase III Study of Atezolizumab (atezo) as Adjuvant Monotherapy After Definitive Therapy of Squamous Cell Carcinoma of the Head and Neck (SCCHN)**

R. Haddad<sup>1</sup>, D. Wong<sup>2</sup>, Y. Guo<sup>3</sup>, J. Fayette<sup>4</sup>, E. Cohen<sup>5</sup>, M. Kowgier<sup>6</sup>, A. Sandler<sup>7</sup>, C. Matheny<sup>8</sup>, F. Kabbinavar<sup>9</sup>, D. Raben<sup>10</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>UCLA - School of Medicine, Los Angeles, US, <sup>3</sup>Tongji University East Hospital, Shanghai, CN, <sup>4</sup>Centre Léon Bérard, Lyon, FR, <sup>5</sup>University of California San Diego, La Jolla, US, <sup>6</sup>F. Hoffmann-La Roche, Ltd, Mississauga, CA, <sup>7</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>8</sup>Genentech, Inc., South San Francisco, US, <sup>9</sup>Genentech, Inc., San Francisco, US, <sup>10</sup>University of Colorado, Denver, US

12:45 - 12:45

**1118TiP - A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)**

N. Ngamphaiboon<sup>1</sup>, S. Lukerak<sup>1</sup>, C. Jiarpinitnun<sup>1</sup>, A. Jinawath<sup>2</sup>, N. Jinawath<sup>1</sup>, J. Juengsamarn<sup>1</sup>, L. Arsa<sup>1</sup>, J. Konmun<sup>1</sup>, N. Kongsuphon<sup>1</sup>, N. Sankaseam<sup>1</sup>, E. Sirachainan<sup>1</sup>, P. Witoonpanich<sup>1</sup>, A. Kositwattanarek<sup>1</sup>, P. Pattaranutaporn<sup>1</sup>, <sup>1</sup>Ramathibodi Hospital, Bangkok, TH, <sup>2</sup>AstraZeneca Thailand, Bangkok, TH

12:45 - 12:45

**1119TiP - Randomized phase II multicenter study comparing modified PFE regimen with modified TPEX regimen in recurrent or metastatic squamous cell carcinoma of the head and neck: TEMPER study**

M. Shimokawa<sup>1</sup>, M. Suzuki<sup>2</sup>, M. Sugasawa<sup>3</sup>, K. Shiga<sup>4</sup>, T. Satoh<sup>2</sup>, H. Inohara<sup>5</sup>, <sup>1</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>2</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>3</sup>Saitama Medical University International Medical Center, Hidaka, JP, <sup>4</sup>Iwate Medical University School of Medicine, Morioka, JP, <sup>5</sup>Osaka University, Osaka, JP

12:45 - 12:45

**1120TiP - Randomized phase III study in EBV positive locally advanced nasopharyngeal carcinoma treated with concurrent chemo-radiotherapy with or without Anti-Viral drug.**

K. Alsaleh, A. Elbasmi, A. Hussein, F. Alshaflan, M. El-Sherify, Kuwait Cancer Control Centre Al Sabah Hospital, Shuwaikh, KW

12:45 - 12:45

**1121TiP - KEYNOTE-412: Phase 3 Study of Pembrolizumab Plus Chemoradiation vs Chemoradiation Alone for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)**

J.-P. Machiels<sup>1</sup>, L. Licitra<sup>2</sup>, Y.G. Tao<sup>3</sup>, C.-J. Yen<sup>4</sup>, D. Rischin<sup>5</sup>, J. Waldron<sup>6</sup>, B. Burtness<sup>7</sup>, V.



Gregoire<sup>8</sup>, S. Agarwala<sup>9</sup>, J. Yorio<sup>10</sup>, J.-P. Delord<sup>11</sup>, S. Aksoy<sup>12</sup>, S. Ikeda<sup>13</sup>, R.-L. Hong<sup>14</sup>, J.Y. Ge<sup>15</sup>, H. Brown<sup>15</sup>, B. Bidad<sup>16</sup>, L. Siu<sup>17</sup>, <sup>1</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, IT, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>National Cheng Kung University Hospital, Tainan, TW, <sup>5</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>6</sup>UHN Princess Margaret Cancer Centre, Toronto, CA, <sup>7</sup>Yale University School of Medicine, New Haven, US, <sup>8</sup>Cliniques Universitaires Saint-Luc, Brussels, BE, <sup>9</sup>St. Luke's Hospital & Health Network, Bethlehem, US, <sup>10</sup>Texas Oncology-Austin Central, Austin, US, <sup>11</sup>Institut Claudius Régaud, Toulouse, FR, <sup>12</sup>Hacettepe University Faculty of Medicine, Ankara, TR, <sup>13</sup>Tokyo Medical and Dental University, Tokyo, JP, <sup>14</sup>National Taiwan University Hospital, Taipei, TW, <sup>15</sup>Merck & Co., Inc., Kenilworth, US, <sup>16</sup>MSD - Merck & Co USA, Kenilworth, US, <sup>17</sup>Princess Margaret Hospital, Toronto, CA

12:45 - 12:45

**1122TiP - Pembrolizumab in Patients With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC): The Phase 2 KEYNOTE-629 Study**

L. Licitra<sup>1</sup>, L. Siu<sup>2</sup>, E. Cohen<sup>3</sup>, P. Zhang<sup>4</sup>, B. Gumuscu<sup>4</sup>, R. Swaby<sup>4</sup>, K. Harrington<sup>5</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Princess Margaret Hospital, Toronto, CA, <sup>3</sup>University of California San Diego, La Jolla, US, <sup>4</sup>Merck & Co., Inc., Kenilworth, US, <sup>5</sup>The Institute of Cancer Research, London, GB

12:45 - 12:45

**1123TiP - A Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy Followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk, HPV-Positive, Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)**

A. Spreafico<sup>1</sup>, K. Sultanem<sup>2</sup>, B. Chen<sup>3</sup>, S. Bratman<sup>1</sup>, J. Ringash<sup>1</sup>, A. Louie<sup>4</sup>, A. Mcniven<sup>1</sup>, K. Whelan<sup>3</sup>, J. Hilton<sup>5</sup>, J. Yoo<sup>4</sup>, J.-P. Machiels<sup>6</sup>, L. Licitra<sup>7</sup>, S. Oosting<sup>8</sup>, J. Waldron<sup>9</sup>, L. Siu<sup>10</sup>, W. Parulekar<sup>3</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>The Jewish General Hospital, Montreal, Montreal, CA, <sup>3</sup>Canadian Cancer Trial Group, Kingston, ON Canada, Kingston, CA, <sup>4</sup>London Health Science Centre, London, CA, <sup>5</sup>The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, <sup>6</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>7</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>8</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>9</sup>UHN Princess Margaret Cancer Centre, Toronto, CA, <sup>10</sup>Princess Margaret Hospital, Toronto, CA

12:45 - 12:45

**1124TiP - Randomized, Phase II Study of Ficlaturuzumab with or without Cetuximab in Patients (pts) with Cetuximab-Resistant, Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)**

J. Bauman, University of Arizona Cancer Center, Tucson, US

12:45 - 12:45

**1125P - Prophylactic versus reactive enternal nutritional supplement in local advanced nasopharyngeal carcinoma patients receiving radical chemo-radiotherapy: A prospective, randomized, controlled clinical trial (NCT02948699)**

Y.-Y. Chen, S. Huang, X. Chen, Q. Hu, Zhejiang cancer hospital, Hangzhou, CN

12:45 - 12:45

**1126TiP - Nivolumab and Ipilimumab in Combination with Radiotherapy in Patients with Locally Advanced Head and Neck Cancer**



J. Johnson<sup>1</sup>, V. Bar Ad<sup>1</sup>, E. Lorber<sup>1</sup>, A. Luginbuhl<sup>1</sup>, J. Curry<sup>1</sup>, D. Cagnetti<sup>1</sup>, S. Keith<sup>1</sup>, R. Axelrod<sup>1</sup>, R. Zinner<sup>1</sup>, U. Rodeck<sup>1</sup>, L. Harshyne<sup>1</sup>, A. Argiris<sup>2</sup>, <sup>1</sup>Thomas Jefferson University, Philadelphia, US, <sup>2</sup>Hygeia Hospital, Athens, GR

12:45 - 12:45 **Melanoma and other skin tumors**

12:45 - 12:45 **1250P - Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial**

R. Dummer<sup>1</sup>, D. Schadendorf<sup>2</sup>, A. Hauschild<sup>3</sup>, M. Santinami<sup>4</sup>, V. Atkinson<sup>5</sup>, M. Mandala<sup>6</sup>, V. Chiarion Sileni<sup>7</sup>, J. Larkin<sup>8</sup>, M. Nyakas<sup>9</sup>, C. Dutriaux<sup>10</sup>, A. Haydon<sup>11</sup>, L. Mortier<sup>12</sup>, C. Robert<sup>13</sup>, J. Schachter<sup>14</sup>, X. Feng<sup>15</sup>, E. De Jong<sup>15</sup>, B. Mookerjee<sup>15</sup>, R. Kefford<sup>16</sup>, J. Kirkwood<sup>17</sup>, G. Long<sup>18</sup>, <sup>1</sup>Universitätsspital Zürich, Zurich, CH, <sup>2</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>3</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>4</sup>Fondazione Istituto Nazionale Tumori, Milano, Italy, Milano, IT, <sup>5</sup>Princess Alexandra Hospital, Woolloongabba, AU, <sup>6</sup>Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, <sup>7</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>8</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>9</sup>Oslo University Hospital, Oslo, NO, <sup>10</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>11</sup>Alfred Hospital, Melbourne, AU, <sup>12</sup>Hôpital Huriez, Lille University Hospital, lille, FR, <sup>13</sup>Institut Gustave Roussy, Villejuif, FR, <sup>14</sup>The Ella Institute for Treatment and Research of Melanoma and Skin Cancer, Ramat Gan, IL, <sup>15</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>16</sup>Macquarie University, Melanoma Institute Australia, Westmead Hospital, and The University of Sydney, Sydney, AU, <sup>17</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>18</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU

12:45 - 12:45 **1251P - Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial**

V. Atkinson<sup>1</sup>, A. Hauschild<sup>2</sup>, M. Santinami<sup>3</sup>, M. Mandala<sup>4</sup>, V. Chiarion Sileni<sup>5</sup>, J. Larkin<sup>6</sup>, M. Nyakas<sup>7</sup>, C. Dutriaux<sup>8</sup>, A. Haydon<sup>9</sup>, L. Mortier<sup>10</sup>, C. Robert<sup>11</sup>, J. Schachter<sup>12</sup>, D. Schadendorf<sup>13</sup>, X. Feng<sup>14</sup>, E. De Jong<sup>14</sup>, B. Mookerjee<sup>14</sup>, R. Kefford<sup>15</sup>, R. Dummer<sup>16</sup>, J. Kirkwood<sup>17</sup>, G. Long<sup>18</sup>, <sup>1</sup>Princess Alexandra Hospital, Woolloongabba, AU, <sup>2</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>3</sup>Fondazione Istituto Nazionale Tumori, Milano, Italy, Milano, IT, <sup>4</sup>Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, <sup>5</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>6</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>7</sup>Oslo University Hospital, Oslo, NO, <sup>8</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>9</sup>Alfred Hospital, Melbourne, AU, <sup>10</sup>Hôpital Huriez, Lille University Hospital, lille, FR, <sup>11</sup>Institut Gustave Roussy, Villejuif, FR, <sup>12</sup>The Ella Institute for Treatment and Research of Melanoma and Skin Cancer, Ramat Gan, IL, <sup>13</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>14</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>15</sup>Macquarie University, Melanoma Institute Australia, Westmead Hospital, and The University of Sydney, Sydney, AU, <sup>16</sup>Universitätsspital Zürich, Zurich, CH, <sup>17</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>18</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU

12:45 - 12:45 **1252P - Management of melanoma recurrence following adjuvant anti-PD1 therapy**

C. Owen<sup>1</sup>, D. Palmieri<sup>2</sup>, A. Guminski<sup>3</sup>, M. Carlino<sup>4</sup>, A. Menzies<sup>5</sup>, G. Long<sup>5</sup>, <sup>1</sup>Melanoma

Institute Australia, Sydney, AU, <sup>2</sup>Westmead Hospital, Westmead, AU, <sup>3</sup>Royal North Shore Hospital, St Leonards, AU, <sup>4</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>5</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU

- 12:45 - 12:45 **1253P - High Response Rate with T-VEC in Early Metastatic Melanoma (Stage IIIB/C-IVM1a)**  
V. Franke<sup>1</sup>, D. Berger<sup>1</sup>, W. Klop<sup>1</sup>, B. Van Der Hiel<sup>1</sup>, B. Van De Wiel<sup>1</sup>, S. Ter Meulen<sup>1</sup>, M. Wouters<sup>2</sup>, W. Van Houdt<sup>3</sup>, A. Van Akkooi<sup>3</sup>, <sup>1</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>2</sup>NKI-AVL, NKI-AVL, NL, <sup>3</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:45 - 12:45 **1254P - Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR trial**  
S. Blankenstein<sup>1</sup>, M. Rohaan<sup>1</sup>, W. Klop<sup>2</sup>, B. Van Der Hiel<sup>3</sup>, B. Van De Wiel<sup>3</sup>, D. Peeper<sup>4</sup>, A. Van Akkooi<sup>3</sup>, J. Haanen<sup>3</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>3</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>4</sup>The Netherlands Cancer Institute, Amsterdam, NL
- 12:45 - 12:45 **1255P - Impact of Intralesional Interleukin 2 (IL2) for In-transit Melanoma in two Canadian Centres**  
D.S. Ernst<sup>1</sup>, V. Hayward<sup>2</sup>, H. Mcconkey<sup>3</sup>, X. Teng<sup>4</sup>, E. Saettler<sup>5</sup>, T. Cheng<sup>6</sup>, C. Temple-Oberle<sup>6</sup>, F. Gwadry-Sridhar<sup>5</sup>, <sup>1</sup>London Regional Cancer Program, London, CA, <sup>2</sup>University of British Columbia, Kelowna, CA, <sup>3</sup>Global Melanoma Research Network, London, CA, <sup>4</sup>Pulse Inframe Inc., London, CA, <sup>5</sup>Western University, London, CA, <sup>6</sup>University of Calgary, Calgary, CA
- 12:45 - 12:45 **1256P - Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients**  
H. Dearden<sup>1</sup>, R. Mason<sup>2</sup>, B. Nguyen<sup>3</sup>, J. Soon<sup>4</sup>, J. Smith<sup>5</sup>, M. Randhawa<sup>6</sup>, A. Mant<sup>7</sup>, L. Warburton<sup>3</sup>, S. Lo<sup>1</sup>, T. Meniawy<sup>8</sup>, A. Guminski<sup>9</sup>, P. Parente<sup>10</sup>, S. Ali<sup>6</sup>, A. Haydon<sup>11</sup>, G. Long<sup>12</sup>, M. Carlino<sup>5</sup>, M. Millward<sup>8</sup>, V. Atkinson<sup>13</sup>, A. Menzies<sup>12</sup>, <sup>1</sup>Melanoma Institute Australia, Sydney, AU, <sup>2</sup>Gold Coast University Hospital (GCUH), Southport, AU, <sup>3</sup>Sir Charles Gairdner Hospital, Perth, AU, <sup>4</sup>Eastern Health, Box Hill, AU, <sup>5</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>6</sup>The Canberra Hospital, Garran, AU, <sup>7</sup>Frankston Hospital, Frankston, AU, <sup>8</sup>School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU, <sup>9</sup>Royal North Shore Hospital, St Leonards, AU, <sup>10</sup>Box Hill Hospital-Eastern health, Box Hill, AU, <sup>11</sup>Alfred Hospital, Melbourne, AU, <sup>12</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>13</sup>Princess Alexandra Hospital, Woolloongabba, AU
- 12:45 - 12:45 **1257P - KEYNOTE-151: a Phase 1b Study of Second-Line Pembrolizumab (Pembro) for Chinese Patients (Pts) With Advanced or Metastatic Melanoma**  
L. Si<sup>1</sup>, X. Zhang<sup>2</sup>, Y. Shu<sup>3</sup>, H. Pan<sup>4</sup>, D. Wu<sup>5</sup>, J. Liu<sup>6</sup>, F. Lou<sup>4</sup>, X. Wang<sup>7</sup>, X. Wen<sup>2</sup>, Y. Gu<sup>8</sup>, L. Zhu<sup>8</sup>, S. Lan<sup>5</sup>, X. Cai<sup>6</sup>, Y. Zhou<sup>9</sup>, J. Ge<sup>10</sup>, J. Li<sup>10</sup>, H. Wu<sup>10</sup>, J. Guo<sup>7</sup>, <sup>1</sup>Peking University

Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, <sup>2</sup>Sun Yat-sen University Cancer Centre, Guangzhou, CN, <sup>3</sup>The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, CN, <sup>4</sup>Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN, <sup>5</sup>The First Hospital of Jilin University, Jilin, CN, <sup>6</sup>The First Affiliated Hospital of Dalian Medical University, Liaoning Sheng, CN, <sup>7</sup>Beijing Cancer Hospital, Beijing, CN, <sup>8</sup>Jiangsu Province Hospital, Nanjing, CN, <sup>9</sup>MSD China, Shanghai, CN, <sup>10</sup>MSD China, Beijing, CN

12:45 - 12:45

**1258P - Baseline Predictive Factors for efficacy of AntiPD1 used in first line in Melanoma Patients: an Italian Melanoma Intergroup study**

R. Marconcini<sup>1</sup>, E. Tanda<sup>2</sup>, L. Di Guardo<sup>3</sup>, O. Nigro<sup>4</sup>, P. Fava<sup>5</sup>, A. Todisco<sup>6</sup>, F. Morgese<sup>7</sup>, A. Cortellini<sup>8</sup>, E. Stroppa<sup>9</sup>, G. Gallizzi<sup>10</sup>, L. Festino<sup>11</sup>, E. Grego<sup>12</sup>, S. Quadrini<sup>13</sup>, C. Orlandini<sup>14</sup>, A. Nuzzo<sup>14</sup>, S. Manacorda<sup>14</sup>, F. Bloise<sup>14</sup>, A. Indini<sup>3</sup>, C. Astrua<sup>5</sup>, A. Falcone<sup>1</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria S.Chiana, Pisa, IT, <sup>2</sup>IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro,, Genova, IT, <sup>3</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>4</sup>ASST-Settelaghi, Ospedale di Circolo di Varese,, Varese, IT, <sup>5</sup>AOU Città della salute e della Scienza, Torino, IT, <sup>6</sup>University of Bari, Bari, IT, <sup>7</sup>Azienda Ospedaliero-Universitaria Umberto I, ancona, IT, <sup>8</sup>Ospedale Civile San Salvatore, L'Aquila, IT, <sup>9</sup>Ospedale "Guglielmo de Saliceto",, Piacenza, IT, <sup>10</sup>Ospedale SS Antonio e Biagio e C. Arrigo,, Alessandria, IT, <sup>11</sup>AOU Policlinico Federico II, Napoli, IT, <sup>12</sup>Struttura Ospedaliera S. Chiara,, Trento, IT, <sup>13</sup>Ospedale SS Trinità, Sora, IT, <sup>14</sup>Unit of medical oncology, Azienda ospedaliero Universitaria Pisana, Pisa, IT

12:45 - 12:45

**1259P - Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: a retrospective analysis of patients with advanced BRAF mutated melanoma.**

I. Reijers<sup>1</sup>, E. Rozeman<sup>2</sup>, H. Mallo<sup>3</sup>, W. Uytendinck<sup>1</sup>, S. Adriaansz<sup>1</sup>, J. Lijnsvelt<sup>1</sup>, S. Wilgenhof<sup>2</sup>, J. Van Thienen<sup>1</sup>, J. Haanen<sup>1</sup>, C. Blank<sup>1</sup>, <sup>1</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>3</sup>Netherlands Cancer institute, Amsterdam, NL

12:45 - 12:45

**1260P - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma**

P. Saiag<sup>1</sup>, C. Robert<sup>2</sup>, J.J. Grob<sup>3</sup>, L. Mortier<sup>4</sup>, O. Dereure<sup>5</sup>, C. Lebbé<sup>6</sup>, S. Mansard<sup>7</sup>, F. Grange<sup>8</sup>, E.-M. Neidhardt<sup>9</sup>, T. Lesimple<sup>10</sup>, L. Machet<sup>11</sup>, C. Bedane<sup>12</sup>, G. Jeudy<sup>13</sup>, F. Aubin<sup>14</sup>, B. Dreno<sup>15</sup>, A. Sznik<sup>16</sup>, A. Denden<sup>16</sup>, C. Dutriaux<sup>17</sup>, <sup>1</sup>Hopital Ambroise Pare, Boulogne-Billancourt, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>4</sup>Hopital Claude Huriez, Lille, FR, <sup>5</sup>CHU Montpellier, Montpellier, FR, <sup>6</sup>Hôpital Saint Louis, Paris, FR, <sup>7</sup>CHU Estaing, Clermont-Ferrand, FR, <sup>8</sup>CHU Reims - Hospital Robert-Debré, Reims, FR, <sup>9</sup>Centre Léon Bérard, Lyon, FR, <sup>10</sup>Eugene Marquis Center, Rennes, FR, <sup>11</sup>CHRU de Tours et Université François Rabelais de Tours, Tours, FR, <sup>12</sup>CHU Limoges - Hopital Dupuytren, Limoges, FR, <sup>13</sup>Dijon university hospital, Dijon, FR, <sup>14</sup>Department of Dermatology, Besançon, FR, <sup>15</sup>Polyclinic Saint Jean, Cagnes-sur-Mer, FR, <sup>16</sup>Novartis Pharma - France, Rueil-Malmaison, FR, <sup>17</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR

12:45 - 12:45



**1261P - Loss of HLA class I expression and T-cell infiltration or PD-L1 expression are associated with different response patterns to pembrolizumab in melanoma**

A. Degraeuwe<sup>1</sup>, N. Van Baren<sup>1</sup>, F. Cornelis<sup>2</sup>, P. Van Eeckhout<sup>3</sup>, J.-F. Baurain<sup>2</sup>, <sup>1</sup>Université catholique Louvain, Bruxelles, BE, <sup>2</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>3</sup>Cliniques Universitaires St. Luc, Bruxelles, BE

12:45 - 12:45 **1262P - Soluble PD-L1 as a prognostic factor in advanced acral and mucosal melanoma**

X. Wang<sup>1</sup>, C. Cui<sup>2</sup>, J. Yu<sup>3</sup>, Y. Kong<sup>2</sup>, L. Si<sup>2</sup>, Z. Chi<sup>1</sup>, X. Sheng<sup>1</sup>, L. Mao<sup>1</sup>, B. Lian<sup>2</sup>, B. Tang<sup>1</sup>, X. Yan<sup>1</sup>, J. Guo<sup>1</sup>, <sup>1</sup>Beijing Cancer Hospital, Beijing, CN, <sup>2</sup>Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, <sup>3</sup>Beijing Cancer Hospital, Beijing, CN

12:45 - 12:45 **1263P - The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice.**

A. Czarnecka<sup>1</sup>, P. Tetrycz<sup>2</sup>, I. Lugowska<sup>2</sup>, P. Rogala<sup>2</sup>, T. Switaj<sup>3</sup>, P. Rutkowski<sup>4</sup>, <sup>1</sup>Military Medical Institute, Warsaw, PL, <sup>2</sup>The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, <sup>3</sup>No place of work provided Iran, Teheran, IR, <sup>4</sup>The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL

12:45 - 12:45 **1264P - Long-term survivors among patients with metastatic melanoma treated with targeted agents and/or checkpoint inhibitors**

H. Linardou<sup>1</sup>, A. Laskarakis<sup>2</sup>, A. Molfeta<sup>1</sup>, K. Sakellariou<sup>1</sup>, A. Tarampikou<sup>1</sup>, E. Soroli<sup>1</sup>, K. Gkiati<sup>1</sup>, D. Bafaloukos<sup>1</sup>, <sup>1</sup>Metropolitan Hospital, Athens, GR, <sup>2</sup>Metropolitan Hospital of Athens, Piraeus, GR

12:45 - 12:45 **1265P - Phase 1b/2 study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy**

A. Ribas<sup>1</sup>, I. Mehmi<sup>2</sup>, T. Medina<sup>3</sup>, C. Lao<sup>4</sup>, S. Kummar<sup>5</sup>, A. Amin<sup>6</sup>, S. Deva<sup>7</sup>, A. Salama<sup>8</sup>, T. Tueting<sup>9</sup>, M. Milhem<sup>10</sup>, C. Hoimes<sup>11</sup>, G. Daniels<sup>12</sup>, M. Shaheen<sup>13</sup>, S. Jang<sup>14</sup>, M. Barve<sup>15</sup>, A. Powell<sup>16</sup>, S. Chandra<sup>17</sup>, E. Schmidt<sup>18</sup>, R. Janssen<sup>19</sup>, G. Long<sup>20</sup>, <sup>1</sup>Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, <sup>2</sup>West Virginia University, Morgantown, US, <sup>3</sup>University of Colorado Cancer Center, Aurora, US, <sup>4</sup>University of Michigan Health System, Ann Arbor, US, <sup>5</sup>Stanford University School of Medicine, Stanford, US, <sup>6</sup>Levine Cancer Institute, Charlotte, US, <sup>7</sup>Auckland City Hospital, Auckland, NZ, <sup>8</sup>Duke University, Durham, US, <sup>9</sup>University Hospital Magdeburg, Magdeburg, DE, <sup>10</sup>University of Iowa, Iowa City, US, <sup>11</sup>Case Western Reserve University, Cleveland, US, <sup>12</sup>University of California, San Diego, San Diego, US, <sup>13</sup>University of Arizona Cancer Center North, Tucson, US, <sup>14</sup>Inova Schar Cancer Institute, Fairfax, US, <sup>15</sup>Mary Crowley Cancer Research, Dallas, US, <sup>16</sup>Affinity Research, Nedlands, AU, <sup>17</sup>Northwestern University, Chicago, US, <sup>18</sup>Merck & Co Inc, North Wales, US, <sup>19</sup>Dynavax Technologies Corporation, Berkeley, US, <sup>20</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU

12:45 - 12:45 **1266P - Update on the randomised Phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma**



C. Schuster<sup>1</sup>, G. Gausdal<sup>2</sup>, B. Gjertsen<sup>3</sup>, J. Lorens<sup>4</sup>, O. Straume<sup>1</sup>, <sup>1</sup>Haukeland Universitetssykehus, Bergen, NO, <sup>2</sup>BerGenBio ASA, Bergen, NO, <sup>3</sup>Helse Bergen Haukeland University Hospital, Bergen, NO, <sup>4</sup>University of Bergen, Bergen, NO

12:45 - 12:45

**1267P - Topline Results from Phase II of Combination Treatment with Canerpatrev (HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Patients with Unresectable or Metastatic Melanoma after Anti-PD-1 Therapy**

T. Isei<sup>1</sup>, K. Yokota<sup>2</sup>, H. Uhara<sup>3</sup>, Y. Fujisawa<sup>4</sup>, T. Takenouchi<sup>5</sup>, Y. Kiyohara<sup>6</sup>, H. Uchi<sup>7</sup>, H. Saruta<sup>8</sup>, H. Ihn<sup>9</sup>, T. Inozume<sup>10</sup>, D. Watanabe<sup>11</sup>, A. Takahashi<sup>12</sup>, S. Fukushima<sup>9</sup>, M. Tanaka<sup>13</sup>, N. Yamazaki<sup>12</sup>, <sup>1</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>2</sup>Nagoya University Hospital, Nagoya, JP, <sup>3</sup>Sapporo Medical University Hospital, Sapporo, JP, <sup>4</sup>University of Tsukuba, Tsukuba, Ibaraki, JP, <sup>5</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>6</sup>Shizuoka Cancer Center Hospital, Shizuoka, JP, <sup>7</sup>University of Kyushu, Hakata, JP, <sup>8</sup>Kurume University School of Medicine, Kurume, JP, <sup>9</sup>Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, JP, <sup>10</sup>University of Yamanashi, Yamanashi, JP, <sup>11</sup>Aichi Medical University School of Medicine, Nagakute, JP, <sup>12</sup>National Cancer Center Hospital, Tokyo, JP, <sup>13</sup>TAKARA BIO INC., Kusatsu, JP

12:45 - 12:45

**1268P - NCI 9922: Phase 2 Study of Ibrutinib in Treatment-Refractory Distant Metastatic Cutaneous Melanoma (DMCM)**

S. Moschos<sup>1</sup>, Z. Eroglu<sup>2</sup>, N. Khushalani<sup>2</sup>, K. Kendra<sup>3</sup>, G. Ansstas<sup>4</sup>, G. In<sup>5</sup>, P. Wang<sup>6</sup>, G. Liu<sup>7</sup>, F. Collichio<sup>8</sup>, C. Arrowood<sup>9</sup>, J. Reed<sup>8</sup>, N. Garrett-Mead<sup>9</sup>, N. Thomas<sup>8</sup>, D. Ollila<sup>8</sup>, S.P. Ivy<sup>10</sup>, A. Ivanova<sup>8</sup>, E. Dees<sup>8</sup>, J. Abbruzzese<sup>9</sup>, <sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>2</sup>Moffitt Cancer Center, Tampa, US, <sup>3</sup>Ohio State University Comprehensive Cancer Center - James, Columbus, US, <sup>4</sup>Washington University School of Medicine in St. Louis, St. Louis, US, <sup>5</sup>Keck School of Medicine at University of Southern California, Los Angeles, US, <sup>6</sup>UK Markey Cancer Center, Lexington, US, <sup>7</sup>University of Wisconsin, Madison, US, <sup>8</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>9</sup>Duke Cancer Institute, Durham, US, <sup>10</sup>National Cancer Institute, Bethesda, US

12:45 - 12:45

**1269P - Initial cohort expansion results of sustained arginine depletion with Pegzilarginase in melanoma patients in a Phase 1 advanced solid tumor trial**

B. Chmielowski<sup>1</sup>, M. Gordon<sup>2</sup>, E. Buchbinder<sup>3</sup>, R. Sullivan<sup>4</sup>, J. Cohen<sup>4</sup>, B. Curti<sup>5</sup>, D. Davar<sup>6</sup>, J. Homsy<sup>7</sup>, K. Komatsubara<sup>8</sup>, H. Lara-Guerra<sup>9</sup>, S. Alters<sup>9</sup>, S. Ferrati<sup>9</sup>, S. Eckert<sup>9</sup>, S. Rowlinson<sup>9</sup>, J. Wooldridge<sup>10</sup>, A. Ribas<sup>11</sup>, R. Carvajal<sup>12</sup>, <sup>1</sup>University of California, Los Angeles, Los Angeles, US, <sup>2</sup>HonorHealth Virginia G Piper Cancer Care Network, Scottsdale, US, <sup>3</sup>Dana-Farber Cancer Institute, Boston, US, <sup>4</sup>Massachusetts General Hospital, Boston, US, <sup>5</sup>Providence Cancer Institute, Portland, US, <sup>6</sup>University of Pittsburgh, Pittsburgh, US, <sup>7</sup>MD Anderson Cancer Center, Houston, US, <sup>8</sup>Herbert Irving Comprehensive Cancer Center, New York, US, <sup>9</sup>Aeglea Biotherapeutics, Austin, US, <sup>10</sup>Eli Lilly, Indianapolis, US, <sup>11</sup>Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, <sup>12</sup>Memorial Sloan-Kettering Cancer Center, New York, US

12:45 - 12:45

**1270P - Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma**

C. Mignard<sup>1</sup>, A. Deschamps-Huvier<sup>1</sup>, A.-B. Duval-Modeste<sup>2</sup>, C. Dutriaux<sup>3</sup>, A. Khammari<sup>4</sup>, M.-F. Avril<sup>5</sup>, L. Mortier<sup>6</sup>, T. Lesimple<sup>7</sup>, C. Gaudy-Marqueste<sup>8</sup>, C. Lesage<sup>9</sup>, L. Mchet<sup>10</sup>, F.

Aubin<sup>11</sup>, N. Meyer<sup>12</sup>, N. Beneton Benhard<sup>13</sup>, G. Jeudy<sup>14</sup>, H. Montaudié<sup>15</sup>, J.-P. Arnault<sup>16</sup>, M.-T. Leccia<sup>17</sup>, P. Joly<sup>2</sup>, S.F.D. Oncology Research Group Of The French Society Of Dermatology<sup>18</sup>, <sup>1</sup>Hop. Charles Nicolle, Rouen, FR, <sup>2</sup>Institute for Research and Innovation in Biomedicine, INSERM 1234, Rouen University Hospital, University of Normandie, Rouen, FR, <sup>3</sup>Oncology Unit, Saint André Hospital, Bordeaux, FR, <sup>4</sup>CHU Nantes, CRCINA, CIC1413, university Nantes, Nantes, FR, <sup>5</sup>APHP Cochin Hospital, Paris, FR, <sup>6</sup>Hôpital Huriez, Lille University Hospital, lille, FR, <sup>7</sup>Eugene Marquis Center, Rennes, FR, <sup>8</sup>La Timone Hospital, Marseille, FR, <sup>9</sup>Montpellier University Hospital, Montpellier, FR, <sup>10</sup>CHRU de Tours et Université François Rabelais de Tours, Tours, FR, <sup>11</sup>Department of Dermatology, Besançon, FR, <sup>12</sup>Toulouse III University - Paul Sabatier, Institut universitaire du Cancer and Toulouse University Hospital, Toulouse, FR, <sup>13</sup>Centre Hospitalier Du Mans, Le Mans, FR, <sup>14</sup>Dijon university hospital, Dijon, FR, <sup>15</sup>Nice university hospital, INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, Team 12, Nice, FR, <sup>16</sup>Amiens-Picardie University Hospital, Amiens, FR, <sup>17</sup>CHU Grenoble Alpes, Grenoble, FR, <sup>18</sup>French Society of Dermatology, Paris, FR

12:45 - 12:45

**1271P - Retrospective analysis of the treatment of metastatic uveal melanoma comparing systemic chemotherapy and transarterial chemoembolization**

C.A. Peuker<sup>1</sup>, L. Polzin<sup>2</sup>, S. Ochsenreither<sup>3</sup>, M. De Bucourt<sup>2</sup>, S. Leyvraz<sup>4</sup>, U. Keilholz<sup>5</sup>, A. Jousen<sup>2</sup>, J. Eucker<sup>1</sup>, <sup>1</sup>Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, <sup>2</sup>Charité - University Medicine Berlin, Berlin, DE, <sup>3</sup>Charité University of Medicine, Berlin, DE, <sup>4</sup>Charité Comprehensive Cancer Center, Berlin, DE, <sup>5</sup>Charité - Universitätsmedizin Berlin, Berlin, DE

12:45 - 12:45

**1272P - Outcome of an active surveillance programme for patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): single-institution 10-year experience**

C.L. Lee<sup>1</sup>, G. Gullo<sup>1</sup>, N. Horgan<sup>2</sup>, D. Smith<sup>1</sup>, M. Moran<sup>1</sup>, J. Crown<sup>1</sup>, <sup>1</sup>St Vincents University Hospital, Dublin, IE, <sup>2</sup>Royal Victoria Eye & Ear Hospital,, Dublin, IE

12:45 - 12:45

**1273P - Activation of Non-Canonical NF\_κB (NC-NF\_κB) Pathway in Inflammatory Environment of Uveal Melanoma**

M. Singh<sup>1</sup>, R. Meel<sup>1</sup>, N. Pushker<sup>1</sup>, S. Sen<sup>1</sup>, K. Chodsol<sup>2</sup>, S. Bakhshi<sup>1</sup>, S. Kashyap<sup>1</sup>, <sup>1</sup>All India Institute of Medical Sciences, New Delhi, IN, <sup>2</sup>All India Institute of Medical Sciences, NEW DELHI, IN

12:45 - 12:45

**1274P - The use of PD-1 inhibitors for the advanced melanoma of esophagus**

L. Mao<sup>1</sup>, X. Wang<sup>1</sup>, L. Si<sup>2</sup>, Y. Kong<sup>2</sup>, Z. Chi<sup>1</sup>, X. Sheng<sup>1</sup>, C. Cui<sup>2</sup>, B. Lian<sup>2</sup>, B. Tang<sup>1</sup>, X. Yan<sup>1</sup>, J. Guo<sup>1</sup>, <sup>1</sup>Beijing Cancer Hospital, Beijing, CN, <sup>2</sup>Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN

12:45 - 12:45

**1275P - Phase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma.**

M. Nomura<sup>1</sup>, M. Andoh<sup>2</sup>, T. Yokota<sup>3</sup>, T. Miyazaki<sup>4</sup>, H. Satake<sup>5</sup>, S. Iwasawa<sup>6</sup>, A. Sonoda<sup>7</sup>, K. Kato<sup>8</sup>, M. Muto<sup>9</sup>, <sup>1</sup>Kyoto University-Graduate school of medicine, Kyoto, JP, <sup>2</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>3</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>4</sup>Kurashiki Central Hospital, Kurashiki, JP, <sup>5</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>6</sup>Chiba University Graduate School of Medicine, Chiba, JP, <sup>7</sup>Shiga University of Medical

Science, Otsu, JP, <sup>8</sup>National Cancer Center Hospital, Tokyo, JP, <sup>9</sup>Department of Therapeutic Oncology, Kyoto city, JP

12:45 - 12:45

**1276P - Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population**

M. Van Zeijl<sup>1</sup>, M. Wouters<sup>2</sup>, A. Van Den Eertwegh<sup>3</sup>, M. Aarts<sup>4</sup>, A. Van Akkooi<sup>5</sup>, F. Van Den Berkmortel<sup>6</sup>, M. Franken<sup>7</sup>, J.W. De Groot<sup>8</sup>, K. Herbschleb<sup>1</sup>, J. Van Der Hoeven<sup>1</sup>, G. Hospers<sup>9</sup>, E. Kapiteijn<sup>1</sup>, D. Piersma<sup>10</sup>, R. Van Rijn<sup>11</sup>, K. Suijkerbuijk<sup>12</sup>, A. Ten Tije<sup>13</sup>, A. Van Der Veldt<sup>14</sup>, G. Vreugdenhil<sup>15</sup>, J. Haanen<sup>5</sup>, <sup>1</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>2</sup>DICA - Dutch Institute for Clinical Auditing, Leiden, NL, <sup>3</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>4</sup>Atrium Medisch Centrum, Maastricht, NL, <sup>5</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>6</sup>Zuyderland Medical Centre, Heerlen, NL, <sup>7</sup>Erasmus University, Rotterdam, NL, <sup>8</sup>Isala Hospital, Zwolle, NL, <sup>9</sup>University Medical Centre Groningen, Groningen, NL, <sup>10</sup>Medisch Spectrum Twente (MST), Enschede, NL, <sup>11</sup>Leeuwarden Medical Centre, Leeuwarden, NL, <sup>12</sup>University Medical Centre Utrecht, Utrecht, NL, <sup>13</sup>Amphia Ziekenhuis-location Molengracht, Breda, NL, <sup>14</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>15</sup>Maxima Medisch Centrum -Veldhoven, Veldhoven, NL

12:45 - 12:45

**1277P - Stereotactic radiation therapy in melanoma brain metastasis: a European, multicentric cohort**

A. Paix<sup>1</sup>, F. Thillays<sup>2</sup>, F. Courtault-Deslandes<sup>3</sup>, I. Popp<sup>4</sup>, H. Herrscher<sup>5</sup>, J. Biau<sup>6</sup>, O. Briard<sup>7</sup>, A.-L. Grosu<sup>8</sup>, G. Noël<sup>9</sup>, <sup>1</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>2</sup>Institut cancérologique de l'ouest, Saint Herblain, FR, <sup>3</sup>Centre Georges-Francois Leclerc, Dijon, FR, <sup>4</sup>Universitätsklinikum Freiburg, Freiburg, DE, <sup>5</sup>University Hospital Strasbourg, Strasbourg, FR, <sup>6</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>7</sup>Centre Henry Kaplan - Centre Hospitalier Universitaire de Tours, Tours, FR, <sup>8</sup>Univeristy of Freiburg, Freiburg, DE, <sup>9</sup>Centre Paul Strauss, Strasbourg, FR

12:45 - 12:45

**1278P - Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: an international randomized double-blind phase 3 trial.**

C. Coens<sup>1</sup>, A. Bottomley<sup>1</sup>, C. Blank<sup>2</sup>, M. Mandala<sup>3</sup>, G. Long<sup>4</sup>, V. Atkinson<sup>5</sup>, S. Dalle<sup>6</sup>, A. Haydon<sup>7</sup>, M. Lichinitser<sup>8</sup>, A. Khatkhat<sup>9</sup>, M. Carlino<sup>10</sup>, S. Sandhu<sup>11</sup>, J. Larkin<sup>12</sup>, S. Puig Sarda<sup>13</sup>, P. Ascierto<sup>14</sup>, D. Schadendorf<sup>15</sup>, N. Ibrahim<sup>16</sup>, S. Suci<sup>1</sup>, C. Robert<sup>17</sup>, A. Eggermont<sup>17</sup>, <sup>1</sup>EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, <sup>2</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup>Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, <sup>4</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>5</sup>Princess Alexandra Hospital, Woolloongabba, AU, <sup>6</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>7</sup>Alfred Hospital, Melbourne, AU, <sup>8</sup>N. N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>9</sup>Fiona Stanley Hospital, Murdoch, AU, <sup>10</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>11</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>12</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>13</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>14</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>15</sup>University Hospital Essen, Essen, DE, <sup>16</sup>Merck & Co., Inc., Kenilworth, US, <sup>17</sup>Institut Gustave Roussy, Villejuif, FR



- 12:45 - 12:45 **1279P - The real-world impact of modern treatments on the survival of patients with metastatic melanoma**  
M. Donia<sup>1</sup>, E. Ellebaek<sup>1</sup>, T. Øllegaard<sup>2</sup>, L. Duval<sup>2</sup>, J. Aaby<sup>3</sup>, L. Højberg<sup>3</sup>, U. Kähler<sup>4</sup>, H. Schmidt<sup>2</sup>, L. Bastholt<sup>3</sup>, I.-M. Svane<sup>5</sup>, <sup>1</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>2</sup>Aarhus University Hospital, Aarhus C, DK, <sup>3</sup>Odense University Hospital, Odense C, DK, <sup>4</sup>Braintrust Consult, Odense, DK, <sup>5</sup>Herlev Hospital, Herlev, DK
- 12:45 - 12:45 **1280P - Treatment patterns of melanoma by BRAF mutation status in the US in 2011-2017: a retrospective cohort study**  
L. Raskin, S. Shah, M. Braunlin, J. Buchanan, D. Cohan, AMGEN (Headquarters) - USA, Thousand Oaks, US
- 12:45 - 12:45 **1281P - Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: a retrospective cohort study**  
M. Freeman<sup>1</sup>, K. Gupte-Singh<sup>2</sup>, M. You<sup>2</sup>, T.K. Le<sup>2</sup>, C. Ritchings<sup>2</sup>, S. Rao<sup>2</sup>, S. Jang<sup>3</sup>, <sup>1</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>2</sup>Bristol-Myers Squibb, Princeton, US, <sup>3</sup>Inova Schar Cancer Institute, Fairfax, US
- 12:45 - 12:45 **1282P - Responder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab**  
S. D'Angelo<sup>1</sup>, F. Fofana<sup>2</sup>, M. Schlichting<sup>3</sup>, M. Henry-Szatkowski<sup>4</sup>, M. Hennessy<sup>5</sup>, M. Bharmal<sup>3</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>Mapi Group, Leiden, NL, <sup>3</sup>Merck KGaA, Darmstadt, DE, <sup>4</sup>Mapi Group, Lyon, FR, <sup>5</sup>EMD Serono, Billerica, US
- 12:45 - 12:45 **1283P - Treatment Pattern and Clinical Outcomes of Patients With Locally Advanced and Metastatic Melanoma in a Real-World Setting in China**  
C. Cui<sup>1</sup>, X. Yan<sup>2</sup>, S. Liu<sup>3</sup>, A. Deitz<sup>4</sup>, L. Si<sup>1</sup>, Z. Chi<sup>2</sup>, X. Sheng<sup>2</sup>, B. Lian<sup>2</sup>, J. Li<sup>3</sup>, J. Ge<sup>3</sup>, X. Wang<sup>2</sup>, L. Mao<sup>2</sup>, B. Tang<sup>2</sup>, L. Zhou<sup>2</sup>, X. Bai<sup>2</sup>, S. Li<sup>2</sup>, B. Li<sup>3</sup>, H. Wu<sup>3</sup>, J. Guo<sup>2</sup>, <sup>1</sup>Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, <sup>2</sup>Beijing Cancer Hospital, Beijing, CN, <sup>3</sup>MSD China, Beijing, CN, <sup>4</sup>Merck & Co., Inc., Kenilworth, US
- 12:45 - 12:45 **1284P - Real life costs associated with the management of unresectable metastatic melanoma (uMM)**  
D. Strens<sup>1</sup>, M. Peeters<sup>2</sup>, P. Specenier<sup>3</sup>, <sup>1</sup>Realidad, Grimbergen, BE, <sup>2</sup>U.Z.A. University Hospital Antwerp, Edegem, BE, <sup>3</sup>Antwerp University Hospital, Grimbergen, BE
- 12:45 - 12:45 **1285P - Drug treatment in melanoma: a real-world analysis across Europe and Japan**  
A. Martinez De Pinillos, P. Nasuti, C. Anger, IQVIA, London, GB
- 12:45 - 12:45 **1286P - EUMelaReg - a European platform for outcome research on real world treatment data of patients with advanced melanoma.**  
M. Weichenthal<sup>1</sup>, A. Van Akkooi<sup>2</sup>, P. Mohr<sup>3</sup>, E. Ellebaek<sup>4</sup>, I.-M. Svane<sup>5</sup>, S. Ugurel-Becker<sup>6</sup>, U. Leiter<sup>7</sup>, L. Højberg<sup>8</sup>, J. Haanen<sup>2</sup>, H. Schmidt<sup>9</sup>, T.H. Oellegaard<sup>9</sup>, M. Wouters<sup>10</sup>, D.



Schadendorf<sup>11</sup>, L. Bastholt<sup>8</sup>, <sup>1</sup>University of Kiel, Kiel, DE, <sup>2</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup>Dermatologic Center Buxtehude, Buxtehude, DE, <sup>4</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>5</sup>Herlev Hospital, Herlev, DK, <sup>6</sup>Medical University of Graz - Institute of Pathology, Graz, AT, <sup>7</sup>Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Tuebingen, DE, <sup>8</sup>Odense University Hospital, Odense C, DK, <sup>9</sup>Aarhus University Hospital, Aarhus C, DK, <sup>10</sup>DICA - Dutch Institute for Clinical Auditing, Leiden, NL, <sup>11</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

12:45 - 12:45

**1287P - Advanced melanoma treatment patterns in the modern era: United Kingdom (UK) real world retrospective chart review study**

J. Sacco<sup>1</sup>, P. Corrie<sup>2</sup>, O. Oladipo<sup>3</sup>, M. Payne<sup>4</sup>, J. Larkin<sup>5</sup>, T. Talbot<sup>6</sup>, J. Wagstaff<sup>7</sup>, S. Cheetham<sup>2</sup>, D. Stein<sup>8</sup>, M. Soni<sup>9</sup>, C. Coombs<sup>10</sup>, A. Amadi<sup>11</sup>, M. Wang<sup>11</sup>, J. Ellis<sup>11</sup>, <sup>1</sup>Clatterbridge Cancer Center, Wirral, GB, <sup>2</sup>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, <sup>3</sup>Belfast City Hospital, Belfast, GB, <sup>4</sup>Churchill Hospital, Oxford, GB, <sup>5</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>6</sup>Royal Cornwall Hospital, Cornwall, GB, <sup>7</sup>Singleton Hospital, Swansea, GB, <sup>8</sup>Evidera (European Headquarter), London, GB, <sup>9</sup>Evidera, London, GB, <sup>10</sup>Evidera, Bethesda, US, <sup>11</sup>Bristol-Myers Squibb, London, GB

12:45 - 12:45

**1288P - The National Melanoma Research Registry: a fundamental for disease characterization and epidemiology**

F. Gwadry-Sridhar<sup>1</sup>, H. Mcconkey<sup>2</sup>, X. Teng<sup>3</sup>, D.S. Ernst<sup>4</sup>, <sup>1</sup>Pulse infoframe Inc., London, CA, <sup>2</sup>Global Melanoma Research Network, London, CA, <sup>3</sup>Pulse Infoframe Inc., London, CA, <sup>4</sup>London Regional Cancer Program, London, CA

12:45 - 12:45

**1289P - assessment of quality of life in patients with metastatic melanoma in real clinical practice in france**

M. Kandel<sup>1</sup>, C. Allayous<sup>2</sup>, S. Dalle<sup>3</sup>, L. Mortier<sup>4</sup>, S. Dalac Rat<sup>5</sup>, C. Dutriaux<sup>6</sup>, M.-T. Leccia<sup>7</sup>, B. Guillot<sup>8</sup>, P. Saiag<sup>9</sup>, J.-P. Lacour<sup>10</sup>, D. Legoupil<sup>11</sup>, F. Brunet-Possenti<sup>12</sup>, B. Dreno<sup>13</sup>, A. Ballon<sup>14</sup>, A. Bardet<sup>1</sup>, S. Michiels<sup>1</sup>, C. Lebbe<sup>2</sup>, I. Borget<sup>15</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>Hôpital St. Louis, Paris, FR, <sup>3</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>4</sup>Hopital Claude Huriez, Lille, FR, <sup>5</sup>CHU Dijon, Dijon, FR, <sup>6</sup>Oncology Unit, Saint André Hospital, Bordeaux, FR, <sup>7</sup>CHU Grenoble - Hopital Michallon, La Tronche, FR, <sup>8</sup>CHU de Montpellier, Montpellier, FR, <sup>9</sup>Hopital Ambroise Pare, Boulogne-Billancourt, FR, <sup>10</sup>Archet hospital, CHU Nice, Nice, FR, <sup>11</sup>Brest hospital, Brest, FR, <sup>12</sup>AP-HP Bichat hospital, Paris, FR, <sup>13</sup>Polyclinic Saint Jean, Cagnes-sur-Mer, FR, <sup>14</sup>AP-HP, Saint-Louis hospital, Paris, FR, <sup>15</sup>Institut Gustave Roussy, Villejuif, FR

12:45 - 12:45

**1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP)**

P. Nathan<sup>1</sup>, V. Kasturi<sup>2</sup>, L. Dirix<sup>3</sup>, E. Fenig<sup>4</sup>, P. Ascierto<sup>5</sup>, M. Hennessy<sup>6</sup>, J. Reed<sup>6</sup>, A. Engelsberg<sup>7</sup>, S. Hariharan<sup>8</sup>, C. Lebbe<sup>9</sup>, <sup>1</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>2</sup>EMD Serono USA, Rockland, US, <sup>3</sup>GZA Ziekenhuizen Campus Sint-Augustinus University of Antwerp, Antwerp, BE, <sup>4</sup>University of Tel Aviv, Tel Aviv, IL, <sup>5</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>6</sup>EMD Serono, Billerica, US, <sup>7</sup>Pfizer Pharma GmbH, Berlin, DE, <sup>8</sup>Pfizer, New York, US, <sup>9</sup>Hôpital Saint-Louis, Paris, FR

- 12:45 - 12:45 **1291P - Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC)**  
M. Bharmal<sup>1</sup>, A. Amin<sup>2</sup>, C. Stapelkamp<sup>2</sup>, C. Pescott<sup>1</sup>, A. Hatswell<sup>3</sup>, C. Lilley<sup>4</sup>, A. Bullement<sup>4</sup>, A. Willis<sup>4</sup>, <sup>1</sup>Merck Germany, Darmstadt, DE, <sup>2</sup>Merck Serono Ltd, Feltham, GB, <sup>3</sup>University College London and Delta Hat Limited, London, GB, <sup>4</sup>BresMed Health Solutions, Sheffield, GB
- 12:45 - 12:45 **1292P - Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): longer follow-up efficacy and safety data**  
T. Owonikoko<sup>1</sup>, K. Papadopoulos<sup>2</sup>, M. Gil-Martin<sup>3</sup>, V. Moreno<sup>4</sup>, A. Salama<sup>5</sup>, E. Calvo<sup>6</sup>, H. Safran<sup>7</sup>, A. González-Martín<sup>8</sup>, R. Aljumaily<sup>9</sup>, D. Mahadevan<sup>10</sup>, J. Niu<sup>11</sup>, K. Kal Mohan<sup>12</sup>, J. Li<sup>13</sup>, E. Stankevich<sup>13</sup>, M. Mathias<sup>12</sup>, I. Lowy<sup>12</sup>, M. Fury<sup>12</sup>, H. Babiker<sup>14</sup>, <sup>1</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>2</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>3</sup>Institut Català d'Oncologia, Barcelona, ES, <sup>4</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>5</sup>Duke University, Durham, US, <sup>6</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>7</sup>Brown University, Providence, US, <sup>8</sup>Clinica Universidad de Navarra, formerly of MD Anderson International España, Madrid, ES, <sup>9</sup>Oklahoma University Medical Center, Oklahoma City, US, <sup>10</sup>The University of Arizona Cancer Center, Tucson, AZ, USA. Formerly of The University of Tennessee Health Science Center and West Cancer Center, Memphis, US, <sup>11</sup>Banner MD Anderson Cancer Center, Gilbert, US, <sup>12</sup>Regeneron Pharmaceuticals, Inc., Tarrytown, US, <sup>13</sup>Regeneron Pharmaceuticals, Inc., Basking Ridge, US, <sup>14</sup>University of Arizona Cancer Center, Tucson, US
- 12:45 - 12:45 **1293P - Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective - A real-life analysis.**  
F. Peyrade<sup>1</sup>, M. Kogay<sup>1</sup>, J. Viotti<sup>2</sup>, P. Combemale<sup>3</sup>, C. Dutriaux<sup>4</sup>, N. Dupin<sup>5</sup>, C. Robert<sup>6</sup>, L. Mortier<sup>7</sup>, A.-B. Duval-Modeste<sup>8</sup>, S. Dalle<sup>9</sup>, J. De Quatrebarbes<sup>10</sup>, A. Stefan<sup>11</sup>, F. Brunet-Possenti<sup>12</sup>, A. Picard<sup>13</sup>, G. Poissonnet<sup>2</sup>, H. Montaudié<sup>14</sup>, <sup>1</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>2</sup>Centre Antoine Lacassagne, Nice, FR, <sup>3</sup>Centre Léon Bérard, Lyon, FR, <sup>4</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>5</sup>APHP, Hôpital Cochin, Paris, FR, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>Hopital Claude Huriez, Lille, FR, <sup>8</sup>Institute for Research and Innovation in Biomedicine, INSERM 1234, Rouen University Hospital, University of Normandie, Rouen, FR, <sup>9</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>10</sup>CH Annecy Genevois, Annecy, FR, <sup>11</sup>CHU de Caen, Caen, FR, <sup>12</sup>AP-HP BICHAT, Paris, FR, <sup>13</sup>Centre Hospitalier Universitaire, Hôpital Archet, Nice, Nice, FR, <sup>14</sup>Nice university hospital, INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire, Team 12, Nice, FR
- 12:45 - 12:45 **1294P - Sonidegib Preplanned Subgroups Analyses of Objective Response Rates: Final 42-Month Results from the BOLT Study**  
R. Dummer, Universitätsspital Zürich, Zurich, CH
- 12:45 - 12:45 **1295P - Treatment of Advanced Basal Cell Carcinoma With Sonidegib: Duration of Response and Quality of Life Evaluation From BOLT**  
M. Migden, The University of Texas M. D. Anderson Cancer Center, Houston, US

- 12:45 - 12:45 **1296P - Discovery of novel germline genetic biomarkers of melanoma recurrence impacting exonic and long non-coding RNA (lncRNA) transcripts.**  
T. Kirchhoff<sup>1</sup>, D. Simpson<sup>2</sup>, T. Hekal<sup>2</sup>, R. Ferguson<sup>2</sup>, E. Kazlow<sup>2</sup>, U. Moran<sup>2</sup>, Y. Lee<sup>2</sup>, A. Izsak<sup>2</sup>, M. Wilson<sup>3</sup>, R. Shapiro<sup>3</sup>, A. Pavlick<sup>3</sup>, I. Osman<sup>2</sup>, <sup>1</sup>New York University, New York, US, <sup>2</sup>New York University Medical Center, New York, US, <sup>3</sup>New York University - Perlmutter Cancer Center - Langone Medical Center, New York, US
- 12:45 - 12:45 **1297P - Pilot Study: Localizing target lymph node using a magnetic marker allows reliable and representative judgement of pathological responses after neo-adjuvant Ipilimumab (IPI) + Nivolumab (NIVO) in macroscopic stage III melanoma**  
A. Van Akkooi<sup>1</sup>, B. Schermers<sup>1</sup>, V. Franke<sup>2</sup>, M. Wouters<sup>3</sup>, C. Zuur<sup>2</sup>, W. Klop<sup>2</sup>, E. Rozeman<sup>4</sup>, B. Van De Wiel<sup>2</sup>, T. Ruers<sup>1</sup>, C. Blank<sup>1</sup>, <sup>1</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>3</sup>NKI-AVL, NKI-AVL, NL, <sup>4</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL
- 12:45 - 12:45 **1298P - Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma**  
S. Lundgren<sup>1</sup>, H. Fagerström-Vahman<sup>2</sup>, L. Ben-Dror<sup>2</sup>, B. Nodin<sup>3</sup>, K. Jirstrom<sup>4</sup>, <sup>1</sup>Lund University-Institution of Clinical Sciences-Oncology and Pathology, Lund, SE, <sup>2</sup>Division of Oncology and Pathology, Lund, SE, <sup>3</sup>Clinical Sciences, Lund, SE, <sup>4</sup>Lund University, Lund, SE
- 12:45 - 12:45 **1299P - BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation**  
M. Wasylecka-Juszczyńska<sup>1</sup>, P. Górniak<sup>2</sup>, M. Szydłowski<sup>2</sup>, A. Polak<sup>2</sup>, P. Juszczyński<sup>2</sup>, <sup>1</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>2</sup>Institute of Hematology and Transfusion Medicine, Warsaw, PL
- 12:45 - 12:45 **1300TiP - A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)**  
P. Corrie<sup>1</sup>, R. Matin<sup>2</sup>, A. Gupta<sup>3</sup>, W. Qian<sup>1</sup>, S. Wordsworth<sup>4</sup>, E. Gibbons<sup>4</sup>, A. Chhabra<sup>5</sup>, C. Harman<sup>6</sup>, C. Mather<sup>7</sup>, M. Middleton<sup>8</sup>, <sup>1</sup>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, <sup>2</sup>Oxford University Hospitals NHS Trust, Oxford, GB, <sup>3</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>4</sup>University of Oxford, Oxford, GB, <sup>5</sup>Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital, Oxford, GB, <sup>6</sup>Cambridge University Hospitals NHS Foundation Trust, Oxford, GB, <sup>7</sup>Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, <sup>8</sup>Churchill Hospital University of Oxford, Oxford, GB
- 12:45 - 12:45 **1301TiP - A Phase I/Ib Study of Concurrent Intravenous (IV) and Intrathecal (IT) Nivolumab (Nivo) for Melanoma Patients (pts) with Leptomeningeal Disease (LMD)**  
I. Glitza<sup>1</sup>, M. Rohlf<sup>2</sup>, M. Iqbal<sup>2</sup>, J. Richard<sup>2</sup>, E. Burton<sup>2</sup>, S. Duncan<sup>2</sup>, C. Brown<sup>2</sup>, J. Anderson<sup>2</sup>, P. Hwu<sup>2</sup>, W.-J. Hwu<sup>2</sup>, M. Wong<sup>2</sup>, C. Yee<sup>2</sup>, S. Patel<sup>1</sup>, S. Woodman<sup>2</sup>, R. Amaria<sup>2</sup>,



A. Diab<sup>2</sup>, H. Tawbi<sup>2</sup>, M. Davies<sup>2</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>MD Anderson Cancer Center, Houston, US

- 12:45 - 12:45 **1302TiP - CA224-047: A Randomized, Double-Blind, Phase 2/3 Study of Relatlimab (Anti-LAG-3) in Combination With Nivolumab (Anti-PD-1) Versus Nivolumab Alone in Previously Untreated Metastatic or Unresectable Melanoma**
- E. Lipson<sup>1</sup>, G. Long<sup>2</sup>, H. Tawbi<sup>3</sup>, D. Schadendorf<sup>4</sup>, V. Atkinson<sup>5</sup>, M. Maurer<sup>6</sup>, K. Simonsen<sup>6</sup>, C. Harbison<sup>6</sup>, F.S. Hodi<sup>7</sup>, <sup>1</sup>Johns Hopkins University, Baltimore, US, <sup>2</sup>Melanoma Institute Australia, The University Of Sydney Northern Clinical School and Royal North Shore Hospital, Sydney, AU, <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>4</sup>University Hospital Essen, Essen, DE, <sup>5</sup>Gallipoli Medical Research Foundation, Greenslopes Private Hospital and University of Queensland, Brisbane, AU, <sup>6</sup>Bristol-Myers Squibb, Princeton, US, <sup>7</sup>Dana-Farber Cancer Institute, Boston, US
- 12:45 - 12:45 **1303TiP - Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma**
- M. Rohaan<sup>1</sup>, T. Borch<sup>2</sup>, J. Van Den Berg<sup>3</sup>, M. Geukes Foppen<sup>1</sup>, M. Donia<sup>2</sup>, Ö. Met<sup>2</sup>, B. Nuijen<sup>4</sup>, M. Van Zon<sup>3</sup>, E. Bakker<sup>3</sup>, R. De Boer<sup>3</sup>, L. Pronk<sup>1</sup>, S. Wilgenhof<sup>1</sup>, C. Blank<sup>5</sup>, J. Van Thienen<sup>1</sup>, A. Van Akkooi<sup>5</sup>, I.-M. Svane<sup>6</sup>, J. Haanen<sup>5</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>3</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>4</sup>The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, NL, <sup>5</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>6</sup>Herlev Hospital, Herlev, DK
- 12:45 - 12:45 **1304TiP - A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)**
- J. Weber<sup>1</sup>, G. Long<sup>2</sup>, J. Haanen<sup>3</sup>, A. Arance<sup>4</sup>, R. Dummer<sup>5</sup>, P. Nathan<sup>6</sup>, A. Ribas<sup>7</sup>, P. Ascierto<sup>8</sup>, C. Robert<sup>9</sup>, E. Gasal<sup>10</sup>, A. D'Amelio Jr<sup>11</sup>, S. Bettinger<sup>12</sup>, A. Boran<sup>11</sup>, D. Schadendorf<sup>13</sup>, <sup>1</sup>Laura and Isaac Perlmutter Cancer Center, New York, US, <sup>2</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>3</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>4</sup>Hospital Clínic Barcelona, Barcelona, ES, <sup>5</sup>Universitätsspital Zürich, Zurich, CH, <sup>6</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>7</sup>Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, <sup>8</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>9</sup>Institut Gustave Roussy, Villejuif, FR, <sup>10</sup>Novartis Pharmaceuticals Corporation, New Jersey, US, <sup>11</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>12</sup>Novartis Campus Switzerland, Basel, CH, <sup>13</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
- 12:45 - 12:45 **1305TiP - Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors**
- P. Terheyden<sup>1</sup>, C. Weishaupt<sup>2</sup>, L. Heinzerling<sup>3</sup>, U. Klinkhardt<sup>4</sup>, J. Krauss<sup>5</sup>, P. Mohr<sup>6</sup>, F. Kiecker<sup>7</sup>, J. Becker<sup>8</sup>, A. Dähling (Submitter)<sup>4</sup>, F. Döner<sup>9</sup>, R. Heidenreich<sup>9</sup>, B. Scheel<sup>9</sup>, O. Schönborn-Kellenberger<sup>10</sup>, T. Seibel<sup>4</sup>, U. Gnad-Vogt<sup>4</sup>, <sup>1</sup>Universitätsklinikum Schleswig-Holstein, Lübeck, DE, <sup>2</sup>Universitätsklinikum Münster (UKM), Münster, DE, <sup>3</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>4</sup>CureVac AG, Frankfurt am Main, DE, <sup>5</sup>Universitätsklinikum Heidelberg (NCT), Heidelberg, DE, <sup>6</sup>Dermatologic Center



Buxtehude, Buxtehude, DE, <sup>7</sup>Charité Universitätsmedizin Berlin, Berlin, DE, <sup>8</sup>Universitätsklinikum Essen, Essen, DE, <sup>9</sup>CureVac AG, Tübingen, DE, <sup>10</sup>Cogitars GmbH, Heidelberg, DE

12:45 - 12:45 **1306TiP - ILLUMINATE 301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab (ipi) versus Ipi Alone in Subjects with Anti PD 1 Refractory Melanoma**

P. Ascierto<sup>1</sup>, P. Arenberger<sup>2</sup>, V. Atkinson<sup>3</sup>, J. Hansson<sup>4</sup>, E. Kapiteijn<sup>5</sup>, C. Loquai<sup>6</sup>, S. Negrier<sup>7</sup>, H. Shaw<sup>8</sup>, A. Tarhini<sup>9</sup>, J. Walker<sup>10</sup>, J. Geib<sup>11</sup>, S. Rahimian<sup>11</sup>, S. Swann<sup>11</sup>, A. Diab<sup>12</sup>, <sup>1</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>2</sup>Fakultni nemocnice Kralovske Vinohrady, Prague, CZ, <sup>3</sup>Gallipoli Medical Research Foundation, Greenslopes Private Hospital and University of Queensland, Brisbane, AU, <sup>4</sup>Karolinska Institutet, Stockholm, SE, <sup>5</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>6</sup>Universitätsmedizin Mainz, Mainz, DE, <sup>7</sup>Centre Léon Bérard, Lyon, FR, <sup>8</sup>University College London Hospital UCLH NHS Foundation Trust, London, GB, <sup>9</sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, US, <sup>10</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>11</sup>Idera Pharmaceuticals, Exton, US, <sup>12</sup>MD Anderson Cancer Center, Houston, US

12:45 - 12:45 **Endocrine and neuroendocrine tumors**

12:45 - 12:45 **1314P - Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase 3 double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies**

D. Hörsch<sup>1</sup>, R. Garcia-Carbonero<sup>2</sup>, J. Valle<sup>3</sup>, P. Perros<sup>4</sup>, S. Welin<sup>5</sup>, L. Keeber<sup>6</sup>, A. Houchard<sup>7</sup>, P. Lapuerta<sup>8</sup>, <sup>1</sup>ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, DE, <sup>2</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>3</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>4</sup>Royal Victoria Infirmary, Newcastle upon Tyne, GB, <sup>5</sup>Uppsala University Hospital, Uppsala, SE, <sup>6</sup>Ipsen Ltd, Slough, GB, <sup>7</sup>Ipsen Pharma France, Boulogne-Billancourt, FR, <sup>8</sup>Lexicon Pharmaceuticals, Princeton, US

12:45 - 12:45 **1315P - Development and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study.**

R. Garcia-Carbonero<sup>1</sup>, V. Alonso<sup>2</sup>, J. Capdevila Castillon<sup>3</sup>, M. Sanchez Canovas<sup>4</sup>, T. Alonso<sup>5</sup>, M. Benavent<sup>6</sup>, A. Custodio<sup>7</sup>, G. Crespo Herrero<sup>8</sup>, C. Lopez<sup>9</sup>, J. Hernando<sup>10</sup>, M.C. Riesco Martinez<sup>1</sup>, P. Escudero<sup>11</sup>, J. Gallego Plazas<sup>12</sup>, M. Marazuela<sup>13</sup>, J.A. Diaz<sup>14</sup>, M. Llanos-Munoz<sup>15</sup>, A. La Casta<sup>16</sup>, J.C. Percovich<sup>17</sup>, P. Jimenez-Fonseca<sup>18</sup>, A. Carmona-Bayonas<sup>4</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Hospital Universitario Morales Meseguer, Murcia, ES, <sup>5</sup>Hospital Ramón y Cajal, Madrid, ES, <sup>6</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>7</sup>Hospital Universitario La Paz, Madrid, ES, <sup>8</sup>Hospital Universitario de Burgos, Burgos, ES, <sup>9</sup>Marques de Valdecilla University Hospital, Santander, ES, <sup>10</sup>Vall d'Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>11</sup>Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, <sup>12</sup>Hospital General Universitario de Elche, Elche, ES, <sup>13</sup>Hospital

Universitario La Princesa, Madrid, ES, <sup>14</sup>Hospital Universitario Clínico San Carlos, Madrid, ES, <sup>15</sup>Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, <sup>16</sup>Donosti University Hospital, Donosti, ES, <sup>17</sup>Hospital Universitario Gregorio Marañón, Madrid, ES, <sup>18</sup>Hospital Universitario Central de Asturias, Oviedo, ES

- 12:45 - 12:45 **1316P - Impact of liver tumor burden on therapeutic effect of <sup>177</sup>Lu-Dotatate treatment in NETTER-1 study**
- J. Strosberg<sup>1</sup>, A. Hendifar<sup>2</sup>, J. Yao<sup>3</sup>, M. Kulke<sup>4</sup>, T. O'Doriso<sup>1</sup>, M. Caplin<sup>5</sup>, R. Baum<sup>6</sup>, P. Kunz<sup>7</sup>, T. Hobday<sup>8</sup>, E. Wolin<sup>9</sup>, E. Mittra<sup>10</sup>, K. Oberg<sup>11</sup>, P. Ruzzniewski<sup>12</sup>, B. Polack<sup>13</sup>, B. He<sup>14</sup>, D. Barton<sup>13</sup>, P. Santaro<sup>13</sup>, E. Krenning<sup>15</sup>, <sup>1</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>4</sup>Dana-Farber Cancer Institute, Boston, US, <sup>5</sup>Royal Free Hospital School of Medicine, London, GB, <sup>6</sup>Zentralklinik, Bad Berska, DE, <sup>7</sup>Stanford University, California, US, <sup>8</sup>Mayo Clinic College of Medicine, Rochester, US, <sup>9</sup>Montefiore Einstein Center for Cancer Care, Bronx, US, <sup>10</sup>Oregon Health and Science University, Portland, US, <sup>11</sup>University Hospital, Uppsala, SE, <sup>12</sup>Hôpital Beaujon, Clichy, FR, <sup>13</sup>Advanced Accelerator Applications, a Novartis company, New York, US, <sup>14</sup>Advanced Accelerator Applications, a Novartis company, Geneva, CH, <sup>15</sup>Rotterdam, Rotterdam, NL
- 12:45 - 12:45 **1317P - Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3)**
- L. Apostolidis<sup>1</sup>, D. Jäger<sup>2</sup>, E. Winkler<sup>3</sup>, <sup>1</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>2</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, <sup>3</sup>National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, DE
- 12:45 - 12:45 **1318P - Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); real-world findings from two European Neuroendocrine Tumour Society Centres of Excellence.**
- M. Frizziero<sup>1</sup>, F. Spada<sup>2</sup>, A. Lamarca<sup>1</sup>, Z. Kordatou<sup>1</sup>, J. Barriuso<sup>1</sup>, C. Nuttall<sup>1</sup>, M. Mcnamara<sup>1</sup>, R. Hubner<sup>1</sup>, W. Mansoor<sup>1</sup>, P. Manoharan<sup>1</sup>, N. Fazio<sup>2</sup>, J. Valle<sup>1</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Istituto Europeo di Oncologia, Milan, IT
- 12:45 - 12:45 **1319P - Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO)**
- S. Pusceddu<sup>1</sup>, C. Vernieri<sup>1</sup>, M. Di Maio<sup>2</sup>, N. Prinzi<sup>1</sup>, M. Torchio<sup>3</sup>, R. Buzzoni<sup>1</sup>, X.-M. Truong-Thanh<sup>4</sup>, V. Mazzaferro<sup>1</sup>, F.G. De Braud<sup>5</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>2</sup>"Ordine Mauriziano" Hospital, Torino, IT, <sup>3</sup>Azienda Ospedaliera della Provincia di Pavia, Ospedale Civile di Vigevano, Vigevano, IT, <sup>4</sup>Ipsen Pharma France, Boulogne-Billancourt, FR, <sup>5</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 12:45 - 12:45 **1320P - The Prognostic Role of Morphology and Ki67 in Grade 3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NEN)**
- A. Hayes<sup>1</sup>, M. Furnace<sup>2</sup>, C. Rundell<sup>3</sup>, R. Shah<sup>3</sup>, G. Muller<sup>3</sup>, C. Thirlwell<sup>1</sup>, T.V. Luong<sup>4</sup>, C.

Toumpanakis<sup>4</sup>, M. Caplin<sup>1</sup>, D. Mandair<sup>4</sup>, <sup>1</sup>Royal Free Hospital School of Medicine, London, GB, <sup>2</sup>Royal Free London NHS Foundation Trust, London, GB, <sup>3</sup>University College of London, London, GB, <sup>4</sup>Royal Free Hospital, London, GB

12:45 - 12:45 **1321P - Surgical resection of primary tumor is prolonged survival in metastatic pancreatic neuroendocrine carcinoma**

T. Feng, Zhejiang Cancer Hospital, Hangzhou, CN

12:45 - 12:45 **1322P - The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET)**

E. Segelov<sup>1</sup>, E. Bergsland<sup>2</sup>, C. Card<sup>3</sup>, T. Hope<sup>4</sup>, P. Kunz<sup>5</sup>, D. Laidley<sup>6</sup>, B. Lawrence<sup>7</sup>, S. Leyden<sup>8</sup>, M. Michael<sup>9</sup>, L. Modahl<sup>10</sup>, S. Myrehaug<sup>11</sup>, S. Padda<sup>12</sup>, R. Pommier<sup>13</sup>, R. Ramirez<sup>14</sup>, M. Soulen<sup>15</sup>, J. Strosberg<sup>16</sup>, A. Thawer<sup>17</sup>, B. Wei<sup>18</sup>, S. Singh<sup>11</sup>, <sup>1</sup>Monash Medical Centre, Clayton, AU, <sup>2</sup>University of California, San Francisco, US, <sup>3</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>4</sup>University of California San Francisco, San Francisco, US, <sup>5</sup>Stanford University, California, US, <sup>6</sup>London health Sciences Centre, London, CA, <sup>7</sup>University of Auckland Faculty of Medical & Health Sciences, Auckland, NZ, <sup>8</sup>Unicorn Foundation, Blairgowrie, AU, <sup>9</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>10</sup>Auckland Radiology Group, Auckland, NZ, <sup>11</sup>Sunnybrook Health Sciences Centre, Toronto, CA, <sup>12</sup>Stanford University School of Medicine, California, US, <sup>13</sup>Oregon Health & Science University, Portland, US, <sup>14</sup>Ochsner Medical Centre, Jefferson, US, <sup>15</sup>Abramson Cancer Centre, Philadelphia, US, <sup>16</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, <sup>17</sup>Sunnybrook Odette Cancer Center, Sunnybrook HSC, Toronto, CA, <sup>18</sup>University of Alabama-Birmingham Medical Centre, Birmingham, US

12:45 - 12:45 **1323P - Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) in Patients with Pulmonary Carcinoid Tumours: Prevalence and Prognosis of an Under-Recognised Disease**

A. Hayes<sup>1</sup>, J. Banks<sup>2</sup>, H. Shah<sup>2</sup>, T.V. Luong<sup>3</sup>, S. Navalkissoor<sup>3</sup>, A. Grossman<sup>4</sup>, D. Mandair<sup>3</sup>, C. Toumpanakis<sup>3</sup>, M. Caplin<sup>1</sup>, <sup>1</sup>Royal Free Hospital School of Medicine, London, GB, <sup>2</sup>University College of London, London, GB, <sup>3</sup>Royal Free Hospital, London, GB, <sup>4</sup>Churchill Hospital University of Oxford, Oxford, GB

12:45 - 12:45 **1324P - The role of modulation of Somatostatin Analogues (SSAs) in association to Peptide Receptor Radionuclide Therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) Entero-Pancreatic Neuroendocrine Tumours (EP-NETs)**

N. Prinzi<sup>1</sup>, E. Seregni<sup>1</sup>, A. Raimondi<sup>2</sup>, M. Maccauro<sup>1</sup>, F. Corti<sup>1</sup>, G. Lo Russo<sup>3</sup>, F. Nichetti<sup>1</sup>, M. Torchio<sup>4</sup>, J. Coppa<sup>1</sup>, G. Peverelli<sup>5</sup>, F. Pagani<sup>1</sup>, M. Di Bartolomeo<sup>6</sup>, V. Mazzaferro<sup>1</sup>, F. De Braud<sup>3</sup>, S. Pusceddu<sup>1</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>4</sup>Azienda Ospedaliera della Provincia di Pavia, Ospedale Civile di Vigevano, Vigevano, IT, <sup>5</sup>Istituto Nazionale dei Tumori di Milano, Milan, IT, <sup>6</sup>Fondazione IRCCS, Milan, IT

12:45 - 12:45 **1325P - Prognostic Importance of Lymph Node (LN) yield after Curative Resection of GastroEnteroPancreatic NeuroEndocrineTumours (GEP NETs)**



J. Chiramel<sup>1</sup>, R. Almond<sup>1</sup>, A. Slagter<sup>2</sup>, A. Khan<sup>1</sup>, K.H.J. Lim<sup>1</sup>, B. Chakrabarty<sup>1</sup>, A. Minicozzi<sup>3</sup>, A. Lamarca<sup>1</sup>, W. Mansoor<sup>1</sup>, R. Hubner<sup>1</sup>, J. Valle<sup>1</sup>, M. Mcnamara<sup>1</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>NKI-AVL, Amsterdam, NL, <sup>3</sup>The Christie Hospital NHS Foundation Trust, Manchester, GB

12:45 - 12:45 **1326P - Evaluation of the efficacy and safety of everolimus as a first-line treatment in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors**

A. Koumari<sup>1</sup>, D. Pectasides<sup>2</sup>, K. Manousou<sup>3</sup>, D. Dionysopoulos<sup>4</sup>, G. Kaltsas<sup>5</sup>, D. Kolomodi<sup>6</sup>, C. Poulis<sup>3</sup>, M. Skondra<sup>2</sup>, E. Samantas<sup>7</sup>, G. Pentheroudakis<sup>8</sup>, G. Fountzilas<sup>4</sup>, <sup>1</sup>Attikon University Hospital, Athens, GR, <sup>2</sup>Hippokration General Hospital, Athens, GR, <sup>3</sup>Hellenic Cooperative Oncology Group (HeCOG), Athens, GR, <sup>4</sup>Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, GR, <sup>5</sup>National and Kapodistrian University of Athens, Athens, GR, <sup>6</sup>Vioiatriki, Athens, GR, <sup>7</sup>General Oncological Hospital of Kifisia "Agioli Anargyroi", Kifisia, GR, <sup>8</sup>University Hospital of Ioannina, Ioannina, GR

12:45 - 12:45 **1327P - Improved Quality of Life in Patients with GEP-NETs Treated with 177Lu-DOTATATE**

B. Saravana-Bawan<sup>1</sup>, M. Wieler<sup>1</sup>, T. McMullen<sup>2</sup>, A. Mcewan<sup>1</sup>, <sup>1</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>2</sup>University of Alberta, Edmonton, CA

12:45 - 12:45 **1328P - Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals**

C. Bouvier<sup>1</sup>, M. Caplin<sup>2</sup>, S. Conroy<sup>3</sup>, P. Davies<sup>4</sup>, S. Dureja<sup>5</sup>, M. Falconi<sup>6</sup>, P. Ferolla<sup>7</sup>, G. Fisher<sup>8</sup>, G. Goldstein<sup>9</sup>, R. Hicks<sup>10</sup>, R. Hollander<sup>11</sup>, T. Kolarova<sup>12</sup>, B. Lawrence<sup>13</sup>, S. Leyden<sup>14</sup>, Y. Majima<sup>15</sup>, D. Metz<sup>16</sup>, D. O'Toole<sup>17</sup>, P. Ruzniewski<sup>18</sup>, B. Wiedenmann<sup>19</sup>, <sup>1</sup>NET Patient Foundation, Leamington Spa, GB, <sup>2</sup>Royal Free Hospital School of Medicine, London, GB, <sup>3</sup>Unicorn Foundation, Auckland, NZ, <sup>4</sup>Royal Free London NHS Foundation Trust, London, GB, <sup>5</sup>Fortis Memorial Research Institute, Gurgaon, IN, <sup>6</sup>IRCCS San Raffaele, Milan, IT, <sup>7</sup>Umbria Regional Cancer Network, Perugia, IT, <sup>8</sup>Stanford University Medical Center, Stanford, US, <sup>9</sup>The Carcinoid Cancer Foundation, New York, US, <sup>10</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>11</sup>Neuroendocrine Tumor Research Foundation NET, Boston, US, <sup>12</sup>International Neuroendocrine Cancer Alliance (INCA), Boston, US, <sup>13</sup>University of Auckland Faculty of Medical & Health Sciences, Auckland, NZ, <sup>14</sup>Unicorn Foundation, Blairgowrie, AU, <sup>15</sup>NPO PanCAN Japan, Tokyo, JP, <sup>16</sup>University of Pennsylvania, Philadelphia, US, <sup>17</sup>St Vincents University Hospital, Dublin, IE, <sup>18</sup>Hôpital Beaujon, Clichy, FR, <sup>19</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE

12:45 - 12:45 **1329P - Efficacy and safety of Vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy.**

J. Hernando Cubero<sup>1</sup>, E. Grande<sup>2</sup>, P. Jimenez Fonseca<sup>3</sup>, C. Villabona<sup>4</sup>, J. Trigo Perez<sup>5</sup>, J. Martinez Trufero<sup>1</sup>, I. Pajares Bernad<sup>1</sup>, C. Lopez<sup>6</sup>, T. Alonso<sup>7</sup>, J. Biarnes<sup>8</sup>, T. Ramón Y Cajal<sup>9</sup>, M. Duran<sup>10</sup>, J. Grau<sup>11</sup>, S. Arevalo Lobera<sup>12</sup>, R. Mesia Nin<sup>13</sup>, M. Llanos<sup>14</sup>, E. Dalmau Portulas<sup>15</sup>, C. Alvarez<sup>16</sup>, C. Zafon<sup>17</sup>, J. Capdevila Castillon<sup>17</sup>, <sup>1</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>2</sup>MD Anderson Cancer Center Center Espana, Madrid, ES, <sup>3</sup>Hospital Universitario Central de Asturias, Oviedo, ES, <sup>4</sup>Hospital Universitario de



Bellvitge, Barcelona, ES, <sup>5</sup>Hospital Universitario Virgen de la Victoria, Málaga, ES, <sup>6</sup>Marques de Valdecilla University Hospital, Santander, ES, <sup>7</sup>Hospital Ramón y Cajal, Madrid, ES, <sup>8</sup>Hospital Universitario Doctor Josep Trueta, Gerona, ES, <sup>9</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>10</sup>Hospital Universitario Rey Juan Carlos, Madrid, ES, <sup>11</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>12</sup>Hospital Donostia, San Sebastian, ES, <sup>13</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>14</sup>Hospital Universitario de Canarias, Santa Cruz de Tenerife, ES, <sup>15</sup>Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES, <sup>16</sup>Hospital Universitario La Paz, Madrid, ES, <sup>17</sup>Vall d'Hebron University Hospital, Barcelona, ES

12:45 - 12:45

**1330P - Development and validation of neuroendocrine tumor marker panel in small biopsies using multiplexed mass spectrometry**

S. Thyparambil<sup>1</sup>, E. An<sup>2</sup>, S. Sellappan<sup>3</sup>, E. Wertheimer<sup>2</sup>, S. Landolfi<sup>4</sup>, J. Capdevila Castillon<sup>4</sup>, F. Cecchi<sup>5</sup>, P. Nuciforo<sup>4</sup>, R. Heaton<sup>3</sup>, T. Hembrough<sup>2</sup>, <sup>1</sup>OncoPlexDx, Rockville, US, <sup>2</sup>NantOmics, LLC, Rockville, US, <sup>3</sup>NantOmics, Rockville, US, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>NantOmics, LLC., New York, US

12:45 - 12:45

**1331P - Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)**

V. Prasad<sup>1</sup>, R. Srirajaskanthan<sup>2</sup>, C. Grana<sup>3</sup>, S. Baldari<sup>4</sup>, T. Shah<sup>5</sup>, A. Lamarca<sup>6</sup>, F. Courbon<sup>7</sup>, K. Scheidhauer<sup>8</sup>, E. Baudin<sup>9</sup>, X.-M. Truong-Thanh<sup>10</sup>, A. Houchard<sup>10</sup>, L. Bodei<sup>11</sup>, <sup>1</sup>Universitaetsfrauenklinik Ulm, Ulm, DE, <sup>2</sup>Kings College Hospital, London, GB, <sup>3</sup>European Institute of Oncology, Milan, IT, <sup>4</sup>University of Messina, Messina, IT, <sup>5</sup>Queen Elizabeth Hospital Birmingham, Birmingham, GB, <sup>6</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>7</sup>Institut Claudius Regaud, Toulouse, FR, <sup>8</sup>Technical University Muenchen, Munich, DE, <sup>9</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>10</sup>Ipsen Pharma France, Boulogne-Billancourt, FR, <sup>11</sup>Memorial Sloan-Kettering Cancer Center, New York, US

12:45 - 12:45

**1332P - Detection of mutations and copy number alterations in circulating DNA from pancreatic neuroendocrine tumor patients**

G. Boons<sup>1</sup>, K. Op De Beeck<sup>2</sup>, T. Vandamme<sup>3</sup>, M. Beyens<sup>2</sup>, G. Roeyen<sup>3</sup>, K. Janssens<sup>2</sup>, K. Zwaenepoel<sup>4</sup>, G. Van Camp<sup>2</sup>, M. Peeters<sup>4</sup>, <sup>1</sup>University of Antwerp, Antwerp, BE, <sup>2</sup>University of Antwerp, Edegem, BE, <sup>3</sup>Antwerp University Hospital, Edegem, BE, <sup>4</sup>U.Z.A. University Hospital Antwerp, Edegem, BE

12:45 - 12:45

**1333TiP - CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CARcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)**

A. Bongiovanni<sup>1</sup>, S. Pusceddu<sup>2</sup>, S. Leo<sup>3</sup>, G. Di Meglio<sup>4</sup>, F. Gelsomino<sup>5</sup>, F. Pucci<sup>6</sup>, R. Berardi<sup>7</sup>, S. Ricci<sup>8</sup>, I. Lolli<sup>9</sup>, F. Bergamo<sup>10</sup>, D. Campana<sup>11</sup>, D. Santini<sup>12</sup>, S. Tamperi<sup>13</sup>, D. Pastorelli<sup>14</sup>, M. Cives<sup>15</sup>, N. Silvestris<sup>16</sup>, A. Russo<sup>17</sup>, A. Buonadonna<sup>18</sup>, F. Foca<sup>19</sup>, T. Ibrahim<sup>1</sup>, <sup>1</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>Ospedale Vito Fazzi, Lecce, IT, <sup>4</sup>Hospital of Bolzano, Bolzano, IT, <sup>5</sup>University Hospital of Modena, Modena, IT, <sup>6</sup>University Hospital of Parma, Parma, IT, <sup>7</sup>AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, <sup>8</sup>Azienda Ospedaliero-Universitaria S. Chiara, Pisa, IT, <sup>9</sup>IRCCS Saverio de Bellis, Castellana Grotte, IT, <sup>10</sup>Veneto Institute of Oncology IOV - IRCCS, Padula, IT,

<sup>11</sup>Policlinico Sant'Orsola-Malpighi, Bologna, IT, <sup>12</sup>Campus Bio-Medico di Roma, Rome, IT, <sup>13</sup>Ospedale degli Infermi, Faenza, IT, <sup>14</sup>ULSS 1 Dolomiti - Feltre, Feltre, IT, <sup>15</sup>University of Bari, Bari, IT, <sup>16</sup>Ospedale Oncologico "Giovanni Paolo II"- IRCCS, bari, IT, <sup>17</sup>AOU Policlinico "Paolo Giaccone", Palermo, IT, <sup>18</sup>CRO di Aviano, Aviano, IT, <sup>19</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I.R.S.T. IRCCS, Meldola, IT

- 12:45 - 12:45 **1334TiP - A Phase 1 Study of Oncolytic Immunotherapy of Metastatic Neuroendocrine Tumours using Intralesional Rose Bengal Disodium**  
T. Price<sup>1</sup>, G. Cehic<sup>2</sup>, I. Kirkwood<sup>3</sup>, G. Maddern<sup>2</sup>, E. Wachter<sup>4</sup>, D. Sarson<sup>5</sup>, R. Sebben<sup>2</sup>, L. Leopardi<sup>2</sup>, J. Reid<sup>2</sup>, S. Neuhaus<sup>6</sup>, <sup>1</sup>Queen Elizabeth Hospital, Woodville, AU, <sup>2</sup>The Queen Elizabeth Hospital, Woodville, AU, <sup>3</sup>Royal Adelaide Hospital, Adelaide, AU, <sup>4</sup>Provectus Pharmaceuticals, Knoxville, US, <sup>5</sup>Provectus Biopharmaceuticals, Sydney, AU, <sup>6</sup>University of Adelaide, Woodville, AU
- 12:45 - 12:45 **1335TiP - COMPETE trial - Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-Edotreotide vs. Everolimus in progressive GEP-NET**  
M. Pavel<sup>1</sup>, A. Rinke<sup>2</sup>, R. Baum<sup>3</sup>, <sup>1</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>2</sup>University Hospital of Marburg Klinik fuer Innere Medizin,, Marburg, DE, <sup>3</sup>Zentralklinik Bad Berka GmbH, Bad Berka, DE
- 12:45 - 12:45 **Thyroid cancers**
- 12:45 - 12:45 **1823P - Synergistic anti-cancer effect of Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway**  
S.Y. Kim<sup>1</sup>, Y.S. Lee<sup>2</sup>, H. Chang<sup>1</sup>, H.-S. Chang<sup>1</sup>, C.S. Park<sup>1</sup>, <sup>1</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, seoul, KR, <sup>2</sup>Yonsei University, Seoul, KR
- 12:45 - 12:45 **1824P - Lenvatinib and Pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)**  
C. Dierks, C. Miething, O. Thomusch, N. Von Bubnoff, J. Duyster, University Medical Center Freiburg, Freiburg, DE
- 12:45 - 12:45 **1825P - Both HIF-1\_ and GAB1 can regulate Pim-1 in the papillary thyroid carcinoma**  
X. Zhu, Q. Wen, M. Ge, Zhejiang Cancer Hospital, Hangzhou, CN
- 12:45 - 12:45 **1826P - Increase in Thyroid Cancer (TC) Incidence in Cyprus: Overdiagnosis or True Increase of clinically relevant TC?**  
H. Charalambous<sup>1</sup>, A. Demetriou<sup>2</sup>, S. Frangos<sup>1</sup>, P. Pavlou<sup>2</sup>, <sup>1</sup>Bank of Cyprus Oncology Centre, Nicosia, CY, <sup>2</sup>Ministry of Health, Nicosia, CY
- 12:45 - 12:45 **1827P - Surgery for lymph node metastases of sporadic medullary thyroid carcinoma**  
W. Fan, H. Jiang, The First Affiliated Hospital, Zhejiang University, Hangzhou, CN

- 12:45 - 12:45 **1828P - Role of SPECT-CT somatostatin-receptor scintigraphy in the management of Medullary Thyroid Cancer (MTC)**  
S. Sergieva<sup>1</sup>, M. Atanasova<sup>2</sup>, A. Fakirova<sup>3</sup>, S. Velchova<sup>4</sup>, <sup>1</sup>Specialized Hospital for Active Treatment in Oncological Diseases-Sofia City, Sofia, BG, <sup>2</sup>UH "City Clinic", Sofia, BG, <sup>3</sup>Military Medical Academy, Sofia, BG, <sup>4</sup>Sofia Cancer Center, Sofia, BG
- 12:45 - 12:45 **Tumour biology and pathology**
- 12:45 - 12:45 **1829TiP - A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)**  
J. Krajewska<sup>1</sup>, B. Robinson<sup>2</sup>, B. Keam<sup>3</sup>, J. Capdevila Castillon<sup>4</sup>, A. Klochikhin<sup>5</sup>, H. Gan<sup>6</sup>, E. Kapiteijn<sup>7</sup>, R. Elisei<sup>8</sup>, J. Partyka<sup>9</sup>, A. Borgman<sup>9</sup>, M. Schlumberger<sup>10</sup>, <sup>1</sup>M. Skłodowska-Curie Institute, Gliwice, PL, <sup>2</sup>The University of Sydney, Sydney, AU, <sup>3</sup>Seoul National University Hospital, Seoul, KR, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, RU, <sup>6</sup>Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU, <sup>7</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>8</sup>University Hospital of Pisa, Pisa, IT, <sup>9</sup>Exelixis, Inc, San Francisco, US, <sup>10</sup>Gustave Roussy, Villejuif, FR
- 12:45 - 12:45 **1898P - The role of SWI/SNF chromatin remodelling complex ATPase subunit - BRM in TNBC**  
I. Jancewicz<sup>1</sup>, N. Rusetska<sup>1</sup>, A. Armatowska<sup>2</sup>, M. Stachowiak<sup>3</sup>, K. Pogoda<sup>4</sup>, A. Niwińska<sup>3</sup>, W. Olszewski<sup>5</sup>, Z. Nowecki<sup>5</sup>, T. Sarnowski<sup>6</sup>, E. Sarnowska<sup>5</sup>, J. Siedlecki<sup>1</sup>, <sup>1</sup>Marii Skłodowska-Curie Cancer Center, Warsaw, PL, <sup>2</sup>Warsaw University of Technology, Warsaw, PL, <sup>3</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, PL, <sup>4</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>5</sup>The Maria Skłodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, <sup>6</sup>Institute of Biochemistry and Biophysics PAS, Warsaw, PL
- 12:45 - 12:45 **1899P - Fluoropyrimidine and Inflammatory Genes Promoter Methylation in Egyptian CRC patients**  
M. Fouad<sup>1</sup>, S. Salem<sup>2</sup>, M. Hussein<sup>2</sup>, A. Zekri<sup>2</sup>, D. Badr<sup>2</sup>, H. Hafez<sup>2</sup>, E. Eldesouky<sup>2</sup>, S. Shouman<sup>2</sup>, <sup>1</sup>National Cancer Institute-Cairo University, Cairo, EG, <sup>2</sup>National cancer Institute-Cairo University, Cairo, EG
- 12:45 - 12:45 **1900P - Realworld prospective data of small biopsy samples for tumor PD-L1 expression in non-small-cell lung cancer**  
K. Morikawa, A. Tsunoda, T. Inoue, M. Mineshita, St. Marianna University School of Medicine, Kawasaki, JP
- 12:45 - 12:45 **1901P - ATM as a DNA Damage Response Protein in Uveal Melanoma: Association with Clinicopathological Factors and Prognostic Outcome**  
J. Jha, M. Singh, N. Pushker, S. Sen, S. Kashyap, All India Institute of Medical Sciences, New Delhi, IN

- 12:45 - 12:45 **1902P - BRCA mutation and castration-resistant prostate cancer**  
L. Spirina, Tomsk Cancer Research Institute RAMS, Tomsk, RU
- 12:45 - 12:45 **1903P - Prevalence of KRAS mutation subtypes and MSI status in Pancreatic Cancer.**  
P. Gultawatvichai, I. Puthawala, K. Tomaszewicz, V. Bathini, L. Hutchinson, University of Massachusetts Medical center UMass Memorial Medical Center, Worcester, US
- 12:45 - 12:45 **1904P - Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES Study**  
F. Zanelli<sup>1</sup>, M. Pagano<sup>1</sup>, C. Bonelli<sup>1</sup>, R. Gnoni<sup>2</sup>, L. Boni<sup>3</sup>, G.L. Ceresoli<sup>4</sup>, M. Larocca<sup>2</sup>, M. Tiseo<sup>5</sup>, P. Zucali<sup>6</sup>, F. Grosso<sup>7</sup>, F. Cappuzzo<sup>8</sup>, A. Ciarrocchi<sup>9</sup>, F. Torricelli<sup>9</sup>, C. Pinto<sup>1</sup>, <sup>1</sup>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>2</sup>AUSL di Reggio Emilia-IRCCS, Reggio Emilia, IT, <sup>3</sup>clinical trial coordinating center, AOU careggi, firenze, IT, <sup>4</sup>Humanitas Gavazzeni, Bergamo, IT, <sup>5</sup>AOU di Parma, Parma, IT, <sup>6</sup>Humanitas Clinical and Research Hospital, Rozzano, IT, <sup>7</sup>Ospedale di Alessandria, Alessandria, IT, <sup>8</sup>Ospedale Civile di Ravenna - S.ta Maria delle Croci, Ravenna, IT, <sup>9</sup>AUSL-IRCCS Reggio Emilia, Reggio Emilia, IT
- 12:45 - 12:45 **1905P - N-Myc and STAT interactor (NMI) as a key determinant of chemosensitivity in breast cancer: proteomic-based computing network mapping and in vivo verification with a mouse model**  
H. Lee<sup>1</sup>, K.-M. Lee<sup>2</sup>, D. Han<sup>2</sup>, H. Ryu<sup>2</sup>, <sup>1</sup>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine,, Seoul, KR, <sup>2</sup>Seoul National University Hospital (SNUH)-Yongon Campus, Seoul, KR
- 12:45 - 12:45 **1906P - Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing**  
F. Grossi<sup>1</sup>, C. Genova<sup>2</sup>, D. Cittaro<sup>3</sup>, S. Bonfiglio<sup>3</sup>, S. Boccardo<sup>1</sup>, I. Vanni<sup>1</sup>, M. Mora<sup>1</sup>, M.G. Dal Bello<sup>1</sup>, F. Biello<sup>1</sup>, E. Rijavec<sup>1</sup>, C. Sini<sup>1</sup>, G. Rossi<sup>1</sup>, M. Tagliamento<sup>1</sup>, A. Alama<sup>1</sup>, G. Burrafato<sup>1</sup>, G. Barletta<sup>1</sup>, A. Ballestrero<sup>4</sup>, S. Coco<sup>1</sup>, <sup>1</sup>Ospedale Policlinico San Martino, Genoa, IT, <sup>2</sup>Ospedale Policlinico San Martino, Genova, IT, <sup>3</sup>IRCCS San Raffaele Scientific Institute,, Milan, IT, <sup>4</sup>University of Genoa, Genoa, IT
- 12:45 - 12:45 **1907P - Discordance of the PAM50 intrinsic subtypes compared with IHC-based surrogate in breast cancer patients: Potential implication of genomic alterations of discordance**  
Y.H. Park, H.K. Kim, J.H. Cho, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR
- 12:45 - 12:45 **1908P - Impact of Invasive Lobular Carcinoma in Latin American Breast Cancer Patients' Disease-Free Survival. The new paradox.**  
D. Flores-Díaz<sup>1</sup>, C. Arce Salinas<sup>1</sup>, L. Flores<sup>2</sup>, F. Lara<sup>3</sup>, J.A. Matus Santos<sup>4</sup>, J.E. Bargallo Rocha<sup>4</sup>, V. Perez<sup>4</sup>, N. Reynoso-Noveron<sup>4</sup>, P.A. Cabrera-Galeana<sup>5</sup>, A. Mohar<sup>4</sup>, <sup>1</sup>Instituto Nacional de Cancerología, Mexico City, MX, <sup>2</sup>Instituto Nacional de Salud Publica, Mexico City, MX, <sup>3</sup>Private Practice - Lara, Ciudad de México, MX, <sup>4</sup>Instituto Nacional de Cancerologia, Mexico City, MX, <sup>5</sup>Instituto Nacional de Cancerologia, Ciudad de México, MX



- 12:45 - 12:45 **1909P - Clinical validation of a NGS-based assay for the detection of BRCA1 and BRCA2 variants in Chinese patients with breast cancer or ovarian cancer**  
Q. Gao, G. Zhu, H. Ge, X. Li, L. Ruan, Amoy Diagnostics Co., Ltd., Xiamen, CN
- 12:45 - 12:45 **1910P - Correlation between the expression of androgens receptor (RA) and histopathological characteristics and survival parameters of breast cancer**  
I. Delgado Sillero<sup>1</sup>, A. López González<sup>2</sup>, L.F. Sanchez Cousido<sup>2</sup>, M. López-Flores<sup>2</sup>, E. Honrado Franco<sup>2</sup>, L. Lopez Gonzalez<sup>2</sup>, O. Sanz<sup>2</sup>, C. Castañón López<sup>2</sup>, A. García Palomo<sup>2</sup>,  
<sup>1</sup>Complejo Asistencial Universitario de León, Leon, ES, <sup>2</sup>Complejo Asistencial Universitario de León, León, ES
- 12:45 - 12:45 **1911P - Metabolic Syndrome in Breast Cancer Patients: An Observational Study**  
S. Khare, PGIMER, Chandigarh, Chandigarh, IN
- 12:45 - 12:45 **1912P - The prognostic value of different molecular subtypes of breast cancer in relation to Enhancer-of-zeste homologue 2 expression**  
Z. Sanaat<sup>1</sup>, R. Dolatkhan<sup>2</sup>, <sup>1</sup>Shahid Ghazi Medical Center,Tabriz University of Medical Sciences, Tabriz, IR, <sup>2</sup>Hematology and Oncology Research Center,Tabriz University Of Medical Science,Tabriz,Iran, Tabriz, IR
- 12:45 - 12:45 **1913P - A guided and personnalized treatment in metastatic breast cancer: optimisation of gene and protein expression in tumor tissue.**  
E. Seront<sup>1</sup>, S. Lejeune<sup>1</sup>, B. Petit<sup>1</sup>, V. Samartzy<sup>1</sup>, S. Sauvage<sup>2</sup>, J.-F. Laes<sup>2</sup>, <sup>1</sup>Centre Hospitalier Jolimont-Lobbes, Haine Saint Paul, BE, <sup>2</sup>OncoDNA, Gosselies, BE
- 12:45 - 12:45 **1914P - HER2 staining intensity has prognostic impact on patients with HER2 type invasive breast cancer**  
H. Yi-Hsuan<sup>1</sup>, L. Yen-Shu<sup>2</sup>, H. Chih-Yi<sup>2</sup>, T. Ling-Ming<sup>2</sup>, <sup>1</sup>Fu Jen Catholic University, New Taipei, TW, <sup>2</sup>Taipei Veterans Hospital, Taipei, TW
- 12:45 - 12:45 **1915P - Does the minimal axillary approach lead to lose of prognostic factors in breast cancer?**  
R. De Araujo<sup>1</sup>, C. Nascimento<sup>2</sup>, C. Da Cunha<sup>2</sup>, E. Marinho<sup>2</sup>, E. Mosca<sup>2</sup>, F. Da Luz<sup>2</sup>, P. Delfino<sup>2</sup>, R. Antonioli<sup>2</sup>, T. Mendes<sup>2</sup>, M. Silva<sup>2</sup>, <sup>1</sup>COT - Centro Oncológico do Triângulo, Uberlandia, BR, <sup>2</sup>Universidade Federal de Uberlândia, Uberlândia, BR
- 12:45 - 12:45 **1916P - The influence of the surgical approach in women diagnosed with breast neoplasia**  
R. De Araujo<sup>1</sup>, C. Nascimento<sup>2</sup>, C. Da Cunha<sup>2</sup>, E. Marinho<sup>2</sup>, E. Mosca<sup>2</sup>, F. Da Luz<sup>2</sup>, P. Delfino<sup>2</sup>, R. Antonioli<sup>2</sup>, T. Mendes<sup>2</sup>, M. Silva<sup>2</sup>, <sup>1</sup>COT - Centro Oncológico do Triângulo, Uberlandia, BR, <sup>2</sup>Universidade Federal de Uberlândia, Uberlândia, BR
- 12:45 - 12:45 **1917P - Use of comparative proteomics to identify potential cisplatin resistance mechanisms in neuroblastoma**  
M.A. Merlos Rodrigo<sup>1</sup>, H. Buchtelova<sup>2</sup>, V. Strmiska<sup>2</sup>, Z. Heger<sup>2</sup>, V. Adam<sup>2</sup>, <sup>1</sup>Medical

Faculty, University of Brno, Prague, CZ, <sup>2</sup>Mendel University in Brno, Brno, CZ

- 12:45 - 12:45 **1918P - Acquired resistance mechanism of Osimertinib targeting EGFR in human lung cancer**  
V. Ciaramella<sup>1</sup>, C.M. Della Corte<sup>1</sup>, G. Barra<sup>2</sup>, R. Di Liello<sup>1</sup>, G. Viscardi<sup>1</sup>, M. Orditura<sup>1</sup>, E. Martinelli<sup>1</sup>, F. Ciardiello<sup>1</sup>, F. Morgillo<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT
- 12:45 - 12:45 **1919P - Interaction of Oncostatin M and its receptor OSMR promotes gastric cancer progression via STAT3/FAK/Src signaling**  
L. Su<sup>1</sup>, X. Wu<sup>2</sup>, J. Li<sup>1</sup>, Z. Yu<sup>2</sup>, B. Liu<sup>1</sup>, <sup>1</sup>Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN, <sup>2</sup>Shanghai Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, CN
- 12:45 - 12:45 **1920P - Role of Pioglitazone on gene/protein expression profile, bioenergetics and TGF $\beta$ /SMAD signaling pathway in NSCLC**  
R. Di Liello<sup>1</sup>, G. Viscardi<sup>1</sup>, V. Ciaramella<sup>1</sup>, G. Barra<sup>2</sup>, G. Esposito<sup>2</sup>, M. Fasano<sup>3</sup>, F. Ciardiello<sup>1</sup>, F. Morgillo<sup>1</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, IT, <sup>3</sup>AOU Policlinico Federico II, Napoli, IT
- 12:45 - 12:45 **1921P - Somatostatin receptor 2 expression and clinical significance in pulmonary lymphoepithelioma-like carcinoma**  
S. Han<sup>1</sup>, J. Yeong<sup>2</sup>, C. Lim<sup>3</sup>, M.-K. Ang<sup>3</sup>, W. Lim<sup>3</sup>, C.K. Toh<sup>3</sup>, Q.S. Ng<sup>3</sup>, D.S.W. Tan<sup>1</sup>, T. Lim<sup>2</sup>, J.H. Loh<sup>2</sup>, A. Tanako<sup>2</sup>, R. Kanesvaran<sup>3</sup>, W.L. Tan<sup>3</sup>, T. Rajasekaran<sup>4</sup>, W. Nei<sup>3</sup>, A. Jain<sup>3</sup>, <sup>1</sup>National Cancer Center Singapore, Singapore, SG, <sup>2</sup>Singapore General Hospital, Singapore, SG, <sup>3</sup>National Cancer Centre Singapore, Singapore, SG, <sup>4</sup>National Cancer Center, Singapore, SG
- 12:45 - 12:45 **1922P - The Role of Neurotrophic Factors in Nerve-Cancer Crosstalk**  
A. Planken<sup>1</sup>, L. Truu<sup>2</sup>, K. Oselin<sup>1</sup>, V. Valvere<sup>1</sup>, <sup>1</sup>North Estonia Medical Centre Foundation, Tallinn, EE, <sup>2</sup>National Institute of Chemical Physics and Biophysics, Tallinn, EE
- 12:45 - 12:45 **Thyroid hormone negatively regulates tumorigenicity by suppression of BC200 in liver cancer**  
K.-H. Lin<sup>1</sup>, M.-H. Wu<sup>1</sup>, Y.H. Lin<sup>2</sup>, <sup>1</sup>Chung Gung University, Taoyuan, TW, <sup>2</sup>Memorial Hospital, Linkou, Taoyuan, TW
- 12:45 - 12:45 **1924P - Glutathione S-transferase M subfamily in TMZ-resistant glioblastoma cells**  
S.Y. Cheng<sup>1</sup>, W.-F. Chen<sup>2</sup>, Z.-H. Wen<sup>1</sup>, <sup>1</sup>National Sun Yat-sen University, Kaohsiung, TW, <sup>2</sup>Chang Gung Memorial Hospital, Kaohsiung, TW
- 12:45 - 12:45 **1925P - Combining 2D angiogenesis and 3D Osteosarcoma microtissues to**

**improve vascularization**

H. Chaddad, Faculte de medecine de strasbourg, Strasbourg, FR

- 12:45 - 12:45 **1926P - Survival analysis of sorafenib in hepatocellular carcinoma patients with microvascular invasion after hepatectomy**  
Z. Zhang, Y. Huang, Y. Zhou, J. Yang, K. Hu, Z. Wang, Xiangya Hospital of Central South University, Changsha, CN
- 12:45 - 12:45 **1927P - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.**  
K. Saeki<sup>1</sup>, H. Onishi<sup>2</sup>, Y. Oda<sup>3</sup>, M. Nakamura<sup>2</sup>, <sup>1</sup>Graduate School of Medical Sciences, Fukuoka-City, JP, <sup>2</sup>Kyushu University Hospital, FUKUOKA, JP, <sup>3</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP
- 12:45 - 12:45 **1928P - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)**  
A. Weissferdt<sup>1</sup>, B. Sepesi<sup>1</sup>, A. Pataer<sup>1</sup>, N. Kalhor<sup>1</sup>, C. Moran<sup>1</sup>, W. William<sup>2</sup>, X. Le<sup>2</sup>, B. Glisson<sup>2</sup>, F. Skoulidis<sup>3</sup>, G. Blumenschein<sup>2</sup>, J. Zhang<sup>2</sup>, M. Altan<sup>1</sup>, D. Rice<sup>1</sup>, R. Mehran<sup>1</sup>, J. Lee<sup>2</sup>, A. Vaporciyan<sup>1</sup>, D. Gibbons<sup>4</sup>, S. Swisher<sup>1</sup>, J. Heymach<sup>2</sup>, T. Cascone<sup>3</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>MD Anderson Cancer Center, Houston, US, <sup>3</sup>UT MD Anderson Cancer Center, Houston, US, <sup>4</sup>MD ANDERSON CANCER CENTER, HOUSTON, US
- 12:45 - 12:45 **1929P - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma**  
M.H. Hong<sup>1</sup>, S.-J. Shin<sup>2</sup>, Y.-L. Choi<sup>3</sup>, B.C. Cho<sup>4</sup>, H.R. Kim<sup>1</sup>, <sup>1</sup>Yonsei Cancer Center Yonsei University, Seoul, KR, <sup>2</sup>College of Medicine, Hanyang University, Seoul, KR, <sup>3</sup>Samsung Medical Center, Seoul, KR, <sup>4</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR
- 12:45 - 12:45 **1930P - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma**  
M.-W. Lee<sup>1</sup>, N. Kim<sup>2</sup>, S. Kim<sup>2</sup>, M. Joo<sup>2</sup>, H. Ryu<sup>1</sup>, H.J. Lee<sup>2</sup>, <sup>1</sup>Chungnam National University Hospital, Daejeon, KR, <sup>2</sup>Chungnam National University, Daejeon, KR
- 12:45 - 12:45 **1931P - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis**  
T. Mrowiec<sup>1</sup>, F. Wilm<sup>1</sup>, E. Frick-Krieger<sup>1</sup>, M. Silva<sup>1</sup>, L. Terracciano<sup>2</sup>, I. Dussault<sup>3</sup>, C. Ihling<sup>1</sup>, <sup>1</sup>Merck KGaA, Darmstadt, DE, <sup>2</sup>University of Basel, Basel, CH, <sup>3</sup>EMD Serono, Billerica, US
- 12:45 - 12:45 **1932P - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.**  
N. Sato<sup>1</sup>, T. Tasaki<sup>1</sup>, H. Noguchi<sup>1</sup>, K. Irie<sup>2</sup>, T. Nakayama<sup>1</sup>, <sup>1</sup>University of Occupational and Environmental Health, Kitakyushu, JP, <sup>2</sup>Kitakyushu General Hospital, Kitakyushu, JP

- 12:45 - 12:45 **1933P - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors**  
M. López Gómez<sup>1</sup>, E. Casado<sup>2</sup>, M. Muñoz<sup>3</sup>, S. Alcalá<sup>4</sup>, J. Moreno-Rubio<sup>5</sup>, S. Salinas<sup>3</sup>, F. Zambrana<sup>2</sup>, A.M. Jiménez-Gordo<sup>6</sup>, B. Sainz Jr<sup>4</sup>, <sup>1</sup>Hospital Universitario Infanta Sofía, San Sebastian de los Reyes, ES, <sup>2</sup>Hospital Infanta Sofia, Madrid, ES, <sup>3</sup>Infanta Sofia University Hospital, San Sebastian de los Reyes, ES, <sup>4</sup>Universidad Autónoma de Madrid, Madrid, ES, <sup>5</sup>Hospital Infanta Sofia, San Sebastian De Los Reyes, ES, <sup>6</sup>Hospital Infanta Sofia, San Sebastián De Los Reyes, ES
- 12:45 - 12:45 **1934P - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells**  
K. Morita<sup>1</sup>, T. Fujii<sup>1</sup>, K. Shimada<sup>2</sup>, H. Itami<sup>1</sup>, K. Hatakeyama<sup>1</sup>, M. Miyake<sup>1</sup>, K. Fujimoto<sup>1</sup>, C. Ohbayashi<sup>1</sup>, <sup>1</sup>Nara Medical University, Nara, JP, <sup>2</sup>Nara City Hospital, Nara, JP
- 12:45 - 12:45 **1935P - Somatic-stem transition of tumor cells is a key link in the metastasis**  
N. Litviakov<sup>1</sup>, M. Ibragimova<sup>2</sup>, E. Slonimskaya<sup>3</sup>, E. Skurikhin<sup>4</sup>, M. Tsyganov<sup>3</sup>, O. Pershina<sup>4</sup>, I. Deriusheva<sup>5</sup>, P. Kazantseva<sup>3</sup>, <sup>1</sup>Tomsk Cancer Research Institute RAMS, Tomsk, RU, <sup>2</sup>National Research Tomsk State University, Tomsk, RU, <sup>3</sup>Tomsk Cancer Research Institute, Tomsk, RU, <sup>4</sup>Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RU, <sup>5</sup>Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RU

**13:00 - 14:30 Type: Industry Satellite Symposium ICM - Room 1**  
**Title: Industry satellite symposium 28**

- 13:00 - 13:08 **Presentation 1**  
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 13:08 - 13:23 **Presentation 2**  
M. Untch, Klinik für Gynäkologie und Geburtshilfe, Berlin, DE
- 13:23 - 13:43 **Presentation 3**  
V. Guarneri, Istituto Oncologico Veneto IRCCS, Padova, IT
- 13:43 - 14:03 **Presentation 4**  
J. Crown, St Vincents University Hospital, Dublin, IE
- 14:03 - 14:26 **Presentation 5**  
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 14:26 - 14:28 **Presentation 6**  
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

**13:00 - 14:30 Type: Industry Satellite Symposium ICM - Room 14b**  
**Title: Industry satellite symposium 29**



<b>13:00 - 14:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 30</b>	<b>ICM - Room 13</b>
<b>13:00 - 14:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 31</b>	<b>Hall A1 - Room 16</b>
<b>13:00 - 14:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium - EONS 5</b>	<b>Hall B3 - Room 23</b>
13:00 - 13:15	<b>Introduction</b> <u>E. Woodford</u> , EONS, Brussels, BE	
13:15 - 13:35	<b>Presentation 1</b> <u>B. Grube</u> , Copenhagen, DK	
13:35 - 13:55	<b>Presentation 2</b> <u>J. Daly</u> , Munich, IE	
13:55 - 14:15	<b>Presentation 3</b> <u>O. Marschal</u> , We need an affiliation, Braunschweig, DE	
14:15 - 14:30	<b>Discussion</b> <u>E. Woodford</u> , EONS, Brussels, BE	
<b>13:00 - 14:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 32</b>	<b>Hall B3 - Room 20</b>

**13:00 - 14:30**    **Type: ESMO Colloquium**    **Hall B3 - Room 22**  
**Title: ESMO COLLOQUIUM - Immune check point inhibitors: Are we ready for combination?**  
 Chair(s): John Haanen, NL

13:00 - 13:00    **Session DOI**

13:00 - 13:05    **Introduction**

J. Haanen, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

13:05 - 13:15    **Mechanisms of chemotherapy-induced increased immune response**

J. Vansteenkiste, University Hospitals Leuven, Leuven, BE

13:15 - 13:40    **Achievements and present development in lung cancer**

M. Garassino, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

13:40 - 14:05    **Where do we stand in TNBC breast cancer?**

S. Loi, Peter MacCallum Cancer Center, Melbourne, AU

14:05 - 14:25    **Which patients do benefit? How to select and for which benefit?**

J. Haanen, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:25 - 14:30    **Conclusion**

J. Haanen, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 19**  
**Title: Industry satellite symposium 34**

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 24**  
**Title: Industry satellite symposium - EONS 6**

13:00 - 13:20    **Presentation**  
B. Grube, Copenhagen, DK

13:20 - 13:40    **Presentation 1**  
A. Margulies, Zurich, CH

13:40 - 14:00    **Presentation 2**  
B. Kirchhofer, Berlin, DE

14:00 - 14:20    **Presentation 3**  
A. Kinneally, Dublin, IE

14:20 - 14:40    **Presentation 4**  
F. Peccatori, Istituto Europeo di Oncologia, Milan, IT

14:40 - 15:00    **Presentation 5**  
J. Ouwerkerk, Amsterdam, NL

15:00 - 15:20    **Presentation 6**  
E. Van Muilekom, Amsterdam, NL

**14:30 - 16:30**    **Type: Clinical Practice Guidelines**    **Hall A1 - Room 15**  
**Title: ESMO Clinical Practice Guidelines 2**  
 Chair(s): George Pentheroudakis, GR; Cristiana Sessa, CH

14:30 - 14:30    **Session DOI**

14:30 - 14:40    **Introduction to the ESMO Clinical Practice Guidelines**  
G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR

14:40 - 14:50    **Questionnaire**  
C. Sessa, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

14:50 - 15:00    **Early HER2-positive breast cancer**  
S. Volovat, Victoria Hospital (Euroclinic Oncology Center), Iasi, RO

15:00 - 15:10    **Discussant**  
E. Senkus-Konefka, Medical University of Gdansk, Gdansk, PL

- 15:10 - 15:15 **Q&A**
- 15:15 - 15:25 **Soft tissue sarcoma**  
B. Lopes David, Hospital Geral de Bonsucesso, Rio de Janeiro, BR
- 15:25 - 15:35 **Discussant**  
S. Stacchiotti, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 15:35 - 15:40 **Q&A**
- 15:40 - 15:50 **Cancer cachexia**  
T. Solheim, St. Olavs Hospital HF, Trondheim, NO
- 15:50 - 16:00 **Discussant**  
J. Arends, Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg, DE
- 16:00 - 16:05 **Q&A**
- 16:05 - 16:15 **Prostate cancer**  
M. Serra, Institute of Cancer Research and Royal Marsden, Sutton, GB
- 16:15 - 16:25 **Discussant**  
C. Parker, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 16:25 - 16:30 **Q&A**



**14:30 - 17:30**    **Type: Young Oncologist session**    **ICM -**  
**Title: YO Masterclass: From genetic data to clinical trial design:**    **Room 14c**  
**Joint session EACR and ESMO YOC**  
 Chair(s): Guillem Argiles, ES; Therese Sørлие, NO

14:30 - 14:30    **Session DOI**

14:30 - 15:10    **Next generation sequencing of cancer**  
N. Normanno, Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

15:10 - 15:50    **Fighting cancer with biomarker data analysis**  
S. Michiels, Gustave Roussy, Villejuif, FR

15:50 - 16:10    **Break**

16:10 - 16:50    **Immuno genetics & immuno genomics**  
N. Halama, Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE

16:50 - 17:30    **Crystallising Knowledge, new trial designs in the molecular oncology era**  
J. Rodon, UT MD Anderson Cancer Center, Houston, US

**14:45 - 16:15**    **Type: Special Symposium**    **Hall A1 - Room 17**  
**Title: Tumour heterogeneity in gynaecological cancers**  
 Chair(s): David Huntsman, CA; Susana Banerjee, GB

14:45 - 14:45    **Session DOI**

14:45 - 14:50    **Introduction**

D. Huntsman, British Columbia Cancer Agency, Vancouver, CA

14:50 - 15:10    **The molecular classification of endometrial cancer: Applications for treatment decisions**

C. Creutzberg, Leiden University Medical Center (LUMC), Leiden, NL

15:10 - 15:30    **Intratumour heterogeneity in high grade serous ovarian cancer and beyond**

B. Davidson, Oslo University Hospital, Oslo, NO

15:30 - 15:50    **The immune response and heterogeneity in gynaecological cancers: Treatment opportunities**

A. González Martín, Clínica Universidad de Navarra, Madrid, ES

15:50 - 16:10    **Genomics of rare ovarian cancers: What have we learned and who how can it influence practice?**

D. Huntsman, British Columbia Cancer Agency, Vancouver, CA

16:10 - 16:15    **Conclusions and perspectives**

S. Banerjee, Royal Marsden Hospital NHS Foundation Trust, London, GB

**14:45 - 16:15**    **Type: Special Symposium**    **Hall A2 - Room 18**  
**Title: Combination strategies of immunotherapy in breast cancer**  
 Chair(s): Giuseppe Curigliano, IT; Shinji Ohno, JP

14:45 - 14:45    **Session DOI**

14:45 - 14:50    **Introduction**

S. Ohno, National Kyushu Cancer Center, Fukuoka, JP

14:50 - 15:10    **Integrating genomic data and immuno-markers in breast cancer**

G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

15:10 - 15:30    **Combining chemotherapy and immunotherapy in TNBC**

L. Carey, UNC - Lineberger Cancer Center, Chapel Hill, US

15:30 - 15:50    **Combining anti HER2 with immunotherapy in HER2+ patients**

S. Loi, Peter MacCallum Cancer Center, Melbourne, AU

15:50 - 16:10    **Immunotherapy strategies for luminal breast cancer**

M. Kok, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL

16:10 - 16:15    **Conclusions and perspectives**

G. Curigliano, Istituto Europeo di Oncologia, Milan, IT

**14:45 - 16:00**    **Type: Poster Discussion session**    **ICM - Room 1**  
**Title: Poster Discussion session - Non-metastatic NSCLC and other thoracic malignancies**  
 Chair(s): Wilfried Eberhardt, DE; Pieter Postmus, NL; Jean-Louis Pujol, FR; Cécile Le Pechoux, FR

14:45 - 14:45    **Session DOI**

14:45 - 14:45    **1348PD - Genomic landscape and its correlation with TMB, CD8 TILs and PD-L1 expression in Chinese lung squamous cell carcinoma**

C. Zhou, T. Jiang, Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN

14:45 - 14:45    **1349PD - Gene expression signature of DNA damage response to predict the prognosis of early stage lung adenocarcinoma**

Z. Wang<sup>1</sup>, C. Xu<sup>2</sup>, J. Zhao<sup>3</sup>, X. Zhao<sup>3</sup>, S. Cai<sup>4</sup>, Y. Song<sup>5</sup>, J. Wang<sup>6</sup>, <sup>1</sup>National Cancer Center Cancer Hospital, Beijing, CN, <sup>2</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>3</sup>Shanghai 3D Medicines.Inc, Shanghai, CN, <sup>4</sup>3D medicines Inc., Shanghai, CN, <sup>5</sup>Jinling Hospital,

Nanjing, CN, <sup>6</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

- 14:45 - 14:45 **1350PD\_PR - Social and behavioral indicators of undergoing a screening test for lung cancer**  
S. Couraud<sup>1</sup>, J.F. Morère<sup>2</sup>, J. Viguier<sup>3</sup>, M. Roupert<sup>4</sup>, L. Brignoli-Guibaudet<sup>5</sup>, C. Lhomel<sup>6</sup>, T. De La Motte Rouge<sup>7</sup>, F. Eisinger<sup>8</sup>, L. Greillier<sup>9</sup>, <sup>1</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>2</sup>Hôpital Paul Brousse, Villejuif, FR, <sup>3</sup>Institut National du Cancer, Boulogne-Billancourt, FR, <sup>4</sup>Hôpital Universitaire Pitié-Salpêtrière, Paris, FR, <sup>5</sup>Kantar Health, Paris, FR, <sup>6</sup>Products Roche - France, Neuilly-sur-Seine, FR, <sup>7</sup>Centre Eugene - Marquis, Rennes, FR, <sup>8</sup>Institute Paoli Calmettes, Marseille, FR, <sup>9</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR
- 14:45 - 15:00 **Invited Discussant 1348PD, 1349PD and 1350PD\_PR**  
W. Eberhardt, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
- 15:00 - 15:10 **Q&A led by Discussant**
- 15:10 - 15:10 **1364PD - Cardiac events in stage III non-small cell lung cancer (NSCLC) treated in daily clinical practice: is it time for cardiovascular screening and follow-up?**  
J. Degens<sup>1</sup>, D. De Ruyscher<sup>2</sup>, B. Kietselaer<sup>3</sup>, G. Bootsma<sup>4</sup>, A. Schols<sup>5</sup>, A.-M. Dingemans<sup>6</sup>, <sup>1</sup>Academisch Ziekenhuis Maastricht (AZM), Maastricht, NL, <sup>2</sup>Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL, <sup>3</sup>Zuyderland Medical Center, Geleen, NL, <sup>4</sup>Zuyderland Medical Center - Heerlen, Heerlen, NL, <sup>5</sup>NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, NL, <sup>6</sup>Maastricht University Medical Center (MUMC), Maastricht, NL
- 15:10 - 15:10 **1806PD - Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: incidence and outcome**  
S. Cedres Perez<sup>1</sup>, M. Sanso<sup>2</sup>, A. Hernando-Calvo<sup>2</sup>, A. Callejo<sup>3</sup>, N. Pardo Aranda<sup>1</sup>, A. Navarro Mendivil<sup>1</sup>, A. Martinez<sup>1</sup>, J. Remon<sup>1</sup>, J.M. Miquel<sup>2</sup>, G. Rodriguez<sup>2</sup>, V. Monton<sup>2</sup>, G. Villacampa<sup>1</sup>, R. Dienstmann<sup>1</sup>, A. Vivancos<sup>1</sup>, E. Felip<sup>1</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>Vall d'Hebron University Hospital/Vall d'Hebron Institute Oncology, Barcelona, ES, <sup>3</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES
- 15:10 - 15:20 **Invited Discussant 1364PD and 1806PD**  
P. Postmus, Leiden University Medical Center (LUMC), Leiden, NL
- 15:20 - 15:25 **Q&A led by Discussant**
- 15:25 - 15:25 **1665PD - Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from Arm A of the Phase II BALTIC study**  
I. Bondarenko<sup>1</sup>, O. Juan-Vidal<sup>2</sup>, G. Pajkos<sup>3</sup>, A. Kryzhanivska<sup>4</sup>, Z. Pápai Székely<sup>5</sup>, D. Vicente<sup>6</sup>, I. Vynnychenko<sup>7</sup>, S. Jones<sup>8</sup>, Y. Wang<sup>8</sup>, H. Jiang<sup>8</sup>, N. Reinmuth<sup>9</sup>, <sup>1</sup>Dnipropetrovsk



State Medical Academy, City Clinical Hospital, Dnipropetrovsk, UA, <sup>2</sup>La Fe University Hospital, Valencia, ES, <sup>3</sup>Bacs-Kiskun County Hospital, Kecskemét, HU, <sup>4</sup>Ivano-Frankivsk National Medical University, Ivano-Frankivsk, UA, <sup>5</sup>St George Hospital of Fejér County, Szekesfehervar, HU, <sup>6</sup>Hospital Universitario Virgen Macarena, Seville, ES, <sup>7</sup>Sumy Regional Oncology Center, Sumy, UA, <sup>8</sup>AstraZeneca, Gaithersburg, US, <sup>9</sup>Asklepios Lung Clinic, Munich-Gauting, DE

15:25 - 15:25 **1666PD - Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy**

K. Dragnev<sup>1</sup>, T. Owonikoko<sup>2</sup>, T. Csoszi<sup>3</sup>, M. Maglakelidze<sup>4</sup>, J. Beck<sup>5</sup>, M. Domine Gomez<sup>6</sup>, A. Lowczak<sup>7</sup>, A. Fulop<sup>8</sup>, R. Hoyer<sup>9</sup>, W. Hanna<sup>10</sup>, P. Lowry<sup>11</sup>, R. Aljumaily<sup>12</sup>, V. Chiu<sup>13</sup>, I. Bulat<sup>14</sup>, Z. Yang<sup>15</sup>, P. Roberts<sup>16</sup>, J. Antal<sup>17</sup>, R. Malik<sup>18</sup>, S. Morris<sup>15</sup>, J. Weiss<sup>19</sup>, <sup>1</sup>Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, <sup>2</sup>Emory University Winship Cancer Institute, Atlanta, US, <sup>3</sup>Hetyenyi Geza Korhaz, Onkologiai Kozpont, Szolnok, HU, <sup>4</sup>Research Institute of Clinical Medicine, Tbilisi, GE, <sup>5</sup>Highlands Oncology Group, Fayetteville, US, <sup>6</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>7</sup>Samodzielny Publiczny Zespól Gruzlicy i Chorob Pluc, Olsztyn, PL, <sup>8</sup>OKTPI-Korányi National Institute for Tuberculosis and Pulmonology, Budapest, HU, <sup>9</sup>Memorial Hospital, University of Colorado Health, Colorado Springs, US, <sup>10</sup>University of Tennessee Medical Center, Knoxville, US, <sup>11</sup>Guthrie Medical Group, Sayre, US, <sup>12</sup>Oklahoma University Medical Center, Oklahoma City, US, <sup>13</sup>University of New Mexico Comprehensive Cancer Center, Albuquerque, US, <sup>14</sup>ICS ARENSIA Exploratory Medicine SRL, Chisinau, MD, <sup>15</sup>G1 Therapeutics, Inc., Research Triangle Park, US, <sup>16</sup>G1 Therapeutics, Inc, Research Triangle Park, US, <sup>17</sup>G1 Therapeutics, Research Triangle Park, US, <sup>18</sup>G1 Therapeutics, Inc., Research Triangle Park, US, <sup>19</sup>University of North Carolina at Chapel Hill, Chapel Hill, US

15:25 - 15:35 **Invited Discussant 1665PD and 1666PD**

J.-L. Pujol, Hopital Arnaud de Villeneuve, Montpellier, FR

15:35 - 15:40 **Q&A led by Discussant**

15:40 - 15:40 **1667PD - Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small-cell lung cancer. A multicenter phase II trial (SAKK 15/12)**

H. Veas<sup>1</sup>, F. Caparrotti<sup>2</sup>, A. Xyrafas<sup>3</sup>, A. Fuhrer<sup>3</sup>, U. Meier<sup>4</sup>, M. Mark<sup>5</sup>, O. Elicin<sup>6</sup>, D. Aebbersold<sup>6</sup>, D. Betticher<sup>7</sup>, C. Biaggi Rudolf<sup>3</sup>, K. Ribi<sup>8</sup>, T. Finazzi<sup>9</sup>, D. Zwahlen<sup>5</sup>, <sup>1</sup>Hirslanden Klinik Zürich, Zurich, CH, <sup>2</sup>Hôpitaux Universitaires de Genève - HUG, Geneva, CH, <sup>3</sup>SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, <sup>4</sup>Kantonsspital Winterthur, Winterthur, CH, <sup>5</sup>Kantonsspital Graubünden, Chur, CH, <sup>6</sup>Inselspital - Universitätsspital Bern, Bern, CH, <sup>7</sup>Medical Oncology, Fribourg, CH, <sup>8</sup>IBCSG International Breast Cancer Study Group, Bern, CH, <sup>9</sup>Universitaetsspital Basel, Basel, CH

15:40 - 15:40 **1365PD - Screening for brain metastases (BM) in patients (pts) with stage III non-small cell lung cancer (NSCLC), magnetic resonance imaging (MRI) or dedicated contrast-enhanced computed tomography (dCE-CT)? A prospective**

**observational study**

J. Schoenmaekers<sup>1</sup>, P. Hofman<sup>2</sup>, G. Bootsma<sup>3</sup>, M. Westenend<sup>4</sup>, M. De Booi<sup>3</sup>, W. Schreurs<sup>5</sup>, R. Houben<sup>6</sup>, D. De Ruysscher<sup>7</sup>, A.-M. Dingemans<sup>8</sup>, L. Hendriks<sup>8</sup>, <sup>1</sup>Academisch Ziekenhuis Maastricht (AZM), Maastricht, NL, <sup>2</sup>MUMC, Maastricht, NL, <sup>3</sup>Zuyderland Medical Center - Heerlen, Heerlen, NL, <sup>4</sup>Viercurie hospital Venlo, Venlo, NL, <sup>5</sup>Zuyderland hospital Heerlen, Heerlen, NL, <sup>6</sup>Maastricht, Maastricht, NL, <sup>7</sup>Maastricht University Medical Centre (MUMC)-MAASTRO clinic, Maastricht, NL, <sup>8</sup>Maastricht University Medical Center (MUMC), Maastricht, NL

15:40 - 15:50 **Invited Discussant 1667PD and 1365PD**  
C. Le Pechoux, Institut Gustave Roussy, Villejuif, FR

15:50 - 15:55 **Q&A led by Discussant**

14:45 - 16:15	<b>Type: Educational session</b> <b>Title: Revisiting systemic therapy in HNSCC in the era of immunotherapy</b> Chair(s): Ana Filipa Castro, PT; Ezra Cohen, US	<b>ICM - Room 13</b>
---------------	---	--------------------------

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **New data from randomised studies in recurrent metastatic setting**  
M. Merlano, Azienda Ospedaliera St. Croce e Carle, Cuneo, IT

15:10 - 15:35 **Management of toxicities**  
A.F. Castro, Lenitudes Medical Center & Research, Espargo, PT

15:35 - 16:00 **Patients selection**  
I. Braña Garcia, Vall d'Hebron University Hospital, Barcelona, ES

**14:45 - 16:15**    **Type: Educational session**    **Hall B3 - Room 21**  
**Title: Sarcomas as a key foundation for molecular-targeted basket trials**  
 Chair(s): George D. Demetri, US; Sebastian Bauer, DE

14:45 - 14:45    **Session DOI**

14:45 - 15:10    **Targeting translocations in sarcomas: From EWS to NTRK-translocated sarcomas**  
G. Demetri, Dana-Farber Cancer Institute, Boston, US

15:10 - 15:35    **A basket of epigenetic changes in sarcomas: EZH2 inhibitor development and targeting the SWI/SNF complex in synovial sarcomas**  
R. Jones, Royal Marsden Hospital NHS Foundation Trust, London, GB

15:35 - 16:00    **Current and emerging spectra of kinase targeting: From PDGFRA in STS to mTOR in PEComas**  
S. Bauer, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

16:00 - 16:15    **Discussion**

**14:45 - 16:15**    **Type: Proffered Paper session**    **Hall B3 - Room 20**  
**Title: Proffered paper session - Supportive and palliative care**  
 Chair(s): Karin Jordan, DE; Jorn Herrstedt, DK

14:45 - 14:45    **Session DOI**

14:45 - 14:57    **16810 - Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLs) adherence based on real-world prescribing data**

M. Aapro<sup>1</sup>, F. Scotté<sup>2</sup>, Y. Escobar<sup>3</sup>, L. Celio<sup>4</sup>, R. Berman<sup>5</sup>, A. Franceschetti<sup>6</sup>, D. Bell<sup>7</sup>, K. Jordan<sup>8</sup>, <sup>1</sup>Clinique de Genolier, Genolier, CH, <sup>2</sup>Hopital Foch, Suresnes, FR, <sup>3</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>4</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>5</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>6</sup>Ipsos MORI, London, GB, <sup>7</sup>Ipsos Healthcare, Mahwah, US, <sup>8</sup>University of Heidelberg, Heidelberg, DE

14:57 - 15:09    **16820\_PR - Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced diarrhea in cancer patients receiving fluropyrimidines and/or irinotecan based therapy**

A. Sharma<sup>1</sup>, S. Chaudhary<sup>2</sup>, V. Raina<sup>2</sup>, N. Shukla<sup>2</sup>, V. Sreenivas<sup>3</sup>, S. Prakash<sup>3</sup>, P. Priyatma<sup>3</sup>, S. Bharti<sup>3</sup>, <sup>1</sup>All India Institute of Medical Sciences, new delhi, IN, <sup>2</sup>B.R.

Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN, <sup>3</sup>All India Institute of Medical Sciences, New Delhi, IN

15:09 - 15:24 **Invited Discussant 16810 and 16820**

J. Herrstedt, University Hospital Zealand, Roskilde, DK

15:24 - 15:36 **15110 - Training oncologists and preparing patients for shared decision making about palliative systemic treatment: results from the randomized controlled CHOICE study**

H. Van Laarhoven<sup>1</sup>, I. Henselmans<sup>2</sup>, P. Van Maarschalkerweerd<sup>2</sup>, H. De Haes<sup>2</sup>, D. Sommeijer<sup>2</sup>, P.B. Ottevanger<sup>3</sup>, H.-B. Fiebrich<sup>3</sup>, S. Dohmen<sup>4</sup>, G.-J. Creemers<sup>5</sup>, F. De Vos<sup>6</sup>, E. Smets<sup>7</sup>, <sup>1</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL, <sup>2</sup>Academic Medical Center, Amsterdam, NL, <sup>3</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>4</sup>Bovenij Hospital, Amsterdam, NL, <sup>5</sup>Catharina Hospital Eindhoven, Eindhoven, NL, <sup>6</sup>University Hospital Utrecht, Utrecht, NL, <sup>7</sup>Academic Medical Center (AMC), Amsterdam, NL

15:36 - 15:48 **15120 - Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data**

M. Gensheimer<sup>1</sup>, A. Henry<sup>1</sup>, D. Wood<sup>1</sup>, T. Hastie<sup>1</sup>, S. Aggarwal<sup>1</sup>, S. Dudley<sup>1</sup>, P. Pradhan<sup>1</sup>, I. Banerjee<sup>1</sup>, E. Cho<sup>2</sup>, K. Ramchandran<sup>1</sup>, E. Pollom<sup>1</sup>, A. Koong<sup>1</sup>, D. Rubin<sup>1</sup>, D. Chang<sup>1</sup>, <sup>1</sup>Stanford University School of Medicine, Stanford, US, <sup>2</sup>Genentech, South San Francisco, US

15:48 - 16:00 **15390 - Posttraumatic Growth and Death anxiety in Caregivers of Cancer Patients: PHOENIX Study**

A. Alkan<sup>1</sup>, E.B. Köksoy<sup>2</sup>, E. Karıcı<sup>3</sup>, H. Burgaç<sup>4</sup>, A. Arıkanoğlu Soğancı<sup>4</sup>, D. Yaman<sup>4</sup>, F. Çay Şenler<sup>5</sup>, <sup>1</sup>Osmanyie Devlet Hastanesi - Osmaniye Public Hospital, Osmaniye, TR, <sup>2</sup>Kastamonu Public Hospital, Kastamonu, TR, <sup>3</sup>Bağcılar Education and Research Hospital, İstanbul, TR, <sup>4</sup>Osmaniye Public Hospital, Osmaniye, TR, <sup>5</sup>Ankara University School of Medicine, İstanbul, TR

16:00 - 16:15 **Invited Discussant 15120 and 15390**

L. Travado, Champalimaud Foundation Cancer Center, Lisbon, PT



**14:45 - 16:15**    **Type: Special Symposium**    **Hall B3 - Room 22**  
**Title: Emerging therapies in neuroendocrine and endocrine malignancies**  
 Chair(s): Marianne Pavel, DE; Eric Baudin, FR

14:45 - 14:45    **Session DOI**

14:45 - 14:50    **Introduction**

M. Pavel, Universitätsklinik Erlangen, Erlangen, DE

14:50 - 15:05    **Immunotherapy in NETs: Where are we now?**

K. Oeberg, University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE

15:05 - 15:20    **Novel targeted therapies in NETs**

R. Garcia-Carbonero, University Hospital 12 De Octubre, Madrid, ES

15:20 - 15:35    **Novel targeted therapies in thyroid carcinoma**

S. Leboulleux, Gustave Roussy, Villejuif, FR

15:35 - 15:50    **Novel therapies in adrenal malignancies**

M. Fassnacht, University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), Würzburg, DE

15:50 - 16:05    **Novel approaches in mixed adenoneuroendocrine carcinoma**

A. Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

16:05 - 16:15    **Conclusions and clinical perspectives**

E. Baudin, Gustave Roussy Institut de Cancérologie, Villejuif, FR

<b>14:45 - 16:15</b>	<b>Type: EONS session</b> <b>Title: The essential elements of safety standards for systemic cancer therapies</b> Chair(s): Theresa Wiseman, GB	<b>Hall B4 - Room 24</b>
14:45 - 14:45	<b>Session DOI</b>	
14:45 - 15:00	<b>The pharmacist's perspective</b> <u>K. Meier</u> , European Society of Oncology Pharmacy (ESOP), Hamburg, DE	
15:00 - 15:15	<b>The oncologist's perspective</b> <u>F. Overkamp</u> , OncoConsult.Hamburg, Hamburg, DE	
15:15 - 15:30	<b>The nurse manager's perspective</b> <u>C. Lacerda</u> , European Oncology Nursing Society - EONS, London, GB	
15:30 - 15:45	<b>The clinical nurse's perspective</b> <u>H. Titzer</u> , Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT	
15:45 - 16:00	<b>The patient's perspective</b> <u>M. Järvinen</u> , Association of Cancer Patients in Finland, Helsinki, FI	
16:00 - 16:15	<b>Discussion</b>	

<b>14:45 - 16:15</b>	<b>Type: Special session</b> <b>Title: Are there enough cancer services and oncologists in your country?</b> Chair(s): Alexandru Eniu, RO; André Ilbawi, CH	<b>ICM - Room 14a</b>
14:45 - 14:45	<b>Session DOI</b>	
14:45 - 14:50	<b>Introduction</b> <u>A. Eniu</u> , Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, RO	
14:50 - 15:10	<b>Where does the world stand on global cancer control?</b> <u>A. Ilbawi</u> , WHO - World Health Organization, Geneva, CH	
15:10 - 15:30	<b>Tools that show how investing in cancer care pays off</b> <u>A. Ilbawi</u> , WHO - World Health Organization, Geneva, CH	
15:30 - 15:50	<b>How many patients can one oncologist care for?</b> <u>D. Trapani</u> , European Institute of Oncology, Milan, IT	
15:50 - 16:10	<b>WHO-ESMO Workforce Survey: How can your country assure enough oncologists for the future?</b> <u>D. Trapani</u> , European Institute of Oncology, Milan, IT	
16:10 - 16:15	<b>Conclusions</b> <u>R. Giuliani</u> , Azienda Ospedaliera S. Camillo Forlanini, Rome, IT	

**15:00 - 16:05**    **Type: Multidisciplinary interactive sessions**    **ICM - Room 14b**  
**Title: Locally advanced pancreatic cancer**  
 Chair(s): Michel Ducreux, FR

15:00 - 15:00    **Session DOI**

15:00 - 15:05    **Case presentation**

M. Ducreux, Gustave Roussy Cancer Campus Grand Paris, Villejuif, FR

15:05 - 15:15    **The surgical point of view: What is resectable?**

A. Sa Cunha, Universite Paris Sud, Orsay, FR

15:15 - 15:25    **The radiation oncologist's point of view**

M. Verheij, Radboud University Medical Centre Nijmegen, Nijmegen, NL

15:25 - 15:35    **The medical oncologist's point of view**

M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

15:35 - 16:05    **Discussion**

**15:00 - 16:00**    **Type: Multidisciplinary interactive sessions**    **Hall A1 - Room 16**  
**Title: Management of toxicities of immunotherapy**  
 Chair(s): James Larkin, GB

15:00 - 15:00    **Session DOI**

15:00 - 15:10    **GI toxicity**

H. Gogas, Laiko General Hospital of Athens, Athens, GR

15:10 - 15:20    **Neurotoxicity**

C. Robert, Institut Gustave Roussy, Villejuif, FR

15:20 - 15:30    **How to treat beyond acute toxicity**

J. Larkin, Royal Marsden Hospital NHS Foundation Trust, London, GB

15:30 - 16:00    **Discussion**



**15:00 - 16:00** **Type: Special session** **Hall B3 - Room 23**  
**Title: Precision medicine in daily practice: Recommendations from the ESMO Precision Medicine Working Group**  
 Chair(s): Fabrice André, FR

15:00 - 15:00 **Session DOI**

15:00 - 15:05 **Multigene sequencing for hard-to-treat cancers**  
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

15:05 - 15:20 **A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)**  
J. Mateo, The Institute of Cancer Research, London, GB

15:20 - 15:35 **Detecting MSI and TRK fusion using NGS: ESMO recommendations**  
J. Reis-Filho, Memorial Sloan-Kettering Cancer Center, New York, US

15:35 - 15:50 **How to handle with genetic variants detected by multigene sequencing in practice**  
A. George, Royal Marsden Hospital NHS Foundation Trust, London, GB

15:50 - 16:00 **Discussion**

**16:30 - 18:10** **Type: Proffered Paper session** **Hall A2 - Room 18**  
**Title: Presidential Symposium 2**  
 Chair(s): Josep Tabernero, ES; Fortunato Ciardiello, IT

16:30 - 16:30 **Session DOI**

16:30 - 16:45 **LBA4 - Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer**  
A. Hoyle<sup>1</sup>, S.A. Ali<sup>2</sup>, N. James<sup>3</sup>, C. Parker<sup>4</sup>, A. Cook<sup>5</sup>, G. Attard<sup>6</sup>, S. Chowdhury<sup>7</sup>, W. Cross<sup>8</sup>, D. Dearnaley<sup>9</sup>, J. De Bono<sup>9</sup>, C. Gilson<sup>5</sup>, S. Gillessen<sup>1</sup>, R. Jones<sup>10</sup>, D. Matheson<sup>11</sup>, M. Mason<sup>12</sup>, A. Ritchie<sup>5</sup>, M. Russell<sup>13</sup>, M. Parmar<sup>11</sup>, M. Sydes<sup>5</sup>, N. Clarke<sup>14</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Genito-Urinary Cancer Research Group Manchester Cancer Research Centre The University of Manchester, Manchester, GB, <sup>3</sup>Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB, <sup>4</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>5</sup>Institute of Clinical Trials and Methodology-UCL, London, GB, <sup>6</sup>The Institute of Cancer Research and The Royal Marsden, London, GB, <sup>7</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>8</sup>LIMM - Leeds Institute of Molecular Medicine, Leeds, GB, <sup>9</sup>The Institute of Cancer Research (ICR), London, GB, <sup>10</sup>University

of Glasgow, Glasgow, GB, <sup>11</sup>MRC Clinical Trials Unit at UCL, London, GB, <sup>12</sup>Velindre Cancer Centre Velindre Hospital, Cardiff, GB, <sup>13</sup>Raigmore Hospital, Inverness, GB, <sup>14</sup>The Christie and Salford Royal Hospitals, Manchester, GB

16:45 - 16:55 **Invited discussant**

K. Fizazi, Gustave Roussy, Villejuif, FR

16:55 - 17:10 **LBA5\_PR - Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476)**

C. Parker<sup>1</sup>, N. James<sup>2</sup>, C. Brawley<sup>3</sup>, N. Clarke<sup>4</sup>, G. Attard<sup>5</sup>, S. Chowdhury<sup>6</sup>, W. Cross<sup>7</sup>, D. Dearnaley<sup>8</sup>, C. Gilson<sup>3</sup>, R. Jones<sup>9</sup>, M. Mason<sup>10</sup>, R. Millman<sup>11</sup>, S. Gillissen<sup>12</sup>, C. Eswar<sup>13</sup>, J. Gale<sup>14</sup>, J. Lester<sup>10</sup>, D. Sheehan<sup>15</sup>, A. Tran<sup>12</sup>, M. Parmar<sup>16</sup>, M. Sydes<sup>3</sup>, <sup>1</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>2</sup>Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB, <sup>3</sup>Institute of Clinical Trials and Methodology-UCL, London, GB, <sup>4</sup>The Christie and Salford Royal Hospitals, Manchester, GB, <sup>5</sup>The Institute of Cancer Research and The Royal Marsden, London, GB, <sup>6</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>7</sup>LIMM - Leeds Institute of Molecular Medicine, Leeds, GB, <sup>8</sup>The Institute of Cancer Research (ICR), London, GB, <sup>9</sup>University of Glasgow, Glasgow, GB, <sup>10</sup>Velindre Cancer Centre Velindre Hospital, Cardiff, GB, <sup>11</sup>Medical Research Council - MRC Clinical Trials Unit, London, GB, <sup>12</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>13</sup>The Clatterbridge Cancer Centre, Liverpool, GB, <sup>14</sup>St. Mary's Hospital Portsmouth Oncology Centre, Portsmouth, GB, <sup>15</sup>Royal Devon and Exeter Hospital, Devon, GB, <sup>16</sup>MRC Clinical Trials Unit at UCL, London, GB

17:10 - 17:20 **Invited discussant**

R. Bristow, Cancer Research UK Manchester Institute, Manchester, GB

17:20 - 17:35 **LBA6\_PR - JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)**

R. Motzer<sup>1</sup>, K. Penkov<sup>2</sup>, J. Haanen<sup>3</sup>, B. Rini<sup>4</sup>, L. Albiges<sup>5</sup>, M. Campbell<sup>6</sup>, C. Kollmannsberger<sup>7</sup>, S. Negrier<sup>8</sup>, M. Uemura<sup>9</sup>, J.L. Lee<sup>10</sup>, H. Gurney<sup>11</sup>, R. Berger<sup>12</sup>, M. Schmidinger<sup>13</sup>, J. Larkin<sup>14</sup>, M. Atkins<sup>15</sup>, J. Wang<sup>16</sup>, P. Robbins<sup>17</sup>, A. Chudnovsky<sup>16</sup>, A. Di Pietro<sup>18</sup>, T. Choueiri<sup>19</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>Euromedservice, St. Petersburg, RU, <sup>3</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>4</sup>Cleveland Clinic, Cleveland, US, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>7</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>8</sup>Centre Léon Bérard, Lyon, FR, <sup>9</sup>Osaka University Hospital, Osaka, JP, <sup>10</sup>University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, <sup>11</sup>Macquarie University, Macquarie Park, AU, <sup>12</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>13</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>14</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>15</sup>Lombardi Cancer Center Georgetown University, Washington DC, US, <sup>16</sup>Pfizer, Cambridge, US, <sup>17</sup>Pfizer, San Diego, US, <sup>18</sup>Pfizer, Milan, IT, <sup>19</sup>The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, US

17:35 - 17:45 **Invited discussant**

V. Grünwald, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

17:45 - 18:00 **LBA7\_PR - Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial**

K. Moore<sup>1</sup>, N. Colombo<sup>2</sup>, G. Scambia<sup>3</sup>, B.-G. Kim<sup>4</sup>, A. Oaknin<sup>5</sup>, M. Friedlander<sup>6</sup>, A. Lisyanskaya<sup>7</sup>, A. Floquet<sup>8</sup>, A. Leary<sup>9</sup>, G. Sonke<sup>10</sup>, C. Gourley<sup>11</sup>, S. Banerjee<sup>12</sup>, A. Oza<sup>13</sup>, A. González-Martín<sup>14</sup>, C. Aghajanian<sup>15</sup>, W. Bradley<sup>16</sup>, E. Lowe<sup>17</sup>, R. Bloomfield<sup>18</sup>, P. Disilvestro<sup>19</sup>, <sup>1</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>2</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Policlinico Universitario A. Gemelli, Roma, IT, <sup>4</sup>Samsung Medical Center, Seoul, KR, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>Prince of Wales Hospital, Randwick, AU, <sup>7</sup>St Petersburg City Oncology Dispensary, St Petersburg, RU, <sup>8</sup>Institute Bergonié, Bordeaux, FR, <sup>9</sup>Institut Gustave Roussy, Villejuif, FR, <sup>10</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>11</sup>Edinburgh Cancer Research UK Centre, Edinburgh, GB, <sup>12</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>13</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>14</sup>Clinica Universidad de Navarra, formerly of MD Anderson International España, Madrid, ES, <sup>15</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>16</sup>Froedtert and the Medical College of Wisconsin, Milwaukee, US, <sup>17</sup>AstraZeneca, Gaithersburg, US, <sup>18</sup>AstraZeneca, Cambridge, GB, <sup>19</sup>Women and Infants Hospital, Providence, US

18:00 - 18:10 **Invited discussant**

J. Ledermann, University College London Cancer Institute, London, GB

16:30 - 18:00	<b>Type: Educational session</b> <b>Title: Unresolved questions in melanoma</b> Chair(s): Marisol Soengas, ES; Helen Gogas, GR	<b>ICM - Room 1</b>
---------------	--	---------------------

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **Emerging prognostic factors in primary melanoma**

P. Lorigan, The Christie NHS Foundation Trust, Manchester, GB

16:55 - 17:20 **Treatment in advanced melanoma patients with a worse prognosis**

R. Dummer, Universitätsspital Zürich, Zurich, CH

17:20 - 17:45 **Patient treatment resistance in melanoma**

J. Haanen, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

17:45 - 18:00 **Discussion**

**16:30 - 17:30**    **Type: Multidisciplinary interactive sessions**    **Hall A1 - Room 16**  
**Title: Molecular tumour boards in the practice of precision oncology**

Chair(s): Pierre Saintigny, FR

16:30 - 16:30    **Session DOI**

16:30 - 16:40    **The clinician's perspective**

D. Planchard, Institut Gustave Roussy, Villejuif, FR

16:40 - 16:50    **The bioinformatician's perspective**

F. Mancuso, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

16:50 - 17:00    **The germline genetician's perspective**

M. Krebs, The Christie NHS Foundation Trust, Manchester, GB

17:00 - 17:20    **Discussion**

**16:30 - 17:45**    **Type: Poster Discussion session**    **Hall B3 - Room 21**  
**Title: Poster Discussion session - Haematological malignancies**

Chair(s): Marion Subklewe, DE; Andres Ferreri, IT; Michele Ghilmini, CH

16:30 - 16:30    **Session DOI**

16:30 - 16:30    **1008PD - CD13 and CD33 CAR-T cells for the treatment of myeloid malignancies.**

K. Lee<sup>1</sup>, K. Gowrishankar<sup>2</sup>, D. Gottlieb<sup>1</sup>, E. Blyth<sup>1</sup>, K. Micklethwaite<sup>1</sup>, <sup>1</sup>Westmead Hospital, Westmead, AU, <sup>2</sup>Westmead institute for medical research, Westmead, AU

16:30 - 16:30    **1009PD - The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS**

H. Medyouf<sup>1</sup>, I. Tirado-Gonzalez<sup>1</sup>, A. Mies<sup>2</sup>, A. Nevmerzhitskaya<sup>3</sup>, A.-S. Kubasch<sup>2</sup>, U. Platzbecker<sup>4</sup>, <sup>1</sup>Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, DE, <sup>2</sup>TU Dresden, Dresden, DE, <sup>3</sup>Georg-Speyer-Haus, Frankfurt am Main, DE, <sup>4</sup>Universitätsklinikum Dresden, Dresden, DE

16:30 - 16:45    **Invited Discussant 1008PD and 1009PD**

M. Subklewe, LMU Klinikum der Universität München, Munich, DE

16:45 - 16:55    **Q&A led by Discussant**



- 16:55 - 16:55 **1010PD - ALK positive Anaplastic large cell lymphoma: molecular diagnosis and minimal residual disease monitoring**  
M. Kalinova<sup>1</sup>, L. Krskova<sup>2</sup>, M. Mrhalova<sup>1</sup>, E. Kabickova<sup>2</sup>, P. Riha<sup>2</sup>, R. Kodet<sup>2</sup>, <sup>1</sup>Motol University Hospital, Prague, CZ, <sup>2</sup>2nd Faculty of Medicine Motol University Hospital, Prague, CZ
- 16:55 - 16:55 **1011PD - Intensified 14 day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.**  
J. Sandoval-Sus<sup>1</sup>, S. Dalia<sup>2</sup>, R. Mhaskar<sup>3</sup>, J. Chavez<sup>4</sup>, A. Ausekar<sup>5</sup>, K. Purnapatre<sup>5</sup>, J. Scheiber<sup>5</sup>, L. Sokol<sup>4</sup>, <sup>1</sup>Moffitt Cancer Center, Pembroke Pines, US, <sup>2</sup>Mercy Clinic, Joplin, US, <sup>3</sup>University of South Florida, Tampa, US, <sup>4</sup>Moffitt Cancer Center, Tampa, US, <sup>5</sup>Personome, Munich, DE
- 16:55 - 16:55 **1012PD - Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice**  
M. Dreyling<sup>1</sup>, G. Hess<sup>2</sup>, M. Woike<sup>3</sup>, G. Krekeler<sup>4</sup>, <sup>1</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>2</sup>Universitätsmedizin der Johannes Gutenberg-Universität, Mainz, DE, <sup>3</sup>No place of work provided, No City Provided, NA, <sup>4</sup>Pfizer - Germany, Berlin, DE
- 16:55 - 16:55 **1013PD - A comparative study of 18F-FDG PET/CT with bilateral bone marrow trephine biopsy for assessment of bone marrow infiltration by lymphoma**  
D. Arjunan<sup>1</sup>, G. Prakash<sup>2</sup>, P. Malhotra<sup>2</sup>, N. Varma<sup>2</sup>, S. Varma<sup>2</sup>, A. Das<sup>1</sup>, B. Mittal<sup>3</sup>, R. Basher<sup>3</sup>, D. Lad<sup>2</sup>, S. Kumari<sup>2</sup>, A. Khadwal<sup>2</sup>, S. Vikas<sup>2</sup>, S. Naseem<sup>3</sup>, A. Bal<sup>3</sup>, <sup>1</sup>PGIMER, Chandigarh, Chandigarh, IN, <sup>2</sup>PGIMER, Chandigarh, IN, <sup>3</sup>Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, IN
- 16:55 - 17:10 **Invited Discussant 1010PD, 1011PD, 1012PD and 1013PD**  
A. Ferreri, IRCCS Ospedale San Raffaele, Milan, IT
- 17:10 - 17:20 **Q&A led by Discussant**
- 17:20 - 17:20 **1014PD - Phase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies**  
W. Jurczak<sup>1</sup>, S. Rule<sup>2</sup>, W. Townsend<sup>3</sup>, D. Tucker<sup>2</sup>, B. Sarholz<sup>4</sup>, J. Scheele<sup>4</sup>, J. Gribben<sup>5</sup>, P. Zinzani<sup>6</sup>, <sup>1</sup>Jagiellonian University, Krakow, PL, <sup>2</sup>Plymouth University, Plymouth, GB, <sup>3</sup>National Institute of Health Research/University College London Hospitals Clinical Research Facility, London, GB, <sup>4</sup>Merck KGaA, Darmstadt, DE, <sup>5</sup>Barts Hospital Cancer Institute, London, GB, <sup>6</sup>University of Bologna, Bologna, IT
- 17:20 - 17:20 **1015PD - A prospective study of first-line Helicobacter pylori eradication therapy**

**in treating localized extragastric mucosa-associated lymphoid tissue lymphoma**

S.-H. Kuo, M. Yao, C.-H. Tsai, C.-W. Lin, J.-M. Liou, W.-L. Ma, A.-L. Cheng, National Taiwan University Hospital, Taipei, TW

17:20 - 17:20 **1016PD - Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma; a preliminary analysis of a multicenter, prospective phase II study (BRiZ2012).**

M. Kanno<sup>1</sup>, K. Miura<sup>2</sup>, Y. Masaki<sup>3</sup>, H. Tsujimura<sup>4</sup>, M. Iino<sup>5</sup>, J. Takizawa<sup>6</sup>, Y. Maeda<sup>7</sup>, K. Yamamoto<sup>8</sup>, S. Tamura<sup>9</sup>, A. Yoshida<sup>10</sup>, H. Yagi<sup>11</sup>, I. Yoshida<sup>12</sup>, K. Kitazume<sup>13</sup>, T. Masunari<sup>14</sup>, I. Choi<sup>15</sup>, Y. Kakinoki<sup>16</sup>, T. Yoshino<sup>17</sup>, S. Nakamura<sup>18</sup>, T. Yoshida<sup>19</sup>, <sup>1</sup>Nara Medical University Hospital, Kashihara, JP, <sup>2</sup>Nihon University School of Medicine, Tokyo, JP, <sup>3</sup>Kanazawa Medical University, Ishikawa, JP, <sup>4</sup>Chiba Cancer Center Hospital, Chiba, JP, <sup>5</sup>Yamanashi Prefectural Central Hospital, Kofu, JP, <sup>6</sup>Niigata University Faculty of Medicine, Niigata, JP, <sup>7</sup>Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JP, <sup>8</sup>Okayama City Hospital, Okayama, JP, <sup>9</sup>Kinan Hospital, Minamimure, JP, <sup>10</sup>Toyama Prefectural Central Hospital, Toyama, JP, <sup>11</sup>Kinki University Nara Hospital, Ikoma, JP, <sup>12</sup>National Hospital Organization, Shikoku Cancer Center, Matsuyama, JP, <sup>13</sup>Showa General Hospital, Tokyo, JP, <sup>14</sup>Chugoku Central Hospital, Fukuyama, JP, <sup>15</sup>National Hospital Organization, Kyushu Cancer Center, Fukuoka, JP, <sup>16</sup>Asahikawa City Hospital, Asahikawa, JP, <sup>17</sup>Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, JP, <sup>18</sup>Nagoya University Graduate School of Medicine, Nagoya, JP, <sup>19</sup>Society of Lymphoma Treatment in Japan, Kanazawa, JP

17:20 - 17:35 **Invited Discussant 1014PD, 1015PD and 1016PD**

M. Ghilmini, IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH

17:35 - 17:45 **Q&A led by Discussant**

**16:30 - 18:00**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Improving communication in cancer nursing**  
Chair(s): Patrick Crombez, BE

16:30 - 16:30    **Session DOI**

16:30 - 16:50    **How to communicate well with people with advanced disease**  
E. Patiraki, National and Kapodistrian University of Athens, Athens, GR

16:50 - 17:10    **Be silent, or say something better than silence**  
E. Masel, Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

17:10 - 17:30    **Dealing with impending death in young adult cancer patients: How to communicate and offer effective support in practice**  
M. Bisset, University College London Hospital, London, GB

17:30 - 18:00    **Discussion**

<b>16:30 - 18:30</b>	<b>Type: Special session</b> <b>Title: Improving research, education and clinical practice in oncology and palliative care - 5th ESMO Designated Centres Community Session and Awards</b> Chair(s): Stein Kaasa, NO; Gudrun Kreye, AT	<b>ICM - Room 14a</b>
16:30 - 16:30	<b>Session DOI</b>	
16:30 - 16:40	<b>Can we arrive at common research projects?</b> S. Kaasa, Oslo University Hospital, Oslo, NO	
16:40 - 16:55	<b>Education of palliative care specialists in oncology and palliative care to oncologists</b> J. Wood, Royal Marsden Hospital NHS Foundation Trust, London, GB	
16:55 - 17:00	<b>How can the designated centers and ESMO collaborate? - Discussion</b>	
17:00 - 17:15	<b>What is specialised cancer palliative care? Professional competences needed and how to organise the services?</b> C. Zimmermann, Princess Margaret Cancer Center, Toronto, CA	
17:15 - 17:20	<b>What are the standards? - Discussion</b>	
17:20 - 17:50	<b>Panel Discussion - Future of the DC Programme how can we improve in research, education and standards of organization?</b> S. Kaasa <sup>1</sup> , G. Kreye <sup>2</sup> , R. Catane <sup>3</sup> , F. Strasser <sup>4</sup> , J.H. Loge <sup>1</sup> , <sup>1</sup> Oslo University Hospital, Oslo, NO, <sup>2</sup> Universitätsklinikum Krems, Krems, AT, <sup>3</sup> Chaim Sheba Medical Center, Ramat Gan, IL, <sup>4</sup> Kantonsspital St. Gallen, St. Gallen, CH	
17:50 - 18:00	<b>Conclusions</b> G. Kreye, Universitätsklinikum Krems, Krems, AT	
18:00 - 18:30	<b>Designated Centre and Palliative Care Fellowship Awards</b> G. Kreye, Universitätsklinikum Krems, Krems, AT	
<b>16:45 - 17:45</b>	<b>Type: Poster Discussion session</b> <b>Title: Poster Discussion session - Gastrointestinal tumours, colorectal 2</b> Chair(s): Silvia Marsoni, IT; Richard Adams, GB	<b>ICM - Room 14b</b>
16:45 - 16:45	<b>Session DOI</b>	



- 16:45 - 16:45 **456PD - Serial circulating tumor DNA analysis for detection of residual disease, assessment of adjuvant therapy efficacy and for early recurrence detection in colorectal cancer**  
T. Reinert<sup>1</sup>, T. Henriksen<sup>1</sup>, M. Rasmussen<sup>1</sup>, H. Sethi<sup>2</sup>, R. Salari<sup>2</sup>, S. Shchegrova<sup>3</sup>, R. Swenerton<sup>2</sup>, H.-T. Wu<sup>2</sup>, S. Sharma<sup>2</sup>, E. Christensen<sup>1</sup>, P. Natarajan<sup>3</sup>, S. Dashner<sup>3</sup>, T. Tin<sup>3</sup>, A. Olson<sup>4</sup>, H. Pawar<sup>4</sup>, B. Zimmermann<sup>4</sup>, L. Iversen<sup>1</sup>, M. Madsen<sup>5</sup>, J. Lin<sup>4</sup>, C. Andersen<sup>1</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Natera Inc., San Carlos, US, <sup>3</sup>Natera Inc, San Carlos, US, <sup>4</sup>Natera, San Carlos, US, <sup>5</sup>Herning Regional Hospital, Herning, DK
- 16:45 - 16:45 **457PD - Kinase Fusions in Colorectal Cancers: A Unique Biologic Subset**  
R. Madison<sup>1</sup>, F. Pietrantonio<sup>2</sup>, L. Juckett<sup>1</sup>, C. Cremolini<sup>3</sup>, J. Chung<sup>4</sup>, L. Albacker<sup>5</sup>, V. Miller<sup>4</sup>, S. Klempner<sup>6</sup>, M. Resnick<sup>7</sup>, E. Yakirevich<sup>7</sup>, S.-H. Ou<sup>8</sup>, M. Fakih<sup>9</sup>, A. Schrock<sup>4</sup>, J. Ross<sup>10</sup>, S. Ali<sup>4</sup>, <sup>1</sup>Foundation Medicine, Cambridge, US, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, <sup>4</sup>Foundation Medicine, Inc., Cambridge, US, <sup>5</sup>Foundation Medicine, Inc., Cambridge, MA, US, <sup>6</sup>The Angeles Clinic and Research Institute, Los Angeles, US, <sup>7</sup>Rhode Island Hospital & Alpert Medical School of Brown University, Providence, US, <sup>8</sup>Chao Family Comprehensive Cancer Center, Irvine, US, <sup>9</sup>City of Hope, Duarte, US, <sup>10</sup>Foundation Medicine Inc., Cambridge, US
- 16:45 - 16:45 **LBA24 - A Multi-Omic Analysis for Prospective Patient Stratification in Localised Colorectal Cancer (CRC).**  
N. Tarazona Llavero<sup>1</sup>, E. Fontana<sup>2</sup>, V. Gambardella<sup>3</sup>, F. Gimeno-Valiente<sup>3</sup>, J. Castillo<sup>3</sup>, A. Calon<sup>4</sup>, C. Martínez-Ciarpaglini<sup>3</sup>, L. Peiró-Chova<sup>3</sup>, M. Huerta<sup>3</sup>, S. Zuñiga<sup>3</sup>, P. Rentero-Garrido<sup>3</sup>, J. Montón-Bueno<sup>3</sup>, D. Roda<sup>3</sup>, S. Roselló<sup>3</sup>, B. Bellosillo<sup>4</sup>, A. Vivancos<sup>5</sup>, G. Nyamundana<sup>6</sup>, C. Montagut<sup>4</sup>, A. Sadanandam<sup>6</sup>, A. Cervantes<sup>1</sup>, <sup>1</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>2</sup>The Institute of Cancer Research, NG, GB, <sup>3</sup>Biomedical Research Institute INCLIVA, Valencia, ES, <sup>4</sup>Hospital del Mar-IMIM, Barcelona, ES, <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>6</sup>The Institute of Cancer Research, London, GB
- 16:45 - 16:45 **458PD - Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1\_) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)**  
R. Das<sup>1</sup>, L. Furchtgott<sup>1</sup>, F.-S. Ou<sup>2</sup>, D. Swanson<sup>3</sup>, B. Hayete<sup>1</sup>, B. Harms<sup>1</sup>, D. Cunha<sup>1</sup>, J. Latourelle<sup>1</sup>, D. Wuest<sup>1</sup>, I. Khalil<sup>1</sup>, C. Washburn<sup>1</sup>, K. Rich<sup>1</sup>, C. Blanke<sup>4</sup>, J. Meyerhardt<sup>5</sup>, D. Niedzwiecki<sup>6</sup>, A. Nixon<sup>6</sup>, E. O'Reilly<sup>7</sup>, F. Innocenti<sup>8</sup>, H.-J. Lenz<sup>9</sup>, A. Venook<sup>10</sup>, <sup>1</sup>GNS Healthcare, Inc, Cambridge, MA, US, <sup>2</sup>Mayo Clinic, Rochester, US, <sup>3</sup>Oslo University Hospital, Oslo, NO, <sup>4</sup>Oregon Health Science University, Portland, US, <sup>5</sup>Dana-Farber Cancer Institute, Boston, US, <sup>6</sup>Duke University Medical Center, Durham, US, <sup>7</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>8</sup>UNC-Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, US, <sup>9</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>10</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 16:45 - 17:00 **Invited Discussant 456PD, 457PD, LBA24 and 458PD**  
S. Marsoni, IRCCS Istituto di Candiolo, Candiolo, IT

17:00 - 17:15 **Q&A led by Discussant**

17:15 - 17:15 **459PD - Long-term Results of Postoperative Chemoradiation Therapy With Capecitabine and Oxaliplatin Versus Capecitabine Alone for Locally Advanced Rectal Cancer: A Randomized, Multicenter, Phase 3 Trial**

N. Li<sup>1</sup>, J. Jin<sup>2</sup>, Y. Li<sup>1</sup>, Y. Zhu<sup>3</sup>, W. Wang<sup>4</sup>, J. Wang<sup>5</sup>, Y. Feng<sup>3</sup>, L. Liu<sup>3</sup>, S. Wang<sup>1</sup>, Y. Song<sup>1</sup>, Y. Liu<sup>1</sup>, Y. Tang<sup>6</sup>, W. Liu<sup>1</sup>, H. Ren<sup>1</sup>, H. Fang<sup>1</sup>, <sup>1</sup>Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>2</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, <sup>3</sup>Cancer Hospital, Zhejiang Province, Hangzhou, CN, <sup>4</sup>Guizhou Cancer Hospital, Guiyang, CN, <sup>5</sup>Hebei Provincial Cancer Hospital, Shijiazhuang, CN, <sup>6</sup>Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN

17:15 - 17:15 **460PD - The value of chemotherapy in Stage II colon cancer: much less than we thought**

L. Wu<sup>1</sup>, J. Fu<sup>2</sup>, W. Fu<sup>3</sup>, J. Du<sup>2</sup>, L. Wang<sup>1</sup>, <sup>1</sup>2nd Affiliated Hospital of Zhejiang University University School of Medicine, Hangzhou, CN, <sup>2</sup>Zhejiang University Jinhua Hospital, Jinhua, CN, <sup>3</sup>Johns Hopkins University School of Medicine, Baltimore, US

17:15 - 17:15 **461PD - Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial)**

S. Pernot<sup>1</sup>, P. Artru<sup>2</sup>, D. Tougeron<sup>3</sup>, C. Montérymard<sup>4</sup>, D. Smith<sup>5</sup>, C. De La Fouchardière<sup>6</sup>, J.-L. Raoul<sup>7</sup>, L. Dahan<sup>8</sup>, R. Guimbaud<sup>9</sup>, P. Michel<sup>10</sup>, J.-L. Jouve<sup>11</sup>, O. Pellerin<sup>12</sup>, J. Taieb<sup>1</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>Hôpital privé Jean Mermoz, Lyon, FR, <sup>3</sup>CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR, <sup>4</sup>FFCD-, Dijon, FR, <sup>5</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>6</sup>Centre Léon Berard, LYON, FR, <sup>7</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>8</sup>CHU La Timone Enfants, Marseille, FR, <sup>9</sup>Institut Claudius Regaud, Toulouse, FR, <sup>10</sup>CHU Charles Nicolle, ROUEN, FR, <sup>11</sup>CHU Le Bocage (Dijon), Dijon, FR, <sup>12</sup>Hopital Européen Georges Pompidou, Paris, FR

17:15 - 17:15 **462PD - Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): post hoc analysis of the MOSAIC trial.**

E. Auclin<sup>1</sup>, T. Andre<sup>2</sup>, J. Taieb<sup>1</sup>, M. Banzi<sup>3</sup>, J.-L. Van Laethem<sup>4</sup>, J. Tabernero<sup>5</sup>, T. Hickish<sup>6</sup>, A. De Gramont<sup>7</sup>, D. Vernerey<sup>8</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>Sorbonne Université et Hôpital Saint-Antoine, Paris, FR, <sup>3</sup>arcispedale santa maria nuova-IRCCS, reggio emilia, IT, <sup>4</sup>Erasmus University Hospital-(Universite Libre de Bruxelles), Brussels, BE, <sup>5</sup>Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology VHIO., Barcelona, ES, <sup>6</sup>Royal Bournemouth Hospital and University, Bournemouth, GB, <sup>7</sup>Institut hospitalier Franco-Britannique, Levallois Perret, FR, <sup>8</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR

17:15 - 17:30 **Invited Discussant 459PD, 460PD, 461PD and 462PD**

R. Adams, Velindre Cancer Centre Velindre Hospital, Cardiff, GB

17:30 - 17:45 **Q&A led by Discussant**

**16:45 - 17:45** **Type: Poster Discussion session** **ICM - Room 13**  
**Title: Poster Discussion session - NSCLC, metastatic 2**  
 Chair(s): Simon Ekman, SE; Sanjay Popat, GB

16:45 - 16:45 **Session DOI**

16:45 - 16:45 **LBA62 - Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: data from KEYNOTE-407**

J. Mazieres<sup>1</sup>, D. Kowalski<sup>2</sup>, A. Luft<sup>3</sup>, D. Vicente<sup>4</sup>, A. Tafreshi<sup>5</sup>, M. Gümüş<sup>6</sup>, K. Laktionov<sup>7</sup>, B. Hermes<sup>8</sup>, I. Cicin<sup>9</sup>, J. Rodríguez-Cid<sup>10</sup>, J. Wilson<sup>11</sup>, T. Kato<sup>12</sup>, R. Ramlau<sup>13</sup>, S. Novello<sup>14</sup>, S. Reddy<sup>15</sup>, B. Piperdi<sup>16</sup>, X. Li<sup>16</sup>, T. Burke<sup>16</sup>, L. Paz-Ares<sup>17</sup>, <sup>1</sup>Hospital Larrey, Toulouse, FR, <sup>2</sup>Maria Skłodowska-Curie, Warsaw, PL, <sup>3</sup>Leningrad Regional, St. Petersburg, RU, <sup>4</sup>Hospital Universitario Virgen Macarena, Seville, ES, <sup>5</sup>Wollongong Oncology and University of Wollongong, Wollongong, AU, <sup>6</sup>Istanbul Medeniyet University Hospital, Istanbul, TR, <sup>7</sup>N.N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>8</sup>Universitätsklinikum Tübingen, Tübingen, DE, <sup>9</sup>Trakya University, Edirne, TR, <sup>10</sup>Oncology Center, Mexico City, MX, <sup>11</sup>Humber River Regional Hospital, Toronto, CA, <sup>12</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>13</sup>Poznan University of Medical Sciences, Poznan, PL, <sup>14</sup>University of Turin, Orbassano, IT, <sup>15</sup>Northside Hospital Cancer Institute, Atlanta, US, <sup>16</sup>Merck & Co., Inc., Kenilworth, US, <sup>17</sup>CNIO, Universidad Complutense and Ciberonc, Madrid, ES

16:45 - 16:45 **LBA63 - Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro)**

R.S. Herbst<sup>1</sup>, E. Garon<sup>2</sup>, D.-W. Kim<sup>3</sup>, B. Chul Cho<sup>4</sup>, J.L. Pérez Gracia<sup>5</sup>, J.-Y. Han<sup>6</sup>, C. Dubos Arvis<sup>7</sup>, M. Majem<sup>8</sup>, M. Forster<sup>9</sup>, I. Monnet<sup>10</sup>, S. Novello<sup>11</sup>, Z. Szalai<sup>12</sup>, M. Gubens<sup>13</sup>, W.-C. Su<sup>14</sup>, G.L. Ceresoli<sup>15</sup>, A. Samkari<sup>16</sup>, E. Jensen<sup>17</sup>, G. Lubiniecki<sup>17</sup>, P. Baas<sup>18</sup>, <sup>1</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>2</sup>Los Angeles, Santa Monica, US, <sup>3</sup>University Hospital, Seoul, KP, <sup>4</sup>Yonsei Cancer Center, Seoul, KP, <sup>5</sup>Clinica Universidad de Navarra, Pamplona, ES, <sup>6</sup>National Cancer Center (Korea), Goyang-si, KP, <sup>7</sup>Centre François Baclesse, Caen, FR, <sup>8</sup>Hospital de la Santa Creu I Sant Pau, Barcelona, ES, <sup>9</sup>University College Hospital, London, GB, <sup>10</sup>Centre Hospitalier Intercommunal Créteil, Créteil, FR, <sup>11</sup>Azienda Ospedaliero-Universitaria San Luigi, Orbassano, IT, <sup>12</sup>Petz Aladár Megyei Oktató Kórház, Győr, HU, <sup>13</sup>San Francisco, San Francisco, US, <sup>14</sup>National Cheng Kung University Hospital, Tainan, TW, <sup>15</sup>Humanitas Gavazzeni, Bergamo, IT, <sup>16</sup>Merck & Co Inc, North Wales, US, <sup>17</sup>Merck & Co., Inc., Kenilworth, US, <sup>18</sup>The Academic Medical Hospital Amsterdam, Amsterdam, NL

16:45 - 16:45 **1384PD - Pembrolizumab in performance status 2 patients with non-small-cell lung cancer (NSCLC): results of the PePS2 trial**

G. Middleton<sup>1</sup>, K. Brock<sup>1</sup>, Y. Summers<sup>2</sup>, J. Connibear<sup>3</sup>, R. Shah<sup>4</sup>, C. Ottensmeier<sup>5</sup>, P. Shaw<sup>6</sup>, S. Ming-Lee<sup>7</sup>, S. Popat<sup>8</sup>, C. Barrie<sup>9</sup>, G. Barone<sup>10</sup>, R. Mant<sup>1</sup>, J. Savage<sup>11</sup>, L.



Billingham<sup>1</sup>, <sup>1</sup>University of Birmingham, Birmingham, GB, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>3</sup>Barts Health NHS Trust, London, GB, <sup>4</sup>Maidstone and Tunbridge Wells NHS Trust, Maidstone, GB, <sup>5</sup>University Hospital Southampton NHS Foundation Trust, Southampton, GB, <sup>6</sup>Velindre NHS Trust, Cardiff, GB, <sup>7</sup>University College London Hospitals NHS Foundation Trust, London, GB, <sup>8</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>9</sup>NHS Lothian, Edinburgh, GB, <sup>10</sup>United Lincolnshire Hospitals NHS Trust, Lincoln, GB, <sup>11</sup>The Institute of Cancer and Genomic Sciences, Birmingham, GB

16:45 - 17:05

**Invited Discussant LBA62, LBA63 and 1384PD**

S. Ekman, Karolinska University Hospital-Solna, Stockholm, SE

17:05 - 17:15

**Q&A led by Discussant**

17:15 - 17:15

**1385PD - A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial.**

S. Peters<sup>1</sup>, S. Danson<sup>2</sup>, B. Hasan<sup>3</sup>, N. Reinmuth<sup>4</sup>, M. Majem<sup>5</sup>, K. Tournoy<sup>6</sup>, M. Mark<sup>7</sup>, M. Pless<sup>8</sup>, M. Cobo<sup>9</sup>, D. Rodriguez-Abreu<sup>10</sup>, L. Falchero<sup>11</sup>, B. Massuti<sup>12</sup>, L. Coate<sup>13</sup>, R. Von Moos<sup>7</sup>, C. Zielinski<sup>14</sup>, E. De Maio<sup>15</sup>, M. O'Brien<sup>16</sup>, H. Roschitzki-Voser<sup>17</sup>, U. Dafni<sup>18</sup>, R. Stahel<sup>19</sup>, <sup>1</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>2</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, <sup>3</sup>European Organisation for Research and Treatment of Cancer (EORTC), Brussels,, BE, <sup>4</sup>Asklepios Kliniken GmbH, Gauting, DE, <sup>5</sup>Hospital De La Santa Creu I Sant Pau, Barcelona, ES, <sup>6</sup>and Faculty of Medicine and Life Sciences, Ghent University, Aalst, BE, <sup>7</sup>Kantonsspital Graubünden, Chur, CH, <sup>8</sup>Kantonsspital Winterthur, Winterthur, CH, <sup>9</sup>Hospital Regional Universitario Carlos Haya, Málaga, ES, <sup>10</sup>Hospital Insular De Gran Canaria, Las Palmas, ES, <sup>11</sup>Hopital Nord-Ouest Villefranche, Gleizé, FR, <sup>12</sup>Hospital General Universitario Alicante, Alicante, ES, <sup>13</sup>University Hospital Limerick, Dooradoyle, IE, <sup>14</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>15</sup>European Organisation for Research and Treatment of Cancer (EORTC), Brussels, BE, <sup>16</sup>Royal Marsden Hospital, Sutton, GB, <sup>17</sup>ETOP - European Thoracic Oncology Platform, Bern, CH, <sup>18</sup>University of Athens, Athens, GR, <sup>19</sup>University Hospital Zürich, Zurich, CH

17:15 - 17:15

**LBA64 - nab-Paclitaxel + Carboplatin Induction Followed by nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Results From the ABOUND.sqm Study**

D. Spigel<sup>1</sup>, R. Jotte<sup>2</sup>, S. Ponce Aix<sup>3</sup>, L. Gressot<sup>4</sup>, D. Morgensztern<sup>5</sup>, M. Mccleod<sup>6</sup>, M. Socinski<sup>7</sup>, D. Daniel<sup>8</sup>, O. Juan-Vidal<sup>9</sup>, E. Kim<sup>10</sup>, H. West<sup>11</sup>, T. Chen<sup>12</sup>, R. Bhore<sup>12</sup>, T. Ong<sup>12</sup>, C. Gridelli<sup>13</sup>, M. Thomas<sup>14</sup>, <sup>1</sup>Sarah Cannon Research Institute, Nashville, US, <sup>2</sup>Rocky Mountain Cancer Centers, Denver, US, <sup>3</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>4</sup>North Cypress Cancer Center, Cypress, US, <sup>5</sup>Washington University School of Medicine, St. Louis, US, <sup>6</sup>Florida Cancer Specialists, Fort Myers, US, <sup>7</sup>Florida Hospital Cancer Institute, Orlando, US, <sup>8</sup>Tennessee Oncology, Chattanooga, US, <sup>9</sup>Hospital Universitari i Politècnic La Fe, Valencia, ES, <sup>10</sup>Levine Cancer Institute, Atrium Health, Charlotte, US, <sup>11</sup>Swedish Cancer Institute, Seattle, US, <sup>12</sup>Celgene Corporation, Summit, US, <sup>13</sup>Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT, <sup>14</sup>Internistische Onkologie



der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, DE

17:15 - 17:15 **LBA65 - IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC**

M. Socinski<sup>1</sup>, A. Rittmeyer<sup>2</sup>, D. Shapovalov<sup>3</sup>, F. Orlandi<sup>4</sup>, M. Mccleod<sup>5</sup>, R. Soo<sup>6</sup>, R. Palmero<sup>7</sup>, T. Kozuki<sup>8</sup>, M.R. Migliorino<sup>9</sup>, K. Koynov<sup>10</sup>, H. Berard<sup>11</sup>, B. Hughes<sup>12</sup>, W. Yu<sup>13</sup>, V. Graupner<sup>14</sup>, S. Sun<sup>13</sup>, M. Kowanetz<sup>15</sup>, T. Hoang<sup>16</sup>, W. Lin<sup>17</sup>, R. Jotte<sup>18</sup>, <sup>1</sup>Florida Hospital Cancer Institute, Orlando, US, <sup>2</sup>LKI Lungenfachklinik Immenhausen, Immenhausen, DE, <sup>3</sup>Communal Non-Profit Enterprise Regional Center of Oncology, Kharkiv, UA, <sup>4</sup>Oncología - Health & Care SPA, Santiago de Chile, CL, <sup>5</sup>Florida Cancer Specialists, Fort Myers, US, <sup>6</sup>National University Hospital, Singapore, SG, <sup>7</sup>Catalan Institute of Oncology, Bellvitge, ES, <sup>8</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>9</sup>Azienda Ospedaliera S. Camillo Forlanini, Rome, IT, <sup>10</sup>Hospital for active treatment Serdika, Sofia, BG, <sup>11</sup>Hôpital d'Instruction des Armées (HIA) Ste Anne, Toulon, FR, <sup>12</sup>Royal Brisbane and Women's Hospital, Brisbane, AU, <sup>13</sup>Genentech, Inc., South San Francisco, US, <sup>14</sup>F. Hoffmann-La Roche AG - Switzerland, Basel, CH, <sup>15</sup>GENENTECH, INC, South San Francisco, US, <sup>16</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>17</sup>F. Hoffmann - La Roche Ltd, Basel, CH, <sup>18</sup>Rocky Mountain Cancer Centers, Denver, US

17:15 - 17:15 **1386PD - IMpower150: clinical safety, tolerability and immune-related adverse events in a Phase III study of atezolizumab (atezo) + chemotherapy (chemo) \_ bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC**

M. Reck<sup>1</sup>, T. Wehler<sup>2</sup>, F. Orlandi<sup>3</sup>, N. Nogami<sup>4</sup>, C. Barone<sup>5</sup>, D. Moro-Sibilot<sup>6</sup>, M. Shtivelband<sup>7</sup>, J. González Larriba<sup>8</sup>, J. Rothenstein<sup>9</sup>, M. Frueh<sup>10</sup>, G. Shankar<sup>11</sup>, A. Lee<sup>11</sup>, Y. Deng<sup>11</sup>, H. Patel<sup>11</sup>, C. Kelsch<sup>11</sup>, W. Lin<sup>11</sup>, M. Socinski<sup>12</sup>, <sup>1</sup>Krankenhaus Grosshansdorf, Grosshansdorf, DE, <sup>2</sup>Valeo-Kliniken GmbH, Hamm, DE, <sup>3</sup>Oncología - Health & Care SPA, Santiago de Chile, CL, <sup>4</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>5</sup>Università Cattolica del Sacro Cuore, Roma, IT, <sup>6</sup>Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, FR, <sup>7</sup>Ironwood Cancer & Research Center, Chandler, AZ, US, <sup>8</sup>Hospital Clinico San Carlos, Madrid, ES, <sup>9</sup>LakeRidge Health (Oshawa), Oshawa, CA, <sup>10</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>11</sup>Genentech, Inc., South San Francisco, US, <sup>12</sup>Florida Hospital Cancer Institute, Orlando, US

17:15 - 17:35 **Invited Discussant 1385PD, LBA64, LBA65 and 1386PD**

S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

17:35 - 17:45 **Q&A led by Discussant**

<b>16:45 - 17:45</b>	<b>Type: Controversy Session</b> <b>Title: Gene expression signatures should be used in luminal node negative breast cancer</b> Chair(s): Suzette Delaloge, FR	<b>Hall A1 - Room 15</b>
16:45 - 16:45	<b>Session DOI</b>	
16:45 - 16:55	<b>Introduction and 1st vote</b> <u>S. Delaloge</u> , Gustave Roussy, Villejuif, FR	
16:55 - 17:15	<b>Pro</b> <u>N. Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, DE	
17:15 - 17:35	<b>Contra</b> <u>P. Pharoah</u> , University of Cambridge-Public Health and Primary Care, Cambridge, GB	
17:35 - 17:45	<b>2nd vote and conclusions</b> <u>S. Delaloge</u> , Gustave Roussy, Villejuif, FR	
<b>18:00 - 19:30</b>	<b>Type: Patient Advocacy Track</b> <b>Title: Snake oil sold as science: How to protect patients from Pseudoscience</b> Chair(s): Gilliosa Spurrier, FR; Matthias Preusser, AT	<b>ICM - Room 5</b>
18:00 - 18:00	<b>Session DOI</b>	
18:00 - 18:15	<b>Pseudoscience and having to destroy false hope: The oncologist's perspective</b> <u>P. Wolter</u> , CHR Verviers, Verviers, BE	
18:15 - 18:30	<b>Characteristics of pseudoscience</b> <u>E. Ernst</u> , Peninsula Medical School, Exeter, GB	
18:30 - 18:45	<b>The responsibility of journalism in science reporting</b> <u>H. Scowcroft</u> , Cancer Research UK, London, GB	
18:45 - 19:00	<b>Preventing pseudoscience on patient forums</b> <u>G. Spurrier</u> , MelanomeFrance and Melanoma Patients Network Europe, Teilhet, FR	
19:00 - 19:30	<b>Discussion</b>	

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 1**  
**Title: Industry satellite symposium 35**

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 14b**  
**Title: Industry satellite symposium 36**

18:30 - 20:00    **Presentation**

J. Yao<sup>1</sup>, J. Valle<sup>2</sup>, J. Capdevila Castillon<sup>3</sup>, R. Riechelmann<sup>4</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>A. C. Camargo Cancer Center, Sao Paulo, BR

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **ICM - Room 13**  
**Title: Industry satellite symposium 37**

18:30 - 20:00    **Presentation**

M. Reck<sup>1</sup>, L. Horn<sup>2</sup>, J. Wolf<sup>3</sup>, <sup>1</sup>Krankenhaus Grosshansdorf, Grosshansdorf, DE, <sup>2</sup>Vanderbilt Ingram Cancer Center, Nashville, US, <sup>3</sup>University Hospital Cologne, Cologne, DE

**18:30 - 20:00**    **Type: ESMO Colloquium**    **Hall A1 - Room 15**  
**Title: ESMO COLLOQUIUM - Acute Myeloid Leukemia - Focus on FLT3-ITD mutation**  
 Chair(s): Jorge Cortes, US

18:30 - 18:30    **Session DOI**

18:30 - 18:35    **Introduction**

J. Cortes, University of Texas MD Anderson Cancer Center, Houston, US

18:35 - 18:55    **Molecular profile of AML and prognostication/risk classification**

L. Bullinger, Ulm Medical University, Ulm, DE

18:55 - 19:10    **Are present clinical practice GL for the management of AML obsolete?**

M. Heuser, Hannover Medical School, Hannover, DE

19:10 - 19:25    **FLT3-ITD mutated AML: A special entity?**

K. Metzeler, Ludwig Maximilians University - Grosshadern, Munich, DE

19:25 - 19:45    **New approaches on the management of relapsed or refractory FLT3-ITD mutated AML**

J. Cortes, University of Texas MD Anderson Cancer Center, Houston, US

19:45 - 19:55    **Q&A and discussion led by Chair and Speakers**

19:55 - 20:00    **Conclusion**

J. Cortes, University of Texas MD Anderson Cancer Center, Houston, US



**18:30 - 20:00**    **Type: ESMO Colloquium**    **Hall A1 - Room 16**  
**Title: ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?**  
 Chair(s): E.G. Elisabeth de Vries, NL; Martina Weiss, DE

18:30 - 18:30    **Session DOI**

18:30 - 18:35    **Introduction**

E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

18:35 - 18:45    **Acceptance of oncology biosimilars in supportive care: a success story**

M. Weiss, German CHMP Alternate, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, DE

18:45 - 18:55    **Existing challenges for uptake of oncology biosimilars - ESMO survey results**

M. Vyas, ESMO - European Society for Medical Oncology, Lugano, CH

18:55 - 19:05    **In practice (UK): patients being switched from a biologic to a biosimilar - UK**

S. Scowcroft, Lymphoma Association, Harpenden, GB

19:05 - 19:15    **One year on - state of play in the EU on oncology biosimilars**

M. Aitken, IMS Health, Parsippany, US

19:15 - 19:25    **Supplementary Protection Certificates & their potential impact on availability of biosimilars**

R. Romandini, Max Planck Institute of Immunobiology and Epigenetics, Freiburg im Breisgau, DE

19:25 - 19:55    **Panel with industry representatives**

J. Coindreau<sup>1</sup>, J. Hippenmeyer<sup>2</sup>, A. Krendyukov<sup>3</sup>, A. Roediger<sup>4</sup>, <sup>1</sup>Hwang, Bien & Associates, New York City, US, <sup>2</sup>Amgen (Europe) - Switzerland, Zug, CH, <sup>3</sup>Hexal AG, Holzkirchen, DE, <sup>4</sup> Kriens, CH

19:55 - 20:00    **Conclusion**

E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 20**  
**Title: Industry satellite symposium 40**

18:30 - 20:00    **Presentation 1**

B. Tombal<sup>1</sup>, C. Higano<sup>2</sup>, N. James<sup>3</sup>, <sup>1</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>2</sup>University of Washington, Seattle, US, <sup>3</sup>Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 19**  
**Title: Industry satellite symposium 41**

18:30 - 20:00    **Presentation**  
F. Griesinger, Pius Hospital, Oldenburg, DE

20:00 - 20:20    **Presentation 2**  
D. Moro-Sibilot, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, FR

**18:30 - 20:00**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 24**  
**Title: Industry satellite symposium - EONS 7**

18:30 - 18:50    **Presentation 1**  
J. Larkin, Royal Marsden Hospital NHS Foundation Trust, London, GB

18:50 - 19:10    **Presentation 2**  
N. Hunter, London, GB

19:10 - 19:30    **Presentation 3**  
T. Wiseman, The Royal Marsden NHS Foundation Trust, London, GB

19:30 - 19:50    **Presentation 4**  
J. Daly, Munich, IE

22.10.2018

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall A1 -**  
**Title: Optimal treatment of patients with metastatic colorectal cancer: Planned sequencing, or just taking the next best option?** **Room 16**  
 Chair(s): Alfredo Falcone, IT

08:00 - 08:10 **Optimal treatment of patients with metastatic colorectal cancer: Planned sequencing, or just taking the next best option?**  
A. Stein, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

08:10 - 09:00 **Discussion led by**  
A. Falcone, Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 21**  
**Title: Optimal management of luminal advanced breast cancer**  
 Chair(s): Nadia Harbeck, DE

08:00 - 08:10 **Optimal management of luminal advanced breast cancer**  
F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT

08:10 - 09:00 **Discussion led by**  
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **Hall B3 - Room 23**  
**Title: Clinical application of liquid biopsy in metastatic lung cancer**  
 Chair(s): Sanjay Popat, GB

08:00 - 08:10 **Clinical application of liquid biopsy in metastatic lung cancer**  
C. Rolfo, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, US

08:10 - 09:00 **Discussion led by**  
S. Popat, Royal Marsden Hospital NHS Foundation Trust, London, GB

**08:00 - 09:00**    **Type: Challenge Your Expert (CYE) session**    **Hall B3 - Room 20**  
**Title: Salivary gland cancers**  
 Chair(s): Lisa Licitra, IT

08:00 - 08:10    **Salivary gland cancers**  
A. Ho, Memorial Sloan Kettering Cancer Center, New York City, US

08:10 - 09:00    **Discussion led by**  
L. Licitra, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

**08:00 - 09:00**    **Type: Challenge Your Expert (CYE) session**    **Hall B3 - Room 22**  
**Title: What is the role of intratumour therapy?**  
 Chair(s): Caroline Robert, FR

08:00 - 08:10    **What is the role of intratumour therapy?**  
O. Michielin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

08:10 - 09:00    **Discussion led by**  
C. Robert, Institut Gustave Roussy, Villejuif, FR

**08:00 - 09:00**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Assessments and monitoring in advanced cancer nursing**  
 Chair(s): Christian Wylegalla, DE

08:00 - 08:20    **How to observe and manage the acutely ill patient**  
C. De Los Rios De La Serna, Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB

08:20 - 08:40    **Reflections on systematic symptom assessment and monitoring in advanced cancer patients in the late palliative phase/terminal phase in hospital, at home and/or hospice**  
S. Teunissen, UMC - University Medical Center Utrecht, Utrecht, NL

08:40 - 09:00    **Discussion**



**08:00 - 09:00** **Type: Challenge Your Expert (CYE) session** **ICM - Room 14a**  
**Title: Health care decision making and the international context**  
 Chair(s): Francesco Perrone, IT

08:00 - 08:10 **Health care decision making and the international context**  
H. Severens, Erasmus University Medical Center, Rotterdam, NL

08:10 - 09:00 **Discussion led by**  
F. Perrone, Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

**08:15 - 09:00** **Type: Keynote lecture** **Hall A1 - Room 17**  
**Title: Beyond resistance in immuno-oncology**  
 Chair(s): Solange Peters, CH

08:15 - 09:00 **Beyond resistance in immuno-oncology**  
A. Ribas, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

**09:15 - 11:00** **Type: Proffered Paper session** **Hall A1 - Room 17**  
**Title: Proffered paper session- NSCLC, metastatic**  
 Chair(s): Martin Reck, DE; Benjamin Besse, FR

09:15 - 09:30 **LBA53 - IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC**  
F. Cappuzzo<sup>1</sup>, M. McCleod<sup>2</sup>, M. Hussein<sup>3</sup>, A. Morabito<sup>4</sup>, A. Rittmeyer<sup>5</sup>, H. Conter<sup>6</sup>, H.-G. Kopp<sup>7</sup>, D. Daniel<sup>8</sup>, S. Mccune<sup>9</sup>, T. Mekhail<sup>10</sup>, A. Zer<sup>11</sup>, N. Reinmuth<sup>12</sup>, A. Sadiq<sup>13</sup>, V. Archer<sup>14</sup>, T. Ochi Lohmann<sup>15</sup>, L. Wang<sup>16</sup>, M. Kowanetz<sup>17</sup>, W. Lin<sup>18</sup>, A. Sandler<sup>19</sup>, H. West<sup>20</sup>, <sup>1</sup>Ospedale Civile di Ravenna - S.ta Maria delle Croci, Ravenna, IT, <sup>2</sup>Florida Cancer Specialists, Fort Myers, US, <sup>3</sup>Sarah Cannon Research Institute/Florida Cancer Specialists, Leesburg, US, <sup>4</sup>Istituto Nazionale Tumori "Fondazione G.Pascale", Naples, IT, <sup>5</sup>LKI Lungenfachklinik Immenhausen, Immenhausen, DE, <sup>6</sup>William Osler Health System Foundation, Brampton, CA, <sup>7</sup>Universitätsklinikum Tübingen Medizinische Universitätsklinik, Tübingen, DE, <sup>8</sup>Tennessee Oncology, Chattanooga, US, <sup>9</sup>Oncology Centers, Marietta, US, <sup>10</sup>Florida Hospital Cancer Institute, Orlando, US, <sup>11</sup>Rabin Medical Center, Petah Tikva, IL, <sup>12</sup>Asklepios Kliniken GmbH, Gauting, DE, <sup>13</sup>Fort Wayne Medical, Fort Wayne, US, <sup>14</sup>Roche Products Limited, Welwyn Garden City, GB, <sup>15</sup>PD Oncology, Basel, CH, <sup>16</sup>Biostatistics, South San Francisco, US, <sup>17</sup>GENENTECH, INC, South San Francisco, US, <sup>18</sup>Genentech, Inc., South San Francisco, US, <sup>19</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>20</sup>Swedish Cancer Institute, Seattle, US

09:30 - 09:45 **LBA54 - IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)**  
F. Barlesi<sup>1</sup>, M. Nishio<sup>2</sup>, M. Cobo<sup>3</sup>, N. Steele<sup>4</sup>, V. Paramonov<sup>5</sup>, B. Parente<sup>6</sup>, R. Dear<sup>7</sup>, H.

Berard<sup>8</sup>, N. Peled<sup>9</sup>, L. Seneviratne<sup>10</sup>, E. Baldini<sup>11</sup>, S. Watanabe<sup>12</sup>, K. Goto<sup>13</sup>, D. Mendus<sup>14</sup>, H. Patel<sup>14</sup>, Y. Deng<sup>14</sup>, M. Kowanetz<sup>15</sup>, T. Hoang<sup>16</sup>, W. Lin<sup>14</sup>, V. Papadimitrakopoulou<sup>17</sup>, <sup>1</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>2</sup>The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, <sup>3</sup>Hospital Regional Universitario Carlos Haya, Málaga, ES, <sup>4</sup>The Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>5</sup>Cherkassy Regional Oncology Dispensary, Cherkassy, UA, <sup>6</sup>Hospital CUF Porto, Porto, PT, <sup>7</sup>The Kinghorn Cancer Centre, Darlinghurst, AU, <sup>8</sup>hôpital Sainte-Anne, Toulon, FR, <sup>9</sup>Soroka University Medical Center, Beer Sheva, IL, <sup>10</sup>Los Angeles Cancer Network, Los Angeles, US, <sup>11</sup>S. Luca Hospital,, Lucca, IT, <sup>12</sup>Niigata University Medical & Dental Hospital, Niigata, JP, <sup>13</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>14</sup>Genentech, Inc., South San Francisco, US, <sup>15</sup>GENENTECH, INC, South San Francisco, US, <sup>16</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>17</sup>MD Anderson Cancer Center, Houston, US

09:45 - 10:00

**LBA55 - Primary efficacy results from B-F1RST, a prospective Phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)**

E. Kim<sup>1</sup>, V. Velcheti<sup>2</sup>, T. Mekhail<sup>3</sup>, T. Leal<sup>4</sup>, J. Dowell<sup>5</sup>, M. Tsai<sup>6</sup>, C. Dakhil<sup>7</sup>, P. Stella<sup>8</sup>, V. Shen<sup>9</sup>, S. Hu<sup>10</sup>, S. Paul<sup>10</sup>, D. Shames<sup>10</sup>, E. Schleifman<sup>10</sup>, D. Fabrizio<sup>11</sup>, C. Yun<sup>10</sup>, S. Phan<sup>10</sup>, M. Socinski<sup>3</sup>, <sup>1</sup>Levine Cancer Institute, Charlotte, US, <sup>2</sup>Cleveland Clinic, Cleveland, US, <sup>3</sup>Florida Hospital Cancer Institute, Orlando, US, <sup>4</sup>University of Wisconsin School of Medicine and Public Health, Madison, US, <sup>5</sup>Veterans Affairs North Texas Healthcare System, University of Texas Southwestern Medical Center, Dallas, US, <sup>6</sup>Minnesota Oncology, Minneapolis, US, <sup>7</sup>Cancer Center of Kansas, Wichita, US, <sup>8</sup>St. Joseph Mercy Hospital, Ann Arbor, US, <sup>9</sup>F. Hoffmann-La Roche, Ltd, Mississauga, CA, <sup>10</sup>Genentech, Inc., South San Francisco, US, <sup>11</sup>Foundation Medicine, Inc., Cambridge, US

10:00 - 10:15

**Invited Discussant LBA53, LBA54 and LBA55**

B. Besse, Gustave Roussy - Cancer Campus, Villejuif, FR

10:15 - 10:30

**13780 - ARCTIC: durvalumab + tremelimumab and durvalumab monotherapy vs SoC in \_3L advanced NSCLC treatment**

D. Kowalski<sup>1</sup>, N. Reinmuth<sup>2</sup>, S. Orlov<sup>3</sup>, J. Fischer<sup>4</sup>, S. Sugawara<sup>5</sup>, S. Mandziuk<sup>6</sup>, D. Medine<sup>7</sup>, S. Novello<sup>8</sup>, Y. Takeda<sup>9</sup>, R. Soo<sup>10</sup>, K. Park<sup>11</sup>, M. Mccleod<sup>12</sup>, S. Geater<sup>13</sup>, M. Powell<sup>14</sup>, R. May<sup>14</sup>, P. Stockman<sup>15</sup>, D. Planchard<sup>16</sup>, <sup>1</sup>The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, <sup>2</sup>Asklepios Kliniken GmbH, Gauting, DE, <sup>3</sup>Pavlov Medical University, St.Petersburg, RU, <sup>4</sup>Klinik Loewenstein GmbH Med Klinik II Onkologie, Loewenstein, DE, <sup>5</sup>Sendai Kousei Hospital, Sendai, JP, <sup>6</sup>Centrum Medyczne Luxmed Sp, Lublin, PL, <sup>7</sup>Hospital Universitari Arnau de Vilanova, Lleida, ES, <sup>8</sup>Università Degli Studi Di Torino - Orbassano, Orbassano, IT, <sup>9</sup>National Center for Global Health and Medicine, Tokyo, JP, <sup>10</sup>National University Hospital, Singapore, SG, <sup>11</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>12</sup>Florida Cancer Specialists, Fort Myers, US, <sup>13</sup>Prince of Songkla University, Songkhla, TH, <sup>14</sup>AstraZeneca, Gaithersburg, US, <sup>15</sup>AstraZeneca, Macclesfield, GB, <sup>16</sup>Institut Gustave Roussy, Villejuif, FR

10:30 - 10:45

**LBA56 - Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-**

**small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase 3 trial**

E. Quoix<sup>1</sup>, C. Audigier Valette<sup>2</sup>, A. Lavolé<sup>3</sup>, O. Molinier<sup>4</sup>, V. Westeel<sup>5</sup>, F. Barlesi<sup>6</sup>, J. Le Treut<sup>7</sup>, E. Pichon<sup>8</sup>, J. Dauba<sup>9</sup>, J. Otto<sup>10</sup>, P. Dumont<sup>11</sup>, L. Moreau<sup>12</sup>, J. Madelaine<sup>13</sup>, J. Margery<sup>14</sup>, D. Debieuvre<sup>15</sup>, P. Renault<sup>16</sup>, A. Langlais<sup>17</sup>, F. Morin<sup>18</sup>, D. Moro-Sibilot<sup>19</sup>, P.-J. Souquet<sup>20</sup>, <sup>1</sup>Faculte de medecine de strasbourg, Strasbourg, FR, <sup>2</sup>Hospital Sainte Musse, Toulon, FR, <sup>3</sup>Hospital Tenon, APHP, Paris, FR, <sup>4</sup>Centre Hospitalier Du Mans, Le Mans, FR, <sup>5</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>6</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>7</sup>CH du Pays d'Aix, Aix-en-Provence, FR, <sup>8</sup>CHRU Bretonneau, Tours, FR, <sup>9</sup>Centre hospitalier de Mont-de-Marsan (site Layné), Mont de Marsan, FR, <sup>10</sup>Centre Antoine Lacassagne, Nice, FR, <sup>11</sup>CH DE Chauny, Chauny, FR, <sup>12</sup>Hopitaux Civils de Colmar, Colmar, FR, <sup>13</sup>CHU de Caen, Caen, FR, <sup>14</sup>HIA Percy, Clamart, FR, <sup>15</sup>Hopital Emile Muller, Mulhouse, FR, <sup>16</sup>Centre Hospitalier, Pau, FR, <sup>17</sup>IFCT, Paris, FR, <sup>18</sup>French Cooperative Thoracic Intergroup, Paris, FR, <sup>19</sup>Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, FR, <sup>20</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR

10:45 - 11:00 **Invited Discussant 13780 and LBA56**

N. Rizvi, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

**09:15 - 11:00** **Type: Proffered Paper session** **Hall A2 - Room 18**  
**Title: Proffered paper session - Gastrointestinal tumours, colorectal**  
 Chair(s): Dirk Arnold, DE; Alfredo Falcone, IT

09:15 - 09:27 **LBA18\_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC)**

H.-J. Lenz<sup>1</sup>, E. Van Cutsem<sup>2</sup>, M.L. Limon<sup>3</sup>, K.Y. Wong<sup>4</sup>, A. Hendlisz<sup>5</sup>, M. Aglietta<sup>6</sup>, P. Garcia-Alfonso<sup>7</sup>, B. Neyns<sup>8</sup>, G. Luppi<sup>9</sup>, D. Cardin<sup>10</sup>, T. Dragovich<sup>11</sup>, U. Shah<sup>12</sup>, A. Atasoy<sup>13</sup>, R. Postema<sup>14</sup>, Z. Boyd<sup>13</sup>, J.-M. Ledezine<sup>13</sup>, M. Overman<sup>15</sup>, S. Lonardi<sup>16</sup>, <sup>1</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>2</sup>University Hospitals Leuven, Leuven, BE, <sup>3</sup>Servicio Oncologia - Edificio General, Seville, ES, <sup>4</sup>The University of Sydney, New South Wales, AU, <sup>5</sup>Institut Jules Bordet, Bruxelles, BE, <sup>6</sup>University of Torino, Torino, IT, <sup>7</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>8</sup>Vrije Universiteit Brussel-Campus Jette, Brussels, BE, <sup>9</sup>Private Practice, Modena, IT, <sup>10</sup>Vanderbilt University, Nashville, US, <sup>11</sup>Banner MD Anderson, Gilbert, US, <sup>12</sup>Lehigh Valley Hospital, Allentown, US, <sup>13</sup>Bristol-Myers Squibb Company, Princeton, US, <sup>14</sup>Bristol-Myers Squibb Company, London, GB, <sup>15</sup>MD Anderson, Houston, US, <sup>16</sup>Istituto Oncologico Veneto IRCCS, Padova, IT

09:27 - 09:39 **LBA19 - Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy**

A. Grothey<sup>1</sup>, J. Tabernero<sup>2</sup>, D. Arnold<sup>3</sup>, A. De Gramont<sup>4</sup>, M. Ducreux<sup>5</sup>, P. O'Dwyer<sup>6</sup>, E. Van Cutsem<sup>7</sup>, I. Bosanac<sup>8</sup>, S. Srock<sup>8</sup>, C. Mancao<sup>8</sup>, F. Gilberg<sup>8</sup>, J. Winter<sup>8</sup>, H.-J. Schmoll<sup>9</sup>, <sup>1</sup>West Cancer Center, Germantown, US, <sup>2</sup>Vall d'Hebron University Hospital. Vall



d'Hebron Institute of Oncology VHIO., Barcelona, ES, <sup>3</sup>Asklepios Klinik Altona, Hamburg, DE, <sup>4</sup>Institut hospitalier Franco-Britannique, Levallois Perret, FR, <sup>5</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>6</sup>University of Pennsylvania, Philadelphia, US, <sup>7</sup>University Hospitals Leuven, Leuven, BE, <sup>8</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>9</sup>Martin-Luther-University, Halle, DE

09:39 - 09:54 **Invited Discussant LBA18\_PR and LBA19**

J. Taieb, Hopital European George Pompidou, Paris, FR

09:54 - 10:06 **LBA20 - TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).**

C. Cremolini<sup>1</sup>, C. Antoniotti<sup>1</sup>, S. Lonardi<sup>2</sup>, D. Rossini<sup>3</sup>, F. Pietrantonio<sup>4</sup>, S.S. Cordio<sup>5</sup>, S. Murgioni<sup>2</sup>, F. Marmorino<sup>6</sup>, E. Maiello<sup>7</sup>, A. Passardi<sup>8</sup>, G. Masi<sup>1</sup>, E. Tamburini<sup>9</sup>, D. Santini<sup>10</sup>, R. Grande<sup>11</sup>, A. Zaniboni<sup>12</sup>, C. Granetto<sup>13</sup>, F. Loupakis<sup>2</sup>, L. Delliponti<sup>14</sup>, L. Boni<sup>15</sup>, A. Falcone<sup>1</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT, <sup>2</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>3</sup>Dipint, Pisa, IT, <sup>4</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>5</sup>Azienda Ospedaliera ARNAS Garibaldi, Catania, IT, <sup>6</sup>University of Pisa - DAM, Pisa, IT, <sup>7</sup>Hospital Casa Sollievo della Sofferenza-IRCCS, san giovanni rotondo, IT, <sup>8</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>9</sup>Ospedale Infermi, Rimini, IT, <sup>10</sup>Campus Bio-Medico di Roma, Rome, IT, <sup>11</sup>Ospedale Fabrizio Spaziani-ASL Frosinone, Frosinone, IT, <sup>12</sup>Casa di Cura Poliambulanza, Brescia, IT, <sup>13</sup>Azienda Sanitaria Ospedaliera Santa Croce e Carle, Cuneo, IT, <sup>14</sup>University of Pisa, Pisa, IT, <sup>15</sup>clinical trial coordinating center, AOU careggi ,, firenze, IT

10:06 - 10:18 **4520 - DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD\*2A, c.2846A>T, c.1679T>G and c.1236G>A**

L. Henricks<sup>1</sup>, C. Lunenburg<sup>2</sup>, F. De Man<sup>3</sup>, D. Meulendijks<sup>4</sup>, G. Frederix<sup>5</sup>, E. Kienhuis<sup>3</sup>, G.-J. Creemers<sup>6</sup>, A. Baars<sup>7</sup>, V. Dezentjé<sup>8</sup>, H. Rosing<sup>9</sup>, J. Beijnen<sup>9</sup>, E. Van Werkhoven<sup>1</sup>, A. Van Kuilenburg<sup>10</sup>, R. Van Schaik<sup>11</sup>, R. Mathijssen<sup>12</sup>, J. Swen<sup>13</sup>, H. Gelderblom<sup>2</sup>, A. Cats<sup>14</sup>, H.-J. Guchelaar<sup>13</sup>, J. Schellens<sup>1</sup>, <sup>1</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>2</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>3</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>4</sup>CBG-MEB, Utrecht, NL, <sup>5</sup>University Medical Center Utrecht, Utrecht, NL, <sup>6</sup>Catharina Hospital Eindhoven, Eindhoven, NL, <sup>7</sup>Ziekenhuis Gelderse Vallei, Ede, NL, <sup>8</sup>Reinier de Graaf Hospital, Delft, NL, <sup>9</sup>The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, NL, <sup>10</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL, <sup>11</sup>Erasmus Medical Center, Rotterdam, NL, <sup>12</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>13</sup>Leiden University Medical Center, Leiden, NL, <sup>14</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

10:18 - 10:30 **LBA21 - InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial.**

S. Rao<sup>1</sup>, F. Sclafani<sup>2</sup>, C. Eng<sup>3</sup>, M. Grønlie Guren<sup>4</sup>, R. Adams<sup>5</sup>, A. Benson<sup>6</sup>, D. Sebag-Montefiore<sup>7</sup>, E. Segelov<sup>8</sup>, A. Bryant<sup>1</sup>, C. Peckitt<sup>1</sup>, A. Roy<sup>9</sup>, M. Seymour<sup>10</sup>, J. Welch<sup>11</sup>, M. Saunders<sup>12</sup>, R. Muirhead<sup>13</sup>, J. Bridgewater<sup>14</sup>, S. Falk<sup>15</sup>, R. Glynn-Jones<sup>16</sup>, D. Arnold<sup>17</sup>,



D. Cunningham<sup>2</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>3</sup>M. D. Anderson Cancer Center, Houston, US, <sup>4</sup>Oslo University Hospital, Oslo, NO, <sup>5</sup>Cardiff University, Cardiff, GB, <sup>6</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, US, <sup>7</sup>University of Leeds, Leeds, GB, <sup>8</sup>Monash Medical Centre, Clayton, AU, <sup>9</sup>Flinders Centre for Innovation in Cancer, Bedford Park, AU, <sup>10</sup>St. James's University Hospital Leeds, Leeds, GB, <sup>11</sup>NCI-CGH, New York, US, <sup>12</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>13</sup>Churchill Hospital, Oxford, GB, <sup>14</sup>University College London Hospitals, London, GB, <sup>15</sup>Bristol University Hospitals NHS Foundation Trust, Bristol, GB, <sup>16</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>17</sup>Asklepios Klinik Altona, Hamburg, DE

10:30 - 10:50 **Invited Discussant LBA20, 452O and LBA21**

C.-H. Koehne, Klinikum Oldenburg, Oldenburg, DE

**09:15 - 10:45 Type: Proffered Paper session ICM - Room 1**  
**Title: Proffered paper session - Melanoma and other skin tumours**  
 Chair(s): Caroline Robert, FR; Reinhard Dummer, CH

09:15 - 09:30 **LBA42 - OpACIN-neo - A Multicenter Phase 2 Study to identify the Optimal neo-Adjuvant Combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO).**

E. Rozeman<sup>1</sup>, A. Menzies<sup>2</sup>, B. Van De Wiel<sup>3</sup>, C. Adhikari<sup>2</sup>, K. Sikorska<sup>3</sup>, O. Krijgsman<sup>3</sup>, H. Eriksson<sup>4</sup>, C. Bierman<sup>3</sup>, L. Grijpink-Ongering<sup>3</sup>, M. Gonzalez<sup>2</sup>, A. Broeks<sup>3</sup>, A. Guminski<sup>5</sup>, A. Spillane<sup>2</sup>, W. Klop<sup>6</sup>, R. Saw<sup>2</sup>, R. Scolyer<sup>7</sup>, A. Van Akkooi<sup>3</sup>, J. Hansson<sup>4</sup>, G. Long<sup>2</sup>, C. Blank<sup>3</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>3</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>4</sup>Karolinska Institutet, Stockholm, SE, <sup>5</sup>Royal North Shore Hospital, St Leonards, AU, <sup>6</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, <sup>7</sup>Royal Prince Alfred Hospital, Camperdown, AU

09:30 - 09:45 **LBA43 - Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma**

G. Long<sup>1</sup>, A. Hauschild<sup>2</sup>, M. Santinami<sup>3</sup>, V. Atkinson<sup>4</sup>, M. Mandala<sup>5</sup>, V. Chiarion-Sileni<sup>6</sup>, J. Larkin<sup>7</sup>, C. Robert<sup>8</sup>, D. Schadendorf<sup>9</sup>, K. Dasgupta<sup>10</sup>, M. Shilkrut<sup>11</sup>, J. Garrett<sup>12</sup>, J.C. Brase<sup>13</sup>, R. Kefford<sup>14</sup>, J. Kirkwood<sup>15</sup>, R. Dummer<sup>16</sup>, <sup>1</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>2</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>3</sup>Fondazione Istituto Nazionale Tumori, Milano, IT, <sup>4</sup>Princess Alexandra Hospital, Woolloongabba, AU, <sup>5</sup>Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, <sup>6</sup>Veneto Institute of Oncology IOV-IRCCS, Padua, IT, <sup>7</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>8</sup>Institut Gustave Roussy, Villejuif, FR, <sup>9</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>10</sup>Novartis Pharmaceuticals Corporation, Hyderabad, IN, <sup>11</sup>Novartis, East Hanover, US, <sup>12</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>13</sup>Novartis Pharma AG, Basel, CH, <sup>14</sup>Macquarie University, Melanoma Institute Australia, Westmead Hospital, and The University of Sydney, Sydney, AU, <sup>15</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>16</sup>Universitätsspital Zürich, Zurich, CH

09:45 - 10:00 **Invited Discussant one LBA TBC, LBA42 and LBA43**

C. Robert, Institut Gustave Roussy, Villejuif, FR

10:00 - 10:15 **LBA44 - Overall survival at 4 years of follow-up in a phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)**

F. Hodi<sup>1</sup>, V. Chiarion-Sileni<sup>2</sup>, R. Gonzalez<sup>3</sup>, J.J. Grob<sup>4</sup>, P. Rutkowski<sup>5</sup>, C.L. Cowey<sup>6</sup>, C. Lao<sup>7</sup>, D. Schadendorf<sup>8</sup>, J. Wagstaff<sup>9</sup>, R. Dummer<sup>10</sup>, P.F. Ferrucci<sup>11</sup>, M. Smylie<sup>12</sup>, A. Hill<sup>13</sup>, D. Hogg<sup>14</sup>, I. Marquez-Rodas<sup>15</sup>, J. Jiang<sup>16</sup>, J. Rizzo<sup>16</sup>, J. Larkin<sup>17</sup>, J. Wolchok<sup>18</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>Veneto Institute of Oncology IOV-IRCCS, Padua, IT, <sup>3</sup>University of Colorado Cancer Center, Denver, US, <sup>4</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>5</sup>Maria Sklodowska-Curie Institute - Oncology Center, Warszawa, PL, <sup>6</sup>Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, <sup>7</sup>University of Michigan Health System, Ann Arbor, US, <sup>8</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>9</sup>Singleton Hospital, Swansea, GB, <sup>10</sup>Universitätsspital Zürich, Zurich, CH, <sup>11</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>12</sup>Cross Cancer Institute, Edmonton, CA, <sup>13</sup>Tasman Oncology Research, Southport, AU, <sup>14</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>15</sup>General University Hospital Gregorio Marañón, Madrid, ES, <sup>16</sup>Bristol-Myers Squibb, Princeton, US, <sup>17</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>18</sup>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US

10:15 - 10:30 **12440 - KEYNOTE-022 Part 3: Phase 2 Randomized Study of 1L Dabrafenib (D) and Trametinib (T) Plus Pembrolizumab (Pembro) or Placebo (PBO) for BRAF-Mutant Advanced Melanoma**

P. Ascierto<sup>1</sup>, P.F. Ferrucci<sup>2</sup>, R. Stephens<sup>3</sup>, M. Del Vecchio<sup>4</sup>, V. Atkinson<sup>5</sup>, H. Schmidt<sup>6</sup>, J. Schachter<sup>7</sup>, P. Queirolo<sup>8</sup>, G. Long<sup>9</sup>, A. Di Giacomo<sup>10</sup>, I. Svane<sup>11</sup>, M. Lotem<sup>12</sup>, G. Bar-Sela<sup>13</sup>, F. Couture<sup>14</sup>, B. Mookerjee<sup>15</sup>, R. Ghorri<sup>16</sup>, N. Ibrahim<sup>16</sup>, B. Homet Moreno<sup>16</sup>, A. Ribas<sup>17</sup>, <sup>1</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>2</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Auckland City Hospital, Auckland, NZ, <sup>4</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>5</sup>Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Brisbane, AU, <sup>6</sup>Aarhus University Hospital, Aarhus C, DK, <sup>7</sup>The Ella Institute for Treatment and Research of Melanoma and Skin Cancer, Ramat Gan, IL, <sup>8</sup>IRCCS San Martino-IST, Genova, IT, <sup>9</sup>Melanoma Institute Australia, University of Sydney, North Sydney, AU, <sup>10</sup>Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT, <sup>11</sup>Herlev Hospital, University of Copenhagen, Herlev, DK, <sup>12</sup>Sharett Institute of Oncology, Hadassah Hebrew Medical Center, Jerusalem, IL, <sup>13</sup>Rambam Health Care Center, Haifa, IL, <sup>14</sup>Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec, CA, <sup>15</sup>Novartis, East Hanover, US, <sup>16</sup>Merck & Co., Inc., Kenilworth, US, <sup>17</sup>Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

10:30 - 10:45 **Invited Discussant LBA44 and 12440**

R. Dummer, Universitätsspital Zürich, Zurich, CH

**09:15 - 10:45**    **Type: Special Symposium**    **ICM - Room 14b**  
**Title: Strategies to improve the outcome of advanced prostate cancer**  
 Chair(s): Johann de Bono, GB; Scott Tomlins, US

09:15 - 09:20    **Introduction**  
J. De Bono, The Institute of Cancer Research (ICR), London, GB

09:20 - 09:40    **Heterogeneity in prostate cancer**  
S. Tomlins, University of Michigan, Ann Arbor, US

09:40 - 10:00    **Improving treatment outcome by dissecting heterogeneity**  
J. De Bono, The Institute of Cancer Research (ICR), London, GB

10:00 - 10:20    **Improving outcome by optimising combination and/or sequencing of treatments**  
E. Efstathiou, The M. D. Anderson Cancer Center, Houston, US

10:20 - 10:40    **Improving treatment outcome by manipulating the immune system**  
W. Gerritsen, Radboud University Medical Centre Nijmegen, Nijmegen, NL

10:40 - 10:45    **Conclusions and perspectives**  
S. Tomlins, University of Michigan, Ann Arbor, US

**09:15 - 10:45**    **Type: Special Symposium**    **ICM - Room 13**  
**Title: Minimising potentially futile treatments in advanced disease**  
 Chair(s): Florian Scotté, FR; Matti Aapro, CH

09:15 - 09:20    **Introduction**  
M. Aapro, Clinique de Genolier, Genolier, CH

09:20 - 09:40    **Monitoring toxicities**  
C. Ruhlmann, Odense University Hospital, Odense C, DK

09:40 - 10:00    **Prediction of relevant toxicities using the example of neuro toxicities**  
G. Cavaletti, Università degli Studi di Milano Bicocca - Facoltà di Medicina e Chirurgia, Monza, IT

10:00 - 10:20    **Decisional processes (with patients) to minimise futility**  
F. Strasser, Kantonsspital St. Gallen, St. Gallen, CH

10:20 - 10:40    **Integration of palliative care based on (ESMO) guidelines**  
S. Kaasa, Oslo University Hospital, Oslo, NO

10:40 - 10:45    **Conclusions and perspectives**  
F. Scotté, Hopital Foch, Suresnes, FR

**09:15 - 10:45**    **Type: Educational session**    **Hall A1 - Room 15**  
**Title: Multiple myeloma**  
 Chair(s): Meletios Dimopoulos, GR; Hervé Avet-Loiseau, FR

09:15 - 09:40    **Next generation diagnostics**  
H. Avet-Loiseau, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR

09:40 - 10:05    **Frontline treatment**  
M.-V. Mateos, University Hospital of Salamanca, Salamanca, ES

10:05 - 10:30    **Relapsed disease**  
M. Dimopoulos, Alexandra Hospital, Athens, GR

10:30 - 10:45    **Discussion**



**09:15 - 10:45**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Complex symptom burden and management related to multimodality cancer treatment**  
 Chair(s): Wendy Oldenmenger, NL

09:15 - 09:30    **Effects of lavender oil on sleep quality of patients with cancer: A RCT of lavender oil versus sweet almond oil**  
C. Wylegalla, University Medical Center Freiburg, Freiburg, DE

09:30 - 09:45    **Advanced care planning**  
I. Korfage, Erasmus University Medical Center, Rotterdam, NL

09:45 - 10:00    **Cancer pain and associated symptoms**  
A. Koller, University of Vienna, Vienna, AT

10:00 - 10:15    **CN55 - Evaluation of a nursing aftercare intervention for patients with head and neck cancer treated with chemoradiation**  
C. Braat<sup>1</sup>, G. Verduijn<sup>2</sup>, H. Van Der Stege<sup>3</sup>, M. Offerman<sup>4</sup>, M. Peeters<sup>3</sup>, A. Van Staa<sup>3</sup>, W. Oldenmenger<sup>2</sup>, <sup>1</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>2</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>3</sup>Hogeschool Rotterdam, Rotterdam, NL, <sup>4</sup>Erasmus MC, Rotterdam, NL

10:15 - 10:30    **CN56 - When symptom complexity is the norm: a mediation analysis between pain, anxiety, depression and fatigue**  
A. Charalambous, Cyprus University of Technology - Nursing Science, Limassol, CY

10:30 - 10:45    **Discussion**

**09:30 - 10:40**    **Type: Poster Discussion session**    **Hall B3 - Room 21**  
**Title: Poster Discussion session - Immunotherapy of cancer 2**  
 Chair(s): Pedro Romero, CH; Aurélien Marabelle, FR; Inge-Marie Svane, DK

09:30 - 09:30    **Session DOI**

09:30 - 09:30    **1135PD - Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations**  
J. Luke<sup>1</sup>, R. Edwards<sup>2</sup>, C. Hedvat<sup>2</sup>, D. Pandya<sup>2</sup>, S. Ely<sup>2</sup>, R. Meier<sup>2</sup>, D. McDonald<sup>3</sup>, C. Harbison<sup>2</sup>, V. Baxi<sup>2</sup>, G. Lee<sup>2</sup>, P. Szabo<sup>2</sup>, T. Garcia<sup>1</sup>, R. Bao<sup>1</sup>, T. Reilly<sup>2</sup>, E. Jaffee<sup>4</sup>, F. Hodi<sup>5</sup>, <sup>1</sup>The University of Chicago Medical Centre, Chicago, US, <sup>2</sup>Bristol-Myers Squibb, Princeton, US, <sup>3</sup>Bristol-Myers Squibb Company, New York, US, <sup>4</sup>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, US, <sup>5</sup>Dana-Farber Cancer Institute, Boston, US

09:30 - 09:30    **1136PD - Discrepancy of tumor neoantigen burden between primary lesions and**

**matched metastases in lung cancer**

T. Jiang, C. Zhou, Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN

09:30 - 09:30

**1137PD - Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444**

S. Willingham<sup>1</sup>, A. Hotson<sup>1</sup>, G. Laport<sup>1</sup>, L. Kwei<sup>1</sup>, L. Fong<sup>2</sup>, M. Sznol<sup>3</sup>, J. Powderly<sup>4</sup>, R. Miller<sup>1</sup>, <sup>1</sup>Corvus Pharmaceuticals, Burlingame, US, <sup>2</sup>University of California, San Francisco, San Francisco, US, <sup>3</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>4</sup>Carolina Biooncology Cancer Therapy, Huntersville, US

09:30 - 09:45

**Invited Discussant 1135PD, 1136PD and 1137PD**

P. Romero, Ludwig Center for Cancer Research of the UNIL, Epalinges, CH

09:45 - 09:55

**Q&A led by Discussant**

09:55 - 09:55

**1138PD - First in Human Study with GSK3359609 [GSK609], Inducible T cell Co-stimulator (ICOS) Receptor Agonist in Patients [Pts] with Advanced, Solid Tumors: Preliminary Results from INDUCE-1**

A. Hansen<sup>1</sup>, T. Bauer<sup>2</sup>, V. Moreno<sup>3</sup>, M. Maio<sup>4</sup>, S. Groenland<sup>5</sup>, J. Martin-Liberal<sup>6</sup>, H. Gan<sup>7</sup>, D. Rischin<sup>8</sup>, M. Millward<sup>9</sup>, A. Olszanski<sup>10</sup>, D. Cho<sup>11</sup>, E. Paul<sup>12</sup>, M. Ballas<sup>13</sup>, C. Ellis<sup>13</sup>, H. Zhou<sup>13</sup>, S. Yadavilli<sup>13</sup>, J. Sadik Shaik<sup>13</sup>, E. Schmidt<sup>14</sup>, A. Hoos<sup>15</sup>, E. Angevin<sup>16</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>3</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>4</sup>University Hospital of Siena, Istituto Toscano Tumori, Siena, IT, <sup>5</sup>Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NL, <sup>6</sup>Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>7</sup>(Austin Health) Austin Hospital, Melbourne, AU, <sup>8</sup>Peter MacCallum Cancer Centre, and the University of Melbourne, Melbourne, AU, <sup>9</sup>School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU, <sup>10</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>11</sup>New York University Langone Medical Center, New York, US, <sup>12</sup>GlaxoSmithKline, Research Triangle Park, US, <sup>13</sup>GlaxoSmithKline, Colleagueville, US, <sup>14</sup>Merck & Co Inc, North Wales, US, <sup>15</sup>GlaxoSmithKline USA, Colleagueville, US, <sup>16</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR

09:55 - 09:55

**1139PD - Novel Small-Molecule ROR\_ Agonist Immuno-oncology Agent LYC-55716: Safety and Efficacy in a Phase 2A Open-Label, Multicenter Trial**

J. Wang<sup>1</sup>, S. Liu<sup>2</sup>, H. Uronis<sup>3</sup>, C. Wu<sup>4</sup>, D. Mahalingam<sup>5</sup>, A. Spira<sup>6</sup>, L. Carter<sup>7</sup>, X. Hu<sup>7</sup>, G. Weems<sup>8</sup>, H. Wilkins<sup>8</sup>, L. Duska<sup>9</sup>, K. Kelly<sup>10</sup>, <sup>1</sup>Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, US, <sup>2</sup>Georgetown University Medical Center, Washington, DC, US, <sup>3</sup>Duke University Medical Center, Durham, US, <sup>4</sup>Emory University, Atlanta, US, <sup>5</sup>Northwestern University, Chicago, US, <sup>6</sup>Virginia Cancer Specialists Research Institute, Fairfax, US, <sup>7</sup>Lycera Corp., Ann Arbor, US, <sup>8</sup>Lycera, Philadelphia, US, <sup>9</sup>University of Virginia Health System, Charlottesville, US, <sup>10</sup>University of California Davis Cancer Center, Sacramento, US

- 09:55 - 09:55 **1140PD - Phase I Study of KN035, a novel fusion Anti-PD-L1 Antibody administered subcutaneously in Patients with Advanced Solid Tumors in the USA**  
K. Papadopoulos<sup>1</sup>, W. Harb<sup>2</sup>, N. Lu<sup>3</sup>, X. Ma<sup>4</sup>, Y. He<sup>5</sup>, L. Yuan<sup>6</sup>, M. Fu<sup>3</sup>, Y. Lin<sup>6</sup>, W. Xu<sup>7</sup>, X. Wang<sup>8</sup>, P. Wang<sup>8</sup>, T. Xu<sup>8</sup>, R. Dong<sup>6</sup>, J. Gong<sup>6</sup>, <sup>1</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>2</sup>Horizon BioAdvance, Lafayette, US, <sup>3</sup>D Medicines (Beijing) Co., Ltd., Beijing, CN, <sup>4</sup>3D Medicines (Beijing) Co., Ltd., Shanghai, CN, <sup>5</sup>3D Medicines Co., Ltd, Shanghai, CN, <sup>6</sup>3D Medicines Co., Ltd., Shanghai, CN, <sup>7</sup>3D Medicines Co., Ltd., Beijing, CN, <sup>8</sup>Suzhou Alphamab Co., Ltd., Suzhou, CN
- 09:55 - 10:10 **Invited Discussant 1138PD, 1139PD and 1140PD**  
A. Marabelle, Gustave Roussy, Villejuif, FR
- 10:10 - 10:20 **Q&A led by Discussant**
- 10:20 - 10:20 **1141PD - Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1**  
M. Kfoury<sup>1</sup>, A.-L. Voisin<sup>2</sup>, M. Najean<sup>2</sup>, S. Champiat<sup>3</sup>, S. Laghouati<sup>4</sup>, J.-M. Michot<sup>4</sup>, C. Robert<sup>4</sup>, C. Mateus<sup>4</sup>, L. Albiges<sup>4</sup>, B. Besse<sup>5</sup>, C. Massard<sup>6</sup>, M. Texier<sup>6</sup>, O. Lambotte<sup>7</sup>, A. Marabelle<sup>3</sup>, <sup>1</sup>Université Paris5, Paris, FR, <sup>2</sup>Gustave Roussy Institute, Villejuif, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR, <sup>5</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>6</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>7</sup>Hôpital Bicêtre, Le Kremlin-Bicêtre, FR
- 10:20 - 10:20 **1142PD - Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: data from a French multicentric cohort**  
C. Domblides<sup>1</sup>, I. Monnet<sup>2</sup>, J. Mazieres<sup>3</sup>, F. Barlesi<sup>4</sup>, V. Gounant<sup>5</sup>, S. Baldacci<sup>6</sup>, B. Mennequier<sup>7</sup>, A.C. Toffart<sup>8</sup>, C. Audigier Valette<sup>9</sup>, L. Doucet<sup>10</sup>, E. Giroux-Leprieur<sup>11</sup>, F. Guisier<sup>12</sup>, O. Molinier<sup>13</sup>, M. Perol<sup>14</sup>, E. Pichon<sup>15</sup>, G. Robinet<sup>16</sup>, D. Templement Grangerat<sup>17</sup>, A.-M. Ruppert<sup>18</sup>, M. Wislez<sup>18</sup>, <sup>1</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>2</sup>CH Intercommunal de Créteil, Créteil, FR, <sup>3</sup>Hospital Larrey, Toulouse, FR, <sup>4</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>5</sup>Hopital Bichat Claude Bernard, Paris, FR, <sup>6</sup>Hopital Calmette, CHRU Lille, Lille, FR, <sup>7</sup>C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, <sup>8</sup>CHU de Grenoble, La Tronche, FR, <sup>9</sup>Hopital Sainte Musse, Toulon, FR, <sup>10</sup>Hôpital St. Louis, Paris, FR, <sup>11</sup>Hopital Ambroise Pare, Boulogne-Billancourt, FR, <sup>12</sup>CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR, <sup>13</sup>Centre Hospitalier Du Mans, Le Mans, FR, <sup>14</sup>Centre Léon Bérard, Lyon, FR, <sup>15</sup>CHRU Bretonneau, Tours, FR, <sup>16</sup>C.H.U. Brest - Hôpital Morvan, Brest, FR, <sup>17</sup>Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, <sup>18</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR
- 10:20 - 10:30 **Invited Discussant 1041PD and 1042PD**  
I.-M. Svane, Herlev Hospital, Herlev, DK
- 10:30 - 10:40 **Q&A led by Discussant**

**09:30 - 10:30** **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 23**  
**Title: Managing early breast cancer during pregnancy**  
 Chair(s): Sabine Linn, NL

09:30 - 09:30 **Session DOI**

09:30 - 09:40 **Pathology of breast cancer and pregnancy**  
E. Provenzano, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

09:40 - 09:50 **Chemotherapy during pregnancy**  
F. Amant, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

09:50 - 10:00 **Her2-targeted therapy during pregnancy**  
S. Linn, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

10:00 - 10:30 **Discussion**

**09:30 - 10:30** **Type: Multidisciplinary interactive sessions** **Hall B3 - Room 20**  
**Title: At the heyday of molecular classification of cancer**  
 Chair(s): Rebecca Fitzgerald, GB

09:30 - 09:30 **Session DOI**

09:30 - 09:35 **Introduction**  
R. Fitzgerald, University of Cambridge - MRC Cancer Unit, Cambridge, GB

09:35 - 09:50 **Pathology**  
M. Sobrinho Simões, IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT

09:50 - 10:05 **Molecular classification**  
R. Bristow, Cancer Research UK Manchester Institute, Manchester, GB

10:05 - 10:30 **Moderated panel discussion with Q&A by audience**  
R. Fitzgerald, University of Cambridge - MRC Cancer Unit, Cambridge, GB



**09:30 - 10:30**    **Type: Challenge Your Expert (CYE) session**    **Hall B3 - Room 22**  
**Title: Tumour sequencing in drug development**  
 Chair(s): Matthew Krebs, GB

09:30 - 09:30    **Session DOI**

09:30 - 09:40    **Tumour sequencing in drug development**  
C. Le Tourneau, Institut Curie, Paris, FR

09:40 - 10:30    **Discussion led by**  
M. Krebs, The Christie NHS Foundation Trust, Manchester, GB

**09:30 - 10:30**    **Type: Challenge Your Expert (CYE) session**    **ICM - Room 14a**  
**Title: Neuroendocrine tumours: Role of theranostics and nuclear medicine**  
 Chair(s): Marianne Pavel, DE

09:30 - 09:30    **Session DOI**

09:30 - 09:40    **Neuroendocrine tumours: Role of theranostics and nuclear medicine**  
R. Baum, Zentralklinik, Bad Berska, DE

09:40 - 10:30    **Discussion led by**  
M. Pavel, Universitätsklinik Erlangen, Erlangen, DE

**09:30 - 10:30**    **Type: Young Oncologist session**    **ICM - Room 14c**  
**Title: YO Mentorship Session: Career paths in oncology**  
 Chair(s): Jesus Corral, ES; Teresa Amaral, PT

09:30 - 09:30    **Session DOI**

09:30 - 09:30    **Clinical**

E. Martinelli<sup>1</sup>, C. Zielinski<sup>2</sup>, <sup>1</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>2</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

09:30 - 09:30    **Basic science**

M. Sibilia<sup>1</sup>, R. Pio<sup>2</sup>, <sup>1</sup>Medizinische Universität Wien (Medical University of Vienna), Vienna, AT, <sup>2</sup>Universidad de Navarra, Pamplona, ES

09:30 - 09:30    **Translational research**

M. Hegi<sup>1</sup>, A. Prat<sup>2</sup>, <sup>1</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>2</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

09:30 - 09:30    **Industry**

E. Thalmann<sup>1</sup>, W. Pao<sup>2</sup>, <sup>1</sup>Janssen-Cilag Pharma - Austria, Vienna, AT, <sup>2</sup>F. Hoffmann-La Roche AG - Switzerland, Basel, CH

**11:00 - 12:30**    **Type: Special session**    **ICM - Room 13**  
**Title: Liquid biopsies in cancer management**  
 Chair(s): Klaus Pantel, DE; Michael Speicher, AT

11:00 - 11:00    **DOI Session**

11:00 - 11:25    **What are the limitations of liquid biopsies**

M. Speicher, Medical University of Graz, Graz, AT

11:25 - 11:50    **Circulating tumour cells**

K. Pantel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

11:50 - 12:15    **Liquid biopsies in haematological malignancies**

G. Gaidano, Amedeo Avogadro University, Novara, IT

12:15 - 12:30    **Discussion**

**11:00 - 12:30**    **Type: Special session**    **Hall B3 - Room 21**  
**Title: The changing scenario of drug registration**

Chair(s): Christian Dittrich, AT; Ian Tannock, CA

11:00 - 11:00    **Session DOI**

11:00 - 11:05    **Introduction**

I. Tannock, Princess Margaret Hospital, Toronto, CA

11:05 - 11:25    **Accelerated / conditional approval as a new regular way of drug registration**

F. Pignatti, European Medicines Agency (EMA), London, GB

11:25 - 11:45    **Reasons for not lowering the bar for new drugs registration**

I. Tannock, Princess Margaret Hospital, Toronto, CA

11:45 - 12:05    **Patients expectations from drug regulators: The view of the patient advocate**

B. Ryll, Melanoma Patient network Europe, Uppsala, SE

12:05 - 12:15    **Conclusions**

C. Dittrich, Angewandte Krebsforschung - Institution für Translationale Forschung Wien (ACR-ITR VIENNA), Vienna, AT

**11:00 - 12:15**    **Type: Poster Discussion session**    **Hall B3 - Room 23**  
**Title: Poster Discussion session - Sarcoma**

Chair(s): Maud Toulmonde, FR; Anastasia Constantinidou, CY; Eva Wardelmann, DE

11:00 - 11:00    **DOI Session**

11:00 - 11:00    **1604PD - Health-related quality of life in patients with advanced soft tissue sarcoma (ASTS): Results from the TSAR randomized phase III trial of the French Sarcoma Group**

A. Le Cesne, R. Kapso Kapnang, S. Foulon, J. Bonastre, Gustave Roussy, Villejuif, FR

11:00 - 11:00    **1605PD - Health-related Quality of Life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line**

V. Grünwald<sup>1</sup>, M. Schuler<sup>2</sup>, P. Schöffski<sup>3</sup>, H.-G. Kopp<sup>4</sup>, S. Bauer<sup>1</sup>, B. Kasper<sup>5</sup>, L. Lindner<sup>6</sup>, J. Chemnitz<sup>7</sup>, M. Crysandt<sup>8</sup>, A. Stein<sup>9</sup>, B. Steffen<sup>10</sup>, S. Richter<sup>11</sup>, M. Kneba<sup>12</sup>, G. Egerer<sup>13</sup>, S. Zimmermann<sup>14</sup>, A. Karch<sup>14</sup>, A. Kunitz<sup>15</sup>, <sup>1</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>2</sup>Helios Klinikum Emil von Behring, Berlin, DE, <sup>3</sup>University Hospitals Leuven, Leuven, BE, <sup>4</sup>Universitätsklinikum Tübingen Medizinische Universitätsklinik, Tübingen, DE, <sup>5</sup>Universitätsklinikum Mannheim, Mannheim, DE, <sup>6</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>7</sup>Ev. Strift

St. Martin, Koblenz, DE, <sup>8</sup>University Hospital Aachen, Aachen, DE, <sup>9</sup>UKE  
Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>10</sup>University Hospital  
Frankfurt, Frankfurt, DE, <sup>11</sup>University Hospital Carl Gustav Carus, Dresden, DE,  
<sup>12</sup>University Hospital Kiel, Kiel, DE, <sup>13</sup>University Hospital Heidelberg, Heidelberg, DE,  
<sup>14</sup>Hannover Medical School, Hannover, DE, <sup>15</sup>Universitätsklinik Charité, Campus  
Virchow Klinikum, Berlin, DE

- 11:00 - 11:00 **1606PD - Quality of Life in patients with soft tissue sarcoma undergoing palliative treatment - A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12)**  
L. Hentschel<sup>1</sup>, S. Richter<sup>2</sup>, H.-G. Kopp<sup>3</sup>, B. Kasper<sup>4</sup>, A. Kunitz<sup>5</sup>, V. Grünwald<sup>6</sup>, T. Kessler<sup>7</sup>, J.-M. Chemnitz<sup>8</sup>, U. Pelzer<sup>5</sup>, U. Schuler<sup>9</sup>, J. Freitag<sup>2</sup>, A. Schilling<sup>2</sup>, B. Hornemann<sup>2</sup>, K. Arndt<sup>10</sup>, G. Ehniger<sup>9</sup>, M. Bornhäuser<sup>9</sup>, M. Schuler<sup>2</sup>, <sup>1</sup>University Hospital Carl-Gustav-Carus, Dresden, DE, <sup>2</sup>University Hospital Carl Gustav Carus, Dresden, DE, <sup>3</sup>Universitätsklinikum Tübingen Medizinische Universitätsklinik, Tübingen, DE, <sup>4</sup>Universitätsklinikum Mannheim, Mannheim, DE, <sup>5</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>6</sup>Medical School Hannover, Hannover, DE, <sup>7</sup>University Hospital of Münster, Münster, DE, <sup>8</sup>St. Martin Hospital, Koblenz, DE, <sup>9</sup>Universitätsklinikum Dresden, Dresden, DE, <sup>10</sup>Das Lebenshaus e.V., Wölfersheim, DE
- 11:00 - 11:15 **Invited Discussant 1604PD, 1605PD and 1606PD**  
A. Constantinidou, Bank of Cyprus Oncology Centre, Nicosia, CY
- 11:15 - 11:25 **Q&A led by Discussant**
- 11:25 - 11:25 **1607PD - Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy**  
S. Chawla<sup>1</sup>, S. Pollack<sup>2</sup>, M. Block<sup>3</sup>, M. Druta<sup>4</sup>, K. Do<sup>5</sup>, J. Morris<sup>6</sup>, J. Kim<sup>7</sup>, C. Bohac<sup>8</sup>, H. Lu<sup>9</sup>, S. Gnjatic<sup>10</sup>, R. Jones<sup>11</sup>, P. Hwu<sup>12</sup>, N. Somaiah<sup>13</sup>, <sup>1</sup>Sarcoma Oncology Research Center, Santa Monica, US, <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, US, <sup>3</sup>Mayo Clinic, Rochester, US, <sup>4</sup>Moffitt Cancer Center, Tampa, US, <sup>5</sup>Dana Farber Cancer Institute, Boston, US, <sup>6</sup>University of Cincinnati, Cincinnati, US, <sup>7</sup>Yale University, New Haven, US, <sup>8</sup>AMGEN (Headquarters) - USA, Thousand Oaks, US, <sup>9</sup>Immune Design, Seattle, US, <sup>10</sup>Mt Sinai, New York City, US, <sup>11</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>12</sup>MD Anderson Cancer Center, Houston, US, <sup>13</sup>Medical University of South Carolina, Charleston, US
- 11:25 - 11:25 **1608PD - Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients.**  
J.-B. Delhorme<sup>1</sup>, E. Nassif<sup>2</sup>, G. Ferron<sup>3</sup>, E. Bompas<sup>4</sup>, J. Adam<sup>5</sup>, O. Glehen<sup>6</sup>, A. Italiano<sup>7</sup>, F. Bertucci<sup>8</sup>, D. Orbach<sup>9</sup>, A. Le Cesne<sup>10</sup>, J. Blay<sup>11</sup>, C. Chevreau<sup>12</sup>, O. Mir<sup>5</sup>, C. Honoré<sup>10</sup>, <sup>1</sup>Haute-pierre University Hospital, Strasbourg, FR, <sup>2</sup>Paris Descartes University, Paris, FR, <sup>3</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>4</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>7</sup>Institute Bergonié, Bordeaux, FR, <sup>8</sup>Institute Paoli Calmettes, Marseille, FR, <sup>9</sup>Institut Curie, Paris, FR, <sup>10</sup>Gustave Roussy - Cancer



Campus, Villejuif, FR, <sup>11</sup>Centre Léon Bérard, Lyon, FR, <sup>12</sup>Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR

11:25 - 11:25

**1609PD - Preoperative hypofractionated radiotherapy (RT) in patients with locally advanced myxoid liposarcomas: interim analysis of prospective phase II clinical trial**

H. Kosela Paterczyk<sup>1</sup>, M. Spalek<sup>2</sup>, M. Wagrodzki<sup>3</sup>, A. Borkowska<sup>2</sup>, A. Szumera-Cieckiewicz<sup>4</sup>, A. Cieszanowski<sup>2</sup>, T. Morysinski<sup>1</sup>, J. Palucki<sup>2</sup>, P. Rutkowski<sup>5</sup>, <sup>1</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>2</sup>Maria Skłodowska-Curie Institute - Oncology Center, Warsaw, PL, <sup>3</sup>Oncology Center in Warsaw, Warsaw, PL, <sup>4</sup>Institute of Hematology and Transfusion Medicine, Warsaw, PL, <sup>5</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL

11:25 - 11:25

**1610PD - A Phase II Study of pazopanib with Oral Topotecan in Patients with Metastatic Osteosarcoma**

B. Van Tine<sup>1</sup>, N. Mohindra<sup>2</sup>, M. Milhem<sup>3</sup>, S. Attia<sup>4</sup>, S. Robinson<sup>5</sup>, A. Rademaker<sup>2</sup>, S. Okuno<sup>5</sup>, M. Agulnik<sup>2</sup>, <sup>1</sup>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University, St. Louis, US, <sup>2</sup>Northwestern University, Chicago, US, <sup>3</sup>University of Iowa, Iowa City, US, <sup>4</sup>Mayo Clinic, Jacksonville, US, <sup>5</sup>Mayo Clinic, Rochester, US

11:25 - 11:40

**Invited Discussant 1607PD, 1608PD, 1609PD and 1610PD**

M. Toulmonde, Institute Bergonié, Bordeaux, FR

11:40 - 11:50

**Q&A led by Discussant**

11:50 - 11:50

**1611PD - A phase 2, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)**

S. Stacchiotti<sup>1</sup>, J.-Y. Blay<sup>2</sup>, R. Jones<sup>3</sup>, G.D. Demetri<sup>4</sup>, O. Mir<sup>5</sup>, A. Italiano<sup>6</sup>, D. Thomas<sup>7</sup>, T.W.-W. Chen<sup>8</sup>, P. Schöffski<sup>9</sup>, T. Gil<sup>10</sup>, T. Jahan<sup>11</sup>, G. Cote<sup>12</sup>, R. Ratan<sup>13</sup>, S. Attia<sup>14</sup>, M. Roche<sup>15</sup>, S. Daigle<sup>15</sup>, I. Sapir<sup>15</sup>, A. Clawson<sup>15</sup>, M. Gounder<sup>16</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Centre Léon Bérard, Lyon, FR, <sup>3</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>4</sup>Dana-Farber Cancer Institute, Boston, US, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>Institute Bergonié, Bordeaux, FR, <sup>7</sup>Garvan Institute of Medical Research, Darlinghurst, AU, <sup>8</sup>National Taiwan University Hospital, Taipei City, TW, <sup>9</sup>University Hospitals Leuven, Leuven, BE, <sup>10</sup>Institute Jules Bordet, Brussels, BE, <sup>11</sup>University of California, San Francisco, US, <sup>12</sup>Massachusetts General Hospital, Boston, US, <sup>13</sup>MD Anderson Cancer Center, Houston, US, <sup>14</sup>Mayo Clinic, Jacksonville, US, <sup>15</sup>Epizyme, Cambridge, US, <sup>16</sup>Memorial Sloan-Kettering Cancer Center, New York, US

11:50 - 11:50

**1612PD - A phase 2, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)**

R. Jones<sup>1</sup>, J.-Y. Blay<sup>2</sup>, M. Agulnik<sup>3</sup>, R. Chugh<sup>4</sup>, O. Mir<sup>5</sup>, A. Italiano<sup>6</sup>, D. Thomas<sup>7</sup>, A. Gupta<sup>8</sup>, T. Jahan<sup>9</sup>, G. Cote<sup>10</sup>, V. Villalobos<sup>11</sup>, G.D. Demetri<sup>12</sup>, M. Roche<sup>13</sup>, I. Sapir<sup>13</sup>, S. Daigle<sup>13</sup>, A. Clawson<sup>13</sup>, M. Gounder<sup>14</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust,

London, GB, <sup>2</sup>Centre Léon Bérard, Lyon, FR, <sup>3</sup>Northwestern University, Chicago, US, <sup>4</sup>Michigan Medicine Comprehensive Cancer Center, Ann Arbor, US, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>Institute Bergonié, Bordeaux, FR, <sup>7</sup>Garvan Institute of Medical Research, Darlinghurst, AU, <sup>8</sup>Hospital for Sick Children, Toronto, CA, <sup>9</sup>University of California, San Francisco, US, <sup>10</sup>Massachusetts General Hospital, Boston, US, <sup>11</sup>University of Colorado, Denver, US, <sup>12</sup>Dana-Farber Cancer Institute, Boston, US, <sup>13</sup>Epizyme, Cambridge, US, <sup>14</sup>Memorial Sloan-Kettering Cancer Center, New York, US

11:50 - 11:50

**1613PD - mTOR inhibitors in uterine and extra-uterine malignant PEComas: a multicenter international case series retrospective analysis.**

R. Sanfilippo<sup>1</sup>, R. Jones<sup>2</sup>, S. Provenzano<sup>3</sup>, G. Antoniou<sup>4</sup>, J.-Y. Blay<sup>5</sup>, E. Fumagalli<sup>3</sup>, S. Stacchiotti<sup>1</sup>, R.M. Bertulli<sup>3</sup>, O. Mir<sup>6</sup>, N. Hindi<sup>7</sup>, M. Brahmi<sup>5</sup>, A. Dufresne<sup>5</sup>, A.P. Dei Tos<sup>8</sup>, P.G. Casali<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>3</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>4</sup>Royal Marsden Hospital, London, GB, <sup>5</sup>Centre Léon Bérard, Lyon, FR, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>8</sup>Istituto Oncologico Veneto IRCCS, Padova, IT

11:50 - 11:50

**1614PD - A Phase II Study of Preoperative Chemoradiation plus Sorafenib (S) for High-Risk Extremity Soft Tissue Sarcomas (STS)**

C. Ryan, L. Davis, Y.-C. Doung, J. Davis, A. Hung, J. Hayden, K. Gundle, J. Vetto, A. Mansoor, B. Beckett, P. Norr, S. Bertolone-Smith, W. Huang, Oregon Health Science University, Portland, US

11:50 - 11:50

**1615PD - A phase 2, multicenter study of the EZH2 inhibitor tazemetostat in adults: (epithelioid sarcoma cohort) (NCT02601950)**

M. Gounder<sup>1</sup>, P. Schöffski<sup>2</sup>, V. Villalobos<sup>3</sup>, G. Cote<sup>4</sup>, R. Chugh<sup>5</sup>, T.W.-W. Chen<sup>6</sup>, T. Jahan<sup>7</sup>, E. Loggers<sup>8</sup>, A. Italiano<sup>9</sup>, A. Gupta<sup>10</sup>, M. Agulnik<sup>11</sup>, S. Attia<sup>12</sup>, R. Jones<sup>13</sup>, B. Van Tine<sup>14</sup>, G.D. Demetri<sup>15</sup>, M. Roche<sup>16</sup>, I. Sapir<sup>16</sup>, S. Daigle<sup>16</sup>, A. Clawson<sup>16</sup>, S. Stacchiotti<sup>17</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>University Hospitals Leuven, Leuven, BE, <sup>3</sup>University of Colorado, Denver, US, <sup>4</sup>Massachusetts General Hospital, Boston, US, <sup>5</sup>Michigan Medicine Comprehensive Cancer Center, Ann Arbor, US, <sup>6</sup>National Taiwan University Hospital, Taipei City, TW, <sup>7</sup>University of California, San Francisco, US, <sup>8</sup>Seattle Cancer Care Alliance, Seattle, US, <sup>9</sup>Institute Bergonié, Bordeaux, FR, <sup>10</sup>Hospital for Sick Children, Toronto, CA, <sup>11</sup>Northwestern University, Chicago, US, <sup>12</sup>Mayo Clinic, Jacksonville, US, <sup>13</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>14</sup>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University, St. Louis, US, <sup>15</sup>Dana-Farber Cancer Institute, Boston, US, <sup>16</sup>Epizyme, Cambridge, US, <sup>17</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

11:50 - 12:05

**Invited Discussant 1611PD, 1612PD, 1613PD and 1614PD**

E. Wardelmann, University Hospital Muenster-Gerhard Domagk Institute of Pathology, Münster, DE

12:05 - 12:15

**Q&A led by Discussant**

**11:00 - 12:30**    **Type: Special Symposium**    **Hall B3 - Room 20**  
**Title: Global surveillance of cancer survival: Impact on cancer control**  
 Chair(s): Michel Coleman, GB

11:00 - 11:00    **Session DOI**

11:00 - 11:05    **Introduction: Global surveillance of cancer survival will stimulate policy and improve equity**

M. Coleman, London School of Hygiene and Tropical Medicine, London, GB

11:05 - 11:25    **Trends and inequalities in cancer survival world-wide: The latest results**

C. Allemani, London School of Hygiene and Tropical Medicine, London, GB

11:25 - 11:45    **Information for cancer patients, their families and care-givers: Improving outcomes in low- and middle-income countries**

S. Cowal, American Cancer Society, Atlanta, US

11:45 - 12:05    **Cancer survival comparisons as a tool to improve the quality of health care: The experience from OECD**

N. Klazinga, OECD, Paris, FR

12:05 - 12:25    **Delivering affordable cancer care in developed and developing countries**

R. Sullivan, Institute of cancer policy, London, GB

12:25 - 12:30    **Panel discussion led by chair**

**11:00 - 12:15**    **Type: Poster Discussion session**    **Hall B3 - Room 22**  
**Title: Poster Discussion session - NETs and endocrine tumours**  
 Chair(s): Aldo Scarpa, IT; Rossella Elisei, IT; Enrique Grande, ES

11:00 - 11:00    **Session DOI**

11:00 - 11:00    **450PD - Potential Therapeutic Targets in Recurrent and Metastatic Parathyroid Carcinomas revealed by next-generation sequencing.**

M. Cui, Y. Hu, Q. Liao, Y. Zhao, PUMCH, Beijing, CN

11:00 - 11:00    **1310PD - Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms**

L. Apostolidis<sup>1</sup>, S. Kreutzfeldt<sup>2</sup>, M. Oles<sup>3</sup>, L. Geldon<sup>4</sup>, C. Heining<sup>5</sup>, P. Horak<sup>3</sup>, B. Hutter<sup>6</sup>, M. Fröhlich<sup>6</sup>, B. Klink<sup>4</sup>, M. Lamping<sup>7</sup>, S. Uhrig<sup>6</sup>, A. Stenzinger<sup>8</sup>, E. Winkler<sup>9</sup>, B.

Wiedenmann<sup>10</sup>, D. Jäger<sup>11</sup>, E. Schröck<sup>4</sup>, U. Keilholz<sup>12</sup>, M. Pavel<sup>13</sup>, H. Glimm<sup>5</sup>, S. Fröhling<sup>3</sup>, <sup>1</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>2</sup>German Cancer Research Center, Heidelberg, DE, <sup>3</sup>National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, DE, <sup>4</sup>Faculty of Medicine Carl Gustav Carus, Dresden, DE, <sup>5</sup>University Hospital Carl Gustav Carus, Dresden, DE, <sup>6</sup>German Cancer Consortium (DKTK), Heidelberg, DE, <sup>7</sup>Charité University Medicine, Berlin, DE, <sup>8</sup>University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, <sup>9</sup>National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, DE, <sup>10</sup>Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, <sup>11</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, <sup>12</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>13</sup>Universitätsklinik Erlangen, Erlangen, DE

11:00 - 11:15 **Invited Discussant 450PD and 1310PD**

A. Scarpa, AOU Integrata Verona "Borgo Roma", Verona, IT

11:15 - 11:25 **Q&A led by Discussant**

11:25 - 11:25 **1820PD - Synergistic anti-cancer activity of tyrosine kinase inhibitors and paclitaxel with radiation on anaplastic thyroid cancer in vitro and in vivo**

Y.S. Lee<sup>1</sup>, H. Chang<sup>2</sup>, S.Y. Kim<sup>2</sup>, H.-S. Chang<sup>2</sup>, C.S. Park<sup>2</sup>, <sup>1</sup>Yonsei University, Seoul, KR, <sup>2</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, seoul, KR

11:25 - 11:25 **1821PD - Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC)**

B. Keam<sup>1</sup>, R. Kreitman<sup>2</sup>, Z. Wainberg<sup>3</sup>, M. Cabanillas<sup>4</sup>, D. Cho<sup>5</sup>, A. Italiano<sup>6</sup>, A. Stein<sup>7</sup>, J.Y. Cho<sup>8</sup>, J. Schellens<sup>9</sup>, P. Wen<sup>10</sup>, C. Zielinski<sup>11</sup>, A. Boran<sup>12</sup>, B. Mookerjee<sup>12</sup>, P. Burgess<sup>13</sup>, F. Rangwala<sup>14</sup>, V. Subbiah<sup>15</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>National Institutes of Health, Bethesda, US, <sup>3</sup>David Geffen School of Medicine at UCLA, Los Angeles, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>New York University Langone Medical Center, New York, US, <sup>6</sup>Institute Bergonié, Bordeaux, FR, <sup>7</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>8</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>9</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>10</sup>Dana-Farber Cancer Institute, Boston, US, <sup>11</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>12</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>13</sup>Novartis Pharma AG, Basel, CH, <sup>14</sup>Novartis Pharmaceuticals, Morrisville, US, <sup>15</sup>The University of Texas, MD Anderson Cancer Center, Houston, US

11:25 - 11:40 **Invited Discussant 1820PD and 1821PD**

R. Elisei, University Hospital of Pisa, Pisa, IT

11:40 - 11:50 **Q&A led by Discussant**

11:50 - 11:50 **1311PD - Health-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine**



**tumors (mmNETs) in the phase IIIb PROMID trial**

A. Rinke<sup>1</sup>, M. Neary<sup>2</sup>, J. Eriksson<sup>3</sup>, M. Hunger<sup>4</sup>, T. Doan<sup>5</sup>, D. Karli<sup>5</sup>, R. Arnold<sup>1</sup>, <sup>1</sup>Philipps-University of Marburg, Marburg, DE, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, SE, <sup>3</sup>Mapi Group, Stockholm, SE, <sup>4</sup>Mapi (ICON plc), Munich, DE, <sup>5</sup>Novartis Ireland Ltd., Dublin, IE

11:50 - 11:50 **1312PD - Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: the FFCD 1104-EVACEL-GTE phase II study**

T. Walter<sup>1</sup>, C. Lepage<sup>2</sup>, R. Coriat<sup>3</sup>, E. Barbier<sup>4</sup>, G. Cadiot<sup>5</sup>, F.X. Caroli Bosc<sup>6</sup>, T. Aparicio<sup>7</sup>, K. Bouhier Leporrier<sup>8</sup>, O. Hentic Dhome<sup>9</sup>, A.-C. Dupont-Gossart<sup>10</sup>, M. Duluc<sup>11</sup>, C. Lepere<sup>12</sup>, T. Lecomte<sup>13</sup>, D. Smith<sup>14</sup>, C. Petorin<sup>15</sup>, I. Iwanicki Caron<sup>16</sup>, M. Ducreux<sup>17</sup>, C. Lombard Bohas<sup>18</sup>, T. De Baere<sup>19</sup>, <sup>1</sup>CHU Edouard Herriot, LYON, FR, <sup>2</sup>CHU Dijon, Dijon, FR, <sup>3</sup>Hôpital Cochin, Paris, FR, <sup>4</sup>FFCD-, Dijon, FR, <sup>5</sup>CHU de Reims - Hôpital Robert Debré, Reims, FR, <sup>6</sup>CHU Angers, Angers, FR, <sup>7</sup>Hôpital Avicenne, Bobigny, FR, <sup>8</sup>CHU de Caen, Caen, FR, <sup>9</sup>Hôpital Beaujon, Clichy, FR, <sup>10</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>11</sup>CHU La Timone Adultes, Marseille, FR, <sup>12</sup>European George Pompidou Hospital, Paris, FR, <sup>13</sup>CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, <sup>14</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>15</sup>CHU Estaing, Clermont-Ferrand, FR, <sup>16</sup>CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR, <sup>17</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>18</sup>Hopital Edouard Herriot Pav. E bis, Lyon, FR, <sup>19</sup>Institut Gustave Roussy, Villejuif, FR

11:50 - 11:50 **1313PD - A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained chemotherapy**

H. Okuyama<sup>1</sup>, M. Ikeda<sup>2</sup>, T. Okusaka<sup>3</sup>, J. Furuse<sup>4</sup>, M. Furukawa<sup>5</sup>, S. Ohkawa<sup>6</sup>, A. Hosokawa<sup>7</sup>, Y. Kojima<sup>8</sup>, K. Yamaguchi<sup>9</sup>, G. Murohisa<sup>10</sup>, K. Shioji<sup>11</sup>, H. Ishii<sup>12</sup>, N. Mizuno<sup>13</sup>, M. Kojima<sup>14</sup>, T. Yamanaka<sup>15</sup>, <sup>1</sup>Kagawa University Faculty of Medicine/Graduate School of Medicine, Kagawa, JP, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>National Cancer Center Hospital, Tokyo, JP, <sup>4</sup>Kyorin University, Tokyo, JP, <sup>5</sup>National Kyushu Cancer Center, Fukuoka, JP, <sup>6</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>7</sup>University of Toyoma, Toyoma, JP, <sup>8</sup>National Center for Global Health and Medicine, Tokyo, JP, <sup>9</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>10</sup>Seirei Hamamatsu General Hospital, Hamamatsu, JP, <sup>11</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>12</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>13</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>14</sup>National Cancer Center, Kashiwa, JP, <sup>15</sup>Yokohama City University Hospital, Yokohama, JP

11:50 - 12:05 **Invited Discussant 1311PD, 1312PD and 1313PD**

E. Grande, MD Anderson Cancer Center Center Espana, Madrid, ES

12:05 - 12:15 **Q&A led by Discussant**

**11:00 - 12:30**    **Type: Educational session**    **Hall B4 - Room 19**  
**Title: Epigenetics**  
 Chair(s): Anton Berns, NL

11:00 - 11:00    **Session DOI**

11:00 - 11:25    **Novel technologies to study cancer epigenetics**  
E. Shema, Weizmann Institute of Science, Rehovot, IL

11:25 - 11:50    **Epigenetic reprogramming in paediatric malignancies**  
S. Armstrong, Dana Farber Cancer Institute, Boston, US

11:50 - 12:15    **Epigenetic regulation of cancer**  
F. Di Nicolantonio, IRCCS Istituto di Candiolo, Candiolo, IT

12:15 - 12:30    **Discussion**

**11:00 - 12:30**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: Nurse-led cancer services**  
 Chair(s): Daniel Kelly, GB

11:00 - 11:00    **Session DOI**

11:00 - 11:15    **Nurse led acute oncology service developments**  
M. Fowler, Heartlands Hospital-Heart of England NHS Foundation Trust, Birmingham, GB

11:15 - 11:30    **Introduction of a new advanced cancer nursing role in Sweden**  
L. Sharp, Regional Cancer Center Stockholm Gotland, Stockholm, SE

11:30 - 11:45    **Towards implementation of an eHealth-powered integrated model of care in allogeneic hematopoietic stem cell transplantation: The SMILE project**  
L. Leppla, University Medical Center Freiburg, Freiburg, DE

11:45 - 12:00    **Psychosexual support service development**  
I. White, The Royal Marsden NHS Foundation Trust, London, GB

12:00 - 12:30    **Discussion**

<b>11:00 - 11:45</b>	<b>Type: Young Oncologist session</b> <b>Title: YO Brunch 3: Biosimilars: What they are and their use in oncology</b>	<b>ICM - Room 14a</b>
	Chair(s): Radu Vidra, RO; Ioannis Litos, GR	
11:00 - 11:00	<b>DOI Session</b>	
11:00 - 11:45	<b>Biosimilars: What they are and their use in oncology</b> <u>R. Giuliani</u> , Azienda Ospedaliera S. Camillo Forlanini, Rome, IT	
<b>11:15 - 12:45</b>	<b>Type: Special Symposium</b> <b>Title: Changing landscape in renal and bladder cancer</b>	<b>Hall A1 - Room 17</b>
	Chair(s): Karim Fizazi, FR; Manuela Schmidinger, AT	
11:15 - 11:15	<b>DOI Session</b>	
11:15 - 11:20	<b>Introduction</b> <u>K. Fizazi</u> , Gustave Roussy, Villejuif, FR	
11:20 - 11:40	<b>Challenging established frontline therapies in renal cancer</b> <u>L. Albiges</u> , Institut Gustave Roussy, Villejuif, FR	
11:40 - 12:00	<b>Challenging established frontline therapies in bladder cancer</b> <u>T. Powles</u> , St. Bartholomew's Hospital, London, GB	
12:00 - 12:20	<b>Can biology help guide treatment decisions in renal cancer?</b> <u>M. Schmidinger</u> , Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT	
12:20 - 12:40	<b>Can biology help guide treatment decisions in bladder cancer?</b> <u>M. Galsky</u> , Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US	
12:40 - 12:45	<b>Conclusion and perspectives</b> <u>K. Fizazi</u> , Gustave Roussy, Villejuif, FR	

**11:15 - 12:15**    **Type: Multidisciplinary interactive sessions**    **ICM - Room 1**  
**Title: The paradigm of oligometastatic disease and ablative treatment**  
 Chair(s): Gerald Prager, AT

11:15 - 11:15    **DOI Session**

11:15 - 11:25    **Choice of systemic therapy in oligometastatic disease**  
G. Prager, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

11:25 - 11:35    **Local ablative treatments: Which instruments - and why used?**  
T. Helmberger, Klinikum Neuperlach-Staedtisches Klinikum Muenchen, Munich, DE

11:35 - 11:45    **Surgery in mCRC: How invasive should our patients be treated in a non-curative setting?**  
P. Naredi, Umea University, Umea, SE

11:45 - 12:15    **Discussion**

**11:15 - 12:15**    **Type: Multidisciplinary interactive sessions**    **Hall A1 - Room 15**  
**Title: Different approaches and advances in the management of HPV+ patients**  
 Chair(s): Jean-Pascal Machiels, BE; Esat Mahmut Ozsahin, CH; Hisham Mehanna, GB

11:15 - 11:15    **DOI Session**

11:15 - 11:25    **New staging system (for HPV+ patients)**  
H. Mehanna, The University of Birmingham Institute for Cancer Studies, Birmingham, GB

11:25 - 11:35    **Unique radiation considerations (in HPV+ patients)**  
E.M. Ozsahin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

11:35 - 11:45    **Integrating systemic therapy (in HPV+ patients)**  
J.-P. Machiels, Cliniques Universitaires St. Luc, Brussels, BE

11:45 - 12:15    **Discussion**



**11:15 - 12:20** **Type: Multidisciplinary interactive sessions** **Hall A1 - Room 16**  
**Title: Recurrent cervical cancer**  
 Chair(s): Ana Oaknin, ES

11:15 - 11:15 **DOI Session**

11:15 - 11:20 **Case presentation**

D. Cibula, General Faculty Hospital, VFN Charles University, Prague, CZ

11:20 - 11:30 **The surgeon's perspective**

D. Cibula, General Faculty Hospital, VFN Charles University, Prague, CZ

11:30 - 11:40 **The radiotherapist's perspective**

A. Taylor, Royal Marsden Hospital NHS Foundation Trust, London, GB

11:40 - 11:50 **The medical oncologist's perspective**

A. Oaknin, Vall d'Hebron University Hospital, Barcelona, ES

11:50 - 12:20 **Discussion**

**11:15 - 12:45** **Type: Proffered Paper session** **Hall A2 - Room 18**  
**Title: Proffered paper session - Immunotherapy of Cancer**  
 Chair(s): George Coukos, CH; Inge Svane, DK

11:15 - 11:15 **DOI Session**

11:15 - 11:27 **LBA37\_PR - Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer**

M. Chalabi<sup>1</sup>, L. Fanchi<sup>2</sup>, J. Van Den Berg<sup>2</sup>, G. Beets<sup>2</sup>, M. Lopez-Yurda<sup>2</sup>, A. Aalbers<sup>3</sup>, C. Grootsholten<sup>1</sup>, P. Snaebjornsson<sup>2</sup>, M. Maas<sup>2</sup>, M. Mertz<sup>2</sup>, E. Nuijten<sup>2</sup>, M. Kuiper<sup>2</sup>, M. Kok<sup>1</sup>, M. Van Leerdam<sup>2</sup>, T. Schumacher<sup>4</sup>, E. Voest<sup>4</sup>, J. Haanen<sup>2</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>3</sup>The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, NL, <sup>4</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

11:27 - 11:39 **11270 - A Personal Neoantigen Vaccine, NEO-PV-01, with anti-PD1 Induces Broad De Novo Anti-Tumor Immunity in Patients with Metastatic Melanoma, NSCLC, and Bladder Cancer**

P. Ott<sup>1</sup>, R. Govindan<sup>2</sup>, A. Naing<sup>3</sup>, T. Friedlander<sup>4</sup>, K. Margolin<sup>5</sup>, J. Lin<sup>6</sup>, N. Bhardwaj<sup>7</sup>, M. Hellman<sup>8</sup>, L. Srinivasan<sup>9</sup>, J. Greshock<sup>9</sup>, M. Moles<sup>9</sup>, R. Gaynor<sup>10</sup>, M. Goldstein<sup>10</sup>, S. Hu-Lieskovan<sup>11</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>Washington University in St.

Louis, St. Louis, US, <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>4</sup>UCSF, San Francisco, US, <sup>5</sup>City of Hope National Medical Center, Duarte, US, <sup>6</sup>Massachusetts General Hospital, Boston, US, <sup>7</sup>Mt. Sinai School of Medicine, New York, US, <sup>8</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>9</sup>Neon Therapeutics, Inc., Cambridge, US, <sup>10</sup>Neon Therapeutics, Boston, US, <sup>11</sup>UCLA, Los Angeles, US

11:39 - 11:54 **Invited Discussant LBA37\_PR and 11270**

G. Coukos, Ludwig Center for Cancer Research of the UNIL, Epalinges, CH

11:54 - 12:06 **11280 - Pre-specified interim analysis of a randomized phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients**

D. Hale<sup>1</sup>, E.A. Mittendorf<sup>2</sup>, T. Brown<sup>3</sup>, G. Clifton<sup>3</sup>, T. Vreeland<sup>2</sup>, J. Myers<sup>3</sup>, K. Peace<sup>3</sup>, D. Jackson<sup>3</sup>, J. Greene<sup>3</sup>, J. Holmes<sup>4</sup>, G. Peoples<sup>5</sup>, <sup>1</sup>SAMMC, San Antonio, US, <sup>2</sup>MD Anderson Cancer Center, Houston, US, <sup>3</sup>San Antonio Military Medical Center, Fort Sam Houston, US, <sup>4</sup>Naval Medical Center San Diego, San Diego, US, <sup>5</sup>Cancer Insight, LLC, SAN ANTONIO, US

12:06 - 12:18 **11290 - Stage 2 enrollment complete: Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy**

T. Leal<sup>1</sup>, A. Spira<sup>2</sup>, C. Blakely<sup>3</sup>, K. He<sup>4</sup>, D. Berz<sup>5</sup>, D. Richards<sup>6</sup>, J. Uyeki<sup>7</sup>, A. Savage<sup>8</sup>, T. Roque<sup>9</sup>, E. Massarelli<sup>10</sup>, R. Jotte<sup>11</sup>, I. Chen<sup>12</sup>, J. Christensen<sup>13</sup>, P. Olson<sup>13</sup>, V. Tassell<sup>13</sup>, L. Horn<sup>14</sup>, <sup>1</sup>University of Wisconsin School of Medicine and Public Health, Madison, US, <sup>2</sup>Virginia Cancer Specialists, Fairfax, US, <sup>3</sup>University of California San Francisco, San Francisco, US, <sup>4</sup>The Ohio State University Comprehensive Cancer Center, Columbus, US, <sup>5</sup>Beverly Hills Cancer Center, Beverly Hill, US, <sup>6</sup>Texas Oncology P.A., Houston, US, <sup>7</sup>Texas Oncology - Austin Midtown, Austin, US, <sup>8</sup>Hematology Oncology Associates - Barnett Office, Medford, US, <sup>9</sup>USO, Sherman, US, <sup>10</sup>City of Hope, Duarte, US, <sup>11</sup>Rocky Mountain Cancer Centers, Denver, US, <sup>12</sup>Mir, San Diego, US, <sup>13</sup>Mirati Therapeutics, Inc., San Diego, US, <sup>14</sup>Vanderbilt Ingram Cancer Center, Nashville, US

12:18 - 12:30 **11300 - Responses and Durability of Clinical Benefit in Renal Cell Carcinoma Treated with Pegilodecakin in Combination With Anti-PD-1 Inhibitors**

N. Tannir<sup>1</sup>, A. Naing<sup>2</sup>, K. Papadopoulos<sup>3</sup>, D. Wong<sup>4</sup>, W.M. Korn<sup>5</sup>, R. Aljumaily<sup>6</sup>, K. Autio<sup>7</sup>, S. Pant<sup>8</sup>, T. Bauer<sup>9</sup>, A. Drakaki<sup>10</sup>, N. Daver<sup>11</sup>, A. Hung<sup>12</sup>, M. Oft<sup>12</sup>, J. Leveque<sup>12</sup>, <sup>1</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>START Center for Cancer Care, San Antonio, US, <sup>4</sup>UCLA - School of Medicine, Los Angeles, US, <sup>5</sup>Caris Life Sciences, Phoenix, US, <sup>6</sup>Oklahoma University Medical Center, Oklahoma City, US, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>College of Pharmacy, OUHSC, Oklahoma City, US, <sup>9</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>10</sup>UCLA Medical Center, Los Angeles, US, <sup>11</sup>MD Anderson Cancer Center, Houston, US, <sup>12</sup>ARMO BioSciences, Redwood City, US

12:30 - 12:45 **Invited Discussant 11280, 11290 and 11300**

D. Jäger, Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE

**12:30 - 13:00** Type: **Poster Display session** Hall B4 - Room 24  
Title: **EONS Poster display**

- 12:30 - 12:30 **CN5 - Patients - power sources for cancer nurses**  
C. Beisel, University Hospital Heidelberg, Heidelberg, DE
- 12:30 - 12:30 **CN6 - BRAF/MEK-inhibition for patients with metastatic melanoma: towards patient-centered care**  
J. Koldenhof<sup>1</sup>, S. Vervoort<sup>2</sup>, C. Nierop<sup>3</sup>, K. Suijkerbuijk<sup>4</sup>, <sup>1</sup>UMC - University Medical Center Utrecht, Utrecht, NL, <sup>2</sup>University Medical Center Utrecht, Utrecht, NL, <sup>3</sup>HU University of Applied sciences, Utrecht, NL, <sup>4</sup>University Hospital Utrecht, Utrecht, NL
- 12:30 - 12:30 **CN7 - Perceptions of Rural Nurses Extending Their Role to Administer Chemotherapy**  
Q. Alnasser<sup>1</sup>, K. Cameron<sup>2</sup>, J. Prouse<sup>3</sup>, <sup>1</sup>King Faisal Specialist Hospital and Research Center, Riyadh, SA, <sup>2</sup>King Faisal Specialist Hospital & Research Center, Riyadh, SA, <sup>3</sup>Royal Adelaide Hospital, Adelaide, AU
- 12:30 - 12:30 **CN8 - AYA cancer nursing - An emerging sub-speciality - the first book about AYA cancer nursing, edited and authored by nurses.**  
S. Smith, Aarhus University Hospital, Aarhus C, DK
- 12:30 - 12:30 **CN9 - Nurse led follow-up for CML patients on oral cancer treatment**  
S. De Wilde<sup>1</sup>, J. De Munter<sup>2</sup>, M. Quaghebeur<sup>2</sup>, D. Mazure<sup>2</sup>, A. De Pauw<sup>2</sup>, B. Casteels<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University hospital Ghent, Gent, BE
- 12:30 - 12:30 **CN10 - Introducing a new role in cancer care, Coordinating Contact Nurses - patient-reported evaluation.**  
B. Westman<sup>1</sup>, H. Ullgren<sup>2</sup>, L. Sharp<sup>1</sup>, <sup>1</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE, <sup>2</sup>Karolinska University Hospital-Solna, Stockholm, SE
- 12:30 - 12:30 **CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: preliminary study.**  
E. Mahía<sup>1</sup>, G. Simó<sup>1</sup>, E. Heras<sup>2</sup>, M. Pascual<sup>2</sup>, F. Cobo<sup>1</sup>, J. Pujadas<sup>1</sup>, S. Albiol<sup>3</sup>, <sup>1</sup>Servei Andorra Atenció Sanitaria, Escaldes-Engordany, AD, <sup>2</sup>Servei Andorra Atenció Sanitaria, Escaldes-Engordany, AD, <sup>3</sup>Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, AD
- 12:30 - 12:30 **CN12 - Systemic Anticancer Therapy Administration Safety**  
S. Toland<sup>1</sup>, A. Simons<sup>2</sup>, <sup>1</sup>Birmingham City University, Birmingham, GB, <sup>2</sup>Birmingham City University, Birmingham city university, GB
- 12:30 - 12:30 **CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: the role of the nurse practitioner for early recognition and management**  
C. Roth, M. Labots, A. Eertwegh, Vrije University Medical Centre (VUMC), Amsterdam,

NL

- 12:30 - 12:30 **CN14 - Experiences from a new advanced cancer nursing role in Sweden, an analysis based on EONS Cancer Nursing Education Framework using the Delphi method**  
H. Ullgren, Karolinska University Hospital-Solna, Stockholm, SE
- 12:30 - 12:30 **CN15 - Opinions and Experiences of Patients Receiving Oral Chemotherapy: A Qualitative Study**  
S. Kutlutürkan<sup>1</sup>, Ö. Yurtal<sup>1</sup>, K. Kirca<sup>2</sup>, <sup>1</sup>Gazi Üniversitesi, Ankara, TR, <sup>2</sup>Kırıkkale Üniversitesi, Kırıkkale, TR
- 12:30 - 12:30 **CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for Adolescents and Young Adults (AYAs) with an hematological disease**  
J. De Munter<sup>1</sup>, S. De Wilde<sup>1</sup>, M. Quaghebeur<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University hospital Ghent, Gent, BE
- 12:30 - 12:30 **CN17 - Standardising the psychosocial assessment of oncological patients at Donostia University Hospital**  
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria, Hospital Donostia, San Sebastian, ES
- 12:30 - 12:30 **CN18 - Are there differences between nurses' and patients' perceptions of cancer patients' quality of life in Greece?**  
M. Lavdaniti<sup>1</sup>, E. Gogou<sup>1</sup>, G.-C. Karagiannidou<sup>1</sup>, M. Delibaltidou<sup>1</sup>, E. Zioga<sup>1</sup>, K. Marmara<sup>2</sup>, E. Fradelos<sup>1</sup>, <sup>1</sup>Alexander Technological Educational Institute, Thessaloniki, GR, <sup>2</sup>Alexander Technological Educational Institute, thessaloniki, GR
- 12:30 - 12:30 **CN19 - How an empowerment program can touch cancer survivor's life by improving posttraumatic growth?**  
Y.S. Uzar Ozcetin, Hacettepe University Faculty of Nursing, Ankara, TR
- 12:30 - 12:30 **CN20 - Organising a general oncology nursing outpatient clinic**  
C. Lundgren<sup>1</sup>, A. Lagerquist<sup>1</sup>, M. Högman<sup>2</sup>, U. Östlund<sup>3</sup>, <sup>1</sup>Sjukhus Gävle, Gävle, SE, <sup>2</sup>Uppsala University, Uppsala, SE, <sup>3</sup>Region Gävleborg, Gävle, SE
- 12:30 - 12:30 **CN21 - Job content of advanced practice nurses in Flanders**  
E. Decoene<sup>1</sup>, A. Van Hecke<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>University Ghent, Gent, BE
- 12:30 - 12:30 **CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professionals self-efficacy when supporting parents newly diagnosed with cancer who have dependent children**  
C. Semple<sup>1</sup>, E. Mccaughan<sup>2</sup>, <sup>1</sup>Ulster University / South Eastern Health and Social Care



Trust, Belfast, GB, <sup>2</sup>Ulster University, Coleraine, GB

- 12:30 - 12:30 **CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals**  
J. Bird<sup>1</sup>, M. Nolan<sup>2</sup>, S. Danson<sup>3</sup>, <sup>1</sup>Weston Park Hospital Cancer Research Centre, Sheffield, GB, <sup>2</sup>University of Sheffield, Sheffield, GB, <sup>3</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB
- 12:30 - 12:30 **CN24 - Assessing the effect of telephone support on patients with myeloma Multiple (MM) in The Catalan Oncology Institut in Girona**  
C. Puigmarti, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona, ES
- 12:30 - 12:30 **CN28 - Transmural collaborative care in oncology: Experiences of general practitioners**  
M. Daem<sup>1</sup>, E. Van Roekeghem<sup>2</sup>, M. Grypdonck<sup>2</sup>, P. Pype<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>Ghent University, Ghent, BE
- 12:30 - 12:30 **CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: a systematic review**  
S. Colomer-Lahiguera<sup>1</sup>, D. Bryant-Lukosius<sup>2</sup>, S. Rietkoetter<sup>2</sup>, L. Martelli<sup>2</sup>, K. Ribic<sup>3</sup>, A. Orcurto<sup>1</sup>, R. Juergens<sup>4</sup>, M. Eicher<sup>5</sup>, <sup>1</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>2</sup>McMaster University, Hamilton, CA, <sup>3</sup>IBCSG International Breast Cancer Study Group, Bern, CH, <sup>4</sup>Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, CA, <sup>5</sup>University of Lausanne, Lausanne, CH
- 12:30 - 12:30 **CN30 - Laryngectomized patients caregivers' life experience: a phenomenological study**  
V. Bressan<sup>1</sup>, E. Dri<sup>1</sup>, S. Stevanin<sup>2</sup>, L. Cadorin<sup>3</sup>, A. Rizzuto<sup>4</sup>, G. Bulfone<sup>1</sup>, L. Ghirrotto<sup>5</sup>, <sup>1</sup>University of Udine, Udine, IT, <sup>2</sup>Veneto Region, Venice, IT, <sup>3</sup>National Cancer Institute CRO Aviano, Aviano, IT, <sup>4</sup>Udine University Hospital, Udine, IT, <sup>5</sup>Azienda Santa Maria Nuova-IRCCS, Reggio Emilia, IT
- 12:30 - 12:30 **CN31 - Comparing nurses' and patients' research priorities in cancer care: A mixed methods systematic review**  
L. Cadorin<sup>1</sup>, I. Truccolo<sup>2</sup>, V. Bressan<sup>3</sup>, N. Suter<sup>4</sup>, <sup>1</sup>Cro, Pordenone, IT, <sup>2</sup>CRO Aviano National Cancer Institute, Aviano, IT, <sup>3</sup>University of Udine, Udine, IT, <sup>4</sup>CRO Aviano National Cancer Institute, Pordenone, IT
- 12:30 - 12:30 **CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy**  
A. Psychogyiou, S. Katsaragakis, C. Lemonidou, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:30 - 12:30 **CN33 - A new beginning of collaboration - the Danish Cancer Nursing Research Network**  
K. Dieperink<sup>1</sup>, M. Kjerholt<sup>2</sup>, P. Riis Olsen<sup>3</sup>, <sup>1</sup>Odense University Hospital, Odense C, DK,

<sup>2</sup>Sjællands Universitets Hospital, Roskilde, DK, <sup>3</sup>Aarhus University Hospital, Aarhus, DK

- 12:30 - 12:30 **CN34 - Individual network meetings in cancer care - From young people with cancer to adults with brain tumours**  
P. Riis Olsen, Aarhus University Hospital, Aarhus, DK
- 12:30 - 12:30 **CN35 - Does being cancer patient or family caregiver of cancer patient effect bone marrow donation awareness?**  
G. Bagcivan<sup>1</sup>, N. Ozen<sup>2</sup>, D. Bayrak<sup>3</sup>, F.I. Cinar<sup>4</sup>, <sup>1</sup>Gulhane Training and Reseach Hospital, Ankara, TR, <sup>2</sup>Istinye University, Istanbul, TR, <sup>3</sup>Cankiri Karatekin University, Cankiri, TR, <sup>4</sup>University of Health Sciences, Ankara, TR
- 12:30 - 12:30 **CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment**  
C. Johnston<sup>1</sup>, M. Tanay<sup>2</sup>, <sup>1</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>2</sup>King's College London, London, GB
- 12:30 - 12:30 **CN37 - Evaluation of support and information needs for patients with cancer in a Phase I trials unit.**  
S. Stapleton<sup>1</sup>, L. O'Leary<sup>1</sup>, M. Van Zyl<sup>2</sup>, J. Hanwell<sup>1</sup>, T. Wiseman<sup>3</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>Royal Marsden Hospital NHS Foundation Trust, london, GB, <sup>3</sup>The Royal Marsden NHS Foundation Trust, London, GB
- 12:30 - 12:30 **CN38 - Dignity of Greek patients with advanced cancer: a cross-sectional study**  
S. Katsaragakis, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:30 - 12:30 **CN39 - Development and implementation of national guidelines on lifestyle issues and cancer -Report from an on-going quality improvement project**  
K. Vuollet Karlsson<sup>1</sup>, C. Landegren<sup>2</sup>, B. Westman<sup>2</sup>, <sup>1</sup>Norrlands universitetssjukhus, Umea, SE, <sup>2</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:30 - 12:30 **CN40 - Developing a Patient Reported Experience Measure (PREM) in Secondary Breast Cancer (SBC)**  
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke, The Christie NHS Foundation Trust, Manchester, GB
- 12:30 - 12:30 **CN41 - Cancer situation in sub-Saharan Countries: development of educational, diagnosis and treatment plans.**  
J. De La Torre-Montero<sup>1</sup>, N. Gil-Gómez<sup>2</sup>, J. Ribes Bernal<sup>3</sup>, N. Domenech Climent<sup>4</sup>, A. Ojer Perea<sup>5</sup>, P. Beorlegui Murillo<sup>5</sup>, J.M. Gavala Arjona<sup>6</sup>, R. Cumplido Corbacho<sup>7</sup>, I. Magallon Pedrera<sup>8</sup>, M.A. Peñuelas Saiz<sup>8</sup>, <sup>1</sup>SPANISH SOCIETY OF ONCOLOGY NURSING, Madrid, ES, <sup>2</sup>HOSPITAL QUIRÓN MADRID, MADRID, ES, <sup>3</sup>HOSPITAL CLINIC, BARCELONA, ES, <sup>4</sup>HOSPITAL VIRGEN DE LOS LIRIOS, ALCOY, ES, <sup>5</sup>CLINICA UNIVERSITARIA DE NAVARRA, PAMPLONA, ES, <sup>6</sup>HOSPITAL SON ESPASES, PALMA DE MALLORCA, ES, <sup>7</sup>HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLE, ES, <sup>8</sup>Hospital Universitari

Vall d'Hebron, BARCELONA, ES

- 12:30 - 12:30 **CN42 - The Gastrointestinal and Lymphoma unit Lead Nurse Research role in Royal Marsden Hospital.**  
J. Duncan<sup>1</sup>, V. Michalarea<sup>2</sup>, T. Coyne<sup>1</sup>, J. Thomas<sup>1</sup>, D. Cunningham<sup>2</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 12:30 - 12:30 **CN43 - Patients' learning and participation in their breast cancer care**  
L. Boman<sup>1</sup>, K. Sandelin<sup>2</sup>, Y. Wengström<sup>3</sup>, C. Silén<sup>1</sup>, <sup>1</sup>Karolinska Institute, Stockholm, SE, <sup>2</sup>Karolinska Institutet - Dept of Oncology-Pathology, Stockholm, SE, <sup>3</sup>Karolinska Institutet, Huddinge, SE
- 12:30 - 12:30 **CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration.**  
S.Y. Oh<sup>1</sup>, J.M. Lee<sup>1</sup>, J.W. Kim<sup>1</sup>, S.H. Kim<sup>1</sup>, J.M. Park<sup>1</sup>, G.Y. Yeo<sup>1</sup>, J.E. Hyun<sup>1</sup>, J.-H. Park<sup>2</sup>, <sup>1</sup>Asan Medical Center, Seoul, KR, <sup>2</sup>Ajou Univ. Hospital, Suwon, KR
- 12:30 - 12:30 **CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy**  
A. Frade, S. Miguel, Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P.E., LISBOA, PT
- 12:30 - 12:30 **CN46 - Safe navigation of CARs in a changing landscape**  
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite, The Christie NHS Foundation Trust, Manchester, GB
- 12:30 - 12:30 **CN47 - Patients' interpretations and experiences of participation in cancer care**  
J. Jackson, J. Rundgren, Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:30 - 12:30 **CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab**  
M. Qiu<sup>1</sup>, Y. Chen<sup>2</sup>, B.-L. Zhang<sup>2</sup>, X.-Y. Wang<sup>2</sup>, <sup>1</sup>West China Hospital, Sichuan University, Chengdu, Sichuan Province, CN, <sup>2</sup>West China Hospital, Chengdu, CN
- 12:30 - 12:30 **CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care**  
J. De Munter<sup>1</sup>, P. Crombez<sup>2</sup>, <sup>1</sup>Gent University Hospital, Gent, BE, <sup>2</sup>Jules Bordet, Brussel, BE
- 12:30 - 12:30 **CN50 - Overview of an Acute Oncology Service in A UK Cancer Centre**  
M. Foulkes, Royal Berkshire Hospital - NHS Foundation Trust, Reading, GB
- 12:30 - 12:30 **CN51 - The development and evaluation of an online oncology portal**  
J. De Munter<sup>1</sup>, E. Decoene<sup>2</sup>, A. Van Hecke<sup>3</sup>, <sup>1</sup>Ghent University Hospital, Ghent, BE, <sup>2</sup>Gent

University Hospital, Gent, BE, <sup>3</sup>University Ghent, Gent, BE

- 12:30 - 12:30 **CN52 - Pilot Study - Nurses' Role in Management of Cutaneous Toxicity in Patients with Targeted Therapies Anti EGFR-Is' Treatment.**  
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso, Istituto Oncologico Veneto IRCCS, Padova, IT
- 12:30 - 12:30 **CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?**  
D. Oliva<sup>1</sup>, F. Lewin<sup>1</sup>, N. Lewin<sup>2</sup>, M. Nilsson<sup>3</sup>, M. Strandéus<sup>1</sup>, B.-Å. Andersson<sup>2</sup>, L. Sharp<sup>4</sup>, <sup>1</sup>County Hospital Ryhov, Jönköping, SE, <sup>2</sup>Laboratory Medicine, Jönköping, SE, <sup>3</sup>Futurum - , Jönköping, SE, <sup>4</sup>Regional Cancer Center Stockholm Gotland, Stockholm, SE
- 12:30 - 12:30 **CN58 - Effect of Aromatherapy Massage on Chemotherapy-Induced Peripheral Neuropathic Pain and Fatigue in Patients Receiving Oxaliplatin**  
N. Izgu<sup>1</sup>, L. Ozdemir<sup>2</sup>, F. Bugdayci Basal<sup>3</sup>, <sup>1</sup>Hacettepe University Faculty of Nursing, Ankara, TR, <sup>2</sup>Hacettepe University, Ankara, TR, <sup>3</sup>Ataturk Egitim ve Arastirma Hastanesi tibbi onkoloji klinik, Izmir, TR
- 12:30 - 12:30 **CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital**  
C. Palassari, S. Katsaragakis, J. Kaklamanos, D. Protogiros, E. Patiraki, National and Kapodistrian University of Athens, Athens, GR
- 12:30 - 12:30 **CN60 - The experience of dysgeusia in allogeneic hematopoietic cell transplantation survivors: a qualitative study**  
D. Bomben<sup>1</sup>, A. Bin<sup>2</sup>, M. Venturini<sup>1</sup>, T. Bulfone<sup>1</sup>, L. Ghirotto<sup>3</sup>, V. Bressan<sup>1</sup>, <sup>1</sup>University of Udine, Udine, IT, <sup>2</sup>Udine University Hospital, Udine, IT, <sup>3</sup>Azienda Santa Maria Nuova-IRCCS, Reggio Emilia, IT
- 12:30 - 12:30 **CN61 - "It may not affect you" -- Lived experiences and support needs of women who developed peripheral neuropathy following chemotherapy treatment for cancer.**  
M. Tanay<sup>1</sup>, J. Armes<sup>2</sup>, <sup>1</sup>King's College London, London, GB, <sup>2</sup>University of Surrey, Surrey, GB
- 12:30 - 12:30 **CN62 - App about chemotherapy - helping the patient with cancer**  
B. Espersen, Aarhus University Hospital, Aarhus, DK
- 12:30 - 12:30 **CN63 - Usability Test For a CINV Diary Application For Smartphones at Oncology Nursing**  
P. Fernández- Ortega<sup>1</sup>, Y. Escobar<sup>2</sup>, E. Trigos<sup>3</sup>, R. Blat<sup>4</sup>, M. Cantero<sup>2</sup>, A. Alvarez<sup>5</sup>, <sup>1</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>2</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>3</sup>Hospital La Fé, Valencia, ES, <sup>4</sup>Hospital Mar Parc Salut, Barcelona, ES, <sup>5</sup>Hospital de Leon, Leon, ES



- 12:30 - 12:30 **CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the Memorial Symptom Assessment Scale**  
D. Palitzika<sup>1</sup>, E. Fradelos<sup>1</sup>, V. Alikari<sup>1</sup>, P. Charitopoulos<sup>1</sup>, E. Zioga<sup>1</sup>, S. Zyga<sup>2</sup>, M. Lavdaniti<sup>1</sup>, <sup>1</sup>Alexander Technological Educational Institute, Thessaloniki, GR, <sup>2</sup>University of Peloponnesus, Thessaloniki, GR
- 12:30 - 12:30 **CN65 - How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool "Onco'nect®"**  
M. Belhadj<sup>1</sup>, E. Kempf<sup>2</sup>, A. Lebel<sup>2</sup>, A. Guillemin<sup>2</sup>, H. Boussion<sup>3</sup>, C. Joly<sup>2</sup>, I. Baumgaertner<sup>4</sup>, E. Assaf<sup>5</sup>, C. Saldana<sup>4</sup>, B. Rousseau<sup>4</sup>, C. Tournigand<sup>4</sup>, <sup>1</sup>Université Paris-Est Créteil Val de Marne, Faculté de Médecine, Créteil, FR, <sup>2</sup>Hôpital Henri Mondor, AP-HP, Créteil, FR, <sup>3</sup>Assistance Publique - Hopitaux De Paris, Paris, FR, <sup>4</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>5</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR
- 12:30 - 12:30 **CN66 - Medical makeup in cancer patients and its impact in their quality of life**  
R. Lechou, M. Lavdaniti, Alexander Technological Educational Institute, Thessaloniki, GR

**12:30 - 14:00**    **Type: Patient Advocacy Track**    **ICM - Room 5**  
**Title: The Hans Keulen Memorial Debate - Cancer heroes: Do they exist? And who are they?**  
 Chair(s): Kathy Oliver, GB

12:30 - 12:30    **DOI Session**

12:30 - 12:40    **Introduction**

K. Oliver, International Brain Tumour Alliance, GB

12:40 - 13:20    **Debate**

13:20 - 13:20    **Debate: Team 1**

A. Waldman<sup>1</sup>, M. Inderbitzin<sup>2</sup>, <sup>1</sup>Myeloma Euronet, Rüsselsheim, DE, <sup>2</sup>My Survival Story Foundation, Zurich, CH

13:20 - 13:20    **Debate: Team 2**

F. Strasser<sup>1</sup>, A. Charalambous<sup>2</sup>, <sup>1</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>2</sup>Cyprus University of Technology - Nursing Science, Limassol, CY

13:20 - 13:50    **Discussion with the audience**

13:50 - 14:00    **Conclusions and take-home messages**

**12:45 - 13:45**    **Type: Poster Display session**    **Hall A3 - Poster Area**  
**Title: Poster display session: Breast cancer - early stage, locally advanced &&**    **Networking Hub**

12:45 - 12:45    **Breast cancer, early stage**

12:45 - 12:45    **194P - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations**

S. Barni<sup>1</sup>, E. Curtit<sup>2</sup>, F. Cognetti<sup>3</sup>, D. Bourgeois<sup>4</sup>, R. Masetti<sup>5</sup>, S. Zilberman<sup>6</sup>, G. Naso<sup>7</sup>, J. Gligorov<sup>8</sup>, <sup>1</sup>Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, IT, <sup>2</sup>CHU Besançon, Hôpital Jean Minjot, Besançon, FR, <sup>3</sup>Istituto Nazionale Tumori Regina Elena, Rome, IT, <sup>4</sup>ARETASC - Clinique Hartmann, Neuilly-sur-Seine, FR, <sup>5</sup>Policlinico Universitario Agostino Gemelli, Roma, IT, <sup>6</sup>Hôpital Tenon, Paris, FR, <sup>7</sup>Policlinico Umberto I, Roma, IT, <sup>8</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR

12:45 - 12:45    **195P - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-**

**negative, invasive lobular carcinoma of the breast**

A. De Nonneville<sup>1</sup>, C. Jauffret<sup>1</sup>, A. Gonçalves<sup>1</sup>, J.-M. Classe<sup>2</sup>, M. Cohen<sup>1</sup>, F. Reyat<sup>3</sup>, C. Mazouni<sup>4</sup>, M.-P. Chauvet<sup>5</sup>, N. Chopin<sup>6</sup>, P.-E. Colombo<sup>7</sup>, E. Jouve<sup>8</sup>, E. Darai<sup>9</sup>, R. Rouzier<sup>3</sup>, C. Coutant<sup>10</sup>, P. Gimbergues<sup>11</sup>, A.-S. Azuar<sup>12</sup>, C. Tunon De Lara<sup>13</sup>, E. Lambaudie<sup>1</sup>, G. Houvenaeghel<sup>1</sup>, <sup>1</sup>Institute Paoli Calmettes, Marseille, FR, <sup>2</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>3</sup>Institut Curie, Paris, FR, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR, <sup>5</sup>Centre Oscar Lambret, Lille, FR, <sup>6</sup>Centre Leon Berard, Lyon, FR, <sup>7</sup>CLCC Val d'Aurelle, Montpellier, FR, <sup>8</sup>Centre Claudius Regaud, Toulouse, FR, <sup>9</sup>Hôpital Tenon, Paris, FR, <sup>10</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>11</sup>Centre Jean-Perrin, Clermont-Ferrand, FR, <sup>12</sup>Hôpital de Grasse, Grasse, FR, <sup>13</sup>Institut Bergonié, Bordeaux, FR

12:45 - 12:45 **196P - Baseline lymphocyte counts predict distant recurrence in early breast cancer**

G.M. Kim<sup>1</sup>, H.D. Koh<sup>1</sup>, J.H. Kim<sup>2</sup>, B.-W. Park<sup>2</sup>, Y.U. Cho<sup>2</sup>, S.I. Kim<sup>2</sup>, H.S. Park<sup>2</sup>, J.Y. Kim<sup>2</sup>, M.J. Kim<sup>2</sup>, J.H. Jeong<sup>1</sup>, J. Sohn<sup>2</sup>, <sup>1</sup>Yonsei Cancer Center Yonsei University, Seoul, KR, <sup>2</sup>Yonsei University College of Medicine, Seoul, KR

12:45 - 12:45 **197P - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).**

L. Carbognin<sup>1</sup>, I. Sperduti<sup>2</sup>, G. Arpino<sup>3</sup>, M.V. Dieci<sup>4</sup>, F. Schettini<sup>5</sup>, G. Griguolo<sup>6</sup>, M. Brunelli<sup>7</sup>, V. Guarneri<sup>4</sup>, R. Nortilli<sup>8</sup>, E. Fiorio<sup>9</sup>, S. Pilotto<sup>1</sup>, E. Orvieto<sup>10</sup>, E. Manfrin<sup>7</sup>, P. Conte<sup>4</sup>, S. De Placido<sup>3</sup>, G. Scambia<sup>11</sup>, G. Tortora<sup>12</sup>, E. Bria<sup>13</sup>, <sup>1</sup>AOU Integrata Verona "Borgo Roma", Verona, IT, <sup>2</sup>Regina Elena National Cancer Institute, Rome, IT, <sup>3</sup>AOU Policlinico Federico II, Napoli, IT, <sup>4</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>5</sup>Azienda Universitaria Ospedaliera Federico II, Napoli, IT, <sup>6</sup>IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, <sup>7</sup>University and Hospital Trust of Verona, Verona, IT, <sup>8</sup>University of Verona, AOUI Verona, Verona, IT, <sup>9</sup>AOU Integrata Verona "Borgo Trento", Verona, IT, <sup>10</sup>Ulss 5 Polesana, Rovigo, IT, <sup>11</sup>Policlinico Universitario A. Gemelli, Roma, IT, <sup>12</sup>Università di Verona, Azienda Ospedaliera Universitaria Integrata, Verona, IT, <sup>13</sup>Università Cattolica del Sacro Cuore - Fondazione Policlinico Universitario Agostino Gemelli, Rome, IT

12:45 - 12:45 **198P - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas**

A. De Nonneville<sup>1</sup>, A. Gonçalves<sup>1</sup>, J.-M. Boher<sup>1</sup>, J.-M. Classe<sup>2</sup>, M. Cohen<sup>1</sup>, P.-E. Colombo<sup>3</sup>, F. Reyat<sup>4</sup>, M.-P. Chauvet<sup>5</sup>, E. Jouve<sup>6</sup>, E. Darai<sup>7</sup>, G. Blache<sup>8</sup>, C. Coutant<sup>9</sup>, P. Gimbergues<sup>10</sup>, C. Mazouni<sup>11</sup>, R. Rouzier<sup>4</sup>, R. Villet<sup>12</sup>, P. Crochet<sup>13</sup>, A.-S. Azuar<sup>14</sup>, E. Lambaudie<sup>1</sup>, G. Houvenaeghel<sup>1</sup>, <sup>1</sup>Institute Paoli Calmettes, Marseille, FR, <sup>2</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>3</sup>CLCC Val d'Aurelle, Montpellier, FR, <sup>4</sup>Institut Curie, Paris, FR, <sup>5</sup>Centre Oscar Lambret, Lille, FR, <sup>6</sup>Institut Universitaire du Cancer Toulouse Oncopole, Paris, FR, <sup>7</sup>Hôpital Tenon, Paris, FR, <sup>8</sup>Centre Leon Berard, Lyon, FR, <sup>9</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>10</sup>Centre Jean-Perrin, Clermont-Ferrand, FR, <sup>11</sup>Institut Gustave Roussy, Villejuif, FR, <sup>12</sup>Hôpital des Diaconesses, Paris, FR, <sup>13</sup>Hopital de la Conception, Marseille, FR, <sup>14</sup>Hôpital de Grasse, Grasse, FR

12:45 - 12:45

**199P - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study**

A. Prat<sup>1</sup>, B. Adamo<sup>2</sup>, J.A. Perez Fidalgo<sup>3</sup>, S. Blanch<sup>4</sup>, N. Martinez<sup>5</sup>, P. Gomez Pardo<sup>6</sup>, A. López González<sup>7</sup>, L. Murillo Jusó<sup>8</sup>, K. Amillano<sup>9</sup>, M. Vidal<sup>10</sup>, T. Pascual<sup>11</sup>, L. Pare<sup>12</sup>, J. Canes<sup>13</sup>, P. Galvan<sup>1</sup>, B. Gonzalez Farre<sup>10</sup>, V. Ortega Cebrian<sup>14</sup>, X. Gonzalez<sup>15</sup>, M. Bellet Ezquerro<sup>6</sup>, P. Villagrasa<sup>13</sup>, E. Ciruelos<sup>16</sup>, <sup>1</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>2</sup>AOU Policlinico G. Martino Università di Messina, Messina, IT, <sup>3</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>4</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>5</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>Complejo Asistencial Universitario de León, León, ES, <sup>8</sup>Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, <sup>9</sup>University Hospital St. Joan de Reus, Reus, ES, <sup>10</sup>Hospital Clinic i Provincial de Barcelona, Barcelona, ES, <sup>11</sup>Hospital Universitario de La Princesa, Madrid, ES, <sup>12</sup>IDIBAPS / SOLTI Breast Cancer Research Group, Barcelona, ES, <sup>13</sup>SOLTI, Barcelona, ES, <sup>14</sup>Hospital General de Granollers, Granollers, ES, <sup>15</sup>Hospital Universitario Quirón Dexeus, Barcelona, ES, <sup>16</sup>Hospital Universitario 12 de Octubre, Madrid, ES

12:45 - 12:45 **200P - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer**

E.Y. Kim, C.H. Park, S.-I. Do, Kangbuk Samsung Hospital Sungkyunkwan University, Seoul, KR

12:45 - 12:45 **201P - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience**

A. Alsayed<sup>1</sup>, T. Al-Twejeri<sup>1</sup>, K. Suleman<sup>1</sup>, A. Tulbah<sup>2</sup>, D. Ajarim<sup>1</sup>, <sup>1</sup>King Faisal Specialist Hospital and Research Center, Riyadh, SA, <sup>2</sup>King Faisal Specialist Hospital and Research Center, riyadh, SA

12:45 - 12:45 **202P - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.**

S. Elmorshidy<sup>1</sup>, O. Abd Elffatah<sup>1</sup>, H. Essa<sup>1</sup>, A. Ibrahim<sup>2</sup>, D. Sayed<sup>3</sup>, S. Shehata<sup>1</sup>, <sup>1</sup>Assiut University Hospitals, Assiut, EG, <sup>2</sup>Assiut University Hospital, Faculty of Medicine, Assiut University, Egypt, Assiut, EG, <sup>3</sup>South Egypt Cancer Institute, Assiut, EG

12:45 - 12:45 **203P - Molecular subtyping of breast cancer by dedicated breast PET**

S. Sueoka<sup>1</sup>, S. Sasada<sup>2</sup>, E. Suzuki<sup>3</sup>, N. Goda<sup>3</sup>, K. Kajitani<sup>3</sup>, A. Emi<sup>3</sup>, N. Masumoto<sup>3</sup>, T. Kadoya<sup>3</sup>, R. Haruta<sup>3</sup>, T. Kataoka<sup>3</sup>, M. Okada<sup>3</sup>, <sup>1</sup>Breast Surgery, Hiroshima University Hospital, Hiroshima, JP, <sup>2</sup>Hiroshima University, Hiroshima, JP, <sup>3</sup>Hiroshima University Hospital, Hiroshima, JP

12:45 - 12:45 **204P - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer**

T. Loughman<sup>1</sup>, A. Chan-Ju Wang<sup>2</sup>, P. Dynoodt<sup>3</sup>, B. Fender<sup>3</sup>, C. Lopez Ruiz<sup>3</sup>, S. Barron<sup>4</sup>, S. Stapleton<sup>3</sup>, D. O'Leary<sup>4</sup>, A. Fabre<sup>5</sup>, C. Quinn<sup>6</sup>, B. Nodin<sup>7</sup>, K. Jirstrom<sup>8</sup>, A. Bracken<sup>9</sup>, W. Gallagher<sup>1</sup>, <sup>1</sup>University College Dublin, Dublin, IE, <sup>2</sup>Oncomark, Dublin, IE, <sup>3</sup>OncoMark,



Dublin, IE, <sup>4</sup>OncoMark Ltd, Dublin, IE, <sup>5</sup>St Vincents University Hospital, Dublin, IE, <sup>6</sup>St. Vincent's University Hospital, Dublin, IE, <sup>7</sup>Clinical Sciences, Lund, SE, <sup>8</sup>Lund University, Lund, SE, <sup>9</sup>Trinity College Dublin, Dublin, IE

- 12:45 - 12:45 **205P - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.**  
G.E. Lee<sup>1</sup>, W.H. Hor<sup>2</sup>, <sup>1</sup>National Cancer Center Singapore, Singapore, SG, <sup>2</sup>Imperial College London, Singapore, SG
- 12:45 - 12:45 **206P - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers**  
A. Losurdo<sup>1</sup>, R. De Sanctis<sup>2</sup>, B. Fernandes<sup>3</sup>, V. Errico<sup>4</sup>, A. Sagona<sup>4</sup>, G. Masci<sup>3</sup>, M. Zuradelli<sup>3</sup>, E. Agostinetto<sup>4</sup>, R. Torrasi<sup>3</sup>, W. Gatzemeier<sup>4</sup>, A. Testori<sup>4</sup>, M. Roncalli<sup>3</sup>, M. Alloisio<sup>4</sup>, C. Tinterri<sup>4</sup>, A. Santoro<sup>3</sup>, <sup>1</sup>Humanitas University, Milan, IT, <sup>2</sup>Policlinico Umberto I, Roma, IT, <sup>3</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>4</sup>Istituto Clinico Humanitas, Rozzano (Milan), IT
- 12:45 - 12:45 **207P - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer**  
C. Cha<sup>1</sup>, S.J. Bae<sup>1</sup>, C.-I. Yoon<sup>2</sup>, S.E. Park<sup>1</sup>, Y. Kim<sup>1</sup>, S.G. Ahn<sup>3</sup>, K.A. Lee<sup>1</sup>, J. Jeong<sup>3</sup>, <sup>1</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>Yonsei University, Seoul, KR, <sup>3</sup>Gananam Severance Hospital, Seoul, KR
- 12:45 - 12:45 **208P - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)**  
A. Hassan<sup>1</sup>, N. Keegan<sup>2</sup>, C. O'Leary<sup>3</sup>, L. Mcsorley<sup>3</sup>, T. Mahgoub<sup>4</sup>, S. O'Reilly<sup>5</sup>, J. Walshe<sup>6</sup>, M. Kennedy<sup>7</sup>, L. Coate<sup>8</sup>, M. O'Connor<sup>9</sup>, M. Keane<sup>10</sup>, C. Kelly<sup>11</sup>, M. Milewski<sup>3</sup>, S. Molloy<sup>3</sup>, K. Eagan<sup>3</sup>, V. Murphy<sup>12</sup>, O. Breathnach<sup>13</sup>, L. Grogan<sup>13</sup>, B. Hennessy<sup>13</sup>, P. Morris<sup>13</sup>, <sup>1</sup>Home Address - Anees Hassan, Dublin, IE, <sup>2</sup>Royal College of Surgeons in Ireland, Dublin, IE, <sup>3</sup>Beaumont Hospital, Dublin 9, Ireland, Dublin, IE, <sup>4</sup>St Vincents University Hospital, Dublin, IE, <sup>5</sup>Cork University Hospital, Cork, IE, <sup>6</sup>St Vincent's University Hospital, Dublin, IE, <sup>7</sup>St James's Hospital, Dublin, IE, <sup>8</sup>University Hospital Limerick, Dooradoyle, IE, <sup>9</sup>University Hospital Waterford, Waterford, IE, <sup>10</sup>University Hospital Galway, Galway, IE, <sup>11</sup>Mater Misericordiae University Hospital University College Dublin, Dublin, IE, <sup>12</sup>Cancer Trials Ireland, Dublin, IE, <sup>13</sup>Beaumont Hospital, Dublin, IE
- 12:45 - 12:45 **209P - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases**  
D.Y. Lee<sup>1</sup>, S.E. Park<sup>2</sup>, C. Cha<sup>1</sup>, C.-I. Yoon<sup>3</sup>, S.J. Bae<sup>1</sup>, S.G. Ahn<sup>4</sup>, J. Jeong<sup>4</sup>, <sup>1</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>Yonsei University, Seoul, KR, <sup>4</sup>Gananam Severance Hospital, Seoul, KR
- 12:45 - 12:45 **210P - Genetic Alterations of Early-Stage Breast Cancers by next-generation**

**sequencing (NGS)**

Y. Xu<sup>1</sup>, M. Zhang<sup>2</sup>, R. Chen<sup>3</sup>, X. Xia<sup>3</sup>, <sup>1</sup>Daping Hospital of Chongqing, Chongqing, CN, <sup>2</sup>Geneplus-Beijing Institution, Beijing, CN, <sup>3</sup>Geneplus-Beijing Institute, Beijing, CN

- 12:45 - 12:45 **211P - Oncotype Dx results in patients <40 years, Does age matters?: new insights**  
F. Namuche<sup>1</sup>, R. Ruiz<sup>2</sup>, Z. Morante Cruz<sup>2</sup>, D. Urrunaga<sup>3</sup>, G. Ziegler<sup>4</sup>, R. Mantilla<sup>4</sup>, M. Leon Rivera<sup>5</sup>, M. Chavez Mac Gregor<sup>6</sup>, H. Gomez Moreno<sup>7</sup>, <sup>1</sup>Oncosalud, Lima, PE, <sup>2</sup>Instituto Nacional de Enfermedades Neoplasicas - INEN, Lima, PE, <sup>3</sup>USMP, Lima, PE, <sup>4</sup>URP, Lima, PE, <sup>5</sup>CLINICA RICARDO PALMA, Lima, PE, <sup>6</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>7</sup>Instituto Nacional de Enfermedades Neoplasicas, INEN, Lima, PE
- 12:45 - 12:45 **212P - Impact of BRCA status on outcomes and survival in high-risk early breast cancers**  
E. Klajer<sup>1</sup>, S. Paget-Bailly<sup>1</sup>, G. Meynard<sup>1</sup>, A. Meurisse<sup>1</sup>, F. Bazan<sup>1</sup>, L. Chaigneau<sup>1</sup>, E. Dobi<sup>1</sup>, N. Meneveau<sup>1</sup>, P. Montcuquet<sup>1</sup>, C. Villanueva<sup>1</sup>, A. Thiery-Vuillemin<sup>1</sup>, E. Kalbacher<sup>1</sup>, C. Populaire<sup>1</sup>, M.-A. Collonge-Rame<sup>1</sup>, J. Gligorov<sup>2</sup>, E. Curtit<sup>1</sup>, X. Pivot<sup>3</sup>, L. Mansi<sup>1</sup>, <sup>1</sup>CHU Besançon, Hôpital Jean Minjot, Besançon, FR, <sup>2</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>3</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR
- 12:45 - 12:45 **213P - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy**  
N. Hajjaji, Y.M. Robin, D. Bertin, J. Bonnetterre, Centre Oscar Lambret, Lille, FR
- 12:45 - 12:45 **214P - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer**  
F. Namuche<sup>1</sup>, R. Ruiz<sup>2</sup>, Z. Morante Cruz<sup>2</sup>, D. Urrunaga<sup>3</sup>, A. Aguilar Cartagena<sup>4</sup>, H. Gomez Moreno<sup>5</sup>, <sup>1</sup>Oncosalud, Lima, PE, <sup>2</sup>Instituto Nacional de Enfermedades Neoplasicas - INEN, Lima, PE, <sup>3</sup>USMP, Lima, PE, <sup>4</sup>Oncosalud SAC, Lima, PE, <sup>5</sup>Instituto Nacional de Enfermedades Neoplasicas, INEN, Lima, PE
- 12:45 - 12:45 **215P - Genetic signatures always suggest undertreatment? Experience with PAM50**  
C. Sales, I. Vieira, M. Cassiano, C. Oliveira, C. Vieira, M. Ferreira, A. Rodrigues, A. Ferreira, M.I. Pousa, R. Couto, C. Leal, J. Abreu, M. Teixeira, D. Pereira, S. Sousa, M. Abreu, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto, PT
- 12:45 - 12:45 **216P - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score**  
M. Nesrine<sup>1</sup>, H. El Benna<sup>1</sup>, Y. Berrazegua<sup>1</sup>, S. Labidi<sup>1</sup>, N. Daoud<sup>1</sup>, H. Boussen<sup>2</sup>, <sup>1</sup>Abderrahmen Mami Hospital, Ariana, TN, <sup>2</sup>Hopital Abderrahman Mami, Ariana, TN
- 12:45 - 12:45 **217P - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients**

J. Cortes Castan<sup>1</sup>, M. Pegram<sup>2</sup>, X. Pivot<sup>3</sup>, G. Curigliano<sup>4</sup>, J.Y. Lim<sup>5</sup>, S. Song<sup>5</sup>, Y.C. Yoon<sup>5</sup>,  
1Vall d'Hebron University Hospital, Barcelona, ES, 2Stanford Comprehensive Cancer  
Institute, Stanford, US, 3Centre Paul Strauss Centre de Lutte contre le Cancer,  
Strasbourg, FR, 4Istituto Europeo di Oncologia, Milan, IT, 5Samsung Bioepis, Suwon, KR

12:45 - 12:45 **218P - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial**

A. Sonnenblick<sup>1</sup>, A. Bailey<sup>2</sup>, B. Uziely<sup>3</sup>, M. Untch<sup>4</sup>, I. Smith<sup>5</sup>, L. Gianni<sup>6</sup>, J. Baselga<sup>7</sup>, C. Jackisch<sup>8</sup>, D. Cameron<sup>9</sup>, R. Bell<sup>10</sup>, D. Zardavas<sup>11</sup>, N. Al-Sakaff<sup>12</sup>, R. Gelber<sup>13</sup>, M. Dowsett<sup>14</sup>, B. Leyland-jones<sup>15</sup>, M. Piccart<sup>16</sup>, E. De Azambuja<sup>16</sup>, 1Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, 2Frontier Science, Kingussie, GB, 3Hadassah Medical Center, Jerusalem, IL, 4Helios Klinikum Berlin Buch, Berlin, DE, 5Royal Marsden Hospital NHS Foundation Trust, London, GB, 6IRCCS San Raffaele, Milan, IT, 7Memorial Sloan-Kettering Cancer Center, New York, US, 8Klinikum Offenbach GmbH, Offenbach, DE, 9Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB, 10Deakin University Waurin Ponds, Geelong, AU, 11Breast International Group, Brussels, BE, 12F. Hoffmann-La Roche AG - Switzerland, Basel, CH, 13Dana-Farber Cancer Institute, Boston, US, 14Academic Department of Biochemistry, London, GB, 15Avera Cancer Institute, Sioux Falls, US, 16Institute Jules Bordet, Brussels, BE

12:45 - 12:45 **219P - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era**

A. De Nonneville<sup>1</sup>, A. Gonçalves<sup>1</sup>, J.-M. Boher<sup>1</sup>, M. Cohen<sup>1</sup>, F. Reyal<sup>2</sup>, J.-M. Classe<sup>3</sup>, S. Giard<sup>4</sup>, P.-E. Colombo<sup>5</sup>, X. Muracciole<sup>6</sup>, E. Darai<sup>7</sup>, E. Jouve<sup>8</sup>, C. Mazouni<sup>9</sup>, P. Gimbergues<sup>10</sup>, A.-S. Azuar<sup>11</sup>, E. Barranger<sup>12</sup>, R. Rouzier<sup>2</sup>, R. Villet<sup>13</sup>, N. Chopin<sup>14</sup>, E. Lambaudie<sup>1</sup>, G. Houvenaeghel<sup>1</sup>, 1Institute Paoli Calmettes, Marseille, FR, 2Institut Curie, Paris, FR, 3ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, 4Centre Oscar Lambret, Lille, FR, 5CLCC Val d'Aurelle, Montpellier, FR, 6Hopital de la Timone, Marseille, FR, 7Hôpital Tenon, Paris, FR, 8Centre Claudius Regaud, Toulouse, FR, 9Institut Gustave Roussy, Villejuif, FR, 10Centre Jean-Perrin, Clermont-Ferrand, FR, 11Hôpital de Grasse, Grasse, FR, 12Centre Antoine Lacassagne, Nice, FR, 13Hôpital des Diaconesses, Paris, FR, 14Centre Leon Berard, Lyon, FR

12:45 - 12:45 **220P - Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study**

J.-P. Jacquin<sup>1</sup>, L. Uwer<sup>2</sup>, A. Savignoni<sup>3</sup>, J.-M. Ferrero<sup>4</sup>, A. Lortholary<sup>5</sup>, D. Solub<sup>6</sup>, H. Attar-Rabia<sup>7</sup>, S. Deblay<sup>8</sup>, S. Pibre<sup>8</sup>, Y. Belkacemi<sup>9</sup>, 1Institut de Cancérologie Lucien Neuwirth, Saint-etienne, FR, 2Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, 3Institut Curie, Paris, FR, 4Centre Antoine Lacassagne, Nice, FR, 5Centre Catherine de Sienne, Nantes, FR, 6Hôpitaux de Chartres, Chartres, FR, 7Roche S.A.S - France, Boulogne-Billancourt Cedex, FR, 8Roche S.A.S - France, Boulogne billancourt, FR, 9AP-HP, Henri Mondor University Hospital, Créteil, FR

12:45 - 12:45 **221P - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.**

R. De Sanctis<sup>1</sup>, F. D'Antonio<sup>2</sup>, E. Agostinetto<sup>3</sup>, A. Marinello<sup>3</sup>, G. Masci<sup>4</sup>, M. Zuradelli<sup>4</sup>, A. Losurdo<sup>4</sup>, D. Guiducci<sup>3</sup>, C. Tinterri<sup>3</sup>, A. Testori<sup>3</sup>, W. Gatzemeier<sup>3</sup>, V. Errico<sup>3</sup>, R. Torrisi<sup>4</sup>,



A. Santoro<sup>4</sup>, <sup>1</sup>Policlinico Umberto I, Roma, IT, <sup>2</sup>Campus Bio-Medico di Roma, Roma, IT, <sup>3</sup>Istituto Clinico Humanitas, Rozzano (Milan), IT, <sup>4</sup>Istituto Clinico Humanitas, Rozzano, IT

- 12:45 - 12:45 **222P - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab**  
X. Pivot<sup>1</sup>, Y.J. Lee<sup>2</sup>, J.Y. Lim<sup>2</sup>, S.J. Song<sup>2</sup>, H.S. Kim<sup>2</sup>, Y.C. Yoon<sup>2</sup>, <sup>1</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>2</sup>Samsung Bioepis, Suwon, KR
- 12:45 - 12:45 **223P - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience**  
S. Forner<sup>1</sup>, V.R. Sim<sup>2</sup>, J. Glendenning<sup>3</sup>, R. Burcombe<sup>1</sup>, <sup>1</sup>Maidstone Hospital Maidstone & Tunbridge NHS TRUST, Maidstone, GB, <sup>2</sup>Leaders Of Oncology Care, London, GB, <sup>3</sup>King's College London Guy's Hospital, London, GB
- 12:45 - 12:45 **224P - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)**  
J. Litton<sup>1</sup>, S. Moulder<sup>1</sup>, K. Hess<sup>2</sup>, S. Damodaran<sup>3</sup>, G. Rauch<sup>2</sup>, R. Candelaria<sup>2</sup>, B. Adrada<sup>2</sup>, F. Symmans<sup>1</sup>, R. Murthy<sup>2</sup>, T. Helgason<sup>2</sup>, A. Clayborn<sup>2</sup>, S. Prabhakaran<sup>2</sup>, V. Valero<sup>1</sup>, A.M. Thompson<sup>1</sup>, E.A. Mittendorf<sup>1</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>The M. D. Anderson Cancer Center, Houston, US
- 12:45 - 12:45 **225P - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)**  
C. Hall<sup>1</sup>, K. Hess<sup>2</sup>, L. Ravenberg<sup>3</sup>, A. Clayborn<sup>2</sup>, G. Rauch<sup>2</sup>, R. Candelaria<sup>2</sup>, E.A. Mittendorf<sup>4</sup>, S. Moulder<sup>4</sup>, A. Thompson<sup>5</sup>, A. Lucci<sup>5</sup>, <sup>1</sup>MD Anderson, houston, US, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>MD Anderson, Houston, US, <sup>4</sup>MD Anderson Cancer Center, Houston, US, <sup>5</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US
- 12:45 - 12:45 **226P - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients**  
L. Häberle<sup>1</sup>, R. Erber<sup>2</sup>, P. Gaß<sup>2</sup>, A. Hein<sup>3</sup>, S. Jud<sup>2</sup>, H. Langemann<sup>2</sup>, C. Rauh<sup>2</sup>, C. Hack<sup>2</sup>, R. Schulz-Wendtland<sup>2</sup>, A. Hartmann<sup>2</sup>, M. Beckmann<sup>2</sup>, M. Lux<sup>2</sup>, P.A. Fasching<sup>1</sup>, <sup>1</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>2</sup>Erlangen University Hospital, Erlangen, DE, <sup>3</sup>AGO Study Group & Erlangen University Hospital, Erlangen, DE
- 12:45 - 12:45 **227P - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes**  
P.A. Fasching<sup>1</sup>, M. Laible<sup>2</sup>, K. Weber<sup>3</sup>, R.M. Wirtz<sup>4</sup>, C. Denkert<sup>5</sup>, K. Schlombs<sup>2</sup>, S. Schmatloch<sup>6</sup>, O. Camara<sup>7</sup>, H.J. Lück<sup>8</sup>, J. Huober<sup>9</sup>, T. Karn<sup>10</sup>, M. Van Mackelenbergh<sup>11</sup>, F. Marme<sup>12</sup>, V. Müller<sup>13</sup>, C. Schem<sup>14</sup>, E. Stickeler<sup>15</sup>, U. Sahin<sup>16</sup>, S. Loibl<sup>3</sup>, M. Untch<sup>17</sup>, <sup>1</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>2</sup>BioNTech Diagnostics GmbH, Mainz, DE, <sup>3</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>4</sup>Paracelsus Medical University Nuremberg General Hospital, Nuremberg, DE, <sup>5</sup>Charite Berlin Mitte, Berlin,



DE, <sup>6</sup>Elisabeth Krankenhaus, Kassel, DE, <sup>7</sup>Hufeland Klinikum, Bad Langensalza, DE, <sup>8</sup>Gynäkologisch-Onkologische Praxis, Hannover, DE, <sup>9</sup>Universitätsfrauenklinik Ulm, Ulm, DE, <sup>10</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>11</sup>University Hospital Schleswig-Holstein, Kiel, DE, <sup>12</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, <sup>13</sup>Hamburg-Eppendorf University Medical Center, Hamburg, DE, <sup>14</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>15</sup>Uniklinik RWTH, Aachen, DE, <sup>16</sup>BioNTech AG, Mainz, DE, <sup>17</sup>Helios Klinikum Berlin Buch, Berlin, DE

12:45 - 12:45

**228P - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)**

C. Yam<sup>1</sup>, S. Seth<sup>1</sup>, K. Hess<sup>1</sup>, E.A. Mittendorf<sup>2</sup>, R. Murthy<sup>1</sup>, S. Damodaran<sup>3</sup>, T. Helgason<sup>1</sup>, L. Huo<sup>1</sup>, A.M. Thompson<sup>2</sup>, M. Barton<sup>1</sup>, M. Huang<sup>1</sup>, E. Arribas<sup>1</sup>, D. Lane<sup>1</sup>, G. Rauch<sup>1</sup>, B. Adrada<sup>1</sup>, M. Gilcrease<sup>1</sup>, J. Chang<sup>1</sup>, S. Moulder<sup>2</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>MD Anderson Cancer Center, Houston, US, <sup>3</sup>The M. D. Anderson Cancer Center, Houston, US

12:45 - 12:45

**229P - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)**

D. Machado<sup>1</sup>, F. Branco<sup>2</sup>, F. Silva<sup>3</sup>, S. André<sup>1</sup>, M. Brito<sup>4</sup>, M. Casanova<sup>5</sup>, M. Nave<sup>6</sup>, A. Moreira<sup>1</sup>, J. Passos-Coelho<sup>6</sup>, <sup>1</sup>Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon, PT, <sup>2</sup>Hospital Beatriz Angelo-Loures, Loures, PT, <sup>3</sup>Hospital da Luz, Lisboa, PT, <sup>4</sup>Instituto Português de Oncologia, Lisboa, PT, <sup>5</sup>Hospital Beatriz Ângelo, Loures, PT, <sup>6</sup>Hospital da Luz, Lisbon, PT

12:45 - 12:45

**230P - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens**

M. Marin Alcala, G. Lloret Pursals, J.H. Del Riego Ferrari, J. Giner, F.X. Andreu Navarro, S. Medina, O. Aparicio, E. Dalmau Portulas, P. Ribera Fernandez, H. Oliveres, C. Martinez Vila, J. Cabrera Romero, M.A. Segui Palmer, L.A. Fernandez Morales, Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES

12:45 - 12:45

**231P - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)**

B. Seliger, Martin Luther University of Halle, Halle, DE

12:45 - 12:45

**233P - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer**

Y.-C. Tsai, H.C. Cheng, C.C. Horng, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, TW

12:45 - 12:45

**234P - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients - Indian Scenario**

T. Sood<sup>1</sup>, A. Rauthan<sup>1</sup>, P. Patil<sup>1</sup>, S. Kulkarni<sup>1</sup>, S.P. Somashekhar<sup>2</sup>, S. Zaveri<sup>1</sup>, V. Ahuja<sup>1</sup>, K.R. Ashwin<sup>1</sup>, <sup>1</sup>Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN,

<sup>2</sup>Manipal Comprehensive Cancer Care, Bangalore, IN

- 12:45 - 12:45 **235P - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.**  
B. Rapoport<sup>1</sup>, J. Barnard-Tidy<sup>1</sup>, T. Smit<sup>1</sup>, S. Nayler<sup>2</sup>, C. Benn<sup>3</sup>, <sup>1</sup>The Medical Oncology Centre of Rosebank, Sandton, ZA, <sup>2</sup>Grtizman & Thatcher, Parklands, ZA, <sup>3</sup>Breast Care Centre of Excellence, Parklands, ZA
- 12:45 - 12:45 **236P - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience**  
N. Sistany Allahabadi<sup>1</sup>, H. Yahyazadeh<sup>2</sup>, M. Hashemian<sup>2</sup>, M. Rajabpour<sup>2</sup>, S. Aminmozaffari<sup>2</sup>, M. Zaree<sup>2</sup>, A. Rezazadeh Mafi<sup>3</sup>, <sup>1</sup>clinical cancer research center, Tehran, IR, <sup>2</sup>Clinical Cancer Research Center, Tehran, IR, <sup>3</sup>Shahid Beheshti University of Medical Sciences, Teheran, IR
- 12:45 - 12:45 **237P - Index BRCA1/2 testing under a multidisciplinary program**  
D. Machado, S. Fragoso, A. Opinião, A. Clara, S. Bento, A.C. Luís, I. Miguel, S. Santos, P. Machado, P. Rodrigues, J. Parreira, F. Vaz, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPOLFG EPE), Lisbon, PT
- 12:45 - 12:45 **238P - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients**  
A. Friedlaender<sup>1</sup>, A. Vuillemier<sup>1</sup>, V. Viassolo<sup>1</sup>, A. Ayme<sup>1</sup>, S. De Talhouet<sup>2</sup>, J.-D. Combes<sup>3</sup>, J. Peron<sup>4</sup>, A. Bodmer<sup>1</sup>, S. Giraud<sup>4</sup>, A. Buisson<sup>4</sup>, V. Bonadona<sup>5</sup>, I. Gauchat-Bouchardy<sup>1</sup>, O. Tredan<sup>2</sup>, P. Chappuis<sup>1</sup>, S.I. Labidi-Galy<sup>1</sup>, <sup>1</sup>Hopitaux Universitaires de Geneve, Geneva, CH, <sup>2</sup>Centre Léon Bérard, Lyon, FR, <sup>3</sup>International Agency for Research on Cancer, Lyon, FR, <sup>4</sup>Hospices Civils de Lyon, Pierre-Bénite, FR, <sup>5</sup>Centre Leon Berard, Lyon, FR
- 12:45 - 12:45 **239P - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors**  
E. Imyanitov<sup>1</sup>, E. Preobrazhenskaya<sup>1</sup>, A. Shlejkina<sup>1</sup>, A. Sokolenko<sup>2</sup>, E. Anisimova<sup>3</sup>, A. Ivantsov<sup>1</sup>, A. Togo<sup>1</sup>, <sup>1</sup>N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, <sup>2</sup>St. Petersburg Clinical and Scientific Oncological Center, Saint-Petersburg, RU, <sup>3</sup>Leningrad Regional Oncology Dispensary, Saint Petersburg, RU
- 12:45 - 12:45 **240P - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing**  
E. Shagimardanova<sup>1</sup>, L. Shigapova<sup>2</sup>, R. Enikeev<sup>3</sup>, M. Druzhkov<sup>3</sup>, A. Nikitin<sup>4</sup>, O. Gusev<sup>1</sup>, M. Gordiev<sup>5</sup>, <sup>1</sup>Kazan Volga Region Federal University, Kazan, RU, <sup>2</sup>Kazan Federal University, Kazan, RU, <sup>3</sup>Kazan Clinical Oncology Center, Kazan, RU, <sup>4</sup>Federal Research and Clinical Center, FMBA, Moscow, RU, <sup>5</sup>Tatarstan Cancer Center, Kazan, RU
- 12:45 - 12:45 **241P - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Hereditary Oncogenomics project**  
M. Gordiev<sup>1</sup>, L. Shigapova<sup>2</sup>, O. Brovkina<sup>3</sup>, R. Enikeev<sup>4</sup>, M. Druzhkov<sup>4</sup>, A. Nikitin<sup>5</sup>, E.

Shagimardanova<sup>6</sup>, O. Gusev<sup>6</sup>, <sup>1</sup>Tatarstan Cancer Center, Kazan, RU, <sup>2</sup>Kazan Federal University, Kazan, RU, <sup>3</sup>Federal Research and Clinical Center, FMBA of Russia, Moscow, RU, <sup>4</sup>Kazan Clinical Oncology Center, Kazan, RU, <sup>5</sup>Federal Research and Clinical Center, FMBA, Moscow, RU, <sup>6</sup>Kazan Volga Region Federal University, Kazan, RU

12:45 - 12:45 **242P - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)**

N. Olympios<sup>1</sup>, M. Lambertini<sup>2</sup>, C. Calbrix<sup>1</sup>, M. Saint-Ghislain<sup>1</sup>, M. Fontanilles<sup>1</sup>, A. Loeb<sup>1</sup>, M. Leheurteur<sup>1</sup>, I. Demeestere<sup>3</sup>, F. Di Fiore<sup>4</sup>, A. Perdrix<sup>1</sup>, F. Clatot<sup>1</sup>, <sup>1</sup>Centre Henri Becquerel, Rouen, FR, <sup>2</sup>Institute Jules Bordet, Brussels, BE, <sup>3</sup>Hopital Erasme, Brussels, BE, <sup>4</sup>CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, FR

12:45 - 12:45 **243P - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study**

E. Pohl<sup>1</sup>, A. Schneeweiss<sup>2</sup>, J. Hauke<sup>1</sup>, V. Moebus<sup>3</sup>, J. Furlanetto<sup>4</sup>, C. Denkert<sup>5</sup>, P.A. Fasching<sup>6</sup>, C. Hanusch<sup>7</sup>, H. Tesch<sup>8</sup>, N. Weber-Lassalle<sup>1</sup>, V. Müller<sup>9</sup>, K. Rhiem<sup>10</sup>, M. Untch<sup>11</sup>, K. Luebbe<sup>12</sup>, B. Lederer<sup>13</sup>, C. Jackisch<sup>14</sup>, V. Nekljudova<sup>4</sup>, R. Schmutzler<sup>15</sup>, E. Hahnen<sup>1</sup>, S. Loibl<sup>4</sup>, <sup>1</sup>UNIVERSITY HOSPITAL COLOGNE, Cologne, DE, <sup>2</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>3</sup>Klinikum Frankfurt Höchst, Academic Hospital of the Goethe University Frankfurt, Frankfurt, DE, <sup>4</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>5</sup>Charite Berlin Mitte, Berlin, DE, <sup>6</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>7</sup>Rotkreuzklinikum, Munich, DE, <sup>8</sup>Bethanien-Krankenhaus, Frankfurt, DE, <sup>9</sup>Hamburg-Eppendorf University Medical Center, Hamburg, DE, <sup>10</sup>University Hospital Cologne, Cologne, DE, <sup>11</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>12</sup>Diakovere Henriettenstift, Hannover, DE, <sup>13</sup>German Breast Group Forschungs GmbH, Neu-Isenburg, DE, <sup>14</sup>Klinikum Offenbach GmbH, Offenbach, DE, <sup>15</sup>Uniklinik Köln, Universitätsfrauenklinik Köln, Köln, DE

12:45 - 12:45 **244P - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity**

D. O Reilly<sup>1</sup>, L. Dooley<sup>2</sup>, G. Watson<sup>1</sup>, R. Clarke<sup>1</sup>, A. Nolan<sup>1</sup>, C. Nolan<sup>1</sup>, E. Berkeley<sup>1</sup>, M. Farrell<sup>1</sup>, D. Gallagher<sup>1</sup>, <sup>1</sup>St James's Hospital, Dublin, IE, <sup>2</sup>St Lukes Hospital, Dublin, IE

12:45 - 12:45 **245P - Incidence and Survival among Young Women with Stage I-III Breast Cancer**

A. Thomas<sup>1</sup>, A. Rhoads<sup>2</sup>, E. Pinkerton<sup>2</sup>, M. Schroeder<sup>2</sup>, J. Oelson<sup>2</sup>, L. McNally<sup>1</sup>, W. Hundley<sup>1</sup>, K. Conway<sup>2</sup>, C. Lynch<sup>2</sup>, P. Romitti<sup>2</sup>, <sup>1</sup>Wake Forest University Comprehensive Cancer Center, Winston Salem, US, <sup>2</sup>University of Iowa, Iowa City, US

12:45 - 12:45 **246P - Toxicity and Clinical Outcomes of Partial Breast Irradiation (PBI) Compared to Whole Breast Irradiation (WBI) for Early Stage Breast Cancer: A Systematic Review and Meta-analysis**

H. Goldvaser, A. Fyles, D. Shepshelovich, E. Amir, Y. Korzets, Princess Margaret Cancer Centre, Toronto, CA

12:45 - 12:45 **247P - Should anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized**

**controlled trials (RCTs)**

R. Bitton<sup>1</sup>, M. Bruzzone<sup>2</sup>, F. Poggio<sup>3</sup>, M. Ceppi<sup>3</sup>, E. De Azambuja<sup>1</sup>, M. Lambertini<sup>1</sup>,  
<sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>San Martino Hospital, Genova, IT, <sup>3</sup>IRCCS AOU  
San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

12:45 - 12:45 **248P - Taxane &&**

P. Ntellas<sup>1</sup>, N. Spathas<sup>2</sup>, D. Zylis<sup>3</sup>, S. Agelaki<sup>4</sup>, E. Zintzaras<sup>5</sup>, E. Saloustros<sup>6</sup>,  
<sup>1</sup>Biostatistics and Clinical Bioinformatics, Larissa, GR, <sup>2</sup>Attikon University Hospital,  
Athens, GR, <sup>3</sup>Agios Savvas Regional Cancer Hospital, Athens, GR, <sup>4</sup>School of Medicine,  
University of Crete, Heraklion, CRETE, GR, <sup>5</sup>Faculty of Medicine, University of Thessaly,  
Larissa, GR, <sup>6</sup>Venizeleio General Hospital, Heraklion, GR

12:45 - 12:45 **249P - Risk of cardiovascular late effects in breast cancer survivors: a population-based study**

J. Lee<sup>1</sup>, I.Y. Chung<sup>2</sup>, Z. Kim<sup>1</sup>, H. Hur<sup>3</sup>, J.W. Lee<sup>2</sup>, H.J. Youn<sup>4</sup>, <sup>1</sup>Soonchunhyang University  
Hospital Seoul, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KR, <sup>3</sup>National Health Insurance  
Service Ilsan Hospital, Goyang, KR, <sup>4</sup>Chonbuk National University Medical School,  
Jeonju, KR

12:45 - 12:45 **250P - Diagnostic Value of Contrast Enhanced Digital Mammography versus Contrast Enhanced MRI for Preoperative Evaluation of Breast Cancer**

E.Y. Kim, I. Youn, C.H. Park, S.H. Kook, Kangbuk Samsung Hospital Sungkyunkwan  
University, Seoul, KR

12:45 - 12:45 **251P\_PR - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients**

J. Martin-Babau<sup>1</sup>, F. Toudic-Emily<sup>2</sup>, A.-H. Boivin<sup>3</sup>, P. Burbat-Provost<sup>2</sup>, B. Vie<sup>4</sup>, P.-L.  
Etienne<sup>1</sup>, B. Lamezec<sup>5</sup>, E. Le Fur<sup>2</sup>, A. Vincent<sup>3</sup>, D. Besson<sup>1</sup>, A.-C. Hardy-Bessard<sup>5</sup>,  
<sup>1</sup>Hôpital Privé des Côtes d'Armor, Plérin, FR, <sup>2</sup>Centre Armoricaïn de Radiothérapie  
Imagerie Médicale et Oncologie, Plérin, FR, <sup>3</sup>Hopital Prive des Cotes d'Armor, Plérin, FR,  
<sup>4</sup>Polyclinique du Parc, Caen, FR, <sup>5</sup>Clinique Armoricaïne de Radiologie, St. Briec, FR

12:45 - 12:45 **252P - Relationship between androgen receptor and tumor infiltrating lymphocytes in triple negative breast cancer**

L.F. Sánchez-Cousido<sup>1</sup>, A. López-González<sup>1</sup>, E. Honrado Franco<sup>2</sup>, E. Vallejo Pascual<sup>3</sup>, O.  
Sanz<sup>2</sup>, L. Lopez Gonzalez<sup>2</sup>, I. Delgado<sup>1</sup>, M. López-Flores<sup>2</sup>, A. García Palomo<sup>2</sup>, <sup>1</sup>Complejo  
Asistencial Universitario de León, Leon, ES, <sup>2</sup>Complejo Asistencial Universitario de León,  
León, ES, <sup>3</sup>Universidad de León, León, ES

12:45 - 12:45 **253P - Use of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: biological and clinical implications from a randomized clinical trial**

C. Ferraris<sup>1</sup>, B. Ballestra<sup>2</sup>, V. Cappelletti<sup>1</sup>, C. Listorti<sup>1</sup>, P. Miodini<sup>1</sup>, I. Pulice<sup>1</sup>, L. Mariani<sup>1</sup>,  
E. Ferrari<sup>1</sup>, A. Gambaro<sup>2</sup>, I. Maugeri<sup>2</sup>, G. Martelli<sup>2</sup>, S. Folli<sup>2</sup>, <sup>1</sup>Istituto Nazionale dei  
Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Istituto Nazionale dei Tumori di Milano  
- Fondazione IRCCS, Milano, IT



- 12:45 - 12:45 **254P - PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study**  
I. Kindts<sup>1</sup>, A. Laenen<sup>2</sup>, M. Van Den Akker<sup>3</sup>, C. Weltens<sup>1</sup>, <sup>1</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>2</sup>KU Leuven University, Leuven, BE, <sup>3</sup>Maastricht University, Maastricht, NL
- 12:45 - 12:45 **255P - Impact on disease-free survival (DFS) of the surgical waiting time (SWT) for patients (Pts) with early breast cancer (BC)**  
R. Nakamura<sup>1</sup>, N. Yamamoto<sup>2</sup>, T. Miyaki<sup>1</sup>, <sup>1</sup>Chiba Cancer Center Hospital, Chiba, JP, <sup>2</sup>Chiba Cancer Center, Chiba, JP
- 12:45 - 12:45 **256P - Oncological outcome of fat grafting for breast reconstruction after cancer**  
G. Griguolo<sup>1</sup>, F. Miglietta<sup>2</sup>, M.V. Dieci<sup>3</sup>, V. Vindigni<sup>2</sup>, F. Bassetto<sup>2</sup>, E. De Antoni<sup>2</sup>, I. Polico<sup>4</sup>, A. Marchet<sup>5</sup>, E. Baldan<sup>4</sup>, G. Vernaci<sup>3</sup>, T. Saibene<sup>4</sup>, S. Michieletto<sup>4</sup>, V. Guarneri<sup>3</sup>, <sup>1</sup>IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, <sup>2</sup>University of Padova, Padova, IT, <sup>3</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>4</sup>Istituto Oncologico Veneto - IRCCS, Padova, IT, <sup>5</sup>Azienda Ospedaliera di Padova, Padova, IT
- 12:45 - 12:45 **257P - Changes in body weight over 18-months follow-up among Chinese patients after breast cancer diagnosis**  
W. Yeo<sup>1</sup>, Y. Lei<sup>1</sup>, A. Cheng<sup>2</sup>, C. Kwok<sup>3</sup>, K. Cheung<sup>1</sup>, I. Lee<sup>1</sup>, R. Lee<sup>1</sup>, S. Ho<sup>1</sup>, <sup>1</sup>The Chinese University of Hong Kong, Shatin, HK, <sup>2</sup>Princess Margaret Hospital, Kowloon, HK, <sup>3</sup>Princess Margaret Hospital, Shatin, HK
- 12:45 - 12:45 **258P - Incidence of clinically significant toxicities in patients with high endoxifen concentrations**  
S. Groenland<sup>1</sup>, A. Sanchez-Spitman<sup>2</sup>, D.J.A.R. Moes<sup>2</sup>, S. Koolen<sup>3</sup>, V. Dezentjé<sup>4</sup>, N. Van Erp<sup>5</sup>, R. Mathijssen<sup>6</sup>, H.-J. Guchelaar<sup>2</sup>, A. Huitema<sup>7</sup>, N. Steeghs<sup>8</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>Leiden University Medical Center, Leiden, NL, <sup>3</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>4</sup>Reinier de Graaf Hospital, Delft, NL, <sup>5</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>6</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>7</sup>The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, NL, <sup>8</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 12:45 - 12:45 **259P - Male Breast Cancer: Clinical and Epidemiological Patterns in the United States**  
M. Gouda, Faculty of Medicine - Menoufia University, Shebin El Kom, EG
- 12:45 - 12:45 **260P - The aesthetic results after oncoplastic surgery in early breast cancer**  
A. Zikiryahodjaev<sup>1</sup>, A. Sukhotko<sup>2</sup>, A. Tukmakov<sup>1</sup>, <sup>1</sup>P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia, Moscow, RU, <sup>2</sup>Herzen Cancer Research Institute, Moscow, RU
- 12:45 - 12:45 **261P - The application of indocyanine green fluorescence navigation method to a sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer**

K. Yamagami<sup>1</sup>, H. Matsumoto<sup>1</sup>, T. Hashimoto<sup>2</sup>, S. Yanai<sup>1</sup>, S. Yuen<sup>1</sup>, Y. Yata<sup>1</sup>, Y. Ichinose<sup>1</sup>, T. Deai<sup>2</sup>, M. Toi<sup>3</sup>, <sup>1</sup>Shinko Hospital, Kobe, JP, <sup>2</sup>Hashimoto Clinic, Kobe, JP, <sup>3</sup>Kyoto University, Kyoto, JP

- 12:45 - 12:45 **262P - Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Cytology Proven Axillary Node-Positive Breast Cancer at Diagnosis**  
H.J. Choi, S.M. Jung, J.M. Ryu, I. Kim, S.J. Nam, S.W. Kim, J. Yu, S.K. Lee, J.E. Lee, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR
- 12:45 - 12:45 **263P - Omission of Axillary Lymph Node Dissection after Positive Sentinel Lymph Node: Validity and Safety among Early Breast Cancer Patients Treated with Mastectomy**  
A. Matsumoto<sup>1</sup>, Y. Umemoto<sup>1</sup>, H. Jinno<sup>2</sup>, <sup>1</sup>Teikyo University School of Medicine, Tokyo, JP, <sup>2</sup>Teikyo University, Tokyo, JP
- 12:45 - 12:45 **264P - Pathologic response as a strong predictor of survival irrespective of phenotype in early Breast Cancer**  
A. Gasol Cudos, S. Morales Murillo, J. Veas Rodriguez, F. Vilardell Vilellas, D. Sanchez Guzman, E. Iglesias Martinez, Hospital Arnau de Vilanova, Lleida, ES
- 12:45 - 12:45 **265P - Nomogram to predict non-sentinel lymph node status of breast cancer using total tumor load determined by one-step nucleic acid amplification (OSNA)**  
P. O-Charoenrat<sup>1</sup>, D. Sa-Nguanraksa<sup>2</sup>, A. Kulprom<sup>2</sup>, <sup>1</sup>Mahidol university, Bangkok, TH, <sup>2</sup>Siriraj Hospital, Mahidol University, Bangkok, TH
- 12:45 - 12:45 **266P - Detecting Bone Density in Early Breast Cancer Survivors: The Arm-DXA method**  
Y. Al-Farhat, Tolna County Teaching Hospital, Szeksyard, HU
- 12:45 - 12:45 **267P - Voluntary deep inspiration breathhold (DIBH) experience in the radiotherapy for left sided breast cancer**  
I. Gueorguiev<sup>1</sup>, N. Nedev<sup>2</sup>, A. Avramov<sup>2</sup>, A. Tonev<sup>2</sup>, N. Velikova<sup>2</sup>, <sup>1</sup>Pfizer - Bulgaria, Sofia, BG, <sup>2</sup>Acibadem City Clinic Cancer Center, Sofia, BG
- 12:45 - 12:45 **268P - Psychological distress and health-related quality of life in women recently diagnosed with breast cancer in the Epi-GEICAM study.**  
N.. Fernández-De-Larrea<sup>1</sup>, B. Pérez-Gómez<sup>2</sup>, A. Ruiz<sup>3</sup>, A.M. Casas<sup>4</sup>, B. Bermejo<sup>5</sup>, J.M. Baena-Cañada<sup>6</sup>, S. Antolin<sup>7</sup>, P. Sánchez Rovira<sup>8</sup>, M. Ramos Vázquez<sup>9</sup>, J.A. Garcia-Saénz<sup>10</sup>, A. Anton Torres<sup>11</sup>, M. Muñoz<sup>12</sup>, C. Jara<sup>13</sup>, M. Gil-Gil<sup>14</sup>, E. Adrover<sup>15</sup>, A. Oltra<sup>16</sup>, J. Brunet<sup>17</sup>, S. Bezares<sup>18</sup>, M. Martín<sup>19</sup>, M. Pollán<sup>2</sup>, <sup>1</sup>National Center for Epidemiology. Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP). University of Alcalá., Madrid, Alcalá de Henares., ES, <sup>2</sup>National Center for Epidemiology. Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP)., Madrid, ES, <sup>3</sup>Instituto Valenciano de Oncología. GEICAM., Valencia. Madrid., ES, <sup>4</sup>Hospital Virgen del Rocío. GEICAM., Sevilla. Madrid., ES, <sup>5</sup>Hospital Clinico de Valencia. GEICAM., Valencia. Madrid., ES, <sup>6</sup>Hospital Puerta del Mar. GEICAM., Cadiz. Madrid., ES, <sup>7</sup>Complejo Hospitalario Universitario, A Coruña. GEICAM., A Coruña. Madrid, ES, <sup>8</sup>Complejo Hospitalario de Jaén. GEICAM., Jaén. Madrid., ES, <sup>9</sup>Centro Oncológico de

Galicia. GEICAM., A Coruña. Madrid., ES, <sup>10</sup>Hospital Clínico Universitario San Carlos. GEICAM., Madrid., ES, <sup>11</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>12</sup>Hospital Clinic I Provincial. GEICAM., Barcelona. Madrid., ES, <sup>13</sup>Hospital Universitario Fundación Alcorcón, Madrid, ES, <sup>14</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>15</sup>Complejo Hospitalario Universitario de Albacete. GEICAM., Alicante. Madrid., ES, <sup>16</sup>Hospital Virgen de los Lirios. GEICAM, Alicante. Madrid., ES, <sup>17</sup>Josep Trueta University Hospital, Catalan Institute of Oncology, Girona, ES, <sup>18</sup>GEICAM, Madrid, ES, <sup>19</sup>Universidad Complutense, Madrid, ES

12:45 - 12:45

**232TiP - A multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study).**

J.-M. Nabholz<sup>1</sup>, K. Al Saleh<sup>1</sup>, A. Bounedjar<sup>2</sup>, H. Abdel-Razeq<sup>3</sup>, H. Errihani<sup>4</sup>, A. Saadeddin<sup>5</sup>, M. Al Foheidi<sup>6</sup>, M. Ghosn<sup>7</sup>, H. El Zawahry<sup>8</sup>, A. Kandil<sup>9</sup>, N. Abdel-Aziz<sup>1</sup>, F. Dabouz<sup>10</sup>, S. Kullab<sup>1</sup>, <sup>1</sup>King Saud University Medical City (KSUMC), Riyadh, SA, <sup>2</sup>Centre Hospitalo Universitaire de Blida, Blida, DZ, <sup>3</sup>King Hussein Cancer Center, Amman, JO, <sup>4</sup>Institut National d'Oncologie université Mohammed V, Rabat, MA, <sup>5</sup>National Guard Health Affairs (NGHA), Riyadh, SA, <sup>6</sup>National Guard Health Affairs (NGHA) - King AbdulAziz Medical City, Jeddah, SA, <sup>7</sup>Hôtel-Dieu de France, Université Saint-Joseph, Beirut, LB, <sup>8</sup>National Cancer Institute (NCI)/ Cairo, cairo, EG, <sup>9</sup>Clinical Research Center- Faculty of Medicine- Alexandria University, Alexandria, EG, <sup>10</sup>International Cancer Research Group (ICRG), Sharjah, AE

12:45 - 12:45

**269TiP - Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for early breast cancer (RAFAELO study)**

T. Kinoshita<sup>1</sup>, S. Ohtani<sup>2</sup>, H. Doihara<sup>3</sup>, M. Takahashi<sup>4</sup>, T. Fujisawa<sup>5</sup>, N. Yamamoto<sup>6</sup>, K. Aogi<sup>7</sup>, T. Hojo<sup>8</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Hiroshima City Hospital, Hiroshima, JP, <sup>3</sup>Okayama University Hospital, Okayama, JP, <sup>4</sup>Hokkaido Cancer Center, Sapporo, JP, <sup>5</sup>Gunma Prefectural Cancer Center, Gunma, JP, <sup>6</sup>Chiba Cancer Center, Chiba, JP, <sup>7</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>8</sup>National Cancer Center Hospital East, Chiba, JP

12:45 - 12:45

**270TiP - Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)**

L. Heesen<sup>1</sup>, K. Frenzel<sup>1</sup>, S. Bolte<sup>1</sup>, V. Bukur<sup>1</sup>, M. Diken<sup>1</sup>, E. Derhovanessian<sup>1</sup>, S. Kreiter<sup>1</sup>, A. Kuhn<sup>1</sup>, K. Kühlcke<sup>2</sup>, M. Löwer<sup>3</sup>, H. Lindman<sup>4</sup>, S. Pascolo<sup>5</sup>, M. Schmidt<sup>6</sup>, A. Schneeweiss<sup>7</sup>, T. Sjöblom<sup>8</sup>, K. Thielemans<sup>9</sup>, L. Zitvogel<sup>10</sup>, Ö. Türeci<sup>11</sup>, U. Sahin<sup>1</sup>, <sup>1</sup>BioNTech AG, Mainz, DE, <sup>2</sup>BioNTech IMFS, Idar-Oberstein, DE, <sup>3</sup>TRON gGmbH, Mainz, DE, <sup>4</sup>University Hospital Uppsala Akademiska Sjukhuset, Uppsala, SE, <sup>5</sup>University of Zurich, Zurich, CH, <sup>6</sup>Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>7</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>8</sup>Uppsala University, Uppsala, SE, <sup>9</sup>University Hospital Brussels, Brussels, BE, <sup>10</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>11</sup>Cluster for Individualized Immune Intervention, Mainz, DE

12:45 - 12:45

**271TiP - Preoperative Pembrolizumab (Pembro) with Radiation Therapy (RT) in Patients with Operable Triple-Negative Breast Cancer (TNBC)**

H. Mcarthur<sup>1</sup>, R. Basho<sup>2</sup>, S. Shiao<sup>2</sup>, D. Park<sup>3</sup>, C. Dang<sup>3</sup>, S. Karlan<sup>3</sup>, S. Knott<sup>2</sup>, M. Mita<sup>1</sup>, C. Dilauro Abaya<sup>2</sup>, A. Giuliano<sup>3</sup>, F. Dadmanesh<sup>2</sup>, A. Ho<sup>4</sup>, <sup>1</sup>Samuel Oschin Comprehensive



Cancer Institute Cedars-Sinai Medical Center, Los Angeles, US, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>3</sup>Cedars-Sinai Medical Center, Beverly Hills, US, <sup>4</sup>Massachusetts General Hospital, Boston, US

- 12:45 - 12:45 **272TiP - Development of mPRO Mamma mobile application and its impact on the quality of life and health resource usage in patients with early stage and locally advanced breast cancer receiving chemotherapy**  
C. Grasic Kuhar<sup>1</sup>, T. Gortnar<sup>2</sup>, E. Drmota<sup>2</sup>, T. Kovač<sup>2</sup>, M. Kukar<sup>2</sup>, <sup>1</sup>Institute of Oncology Ljubljana, Ljubljana, SI, <sup>2</sup>University of Ljubljana, Ljubljana, SI
- 12:45 - 12:45 **Breast cancer, locally advanced**
- 12:45 - 12:45 **274P - CD8+, CD4+ and FOXP3+ cell profiles and their change after neoadjuvant chemotherapy in patients with triple negative breast cancer**  
N. Verovkina<sup>1</sup>, S. Lyalkin<sup>2</sup>, L. Syvak<sup>1</sup>, A. Askolskyi<sup>2</sup>, N. Majdanevych<sup>2</sup>, <sup>1</sup>National Cancer Institute of the MPH Ukraine, Kiev, UA, <sup>2</sup>National Cancer Institute, Kiev, UA
- 12:45 - 12:45 **275P - Multiplex immunoassays analysis of plasma biomarker levels and response to neoadjuvant chemotherapy for locally advanced breast cancer**  
J.H. Cho, K. Park, E. Lee, Y. Kim, S. Park, S.E. Yoon, K.K. Lee, J.Y. Hur, S.K. Lee, J.E. Lee, S.W. Kim, S.J. Nam, J. Yu, J.-Y. Kim, H.H. Jung, Y.H. Park, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR
- 12:45 - 12:45 **276P - Prognostic role of changes in neutrophil-to-lymphocyte ratio, tumor-infiltrating lymphocyte with programmed death ligand-1 in triple-negative breast cancer**  
E.K. Joung<sup>1</sup>, J.E. Lee<sup>2</sup>, <sup>1</sup>The Catholic University of Korea, College of Medicine, Seoul, KR, <sup>2</sup>Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR
- 12:45 - 12:45 **277P - Expression of Sp17 and its association with clinicopathological parameters of breast cancer**  
Y.-T. Zhou, West China Hospital, Sichuan University, Chengdu, CN
- 12:45 - 12:45 **278P - Intratumoral heterogeneity on dedicated breast positron emission tomography before chemotherapy predicts the outcome of neoadjuvant chemotherapy in breast cancer**  
N. Masumoto<sup>1</sup>, T. Kadoya<sup>2</sup>, E. Suzuki<sup>2</sup>, S. Sueoka<sup>2</sup>, N. Goda<sup>2</sup>, S. Sasada<sup>1</sup>, A. Emi<sup>2</sup>, R. Haruta<sup>2</sup>, T. Kataoka<sup>2</sup>, M. Okada<sup>1</sup>, <sup>1</sup>Hiroshima University, Hiroshima, JP, <sup>2</sup>Hiroshima University Hospital, Hiroshima, JP
- 12:45 - 12:45 **279P - Results from NRG Oncology/NSABP protocol DMP-1: Physician Counseling**  
C. Holmberg<sup>1</sup>, H. Bandos<sup>2</sup>, W. Mccaskill-Stevens<sup>3</sup>, D.L. Wickerham<sup>4</sup>, T. Battaglia<sup>5</sup>, T. Bevers<sup>6</sup>, A. Fagerlin<sup>7</sup>, <sup>1</sup>Institute of Social Medicine and Epidemiology, Medical School Brandenburg Theodor Fontane Brandenburg/Havel, Berlin, DE, <sup>2</sup>NRG Oncology, Pittsburgh, US, <sup>3</sup>National Cancer Institute Div. Cancer Treatment, Rockville, US, <sup>4</sup>NRG



Oncology/NSABP; and The Allegheny Health Network Cancer Institute, Pittsburgh, US, <sup>5</sup>Women's Health Unit, Section of General Internal Medicine, Boston, US, <sup>6</sup>The University of Texas M.D. Anderson Cancer Center, Houston, US, <sup>7</sup>University of Utah School of Medicine/VA Salt Lake City (current); University of Michigan/VA Ann Arbor Center for Clinical Management (research conducted), Salt Lake City, US

12:45 - 12:45

**280P - Neoadjuvant eribulin plus carboplatin vs. paclitaxel plus carboplatin in patients with triple-negative breast cancer (TNBC)**

L. Gigolaeva<sup>1</sup>, P. Krivorotko<sup>1</sup>, S. Khadzhimatova<sup>1</sup>, E. Zhiltsova<sup>2</sup>, S. Yerechshenko<sup>2</sup>, M. Nikitina<sup>2</sup>, V. Ni<sup>2</sup>, A. Emelyanov<sup>2</sup>, E. Imyanitov<sup>3</sup>, A. Sokolenko<sup>4</sup>, T. Tabagua<sup>2</sup>, <sup>1</sup>N.N.Petrov Research Inst. of Oncology, Saint Petersburg, RU, <sup>2</sup>N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, <sup>3</sup>N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, <sup>4</sup>St. Petersburg Clinical and Scientific Oncological Center, Saint-Petersburg, RU

12:45 - 12:45

**Breast cancer, metastatic**

12:45 - 12:45

**281TiP - A phase Ib/II study of Durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE).**

A. Devaux<sup>1</sup>, J.-L. Canon<sup>2</sup>, F. Duhoux<sup>3</sup>, P. Delrée<sup>4</sup>, C. Galant<sup>3</sup>, P. Coulie<sup>5</sup>, I. Bar<sup>6</sup>, M. Constant<sup>7</sup>, S. Haussy<sup>8</sup>, O. Bricard<sup>5</sup>, K. Missault<sup>5</sup>, M. Berlière<sup>3</sup>, T. Willems<sup>2</sup>, J. Carrasco<sup>2</sup>, <sup>1</sup>UCL Woluwé, Brussels, BE, <sup>2</sup>Grand Hopital de Charleroi Site Notre Dame, Charleroi, BE, <sup>3</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>4</sup>Grand Hopital de Charleroi Site Notre Dame/Institut de Pathologie et Génétique, Gosselies, BE, <sup>5</sup>de Duve Institute, Brussels, BE, <sup>6</sup>Institut de Pathologie et de Génétique, Gosselies, BE, <sup>7</sup>Grand Hopital de Charleroi/Institut de Pathologie et Génétique, Gosselies, BE, <sup>8</sup>Institute Jules Bordet, Brussels, BE

12:45 - 12:45

**282TiP - Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: the RIBANNA study**

P.A. Fasching<sup>1</sup>, T. Decker<sup>2</sup>, G. Guderian<sup>3</sup>, J. Heim<sup>4</sup>, C. Jackisch<sup>5</sup>, H.-J. Lueck<sup>6</sup>, D. Lüftner<sup>7</sup>, F. Marmé<sup>8</sup>, T. Reimer<sup>9</sup>, A. Woeckel<sup>10</sup>, <sup>1</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>2</sup>Onkologie Ravensburg, Ravensburg, DE, <sup>3</sup>Novartis Pharma Germany, Nürnberg, DE, <sup>4</sup>Novartis Pharma GmbH, Nuernberg, DE, <sup>5</sup>Klinikum Offenbach GmbH, Offenbach, DE, <sup>6</sup>Gynökologisch-onkologische Praxis, Hamburg, DE, <sup>7</sup>Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, <sup>8</sup>AGO Study Group & National Center for Tumor disease, University of Heidelberg, Heidelberg, DE, <sup>9</sup>University of Rostock, Rostock, DE, <sup>10</sup>University Hospital Wuerzburg, Würzburg, DE

12:45 - 12:45

**295P - Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial VicTORia.**

T. Decker<sup>1</sup>, A. Mündlein<sup>2</sup>, N. Marschner<sup>3</sup>, A. Welt<sup>4</sup>, T. Riedt<sup>5</sup>, V. Hagen<sup>6</sup>, J. Rauh<sup>7</sup>, D.

Klein<sup>5</sup>, K. Potthoff<sup>5</sup>, P. Jähmig<sup>8</sup>, H. Schröder<sup>9</sup>, S. Hegewisch-Becker<sup>10</sup>, C. Lerchenmüller<sup>11</sup>, <sup>1</sup>Onkologie Ravensburg, Ravensburg, DE, <sup>2</sup>VIVIT Molekularbiologisches Labor, Dornbirn, AT, <sup>3</sup>Praxis für Interdisziplinäre Onkologie, Freiburg, DE, <sup>4</sup>Universitätsklinikum Essen (AöR), Essen, DE, <sup>5</sup>iOMEDICO AG, Freiburg, DE, <sup>6</sup>St.-Johannes-Hospital Dortmund, Dortmund, DE, <sup>7</sup>GIM - Gemeinschaftspraxis Innere Medizin, Witten, DE, <sup>8</sup>ICRC Weyer GmbH, Berlin, DE, <sup>9</sup>AIO-Studien-gGmbH, Berlin, DE, <sup>10</sup>Hämatologisch-Onkologische Praxis Eppendorf, Hamburg, DE, <sup>11</sup>Hämatologisch-Onkologische Gemeinschaftspraxis, Münster, DE

12:45 - 12:45

**296P - Applicability of the Lung Immune Prognostic Index (LIPI) to metastatic Triple negative Breast Cancer (mTNBC) patients treated with Immune Checkpoint Targeted Monoclonal Antibodies (ICT mAbs)**

A. Vozy<sup>1</sup>, A. Simonaggio<sup>2</sup>, E. Auclin<sup>2</sup>, L. Mezquita Pérez<sup>3</sup>, C. Baldini<sup>3</sup>, P. Martin-Romano<sup>4</sup>, B. Pistilli<sup>3</sup>, A. Gazzah<sup>4</sup>, R. Bahleda<sup>5</sup>, V. Ribrag<sup>3</sup>, S. Postel-Vinay<sup>4</sup>, S. Champiat<sup>3</sup>, J.-C. Soria<sup>6</sup>, F. André<sup>7</sup>, C. Massard<sup>5</sup>, B. Besse<sup>7</sup>, S. Delaloge<sup>3</sup>, A. Varga<sup>3</sup>, <sup>1</sup>Hôpitaux Paris Centre AP-HP, Paris, FR, <sup>2</sup>Hopital European George Pompidou, Paris, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR, <sup>5</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>6</sup>Medimmune, Gaithersburg, US, <sup>7</sup>Gustave Roussy - Cancer Campus, Villejuif, FR

12:45 - 12:45

**297P - Peripheral Blood Mononuclear Cell Biomarkers Predict Response to Immune Checkpoint Inhibitor Therapy in Metastatic Breast Cancer**

Y. Yuan, W. Hou, S. Padam, P. Frankel, M. Sedrak, J. Portnow, J. Mortimer, C. Yeon, A. Hurria, A. Tang, N. Martinez, P. Lee, City of Hope, Duarte, US

12:45 - 12:45

**298P - Circulating exosomal microRNA profiling to depict mechanisms of chemotherapy resistance among triple negative breast cancer**

Y. He<sup>1</sup>, T. Jinhai<sup>2</sup>, <sup>1</sup>Jiangsu Province Hospital, Nanjing, CN, <sup>2</sup>the First Affiliated Hospital with Nanjing Medical University, Nanjing, CN

12:45 - 12:45

**299P - The Prevalence of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)**

K. Wan<sup>1</sup>, Y. Wang<sup>2</sup>, M. Kaper<sup>3</sup>, M. Fritzscheier<sup>2</sup>, N. Babbar<sup>4</sup>, <sup>1</sup>Novartis Pharma AG, Basel, CH, <sup>2</sup>Novartis Institutes for BioMedical Research, Cambridge, US, <sup>3</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>4</sup>Novartis, East Hanover, US

12:45 - 12:45

**300P - Differential molecular signature in patients from African origin with Triple-Negative Breast Cancer**

A.T. Matias<sup>1</sup>, A. Jacinta-Fernandes<sup>2</sup>, R. Magno<sup>2</sup>, J. Xavier<sup>2</sup>, M. Cabral<sup>3</sup>, A. Jacinto<sup>3</sup>, A. Maia<sup>2</sup>, S. Braga<sup>3</sup>, <sup>1</sup>CEDOC, Lisbon, PT, <sup>2</sup>Centre for Biomedical Research (CBMR), University of Algarve, Campus de Gambelas, Faro, Portugal, Faro, PT, <sup>3</sup>NOVA Medical School, Lisbon, PT

12:45 - 12:45

**301P - Analysis of the JAK2 gene in TNBC**

L. Stanek<sup>1</sup>, P. Tesarova<sup>2</sup>, M. Vocka<sup>2</sup>, L. Petruzela<sup>2</sup>, <sup>1</sup>General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, CZ, <sup>2</sup>General Faculty Hospital, VFN Charles University, Prague, CZ

- 12:45 - 12:45 **302P - A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients.**
- G. Pelizzari<sup>1</sup>, L. Gerratana<sup>2</sup>, D. Basile<sup>3</sup>, S. Zago<sup>4</sup>, M.G. Vitale<sup>3</sup>, M. Bartoletti<sup>3</sup>, C. Lisanti<sup>1</sup>, V. Fanotto<sup>5</sup>, C. Corvaja<sup>6</sup>, L. Bortot<sup>3</sup>, A. Liguori<sup>7</sup>, M. Cinausero<sup>3</sup>, S. Russo<sup>8</sup>, C. Andreetta<sup>2</sup>, M. Bonotto<sup>9</sup>, M. Mansutti<sup>2</sup>, A. Minisini<sup>9</sup>, F. Curcio<sup>8</sup>, G. Fasola<sup>1</sup>, F. Puglisi<sup>6</sup>, <sup>1</sup>Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, <sup>2</sup>AOU Santa Maria della Misericordia, Udine, IT, <sup>3</sup>University of Udine, Udine, IT, <sup>4</sup>Hospital "Santa Maria degli Angeli", Pordenone, IT, <sup>5</sup>University Hospital of Udine, Udine, IT, <sup>6</sup>CRO di Aviano, Aviano, IT, <sup>7</sup>AOU Policlinico G. Martino Università di Messina, Messina, IT, <sup>8</sup>ASUI Udine University Hospital, Udine, IT, <sup>9</sup>ASUIUD Azienda Ospedaliero-Universitaria di Udine, Udine, IT
- 12:45 - 12:45 **303P - EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment**
- M. Martín<sup>1</sup>, W. Eiermann<sup>2</sup>, H. Rugo<sup>3</sup>, J. Ettl<sup>4</sup>, S. Hurvitz<sup>5</sup>, A. Gonçalves<sup>6</sup>, R. Yerushalmi<sup>7</sup>, D. Markova<sup>8</sup>, I.C. Tudor<sup>8</sup>, J. Blum<sup>9</sup>, A. Hannah<sup>10</sup>, J. Litton<sup>11</sup>, <sup>1</sup>Universidad Complutense, Madrid, ES, <sup>2</sup>No place of work provided Iran, Teheran, IR, <sup>3</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>4</sup>Technische Universität München, Munich, DE, <sup>5</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>6</sup>Institute Paoli Calmettes, Marseille, FR, <sup>7</sup>Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, <sup>8</sup>Pfizer, Inc., San Francisco, US, <sup>9</sup>Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, US, <sup>10</sup>Consultant, New York, US, <sup>11</sup>MD Anderson Cancer Center, Houston, US
- 12:45 - 12:45 **304P - EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis**
- A. Gonçalves<sup>1</sup>, W. Eiermann<sup>2</sup>, H. Rugo<sup>3</sup>, J. Ettl<sup>4</sup>, S. Hurvitz<sup>5</sup>, R. Yerushalmi<sup>6</sup>, M. Martín<sup>7</sup>, M. Al-Adhami<sup>8</sup>, I.C. Tudor<sup>9</sup>, J. Blum<sup>10</sup>, A. Hannah<sup>11</sup>, J. Litton<sup>12</sup>, <sup>1</sup>Institute Paoli Calmettes, Marseille, FR, <sup>2</sup>No place of work provided Iran, Teheran, IR, <sup>3</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>4</sup>Technische Universität München, Munich, DE, <sup>5</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>6</sup>Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL, <sup>7</sup>Universidad Complutense, Madrid, ES, <sup>8</sup>Pfizer Inc., Groton, US, <sup>9</sup>Pfizer, Inc., San Francisco, US, <sup>10</sup>Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, US, <sup>11</sup>Consultant, New York, US, <sup>12</sup>MD Anderson Cancer Center, Houston, US
- 12:45 - 12:45 **305P - Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase 3 EMBRACA trial**
- Y. Yu<sup>1</sup>, M. Elmeliogy<sup>2</sup>, J. Litton<sup>3</sup>, I.C. Tudor<sup>4</sup>, A. Czibere<sup>5</sup>, J. Zheng<sup>6</sup>, D. Wang<sup>1</sup>, <sup>1</sup>Pfizer, Inc., La Jolla, US, <sup>2</sup>Novartis Pharmaceuticals, East Hanover, US, <sup>3</sup>MD Anderson Cancer Center, Houston, US, <sup>4</sup>Pfizer, Inc., San Francisco, US, <sup>5</sup>Merrimack Pharmaceuticals, Inc., New York, US, <sup>6</sup>Pfizer, Inc., Collegeville, US
- 12:45 - 12:45 **306P - Exposure-safety analyses in breast cancer patients with germline**



**BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials**

M. Elmeliegy<sup>1</sup>, Y. Yu<sup>2</sup>, J. Litton<sup>3</sup>, N. Turner<sup>4</sup>, A. Czibere<sup>5</sup>, G. Wilson<sup>6</sup>, I.C. Tudor<sup>7</sup>, J. Zheng<sup>8</sup>, D. Wang<sup>2</sup>, <sup>1</sup>Novartis Pharmaceuticals, East Hanover, US, <sup>2</sup>Pfizer, Inc., La Jolla, US, <sup>3</sup>MD Anderson Cancer Center, Houston, US, <sup>4</sup>Royal Marsden Hospital and Institute of Cancer Research, London, GB, <sup>5</sup>Merrimack Pharmaceuticals, Inc., New York, US, <sup>6</sup>Pfizer, Inc., New York, US, <sup>7</sup>Pfizer, Inc., San Francisco, US, <sup>8</sup>Pfizer, Inc., Collegeville, US

12:45 - 12:45 **307P - An international systematic review (SR) of breast cancer (BC) BRCA mutation (BRCAm) prevalence**

N. Armstrong<sup>1</sup>, S. Ryder<sup>1</sup>, C. Forbes<sup>1</sup>, A. Chalker<sup>1</sup>, J. Ross<sup>1</sup>, R. Quek<sup>2</sup>, <sup>1</sup>Kleijnen Systematic Reviews Ltd, York, GB, <sup>2</sup>Pfizer, Inc., San Francisco, US

12:45 - 12:45 **308P - Genetic screening, counselling, and treatment of BRCA mutation (BRCAm) carriers: a systematic review (SR) of international breast cancer (BC) guidelines**

C. Forbes<sup>1</sup>, D. Fayter<sup>1</sup>, C. Clar<sup>1</sup>, K. Reid<sup>1</sup>, S. De Kock<sup>1</sup>, R. Quek<sup>2</sup>, <sup>1</sup>Kleijnen Systematic Reviews Ltd, York, GB, <sup>2</sup>Pfizer, Inc., San Francisco, US

12:45 - 12:45 **309P - Efficacy and toxicity of endocrine therapy + cyclin-dependent kinases 4/6 inhibitors (iCDK4/6) in metastatic breast cancer patients according to gBRCA status**

L. Bruno, M. Costanzo, C. Ostinelli, A. Nervo, J. Nadal, F. Colo, J. Loza, C. Loza, C. Ponce, V. Fabiano, A. Blanco, C. Perez De La Puente, R. Chacon, Alexander Fleming Institute, Buenos Aires, AR

12:45 - 12:45 **310P - Clinical Outcomes, Treatment Patterns and Health Resource Utilization (HRU) Among Metastatic Breast Cancer (mBC) Patients (pts) with Germline BRCA Mutation (gBRCAm)**

R. Quek, J. Mardekian, Pfizer, Inc., San Francisco, US

12:45 - 12:45 **311P - Early Results from an Open-label Phase 1b/2 Study of Eribulin Mesylate (EM) + Pegvorhialuronidase Alfa (PEGHP20) Combination for the Treatment of Patients (Pts) with HER2-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)**

M. Shum<sup>1</sup>, V. Assikis<sup>2</sup>, C. Savulsky<sup>3</sup>, W. Zhu<sup>4</sup>, P. Iyer<sup>4</sup>, D. Xing<sup>4</sup>, C. Berman<sup>5</sup>, N. Lokker<sup>6</sup>, R. Alvarez<sup>7</sup>, <sup>1</sup>Oncology Institute of Hope and Innovation, Whittier, US, <sup>2</sup>Piedmont Cancer Institute, Newman, US, <sup>3</sup>Eisai Ltd., Hatfield, GB, <sup>4</sup>Eisai Inc., Woodcliff Lake, US, <sup>5</sup>Halozyne Therapeutics, Inc, San Diego, US, <sup>6</sup>BioMarin Pharmaceutical Inc., Novato, US, <sup>7</sup>Cancer Treatment Centers of America, Newnan, US

12:45 - 12:45 **312P - Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer**

K. Sakaguchi, K. Nakatsukasa, T. Taguchi, Kyoto Prefectural University of Medicine, Kyoto, JP

12:45 - 12:45 **313P - Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study**



M. Jafri<sup>1</sup>, H. Kristeleit<sup>2</sup>, V. Misra<sup>3</sup>, M. Baxter<sup>4</sup>, S. Ahmed<sup>5</sup>, A. Jegnnathen<sup>6</sup>, A. Jain<sup>7</sup>, D. Maskell<sup>8</sup>, U. Barthakur<sup>9</sup>, G. Edwards<sup>10</sup>, H. Walter<sup>5</sup>, R. Walter<sup>3</sup>, M. Khan<sup>11</sup>, A. Borley<sup>12</sup>, P. Nightingale<sup>1</sup>, D. Rea<sup>13</sup>, <sup>1</sup>Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB, <sup>2</sup>Guy's Cancer Centre, rt, GB, <sup>3</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>4</sup>Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>5</sup>University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, GB, <sup>6</sup>University Hospitals of North Midlands, ST QG, GB, <sup>7</sup>The Royal Wolverhampton Hospitals NHS Trust New Cross Hospital, Wolverhampton, GB, <sup>8</sup>Norfolk and Norwich University Hospita, nruy, GB, <sup>9</sup>Taunton and Somerset NHS Foundation trust, TA DA, GB, <sup>10</sup>Personal address, Cardiff, GB, <sup>11</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>12</sup>velindre Cancer Centre, cf TL, GB, <sup>13</sup>The University of Birmingham Institute for Cancer Studies, Birmingham, GB

12:45 - 12:45 **314P - Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: a real-world prospective study**

M. Takahashi<sup>1</sup>, K. Inoue<sup>2</sup>, H. Mukai<sup>3</sup>, T. Yamanaka<sup>4</sup>, C. Egawa<sup>5</sup>, Y. Sakata<sup>6</sup>, H. Ikezawa<sup>6</sup>, T. Matsuoka<sup>6</sup>, J. Tsurutani<sup>7</sup>, <sup>1</sup>Hokkaido Cancer Center, Sapporo, JP, <sup>2</sup>Saitama Cancer Center, Kita-adachi Ina, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>5</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>6</sup>Eisai Co., Ltd., Tokyo, JP, <sup>7</sup>Kindai University School of Medicine, Osaka, JP

12:45 - 12:45 **315P - Prospective Cohort Study of Real World Chemotherapy Sequence for Metastatic Breast Cancer (KBCRN A001: E-SPEC Study)**

K. Nakatsukasa<sup>1</sup>, Y. Kikawa<sup>2</sup>, T. Kotake<sup>3</sup>, K. Yamagami<sup>4</sup>, S. Tsuyuki<sup>5</sup>, H. Yamashiro<sup>6</sup>, H. Suwa<sup>7</sup>, T. Sugie<sup>8</sup>, T. Okuno<sup>9</sup>, H. Kato<sup>2</sup>, S. Takahara<sup>10</sup>, I. Nakayama<sup>11</sup>, N. Ogura<sup>12</sup>, Y. Moriguchi<sup>13</sup>, M. Takata<sup>3</sup>, E. Suzuki<sup>3</sup>, H. Yoshibayashi<sup>14</sup>, H. Ishiguro<sup>15</sup>, T. Taguchi<sup>1</sup>, M. Toi<sup>3</sup>, <sup>1</sup>Kyoto Prefectural University of Medicine, Kyoto, JP, <sup>2</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>3</sup>Kyoto University-Graduate school of medicine, Kyoto, JP, <sup>4</sup>Shinko Hospital, Kobe, JP, <sup>5</sup>Osaka Red Cross Hospital, Osaka, JP, <sup>6</sup>Tenri Hospital, Nara, JP, <sup>7</sup>Hyogo Prefectural Amagasaki General Medical Center, Hyogo, JP, <sup>8</sup>Kansai Medical University Hospital, Osaka, JP, <sup>9</sup>Kobe City Nishi-Kobe Medical Center, Kobe, JP, <sup>10</sup>Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, JP, <sup>11</sup>Kyoto Min-iren Chuo Hospital, Kyoto, JP, <sup>12</sup>Kansai Electric Power Hospital, Osaka, JP, <sup>13</sup>Kyoto City Hospital, Kyoto, JP, <sup>14</sup>Japanese Red Cross Wakayama Medical Cente, Wakayama, JP, <sup>15</sup>International University of Health and Welfare, Nasushiobara, JP

12:45 - 12:45 **316P - Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice**

T. Luhn<sup>1</sup>, S. Chui<sup>2</sup>, A. Hsieh<sup>2</sup>, J. Yi<sup>3</sup>, A. Mecke<sup>4</sup>, P. Bajaj<sup>2</sup>, W. Hasnain<sup>1</sup>, A. Falgas<sup>4</sup>, T. Ton<sup>2</sup>, A. Kurian<sup>5</sup>, <sup>1</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>2</sup>Genentech, Inc., South San Francisco, US, <sup>3</sup>Genesis Research, Hoboken, US, <sup>4</sup>Roche, Basel, CH, <sup>5</sup>Stanford University School of Medicine, Stanford, US

12:45 - 12:45 **317P - Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: a phase II randomized study (JBCRG-19)**

K.-I. Watanabe<sup>1</sup>, K. Aogi<sup>2</sup>, M. Kitada<sup>2</sup>, T. Sangai<sup>3</sup>, S. Ohtani<sup>4</sup>, T. Aruga<sup>5</sup>, H. Kawaguchi<sup>6</sup>, T. Fujisawa<sup>7</sup>, S. Maeda<sup>8</sup>, T. Morimoto<sup>9</sup>, S. Morita<sup>10</sup>, N. Masuda<sup>11</sup>, M. Toi<sup>12</sup>, S. Ohno<sup>13</sup>,

<sup>1</sup>Hokkaido Cancer Center, Sapporo, JP, <sup>2</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>3</sup>Chiba University Graduate School of Medicine, Chiba, JP, <sup>4</sup>Hiroshima City Hospital, Hiroshima, JP, <sup>5</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, <sup>6</sup>Matsuyama Red Cross Hospital, Matsuyama, JP, <sup>7</sup>Gunma Prefectural Cancer Center, Gunma, JP, <sup>8</sup>National Nagasaki Medical Center, Omura, JP, <sup>9</sup>Yao Municipal Hospital, Yao, JP, <sup>10</sup>Kyoto University Graduate School of Medicine 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, JP, <sup>11</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>12</sup>Kyoto University-Graduate school of medicine, Kyoto, JP, <sup>13</sup>National Kyushu Cancer Center, Fukuoka, JP

- 12:45 - 12:45 **318P - Clinical utility of hepatic arterial infusion chemotherapy for heavily pretreated metastatic breast cancer patients: A review of a single institution**  
M. Furuta, J. Watanabe, T. Aramaki, Shizuoka Cancer Center, Shizuoka, JP
- 12:45 - 12:45 **319P - A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)**  
P. Krivorotko<sup>1</sup>, B. Karaszewska<sup>2</sup>, S. Chan<sup>3</sup>, M. Wieczorek-Rutkowska<sup>4</sup>, T. Sarosiek<sup>5</sup>, M. Shomova<sup>6</sup>, E. Ovchinnikova<sup>7</sup>, J.P. Zarate<sup>8</sup>, C. Babanrao Pisal<sup>9</sup>, L. Smith<sup>10</sup>, A. Manikhas<sup>11</sup>, <sup>1</sup>N.N.Petrov Research Inst. of Oncology, Saint Petersburg, RU, <sup>2</sup>Regional Hospital, Konin, PL, <sup>3</sup>Nottingham University Hospital NHS Trust (City Hospital Campus), Nottingham, GB, <sup>4</sup>Copernicus PL Sp.z o.o Wojewodzkie Centrum Onkologii, St.Peterburg, RU, <sup>5</sup>Magodent Szpital Elblaska, Warsaw, PL, <sup>6</sup>Ryazan Regional Clinical Oncology Center, Ryazan, RU, <sup>7</sup>Nizhny Novgorod Regional Hospital, Nizhny Novgorod, RU, <sup>8</sup>Novartis, US, <sup>9</sup>Novartis Healthcare Private Limited, Hyderabad, IN, <sup>10</sup>Novartis Pharmaceutical Corporation, East Hanover, US, <sup>11</sup>City Clinical Oncology Dispensary, Saint Petersburg, RU
- 12:45 - 12:45 **320P - Nab-paclitaxel (nab-P) in mEtastatic bREast cancer (MBC) In elDerly patiEnts: a real life setting - NEREIDE Study**  
V. Adamo<sup>1</sup>, G.R.R. Ricciardi<sup>2</sup>, S. Schifano<sup>2</sup>, A. Russo<sup>3</sup>, V. Gebbia<sup>4</sup>, L. Blasi<sup>5</sup>, D. Giuffrida<sup>6</sup>, G. Scandurra<sup>7</sup>, A. Savarino<sup>8</sup>, A. Butera<sup>9</sup>, N. Borsellino<sup>10</sup>, F. Verderame<sup>11</sup>, M. Caruso<sup>7</sup>, <sup>1</sup>AOU Policlinico G. Martino Università di Messina, Messina, IT, <sup>2</sup>Centro Oncologico Ospedale Papardo, Messina, IT, <sup>3</sup>AOU Policlinico "Paolo Giaccone", Palermo, IT, <sup>4</sup>Ospedale La Maddalena, Palermo, IT, <sup>5</sup>Fondazione Istituto San Raffaele - G. Giglio di Cefalù, Cefalù, IT, <sup>6</sup>Istituto Oncologico del Mediterraneo, Viagrande, IT, <sup>7</sup>Humanitas Centro Catanese di Oncologia, Catania, IT, <sup>8</sup>Ospedale Barone Lombardo-Presidio Ospedaliero Canicattì, Canicattì, IT, <sup>9</sup>Azienda Ospedaliera St. Giovannino di Dio, Agrigento, IT, <sup>10</sup>Ospedali Buccheri la Ferla, Palermo, IT, <sup>11</sup>Presidio Ospedaliero Cervello, Palermo, IT
- 12:45 - 12:45 **321P - Response evaluation of cancer therapeutics in metastatic breast cancer to the bone: a single arm phase 2 study of whole-body magnetic resonance imaging**  
M. Kosmin<sup>1</sup>, A. Padhani<sup>2</sup>, A. Gogbashian<sup>2</sup>, D. Woolf<sup>3</sup>, M.-L. Ah-See<sup>1</sup>, P. Ostler<sup>1</sup>, S. Sutherland<sup>1</sup>, D. Miles<sup>1</sup>, J. Noble<sup>4</sup>, A. Marshall<sup>5</sup>, J. Dunn<sup>5</sup>, A. Makris<sup>1</sup>, <sup>1</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>2</sup>Paul Strickland Scanner Centre, Northwood, GB, <sup>3</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>4</sup>The Royal Marsden Hospital, Sutton, GB, <sup>5</sup>University of Warwick, Coventry, GB

- 12:45 - 12:45 **322P - Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide**  
J. Zimmermann<sup>1</sup>, T. Remus<sup>1</sup>, G. Lemercier<sup>1</sup>, D. Barker<sup>2</sup>, D. Obrecht<sup>1</sup>, G. Gambino<sup>1</sup>, G. Douglas<sup>1</sup>, <sup>1</sup>Polyphor Ltd, Allschwil, CH, <sup>2</sup>Polyphor AG, Allschwil, CH
- 12:45 - 12:45 **323P - Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis**  
S. Kümmel<sup>1</sup>, C. Tondini<sup>2</sup>, J. Abraham<sup>3</sup>, Z. Nowecki<sup>4</sup>, B. Itrych<sup>5</sup>, E. Hitre<sup>6</sup>, B. Karaszewska<sup>7</sup>, A. Juarez<sup>8</sup>, F. Morales-Vásquez<sup>9</sup>, J. Pérez García<sup>10</sup>, S. Cardona-Huerta<sup>11</sup>, D. Heinzmann<sup>12</sup>, J. He<sup>13</sup>, A.N. Duc<sup>14</sup>, A. Crepelle-Fléchais<sup>14</sup>, M. Martín<sup>15</sup>, <sup>1</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>2</sup>Ospedali Riuniti di Bergamo, Bergamo, IT, <sup>3</sup>Velindre Cancer Centre, Cardiff, GB, <sup>4</sup>The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL, <sup>5</sup>Indywidualna Praktyka Lekarska Bartosz Itrych, Warsaw, PL, <sup>6</sup>National Institute of Oncology Hungary, Budapest, HU, <sup>7</sup>Regional Hospital, Konin, PL, <sup>8</sup>Centro Medico Nacional 20 de Noviembre ISSSTE Hospital de la Mujer SSA, Ciudad de México, MX, <sup>9</sup>FUCAM and Instituto Nacional de Cancerologia de Mexico, Mexico City, MX, <sup>10</sup>Hospital Universitari Vall d'Hebron, Barcelona, ES, <sup>11</sup>Hospital Zambrano-Helion, Tecnológico de Monterrey, Monterrey, MX, <sup>12</sup>F. Hoffmann-La Roche AG - Switzerland, Basel, CH, <sup>13</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>14</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>15</sup>Universidad Complutense, Madrid, ES
- 12:45 - 12:45 **324P - Settings-Based Efficacy Comparison of Trastuzumab Biosimilars in Breast Cancer: A Systematic Literature Review**  
H. Rugo<sup>1</sup>, G. Curigliano<sup>2</sup>, F. Cardoso<sup>3</sup>, W. Gradishar<sup>4</sup>, M. Pegram<sup>5</sup>, C. Barrios<sup>6</sup>, J. Cortes Castan<sup>7</sup>, E. Pennella<sup>8</sup>, R. Muniz<sup>8</sup>, <sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Champalimaud Foundation Cancer Center, Lisbon, PT, <sup>4</sup>Northwestern University Feinberg School of Medicine, Chicago, US, <sup>5</sup>Stanford Comprehensive Cancer Institute, Stanford, US, <sup>6</sup>PUCRS-Pontificia Universidade do Rio Grande do Sul, Porto Alegre, BR, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Mylan, Canonsburg, US
- 12:45 - 12:45 **325P - Pertuzumab, Trastuzumab and Taxane combination for Visceral Organ Metastatic Patients: Real Life Practice Results**  
E. Esin<sup>1</sup>, O.B. Cakmak Oksuzoglu<sup>2</sup>, A. Bilici<sup>3</sup>, I. Cicin<sup>4</sup>, S. Aksoy<sup>1</sup>, A. Alacacioglu<sup>5</sup>, M.A. Kaplan<sup>6</sup>, D. Cabuk<sup>7</sup>, A. Sumbul<sup>8</sup>, S. Paydas<sup>9</sup>, A. Sakin<sup>10</sup>, Ö. Er<sup>11</sup>, T. Korkmaz<sup>12</sup>, N. Yildirim<sup>13</sup>, M. Artac<sup>14</sup>, H. Harputluoglu<sup>15</sup>, P. Yumuk<sup>16</sup>, G. Basaran<sup>17</sup>, B. Oyan Uluc<sup>18</sup>, U. Demirci<sup>2</sup>, <sup>1</sup>Hacettepe University Faculty of Medicine, Ankara, TR, <sup>2</sup>Dr. Abdurrahman Yurtaslan Ankara Onkoloji Training and Research Hospital, Ankara, TR, <sup>3</sup>Medipol Mega Hospitals Complex (University Hospital), Istanbul, TR, <sup>4</sup>Trakya University Faculty of Medicine, Edirne, TR, <sup>5</sup>Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, TR, <sup>6</sup>Dicle University, Diyarbakir, TR, <sup>7</sup>Kocaeli University, Kocaeli, TR, <sup>8</sup>Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana, TR, <sup>9</sup>Cukurova University, Adana, TR, <sup>10</sup>Okmeydanı Education and Research Hospital, Istanbul, TR, <sup>11</sup>Ac?badem Maslak Hastanesi, Istanbul, TR, <sup>12</sup>Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, TR, <sup>13</sup>Gaziantep Dr. Ersin Arslan Government Hospital, Gaziantep, TR, <sup>14</sup>Necmettin Erbakan University, Konya, TR, <sup>15</sup>Inonu University



Turgut Ozal Institute, Diyarbakir, TR, <sup>16</sup>Marmara University, Istanbul, TR, <sup>17</sup>Marmara University Hospital, Istanbul, TR, <sup>18</sup>Acibadem Antunizade Hospital, TR

- 12:45 - 12:45 **326P - Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab.**
- B. Conte<sup>1</sup>, A. Fabi<sup>2</sup>, F. Poggio<sup>1</sup>, E. Blondeaux<sup>1</sup>, C. Dellepiane<sup>1</sup>, A. D'Alonzo<sup>3</sup>, A. Staiano<sup>3</sup>, G. Buono<sup>4</sup>, G. Arpino<sup>5</sup>, V. Magri<sup>6</sup>, G. Naso<sup>7</sup>, D. Presti<sup>8</sup>, S. Mura<sup>9</sup>, A. Fontana<sup>10</sup>, F. Cognetti<sup>2</sup>, C. Molinelli<sup>3</sup>, S. Pastorino<sup>3</sup>, C. Bighin<sup>3</sup>, M. Lambertini<sup>11</sup>, L. Del Mastro<sup>3</sup>, <sup>1</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>2</sup>Istituto Nazionale Tumori Regina Elena, Rome, IT, <sup>3</sup>Ospedale Policlinico San Martino, Genova, IT, <sup>4</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>5</sup>AOU Policlinico Federico II, Napoli, IT, <sup>6</sup>Policlinico Umberto I, Rome, IT, <sup>7</sup>Policlinico Umberto I, Roma, IT, <sup>8</sup>Istituto Fondazione Maugeri, Pavia, IT, <sup>9</sup>Ospedale Santissima Annunziata, Sassari, IT, <sup>10</sup>Azienda Ospedaliera Universitaria S. Chiara, Pisa, IT, <sup>11</sup>Institute Jules Bordet, Brussels, BE
- 12:45 - 12:45 **327P - Survival of HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine - a national population-based study: long-term analysis.**
- B. Jagielska<sup>1</sup>, P. Tokajuk<sup>2</sup>, T. Pieńkowski<sup>3</sup>, A. Czubek<sup>4</sup>, M. Krzakowski<sup>5</sup>, M. Wojtukiewicz<sup>2</sup>, <sup>1</sup>Cancer Center, Warsaw, PL, <sup>2</sup>Comprehensive Cancer Center Bialostockie Centrum Onkologii, Bialystok, PL, <sup>3</sup>Radomskie Centrum Onkologii, Radom, PL, <sup>4</sup>Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>5</sup>The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, PL
- 12:45 - 12:45 **328P - Ribociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompleEment-1 trial**
- H. Abdel-Razek<sup>1</sup>, P. Cottu<sup>2</sup>, A. Ring<sup>3</sup>, M. De Laurentiis<sup>4</sup>, J. Lu<sup>5</sup>, H. Azim<sup>6</sup>, C. Zamagni<sup>7</sup>, K. Zhou<sup>8</sup>, J. Wu<sup>8</sup>, L. Menon<sup>8</sup>, M. Martín<sup>9</sup>, <sup>1</sup>King Hussein Cancer Center, Amman, JO, <sup>2</sup>Institut Curie, Paris, FR, <sup>3</sup>The Royal Marsden NHS Foundation Trust, Surrey, GB, <sup>4</sup>Istituto Nazionale Tumori, Napoli, IT, <sup>5</sup>University of Southern California, Los Angeles, US, <sup>6</sup>Cairo Oncology Center Cairo University-CairoCure, Cairo, EG, <sup>7</sup>AOU Policlinico S. Orsola-Malpighi, F. Addarii, Bologna, IT, <sup>8</sup>Novartis Pharmaceuticals, East Hanover, US, <sup>9</sup>Universidad Complutense, Madrid, ES
- 12:45 - 12:45 **329P - Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)**
- E.-M. Grischke<sup>1</sup>, P. Neven<sup>2</sup>, Y. Lin<sup>3</sup>, P. Kaufman<sup>4</sup>, G. Sledge<sup>5</sup>, <sup>1</sup>University Clinics Tuebingen, Tuebingen, DE, <sup>2</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>3</sup>Eli Lilly and Company, Indianapolis, US, <sup>4</sup>Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, US, <sup>5</sup>Stanford University, Stanford, US
- 12:45 - 12:45 **330P - Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with**



**ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis**

A. Bardia<sup>1</sup>, S. Campos-Gomez<sup>2</sup>, S. Hurvitz<sup>3</sup>, Y.-S. Lu<sup>4</sup>, S.-A. Im<sup>5</sup>, F. Franke<sup>6</sup>, L. Chow<sup>7</sup>, P. Wheatley-Price<sup>8</sup>, F. Melo Cruz<sup>9</sup>, J. Alam<sup>10</sup>, O. Kong<sup>10</sup>, I. Diaz-Padilla<sup>11</sup>, M. Miller<sup>10</sup>, D. Tripathy<sup>12</sup>, <sup>1</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>2</sup>Centro Oncológico Estatal, Toluca, MX, <sup>3</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>4</sup>National Taiwan University Hospital, Taipei, TW, <sup>5</sup>Seoul National University Hospital, Seoul, KR, <sup>6</sup>Hospital de Caridade de Ijuí, Ijuí, BR, <sup>7</sup>Organisation for Oncology and Translational Research, Hong Kong, HK, <sup>8</sup>University of Ottawa, Ottawa, CA, <sup>9</sup>ABC Foundation School of Medicine, Santo André, BR, <sup>10</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>11</sup>Novartis Pharma AG, Basel, CH, <sup>12</sup>MD Anderson Cancer Center, Houston, US

12:45 - 12:45

**331P - Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3**

G. Jerusalem<sup>1</sup>, P.A. Fasching<sup>2</sup>, M. Martín<sup>3</sup>, X. Pivot<sup>4</sup>, K. Petrakova<sup>5</sup>, G. Bianchi<sup>6</sup>, A. Nusch<sup>7</sup>, G. Sonke<sup>8</sup>, L. De La Cruz Merino<sup>9</sup>, E. Vagnon<sup>10</sup>, J. Alam<sup>11</sup>, O. Kong<sup>11</sup>, D. Chandiwana<sup>11</sup>, M. De Laurentiis<sup>12</sup>, <sup>1</sup>Centre Hospitalier Universitaire Sart Tilman, Liège, BE, <sup>2</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>3</sup>Universidad Complutense, Madrid, ES, <sup>4</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>5</sup>Masaryk Memorial Cancer Institute, Brno, CZ, <sup>6</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, IT, <sup>7</sup>Onkologische Praxis Velbert, Velbert, DE, <sup>8</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>9</sup>Hospital Universitario Virgen Macarena, Sevilla, ES, <sup>10</sup>Novartis Pharma AG, Basel, CH, <sup>11</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>12</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

12:45 - 12:45

**332P - Clinical Outcomes in Patients (pts) With Estrogen Receptor-Positive (ER+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) With Objective Response (OR) or Without Objective Response (non-OR) in PALOMA-2**

H. Rugo<sup>1</sup>, R. Finn<sup>2</sup>, K. Gelmon<sup>3</sup>, A.A. Joy<sup>4</sup>, O. Lipatov<sup>5</sup>, N. Harbeck<sup>6</sup>, A. Castrellon<sup>7</sup>, H. Mukai<sup>8</sup>, J. Walshe<sup>9</sup>, A. Mori<sup>10</sup>, E. Gauthier<sup>11</sup>, D. Lu<sup>12</sup>, E. Bananis<sup>13</sup>, M. Martín<sup>14</sup>, V. Dieras<sup>15</sup>, <sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>UCLA - School of Medicine, Los Angeles, US, <sup>3</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>4</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>5</sup>Republican Clinical Oncology Dispensary, Ufa, RU, <sup>6</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>7</sup>Memorial Healthcare System, Pembroke Pines, US, <sup>8</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>9</sup>Cancer Trials Ireland, Dublin, IE, <sup>10</sup>Pfizer S.r.l., Milan, IT, <sup>11</sup>Pfizer Inc, San Francisco, US, <sup>12</sup>Pfizer Inc, La Jolla, US, <sup>13</sup>Pfizer Oncology, New York, US, <sup>14</sup>Universidad Complutense, Madrid, ES, <sup>15</sup>Centre Eugene - Marquis, Rennes, FR

12:45 - 12:45

**333P - Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase 3b CompleEment-1 trial**

F. Cardoso<sup>1</sup>, K. Papazisis<sup>2</sup>, M. De Laurentiis<sup>3</sup>, A. Ring<sup>4</sup>, J. Lu<sup>5</sup>, M. Martín<sup>6</sup>, H. Azim<sup>7</sup>, C. Zamagni<sup>8</sup>, K. Zhou<sup>9</sup>, J. Wu<sup>9</sup>, J.P. Zarate<sup>10</sup>, P. Cottu<sup>11</sup>, <sup>1</sup>Champalimaud Foundation Cancer Center, Lisbon, PT, <sup>2</sup>Euromedica General Clinic, Thessaloniki, GR, <sup>3</sup>Istituto Nazionale Tumori, Napoli, IT, <sup>4</sup>The Royal Marsden NHS Foundation Trust, Surrey, GB, <sup>5</sup>University of Southern California, Los Angeles, US, <sup>6</sup>Universidad Complutense, Madrid, ES, <sup>7</sup>Cairo Oncology Center Cairo University-CairoCure, Cairo, EG, <sup>8</sup>AOU Policlinico S. Orsola-Malpighi, F.Addarii, Bologna, IT, <sup>9</sup>Novartis Pharmaceuticals, East Hanover, US, <sup>10</sup>Novartis, US, <sup>11</sup>Institut Curie, Paris, FR

12:45 - 12:45

**334P - Health related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany**

M. De Laurentiis<sup>1</sup>, A. König<sup>2</sup>, K. Davis<sup>3</sup>, D. Mitra<sup>4</sup>, C.M.A. Nuzzo<sup>5</sup>, M. Ajmera<sup>3</sup>, S. De Placido<sup>6</sup>, S. Brucker<sup>7</sup>, N. Harbeck<sup>8</sup>, <sup>1</sup>Istituto Nazionale Tumori, Napoli, IT, <sup>2</sup>Brustzentrum der Universitaet Muenchen (LMU), München, DE, <sup>3</sup>RTI Health Solutions, Research Triangle Park, US, <sup>4</sup>Pfizer, New York, US, <sup>5</sup>Pfizer Inc, Roma, IT, <sup>6</sup>AOU Policlinico Federico II, Napoli, IT, <sup>7</sup>Center for Women's Health, University of Tübingen, Tübingen, DE, <sup>8</sup>Ludwig Maximilians University - Grosshadern, Munich, DE

12:45 - 12:45

**335P - Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2\_) postmenopausal women: final analysis of the French observational TANGO study**

C. Villanueva<sup>1</sup>, G. Yazbek<sup>2</sup>, P. Beuzeboc<sup>3</sup>, E. Viel<sup>4</sup>, N. Dohollou<sup>5</sup>, E. Luporsi<sup>6</sup>, J.-C. Eymard<sup>7</sup>, E. Levy<sup>8</sup>, M.-A. Mouret-Reynier<sup>9</sup>, L.-M. Dourthe<sup>10</sup>, E. Malaurie<sup>11</sup>, M. Madelenat<sup>12</sup>, A. Denden<sup>12</sup>, E.-C. Antoine<sup>13</sup>, <sup>1</sup>CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, <sup>2</sup>CHU de Reims - Hôpital Robert Debré, Reims, FR, <sup>3</sup>Institut Curie, Paris, FR, <sup>4</sup>Cabinet D'Oncologie Médicale, Chalon-sur-Saône, FR, <sup>5</sup>Polyclinique Bordeaux Nord Aquitaine, Bordeaux, FR, <sup>6</sup>Hopital de Mercy - CHR Metz Thionville, Ars Laquenexy, FR, <sup>7</sup>Institut Jean Godinot, Reims, FR, <sup>8</sup>Clinique Bizet, Paris, FR, <sup>9</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>10</sup>Clinique Sainte-Anne, Strasbourg Cedex, FR, <sup>11</sup>CHI de Créteil, Créteil, FR, <sup>12</sup>Novartis Pharma - France, Rueil-Malmaison, FR, <sup>13</sup>ARETASC - Clinique Hartmann, Neuilly-sur-Seine, FR

12:45 - 12:45

**336P - Everolimus in advanced breast cancer: a systematic review and meta-analysis**

J. Raphael<sup>1</sup>, C. Lefebvre<sup>2</sup>, A. Allan<sup>2</sup>, J. Helou<sup>3</sup>, G. Boldt<sup>2</sup>, T. Vandenberg<sup>4</sup>, <sup>1</sup>London Regional Cancer Program, Western University, London, CA, <sup>2</sup>Western University, London, CA, <sup>3</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>4</sup>Western University - London Regional Cancer Program, London, CA

12:45 - 12:45

**337P - First-line treatment for endocrine sensitive bone-only metastatic breast cancer: is more always better?**

A. Toss<sup>1</sup>, M. Venturelli<sup>1</sup>, I. Sperduti<sup>2</sup>, C. Isca<sup>1</sup>, E. Barbieri<sup>3</sup>, F. Piacentini<sup>1</sup>, C. Omarini<sup>4</sup>, L. Cortesi<sup>1</sup>, S. Cascinu<sup>1</sup>, L. Moscetti<sup>5</sup>, <sup>1</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>2</sup>IRCCS Regina Elena National Cancer Institute, Rome, Italy, Roma, IT, <sup>3</sup>Policlinico S. Orsola-Malpighi-"F.Addarii", Bologna, IT, <sup>4</sup>Università degli studi di Modena e Reggio Emilia, Modena, IT, <sup>5</sup>Azienda Universitaria Ospedaliera Policlinico di Modena, Modena, IT

- 12:45 - 12:45 **338P - Real world treatment patterns associated with palbociclib combination therapy in Germany: Results from the IRIS Study**  
D. Mitra<sup>1</sup>, G. Taylor-Stokes<sup>2</sup>, J. Waller<sup>2</sup>, K. Gibson<sup>2</sup>, G. Milligan<sup>2</sup>, S. Iyer<sup>3</sup>, <sup>1</sup>Pfizer, New York, US, <sup>2</sup>Adelphi Real World, Bollington, GB, <sup>3</sup>Pfizer Inc - USA, New York, US
- 12:45 - 12:45 **339P - Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: analysis of the MONARCH trials**  
H. Rugo<sup>1</sup>, S. Tolaney<sup>2</sup>, J. Huober<sup>3</sup>, M. Toi<sup>4</sup>, V. André<sup>5</sup>, S. Barriga<sup>6</sup>, T. Forrester<sup>7</sup>, G. Sledge<sup>8</sup>, M.P. Goetz<sup>9</sup>, <sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>Dana-Farber Cancer Institute, Boston, US, <sup>3</sup>Universitaetsfrauenklinik Ulm, Ulm, DE, <sup>4</sup>Kyoto University-Graduate school of medicine, Kyoto, JP, <sup>5</sup>Eli Lilly and Company, Paris, FR, <sup>6</sup>Eli Lilly and Company Limited, Windlesham, GB, <sup>7</sup>Eli Lilly and Company, Indianapolis, US, <sup>8</sup>Stanford University, Stanford, US, <sup>9</sup>Mayo Clinic, Rochester, US
- 12:45 - 12:45 **340P - Progression Free Survival (PFS) Benefit from First line Endocrine Based Therapies in Postmenopausal Women with HR+ HER2- Metastatic Breast Cancer (MBC) according to different Prognostic Subgroups: A Combined Analysis of Data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT Trials**  
V. Rossi<sup>1</sup>, D. Giannarelli<sup>2</sup>, P. Berchiolla<sup>3</sup>, C. Nisticò<sup>2</sup>, G. Ferretti<sup>4</sup>, S. Gasparro<sup>2</sup>, P. Malaguti<sup>2</sup>, M. Russillo<sup>5</sup>, G. Catania<sup>2</sup>, L. Vigna<sup>1</sup>, R. Mancusi<sup>6</sup>, F. Cognetti<sup>5</sup>, A. Fabi<sup>5</sup>, <sup>1</sup>Azienda Ospedaliera S. Camillo Forlanini, Rome, IT, <sup>2</sup>Istituto Regina Elena, Rome, IT, <sup>3</sup>University of Turin, turin, IT, <sup>4</sup>Istituto Regina Elena, Roma, IT, <sup>5</sup>Istituto Nazionale Tumori Regina Elena, Rome, IT, <sup>6</sup>Università Tor Vergata, Rome, IT
- 12:45 - 12:45 **341P - Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study**  
M. Welslau<sup>1</sup>, M. Zaiss<sup>2</sup>, U. Söling<sup>3</sup>, M. Untch<sup>4</sup>, L. Müller<sup>5</sup>, D. Lüftner<sup>6</sup>, J. Meiler<sup>7</sup>, A. Welt<sup>8</sup>, J. Sahlmann<sup>9</sup>, L. Houet<sup>9</sup>, E. Runkel<sup>10</sup>, N. Marschner<sup>10</sup>, <sup>1</sup>Klinikum Aschaffenburg, Aschaffenburg, DE, <sup>2</sup>Praxis für Interdisziplinäre Onkologie, Freiburg, DE, <sup>3</sup>Onkologische Gemeinschaftspraxis, Kassel, DE, <sup>4</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>5</sup>Onkologie Unterems, Leer, DE, <sup>6</sup>Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, <sup>7</sup>Klinik Dr. Hancken GmbH, Stade, DE, <sup>8</sup>Universitätsklinikum Essen (AöR), Essen, DE, <sup>9</sup>iOMEDICO, Freiburg, DE, <sup>10</sup>iOMEDICO AG, Freiburg, DE
- 12:45 - 12:45 **342P - Response to primary treatment for first recurrence independently influences survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 236 recurrent metastatic patients.**  
J. Yamamura<sup>1</sup>, S. Kamigaki<sup>1</sup>, M. Tsujie<sup>1</sup>, J. Fujita<sup>1</sup>, H. Osato<sup>1</sup>, C. Higashi<sup>2</sup>, H. Kanaizumi<sup>2</sup>, Y. Tanaka<sup>2</sup>, M. Hamada<sup>2</sup>, W. Shinzaki<sup>2</sup>, Y. Hasimoto<sup>2</sup>, Y. Komoike<sup>2</sup>, <sup>1</sup>Sakai City Medical Center, Sakai, JP, <sup>2</sup>Kindai University Faculty of Medicine, Sayama, JP
- 12:45 - 12:45 **343P - Application of CDK4/6 inhibitors in practice: effect of online education on clinician competence and confidence**  
C. Day<sup>1</sup>, D. Middleton<sup>2</sup>, S. Loibl<sup>3</sup>, <sup>1</sup>Geofish Medical Marketing Limited, Prestatyn, GB,



<sup>2</sup>Medscape, New Jersey, US, <sup>3</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

- 12:45 - 12:45 **344P - First Report of Real-World Patient Characteristics and Treatment Patterns From POLARIS: Palbociclib in Hormone Receptor-Positive (HR+) Advanced Breast Cancer - A Prospective, Multicenter, Noninterventional Study**  
J. Blum<sup>1</sup>, S. Mccune<sup>2</sup>, M. Salkeni<sup>3</sup>, D. Anderson<sup>4</sup>, J. Migas<sup>5</sup>, S. Lakhanpal<sup>6</sup>, K. Patel<sup>7</sup>, A. Bardia<sup>8</sup>, G. Rocque<sup>9</sup>, J. Wang<sup>10</sup>, J. Cappelleri<sup>11</sup>, G. Comstock<sup>12</sup>, Y. Wang<sup>13</sup>, D. Tripathy<sup>14</sup>, <sup>1</sup>Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, US, <sup>2</sup>Northwest Georgia Oncology Centers, Marietta, US, <sup>3</sup>West Virginia University Cancer Institute, Morgantown, US, <sup>4</sup>Health Partners Institute, St Paul, US, <sup>5</sup>OSF St. Joseph Medical Center, Bloomington, US, <sup>6</sup>Saint Vincent's Birmingham, Birmingham, US, <sup>7</sup>CARTI Cancer Center, Little Rock, US, <sup>8</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>9</sup>University of Alabama at Birmingham, Birmingham, US, <sup>10</sup>Cytel Inc, Waltham, US, <sup>11</sup>Pfizer Inc, Groton, US, <sup>12</sup>Pfizer Inc, Santa Rosa, US, <sup>13</sup>Pfizer Inc, New York, US, <sup>14</sup>The University of Texas MD Anderson Cancer Center, Houston, US
- 12:45 - 12:45 **345P - Everolimus-based therapy versus conventional therapy for refractory breast cancer patients with PI3K/AKT/mTOR mutations**  
Z. Chen<sup>1</sup>, Y. Zheng<sup>1</sup>, W. Cao<sup>1</sup>, Y. Zhang<sup>2</sup>, S. Cai<sup>2</sup>, X. Shao<sup>3</sup>, J. Huang<sup>3</sup>, W. Ye<sup>3</sup>, Y. Huang<sup>3</sup>, Y. Yin<sup>4</sup>, X. Wang<sup>5</sup>, <sup>1</sup>Department of Breast Medical Oncology, Zhejiang, CN, <sup>2</sup>3D medicines Inc., Shanghai, CN, <sup>3</sup>Department of Breast Medical Oncology, Hangzhou, CN, <sup>4</sup>jiangsu province hospital, nanjing, CN, <sup>5</sup>zhejiang cancer hospital, hangzhou, CN
- 12:45 - 12:45 **346P - Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses**  
P. Neven<sup>1</sup>, K. Petrakova<sup>2</sup>, G. Bianchi<sup>3</sup>, L. De La Cruz Merino<sup>4</sup>, G. Jerusalem<sup>5</sup>, J. Beck<sup>6</sup>, G. Sonke<sup>7</sup>, S. Chia<sup>8</sup>, S. Brucker<sup>9</sup>, Y. Wang<sup>10</sup>, W. He<sup>11</sup>, K. Rodriguez Lorenc<sup>12</sup>, F. Su<sup>12</sup>, S.-A. Im<sup>13</sup>, <sup>1</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>2</sup>Masaryk Memorial Cancer Institute, Brno, CZ, <sup>3</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, IT, <sup>4</sup>Hospital Universitario Virgen Macarena, Sevilla, ES, <sup>5</sup>Centre Hospitalier Universitaire Sart Tilman, Liège, BE, <sup>6</sup>Highlands Oncology Group, Fayetteville, US, <sup>7</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>8</sup>BC Cancer Agency, Vancouver, CA, <sup>9</sup>Center for Women's Health, University of Tübingen, Tübingen, DE, <sup>10</sup>Novartis Pharma AG, Basel, CH, <sup>11</sup>Novartis Institutes for BioMedical Research, Cambridge, US, <sup>12</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>13</sup>Seoul National University Hospital, Seoul, KR
- 12:45 - 12:45 **347P - Potential Survival Gains from First-Line (1L) Systemic Therapy Advances in Metastatic Triple-Negative Breast Cancer (mTNBC)**  
P. Bajaj<sup>1</sup>, J. Roth<sup>2</sup>, S. Sullivan<sup>3</sup>, A. Stein<sup>4</sup>, R. Mahtani<sup>5</sup>, S. Ramsey<sup>2</sup>, <sup>1</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, US, <sup>3</sup>University of Washington, Seattle, US, <sup>4</sup>Genentech, San Francisco, US, <sup>5</sup>University of Miami Health System, Deerfield Beach, US
- 12:45 - 12:45 **348P - Economic evaluation of eribulin in the treatment of triple negative breast cancer in the United Kingdom**



J. Wex<sup>1</sup>, C. Bodnar<sup>2</sup>, C. Simon<sup>3</sup>, F. Fernandes<sup>3</sup>, N. Tanova<sup>4</sup>, <sup>1</sup>Pharmarchitecture, Chesham, GB, <sup>2</sup>Eisai Europe, Hatfield, GB, <sup>3</sup>Eisai, Hatfield, GB, <sup>4</sup>Amaris, London, GB

12:45 - 12:45

**349P - Use of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC).**

M. Chavez Mac Gregor<sup>1</sup>, X. Lei<sup>1</sup>, H. Zhao<sup>1</sup>, C. Van Poznak<sup>2</sup>, S. Giordano<sup>1</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Michigan, Ann Arbor, US

12:45 - 12:45

**350P - liver surgery of breast cancer liver metastases: rapid surgical decision after diagnosis does not negatively impact long-term results**

V. Lucidi<sup>1</sup>, G. Liberale<sup>2</sup>, D. Germanova<sup>3</sup>, M. Bez<sup>1</sup>, V. Donckier<sup>4</sup>, <sup>1</sup>Erasme University Hospital-(Universite Libre de Bruxelles), Brussels, BE, <sup>2</sup>Institut Jules Bordet, Brussels, BE, <sup>3</sup>Erasme University Hospital ULB, Brussels, BE, <sup>4</sup>Institute Jules Bordet, Brussels, BE

12:45 - 12:45

**351P - Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort.**

W. Jacot<sup>1</sup>, G. Louvel<sup>2</sup>, A. Darlix<sup>1</sup>, J. Fraisse<sup>1</sup>, E. Brain<sup>3</sup>, M. Debled<sup>4</sup>, M.A. Mouret Reynier<sup>5</sup>, A. Goncalves<sup>6</sup>, F. Dalenc<sup>7</sup>, P. Augereau<sup>8</sup>, J.-M. Ferrero<sup>9</sup>, C. Levy<sup>10</sup>, J.-D. Fumet<sup>11</sup>, C. Jouannaud<sup>12</sup>, C. Veyret<sup>13</sup>, V. Dieras<sup>14</sup>, M. Robain<sup>15</sup>, C. Courtinard<sup>15</sup>, D. Pasquier<sup>16</sup>, T. Bachelot<sup>17</sup>, <sup>1</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Institut Curie, Paris & Saint-Cloud, FR, <sup>4</sup>Institute Bergonié, Bordeaux, FR, <sup>5</sup>Centre Jean Perrin, Clermont-Ferrand, FR, <sup>6</sup>Institute Paoli Calmettes, Marseille, FR, <sup>7</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>8</sup>Centre Paul Papin, Angers, FR, <sup>9</sup>Centre Antoine Lacassagne, Nice, FR, <sup>10</sup>Centre Francois Baclesse, Caen, FR, <sup>11</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>12</sup>Institut Jean Godinot, Reims, FR, <sup>13</sup>Centre Henri Becquerel, Rouen, FR, <sup>14</sup>Centre Eugene - Marquis, Rennes, FR, <sup>15</sup>Unicancer, Paris, FR, <sup>16</sup>Centre Oscar Lambret, Lille, FR, <sup>17</sup>Centre Léon Bérard, Lyon, FR

12:45 - 12:45

**352P - Features Associated with Long-Term Survival in Metastatic Breast Cancer**

N. Klar<sup>1</sup>, M. Rosenzweig<sup>2</sup>, B. Diergaard<sup>2</sup>, A. Brufsky<sup>3</sup>, <sup>1</sup>UPMC Presbyterian Hospital, Pittsburgh, US, <sup>2</sup>University of Pittsburgh, Pittsburgh, US, <sup>3</sup>Magee-Womens Hospital of UPMC, Pittsburgh, US

12:45 - 12:45

**353P - Physical activity and lifestyle in women with metastatic breast cancer: the ABLE study**

B. Fervers<sup>1</sup>, L. Delrieu<sup>1</sup>, O. Pérol<sup>1</sup>, O. Febvey-Combes<sup>2</sup>, A. Dufresne<sup>3</sup>, T. Bachelot<sup>1</sup>, P. Heudel<sup>1</sup>, O. Tredan<sup>1</sup>, M. Touillaud<sup>1</sup>, V. Pialoux<sup>4</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, FR, <sup>2</sup>Centre Léon Bérard, Lyon, FR, <sup>3</sup>Hopital Edouard Herriot Pav. E bis, Lyon, FR, <sup>4</sup>Université Claude Bernard Lyon1, Villeurbanne, FR

12:45 - 12:45

**What Research questions matters most to patients? Final Results of the Metastatic Breast Cancer Priority Setting Partnership**

N. Nixon<sup>1</sup>, C. Simmons<sup>2</sup>, J. Lemiux<sup>3</sup>, S. Verma<sup>1</sup>, <sup>1</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>2</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>3</sup>Chu De Quebec, Quebec, CA

- 12:45 - 12:45 **355P - Establishment and validation of M1 stage subdivisions for patients with de novo metastatic breast cancer: a population-based study**  
C. Lin, J. Wu, L. Zhu, Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN
- 12:45 - 12:45 **356P - A Prospective Observational Study of Mobile Application-Based Patient-Reported Outcomes (PRO) in Advanced Breast Cancer: Interim Baseline Data From the MADELINE study**  
D. Odom<sup>1</sup>, D. Mitra<sup>2</sup>, K. Hollis<sup>1</sup>, D. Richardson<sup>1</sup>, J. Kaye<sup>1</sup>, L. Mcroy<sup>3</sup>, <sup>1</sup>RTI Health Solutions, Research Triangle Park, US, <sup>2</sup>Pfizer, New York, US, <sup>3</sup>Pfizer Inc, New York, US
- 12:45 - 12:45 **357P - Stereotactic Radiosurgery (SRS) for brain metastases (BM) from breast cancer (BC) - a single centre experience of factors influencing survival**  
T. Wilson<sup>1</sup>, T. Robinson<sup>1</sup>, C. Macfarlane<sup>2</sup>, T. Spencer<sup>1</sup>, C. Herbert<sup>1</sup>, J. Braybrooke<sup>1</sup>, <sup>1</sup>University Hospitals Bristol NHS Trust Bristol Haematology and Oncology Centre, Bristol, GB, <sup>2</sup>University Hospital Southampton NHS Foundation Trust, Southampton, GB
- 12:45 - 12:45 **358P - Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer**  
E. Curtit<sup>1</sup>, F. Bazan<sup>1</sup>, L. Chaigneau<sup>1</sup>, G. Mouillet<sup>1</sup>, E. Dobi<sup>1</sup>, L. Mansi<sup>1</sup>, N. Meneveau<sup>1</sup>, M.-J. Paillard<sup>1</sup>, G. Meynard<sup>1</sup>, E. Klajer<sup>1</sup>, C. Villanueva<sup>1</sup>, P. Montcuquet<sup>1</sup>, X. Pivot<sup>2</sup>, L. Cals<sup>1</sup>, <sup>1</sup>CHU Besançon, Hôpital Jean Minjot, Besançon, FR, <sup>2</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR
- 12:45 - 12:45 **359P - Surgery of the primary tumor for de novo metastatic breast cancer: the controversy continues.**  
B. López De San Vicente<sup>1</sup>, E. Galve Calvo<sup>1</sup>, A. Zumarraga<sup>1</sup>, F. Pikab Ea<sup>1</sup>, J.F. Arango Arteaga<sup>1</sup>, M. López Santillan<sup>1</sup>, C. Figaredo<sup>1</sup>, M.A. Sala Gonzalez<sup>2</sup>, M. Nuño Escolastico<sup>2</sup>, P. Novas Vidal<sup>1</sup>, J. Legaspi<sup>2</sup>, P. Martinez Del Prado<sup>2</sup>, <sup>1</sup>Hospital Universitario Basurto, Bilbao, ES, <sup>2</sup>Hospital de Basurto, Bilbao, ES
- 12:45 - 12:45 **360P\_PR - Breast cancer in Twitter: a real-world data exploratory study**  
R. Sanchez Bayona<sup>1</sup>, L. Chang-Azancot<sup>2</sup>, M.A. Alvarez De Mon<sup>1</sup>, M. Llaverro<sup>1</sup>, M. Vallejo<sup>1</sup>, I. Gardeazabal<sup>1</sup>, D. Salas<sup>3</sup>, P. Sala Elarre<sup>1</sup>, I. Baraibar Argota<sup>1</sup>, I. Eguren<sup>1</sup>, M. Santisteban Eslava<sup>4</sup>, L. Ceniceros<sup>1</sup>, E. Castanon Alvarez<sup>1</sup>, <sup>1</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>2</sup>C. H. Albacete, Albacete, ES, <sup>3</sup>Clinica Universidad de Navarra, Pamplona, ES, <sup>4</sup>CLIN. UNIVERSITARIA NAVARRA, Pamplona, ES
- 12:45 - 12:45 **361TiP - A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer. (JCOG1607 HERB TEA study)**  
A. Shimomura<sup>1</sup>, K. Tamura<sup>1</sup>, T. Mizutani<sup>1</sup>, T. Shibata<sup>1</sup>, F. Hara<sup>2</sup>, T. Fujisawa<sup>3</sup>, N. Niikura<sup>4</sup>, T. Hojo<sup>5</sup>, C. Kambayashi<sup>6</sup>, S. Saji<sup>7</sup>, N. Masuda<sup>8</sup>, M. Sawaki<sup>9</sup>, N. Yamamoto<sup>10</sup>, F. Nagashima<sup>11</sup>, T. Shien<sup>12</sup>, H. Iwata<sup>13</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>NHO Shikoku Cancer Center, Matsuyama, JP, <sup>3</sup>Gunma Prefectural Cancer Center, Gunma, JP, <sup>4</sup>Tokai University School of Medicine Isehara Campus, Isehara, JP, <sup>5</sup>National Cancer

Center Hospital East, Chiba, JP, <sup>6</sup>Niigata Cancer Center, Niigata, JP, <sup>7</sup>Fukushima Medical University, Fukushima, JP, <sup>8</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>9</sup>Aichi Cancer Center Hospital, Aichi, JP, <sup>10</sup>Chiba Cancer Center, Chiba, JP, <sup>11</sup>Kyorin university Hospital, Tokyo, JP, <sup>12</sup>Okayama University Hospital, Okayama, JP, <sup>13</sup>Aichi Cancer Center Hospital, Nagoya, JP

- 12:45 - 12:45 **362TiP - ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)**
- D. Tripathy<sup>1</sup>, S. Tolaney<sup>2</sup>, A. Seidman<sup>3</sup>, C. Anders<sup>4</sup>, N. Ibrahim<sup>1</sup>, H. Rugo<sup>5</sup>, C. Twelves<sup>6</sup>, V. Dieras<sup>7</sup>, V. Müller<sup>8</sup>, A. Hannah<sup>9</sup>, M. Tagliaferri<sup>10</sup>, J. Cortes Castan<sup>11</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>Dana-Farber Cancer Institute, Boston, US, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>4</sup>University of North Carolina, Chapel Hill, US, <sup>5</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>6</sup>St. James's University Hospital Leeds, Leeds, GB, <sup>7</sup>Centre Eugene - Marquis, Rennes, FR, <sup>8</sup>Hamburg-Eppendorf University Medical Center, Hamburg, DE, <sup>9</sup>Consultant, New York, US, <sup>10</sup>Nektar Therapeutics, San Francisco, US, <sup>11</sup>Vall d'Hebron University Hospital, Barcelona, ES
- 12:45 - 12:45 **363TiP - Phase 1b/2a study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68, which prevents nuclear  $\beta$ -catenin Translocation in patients with Triple Negative Breast Cancer**
- J. Diamond<sup>1</sup>, E. Andreopoulou<sup>2</sup>, A. Favret<sup>3</sup>, R. Nanda<sup>4</sup>, C. Peterson<sup>5</sup>, E. Benaim<sup>6</sup>, <sup>1</sup>University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, <sup>2</sup>Weill Cornell Medicine/New York Presbyterian Hospital, New York, US, <sup>3</sup>Virginia Cancer Specialists, Fairfax, US, <sup>4</sup>University of Chicago, Chicago, US, <sup>5</sup>Rexahn Pharmaceuticals, Inc, Rockville, US, <sup>6</sup>Rexahn Pharmaceuticals, Rockville, US
- 12:45 - 12:45 **364TiP - Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: a phase II trial (AMICA) GBG 97**
- T. Decker<sup>1</sup>, C. Denkert<sup>2</sup>, K. Lübke<sup>3</sup>, V. Müller<sup>4</sup>, C. Mundhenke<sup>5</sup>, J. Furlanetto<sup>6</sup>, M. Schmidt<sup>7</sup>, M. Thill<sup>8</sup>, V. Tierbach<sup>6</sup>, F. Seither<sup>6</sup>, S. Loibl<sup>6</sup>, <sup>1</sup>Onkologie Ravensburg, Ravensburg, DE, <sup>2</sup>Charite Berlin Mitte, Berlin, DE, <sup>3</sup>DIAKOVERE gGmbH, Hannover, DE, <sup>4</sup>Hamburg-Eppendorf University Medical Center, Hamburg, DE, <sup>5</sup>Universität Kiel, Kiel, DE, <sup>6</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>7</sup>Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>8</sup>Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, DE
- 12:45 - 12:45 **365TiP - SAMANTHA: A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants with HER2-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC)**
- G. Steger<sup>1</sup>, F. Puglisi<sup>2</sup>, C. Timcheva<sup>3</sup>, L. Costa<sup>4</sup>, M. Casa-Nova<sup>5</sup>, D. Hitzl<sup>6</sup>, B. Dampier<sup>7</sup>, N. Lindegger<sup>8</sup>, <sup>1</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>2</sup>CRO di Aviano, Aviano, IT, <sup>3</sup>MHAT for Women Health Nadezhda OOD, Sofia, BG, <sup>4</sup>Institute of Molecular Medicine, Lissabon, PT, <sup>5</sup>Hospital Beatriz Angelo-Loures, Loures, PT, <sup>6</sup>Roche Austria, Vienna, AT, <sup>7</sup>Clinical Research Consulting, Vienna, AT, <sup>8</sup>F. Hoffmann-



La Roche AG - Switzerland, Basel, CH

- 12:45 - 12:45 **366TiP - The NAME trial: A direct comparison of Oral Navelbine given either classic or Metronomic in metastatic HER2 neg breast cancer.**  
S. Langkjer<sup>1</sup>, J. Kenholm<sup>2</sup>, J. Jensen<sup>3</sup>, K. Wedervang<sup>4</sup>, A. Brixen<sup>5</sup>, M. Grunnet<sup>6</sup>, L. Stenbygaard<sup>7</sup>, H. Danø<sup>8</sup>, V. Glavicic<sup>9</sup>, E. Jacobsen<sup>10</sup>, A. Brems-Eskildsen<sup>1</sup>, H. Kruse<sup>1</sup>, T. Dongsgaard<sup>2</sup>, J. Neimann<sup>1</sup>, J. Geisler<sup>11</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus C, DK, <sup>2</sup>Regionshospitalet Herning, Herning, DK, <sup>3</sup>Odense University Hospital, Odense, DK, <sup>4</sup>Sønderborg Sygehus, Sønderborg, DK, <sup>5</sup>Herlev Hospital, herlev, DK, <sup>6</sup>Rigshospitalet, Copenhagen, DK, <sup>7</sup>Aalborg Sygehus Syd, Aalborg, DK, <sup>8</sup>Hilleroed Hospital, Hilleroed, DK, <sup>9</sup>Naestved, Naestved, DK, <sup>10</sup>Sydvestjysk Sygehus Esbjerg, Esbjerg, DK, <sup>11</sup>Ankerhus University Hospital, Oslo, NO
- 12:45 - 12:45 **367TiP - LUCY: A Phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation**  
K. Gelmon<sup>1</sup>, G. Walker<sup>2</sup>, G. Fisher<sup>3</sup>, S. Mccutcheon<sup>4</sup>, <sup>1</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>2</sup>Astra Zeneca UK, Luton, GB, <sup>3</sup>AstraZeneca Academy House, Cambridge, GB, <sup>4</sup>AstraZeneca, Cambridge, GB
- 12:45 - 12:45 **368TiP - START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)**  
H. Bonnefoi<sup>1</sup>, C. Levy<sup>2</sup>, G. Macgrogan<sup>3</sup>, T. Grellety<sup>3</sup>, B. Asselain<sup>4</sup>, M. Pulido<sup>3</sup>, S. Everhard<sup>4</sup>, J. Lemonnier<sup>5</sup>, A. Gonçalves<sup>6</sup>, <sup>1</sup>Institut Bergonié, Bordeaux, FR, <sup>2</sup>Centre Francois Baclesse, Caen, FR, <sup>3</sup>Institute Bergonié, Bordeaux, FR, <sup>4</sup>UNICANCER, Paris, FR, <sup>5</sup>Unicancer, Paris, FR, <sup>6</sup>Institute Paoli Calmettes, Marseille, FR
- 12:45 - 12:45 **369TiP - PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy (ET) vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (MBC)**  
S. Loibl<sup>1</sup>, O. Metzger<sup>2</sup>, S. Mandrekar<sup>3</sup>, C. Mundhenke<sup>4</sup>, S. Seiler<sup>1</sup>, P. Valagussa<sup>5</sup>, A. Demichele<sup>6</sup>, E. Lim<sup>7</sup>, D. Tripathy<sup>8</sup>, E. Winer<sup>9</sup>, C. Huang<sup>10</sup>, L. Carey<sup>11</sup>, P. Francis<sup>12</sup>, K. Miller<sup>13</sup>, M.P. Goetz<sup>3</sup>, A. Prat<sup>14</sup>, S. Loi<sup>12</sup>, I. Krop<sup>2</sup>, L. Gianni<sup>15</sup>, E. Ciruelos<sup>16</sup>, <sup>1</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>2</sup>Dana Farber Cancer Institute, Boston, US, <sup>3</sup>Mayo Clinic, Rochester, US, <sup>4</sup>Universität Kiel, Kiel, DE, <sup>5</sup>Fondazione Michelangelo, Milan, IT, <sup>6</sup>University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia, US, <sup>7</sup>The Kinghorn Cancer Centre, Darlinghurst, AU, <sup>8</sup>MD Anderson Cancer Center, Houston, US, <sup>9</sup>Dana-Farber Cancer Institute, Boston, US, <sup>10</sup>Pfizer Oncology, New York, US, <sup>11</sup>UNC - Lineberger Cancer Center, Chapel Hill, US, <sup>12</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>13</sup>Indiana University Simon Cancer Center, Indianapolis, US, <sup>14</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>15</sup>IRCCS San Raffaele, Milan, IT, <sup>16</sup>Hospital Universitario 12 de Octubre, Madrid, ES
- 12:45 - 12:45 **370TiP - A phase 1b, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer**  
S. Hurvitz<sup>1</sup>, M. Galsky<sup>2</sup>, J. Shahidi<sup>3</sup>, G. Zhang<sup>4</sup>, S. Raza<sup>4</sup>, A. Necchi<sup>5</sup>, <sup>1</sup>UCLA



Hematology/Oncology Santa Monica, Santa Monica, US, <sup>2</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, <sup>3</sup>Javad Shahidi, Basking Ridge, US, <sup>4</sup>Daiichi Sankyo Inc., Basking Ridge, US, <sup>5</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

12:45 - 12:45 **CNS tumours**

12:45 - 12:45 **383P - Worldwide trends in survival from adult glioma 2000-2014 (CONCORD-3): impact of morphology.**

F. Girardi, V. Di Carlo, A. Bonaventure, C. Allemani, M. Coleman, Concord Working Group, London School of Hygiene and Tropical Medicine, London, GB

12:45 - 12:45 **384P - Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD)**

L. Mitrofan<sup>1</sup>, M. Krukas-Hampel<sup>2</sup>, L. Mendoza<sup>3</sup>, <sup>1</sup>IMS Health, Paris, FR, <sup>2</sup>IQVIA Global Consulting Services, New York, US, <sup>3</sup>Quintiles, Prague, CZ

12:45 - 12:45 **385P - Radiotherapy versus Combined Radiochemotherapy for Unresectable Glioblastoma: a SEER Based Analysis**

M. Osman, Zagazig University Faculty of Medicine, Zagazig, EG

12:45 - 12:45 **386P - Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data**

L. Mitrofan<sup>1</sup>, M. Krukas-Hampel<sup>2</sup>, L. Mendoza<sup>3</sup>, <sup>1</sup>IMS Health, Paris, FR, <sup>2</sup>IQVIA Global Consulting Services, New York, US, <sup>3</sup>Quintiles, Prague, CZ

12:45 - 12:45 **387P - Corticosteroids administration as a prognostic factor in glioblastoma patients: An Egyptian experience**

K. Abdel Karim<sup>1</sup>, M. Kelany<sup>2</sup>, O. Abdelrahman<sup>3</sup>, A. El-Adawy<sup>2</sup>, <sup>1</sup>Ain Shams University Faculty of Medicine, Cairo, EG, <sup>2</sup>Ain Shams University, Faculty of Medicine, Cairo, EG, <sup>3</sup>Private Practice - Cairo Egypt, Cairo, EG

12:45 - 12:45 **388P - Impaired survival in resected glioblastoma multiforme patients treated with early chemoradiation.**

L. Del Carpio, P. Gomila, S.D. Camacho, S. Moron, M. Riudavets, C. Molto, A. Bujosa, M. Borrell, R. Teres, B. Martin, P. Gallardo, E. Acosta, L. Tilea, A. Soto, C. De Quintana, J. Craven-Bartle, A. Gallardo, B. Gomez, S. Bonilla, O. Gallego, Hospital de la Santa Creu i Sant Pau, Barcelona, ES

12:45 - 12:45 **389P - Bevacizumab-induced hypertension correlation with survival in recurrent Glioblastoma multiforme**

N. Tavares<sup>1</sup>, J. Simões<sup>2</sup>, C. Borges<sup>2</sup>, S. Meireles<sup>2</sup>, A. Costa<sup>2</sup>, C. Fernandes<sup>2</sup>, C. Caeiro<sup>2</sup>, M. Damasceno<sup>2</sup>, <sup>1</sup>HSJ - Hospital de São João, EPE, Porto, PT, <sup>2</sup>Centro Hospitalar de São João, EPE, Porto, PT

- 12:45 - 12:45 **390P - +405C>G polymorphism of VEGF in randomly selected GBM patients**  
I. Djan<sup>1</sup>, M. Djan<sup>2</sup>, N. Vucinic<sup>3</sup>, B. Nikolin<sup>4</sup>, S. Salma<sup>4</sup>, S. Lucic<sup>4</sup>, N. Vuckovic<sup>3</sup>, M. Lucic<sup>4</sup>,  
<sup>1</sup>Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica, RS, <sup>2</sup>Faculty of Sciences, Novi Sad, RS, <sup>3</sup>University of Novi Sad Faculty of Medicine, Novi Sad, RS, <sup>4</sup>Oncology Institute of Vojvodina, Sremska Kamenica, RS
- 12:45 - 12:45 **391P - Expression and clinical prognostic role of ZWINT in glioma: analysis based on data-mining and integration of gene databases**  
Z. Mengxian, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN
- 12:45 - 12:45 **392P - Lipid peroxidation and cognitive impairment in patients with brain cancers**  
S. Kim<sup>1</sup>, S. Kim<sup>2</sup>, <sup>1</sup>Dongsan Medical Center Kemyung University Hospital, Daegu, KR, <sup>2</sup>Uijeongbu City Hall, Uijeongbu City, KR
- 12:45 - 12:45 **393P - FAT1 on YAP1-TEAD1 interaction augments oncogenic potential of GBM cells**  
Y. Gupta<sup>1</sup>, S. Shivajirao<sup>1</sup>, K. Irshad<sup>1</sup>, B. Dikshit<sup>1</sup>, T. Srivastava<sup>2</sup>, P. Chattopadhyay<sup>1</sup>, S. Sinha<sup>1</sup>, K. Chosdol<sup>1</sup>, <sup>1</sup>AIIMS, New Delhi, IN, <sup>2</sup>University of Delhi, New Delhi, IN
- 12:45 - 12:45 **394P - Extracts of Cerbera manghas L. effectively inhibit the growth of glioblastoma cells and their stemloids**  
Y.-J. Lai, J.-C. Tsai, W.-S. Liu, H.-I. Lam, National Taiwan Normal University, Taipei, TW
- 12:45 - 12:45 **395P - Contrast enhancement in low grade gliomas: a classic prognostic factor in the molecular age**  
F. Castet<sup>1</sup>, E. Alanya<sup>2</sup>, M. Gil-Gil<sup>1</sup>, N. Vidal<sup>3</sup>, C. Izquierdo<sup>4</sup>, C. Mesia<sup>5</sup>, J. Bruna<sup>6</sup>, <sup>1</sup>Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, ES, <sup>2</sup>Aliada - Contra el càncer, Lima, PE, <sup>3</sup>Hospital Universitari de Bellvitge, Barcelona, ES, <sup>4</sup>Hospices Civils de Lyon, Groupe Hospitalier Est, Lyon, FR, <sup>5</sup>Institut Catala de Oncologia, L'Hospitalet de Llobregat, ES, <sup>6</sup>Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES
- 12:45 - 12:45 **396P - can diffusion tensor mr imaging identify glioma idh mutation status?**  
S. Bisdas<sup>1</sup>, J. Yuan<sup>2</sup>, L. Mancini<sup>2</sup>, D. Roettger<sup>3</sup>, <sup>1</sup>University College London, London, GB, <sup>2</sup>University College London Hospitals NHS Trust, London, GB, <sup>3</sup>Image Analysis Ltd, London, GB
- 12:45 - 12:45 **397P - Comparative Assessment of Orthotopic Brain Tumor Growth Using Bioluminescence and Magnetic Resonance Imaging**  
Y. Tsvetkova<sup>1</sup>, C. Green<sup>1</sup>, G. Schuetz<sup>1</sup>, J. Hoffmann<sup>2</sup>, D. Zopf<sup>1</sup>, P. Lejeune<sup>1</sup>, <sup>1</sup>Bayer AG, Berlin, DE, <sup>2</sup>EPO Berlin-Buch GmbH, Berlin, DE
- 12:45 - 12:45 **398P - Radiologically evident treatment effects in patients with glioblastoma (GBM) and its clinical implications**  
H. Gan<sup>1</sup>, C. Murone<sup>2</sup>, M. Wong<sup>3</sup>, G. Fitt<sup>2</sup>, E. Kennedy<sup>4</sup>, D. Maag<sup>5</sup>, K. Aldape<sup>6</sup>, <sup>1</sup>Olivia

Newton John Cancer & Wellness Centre, Heidelberg, AU, <sup>2</sup>Austin Health and Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Melbourne, AU, <sup>3</sup>Sydney Medical School, The University of Sydney, Sydney, AU, <sup>4</sup>AbbVie Inc., North Chicago, US, <sup>5</sup>AbbVie Inc USA, North Chicago, US, <sup>6</sup>Toronto General Hospital/Research Institute (UHN), Toronto, CA

- 12:45 - 12:45 **399P - Melanoma with brain metastases. Experience of immunotherapy in a single center.**  
D. Naskhletashvili, L. Demidov, A. Bekyashev, V. Aloshin, E. Prozorenko, N. N. Blokhin  
 Russian Cancer Research Center, Moscow, RU
- 12:45 - 12:45 **400P - Systemic management of malignant meningioma: A comparative survival and molecular marker analysis between Ocreotide in combination with Everolimus compared to Sunitinib**  
A. Cardona Zorrilla<sup>1</sup>, A. Ruiz-Patiño<sup>2</sup>, O. Arrieta<sup>3</sup>, L. Zatarain-Barron<sup>3</sup>, F. Hakim<sup>4</sup>, E. Jimenez<sup>4</sup>, J.A. Mejia<sup>4</sup>, F. Ramon<sup>4</sup>, N. Useche<sup>4</sup>, S. Bermudez<sup>4</sup>, D. Pineda<sup>5</sup>, H. Cifuentes<sup>5</sup>, L. Rojas<sup>2</sup>, L.E. Pino Villareal<sup>6</sup>, C. Balana<sup>7</sup>, <sup>1</sup>Fundacion Sta Fe de Bogota Instituto de Oncologia, Bogotá, CO, <sup>2</sup>Hospital Universitario San Ignacio-Pontificia Universidad Javeriana, Bogotá, CO, <sup>3</sup>Instituto Nacional de Cancerologia, Ciudad de México, MX, <sup>4</sup>Fundacion Santa Fe de Bogota, Bogota, CO, <sup>5</sup>Clinica Del Country, Bogota, CO, <sup>6</sup>Hospital Militar Central, Bogotá, CO, <sup>7</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES
- 12:45 - 12:45 **401P - Impact of postoperative residual tumor and meningeal dissemination in adult medulloblastoma: a retrospective analysis.**  
R. Barreto<sup>1</sup>, P. Viveiros<sup>2</sup>, M. Mesquita<sup>1</sup>, V. Santos<sup>2</sup>, O. Feher<sup>2</sup>, <sup>1</sup>ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR, <sup>2</sup>ICESP - Instituto do Câncer do Estado de São Paulo, São Paulo, BR
- 12:45 - 12:45 **402P - Adult medulloblastoma : an oncology radiation therapy department experience with 22 cases**  
M. Kallel, Z. Fessi, W. Siala, W. Mnejja, N. Fourati, H. Daoud, T. Boudawara, Z. Boudawara, M. Frikha, J. Daoud, Hopital Habib Bourguiba - Sfax University, Sfax, TN
- 12:45 - 12:45 **403P - Pineal parenchymal tumors: Patterns of care from a tertiary cancer centre in India**  
B. Devnani<sup>1</sup>, S. Gupta<sup>1</sup>, H. Kp<sup>1</sup>, P. Julka<sup>2</sup>, G. Rath<sup>2</sup>, <sup>1</sup>All India Institute of Medical Sciences, Delhi, IN, <sup>2</sup>B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), New Delhi, IN
- 12:45 - 12:45 **404P - Advantages of next-generation sequencing in revealing low-level somatic mosaicism in blood samples of retinoblastoma patients**  
E. Alekseeva<sup>1</sup>, V. Kozlova<sup>2</sup>, T. Ushakova<sup>2</sup>, A. Tanas<sup>1</sup>, O. Babenko<sup>1</sup>, T. Kazubskaya<sup>3</sup>, V. Strelnikov<sup>4</sup>, D. Zaletaev<sup>5</sup>, <sup>1</sup>Research Centre for Medical Genetics, Moscow, RU, <sup>2</sup>N.N. Blokhin Russian Research Center for Oncology, Moscow, RU, <sup>3</sup>N. N. Blokhin Science Medical Research Center of Oncology, Moscow, RU, <sup>4</sup>Institute of molecular medicine, Moscow, RU, <sup>5</sup>Sechenov First Moscow State Medical University, Moscow, RU

- 12:45 - 12:45 **405TiP - Avelumab in Newly Diagnosed Glioblastoma Multiforme - The SEJ Study**  
F. Jacques<sup>1</sup>, G. Nicholas<sup>2</sup>, I. Lorimer<sup>3</sup>, <sup>1</sup>Clinique Neuro-Outaouais, Gatineau, CA, <sup>2</sup>Ottawa Hospital General campus, Ottawa, CA, <sup>3</sup>Ottawa Hospital Research Institute, Ottawa, CA
- 12:45 - 12:45 **406TiP - Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients - OLA-TMZ-RTE-01**  
D. Stefan, P. Lesueur, J. Lequesne, E. Coquan, P.E. Brachet, L. Castera, N. Goardon, J. Lacroix, M. Lange, A. Capel, B. Andre, J.-M. Grellard, B. Clarisse, Centre Francois Baclesse, Caen, FR
- 12:45 - 12:45 **407TiP - Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG)**  
D. Hargrave<sup>1</sup>, O. Witt<sup>2</sup>, K. Cohen<sup>3</sup>, R. Packer<sup>4</sup>, A. Lissat<sup>5</sup>, U. Kordes<sup>6</sup>, T. Laetsch<sup>7</sup>, L. Hoffman<sup>8</sup>, A. Lassaletta<sup>9</sup>, N. Gerber<sup>10</sup>, S. Gilheeney<sup>11</sup>, S. Holm<sup>12</sup>, C. Kramm<sup>13</sup>, D. Sumerauer<sup>14</sup>, C. Reitmann<sup>15</sup>, M. Russo<sup>15</sup>, E. Bouffet<sup>16</sup>, <sup>1</sup>Great Ormond Street Hospital for Children NHS Foundation Trust, London, GB, <sup>2</sup>Hopp Children's Cancer Center at the NCT Heidelberg, Heidelberg, DE, <sup>3</sup>Johns Hopkins Hospital, Baltimore, US, <sup>4</sup>Children's National Health System, Washington, D.C., US, <sup>5</sup>Universitätsmedizin Berlin, Berlin, DE, <sup>6</sup>University Medical Center Eppendorf, Hamburg, DE, <sup>7</sup>University of Texas Southwestern Medical Center at Dallas, Dallas, US, <sup>8</sup>Children's Hospital Colorado, Aurora, US, <sup>9</sup>Hospital Infantil Universitario Niño Jesus, Madrid, ES, <sup>10</sup>Universitäts-Kinderspital Zürich, Zurich, CH, <sup>11</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>12</sup>Karolinska Institutet, Stockholm, SE, <sup>13</sup>University of Goettingen, Goettingen, DE, <sup>14</sup>Faculty Hospital Motol, Prague, CZ, <sup>15</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>16</sup>University of Toronto, The Hospital for Sick Children, Toronto, CA
- 12:45 - 12:45 **419P - Double Blind concordance Study Of Colo-Rectal Cancer Treatment Recommendations Between Artificial Intelligence Advisory Programme Watson For Oncology(WFO) & Multidisciplinary Tumor Board(MDT)**  
S. Sampige Prasannakumar<sup>1</sup>, M. Sepulveda<sup>2</sup>, C. Rohit Kumar<sup>3</sup>, A. Rauthan<sup>1</sup>, P. Patil<sup>1</sup>, Y. Ramya<sup>3</sup>, <sup>1</sup>Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN, <sup>2</sup>IBM Health, Florida, US, <sup>3</sup>Manipal Comprehensive Cancer Centre Manipal Hospital, Bangalore, IN
- 12:45 - 12:45 **Developmental therapeutics**
- 12:45 - 12:45 **420P - Phase 1/2 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours**  
P. Bono<sup>1</sup>, C. Massard<sup>2</sup>, K. Peltola<sup>3</sup>, A. Azaro<sup>4</sup>, A. Italiano<sup>5</sup>, R. Kristeleit<sup>6</sup>, U. Lassen<sup>7</sup>, H.-T. Arkenau<sup>8</sup>, P. Hakulinen<sup>9</sup>, C. Garratt<sup>10</sup>, T. Ikonen<sup>11</sup>, M. Mustonen<sup>11</sup>, J. Rodon<sup>12</sup>, <sup>1</sup>Helsinki University Central Hospital (HUCH), Helsinki, FI, <sup>2</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>3</sup>Helsinki University Central Hospital, Helsinki, FI, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Institute Bergonié, Bordeaux, FR, <sup>6</sup>University College London UCL Cancer Institute, London, GB, <sup>7</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>8</sup>Sarah Cannon Research Institute SCRI UK, London, GB, <sup>9</sup>Orion Corporation Orion Pharma, Espoo, FI, <sup>10</sup>Orion Pharma, Newbury,



GB, <sup>11</sup>Orion Corporation Finland, Espoo, FI, <sup>12</sup>UT MD Anderson Cancer Center, Houston, US

12:45 - 12:45

**421P - Preliminary Results of Pamiparib (BGB-290), a PARP1/2 Inhibitor, in Combination with Temozolomide (TMZ) in Patients (pts) with Locally Advanced or Metastatic Solid Tumors**

M. Johnson<sup>1</sup>, M. Galsky<sup>2</sup>, M. Barve<sup>3</sup>, S. Goel<sup>4</sup>, H. Park<sup>5</sup>, B. Du<sup>6</sup>, S. Mu<sup>7</sup>, V. Ramakrishnan<sup>6</sup>, K. Wood<sup>6</sup>, V. Wang<sup>6</sup>, N. Lakhani<sup>8</sup>, <sup>1</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>2</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, <sup>3</sup>Mary Crowley Cancer Research, Dallas, US, <sup>4</sup>Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, <sup>5</sup>Washington University, St. Louis, US, <sup>6</sup>Beigene USA, Inc, San Mateo, US, <sup>7</sup>BeiGene USA, Inc., Fort Lee, US, <sup>8</sup>START - Midwest, Grand Rapids, US

12:45 - 12:45

**422P - First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies**

P. Lorusso<sup>1</sup>, S. Chawla<sup>2</sup>, J. Bendell<sup>3</sup>, A. Shields<sup>4</sup>, G. Shapiro<sup>5</sup>, P. Rajagopalan<sup>6</sup>, C. Cyris<sup>6</sup>, I. Bruns<sup>6</sup>, J. Mei<sup>6</sup>, F. Souza<sup>7</sup>, D. Rasco<sup>8</sup>, J.P. Eder<sup>9</sup>, A. Tolcher<sup>10</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, US, <sup>2</sup>Sarcoma Oncology Research Center, Santa Monica, US, <sup>3</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>4</sup>Karmanos Cancer Institute, Detroit, US, <sup>5</sup>Dana-Farber Cancer Institute, Boston, US, <sup>6</sup>Bayer HealthCare Pharmaceuticals Inc, New York, US, <sup>7</sup>Bayer HealthCare Pharmaceuticals Inc., Whippany, US, <sup>8</sup>START, San Antonio, US, <sup>9</sup>MSD International Switzerland, Luzern, CH, <sup>10</sup>NEXT OncologyTM, San Antonio, US

12:45 - 12:45

**423P - Phase 1 study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors**

N. Yamamoto<sup>1</sup>, Y. Fujiwara<sup>1</sup>, S. Kondo<sup>1</sup>, S. Iwasa<sup>1</sup>, K. Yonemori<sup>1</sup>, A. Shimomura<sup>1</sup>, S. Kitano<sup>1</sup>, T. Shimizu<sup>2</sup>, T. Koyama<sup>1</sup>, T. Ebata<sup>3</sup>, N. Sato<sup>4</sup>, K. Nakai<sup>4</sup>, M. Inatani<sup>4</sup>, K. Tamura<sup>1</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Kinki University School of Medicine, Osaka, JP, <sup>3</sup>Chiba University, School of Medicine, Chiba, JP, <sup>4</sup>Chugai Pharmaceutical Co., Ltd., Tokyo, JP

12:45 - 12:45

**424P\_PR - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?**

A. Vozy<sup>1</sup>, P. Berlanga Charriel<sup>2</sup>, B. Georger<sup>3</sup>, C. Massard<sup>4</sup>, N. Gaspar<sup>3</sup>, <sup>1</sup>Hôpitaux Paris Centre AP-HP, Paris, FR, <sup>2</sup>Private Practice - Berlanga Charriel, Valencia, ES, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR

12:45 - 12:45

**425P - SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer**

S. Crabb<sup>1</sup>, S. Danson<sup>2</sup>, D. Dunkley<sup>1</sup>, M. Kalevras<sup>1</sup>, A. Whitehead<sup>1</sup>, S. Hill<sup>1</sup>, K. Fines<sup>1</sup>, C. Robb<sup>1</sup>, J. Bennett<sup>1</sup>, L. Ksiazek<sup>1</sup>, S. Brown<sup>3</sup>, L. Evans<sup>4</sup>, M. Serra<sup>5</sup>, K. Jones<sup>6</sup>, C. Mcdowell<sup>7</sup>, J. Catto<sup>3</sup>, R. Huddart<sup>5</sup>, G. Griffiths<sup>1</sup>, <sup>1</sup>University of Southampton, Southampton, GB, <sup>2</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, <sup>3</sup>University of Sheffield, Sheffield, GB, <sup>4</sup>Weston Park Hospital, Sheffield, GB, <sup>5</sup>Institute of Cancer

Research and Royal Marsden, Sutton, GB, <sup>6</sup>Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, <sup>7</sup>Cancer Research UK, London, GB

- 12:45 - 12:45 **426P - Zirconium-89 (89Zr)-labeled bispecific T-cell engager (BiTE®) AMG 211 PET imaging to determine AMG 211 biodistribution in patients with gastrointestinal (GI) adenocarcinomas**  
 K. Moek<sup>1</sup>, S. Waaijer<sup>2</sup>, I.C. Kok<sup>2</sup>, F.V. Suurs<sup>2</sup>, A. Brouwers<sup>3</sup>, C.W. Menke-Van Der Houven Van Oordt<sup>4</sup>, T.T. Wind<sup>2</sup>, J. Gietema<sup>1</sup>, C.P. Schroder<sup>2</sup>, S.V.K. Mahesh<sup>2</sup>, A. Jorritsma-Smit<sup>2</sup>, M.N. Lub-De Hooge<sup>2</sup>, R. Fehrmann<sup>1</sup>, D.J. De Groot<sup>1</sup>, E.G.E. De Vries<sup>1</sup>, <sup>1</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>2</sup>University Medical Center Groningen, Groningen, NL, <sup>3</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>4</sup>VUMC Cancer Centre Amsterdam, Amsterdam, NL
- 12:45 - 12:45 **427P - Phase 1 Study of AMG 211/MEDI-565 Administered as Continuous Intravenous Infusion (cIV) for Relapsed/Refractory Gastrointestinal (GI) Adenocarcinoma**  
 K. Moek<sup>1</sup>, W. Fiedler<sup>2</sup>, J.C. Von Einem<sup>3</sup>, H. Verheul<sup>4</sup>, T. Seufferlein<sup>5</sup>, D.J. De Groot<sup>1</sup>, V. Heinemann<sup>6</sup>, M. Kebenko<sup>7</sup>, C.W. Menke-Van Der Houven Van Oordt<sup>8</sup>, T. Ettrich<sup>5</sup>, E. Rasmussen<sup>9</sup>, P. Bogner<sup>10</sup>, B. Sable<sup>9</sup>, S. Stienen<sup>11</sup>, E.G.E. De Vries<sup>1</sup>, <sup>1</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>2</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>3</sup>University Hospital Grosshadern, Munich, DE, <sup>4</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>5</sup>Ulm Medical University, Ulm, DE, <sup>6</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>7</sup>University Medical Center Hamburg-Eppendorf, Hamburg, DE, <sup>8</sup>VUMC Cancer Centre Amsterdam, Amsterdam, NL, <sup>9</sup>Amgen Inc, Thousand Oaks, US, <sup>10</sup>Amgen Research (Munich) GmbH, Munich, DE, <sup>11</sup>Amgen Research (Munich) GmbH - Germany, Munich, DE
- 12:45 - 12:45 **428P - Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors**  
 T. Bauer<sup>1</sup>, M. Barve<sup>2</sup>, E.G. Chiorean<sup>3</sup>, P. Lorusso<sup>4</sup>, K. Courtney<sup>5</sup>, D. Qi<sup>6</sup>, A. Olguin<sup>6</sup>, J. Bullington<sup>6</sup>, M. Sardone<sup>6</sup>, V. Dunn<sup>6</sup>, S. Shemesh<sup>6</sup>, J. Chen<sup>6</sup>, C. Brooks<sup>7</sup>, J. Wang<sup>8</sup>, <sup>1</sup>Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, <sup>2</sup>Mary Crowley Cancer Research, Dallas, US, <sup>3</sup>University of Washington, Seattle, US, <sup>4</sup>Yale University School of Medicine, New Haven, US, <sup>5</sup>UT Southwestern Medical Center, Dallas, US, <sup>6</sup>Stemline Therapeutics, New York, US, <sup>7</sup>Memorial Sloan Kettering Memorial Hospital, New York, US, <sup>8</sup>Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, US
- 12:45 - 12:45 **429P - NEO2734 - A novel potent oral dual BET and P300/CBP inhibitor**  
 F. Giles<sup>1</sup>, M. Witcher<sup>2</sup>, B. Brown<sup>3</sup>, <sup>1</sup>Northwestern University, Chicago, US, <sup>2</sup>DTC, Chicago, US, <sup>3</sup>NEOMED Therapeutics 1 Inc, Montreal, CA
- 12:45 - 12:45 **430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid tumours**  
 A. Seet<sup>1</sup>, S.P. Choo<sup>2</sup>, D. Tai<sup>1</sup>, Y.C.J. Lam<sup>1</sup>, W.T. Teng<sup>1</sup>, C. Lim<sup>1</sup>, T. Lim<sup>3</sup>, I. Tan<sup>1</sup>, E. Petricoin<sup>4</sup>, M. Ng<sup>5</sup>, <sup>1</sup>National Cancer Centre Singapore, Singapore, SG, <sup>2</sup>National Cancer Center Singapore, Singapore, SG, <sup>3</sup>Singapore General Hospital, Singapore, SG,

<sup>4</sup>Perthera, McLean, US, <sup>5</sup>National Cancer Centre (NCC), Singapore, Singapore, SG

- 12:45 - 12:45 **431P - Phase 1b study of safety and tolerability of Selinexor in Asian patients with advanced solid cancers**  
V. Heong<sup>1</sup>, M.L. Goh<sup>2</sup>, W.P. Yong<sup>3</sup>, R. Soo<sup>2</sup>, C.E. Chee<sup>3</sup>, S. Raghav<sup>4</sup>, B.-C. Goh<sup>2</sup>, S.C. Lee<sup>3</sup>, J. Lim<sup>3</sup>, A. Wong<sup>3</sup>, D. Tan<sup>5</sup>, <sup>1</sup>National University Cancer Institute Singapore (NCIS), Singapore, SG, <sup>2</sup>National University Hospital, Singapore, SG, <sup>3</sup>National University Cancer Institute, Singapore, SG, <sup>4</sup>National University Cancer Institute, Singapore, Singapore, SG, <sup>5</sup>National University Cancer Institute, Singapore (NCIS), National University Hospital (NUH), Singapore, SG
- 12:45 - 12:45 **432P - Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients**  
Y. Yu<sup>1</sup>, C. Durairaj<sup>1</sup>, H. Shi<sup>2</sup>, D. Wang<sup>1</sup>, <sup>1</sup>Pfizer, Inc., San Diego, US, <sup>2</sup>Pfizer, Inc., Groton, US
- 12:45 - 12:45 **433P - An open-label, phase 1, dose escalating study evaluating safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients with solid tumors**  
J. Palshof<sup>1</sup>, I. Kümler<sup>1</sup>, P. Sørensen<sup>1</sup>, B. Jensen<sup>2</sup>, D. Nielsen<sup>2</sup>, <sup>1</sup>Herlev Hospital, Herlev, DK, <sup>2</sup>Herlev and Gentofte Hospital, Herlev, DK
- 12:45 - 12:45 **434P - Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: the French national AcSé Program**  
G. Vassal<sup>1</sup>, N. Cozic<sup>1</sup>, R. Houot<sup>2</sup>, L. Brugières<sup>3</sup>, T. Aparicio<sup>4</sup>, J.-Y. Blay<sup>5</sup>, M. Perol<sup>5</sup>, P. Brice<sup>6</sup>, E. Meriaux<sup>7</sup>, B. Georger<sup>8</sup>, M. El Bejjani<sup>9</sup>, S. Moalla<sup>9</sup>, I. Bièche<sup>10</sup>, S. Lantuejoul<sup>5</sup>, C. Mahier Ait Oukhatar<sup>11</sup>, N. Hoog Labouret<sup>12</sup>, D. Moro-Sibilot<sup>13</sup>, <sup>1</sup>Gustave Roussy Cancer Campus Grand Paris, Villejuif, FR, <sup>2</sup>Centre Hospitalier Universitaire de Rennes, Rennes, FR, <sup>3</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>4</sup>Hôpital Avicenne, Bobigny, FR, <sup>5</sup>Centre Léon Bérard, Lyon, FR, <sup>6</sup>Hôpital St. Louis, Paris, FR, <sup>7</sup>ICO Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>8</sup>Institut Gustave Roussy, Villejuif, FR, <sup>9</sup>Gustave Roussy Cancer Campus, Villejuif, FR, <sup>10</sup>Institut Curie, PARIS, FR, <sup>11</sup>UNICANCER, Paris, FR, <sup>12</sup>Institut National du Cancer, Boulogne Billancourt, FR, <sup>13</sup>Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, FR
- 12:45 - 12:45 **435P - Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors**  
V. Boni<sup>1</sup>, J. Garcia-Corbacho<sup>2</sup>, P. Ott<sup>3</sup>, D. Cho<sup>4</sup>, K. Autio<sup>5</sup>, N. Uboha<sup>6</sup>, A. Spira<sup>7</sup>, R. Humphrey<sup>8</sup>, M. Will<sup>8</sup>, A. Naing<sup>9</sup>, F. Thistlethwaite<sup>10</sup>, E.G.E. De Vries<sup>11</sup>, H.-T. Arkenau<sup>12</sup>, <sup>1</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>2</sup>Hospital Clinic Barcelona, Barcelona, ES, <sup>3</sup>Dana-Farber Cancer Institute, Boston, US, <sup>4</sup>New York University Langone Medical Center, New York, US, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>6</sup>University of Wisconsin, Madison, US, <sup>7</sup>Virginia Cancer Specialists, Fairfax, US, <sup>8</sup>CytomX Therapeutics, South San Francisco, US, <sup>9</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>10</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>11</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>12</sup>Sarah Cannon Research Institute SCRI UK, London, GB



- 12:45 - 12:45 **436P - Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 Probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors**
- R. Plummer<sup>1</sup>, R. Sanborn<sup>2</sup>, E.G.E. De Vries<sup>3</sup>, P. Lorusso<sup>4</sup>, H.-T. Arkenau<sup>5</sup>, N. Uboha<sup>6</sup>, J. Wydmanski<sup>7</sup>, M.J. Fidler<sup>8</sup>, V. Boni<sup>9</sup>, J. Garcia-Corbacho<sup>10</sup>, R. Humphrey<sup>11</sup>, M. Will<sup>11</sup>, K. Autio<sup>12</sup>, A. El-Khoueiry<sup>13</sup>, C.W. Menke-Van Der Houven Van Oordt<sup>14</sup>, F. Thistlethwaite<sup>15</sup>, <sup>1</sup>Northern Institute for Cancer Research University of Newcastle, Newcastle upon Tyne, GB, <sup>2</sup>Providence Cancer Institute, Portland, US, <sup>3</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>4</sup>Yale University School of Medicine, New Haven, US, <sup>5</sup>Sarah Cannon Research Institute SCRI UK, London, GB, <sup>6</sup>University of Wisconsin, Madison, US, <sup>7</sup>NZOZ, Katowice, PL, <sup>8</sup>Rush University Medical Center, Chicago, US, <sup>9</sup>START Madrid-CIOCC HM Hospital Sanchinarro, Madrid, ES, <sup>10</sup>Hospital Clinic Barcelona, Barcelona, ES, <sup>11</sup>CytomX Therapeutics, South San Francisco, US, <sup>12</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>13</sup>USC/Norris Comprehensive Cancer Center, Los Angeles, US, <sup>14</sup>VUMC Cancer Centre Amsterdam, Amsterdam, NL, <sup>15</sup>The Christie NHS Foundation Trust, Manchester, GB
- 12:45 - 12:45 **437P - PT-112: A Well-Tolerated Novel Immunogenic Cell Death (ICD) Inducer with Activity in Advanced Solid Tumors**
- D. Karp<sup>1</sup>, D. Camidge<sup>2</sup>, J. Infante<sup>3</sup>, T. Ames<sup>4</sup>, J. Jimeno<sup>4</sup>, A. Bryce<sup>5</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>University of Colorado Cancer Center, Aurora, US, <sup>3</sup>Sarah Cannon Research Institute-cancer centre, Nashville, US, <sup>4</sup>Phosplatin Therapeutics LLC, New York, US, <sup>5</sup>Mayo Clinic Cancer Center, Phoenix, US
- 12:45 - 12:45 **438P - Safety and Efficacy of the PD-1 Inhibitor ABBV-181 in Patients with Advanced Solid Tumors: Preliminary Phase 1 Results from Study M15-891**
- J. Powderly<sup>1</sup>, P. Cassier<sup>2</sup>, A. Cervantes<sup>3</sup>, B. Gao<sup>4</sup>, A. Gazzah<sup>5</sup>, A. Italiano<sup>6</sup>, C.-C. Lin<sup>7</sup>, J. Luke<sup>8</sup>, V. Moreno<sup>9</sup>, K. Peltola<sup>10</sup>, D. Rasco<sup>11</sup>, A. Spira<sup>12</sup>, M. Tanner<sup>13</sup>, D. Tosi<sup>14</sup>, D. Afar<sup>15</sup>, S. Englert<sup>16</sup>, A. Parikh<sup>15</sup>, A. Reddy<sup>15</sup>, G. Vosgianian<sup>17</sup>, A. Tolcher<sup>18</sup>, <sup>1</sup>Carolina Biooncology Cancer Therapy, Huntersville, US, <sup>2</sup>Centre Léon Bérard, Lyon, FR, <sup>3</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>4</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>5</sup>Institut Gustave Roussy, Villejuif, FR, <sup>6</sup>Institute Bergonié, Bordeaux, FR, <sup>7</sup>National Taiwan University Hospital, Taipei city, TW, <sup>8</sup>The University of Chicago Medical Centre, Chicago, US, <sup>9</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>10</sup>Helsinki University Central Hospital, Helsinki, FI, <sup>11</sup>START, San Antonio, US, <sup>12</sup>Virginia Cancer Specialists, Fairfax, US, <sup>13</sup>Tampere University Hospital (Tays), Tampere, FI, <sup>14</sup>Institut du Cancer de Montpellier, Montpellier, FR, <sup>15</sup>AbbVie Inc., Redwood City, US, <sup>16</sup>Abbvie, Inc, Mettawa, US, <sup>17</sup>Gilead Sciences, Inc., Foster City, US, <sup>18</sup>NEXT Oncology™, San Antonio, US
- 12:45 - 12:45 **439P - Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials**
- C. Massard<sup>1</sup>, N. Segal<sup>2</sup>, D. Cho<sup>3</sup>, V. Papadimitrakopoulou<sup>4</sup>, N. Rizvi<sup>5</sup>, B.C. Cho<sup>6</sup>, L. Yu<sup>7</sup>, H. Yang<sup>7</sup>, H.-J. Hsieh<sup>7</sup>, J. Zhang<sup>7</sup>, W. Zhao<sup>7</sup>, G. Gao<sup>7</sup>, X. Guo<sup>7</sup>, S. Abdullah<sup>7</sup>, J. Englert<sup>7</sup>, J.-C. Soria<sup>8</sup>, M. Dar<sup>7</sup>, L. Roskos<sup>7</sup>, C. Ferte<sup>7</sup>, S. Antonia<sup>9</sup>, <sup>1</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>New York University Langone Medical Center, New York, US, <sup>4</sup>MD Anderson Cancer Center, Houston, US, <sup>5</sup>Columbia University Medical Center College of Physicians &



Surgeons - New York Presbyterian Hospital, New York, US, <sup>6</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>7</sup>MedImmune, Gaithersburg, US, <sup>8</sup>Medimmune, Gaithersburg, US, <sup>9</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US

- 12:45 - 12:45 **440P - Intratumoral administration of pro-inflammatory allogeneic , "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect**  
A. Karlsson-Parra, G. Fotaki, D. Yu, M. Essand, Uppsala University, Uppsala, SE
- 12:45 - 12:45 **441P - OT-1096, a first-in-class immunoactivating small molecule that targets the thioredoxin reductase/thioredoxin axis causes strong tumor growth inhibition by downregulating intratumoral Tregs in a humanized TNBC-PDX model.**  
O. Orwar<sup>1</sup>, I. Lowstedt<sup>1</sup>, K. Andersson<sup>1</sup>, G. Gannedahl<sup>1</sup>, G. Willman<sup>1</sup>, M. Davidsson<sup>1</sup>, W. Stafford<sup>2</sup>, C. Trkulja<sup>1</sup>, <sup>1</sup>Oblique Therapeutics AB, Gothenburg, SE, <sup>2</sup>Oblique Therapeutics AB, Gotheburg, SE
- 12:45 - 12:45 **442TiP - A Phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies**  
S. Blagden<sup>1</sup>, P. Spiliopoulou<sup>2</sup>, L. Spiers<sup>1</sup>, C. Gnanaranjan<sup>3</sup>, C. Qi<sup>4</sup>, V. Woodcock<sup>1</sup>, J. Moschandreas<sup>4</sup>, H. Tyrrell<sup>1</sup>, L. Griffiths<sup>5</sup>, C. Butcher<sup>5</sup>, E. Ghazaly<sup>6</sup>, T.R.J. Evans<sup>7</sup>, <sup>1</sup>Churchill Hospital University of Oxford, Oxford, GB, <sup>2</sup>Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>3</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>4</sup>Centre for Statistics in Medicine, Oxford, GB, <sup>5</sup>University of Oxford, Oxford, GB, <sup>6</sup>Barts Cancer Centre, London, GB, <sup>7</sup>Beatson Institute for Cancer Research, Glasgow, GB
- 12:45 - 12:45 **443TiP - First-in-Human trial design for W0101, a first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population**  
C. Gomez-Roca<sup>1</sup>, E. Garralda-Cabanas<sup>2</sup>, F. Cruzalegui<sup>3</sup>, F. Ausseil<sup>3</sup>, G. Zorza<sup>3</sup>, O. Delfour<sup>4</sup>, J. Besse<sup>5</sup>, B. Akla<sup>6</sup>, S. Gautier<sup>7</sup>, J. Adam<sup>8</sup>, M. Lacroix-Triki<sup>1</sup>, A. Passiukov<sup>3</sup>, R. Roche<sup>9</sup>, M. Pavlyuk<sup>3</sup>, C. Massard<sup>10</sup>, <sup>1</sup>Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, <sup>2</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>3</sup>Pierre Fabre Centre De Recherche France, Toulouse, FR, <sup>4</sup>Institut de Recherches Pierre Fabre, Toulouse, FR, <sup>5</sup>Institut de Recherche Pierre Fabre, Toulouse, FR, <sup>6</sup>Institut de Recherche Pierre Fabre, St Julien en Genevois, FR, <sup>7</sup>IRPF, Pierre Fabre, Toulouse, FR, <sup>8</sup>Institut Gustave Roussy, Villejuif, FR, <sup>9</sup>Institut de Recherche Pierre fabre, Toulouse, FR, <sup>10</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR
- 12:45 - 12:45 **444TiP - Phase 1/2 Study Investigating Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors**  
J. Desai<sup>1</sup>, M. Voskoboynik<sup>2</sup>, B. Markman<sup>3</sup>, J. Hou<sup>4</sup>, D. Zeng<sup>4</sup>, T. Meniawy<sup>5</sup>, <sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>2</sup>Nucleus Network, Melbourne, AU, <sup>3</sup>Monash Health and Monash University, Melbourne, AU, <sup>4</sup>BeiGene USA, Inc., Emeryville, US, <sup>5</sup>School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU

- 12:45 - 12:45 **445TiP - Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO - A Phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy**  
A. Krämer<sup>1</sup>, F. Losa<sup>2</sup>, L. Gay<sup>3</sup>, D. Page<sup>4</sup>, S. Foser<sup>4</sup>, T. Mughal<sup>5</sup>, J. Ross<sup>6</sup>, G. Baciarello<sup>7</sup>, L. Mileschkin<sup>8</sup>, S. Osborne<sup>9</sup>, H. Moch<sup>10</sup>, <sup>1</sup>HI-STEM gGmbH im Deutschen Krebsforschungszentrum DKFZ, Heidelberg, DE, <sup>2</sup>Hospital Sant Joan Despí - Moises Broggi, Barcelona, ES, <sup>3</sup>Foundation Medicine, Inc., Cambridge, US, <sup>4</sup>F. Hoffmann-La Roche AG - Switzerland, Basel, CH, <sup>5</sup>Tufts University Medical Center, Boston, US, <sup>6</sup>Foundation Medicine Inc., Cambridge, US, <sup>7</sup>Gustave Roussy, Villejuif, FR, <sup>8</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>9</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>10</sup>University Hospital Zurich, Zurich, CH
- 12:45 - 12:45 **446TiP - REVEAL: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies**  
A. Diab<sup>1</sup>, M. Marcondes<sup>2</sup>, M. Tagliaferri<sup>2</sup>, U. Hoch<sup>2</sup>, J. Zhang<sup>2</sup>, W. Rubas<sup>2</sup>, S. Kivimae<sup>2</sup>, J. Zalevsky<sup>2</sup>, A. Conley<sup>1</sup>, E. Borazanci<sup>3</sup>, S. D'Angelo<sup>4</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, US, <sup>2</sup>Nektar Therapeutics, San Francisco, US, <sup>3</sup>Honor Health/TGen, Scottsdale, US, <sup>4</sup>Memorial Sloan-Kettering Cancer Center, New York, US
- 12:45 - 12:45 **447TiP - The Cancer Molecular Screening and Therapeutics Program (MoST) - A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies**  
S. Thavaneswaran<sup>1</sup>, L. Sebastian<sup>2</sup>, M. Ballinger<sup>3</sup>, M. Cowley<sup>3</sup>, J. Grady<sup>3</sup>, A. Joshua<sup>1</sup>, C. Lee<sup>2</sup>, K. Sjoquist<sup>2</sup>, W. Hague<sup>2</sup>, J. Simes<sup>2</sup>, D. Thomas<sup>3</sup>, <sup>1</sup>The Kinghorn Cancer Centre, Darlinghurst, AU, <sup>2</sup>The NHMRC Clinical Trials Centre, Camperdown, AU, <sup>3</sup>The Garvan Institute of Medical Research, Darlinghurst, AU
- 12:45 - 12:45 **448TiP - MEDIOLA: A Phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts**  
R. Penson<sup>1</sup>, Y. Drew<sup>2</sup>, M. De Jonge<sup>3</sup>, S.-H. Hong<sup>4</sup>, Y.H. Park<sup>5</sup>, A. Wolfer<sup>6</sup>, J. Brown<sup>7</sup>, M. Ferguson<sup>8</sup>, M. Gore<sup>9</sup>, R. Alvarez<sup>10</sup>, B. Kaufman<sup>11</sup>, C. Gresty<sup>12</sup>, H. Angell<sup>12</sup>, K. Meyer<sup>13</sup>, M. Lanasa<sup>14</sup>, P. Herbolzheimer<sup>14</sup>, S. Domchek<sup>15</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, US, <sup>2</sup>Newcastle General Hospital Northern Centre for Cancer Treatment, Newcastle upon Tyne, GB, <sup>3</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>4</sup>Catholic University of Korea, Seoul, KR, <sup>5</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>6</sup>Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, <sup>7</sup>Beatson Institute for Cancer Research, Glasgow, GB, <sup>8</sup>Ninewells Hospital, Dundee, GB, <sup>9</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>10</sup>Cancer Treatment Centers of America, Newnan, US, <sup>11</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>12</sup>AstraZeneca, Cambridge, GB, <sup>13</sup>AstraZeneca, Gaithersburg, US, <sup>14</sup>AstraZeneca USA, Gaithersburg, US, <sup>15</sup>Private Practice - Domchek, Philadelphia, US
- 12:45 - 12:45 **449TiP - MASTER KEY Project - a basket/umbrella trial for rare cancers in Japan**  
S. Noda<sup>1</sup>, K. Yonemori<sup>1</sup>, N. Shirakawa<sup>1</sup>, H. Okuma<sup>1</sup>, T. Shimizu<sup>1</sup>, A. Hirakawa<sup>2</sup>, T. Shibata<sup>1</sup>, T. Sukigara<sup>1</sup>, N. Okita<sup>3</sup>, A. Kawai<sup>1</sup>, N. Yamamoto<sup>1</sup>, K. Nakamura<sup>4</sup>, H. Mano<sup>5</sup>, T.

Nishida<sup>1</sup>, Y. Fujiwara<sup>6</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>The University of Tokyo, Tokyo, JP, <sup>3</sup>National Cancer Center Research Institute, Tokyo, JP, <sup>4</sup>National Cancer Center, Tokyo, JP, <sup>5</sup>National Cancer Center Research Institute, Tokyo, JP, <sup>6</sup>Pharmaceutical and Medical Devices Agency, Tokyo, JP

12:45 - 12:45 **Genitourinary tumours, prostate**

12:45 - 12:45 **800P - The prognostic value of the proportion and subtype patterns of intraductal carcinoma of the prostate in patients with de novo metastatic prostate cancer: a propensity score matching study**

J. Zhao<sup>1</sup>, J. Liu<sup>1</sup>, G. Sun<sup>1</sup>, P. Shen<sup>1</sup>, J. Chen<sup>1</sup>, X. Zhang<sup>2</sup>, H. Zhang<sup>1</sup>, Z. Liu<sup>1</sup>, Y. Bao<sup>1</sup>, Y. Yang<sup>1</sup>, P. Zhao<sup>1</sup>, K. Shu<sup>2</sup>, H. Zeng<sup>1</sup>, <sup>1</sup>West China Hospital, Sichuan University, Chengdu, CN, <sup>2</sup>West China Hospital, Chengdu, CN

12:45 - 12:45 **801P - Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel**

P. Lara<sup>1</sup>, E. Mayerson<sup>2</sup>, E. Gertz<sup>3</sup>, C. Tangen<sup>2</sup>, A. Goldkorn<sup>4</sup>, M. Van Loan<sup>3</sup>, M. Hussain<sup>5</sup>, S. Gupta<sup>6</sup>, J. Zhang<sup>7</sup>, P. Twardowski<sup>8</sup>, D. Quinn<sup>9</sup>, N. Vogelzang<sup>10</sup>, I. Thompson<sup>11</sup>, N. Agarwal<sup>12</sup>, <sup>1</sup>University of California Davis Cancer Center, Sacramento, US, <sup>2</sup>FHCRC, Seattle, US, <sup>3</sup>UC Davis, Davis, US, <sup>4</sup>University of Southern California, Los Angeles, US, <sup>5</sup>Northwestern University Feinberg School of Medicine, Chicago, US, <sup>6</sup>University of Minnesota, Minneapolis, US, <sup>7</sup>Moffitt Comprehensive Cancer Center, Tampa, US, <sup>8</sup>City of Hope, Duarte, US, <sup>9</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>10</sup>US Oncology Research c/o Comprehensive Cancer Crts of NV, Las Vegas, US, <sup>11</sup>Christus Health, San Antonio, US, <sup>12</sup>Huntsman Cancer Institute, Salt Lake City, US

12:45 - 12:45 **802P - Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China**

W. Jiang<sup>1</sup>, S. Qu<sup>2</sup>, Y. Liu<sup>2</sup>, X. Yao<sup>3</sup>, M. Liu<sup>4</sup>, <sup>1</sup>Fujian Medical University Union Hospital, Shanghai, CN, <sup>2</sup>IQVIA, Shanghai, CN, <sup>3</sup>Sanofi, Shanghai, CN, <sup>4</sup>Fujian Medical University Union Hospital, Fuzhou, CN

12:45 - 12:45 **803P - Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)**

U. Vaishampayan<sup>1</sup>, L. Heilbrun<sup>2</sup>, P. Monk<sup>3</sup>, G. Sonpavde<sup>4</sup>, S. Tejwani<sup>5</sup>, E. Heath<sup>2</sup>, J. Fontana<sup>2</sup>, S. Chinni<sup>2</sup>, <sup>1</sup>Karmanos Cancer Institute, Detroit, US, <sup>2</sup>Karmanos Cancer Center, Detroit, US, <sup>3</sup>The Ohio State University James Cancer Hospital, Columbus, US, <sup>4</sup>Dana Farber Cancer Institute, Boston, US, <sup>5</sup>Henry Ford Hospital, Detroit, US

12:45 - 12:45 **804P - Health-Related Quality of Life (HRQoL) After Progressive Disease (PD) in SPARTAN: a Phase 3 Trial of Apalutamide (APA) Versus Placebo (PBO) in Men with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)**



E. Small<sup>1</sup>, D. Cella<sup>2</sup>, K. Mcquarrie<sup>3</sup>, F. Saad<sup>4</sup>, B. Hadaschik<sup>5</sup>, J. Graff<sup>6</sup>, H. Uemura<sup>7</sup>, S. Oudard<sup>8</sup>, M. Yu<sup>9</sup>, S. Hudgens<sup>10</sup>, A. Lopez-Gitlitz<sup>9</sup>, B. Rooney<sup>11</sup>, M. Morris<sup>12</sup>, M. Smith<sup>13</sup>,  
<sup>1</sup>University of California San Francisco, San Francisco, US, <sup>2</sup>Northwestern University, Chicago, US, <sup>3</sup>Janssen Research & Development, Horsham, US, <sup>4</sup>Hospital St. Luc du CHUM, Montreal, CA, <sup>5</sup>University of Duisburg-Essen, German Cancer Consortium (DKTK), partner site University Hospital Essen, Essen, and Ruprecht-Karls University Heidelberg, Heidelberg, DE, <sup>6</sup>Oregon Health Science University, Portland, US, <sup>7</sup>Yokohama City University, Yokohama, JP, <sup>8</sup>Hopital European George Pompidou, Paris, FR, <sup>9</sup>Janssen Research & Development, Los Angeles, US, <sup>10</sup>Clinical Outcomes Solutions, Tucson, US, <sup>11</sup>Janssen Research & Development, High Wycombe, GB, <sup>12</sup>Clinical Outcomes Solutions, Folkestone, GB, <sup>13</sup>Massachusetts General Hospital, Boston, US

12:45 - 12:45

**805P - A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): results of PROSPER by age and region**

K. Fizazi<sup>1</sup>, M. Hussain<sup>2</sup>, F. Saad<sup>3</sup>, N. Shore<sup>4</sup>, U. De Giorgi<sup>5</sup>, E. Efstathiou<sup>6</sup>, U. Ferreira<sup>7</sup>, P. Ivashchenko<sup>8</sup>, K. Madziarska<sup>9</sup>, M. Al-Adhami<sup>10</sup>, K. Modelska<sup>11</sup>, D. Phung<sup>12</sup>, J. Steinberg<sup>13</sup>, C. Sternberg<sup>14</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, US, <sup>3</sup>Hospital St. Luc du CHUM, Montreal, CA, <sup>4</sup>Medical Director, Myrtu Beach, US, <sup>5</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Piero Maroncelli,, IT, <sup>6</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>7</sup>State University of Campinas (Unicamp), Cidade Universitária Zeferino Vaz - Barão Geraldo, BR, <sup>8</sup>Kyiv City Clinical Hospital #3, Kiev, Petra Zaporozhtza,, UA, <sup>9</sup>Wroclaw Medical University, Wroclaw, PL, <sup>10</sup>Pfizer Inc., Groton, US, <sup>11</sup>Pfizer Inc., San Francisco, US, <sup>12</sup>Astellas, Leiden, NL, <sup>13</sup>Astellas Pharma US, Inc., Northbrook, US, <sup>14</sup>Azienda Ospedaliera S. Camillo Forlanini, Rome, IT

12:45 - 12:45

**806P - Relationship Between Apalutamide (APA) Exposure and Metastasis-Free Survival (MFS) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN**

M. Smith<sup>1</sup>, C. Perez-Ruixo<sup>2</sup>, O. Ackaert<sup>2</sup>, D. Ouellet<sup>3</sup>, C. Chien<sup>3</sup>, H. Uemura<sup>4</sup>, D. Olmos<sup>5</sup>, P. Mainwaring<sup>6</sup>, J.Y. Lee<sup>7</sup>, M. Yu<sup>8</sup>, J.-J. Perez-Ruixo<sup>2</sup>, E. Small<sup>9</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, US, <sup>2</sup>Janssen Research & Development, Antwerp, BE, <sup>3</sup>Janssen Research & Development, Spring House, US, <sup>4</sup>Yokohama City University, Yokohama, JP, <sup>5</sup>CNIO - Spanish National Cancer Center, Madrid, ES, <sup>6</sup>ICON Cancer Care, Brisbane, AU, <sup>7</sup>The Catholic University of Korea, Seoul, KR, <sup>8</sup>Janssen, Los Angeles, US, <sup>9</sup>University of California San Francisco, San Francisco, US

12:45 - 12:45

**807P - Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: results from the PROSPER study**

B. Tombal<sup>1</sup>, M. Hussain<sup>2</sup>, D. Penson<sup>3</sup>, G. Attard<sup>4</sup>, C. Sternberg<sup>5</sup>, D. Phung<sup>6</sup>, R. Morlock<sup>7</sup>, K. Modelska<sup>8</sup>, K. Ramaswamy<sup>9</sup>, C. Ivanescu<sup>10</sup>, F. Saad<sup>11</sup>, <sup>1</sup>McCann Complete Medical Limited, Cheshire, GB, <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, US, <sup>3</sup>Vanderbilt University Medical Center, Nashville, US, <sup>4</sup>The Institute of Cancer Research and The Royal Marsden, London, GB, <sup>5</sup>San Camillo Forlanini Hospital, Rome, IT, <sup>6</sup>Astellas, Leiden, NL, <sup>7</sup>Astellas Pharma Global Development, Inc., Northbrook, US, <sup>8</sup>Pfizer Inc., San Francisco, US, <sup>9</sup>Pfizer Inc., New York, US, <sup>10</sup>IQVIA, Hoofddorp, NL, <sup>11</sup>Hospital St. Luc du CHUM, Montreal, CA



- 12:45 - 12:45 **808P - Non-metastatic castration-resistant prostate cancer (nmCRPC): meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide**
- D. Almeida<sup>1</sup>, C. De Oliveira<sup>2</sup>, R. Mariano<sup>2</sup>, F. Kater<sup>3</sup>, M.C. Souza<sup>4</sup>, V. Ruiz-Schutz<sup>5</sup>, R. Yamamura<sup>6</sup>, R. Saraiva De Carvalho<sup>6</sup>, F. Maluf<sup>7</sup>, A. Morgans<sup>8</sup>, S. Srinivas<sup>9</sup>, S. Gupta<sup>10</sup>, T. Dorff<sup>11</sup>, E. Yu<sup>12</sup>, F.A. Schutz<sup>13</sup>, <sup>1</sup>Hospital São Jose - Beneficencia Portuguesa de São Paulo, Sao Paulo, BR, <sup>2</sup>BP - A Beneficência Portuguesa de São Paulo, Sao Paulo, BR, <sup>3</sup>Centro Paulista de Oncologia, Sao Paulo, BR, <sup>4</sup>ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR, <sup>5</sup>Universidade de Sao Paulo, Sao Paulo, BR, <sup>6</sup>Hospital São José, Sao Paulo, BR, <sup>7</sup>Hospital Beneficencia Portuguesa of Sao Paulo, Sao Paulo, BR, <sup>8</sup>Northwestern University Feinberg School of Medicine, Chicago, US, <sup>9</sup>Stanford University, Stanford, US, <sup>10</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, <sup>11</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>12</sup>University of Washington, Seattle, US, <sup>13</sup>Sirio Libanes Hospital, Sao Paulo, BR
- 12:45 - 12:45 **809P - Statin Use and Outcome in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts) Treated in the TROPIC trial**
- D. Lorente<sup>1</sup>, G.A. De Velasco Oria<sup>2</sup>, J. Carles<sup>3</sup>, S. Gillessen<sup>4</sup>, K. Fizazi<sup>5</sup>, A. Joshua<sup>6</sup>, M. Eisenberger<sup>7</sup>, O. Sartor<sup>8</sup>, J. De Bono<sup>9</sup>, <sup>1</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>2</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>3</sup>Vall Hebron Institute of Oncology, Barcelona, ES, <sup>4</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>5</sup>Gustave Roussy, Villejuif, FR, <sup>6</sup>The Kinghorn Cancer Centre, Darlinghurst, AU, <sup>7</sup>Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, <sup>8</sup>Tulane Medical School, New Orleans, US, <sup>9</sup>The Institute of Cancer Research (ICR), London, GB
- 12:45 - 12:45 **810P - Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: results from the SPARE-trial (NCT02077634)**
- C. Ohlmann<sup>1</sup>, Z. Roger<sup>2</sup>, C. Rüssel<sup>3</sup>, E. Hellmis<sup>4</sup>, H. Suttman<sup>5</sup>, M. Janssen<sup>6</sup>, A. Hübner<sup>7</sup>, J. Dahm<sup>8</sup>, J. Gleißner<sup>9</sup>, M. Scheffler<sup>10</sup>, S. Feyerabend<sup>11</sup>, J. Telle<sup>12</sup>, J. Klier<sup>13</sup>, <sup>1</sup>Malteser Krankenhaus Bonn, Bonn, DE, <sup>2</sup>Praxis für Urologie Pankow, Berlin, DE, <sup>3</sup>Praxisgemeinschaft für Urologie, Borken, DE, <sup>4</sup>Urologikum Duisburg, Duisburg, DE, <sup>5</sup>Urologikum Hamburg, Hamburg, DE, <sup>6</sup>Saarland University Medical Center, Hamburg, DE, <sup>7</sup>WK Nord GmbH & Co. KG, Rostock, DE, <sup>8</sup>PandaMED - ÜBAG, Wuppertal, DE, <sup>9</sup>DGU Wuppertal, Wuppertal, DE, <sup>10</sup>Gemeinschaftspraxis für Urologie, Zwickau, DE, <sup>11</sup>University of Tübingen, Tübingen, DE, <sup>12</sup>Urologische Praxis Würzburg, Würzburg, DE, <sup>13</sup>Praxis, Köln, DE
- 12:45 - 12:45 **811P - Association of Grade \_3 neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel**
- A. Meisel<sup>1</sup>, R. De Wit<sup>2</sup>, S. Oudard<sup>3</sup>, O. Sartor<sup>4</sup>, F. Stenner-Liewen<sup>5</sup>, Z. Shun<sup>6</sup>, A. Ozatilgan<sup>7</sup>, M. Eisenberger<sup>8</sup>, J. De Bono<sup>9</sup>, <sup>1</sup>Stadtspital Waid, Zürich, CH, <sup>2</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>3</sup>Hôpital Européen George Pompidou, Paris, FR, <sup>4</sup>Tulane Medical School, New Orleans, US, <sup>5</sup>University Hospital of Basel, Basel, CH, <sup>6</sup>Sanofi, New Jersey, US, <sup>7</sup>Sanofi, Cambridge, US, <sup>8</sup>Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, <sup>9</sup>Royal Marsden NHS Foundation Trust/The Institute of Cancer

Research, Sutton, GB

- 12:45 - 12:45 **812P - Post hoc responder analysis of health-related quality of life (HRQL) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the Phase III PROSELICA and FIRSTANA trials**  
A. Thiery Vuillemin<sup>1</sup>, K. Fizazi<sup>2</sup>, O. Sartor<sup>3</sup>, S. Oudard<sup>4</sup>, D. Bury<sup>5</sup>, S. Guillonnet<sup>6</sup>, A. Ozatilgan<sup>7</sup>, M. Eisenberger<sup>8</sup>, J. De Bono<sup>9</sup>, <sup>1</sup>CHU Besançon, Hôpital Jean Minjot, Besançon, FR, <sup>2</sup>Gustave Roussy, Villejuif, FR, <sup>3</sup>Tulane Medical School, New Orleans, US, <sup>4</sup>Hopital European George Pompidou, Paris, FR, <sup>5</sup>Sanofi US, Cambridge, US, <sup>6</sup>Sanofi, Chilly-Mazarin, FR, <sup>7</sup>Sanofi, Cambridge, US, <sup>8</sup>Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, <sup>9</sup>The Institute of Cancer Research (ICR), London, GB
- 12:45 - 12:45 **813P - Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment**  
D. Robbrecht<sup>1</sup>, R. Van Soest<sup>2</sup>, I. Tannock<sup>3</sup>, S. Oudard<sup>4</sup>, B. Tombal<sup>5</sup>, M. Eisenberger<sup>6</sup>, F. Mercier<sup>7</sup>, R. De Wit<sup>2</sup>, <sup>1</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>2</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>3</sup>Princess Margaret Hospital, Toronto, CA, <sup>4</sup>Hopital European George Pompidou, Paris, FR, <sup>5</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>6</sup>Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, <sup>7</sup>Sanofi, Charlotte, FR
- 12:45 - 12:45 **814P - Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects - a multicentre retrospective analysis**  
S. Gillessen<sup>1</sup>, S. Schmid<sup>2</sup>, H. Beltran<sup>3</sup>, D. Almeida<sup>4</sup>, N. Mehra<sup>5</sup>, P. Lavaud<sup>6</sup>, R. Morales Barrera<sup>7</sup>, D. Pignataro<sup>8</sup>, E. Castro Marcos<sup>9</sup>, V. Conteduca<sup>10</sup>, E. Efsthathiou<sup>11</sup>, H.M.L. Le<sup>12</sup>, C. Pezaro<sup>13</sup>, H. Suzuki<sup>14</sup>, A. Zivi<sup>15</sup>, D. Klingbiel<sup>16</sup>, A. Omlin<sup>2</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>3</sup>Weill Cornell Medical College, New York, US, <sup>4</sup>Hospital São Jose - Beneficencia Portuguesa de São Paulo, Sao Paulo, BR, <sup>5</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>6</sup>IGR - Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, <sup>9</sup>CNIO- Spanish National Cancer Center, Madrid, ES, <sup>10</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>11</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>12</sup>Guy's and St.Thomas Hospital, London, AE, <sup>13</sup>Eastern Health, Box Hill, AU, <sup>14</sup>Toho University Sakura Medical Center, Tokio, JP, <sup>15</sup>Dr. Andrea Zivi, Roma, IT, <sup>16</sup>SAKK, Bern, CH
- 12:45 - 12:45 **815P - Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients: results from CAPRI**  
M. Kuppen<sup>1</sup>, H. Westgeest<sup>2</sup>, A.J.M. Van Den Eertwegh<sup>3</sup>, J. Van Moorselaar<sup>3</sup>, N. Mehra<sup>4</sup>, I. Van Oort<sup>4</sup>, A. Van Den Bergh<sup>5</sup>, J.L. Coenen<sup>6</sup>, K. Aben<sup>7</sup>, R. Somford<sup>8</sup>, J. Lavalaye<sup>9</sup>, A. Bergman<sup>10</sup>, C. Uyl-De Groot<sup>11</sup>, W. Gerritsen<sup>4</sup>, <sup>1</sup>Erasmus School of Health Policy and Management, Rotterdam, NL, <sup>2</sup>Amphia Ziekenhuis-location Langendijk, Breda, NL, <sup>3</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>4</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>5</sup>UMCG, Groningen, NL, <sup>6</sup>Isala Klinieken, Zwolle, NL, <sup>7</sup>Comprehensive cancer centre, Nijmegen, NL, <sup>8</sup>Canisius Wilhelmina Ziekenhuis, Nijmegen, NL, <sup>9</sup>Antonius Ziekenhuis, Nieuwegein, NL, <sup>10</sup>Division of Internal Medicine (MOD) and Oncogenomics, Amsterdam, NL, <sup>11</sup>Institute for Medical Technology Assessment, Erasmus University, Rotterdam, NL

- 12:45 - 12:45 **816P - Androgen Decline and Outcome in Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel (Doc), Prednisone +/- Bevacizumab (B)**  
C. Ryan<sup>1</sup>, S. Dutta<sup>2</sup>, W. Kelly<sup>3</sup>, M. Morris<sup>4</sup>, M.-E. Taplin<sup>5</sup>, S. Halabi<sup>2</sup>, <sup>1</sup>Masonic Cancer Center, Minneapolis, US, <sup>2</sup>Duke University, Durham, US, <sup>3</sup>Thomas Jefferson University, Philadelphia, US, <sup>4</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>5</sup>Dana-Farber Cancer Institute, Boston, US
- 12:45 - 12:45 **817P - Cabazitaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) clinical trials compared to usual care in CAPRI: an observational study in the Netherlands.**  
H. Westgeest<sup>1</sup>, M. Kuppen<sup>2</sup>, A. Van Den Eertwegh<sup>3</sup>, J. Van Moorselaar<sup>4</sup>, N. Mehra<sup>5</sup>, I. Van Oort<sup>5</sup>, A. Van Den Bergh<sup>6</sup>, J.L. Coenen<sup>7</sup>, K. Aben<sup>8</sup>, R. Somford<sup>9</sup>, R. De Wit<sup>10</sup>, A. Bergman<sup>11</sup>, J. Lavalaye<sup>12</sup>, C. Uyl-De Groot<sup>13</sup>, W. Gerritsen<sup>5</sup>, <sup>1</sup>Amphia Ziekenhuis-location Langendijk, Breda, NL, <sup>2</sup>Erasmus School of Health Policy and Management, Rotterdam, NL, <sup>3</sup>VU Medical Center, Amsterdam, NL, <sup>4</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>5</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>6</sup>UMCG, Groningen, NL, <sup>7</sup>Isala Klinieken, Zwolle, NL, <sup>8</sup>Comprehensive cancer centre, Nijmegen, NL, <sup>9</sup>Canisius Wilhelmina Ziekenhuis, Nijmegen, NL, <sup>10</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>11</sup>Division of Internal Medicine (MOD) and Oncogenomics, Amsterdam, NL, <sup>12</sup>Antonius Ziekenhuis, Nieuwegein, NL, <sup>13</sup>Institute for Medical Technology Assessment, Erasmus University, Rotterdam, NL
- 12:45 - 12:45 **818P - Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry**  
Z. Malik<sup>1</sup>, A. Pichler<sup>2</sup>, G. Di Lorenzo<sup>3</sup>, U. De Giorgi<sup>4</sup>, S. Hitier<sup>5</sup>, E. Ecstein-Fraisse<sup>6</sup>, A. Ozatilgan<sup>7</sup>, J. Carles<sup>8</sup>, <sup>1</sup>The Clatterbridge Cancer Centre, Wirral, GB, <sup>2</sup>Landeskrankenhaus LKH Leoben, Leoben, AT, <sup>3</sup>AOU Policlinico Federico II, Napoli, IT, <sup>4</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>5</sup>Sanofi, Chilly-Mazarin, FR, <sup>6</sup>Sanofi, Paris, FR, <sup>7</sup>Sanofi, Cambridge, US, <sup>8</sup>Vall Hebron Institute of Oncology, Barcelona, ES
- 12:45 - 12:45 **819P - Prognostic associations of early prostate-specific antigen (PSA) changes in patients with Metastatic Castration-resistant Prostate Cancer treated with with abiraterone acetate or enzalutamide**  
F. López Campos<sup>1</sup>, I. Moreno<sup>2</sup>, A. Conde-Moreno<sup>3</sup>, A. Gómez-Iturriaga<sup>4</sup>, M. Ruiz Vico<sup>5</sup>, N. Romero Laorden<sup>6</sup>, I. Henríquez López<sup>7</sup>, P. Peleteiro Higuero<sup>8</sup>, R. Lozano Mejorada<sup>9</sup>, T. Piquer<sup>10</sup>, M. Couselo<sup>11</sup>, J. Gómez Ramos<sup>7</sup>, J. Navarro<sup>11</sup>, P. Barrionuevo Castillo<sup>1</sup>, R. García<sup>12</sup>, R. Villatoro<sup>13</sup>, A. Montesa<sup>14</sup>, M. Saez<sup>15</sup>, B. Herrera<sup>14</sup>, E. Castro Marcos<sup>6</sup>, <sup>1</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>2</sup>Hospital Universitario Virgen de la Victoria, Malaga, ES, <sup>3</sup>Hospital Universitario y Politécnico La Fe, Valencia, ES, <sup>4</sup>Hospital de Cruces, Baracaldo, ES, <sup>5</sup>Hospital Regional Universitario Carlos Haya, Malaga, ES, <sup>6</sup>CNIO- Spanish National Cancer Center, Madrid, ES, <sup>7</sup>Hospital Universitario San Joan de Reus, Reus, ES, <sup>8</sup>Hospital Clínico Universitario De Santiago de Compostela, Santiago de Compostela, ES, <sup>9</sup>Hospital Universitario de Salamanca, Salamanca, ES, <sup>10</sup>Hospital Provincial de Castellón, Castellón, ES, <sup>11</sup>Hospital Central de la Defensa Gómez Ulla, Madrid, ES, <sup>12</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>13</sup>Hospital Costa del Sol, Malaga, ES, <sup>14</sup>Hospitales Universitarios Virgen de la Victoria y Regional de



Málaga, Malaga, ES, <sup>15</sup>H Universitarios Virgen de la victoria y Regional de Málaga, Malaga, ES

- 12:45 - 12:45 **820P - Cabazitaxel under routine conditions for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) - Interim results of the non-interventional SCOPE study.**  
J. Gschwend<sup>1</sup>, C. Lange<sup>2</sup>, C. Bokemeyer<sup>3</sup>, <sup>1</sup>Klinikum Rechts der Isar, Munich, DE, <sup>2</sup>Medical Office Bernburg, Bernburg, DE, <sup>3</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
- 12:45 - 12:45 **821P - Kinetics of prostate-specific antigen (PSA) as a marker of abiraterone acetate (AA) efficacy in patients (p) with metastatic castrate-resistant prostate cancer (mCRPC)**  
S. España Fernandez<sup>1</sup>, J.M. Piulats<sup>2</sup>, N. Sala<sup>3</sup>, J.M. Velarde<sup>1</sup>, U. Ferrandiz<sup>1</sup>, O. Etxaniz Ulazia<sup>1</sup>, L. Heras Lopez<sup>4</sup>, M.P. Barretina Ginesta<sup>5</sup>, X. Garcia Del Muro<sup>6</sup>, A. Font<sup>1</sup>, <sup>1</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>2</sup>Catalan Institute of Oncology, Barcelona, ES, <sup>3</sup>ICO Girona, Hospital Josep Trueta, Girona, ES, <sup>4</sup>ICO, Barcelona, ES, <sup>5</sup>Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona, ES, <sup>6</sup>Institut Català d'Oncologia L'Hospitalet, Barcelona, ES
- 12:45 - 12:45 **822P - Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel.**  
J. Puente<sup>1</sup>, M.J. Mendez Vidal<sup>2</sup>, M. Saez<sup>3</sup>, A. Font Pous<sup>4</sup>, I. Duran Martinez<sup>5</sup>, D. Castellano Gauna<sup>6</sup>, M.J. Juan Fita<sup>7</sup>, C. Santander<sup>8</sup>, J. Arranz Arija<sup>9</sup>, A. Sanchez-Hernandez<sup>10</sup>, B. Mellado<sup>11</sup>, T. Alonso<sup>12</sup>, M.A. Gonzalez Del Alba Baamonde<sup>13</sup>, P. Maroto<sup>14</sup>, M. Lazaro<sup>15</sup>, E. Esteban<sup>16</sup>, J. Cassinello<sup>17</sup>, M.A. Climent Duran<sup>7</sup>, <sup>1</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>2</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>3</sup>H Universitarios Virgen de la victoria y Regional de Málaga, Malaga, ES, <sup>4</sup>Institut Català d' Oncologia, Badalona, ES, <sup>5</sup>Hospital Universitario Marques de Valdecilla, Santander, ES, <sup>6</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>7</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>8</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>9</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>10</sup>Hospital Provincial de Castellón, Castellon de la Plana, ES, <sup>11</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>12</sup>Hospital Ramón y Cajal, Madrid, ES, <sup>13</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>14</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>15</sup>Complejo Hospitalario Universitario de Vigo, Vigo, ES, <sup>16</sup>Hospital Universitario Central de Asturias, Oviedo, ES, <sup>17</sup>University General Hospital, Guadalajara, ES
- 12:45 - 12:45 **823P - Efficacy of therapies after progression to up-front Docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)**  
P. Gajate Borau<sup>1</sup>, A. Martin Marino<sup>2</sup>, I. Gallegos Sancho<sup>3</sup>, J.C. Villa Guzman<sup>4</sup>, A. Velastegui<sup>5</sup>, T. Alonso Gordo<sup>1</sup>, D. Castellano Gauna<sup>6</sup>, G. Rubio Romero<sup>7</sup>, A. Pinto Marin<sup>8</sup>, L. Villalobos Leon<sup>9</sup>, C. Maximiano Alonso<sup>10</sup>, M. Sotelo-Lezama<sup>11</sup>, M. Sereno Moyano<sup>12</sup>, J.F. Rodríguez<sup>13</sup>, C. Perezagua Marin<sup>14</sup>, J. Ballesteros<sup>15</sup>, D. Marrupe Gonzalez<sup>16</sup>, L. Rodriguez Lajusticia<sup>17</sup>, J.J. Tafalla García<sup>18</sup>, C. Aguado<sup>19</sup>, <sup>1</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>2</sup>Hospital Universitario Infanta Leonor, Madrid,



ES, <sup>3</sup>Complejo Asistencial de Segovia, Segovia, ES, <sup>4</sup>Hospital General Ciudad Real, Ciudad Real, ES, <sup>5</sup>Hospital Universitario Rey Juan Carlos, Móstoles (Madrid), ES, <sup>6</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>7</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>8</sup>Hospital Universitario La Paz, Madrid, ES, <sup>9</sup>Hospital Principe de Asturias, Madrid, ES, <sup>10</sup>Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, ES, <sup>11</sup>Hospital Infanta Cristina, Parla (Madrid), ES, <sup>12</sup>Hospital Infanta Sofia, Madrid, ES, <sup>13</sup>HM San Chinarro, Madrid, ES, <sup>14</sup>University Hospital del Henares, Coslada, ES, <sup>15</sup>Hospital Universitario del Sureste, Madrid, ES, <sup>16</sup>Hospital General de Mostoles, Mostoles, ES, <sup>17</sup>Hospital Universitario de Fuenlabrada, Madrid, ES, <sup>18</sup>Hospital Central de la Defensa, Madrid, ES, <sup>19</sup>Hospital Clinico Universitario San Carlos, Madrid, ES

12:45 - 12:45 **824P - Radium-223 (Ra-223) therapy after abiraterone (Abi): analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)**

K. Miller<sup>1</sup>, D. Heinrich<sup>2</sup>, J. O'Sullivan<sup>3</sup>, J. Carles<sup>4</sup>, M. Wirth<sup>5</sup>, S. Nilsson<sup>6</sup>, L. Huang<sup>7</sup>, J. Kalinovsky<sup>8</sup>, A. Heidenreich<sup>9</sup>, F. Saad<sup>10</sup>, <sup>1</sup>Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, <sup>2</sup>Akershus University Hospital, Lørenskog, NO, <sup>3</sup>Queen's University Belfast, Belfast, GB, <sup>4</sup>Vall Hebron Institute of Oncology, Barcelona, ES, <sup>5</sup>Technical University Dresden, Dresden, DE, <sup>6</sup>Karolinska University Hospital, Stockholm, SE, <sup>7</sup>Bayer HealthCare Pharmaceuticals, Whippany, US, <sup>8</sup>Bayer Consumer Care AG, Basel, CH, <sup>9</sup>University Hospital Cologne, Cologne, DE, <sup>10</sup>Hospital St. Luc du CHUM, Montreal, CA

12:45 - 12:45 **825P - Randomized Phase II Trial of Radium-223 (RA) plus Enzalutamide (EZ) vs. EZ alone in Metastatic Castration Refractory Prostate Cancer (mCRPC)**

B. Maughan<sup>1</sup>, A. Hahn<sup>2</sup>, J. Hoffman<sup>1</sup>, K. Morton<sup>1</sup>, S. Gupta<sup>1</sup>, J. Batten<sup>1</sup>, J. Thorley<sup>1</sup>, J. Hawks<sup>1</sup>, G. Nachaegari<sup>1</sup>, R. Nussenzweig<sup>1</sup>, K. Boucher<sup>1</sup>, N. Agarwal<sup>1</sup>, <sup>1</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>2</sup>University of Utah, Salt Lake City, US

12:45 - 12:45 **826P - Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE**

C. Sternberg<sup>1</sup>, B. Tombal<sup>2</sup>, K. Miller<sup>3</sup>, F. Saad<sup>4</sup>, O. Sartor<sup>5</sup>, J.P. Sade<sup>6</sup>, C. Logothetis<sup>7</sup>, J. Bellmunt<sup>8</sup>, S. Dizdarevic<sup>9</sup>, L. Harshman<sup>10</sup>, J. Logue<sup>11</sup>, S. Baldari<sup>12</sup>, T. Richardson<sup>13</sup>, D. Bottomley<sup>14</sup>, M. Schostak<sup>15</sup>, I. Bayh<sup>16</sup>, J. Kalinovsky<sup>17</sup>, C. Higano<sup>18</sup>, <sup>1</sup>San Camillo Forlanini Hospital, Rome, IT, <sup>2</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>3</sup>Charité Berlin, Berlin, DE, <sup>4</sup>Hospital St. Luc du CHUM, Montreal, CA, <sup>5</sup>Tulane Medical School, New Orleans, US, <sup>6</sup>Instituto Alexander Fleming, Buenos Aires, AR, <sup>7</sup>MD Anderson Cancer Center, Houston, US, <sup>8</sup>Hospital del Mar, Barcelona, ES, <sup>9</sup>Brighton and Sussex University Hospitals NHS Trust, Brighton, GB, <sup>10</sup>Dana-Farber Cancer Institute, Boston, US, <sup>11</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>12</sup>University of Messina, Messina, IT, <sup>13</sup>Wichita Urology, Wichita, US, <sup>14</sup>St. James's Institute of Oncology, Leeds, GB, <sup>15</sup>University Hospital Magdeburg, Magdeburg, DE, <sup>16</sup>SBU Oncology, Pharmaceuticals, Wuppertal, DE, <sup>17</sup>Bayer Consumer Care AG, Basel, CH, <sup>18</sup>University of Washington, Seattle, US

- 12:45 - 12:45 **827P - Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)**
- C. Higano<sup>1</sup>, B. Tombal<sup>2</sup>, K. Miller<sup>3</sup>, F. Saad<sup>4</sup>, O. Sartor<sup>5</sup>, K. Tangirala<sup>6</sup>, X. Jiao<sup>7</sup>, J. Kalinovsky<sup>8</sup>, C. Sternberg<sup>9</sup>, <sup>1</sup>University of Washington Medical Center, Seattle, US, <sup>2</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>3</sup>Charité Berlin, Berlin, DE, <sup>4</sup>Hospital St. Luc du CHUM, Montreal, CA, <sup>5</sup>Tulane Medical School, New Orleans, US, <sup>6</sup>Bayer Healthcare, Whippany, US, <sup>7</sup>Bayer U.S. LLC, Pharmaceuticals, Whippany, US, <sup>8</sup>Bayer Consumer Care AG, Basel, CH, <sup>9</sup>San Camillo Forlanini Hospital, Rome, IT
- 12:45 - 12:45 **828P - Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, non-interventional study (PARABO)**
- T. Poeppel<sup>1</sup>, S. Eschmann<sup>2</sup>, A. Werner<sup>3</sup>, I. Selinski<sup>4</sup>, M.-O. Möllers<sup>5</sup>, T. Neußer<sup>6</sup>, A. Benson<sup>7</sup>, J. Kalinovsky<sup>8</sup>, H. Palmedo<sup>9</sup>, <sup>1</sup>University Hospital Essen, Essen, DE, <sup>2</sup>Marienhospital, Stuttgart, DE, <sup>3</sup>Radiology Schwetzingen, Schwetzingen, DE, <sup>4</sup>Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, DE, <sup>5</sup>Prof. Dr. Uhlenbrock & Partner, Dortmund, DE, <sup>6</sup>Bayer Vital GmbH, Leverkusen, DE, <sup>7</sup>Bayer HealthCare, Whippany, US, <sup>8</sup>Bayer Consumer Care Switzerland, Basel, CH, <sup>9</sup>Nuclear Medicine Center for Radiology, Bonn, DE
- 12:45 - 12:45 **829P - Pain and quality of life in metastasized Castration Resistant Prostate Cancer patients treated with Radium-223 (ROTOR registry); a prospective observational registry in a non-study population**
- R. Louhanepessy<sup>1</sup>, S. Badrising<sup>2</sup>, V. Vd Noort<sup>3</sup>, J.L. Coenen<sup>4</sup>, A. Oostdijk<sup>4</sup>, P. Hamberg<sup>5</sup>, J.M. Zuetenhorst<sup>5</sup>, A. Beeker<sup>6</sup>, N. Wagenaar<sup>7</sup>, M. Lam<sup>8</sup>, F. Celik<sup>9</sup>, E. Vegt<sup>3</sup>, W. Zwart<sup>10</sup>, A. Bergman<sup>10</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup>Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, NL, <sup>4</sup>Isala Klinieken, Zwolle, NL, <sup>5</sup>St Franciscus Gasthuis, Rotterdam, NL, <sup>6</sup>Spaarne Ziekenhuis, Hoofddorp, NL, <sup>7</sup>Ziekenhuisgroep Twente, Hengelo, NL, <sup>8</sup>University Medical Center Utrecht, Utrecht, NL, <sup>9</sup>Deventer Ziekenhuis, Deventer, NL, <sup>10</sup>Division of Internal Medicine (MOD) and Oncogenomics, Amsterdam, NL
- 12:45 - 12:45 **830P - Synthetic DNA Immunotherapy in Biochemically Relapsed Prostate Cancer**
- N. Shore<sup>1</sup>, E. Heath<sup>2</sup>, L. Nordquist<sup>3</sup>, H. Cheng<sup>4</sup>, K. Bhatt<sup>5</sup>, M. Morrow<sup>6</sup>, T. McMullan<sup>6</sup>, K. Kraynyak<sup>6</sup>, J. Lee<sup>6</sup>, B. Sacchetta<sup>6</sup>, L. Liu<sup>6</sup>, S. Rosencranz<sup>6</sup>, S. Tagawa<sup>7</sup>, L. Appleman<sup>8</sup>, R. Tutrone<sup>9</sup>, J. Garcia<sup>10</sup>, Y. Whang<sup>11</sup>, W. Kelly<sup>12</sup>, I. Csiki<sup>6</sup>, M. Bagarazzi<sup>13</sup>, <sup>1</sup>Medical Director, Myrtu Beach, US, <sup>2</sup>Karmanos Cancer Center, Detroit, US, <sup>3</sup>Urology Cancer Center and GU Research Network, Omaha, US, <sup>4</sup>University of Washington School of Medicine, seattle, US, <sup>5</sup>Inovio Pharmaceuticals Inc, Plymouth Meeting, US, <sup>6</sup>Inovio Pharmaceuticals, Inc., Plymouth Meeting, US, <sup>7</sup>Weill Cornell Medical College, New York, US, <sup>8</sup>University of Pittsburgh Cancer Institute, Pittsburgh, US, <sup>9</sup>Chesapeake Urology Associates, Towson, US, <sup>10</sup>Lineberger Comprehensive Cancer Center, Cleveland, US, <sup>11</sup>Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>12</sup>Thomas Jefferson University, philadelphia, US, <sup>13</sup>Inovio, Plymouth Meeting, US

- 12:45 - 12:45 **831P - Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer - final analysis**  
R. Tauber<sup>1</sup>, K. Knorr<sup>1</sup>, S. Schwaiger<sup>1</sup>, M. Retz<sup>1</sup>, T. Maurer<sup>1</sup>, C. D'Alessandria<sup>1</sup>, H.-J. Wester<sup>2</sup>, J. Gschwend<sup>1</sup>, W. Weber<sup>1</sup>, M. Schwaiger<sup>1</sup>, M. Heck<sup>1</sup>, M. Eiber<sup>1</sup>, <sup>1</sup>Klinikum rechts der Isar TUM, Muenchen, DE, <sup>2</sup>Technical University Munich, Munich, DE
- 12:45 - 12:45 **832P - Association Between Patient Reported Quality of Life (QOL) and Survival: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer**  
A. Morgans<sup>1</sup>, Y.-H. Chen<sup>2</sup>, D. Jerrard<sup>3</sup>, M. Carducci<sup>4</sup>, R. Dipaola<sup>5</sup>, L. Wagner<sup>6</sup>, D. Cella<sup>7</sup>, C. Sweeney<sup>8</sup>, <sup>1</sup>Northwestern University Feinberg School of Medicine, Chicago, US, <sup>2</sup>ECOG, Boston, US, <sup>3</sup>University of Wisconsin, Madison, US, <sup>4</sup>Johns Hopkins University, Baltimore, US, <sup>5</sup>University of Kentucky, Lexington, US, <sup>6</sup>Wake Forest University School of Medicine, Winston-Salem, US, <sup>7</sup>Northwestern University, Chicago, US, <sup>8</sup>Dana-Farber Cancer Institute, Boston, US
- 12:45 - 12:45 **833P - AZD8186, a potent and selective inhibitor of PI3K&&**  
J. De Bono<sup>1</sup>, A. Hansen<sup>2</sup>, A. Choudhury<sup>3</sup>, N. Cook<sup>4</sup>, E. Heath<sup>5</sup>, C. Higano<sup>6</sup>, M. Linch<sup>7</sup>, J. Martin-Liberal<sup>8</sup>, D. Rathkopf<sup>9</sup>, K. Wisinski<sup>10</sup>, S. Barry<sup>11</sup>, E. De Bruin<sup>11</sup>, W. Brugger<sup>12</sup>, S. Colebrook<sup>13</sup>, T. Klinowska<sup>11</sup>, M. Moschetta<sup>13</sup>, P. Mortimer<sup>14</sup>, L. Siu<sup>15</sup>, G. Shapiro<sup>3</sup>, <sup>1</sup>The Institute of Cancer Research (ICR), London, GB, <sup>2</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>3</sup>Dana-Farber Cancer Institute, Boston, US, <sup>4</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>5</sup>Karmanos Cancer Center, Detroit, US, <sup>6</sup>University of Washington, Seattle, US, <sup>7</sup>UCL Cancer Institute/Paul O'Gorman Building, London, GB, <sup>8</sup>Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, <sup>9</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>10</sup>University of Wisconsin-Madison, Madison, US, <sup>11</sup>AstraZeneca, Cambridge, GB, <sup>12</sup>AstraZeneca UK, Melbourn, GB, <sup>13</sup>AstraZeneca UK, Cambridge, GB, <sup>14</sup>AstraZeneca Academy House, Cambridge, GB, <sup>15</sup>Princess Margaret Hospital, Toronto, CA
- 12:45 - 12:45 **834P - Interim Results of a Phase 1b Study of Niraparib plus Androgen Receptor-Targeted Therapy in Men with Metastatic Castration-Resistant Prostate Cancer**  
F. Saad<sup>1</sup>, K. Chi<sup>2</sup>, N. Shore<sup>3</sup>, J. Graff<sup>4</sup>, E. Posadas<sup>5</sup>, S. Freeman<sup>6</sup>, J. Tryon<sup>7</sup>, G. Trudel<sup>6</sup>, J. De Jong<sup>8</sup>, J. Meltzer<sup>7</sup>, X. Zhao<sup>9</sup>, N. Tran<sup>6</sup>, A. Rezazadeh<sup>10</sup>, <sup>1</sup>Hospital St. Luc du CHUM, Montreal, CA, <sup>2</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>3</sup>Medical Director, Myrtu Beach, US, <sup>4</sup>Oregon Health Science University, Portland, US, <sup>5</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>6</sup>Janssen R&D, Los Angeles, US, <sup>7</sup>Janssen R&D, Raritan, US, <sup>8</sup>Janssen R&D, San Diego, US, <sup>9</sup>Janssen R&D, San Francisco, US, <sup>10</sup>Norton Healthcare, Louisville, US
- 12:45 - 12:45 **835P - CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer**  
R. Oksala<sup>1</sup>, K. Räsänen<sup>2</sup>, M. Karimaa<sup>2</sup>, R. Riikonen<sup>2</sup>, M. Ramela<sup>2</sup>, P. Vehmaan-Kreula<sup>2</sup>, O. Simola<sup>2</sup>, P. Rummakko<sup>2</sup>, G. Wohlfahrt<sup>2</sup>, M. Mustonen<sup>3</sup>, <sup>1</sup>Orion Corporate, Orion Pharma, Turku, FI, <sup>2</sup>Orion Pharma, Espoo, FI, <sup>3</sup>Orion Corporation Finland, Espoo, FI



- 12:45 - 12:45 **837P - Prediction of Prostate Cancer Gleason Score Upgrading from Biopsy to Radical Prostatectomy (RP) using a Validated 17-Gene Panel Assay**  
J. Cullen<sup>1</sup>, H. Lawrence<sup>2</sup>, Y. Chen<sup>3</sup>, R. Lu<sup>2</sup>, S. Srivastava<sup>3</sup>, I. Rosner<sup>3</sup>, T. Brand<sup>3</sup>, I. Sesterhenn<sup>3</sup>, <sup>1</sup>Center for Prostate Disease Center, Rockville, US, <sup>2</sup>Genomic Health, Redwood City, US, <sup>3</sup>Center for Prostate Disease Research, USUHS, Rockville, US
- 12:45 - 12:45 **836P - Use of Nuclear-Localized Androgen Receptor Splice Variant 7 Protein in CTCs after 1st Androgen Receptor Signaling Inhibitor (ARSi) as a Predictive Biomarker for Overall Survival on a Second ARSi or Taxane Chemotherapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)**  
H. Scher<sup>1</sup>, R. Graf<sup>2</sup>, M. Hulling<sup>1</sup>, E. Carbone<sup>1</sup>, R. Dittamore<sup>3</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>Epic Sciences, Inc., San Diego, US, <sup>3</sup>Epic Sciences, San Diego, US
- 12:45 - 12:45 **838P - PI3K/AKT pathway deleterious mutations in lethal prostate cancer**  
P. Rescigno<sup>1</sup>, M. Rediti<sup>2</sup>, D. Dolling<sup>3</sup>, D.N. Rodrigues<sup>2</sup>, D. Bianchini<sup>2</sup>, R. Riisnaes<sup>4</sup>, C. Messina<sup>2</sup>, M. Barrero<sup>2</sup>, A. Petremolo<sup>2</sup>, A. Sharp<sup>2</sup>, S. Sumanasuriya<sup>2</sup>, G. Seed<sup>3</sup>, I. Figueiredo<sup>3</sup>, S. Miranda<sup>3</sup>, J. Goodall<sup>3</sup>, J. Mateo<sup>3</sup>, R. Chandler<sup>2</sup>, W. Yuan<sup>3</sup>, S. Carreira<sup>3</sup>, J. De Bono<sup>5</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>2</sup>The Royal Marsden Hospital and Institute of Cancer Research, London, GB, <sup>3</sup>The Institute of Cancer Research, London, GB, <sup>4</sup>The Royal MaThe Institute of Cancer Research, London, GB, <sup>5</sup>The Institute of Cancer Research (ICR), London, GB
- 12:45 - 12:45 **842P - CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)**  
M. Morris<sup>1</sup>, N. Vogelzang<sup>2</sup>, O. Sartor<sup>3</sup>, A. Armour<sup>4</sup>, R. Messmann<sup>5</sup>, M. Groaning<sup>5</sup>, A. Robarts<sup>6</sup>, A. Tolcher<sup>7</sup>, M. Gordon<sup>8</sup>, H. Babiker<sup>9</sup>, P. Kuo<sup>9</sup>, M. Kearney<sup>10</sup>, A. Jendrisak<sup>10</sup>, Y. Wang<sup>10</sup>, M. Landers<sup>10</sup>, D. Petrylak<sup>11</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>US Oncology Research c/o Comprehensive Cancer Crts of NV, Las Vegas, US, <sup>3</sup>Tulane Medical School, New Orleans, US, <sup>4</sup>Endocyte, Indianapolis, US, <sup>5</sup>Endocyte, West Lafayette, US, <sup>6</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>7</sup>NEXT OncologyTM, San Antonio, US, <sup>8</sup>HonorHealth Virginia G Piper Cancer Care Network, Scottsdale, US, <sup>9</sup>University of Arizona Cancer Center, Tucson, US, <sup>10</sup>Epic Sciences, San Diego, US, <sup>11</sup>Yale University School of Medicine Medical Oncology, New Haven, US
- 12:45 - 12:45 **843P - The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study**  
T. Loubersac<sup>1</sup>, S. Chakak<sup>2</sup>, M. Nguile-Makao<sup>2</sup>, V. Fradet<sup>2</sup>, P. Toren<sup>2</sup>, <sup>1</sup>CHU de Nantes, Nantes, FR, <sup>2</sup>CHU Hotel dieu quebec, Quebec city, CA
- 12:45 - 12:45 **845P - Phase 3 Double-Blind Study Evaluating Lens Opacifications (LO) in Patients with Nonmetastatic Prostate Cancer (PCa) Receiving Denosumab (Dmab) for Bone Loss Due to Androgen Deprivation Therapy (ADT)**  
S. Tagawa<sup>1</sup>, T. Dai<sup>2</sup>, D. Jandial<sup>2</sup>, <sup>1</sup>Weill Cornell Medical College, New York, US, <sup>2</sup>Amgen Inc., Thousand Oaks, US
- 12:45 - 12:45 **844P - The Clinical Impact of Targeted Next Generation Sequencing (tNGS) In**



**the Treatment of Metastatic Prostate Cancer**

P.M. Coelho Barata<sup>1</sup>, P. Mendiratta<sup>2</sup>, M. Sadaps<sup>2</sup>, S. Klek<sup>2</sup>, M. Ornstein<sup>2</sup>, T. Gilligan<sup>2</sup>, P. Grivas<sup>2</sup>, B. Rini<sup>2</sup>, D. Sohal<sup>2</sup>, J. Garcia<sup>2</sup>, <sup>1</sup>Hospital de Sto. Antonio Capuchos, Lisbon, PT, <sup>2</sup>Taussig Cancer Institute Cleveland Clinic, Cleveland, US

12:45 - 12:45 **840P - Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).**

C. Reuter<sup>1</sup>, S. Brunotte<sup>1</sup>, P. Ivanyi<sup>1</sup>, M. Morgan<sup>1</sup>, V. Grünwald<sup>2</sup>, <sup>1</sup>Hannover Medical School, Hannover, DE, <sup>2</sup>Medical School Hannover, Hannover, DE

12:45 - 12:45 **846P - Patterns of Therapy in Pelvic Lymph Node Positive Prostate Cancer in Europe and Asia: A Real-world Data Analysis**

M. Prentice<sup>1</sup>, S. Mpima<sup>2</sup>, P. Nasuti<sup>2</sup>, A. Martinez-Pinillos<sup>2</sup>, I. Wong<sup>3</sup>, K. Durno<sup>1</sup>, R. Davda<sup>1</sup>, H. Payne<sup>1</sup>, <sup>1</sup>University College London Hospital UCLH NHS Foundation Trust, London, GB, <sup>2</sup>IQVIA, London, GB, <sup>3</sup>UCL School of Pharmacy, London, GB

12:45 - 12:45 **841P - Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC)**

A. Hahn<sup>1</sup>, A. Kapron<sup>2</sup>, J. Boyle<sup>2</sup>, W. Kohlmann<sup>3</sup>, A. Poole<sup>3</sup>, D. Gill<sup>3</sup>, S. Greenberg<sup>3</sup>, P. Hale<sup>3</sup>, C. Teerlink<sup>2</sup>, B. Maughan<sup>3</sup>, L. Cannon-Albright<sup>2</sup>, N. Agarwal<sup>1</sup>, K. Cooney<sup>3</sup>, <sup>1</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>2</sup>University of Utah, Salt Lake City, US, <sup>3</sup>Huntsman Cancer Institute/University of Utah, Salt Lake City, US

12:45 - 12:45 **848P - Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems**

J. Hornberger<sup>1</sup>, R. Graf<sup>2</sup>, M. Hulling<sup>3</sup>, G. Attard<sup>4</sup>, A. Allan<sup>5</sup>, R. Dittamore<sup>6</sup>, H. Scher<sup>3</sup>, <sup>1</sup>Genomic Health, Redwood City, US, <sup>2</sup>Epic Sciences, Inc., San Diego, US, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>4</sup>The Institute of Cancer Research and The Royal Marsden, London, GB, <sup>5</sup>Western University, London, CA, <sup>6</sup>Epic Sciences, San Diego, US

12:45 - 12:45 **853P - Long-term Adverse Effects (AEs) after dose-escalation with High-Dose Rate Brachytherapy in combination with External Beam Radiation Therapy (BT/RT). Comparison to External Beam Radiation Therapy alone (RT)**

T. Wedde<sup>1</sup>, S. Fosså<sup>2</sup>, A. Dahl<sup>1</sup>, M.-B. Schulz<sup>1</sup>, W. Lilleby<sup>3</sup>, <sup>1</sup>Oslo University Hospital, Oslo, NO, <sup>2</sup>Oslo University Hospital Rikshospitalet - Radiumhospitalet Trust, Oslo, NO, <sup>3</sup>University of Oslo, Institute of Clinical medicine, Oslo, NO

12:45 - 12:45 **851P - Pharmacokinetic/Pharmacodynamic relationship of Enzalutamide and its active metabolite N-desmethyl Enzalutamide in metastatic castration-resistant prostate cancer patients**

M.-L. Joulia<sup>1</sup>, E. Carton Vienet Legue<sup>2</sup>, M. Allard<sup>3</sup>, O. Huillard<sup>3</sup>, M. Peyromaure<sup>3</sup>, M. Zerbib<sup>3</sup>, M. Vidal<sup>3</sup>, F. Goldwasser<sup>3</sup>, J. Alexandre<sup>4</sup>, B. Blanchet<sup>3</sup>, <sup>1</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>2</sup>Hôpitaux Paris Centre AP-HP, Paris, FR, <sup>3</sup>Hôpital Cochin, Paris, FR, <sup>4</sup>ONCO CARC CANCER, La Varenne Saint-Hilaire, FR

- 12:45 - 12:45 **849P - Quality of Docetaxel Toxicity Reporting for Castration Resistant Prostate Cancer (CRPC): A Systematic Review**  
S. Cheng<sup>1</sup>, M. Qureshi<sup>2</sup>, V. Arciero<sup>2</sup>, K.K.-W. Chan<sup>3</sup>, U. Emmenegger<sup>1</sup>, <sup>1</sup>Sunnybrook Odette Cancer Center, Sunnybrook HSC, Toronto, CA, <sup>2</sup>Sunnybrook Odette Cancer Center, Toronto, CA, <sup>3</sup>Sunnybrook Hospital, Toronto, CA
- 12:45 - 12:45 **839P - Clinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)**  
V. Conteduca<sup>1</sup>, C. Oromendia<sup>2</sup>, M. Sigouros<sup>2</sup>, A. Sborner<sup>2</sup>, D.M. Nanus<sup>2</sup>, S. Tagawa<sup>2</sup>, K. Ballman<sup>2</sup>, H. Beltran<sup>2</sup>, <sup>1</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>2</sup>Weill Cornell Medical College, New York, US
- 12:45 - 12:45 **850P - Intermittent Short Course Enzalutamide in Biochemically Recurrent Prostate Cancer: Analysis of PSA Recovery, Testosterone Levels and Tolerability**  
M. Al Harthy<sup>1</sup>, H. Singh<sup>2</sup>, F. Karzai<sup>3</sup>, P. Arlen<sup>4</sup>, M. Theoret<sup>5</sup>, J. Marte<sup>1</sup>, M. Bilusic<sup>6</sup>, A. Couvillon<sup>1</sup>, H. Owens<sup>1</sup>, A. Hankin<sup>1</sup>, L. Cordes<sup>1</sup>, I. Rosner<sup>7</sup>, J. Strauss<sup>1</sup>, W. Figg<sup>3</sup>, J. Schlom<sup>1</sup>, W. Dahut<sup>1</sup>, J. Gulley<sup>1</sup>, R. Madan<sup>1</sup>, <sup>1</sup>National Cancer Institute, Bethesda, US, <sup>2</sup>Food and Drug Administration, Silver spring, US, <sup>3</sup>NCI /NIH, Bethesda, US, <sup>4</sup>Precision Biologics, Rockville, US, <sup>5</sup>Food and Drug Administration, Silver Spring, US, <sup>6</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>7</sup>Walter Reed Medical Center, Washington, US
- 12:45 - 12:45 **847P - The Prognostic Significance of the 2014 International Society of Urological Pathology (ISUP) Grading System in Patients with High-Risk Prostate Cancer**  
J. Liu, J. Zhao, West China Hospital, Sichuan University, Chengdu, CN
- 12:45 - 12:45 **854P - Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate (NEPC)**  
L. Apostolidis<sup>1</sup>, C. Nientiedt<sup>2</sup>, E. Winkler<sup>2</sup>, A. Berger<sup>2</sup>, C. Kratochwil<sup>1</sup>, A. Kaiser<sup>3</sup>, D. Jäger<sup>4</sup>, M. Hohenfellner<sup>1</sup>, C. Hüttenbrink<sup>3</sup>, S. Pahernik<sup>3</sup>, F. Distler<sup>3</sup>, C. Grüllich<sup>2</sup>, <sup>1</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>2</sup>National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, DE, <sup>3</sup>Klinikum Nürnberg, Paracelsus Medical University, Nürnberg, DE, <sup>4</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE
- 12:45 - 12:45 **852P - Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)**  
A. Tripathi<sup>1</sup>, J. Supko<sup>2</sup>, K. Gray<sup>3</sup>, Z. Melnick<sup>3</sup>, M.-E. Taplin<sup>3</sup>, A. Choudhury<sup>3</sup>, M. Pomerantz<sup>3</sup>, J. Bellmunt<sup>4</sup>, C. Yu<sup>3</sup>, Z. Sun<sup>5</sup>, S. Srinivas<sup>5</sup>, P. Kantoff<sup>3</sup>, C. Sweeney<sup>3</sup>, L. Harshman<sup>3</sup>, <sup>1</sup>Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, <sup>2</sup>Massachusetts general Hospital, Boston, US, <sup>3</sup>Dana-Farber Cancer Institute, Boston, US, <sup>4</sup>Hospital del Mar, Barcelona, ES, <sup>5</sup>Stanford University, Stanford, US
- 12:45 - 12:45 **855P - Effect of Prednisone on Docetaxel Pharmacokinetics in Metastatic Prostate Cancer: A Randomized Drug-drug Interaction Study.**  
B. Belderbos<sup>1</sup>, K. Hussaarts<sup>2</sup>, L. Van Harten<sup>2</sup>, E. Oomen-De Hoop<sup>2</sup>, P. De Bruijn<sup>2</sup>, P.

Hamberg<sup>3</sup>, R. Van Alphen<sup>4</sup>, B. Haberkorn<sup>5</sup>, R. Van Soest<sup>6</sup>, R. De Wit<sup>6</sup>, R. Mathijssen<sup>2</sup>,  
<sup>1</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>2</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>3</sup>St Franciscus Gasthuis, Rotterdam, NL, <sup>4</sup>Twee Steden Ziekenhuis, Tilburg, NL, <sup>5</sup>Maasstad, Rotterdam, NL, <sup>6</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL

12:45 - 12:45 **857P - United in Fight against prostate cancer registry (UFO): first results from a large, multi-center, prospective, longitudinal cohort study in Asia**

H. Uemura<sup>1</sup>, D. Ye<sup>2</sup>, R. Kanesvaran<sup>3</sup>, H. Zeng<sup>4</sup>, Y.-S. Pu<sup>5</sup>, E. Chiong<sup>6</sup>, B. Lojanapiwat<sup>7</sup>, S.K. Rawal<sup>8</sup>, B.H. Chung<sup>9</sup>, A.H.A. Razack<sup>10</sup>, Y.-S. Tsai<sup>11</sup>, Y. Liu<sup>12</sup>, M. Asinas-Tan<sup>13</sup>, W. Liu<sup>14</sup>, G.K.M. Low<sup>15</sup>, M. Van Kooten Losio<sup>16</sup>, <sup>1</sup>Kinki University Hospital, Osaka, JP, <sup>2</sup>Fudan University Shang Hai Cancer Center, Shang Hai, CN, <sup>3</sup>National Cancer Centre Singapore, Singapore, SG, <sup>4</sup>Sichuan University, Sichuan, CN, <sup>5</sup>National Taiwan University Hospital, Taiwan, TW, <sup>6</sup>National University Cancer Institute, Singapore, Singapore, SG, <sup>7</sup>Chiang Mai University, Chiang Mai, TH, <sup>8</sup>Rajeev Gandhi Cancer Institute, New Delhi, IN, <sup>9</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>10</sup>University of Malaya, Kuala Lumpur, MY, <sup>11</sup>National Cheng Kung University Hospital, Tainan, TW, <sup>12</sup>Epidemiology, Titusville, US, <sup>13</sup>Janssen Research and Development, Singapore, SG, <sup>14</sup>Janssen (China) Research & Development Center, Shanghai, CN, <sup>15</sup>Janssen Medical Affairs, Singapore, SG, <sup>16</sup>Janssen Cilag Australia, Macquarie Park, AU

12:45 - 12:45 **856P - Differences in treatment recommendations for advanced prostate cancer according to region and medical specialization - analysis of the APCCC 2017 voting results**

S. Fischer<sup>1</sup>, S. Gillessen<sup>2</sup>, M. Sydes<sup>3</sup>, A. Omlin<sup>1</sup>, <sup>1</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>3</sup>Institute of Clinical Trials and Methodology-UCL, London, GB

12:45 - 12:45 **858P - Deployment of advanced real-world data (RWD) analytics for the accelerated recruitment of patients into an ongoing metastatic castrate-resistant prostate cancer (mCRPC) trial, together with the development of a sophisticated patient referral network**

M. Cushion, IQVIA, London, GB

12:45 - 13:05 **859TiP - TALAPRO-1: An open-label, response rate phase 2 study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on 1 novel hormonal therapy (NHT)**

J. De Bono<sup>1</sup>, C. Higano<sup>2</sup>, F. Saad<sup>3</sup>, K. Miller<sup>4</sup>, M. Casey<sup>5</sup>, A. Czibere<sup>6</sup>, C. Healy<sup>7</sup>, K. Fizazi<sup>8</sup>, <sup>1</sup>The Institute of Cancer Research (ICR), London, GB, <sup>2</sup>University of Washington, Seattle, US, <sup>3</sup>Hospital St. Luc du CHUM, Montreal, CA, <sup>4</sup>Charité Berlin, Berlin, DE, <sup>5</sup>Pfizer Inc, Collegeville, US, <sup>6</sup>Merrimack Pharmaceuticals, Inc., New York, US, <sup>7</sup>Pfizer, Inc., Collegeville, US, <sup>8</sup>Gustave Roussy, Villejuif, FR

13:05 - 13:05 **860TiP - Phase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response**

M.J. Juan Fita<sup>1</sup>, L. Heras Lopez<sup>2</sup>, B. Mellado<sup>3</sup>, M.J. Mendez Vidal<sup>4</sup>, U. Anido<sup>5</sup>, D. Lorente<sup>6</sup>,



J.M. Sepulveda<sup>7</sup>, C. Alvarez<sup>8</sup>, <sup>1</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>2</sup>ICO, Barcelona, ES, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>5</sup>CHU Santiago, Santiago, ES, <sup>6</sup>HULa Fe, Valencia, ES, <sup>7</sup>Juan Manuel Sepúlveda, Valencia, ES, <sup>8</sup>HCU Asturias, Asturias, ES

13:05 - 13:05 **861TiP - Multimodality treatment for pN1 prostate cancer - Adding elective para-aortic radiation in the PART trial**

C. Berghen<sup>1</sup>, S. Joniau<sup>2</sup>, C. Draulans<sup>3</sup>, G. De Meerleer<sup>2</sup>, <sup>1</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>2</sup>University Hospitals Leuven, Leuven, BE, <sup>3</sup>University Hospitals of Leuven, Leuven, BE

13:05 - 13:05 **862TiP - ReCab II: A phase II trial of Cabazitaxel +/- Rhenium -188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment**

E. Bouman-Wammes<sup>1</sup>, J.M. Van Dodewaard-De Jong<sup>2</sup>, H. Bloemendal<sup>2</sup>, H. Verheul<sup>1</sup>, J.M.H. De Klerk<sup>3</sup>, A.J.M. Van Den Eertwegh<sup>1</sup>, <sup>1</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>2</sup>Meander Medical Center, Amersfoort, NL, <sup>3</sup>Meander Medical Center, AMERSFOORT, NL

13:05 - 13:05 **Genitourinary tumours, non-prostate**

13:05 - 13:05 **871P - KEYNOTE-427 Cohort A: Pembrolizumab Monotherapy as First-Line Therapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC)**

F. Donskov<sup>1</sup>, D. Mcdermott<sup>2</sup>, J. Lee<sup>3</sup>, C. Szczylik<sup>4</sup>, J. Malik<sup>5</sup>, B. Alekseev<sup>6</sup>, J. Larkin<sup>7</sup>, V.B. Matveev<sup>8</sup>, R. Airatovich Gafanov<sup>9</sup>, P. Tomczak<sup>10</sup>, S. Tykodi<sup>11</sup>, P. Geertsens<sup>12</sup>, P. Wiechno<sup>13</sup>, S.J. Shin<sup>14</sup>, F. Pouliot<sup>15</sup>, T. Alonso Gordo<sup>16</sup>, R. Kloss Silverman<sup>17</sup>, R. Perini<sup>17</sup>, C. Schloss<sup>17</sup>, M. Atkins<sup>18</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Beth Israel Deaconess Med. Center, Boston, US, <sup>3</sup>Asan Medical Center, Seoul, KR, <sup>4</sup>Wojskowy Instytut Medyczny, Warsaw, PL, <sup>5</sup>Edinburgh Cancer Centre, Edinburgh, GB, <sup>6</sup>Herzen Cancer Research Institute, Moscow, RU, <sup>7</sup>Institute of Cancer Research, London, GB, <sup>8</sup>N.N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>9</sup>Russian Scientific Center of Roentgenoradiology, Moscow, RU, <sup>10</sup>Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Poznań, PL, <sup>11</sup>Fred Hutchinson Cancer Research Center, Seattle, US, <sup>12</sup>Herlev Hospital, University of Copenhagen, Herlev, DK, <sup>13</sup>Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, PL, <sup>14</sup>Yonsei University College of Medicine, Seoul, KR, <sup>15</sup>Université Laval, Quebec, CA, <sup>16</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>17</sup>Merck & Co., Inc., Kenilworth, US, <sup>18</sup>Georgetown Lombardi Comprehensive Cancer Center, Washington, US

13:05 - 13:05 **872P - Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)**

N. Agarwal<sup>1</sup>, U. Vaishampayan<sup>2</sup>, M. Green<sup>3</sup>, F. Di Nucci<sup>4</sup>, P.-Y. Chang<sup>5</sup>, C. Scheffold<sup>6</sup>, S. Pal<sup>7</sup>, <sup>1</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>2</sup>Karmanos Cancer Center, Detroit, US, <sup>3</sup>Genentech, Inc., South San Francisco, US, <sup>4</sup>Genentech, South San Francisco, US, <sup>5</sup>Exelixis Inc., South San Francisco, US, <sup>6</sup>Exelixis, Inc., South San Francisco, US, <sup>7</sup>City of Hope, Duarte, US



- 13:05 - 13:05 **873P - Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): pooled analysis of IMmotion150 and IMmotion151**
- C. Suarez<sup>1</sup>, T. Choueiri<sup>2</sup>, D. McDermott<sup>3</sup>, B. Escudier<sup>4</sup>, M. Atkins<sup>5</sup>, T. Powles<sup>6</sup>, B. Rini<sup>7</sup>, R. Motzer<sup>8</sup>, S. Pal<sup>9</sup>, L. Fong<sup>10</sup>, U. De Giorgi<sup>11</sup>, Y. Wang<sup>12</sup>, T. Khaznadar<sup>13</sup>, F. Di Nucci<sup>14</sup>, C. Kaiser<sup>14</sup>, D. Tayama<sup>15</sup>, F. Donskov<sup>16</sup>, <sup>1</sup>Universitat Autònoma de Barcelona, Barcelona, ES, <sup>2</sup>Dana-Farber Cancer Institute, Boston, US, <sup>3</sup>Beth Israel Deaconess Med. Center, Boston, US, <sup>4</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>5</sup>Lombardi Cancer Center Georgetown University, Washington DC, US, <sup>6</sup>St. Bartholomew's Hospital, London, GB, <sup>7</sup>Taussig Cancer Institute Cleveland Clinic, Cleveland, US, <sup>8</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>9</sup>City of Hope, Duarte, US, <sup>10</sup>University of California, San Francisco, San Francisco, US, <sup>11</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>12</sup>Genetehc, Inc., South San Francisco, US, <sup>13</sup>F. Hoffmann-La Roche AG - Switzerland, Basel, CH, <sup>14</sup>Genentech, Inc., South San Francisco, US, <sup>15</sup>Genentech Inc. - Roche - USA, South San Francisco, US, <sup>16</sup>Aarhus University Hospital, Aarhus, DK
- 13:05 - 13:05 **874P - Treatment-Free Interval (TFI) Following Discontinuation of First-Line Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Advanced Renal Cell Carcinoma (aRCC): CheckMate 214 Analysis**
- D. McDermott<sup>1</sup>, B. Rini<sup>2</sup>, R. Motzer<sup>3</sup>, N. Tannir<sup>4</sup>, B. Escudier<sup>5</sup>, C. Kollmannsberger<sup>6</sup>, H. Hammers<sup>7</sup>, C. Porta<sup>8</sup>, S. George<sup>9</sup>, F. Donskov<sup>10</sup>, H. Gurney<sup>11</sup>, M.-O. Grimm<sup>12</sup>, M. Harrison<sup>13</sup>, T. Hutson<sup>14</sup>, J. Doan<sup>15</sup>, S. Yang<sup>16</sup>, S. Rao<sup>16</sup>, S. Mekan<sup>17</sup>, A. Ambavane<sup>18</sup>, T. Powles<sup>19</sup>, <sup>1</sup>Beth Israel Deaconess Med. Center, Boston, US, <sup>2</sup>Taussig Cancer Institute Cleveland Clinic, Cleveland, US, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>4</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>5</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>6</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>7</sup>University of Texas Southwestern Medical Center at Dallas, Dallas, US, <sup>8</sup>Ospedale San Matteo, Pavia, IT, <sup>9</sup>Roswell Park Cancer Institute, Buffalo, US, <sup>10</sup>Aarhus University Hospital, Aarhus, DK, <sup>11</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>12</sup>Universitätsklinikum Jena, Jena, DE, <sup>13</sup>Duke University Medical Center, Durham, US, <sup>14</sup>Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, <sup>15</sup>Bristol-Myers Squibb USA, Wallingford, US, <sup>16</sup>Bristol-Myers Squibb, Princeton, US, <sup>17</sup>Bristol-Myers Squibb Company, Lawrenceville, US, <sup>18</sup>Evidera Inc, London, GB, <sup>19</sup>Barts Cancer Institute, London, GB
- 13:05 - 13:05 **875P - Characterization of Response to Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Previously Untreated Advanced Renal Cell Carcinoma (aRCC): CheckMate 214**
- B. Rini<sup>1</sup>, N. Tannir<sup>2</sup>, B. Escudier<sup>3</sup>, D. McDermott<sup>4</sup>, M.-O. Grimm<sup>5</sup>, C. Porta<sup>6</sup>, T. Powles<sup>7</sup>, C. Kollmannsberger<sup>8</sup>, H. Gurney<sup>9</sup>, S. Tykodi<sup>10</sup>, M. Harrison<sup>11</sup>, D. Heng<sup>1</sup>, V. Grünwald<sup>12</sup>, T. Choueiri<sup>13</sup>, S. Mekan<sup>14</sup>, M.B. Mchenry<sup>14</sup>, H. Hammers<sup>15</sup>, R. Motzer<sup>16</sup>, S. George<sup>17</sup>, <sup>1</sup>Cleveland Clinic, Cleveland, US, <sup>2</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>3</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>4</sup>Beth Israel Deaconess Med. Center, Boston, US, <sup>5</sup>Universitätsklinikum Jena, Jena, DE, <sup>6</sup>Ospedale San Matteo, Pavia, IT, <sup>7</sup>Barts Cancer Institute, London, GB, <sup>8</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>9</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>10</sup>Fred Hutchinson Cancer Research Center, Seattle, US, <sup>11</sup>Duke University Medical Center, Durham, US, <sup>12</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>13</sup>Dana-Farber

Cancer Institute, Boston, US, <sup>14</sup>Bristol-Myers Squibb Company, Lawrenceville, US, <sup>15</sup>University of Texas Southwestern Medical Center at Dallas, Dallas, US, <sup>16</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>17</sup>Roswell Park Cancer Institute, Buffalo, US

- 13:05 - 13:05 **876P - A new prognostic model for overall survival (OS) in second line (2L) for metastatic renal cell carcinoma (mRCC): Development and external validation**  
L. Derosa<sup>1</sup>, M.A. Bayar<sup>1</sup>, L. Albiges<sup>1</sup>, G. Le Teuff<sup>1</sup>, B. Escudier<sup>2</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 13:05 - 13:05 **877P - First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase 1b JAVELIN Solid Tumor trial**  
U. Vaishampayan<sup>1</sup>, P. Schöffski<sup>2</sup>, A. Ravaud<sup>3</sup>, C. Borel<sup>4</sup>, T. Song<sup>5</sup>, S. Guenther<sup>6</sup>, J. Grewal<sup>5</sup>, J. Gulley<sup>7</sup>, <sup>1</sup>Karmanos Cancer Institute, Detroit, US, <sup>2</sup>University Hospitals Leuven, Leuven, BE, <sup>3</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>4</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>5</sup>EMD Serono, Billerica, US, <sup>6</sup>Merck KGaA, Darmstadt, DE, <sup>7</sup>National Cancer Institute, Bethesda, US
- 13:05 - 13:05 **878P - TiNivo: Tivozanib combined with nivolumab: safety and efficacy in patients with metastatic renal cell carcinoma (mRCC).**  
P. Barthelemy<sup>1</sup>, B. Escudier<sup>2</sup>, A. Ravaud<sup>3</sup>, S. Negrier<sup>4</sup>, M. Needle<sup>5</sup>, L. Albiges<sup>6</sup>, <sup>1</sup>C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, <sup>2</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>3</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>4</sup>Centre Léon Bérard, Lyon, FR, <sup>5</sup>AVEO Pharmaceuticals Inc, Cambridge, US, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR
- 13:05 - 13:05 **879P - Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)**  
B. Mcgregor<sup>1</sup>, A.-K. Lalani<sup>2</sup>, W. Xie<sup>1</sup>, J. Steinharter<sup>1</sup>, D. Martini<sup>3</sup>, P. Nuzzo<sup>1</sup>, N. Martinez Chanza<sup>1</sup>, L. Harshman<sup>4</sup>, M. Bilen<sup>5</sup>, T. Choueiri<sup>4</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>McMaster University, Hamilton, CA, <sup>3</sup>Emory University School of Medicine, Atlanta, US, <sup>4</sup>Dana-Farber Cancer Institute, Boston, US, <sup>5</sup>Emory University Winship Cancer Institute, Atlanta, US
- 13:05 - 13:05 **880P - Subgroups analysis and circulating biomarkers evaluation of RESORT trial: a randomized phase 2 study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of Sorafenib after metastasectomy**  
G. Procopio<sup>1</sup>, F. Cognetti<sup>2</sup>, R. Miceli<sup>3</sup>, M. Milella<sup>2</sup>, A. Mosca<sup>4</sup>, V. Chiuri<sup>5</sup>, A. Bearz<sup>6</sup>, F. Morelli<sup>7</sup>, C. Ortega<sup>8</sup>, F. Atzori<sup>9</sup>, R. Passalacqua<sup>10</sup>, R. Ratta<sup>11</sup>, F.G. De Braud<sup>1</sup>, V. Cappelletti<sup>1</sup>, E. Verzoni<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Istituto Nazionale Tumori Regina Elena, Rome, IT, <sup>3</sup>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>4</sup>Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, IT, <sup>5</sup>Ospedale Vito Fazzi, Lecce, IT, <sup>6</sup>National Institute for Cancer Research, Aviano, IT, <sup>7</sup>Ospedale Casa Sollievo della Sofferenza, san giovanni rotondo, IT, <sup>8</sup>IRCCS Istituto di Candiolo, Candiolo, IT, <sup>9</sup>Azienda Ospedaliera Universitaria di Cagliari, Monserrato, IT, <sup>10</sup>Istituti Ospitalieri di Cremona, Cremona, IT, <sup>11</sup>Istituto Nazionale dei Tumori di Milano, Milan, IT

- 13:05 - 13:05 **881P - Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: results from S-TRAC trial**
- D. George<sup>1</sup>, A. Pantuck<sup>2</sup>, R. Figlin<sup>3</sup>, B. Escudier<sup>4</sup>, S. Halabi<sup>5</sup>, M. Casey<sup>6</sup>, X. Lin<sup>7</sup>, L. Serfass<sup>8</sup>, M. Lechuga Freañ<sup>9</sup>, A. Ravaud<sup>10</sup>, <sup>1</sup>Duke University Medical Center, Durham, US, <sup>2</sup>Ronald Reagan UCLA Medical Center, Los Angeles, US, <sup>3</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>4</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>5</sup>Duke University, Durham, US, <sup>6</sup>Pfizer Inc, Collegetown, US, <sup>7</sup>Pfizer Inc, La Jolla, US, <sup>8</sup>Pfizer - France, Paris, FR, <sup>9</sup>Pfizer - Italy, Milan, IT, <sup>10</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR
- 13:05 - 13:05 **882P - Potent Natural Killer (NK) and myeloid blood cell remodeling by Cabozantinib (Cabo) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts)**
- E. Verzoni<sup>1</sup>, S. Ferro<sup>2</sup>, G. Procopio<sup>1</sup>, A. Cova<sup>2</sup>, R. Ratta<sup>3</sup>, A. Raimondi<sup>1</sup>, P. Sepe<sup>4</sup>, P. Squarcina<sup>2</sup>, L. Lalli<sup>2</sup>, V. Huber<sup>2</sup>, D. Rinchai<sup>5</sup>, D. Bedognetti<sup>5</sup>, L. Rivoltini<sup>4</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>Istituto Nazionale dei Tumori di Milano, Milan, IT, <sup>4</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>5</sup>Research Branch, Doha, QA
- 13:05 - 13:05 **883P - Metastatic clear cell renal cell carcinoma patients with ECOG Performance Status 2 treated with Pazopanib: The Pazo2 trial of efficacy and safety.**
- E. Porfiri<sup>1</sup>, S. Pirrie<sup>2</sup>, A.-M. Hodgkins<sup>3</sup>, D. Farrugia<sup>4</sup>, K. Fife<sup>5</sup>, C. McDonald-Smith<sup>6</sup>, N. Vasudev<sup>7</sup>, G. Nixon<sup>3</sup>, N. James<sup>1</sup>, C. Stubbs<sup>3</sup>, <sup>1</sup>Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB, <sup>2</sup>The University of Birmingham, Birmingham, GB, <sup>3</sup>The University of Birmingham - College of Dental and Medical Sciences, Birmingham, GB, <sup>4</sup>Cheltenham General Hospital Gloucestershire Oncology Centre, Cheltenham, GB, <sup>5</sup>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, <sup>6</sup>Ysbyty Gwynedd, Bangor, GB, <sup>7</sup>St. James's University Hospital Leeds, Leeds, GB
- 13:05 - 13:05 **884P - Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL Study)**
- G. Procopio<sup>1</sup>, A. Bamias<sup>2</sup>, M. Schmidinger<sup>3</sup>, R. Hawkins<sup>4</sup>, A. Rodriguez Sanchez<sup>5</sup>, S. Vazquez<sup>6</sup>, N. Srihari<sup>7</sup>, H. Kalofonos<sup>8</sup>, P. Bono<sup>9</sup>, C. Pisal<sup>10</sup>, Y. Hirschberg<sup>11</sup>, L. Dezzani<sup>11</sup>, Q. Ahmad<sup>11</sup>, C. Suarez Rodriguez<sup>12</sup>, E. Jonasch<sup>13</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>University of Athens, Sotiria General Chest Diseases Hospital, Athens, GR, <sup>3</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>4</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>5</sup>University Hospital of Leon, Leon, ES, <sup>6</sup>Hospital Lucus Augusti, Lugo, ES, <sup>7</sup>Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, GB, <sup>8</sup>University of Patras, Patras, GR, <sup>9</sup>Helsinki University Hospital, Helsinki, FI, <sup>10</sup>Novartis Healthcare Private Limited, Hyderabad, IN, <sup>11</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>12</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>13</sup>The University of Texas MD Anderson Cancer Center, Houston, US



- 13:05 - 13:05 **885P - Are adverse events (AEs) predictive of Nivolumab activity? Data from the Italian Expanded Access Program in metastatic renal cell carcinoma (mRCC)**  
E. Verzoni<sup>1</sup>, G. Carteni<sup>2</sup>, E. Cortesi<sup>3</sup>, F. Roila<sup>4</sup>, M.G. Vitale<sup>5</sup>, S. Buti<sup>6</sup>, S. Pignata<sup>7</sup>, F. Cognetti<sup>8</sup>, L. Giustini<sup>9</sup>, A. Damiani<sup>10</sup>, D. Turci<sup>11</sup>, C. Sternberg<sup>12</sup>, C. Porta<sup>13</sup>, F. Carrozza<sup>14</sup>, G. Tortora<sup>15</sup>, D. Tassinari<sup>16</sup>, R. Passalacqua<sup>17</sup>, A. Pazzola<sup>18</sup>, G. Surico<sup>19</sup>, G. Procopio<sup>1</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>A. Cardarelli Hospital, Naples, IT, <sup>3</sup>Policlinico Umberto I, roma, IT, <sup>4</sup>Azienda Ospedaliera Sta Maria, Terni, IT, <sup>5</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>6</sup>Azienda Ospedaliera di Parma, Parma, IT, <sup>7</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>8</sup>Istituto Nazionale Tumori Regina Elena, Rome, IT, <sup>9</sup>UOC Oncologia Area Vasta 4, Fermo, Fermo, IT, <sup>10</sup>san martino Hospital, Genova, IT, <sup>11</sup>Ospedale Sta Maria delle Croci, Ravenna, IT, <sup>12</sup>Azienda Ospedaliera S. Camillo Forlanini, Rome, IT, <sup>13</sup>Ospedale San Matteo, Pavia, IT, <sup>14</sup>Ospedale Umberto I (AUSL Romagna), Lugo, IT, <sup>15</sup>Fondazione Policlinico Universitario Gemelli -IRCCS Rome, Rome, IT, <sup>16</sup>Ospedale Infermi, Rimini, IT, <sup>17</sup>Istituti Ospitalieri di Cremona, Cremona, IT, <sup>18</sup>Ospedale Civile SS Annunziata, Sassari, IT, <sup>19</sup>Ospedale Vito Fazzi, Lecce, IT
- 13:05 - 13:05 **886P - Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance**  
G. Sun, X. Zhang, J. Zhao, J. Chen, P. Shen, Z. Liu, H. Zeng, West China Hospital, Sichuan University, Chengdu, CN
- 13:05 - 13:05 **887P - Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC)**  
A. Guida<sup>1</sup>, G. Le Teuff<sup>2</sup>, E. Colomba<sup>2</sup>, G. Baciarello<sup>2</sup>, L. Derosa<sup>2</sup>, Y. Loriot<sup>3</sup>, K. Fizazi<sup>2</sup>, C. Massard<sup>4</sup>, B. Escudier<sup>5</sup>, L. Albiges<sup>3</sup>, <sup>1</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>2</sup>Gustave Roussy, Villejuif, FR, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>5</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 13:05 - 13:05 **888P - Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)**  
S. Verhoeff<sup>1</sup>, S. Es<sup>2</sup>, E. Boon<sup>3</sup>, E. Van Helden<sup>4</sup>, L. Angus<sup>5</sup>, S. Elias<sup>6</sup>, S. Oosting<sup>7</sup>, E. Aarntzen<sup>1</sup>, A. Brouwers<sup>1</sup>, S. Heskamp<sup>1</sup>, O. Hoekstra<sup>4</sup>, H. Verheul<sup>4</sup>, A. Van Der Veldt<sup>5</sup>, E.G.E. De Vries<sup>7</sup>, O. Boerman<sup>1</sup>, W. Van Der Graaf<sup>8</sup>, W. Oyen<sup>1</sup>, C. Van Herpen<sup>1</sup>, <sup>1</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>2</sup>UMCGroningen, Groningen, NL, <sup>3</sup>Radboudumc, Nijmegen, NL, <sup>4</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>5</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>6</sup>Julius Center of Health Academy, Utrecht, NL, <sup>7</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>8</sup>Royal Marsden Hospital Institute of Cancer Research, Sutton, GB
- 13:05 - 13:05 **889P - Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors (TKI) and Mammalian Target of Rapamycin Inhibitors (mTORI) after Immuno-oncology (IO) Checkpoint Inhibitors**  
J. Graham<sup>1</sup>, J. Wells<sup>1</sup>, R. Mckay<sup>2</sup>, U. Vaishampayan<sup>3</sup>, A. Hansen<sup>4</sup>, F. Donskov<sup>5</sup>, G. Bjarnason<sup>6</sup>, B. Beuselinck<sup>7</sup>, G. De Velasco<sup>8</sup>, M. Duh<sup>9</sup>, L. Huynh<sup>9</sup>, R. Chang<sup>9</sup>, G. Zanotti<sup>10</sup>,



K. Ramaswamy<sup>11</sup>, T. Choueiri<sup>12</sup>, D. Heng<sup>13</sup>, <sup>1</sup>University of Calgary, Calgary, CA, <sup>2</sup>University of California San Diego, San Diego, US, <sup>3</sup>Karmanos Cancer Institute, Detroit, US, <sup>4</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>5</sup>Aarhus University Hospital, Aarhus, DK, <sup>6</sup>Sunnybrook Odette Cancer Center, Sunnybrook HSC, Toronto, CA, <sup>7</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>8</sup>University Hospital 12 de Octubre, Madrid, ES, <sup>9</sup>Analysis Group, Inc, Boston, US, <sup>10</sup>Pfizer, Inc., New York, US, <sup>11</sup>Pfizer Inc., New York, US, <sup>12</sup>Dana-Farber Cancer Institute, Boston, US, <sup>13</sup>Cleveland Clinic, Cleveland, US

13:05 - 13:05

**890P - Everolimus as first-line or after cytokine therapy in patients with metastatic recurrent and/or unresectable renal cell carcinoma (RCC) (EVERMORE)**

A. Abdel Hakim<sup>1</sup>, Y. Nour<sup>2</sup>, R. Taran<sup>3</sup>, D. Amokrane<sup>4</sup>, M. Ghosn<sup>5</sup>, B. Larbaoui<sup>6</sup>, C. Pripatnanont<sup>7</sup>, K. Slimane<sup>8</sup>, V. Pilipovic<sup>9</sup>, H. Boussen<sup>10</sup>, <sup>1</sup>Cairo University, Cairo, EG, <sup>2</sup>La Rabta Hospital, Tunis, TN, <sup>3</sup>CHL-Hospitals and CHL-CBCC Cancer Center, Indore, IN, <sup>4</sup>Pierre and Marie Curie Center, Algiers, DZ, <sup>5</sup>Saint Joseph University, Beirut, LB, <sup>6</sup>Anti Cancer Center "Emir Abdel Kader", Oran, DZ, <sup>7</sup>Prince of Songkla University, Songkla, TH, <sup>8</sup>Novartis Pharma S.A.S, Rueil-Malmaison, FR, <sup>9</sup>Novartis Pharma AG, Basel, CH, <sup>10</sup>Hopital Abderrahman Mami, Ariana, TN

13:05 - 13:05

**891P - Correlation between Immuno-Related Adverse Events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study.**

M.G. Vitale<sup>1</sup>, S. Pipitone<sup>1</sup>, S. Scagliarini<sup>2</sup>, P.A. Zucali<sup>3</sup>, L. Galli<sup>4</sup>, S. Rossetti<sup>2</sup>, C. Caserta<sup>5</sup>, R. Iacovelli<sup>6</sup>, C. Masini<sup>7</sup>, C. Ficarella<sup>8</sup>, S. Di Girolamo<sup>9</sup>, S. Buti<sup>10</sup>, B. Benedetti<sup>11</sup>, M. Santoni<sup>12</sup>, C. Porta<sup>13</sup>, S. Bracarda<sup>14</sup>, C. Baldessari<sup>1</sup>, S. Giaquinta<sup>1</sup>, S. Cascinu<sup>1</sup>, R. Sabbatini<sup>1</sup>, <sup>1</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>2</sup>AOU Policlinico Federico II, Napoli, IT, <sup>3</sup>Humanitas Cancer Center Istituto Clinico Humanitas - IRCCS, Rozzano, IT, <sup>4</sup>Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori, Pisa, IT, <sup>5</sup>Azienda Ospedaliera Sta Maria, Terni, IT, <sup>6</sup>Policlinico Umberto I, Roma, IT, <sup>7</sup>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>8</sup>Dr. Corrado Ficarella, Milan, IT, <sup>9</sup>Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>10</sup>Azienda Ospedaliera di Parma, Parma, IT, <sup>11</sup>Ospedale degli Infermi, Faenza, IT, <sup>12</sup>AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, Ancona, IT, <sup>13</sup>Ospedale San Matteo, Pavia, IT, <sup>14</sup>Ospedale San Donato and U.O.C. of Medical Oncology, Arezzo, IT

13:05 - 13:05

**892P - Treatment sequences in metastatic renal cell carcinoma: efficacy results from the Czech registry (RENIS)**

J. Finek<sup>1</sup>, R. Demlova<sup>2</sup>, K. Kopeckova<sup>3</sup>, T. Buchler<sup>4</sup>, B. Melichar<sup>5</sup>, J. Prausova<sup>3</sup>, A. Poprach<sup>2</sup>, T. Hrnčiarova<sup>6</sup>, T. Mlcoch<sup>6</sup>, T. Dolezal<sup>6</sup>, <sup>1</sup>University Hospital Plzen, Plzen, CZ, <sup>2</sup>Masaryk Memorial Cancer Institute, Brno, CZ, <sup>3</sup>Fakultni Nemocnice V Motole, Prague, CZ, <sup>4</sup>Thomayer University Hospital, Prague, CZ, <sup>5</sup>University Hospital Olomouc, Olomouc, CZ, <sup>6</sup>Institute of Health Economics and Technology Assessment, Prague, CZ

13:05 - 13:05

**893P - Cabozantinib in metastatic renal cell carcinoma (mRCC): data from UK expanded access program (EAP)**

A. Gomez De Liano Lista<sup>1</sup>, B. Venugopal<sup>2</sup>, K. Fife<sup>3</sup>, S. Symeonides<sup>4</sup>, N. Vasudev<sup>5</sup>, S. Rudman<sup>6</sup>, S. Vohra<sup>2</sup>, L. Khasati<sup>3</sup>, C. Pettinger<sup>4</sup>, B. Szabados<sup>7</sup>, L. Morrison<sup>8</sup>, T. Powles<sup>7</sup>, E.

Boleti<sup>8</sup>, <sup>1</sup>Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, <sup>2</sup>Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>3</sup>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB, <sup>4</sup>Cancer Research UK Edinburgh Centre, Edinburgh, GB, <sup>5</sup>St. James's University Hospital Leeds, Leeds, GB, <sup>6</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>7</sup>Barts Cancer Institute, London, GB, <sup>8</sup>Royal Free Hospital School of Medicine, London, GB

13:05 - 13:05 **894P - Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC)**

N. Dizman<sup>1</sup>, P. Bergerot<sup>1</sup>, C. Bergerot<sup>1</sup>, E. Philip<sup>2</sup>, M. Salgia<sup>1</sup>, J. Hsu<sup>1</sup>, J. Adashek<sup>1</sup>, S. Pal<sup>1</sup>, <sup>1</sup>City of Hope, Duarte, US, <sup>2</sup>University of Notre Dame, Notre Dame, US

13:05 - 13:05 **895P - Advanced Treatment Line (ATL) with Lenvatinib and Everolimus (Len+Eve) for Metastatic Renal Cell Carcinoma (mRCC); Analysis of a National Early Access Program (EAP).**

A. Peer<sup>1</sup>, M. Kolin<sup>1</sup>, K. Rouvinov<sup>2</sup>, D. Keizman<sup>3</sup>, D. Sarid<sup>4</sup>, R. Leibowitz-Amit<sup>5</sup>, R. Berger<sup>5</sup>, A. Sella<sup>6</sup>, A. Rasco<sup>7</sup>, E. Rosenbaum<sup>8</sup>, C. Maurice-Dror<sup>1</sup>, A. Neumann<sup>3</sup>, V. Neiman<sup>8</sup>, <sup>1</sup>Rambam Health Care Center, Haifa, IL, <sup>2</sup>Soroka University Medical Center, Beer Sheva, IL, <sup>3</sup>Meir Medical Center, Kfar Saba, IL, <sup>4</sup>Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, <sup>5</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>6</sup>Asaf Harofeh Medical Center, Zerifin, IL, <sup>7</sup>No place of work provided Israel, Tel Aviv, IL, <sup>8</sup>Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL

13:05 - 13:05 **896P - Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)**

H.-W. Sim<sup>1</sup>, A. Stundzia<sup>1</sup>, S. Pierre<sup>1</sup>, U. Metser<sup>1</sup>, M. O'Malley<sup>1</sup>, E. Elimova<sup>1</sup>, S. Sridhar<sup>2</sup>, A. Hansen<sup>1</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>Princess Margaret Hospital, Toronto, CA

13:05 - 13:05 **897P - A phase 1b study of safety and preliminary efficacy of extracranial stereotactic body radiation therapy (SBRT) in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy**

N. Dengina<sup>1</sup>, T. Mitin<sup>2</sup>, S. Gamayunov<sup>3</sup>, S. Safina<sup>4</sup>, Y. Kreinina<sup>5</sup>, I. Tsimafeyeu<sup>6</sup>, <sup>1</sup>Ulyanovsk Regional Clinical Cancer Center, Ulyanovsk, RU, <sup>2</sup>Oregon Health@Science University, Portland, US, <sup>3</sup>Cheboksary Regional Clinical Cancer Center, Cheboksary, RU, <sup>4</sup>Republical Clinical Cancer Center, Kazan, RU, <sup>5</sup>Russian Scientific Center of Roentgen Radiology, Moscow, RU, <sup>6</sup>Russian Society of Clinical Oncology, Moscow, RU

13:05 - 13:05 **898P - VOTRAGE study Pazopanib in a population of "frail" elderly patients after geriatric assessment. A phase I study with geriatric criteria.**

L. Mourey<sup>1</sup>, A. Ravaud<sup>2</sup>, L. Digue<sup>2</sup>, B. Cabarrou<sup>3</sup>, C. Gomez-Roca<sup>4</sup>, T. Valentin<sup>4</sup>, P. Olivier<sup>5</sup>, A. Fabre<sup>6</sup>, M. Mounier<sup>6</sup>, L. Balardy<sup>7</sup>, T. Filleron<sup>8</sup>, <sup>1</sup>Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse, France, FR, <sup>2</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>3</sup>IUCT-Oncopole, Toulouse, FR, <sup>4</sup>Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, <sup>5</sup>CHU Toulouse, Toulouse, FR, <sup>6</sup>Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, <sup>7</sup>CHU Toulouse Hôpital Purpan, Toulouse, FR, <sup>8</sup>Centre Claudius-Regaud, Toulouse, FR

- 13:05 - 13:05 **899P - A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS)**
- D. Castellano Gauna<sup>1</sup>, I. Duran Martinez<sup>2</sup>, A. Rodríguez-Vida<sup>3</sup>, S. Crabb<sup>4</sup>, M. Van Der Heijden<sup>5</sup>, A. Font Pous<sup>6</sup>, G. Gravis<sup>7</sup>, U. Anido Herranz<sup>8</sup>, A. Protheroe<sup>9</sup>, A. Ravaud<sup>10</sup>, D. Mailet<sup>11</sup>, M. Mendez-Vidal<sup>12</sup>, C. Suarez<sup>13</sup>, A. Lorch<sup>14</sup>, C. Sternberg<sup>15</sup>, M. Linch<sup>16</sup>, S.-J. Sarker<sup>17</sup>, J. Notta<sup>17</sup>, K. Mousa<sup>18</sup>, T. Powles<sup>19</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Hospital Universitario Marques de Valdecilla, Santander, ES, <sup>3</sup>Hospital del Mar, Barcelona, ES, <sup>4</sup>University of Southampton, Southampton, GB, <sup>5</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>6</sup>Institut Català d'Oncologia, Badalona, ES, <sup>7</sup>Institute Paoli Calmettes, Marseille, FR, <sup>8</sup>Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, ES, <sup>9</sup>Churchill Hospital University of Oxford, Oxford, GB, <sup>10</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>11</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>12</sup>Reina Sofia University Hospital, Cordoba, ES, <sup>13</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>14</sup>Universitätsklinikum Düsseldorf, Düsseldorf, DE, <sup>15</sup>San Camillo Forlanini Hospital, Rome, IT, <sup>16</sup>UCL Cancer Institute/Paul O'Gorman Building, London, GB, <sup>17</sup>Queen Mary University of London, London, GB, <sup>18</sup>Imperial College London-Charing Cross Hospital, London, GB, <sup>19</sup>St. Bartholomew's Hospital, London, GB
- 13:05 - 13:05 **900P - Interim results of fight-201, a phase 2, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)**
- A. Necchi<sup>1</sup>, D. Pouessel<sup>2</sup>, R. Leibowitz-Amit<sup>3</sup>, A. Flechon<sup>4</sup>, S. Gupta<sup>5</sup>, P. Barthelemy<sup>6</sup>, M. Maio<sup>7</sup>, X. Zhu<sup>8</sup>, E. Asatiani<sup>9</sup>, G. Serbest<sup>10</sup>, H. Zhen<sup>10</sup>, Y. Loriot<sup>11</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Centre hospitalier universitaire Henri-Mondor, Créteil, FR, <sup>3</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>4</sup>Centre Léon Bérard, Lyon, FR, <sup>5</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>6</sup>C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, <sup>7</sup>University Hospital of Siena, Istituto Toscano Tumori, Siena, IT, <sup>8</sup>Northwell Cancer Institute, Lake Success, US, <sup>9</sup>Covance, Founex, CH, <sup>10</sup>Incyte, Willmington, US, <sup>11</sup>Institut Gustave Roussy, Villejuif, FR
- 13:05 - 13:05 **901P - Impact of Prognostic Factors and Risk Groups on Overall Survival (OS) in Patients Treated With Pembrolizumab vs Investigator's Choice Chemotherapy for advanced Urothelial Cancer (UC): Post Hoc Analysis of KEYNOTE-045**
- J. Bellmunt<sup>1</sup>, R. De Wit<sup>2</sup>, D. Vaughn<sup>3</sup>, Y. Fradet<sup>4</sup>, J.L. Lee<sup>5</sup>, L. Fong<sup>6</sup>, N. Vogelzang<sup>7</sup>, M. Climent<sup>8</sup>, D. Petrylak<sup>9</sup>, T. Choueiri<sup>1</sup>, A. Necchi<sup>10</sup>, W. Gerritsen<sup>11</sup>, H. Gurney<sup>12</sup>, D. Quinn<sup>13</sup>, S. Culine<sup>14</sup>, C. Sternberg<sup>15</sup>, E. Jensen<sup>16</sup>, T. Frenkl<sup>16</sup>, R. Perini<sup>16</sup>, D. Bajorin<sup>17</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>3</sup>Abramson Cancer Center of the University of Pennsylvania, Philadelphia, US, <sup>4</sup>CHU de Québec-Université Laval, Québec City, CA, <sup>5</sup>Asan Medical Center and University of Ulsan College of Medicine, Seoul, KR, <sup>6</sup>University of California, San Francisco, US, <sup>7</sup>US Oncology Research c/o Comprehensive Cancer Crts of NV, Las Vegas, US, <sup>8</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>9</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>10</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>11</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>12</sup>Macquarie University, Macquarie Park, AU, <sup>13</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>14</sup>Hôpital St. Louis, Paris, FR, <sup>15</sup>San Camillo Forlanini Hospital, Rome, IT, <sup>16</sup>Merck & Co., Inc., Kenilworth,



US, <sup>17</sup>Memorial Sloan Kettering Cancer Center, New York, US

13:05 - 13:05 **902P - Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)**

M. Galsky<sup>1</sup>, R. Banchereau<sup>2</sup>, E. Kadel, Iii<sup>2</sup>, T. Ramirez-Montagut<sup>2</sup>, S. Mariathasan<sup>3</sup>, A. Thåström<sup>2</sup>, J. Rosenberg<sup>4</sup>, T. Powles<sup>5</sup>, M. Van Der Heijden<sup>6</sup>, A. Necchi<sup>7</sup>, <sup>1</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, <sup>2</sup>Genentech, Inc., South San Francisco, US, <sup>3</sup>Genentech, Inc., San Francisco, US, <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>5</sup>Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, GB, <sup>6</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>7</sup>Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, IT

13:05 - 13:05 **903P - Neuroendocrine carcinoma of the urinary bladder: a large analysis of the French GETUG consortium**

M. Sroussi<sup>1</sup>, M. Lorcet<sup>2</sup>, M. Tardy<sup>3</sup>, M. Guerin<sup>4</sup>, F. Estrade<sup>5</sup>, R. Delva<sup>6</sup>, P. Barthelemy<sup>7</sup>, P. Lavaud<sup>8</sup>, Y. Neuzillet<sup>9</sup>, N. Penel<sup>10</sup>, N. Houede<sup>11</sup>, D. Pouessel<sup>12</sup>, E. Mussat<sup>13</sup>, M. Gross Goupil<sup>14</sup>, H. Gauthier<sup>15</sup>, A. Gobert<sup>16</sup>, O. Huillard<sup>17</sup>, Y. Allory<sup>18</sup>, R.-T. Elaidi<sup>19</sup>, S. Oudard<sup>19</sup>, <sup>1</sup>Université Paris5, Paris, FR, <sup>2</sup>Centre Léon Bérard, Lyon, FR, <sup>3</sup>Centre Anticancer Antoine Lacassagne, Nice, FR, <sup>4</sup>Institute Paoli Calmettes, Marseille, FR, <sup>5</sup>Centre Eugène Marquis, Rennes, FR, <sup>6</sup>Centre Paul Papin, Angers, FR, <sup>7</sup>C.H.U. Strasbourg-Nouvel Hopital Civil, Strasbourg, FR, <sup>8</sup>IGR - Insitut Gustave Roussy, Villejuif, FR, <sup>9</sup>Hopital Foch, Suresnes, FR, <sup>10</sup>Centre Oscar Lambret, Lille, FR, <sup>11</sup>Institut de cancérologie du Gard, Nimes, FR, <sup>12</sup>IUCT Oncopole, Toulouse, FR, <sup>13</sup>Henri Mondor Hospital, Creteil, FR, <sup>14</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>15</sup>St Louis Hospital, Paris, FR, <sup>16</sup>Slpétrièrè Hospital, Paris, FR, <sup>17</sup>Hôpital Cochin, Paris, FR, <sup>18</sup>Curie Institute, Saint-Cloud, FR, <sup>19</sup>Hopital European George Pompidou, Paris, FR

13:05 - 13:05 **904P - Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC)**

J. Walker<sup>1</sup>, M. Zajac<sup>2</sup>, J. Ye<sup>3</sup>, M. Scott<sup>4</sup>, M. Ratcliffe<sup>5</sup>, P. Scorer<sup>6</sup>, C. Barker<sup>7</sup>, H. Al-Masri<sup>8</sup>, M. Rebelatto<sup>9</sup>, A. Gupta<sup>6</sup>, P. Mukhopadhyay<sup>3</sup>, S. Ferro<sup>3</sup>, T. Powles<sup>10</sup>, J. Williams<sup>6</sup>, <sup>1</sup>AstraZeneca Netherlands, Zoetermeer, NL, <sup>2</sup>AstraZeneca UK, Royston, GB, <sup>3</sup>AstraZeneca, Gaithersburg, US, <sup>4</sup>Astrazeneca, Cambridge, GB, <sup>5</sup>Astrazeneca, Macclesfield, GB, <sup>6</sup>AstraZeneca, Cambridge, GB, <sup>7</sup>AstraZeneca, Little Chesterford, GB, <sup>8</sup>Hematogenix, Tinley Park, US, <sup>9</sup>MedImmune, Gaithersburg, US, <sup>10</sup>Barts Cancer Center, London, GB

13:05 - 13:05 **905P - CD103+ Tissue-resident CD8+ T Cells Correlate with Protective Anti-tumoral Immune Responses in Muscle-invasive Bladder Cancer Patients**

Z. Liu, J. Zhang, B. Dai, Fudan University Shanghai Cancer Center, Shanghai, CN

13:05 - 13:05 **906P - Immune-checkpoint inhibitors in previously treated patients with urothelial carcinoma: a systematic review and meta-analysis.**

E. De Luca<sup>1</sup>, V. Di Nunno<sup>2</sup>, C. Buttigliero<sup>3</sup>, M. Tucci<sup>3</sup>, F. Vignani<sup>1</sup>, C. Zichi<sup>1</sup>, A. Ardizzoni<sup>2</sup>, F. Massari<sup>4</sup>, M. Di Maio<sup>1</sup>, <sup>1</sup>"Ordine Mauriziano" Hospital, Torino, IT,



2S.Orsola-Malpighi Hospital, Bologna, IT, 3"San Luigi Gonzaga" Hospital, Orbassano, Torino, IT, 4AOU Policlinico Sant'Orsola Malpighi, Bologna, IT

13:05 - 13:05 **907P - Match-adjusted indirect comparison of durvalumab and chemotherapy for locally advanced or metastatic urothelial carcinoma (UC) following failure of platinum-based therapy**

C. Hoyle<sup>1</sup>, A. Klein<sup>2</sup>, K. Patel<sup>2</sup>, N. Shire<sup>2</sup>, H. Wang<sup>2</sup>, B.C. Chu<sup>3</sup>, M. Ouwens<sup>4</sup>, B. Nordstrom<sup>5</sup>, L. Horne<sup>1</sup>, H.-T. Arkenau<sup>6</sup>, <sup>1</sup>AstraZeneca Academy House, Cambridge, GB, <sup>2</sup>AstraZeneca, Cambridge, GB, <sup>3</sup>Evidera, San Francisco, US, <sup>4</sup>AstraZeneca Head Office UK, London, GB, <sup>5</sup>Evidera, Waltham, US, <sup>6</sup>Sarah Cannon Research Institute SCRI UK, London, GB

13:05 - 13:05 **908P - Comparative effectiveness of neoadjuvant chemotherapy followed by cystectomy versus cystectomy followed by adjuvant chemotherapy versus palliative chemotherapy versus cystectomy for node -positive bladder cancer: A retrospective analysis: KCSG GU 17-03**

J.H. Byun<sup>1</sup>, H.A. Jung<sup>2</sup>, W.-K. Bae<sup>3</sup>, H.-J. Lee<sup>4</sup>, S.H. Park<sup>5</sup>, H.J. Kim<sup>6</sup>, C.H. Maeng<sup>7</sup>, I. Park<sup>8</sup>, B.S. Sohn<sup>9</sup>, J.A. Kim<sup>10</sup>, K.H. Lee<sup>11</sup>, D.H. Im<sup>12</sup>, J.H. Kim<sup>13</sup>, H. Jang<sup>14</sup>, S.M. Kim<sup>15</sup>, <sup>1</sup>Incheon St. Mary's Hospital, Incheon, KR, <sup>2</sup>Dongtan Sacred Heart Hospital, Hwanseong-si, KR, <sup>3</sup>Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, <sup>4</sup>Chungnam National University College of Medicine, Daejeon, KR, <sup>5</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, <sup>6</sup>Chung-Ang University College of Medicine, Seoul, KR, <sup>7</sup>Kyung Hee University Hospital, Seoul, KR, <sup>8</sup>Gachon University Gil Medical Center, Incheon, KR, <sup>9</sup>Inje University Sanggye Paik Hospital, Seoul, KR, <sup>10</sup>Kangdong Kyung Hee University Hospital, Seoul, KR, <sup>11</sup>Department of Internal Medicine, Daegu, KR, <sup>12</sup>Dankook Univ. Hospital, Cheonan, KR, <sup>13</sup>Gyeongsang National University Hospital, Jinju, KR, <sup>14</sup>International St. Mary's Hospital, Incheon, KR, <sup>15</sup>Samsung Changwon Hospital, Changwon, KR

13:05 - 13:05 **909P - Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer**

L. Nappi<sup>1</sup>, M. Thi<sup>2</sup>, B. Eigl<sup>1</sup>, A. Lum<sup>3</sup>, D. Huntsman<sup>1</sup>, C. Martin<sup>4</sup>, B. O Neil<sup>4</sup>, D. Khalaf<sup>1</sup>, K. Chi<sup>1</sup>, M. Gleave<sup>5</sup>, A. So<sup>2</sup>, P. Black<sup>2</sup>, S. Daneshmand<sup>6</sup>, C. Nichols<sup>7</sup>, C. Kollmannsberger<sup>1</sup>, <sup>1</sup>British Columbia Cancer Agency, Vancouver, CA, <sup>2</sup>Vancouver Prostate Centre, Vancouver, CA, <sup>3</sup>British Columbia Cancer Research Centre, Vancouver, CA, <sup>4</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>5</sup>University of British Columbia Faculty of Medicine, Vancouver, CA, <sup>6</sup>University of South California, Los Angeles, US, <sup>7</sup>Testicular Cancer Commons, Salt Lake Cty, US

13:05 - 13:05 **910P - Increased risk of non-germ cell second cancer (SC) after cisplatin-based chemotherapy (CBCT) in 1-year testicular cancer (TC) survivors (TCS)**

R. Hellesnes<sup>1</sup>, Ø. Kvammen<sup>2</sup>, R. Bremnes<sup>3</sup>, A. Karlsdottir<sup>4</sup>, T.Å. Myklebust<sup>5</sup>, H. Negaard<sup>6</sup>, T. Tandstad<sup>7</sup>, T. Wilsgaard<sup>8</sup>, S. Fosså<sup>9</sup>, H. Haugnes<sup>1</sup>, <sup>1</sup>University Hospital of North Norway, Tromsø, NO, <sup>2</sup>Ålesund sykehus, Ålesund, NO, <sup>3</sup>UiT The Arctic University of Norway, Tromsø, NO, <sup>4</sup>Haukeland Universitetssykehus, Bergen, NO, <sup>5</sup>Cancer Registry of Norway, Oslo, NO, <sup>6</sup>University Hospital of North Norway, Oslo, NO, <sup>7</sup>St. Olavs University Hospita, Trondheim, NO, <sup>8</sup>Arctic University of Tromsø, Tromsø, NO, <sup>9</sup>Oslo University

Hospital Rikshospitalet - Radiumhospitalet Trust, Oslo, NO

- 13:05 - 13:05 **911P - Vascular damage and pulmonary function in very long-term survivors of testicular cancer (TC) treated with cisplatin-based chemotherapy (CT)**  
J. Stelwagen<sup>1</sup>, S. Lubberts<sup>1</sup>, L. Steggink<sup>1</sup>, G. Steursma<sup>1</sup>, L. Kruyt<sup>1</sup>, J. Donkerbroek<sup>1</sup>, A. Van Roon<sup>1</sup>, A. Van Gessel<sup>1</sup>, S. Van De Zande<sup>1</sup>, C. Meijer<sup>1</sup>, J. Wempe<sup>1</sup>, C. Gräfin Zu Eulenburg<sup>1</sup>, J. Nuver<sup>2</sup>, A. Walenkamp<sup>1</sup>, J. Lefrandt<sup>1</sup>, J. Gietema<sup>1</sup>, <sup>1</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>2</sup>University Medical Center Groningen, Groningen, NL
- 13:05 - 13:05 **912P - Sexual function and quality of life in a national cohort of bilateral testicular cancer survivors**  
M. Bandak<sup>1</sup>, J. Lauritsen<sup>1</sup>, C. Johansen<sup>1</sup>, M. Kreiberg<sup>1</sup>, J. Skøtt<sup>1</sup>, M. Agerbaek<sup>2</sup>, N. Holm<sup>3</sup>, K.G. Daugaard<sup>1</sup>, <sup>1</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>2</sup>Aarhus University hospital, Aarhus, DK, <sup>3</sup>Odense University Hospital, Odense, DK
- 13:05 - 13:05 **913P - The prognostic value of DNA damage level in peripheral blood lymphocytes in germ cell cancer patients.**  
M. Mego<sup>1</sup>, Z. Sestakova<sup>2</sup>, K. Kalavska<sup>1</sup>, L. Hurbanova<sup>2</sup>, D. Jurkovicova<sup>2</sup>, J. Gursky<sup>2</sup>, M. Chovanec<sup>2</sup>, D. Svetlovska<sup>1</sup>, V. Miskovska<sup>3</sup>, J. Obertova<sup>1</sup>, P. Palacka<sup>1</sup>, K. Rejlekova<sup>1</sup>, Z. Sycova-Mila<sup>4</sup>, J. Mardiak<sup>1</sup>, M. Chovanec<sup>2</sup>, <sup>1</sup>National Cancer Institute(Národn\_ Onkologick\_ Ustav), Bratislava, SK, <sup>2</sup>Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, SK, <sup>3</sup>St. Elisabeth Cancer Institute, Bratislava, SK, <sup>4</sup>National Cancer Institute(Národný Onkologický Ustav), Bratislava, SK
- 13:05 - 13:05 **914P - Intermediate prognosis in metastatic germ cell tumors (IPGCT) - Outcome and prognostic stratification**  
C. Seidel<sup>1</sup>, K.G. Daugaard<sup>2</sup>, A. Tryakin<sup>3</sup>, A. Necchi<sup>4</sup>, G. Cohn Cedermark<sup>5</sup>, O. Ståhl<sup>6</sup>, M. Hentrich<sup>7</sup>, M. Brito<sup>8</sup>, C. Albany<sup>9</sup>, F. Taza<sup>9</sup>, A. Gerl<sup>10</sup>, K. Oechsle<sup>1</sup>, C. Oing<sup>11</sup>, C. Bokemeyer<sup>1</sup>, <sup>1</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>2</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>3</sup>N.N. Blokhin Russian Cancer Research Center, Moscow, RU, <sup>4</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>5</sup>Karolinska Institutet and Karolinska University Hospital, Stockholm, SE, <sup>6</sup>Lund University Hospital, Lund, SE, <sup>7</sup>Red Cross Hospital Munich, Munich, DE, <sup>8</sup>Instituto Portugues de Oncologia, Lisboa, PT, <sup>9</sup>Indiana University School of Medicine, Indianapolis, US, <sup>10</sup>Ludwig-Maximilians University Munich, Munich, DE, <sup>11</sup>University Medical Center HH-Eppendorf, Hamburg, DE
- 13:05 - 13:05 **915P - Long term follow-up of the MRC TE23 randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) in poor prognosis germ cell tumours (GCT) (CRUK/05/014; ISRCTN53643604)**  
R. Huddart<sup>1</sup>, F. Cafferty<sup>2</sup>, J. White<sup>3</sup>, J. Shamash<sup>4</sup>, I. Hennig<sup>5</sup>, M. Cullen<sup>6</sup>, S. Stenning<sup>2</sup>, <sup>1</sup>Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, <sup>2</sup>UCL, London, GB, <sup>3</sup>Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>4</sup>St Bartholomew's Hospital, London, GB, <sup>5</sup>Nottingham University Hospitals NHS Trust-City Hospital Campus, Nottingham, GB, <sup>6</sup>Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, Birmingham, GB

- 13:05 - 13:05 **916P - Sunitinib tolerance following an initial exposure period: results of longitudinal PRO data from S-TRAC study**  
D. George<sup>1</sup>, R. Figlin<sup>2</sup>, R. Motzer<sup>3</sup>, J. Paty<sup>4</sup>, M. Lechuga Freañ<sup>5</sup>, G. Zanotti<sup>6</sup>, H. Bhattacharyya<sup>7</sup>, K. Ramaswamy<sup>7</sup>, L. Deannuntis<sup>8</sup>, A. Ravaud<sup>9</sup>, <sup>1</sup>Duke University Medical Center, Durham, US, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, US, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>4</sup>IQVIA, Pittsburgh, US, <sup>5</sup>Pfizer - Italy, Milan, IT, <sup>6</sup>Pfizer, Inc., New York, US, <sup>7</sup>Pfizer Inc., New York, US, <sup>8</sup>Pfizer Inc., Collegeville, US, <sup>9</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR
- 13:05 - 13:05 **917TiP - Phase II study of paclitaxel and TAK-228 in metastatic urothelial carcinoma and the impact of PI3K-mTOR pathway genomic alterations**  
A. Rodríguez-Vida<sup>1</sup>, J.L. Pérez-Gracia<sup>2</sup>, A. Taus<sup>1</sup>, T. Bonfill<sup>3</sup>, F. Vázquez-Mazón<sup>4</sup>, S. Galtes<sup>1</sup>, B. Pons<sup>1</sup>, L. Cano<sup>1</sup>, S. Macia<sup>5</sup>, P. Maroto<sup>6</sup>, J. Bellmunt<sup>1</sup>, <sup>1</sup>Hospital del Mar, Barcelona, ES, <sup>2</sup>Clínica Universitaria de Navarra, Pamplona, ES, <sup>3</sup>Hospital Parc Taulí, Barcelona, ES, <sup>4</sup>Hospital General de Elche, Elche, ES, <sup>5</sup>PIVOTAL SL, La Florida, ES, <sup>6</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES
- 13:05 - 13:05 **918TiP - EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy**  
J. Rosenberg<sup>1</sup>, A. Balar<sup>2</sup>, P. O'Donnell<sup>3</sup>, E. Heath<sup>4</sup>, N. Hahn<sup>5</sup>, N. Cavazos<sup>6</sup>, A. Melhem-Bertrandt<sup>7</sup>, D. Petrylak<sup>8</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>NYU Langone Medical Center, New York, US, <sup>3</sup>University of Chicago, Chicago, US, <sup>4</sup>Karmanos Cancer Center, Detroit, US, <sup>5</sup>Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, <sup>6</sup>Seattle Genetics, Bothell, US, <sup>7</sup>Astellas Pharma USA, Northbrook, US, <sup>8</sup>Yale University School of Medicine Medical Oncology, New Haven, US
- 13:05 - 13:05 **919TiP - The potential of patient reported outcomes in urothelial cancer patients receiving immuno- or chemotherapy - a feasibility study of electronic reporting in an aging and comorbid population.**  
G. Taarnhøj<sup>1</sup>, H. Lindberg<sup>2</sup>, H. Pappot<sup>1</sup>, L. Dohn<sup>2</sup>, C. Johansen<sup>1</sup>, <sup>1</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, <sup>2</sup>Copenhagen University Hospital - Herlev, Herlev, DK
- 13:05 - 13:05 **920TiP - Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Patients (pts) With Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRalt): the Phase 3 THOR Study**  
Y. Loriot<sup>1</sup>, A. Necchi<sup>2</sup>, S.H. Park<sup>3</sup>, R. Huddart<sup>4</sup>, E. Burgess<sup>5</sup>, B. Zhong<sup>6</sup>, A. Santiago-Walker<sup>7</sup>, S. Little<sup>8</sup>, T. Roccia<sup>9</sup>, P. De Porre<sup>10</sup>, A. Siefker-Radtke<sup>11</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>Samsung Medical Center, Seoul, KR, <sup>4</sup>Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, <sup>5</sup>Levine Cancer Institute, Carolinas HealthCare System, Charlotte, US, <sup>6</sup>Janssen Research & Development, Spring House, US, <sup>7</sup>Janssen R&D/Johnson & Johnson Pharmaceutical R&D, Spring House, US, <sup>8</sup>Janssen Research & Development, Spring House, US, <sup>9</sup>Janssen Pharmaceuticals, Raritan, US, <sup>10</sup>Janssen EMEA Belgium, Beerse, BE, <sup>11</sup>The M. D. Anderson Cancer Center, Houston, US
- 13:05 - 13:05 **921TiP - An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of**



**von Hippel-Lindau Disease Associated Renal Cell Carcinoma**

E. Jonasch<sup>1</sup>, E. Park<sup>2</sup>, S. Thamake<sup>3</sup>, M. Hirmand<sup>2</sup>, R. Srinivasan<sup>4</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>Medivation, Inc., San Francisco, US, <sup>3</sup>Peloton Inc., San Francisco, US, <sup>4</sup>National Institutes of Health, Bethesda, US

- 13:05 - 13:05 **922TiP - EV-301: An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (la/mUC)**
- D. Petrylak<sup>1</sup>, J. Rosenberg<sup>2</sup>, I. Duran<sup>3</sup>, Y. Loriot<sup>4</sup>, G. Sonpavde<sup>5</sup>, C. Wu<sup>6</sup>, E. Gartner<sup>7</sup>, A. Melhem-Bertrandt<sup>8</sup>, T. Powles<sup>9</sup>, <sup>1</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>Hospital Universitario "Marqués de Valdecilla", Santander, ES, <sup>4</sup>Institut Gustave Roussy, Paris, FR, <sup>5</sup>Dana Farber Cancer Institute, Boston, US, <sup>6</sup>Astellas Pharma, Inc., Northbrook, US, <sup>7</sup>Seattle Genetics, Inc., Bothell, US, <sup>8</sup>Astellas Pharma USA, Northbrook, US, <sup>9</sup>Barts Cancer Institute, London, GB
- 13:05 - 13:05 **923TiP - A phase 2 study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations**
- A. Necchi<sup>1</sup>, J.L. Pérez-Gracia<sup>2</sup>, Y. Loriot<sup>3</sup>, W. Witjes<sup>4</sup>, F. Montorsi<sup>5</sup>, A. Bjartell<sup>6</sup>, S. Shariat<sup>7</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Clínica Universitaria de Navarra, Pamplona, ES, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>European Association of Urology, Arnhem, NL, <sup>5</sup>IRCCS San Raffaele, Milan, IT, <sup>6</sup>Skåne University Hospital Malmö, Malmö, SE, <sup>7</sup>Medical University of Vienna, Vienna, AT
- 13:05 - 13:05 **924TiP - A Phase I Study of HERV-E TCR Transduced Autologous T Cells (HERV-E TCR T Cells) in Patients (pts) with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)**
- R. Nadal<sup>1</sup>, E. Cherkasova<sup>2</sup>, S. Barisic<sup>2</sup>, D. Granadier<sup>2</sup>, G. Aue<sup>2</sup>, B. Wells<sup>2</sup>, G. Hawks<sup>2</sup>, T. Hughes<sup>2</sup>, R. Shalabi<sup>2</sup>, D. Stroncek<sup>3</sup>, S. Highfill<sup>3</sup>, G. Scurti<sup>4</sup>, L. Chen<sup>2</sup>, R. Reger<sup>2</sup>, M. Nishimura<sup>2</sup>, R. Childs<sup>2</sup>, <sup>1</sup>Center for Cancer Research-National Cancer Institute, Bethesda, US, <sup>2</sup>National Heart, Lung, and Blood Institute. NIH, Bethesda, US, <sup>3</sup>National Institutes of Health, Bethesda, US, <sup>4</sup>Loyola University, Chicago, US
- 13:05 - 13:05 **925TiP - Phase 1b/2 study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression**
- J. Rosenberg<sup>1</sup>, A. Necchi<sup>2</sup>, R. Sweis<sup>3</sup>, K. Nakajima<sup>4</sup>, C. Lu<sup>4</sup>, H. Nogai<sup>5</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>3</sup>University of Chicago, Chicago, US, <sup>4</sup>Bayer HealthCare Pharmaceuticals, Whippany, US, <sup>5</sup>Bayer AG, Berlin, DE
- 13:05 - 13:05 **926TiP - Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)**
- N. Van Dijk<sup>1</sup>, C. Blank<sup>2</sup>, P. Kvistborg<sup>2</sup>, T. Schumacher<sup>2</sup>, E. Hooijberg<sup>3</sup>, K. Sikorska<sup>2</sup>, B. Rhijn<sup>1</sup>, M. Van Der Heijden<sup>1</sup>, <sup>1</sup>Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL, <sup>2</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek



Hospital, Amsterdam, NL, <sup>3</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL

13:05 - 13:05

**927TiP - A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Nivolumab Plus Ipilimumab in Patients (pts) With Localized Renal Cell Carcinoma (RCC) Who Are at High Risk Of Relapse After Radical or Partial Nephrectomy (CheckMate 914)**

A. Bex<sup>1</sup>, V. Grünwald<sup>2</sup>, P. Russo<sup>3</sup>, Y. Tomita<sup>4</sup>, E. Berghorn<sup>5</sup>, M.B. Mchenry<sup>6</sup>, R. Motzer<sup>7</sup>,  
<sup>1</sup>The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>4</sup>Niigata University Medical and Dental Hospital, Niigata, JP, <sup>5</sup>Bristol-Myers Squibb, Princeton, US, <sup>6</sup>Bristol-Myers Squibb Company, Lawrenceville, US, <sup>7</sup>Memorial Sloan-Kettering Cancer Center, New York, US

13:05 - 13:05

**928TiP - ATLAS: a phase 2, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma**

S. Chowdhury<sup>1</sup>, S. Feyerabend<sup>2</sup>, Y. Loriot<sup>3</sup>, A. Necchi<sup>4</sup>, S. Gupta<sup>5</sup>, D. Josephs<sup>6</sup>, A. Rodríguez-Vida<sup>7</sup>, S. Srinivas<sup>8</sup>, Y. Zakharia<sup>9</sup>, D. Nepert<sup>10</sup>, K. Wride<sup>10</sup>, D. Thomas<sup>10</sup>, A. Loehr<sup>10</sup>, A. Simmons<sup>11</sup>, P. Grivas<sup>12</sup>, <sup>1</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>2</sup>University of Tübingen, Tübingen, DE, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>5</sup>Huntsman Cancer Institute, Salt Lake City, US, <sup>6</sup>King's College London Guy's Hospital, London, GB, <sup>7</sup>Hospital del Mar, Barcelona, ES, <sup>8</sup>Stanford University, Stanford, US, <sup>9</sup>University of Iowa, Iowa City, US, <sup>10</sup>Clovis Oncology, Boulder, US, <sup>11</sup>Clovis Oncology, San Francisco, US, <sup>12</sup>Taussig Cancer Institute Cleveland Clinic, Cleveland, US

13:05 - 13:05

**929TiP - BAYOU: Phase 2 Study of Efficacy and Safety of Durvalumab plus Olaparib as First-line Therapy in Platinum-ineligible Patients (pts) with Stage IV Urothelial Cancer (UC)**

J. Rosenberg<sup>1</sup>, D. Bajorin<sup>1</sup>, A. Smith<sup>2</sup>, C. D'Cruz<sup>3</sup>, M. Lanasa<sup>4</sup>, <sup>1</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>2</sup>AstraZeneca, Cambridge, GB, <sup>3</sup>AstraZeneca, Gaithersburg, US, <sup>4</sup>AstraZeneca USA, Gaithersburg, US

13:05 - 13:05

**930TiP - Phase 2/3 study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression**

C. Sternberg<sup>1</sup>, J. Bellmunt<sup>2</sup>, H. Nishiyama<sup>3</sup>, D. Petrylak<sup>4</sup>, D. Quinn<sup>5</sup>, K. Nakajima<sup>6</sup>, C. Lu<sup>6</sup>, A. Holynskij<sup>7</sup>, <sup>1</sup>San Camillo Forlanini Hospital, Rome, IT, <sup>2</sup>Dana-Farber Cancer Institute, Boston, US, <sup>3</sup>University of Tsukuba, Tsukuba, JP, <sup>4</sup>Yale University School of Medicine Medical Oncology, New Haven, US, <sup>5</sup>University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, <sup>6</sup>Bayer HealthCare Pharmaceuticals, Whippany, US, <sup>7</sup>Bayer HealthCare Pharmaceuticals Inc., Whippany, US

13:05 - 13:05

**931TiP - PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma**

F. Collinson<sup>1</sup>, S. Brown<sup>2</sup>, H. Buckley<sup>1</sup>, G. Ainsworth<sup>1</sup>, H. Howard<sup>1</sup>, H. Poad<sup>1</sup>, G. Carr<sup>2</sup>, R. Banks<sup>2</sup>, J. Brown<sup>2</sup>, G. Velikova<sup>3</sup>, J. Larkin<sup>4</sup>, P. Nathan<sup>5</sup>, T. Powles<sup>6</sup>, N. Vasudev<sup>3</sup>,  
<sup>1</sup>University of Leeds-Clinical Trials Research Unit, Leeds, GB, <sup>2</sup>University of Leeds,

Leeds, GB, <sup>3</sup>St. James's University Hospital Leeds, Leeds, GB, <sup>4</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>5</sup>Mount Vernon Cancer Centre, Northwood, GB, <sup>6</sup>St. Bartholomew's Hospital, London, GB

13:05 - 13:05 **Palliative care**

13:05 - 13:05 **1516P - Effectiveness of a Randomized Control Trial of an Individualized, Interactive Advance Care Planning Intervention in Improving Terminally Ill Cancer Patients' Psychological Symptoms, Quality of Life and Concordance between Preferred and Received Life-Sustaining Treatments**

S.T. Tang<sup>1</sup>, J.-S. Chen<sup>2</sup>, W.-C. Chou<sup>2</sup>, <sup>1</sup>Chung Gung University, Taoyuan, TW, <sup>2</sup>Chung Gung University, Tao Yuan, TW

13:05 - 13:05 **1517P - Current status of the integration of oncology and palliative care in Japan: A nationwide survey.**

U. Yu<sup>1</sup>, K. Sato<sup>2</sup>, T. Morita<sup>3</sup>, M. Mori<sup>3</sup>, C. Shimizu<sup>4</sup>, Y. Horie<sup>5</sup>, M. Hirakawa<sup>5</sup>, T. Nakajima<sup>5</sup>, S. Tsuneto<sup>6</sup>, M. Muto<sup>7</sup>, <sup>1</sup>Seirei Christopher University, Hamamatsu, JP, <sup>2</sup>Graduate School of Medicine, Nagoya University, Nagoya city, JP, <sup>3</sup>Seirei Mikatahara General Hospital, Hamamatsu city, JP, <sup>4</sup>Center Hospital of National Center for Global Health and Medicine, Tokyo, JP, <sup>5</sup>St Marianna University School of Medicine, Kawasaki city, JP, <sup>6</sup>Department of Human Health Sciences, Kyoto city, JP, <sup>7</sup>Department of Therapeutic Oncology, Kyoto city, JP

13:05 - 13:05 **1518P - Access to Palliative Care before death in French cancer patients during the two first years after diagnosis: the national cancer cohort**

M. Bendiane<sup>1</sup>, A. Janah<sup>2</sup>, D. Leufeuve<sup>3</sup>, P.-J. Bousquet<sup>3</sup>, <sup>1</sup>SESTIM, Marseille, FR, <sup>2</sup>Aix Marseille Univ, INSERM, IRD, Economics and Social Sciences Applied to Health & Analysis of Medical Information (SESSTIM), Marseille, FR, <sup>3</sup>INCa, Paris, FR

13:05 - 13:05 **1519P - Anticancer therapy at the end of life of breast, prostate, and colorectal cancer patients**

V. Heidt<sup>1</sup>, K. Hermes-Moll<sup>1</sup>, K. Blaschke<sup>2</sup>, V. Lappe<sup>2</sup>, P. Ihle<sup>2</sup>, I. Schubert<sup>2</sup>, W. Baumann<sup>1</sup>, <sup>1</sup>WINHO GmbH, Köln, DE, <sup>2</sup>Uniklinik Köln, Köln, DE

13:05 - 13:05 **1520P - Perspectives and attitudes towards the integration of oncology and palliative care in Japan: A nationwide survey.**

U. Yu<sup>1</sup>, K. Sato<sup>2</sup>, T. Morita<sup>3</sup>, M. Mori<sup>3</sup>, C. Shimizu<sup>4</sup>, Y. Horie<sup>5</sup>, M. Hirakawa<sup>5</sup>, T. Nakajima<sup>5</sup>, S. Tsuneto<sup>6</sup>, M. Muto<sup>7</sup>, <sup>1</sup>Seirei Christopher University, Hamamatsu, JP, <sup>2</sup>Graduate School of Medicine, Nagoya University, Nagoya city, JP, <sup>3</sup>Seirei Mikatahara General Hospital, Hamamatsu city, JP, <sup>4</sup>Center Hospital of National Center for Global Health and Medicine, Tokyo, JP, <sup>5</sup>St Marianna University School of Medicine, Kawasaki city, JP, <sup>6</sup>Department of Human Health Sciences, Kyoto city, JP, <sup>7</sup>Department of Therapeutic Oncology, Kyoto city, JP

13:05 - 13:05 **1521P - Evolving Concurrent Integration of Oncology and Palliative Care at an ESMO Designated Center over a Decade**

F. Strasser, T. Silzle, E. Schmidt, Kantonsspital St. Gallen, St. Gallen, CH

- 13:05 - 13:05 **1522P - The impact of inclusion in home palliative program and distance to hospital on chemotherapy near end of life**  
J. Balsalobre<sup>1</sup>, A. Checa-Soriano<sup>2</sup>, P. Cerezuela-Fuentes<sup>2</sup>, M. Martínez-Penella<sup>2</sup>, M.J. Martínez-Ortíz<sup>2</sup>, J.L. Alonso-Romero<sup>1</sup>, M.I. Luengo-Alcázar<sup>2</sup>, M.T. García-García<sup>2</sup>,  
<sup>1</sup>Hospital Universitario Virgen de la Arrixaca, Murcia, ES, <sup>2</sup>Hospital Universitario Santa Lucia, Cartagena, ES
- 13:05 - 13:05 **1523P - Cancer patients' perceptions of palliative care**  
J. Yoong<sup>1</sup>, B. Chosich<sup>2</sup>, M. Burgess<sup>2</sup>, A. Earnest<sup>3</sup>, F. Runacres<sup>2</sup>, L. William<sup>4</sup>, M. Franco<sup>2</sup>, P. Poon<sup>4</sup>,  
<sup>1</sup>Northern Health, Melbourne, AU, <sup>2</sup>Monash Health, Melbourne, AU, <sup>3</sup>Monash University, Melbourne, AU, <sup>4</sup>Monash Medical Centre, Clayton, AU
- 13:05 - 13:05 **1525P - Palliative care in advanced cancer, a clinical and ethical goal achieved?**  
J. Sanchez<sup>1</sup>, R. Gomez-Bravo<sup>2</sup>, A. Morito Aguilar<sup>1</sup>, A. Royuela<sup>2</sup>, B. Núñez García<sup>1</sup>, T. Tojar<sup>2</sup>, A. Ruano Ravina<sup>3</sup>, C. Parejo<sup>2</sup>, B. Cantos<sup>1</sup>, M. Provencio Pulla<sup>4</sup>,  
<sup>1</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, <sup>2</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, <sup>3</sup>University of Santiago de Compostela, Santiago de Compostela, ES, <sup>4</sup>Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, ES
- 13:05 - 13:05 **1524P - Multicenter Feasibility Study of Physician Orders for Life-Sustaining Treatment (POLST) for Terminal Cancer Patients**  
H.J. An<sup>1</sup>, H.J. Jeon<sup>2</sup>, J. Cheon<sup>3</sup>, S.H. Chun<sup>4</sup>, H.A. Jung<sup>5</sup>, H.K. Ahn<sup>6</sup>, K.H. Lee<sup>7</sup>, M.-H. Kim<sup>8</sup>, J.H. Kim<sup>9</sup>, S. Kim<sup>10</sup>, S.-J. Koh<sup>3</sup>,  
<sup>1</sup>St. Vincent's Hospital, College of Medicine, Catholic University of Korea, Seoul, KR, <sup>2</sup>Seoul Medical Center, Seoul, KR, <sup>3</sup>Ulsan University Hospital, Ulsan, KR, <sup>4</sup>Bucheon St. Mary's Hospital, College of Medicine Catholic University of Korea, Seoul, KR, <sup>5</sup>Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Dongtan, KR, <sup>6</sup>Gachon University Gil Hospital, Incheon, KR, <sup>7</sup>Department of Internal Medicine, Daegu, KR, <sup>8</sup>Ewha Institute of Convergence Medicine, Seoul, KR, <sup>9</sup>Department of Hematology and Oncology, Ulsan, KR, <sup>10</sup>Changwon National University, Changwon, KR
- 13:05 - 13:05 **1526P - The experience of Onco-Palliative care Multidisciplinary Meetings in Hotel Dieu de France University Hospital, an ESMO Designated Center of Integrated Oncology and Palliative Care**  
A. Houchan<sup>1</sup>, T. Assi<sup>2</sup>, Z. Bakouny<sup>1</sup>, E. El Rassy<sup>1</sup>, A. Tohme<sup>1</sup>, M.C. Mouhaweij<sup>1</sup>, J. Kattan<sup>3</sup>,  
<sup>1</sup>Saint Joseph University - Faculty of Medicine, Beirut, LB, <sup>2</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>3</sup>Hotel Dieu de France Hospital, Beirut, LB
- 13:05 - 13:05 **1527P - End of life resource utilization among patients receiving immunotherapy for advanced cancer**  
J. Burkart<sup>1</sup>, S. Patel<sup>1</sup>, A. Noonan<sup>1</sup>, P. Monk<sup>2</sup>, C. Presley<sup>1</sup>, T. Olencki<sup>1</sup>, K. Kendra<sup>3</sup>, G. Otterson<sup>1</sup>, J. Gustin<sup>4</sup>, L. Wei<sup>1</sup>, D. Owen<sup>1</sup>,  
<sup>1</sup>The Ohio State University James Cancer Hospital, Columbus, US, <sup>2</sup>The Ohio State University James Cancer Hospital, Columbus, US, <sup>3</sup>Ohio State University Comprehensive Cancer Center - James, Columbus, US, <sup>4</sup>Ohio State University, Columbus, US



- 13:05 - 13:05 **1528P - Palliative chemotherapy for patient with advanced tumor and poor performance status: are oncologists' hopes of benefit justified?**  
V. Vasconcellos<sup>1</sup>, R. Bonadio<sup>1</sup>, G. Avanco<sup>2</sup>, M. Negrão<sup>1</sup>, R. Riechelmann<sup>3</sup>, <sup>1</sup>ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR, <sup>2</sup>ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, <sup>3</sup>A. C. Camargo Cancer Center, Sao Paulo, BR
- 13:05 - 13:05 **1529P - Integration of Oncology and Palliative Care**  
S. Kaasa<sup>1</sup>, J.H. Loge<sup>1</sup>, T. Albrecht<sup>2</sup>, E. Bruera<sup>3</sup>, A. Caraceni<sup>4</sup>, A. Cervantes<sup>5</sup>, I. Higginson<sup>6</sup>, K. Jordan<sup>7</sup>, P. Sjögren<sup>8</sup>, P. Stone<sup>9</sup>, C. Zimmermann<sup>10</sup>, T. Lundebj<sup>1</sup>, <sup>1</sup>Oslo University Hospital, Oslo, NO, <sup>2</sup>National Institute of Public Health of Slovenia, Ljubljana, SI, <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>4</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>5</sup>University Hospital of Valencia, Valencia, ES, <sup>6</sup>King's College London, London, GB, <sup>7</sup>University of Heidelberg, Heidelberg, DE, <sup>8</sup>University of Copenhagen, Copenhagen, DK, <sup>9</sup>University College London, London, GB, <sup>10</sup>Princess Margaret Cancer Center, Toronto, CA
- 13:05 - 13:05 **1530P - Understandability of the Standard Arabic Translation of the EORTC QLQ-C15-PAL Questionnaire by Egyptian Patients with Incurable Cancer**  
H. Masoud<sup>1</sup>, S.-E. Abdelmoneim<sup>1</sup>, M. Ismael<sup>1</sup>, S. Alsirafy<sup>2</sup>, <sup>1</sup>Alexandria Faculty of Medicine, Alexandria, EG, <sup>2</sup>Kasr Al-Ainy School of Medicine, Cairo, EG
- 13:05 - 13:05 **1531P - How to Practice Oncology With a Supportive and Palliative Care Ambulatory Unit: A French Experience (HOASIS)**  
A. Gonzalez Moya<sup>1</sup>, H. Bourgeois<sup>2</sup>, <sup>1</sup>Centre Jean Bernard, Le Mans, FR, <sup>2</sup>Clinique Victor Hugo Le Mans, Le Mans, FR
- 13:05 - 13:05 **1532P - Prognostic impact of end-of-life chemotherapy in the last weeks for patients with advanced cancer**  
S. Hiramoto<sup>1</sup>, A. Kikuch<sup>1</sup>, T. Hori<sup>1</sup>, A. Yoshioka<sup>1</sup>, T. Tamaki<sup>2</sup>, <sup>1</sup>Mitsubishi Kyoto Hospital, Kyoto, JP, <sup>2</sup>Mukogawa Woman's University, Nishinomiya, JP
- 13:05 - 13:05 **1533P - A novel electronic tool to implement palliative sedation (PS) in a department of Oncologic Medicine**  
A. Saviola<sup>1</sup>, S. Cascinu<sup>1</sup>, M. Salati<sup>1</sup>, G. Longo<sup>2</sup>, C. Fiorani<sup>1</sup>, L. Ferrara<sup>1</sup>, N. Malavasi<sup>1</sup>, R. Postiglione<sup>1</sup>, F. Cantile<sup>1</sup>, L. Scarabelli<sup>1</sup>, M. Rimini<sup>3</sup>, F. Ferri<sup>1</sup>, <sup>1</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>2</sup>Azienda Ospealiero-Universitaria Policlinico di Modena, Modena, IT, <sup>3</sup>University Hospital of Modena, Modena, IT
- 13:05 - 13:05 **1534P - Congruence between actual place of death and preferences of Egyptian patients with advanced cancer and their family caregivers**  
S. Alsirafy<sup>1</sup>, O. Zaki<sup>2</sup>, N. Ibrahim<sup>1</sup>, W. Elsherief<sup>3</sup>, A. Hammad<sup>3</sup>, <sup>1</sup>NEMROCK Cairo University, Cairo, EG, <sup>2</sup>Cairo University, Cairo, EG, <sup>3</sup>Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EG
- 13:05 - 13:05 **1535P - Sarawak, Healthcare Professionals' Perception Of Palliative Care at End Of Life**



C. Cheah<sup>1</sup>, L. Winnie<sup>1</sup>, A. Merriman<sup>2</sup>, N.I. Mohd Naseri<sup>1</sup>, S. Chew<sup>3</sup>, <sup>1</sup>Sarawak General Hospital, Kuching, MY, <sup>2</sup>Hospice Uganda, Kampala, UG, <sup>3</sup>University of Bristol, Bristol, GB

- 13:05 - 13:05 **1536P - Factors associated with length of stay in an acute palliative care unit - a retrospective analysis**  
D. Hausner<sup>1</sup>, A. Pope<sup>2</sup>, N. Kevork<sup>2</sup>, L. Le<sup>2</sup>, C. Zimmermann<sup>3</sup>, <sup>1</sup>University of Toronto, Toronto, CA, <sup>2</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>3</sup>Princess Margaret Cancer Center, Toronto, CA
- 13:05 - 13:05 **1537P - Medical-Aid-in-Dying Use in the US Pacific Northwest**  
C. Blanke<sup>1</sup>, M. Leblanc<sup>2</sup>, D. Hershman<sup>2</sup>, F. Meyskens<sup>2</sup>, L. Taylor<sup>3</sup>, L. Ellis<sup>4</sup>, <sup>1</sup>Oregon Health Science University, Portland, US, <sup>2</sup>SWOG, Portland, US, <sup>3</sup>University of Washington Medical Center, Seattle, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US
- 13:05 - 13:05 **1538TiP - Brain Metastases in Norway - A Prospective Cohort Study**  
O. Yri<sup>1</sup>, M. Smebye<sup>2</sup>, M. Hjermsstad<sup>2</sup>, A. Karlson<sup>2</sup>, N. Aass<sup>2</sup>, J.H. Loge<sup>2</sup>, S. Kaasa<sup>2</sup>, <sup>1</sup>Oslo University Hospital Rikshospitalet - Radiumhospitalet Trust, Oslo, NO, <sup>2</sup>Oslo University Hospital, Oslo, NO
- 13:05 - 13:05 **Psycho-oncology**
- 13:05 - 13:05 **1541P - Partners' perceptions of women's body image problems and satisfaction of breast reconstruction long-term after risk-reducing mastectomy**  
L. Bai<sup>1</sup>, B. Arver<sup>1</sup>, H. Johansson<sup>1</sup>, M. Wickman<sup>2</sup>, K. Sandelin<sup>1</sup>, Y. Brandberg<sup>2</sup>, <sup>1</sup>Karolinska Institutet - Dept of Oncology-Pathology, Stockholm, SE, <sup>2</sup>Karolinska Institutet, Stockholm, SE
- 13:05 - 13:05 **1542P - The Effect of Music on the Instant Anxiety Levels of Oncologic Patients Receiving Chemotherapy Treatment**  
A. Alacacioglu<sup>1</sup>, G. Dissiz<sup>2</sup>, S. Iriz<sup>2</sup>, A. Usluoglu<sup>2</sup>, N. Asik<sup>2</sup>, <sup>1</sup>Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, TR, <sup>2</sup>Izmir Katip Celebi University,, izmir, TR
- 13:05 - 13:05 **1544P - Cognitive functions, coping strategies and psychological distress in patients with resected non-advanced cancer receiving chemotherapy: NEOcoping study data.**  
O. Higuera Gomez<sup>1</sup>, C. Calderón<sup>2</sup>, I. Ghanem<sup>3</sup>, A. Carmona-Bayonas<sup>4</sup>, C. Jara<sup>5</sup>, R. Hernández<sup>6</sup>, B. Castelo<sup>1</sup>, M.M. Muñoz<sup>7</sup>, C. Beato<sup>8</sup>, S. García<sup>9</sup>, E. Martínez<sup>10</sup>, M. Mut<sup>11</sup>, A. Ramchandani Vaswani<sup>12</sup>, M. Mangas<sup>13</sup>, O. Donnay<sup>14</sup>, M.T. García-García<sup>15</sup>, M.C. Soriano<sup>7</sup>, R. Carrión<sup>16</sup>, C. Iglesias Gomez<sup>17</sup>, P. Jimenez Fonseca<sup>17</sup>, <sup>1</sup>Hospital Universitario La Paz, Madrid, ES, <sup>2</sup>University of Barcelona, Barcelona, ES, <sup>3</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>4</sup>Hospital Universitario Morales Meseguer, Murcia, ES, <sup>5</sup>Hospital Universitario Fundación Alcorcón, Madrid, ES, <sup>6</sup>Hospital Universitario de Canarias, Tenerife, ES, <sup>7</sup>Hospital Virgen de La Luz, Cuenca, ES, <sup>8</sup>. Hospital Universitario

Virgen de la Macarena, Sevilla, ES, <sup>9</sup>Hospital Universitario de la Santa Cruz i Sant Pablo, Barcelona, ES, <sup>10</sup>Hospital Universitario Marqués de Valdecilla, Santander, ES, <sup>11</sup>Hospital Universitario Son Espases, Mallorca, ES, <sup>12</sup>Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, <sup>13</sup>Hospital Galdakao-Usansolo, Galdakao-Usansolo, ES, <sup>14</sup>Hospital Universitario de La Princesa, Madrid, ES, <sup>15</sup>Hospital Universitario Santa Lucia, Cartagena, ES, <sup>16</sup>Hospital Universitario del Sureste, Madrid, ES, <sup>17</sup>Hospital Universitario Central de Asturias, Oviedo, ES

13:05 - 13:05

**1543P - Ostracism In Adolescent Cancer Patients And Predictors (OSTRACA Study): A Study Of The Palliative Care Working Committee Of The Turkish Oncology Group (TOG)**

A. Alkan<sup>1</sup>, Z.G. Güç<sup>2</sup>, T. Şakalar<sup>3</sup>, G. Zengin<sup>4</sup>, A. Yaşar<sup>5</sup>, Y. Karakas<sup>6</sup>, T. Yavuzsen<sup>7</sup>, O. Oksuzoglu<sup>8</sup>, F. Çay Şenler<sup>9</sup>, <sup>1</sup>Osmanyie Devlet Hastanesi - Osmaniye Public Hospital, Osmaniye, TR, <sup>2</sup>Dokuz Eylül University School of Medicine, İzmir, TR, <sup>3</sup>Erciyes University School of Medicine, Kayseri, TR, <sup>4</sup>Ankara Abdurrahman Yurtaslan Oncology Hospital, Ankara, TR, <sup>5</sup>Ankara University School of Medicine, Ankara, TR, <sup>6</sup>Hacettepe University Faculty of Medicine, Ankara, TR, <sup>7</sup>Dokuz Eylül University School of Medicine, Institute of Oncology, İzmir, TR, <sup>8</sup>Dr. Abdurrahman Yurtaslan Ankara Onkoloji Training and Research Hospital, Ankara, TR, <sup>9</sup>Ankara University School of Medicine, İstanbul, TR

13:05 - 13:05

**1545P - Cancer Stigma related beliefs patients and Providers**

G.S. Bhattacharyya<sup>1</sup>, H. Malhotra<sup>2</sup>, G. Babu<sup>3</sup>, A. Vora<sup>4</sup>, S. Bhattacharyya<sup>5</sup>, <sup>1</sup>G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, Kolkata, IN, <sup>2</sup>Birla Cancer Center, Jaipur, IN, <sup>3</sup>HCG Curie Centre of Oncology, Bangalore, IN, <sup>4</sup>Pratiksha Hospital, Gurugram, Haryana, IN, <sup>5</sup>G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, Kolkata, IN

13:05 - 13:05

**1546P - Relationship between depressive symptoms at social cognitive processing in partners of long term breast cancer survivors.**

G.S. Bhattacharyya<sup>1</sup>, H. Malhotra<sup>2</sup>, G. Babu<sup>3</sup>, A. Vora<sup>4</sup>, T. Shahid<sup>5</sup>, S. Misra Ghosh<sup>6</sup>, <sup>1</sup>G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, Kolkata, IN, <sup>2</sup>Birla Cancer Center, Jaipur, IN, <sup>3</sup>HCG Curie Centre of Oncology, Bangalore, IN, <sup>4</sup>Pratiksha Hospital, Gurugram, Haryana, IN, <sup>5</sup>Apollo Gleneagles Cancer Hospital, Kolkata, IN, <sup>6</sup>Fortis Hospital, Kolkata, Kolkata, IN

13:05 - 13:05

**1547P - Evaluation of the distinction and temporal relationship between prolonged grief disorder and depression in terminally ill cancer patients' caregivers' first two years of bereavement**

W.-I. Tsai<sup>1</sup>, S.-C. Kuo<sup>2</sup>, F.-H. Wen<sup>3</sup>, J.-S. Chen<sup>4</sup>, S.T. Tang<sup>1</sup>, <sup>1</sup>Chung Gung University, Taoyuan, TW, <sup>2</sup>Chang Gung University, Tao-Yuan, TW, <sup>3</sup>Soochow University, taipei, TW, <sup>4</sup>Chung Gung University, Tao Yuan, TW

13:05 - 13:05

**1548P - Patients' and partners' views of treatment and care provided for metastatic castrate resistant prostate cancer (mCRPC) in the UK**

S. Catt<sup>1</sup>, L. Matthews<sup>1</sup>, H. Payne<sup>2</sup>, M. Mason<sup>3</sup>, V. Jenkins<sup>4</sup>, <sup>1</sup>Brighton and Sussex Medical School, University of Sussex, Brighton, GB, <sup>2</sup>University College London Hospital UCLH NHS Foundation Trust, London, GB, <sup>3</sup>Velindre Cancer Centre Velindre Hospital, Cardiff,

GB, <sup>4</sup>BSMS, Brighton, GB

- 13:05 - 13:05 **1549P - Exploring the effectiveness of crisis counselling and psycho-education in relation to improving mental wellbeing, quality of life and treatment compliance of breast cancer patients in Qatar**  
R. Alsulaiman<sup>1</sup>, S. Bujassoum<sup>1</sup>, A. Bener<sup>2</sup>, L. Doodson<sup>3</sup>, S. Ghuloum<sup>4</sup>, A. Lemaux<sup>1</sup>, H. Bugrein<sup>1</sup>, R. Alasaam<sup>1</sup>, A. Karim<sup>1</sup>, <sup>1</sup>National Center for Cancer Care and Research, Doha, QA, <sup>2</sup>Istanbul University, Istanbul, TR, <sup>3</sup>Regent's college, London, GB, <sup>4</sup>Hamad General Hospital, Doha, QA
- 13:05 - 13:05 **1550P - Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma**  
R. Nshimiyimana<sup>1</sup>, C. Guzzetta<sup>2</sup>, M.-M. Brown<sup>3</sup>, Q. Zhou<sup>4</sup>, J. Johnson<sup>5</sup>, T. Sato<sup>6</sup>, S. Keith<sup>5</sup>, <sup>1</sup>Kimmel Cancer Center-Thomas Jefferson University, Philadelphia, US, <sup>2</sup>The George Washington University, Washington DC, US, <sup>3</sup>MedStar Health, Columbia, US, <sup>4</sup>The George Washington University, Ashburn, US, <sup>5</sup>Thomas Jefferson University, Philadelphia, US, <sup>6</sup>Thomas Jefferson University Hospital, Philadelphia, US
- 13:05 - 13:05 **1551P - Making sense of self-conscious and emotion: linking theory of mind and emotion in women with breast cancer.**  
A. Datta<sup>1</sup>, P. (Chaudhuri)<sup>2</sup>, <sup>1</sup>Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, IN, <sup>2</sup>Institute of Psychiatry, Kolkata, IN
- 13:05 - 13:05 **1552P - Characteristics of the psychosomatic state of patients with lung cancer**  
G. Zhukova<sup>1</sup>, A. Shikhlyarova<sup>1</sup>, E. Shirnina<sup>1</sup>, M. Zinkovich<sup>1</sup>, N. Maschenko<sup>1</sup>, E. Zlatnik<sup>1</sup>, S. Pyltsin<sup>1</sup>, P. Anistratov<sup>1</sup>, M. Bragina<sup>1</sup>, A. Zhadobina<sup>1</sup>, L. Vladimirova<sup>2</sup>, <sup>1</sup>Rostov Research Oncology Institute, Rostov-on-Don, RU, <sup>2</sup>Rostov Research Institute of Oncology, Rostov-on-Don, RU
- 13:05 - 13:05 **1553P - Perception, Magnitude and Implications of Cancer Related Fatigue in Breast Cancer Survivors: Study from a Developing Country**  
A. Gupta, S. Hussain, R. Manaktala, Max Institute of Cancer Care, New Delhi, IN
- 13:05 - 13:05 **1554P - Impact of cancer on the quality of life of Tunisian pediatric patients**  
F. Letaief-Ksontini<sup>1</sup>, T. Dorra<sup>2</sup>, S. Masmoudi<sup>3</sup>, K. Meddeb<sup>1</sup>, A. Mokrani<sup>1</sup>, Y. Yahyaoui<sup>1</sup>, A. Gabsi<sup>1</sup>, M. Ayadi<sup>1</sup>, N. Chraiet<sup>1</sup>, H. Raies<sup>4</sup>, A. Mezlini<sup>1</sup>, <sup>1</sup>Salah Azaiez Institute, Tunis, TN, <sup>2</sup>Institut Salah Azaïz, Tunis, TN, <sup>3</sup>Salah Azaiez Institute of Cancer, Tunis, TN, <sup>4</sup>Salah Azaiez Cancer Institute, Tunis, TN
- 13:05 - 13:05 **Public health policy**
- 13:05 - 13:05 **1569P - The impact of primary care access on mortality in lung cancer patients from Bronx, New York**  
C. Su<sup>1</sup>, H. Cheng<sup>2</sup>, <sup>1</sup>Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, <sup>2</sup>Montefiore Medical Center Albert Einstein College of Medicine, Bronx, US

- 13:05 - 13:05 **1570P - Are socioeconomic position and region of residence barriers for referral to phase I trials?**  
K. Gad<sup>1</sup>, S.O. Dalton<sup>2</sup>, A.K. Duun-Henriksen<sup>2</sup>, A. Krøyer<sup>2</sup>, C. Johansen<sup>3</sup>, M. Mau-Sorensen<sup>1</sup>, U. Lassen<sup>3</sup>, <sup>1</sup>SKACCD - Rigshospitalet, Copenhagen, DK, <sup>2</sup>Danish Cancer Society Research Center, Copenhagen, DK, <sup>3</sup>Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK
- 13:05 - 13:05 **1571P - Breast cancer treatment waiting time, Patient and provider contributions; An Egyptian breast cancer centre experience**  
A. Abdelaziz<sup>1</sup>, A. Abdou<sup>1</sup>, C. Habeeb<sup>2</sup>, <sup>1</sup>Ain Shams University Hospital, Cairo, EG, <sup>2</sup>Baheya Foundation for breast cancer, Cairo, EG
- 13:05 - 13:05 **1572P - Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: a national registry study**  
N. Battisti<sup>1</sup>, M. Wallington<sup>2</sup>, A. Ring<sup>3</sup>, S. Payne<sup>4</sup>, R. Birch<sup>5</sup>, M. Bomb<sup>2</sup>, J. Seligmann<sup>6</sup>, T. Kalsi<sup>7</sup>, L. Hounsome<sup>2</sup>, D. Dodwell<sup>8</sup>, S. Underhill<sup>9</sup>, L. Mensah<sup>10</sup>, E. Morris<sup>5</sup>, P. Selby<sup>6</sup>, J. Mansi<sup>4</sup>, <sup>1</sup>The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>2</sup>Public Health England, London, GB, <sup>3</sup>The Royal Marsden NHS Foundation Trust, Surrey, GB, <sup>4</sup>Guy's and St Thomas' NHS Foundation Trust, London, GB, <sup>5</sup>University of Leeds, Leeds, GB, <sup>6</sup>St. James's University Hospital Leeds, Leeds, GB, <sup>7</sup>Guy's and St Thomas' NHS Foundation Trust, London, GB, <sup>8</sup>Leeds Teaching Hospitals NHS Trust, Leeds, GB, <sup>9</sup>Roche, London, GB, <sup>10</sup>Novartis Oncology, London, GB
- 13:05 - 13:05 **1573P - Awareness and attitude towards breast cancer among Egyptian nurses at university affiliated hospitals: Tanta university hospitals experience**  
M. Alm El-Din<sup>1</sup>, S. Amer<sup>2</sup>, M. Elsayed<sup>2</sup>, A. Elgohary<sup>2</sup>, A. Ismael<sup>2</sup>, A. Zakzouk<sup>2</sup>, K. Emarat<sup>2</sup>, F. Elkady<sup>2</sup>, S. Elnahrawy<sup>2</sup>, F. Nada<sup>2</sup>, A. Eissa<sup>2</sup>, <sup>1</sup>Tanta University Hospital, Tanta, EG, <sup>2</sup>Tanta University Hospital, Tanta Faculty of Medicine, Tanta, EG
- 13:05 - 13:05 **1574P - Women oncologists participation at the Spanish Society of Medical Oncology (SEOM) annual meetings from 2009 to 2017 and their position in Spanish scientific societies**  
J. Hidalgo Coloma<sup>1</sup>, A. Ruiz Hernández<sup>2</sup>, <sup>1</sup>Hospital Arnau de Vilanova, Lleida, ES, <sup>2</sup>Hospital Clínico Universitario, Valencia, ES
- 13:05 - 13:05 **1575P - Working arrangements after cancer diagnosis: who, what, when and how?**  
C. Alleaume<sup>1</sup>, A.-D. Bouhnik<sup>2</sup>, M. Bendiane<sup>3</sup>, P. Peretti-Watel<sup>4</sup>, <sup>1</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>2</sup>Aix-Marseille University - Faculté de Médecine Timone, Marseille, FR, <sup>3</sup>SESTIM, Marseille, FR, <sup>4</sup>Aix Marseille Univ, INSERM, IRD, Economics and Social Sciences Applied to Health & Analysis of Medical Information (SESSTIM), Marseille, FR
- 13:05 - 13:05 **1576P\_PR - Financial toxicity in German cancer patients. How does a chronic disease impact the economic situation?**



E. Winkler<sup>1</sup>, K. Mehlis<sup>1</sup>, B. Surmann<sup>2</sup>, J. Witte<sup>2</sup>, R. Lingnau<sup>2</sup>, L. Apostolidis<sup>3</sup>, J. Walther<sup>1</sup>, W. Greiner<sup>2</sup>, <sup>1</sup>Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, <sup>2</sup>Bielefeld University, Bielefeld, DE, <sup>3</sup>University Hospital Heidelberg, Heidelberg, DE

- 13:05 - 13:05 **1579P - Influenza vaccine effectiveness among cancer patients: a population-based study using health administrative and laboratory testing data from Ontario, Canada**  
P. Blanchette<sup>1</sup>, H. Chung<sup>2</sup>, K. Pritchard<sup>3</sup>, C. Earle<sup>2</sup>, M. Campitelli<sup>2</sup>, N. Crowcroft<sup>4</sup>, J. Gubbay<sup>4</sup>, T. Karnachow<sup>5</sup>, K. Katz<sup>6</sup>, A. Mcgeer<sup>7</sup>, D. McNally<sup>5</sup>, D. Richardson<sup>6</sup>, S. Richardson<sup>8</sup>, L. Rosella<sup>2</sup>, A. Simor<sup>9</sup>, M. Smieja<sup>10</sup>, G. Zahariadis<sup>11</sup>, A. Campigotto<sup>12</sup>, J. Kwong<sup>2</sup>, <sup>1</sup>London Regional Cancer Program, Western University, London, CA, <sup>2</sup>Institute of Clinical Evaluative Sciences, Toronto, CA, <sup>3</sup>Sunnybrook Odette Cancer Center, Sunnybrook HSC, Toronto, CA, <sup>4</sup>Public Health Ontario, Toronto, CA, <sup>5</sup>Children's Hospital of Eastern Ontario, Ottawa, CA, <sup>6</sup>North York General Hospital, Toronto, CA, <sup>7</sup>Mount Sinai Hospital, Toronto, CA, <sup>8</sup>The Hospital for Sick Children, Toronto, CA, <sup>9</sup>Sunnybrook Health Sciences Centre, Toronto, CA, <sup>10</sup>McMaster University, Hamilton, CA, <sup>11</sup>Newfoundland and Labrador Public Health Laboratory, St John's, CA, <sup>12</sup>London Health Sciences Centre, London, CA
- 13:05 - 13:05 **1577P - Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: a UK study**  
N. Flaum, G. Papaxoinis, K. Hockenull, J. Barriuso, W. Mansoor, The Christie NHS Foundation Trust, Manchester, GB
- 13:05 - 13:05 **1580P - How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience**  
W. Evans<sup>1</sup>, W. Flanagan<sup>2</sup>, C. Gauvreau<sup>3</sup>, P. Manivong<sup>4</sup>, S. Memon<sup>3</sup>, N. Fitzgerald<sup>3</sup>, J. Goffin<sup>5</sup>, R. Garner<sup>2</sup>, E. Khoo<sup>4</sup>, N. Mittmann<sup>4</sup>, <sup>1</sup>McMaster University, Hamilton, CA, <sup>2</sup>Statistics Canada, Ottawa, CA, <sup>3</sup>Canadian Partnership Against Cancer, Toronto, CA, <sup>4</sup>Cancer Care Ontario, Toronto, CA, <sup>5</sup>Juravinski Cancer centre, Hamilton, CA
- 13:05 - 13:05 **1581P - Anticoagulant treatment of patients (pts) with cancer associated thromboembolism (CAT) in Germany. Real world data from a 4 Million people sample generated by insurance captured data**  
A. Kretschmar<sup>1</sup>, M. May<sup>1</sup>, A. Heinken<sup>2</sup>, H. Riess<sup>3</sup>, <sup>1</sup>Klinikum St. Georg gGmbH, Leipzig, DE, <sup>2</sup>Aspen Germany GmbH, Munich, DE, <sup>3</sup>Charite Berlin Mitte, Berlin, DE
- 13:05 - 13:05 **1583P - Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location**  
C. Ho<sup>1</sup>, B. Leung<sup>2</sup>, H. Rennie<sup>2</sup>, J. Laskin<sup>3</sup>, J. Wu<sup>2</sup>, A. Bates<sup>2</sup>, <sup>1</sup>BC Cancer Research Center, Vancouver, CA, <sup>2</sup>BC Cancer, Vancouver, CA, <sup>3</sup>British Columbia Cancer Agency, Vancouver, CA
- 13:05 - 13:05 **1582P - Age Distribution for Different Types of Cancer in the United States (1996-2015)**  
M. Gouda, Faculty of Medicine - Menoufia University, Shebin El Kom, EG
- 13:05 - 13:05 **1584P - Overview on the use of patient reported outcomes in colorectal cancer**

**care**

L. Neamtiu<sup>1</sup>, S. Deandrea<sup>2</sup>, L. Pylkkanen<sup>3</sup>, Z. Saz Parkinson<sup>1</sup>, <sup>1</sup>JRC - ISPRA, Ispra, IT, <sup>2</sup>ATS Milano, Milan, IT, <sup>3</sup>Cancer Society of Finland, Helsinki, FI

13:05 - 13:05 **1585P - Completeness of staging investigation for colorectal cancer: exploring the role of increasing age and comorbidity using mediation analysis**

S. Benitez Majano<sup>1</sup>, S. Vansteelandt<sup>2</sup>, C. Di Girolamo<sup>1</sup>, M. Morris<sup>1</sup>, S. Walters<sup>1</sup>, B. Racht<sup>1</sup>, <sup>1</sup>London School of Hygiene and Tropical Medicine, London, GB, <sup>2</sup>Ghent University, Ghent, BE

13:05 - 13:05 **1586P - The Quality Oncology Practice Initiative program: Experience in Spain.**

R. Lopez Lopez<sup>1</sup>, A. Anton Torres<sup>2</sup>, E. Aranda Aguilar<sup>3</sup>, A. Carrato Mena<sup>4</sup>, M. Constenla Figueiras<sup>5</sup>, J.J. Cruz Hernandez<sup>6</sup>, E. Diaz Rubio<sup>7</sup>, M. Feyjoo<sup>8</sup>, J. Garcia Foncillas<sup>9</sup>, P. Gascon<sup>10</sup>, V. Guillem Porta<sup>11</sup>, I. Lugo Cuan<sup>12</sup>, A. Rogado<sup>12</sup>, C. Camps<sup>13</sup>, <sup>1</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>2</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>3</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>4</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>5</sup>Complejo Hospitalario de Pontevedra, Pontevedra, ES, <sup>6</sup>Hospital Universitario de Salamanca, Salamanca, ES, <sup>7</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>8</sup>Hospital Universitario La Moraleja, Sanitas, Madrid, ES, <sup>9</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>10</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>11</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>12</sup>Fundación ECO, Madrid, ES, <sup>13</sup>Consortio Hospital General Universitario de Valencia, Valencia, ES

13:05 - 13:05 **1587P - Can Measuring Quality Lead to Improvement? Evidence from International Participants of ASCO's Quality Oncology Practice Initiative (QOPI®) During 2015-2017**

M. Jahanzeb<sup>1</sup>, T. Gilmore<sup>2</sup>, A. Roach<sup>2</sup>, S. Grubbs<sup>2</sup>, D. Blayney<sup>3</sup>, J. Hamm<sup>4</sup>, A. Kamal<sup>5</sup>, R. Kelly<sup>6</sup>, E. Martin<sup>7</sup>, J. Sanchez<sup>8</sup>, R. Siegel<sup>9</sup>, S.T.S. Crist<sup>2</sup>, J. Rosenthal<sup>2</sup>, C. Hendricks<sup>10</sup>, <sup>1</sup>University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, <sup>2</sup>American Society of Clinical Oncology, Alexandria, US, <sup>3</sup>Stanford Comprehensive Cancer Institute, Stanford, US, <sup>4</sup>Norton Health Care Medical Oncology & Hematology, Louisville, US, <sup>5</sup>Duke University School of Medicine, Durham, US, <sup>6</sup>Johns Hopkins University, Baltimore, US, <sup>7</sup>Medical Oncology Hematology Consultants, Newark, US, <sup>8</sup>Hospital Escuela, University of Honduras, Tegucigalpa, HN, <sup>9</sup>St. Francis Hospital, Greenville, US, <sup>10</sup>Associates In Oncology Hematology, Bethesda, US

13:05 - 13:05 **1588P - Treatment algorithm for multiple myeloma: real-world insights across five European countries**

A. Rocci<sup>1</sup>, P. Bulger<sup>1</sup>, A. Martinez De Pinillos<sup>2</sup>, P. Nasuti<sup>2</sup>, C. Anger<sup>2</sup>, F. Manuguid<sup>2</sup>, <sup>1</sup>Manchester University NHS Foundation Trust, Manchester Royal Infirmary, Manchester, GB, <sup>2</sup>IQVIA, London, GB

13:05 - 13:05 **1589P - Are treatment recommendations provided by cognitive computing supported by real world data (Watson for Oncology with Cota RWE) concordant with expert opinions?**

D. Atieh Graham<sup>1</sup>, D. Mcnamara<sup>1</sup>, S. Waintraub<sup>1</sup>, S. Goldberg<sup>2</sup>, A. Norden<sup>3</sup>, J. Hervey<sup>3</sup>, A. Pecora<sup>4</sup>, C. Landstrom<sup>4</sup>, J. Snowdon<sup>5</sup>, P. Francis<sup>5</sup>, N. Jungbluth<sup>5</sup>, C. Wang<sup>5</sup>, L. Latts<sup>5</sup>,

<sup>1</sup>John Theurer Cancer Center, Hackensack, US, <sup>2</sup>The John Theurer Cancer Center, Hackensack, US, <sup>3</sup>Cota, New York, US, <sup>4</sup>Inc, New York, US, <sup>5</sup>IBM, Cambridge, US

- 13:05 - 13:05 **1590P - Body shape trajectories and risk of breast cancer: results from The SUN Study Project**  
R. Sanchez Bayona<sup>1</sup>, C. Sayon<sup>2</sup>, I. Gardeazabal<sup>3</sup>, M.A. Martínez-González<sup>2</sup>, M. Santisteban Eslava<sup>4</sup>, E. Toledo-Atucha<sup>2</sup>, <sup>1</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>2</sup>Universidad de Navarra, Pamplona, ES, <sup>3</sup>Clinica Universidad de Navarra, Pamplona, ES, <sup>4</sup>CLIN. UNIVERSITARIA NAVARRA, Pamplona, ES
- 13:05 - 13:05 **1591P - Total polyphenol intake and breast cancer risk in the SUN Project**  
I. Gardeazabal<sup>1</sup>, A. Romanos-Nanclares<sup>2</sup>, R. Sanchez Bayona<sup>1</sup>, J. Graforio<sup>3</sup>, M.A. Martínez-González<sup>2</sup>, E. Toledo-Atucha<sup>2</sup>, <sup>1</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>2</sup>Universidad de Navarra, Pamplona, ES, <sup>3</sup>Universidad de Jaén, Jaén, ES
- 13:05 - 13:05 **1592P - No effect of length time bias on the genomic risk in ER+ HER2- Stage I-IIA Breast Cancer (BC) patients according to diagnosis in a screening programme: An exploratory analysis**  
I. Gonzalez Barrallo<sup>1</sup>, J.A. Perez Fidalgo<sup>1</sup>, J. Ramirez<sup>2</sup>, O. Burgues<sup>3</sup>, J.V. Sorlí<sup>4</sup>, O. Portoles<sup>2</sup>, C. Hernando<sup>1</sup>, D. Salas<sup>5</sup>, A. Lluch<sup>1</sup>, <sup>1</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>2</sup>University of Valencia, Valencia, ES, <sup>3</sup>Hospital Clínico Universitario de Valencia, Valencia, ES, <sup>4</sup>Universitat de València, Valencia, ES, <sup>5</sup>Research Center in Public Health - Centro Superior de Investigación en Salud Publica (CSISP), Valencia, ES
- 13:05 - 13:05 **1593P - Breast cancer screening: impact on care pathways**  
D. Lefeuvre<sup>1</sup>, N. Catajar<sup>1</sup>, C. Le Bihan Benjamin<sup>1</sup>, F. De Bels<sup>1</sup>, J. Viguier<sup>2</sup>, P.-J. Bousquet<sup>3</sup>, <sup>1</sup>INCA - Institut National du Cancer, Boulogne-Billancourt, FR, <sup>2</sup>Institut National du Cancer, Boulogne-Billancourt, FR, <sup>3</sup>INCa, Paris, FR
- 13:05 - 13:05 **1594P\_PR - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey**  
J.-F. Morere<sup>1</sup>, J. Viguier<sup>2</sup>, L. Greillier<sup>3</sup>, M. Roupert<sup>4</sup>, C. Touboul<sup>5</sup>, C. Lhomel<sup>6</sup>, S. Couraud<sup>7</sup>, T. De La Motte Rouge<sup>8</sup>, F. Eisinger<sup>9</sup>, <sup>1</sup>Hôpital Paul Brousse, Villejuif, FR, <sup>2</sup>Institut National du Cancer, Boulogne-Billancourt, FR, <sup>3</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>4</sup>Hôpital Universitaire Pitié-Salpêtrière, Paris, FR, <sup>5</sup>Kantar Health, Paris, FR, <sup>6</sup>Products Roche - France, Neuilly-sur-Seine, FR, <sup>7</sup>Centre Hospitalier Lyon Sud, Pierre Bénite, FR, <sup>8</sup>Centre Eugene - Marquis, Rennes, FR, <sup>9</sup>Institute Paoli Calmettes, Marseille, FR
- 13:05 - 13:05 **1595P - 10-year results of the Breast Cancer Screening Program in Khanty-Mansiysk State Region - Ugra.**  
N. Zakharova<sup>1</sup>, A. Brentnall<sup>2</sup>, J. Belaya<sup>1</sup>, E. Bilan<sup>3</sup>, <sup>1</sup>Khanty-Mansiysk State Medical Academy, Khanty-Mansiysk, RU, <sup>2</sup>Queen Mary University of London, London, AE, <sup>3</sup>Khanty-Mansiysk State Clinical Hospital, Khanty-Mansiysk, RU

- 13:05 - 13:05 **1596P - Malignant lymphoma detected by screening program with esophagogastroduodenoscopy of one private screening center in Japan**  
T. Nakamura, M. Ikeda, S. Shibata, Y. Kon, K. Konuma, T. Sanada, H. Gonda, Y. Suto, K. Kobayashi, H. Tamura, M. Kobayashi, A. Hasegawa, Y. Amagasa, A. Suzuki, M. Fukuda, C. Aoyagi, N. Matsuura, Y. Kawashima, M. Shimura, N. Takita, Ota Memorial Hospital, Ota, JP
- 13:05 - 13:05 **1597P - Worldwide trends in survival from childhood glioma 2000-2014 (CONCORD-3): preliminary findings and plans for further research.**  
F. Girardi, V. Di Carlo, A. Bonaventure, C. Allemani, M. Coleman, Concord Working Group, London School of Hygiene and Tropical Medicine, London, GB
- 13:05 - 13:05 **1598P - Referral patterns and predictors of survival for Stage IV pancreatic ductal adenocarcinoma**  
A. Suo<sup>1</sup>, P. Tang<sup>1</sup>, D. Tilley<sup>1</sup>, W. Cheung<sup>2</sup>, R. Lee-Ying<sup>1</sup>, <sup>1</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>2</sup>Alberta Health Services, Calgary, CA
- 13:05 - 13:05 **1599P - Gender difference in cancer survivors' perceived information 5-years after diagnosis. Data from the French national study: VICAN 5.**  
G. Gravis<sup>1</sup>, R. Touzani<sup>2</sup>, A.-D. Bouhnik<sup>3</sup>, P. Marino<sup>4</sup>, G. Pignot<sup>1</sup>, M. Bendiane<sup>5</sup>, <sup>1</sup>Institute Paoli Calmettes, Marseille, FR, <sup>2</sup>Aix Marseille University, Marseille, FR, <sup>3</sup>Aix-Marseille University - Faculté de Médecine Timone, Marseille, FR, <sup>4</sup>Institute Paoli-Calmettes, Marseille, FR, <sup>5</sup>SESTIM, Marseille, FR
- 13:05 - 13:05 **1600P - Survival Difference Between Microscopically Confirmed and Microscopically Non-Confirmed Cancers**  
M. Gouda, Faculty of Medicine - Menoufia University, Shebin El Kom, EG
- 13:05 - 13:25 **Sarcoma**
- 13:25 - 13:25 **1616P - Quantitative Multiplexed Immune Profiling of Advanced Gastrointestinal Stromal Tumors (GISTs): Impact of tyrosine kinase inhibitors on immune environment**  
C. Yoo<sup>1</sup>, S.-Y. Kim<sup>2</sup>, J. Kim<sup>1</sup>, Y.-M. Ryu<sup>3</sup>, M.-H. Ryu<sup>1</sup>, Y.-K. Kang<sup>1</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KR, <sup>3</sup>Asan Institute for Life Sciences, Seoul, KR
- 13:25 - 13:25 **1617P - Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST.**  
A. Callejo Goena<sup>1</sup>, S. Faouzi<sup>2</sup>, O. Bouche<sup>3</sup>, T. Chevalier<sup>4</sup>, N. Isambert<sup>5</sup>, F. Duffaud<sup>6</sup>, O. Collard<sup>7</sup>, O. Mir<sup>8</sup>, P. Terrier<sup>8</sup>, J.-Y. Blay<sup>9</sup>, A. Le Cesne<sup>10</sup>, <sup>1</sup>Hospital de Cruces, Barakaldo, ES, <sup>2</sup>Gustave Roussy Institute, Villejuif, FR, <sup>3</sup>CHU de Reims - Hôpital Robert Debré, Reims, FR, <sup>4</sup>CHU La Timone and Aix Marseille Université (AMU), MArseille, FR, <sup>5</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>6</sup>CHU La Timone Adultes, Marseille, FR, <sup>7</sup>Institut de Cancérologie de La Loire - Lucien Neuwirth, La Loire, FR, <sup>8</sup>Institut Gustave Roussy, Villejuif, FR, <sup>9</sup>Centre Léon Bérard, Lyon, FR, <sup>10</sup>Gustave Roussy - Cancer Campus, Villejuif, FR



- 13:25 - 13:25 **1618P - Prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) treatment in patients (pts) with advanced gastrointestinal stromal tumor (GIST)**  
H. Cho<sup>1</sup>, M.-H. Ryu<sup>1</sup>, H. Chae<sup>1</sup>, S.M. Lee<sup>1</sup>, Y. Park<sup>1</sup>, K.-H. Kim<sup>1</sup>, C.W. Kim<sup>1</sup>, B.S. Kim<sup>1</sup>, M.-W. Yoo<sup>1</sup>, J. Ma<sup>1</sup>, M.Y. Beck<sup>2</sup>, M. Kim<sup>1</sup>, Y.-K. Kang<sup>1</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KR
- 13:25 - 13:25 **1619P - Systemic steroid treatment for severe skin rash induced by imatinib in patients with gastrointestinal stromal tumor (GIST): A phase II study**  
E. Kim<sup>1</sup>, M.-H. Ryu<sup>2</sup>, S.R. Park<sup>2</sup>, M.Y. Beck<sup>1</sup>, W.J. Lee<sup>2</sup>, M.W. Lee<sup>2</sup>, Y.-K. Kang<sup>2</sup>, <sup>1</sup>Asan Medical Center, Seoul, KR, <sup>2</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR
- 13:25 - 13:25 **1620P - Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib**  
H. Cho<sup>1</sup>, M.-H. Ryu<sup>1</sup>, B.J. Kim<sup>1</sup>, Y. Park<sup>1</sup>, Y.-S. Na<sup>1</sup>, J. Ma<sup>1</sup>, M.Y. Beck<sup>2</sup>, Y.-K. Kang<sup>1</sup>, <sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KR
- 13:25 - 13:25 **1622P - Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors**  
M. Yamamura<sup>1</sup>, A. Yamauchi<sup>2</sup>, N. Katase<sup>3</sup>, Y. Katata<sup>1</sup>, H. Tanioka<sup>1</sup>, M. Okawaki<sup>1</sup>, T. Nagasaka<sup>4</sup>, Y. Yamaguchi<sup>1</sup>, <sup>1</sup>Kawasaki Medical School Hospital, Kurashiki, JP, <sup>2</sup>Kawasaki Medical School, Kurashiki, JP, <sup>3</sup>Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, JP, <sup>4</sup>Okayama University Hospital, Okayama, JP
- 13:25 - 13:25 **1623P - Correlation of ctDNA and response in patients (pts) with PDGFR\_ D842 GIST treated with avapritinib**  
S. George<sup>1</sup>, S. Bauer<sup>2</sup>, R. Jones<sup>3</sup>, C. Serrano<sup>4</sup>, M. Von Mehren<sup>5</sup>, Y.-K. Kang<sup>6</sup>, P. Schöffski<sup>7</sup>, P. Cassier<sup>8</sup>, F. Eskens<sup>9</sup>, O. Mir<sup>10</sup>, W. Tap<sup>11</sup>, S. Chawla<sup>12</sup>, P. Rutkowski<sup>13</sup>, H. Shi<sup>14</sup>, O. Schmidt-Kittler<sup>14</sup>, B. Mar<sup>14</sup>, M. Heinrich<sup>15</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>University Hospital Essen, Essen, DE, <sup>3</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>4</sup>Vall d' Hebron Institute of Oncology, Barcelona, ES, <sup>5</sup>Fox Chase Cancer Center, Philadelphia, US, <sup>6</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>7</sup>University Hospitals Leuven, Leuven, BE, <sup>8</sup>Centre Léon Bérard, Lyon, FR, <sup>9</sup>Erasmus University Medical Center, Rotterdam, NL, <sup>10</sup>Institut Gustave Roussy, Villejuif, FR, <sup>11</sup>Memorial Sloan Kettering Cancer Centre, New York, US, <sup>12</sup>Sarcoma Oncology Research Center, Santa Monica, US, <sup>13</sup>Maria Sklodowska-Curie Institute - Oncology Center, Warszawa, PL, <sup>14</sup>Blueprint Medicines Corporation, Cambridge, US, <sup>15</sup>Oregon Health and Science University, Portland, US
- 13:25 - 13:25 **1624P - Pathological Grade of Tumorregression after neoadjuvant Chemotherapy with Doxorubicin/Ifosfamid and Regional Hyperthermia correlates with Survival Outcomes in Patients with high-risk Soft Tissue Sarcoma**  
G.-E. Schuebbe<sup>1</sup>, T. Knösel<sup>2</sup>, H.R. Dürr<sup>1</sup>, M. Angele<sup>1</sup>, F. Röder<sup>1</sup>, S. Abdel-Rahman<sup>1</sup>, A.

Alig<sup>1</sup>, R. Issels<sup>3</sup>, D. Di Gioia<sup>1</sup>, L. Lindner<sup>3</sup>, <sup>1</sup>LMU Klinikum der Universität München, Munich, DE, <sup>2</sup>LMU München, Munich, DE, <sup>3</sup>Ludwig Maximilians University - Grosshadern, Munich, DE

13:25 - 13:25

**1625P - Efficacy of metastasectomy on survival in patients with metachronous soft tissue sarcoma-metastasis. Results of a bi-centre study including 135 patients.**

A. Leithner<sup>1</sup>, V. Van Praag<sup>2</sup>, F. Posch<sup>1</sup>, M. Bergovec<sup>1</sup>, L. Leitner<sup>1</sup>, J. Friesenbichler<sup>1</sup>, R. Heregger<sup>1</sup>, F.-M. Smolle-Jüttner<sup>1</sup>, M. Fiocco<sup>2</sup>, M. Van De Sande<sup>2</sup>, J. Riedl<sup>1</sup>, M. Pichler<sup>1</sup>, A. Gerger<sup>1</sup>, J. Szkandera<sup>1</sup>, H. Stöger<sup>1</sup>, B. Liegl-Atzwanger<sup>1</sup>, M. Smolle<sup>1</sup>, <sup>1</sup>Medical University of Graz, Graz, AT, <sup>2</sup>Leiden University Medical Centre, Leiden, NL

13:25 - 13:25

**1626P - Trabectedin and radiotherapy in advanced sarcoma: experience of a Reference Center**

I. Carrasco Garcia<sup>1</sup>, N. Hindi<sup>1</sup>, J. Peinado<sup>1</sup>, I. Rincon<sup>1</sup>, M. Cordeiro<sup>1</sup>, F. Jimenez<sup>2</sup>, A. Falcon Gonzalez<sup>1</sup>, R. Lasso De La Vega<sup>1</sup>, M. Noguer Mediavilla<sup>1</sup>, P. Sancho Marquez<sup>1</sup>, J. Martin-Broto<sup>3</sup>, <sup>1</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>2</sup>Hospital Universitario Juan Ramon Jimenez, Huelva, ES, <sup>3</sup>Hospital Univ. Virgen de Rocío, Seville, ES

13:25 - 13:25

**1627P - Single arm prospective study evaluating the role of neoadjuvant chemotherapy in soft tissue sarcoma**

A. Tiwari<sup>1</sup>, S. Rastogi<sup>2</sup>, S.V.S. Deo<sup>3</sup>, D.N. Sharma<sup>4</sup>, M. Sharma<sup>4</sup>, S. Bakshi<sup>5</sup>, <sup>1</sup>All India Institute of Medical Sciences, Delhi, IN, <sup>2</sup>sameer Rastogi, New Delhi, IN, <sup>3</sup>All India Institute of Medical Sciences, New Delhi, IN, <sup>4</sup>AIIMS, New Delhi, IN, <sup>5</sup>Sameer Bakshi, New Delhi, IN

13:25 - 13:25

**1628P - Preoperative hypofractionated radiotherapy (RT) combined with chemotherapy in primary marginally resectable high grade soft tissue sarcomas (STS) of extremities or trunk wall: interim analysis of prospective phase II clinical trial**

M. Spalek<sup>1</sup>, H. Kosela Paterczyk<sup>2</sup>, A. Borkowska<sup>1</sup>, M. Wagrodzki<sup>3</sup>, A. Cieszanowski<sup>1</sup>, P. Castaneda-Wysocka<sup>1</sup>, T. Switaj<sup>4</sup>, M. Dudzisz-Sledz<sup>5</sup>, A. Czarnecka<sup>6</sup>, E. Dabrowska-Szewczyk<sup>1</sup>, P. Rutkowski<sup>7</sup>, <sup>1</sup>Maria Skłodowska-Curie Institute - Oncology Center, Warsaw, PL, <sup>2</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>3</sup>Oncology Center in Warsaw, Warsaw, PL, <sup>4</sup>No place of work provided Iran, Teheran, IR, <sup>5</sup>Central Clinical Hospital MSWIA-Warsaw Medical University of Warsaw, Warsaw, PL, <sup>6</sup>Military Medical Institute, Warsaw, PL, <sup>7</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL

13:25 - 13:25

**1629P - Basket trial in advanced cancers: a clinical observation of Apatinib in lung metastases and non-lung metastases**

C. Tu, Y. Zhou, K. Yao, Y. Luo, W. Zhang, H. Duan, L. Min, West China Hospital, Sichuan University, Chengdu, CN

13:25 - 13:25

**1630P - Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of therapy, age and dose modification**

Y. Yao<sup>1</sup>, Y. Chi<sup>2</sup>, Z. Fang<sup>3</sup>, S. Wang<sup>4</sup>, G. Huang<sup>5</sup>, Q. Cai<sup>6</sup>, G. Shang<sup>7</sup>, G. Wang<sup>8</sup>, G. Qu<sup>9</sup>, Q.

Wu<sup>10</sup>, Y. Jiang<sup>11</sup>, J. Song<sup>12</sup>, J. Chen<sup>13</sup>, X. Zhu<sup>14</sup>, Z. Cai<sup>15</sup>, C. Bai<sup>16</sup>, Y. Lu<sup>17</sup>, Z. Yu<sup>18</sup>, J. Shen<sup>19</sup>, J. Cai<sup>2</sup>, <sup>1</sup>Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, CN, <sup>2</sup>Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN, <sup>3</sup>Peking University Cancer Hospital, Beijing, CN, <sup>4</sup>Cancer Centre Sun Yat-Sen University, Guangzhou, CN, <sup>5</sup>Hunan Cancer Hospital, Changsha, CN, <sup>6</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>7</sup>Liaoning Cancer Hospital and Institute, Shenyang, CN, <sup>8</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>9</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>10</sup>The first Affiliated Hospital of Bengbu Medical College, Bengbu, CN, <sup>11</sup>West China Hospital, Chengdu, CN, <sup>12</sup>Gansu Provincial Cancer Hospital, Lanzhou, CN, <sup>13</sup>Wuhan Union Hospital (of Tongji Medical College of HUST), Wuhan, CN, <sup>14</sup>The first Affiliated Hospital of Fujian Medical University, Fuzhou, CN, <sup>15</sup>Shanghai General Hospital, Shanghai, CN, <sup>16</sup>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>17</sup>The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, CN, <sup>18</sup>Jiangxi Cancer Hospital, Nanchang, CN, <sup>19</sup>The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN

13:25 - 13:25 **1631P - Efficacy and safety of apatinib in advanced sarcoma**

J. Chen<sup>1</sup>, T. Ye<sup>2</sup>, Z. Zhang<sup>3</sup>, Z. Wang<sup>3</sup>, S. Yang<sup>3</sup>, K. Yang<sup>3</sup>, T. Li<sup>3</sup>, <sup>1</sup>Wuhan Union Hospital (of Tongji Medical College of HUST), Wuhan, CN, <sup>2</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>3</sup>Union hospital, Wuhan, CN

13:25 - 13:25 **1632P\_PR - Characterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration**

A. Bellesoeur<sup>1</sup>, I. Gataa<sup>1</sup>, A. Jouinot<sup>1</sup>, S. El Mershati<sup>2</sup>, J. Arrondeau<sup>1</sup>, C. Tlemsani<sup>1</sup>, B. Blanchet<sup>1</sup>, J. Alexandre<sup>3</sup>, F. Goldwasser<sup>1</sup>, A. Thomas-Schoemann<sup>4</sup>, P. Boudou Rouquette<sup>1</sup>, <sup>1</sup>Hôpital Cochin, Paris, FR, <sup>2</sup>Cochin Hospital, Paris, FR, <sup>3</sup>ONCO CARC CANCER, La Varenne Saint-Hilaire, FR, <sup>4</sup>Cochin Hospital, Paris Descartes University, AP-HP, Paris, FR

13:25 - 13:25 **1633P - Evaluation of hypertension and hand-foot syndrome as Markers of anlotinib Efficacy in advanced soft tissue sarcoma**

Z. Fang<sup>1</sup>, Y. Chi<sup>2</sup>, Y. Yao<sup>3</sup>, S. Wang<sup>4</sup>, G. Huang<sup>5</sup>, Q. Cai<sup>6</sup>, G. Shang<sup>7</sup>, G. Wang<sup>8</sup>, G. Qu<sup>9</sup>, Q. Wu<sup>10</sup>, Y. Jiang<sup>11</sup>, J. Song<sup>12</sup>, J. Chen<sup>13</sup>, X. Zhu<sup>14</sup>, Z. Cai<sup>15</sup>, C. Bai<sup>16</sup>, Y. Lu<sup>17</sup>, Z. Yu<sup>18</sup>, J. Shen<sup>19</sup>, J. Cai<sup>2</sup>, <sup>1</sup>Peking University Cancer Hospital, Beijing, CN, <sup>2</sup>Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN, <sup>3</sup>Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, CN, <sup>4</sup>Cancer Centre Sun Yat-Sen University, Guangzhou, CN, <sup>5</sup>Hunan Cancer Hospital, Changsha, CN, <sup>6</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>7</sup>Liaoning Cancer Hospital and Institute, Shenyang, CN, <sup>8</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>9</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>10</sup>The first Affiliated Hospital of Bengbu Medical College, Bengbu, CN, <sup>11</sup>West China Hospital, Chengdu, CN, <sup>12</sup>Gansu Provincial Cancer Hospital, Lanzhou, CN, <sup>13</sup>Wuhan Union Hospital (of Tongji Medical College of HUST), Wuhan, CN, <sup>14</sup>The first Affiliated Hospital of Fujian Medical University, Fuzhou, CN, <sup>15</sup>Shanghai General Hospital, Shanghai, CN, <sup>16</sup>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>17</sup>The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, CN, <sup>18</sup>Jiangxi Cancer Hospital, Nanchang, CN, <sup>19</sup>The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN



- 13:25 - 13:25 **1634P - “Evolution of Novel, Low Cost, Sustainable Osteosarcoma Care over Two Decades: Reducing Inefficiencies, & Improving Outcomes”**  
I. Bajpai<sup>1</sup>, T. Mondal<sup>1</sup>, V. Simha<sup>2</sup>, A. Chandrashekharan<sup>1</sup>, S. Hingmire<sup>3</sup>, B. Rangarajan<sup>4</sup>, N. Shetty<sup>1</sup>, K. Shah<sup>1</sup>, R. Dusane<sup>1</sup>, B. Rekhi<sup>1</sup>, T. Vora<sup>1</sup>, J. Ghosh<sup>1</sup>, S. Banavali<sup>1</sup>, S. Gupta<sup>1</sup>,  
<sup>1</sup>Tata Memorial Hospital Centre, Mumbai, IN, <sup>2</sup>PGIMER, Chandigarh, Chandigarh, IN, <sup>3</sup>Deenanath Mangeshkar Hospital & Research Centre, Pune, IN, <sup>4</sup>KMCH Comprehensive Cancer Centre, Coimbatore, IN
- 13:25 - 13:25 **1635P - HBP-bound doxorubicin: promising new therapy for bone cancer**  
E. David, S. Cagnol, J.-Y. Goujon, M. Egorov, R. Le Bot, Atlantha, Saint-Herblain, FR
- 13:25 - 13:25 **1636P - Perceptions of Clinical Trial Enrollment in Patients with Bone and Soft Tissue Sarcoma**  
A. Rosenberg, S. Kircher, E. Hahn, A. Rademaker, K. Bilimoria, J. Wayne, M. Agulnik, Northwestern University, Chicago, US
- 13:25 - 13:25 **1637P - Pneumothorax is a novel sensitivity biomarker for targeting VEGFR2 in lung metastatic sarcoma**  
Q. Bao<sup>1</sup>, Y. Shen<sup>2</sup>, W. Zhang<sup>3</sup>, <sup>1</sup>Shanghai Ruijin Hospital, Shanghai Jiao Tong University, College of Medicine, Shanghai, CN, <sup>2</sup>Ruijin hospital, shanghai, CN, <sup>3</sup>Ruijin Hospital, Shanghai, CN
- 13:25 - 13:25 **1638P - Do Royal Marsden Hospital (RMH) and MD Anderson cancer centre (MDACC) prognostic scoring systems predict survival in patients with Bone sarcoma?**  
W. Alselwi<sup>1</sup>, F. Azam<sup>1</sup>, M. Latif<sup>2</sup>, I. Osman<sup>1</sup>, W. Taha<sup>1</sup>, K. Bawazir<sup>1</sup>, A. Farooq<sup>3</sup>, N. Bukhari<sup>4</sup>, F. Ibnshamsah<sup>1</sup>, <sup>1</sup>King Fahad Specialist Hospital, Dammam, SA, <sup>2</sup>Clatterbridge Cancer Center, Wirral, GB, <sup>3</sup>East Lancashire Hospitals NHS Trust, Burnley, GB, <sup>4</sup>King Fahad Specialist Hospital, Dammam, Dammam, SA
- 13:25 - 13:25 **1639P - The study of molecular and genetic markers of apoptosis and proliferation, their role in the treatment and prevention of osteogenic sarcoma**  
M. Tillyashaykhov<sup>1</sup>, D. Polatova<sup>1</sup>, M.-A. Gafur-Akhunov<sup>2</sup>, K. Abdikarimov<sup>1</sup>, U. Islamov<sup>3</sup>, R. Davletov<sup>1</sup>, <sup>1</sup>National Cancer Research Center of Uzbekistan, Tashkent, UZ, <sup>2</sup>City Oncology Centre, Tashkent, UZ, <sup>3</sup>National Research Center of Oncology and Radiology, Tashkent, UZ
- 13:25 - 13:25 **1640P - Outcome of treatment in giant cell tumors of bones. A single institutional retrospective review**  
M. Elshenawy<sup>1</sup>, A. Badran<sup>2</sup>, M. Memon<sup>3</sup>, A. Elshentenawy<sup>4</sup>, T. Elhassan<sup>3</sup>, <sup>1</sup>Faculty of Medicine - Menoufia University, Shebin El Kom, EG, <sup>2</sup>Ain Shams University Hospital, Cairo, EG, <sup>3</sup>king Faisal Specialist Hospital and Research Center, riyadh, SA, <sup>4</sup>NEMROCK Cairo University, Cairo, EG
- 13:25 - 13:25 **1641P - Adriamycin and Ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: results of a retrospective single-center study on 34 patients**



T. Assi<sup>1</sup>, A. Le Cesne<sup>1</sup>, E. Nassif<sup>2</sup>, A. Cavalcanti<sup>3</sup>, M. Faron<sup>3</sup>, T. Ibrahim<sup>4</sup>, C. Le Pechoux<sup>3</sup>, O. Mir<sup>3</sup>, J. Adam<sup>3</sup>, S. Dumont<sup>3</sup>, P. Terrier<sup>3</sup>, C. Honore<sup>3</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Paris Descartes University, Paris, FR, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Hematology Oncology faculty of medicine Saint Joseph University, Beirut, LB

13:25 - 13:25 **1642P - Determination of biological behavior of solitary fibrous tumors**

L. Krsková<sup>1</sup>, M. Kalinova<sup>1</sup>, I. Odintsov<sup>1</sup>, P. Galgonková<sup>1</sup>, R. Kodet<sup>2</sup>, <sup>1</sup>Motol University Hospital, Prague, CZ, <sup>2</sup>2nd Faculty of Medicine Motol University Hospital, Prague, CZ

13:25 - 13:25 **1643P - Pazopanib in advanced or metastatic synovial sarcoma: the Gustave Roussy experience**

M. Sroussi<sup>1</sup>, S. De Percin<sup>2</sup>, A.M. Grecea<sup>3</sup>, M.A. Benderra<sup>3</sup>, M. Velev<sup>3</sup>, S. Akla<sup>3</sup>, N. Lezghed<sup>2</sup>, S. Dumont<sup>3</sup>, C. Le Pechoux<sup>3</sup>, C. Honore<sup>3</sup>, L. Haddag<sup>3</sup>, M. Faron<sup>3</sup>, P. Terrier<sup>3</sup>, O. Mir<sup>3</sup>, A. Le Cesne<sup>4</sup>, <sup>1</sup>Université Paris5, Paris, FR, <sup>2</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Gustave Roussy - Cancer Campus, Villejuif, FR

13:25 - 13:25 **1644P - Identification of effective drug combinations with regorafenib (REG) for the treatment of pediatric rhabdomyosarcomas (RMS)**

Y. Tsvetkova<sup>1</sup>, J. Hoffmann<sup>2</sup>, D. Zopf<sup>1</sup>, <sup>1</sup>Bayer AG, Berlin, DE, <sup>2</sup>EPO Berlin-Buch GmbH, Berlin, DE

13:25 - 13:25 **1645P - KS In The Era Of HAART: A Single Institutional Retrospective Review**

K. Sankar, K. Foster, C. Achenbach, M. Agulnik, Northwestern University, Chicago, US

13:25 - 13:25 **1646P - Carcinosarcoma: Clinical and Epidemiological Patterns in the United States**

M. Gouda, Faculty of Medicine - Menoufia University, Shebin El Kom, EG

13:25 - 13:25 **1647P - First-line Treatment of Desmoid Tumor: Systemic Therapy versus Upfront Surgery**

J. Souza, H. Lourenço, G. Mendes, INCA - Instituto Nacional de Cancer, Rio de Janeiro, BR

13:25 - 13:25 **1648P - Adult rhabdomyosarcoma in Tunisia : Clinical presentation, treatment and outcome**

M. Saadi<sup>1</sup>, D. Tajina<sup>2</sup>, F. Letaief-Ksontini<sup>2</sup>, K. Meddeb<sup>2</sup>, A. Gabsi<sup>2</sup>, Y. Yahyaoui<sup>2</sup>, A. Mokrani<sup>2</sup>, M. Ayadi<sup>2</sup>, N. Chraiet<sup>2</sup>, H. Rais<sup>2</sup>, A. Mezlini<sup>2</sup>, <sup>1</sup>Hospital Abderrahmane Mami, Tunis, TN, <sup>2</sup>Salah Azaiez Institute, Tunis, TN

13:25 - 13:25 **1649P - A Pan-Cancer Landscape analysis reveals a subset of Endometrial Stromal and Pediatric Tumors defined by Internal tandem duplications of BCOR**

L. Juckett<sup>1</sup>, D. Lin<sup>2</sup>, R. Madison<sup>1</sup>, C. Patriquin<sup>1</sup>, G. Frampton<sup>3</sup>, V. Miller<sup>3</sup>, J. Ross<sup>4</sup>, J. Chung<sup>3</sup>, A. Schrock<sup>3</sup>, S. Ali<sup>3</sup>, J. Elvin<sup>3</sup>, <sup>1</sup>Foundation Medicine, Cambridge, US, <sup>2</sup>Beth Israel Deaconess, Boston, US, <sup>3</sup>Foundation Medicine, Inc., Cambridge, US, <sup>4</sup>Foundation Medicine Inc., Cambridge, US

- 13:25 - 13:25 **1650P - The efficacy of eribulin for patients with taxane-resistant cutaneous angiosarcoma: interim result of multi-center, prospective observational study.**  
Y. Fujisawa<sup>1</sup>, K. Yoshino<sup>1</sup>, T. Fujimura<sup>2</sup>, S. Matsushita<sup>3</sup>, H. Uchi<sup>4</sup>, Y. Yamamoto<sup>5</sup>, H. Hata<sup>6</sup>, A. Otsuka<sup>7</sup>, T. Miyagi<sup>8</sup>, M. Ishii<sup>9</sup>, T. Funakoshi<sup>9</sup>, <sup>1</sup>University of Tsukuba, Tsukuba, Ibaraki, JP, <sup>2</sup>Tohoku University, Graduate School of Medicine, Sendai, JP, <sup>3</sup>Kagoshima University, Kagoshima, JP, <sup>4</sup>University of Kyushu, Hakata, JP, <sup>5</sup>Wakayama Medical University, Wakayama, JP, <sup>6</sup>University of Hokkaido, Sapporo, JP, <sup>7</sup>Kyoto University-Graduate school of medicine, Kyoto, JP, <sup>8</sup>University of Ryukyu, Naha, JP, <sup>9</sup>Keio University School of Medicine, Shinjyuku, JP
- 13:25 - 13:25 **1651P - Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma**  
M. Agulnik<sup>1</sup>, B. Van Tine<sup>2</sup>, S. Attia<sup>3</sup>, A. Rademaker<sup>1</sup>, M. Milhem<sup>4</sup>, S. Okuno<sup>5</sup>, <sup>1</sup>Northwestern University, Chicago, US, <sup>2</sup>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University, St. Louis, US, <sup>3</sup>Mayo Clinic, Jacksonville, US, <sup>4</sup>University of Iowa, Iowa City, US, <sup>5</sup>Mayo Clinic, Rochester, US
- 13:25 - 13:25 **1653P - Management of locoregional recurrence after radical resection of a primary non-metastatic retroperitoneal soft tissue sarcoma: results of a retrospective series in a tertiary care center.**  
C. Honoré<sup>1</sup>, M. Faron<sup>2</sup>, O. Mir<sup>2</sup>, L. Haddag<sup>2</sup>, S. Dumont<sup>2</sup>, P. Terrier<sup>2</sup>, J. Adam<sup>2</sup>, C. Lepéchoux<sup>1</sup>, A. Le Cesne<sup>1</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR
- 13:25 - 13:25 **1652P - Outcomes and prognostic factors for angiosarcoma: A 19-year single institution experience**  
M. Chirila<sup>1</sup>, D. Eniu<sup>1</sup>, N. Todor<sup>2</sup>, V.M. Nagy<sup>1</sup>, M. Galatir<sup>2</sup>, D. Coza<sup>2</sup>, V. Cernea<sup>1</sup>, D. Martin<sup>1</sup>, Z. Fekete<sup>1</sup>, <sup>1</sup>Ion Chiricuta Oncology Institute-IOCN, Cluj-Napoca, RO, <sup>2</sup>The Oncology Institute "Prof.Dr.Ion Chiricuta" Cluj-Napoca, Cluj-Napoca, RO
- 13:25 - 13:25 **1654P - Soft tissue sarcomas (STS) in elder patients: No impact of age on overall survival (OS) in an unselected cohort.**  
J.A. Perez Fidalgo<sup>1</sup>, A. Lopez<sup>2</sup>, V. Gambardella<sup>1</sup>, S. Navarro<sup>1</sup>, A. Iranzo<sup>3</sup>, N. Diaz Fernandez<sup>2</sup>, P. Tolosa<sup>4</sup>, A. Silvestre<sup>5</sup>, E. Iriarte Moncho<sup>2</sup>, M.C. Garcia Mora<sup>1</sup>, A. De La Paz<sup>2</sup>, J.J. Soler<sup>1</sup>, A. Cervantes<sup>1</sup>, <sup>1</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>2</sup>Hospital San Juan, Alicante, ES, <sup>3</sup>Hospital Clinico Universitario de Valencia - INCLIVA, Valencia, ES, <sup>4</sup>Hospital Clinico Universitario de Valencia. INCLIVA., Valencia, ES, <sup>5</sup>Hospital Clinico Universitario de Valencia. INCLIVA. CIBERONC Spain, Valencia, ES
- 13:25 - 13:25 **1655P\_PR - The use of complementary and alternative medicine (CAM) in sarcoma patients**  
K.-T. Sungu-Winkler<sup>1</sup>, J. Hübner<sup>2</sup>, F. Menge<sup>1</sup>, B. Kasper<sup>1</sup>, P. Hohenberger<sup>1</sup>, <sup>1</sup>Universitätsklinikum Mannheim, Mannheim, DE, <sup>2</sup>Dept of Medical Oncology/Hematology, Jena, DE
- 13:25 - 13:25 **1657P - Return to work and quality of life in disease-free adult sarcoma patients**

A. Kollar<sup>1</sup>, S. Müller<sup>2</sup>, N. Fankhauser<sup>3</sup>, I. Briner<sup>2</sup>, F. Klenke<sup>2</sup>, J. Bernhard<sup>2</sup>, <sup>1</sup>Inselhospital - Universitätsspital Bern, Bern, CH, <sup>2</sup>University Hospital Bern, Inselhospital, Bern, CH, <sup>3</sup>University of Bern, Bern, CH

13:25 - 13:25 **1658P - No benefit of preoperative chemotherapy for primary retroperitoneal sarcomas: results from a single center propensity-matched analysis.**

M. Faron<sup>1</sup>, S. Dumont<sup>1</sup>, J. Adam<sup>1</sup>, O. Mir<sup>1</sup>, L. Haddag<sup>1</sup>, C. Le Pechoux<sup>1</sup>, P. Terrier<sup>1</sup>, A. Le Cesne<sup>2</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Gustave Roussy - Cancer Campus, Villejuif, FR

13:25 - 13:25 **1659P - Combination of Eribulin plus Gemcitabine in L-Sarcomas**

D. Moura<sup>1</sup>, M. Lopez-Alvarez<sup>1</sup>, A. Salinas-Villegas<sup>1</sup>, P. Sanchez-Bustos<sup>1</sup>, N. Hindi<sup>1</sup>, M. Taron Roca<sup>1</sup>, J. Martin-Broto<sup>2</sup>, <sup>1</sup>Instituto de Biomedicina de Sevilla, Sevilla, ES, <sup>2</sup>Hospital Univ. Virgen de Rocio, Seville, ES

13:25 - 13:25 **1660P - The role of chemotherapy in the landscape of liposarcoma**

A. De Vita<sup>1</sup>, F. Recine<sup>2</sup>, L. Mercatali<sup>1</sup>, G. Miserocchi<sup>1</sup>, C. Liverani<sup>1</sup>, C. Spadazzi<sup>1</sup>, R. Casadei<sup>3</sup>, D. Cavaliere<sup>4</sup>, A. Bongiovanni<sup>5</sup>, F. Pieri<sup>4</sup>, L. Medri<sup>4</sup>, N. Riva<sup>6</sup>, V. Fausti<sup>5</sup>, T. Ibrahim<sup>5</sup>, <sup>1</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>2</sup>Azienda Ospedaliera S. Camillo Forlanini, Roma, IT, <sup>3</sup>Istituto Ortopedico Rizzoli, Bologna, IT, <sup>4</sup>Morgagni-Pierantoni Hospital, Forlì, IT, <sup>5</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>6</sup>Ospedale Pierantoni, Forlì, IT

13:25 - 13:25 **1661TiP - A Randomized Phase III Study of Denosumab before Curettage for Giant Cell Tumor of Bone: Japan Clinical Oncology Group Study JCOG1610**

H. Urakawa<sup>1</sup>, J. Mizusawa<sup>2</sup>, K. Tanaka<sup>3</sup>, J. Eba<sup>2</sup>, H. Hiraga<sup>4</sup>, M. Hosaka<sup>5</sup>, A. Kawai<sup>6</sup>, F. Nakatani<sup>6</sup>, E. Kobayashi<sup>6</sup>, Y. Nishida<sup>1</sup>, T. Okamoto<sup>7</sup>, T. Matsunobu<sup>8</sup>, Y. Iwamoto<sup>8</sup>, H. Fukuda<sup>2</sup>, T. Ozaki<sup>9</sup>, <sup>1</sup>Nagoya University, Graduate School of Medicine, Nagoya, JP, <sup>2</sup>National Cancer Center, Tokyo, JP, <sup>3</sup>Oita University Faculty of Medicine, Yufu, JP, <sup>4</sup>National Hospital Organization Hokkaido Cancer Center, Sapporo, JP, <sup>5</sup>Tohoku University Graduate School of Medicine, Sendai, JP, <sup>6</sup>National Cancer Center Hospital, Tokyo, JP, <sup>7</sup>Kyoto University Graduate School of Medicine, Kyoto, JP, <sup>8</sup>Kyushu Rosai Hospital, Kitakyushu, JP, <sup>9</sup>Okayama University Graduate School of Medicine, Okayama, JP

13:25 - 13:25 **1662TiP - VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)**

S. Bauer<sup>1</sup>, S. George<sup>2</sup>, Y.-K. Kang<sup>3</sup>, W. Tap<sup>4</sup>, T. Zhou<sup>5</sup>, N. Picazio<sup>5</sup>, A. Boral<sup>5</sup>, M. Heinrich<sup>6</sup>, <sup>1</sup>University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, <sup>2</sup>Dana Faber Cancer Institute, Boston, US, <sup>3</sup>Asian Medical Center, Seoul, KR, <sup>4</sup>Memorial Sloan Kettering Cancer Centre, New York, US, <sup>5</sup>Blueprint Medicines Corporation, Boston, US, <sup>6</sup>Oregon Health and Science University, Portland, US

13:25 - 13:25 **Supportive care**

- 13:25 - 13:25 **1691P - Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients**  
K. Thein<sup>1</sup>, S. Ball<sup>2</sup>, M. Zaw<sup>3</sup>, A. Tun<sup>3</sup>, M. Quirch<sup>2</sup>, F. Hardwicke<sup>2</sup>, N. D'Cunha<sup>2</sup>, L. Tijani<sup>2</sup>, C. Jones<sup>2</sup>, T. Oo<sup>4</sup>, <sup>1</sup>TEXAS TECH UNIVERSITY, Lubbock, US, <sup>2</sup>Texas Tech University Health Sciences Center, Lubbock, US, <sup>3</sup>The Brooklyn Hospital Center, Brooklyn, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US
- 13:25 - 13:25 **1692P - Physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): results from the BCY3/BCC 2017 survey**  
M. Lambertini<sup>1</sup>, M. Di Maio<sup>2</sup>, F. Poggio<sup>3</sup>, O. Pagani<sup>4</sup>, G. Curigliano<sup>5</sup>, L. Del Mastro<sup>3</sup>, S. Paluch-Shimon<sup>6</sup>, S. Loibl<sup>7</sup>, A. Partridge<sup>8</sup>, H. Azim Jr.<sup>9</sup>, F. Peccatori<sup>5</sup>, I. Demeestere<sup>10</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>University of Turin, Turin, IT, <sup>3</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, <sup>4</sup>Institute of Oncology of Southern Switzerland, Lugano, CH, <sup>5</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>6</sup>Shaare Zedek M.C, Jerusalem, IL, <sup>7</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>8</sup>Dana-Farber Cancer Institute, Boston, US, <sup>9</sup>American University of Beirut, Beirut, LB, <sup>10</sup>Hopital Erasme, Brussels, BE
- 13:25 - 13:25 **1693P - Analysis of parameters to predict the effectiveness of scalp cooling to prevent chemotherapy-induced alopecia in breast cancer patients**  
C. Kurbacher<sup>1</sup>, S. Herz<sup>2</sup>, A.T. Kurbacher<sup>2</sup>, G. Kolberg<sup>2</sup>, N. Kettelhoit<sup>2</sup>, A. Schott<sup>2</sup>, J. Kurbacher<sup>2</sup>, <sup>1</sup>Medizinisches Zentrum Bonn, Bonn, DE, <sup>2</sup>Gynaecological Center Bonn-Friedensplatz, Bonn, DE
- 13:25 - 13:25 **1694P - A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results**  
M. Lacouture<sup>1</sup>, H. Dion<sup>2</sup>, S. Ravipaty<sup>2</sup>, V. Akmaev<sup>2</sup>, R. Sarangarajan<sup>2</sup>, J. Jimenez<sup>3</sup>, N. Narain<sup>2</sup>, B. Berman<sup>3</sup>, S. Goldfarb<sup>1</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>BERG, LLC, Framingham, US, <sup>3</sup>University of Miami Miller School of Medicine, Miami, US
- 13:25 - 13:25 **1695P - Acupuncture for peripheral neuropathy in cancer patients: TCM diagnosis as a predictor of treatment response**  
W. Liu, A. Qdaisat, G. Lopez, S. Underwood, M. Spano, A.R. Akhila Reddy, Y. Guo, S.-C. Yeung, E. Bruera, M.K. Garcia, L. Cohen, The University of Texas MD Anderson Cancer Center, Houston, US
- 13:25 - 13:25 **1696P - A randomized, open-label, non-inferiority study comparing the efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B-cell Non-Hodgkin lymphomas (B-NHL) - AVOID Neutropenia.**  
H. Link<sup>1</sup>, G. Illerhaus<sup>2</sup>, U. Martens<sup>3</sup>, A. Salar<sup>4</sup>, R. Depenbusch<sup>5</sup>, A. Kohler<sup>6</sup>, M. Engelhardt<sup>7</sup>, S. Mahlmann<sup>8</sup>, M. Zaiss<sup>9</sup>, A. Lammerich<sup>10</sup>, P. Bias<sup>11</sup>, A. Buchner<sup>11</sup>, <sup>1</sup>Praxis Professor Link, Kaiserslautern, DE, <sup>2</sup>Klinikum Stuttgart - Olgahospital, Stuttgart, DE, <sup>3</sup>SLK-Kliniken Heilbronn GmbH, Heilbronn, DE, <sup>4</sup>Hospital del Mar, Barcelona, ES, <sup>5</sup>Onkodok GmbH, Gütersloh, DE, <sup>6</sup>Gemeinschaftspraxis für Hämatologie und Onkologie Dres. Köhler/Fuchs, Langen, DE, <sup>7</sup>University of Freiburg Medical Centre, Freiburg, DE, <sup>8</sup>Westpfalz-Klinikum GmbH, Kaiserslautern, DE, <sup>9</sup>Praxis für Interdisziplinäre Onkologie,



Freiburg, DE, <sup>10</sup>Merckle GmbH (Teva group), Ulm, DE, <sup>11</sup>Merckle GmbH, Ulm, DE

- 13:25 - 13:25 **1697P - Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: pan-European non-interventional study**  
G. Steger<sup>1</sup>, P. Pichler<sup>2</sup>, M. Airoidi<sup>3</sup>, P. Mazza<sup>4</sup>, C. Fontaine<sup>5</sup>, J. Timmer Bonte<sup>6</sup>, J. Walewski<sup>7</sup>, J. Katolicka<sup>8</sup>, M. Mikulova<sup>9</sup>, M. Gasparic<sup>10</sup>, <sup>1</sup>Medical University Vienna; Gaston H. Glock Research Center, Vienna, AT, <sup>2</sup>Landeskrankenhaus St. Poelten, St. Poelten, AT, <sup>3</sup>AOU S. Giovanni Battista - Molinette, Torino, IT, <sup>4</sup>SS Annunziata Hospital, Taranto, IT, <sup>5</sup>Vrije Universiteit Brussel-Campus Jette, Brussels, BE, <sup>6</sup>Alexander Monro Breast Cancer Clinic, Bilthoven, NL, <sup>7</sup>The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>8</sup>St. Anne's University Hospital Brno, Brno, CZ, <sup>9</sup>St. Elisabeth Cancer Institute, Bratislava, SK, <sup>10</sup>Teva Pharmaceuticals Europe B.V., Amsterdam, NL
- 13:25 - 13:25 **1698P - Safety analysis of proposed biosimilar pegfilgrastim in Phase I and Phase III studies**  
N. Harbeck<sup>1</sup>, J. Wang<sup>2</sup>, G. Otto<sup>3</sup>, A. Krendyukov<sup>3</sup>, <sup>1</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>2</sup>Sandoz Inc., Princeton, US, <sup>3</sup>Hexal AG, Holzkirchen, DE
- 13:25 - 13:25 **1699P - New approach to evaluate survival benefit of granulocyte colony-stimulating factor in cancer patients receiving myelosuppressive chemotherapy**  
A. Krendyukov, L. Yau, Hexal AG, Holzkirchen, DE
- 13:25 - 13:25 **1700P - Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: analysis of the results of three clinical trials**  
A. Illes<sup>1</sup>, L. Perjesi<sup>1</sup>, K. Horvat-Karajz<sup>1</sup>, N. Jeszenoi<sup>1</sup>, I. Aradi<sup>1</sup>, N. Singh<sup>2</sup>, S. Mair<sup>2</sup>, Z. Kahan<sup>3</sup>, <sup>1</sup>Gedeon Richter Plc., Budapest, HU, <sup>2</sup>Quotient Sciences, Ruddington, GB, <sup>3</sup>University of Szeged, Szeged, HU
- 13:25 - 13:25 **1701P - Use of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: findings from a large study in German clinical practice (PROTECT)**  
C. Kurbacher<sup>1</sup>, M. Schmidt<sup>2</sup>, M. Geberth<sup>3</sup>, B. Otremba<sup>4</sup>, H. Eschenburg<sup>5</sup>, P. Ramdohr<sup>6</sup>, <sup>1</sup>Medizinisches Zentrum Bonn, Bonn, DE, <sup>2</sup>Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>3</sup>Praxisklinik am Rosengarten, Mannheim, DE, <sup>4</sup>Onkologische Praxis, Oldenburg, DE, <sup>5</sup>Internist, Güstrow, DE, <sup>6</sup>AMGEN - Germany, Munich, DE
- 13:25 - 13:25 **1702P - Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials**  
A. Kristensen<sup>1</sup>, T. Solheim<sup>2</sup>, Ø. Fløtten<sup>3</sup>, B. Grønberg<sup>1</sup>, <sup>1</sup>Norwegian University of Science and Technology, Trondheim, NO, <sup>2</sup>St. Olavs Hospital HF, Trondheim, NO, <sup>3</sup>Haukeland University Hospital, Bergen, NO
- 13:25 - 13:25 **1703P - Incidence of hypocalcemia in a non-inferiority Phase III trial assessing prevention of symptomatic skeletal events (SSE) with Denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12**

**(REDUSE)**

R. Von Moos<sup>1</sup>, H. Hawle<sup>2</sup>, S. Hayoz<sup>2</sup>, R. Cathomas<sup>1</sup>, A. Müller<sup>3</sup>, S. Schmid<sup>4</sup>, O. Pagani<sup>5</sup>, T. Wehrhahn<sup>6</sup>, D. Rauch<sup>7</sup>, S. Anchisi<sup>8</sup>, T. Hermanns<sup>9</sup>, M. Fehr<sup>10</sup>, S. Stoll<sup>11</sup>, P. Bützberger<sup>12</sup>, M. Zweifel<sup>7</sup>, U. Huber<sup>13</sup>, A. Fuhrer<sup>2</sup>, C. Schär<sup>2</sup>, S. Gillessen<sup>14</sup>, A. Templeton<sup>15</sup>,  
<sup>1</sup>Kantonsspital Graubünden, Chur, CH, <sup>2</sup>SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, <sup>3</sup>Kantonsspital Winterthur, Winterthur, CH, <sup>4</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>5</sup>IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, CH, <sup>6</sup>Kantonsspital Aarau, Aarau, CH, <sup>7</sup>Inselspital - Universitätsspital Bern, Bern, CH, <sup>8</sup>Hôpital Régional Sion-Hérens-Contthey, Site de Champsec Centre du Cancer Lausanne, Sion, CH, <sup>9</sup>University Hospital Zürich, Zürich, CH, <sup>10</sup>Kantonsspital Frauenfeld, Frauenfeld, CH, <sup>11</sup>Universitätsspital Zürich, Zürich, CH, <sup>12</sup>Kantonsspital Baden, Baden, CH, <sup>13</sup>Klinik Im Park Oncology Center, Zurich, CH, <sup>14</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>15</sup>St. Claraspital AG, Basel, CH

13:25 - 13:25

**1704P - A Prospective Randomized Controlled Trial of Metoclopramide Combined with Triple Antiemetic Therapy to Prevent Anthracycline-Based Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer**

U. Oflazoglu<sup>1</sup>, U. Varol<sup>2</sup>, A. Alacacioglu<sup>3</sup>, T. Salman<sup>2</sup>, Y. Kucukzeybek<sup>2</sup>, H. Taskaynatan<sup>2</sup>, Y. Yildiz<sup>2</sup>, G. Dissiz<sup>2</sup>, S. Iriz<sup>2</sup>, M. Tarhan<sup>4</sup>, <sup>1</sup>Dokuz Eylul University Hospital, Izmir, TR, <sup>2</sup>Izmir Katip Celebi University,, izmir, TR, <sup>3</sup>Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, TR, <sup>4</sup>Dokuz Eylul University Faculty of Medicine, Izmir, TR

13:25 - 13:25

**1705P - Ramosetron Versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting**

J.H. Kwon<sup>1</sup>, J.-H. Kang<sup>2</sup>, Y.-G. Lee<sup>3</sup>, K.U. Park<sup>4</sup>, H.J. An<sup>5</sup>, J. Sohn<sup>6</sup>, Y.M. Seol<sup>7</sup>, H. Lee<sup>8</sup>, H.-J. Yun<sup>9</sup>, J.S. Ahn<sup>10</sup>, H.J. Kim<sup>11</sup>, <sup>1</sup>Kangdong Sacred Heart Hospital,. Hallym University College of. Medicine, Seoul, KR, <sup>2</sup>The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, KR, <sup>3</sup>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KR, <sup>4</sup>Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, KR, <sup>5</sup>St. Vincent's Hospital, College of Medicine, Catholic University of Korea, Seoul, KR, <sup>6</sup>Yonsei University College of Medicine, Seoul, KR, <sup>7</sup>Pusan National University Hospital, Pusan National University School of Medicine, Busan, KR, <sup>8</sup>School of Medicine Chungnam National University and Chungnam National University Hospital, Suwon, KR, <sup>9</sup>Department of Internal Medicine, Daejeon, KR, <sup>10</sup>Samsung Medical Center, Seoul, KR, <sup>11</sup>ASAN Medical Center, Seoul, KR

13:25 - 13:25

**1706P - Prognostic factors associated with prevalence of nausea, and time to development of nausea in patients receiving guideline-based anti-emetic prophylaxis. A prospective, observational, real world study.**

T. Smit, B. Rapoport, The Medical Oncology Centre of Rosebank, Sandton, ZA

13:25 - 13:25

**1707P - Usefulness of bone modifying agents for non-weight bearing bone metastasis in breast cancer.**

K. Kawaguchi<sup>1</sup>, M. Latif<sup>2</sup>, K. Hayashi<sup>2</sup>, S. Ogita<sup>3</sup>, <sup>1</sup>Iizuka Hospital, Iizuka, JP, <sup>2</sup>St Luke's international university, Tokyo, JP, <sup>3</sup>St Luke's international hospital, Tokyo, JP

13:25 - 13:25

**1708P - Analysis of bone events in patients with aromatase inhibitors (AI)**

S. Arrojo, E. Garcia-Carús, C. Gómez, P. Rodriguez, D. Rivas, L. Faez, C. Iglesias Gomez, M.E. Izquierdo Manuel, Y. Fernandez Perez, Hospital Universitario Central de Asturias, Oviedo, ES

13:25 - 13:25 **1709P - Assessment and treatment of breakthrough cancer pain in Spain: a self-audit study**

R. Lopez Lopez<sup>1</sup>, J.J. Reina Zoilo<sup>2</sup>, D. Monge<sup>3</sup>, F. Caballero<sup>3</sup>, V. Guillem Porta<sup>4</sup>, E. Aranda Aguilar<sup>5</sup>, A. Carrato Mena<sup>6</sup>, E. Diaz Rubio<sup>7</sup>, J. Garcia Foncillas<sup>8</sup>, M. Feyjoo<sup>9</sup>, C. Camps<sup>10</sup>,  
<sup>1</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>2</sup>Hospital Universitario Virgen Macarena, Sevilla, ES, <sup>3</sup>Francisco de Vitoria University, Madrid, ES, <sup>4</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>5</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>6</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>7</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>8</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>9</sup>Hospital Universitario La Moraleja, Sanitas, Madrid, ES, <sup>10</sup>Consortio Hospital General Universitario de Valencia, Valencia, ES

13:25 - 13:25 **1710P - Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project.**

J. Salvador Bofill<sup>1</sup>, V. Guillem Porta<sup>2</sup>, M. Feyjoo<sup>3</sup>, A. Anton Torres<sup>4</sup>, E. Aranda Aguilar<sup>5</sup>, C. Camps<sup>6</sup>, A. Carrato Mena<sup>7</sup>, M. Constenla Figueiras<sup>8</sup>, J.J. Cruz Hernandez<sup>9</sup>, E. Diaz Rubio<sup>10</sup>, J. Garcia Foncillas<sup>11</sup>, P. Gascon<sup>12</sup>, R. Lopez Lopez<sup>13</sup>, B. Soler<sup>14</sup>, Y. Escobar<sup>15</sup>,  
<sup>1</sup>Hospital Virgen Valme, Sevilla, ES, <sup>2</sup>Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>3</sup>Hospital Universitario La Moraleja, Sanitas, Madrid, ES, <sup>4</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>5</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>6</sup>Consortio Hospital General Universitario de Valencia, Valencia, ES, <sup>7</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>8</sup>Complejo Hospitalario de Pontevedra, Pontevedra, ES, <sup>9</sup>Hospital Universitario de Salamanca, Salamanca, ES, <sup>10</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>11</sup>University Hospital "Fundacion Jimenez Diaz", Madrid, ES, <sup>12</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>13</sup>Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>14</sup>E-C-BIO, S.L, Madrid, ES, <sup>15</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES

13:25 - 13:25 **1711P - Opioid-induced Constipation in Patients with Cancer Pain in Japan: Prospective Observational Study Using Rome IV OIC Diagnostic Criteria (OIC-J Study)**

H. Imai<sup>1</sup>, S. Fumita<sup>2</sup>, T. Harada<sup>3</sup>, T. Noriyuki<sup>4</sup>, M. Gamoh<sup>5</sup>, Y. Akashi<sup>6</sup>, H. Sato<sup>7</sup>, Y. Kizawa<sup>8</sup>, A. Tokoro<sup>9</sup>,  
<sup>1</sup>Gunma prefectural Cancer Center, Ota, JP, <sup>2</sup>Kindai University Nara hospital, Ikoma, JP, <sup>3</sup>JCHO Hokkaido Hospital, Sapporo, JP, <sup>4</sup>Onomichi General Hospital, Onomichi, JP, <sup>5</sup>Osaki Citizen Hospital, Osaki, JP, <sup>6</sup>Kindai University Nara Hospital, Ikoma, JP, <sup>7</sup>Shionogi, Osaka, JP, <sup>8</sup>Kobe University Graduate School of Medicine, Kobe, JP, <sup>9</sup>National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, JP

13:25 - 13:25 **1712P - Efficacy and Tolerability of Naldemedine in Patient with Cancer and Opioid-Induced Constipation: A Pooled Subgroup Analysis of 2 Randomized Placebo Controlled Studies**

E. Satomi<sup>1</sup>, H. Ishiki<sup>2</sup>, T. Yokota<sup>3</sup>, Y. Tada<sup>4</sup>, H. Sato<sup>5</sup>, M. Okamoto<sup>4</sup>, I. Osaka<sup>6</sup>,  
<sup>1</sup>National Cancer center Hospital, Tokyo, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>Shionogi Limited, London, GB, <sup>4</sup>SHIONOGI & CO., LTD, Osaka, JP, <sup>5</sup>Shionogi, Osaka, JP, <sup>6</sup>Shizuoka



Cancer Center Hospital, Tokyo, JP

- 13:25 - 13:25 **1713P - Left ventricular ejection fraction(LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillance.**  
J.H. Yeo<sup>1</sup>, H. Ahn<sup>2</sup>, I. Park<sup>3</sup>, Y.S. Kim<sup>3</sup>, S.J. Sym<sup>3</sup>, E.K. Cho<sup>1</sup>, D.B. Shin<sup>3</sup>, <sup>1</sup>Gachon Univeristy Gil Medical Center, Incheon, KR, <sup>2</sup>Gachon University Gil Hospital, Incheon, KR, <sup>3</sup>Gachon University Gil Medical Center, Incheon, KR
- 13:25 - 13:25 **1714P - Predicting the occurrence and prevention of early anthracycline cardiotoxicity of chemotherapy in patients with breast cancer**  
A. Askolskyi<sup>1</sup>, L. Syvak<sup>1</sup>, O. Zharinov<sup>2</sup>, N. Khranovska<sup>1</sup>, <sup>1</sup>National Cancer Institute, Kiev, UA, <sup>2</sup>Shupyk National Medical Academy of Postgraduate Education, Ministry of Healthcare of Ukraine, Kiev, UA
- 13:25 - 13:25 **1715P - Baseline prevalence of cardiovascular disease (CVD) risk factors in women with breast cancer**  
N. Bhoo-Pathy<sup>1</sup>, S. Subramaniam<sup>2</sup>, H. Zaharah<sup>3</sup>, Y.C. Kong<sup>4</sup>, N.A. Taib<sup>1</sup>, A. Deniel<sup>5</sup>, K.-H. Chee<sup>1</sup>, R.S. Bustamam<sup>5</sup>, M.-H. See<sup>1</sup>, A. Fong<sup>6</sup>, C.H. Yip<sup>7</sup>, <sup>1</sup>University Malaya Medical Center, Kuala Lumpur, MY, <sup>2</sup>Ministry of Health Malaysia, Kuala Lumpur, MY, <sup>3</sup>National Cancer Institute, Putrajaya, MY, <sup>4</sup>National Clinical Research Centre, Kuala Lumpur, MY, <sup>5</sup>Kuala Lumpur Hospital, Kuala Lumpur, MY, <sup>6</sup>Sarawak General Hospital, Kuching, MY, <sup>7</sup>Subang Jaya Medical Centre, Subang Jaya, MY
- 13:25 - 13:25 **1716P - Cardiovascular and other competing causes of death among cancer patients, 2006-2015: An Australian population-based study**  
Y. Ye<sup>1</sup>, P. Otahal<sup>2</sup>, T. Marwick<sup>3</sup>, K. Wills<sup>2</sup>, A. Neil<sup>2</sup>, A. Venn<sup>2</sup>, <sup>1</sup>Menzies Institute for Medical Research, University of Tasmania, Hobart, AU, <sup>2</sup>University of Tasmania, Hobart, AU, <sup>3</sup>Baker Heart and Diabetes Institute, Melbourne, AU
- 13:25 - 13:25 **1717P - Cancer Associated Thrombosis with Primary Prophylaxis in a Tertiary Hospital in the Philippines from 2010-2015**  
A.T. Gerona, St. Luke's Medical Center - Quezon City, Quezon City, PH
- 13:25 - 13:25 **1718P - The incidence of recurrent venous thromboembolism (VTE) and bleeding depending on practical treatment pattern of anticoagulation in the cancer patients with VTE**  
S.-M. Bang<sup>1</sup>, J.-H. Kang<sup>2</sup>, M.H. Hong<sup>3</sup>, J.S. Ahn<sup>4</sup>, S.Y. Oh<sup>5</sup>, J.H. Baek<sup>6</sup>, Y.J. Choi<sup>7</sup>, S.H. Shin<sup>8</sup>, Y.-J. Kim<sup>9</sup>, J.-H. Cha<sup>9</sup>, J. Lee<sup>10</sup>, <sup>1</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>2</sup>Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, KR, <sup>3</sup>Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>4</sup>Samsung Medical Center, Seoul, KR, <sup>5</sup>Pusan National University Yangsan Hospital, Yangsan, KR, <sup>6</sup>Ulsan University Hospital, Ulsan, KR, <sup>7</sup>Korea University Anam Hospital, Seoul, KR, <sup>8</sup>Kosin University Gospel Hospital, Busan, KR, <sup>9</sup>Pfizer Pharmaceuticals Korea Ltd., Seoul, KR, <sup>10</sup>Korea University College of Medicine, Seoul, KR
- 13:25 - 13:25 **1719P - Prevention and Prophylaxis of Thrombosis in Cancer Patients**



N. Tsoukalas<sup>1</sup>, P. Papakotoulas<sup>2</sup>, A. Christopoulou<sup>3</sup>, A. Ardavanis<sup>4</sup>, G. Koumakis<sup>4</sup>, C. Papandreou<sup>5</sup>, G. Papatsimpas<sup>5</sup>, P. Papakostas<sup>6</sup>, C. Andreadis<sup>2</sup>, G. Aravantinos<sup>7</sup>, N. Ziras<sup>8</sup>, H. Kalofonos<sup>9</sup>, E. Samantas<sup>7</sup>, M. Sougleri<sup>5</sup>, P. Makrantonakis<sup>10</sup>, G. Pentheroudakis<sup>11</sup>, A. Athanasiadis<sup>12</sup>, E. Bournakis<sup>13</sup>, I.I. Varthalitis<sup>14</sup>, I. Boukovinas<sup>15</sup>, 1417 NIMTS Army Veterans Hospital, Kolonaki, GR, <sup>2</sup>Theagenion Cancer Hospital, Thessaloniki, GR, <sup>3</sup>Hospital AG. Andreas, Patras, GR, <sup>4</sup>Agios Savvas Regional Cancer Hospital, Athens, GR, <sup>5</sup>Hellenic Society of Medical Oncology, Athens, GR, <sup>6</sup>Hippokration General Hospital, Athens, GR, <sup>7</sup>General Oncological Hospital of Kifisia "Agiou Anargyroi", Kifisia, GR, <sup>8</sup>metaxa, athens, GR, <sup>9</sup>University of Patras, Patras, GR, <sup>10</sup>Theagenio Cancer Hospital, Thessaloniki, GR, <sup>11</sup>University Hospital of Ioannina, Ioannina, GR, <sup>12</sup>General Hospital Larisa, Larissa, GR, <sup>13</sup>Areteion Hospital, University of Athens, Athens, GR, <sup>14</sup>Chania General Hospital "St. George", Crete, GR, <sup>15</sup>NORDIX, Athens, GR

13:25 - 13:25 **1720P - Is it appropriate to use a fixed prophylactic dose of enoxaparin for hospitalized cancer patients? Results from a prospective tertiary referral single center study**

C. Maurice-Dror, M. Litvak, A. Keren, S. Akerman, B. Brenner, N. Haim, Y. Nadir, Rambam Health Care Center, Haifa, IL

13:25 - 13:25 **1721P - Long-term prognosis of acute pulmonary embolism: a focus on idiopathic and neoplastic etiologies**

I. Guerreiro<sup>1</sup>, H. Magalhães<sup>2</sup>, S. Coelho<sup>1</sup>, A.M. Ribeiro<sup>3</sup>, S. Ferreira<sup>4</sup>, E. Araújo<sup>4</sup>, M. Fontes-Sousa<sup>1</sup>, P. Bettencourt<sup>5</sup>, P. Lourenço<sup>3</sup>, <sup>1</sup>Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto, PT, <sup>2</sup>Portuguese Oncology Institute of Porto (IPO-Porto), Porto, PT, <sup>3</sup>Hospital Centre of São João, Porto, PT, <sup>4</sup>Centro Hospitalar São João, Porto, PT, <sup>5</sup>CUF Hospital Centre Porto, Porto, PT

13:25 - 13:25 **1722P - Systematic Literature Review and Network Meta-analysis of oral Anticoagulants for the Treatment of Venous Thromboembolism in patients with cancer**

H. Park, J.-C. Kim, J. Cho, J.H. Lim, M.H. Lee, Inha University Hospital, Incheon, KR

13:25 - 13:25 **1723P - Comparison of venous thromboembolism risk assessment models in patients receiving chemotherapy**

K. Talasiewicz<sup>1</sup>, P. Ozdowska<sup>2</sup>, B. Milanowska<sup>2</sup>, K. Gepner<sup>2</sup>, B. Jagielska<sup>3</sup>, <sup>1</sup>The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>2</sup>Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, <sup>3</sup>Cancer Center, Warsaw, PL

13:25 - 13:25 **1724P - Personalised Nutritional care during chemotherapy using survey on taste changes during chemotherapy: first experience from tertiary chemotherapy day care Center in Northern India**

A. Vora<sup>1</sup>, S. Chatterjee<sup>2</sup>, A. Upadhyay<sup>1</sup>, N. Hazarika<sup>1</sup>, G.S. Bhattacharya<sup>3</sup>, <sup>1</sup>H.O.P.E. Oncology Clinic, New Delhi, IN, <sup>2</sup>H.O.P.E. Oncology Clinic, New delhi, IN, <sup>3</sup>Fortis Hospital, Kolkatta, IN

13:25 - 13:25 **1725P - Role of Megestrol acetate versus Dexamethasone for improvement in appetite in patients with cancer associated anorexia cachexia: A randomized controlled Pilot trial**

S. Ostwal<sup>1</sup>, N. Salins<sup>2</sup>, J. Deodhar<sup>2</sup>, M. Maryann<sup>2</sup>, <sup>1</sup>Tata Memorial Hospital Centre, Mumbai, IN, <sup>2</sup>Tata Memorial Hospital, Mumbai, IN

- 13:25 - 13:25 **1726P - Population pharmacokinetics (PPK) of anamorelin (ANAM), an oral selective ghrelin receptor agonist**  
A. Bernareggi<sup>1</sup>, S. Kaasa<sup>2</sup>, M. Fallon<sup>3</sup>, R. Skipworth<sup>3</sup>, D. Currow<sup>4</sup>, <sup>1</sup>Helsinn Healthcare Switzerland, Pazzallo-Lugano, CH, <sup>2</sup>Oslo University Hospital, Oslo, NO, <sup>3</sup>University of Edinburgh, Edinburgh, GB, <sup>4</sup>Faculty of Health, University of Technology Sydney, Sydney, AU
- 13:25 - 13:25 **1727P - Health care providers' experiences of positive and negative effects of parenteral nutrition therapy in cancer patients**  
K. Sand<sup>1</sup>, L. Thoresen<sup>2</sup>, T. Solheim<sup>3</sup>, R. Helgås<sup>4</sup>, E. Løhre<sup>4</sup>, T. Balstad<sup>5</sup>, <sup>1</sup>Norwegian University of Science and Technology, Trondheim, NO, <sup>2</sup>St. Olavs hospital, Trondheim University Hospital, Trondheim, NO, <sup>3</sup>St. Olavs Hospital HF, Trondheim, NO, <sup>4</sup>St. Olavs hospital, Trondheim University Hospital and Norwegian University of Science and Technology, Trondheim, NO, <sup>5</sup>Norwegian University of Science and Technology and St. Olavs hospital, Trondheim University Hospital, Trondheim, NO
- 13:25 - 13:25 **1728P - Assessment of anorexia and weight loss in newly diagnosed upper gastrointestinal cancer patients with localised and metastatic disease, using the Functional Assessment of Anorexia Cachexia Therapy Anorexia/Cachexia Subscale (FAACT A/CS)**  
M. Abraham, Z. Kordatou, W. Mansoor, The Christie NHS Foundation Trust, Manchester, GB
- 13:25 - 13:25 **1729P - Body composition factor is independent prognosticator in advanced pancreatic cancer patients**  
S. Kang<sup>1</sup>, H.S. Park<sup>2</sup>, H.-C. Jeung<sup>1</sup>, <sup>1</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>St. Vincent Hospital, Suwon, KR
- 13:25 - 13:25 **1730P - Current use of clinical nutrition in oncology patients - real world evidence from big data in Italy**  
F. Di Costanzo<sup>1</sup>, R. Caccialanza<sup>2</sup>, A. Santoro<sup>3</sup>, C. Gavazzi<sup>4</sup>, P. Pedrazzoli<sup>5</sup>, <sup>1</sup>Careggi, Firenze, IT, <sup>2</sup>Fondazione IRCCS Policlinico San Matteo, Pavia, IT, <sup>3</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>4</sup>IRCCS Istituto Nazionale die Tumori, Milano, IT, <sup>5</sup>Fondazione IRCCS Policlinico S. Matteo, Pavia, IT
- 13:25 - 13:25 **1731P - Nutritional cancer care: slowly evolving clinical practice reveals regional and professional HCP variability**  
F. Strasser<sup>1</sup>, J. Arends<sup>2</sup>, A. Laviano<sup>3</sup>, A. O'Callaghan<sup>4</sup>, R. Audisio<sup>5</sup>, M. Sawyer<sup>6</sup>, S. Kaasa<sup>7</sup>, <sup>1</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>2</sup>Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg, DE, <sup>3</sup>Sapienza University, Rome, IT, <sup>4</sup>Nutricia Advanced Medical Nutrition, Schiphol Airport, NL, <sup>5</sup>University of Liverpool-Royal Liverpool University Hospital,, Liverpool, GB, <sup>6</sup>University of Alberta Cross Cancer Institute, Edmonton, CA, <sup>7</sup>Oslo University Hospital, Oslo, NO

- 13:25 - 13:25 **1732P - Unidentified cachexia patients in the Oncologic setting: cachexia UFO's do exist.**  
E. De Waele<sup>1</sup>, J. Demol<sup>1</sup>, R. Caccialanza<sup>2</sup>, P. Cotogni<sup>3</sup>, H. Spapen<sup>1</sup>, M. Malbrain<sup>1</sup>, J. De Grève<sup>1</sup>, J. Pen<sup>1</sup>, <sup>1</sup>UZ Brussel, Brussels, BE, <sup>2</sup>Fondazione IRCCS Policlinico San Matteo, Pavia, IT, <sup>3</sup>S. Giovanni Battista Hospital, University of Turin, Turin, IT
- 13:25 - 13:25 **1733P - The Effect of Sarcopenia on Acute Chemotherapy Toxicity in Gastrointestinal Cancer Patients Undergoing Systemic Therapy**  
N. Ozdemir<sup>1</sup>, O. Yazici<sup>1</sup>, K. Silay<sup>2</sup>, G. Ucar<sup>3</sup>, T. Eren<sup>3</sup>, D. Sener Dede<sup>4</sup>, M.A.N. Sendur<sup>5</sup>, M. Akinci<sup>6</sup>, A. Baykal<sup>3</sup>, B. Yalcin<sup>7</sup>, N. Zengin<sup>2</sup>, <sup>1</sup>Ankara Numune Education and Research Hospital, Ankara, TR, <sup>2</sup>Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, TR, <sup>3</sup>Ankara Numune Education and Research Hospital, ANKARA, TR, <sup>4</sup>Ankara Yıldırım Beyazıt Universtiy Faculty of Medicine, Medical Oncology, Ankara, TR, <sup>5</sup>Yildirim Beyazıt University Medical Faculty, Ankaar, TR, <sup>6</sup>Ankara Ataturk Research and Teaching Hospital, Ankara, TR, <sup>7</sup>Diskapi Yildirim Beyazıt Teaching and Research Hospital, Ankara, TR
- 13:25 - 13:25 **1734P - Early detection of skeletal muscle atrophy using a multiple plasma-free amino acid index in the advanced aged patients with advanced pancreatic cancer**  
S. Mitsunaga<sup>1</sup>, M. Takada<sup>2</sup>, S. Nishikawa<sup>3</sup>, A. Imaizumi<sup>3</sup>, M. Ishii<sup>3</sup>, M. Ikeda<sup>1</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Ajinomoto Co, Kawasaki, JP, <sup>3</sup>AJINOMOTO CO.,INC., Kawasaki, JP
- 13:25 - 13:25 **1735P - Trajectory of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) predicts time to progression (TTP) in metastatic colorectal cancer (mCRC) patients.**  
S.A. Kurk<sup>1</sup>, R. Stellato<sup>2</sup>, P. Peeters<sup>2</sup>, M. Oskam<sup>2</sup>, B. Dorresteijn<sup>3</sup>, M. Jourdan<sup>3</sup>, C. Punt<sup>4</sup>, M. Koopman<sup>5</sup>, A. May<sup>5</sup>, <sup>1</sup>UMC - University Medical Center Utrecht, Utrecht, NL, <sup>2</sup>Julius Center for Health Sciences and Primary Care, Utrecht University, Utrecht, NL, <sup>3</sup>Danone Nutricia Research, Utrecht, NL, <sup>4</sup>Academic Medical Center, University of Amsterdam, Amsterdam, NL, <sup>5</sup>University Hospital Utrecht, Utrecht, NL
- 13:25 - 13:25 **1736P - Clinical impact of Whey protein and Nutritional Counseling in Gastrointestinal cancer Patients**  
M. Roberto<sup>1</sup>, E. Sarfati<sup>2</sup>, M. Di Girolamo<sup>2</sup>, F.M. Schipilliti<sup>2</sup>, E. Crimini<sup>3</sup>, A. Botticelli<sup>1</sup>, L. Marchetti<sup>4</sup>, M. Muscaritoli<sup>5</sup>, P. Marchetti<sup>1</sup>, F. Mazzuca<sup>2</sup>, <sup>1</sup>Azienda Ospedaliera St. Andrea, Roma, IT, <sup>2</sup>Az. Ospedaliero-universitaria St. Andrea, Roma, IT, <sup>3</sup>Sapienza University of Rome, Rome, IT, <sup>4</sup>San Pietro FBF Hospital, Roma, IT, <sup>5</sup>Sapienza - Università di Roma, Roma, IT
- 13:25 - 13:25 **1737P - Impact of taste alterations during systemic anti-tumour therapy on the liking of oral nutritional supplements with adapted flavours**  
J. De Haan<sup>1</sup>, Y. Moshage<sup>1</sup>, D. Kluijfhooft<sup>1</sup>, R. Renken<sup>1</sup>, C. Corbier<sup>2</sup>, H. Blanchard<sup>2</sup>, A. Reyners<sup>1</sup>, <sup>1</sup>University Hospital Groningen (UMCG), Groningen, NL, <sup>2</sup>Nutricia Advanced Medical Nutrition, Utrecht, NL

- 13:25 - 13:25 **1738P - Overweight, obesity and weight gain after breast cancer (BC): a prospective clinical study**  
A. Di Meglio<sup>1</sup>, M. El-Mouhebb<sup>2</sup>, S. Michiels<sup>3</sup>, L. Jones<sup>4</sup>, M. Annonay<sup>5</sup>, A. Zingarello<sup>6</sup>, M. Matias<sup>2</sup>, S. Everhard<sup>7</sup>, A.L. Martin<sup>8</sup>, P. Arveux<sup>9</sup>, O. Tredan<sup>10</sup>, P. Soulie<sup>11</sup>, P. Cottu<sup>12</sup>, A. Partridge<sup>13</sup>, L. Del Mastro<sup>14</sup>, J. Ligibel<sup>13</sup>, F. André<sup>1</sup>, I. Vaz-Luis<sup>2</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>5</sup>Institute Bergonié, Bordeaux, FR, <sup>6</sup>Gustave Roussy, Université Paris-Saclay, Villejuif, FR, <sup>7</sup>UNICANCER, Paris, FR, <sup>8</sup>Unicancer, Paris, FR, <sup>9</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>10</sup>Centre Léon Bérard, Lyon, FR, <sup>11</sup>Centre Paul Papin, Angers, FR, <sup>12</sup>Institut Curie, Paris, FR, <sup>13</sup>Dana-Farber Cancer Institute, Boston, US, <sup>14</sup>IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT
- 13:25 - 13:25 **1739P - Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC)**  
A. Di Meglio<sup>1</sup>, M. El-Mouhebb<sup>2</sup>, S. Michiels<sup>3</sup>, L. Jones<sup>4</sup>, E. Martin<sup>2</sup>, M. Matias<sup>2</sup>, A.E. Lohmann Palhares<sup>5</sup>, F. Joly<sup>6</sup>, L. Vanlemmens<sup>7</sup>, S. Everhard<sup>8</sup>, A.L. Martin<sup>9</sup>, J. Lemonnier<sup>9</sup>, P. Arveux<sup>10</sup>, P. Cottu<sup>11</sup>, C. Coutant<sup>10</sup>, L. Del Mastro<sup>12</sup>, A. Partridge<sup>13</sup>, F. André<sup>1</sup>, J. Ligibel<sup>13</sup>, I. Vaz-Luis<sup>2</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>5</sup>Universidade Federal do Rio de Janeiro Hospital Universitário Clementino Fraga Filho, HUCFF, Rio de Janeiro, BR, <sup>6</sup>GINECO & Centre François Baclesse Caen, Caen, FR, <sup>7</sup>Centre Oscar Lambret, Lille, FR, <sup>8</sup>UNICANCER, Paris, FR, <sup>9</sup>Unicancer, Paris, FR, <sup>10</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>11</sup>Institut Curie, Paris, FR, <sup>12</sup>Ospedale Policlinico San Martino, Genova, IT, <sup>13</sup>Dana-Farber Cancer Institute, Boston, US
- 13:25 - 13:25 **1740P - Patient reported outcomes: Web-monitoring versus nurse assessment to improve anticancer therapies**  
M. Korostelev<sup>1</sup>, K. Sejean<sup>1</sup>, C. Lepage<sup>1</sup>, J. Stevens<sup>1</sup>, B. Bonan<sup>1</sup>, P. Beuzeboc<sup>2</sup>, F. Scotté<sup>1</sup>, <sup>1</sup>Hopital Foch, Suresnes, FR, <sup>2</sup>Institut Curie, Paris, FR
- 13:25 - 13:25 **1741P - Polymedication in elderly cancer patients treated with chemotherapy**  
A.-L. Couderc<sup>1</sup>, F. Correard<sup>2</sup>, C. Tabele<sup>2</sup>, E. Nouguerede<sup>1</sup>, L. Greillier<sup>3</sup>, F. Duffaud<sup>4</sup>, P. Auquier<sup>5</sup>, A. Daumas<sup>1</sup>, P. Bertault-Peres<sup>2</sup>, P. Villani<sup>1</sup>, S. Honore<sup>2</sup>, <sup>1</sup>Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>2</sup>Assistance Publique Hopitaux de Marseille, MARSEILLE, FR, <sup>3</sup>Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, <sup>4</sup>CHU La Timone Adultes, Marseille, FR, <sup>5</sup>Aix marseille Université, Marseille, FR
- 13:25 - 13:25 **1742P - Geriatric oncology (GO): long term follow-up of a prospective series of the GO Unit, at A. C. Camargo Cancer Center.**  
A. Dettino<sup>1</sup>, M. Donadio<sup>1</sup>, A. Cabral<sup>1</sup>, V. Jesus<sup>1</sup>, M. Fanelli<sup>2</sup>, S. Sanches<sup>1</sup>, <sup>1</sup>A. C. Camargo Cancer Center, Sao Paulo, BR, <sup>2</sup>Rede D'Or S Luiz, Sao Paulo, BR
- 13:25 - 13:25 **1743P - Developing a predictive model for chemotherapy related toxicities in older Asian adults.**  
S.L.A. Pang<sup>1</sup>, F. Ho<sup>1</sup>, Y.S. Ng<sup>1</sup>, C. Cai<sup>2</sup>, M. Wang<sup>2</sup>, W.C. Yong<sup>1</sup>, B.C. Tai<sup>2</sup>, <sup>1</sup>National



University Cancer Institute, Singapore (NCIS), Singapore, SG, <sup>2</sup>National University of Singapore, Singapore, SG

- 13:25 - 13:25 **1744P - Palliative Local Therapy of advanced Breast Cancer**  
T. Letodiani<sup>1</sup>, M. Shavdia<sup>2</sup>, N. Shavdia<sup>3</sup>, K. Chaava<sup>2</sup>, N. Gegeshidze<sup>2</sup>, <sup>1</sup>National Cancer Center of Georgia (NCCG), Tbilisi, GE, <sup>2</sup>Tbilisi state medical university, Tbilisi, GE, <sup>3</sup>JSC "Neo Medi", Tbilisi, GE
- 13:25 - 13:25 **1745P - General and dedicated cancer emergency room: clinical and financial implications**  
N. Malavasi<sup>1</sup>, C. Fiorani<sup>1</sup>, L. Ferrara<sup>1</sup>, R. Postiglione<sup>1</sup>, L. Scarabelli<sup>1</sup>, F. Cantile<sup>1</sup>, A. Saviola<sup>1</sup>, G. Longo<sup>2</sup>, A. Luciani<sup>3</sup>, S. Cascinu<sup>1</sup>, <sup>1</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>2</sup>Azienda Ospealiero-Universitaria Policlinico di Modena, Modena, IT, <sup>3</sup>Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, IT
- 13:25 - 13:25 **1746P - Comparing cancer patients' and support persons' preferences for the type of consultation and the format of information provided when making a treatment decision**  
A. Herrmann<sup>1</sup>, R. Sanson-Fisher<sup>1</sup>, A. Hall<sup>2</sup>, L. Wall<sup>2</sup>, N. Zdenkowski<sup>3</sup>, A. Waller<sup>2</sup>, <sup>1</sup>The University of Newcastle, Callaghan, AU, <sup>2</sup>University of Newcastle, Callaghan, AU, <sup>3</sup>Calvary Mater Newcastle, Waratah, AU
- 13:25 - 13:25 **1747P - EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide (ENZ) in Combination with Conventional Androgen Deprivation Therapy (ADT) for Hormone Naïve Prostate Cancer (HSPC)**  
M. Harrison<sup>1</sup>, P. Davis<sup>2</sup>, M. Khouri<sup>1</sup>, R. Gupta<sup>1</sup>, A. Armstrong<sup>1</sup>, M. Mcnamara<sup>1</sup>, T. Zhang<sup>1</sup>, M. Anand<sup>1</sup>, K. Onyenwoke<sup>1</sup>, H. Hood<sup>1</sup>, S. Edwardson<sup>3</sup>, D. Craig<sup>3</sup>, Y. Wu<sup>1</sup>, P. Healy<sup>1</sup>, B. Coyne<sup>4</sup>, L. Jones<sup>5</sup>, D. George<sup>6</sup>, <sup>1</sup>Duke Cancer Center, Durham, US, <sup>2</sup>UNCG, Greensboro, US, <sup>3</sup>Duke University, Durham, US, <sup>4</sup>Duke University Health System, Durham, US, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>6</sup>Duke University Medical Center, Durham, US
- 13:25 - 13:25 **1748P - Cancer care-related social media (SM) and internet usage differences between adolescents and young adults (AYA), adults and elderly patients with cancer.**  
L. Eng<sup>1</sup>, J. Bender<sup>2</sup>, K. Hueniken<sup>1</sup>, S. Kassirian<sup>1</sup>, D. Yang<sup>1</sup>, L. Mitchell<sup>3</sup>, C. Paulo<sup>1</sup>, A. Magony<sup>1</sup>, E.C. Smith<sup>1</sup>, M. Liang<sup>1</sup>, M.C. Brown<sup>1</sup>, W. Xu<sup>1</sup>, S. Alibhai<sup>4</sup>, G. Liu<sup>1</sup>, A. Gupta<sup>3</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>Dalla Lana School of Public Health, Toronto, CA, <sup>3</sup>Hospital for Sick Chidlren, Toronto, CA, <sup>4</sup>Toronto General Hospital, Toronto, CA
- 13:25 - 13:25 **1749P - Ultrasound-guided femoro-popliteal block in lower limb sarcoma and cutaneous malignancy patients- Is it the time to abandon spinal anaesthesia for foot and ankle surgeries.**  
N. Moda, IMS & SUM Hospital SOA University, Bhubaneswar, IN

- 13:25 - 13:25 **1750P - Assessment of socio-economic, physical and mental health status of long-term cancer survivors**  
A. Gallego Martínez<sup>1</sup>, B. Martínez<sup>1</sup>, I. Ghanem<sup>2</sup>, E. Espinosa<sup>1</sup>, B. Castelo<sup>1</sup>, M.P. Zamora Aunon<sup>1</sup>, A. Pinto Marin<sup>1</sup>, L. Ruiz-Giménez<sup>1</sup>, A. Redondo<sup>1</sup>, J. Feliu Batlle<sup>1</sup>, <sup>1</sup>Hospital Universitario La Paz, Madrid, ES, <sup>2</sup>University Hospital 12 De Octubre, Madrid, ES
- 13:25 - 13:25 **1751P - Usability testing of EirV3-a computer-based tool for patient reported outcome measures in cancer**  
H. Krogstad<sup>1</sup>, S. Sundt-Hansen<sup>1</sup>, M. Hjermland<sup>2</sup>, L. Hågensen<sup>3</sup>, S. Kaasa<sup>2</sup>, J.H. Loge<sup>2</sup>, S. Raj<sup>4</sup>, A. Steinsbekk<sup>1</sup>, K. Sand<sup>1</sup>, <sup>1</sup>Norwegian University of Science and Technology, Trondheim, NO, <sup>2</sup>Oslo University Hospital, Oslo, NO, <sup>3</sup>Orkdal Region, Orkdal, NO, <sup>4</sup>Norwegian University of Science and Technology and St.Olavs Hospital, Trondheim University Hospital, Trondheim, NO
- 13:25 - 13:25 **1752P - Monitoring Quality of Life in Dutch women with breast cancer: 'the Care Notebook study'**  
R.T. Lugtenberg<sup>1</sup>, M. Fischer<sup>1</sup>, F. De Jongh<sup>1</sup>, K. Inoue<sup>2</sup>, A. Matsuda<sup>3</sup>, S.R.S. Ramai<sup>1</sup>, J. Nortier<sup>1</sup>, H. Putter<sup>1</sup>, K. Yamaoka<sup>4</sup>, K. Kubota<sup>5</sup>, K. Kobayashi<sup>6</sup>, A.A. Kaptein<sup>1</sup>, J. Kroep<sup>1</sup>, <sup>1</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>2</sup>Saitama Cancer Center, Kitadachi Ina, JP, <sup>3</sup>Teikyo University School of Medicine, Tokyo, JP, <sup>4</sup>Teikyo University, Tokyo, JP, <sup>5</sup>Nippon Medical School, Tokyo, JP, <sup>6</sup>Saitama Medical University Internatl Medical Centre, Saitama, JP
- 13:25 - 13:25 **1753P\_PR - Benefits of physical activity and sport integrated into the care pathway of oncology patient**  
L. Vanlemmens<sup>1</sup>, H. Mocaer<sup>1</sup>, T. Ginsbourger<sup>2</sup>, J.M. Descotes<sup>3</sup>, N. Masselin<sup>1</sup>, H. Deroubaix<sup>1</sup>, C. Fabre<sup>4</sup>, J. Devriendt<sup>5</sup>, T. Bouillet<sup>6</sup>, E. Lartigau<sup>1</sup>, <sup>1</sup>Centre Oscar Lambret, Lille, FR, <sup>2</sup>National Federation CAMI Sport Cancer, Paris, FR, <sup>3</sup>National Federation CAMI Sport and Cancer, Paris, FR, <sup>4</sup>University of Lille. URePSSS EA7369, Lille, FR, <sup>5</sup>Nationale Federation CAMI Sport Cancer, Paris, FR, <sup>6</sup>American Hospital of Paris, Neuilly Sur Seine, FR
- 13:25 - 13:25 **1754P - Prognostic factors for critically ill patients with solid cancer tumours admitted to a medical intensive care unit.**  
C. Baylot<sup>1</sup>, A. Francopoulo<sup>2</sup>, A. Quivy<sup>3</sup>, O. Guisset<sup>4</sup>, G. Hilbert<sup>5</sup>, E. Frison<sup>2</sup>, A. Ravaud<sup>3</sup>, A. Daste<sup>3</sup>, <sup>1</sup>Institute Bergonié, Bordeaux, FR, <sup>2</sup>CHU Bordeaux, BORDEAUX, FR, <sup>3</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>4</sup>CHU Bordeaux Hopital St. André, BORDEAUX, FR, <sup>5</sup>CHU Bordeaux, Hôpital pellegrin, BORDEAUX, FR
- 13:25 - 13:25 **1755P - A pilot study of exercise intervention in patients with metastatic cancer: feasibility, safety, and patient reported outcome**  
J.-H. Park<sup>1</sup>, E.Y. Kim<sup>1</sup>, K.D. Park<sup>1</sup>, S.M. Kang<sup>2</sup>, H. Ahn<sup>3</sup>, Y.S. Kim<sup>1</sup>, I. Park<sup>1</sup>, S.J. Sym<sup>1</sup>, D.B. Shin<sup>1</sup>, <sup>1</sup>Gachon University Gil Medical Center, Incheon, KR, <sup>2</sup>Gachon University Gil Medical Center, Incheon, KP, <sup>3</sup>Gachon University Gil Hospital, Incheon, KR
- 13:25 - 13:25 **1756P - A prospective analysis of 30 day mortality following palliative chemotherapy at an Australian tertiary cancer centre.**

J. Mccracken-Skeggs<sup>1</sup>, A. Dabscheck<sup>1</sup>, M. Coperchini<sup>1</sup>, I. Hornung<sup>1</sup>, A. Jalali<sup>2</sup>, G. Akers<sup>1</sup>, A. Karahalios<sup>3</sup>, L. Lipton<sup>4</sup>, <sup>1</sup>Western Health, St Albans, AU, <sup>2</sup>Ballarat Health Research Center, Ballarat, AU, <sup>3</sup>The University of Melbourne, Parkville, AU, <sup>4</sup>Royal Melbourne Hospital, Melbourne, AU

13:25 - 13:25

**1757P - Characterisation of oncologic patient visits at the ED at an austrian tertiary care center**

B. Pauzenberger<sup>1</sup>, T. Fuereder<sup>1</sup>, A. Laggner<sup>1</sup>, C. Zielinski<sup>2</sup>, C. Minichsdorfer<sup>2</sup>, <sup>1</sup>Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, <sup>2</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

13:25 - 13:25

**1758P - High proportion of prostate cancer survivors continue to experience a negative impact on quality of life long after diagnosis: Patient reported outcomes for an Australian population-based sample.**

O. Tran<sup>1</sup>, A. Ward<sup>2</sup>, K. Lisy<sup>3</sup>, J. Bishop<sup>4</sup>, M. Jefford<sup>5</sup>, <sup>1</sup>Prince Charles Hospital, Brisbane, AU, <sup>2</sup>The Social Research Centre, Melbourne, AU, <sup>3</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>4</sup>Victorian Comprehensive Cancer Centre, Melbourne, AU, <sup>5</sup>Peter MacCallum Cancer Center, Melbourne, AU

13:25 - 13:25

**1759P - A systematic approach to smoking cessation in regional cancer centres in Ontario, Canada**

W. Evans<sup>1</sup>, E. Cameron<sup>2</sup>, M. Haque<sup>2</sup>, N. Schwartz<sup>2</sup>, S. Khan<sup>2</sup>, R. Truscott<sup>2</sup>, <sup>1</sup>McMaster University, Hamilton, CA, <sup>2</sup>Cancer Care Ontario, Toronto, CA

13:25 - 13:25

**1760P - A Longitudinal Study of a New Point-of-Care Nerve Conduction Device for Quantitative Assessment of Chemotherapy-Induced Peripheral Neurotoxicity**

A. Matsuoka<sup>1</sup>, O. Maeda<sup>2</sup>, A. Mitsuma<sup>2</sup>, K. Uehara<sup>2</sup>, G. Nakayama<sup>1</sup>, M. Nagino<sup>2</sup>, Y. Koderu<sup>3</sup>, Y. Ando<sup>2</sup>, <sup>1</sup>Nagoya University, Graduate School of Medicine, Nagoya, JP, <sup>2</sup>Nagoya University Hospital, Nagoya, JP, <sup>3</sup>Nagoya University Graduate School of Medicine, Nagoya, JP

13:25 - 13:25

**1761P - Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance**

K. Thein<sup>1</sup>, A. Sultan<sup>2</sup>, M. Zaw<sup>3</sup>, M. Han<sup>4</sup>, N. Yu<sup>5</sup>, H. Igid<sup>2</sup>, C. Jones<sup>2</sup>, N. D'Cunha<sup>2</sup>, S. Awasthi<sup>2</sup>, F. Hardwicke<sup>2</sup>, <sup>1</sup>TEXAS TECH UNIVERSITY, Lubbock, US, <sup>2</sup>Texas Tech University Health Sciences Center, Lubbock, US, <sup>3</sup>The Brooklyn Hospital Center, Brooklyn, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Kingsbrook Jewish Medical Center, Brooklyn, US

13:25 - 13:25

**1762P - Chemotherapy-Induced Peripheral Neurotoxicity (CIPN): what are patients telling us?**

G. Cavaletti, Università degli Studi di Milano Bicocca - Facoltà di Medicina e Chirurgia, Monza, IT

13:25 - 13:25

**1763P - Malnutrition in cancer patients: is a late diagnosis a missed opportunity to improve care?**

C. Tlemsani<sup>1</sup>, G. Zalcman<sup>2</sup>, R. Bernard<sup>3</sup>, A. Zerouali<sup>3</sup>, F. Goldwasser<sup>1</sup>, <sup>1</sup>Hôpital Cochin,

Paris, FR, <sup>2</sup>Hôpital Bichat, Paris, FR, <sup>3</sup>Baxter Healthcare, Guyancourt, FR

- 13:25 - 13:25 **1764P - A Survey on acceptable nomenclature in addressing patient needs among the delegates of a national conference on supportive medicine**  
R. Arora, All India Institute of Medical Sciences, New Delhi, IN
- 13:25 - 13:25 **1765P - A Survey on purview of palliative medicine services among the delegates of a national conference on supportive medicine**  
R. Arora, All India Institute of Medical Sciences, New Delhi, IN
- 13:25 - 13:25 **1766P - Sexual Functioning and Depression among Egyptian Breast Cancer Patients following surgery and neoadjuvant/adjuvant chemotherapy**  
S. Al Hassanin<sup>1</sup>, S. Alsirafy<sup>2</sup>, <sup>1</sup>Faculty of Medicine - Menoufia University, Shebin El Kom, EG, <sup>2</sup>NEMROCK Cairo University, Cairo, EG
- 13:25 - 13:25 **1767P - Supportive care: patient expectations, availability and uptake**  
H. Simon<sup>1</sup>, J. Viguier<sup>2</sup>, G. Ganem<sup>3</sup>, C. Touboul<sup>4</sup>, C. Lhomel<sup>5</sup>, H. Naman<sup>6</sup>, J.F. Morère<sup>7</sup>, F. Eisinger<sup>8</sup>, <sup>1</sup>Clinique de Keraudren, Brest, FR, <sup>2</sup>CHRU Bretonneau, Tours, FR, <sup>3</sup>Centre Jean Bernard, Le Mans, FR, <sup>4</sup>Kantar Health, Paris, FR, <sup>5</sup>Products Roche - France, Neuilly-sur-Seine, FR, <sup>6</sup>Centre Azuréen Cancérologie, Mougins, FR, <sup>7</sup>Hôpital Paul Brousse, Villejuif, FR, <sup>8</sup>Institute Paoli Calmettes, Marseille, FR
- 13:25 - 13:25 **1768P - Novel approach for counselling of young cancer patients**  
U. Seifart<sup>1</sup>, T. Langer<sup>2</sup>, I.-K. Na<sup>3</sup>, J. Schulze<sup>4</sup>, M. Freund<sup>5</sup>, <sup>1</sup>Klinik Sonnenberg, Marburg, DE, <sup>2</sup>University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, DE, <sup>3</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>4</sup>Deutsche Stiftung für junge Erwachsene mit Krebs, Berlin, DE, <sup>5</sup>Klinik und Poliklinik für Innere Medizin Universität Rostock, Rostock, DE
- 13:25 - 13:25 **1769P - Health-related quality of life priorities in adolescents and young adults (AYA) with cancer: discrepancies with health care professionals' perceptions**  
S. Kaal<sup>1</sup>, J. Prins<sup>1</sup>, R. Jansen<sup>1</sup>, E. Manten-Horst<sup>2</sup>, P. Servaes<sup>1</sup>, W. Van Der Graaf<sup>3</sup>, O. Husson<sup>3</sup>, <sup>1</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>2</sup>IKNL, Utrecht, NL, <sup>3</sup>Royal Marsden Hospital Institute of Cancer Research, Sutton, GB
- 13:25 - 13:25 **1770P - What Information and Features do Young and Older Adults with Cancer Want in their Hospital-based Social Media Cancer Resource?**  
C. Paulo<sup>1</sup>, L. Eng<sup>1</sup>, L. Mitchell<sup>2</sup>, I. Geist<sup>1</sup>, S. Kassirian<sup>1</sup>, A. Magony<sup>1</sup>, E.C. Smith<sup>1</sup>, C. Brown<sup>1</sup>, M. Liang<sup>1</sup>, K. Hueniken<sup>1</sup>, D. Yang<sup>1</sup>, W. Xu<sup>1</sup>, G. Liu<sup>1</sup>, A. Gupta<sup>2</sup>, J. Bender<sup>3</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>Hospital for Sick Children, Toronto, CA, <sup>3</sup>Dalla Lana School of Public Health, Toronto, CA
- 13:25 - 13:25 **1771P - Hypothyroidism in cancer patients received multikinase inhibitors: Risk Factors and Outcomes**  
S. Hansuranant<sup>1</sup>, H. Nimitphong<sup>1</sup>, O. Pattanaprteep<sup>1</sup>, R. Phraewphiphat<sup>1</sup>, D. Muntham<sup>2</sup>,



T. Reungwetwattana<sup>1</sup>, <sup>1</sup>Ramathibodi Hospital, Bangkok, TH, <sup>2</sup>Rajamangala University of Technology Suvarnabhumi, Nonthaburi, TH

- 13:25 - 13:25 **1772P - Immune related adverse events across cancer types: incidence, risk factors, and survival**  
D. Owen<sup>1</sup>, J. Burkart<sup>1</sup>, S. Patel<sup>1</sup>, L. Wei<sup>1</sup>, G. Tinoco<sup>1</sup>, D. Liebner<sup>1</sup>, K. He<sup>1</sup>, P. Shields<sup>1</sup>, E. Bertino<sup>1</sup>, C. Presley<sup>1</sup>, A. Johns<sup>1</sup>, E. Folefac<sup>1</sup>, T. Olencki<sup>1</sup>, D. Carbone<sup>2</sup>, C. Verschraegen<sup>3</sup>, G. Otterson<sup>1</sup>, K. Kendra<sup>4</sup>, <sup>1</sup>The Ohio State University James Cancer Hospital, Columbus, US, <sup>2</sup>Ohio State Univ Medical Center, Columbus, US, <sup>3</sup>University of Vermont Cancer Center, Burlington, US, <sup>4</sup>Ohio State University Comprehensive Cancer Center - James, Columbus, US
- 13:25 - 13:25 **1773P - Effect of yoga on Chemo-Radiotherapy induced Diabetes and Hypertension (CRID-H) among cervical cancer patients at a regional cancer institute in South India.**  
N. Nelson<sup>1</sup>, I. Khaleel<sup>1</sup>, M. Roy<sup>2</sup>, R. C<sup>2</sup>, H.B. Govardhan<sup>3</sup>, N. Jasti<sup>2</sup>, S. Suresh<sup>2</sup>, R. Kashyap<sup>2</sup>, L. Lokanath<sup>2</sup>, <sup>1</sup>Kidwai Cancer Institute, Bengaluru, IN, <sup>2</sup>KIDWAI Memorial Institute of oncology, Bangalore, IN, <sup>3</sup>Kidwai Memorial Institute of Oncology, Bangalore, IN
- 13:25 - 13:25 **1774P - Fatigue prevalence and adherence to treatment. A real-world data survey and mathematical model application.**  
D. Vorobiof<sup>1</sup>, E. Malki<sup>2</sup>, I. Deutsch<sup>2</sup>, M. Bivasbenita<sup>2</sup>, <sup>1</sup>Belong, Bnei Atarot, IL, <sup>2</sup>Sandton Oncology Centre, Sandton, ZA
- 13:25 - 13:25 **1775P - A survey on attitude towards Euthanasia among delegates of a national conference on supportive medicine**  
R. Arora, All India Institute of Medical Sciences, New Delhi, IN
- 13:25 - 13:25 **1776P - Acute toxicity of concurrent radiochemotherapy for locally advanced head and neck cancer, a prospective study**  
E. Dewaele<sup>1</sup>, P.J. Van Dam<sup>2</sup>, B. De Laere<sup>3</sup>, C. Verschueren<sup>4</sup>, P. Specenier<sup>5</sup>, <sup>1</sup>St Trudo Ziekenhuis, St Truiden, BE, <sup>2</sup>St-Augustinus Ziekenhuis, Wilrijk, BE, <sup>3</sup>University of Antwerp-Campus Drie Eiken, Antwerp, BE, <sup>4</sup>Antwerp University Hospital, Edegem, BE, <sup>5</sup>Antwerp University Hospital, Grimbergen, BE
- 13:25 - 13:25 **1777P\_PR - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study**  
Q. Tran<sup>1</sup>, A. Schimdt<sup>2</sup>, Z. Lwin<sup>3</sup>, B. Hughes<sup>3</sup>, <sup>1</sup>Prince Charles Hospital, Brisbane, AU, <sup>2</sup>Olivia Newton John Cancer and Wellness Centre, Melbourne, AU, <sup>3</sup>Royal Brisbane and Women's Hospital, Brisbane, AU
- 13:25 - 13:25 **1778P - Chemotherapy effect on daytime sleepiness and contributing factors in older adults with cancer**  
S. Sadighi<sup>1</sup>, B. Saberzadeh-Ardestani<sup>2</sup>, B. Khosravi<sup>2</sup>, J. Zebardast<sup>2</sup>, <sup>1</sup>Central Cancer Institute of Imam Khomeini Hospital, Teheran, IR, <sup>2</sup>Tehran University of Medical Sciences, Tehran, IR

- 13:25 - 13:25 **1779P - Group Pre-Chemotherapy Education: Improving patient experience through education and empowerment**  
K. McIntyre<sup>1</sup>, R. Blackwood<sup>1</sup>, V. Riley<sup>1</sup>, L. Carballo<sup>1</sup>, H. Plant<sup>1</sup>, T. Marler-Hausen<sup>2</sup>,  
<sup>1</sup>University College Hospital London, AG, GB, <sup>2</sup>University College London Hospital UCLH NHS Foundation Trust, London, GB
- 13:25 - 13:25 **1780P - Clinical and Psychometric validation of the BreSAS Questionnaire for Symptom Assessment among Breast Cancer Survivors.**  
R. Giusti<sup>1</sup>, E. Scarpi<sup>2</sup>, K. Cannita<sup>3</sup>, R.R. Silva<sup>4</sup>, M. Filetti<sup>5</sup>, M. Mazzotta<sup>6</sup>, R. Rossi<sup>7</sup>, V. Coccione<sup>8</sup>, T. Sidoni<sup>3</sup>, M. Tudini<sup>4</sup>, C. Ficorella<sup>9</sup>, A. Botticelli<sup>10</sup>, P. Marchetti<sup>10</sup>, G. Porzio<sup>3</sup>, L. Verna<sup>3</sup>, <sup>1</sup>Azienda Ospedaliera St. Andrea, Rome, IT, <sup>2</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, <sup>3</sup>S. Salvatore Hospital, University of L'Aquila, L'Aquila, IT, <sup>4</sup>Ospedale E. Profili U.O. Oncologia Medica, Fabriano, IT, <sup>5</sup>Sapienza, University of Rome, DPT Digestive and Liver Disease, Digestive Neuroendocrine Unit, Rome, IT, <sup>6</sup>Azienda Ospedaliera St. Andrea - Roma, Roma, IT, <sup>7</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), IT, <sup>8</sup>Private Practice, Paganica, IT, <sup>9</sup>Dr. Corrado Ficorella, Milan, IT, <sup>10</sup>Azienda Ospedaliera St. Andrea, Roma, IT
- 13:25 - 13:25 **1781P - Association of phase angle and chemotherapy toxicity among Mexican patients with non-metastatic breast cancer**  
M.T. Nieto Coronel<sup>1</sup>, C. Arce-Salinas<sup>1</sup>, A. Peña-Ruiz<sup>1</sup>, M. Espinoza Cuevas<sup>2</sup>, J. Santamaria-Galicia<sup>1</sup>, <sup>1</sup>Instituto Nacional de Cancerologia - Mexico, Ciudad de México, MX, <sup>2</sup>Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, Mexico, MX
- 13:25 - 13:25 **1782P - Hepatitis screening for patients to undergo chemotherapy in Cyprus**  
P. Kountourakis, A. Agathocleous, E. Kakouri, Y. Marcou, G. Orphanos, F. Kyriacou, D. Papamichael, H. Charalambous, Bank of Cyprus Oncology Centre, Nicosia, CY
- 13:25 - 13:25 **1783P - Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency virus (HIV) screening prior to chemotherapy initiation among patients with solid tumors.**  
S. Giordano<sup>1</sup>, Z. Duan<sup>2</sup>, H. Zhao<sup>1</sup>, J. Hwang<sup>1</sup>, M. Chavez Mac Gregor<sup>1</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>The University of Texas, Houston, US
- 13:25 - 13:25 **1784P - Rapid identification of bloodstream infection pathogens**  
N. Panova<sup>1</sup>, O. Kit<sup>1</sup>, O. Kutsevalova<sup>1</sup>, I. Lysenko<sup>2</sup>, V. Dmitrieva<sup>1</sup>, D. Rozenko<sup>1</sup>, Y. Gevorkyan<sup>1</sup>, E. Pak<sup>1</sup>, O. Kozyuk<sup>1</sup>, E. Kapuza<sup>1</sup>, O. Shatokhina<sup>1</sup>, N. Nikolaeva<sup>3</sup>, E. Kalabanova<sup>1</sup>, I. Mitashok<sup>2</sup>, L. Vladimirova<sup>1</sup>, <sup>1</sup>Rostov Research Institute of Oncology, Rostov-on-Don, RU, <sup>2</sup>Rostov Research Oncology Institute, Rostov-on-Don, RU, <sup>3</sup>FGU Rostov Cancer Research Institute, Rostov-on-Don, RU
- 13:25 - 13:25 **1785P - Pathogens and characteristics of candidemia in hospitals of Rostov-on-Don. Multicenter study in Russia**  
O. Kutsevalova<sup>1</sup>, O. Kit<sup>1</sup>, N. Panova<sup>1</sup>, I. Lysenko<sup>2</sup>, V. Dmitrieva<sup>1</sup>, D. Rozenko<sup>1</sup>, E. Kalabanova<sup>1</sup>, I. Mitashok<sup>2</sup>, G. Klyasova<sup>3</sup>, Y. Shatokhin<sup>4</sup>, I. Snezhko<sup>4</sup>, D. Martynov<sup>4</sup>, V. Malygin<sup>4</sup>, O. Korosteleva<sup>5</sup>, A. Matsuga<sup>5</sup>, K. Aslanyan<sup>6</sup>, L. Vladimirova<sup>1</sup>, <sup>1</sup>Rostov Research

Institute of Oncology, Rostov-on-Don, RU, <sup>2</sup>Rostov Research Oncology Institute, Rostov-on-Don, RU, <sup>3</sup>National Research Center for Hematology, Moscow, RU, <sup>4</sup>Rostov State Medical University, Rostov-on-Don, RU, <sup>5</sup>Hospital, Rostov-on-Don, RU, <sup>6</sup>Rostov Regional Children's Hospital, Rostov-on-Don, RU

- 13:25 - 13:25 **1786P - Antiviral Prophylaxis Cannot Reduce the Risk of Hepatitis B Reactivation During Chemotherapy for non HCC Solid Tumor Patients with Lower HBV DNA Titer : A Retrospective Cohort Study.**  
Q. Qin<sup>1</sup>, A. Zhou<sup>2</sup>, L. Yang<sup>2</sup>, D. Zhong<sup>1</sup>, <sup>1</sup>Tianjin Medical University General Hospital, Tianjin, CN, <sup>2</sup>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 13:25 - 13:25 **1787P - Prospective observational study to evaluate the persistence of treatment with denosumab (dmab) in patients (pts) with bone metastases (BM) from solid tumors (ST) in routine clinical practice: final analysis**  
F. Haslbauer<sup>1</sup>, A. Petzer<sup>2</sup>, M. Safanda<sup>3</sup>, A. Tomova<sup>4</sup>, M. Porubská<sup>5</sup>, Z. Bajory<sup>6</sup>, D. Niepel<sup>7</sup>, C. Jäger<sup>8</sup>, D. Kalinin<sup>9</sup>, R. Greil<sup>10</sup>, <sup>1</sup>Krankenhaus Voecklabruck, Voecklabruck, AT, <sup>2</sup>Krankenhaus der Barmherzigen Schwestern Linz (bhslinz), Linz, AT, <sup>3</sup>Nemocnice Na Homolce, Prague, CZ, <sup>4</sup>Complex Cancer Center, Plovdiv, BG, <sup>5</sup>St. Elisabeth Cancer Institute, Bratislava, SK, <sup>6</sup>SZTE Urológiai Klinika, HU, <sup>7</sup>Amgen GmbH, Zug, CH, <sup>8</sup>AMGEN - Austria, Vienna, AT, <sup>9</sup>Quartesian, Kharkov, UA, <sup>10</sup>Paracelsus Medical University, Salzburg, AT
- 13:25 - 13:25 **1788P - A multicenter retrospective investigation on the efficacy of perioperative oral management in cancer patients**  
S.-I. Yamada<sup>1</sup>, S. Soutome<sup>2</sup>, T. Hasegawa<sup>3</sup>, I. Toujou<sup>4</sup>, H. Nakahara<sup>5</sup>, M. Kawakami<sup>6</sup>, M. Hirose<sup>7</sup>, S. Fujita<sup>4</sup>, T. Komori<sup>3</sup>, T. Kirita<sup>6</sup>, Y. Shibuya<sup>7</sup>, M. Umeda<sup>2</sup>, H. Kurita<sup>1</sup>, <sup>1</sup>Shinshu University, School of Medicine, Matsumoto, JP, <sup>2</sup>Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JP, <sup>3</sup>Kobe University Graduate School of Medicine, Kobe, JP, <sup>4</sup>Wakayama Medical University, Wakayama, JP, <sup>5</sup>Osaka City University Graduate School of Medicine, Osaka, JP, <sup>6</sup>Nara Medical University, Kashihara, JP, <sup>7</sup>Nagoya City University Graduate School of Medical Sciences, Nagoya, JP
- 13:25 - 13:25 **1790P - Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): the CIROCO study**  
J. Desrame<sup>1</sup>, J. Loup Mouysset<sup>2</sup>, T. Altwegg<sup>3</sup>, L. Zelek<sup>4</sup>, N. Baize<sup>5</sup>, <sup>1</sup>Hôpital privé Jean Mermoz, Lyon, FR, <sup>2</sup>Clinique Rambot Provençale, Aix-en-Provence, FR, <sup>3</sup>Institut de Cancérologie de Bourgogne, Dijon, FR, <sup>4</sup>Hôpital Avicenne, Bobigny, FR, <sup>5</sup>CHU Angers, Angers, FR
- 13:25 - 13:25 **1791P - Quality of life, late effects, and related clinical factors among Korean colorectal cancer survivors**  
J.S. Park<sup>1</sup>, T.I. Kim<sup>2</sup>, <sup>1</sup>Yonsei Cancer Center Yonsei University, Seoul, KR, <sup>2</sup>Yonsei University College of Medicine, Seoul, KR
- 13:25 - 13:25 **1792P - Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic**

**chemotherapy. A multicenter, prospective, and observational study.**

M. Araz<sup>1</sup>, M. Karaağaç<sup>2</sup>, L. Korkmaz<sup>3</sup>, L. Koral<sup>4</sup>, F. Inci<sup>5</sup>, I. Beypinar<sup>6</sup>, M. Uysal<sup>7</sup>, M. Artac<sup>3</sup>, <sup>1</sup>Malatya State Hospital, Malatya, TR, <sup>2</sup>Meram University Faculty of Medicine, Konya, TR, <sup>3</sup>Necmettin Erbakan University, Konya, TR, <sup>4</sup>Çanakkale Onsekiz Mart University, Çanakkale, TR, <sup>5</sup>Karabük State Hospital, Karabük, TR, <sup>6</sup>Afyon Kocatepe University Department of Medical Oncology, Afyonkarahisar, TR, <sup>7</sup>Afyon Kocatepe University School of Medicine, Afyonkarahisar, TR

13:25 - 13:25

**1793P - Painkiller-related dizziness in malignant tumors - A systematic review**

R. Spiegel<sup>1</sup>, S. Rothschild<sup>2</sup>, R. Sutter<sup>2</sup>, R. Kalla<sup>3</sup>, <sup>1</sup>Berufsgenossenschaftliche Unfallklinik Tübingen, Tübingen, DE, <sup>2</sup>Universitätsspital Basel, Basel, CH, <sup>3</sup>Inselspital (University Hospital Bern), Bern, CH

13:25 - 13:25

**1794P - Prevalence, risk factors and management of opioid-induced constipation in cancer pain: a nationwide, cross-sectional study in Korea**

S.Y. Lee<sup>1</sup>, Y.S. Hong<sup>2</sup>, K.T. Lee<sup>3</sup>, S.H. Shin<sup>4</sup>, M.Y. Choi<sup>5</sup>, S.J. Sym<sup>6</sup>, H.-S. Oh<sup>7</sup>, S.N. Lee<sup>8</sup>, E.-K. Song<sup>9</sup>, <sup>1</sup>Mundipharma Korea Ltd, Seoul, KR, <sup>2</sup>The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, KR, <sup>3</sup>Soon Chun Hyang University Hospital Cheonan, Cheonan, KR, <sup>4</sup>Kosin University Gospel Hospital, Busan, KR, <sup>5</sup>Inje University Busan Paik Hospital, Busan, KR, <sup>6</sup>Gachon University Gil Medical Center, Incheon, KR, <sup>7</sup>GangNeung Asan Hospital, hosukoh@hanmail.net, KR, <sup>8</sup>Ewha Womans University School of Medicine, Seoul, KR, <sup>9</sup>Chonbuk National University Medical School, Jeonju, KR

13:25 - 13:25

**1795P - Bald is beautiful: no more. The stigma of alopecia during chemotherapy: Brindisi Oncology Dpt experience.**

D. Loparco, L. Orlando, M. Caloro, P. Fedele, P. Schiavone, A. Quaranta, C. Caliolo, M. Cinefra, P. Ferrara, L.L. Falcone, V. Capone, C. Destro, A. Morleo, A. Ricco, V. Bonuso, G. Lotti, M. D'Amico, P. Rizzo, A. Marino, S. Cinieri, Ospedale A. Perrino, Brindisi, IT

13:25 - 13:25

**1796P - A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: methodological approach**

R. Nakov<sup>1</sup>, S. Schussler<sup>2</sup>, S. Schier-Mumzhiu<sup>1</sup>, A. Skerjanec<sup>1</sup>, A. Bellon<sup>1</sup>, J. Wang<sup>2</sup>, A. Krendyukov<sup>1</sup>, G. Otto<sup>1</sup>, <sup>1</sup>Hexal AG, Holzkirchen, DE, <sup>2</sup>Sandoz Inc., Princeton, US

13:25 - 13:25

**1797P - Quality of Life in Breast Cancer Tunisian Women : A monocentric survey**

S. Labidi<sup>1</sup>, C. Bousrih<sup>2</sup>, M. Saadi<sup>3</sup>, H. El Benna<sup>3</sup>, M. Nesrine<sup>1</sup>, N. Daoud<sup>1</sup>, H. Boussen<sup>4</sup>, <sup>1</sup>Abderrahmen Mami Hospital, Ariana, TN, <sup>2</sup>Institut Salah Azaïz, Tunis, TN, <sup>3</sup>Hospital Abderrahmane Mami, Tunis, TN, <sup>4</sup>Hopital Abderrahman Mami, Ariana, TN

13:25 - 13:25

**1798P - Anticancer therapy within the last 30 days of life in a regional cancer centre**

M. Nguyen, Goulburn Valley Health, Shepparton, AU

13:25 - 13:25

**1799P - Febrile Neutropenia Management And Concordance Of Institutional Protocol With Clinical Practice**



A. Oliveira, L. Bretes, I. Furtado, B. Gosalbez Pequeno, J. Magalhaes, Hospital Distrital de Faro, Faro, PT

- 13:25 - 13:25 **1800P - Salient features of an indigenous integrated inpatient model of delivery of supportive medicine services - a narrative review**  
R. Arora, All India Institute of Medical Sciences, New Delhi, IN
- 13:25 - 13:25 **1801P - Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches**  
N. Lankheet<sup>1</sup>, K. Ferrier<sup>1</sup>, S. Gibbons<sup>2</sup>, D. Burger<sup>1</sup>, K. Mcallister<sup>2</sup>, J. Martin<sup>2</sup>, S. Khoo<sup>2</sup>, N. Van Erp<sup>3</sup>, F. Jansman<sup>4</sup>, <sup>1</sup>Radboud University Medical Centre Nijmegen, Nijmegen, NL, <sup>2</sup>University of Liverpool, Liverpool, GB, <sup>3</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>4</sup>Deventer Ziekenhuis, Deventer, NL
- 13:25 - 13:25 **1802P - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database.**  
S. Bun<sup>1</sup>, S. Kunisawa<sup>2</sup>, N. Sasaki<sup>2</sup>, K. Fushimi<sup>3</sup>, K. Matsumoto<sup>3</sup>, A. Yamatani<sup>1</sup>, Y. Imanaka<sup>2</sup>, <sup>1</sup>National Center for Child Health and Development, Tokyo, JP, <sup>2</sup>Kyoto University, Kyoto, JP, <sup>3</sup>Tokyo Medical and Dental University Graduate School, Tokyo, JP
- 13:25 - 13:25 **1803P - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy**  
S. Tsuyuki<sup>1</sup>, K. Yamagami<sup>2</sup>, H. Yoshibayashi<sup>3</sup>, T. Sugie<sup>4</sup>, Y. Mizuno<sup>5</sup>, S. Tanaka<sup>6</sup>, H. Kato<sup>7</sup>, T. Okuno<sup>8</sup>, N. Ogura<sup>9</sup>, H. Yamashiro<sup>10</sup>, H. Takuwa<sup>11</sup>, Y. Kikawa<sup>7</sup>, T. Hashimoto<sup>12</sup>, T. Kato<sup>13</sup>, S. Takahara<sup>14</sup>, A. Yamauchi<sup>15</sup>, T. Inamoto<sup>16</sup>, <sup>1</sup>Osaka Red Cross Hospital, Osaka, JP, <sup>2</sup>Shinko Hospital, Kobe, JP, <sup>3</sup>Japanese Red Cross Wakayama Medical Center, Wakayama, JP, <sup>4</sup>Kansai Medical University Hospital, Osaka, JP, <sup>5</sup>Yokkaichi Municipal Hospital, Yokkaichi, JP, <sup>6</sup>National Hospital Organization Osaka-Minami Medical Center, Kawachinagano, JP, <sup>7</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>8</sup>Kobe City Nishi-Kobe Medical Center, Kobe, JP, <sup>9</sup>Kansai Electric Power Hospital, Osaka, JP, <sup>10</sup>Tenri Hospital, Tenri, JP, <sup>11</sup>Shiga General Hospital, Moriyama, JP, <sup>12</sup>Hashimoto Clinic, Kobe, JP, <sup>13</sup>Yamato Takada Municipal Hospital, Yamatotakada, JP, <sup>14</sup>Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, JP, <sup>15</sup>Nara Prefecture General Medical Center, Nara, JP, <sup>16</sup>Tenri Health Care University, Tenri, JP
- 13:25 - 13:25 **1804P - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)**  
H. Piessevaux<sup>1</sup>, W. Demey<sup>2</sup>, A. Bols<sup>3</sup>, J. Janssens<sup>4</sup>, M. Polus<sup>5</sup>, H. Rezaei Kalantari<sup>6</sup>, S. Laurent<sup>7</sup>, A. Demols<sup>8</sup>, Y. Humblet<sup>1</sup>, G. Deboever<sup>9</sup>, K. Kargar Samani<sup>10</sup>, M. Ferrante<sup>11</sup>, E. Monsaert<sup>12</sup>, T. Rondou<sup>13</sup>, J.-L. Van Laethem<sup>8</sup>, S. Tejpar<sup>14</sup>, <sup>1</sup>Cliniques Universitaires St. Luc, Brussels, BE, <sup>2</sup>A.Z. Klina, Brasschaat, BE, <sup>3</sup>AZ St. Jan Av, Brugge, BE, <sup>4</sup>A.Z. Turnhout, Turnhout, BE, <sup>5</sup>Centre Hospitalier Uuniversitaire Sart Tilman, Liège, BE, <sup>6</sup>CHR Verviers, Verviers, BE, <sup>7</sup>UZ Gent, Gent, BE, <sup>8</sup>Erasmus University Hospital- (Universite Libre de Bruxelles), Brussels, BE, <sup>9</sup>AZ Damiaan, Oostende, BE, <sup>10</sup>CHWAPI, Tournai, BE, <sup>11</sup>A.Z. Sint Maarten, Mechelen, BE, <sup>12</sup>AZ Maria Middelaes, Gent, BE, <sup>13</sup>St-Jozef Kliniek, Bornem, BE, <sup>14</sup>University Hospitals Leuven - Campus Gasthuisberg,

Leuven, BE

13:25 - 13:25 **1805TiP - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)**

A. Mersiades<sup>1</sup>, A. Tognela<sup>2</sup>, P. Haber<sup>3</sup>, M. Stockler<sup>3</sup>, N. Lintzeris<sup>3</sup>, J. Simes<sup>4</sup>, I. Mcgregor<sup>3</sup>, I. Olver<sup>5</sup>, D. Allsop<sup>3</sup>, C. Gedye<sup>6</sup>, A. Kirby<sup>4</sup>, R. Morton<sup>4</sup>, K. Briscoe<sup>7</sup>, P. Fox<sup>8</sup>, M. Aghmesheh<sup>9</sup>, N. Wong<sup>3</sup>, A. Bhardwaj<sup>3</sup>, A. Tran<sup>3</sup>, C. Hahn<sup>10</sup>, P. Grimison<sup>10</sup>, <sup>1</sup>The Crown Princess Mary Cancer Centre, Westmead, AU, <sup>2</sup>Macarthur Cancer Therapy Centre, Sydney, AU, <sup>3</sup>University of Sydney, Sydney, AU, <sup>4</sup>The NHMRC Clinical Trials Centre, Camperdown, AU, <sup>5</sup>University of South Australia, Adelaide, AU, <sup>6</sup>Calvary Mater Newcastle, Newcastle, AU, <sup>7</sup>Mid-North Coast Cancer Institute, Coffs Harbour, AU, <sup>8</sup>Central West Cancer Care Centre, Orange Health Service, Orange, AU, <sup>9</sup>Confident Health Care, Wollongong, AU, <sup>10</sup>Chris O'Brien Lifehouse, Sydney, AU

13:00 - 14:30	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 42</b>	<b>ICM - Room 1</b>
13:00 - 14:30	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 43</b>	<b>ICM - Room 14b</b>
13:00 - 14:30	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 44</b>	<b>ICM - Room 13</b>

13:00 - 14:30 **Presentation**

J. Larkin<sup>1</sup>, A. Hauschild<sup>2</sup>, S. Pignata<sup>3</sup>, <sup>1</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>2</sup>UK-SH, Campus Kiel, Kiel, DE, <sup>3</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

13:00 - 14:30	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 45</b>	<b>Hall A1 - Room 15</b>
13:00 - 14:30	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 46</b>	<b>Hall A1 - Room 16</b>

13:00 - 14:30 **Presentation**

T.S.K. Mok<sup>1</sup>, B. Besse<sup>2</sup>, S. Vallone<sup>3</sup>, <sup>1</sup>Prince of Wales Hospital, Shatin, HK, <sup>2</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>3</sup> Rome, IT

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 23**  
**Title: Industry satellite symposium - EONS 8**

13:00 - 13:15    **Presentation 1**  
P. Jahn, Martin Luther University of Halle, Halle, DE

13:15 - 13:30    **Presentation 2**  
K. Jordan, University of Heidelberg, Heidelberg, DE

13:30 - 13:45    **Presentation 3**  
C. Vidall, London, GB

13:45 - 14:00    **Presentation 4**  
S. Parreira, Hospital CUF Infante Santo, Lisbon, PT

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 20**  
**Title: Industry satellite symposium 47**

13:00 - 14:30    **Presentation**  
G. Long, Melanoma Institute Australia, University of Sydney, North Sydney, AU

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B3 - Room 22**  
**Title: Industry satellite symposium 48**

13:00 - 14:30    **Presentation**  
S. Mahner<sup>1</sup>, M. D'Incalci<sup>2</sup>, R. Kristeleit<sup>3</sup>, A. Walther<sup>4</sup>, A. González Martín<sup>5</sup>, <sup>1</sup>AGO Study Group & University Medical Center Hamburg-Eppendorf and University of Munich; current address University of Munich, München, DE, <sup>2</sup> Milano, IT, <sup>3</sup>University College London UCL Cancer Institute, London, GB, <sup>4</sup> London, GB, <sup>5</sup>Clínica Universidad de Navarra, Madrid, ES

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 19**  
**Title: Industry satellite symposium 49**

**13:00 - 14:30**    **Type: Industry Satellite Symposium**    **Hall B4 - Room 24**  
**Title: Industry satellite symposium - EONS 9**

13:00 - 13:20    **Presentation 1**  
L. Sharp, Regional Cancer Center Stockholm Gotland, Stockholm, SE

13:20 - 13:40    **Presentation 2**  
D. Kelly, Royal College of Nursing, Cardiff, GB

13:40 - 14:00    **Presentation 3**  
M. Andersson, Stockholm, SE

**13:00 - 14:00** Type: **Young Oncologist session** ICM -  
Title: **YO Clinical Case Discussion: Clinical Cases of Solid Tumours -** Room 14c  
**Discussion Forum for Young Oncologists**

13:00 - 13:00 **Session DOI**

13:00 - 13:00 **Soft tissue sarcoma**

P.G. Casali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

13:00 - 13:00 **Prostate cancer**

J. De Bono, The Institute of Cancer Research (ICR), London, GB

13:00 - 13:00 **Non-small cell lung cancer**

T. Cufer, University Clinic Golnik, Golnik, SI



**14:15 - 15:45** **Type: Young Oncologist session** **ICM - Room 14a**  
**Title: YO Fellowship Session: Fellowships in Europe: Educational opportunities for Young Oncologists**  
 Chair(s): Evandro de Azambuja, BE; Guillem Argiles, ES

14:15 - 14:15 **Session DOI**

14:15 - 14:20 **Introduction**

E. De Azambuja, Institute Jules Bordet, Brussels, BE

14:20 - 14:35 **The ESMO Fellowship Programme**

E. De Azambuja, Institute Jules Bordet, Brussels, BE

14:35 - 14:50 **Practical tips from a former fellow**

L. Vecchione, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:50 - 15:05 **Best Paper Derived from an ESMO Fellowship: BRAVE project: Brain metastases (BM) and pancreatic metastases (PM): A clinic-pathological comparison of Various facets of the tumor heterogeneity in renal cell carcinoma (RCC)**

L. Derosa, Gustave Roussy, Villejuif, FR

15:05 - 15:20 **Best Fellowship: Tumor infiltrating lymphocytes (TIL) and host immune response as predictive factors in breast cancer**

A. Matikas, Karolinska University Hospital-Solna, Stockholm, SE

15:20 - 15:45 **Award Ceremony: Presentation of the ESMO 2018 Fellowships and Best Examination Award 2017**

**14:45 - 16:15**    **Type: Special Symposium**    **Hall A1 - Room 17**  
**Title: Early detection of cancer using minimally invasive biomarkers**  
 Chair(s): Jean-Charles Soria, US; Caroline Dive, GB

14:45 - 14:45    **Session DOI**

14:45 - 14:50    **Introduction**

J.-C. Soria, Medimmune, Gaithersburg, US

14:50 - 15:05    **Plasma DNA for early cancer screening**

D.(.-M. Lo, The Chinese University of Hong Kong, Shatin, HK

15:05 - 15:20    **Changes in the innate immune system as early events in cancer**

E. Vivier, Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR

15:20 - 15:35    **Single cells for doing a diagnostic work-up for suspicion of lung cancer**

P. Kuhn, USC University of Southern California - The Kuhn Laboratory, Los Angeles, US

15:35 - 15:50    **Circulating microRNA biomarkers for early detection of lung cancer**

G. Sozzi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:50 - 16:05    **Pharma perspective: Screening, diagnosis or prognosis**

M. Lee, GRAIL, Menlo Park, US

16:05 - 16:15    **Conclusions and clinical perspectives**

C. Dive, Cancer Research UK Manchester Institute, Manchester, GB

**14:45 - 16:15**    **Type: Educational session**    **Hall A2 - Room 18**  
**Title: The force awakens: Immunotherapy in thoracic malignancies**  
 Chair(s): Keith Kerr, GB; Martin Reck, DE

14:45 - 14:45    **Session DOI**

14:45 - 15:10    **Recent updates on biomarkers for immunotherapy beyond PDL1 expression**  
K. Kerr, Aberdeen Royal Infirmary, Aberdeen, GB

15:10 - 15:35    **Mechanisms and management of immunotherapy resistance**  
N. Rizvi, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US

15:35 - 16:00    **Combination and novel approaches to immunotherapy in lung cancer**  
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

16:00 - 16:15    **Discussion**

**14:45 - 16:15**    **Type: Proffered Paper session**    **ICM - Room 14b**  
**Title: Proffered paper session - Head and neck cancer**  
 Chair(s): Amanda Psyrrri, GR; Lillian Siu, CA

14:45 - 14:45    **Session DOI**

14:45 - 15:00    **10440 - A phase 1b/2 study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results**

E. Cohen<sup>1</sup>, K. Harrington<sup>2</sup>, D. Hong<sup>3</sup>, R. Mesia<sup>4</sup>, I. Brana<sup>5</sup>, P. Perez Segura<sup>6</sup>, T. Wise-Draper<sup>7</sup>, M. Scott<sup>8</sup>, P. Mitchell<sup>9</sup>, G. Mugundu<sup>10</sup>, P. Mccoon<sup>8</sup>, C. Cook<sup>8</sup>, M. Mehta<sup>8</sup>, U. Keilholz<sup>11</sup>, <sup>1</sup>The University of Chicago Medical Centre, Chicago, US, <sup>2</sup>Institute of Cancer Research ICR, London, GB, <sup>3</sup>MD Anderson Cancer Center, Houston, US, <sup>4</sup>ICO L'Hospitalet, Barcelona, ES, <sup>5</sup>Vall D'Hebron Institute of Oncology, Barcelona, ES, <sup>6</sup>Hospital Clinico San Carlos, Madrid, ES, <sup>7</sup>University of Cincinnati Cancer Institute, Cincinnati, US, <sup>8</sup>Oncology Translational Medicine Unit, AstraZeneca Pharmaceuticals, Waltham, US, <sup>9</sup>Biometrics, AstraZeneca Pharmaceuticals, Waltham, US, <sup>10</sup>Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca Pharmaceuticals, Waltham, US, <sup>11</sup>Charité - Universitätsmedizin Berlin, Berlin, DE

15:00 - 15:20    **10480 - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ , in patients (pts) with advanced SCCHN: results from a phase 1 cohort**  
B.C. Cho<sup>1</sup>, A. Daste<sup>2</sup>, A. Ravaud<sup>2</sup>, S. Salas<sup>3</sup>, N. Isambert<sup>4</sup>, E. Mcclay<sup>5</sup>, A. Awada<sup>6</sup>, C.

Borel<sup>7</sup>, J. Gulley<sup>8</sup>, L. Ojalvo<sup>9</sup>, C. Helwig<sup>10</sup>, P.A. Rolfe<sup>9</sup>, N. Penel<sup>11</sup>, <sup>1</sup>Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>CHU Bordeaux Hopital St. André, Bordeaux, FR, <sup>3</sup>CHU La Timone Adultes, Marseille, FR, <sup>4</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>5</sup>Institute for Melanoma Research & Education, California Cancer Associates for Research & Excellence, Inc, Encinitas, US, <sup>6</sup>Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BE, <sup>7</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>8</sup>National Cancer Institute, Bethesda, US, <sup>9</sup>EMD Serono, Billerica, US, <sup>10</sup>Merck KGaA, Darmstadt, DE, <sup>11</sup>Centre Oscar Lambret, Lille, FR

15:20 - 15:35 **Invited Discussant 10440 and 10480**

S. Faivre, Hopital Beaujon, Clichy, FR

15:35 - 15:50 **10450 - A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)**

A. Psyrri<sup>1</sup>, P. Economopoulou<sup>1</sup>, I. Kotsantis<sup>1</sup>, G. Koutsodontis<sup>1</sup>, M. Cheila<sup>1</sup>, G. Papaxoinis<sup>2</sup>, D. Pectasides<sup>3</sup>, G. Fountzilias<sup>4</sup>, L. Krikoni<sup>5</sup>, V. Souliotis<sup>5</sup>, <sup>1</sup>Attikon University Hospital, Athens, GR, <sup>2</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>3</sup>Hippokraton General Hospital, Athens, GR, <sup>4</sup>Papageorgiou Hospital Aristotle University of Thessaloniki, Thessaloniki, GR, <sup>5</sup>Institute of Biology, Medicinal Chemistry and Biotechnology (IBMCB), Athens, GR

15:50 - 16:05 **10460 - Preliminary results from a phase 2 trial of tipifarnib in Squamous Cell Carcinomas (SCCs) with HRAS mutations.**

A. Ho<sup>1</sup>, N. Chau<sup>2</sup>, J. Bauman<sup>3</sup>, K. Bible<sup>4</sup>, A. Chintakuntlawar<sup>4</sup>, M. Cabanillas<sup>5</sup>, D. Wong<sup>6</sup>, I. Braña Garcia<sup>7</sup>, M. Brose<sup>8</sup>, V. Boni<sup>9</sup>, C. Even<sup>10</sup>, M. Razaq<sup>11</sup>, V. Mishra<sup>12</sup>, K. Bracken<sup>13</sup>, D. Wages<sup>13</sup>, C. Scholz<sup>13</sup>, A. Gualberto<sup>13</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York City, US, <sup>2</sup>Dana-Farber Cancer Institute, Boston, US, <sup>3</sup>Fox Case Cancer Center, Philadelphia, US, <sup>4</sup>Mayo Clinic, Rochester, US, <sup>5</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>6</sup>UCLA - School of Medicine, Los Angeles, US, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>University of Pennsylvania, Philadelphia, US, <sup>9</sup>Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>10</sup>Institut Gustave Roussy, Villejuif, FR, <sup>11</sup>Stephenson Cancer Center, Oklahoma City, US, <sup>12</sup>Kura Oncology, San Diego, US, <sup>13</sup>Kura Oncology, Cambridge, US

16:05 - 16:20 **Invited Discussant 10450 and 10460**

L. Siu, Princess Margaret Hospital, Toronto, CA



**14:45 - 16:15** **Type: Special Symposium** **ICM - Room 13**  
**Title: Drugging non-conventional targets**  
 Chair(s): Alex A. Adjei, US; Christian Dittrich, AT

14:45 - 14:45 **Session DOI**

14:45 - 14:50 **Introduction**

C. Dittrich, Angewandte Krebsforschung – Institution für Translationale Forschung Wien (ACR-ITR VIENNA), Vienna, AT

14:50 - 15:10 **Inhibiting RAS signaling**

A.A. Adjei, Mayo Clinic, Rochester, US

15:10 - 15:30 **DNA repair and Microsatellite Instability**

A. Duval, INSERM UMR1102, Paris, FR

15:30 - 15:50 **Nuclear transporters**

M. Mau-Sorensen, SKACCD - Rigshospitalet, Copenhagen, DK

15:50 - 16:10 **Tumour metabolism**

B. Van Tine, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University, St. Louis, US

16:10 - 16:15 **Conclusions and perspectives**

A.A. Adjei, Mayo Clinic, Rochester, US

**14:45 - 16:15** **Type: Proffered Paper session** **Hall A1 - Room 16**  
**Title: Proffered paper session - NETs and endocrine tumours**  
 Chair(s): Rocio Garcia-Carbonero, ES; Marianne Pavel, DE

14:45 - 14:45 **Session DOI**

14:45 - 14:57 **13070 - Efficacy of Lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)**

J. Capdevila Castillon<sup>1</sup>, N. Fazio<sup>2</sup>, C. Lopez<sup>3</sup>, A. Teule<sup>4</sup>, J. Valle<sup>5</sup>, S. Tafuto<sup>6</sup>, A. Custodio<sup>7</sup>, N. Reed<sup>8</sup>, M. Raderer<sup>9</sup>, E. Grande<sup>10</sup>, R. Garcia-Carbonero<sup>11</sup>, P. Jimenez Fonseca<sup>12</sup>, V. Alonso<sup>13</sup>, L. Antonuzzo<sup>14</sup>, A. Spallanzani<sup>15</sup>, A. Berruti<sup>16</sup>, I. Sevilla Garcia<sup>17</sup>, A. La Casta<sup>18</sup>, J. Hernando<sup>19</sup>, T. Ibrahim<sup>20</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Marques de Valdecilla University Hospital, Santander, ES, <sup>4</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>5</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>6</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>7</sup>Hospital Universitario La Paz, Madrid, ES, <sup>8</sup>Beatson West of

Scotland Cancer Centre, Glasgow, GB, <sup>9</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>10</sup>MD Anderson Cancer Center Center Espana, Madrid, ES, <sup>11</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>12</sup>Hospital Universitario Central de Asturias, Oviedo, ES, <sup>13</sup>Hospital Miguel Servet, Zaragoza, ES, <sup>14</sup>Azienda Ospedaliera Careggi, Firenze, IT, <sup>15</sup>University Hospital of Modena, Modena, IT, <sup>16</sup>Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT, <sup>17</sup>Hospital Regional Universitario Carlos Haya, Malaga, ES, <sup>18</sup>Donosti University Hospital, Donosti, ES, <sup>19</sup>Vall d'Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>20</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT

14:57 - 15:09

**Invited Discussant 13070**

E. Baudin, Gustave Roussy Institut de Cancérologie, Villejuif, FR

15:09 - 15:21

**18190 - Tumor Growth Rate and Lenvatinib Efficacy in Radioiodine-refractory Differentiated Thyroid Cancer**

S. Leboulleux<sup>1</sup>, E. Lee<sup>2</sup>, L. Bastholt<sup>3</sup>, M. Tahara<sup>4</sup>, L. Wirth<sup>5</sup>, S. Sherman<sup>6</sup>, B. Robinson<sup>7</sup>, A. Teng<sup>8</sup>, P. Joshi<sup>9</sup>, S. Misir<sup>10</sup>, C. Dutcus<sup>10</sup>, R. Tuttle<sup>11</sup>, M. Schlumberger<sup>12</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>National Cancer Center, Goyang-si, KR, <sup>3</sup>Odense University Hospital, Odense C, DK, <sup>4</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>5</sup>Massachusetts General Hospital, Boston, US, <sup>6</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>7</sup>The University of Sydney, Sydney, AU, <sup>8</sup>Eisai Inc., Woodcliff Lake, US, <sup>9</sup>Eisai, New York, US, <sup>10</sup>Eisai Inc, Woodcliff Lake, US, <sup>11</sup>Memorial Sloan-Kettering Cancer Center, New York, US, <sup>12</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR

15:21 - 15:33

**Invited Discussant 18190**

C. Spitzweg, Klinikum der Universität München, Munich, DE

15:33 - 15:45

**13080 - Activity &&**

J. Yao<sup>1</sup>, J. Strosberg<sup>2</sup>, N. Fazio<sup>3</sup>, M. Pavel<sup>4</sup>, P. Ruzniewski<sup>5</sup>, E. Bergsland<sup>6</sup>, D. Li<sup>7</sup>, S. Tafuto<sup>8</sup>, N. Raj<sup>9</sup>, D. Campana<sup>10</sup>, S. Hijioka<sup>11</sup>, M. Raderer<sup>12</sup>, R. Guimbaud<sup>13</sup>, P. Gajate<sup>14</sup>, S. Pusceddu<sup>15</sup>, A. Reising<sup>16</sup>, E. Degtyarev<sup>17</sup>, B. Mookerjee<sup>18</sup>, P. Aimone<sup>19</sup>, S. Singh<sup>20</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, <sup>3</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>4</sup>Universitätsklinik Erlangen, Erlangen, DE, <sup>5</sup>Hôpital Beaujon, Clichy, FR, <sup>6</sup>University of California, San Francisco, US, <sup>7</sup>City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California, US, <sup>8</sup>Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, <sup>9</sup>Memorial Sloan Kettering Cancer Center, New York, New York, US, <sup>10</sup>Policlinico Sant'Orsola-Malpighi, Bologna, IT, <sup>11</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>12</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>13</sup>CHU de Toulouse, Toulouse, France, Toulouse, FR, <sup>14</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>15</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>16</sup>Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, New Jersey, US, <sup>17</sup>Novartis Pharma AG, Basel, Switzerland, Basel, CH, <sup>18</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>19</sup>Novartis Campus Switzerland, Basel, CH, <sup>20</sup>Sunnybrook Health Sciences Centre, Toronto, CA

15:45 - 15:57 **13090 - Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: a non-randomized, open-label, phase 1b trial**

P. Zhang, M. Lu, J. Li, L. Shen, Beijing Cancer Hospital, Beijing, CN

15:57 - 16:09 **Invited Discussant 13080 and 13090**

K. Oberg, University Hospital, Uppsala, SE

**14:45 - 16:15 Type: Educational session** **Hall B3 - Room 21**  
**Title: Undifferentiated sarcomas: From MFH to UPS with more distance still to travel**

Chair(s): Jonathan A. Fletcher, US; Antoine Italiano, FR

14:45 - 14:45 **Session DOI**

14:45 - 15:10 **History of UPS over 2 decades: From MFH to UPS**

K. Thway, The Royal Marsden NHS Foundation Trust in Chelsea, London, GB

15:10 - 15:35 **Genomic landscape of sarcomas with complex genomics: Separate the wheat from the chaff**

J.A. Fletcher, Brigham and Women's Hospital, Boston, US

15:35 - 16:00 **Clinical management of UPS: Retrospective and perspectives in the era of next generation sequencing and immuno-oncology**

A. Italiano, Institute Bergonié, Bordeaux, FR

16:00 - 16:15 **Discussion**

**14:45 - 16:00 Type: Poster Discussion session** **Hall B3 - Room 20**  
**Title: Poster discussion - Basic science**

Chair(s): Therese Sørli, NO; Anton Berns, NL; Leonor David, PT

14:45 - 14:45 **Session DOI**

14:45 - 14:45 **3PD - Human melanoma cells from different disease stages prime amino acid signature of conditional media indicating signalling in the tumor microenvironment**

M. Hohenegger<sup>1</sup>, C. Wasinger<sup>2</sup>, A. Hofer<sup>3</sup>, O. Spadiut<sup>3</sup>, <sup>1</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>2</sup>Medical University Vienna, Vienna, AT, <sup>3</sup>Technical University Vienna, Vienna, AT

14:45 - 14:45 **1893PD - A joint metabolic profile of plasma and tissue samples for discovering**

**novel biomarkers in breast cancer**

N. Harada, H. Tada, M. Miyashita, Y. Hamanaka, A. Sato, T. Ishida, Tohoku University Hospital, Sendai, JP

14:45 - 15:00 **Invited Discussant 3PD and 1893PD**

T. Sørli, Oslo University Hospital, Oslo, NO

15:00 - 15:10 **Q&A led by Discussant**

15:10 - 15:10 **1894PD - Single-cell RNA Sequencing of Triple Negative Breast Cancer Patient-Derived Xenograft Reveals Distinct Cellular Populations Spatially Mapped to Histological Sections**

C. Martinez Ramirez, H. Kuasne, M. Park, D. Zuo, C. Kleinman, Y. Yang, A. Blanchet-Cohen, P. Savage, J. Ragoussis, McGill University, Montreal, CA

15:10 - 15:10 **1895PD - Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA)**

N. Karachaliou<sup>1</sup>, M. Lefterova<sup>2</sup>, J. Draper<sup>2</sup>, M.-A. Molina<sup>3</sup>, I. Chaib<sup>4</sup>, R. Palmero<sup>5</sup>, A. Taus<sup>6</sup>, S. Viteri<sup>7</sup>, M. González Cao<sup>8</sup>, M. Majem Tarruella<sup>9</sup>, E. Carcereny Costa<sup>10</sup>, T. Moran<sup>11</sup>, J. Garde Noguera<sup>12</sup>, E. Felip<sup>13</sup>, S. Olsen<sup>14</sup>, M. Jackson<sup>2</sup>, M. Sampayo<sup>15</sup>, I. Faull<sup>16</sup>, D. Dix<sup>2</sup>, R. Rosell<sup>10</sup>, <sup>1</sup>Institute of Oncology Rosell, Barcelona, ES, <sup>2</sup>Guardant Health, California, US, <sup>3</sup>Pangaea Biotech S.L., Barcelona, ES, <sup>4</sup>Health Sciences Research Institute of the Germans Trias i Pujol Foundation (IGTP), Badalona, ES, <sup>5</sup>Catalan Institute of Oncology, Bellvitge, ES, <sup>6</sup>Hospital del Mar, Barcelona, ES, <sup>7</sup>Instituto Universitario USP Dexeus, Barcelona, ES, <sup>8</sup>QuironSalud Dexeus University Institute, IOR, Barcelona, ES, <sup>9</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>10</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>11</sup>ICO Badalona, Badalona, ES, <sup>12</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>13</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>14</sup>Guardant Health, Redwood City, US, <sup>15</sup>Medica Scientia Innovation Research - MEDSIR, Barcelona, ES, <sup>16</sup>Guardant Health, Barcelona, ES

15:10 - 15:10 **1896PD - Joined analysis of Sarcomatoid Carcinoma (SC) mutational profiles: comparison of lung versus head and neck cancer.**

N. Pecuchet<sup>1</sup>, R. Taouachi<sup>2</sup>, A. Ben Lakhdar<sup>2</sup>, V. Fallet<sup>3</sup>, N. Rabbe<sup>3</sup>, H. Blons<sup>1</sup>, A. Lemoine<sup>4</sup>, M. Antoine<sup>3</sup>, S. Temam<sup>2</sup>, P. Laurent-Puig<sup>5</sup>, M. Wislez<sup>3</sup>, <sup>1</sup>Hopital European George Pompidou, Paris, FR, <sup>2</sup>Gustave Roussy Institute, Villejuif, FR, <sup>3</sup>APHP, CancerEst, Tenon University Hospital, Paris, FR, <sup>4</sup>Hopital Paul Brousse, Villejuif, FR, <sup>5</sup>Paris Descartes University, Paris, FR

15:10 - 15:25 **Invited Discussant 1894PD, 1895PD and 1896PD**

A. Berns, The Netherlands Cancer Institute, Amsterdam, NL

15:25 - 15:35 **Q&A led by Discussant**



- 15:35 - 15:35     **1897PD - Differential expression of Immune Checkpoints (PD-L1, HHLA2, B7x and B7H3) and their Association with Driver Mutations in Pulmonary Sarcomatoid Carcinoma (PSC)**
- H. Cheng<sup>1</sup>, J. Sharma<sup>2</sup>, C. Su<sup>2</sup>, S. Li<sup>3</sup>, X. Zang<sup>4</sup>, R. Perez-Soler<sup>5</sup>, B. Halmos<sup>6</sup>, A. Borczuk<sup>7</sup>,  
<sup>1</sup>A. Einstein College of medicine, New York, US, <sup>2</sup>A. Einstein College of medicine, Bronx, US, <sup>3</sup>Jacobi Medical Center, Bronx, US, <sup>4</sup>Montefiore Medical Center Albert Einstein College of Medicine, Bronx, US, <sup>5</sup>Montefiore Medical Center(East campus) - Medical Park at Eastchester Albert Einstein Cancer Center, Bronx, US, <sup>6</sup>Albert Einstein College of Medicine, New York, US, <sup>7</sup>Weill Cornell Medicine, New York, US
- 15:35 - 15:35     **4PD - Immunomodulatory effect of Hepatocyte growth factor on monocytes in human gastric cancer**
- L. Hirsch<sup>1</sup>, J. Palle<sup>2</sup>, A. Lapeyre-Prost<sup>3</sup>, S. Pernot<sup>3</sup>, T. Voron<sup>2</sup>, E. Tartour<sup>3</sup>, J. Taieb<sup>3</sup>, M. Terme<sup>3</sup>,  
<sup>1</sup>GUSTAVE ROUSSY, Villejuif, FR, <sup>2</sup>Paris Cardiovascular Research Center, Université Paris Descartes, Paris, FR, <sup>3</sup>Hopital European George Pompidou, Paris, FR
- 15:35 - 15:35     **5PD - Patritumab (anti-HER3 antibody) augments anti-tumor immune response of adoptive transfer of autologous activated T cells for patient-derived xenograft models of breast cancer.**
- E. Suzuki, T. Kotake, T. Nishimura, A. Yamaguchi, F. Pu, M. Toi, Kyoto University-Graduate school of medicine, Kyoto, JP
- 15:35 - 15:50     **Invited Discussant 1897PD, 4PD and 5PD**
- L. David, Universidade do Porto - Faculdade de Medicina, Porto, PT
- 15:50 - 16:00     **Q&A led by Discussant**

**14:45 - 16:15** **Type: Proffered Paper session** **Hall B3 - Room 22**  
**Title: Proffered paper session - Public health policy**  
 Chair(s): Carin Uyl-de Groot, NL; Michel Coleman, GB

14:45 - 14:45 **Session DOI**

14:45 - 14:57 **15550\_PR - Magnitude of clinical benefit of cancer drugs and time to health technology assessment (HTA) decisions in Europe**

T. Hwang<sup>1</sup>, K. Vokinger<sup>2</sup>, A. Tibau<sup>3</sup>, B. Gyawali<sup>4</sup>, H. Naci<sup>5</sup>, J. Franklin<sup>1</sup>, R. Beall<sup>1</sup>, A. Kesselheim<sup>1</sup>, <sup>1</sup>Harvard Medical School, Boston, US, <sup>2</sup>University of Zurich Hospital, Zurich, CH, <sup>3</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>4</sup>Brigham and Women's Hospital, Boston, US, <sup>5</sup>London School of Economics, London, GB

14:57 - 15:09 **15560 - Potential for value-based prescribing of oral oncology drugs**

M. Ratain<sup>1</sup>, A. Lichter<sup>2</sup>, <sup>1</sup>The University of Chicago Medical Centre, Chicago, US, <sup>2</sup>American Society of Clinical Oncology, Alexandria, US

15:09 - 15:21 **15570 - Relation between center volumes for pancreatic and esophageal cancer surgeries and outcome in Belgium: a plea for centralization**

H. De Schutter<sup>1</sup>, G. Silversmit<sup>1</sup>, K. Haustermans<sup>2</sup>, L. Van Eycken<sup>3</sup>, <sup>1</sup>Belgian Cancer Registry, Brussels, BE, <sup>2</sup>University Hospitals Leuven, Leuven, BE, <sup>3</sup>Brussels, BE

15:21 - 15:36 **Invited Discussant 15550\_PR, 15560 and 15570**

M. Coleman, London School of Hygiene and Tropical Medicine, London, GB

15:36 - 15:48 **15580 - Worldwide comparison of colorectal cancer survival, by topography and stage at diagnosis (CONCORD-2)**

S. Benitez Majano, V. Di Carlo, M. Nikšić, M. Coleman, C. Allemani, Concord Working Group, London School of Hygiene and Tropical Medicine, London, GB

15:48 - 16:00 **15590 - Increasing colorectal cancer incidence among young adults in England diagnosed during 2001-2014**

A. Exarchakou, L. Donaldson, M. Coleman, London School of Hygiene and Tropical Medicine, London, GB

16:00 - 16:15 **Invited Discussant 15580 and 15590**

B. Jönsson, Stockholm school of economics, Stockholm, SE

**14:45 - 16:15**    **Type: Joint Symposium**    **Hall B4 - Room 19**  
**Title: ESMO-JSMO joint symposium: New predictive biomarkers in breast cancer therapeutics**  
 Chair(s): Fatima Cardoso, PT; Hironobu Minami, JP

14:45 - 14:45    **Session DOI**

14:45 - 14:50    **Introduction**

F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT

14:50 - 15:10    **HER2 and HER3 as predictor of new ADC (DS-8201a and U3-1402)**

H. Iwata, Aichi Cancer Center Hospital, Nagoya, JP

15:10 - 15:30    **CCNE1 expression as a reliable predictor of palbociclib efficacy**

F. Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand, FR

15:30 - 15:50    **Medical oncology in the genome era: Are we ready in breast cancer?**

K. Tamura, National Cancer Center Hospital, Tokyo, JP

15:50 - 16:10    **Is BRCA good enough to select for PARPi?**

R. Dent, National Cancer Centre Singapore, Singapore, SG

16:10 - 16:15    **Conclusions**

H. Minami, Kobe University Hospital, Kobe, JP

**14:45 - 16:15**    **Type: EONS session**    **Hall B4 - Room 24**  
**Title: New cancer nursing roles: Innovation in action**  
 Chair(s): Eileen Furlong, IE

14:45 - 14:45    **Session DOI**

14:45 - 15:00    **Linking patient-reported outcomes and symptom management: The e-SMART study**

L. Mccann, University of Strathclyde, Glasgow, GB

15:00 - 15:15    **Cancer-related financial toxicity: The role of nurses**

J. Bryce, Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT

15:15 - 15:30    **CN2 - The Efficacy of Nurse-led Clinic**

C. Allan, Weston Park Hospital Cancer Research Centre, Sheffield, GB

15:30 - 15:45    **CN3 - Introducing the Role of the Advanced Clinical Practitioner in Haematology and Oncology**

M. Fowler, Heartlands Hospital-Heart of England NHS Foundation Trust, Birmingham, GB

15:45 - 16:00    **CN4 - Nurse Navigators in thoracic oncology: a qualitative study of German nurses' attitudes to nursing role expansion**

L. Hagelskamp<sup>1</sup>, S. Berger<sup>2</sup>, M. Villalobos<sup>1</sup>, M. Thomas<sup>3</sup>, M. Wensing<sup>2</sup>, C. Mahler<sup>2</sup>,  
<sup>1</sup>Thoraxklinik Heidelberg, Heidelberg, DE, <sup>2</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>3</sup>Thoraxklinik, Heidelberg, DE

16:00 - 16:15    **Discussion**

E. Furlong, University College Dublin, Dublin, IE



**15:00 - 16:00**    **Type: Multidisciplinary interactive sessions**    **Hall A1 - Room 15**  
**Title: Optimal management of bone metastases in 2018**  
 Chair(s): Prudence Francis, AU

15:00 - 15:00    **Session DOI**

15:00 - 15:10    **Biology and basis for prediction and prevention**  
R. Gomis, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, ES

15:10 - 15:20    **Medical management**  
P. Francis, Peter MacCallum Cancer Center, Melbourne, AU

15:20 - 15:30    **New radiation techniques**  
P. Poortmans, Institut Curie, Paris, FR

15:30 - 16:00    **Discussion**  
P. Francis<sup>1</sup>, P. Poortmans<sup>2</sup>, <sup>1</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>2</sup>Institut Curie, Paris, FR

**15:00 - 16:00**    **Type: Multidisciplinary interactive sessions**    **Hall B3 - Room 23**  
**Title: The challenges of toxicities from endocrine treatment in men with prostate cancer**  
 Chair(s): Ignacio Duran, ES

15:00 - 15:00    **Session DOI**

15:00 - 15:20    **Case on bone health**  
M. Smith, Massachusetts General Hospital, Boston, US

15:20 - 15:40    **Case on cardiac toxicity**  
B. Tombal, Cliniques Universitaires St. Luc, Brussels, BE

15:40 - 16:00    **Case on fatigue / cognition**  
I. Duran Martinez, Hospital Universitario Marques de Valdecilla, Santander, ES

**16:00 - 17:30**    **Type: Young Oncologist session**    **ICM - Room 14a**  
**Title: YO Forum: Research projects: From ideas to papers**  
 Chair(s): Leticia De Mattos-Arruda, ES; Anna Sophie Berghoff, AT

16:00 - 16:00    **Session DOI**

16:00 - 16:20    **How to select and define your project**

A. Ribas, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

16:20 - 16:40    **How to write a proficient project and get it financed**

L. Paz-Ares, University Hospital 12 De Octubre, Madrid, ES

16:40 - 17:00    **Dealing with obstacles faced during your project**

D. Olmos, CNIO - Spanish National Cancer Center, Madrid, ES

17:00 - 17:20    **Maximising your clinical investigations: How to structure your paper**

F. Ciardiello, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT

17:20 - 17:30    **Discussion**

**16:30 - 18:00**    **Type: Educational session**    **ICM - Room 1**  
**Title: Clinical implementation of PI3K inhibitors**  
 Chair(s): Fabrice André, FR; Evandro de Azambuja, BE

16:30 - 16:30    **Session DOI**

16:30 - 16:55    **Who, when and how to test for PIK3CA mutations**

C. Sotiriou, Institute Jules Bordet, Brussels, BE

16:55 - 17:20    **What is the true impact of PI3K inhibitors in clinical practice?**

F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

17:20 - 17:45    **Managing side effects of PI3K inhibitors**

C. Saura, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

17:45 - 18:00    **Discussion**

**16:30 - 18:00** **Type: Educational session** **Hall A1 - Room 15**  
**Title: State of the art management of GEP- NET**  
 Chair(s): Nicola Fazio, IT; George Pentheroudakis, GR

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **Pathological diagnosis: What is important for the clinician?**  
G. Rindi, Policlinico Universitario A. Gemelli, Rome, IT

16:55 - 17:20 **Therapeutic approaches for syndrome management**  
J. Chan, Dana-Farber Cancer Institute, Boston, US

17:20 - 17:45 **Therapeutic approaches for tumour growth control**  
N. Fazio, Istituto Europeo di Oncologia, Milan, IT

17:45 - 18:00 **Discussion**

**16:30 - 18:00** **Type: Proffered Paper session** **Hall A2 - Room 18**  
**Title: Presidential Symposium 3**  
 Chair(s): Josep Tabernero, ES; Solange Peters, CH

16:30 - 16:30 **Session DOI**

16:30 - 16:45 **LBA8\_PR - KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)**  
B. Burtness<sup>1</sup>, K. Harrington<sup>2</sup>, R. Greil<sup>3</sup>, D. Soulières<sup>4</sup>, M. Tahara<sup>5</sup>, G. De Castro Jr.<sup>6</sup>, A. Psyrri<sup>7</sup>, N. Baste Rotllan<sup>8</sup>, P. Neupane<sup>9</sup>, Å. Bratland<sup>10</sup>, T. Fuereder<sup>11</sup>, B. Hughes<sup>12</sup>, R. Mesia<sup>13</sup>, N. Ngamphaiboon<sup>14</sup>, T. Rordorf<sup>15</sup>, W.Z. Wan Ishak<sup>16</sup>, A. Roy<sup>17</sup>, J. Cheng<sup>18</sup>, F. Jin<sup>17</sup>, D. Rischin<sup>19</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, US, <sup>2</sup>The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, London, GB, <sup>3</sup>Paracelsus Medical University, Salzburg, AT, <sup>4</sup>Centre Hospitalier de l'Université de Montréal, Montréal, CA, <sup>5</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>6</sup>ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paulo, BR, <sup>7</sup>Attikon University Hospital, Athens, GR, <sup>8</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>9</sup>University of Kansas Medical Center, Kansas City, US, <sup>10</sup>Oslo University Hospital, Oslo, NO, <sup>11</sup>Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT, <sup>12</sup>Royal Brisbane and Women's Hospital, Brisbane, AU, <sup>13</sup>ICO L'Hospitalet, Barcelona, ES, <sup>14</sup>Ramathibodi Hospital, Bangkok, TH, <sup>15</sup>University Hospital Zürich, Zurich, CH, <sup>16</sup>University Malaya, Kuala Lumpur, MY, <sup>17</sup>Merck & Co., Inc., Kenilworth, US, <sup>18</sup>Merck & Co Inc, North Wales, US, <sup>19</sup>Peter MacCallum Cancer Center, Melbourne, AU

16:45 - 17:00 **Invited discussant**

J.-P. Machiels, Cliniques Universitaires St. Luc, Brussels, BE

17:00 - 17:15

**LBA9\_PR - Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy**

H. Mehanna<sup>1</sup>, A. Kong<sup>1</sup>, A. Hartley<sup>2</sup>, P. Mistry<sup>3</sup>, M. Dalby<sup>3</sup>, T. Fulton-Lieuw<sup>4</sup>, M. Robinson<sup>5</sup>, A. Gray<sup>6</sup>, B. Foran<sup>7</sup>, M. Sen<sup>8</sup>, L. O'Toole<sup>9</sup>, K. Dyker<sup>10</sup>, H. Al Booz<sup>11</sup>, R. Moleron<sup>12</sup>, S. Brennan<sup>13</sup>, E. Aynsley<sup>14</sup>, A. Chan<sup>15</sup>, D. Srinivasan<sup>16</sup>, J. Buter<sup>17</sup>, J. Dunn<sup>3</sup>,  
<sup>1</sup>The University of Birmingham Institute for Cancer Studies, Birmingham, GB, <sup>2</sup>University Hospitals Birmingham, Birmingham, GB, <sup>3</sup>University of Warwick, Coventry, GB, <sup>4</sup>The University of Birmingham, Birmingham, GB, <sup>5</sup>Newcastle University, Newcastle-upon-Tyne, GB, <sup>6</sup>University of Oxford, Oxford, GB, <sup>7</sup>Weston Park Hospital, Sheffield, GB, <sup>8</sup>St James's Institute of Oncology, Leeds, GB, <sup>9</sup>Castle Hill Hospital, Cottingham, GB, <sup>10</sup>Bradford Institute for Health Research, Bradford, GB, <sup>11</sup>Bristol Haematology and Oncology Centre, Bristol, GB, <sup>12</sup>NHS Grampian, Aberdeen, GB, <sup>13</sup>Saint Luke's Radiation Oncology Network, Dublin, IE, <sup>14</sup>South Tees Hospitals, Middlesbrough, GB, <sup>15</sup>University Hospitals Coventry & Warwickshire, Coventry, GB, <sup>16</sup>Western General Hospital, Edinburgh, GB, <sup>17</sup>VU University Medical Center, Amsterdam, NL

17:15 - 17:30

**Invited discussant**

A. Psyrri, Attikon University Hospital, Athens, GR

17:30 - 17:45

**LBA10 - Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC**

C. Zhou<sup>1</sup>, Y. Lu<sup>2</sup>, S.-W. Kim<sup>3</sup>, T. Reungwetwattana<sup>4</sup>, J. Zhou<sup>5</sup>, Y. Zhang<sup>6</sup>, J. He<sup>7</sup>, J.-J. Yang<sup>8</sup>, Y. Cheng<sup>9</sup>, S.H. Lee<sup>10</sup>, L. Bu<sup>11</sup>, T. Xu<sup>12</sup>, L. Yang<sup>13</sup>, C. Wang<sup>14</sup>, P. Morcos<sup>15</sup>, E. Mitry<sup>16</sup>, T. Liu<sup>11</sup>, L. Zhang<sup>17</sup>,  
<sup>1</sup>Shanghai Pulmonary Hospital, Tongji University, Shanghai, CN, <sup>2</sup>West China Hospital, Sichuan University, Chengdu, CN, <sup>3</sup>Asan Medical Center, Seoul, KR, <sup>4</sup>Ramathibodi Hospital, Bangkok, TH, <sup>5</sup>The First Affiliated Hospital, College of Medicine, Zhejiang University, HangZhou, CN, <sup>6</sup>Zhejiang Cancer Hospital, HangZhou, CN, <sup>7</sup>First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, <sup>8</sup>Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, <sup>9</sup>Jilin Province Tumor Hospital, Changchun, CN, <sup>10</sup>Samsung Medical Center, Seoul, KR, <sup>11</sup>Roche Product Development in Asia Pacific, Shanghai, CN, <sup>12</sup>Roche, Shanghai, CN, <sup>13</sup>Roche (China) Holding, Shanghai, CN, <sup>14</sup>Product development in Shanghai, Shanghai, CN, <sup>15</sup>Roche, New York, US, <sup>16</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>17</sup>Sun Yat-Sen University Cancer Center, Guangzhou, CN

17:45 - 18:00

**Invited discussant**

T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

16:30 - 17:30

**Type: Poster Discussion session**

**Hall B3 - Room**

**Title: Poster Discussion session - Supportive and palliative care 2**

**21**

Chair(s): Christina Ruhlmann, DK; Juliane Brandt, DE

16:30 - 16:30

**Session DOI**



- 16:30 - 16:30 **1540PD - Health-related quality of life in randomized controlled trials: a systematic review of prognostic significance**  
J. Mierzynska<sup>1</sup>, M. Pe<sup>1</sup>, C. Piccinin<sup>1</sup>, F. Martinelli<sup>1</sup>, C. Coens<sup>1</sup>, C. Gotay<sup>2</sup>, A. Eggermont<sup>3</sup>, M. Groenvold<sup>4</sup>, J. Reijneveld<sup>5</sup>, L. Dirven<sup>6</sup>, A. Bottomley<sup>1</sup>, <sup>1</sup>EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, <sup>2</sup>University of British Columbia, Vancouver, CA, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Bispebjerg Hospital, Copenhagen, DK, <sup>5</sup>VU University Medical Center & Brain Tumor Center, Amsterdam, NL, <sup>6</sup>Leiden University Medical Center & Haaglanden Medical Center, Leiden, NL
- 16:30 - 16:30 **1690PD - Acceptability in cancer outpatients of completing routine assessments of patient reported outcomes of common terminology criteria for adverse events (PRO-CTCAE) versus other patient reported symptom outcome tools**  
H. Albaba<sup>1</sup>, M.C. Brown<sup>1</sup>, S. Shakik<sup>1</sup>, S. Su<sup>1</sup>, H. Naik<sup>2</sup>, T. Wang<sup>3</sup>, M. Liang<sup>1</sup>, A. Perez-Cosio<sup>1</sup>, L. Eng<sup>1</sup>, N. Mittmann<sup>4</sup>, W. Xu<sup>1</sup>, G. Liu<sup>1</sup>, D. Howell<sup>1</sup>, T. Barnes<sup>5</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>University of British Columbia, Vancouver, CA, <sup>3</sup>University of Toronto, Toronto, CA, <sup>4</sup>Cancer Care Ontario, Toronto, CA, <sup>5</sup>Northern Beaches Cancer Services, Sydney, AU
- 16:30 - 16:45 **Invited Discussant 1540PD and 1690PD**  
J. Brandt, University Hospital Heidelberg, Heidelberg, DE
- 16:45 - 16:55 **Q&A led by Discussant**
- 16:55 - 16:55 **1686PD - Plinabulin (Plin), a Novel non-G-CSF Molecule for the Prevention of Chemotherapy-Induced Neutropenia (CIN), has the Potential to Positively Impact Tumor Micro Environment**  
D. Blayney<sup>1</sup>, S. Ogenstad<sup>2</sup>, Y.-K. Shi<sup>3</sup>, Q. Zhang<sup>4</sup>, L. Du<sup>5</sup>, L. Huang<sup>6</sup>, R. Mohanlal<sup>6</sup>, <sup>1</sup>Stanford Comprehensive Cancer Institute, Stanford, US, <sup>2</sup>Statogen Consulting, Durham, US, <sup>3</sup>Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN, <sup>4</sup>3rd Affiliated Hospital of Harbin Medical University, Harbin, CN, <sup>5</sup>Wanchun Bulin Pharmaceuticals, Ltd., Dalian, CN, <sup>6</sup>BeyondSpring Pharmaceuticals, New York, US
- 16:55 - 16:55 **1687PD - Neuropathy and Health Behaviors in Cancer Survivors treated with Chemotherapy (CT)**  
M. Matias<sup>1</sup>, A. Di Meglio<sup>2</sup>, A. Zingarello<sup>2</sup>, S. Michiels<sup>3</sup>, A. Partridge<sup>4</sup>, M. Bendiane<sup>5</sup>, M. Ducreux<sup>6</sup>, F. André<sup>6</sup>, I. Vaz Luis<sup>2</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Gustave Roussy, Université Paris-Saclay, Villejuif, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Dana-Farber Cancer Institute, Boston, US, <sup>5</sup>SESTIM, Marseille, FR, <sup>6</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 16:55 - 16:55 **1688PD - Awareness of the cancer and non-cancer related harms of continued smoking in cancer survivors.**  
L. Eng<sup>1</sup>, S. Liu<sup>2</sup>, D. Farzanfar<sup>2</sup>, E.C. Smith<sup>1</sup>, A. McCartney<sup>2</sup>, A. Basgaran<sup>2</sup>, K. Balaratnam<sup>2</sup>, S. Yeung<sup>2</sup>, M.C. Brown<sup>1</sup>, D. Howell<sup>1</sup>, J. Jones<sup>2</sup>, W. Xu<sup>1</sup>, D. Goldstein<sup>3</sup>, W.

Evans<sup>4</sup>, P. Selby<sup>5</sup>, M. Giuliani<sup>6</sup>, G. Liu<sup>1</sup>, <sup>1</sup>Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>Princess Margaret Cancer Centre, University of Toronto, Toronto, CA, <sup>3</sup>Princess Margaret Hospital, Toronto, CA, <sup>4</sup>McMaster University, Hamilton, CA, <sup>5</sup>Centre for Addiction and Mental Health, Toronto, CA, <sup>6</sup>Princess Margaret Cancer Centre, Toronto, CA

16:55 - 16:55 **1689PD - Breast Cancer (BC) related fatigue: a longitudinal investigation of its prevalence, domains and correlates**

I. Vaz Luis<sup>1</sup>, A. Di Meglio<sup>2</sup>, M. El-Mouhebb<sup>3</sup>, A. Dumas<sup>3</sup>, C. Charles<sup>2</sup>, G. Menvielle<sup>4</sup>, C. Mesleard<sup>5</sup>, A.L. Martin<sup>5</sup>, P. Cottu<sup>6</sup>, F. Lerebours<sup>6</sup>, C. Coutant<sup>7</sup>, A. Lesur<sup>8</sup>, S. Dauchy<sup>9</sup>, P. Arveux<sup>7</sup>, S. Delaloge<sup>1</sup>, N. Lin<sup>10</sup>, P. Ganz<sup>11</sup>, A. Partridge<sup>12</sup>, S. Michiels<sup>1</sup>, F. André<sup>13</sup>, <sup>1</sup>Gustave Roussy, Villejuif, FR, <sup>2</sup>GUSTAVE ROUSSY, Villejuif, FR, <sup>3</sup>Institut Gustave Roussy, Villejuif, FR, <sup>4</sup>Faculte de medecine de Saint-Antoine, Paris, FR, <sup>5</sup>Unicancer, Paris, FR, <sup>6</sup>Institut Curie, Paris, FR, <sup>7</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>8</sup>Institut de cancérologie de Lorraine, Nancy, FR, <sup>9</sup>Gustave Roussy Institut de Cancérologie, Villejuif, FR, <sup>10</sup>Dana Farber Cancer Institute, Boston, US, <sup>11</sup>UCLA, Los Angeles, US, <sup>12</sup>Dana-Farber Cancer Institute, Boston, US, <sup>13</sup>Gustave Roussy - Cancer Campus, Villejuif, FR

16:55 - 17:15 **Invited Discussant 1686PD, 1687PD, 1688PD and 1689PD**

C. Ruhlmann, Odense University Hospital, Odense C, DK

17:15 - 17:25 **Q&A led by Discussant**

**16:30 - 18:00** **Type: Educational session** **Hall B3 - Room 22**  
**Title: Affordability and sustainability of new cancer drugs**  
Chair(s): Carin Uyl-de Groot, NL; Fredericus Eskens, NL

16:30 - 16:30 **Session DOI**

16:30 - 16:55 **The economics of innovative medicines**

C. Uyl-De Groot, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, NL

16:55 - 17:20 **The use of scales to determine the magnitude of benefit of drugs**

E.G.E. De Vries, University Hospital Groningen (UMCG), Groningen, NL

17:20 - 17:45 **Differential pricing across Europe: addressing needs of middle- and low income countries**

Z. Kaló, Eotvos Lorand University (ELTE), Budapest, HU

17:45 - 18:00 **Discussion about the role of social media**

<b>16:30 - 18:00</b>	<b>Type: EONS session</b> <b>Title: Awards and closing remarks</b> Chair(s): Andreas Charalambous, CY	<b>Hall B4 - Room 24</b>
16:30 - 16:30	<b>Session DOI</b>	
16:30 - 16:45	<b>Novice Dissemination Award 1</b> <u>N. Izgu</u> , Hacettepe University Faculty of Nursing, Ankara, TR	
16:45 - 17:00	<b>Novice Dissemination Award 2</b> <u>J. Jackson</u> , <u>J. Rundgren</u> , Regional Cancer Center Stockholm Gotland, Stockholm, SE	
17:00 - 17:15	<b>Lifetime Achievement Award</b>	
17:15 - 17:30	<b>Recognising Cancer Nursing Award</b>	
17:30 - 17:40	<b>Poster winner</b> <u>L. Sharp</u> , Regional Cancer Center Stockholm Gotland, Stockholm, SE	
17:40 - 17:40	<b>Closing remarks</b> <u>L. Sharp</u> , Regional Cancer Center Stockholm Gotland, Stockholm, SE	
<b>18:30 - 20:00</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 50</b>	<b>ICM - Room 14b</b>
18:30 - 18:50	<b>Presentation 1</b> <u>S. Hurvitz</u> , UCLA Hematology/Oncology Santa Monica, Santa Monica, US	
<b>18:30 - 20:00</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 51</b>	<b>ICM - Room 13</b>
<b>18:30 - 20:00</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 52</b>	<b>Hall A1 - Room 15</b>
18:30 - 20:00	<b>Presentation</b> <u>F. Griesinger</u> <sup>1</sup> , <u>M. Dietel</u> <sup>2</sup> , <u>A. Stenzinger</u> <sup>3</sup> , <sup>1</sup> Pius Hospital, Oldenburg, DE, <sup>2</sup> Charité – Universitätsmedizin Berlin corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, DE, <sup>3</sup> University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE	
<b>18:30 - 20:00</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 53</b>	<b>Hall A1 - Room 16</b>

18:30 - 20:00	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 54</b>	<b>Hall B3 - Room 20</b>
18:30 - 20:00	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 55</b>	<b>Hall B3 - Room 22</b>
18:30 - 20:00	<b>Type: Industry Satellite Symposium</b> <b>Title: Industry satellite symposium 56</b>	<b>Hall B4 - Room 19</b>

18:30 - 20:00 **presentation**  
R. Bauersachs, Berlin, DE

18:30 - 19:45	<b>Type: Special session</b> <b>Title: ESMO 2018 General Assembly</b>	<b>ICM - Room 14c</b>
---------------	--	-----------------------

18:30 - 18:50 **ESMO 2018 General Assembly**  
J. Taberero, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology  
VHIO., Barcelona, ES



23.10.2018

**09:00 - 12:40**    **Type: Congress Highlights**    **Hall A1 - Room 17**  
**Title: Congress Highlights 2: The best of the Munich 2018 Congress**

Chair(s): Andrés Cervantes, ES; Josep Tabernero, ES

- 09:00 - 09:20    **Gastrointestinal tumours, non-colorectal**  
M. Hidalgo, Beth Israel Deaconess Med. Center, Boston, US
- 09:20 - 09:40    **Gastrointestinal tumours, colorectal**  
D. Arnold, Asklepios Klinik Altona, Hamburg, DE
- 09:40 - 10:00    **NETs and endocrine tumours**  
G. Pentheroudakis, University Hospital of Ioannina, Ioannina, GR
- 10:00 - 10:20    **Public health policy and health economics**  
F. Perrone, Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT
- 10:20 - 10:40    **Haematological malignancies**  
M. Ladetto, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, IT
- 10:40 - 11:00    **Break**
- 11:00 - 11:20    **Supportive and palliative care**  
F. Scotté, Hopital Foch, Suresnes, FR
- 11:20 - 11:40    **Sarcoma**  
S. Bauer, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE
- 11:40 - 12:00    **Gynaecological cancers**  
K. Dahl Steffensen, Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK
- 12:00 - 12:20    **Immunotherapy of cancer**  
G. Coukos, Ludwig Center for Cancer Research of the UNIL, Epalinges, CH
- 12:20 - 12:40    **Melanoma**  
G. Long, Melanoma Institute Australia, University of Sydney, North Sydney, AU

**09:00 - 13:00** **Type: Congress Highlights** **Hall A2 - Room 18**  
**Title: Congress Highlights 1: The best of the Munich 2018 Congress**  
 Chair(s): Solange Peters, CH; Anton Berns, NL

- 09:00 - 09:20 **Basic science**  
T. Helleday, University of Sheffield Medical School, Sheffield, GB
- 09:20 - 09:40 **Translational research**  
M.J. De Miguel, Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, Madrid, ES
- 09:40 - 10:00 **Genitourinary tumours, prostate**  
S. Gillessen, The Christie NHS Foundation Trust, Manchester, GB
- 10:00 - 10:20 **Genitourinary tumours, non-prostate**  
P. Bono, Helsinki University Central Hospital (HUCH), Helsinki, FI
- 10:20 - 10:40 **CNS tumours**  
C. Balana, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES
- 10:40 - 11:00 **Break**
- 11:00 - 11:20 **Head and neck cancer**  
L. Licitra, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 11:20 - 11:40 **Developmental therapeutics**  
T. Troiani, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 11:40 - 12:00 **Breast cancer, early**  
A. Di Leo, Nuovo Ospedale di Prato, Prato, IT
- 12:00 - 12:20 **Breast cancer, metastatic**  
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE
- 12:20 - 12:40 **Non-metastatic NSCLC and other thoracic malignancies**  
S. Ramalingam, Emory University Winship Cancer Institute, Atlanta, US
- 12:40 - 13:00 **NSCLC, metastatic**  
J. Spicer, King's College London Guy's Hospital, London, GB